<SEC-DOCUMENT>0000950170-25-029129.txt : 20250227
<SEC-HEADER>0000950170-25-029129.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227163037
ACCESSION NUMBER:		0000950170-25-029129
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silence Therapeutics plc
		CENTRAL INDEX KEY:			0001479615
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39487
		FILM NUMBER:		25679576

	BUSINESS ADDRESS:	
		STREET 1:		72 HAMMERSMITH ROAD
		CITY:			LONDON
		STATE:			X0
		ZIP:			W14 8TH
		BUSINESS PHONE:		44-0-20-3457 6900

	MAIL ADDRESS:	
		STREET 1:		72 HAMMERSMITH ROAD
		CITY:			LONDON
		STATE:			X0
		ZIP:			W14 8TH
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sln-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T11:19:47.3639+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:sln="http://silence-therapeutics.com/20241231" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_93ed6ebd-7729-45b3-b5fe-4244553c6a13" name="dei:AmendmentFlag" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_d476ad6b-0051-439a-9d97-0f0a9375a8f2" name="dei:DocumentFiscalPeriodFocus" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e">FY</ix:nonNumeric><ix:nonNumeric id="F_47db74ac-229a-42b9-9b68-46d2c3f239c0" name="dei:NoTradingSymbolFlag" contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e">true</ix:nonNumeric><ix:nonNumeric id="F_0753a7d7-2c2c-46ac-b1c0-45326f17eaa9" name="dei:EntityCentralIndexKey" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e">0001479615</ix:nonNumeric><ix:nonNumeric id="F_643965fa-a69a-4c0a-b921-781acf881027" name="dei:EntityTaxIdentificationNumber" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e">00-0000000</ix:nonNumeric><ix:nonFraction id="F_d92f026f-ce71-48af-812d-8e0ff8cabed1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_67dabae8-767d-495f-b035-1a9900d294d1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5" name="us-gaap:NumberOfReportableSegments" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" unitRef="U_Segment" decimals="INF" format="ixt:num-dot-decimal">1</ix:nonFraction><ix:nonNumeric id="F_d068121f-6b77-49ec-9e07-b676d008cab3" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</ix:nonNumeric><ix:nonNumeric id="F_fa405555-b8a0-41d6-bcd0-c5ceffcea501" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonFraction id="F_7e7a64d4-569d-4871-a6b1-2ad84515628e" name="sln:CapitalCommitments" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_40e46a58-04d9-4131-ab73-072c46c316bb" name="sln:CapitalCommitments" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sln-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_803eaafe-148f-4e2c-a1bf-e54187acd2aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80436ca8-6764-4c9d-a92e-0a804aa65353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8184c077-a478-46ed-ad2a-22ca667a1dda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82966b62-872d-49bb-aeec-24612fe0285f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84cedcb8-200d-4f11-afb2-0648fda7c636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_872d05dd-c670-4b96-94c2-e02ca438887f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8927c9e3-b70e-49d9-9480-580bb749557e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b1b366e-04b7-442e-aae8-9b9874416e85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8cda337c-0dec-4a91-83cb-e2a5eab87ddd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f5432bd-fe35-4ec3-a327-b8bc31778b49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fb4cca8-43c3-4e07-8d79-5d79f2a66b76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_92ab0815-ca01-49b9-9495-665a702a4024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9467424c-7058-428d-ad9d-47868639fc92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_952f58d5-0f09-4113-8e23-231dd9d6ed60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95a23c91-e275-4694-9a2b-078f6e447589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_967f4721-a4f1-4503-8847-1f409b6a3092"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97969988-6ccc-4333-8d42-d1661f89dba4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_992c3aa9-ad2c-45d7-abc4-998d7652ae1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_993ce64a-f00f-4229-b0de-9e75b3dd02f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_993f7efa-93c3-4846-afa1-f47122276cef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99e52335-f638-4b2b-ac13-630a9a8f63d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b38472f-f9ad-4927-aa46-e70d32506104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cd4f37d-933a-4a85-beca-f7eadbe8fbd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9cea7a69-a5e3-4fc9-80c0-2433f7e0add4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9db27ca0-901f-4c75-883b-ac5848b73bba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicensesAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f0adb4a-3977-49bd-bd43-31874b535e51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a004f47b-e1d5-4aaa-929b-464b64c386ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0234db5-e0d7-409b-9954-5b243a9daa8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a26298cc-ed94-4046-8318-ff37b7f4550b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a28de7dc-3a37-4a87-b082-7778b559525a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a401c67e-4a4e-4f35-a3e7-52f49f0af333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5aa37ae-e777-4dc1-948b-8abdce9b033b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a616bd36-1676-406f-a437-69e3e0d34cd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a61b329b-79b8-48f7-91c7-c5440305e906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a74d87d0-a1bb-4a4b-a851-11add28ffc71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7b20ad2-f774-44ca-92d9-91406a63fde3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab13cc0c-5775-43dd-a181-db3338b67deb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_add4578b-b18c-498c-9291-73e01f000c88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af8fc429-8807-4280-86d7-4bb3e6b0a403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b214b1bd-0876-4f24-bab9-83c0ee791a74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b68a9405-7a9f-4135-ac8b-98f4d8aa740a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b775d65d-9ac8-4943-bee6-cf41729c880d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b785019b-0762-4563-980b-1d22109b7cc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8115894-8913-43eb-9042-ef3fc8f7d112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b902af35-3fe5-4f8a-ac84-e8d236da4c41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf66dbc2-8413-43ec-bd18-e8293742fcfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0372b91-8945-4668-a516-80774a76ddde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0561958-14fc-4c04-b4c6-29aecabad04e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0f73974-d468-4883-a299-b1954062293c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1fd8902-0499-4006-8b7a-f16708af1815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c26bf700-deb8-4a91-a96d-f882b6d529d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2ca9beb-ad6f-462a-9e3e-0385278c2a72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4e5bcd7-a4a8-4fdd-be71-9205e7a10b8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sln:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5dd0282-7233-442b-9081-aa33c6702629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c74d2467-009d-495a-bebc-222cee797f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8c88df3-dd6e-4dfc-995d-d16e951e1d00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cae9864b-c68c-4743-b935-6556cbeeae9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb624ebe-9f9f-415c-9701-66ebfe607196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc4a6675-6368-4274-a498-7a1407627000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7a493d2-59ec-46f4-87a1-b9e48f3e1f9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-05</xbrli:startDate><xbrli:endDate>2024-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9492943-8f98-4acc-814a-052f211894d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d983b3bf-ce62-495e-8da5-1fec7e50860e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_daee9f0f-917c-4075-9727-a97e4432d952"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbbea4f8-6415-4dd5-b5eb-4a147b35a1df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbe56603-c5ad-4050-8b7a-f9ec17240ff0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc57ec07-2678-46b9-9794-85b715ab415c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc582293-5dac-417e-8bcc-6e2300b7b379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc740331-c44f-436b-8d6a-1313f822c913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dffb0a10-ead0-498a-9a65-80ec339f4808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1315f97-7497-4c58-b13e-bbae64f85ba2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1b8809b-fd1d-4776-97e9-f3f0de39ae40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1e57139-299b-4037-aa4e-2d87f4f5721e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1f5638a-04f4-4c2c-93a3-b700275c8509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e2631f8b-0c37-4dc8-a1cc-38b6a73bdef4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e46d88b1-5076-4a01-af8f-070d4137afe2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e692684b-2681-444f-8b7c-e8b4ef46529b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6c9f868-f62a-4111-ba93-f469fcd0d117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e965a87f-ea8d-4a71-9f84-acedc7eb6357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-22</xbrli:startDate><xbrli:endDate>2024-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb12df02-dc62-4dfe-9745-ea50a6329b7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sln:NonExecutiveChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed7dcfe1-421c-4f79-9232-17d734827b7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edac0d25-e5fa-43db-9447-72b4778d22a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeb3d142-dc2f-4224-b92c-0c451fa14eb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0b63486-f25b-4b73-b4df-2ac2360a659a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1deec49-1e4a-4b33-a7be-f5eb5e43b3d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6142756-44a3-47a1-8793-ebc26a69054b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7e4679a-8036-4192-9419-7bc7f5cca0d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa602d40-17ae-4c95-900d-1dd73992f44c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fabcf318-8597-4509-8bb6-bc105007edc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc0ec39a-48d9-4919-8064-11ecd22f79fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc219a0f-69bc-48c5-8e88-1c1bea1a3b75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00a18a89-651d-454d-8df8-75896d774647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00d2d54e-290c-4d4d-b535-9fdc29adb158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00f55fd7-1fe9-443f-8a1a-565e418119ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_037e26c3-7b8f-42ed-9595-fc5b17699c67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0383529a-c338-4296-a791-e865000b7d3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_049e703a-bbe5-4ce3-afce-99cf7a56663a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_059ba194-dc5a-46d5-b657-d8a5b95f703b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_060925be-2d36-42da-9130-a97cb8b73ba5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0621b0c6-ee4e-42cf-a04a-499414698850"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08dd2d55-0e01-4e62-95a4-087adff7660d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bd98068-47df-4b94-a4e2-24b2b7898f0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicensesAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f952a92-9ec0-42dc-8871-ae65f086585b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11ec3de2-3169-4055-898b-258e9b888703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16908155-fa6d-48d2-86d3-2bd71f67416e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16fd02d7-a435-4779-9d74-c3e225640553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sln:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17e919a1-8144-489c-9e6d-db8d495d267d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1936f5c6-4623-4d59-8f5c-fd61504cd85a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_193e7dca-2118-430b-a24c-39a8be8f2ec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1945b695-781c-4d0b-a167-a95a2b6c877c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_196e5e80-6700-4ee5-83ef-dbd0df792f21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1aed09de-bc50-4e87-9680-f6533b6e32a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_201f659a-3cad-42ab-ab6e-27152af749a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_216e038d-1b18-4522-bfb1-cfa508cf7c03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_217d5192-d77e-4113-b140-4e04d06c0567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21a8db84-e973-428f-b46a-6d101573066a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21f6c7f3-fcd4-4d89-9f96-a6ce7fcf4b29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2375fd1d-98f8-4091-ae30-79225745f3d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_238358c8-8861-4cfb-a53e-08e29a69ca49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23cfb98f-fa5a-4be5-af26-36b14ff411c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23dabf2c-86b8-4fd8-9d01-e013311b7293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2477b135-cd13-49b5-a4d8-b62ae8c75cd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25d05802-ed6f-4b2e-9cc1-86490d680cb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27344b07-296f-4272-8c49-e68d36c05499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2883aa41-3a94-4d8f-bd1b-0dcd31622bf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c48633d-504d-4b47-94ba-86f51f5eff2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c9a8caf-7853-4084-b2c4-9c763a4f1b1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d238315-cfea-49cf-90a8-194b936a027a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e144a57-0ddb-4baf-a9c3-2a52f32e07bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30137f17-19dd-4a65-a75e-44bd27a45a6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3429ff17-b505-421b-8d3e-21a87a489736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3441304e-2e9f-4e16-88d3-2ba15339295c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_350c15e1-d957-4be9-aee7-a256f22c97c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_370fbfa4-fb9b-4a15-a3dc-b8d60d44d568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3807dd5f-7db5-4df7-b6df-54b06e17005f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38e9b6bf-0e2e-4817-ab67-ec146ae446da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39a561a1-a49b-401a-9662-3894f44c8689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a41af0c-23c8-4e76-9243-d601a6c1bae4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c9aca65-1850-401b-8756-d571e815112f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40b17d20-2184-49db-8942-a7eef127d200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_424a567f-bfce-4314-a1cc-dcdfd4446d4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45b856ba-a9f8-4504-b2af-359c27db06df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46a40d66-643e-4949-b548-2f714fd5cbbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4981ab38-3780-4326-a492-3b5aa602b56e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49d393af-f321-42c7-85a7-7d1ab9d9840c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a556b23-31fe-49a9-90a3-49e389ec6b48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ce48f3f-5b8b-44c8-8ccc-45e7cee6a59e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d5d0d9e-bfe8-4d5b-9352-c404dd2ac67a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_504e865b-e8c6-4526-9b0b-319762518420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50fc6d5c-fae9-4564-892e-b943a5104009"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51326ac8-4cf9-4ab6-b452-e838538675cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53771d0d-7cc8-4b66-b57c-8f18749a5839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_537e54b5-1a9a-4794-ab29-9db563b5fb50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53a85070-3252-4961-9ffb-808312baaede"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicenseAndSoftwareNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54971021-ad19-41ea-9f7b-464afa3961a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58dfc602-04c5-4cbf-99d1-064ead7260df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a53c3f0-bfdd-42e8-9d51-31e9dfd10fb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5abd1237-ff52-4950-ac85-db071e0672dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c9bae62-b3d2-43fe-9e77-fe51e795c617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f26855a-a871-47e3-a783-ff3eb99970d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_608d77f8-a60e-4cd0-baf8-518580ca501b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61dbaca8-5fd5-4900-8f20-af4042005ca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62b6b471-c432-4ab7-a3bd-bee9095e34fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_632ad642-d991-4f1b-8dd8-159d5c4836a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_638faea5-e2d8-41ce-a7ed-8338f7223d41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_639d80ab-82dd-47c1-b84d-cedb0693edb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_653d019b-7d15-44db-9acd-920ecd68e80d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6697bf60-6fe3-4afc-9808-67be87d95a10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67267d0e-6a3e-40c0-98fe-e40aa96783a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_675ff913-5424-432c-ac71-3989d7bcca97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6796ff61-ed09-41b6-8d12-60cb26012f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67be7eda-a207-4017-be9a-44dc71c47dc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a334fb1-6955-4d69-b9eb-b49d579d734d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6aaa0880-d729-425c-8313-d4f3cc099532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ad3128e-4140-41e6-b6de-bf526d8f46d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c632d2c-340e-4b65-8cbb-b51f9c4f1f5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d523cee-aad8-4ece-86d0-cf54c441dc67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_72551dd3-af02-4504-9e64-9506ac75dec4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_73d8c6ba-016e-4146-8301-8194bdf092a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicenseAndSoftwareNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74b750e6-0f2c-44dc-9d32-f425b3eac898"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74e6c5aa-7ac8-44e0-8882-bd507123cbea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_758fbdcc-cc27-4b6a-8f98-eac78abfa599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79f81678-d929-47d5-a2dd-7b6bfc53386b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a81abb4-525e-41bc-b9c6-31b36946491e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b15e4df-7de8-4272-a954-8f455cf7b864"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e8eb108-56e8-4953-b71b-5050238e0174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001479615</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_U_iso4217GBP_xbrlishares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>sln:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>sln:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_OrdinaryShare"><xbrli:measure>sln:OrdinaryShare</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d8df02ac-0265-43fc-a0ef-821a94501a40" fromRefs="F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1" fromRefs="F_9c3b9baf-8b05-468b-9c79-830cf81ddc15 F_f045ca95-9039-40d5-91da-1e05384a3b3e"/></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_84b0e8e3-000a-4c2e-81d8-05877a638319" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_e658f97d-0b90-4d94-be1a-97ddce900c11" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b37d9a2-c539-46fd-94e7-e647fa1a94e9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6429baa4-677e-4797-a2b1-fb4c58fde5e8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61bc9c58-c68b-4a0a-b5b1-8c7a9bb2fca8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_495c1432-3083-4114-9459-e1ef8de59310" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;text-indent:18pt;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="text-indent:-18pt;padding-left:18pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ________ </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">________</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75d299e7-e762-494e-8d07-19cdc2836027" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-39487</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b718fb3-3b57-4f31-bd47-3a3938f4effa" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3d1ec10e-4150-48bb-b0b6-f1d94995d04b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_643965fa-a69a-4c0a-b921-781acf881027;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Not Applicable</span></span></span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(I.R.S. Employer Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:50%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_89cbe102-2b94-4e23-9535-f69cdf72cefe" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">72 Hammersmith Road</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a145a88f-2303-4e87-abbf-4b73315d00ee" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">London</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_df1d9cd3-5aa8-47f3-8b55-6a50fd1e3065" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">United Kingdom</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d2b5977b-ee1a-43f0-963a-671fee3d8f22" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">W14 8TH</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Zip code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tel: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb16accf-264b-4bd9-8e30-11cb995eda29" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+44 20</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8025d2d4-7f99-49a2-a4de-f429ecc97417" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3457 6900</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42%;box-sizing:content-box;"/>
    <td style="width:16%;box-sizing:content-box;"/>
    <td style="width:42%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4b3af8e5-d675-4f8a-9d0f-6bd5cfc50556" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">American Depositary Shares, each representing three ordinary shares, nominal value &#163;0.05 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c7d46386-77e3-4360-a960-319ed749bf16" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SLN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a218c60a-fa6b-4dfb-9b32-d9ecb580f720" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:3pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d427eb41-32b8-4916-87a5-64bb71997113" contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ordinary share, nominal value &#163;0.05 per share</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a" contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">*</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*</span><ix:footnote id="FNT_d8df02ac-0265-43fc-a0ef-821a94501a40" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.</span></ix:footnote></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744; Yes &#9746; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f5fa6ff-ffd1-4207-aefc-d4d8f29b8b6d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744;Yes &#9746; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6068400-68e0-4970-b021-ec0fb6635755" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#9746; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b1bb5dc5-05dd-4a97-8d0e-485258b8f0e8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744; No</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04055e4e-6548-48a3-a1bd-18171a8be226" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9744; No</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:22%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.66%;box-sizing:content-box;"/>
    <td style="width:1.12%;box-sizing:content-box;"/>
    <td style="width:14.22%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_128f53b8-896f-4d29-8b45-54a0089912d9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer &#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer &#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company </span><span><ix:nonNumeric id="F_f57fecf1-2b4c-45b4-93ee-699195ecec9e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span><ix:nonNumeric id="F_6907d01f-c08f-4d75-b650-f13acd4c1968" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_effefc53-e77b-432c-911e-01d992805120" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26a8e87e-db93-43cd-bd4f-e57f27023972" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#9744;Yes </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4d65b23-f19e-4179-a31a-32e881eae25e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the ordinary shares held by non-affiliates of the registrant, based upon $19.00, the closing price of the registrant&#8217;s American Depositary Shares on the Nasdaq Global Market on June 28, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f99c1a2-2ff7-42e8-86f7-3ef6f4f32e17" contextRef="C_00d2d54e-290c-4d4d-b535-9fdc29adb158" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">737.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of January 31, 2025, the registrant had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd2f8962-6eee-4016-9d45-b3cb3236bde5" contextRef="C_9cd4f37d-933a-4a85-beca-f7eadbe8fbd1" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,674,074</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares (including ordinary shares in the form of American Depositary Shares) outstanding, nominal value &#163;0.05 per share.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffeb3b84-2e31-41bd-8d96-9f5e78c24d7d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2024.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:86%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unresolved_staff_comments_item"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;text-align:right;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#market_for_registrants_common_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Reserved.</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#managements_discussion_and_analysis"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#quantitative_and_qualitative_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#financial_statements_and_supplementary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#changes_in_and_disagreements_with_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#disclosure_regarding_foreign_jurisdict"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iii"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#directors_executive_officers_and_corpora"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#security_ownership_of_certain_beneficial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#certain_relationship_and_related_transac"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#principal_accountant_fees_and_services"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_iv"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits_and_financial_statement_schedul"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10.1pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10.1pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">i</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10-K, or the Annual Report, contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Annual Report are based upon information available to us as of the date of this Annual Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the development of our product candidates, including statements regarding the timing of initiation, completion and the outcome of preclinical studies or clinical trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them, and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to collaborate, or statements regarding the ongoing collaborations, with third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our plans to research, develop, manufacture and commercialize our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of our regulatory filings for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth potential of the markets for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to raise additional capital;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and retain qualified employees and key personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our estimates regarding future revenue, expenses and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our belief that our existing cash, cash equivalents and future anticipated milestone payments from our existing collaborations will be sufficient to fund our operating expenses and capital expenditure requirements into 2027; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments in the United States, United Kingdom, European Union, or EU, and other jurisdictions.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should refer to the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A. of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GENERAL INFORMATION</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless context otherwise requires, all references in this Annual Report on Form 10-K, or Annual Report, to &#8220;Silence,&#8221; &#8220;Silence Therapeutics,&#8221; &#8220;Silence Therapeutics plc,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Silence Therapeutics plc and, where appropriate, its consolidated subsidiaries.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Annual Report includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this Annual Report appear without the </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#153;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RISK FACTORS SUMMARY</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is subject to a number of risks and uncertainties. If any of the following risks are realized, our business, financial condition and results of operations could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part I, Item 1A. of this Annual Report. Set forth below is a summary list of the principal risk factors as of the date of the filing this Annual Report:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have a history of net losses, and we anticipate that we will continue to incur significant losses for the foreseeable future.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never generated any revenue from product sales and may never be profitable.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will require additional financial resources to continue the ongoing development of our product candidates and pursue our business objectives. If we are unable to obtain these additional resources when needed or on acceptable terms, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our holders, including holders of our American Depositary Shares representing our ordinary shares, or ADSs, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct some aspects of our manufacturing, research and development activities, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of research or clinical testing, or may terminate our agreements. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements, and our products may face future development and regulatory difficulties.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face competition from other companies that are working to develop novel drugs and technology platforms using technologies similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to introduce new products or keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face potential product liability and other claims, and, if successful claims are brought against us, we may incur substantial liability and costs.  </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and related tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign data privacy and security laws, regulations contractual obligations, industry standards, policies, and other obligations, and our (or the third parties with whom we work) actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class actions); fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to our current or future products and product candidates, we may not be able to compete effectively in our markets.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The transition from foreign private issuer to U.S. domestic issuer status effective from January 1, 2025, requires us to comply with the U.S. domestic reporting requirements under the Exchange Act and will result in significant additional compliance activity and increase our costs and expenses.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We no longer qualify as an &#8220;emerging growth company&#8221; as of December 31, 2024, and, as a result, we will no longer be able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our ADSs may be volatile, and you could lose all or part of your investment.  </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future sales, or the possibility of future sales, of a substantial number of our ADSs could adversely affect the price of such securities.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may identify material weaknesses in our internal control over financial reporting. If we experience material weaknesses or significant deficiencies in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a United States person is treated as owning at least 10% of our ordinary shares, such United States person may be subject to adverse U.S. federal income tax consequences.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Claims of U.S. civil liabilities may not be enforceable against us.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our articles of association provide that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT I</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1. Bu</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">siness</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body&#8217;s natural mechanism of RNAi by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced and its level of activity is lowered. In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as &#8220;gene silencing.&#8221; Our proprietary mRNAi GOLD&#153; (GalNAc Oligonucleotide Discovery) platform consists of siRNA product candidates designed to precisely target and &#8216;silence&#8217; specific disease-associated genes in the liver. Using our mRNAi GOLD platform, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: cardiovascular disease, hematology and rare diseases.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran (SLN124) is our wholly owned siRNA product candidate designed to inhibit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> expression in the liver. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a negative regulator of hepcidin, the body's master regulator of iron metabolism, including its absorption, distribution and storage. Divesiran has shown preclinical potential in several hematological disorders and proof-of-mechanism in a Phase 1 healthy volunteer trial. Divesiran is currently being evaluated in the SANRECO Phase 2 clinical trial in polycythemia vera, or PV, patients. We believe divesiran has the potential to be the first-in-class siRNA in PV. PV is a rare, myeloproliferative neoplasm &#8211; a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit, or HCT, levels. By silencing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO clinical trial at the American Society of Hematology (ASH) annual meeting. Interim results showed divesiran substantially reduced phlebotomy requirements and lowered HCT levels following infrequent dosing in a range of PV patients. Divesiran has been well tolerated to-date with no dose-limiting toxicities. In December 2024, we also announced the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial which is currently underway. The U.S. Food and Drug Administration, or FDA, has granted divesiran Fast Track and orphan drug designations for PV. In December 2024, the European Commission, or EC, granted divesiran orphan drug designation for PV in Europe.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zerlasiran (SLN360) is our wholly owned siRNA product candidate, which is designed to lower the body's production of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a), that has been associated with an increased risk of cardiovascular events.  Zerlasiran works by targeting messenger RNA required to translate the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene into particles of Lp(a), effectively &#8216;silencing&#8217; the gene to reduce Lp(a) production. High Lp(a), defined as 125nmol/L or higher, is a genetically determined cardiovascular risk factor affecting at least 20% of the world&#8217;s population and is associated with a high risk of heart attack, stroke and aortic stenosis. Unlike low-density lipoprotein, or LDL, Lp(a) levels are predominantly genetically determined, typically by age five, and unaffected by diet or lifestyle. There are currently no approved medicines that selectively lower Lp(a). Lp(a) levels can be measured by a simple blood test and while there is no generalized consensus on Lp(a) risk thresholds, growing evidence supports three main levels: Low or Normal (less than 75 nmol/L), Elevated (75 nmol/L to 124 nmol/L) and High (125 nmol/L or higher). A recent US based registry study in over 16,000 individuals showed that there is substantial risk of major cardiovascular events in individuals with elevated levels below the current accepted risk threshold of 125 nmol/L. Guidelines from the European Atherosclerosis Society, or EAS, and Canadian Cardiovascular Society, or CCS, suggest at least one test in an adult lifetime. The American College of Cardiology, or ACC, and American Heart Association, or AHA, recommend testing for those with a family history of premature atherosclerotic cardiovascular disease, or ASCVD, or personal history of ASCVD. In Phase 1 and Phase 2 clinical trials, zerlasiran was shown to  substantially lower Lp(a) levels in ASCVD patients with persisting effects following infrequent dosing and was  observed to be well tolerated with no major safety concerns. During the fourth quarter 2024, we received positive regulatory feedback from the FDA and European Medicines Agency, or EMA, on the Phase 3 cardiovascular (CV)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">outcomes study design for zerlasiran in patients with high Lp(a). We are engaged in global partnership discussions to seek a third-party partner for potential Phase 3 development of zerlasiran as well as potential future commercialization activities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our wholly owned clinical pipeline, we have a third siRNA product candidate from our mRNAi GOLD platform in Phase 1 development in an undisclosed indication through our collaboration with AstraZeneca. We believe the potential for our  mRNAi GOLD platform to address disease-associated genes in the liver is substantial and are progressing several undisclosed preclinical programs that have shown promising results. We are committed to maximizing our  mRNAi GOLD platform by advancing a pipeline of both wholly owned and partnered programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are advancing several siRNA programs in the clinic developed from our proprietary mRNAi GOLD platform.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img172674775_0.jpg" alt="img172674775_0.jpg" style="width:624px;height:268px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Background on siRNA Molecules and RNA Interference</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Messenger RNA, or mRNA, plays an essential role in the process used by cells to translate genetic information from DNA to create proteins. Transcription from DNA in the cell nucleus generates different types of RNA, including mRNA, which carries in the sequence of its nucleotides the genetic information which serves as molecular blueprints required for translation, or protein synthesis, outside of the nucleus where proteins are made. In some cases, cells produce mRNA erroneously, resulting in synthesis of too much of a particular protein or a mutated protein variant, which can lead to disease. Our siRNAs are designed to bind to undesirable mRNA, whereupon a natural process known as RNA interference, or RNAi, is triggered, resulting in catalytic degradation of the mRNA and reduced production and activity of the disease-associated protein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. RNAi was discovered by Andrew Fire and Craig Mello, for which they were awarded the 2006 Nobel Prize in Physiology or Medicine. RNAi therapeutics represent a novel advance in drug development that has the potential to transform the care of patients with genetic and other diseases. Historically, the pharmaceutical industry had developed only small molecules or recombinant proteins to inhibit the activity of disease-associated proteins. While this approach is effective for many diseases, a number of proteins cannot be inhibited by either small molecules or recombinant proteins. Some proteins lack the binding pockets small molecules require for interaction. Other proteins are solely intracellular and are therefore inaccessible to recombinant protein-based therapeutics, which are limited to cell surface and extracellular proteins. The unique advantage of RNAi is that, instead of targeting proteins, RNAi silences the expression of genes themselves via the targeted destruction of the mRNAs made from the gene. Rather than seeking to inhibit a protein directly, the RNAi approach works upstream to prevent its creation in the first place.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once inside a cell, siRNA molecules are recognized by the endogenous RNAi cellular machinery, which removes one of the strands, referred to as a passenger strand, of the siRNA construct, thereby allowing the other strand, referred to as a guide strand, to find its target mRNA and bind to it through Watson-Crick base pairing. This site-specific binding triggers the biological process of RNAi interference, by which natural cellular machinery degrades target mRNA bound by the guide strand and thereby prevents it from being translated into functional proteins.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our medicines are designed to harness this natural pathway to develop a new generation of therapeutics by designing tailored siRNA sequences that are able to bind through Watson-Crick base pairing to mRNAs that code for specific disease-associated genes, or genes that regulate them. Our siRNA molecules are administered by subcutaneous injection. Once administered, our siRNA molecules are taken up specifically by target liver cells or cleared from the body within hours. A single siRNA molecule, once in the liver and incorporated into the RNAi cellular machinery, can degrade large numbers of targeted mRNAs due to the catalytic nature of the cell&#8217;s RNAi machinery. Because the catalytic activity of the RNAi pathway eventually fades with gradual degradation of the guide strands, RNAi-mediated protein reduction is not permanent. In our preclinical and clinical studies, we have observed a durable, dose-dependent silencing effect with our product candidates following subcutaneous injection. The graphic below shows the steps involved in the pairing of our siRNA molecules with the bases contained in the mRNA sequence for a particular target gene.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img172674775_1.jpg" alt="img172674775_1.jpg" style="width:575px;height:394px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that siRNA molecules can, in theory, be engineered to bind specifically to and silence almost any gene in the human genome to which siRNA can be delivered. This potentially broad application of siRNA therapeutics could allow them to become a new major class of drugs. We are currently able to deliver siRNA molecules to liver cells using GalNAc for receptor-mediated targeting. GalNAc is an amino-modified monosaccharide that binds to asialoglycoprotein receptors, or ASGPRs, with high affinity and specificity. When GalNAc-conjugated siRNA molecules reach the surface of liver cells, they are internalized in those cells, with those not internalized being excreted. Once internalized, the siRNAs specifically bind to their target mRNAs, degrading them through the cell&#8217;s natural RNAi pathway. This GalNAc-siRNA drug modality is intended to enable precision medicine through the accuracy of Watson-Crick base pairing of the siRNA to its target gene mRNA, coupled with the specificity of GalNAc-mediated delivery to the target gene-containing liver cell.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mRNAi GOLD&#153; platform uses a novel structure of double-stranded RNA with chemical modifications designed to improve the stability and efficacy of our siRNA molecules as well as to enhance delivery to targeted liver cells. We incorporate proprietary chemical modifications to enhance drug properties of our siRNA molecules, such as potency, stability and tissue distribution. We believe this approach results in a powerful modular technology that will be well-suited to tackle life-changing diseases. Particular siRNA molecules are designed to reduce the levels of a disease-associated protein directly, such as in the case of zerlasiran. In preclinical and clinical studies, zerlasiran was shown to directly reduce Lp(a) expression. Alternatively, in cases in which a disease-associated protein is normally subject to inhibition by a regulatory protein, siRNA molecules are designed to increase the levels of the disease-associated protein by silencing the inhibitory protein, thereby relieving inhibition and indirectly increasing levels of the protein normally subject to inhibition. In preclinical and clinical studies, divesiran was shown to indirectly up-regulate hepcidin levels by reducing the expression of a specific gene, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which normally inhibits the production of hepcidin. We will use this approach to address &#8216;iron loading&#8217; anemia conditions in which hepcidin expression is typically low. Using these techniques, we believe we can design siRNA molecules to decrease high protein levels, and in some cases, to increase low protein levels, depending on the particular disease genes being targeted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mRNAi GOLD&#153; Platform</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our mRNAi GOLD&#153; platform comprises elements of our GalNAc-siRNA toolbox, our liver cell targeting technology and our target selection and screening process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GalNAc-siRNA Toolbox</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our mRNAi GOLD&#153; platform is a toolbox comprising several different elements that can be incorporated into our double-stranded siRNA structure, known as blunt-ended 19-mers, either singly or in different combinations depending on individual siRNA sequences. The toolbox elements include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sugar modifications of one or more select individual nucleotides;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stabilizing modifications of one or more internucleoside linkages in the sense and antisense strands;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stabilizing modifications at one or more of the ends of the siRNA molecules; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a versatile linker chemistry for GalNAc ligand conjugation in various numbers and configurations. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When applying these elements of our toolbox, we also aim to reduce the overall content of the sugar modifications and the number of undefined stereogenic centers in the siRNA molecule.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liver Cell Targeting Technology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Blood flow and fenestra, or small openings in the endothelium, result in a large amount of the injected dose of a conjugated siRNA passing through the liver and reaching the main cell type of the liver known as a hepatocyte. Hepatocytes are cuboidal epithelial cells that line the liver sinusoids. Individual hepatocytes have approximately 0.5 to 1.0 million cell surface ASGPRs. GalNAc binds to ASGPRs with high affinity so that when GalNAc-conjugated siRNA reaches the hepatocytes, they are internalized into the cells where siRNA can bind and, as a result, can degrade the target mRNA, which in turn reduces production of the encoded protein and that protein&#8217;s activity, thereby silencing the respective gene. Only a small fraction of the initial dose reaches the hepatocyte and the right compartment of the cell, but once the siRNA is there, it can stay active and intact for several months, allowing a small number of internalized siRNA molecules to exert a potent effect on the target mRNA. We apply the toolbox elements in the lead optimization phase to identify candidates that we believe will be potent with a long duration of action and have a favorable safety profile.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Target Selection and Screening Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">able to source potential product candidates through a proprietary target selection process. The selection of new targets involves a careful analysis of human genetics evidence, the biology underlying an indication, disease epidemiology and addressable population, the current standard of care and resulting medical need, the commercial landscape and the envisaged clinical path.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our screening process relies on a proprietary </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in silico</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> algorithm that seeks to predict the most efficacious and specific siRNAs for any given target. This bioinformatics function is designed to continuously improve </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in silico</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> predictions for finding potentially potent and safe siRNA sequences. The highest scoring drug candidates subsequently undergo a multi-step evaluation process involving several rounds of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">screening in cell lines and primary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hepatocytes to identify the most potent molecules. Top candidates identified </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are then tested for safety and potential efficacy in animal models. At this point in the process, additional modification patterns and new chemistries are introduced for improvement of activity and duration of action while maintaining the desired safety profile. To be selected as a drug candidate for clinical trials, it further needs to be shown that a molecule is well tolerated, elicits no serious adverse effects, and achieves strong and long-lasting knockdown of the targeted gene in a study with non-human primates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our siRNA Product Candidates</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran (SLN124)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran is our wholly owned siRNA product candidate in Phase 2 development for PV. We believe divesiran has the potential to be the first-in-class siRNA in PV. PV is a rare myeloproliferative neoplasm - a type of blood cancer - characterized by the overproduction of blood cells and platelets, often resulting in elevated HCT. Elevated HCT above 45-percent is associated with a four-times higher rate of death from cardiovascular or thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritis and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain HCT less than 45%, a level that is associated with a reduced incidence of thrombosis and cardiovascular-associated death. The current standard of care includes repeated phlebotomies to reduce HCT and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and HCT. PV is a rare disease affecting approximately 150,000 individuals in the United States and around 3.5 million individuals worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran is administered subcutaneously and works by specifically binding to and inducing RNAi-mediated degradation of mRNAs made from the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gene. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a negative regulator of hepcidin, which is the main hormone controlling iron homeostasis in the body. By silencing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO Phase 1/2 clinical trial of divesiran in PV patients at the 66th American Society of Hematology (ASH) Annual Meeting. Interim results showed divesiran substantially reduced phlebotomy requirements and lowered HCT levels following infrequent dosing in a range of PV patients. Further, divesiran has been well tolerated to-date with no dose-limiting toxicities. In December 2024, we also announced that the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial which is currently underway. We anticipate full enrollment by year-end 2025. The FDA has granted divesiran Fast Track and orphan drug designations for PV. In December 2024, the EC granted divesiran orphan drug designation for PV in Europe.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disadvantages of existing treatment options</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary treatment goal in PV is to reduce the risk of thrombotic events by reducing hematocrit (the percent volume of red blood cells in the blood) to within target levels. The mainstay of treatment is therapeutic phlebotomy to reduce the number of blood cells by regularly removing blood from the patient. Phlebotomy results in erratic, suboptimal control of hematocrit, and regular phlebotomies can be burdensome to the patient. Patients over 60, or those with prior thrombotic events or additional cardiovascular risk factors are also treated with chemotherapy drugs (cytoreductive agents) to suppress blood cell production. The majority of these patients are treated with hydroxyurea, which is poorly tolerated and carries the risk of potential long term side effects. Patients who are resistant or intolerant to hydroxyurea may be treated with the JAK2 inhibitor ruxolitinib (Jakafi), which carries the risk of thrombocytopenia (low platelet count). Finally, some patients are treated with synthetic hepcidin mimetic dosed weekly by subcutaneous injection in clinical trials. In contrast to synthetic hepcidin mimetics, divesiran elevates endogenous hepcidin produced and secreted by the liver, avoiding high local concentrations of hepcidin at the injection site. Based on initial results from the Phase 1 portion of the SANRECO clinical trial, divesiran has shown the potential to substantially reduce phlebotomy requirements and lower HCT levels following infrequent dosing in a range of PV patients. Importantly, divesiran has also been well tolerated to-date with no dose-limiting toxicities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GEMINI Trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GEMINI trial was a randomized, double-blind, placebo controlled, single-ascending dose study to investigate the safety, tolerability, PK and PD response of divesiran (1.0, 3.0 and 4.5 mg/kg doses) administered subcutaneously in 24 healthy volunteers. Key outcomes included:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All 3 dose levels were well tolerated with no serious or severe treatment emergent adverse events, or TEAEs, leading to withdrawal. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Average hepcidin, a key endogenous regulator of iron balance and distribution, increased up to ~4-fold after a single dose with effect sustained for at least 2 months.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Serum iron reduced by ~50% after a single dose with effect sustained for at least 2 months.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran was rapidly distributed (median t</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was 4.0 or 5.0 hours) and largely eliminated from plasma within 24 hours post-dose in all dosing groups. Divesiran plasma concentrations increased in a greater than dose-linear fashion between dosing groups.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All divesiran doses induced marked reductions in transferrin saturation, or TSAT; absolute levels of TSAT achieved (10&#8211;16%) are below the level (&lt; 20%) where iron availability to tissue is restricted and at or below that (&lt; 16%) required to support normal erythropoiesis in health.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GEMINI II Phase 1 Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The GEMINI II Phase 1 clinical trial evaluated divesiran in non-transfusion dependent thalassemia patients. In the trial, divesiran was  observed to be well tolerated with no safety issues identified. While proof of mechanism has been established in healthy volunteers, the effects on indicators of iron metabolism were variable in the trial population of heterogeneous thalassemia subjects. Accordingly, we have made the decision to prioritize R&amp;D efforts related to the ongoing PV program and do not have plans to advance development in thalassemia at this time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SANRECO Phase 1/2 Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SANRECO is </span><span style="color:#171716;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">P</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">hase 1/2 clinical trial with an open-label dose escalation phase followed by a randomized placebo controlled and double-blind phase of divesiran in PV patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 portion of the SANRECO clinical trial is a 34-week, open-label study evaluating divesiran (3 mg/kg, 6 mg/kg and 9 mg/kg) administered subcutaneously every six weeks for four doses, with a 16-week follow-up period following the date of the last administered dose in 21 PV patients. Key inclusion criteria include a PV diagnosis and a history of requiring at least three phlebotomies in the last six months or five phlebotomies in the last year prior to screening. Patients are allowed to be on stable doses of cytoreductive agents. Given the exploratory nature of this Phase 1 clinical trial, both well-controlled patients - defined as those with HCT levels at 45% or less &#8211; as well as those with HCT levels greater than 45% at baseline on current standard of care treatment were enrolled.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we presented positive interim results from the Phase 1 Portion of the SANRECO Phase 1/2 clinical trial of divesiran in 19 PV patients at the 66</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ASH Annual Meeting. Interim results showed divesiran substantially reduced phlebotomy requirements and lowered HCT levels following infrequent dosing in a range of PV patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interim results included 19 PV patients with a combined history of 79 phlebotomies prior to enrolment. Following dosing with divesiran , only five phlebotomies occurred during the 18-week treatment period and all five occurred in patients who entered the trial with high baseline HCT levels (over 45%). Two phlebotomies occurred in the 16-week follow-up period following the last administered dose.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A sustained reduction in HCT during the treatment period and favorable effects on indices of iron metabolism were observed. Hepcidin levels increased and were sustained within physiological levels in all dose groups, demonstrating consistent target engagement.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran continues to be well tolerated to-date with no dose limiting toxicities.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 1 portion of the SANRECO clinical trial completed follow-up in February 2025. Phase 1 data presentations are planned for medical congresses in 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we also announced the first subject has been dosed in the Phase 2 portion of the SANRECO clinical trial which is currently underway. We anticipate full enrollment by year-end 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zerlasiran (SLN360)</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zerlasiran is an siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. Available human data validate Lp(a) as an independent risk factor increasing the chances of developing premature cardiovascular diseases, including coronary heart disease and unstable angina, as well as myocardial infarction and ischemic stroke. Zerlasiran is administered by subcutaneous injection and has the potential to reduce these diseases by specifically binding to and inducing RNAi-mediated degradation of the mRNAs made from </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the gene that encodes apolipoprotein(a), a protein specifically found in Lp(a). Zerlasiran&#8217;s mode of action creates an opportunity to develop this product candidate for several indications for which Lp(a) has been shown to be a causal, independent risk factor.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Elevated levels of Lp(a) &#8805; 125 nmol/L or approximately 50mg/dL are considered to affect at least 20% of the world&#8217;s population. The incidence of elevated Lp(a) is thought to be higher in people with established cardiovascular disease and calcific aortic valvular stenosis. Additionally, elevated Lp(a) concentrations are associated with an increased risk of myocardial infarction and ischemic stroke, particularly in stroke patients 55 years of age and younger. There is a genetic link between plasma Lp(a) level and cardiovascular risk. Mutations that genetically cause elevated Lp(a) levels have been linked with increases in myocardial infarction, ischemic stroke, carotid stenosis, peripheral arterial disease (including femoral artery stenosis), abdominal aortic aneurysm, obstructed coronary vessels (i.e. coronary atherosclerotic burden), earlier onset of coronary artery disease, cardiovascular and all-cause mortality, increased risk of heart failure and reduced longevity. Importantly, these causal relationships are independent of concentrations of other lipids and lipoproteins, including low-density lipoprotein, or LDL, and conventional cardiovascular disease risk factors. Conversely, a genetically determined decrease in Lp(a) has been associated with a 29% lower risk of coronary artery disease, 31% lower risk of peripheral vascular disease, 17% lower risk of heart failure, 13% lower risk of stroke and a 37% lower risk of aortic stenosis.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Phase 1 and 2 clinical trials, zerlasiran has shown the potential to substantially reduce Lp(a) levels in ASCVD patients, with maximum reductions exceeding 90% during the treatment period and effects persisting 60 weeks following first dose. Zerlasiran continues to be well tolerated to-date with no major safety issues. Based on clinical data generated to-date, we believe zerlasiran has promising potential to address major unmet needs in cardiovascular disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disadvantages of existing treatment options</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lp(a) is not susceptible to lifestyle changes and there are no currently available pharmacological treatments that cause an appreciable reduction in Lp(a). The only existing treatment to reduce Lp(a) is apheresis, which involves the removal of blood plasma from the body by the withdrawal of blood, its separation into plasma and cells, and the reintroduction of the cells, used especially to remove antibodies in treating autoimmune diseases. This process can take between two and four hours and is performed every one to two weeks. Consequently, it is invasive and burdensome for patients, and it is only available at limited centers at a high cost. Apheresis is primarily used in Europe and it is not incorporated in the treatment guidelines in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no approved lipid-lowering agents specific to Lp(a). Several non-specific agents, largely targeting LDL cholesterol, have been observed to have only marginal or modest Lp(a) reductions, including ezetimibe (7%), niacin therapy (23%), cholesteryl ester transfer protein, or CETP, inhibitors (25-60%), and antisense oligonucleotide-mediated inhibition of apolipoprotein B (ApoB) by mipomersen (26%). Additionally, two monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9, or PCSK9, have been observed to reduce Lp(a)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">levels by 20%-30%. However, randomization studies have suggested that to produce a clinically significant reduction in cardiovascular risk, a larger reduction in Lp(a) may be required, something that we believe may be achieved by targeted RNA-based approaches such as ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">APOLLO Phase 1 Clinical Program</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The APOLLO Phase 1 clinical program was a global randomized, double-blind, placebo controlled, single-ascending dose and multiple-ascending dose study investigating the safety, tolerability, pharmacodynamic and pharmacokinetic response of zerlasiran administered subcutaneously in healthy adults and ASCVD patients with high Lp(a) levels of approximately greater than 60mg/dL or less than 150 nmol/L.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2022, we presented positive results from the single-ascending dose portion of the APOLLO Phase 1 program in 32 healthy adults with high Lp(a) greater than 150 nmol/L in a late-breaking presentation at the American College of Cardiology, or ACC, Annual Scientific Session &amp; Expo. Results were simultaneously published in The Journal of American Medical Association, or JAMA. In the single dose trial, participants in the top two dose groups (300 mg and 600 mg) were observed to have experienced up to a 96% and 98% median reduction in Lp(a) levels, respectively, and median reductions of up to 71% and 81% from baseline persisted at 150 days. Other efficacy measures included the effects of zerlasiran on low-density lipoprotein cholesterol (LDL cholesterol) and ApoB, both of which are associated with an increased risk of cardiovascular events. The highest doses of zerlasiran reduced LDL cholesterol and ApoB by about 25%.</span><span style="color:#003b4c;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#003b4c;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the trial, z</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erlasiran was observed to be well tolerated with no serious safety concerns reported. In November 2022, we presented a further analysis from the APOLLO trial up to 365 days at the American Heart Association&#8217;s 2022 Annual Scientific Sessions. This analysis showed median time-averaged Lp(a) reductions over 150 days exceeded 80% in the zerlasiran 300 mg and 600 mg dose groups. At day 365, some participants still exhibited substantially reduced levels of Lp(a) of approximately 50% compared to baseline. Additionally, the extension data we presented related to dosing of zerlasiran to day 365 showed no new drug related safety findings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we reported positive results from the multiple-ascending dose portion of the APOLLO program in 36 adults with stable ASCVD and high Lp(a) greater than 150 nmol/L. In the multiple dose trial, zerlasiran (200 mg, 300 mg and 450 mg) was administered twice subcutaneously at two different dosing intervals to ASCVD patients. This data demonstrated a significant reduction from baseline in Lp(a) of up to 99% at 90 days following injection of repeated doses. Lp(a) levels remained approximately 90% lower than baseline at 201 days (end of treatment period) at the two highest doses. A dose dependent reduction in low-density lipoprotein cholesterol, or LDL cholesterol, and apolipoprotein B, or ApoB, was also observed. Zerlasiran continued to be observed to be well tolerated with no serious safety issues identified.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, additional results from the APOLLO Phase 1 program were published in the JAMA and our analysis showed that zerlasiran was observed to be well tolerated and significantly reduced Lp(a) after single and multiple dosing regimens.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ALPACAR-360 Phase 2 Clinical Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ALPACAR-360 Phase 2 clinical trial was a randomized, double-blind, placebo-controlled trial in 178 patients with high Lp(a) greater than 125nmol/L at high risk of ASCVD events. Baseline Lp(a) concentration was 213 nmol/L. Patients were randomly assigned to one of three active subcutaneous doses of zerlasiran (300 mg Q16 weeks, 300 mg Q24 weeks, 450 mg Q24 weeks) or placebo. The primary endpoint was time-averaged change in Lp(a) from baseline to 36 weeks. Secondary endpoints included time-averaged changes in LDL-C as well as time-averaged Lp(a) to 48 weeks (end of treatment period) and 60 weeks (end of study). This is the first study to report time-averaged Lp(a) analyses, which more accurately evaluates the effects of treatment over time, including intervals between doses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, positive results from the ALPACAR-360 Phase 2 clinical trial were presented at the American Heart Association&#8217;s 2024 Scientific Sessions and simultaneously published in JAMA. Results from the study showed that zerlasiran produced greater than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over 36 weeks. Maximum Lp(a) reductions exceeded 90%. At the final visit, 60 weeks following initial drug administration, reductions in Lp(a) persisted with infrequent dosing. Zerlasiran was also observed to reduce</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time-averaged LDL-C by ~25-30% and Apo B by ~10-15%.</span><span style="color:#000000;white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our analysis showed that zerlasiran was observed to be well tolerated with no major safety issues identified.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 Preparedness</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter 2024, we received positive regulatory feedback from the FDA and EMA on the Phase 3 cardiovascular outcomes study design for zerlasiran in patients with high Lp(a). We also progressed core Phase 3 readiness activities for zerlasiran, including the scale up of product supply to enable the full start-up of the Phase 3 CVOT study in the first half of 2025. Partnering discussions for this program are ongoing; timing for Phase 3 initiation is dependent on partnership.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborations</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AstraZeneca</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, we entered into a collaboration agreement with AstraZeneca to discover, develop and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020. AstraZeneca made an additional unconditional cash payment to us of $40.0 million which was received in May 2021. In March 2020, an affiliate of AstraZeneca also subscribed for 4,276,580 new ordinary shares for an aggregate subscription price of $20.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collaboration covers five targets initially, with AstraZeneca having the option to extend the collaboration to a further five targets. AstraZeneca has agreed to pay us $10.0 million upon the exercise of each option to collaborate on an additional target. In May 2023, AstraZeneca nominated the first product candidate under our collaboration, triggering a $10 million option fee to us to advance development on an undisclosed program. In February 2024, AstraZeneca initiated a Phase 1 clinical trial for this undisclosed program which triggered another $10 million milestone payment to us. In March 2024, we completed our obligations for the second product candidate under the collaboration. For each target selected, we will be eligible to receive up to $140.0 million in potential milestone payments upon the achievement of milestones relating to the initiation of specified clinical trials, the acceptance of specified regulatory filings and the first commercial sale in specified jurisdictions. For each target selected, we will also be eligible to receive up to $250.0 million in potential commercial milestone payments, upon the achievement of specified annual net sales levels, as well as tiered royalties as a percentage of net sales ranging from the high single digits to the low double digits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mallinckrodt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2019, we entered into a collaboration agreement with Mallinckrodt to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. In connection with the execution of this agreement, Mallinckrodt made an upfront cash payment to us of $20.0 million. Under a separate subscription agreement, Cache Holdings Limited, a wholly owned subsidiary of Mallinckrodt, concurrently subscribed for 5,062,167 new ordinary shares for an aggregate subscription price of $5.0 million. Under the agreement, we granted Mallinckrodt an exclusive worldwide license to our C3 targeting program, SLN501, with options to license two additional undisclosed complement-mediated disease targets from us. In July 2020, Mallinckrodt exercised options on the two additional complement targets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, we reacquired exclusive worldwide rights from Mallinckrodt to the two undisclosed preclinical complement targets. Under the terms of the modified agreement, we did not make any upfront payment to get the two assets back and will potentially pay future success-based milestones and low single digit royalties on net sales if the projects advance. SLN501, the C3 targeting program, remained under the original collaboration agreement. In March 2024, Mallinckrodt notified us that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial. This completion also concludes all required development activities and commitments under the collaboration.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hansoh</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2021, we announced a collaboration agreement with Hansoh, one of the leading biopharmaceutical companies in China, to develop siRNAs for three undisclosed targets leveraging our proprietary mRNAi GOLD&#153; platform. Under the terms of the agreement, Hansoh will have the exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of phase 1 trials. We will retain exclusive rights for those two targets in all other territories. We are responsible for all activities up to option exercise and will retain responsibility for development outside the China region post phase 1 trials. Hansoh will also have the exclusive option to license global rights to a third target at the point of IND filing. Hansoh will be responsible for all development activities post option exercise for the third target. Hansoh made a $16 million upfront payment to us in December 2021. We achieved our first $2 million research milestone payment in the Hansoh collaboration in April 2022. In 2023, we achieved two additional preclinical milestones and received $4 million from the collaboration. In 2024, we achieved an additional preclinical milestone of $2.0 million from the Hansoh Collaboration. In December 2024, Hansoh notified us that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration and we will retain exclusive rights globally for all three targets.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The life sciences industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Many of our competitors may have greater experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do, and may be better resourced financially. Any product candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and recruiting lead clinical trial investigators and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies that complete clinical trials, obtain required regulatory authority approvals and commence commercial sale of their drugs before their competitors may achieve a significant competitive advantage, and our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop and commercialize. Our competitors also may obtain FDA, European Commission or other regulatory approval for their products more rapidly than we obtain approval, which could result in our competitors establishing a strong market position for either the product or a specific indication before we are able to enter the market. Drugs resulting from our research and development efforts or from our joint efforts with collaboration partners therefore may not be commercially competitive with our competitors&#8217; existing products or products under development. Because our products and many potential competing products are in various stages of preclinical and clinical development, and given the inherent unpredictability of drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider a number of companies to be our competitors in developing RNAi therapeutic products. Some of these companies are seeking, as we are, to develop chemically synthesized siRNA molecules as drugs. Others are following a gene therapy approach, with the goal of treating patients not with synthetic siRNAs but with synthetic, exogenously-introduced genes designed to produce siRNA-like molecules within cells. Additionally, other companies may also develop alternative treatments for the diseases we have identified as being potentially treated with our siRNA molecules. To the extent those alternative treatments are more efficacious, less expensive, more convenient or produce fewer side effects, our market opportunity would be reduced.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that we will face intense and increasing competition as new products and therapies enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, delivery, patient friendliness, price and the availability of reimbursement from government and other third-party payers.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patents</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, including seeking, maintaining, enforcing and defending patent rights and protecting our related know-how for our siRNA platform technologies such as siRNA stabilization chemistries, as well as for our specific siRNA targeting sequences and related therapeutics and processes, whether developed internally or licensed to third parties. Our success will depend on our ability to obtain and maintain patent and other protections including data/market exclusivity for our product candidates and platform technology, preserve the confidentiality of our know-how and operate without infringing the valid and enforceable patents and proprietary rights of third parties. See the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk Factors-Risks Related to Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221; section of this report.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our policy is to seek to protect our proprietary position early, generally by filing an initial priority filing in the European Patent Office. This is followed by the filing of one or more international patent applications, including a patent application under the Patent Cooperation Treaty, or PCT, claiming priority from the initial application(s) and then filing regional and national applications for patent grant in territories including, for example, the United States and Europe. In each case, we determine the strategy and territories required after discussion with our patent attorneys and collaboration partners so that we obtain relevant coverage in territories that are commercially important to our technologies and product candidates. With respect to our product candidates and related methods that we intend to develop and commercialize in the normal course of business, we will seek patent protection covering, when legally possible, siRNA sequences alone and with chemical modifications, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes when possible. We intend to additionally rely on data exclusivity, market exclusivity, other regulatory exclusivities and patent term extensions when available. We also rely on trade secrets and know-how relating to our underlying platform technology and product candidates. In each case, we seek to balance the value of patent protection against the advantage of keeping know-how confidential.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issued patents can provide exclusivity on claimed subject matter for varying periods of time, typically starting on the date of patent grant and expiring at the end of the legal term of a patent in the country in which it is granted. In general, patents provide exclusionary rights for 20 years from the effective filing date of a non-provisional patent application in a particular country, or for a PCT international patent application, from the international filing date, assuming all maintenance fees are paid. In some instances, patent terms may be increased or decreased, depending on the laws and regulations of the country or jurisdiction that grants the patent. In the United States, a patent term may be shortened if a patent is terminally disclaimed over another patent or as a result of delays in patent prosecution by the patentee. A U.S. patent&#8217;s term may be lengthened by a patent term adjustment, which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or USPTO, in granting a patent. The patent term of a European patent is 20 years from its effective filing date, which, unlike in the United States, is not subject to patent term adjustments in the same way as U.S. patents.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The level of protection afforded by a patent may vary and depends upon many factors, including the type of patent, the scope of its claim coverage, claim interpretation and patent law in the country or region that granted the patent, the validity and enforceability of the patent under such laws, and the availability of legal remedies in each particular country.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain regions or countries, regulatory-related patent extensions may be available to extend the term of a patent that claims an approved product or method. Regulatory-based patent term extensions allow patentee to recapture a portion of patent term effectively lost as a result of the regulatory review period for a product candidate. The term of a U.S. patent that covers an FDA-approved drug or biologic, for example, may be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug or biologic is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe, Japan, China and other jurisdictions to extend the term of a patent that covers an approved drug, for example Supplementary Protection Certificates in Europe. In very few jurisdictions (such as in the U.S. and Europe), patent or regulatory exclusivities may potentially be further extended by a pediatric extension, to give an additional six months&#8217; extension, if pre-defined clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">data for a pediatric indication are timely submitted and accepted. In the future, if and when our products receive FDA approval, we expect to apply for regulatory patent term extensions on patents covering those products. We anticipate that some of our issued patents may be eligible for patent term extensions in certain jurisdictions based on an approved product or method, but such extensions may not be available and therefore its commercial monopoly may be restricted solely to patent term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we solely owned 62 granted patents (221 including European Patent office national validations), of which 14 are U.S. issued patents; and we owned 150 pending patent applications (138 are solely owned and 12 have co-applicants), 11 of which are pending U.S. applications, 10 of which are solely owned. Also of December 31, 2024, we solely owned six priority applications (priority year</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pending). Commercially or strategically important non-U.S. jurisdictions in which we hold issued or pending patent applications include (in addition to Europe): Australia, Brazil, Canada, Chile, China, Colombia, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa, South Korea, Taiwan, Ukraine and Vietnam.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our granted</span><span style="color:#000000;white-space:pre-wrap;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patents and pending patent applications include compositions of matter claims directed to siRNA molecules and compositions. They also include claims directed to siRNA molecules having specific nucleic acid modifications and linkers as well as specific nucleic acid sequences. In addition, our pending patent applications with an effective filing date after 2003 also include claims directed to methods of use and processes relating to such siRNA molecules and compositions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our earliest filed patent applications directed to 19-mer blunt-ended siRNAs with particular siRNA modification patterns expired in August 2023. Our current patent application families directed to siRNA chemistry toolbox elements, if and when granted, would not be expected to expire until at least 2036. Our current patent families covering siRNA sequences directed to specific target genes and associated uses for our SLN360 and SLN124 product candidates, if and when granted, would not be expected to expire until at least 2038.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval of New Drug Products in the United States</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and non-U.S. statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the drug development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve a pending NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled clinical trials, in accordance with GCP requirements to establish the safety and efficacy of the proposed drug for each indication;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payment of user fees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with the current good manufacturing practice, or cGMP, requirements, and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection of selected clinical sites to assure compliance with GCPs and the integrity of the clinical data; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Studies</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential pharmacology and toxicology. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some nonclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may result in the FDA not allowing clinical trials to commence.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to oversee the clinical trial while it is being conducted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In phase 1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial indication of its effectiveness. In phase 2, the drug typically is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. In phase 3, the drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the safety and efficacy of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted, at least annually, to the FDA, and more frequently if SAEs occur. Phase 1, phase 2 and phase 3 clinical trials might not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements, or if the drug has been associated with unexpected serious harm to patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Approval</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the Pediatric Research Equity Act, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to a product for an indication with orphan designation.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits of the drug outweigh its risks. The REMS could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The testing and approval process for an NDA requires substantial time, effort and financial resources, and takes several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval of an NDA on a timely basis, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs of developing and making the drug available in the United States. Orphan drug designation must be requested before submitting an NDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the FDA approves a sponsor&#8217;s marketing application for a designated orphan drug for use in the rare disease or condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during which the FDA may not approve another sponsor&#8217;s marketing application for a drug with the same active moiety and intended for the same disease or condition as the approved orphan drug, except in limited circumstances, such as if a subsequent sponsor demonstrates its product is clinically superior. During a sponsor&#8217;s orphan drug exclusivity period, competitors, however, may receive approval for drugs with different active moieties for the same disease or condition as the approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different diseases or conditions. A competitor&#8217;s orphan drug exclusivity could block the approval of one of our products for seven years if the competitor obtains approval for a drug with the same active moiety intended for the same disease or condition before we do, unless we are able to demonstrate that grounds for revocation of the competitor&#8217;s orphan drug designation and orphan drug exclusivity exist, or that our product is clinically superior. Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or condition for which it received orphan drug designation, it may not be entitled to exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, many changes to the approved product, such as adding new indications, manufacturing changes or certain labeling changes, are subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee requirements for any marketed products.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that post-approval studies, including phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety or effectiveness information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, untitled letters, warning letters or holds on post-approval clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations and Foreign Equivalents</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and regulations restrict business practices in the biopharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products for which we obtain marketing approval. These laws include anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations, including, without limitation, those laws described below.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting some common activities from prosecution, the exemptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal false claims laws, including the federal civil False Claims Act, prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of products for unapproved, and thus non-reimbursable, uses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, imposes specified requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity and their covered subcontractors. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys' fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, as well as state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to foreign equivalents of all of the above federal or state legislation. For example, outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement in the United States</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The future commercial success of our product candidates or any of our collaborators&#8217; ability to commercialize any approved product candidates successfully will depend in part on the extent to which governmental payer programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payers provide coverage for and establish adequate reimbursement levels for our product candidates. Government health administration authorities, private health insurers and other organizations generally decide which drugs they will pay for and establish reimbursement levels for healthcare. In particular, in the United States, private health insurers and other third-party payers often provide reimbursement for products and services based on the level at which the government, through the Medicare or Medicaid programs, provides reimbursement for such treatments. In the United States, the European Union, and other potentially significant markets for our product candidates, government authorities and third-party payers are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and pricing in general.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party payers are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for medical products. For example, federal and state governments reimburse covered prescription drugs at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of healthcare services and products. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#8217;s determination to provide coverage for a drug product does not assure that other payers will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our products and product candidates or exclusion of our product candidates from coverage. The cost containment measures that healthcare payers and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part. Further, coverage policies and third-party payer reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for products for which we receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been several U.S. government initiatives over the past several years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of our product candidates. If third-party payers do not</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consider our product candidates to be cost-effective compared to other available therapies, they may not cover our product candidates, once approved, as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our product on a profitable basis.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. These and other healthcare reform initiatives may result in additional reductions in Medicare and other healthcare funding. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate price cap, previously set at 100% of a drug&#8217;s average manufacturer price for single source and innovator multiple source products, effective on January 1, 2024. In addition, on August 16, 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. Additionally, the IRA, among other things, (i) directs the U.S. Department of Health and Human Services, or HHS, to negotiate the price of certain high-expenditure, single-source drugs that have been on the market for at least 7 years covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law (the &#8220;Medicare Drug Price Negotiation Program&#8221;), and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. On January 17, 2025, HHS selected fifteen additional products covered under Part D for price negotiation in 2025. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Individual states in the United States also have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program, or SIP, proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. It is possible that other healthcare reform measures may be adopted in the future, particularly in light of the recent U.S. Presidential and Congressional elections.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Corrupt Practices Act, the Bribery Act and Other Laws</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from government contracts.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations are also subject to non-U.S. anti-corruption laws such as the Bribery Act. As with the FCPA, these laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as trade control laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with the Bribery Act, the FCPA and other anti-corruption laws and trade control laws could subject us to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Review and Approval of New Drug Products in the European Union</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, medicinal products are subject to extensive pre- and post-market regulation by regulatory authorities at both the European Union and national levels. An evolving global regulatory view on the classification of RNA therapies could impact the requirements applied to our siRNA compounds. Additionally, there may be local legislation in various EU Member States, which may be more restrictive than the EU legislation, and we would need to comply with such legislation to the extent it applies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trials</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials of medicinal products in the European Union must be conducted in accordance with EU and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials must be manufactured in accordance with the guidelines on cGMP and in a GMP licensed facility, which can be subject to GMP inspections. The sponsor of clinical trials must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#8220;no fault&#8221; compensation to any study subject injured in the clinical trial.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014, or CTR, which entered into application on January 31, 2022, repealing and replacing the Clinical Trials Directive 2001/20/EC, or CTD. The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and relates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CTR foresaw a three-year transition period that ended on January 31, 2025. Since this date, all new or ongoing trials are subject to the provisions of the CTRD during the development of a medicinal product, the EU and national medicines regulators within the European Union provide the opportunity for dialogue and guidance on the development program. At the EU level, developers of medicinal products can ask the EMA for scientific advice and protocol assistance at any stage of development and regardless of whether the medicinal product is eligible for the centralized authorization procedure or not. Assistance is given by the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but this can be waived for orphan medicinal products. Advice from the EMA is provided</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">based on questions concerning, quality aspects (manufacturing, chemical, pharmaceutical and biological testing of the medicine ), nonclinical testing (toxicological and pharmacological tests designed to show the activity of the medicine in the laboratory) and clinical aspects (appropriateness of studies in patients or healthy volunteers, selection of endpoints), methodological issues (statistical tests to use, data analysis, modelling and simulation), overall development strategy (conditional marketing authorization, bridging strategy for generics, safety database), significant benefit for maintaining orphan designation, and pediatric developments. To the extent that we do obtain such scientific advice in the future, while the company is expected to respect the outcome of the scientific advice procedure, such advice is not legally binding.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketing Authorizations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, medicinal products can only be commercialized after a related marketing authorization, or MA, has been granted. To obtain an MA for a product in the EU, an applicant must submit a Marketing Authorization Application, or MAA, either under a centralized procedure administered by the European Medicines Agency, or EMA, or one of the procedures administered by the competent authorities of EU Member States (decentralized procedure, national procedure or mutual recognition procedure). An MA may be granted only to an applicant established in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA (which is comprised of the 27 EU Member States plus Norway, Iceland and Liechtenstein). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for (i) medicinal products derived from biotechnological processes, (ii) products designated as orphan medicinal products, (iii) advanced therapy medicinal products, or ATMPs, and (iv) products with a new active substance indicated for the treatment of HIV/AIDS, cancer, neurodegenerative diseases, diabetes, auto-immune and other immune dysfunctions and viral diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use, or CHMP, conducts the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing MA. The maximum timeframe for the evaluation of an MAA under the centralized procedure is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product targeting an unmet medical need is expected to be of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts a request for accelerated assessment, the time limit of 210 days will be reduced to 150 days (excluding clock stops). The CHMP can, however, revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unlike the centralized authorization procedure, the decentralized MA procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the Heads of Medicines Agencies&#8217; Coordination Group for Mutual Recognition and Decentralised Procedures &#8211; Human, or CMDh, for review. The subsequent decision of the European Commission is binding on all EU Member States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States. Like the decentralized procedure, the mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the MA of a medicinal product by the competent authorities of other EU Member States. The holder of a national MA may submit an application to the competent authority of an EU Member State requesting that this authority recognize the MA delivered by the competent authority of another EU Member State.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An MA has, in principle, an initial validity of five years. The MA may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State in which the original MA was granted. To support the application, the MA holder must provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data concerning the quality, safety and efficacy of the product, including all variations introduced since the MA was granted, at least nine months before the MA ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period for the MA. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for a centralized MA) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines, or PRIME, scheme, which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional MA for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional MA can be converted into a traditional MA. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the MA will cease to be renewed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An MA may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data may be contrary to generally accepted ethical principles. Like a conditional MA, an MA granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard MA. However, unlike the conditional MA, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the MA &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the MA will be withdrawn if the risk-benefit ratio is no longer favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Data Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EU provides opportunities for data and market exclusivity related to MAs. Upon receiving an MA, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial MA of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes. For such products, the results of appropriate preclinical or clinical trials must be provided in support of the MAA, and guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently be approved in the European Union. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge and regulatory experience gained at the time.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Development</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#8217;s Pediatric Committee or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate, or SPC, if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Designation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a medicinal product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (i) the product is intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions; (ii) either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b) the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation (EC) No 847/2000 sets out further provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product. An application for the designation of a medicinal product as an orphan medicinal product must be submitted at any stage of development of the medicinal product but before filing of an MAA. An MA for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10 year period if: (i) if the applicant consents to a second original orphan medicinal product application, (ii) if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii) if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Controls</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports, or PSURs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All new MAAs must include a risk management plan, or RMP, describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pricing and Reimbursement in the European Union</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governments influence the price of medicinal products in the European Union through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. This Health Technology Assessment, or HTA, process is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. In December 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA Regulation, was adopted. The HTA Regulation is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The HTA Regulation entered into application on January 12, 2025, through a phased implementation based on the type of product (i.e. oncology and advanced therapy medicinal products as of 2025, orphan medicinal products as of 2028, and all other medicinal products by 2030) and is intended to harmonize the clinical benefit assessment of HTA across the European Union. Other EU Member States allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription medicines, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory Framework in the United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023, confirming that it would bring forward changes to the legislation and such changes were laid in parliament on December 12, 2024. These resulting legislative amendments will, if implemented in their current form, bring the UK into closer alignment with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketing authorizations in the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are governed by the Human Medicines Regulations (SI 2012/1916), as amended. Since January 1, 2021, an applicant for the EU's centralized procedure marketing authorization can no longer be established in the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As a result, since this date, companies established in the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cannot use the EU's centralized procedure. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to obtain a United Kingdom MA to commercialize products in the United Kingdom, an applicant</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> must </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be established in the United Kingdom and must </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">follow one of the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">United Kingdom </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">national authorization procedures or one of the remaining post-Brexit international cooperation procedures</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Applications are governed by the Human Medicines Regulations (SI 2012/1916) and are made electronically through the MHRA Submissions Portal. The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, a 150-day assessment (subject to clock-stops) and a rolling review procedure. The rolling-review procedure permits the separate or joint submission of quality, non-clinical, and clinical data to the MHRA which can be reviewed on a rolling basis. After an application under the rolling-review procedure has been validated, the decision should be received within 100 days (subject to clock-stops).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, since January 1, 2024, the MHRA may rely on the International Recognition Procedure (&#8220;IRP&#8221;), when reviewing certain types of MAAs. Pursuant to the IRP, the MHRA will take into account the expertise and decision-making of trusted </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> partners (e.g., the regulatory in Australia, Canada, Switzerland, Singapore, Japan, the U.S.A. and the EU). The MHRA will conduct a targeted assessment of IRP applications but retain the authority to reject applications if the evidence provided is considered insufficiently robust. The IRP allows medicinal products approved by such trusted regulatory partners that meet certain criteria to undergo a fast-tracked MHRA review to</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain and/or update a MA in the United Kingdom. Applications should be decided within a maximum of 60 days if there are no major objections identified that cannot be resolved within such 60-day period and the approval from the trusted regulatory partner selected has been granted within the previous 2 years or if there are such major objections identified or such approval hasn&#8217;t been granted within the previous 2 years within 110 days. Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures including line extensions, variations and renewals.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All existing marketing authorizations of the EU for centrally authorized products were automatically converted or grandfathered into the United Kingdom&#8217;s marketing authorization, effective in Great Britain only, free of charge on January 1, 2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland remained within the scope of authorizations of the EU in relation to centrally authorized medicinal products until January 1, 2025. However, on January 1, 2025, a new arrangement as part of the so-called &#8220;Windsor Framework&#8221; came into effect and reintegrated Northern Ireland under the regulatory authority of the MHRA with respect to medicinal products. The Windsor Framework removes EU licensing processes and EU labeling and serialization requirements in relation to Northern Ireland and introduces a UK-wide licensing process for medicines.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU but have been tailored for the market. This includes the criterion that prevalence of the condition in the United Kingdom, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in the United Kingdom.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Source of Supply</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates. Furthermore, there is limited capacity at contract manufacturers that operate under the cGMP requirements of the FDA to meet our timelines and production needs. We currently rely and intend to continue to rely on contract development and manufacturing organizations, or CDMOs, for both drug substance and drug product. Currently, we contract with eleven third-party manufacturers for the manufacture of our development pipeline. We may engage additional third-party manufacturers to support any clinical trials for our product candidates as well as commercialization thereof, if approved, in the U.S. or other jurisdictions. In addition, as our production needs increase, we intend to recruit additional experienced personnel to manage the CDMOs producing our product candidate and other product candidates or products that we may develop in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on CDMOs to perform all chemistry, manufacturing, and controls activities. Our agreements with CDMOs may obligate them to develop or transfer upstream and downstream processes, develop or transfer drug product manufacturing processes, develop or transfer suitable analytical methods for release and stability testing and qualify these methods for use with our products, produce drug substance for preclinical testing, and produce drug substance or drug product under cGMP for use in clinical studies among other activities. In addition, we rely on CDMOs to operate facilities that meet regulatory requirements for production and testing of clinical and commercial products and to work closely with us to validate manufacturing processes prior to commercial launch. We qualify CDMOs prior to initiation of cGMP regulated activities and periodically thereafter as part of the supplier qualification program. We oversee CDMOs by performing technical and quality assurance review and/or approval of cGMP documentation, establishing quality agreements to define responsibilities and expectations for goods and services, and observing production and testing activities as a person-in-plant, among other activities.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 116 full-time employees who work primarily in the United Kingdom, Germany and the United States. Of these employees, 85 are engaged in research and development activities and 31 are engaged in business development, finance, information systems, facilities, human resources or administrative support. Further, we have 37 employees who hold MD or Ph.D. degrees. None of our employees are subject to collective bargaining agreements. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate employees and directors through the granting of equity-based compensation awards.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated as a public limited company under the laws of England and Wales on November 18, 1994, under the name Stanford Rook Holdings plc with company number 2992058. In July 2005, we acquired Atugen AG, a company specializing in siRNA. On April 26, 2007, we changed our name to Silence Therapeutics plc. Our principal executive offices are located at 72 Hammersmith Road, London W14 8TH, United Kingdom and our telephone number is +44 20 3457 6900. Our registered office address is 27 Eastcastle Street, London, W1W 8DH, United Kingdom. Our ADSs were listed on the Nasdaq Capital Market under the symbol &#8220;SLN&#8221; in September 2020. In June 2021, we moved our Nasdaq listing from the Nasdaq Capital Market tier to the Nasdaq Global Market tier. In November 2021, the admission of the Company&#8217;s ordinary shares to trading on AIM of the London Stock Exchange was cancelled. Our website address is www.silence-therapeutics.com. Our agent for service of process in the United States is Silence Therapeutics Inc., c/o Harvard Business Services, Inc., 16192 Coastal Hwy, Lewes, Delaware 19958, USA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Annual Report on Form 10-K (formerly on Form 20-F), Quarterly Reports on Form 10-Q, Current Reports on Form 8-K (formerly on Form 6-K), and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are filed with the Securities and Exchange Commission, or the SEC. Such reports and other information filed by us with the SEC are available free of charge on our website at www.silence-therapeutics.com when such reports are available on the SEC&#8217;s website. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. The information contained on the websites referenced in this Annual Report is not incorporated by reference into this filing. Further, our references to website URLs are intended to be inactive textual references only.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1A. Risk F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actors</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing in American Depositary Shares representing our ordinary shares, or ADSs, involves a high degree of risk. You should carefully consider the following risk factors and all other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, before investing in the ADSs. The risks and uncertainties described below are those significant risk factors, currently known and specific to us, that we believe are relevant to an investment in the ADSs. If any of these risks materialize, our business, results of operations or financial condition could suffer, the price of the ADSs could decline and you could lose part or all of your investment. Additional risks and uncertainties not currently known to us or that we now deem immaterial may also harm us and adversely affect your investment in the ADSs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The risks described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See also the section titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Condition and Need for Additional Capital</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a history of net losses, and we anticipate that we will continue to incur significant losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biopharmaceutical company. As of the date hereof, our operations have been primarily limited to developing our siRNA product platform, undertaking basic research around siRNA targets, conducting preclinical and clinical studies and out-licensing some of our intellectual property rights. We have not yet obtained marketing approval for any product candidates and may not for the foreseeable future, if ever. Consequently, any predictions about our future success or viability, or any evaluation of our business and prospects, may not be accurate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred net losses in each year since our inception. Our net losses were $45.3 million for the year ended December 31, 2024, $54.2 million for the year ended December 31, 2023, and $50.3 million for the year ended December 31, 2022. As of December 31, 2024, we had an accumulated loss of $474.0 million. Our losses have resulted primarily from costs related to our research and development programs, including our preclinical and clinical development activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue incurring significant operating losses for the foreseeable future, although these losses may fluctuate significantly between periods. We anticipate that our expenses will increase substantially as we continue the research, preclinical and clinical development of our product candidates, both independently and under our collaboration agreements with third parties. We would also incur additional expenses in connection with seeking marketing approvals for any product candidates that successfully complete clinical trials, if any, and establishing a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval. We will also need to maintain, expand and protect our intellectual property portfolio, hire additional personnel, and create additional infrastructure to support our operations and our product development efforts. We expect that all of these additional expenses will cause our total expenses to substantially exceed our revenue over the near term, resulting in continuing operating losses and increasing accumulated deficits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have never generated any revenue from product sales and may never be profitable.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, obtain the necessary regulatory approvals for and commercialize our product candidates. We do not anticipate generating revenues from sales of products for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreseeable future, if ever. Our ability to generate future revenues from product sales will depend heavily on our success in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identifying and validating therapeutic targets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completing our research and preclinical development of product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiating and completing clinical trials for product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking, obtaining and maintaining marketing approvals for product candidates that successfully complete clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties, or establishing our own manufacturing capability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">launching and commercializing product candidates for which we obtain marketing approval, either with a collaborator or, if launched independently, successfully establishing a sales force, marketing and distribution infrastructure; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining, expanding and protecting our intellectual property portfolio; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">attracting, hiring and retaining qualified personnel. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of increased expenses and when we will be able to achieve or maintain profitability, if ever. In addition, our expenses could increase if we were required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, the U.K. Medicines and Healthcare products Regulatory Agency, or MHRA, or other regulatory authorities to perform studies and trials in addition to those that we currently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product on our own. Even if we were able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We will require additional financial resources to continue the ongoing development of our product candidates and pursue our business objectives. If we are unable to obtain these additional resources when needed or on acceptable terms, we may be forced to delay or discontinue our planned operations, including clinical testing of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have used substantial funds to develop our RNA interference, or RNAi, technologies and will require substantial funds to conduct further research and development, including preclinical testing and clinical trials of our product candidates, and to manufacture, market and sell any of our products that may be approved for commercial sale. Because the length of time, and the activities associated with, the successful development of our product candidates may be greater than we anticipate, we are unable to estimate the actual funds we will require to develop and commercialize them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect our research and development expenses and net losses to substantially increase in connection with our ongoing activities, particularly as we advance our product candidates towards or through clinical trials. We will need additional capital to fund our operations, including clinical trials for product candidates other than those which are funded by our collaboration partners, and such funding may not be available to us on acceptable terms, or at all. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the foreseeable future, we expect to rely primarily on additional non-dilutive strategic collaboration arrangements, as well as equity or debt financings, to fund our operations. Raising additional capital through the sale of securities could cause significant dilution to our shareholders. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidates. Our ability to raise additional funds will depend, in part, on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient funds will be available to us when required or on acceptable terms, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significantly delay, scale back or discontinue the development or commercialization of any current or future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek strategic alliances for research and development programs at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">dispose of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any future product candidates that we otherwise would seek to develop or commercialize; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">file for bankruptcy or cease operations altogether. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events would have a material adverse effect on our business, operating results and prospects and could significantly impair the value of your investment in our ADSs.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have historically funded our operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options. As of December 31, 2024, we had cash and cash equivalents and short-term investments of $147.3 million. We expect that our existing cash and cash equivalents will provide sufficient funds to continue to meet our liabilities as they fall due and for at least the next twelve months. However, it is possible that our costs will be higher than expected, that our operating plan may change as a result of many factors currently unknown to us, and that we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or license and development agreements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, like we did in February 2024 when we entered into a private placement with certain investors, even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us, or if at all. We believe that our current cash and cash equivalents and short-term investments will be able to fund our operations into 2027. The inability to obtain future funding could impact our financial condition and ability to pursue our business strategies, including being required to delay, reduce or eliminate some of our research and development programs, or being unable to continue operations or unable to continue as a going concern.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our holders, including holders of our ADSs, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional capital will be needed in the future to continue our planned operations, including expanded research and development activities and potential commercialization efforts. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through any or a combination of strategic collaboration arrangements, equity or debt financings, and research grants and tax credits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. In addition, we could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, including in any at-the-market offering through the Sales Agreement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing and preferred equity financing, if available, could result in fixed payment obligations, and we may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">required to accept terms that restrict our ability to incur additional indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to a third party to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we raise funds through research grants or take advantage of research and development tax credits, we may be subject to certain requirements, which may limit our ability to use the funds or require us to share information from our research and development. Raising additional capital through any of these or other means could adversely affect our business and the holdings or rights of our shareholders and may cause the market price of our ADSs to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Discovery, Development, Regulatory Approval and Potential Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The approach we are taking to discover and develop drugs is novel and may never lead to marketable products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our therapeutic product research and development efforts on siRNA technology, and our future success depends on the successful development of this technology and products based on our siRNA product platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The scientific discoveries that form the basis for our efforts to discover and develop product candidates based on siRNA technology are relatively new. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we may not become profitable, and the value of our ordinary shares may decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, our focus solely on siRNA technology for developing drugs as opposed to multiple, more proven technologies for drug development increases the risks associated with the ownership of our ordinary shares. If we are not successful in developing any product candidates using siRNA technology, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and successfully implement an alternative product development strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify or discover potential product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize siRNA therapeutics. Our clinical and pre-clinical research programs may show initial promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our research methodology or that of any strategic collaborator may be unsuccessful in identifying potential product candidates that are successful in clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our current or future strategic collaborators may change their development profiles for potential product candidates or abandon a therapeutic area; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new competitive developments in the evolving field of RNAi, or in other nucleic acid-based approaches, including gene therapy or gene editing, may render our product candidates obsolete or noncompetitive. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to increase our pipeline, including by pursuing additional indications for our current product candidates, identifying additional indications for our proprietary platform technology or in-licensing or acquiring additional product candidates for other indications.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to develop or identify product candidates that are safe, tolerable and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify, in-license or acquire may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical studies and clinical trials of our product candidates may not be successful. If we are unable to generate successful results from these studies and trials, or experience significant delays in doing so, our business may be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have invested a significant portion of our efforts and financial resources in the identification and development of siRNA-based product candidates. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The success of our product candidates will depend on several factors, including, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">inter alia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully designing preclinical studies which may be predictive of clinical outcomes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully conducting and completing clinical trials, including timely patient enrollment and acceptable safety and efficacy data; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining marketing approvals from applicable regulatory authorities on a timely basis, if ever; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining and maintaining patent or trade secret protection for future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties or establishing our own manufacturing capability; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully commercializing our products, if and when approved, whether alone or in collaboration with others. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully complete the development of, or commercialize, our product candidates, which would materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publicly disclose preliminary or &#8220;topline&#8221; data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or clinical trial. As a result, the &#8220;topline&#8221; or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. &#8220;Topline&#8221; data should be viewed with caution until the final data are available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Ordinary Shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the interim, &#8220;topline,&#8221; or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If clinical trials of our product candidates fail to commence or, once commenced fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In clinical development, the risk of failure for product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive regulatory approval. We are the sponsor of Investigational Medicinal Product Dossiers in multiple jurisdictions and must achieve and maintain compliance with the requirements of various regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of product candidates, we or a strategic collaborator must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. As of the date hereof, we have two proprietary product candidates in clinical development, and our other product candidates are preclinical. Clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval for their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events which may result in a delay or unsuccessful completion of clinical development include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching an agreement with the FDA, EMA, MHRA or other regulatory authorities on final trial design; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold on our clinical trial operations or trial sites by the FDA or other regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disruptions at the FDA and other regulatory agencies caused by funding shortages or future global health crises;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inability to adhere to clinical trial requirements directly or with third parties such as CROs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in recruiting suitable patients and clinical investigators to participate in a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in the testing, validation, manufacturing and delivery of the product candidates and patient samples to and from the clinical sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up or ensuring patient compliance with trial protocols; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays caused by patients dropping out of a trial due to protocol procedures or requirements, product side effects or disease progression; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites dropping out of a trial to the detriment of enrollment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">time required to add new clinical sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">negative outcomes, including deficiencies in good clinical practices, or GCP, in routine inspections by regulatory authorities in the countries where our clinical trials are being conducted; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investigator fraud, including data fabrication by clinical trial personnel; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in delivering sufficient supply of clinical trial materials to clinical sites and challenges in patient recruitment, as well as challenges regarding global clinical trial supply shipments, importation and customs clearances.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our current or future strategic collaborators are required to conduct additional clinical trials or other testing of any product candidates beyond those that are currently contemplated, are unable to successfully complete clinical trials of any such product candidates or other testing, or if the results of these trials or tests are not positive or are only moderately positive, or if there are safety concerns, we and they may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as originally intended or desired; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. In addition, our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any inability to successfully complete clinical development, whether independently or with a strategic collaborator, could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestone payments and royalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Conducting successful clinical trials requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of appropriate clinical trial investigators; support staff; the number of ongoing clinical trials in the same indication that compete for the same patients; proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance; the impact of global health crises. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays in subject enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to maintain any of our existing collaborations, or if these arrangements are not successful, or we are unable to enter into future licenses, our business could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into collaborations with other parties, including pharmaceutical and biotechnology companies like Hansoh Pharmaceutical Group Company Limited, or Hansoh, Mallinckrodt plc, or Mallinckrodt, and AstraZeneca</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLC, or AstraZeneca, to develop products based on our RNAi technology, and such collaborations and licensing arrangements currently represent a significant portion of our product candidate pipeline. Certain of our collaborations have provided us with important funding for some of our development programs and we expect to receive additional funding under collaborations in the future if certain milestones are achieved although not all of our collaborations may result in funding to us, and certain collaborations, licenses and agreements may result in increased expenditures by us.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our dependence on collaborators for capabilities and funding means that our business could be adversely affected if any collaborator materially amends or terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and commercialize any affected product candidate. Our current collaborations allow, and we expect that any future collaborations will allow, either party to terminate the collaboration for a material breach by the other party. In addition, our collaborators may have additional termination rights for convenience with respect to the collaboration or a particular program under the collaboration, under certain circumstances. For example, our collaboration agreements with Mallinckrodt, AstraZeneca and Hansoh may each be terminated by the respective collaborator at any time upon prior written notice to us. If we were to lose a collaborator, we may have to attract a new collaborator or develop expanded research and development, sales, distribution and marketing capabilities internally, which would require us to invest significant amounts of financial and management resources.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are actively exploring licenses and other strategic collaborations with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. However, we face significant competition in seeking appropriate collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay our development programs, delay potential commercialization, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct some aspects of our manufacturing, research and development activities, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of research or clinical testing, or may terminate our agreements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not expect to independently conduct all aspects of our manufacturing and drug discovery activities, research or preclinical and clinical studies of product candidates. We currently rely, and expect to continue relying, on third parties to conduct some aspects of our drug development studies and chemical syntheses. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our pre-clinical and clinical studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us to progress viable product candidates for investigational new drug, or IND, submissions or comparable foreign submissions and will not be able to, or may be delayed in our efforts to, advance our clinical trials which would prevent us from successfully developing and commercializing our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although our research and development services can only be performed by us or at our discretion, we rely on third party clinical investigators, CROs, clinical data management organizations, medical institutions and consultants to design, conduct, supervise and monitor preclinical studies and clinical trials in relation to our product candidates. Because we rely on third parties and do not have the ability to conduct clinical trials independently, we have less control over the timing, quality and other aspects of clinical trials than we would if we conducted them on our own. These investigators, CROs and consultants are not our employees, and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources away from our programs. If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of clinical trials or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">meet expected deadlines, our clinical development program could be delayed or otherwise adversely affected. In all events, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. The FDA and comparable foreign regulatory authorities require us to comply with GCP, other applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible, accurate and complete and that the rights, integrity and confidentiality of trial participants are protected. We rely, for example, on third parties for aspects of quality control which are especially important in monitoring compliance with GCP requirements and avoiding any investigator fraud or misconduct in clinical research, such as practices including adherence to an investigational plan; accurate recordkeeping; drug accountability; obtaining completed informed consent forms; timely reporting of any adverse drug reactions; notifying appropriate investigational review boards, or IRBs, and ethics committees of progress reports and any significant changes; and obtaining documented IRB approvals or positive ethics committee opinions. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. The third parties with which we contract might not be diligent, careful or timely in conducting our clinical trials, as a result of which we could experience one or more lapses in quality controls or other aspects of clinical trial management, and the clinical trials could be delayed or unsuccessful. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers to produce our preclinical, clinical product candidates and certain starting material components, and we intend to rely on third parties to produce future clinical supplies of product candidates that we advance into clinical trials and commercial supplies of any approved product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reliance on third-party manufacturers entails risks, including risks that we would not be subject to if we manufactured the product candidates ourselves, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to meet any product specifications and quality requirements consistently; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a delay or inability to procure or expand sufficient manufacturing capacity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing and product quality issues related to scale-up of manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a failure to comply with applicable government regulations and regulatory requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">termination or non-renewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the reliance on a limited number of sources, such that if we were unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell future product candidates in a timely fashion, in sufficient quantities or under acceptable terms; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the losses incurred by us if our insurance coverage is insufficient to cover any loss, contamination or damage of chemical materials, product components or products made by any of our CMOs, once the materials or products have been shipped to us and the risk of loss has been transferred to us. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face risks inherent in relying on contract manufacturing organizations, or CMOs, as any disruption, such as a fire, natural hazards, pandemic, epidemic, war or outbreak of an infectious disease at a CMO&#8239;could significantly interrupt our manufacturing capability. We, or our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved, and significantly harm our business, financial condition, results of operations and prospects. If necessary to avoid future disruption, we may have to establish alternative manufacturing sources. This would require substantial capital on our part, which we may not be able to obtain on commercially acceptable terms or at all. Additionally, we may experience manufacturing delays as we build or locate replacement facilities and seek and obtain necessary regulatory approvals. If this occurs, we will be unable to satisfy manufacturing needs on a timely basis, if at all. Also, operating any new facilities may be more expensive than operating the then existing facility. Further, business interruption insurance may not adequately compensate us for any losses that may occur and we would have to bear the additional cost of any disruption. For these reasons, a significant disruptive event affecting the manufacturing facility could have drastic consequences, including placing our financial stability at risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize a product candidate and we cannot, therefore, predict the timing of any revenue from a future product.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Neither we nor any strategic collaborator can commercialize a product until the appropriate regulatory authorities, such as the FDA, European Commission or MHRA, have reviewed and approved the product candidate. The regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee, or similar foreign governmental institution, recommends restrictions or conditions on approval or recommends non-approval. In addition, we or a strategic collaborator may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency or authority policy during the period of product development, clinical trials and the review process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot be sure that the FDA, the EMA or the European Commission or MHRA will accept the outcome of our preclinical testing and studies as sufficient to support the submission of an IND or a comparable foreign application or that the results of our clinical trials will be sufficient to support marketing approval. Furthermore, later clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory to the FDA, the EMA or European Commission, the MHRA or other comparable regulatory authorities even if we believe those clinical trials to be successful. The FDA, the competent authorities of EU Member States, the MHRA or other comparable regulatory authorities may suspend one or all of our clinical trials or the FDA, EMA or MHRA may require that we conduct additional clinical, preclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any new drug application, or NDA, or comparable foreign regulatory application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs, or may require us to expend more resources than we have available. Regulatory authorities can delay, limit or deny approval of our product candidate for many reasons, including unsatisfactory efficacy and safety data from our trials disagreements over the design of our trial and/or manufacturing issues and a number of other factors which we and the regulators may disagree.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval for a product candidate, we will still face extensive regulatory requirements, and our products may face future development and regulatory difficulties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain regulatory approval in the United States and the European Union, the FDA and the European Commission may still impose significant restrictions on the indicated uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. The holder of an approved NDA in the United States, or a marketing authorization, or MA, in the European Union is obligated to monitor and report adverse events, or AEs, or adverse reactions and any failure of a product to meet the specifications in the NDA, or MA. The holder of an approved NDA or MA must also submit new or supplemental applications and obtain regulatory approval in order to make certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with the relevant regulatory rules and, in the United States and in some EU Member States, are subject to FDA review or national regulatory review, in addition to other potentially applicable federal, state and foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug product manufacturers and their facilities are subject to payment of user fees or may require manufacturing and import authorizations, or MIAs, in the European Union, and continual review and periodic inspections by regulatory authorities for compliance with current good manufacturing practices, or cGMP, including quality control, quality assurance, and the maintenance of records and documentation to ensure that approved products are safe and consistently meet applicable requirements, and adherence to commitments made in the NDA or MA. We or any third party manufacturers we engage may be unable to comply with these cGMP and with other regulatory authority requirements. These requirements are enforced by regulatory authorities through periodic inspections of manufacturing facilities. If we or a regulatory authority discovers previously unknown problems with a product such as AEs of unanticipated severity or frequency, adverse reactions, or product quality issues, or problems with the facility where the product is manufactured, a regulatory authority may impose restrictions relative to that product or the manufacturing facility. A negative outcome from such inspection or a failure to provide adequate and timely corrective actions in response to deficiencies identified could result in enforcement action, including shutdown of the third-party vendor or invalidation of drug product lots or processes, warning letters, fines and civil penalties, suspension of production, suspension, variation or delay in product approval, license revocation, product seizure or recall of product candidates or approved products, plant shutdown, operating restrictions and criminal prosecutions or the delay, withholding, variation or withdrawal of product approval. If the safety of any product is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements, the regulators could take various actions such as:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issuing a warning letter or untitled letter asserting that we are in violation of the law; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seeking an injunction or imposing civil or criminal penalties or monetary fines; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspending, varying or withdrawing regulatory approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspending any ongoing clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusing to approve a pending NDA or MA or supplements to an NDA or MA submitted by us; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seizing product; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusing to allow us to enter into supply contracts, including government contracts. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our future products and generate revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain and maintain approval for our product candidates in one jurisdiction, we may never obtain approval for our product candidates with other regulatory authorities in other jurisdictions. Sales of our product candidates outside of the United States and the European Union will be subject to foreign regulatory requirements governing clinical trials and marketing approval and continual regulatory review. Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We will be subject to ongoing obligations and oversight by regulatory authorities, including adverse event reporting requirements, marketing restrictions and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, the EU and other European countries, may designate drugs or biologics for relatively small patient populations as orphan drugs. In the United States, under the&#8239;Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition. Such diseases and conditions are those that affect fewer than 200,000 individuals in the United States, or if they affect more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug available in the United States for these types of diseases or conditions will be recovered from sales of the drug. However, orphan drug designation must be requested before submitting an NDA and there can be no assurance that any such designation will be granted. If the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, orphan drug designation recipients can take advantage of special incentives provided by the FDA such as (i) potential market exclusivity of the product for seven years as the first sponsor (ii) tax credits for qualified clinical research for a designated orphan product and (iii) waiver of associated fees when submitting a marketing application to the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, in the European Union, orphan designation is intended to promote the development of medicinal products that are intended for (i) the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions (ii) either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b) the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition. In EU, orphan designation entitles a party to a number of incentives, such as fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. This marketing exclusivity period can however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product destination, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidate, divesiran (SLN124), has received orphan drug designation from the European Commission for the treatment of beta-thalassemia and from the FDA for the treatment of beta-thalassemia, myelodysplastic syndrome, or MDS, and polycythemia vera, or PV. Our drug candidate, SLN501, has received orphan drug designation from the FDA for complement 3 glomerulopathy, or C3G. The EMA and the European Commission will reassess eligibility for divesiran orphan exclusivity at the time of MA review and can remove orphan status if the drug no longer meets the eligibility criteria, including offering a significant benefit to those affected, at that time. Moreover, even if we obtain orphan drug exclusivity in the future for a product candidate for these or other indications, such exclusivity may not effectively protect the product candidate from competition because different therapies can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA or European Commission can subsequently approve a different or a similar drug for the same condition if such regulatory authority concludes that the later drug is clinically superior because it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the regulatory authority later determines that the initial request for designation was materially defective. In addition, orphan drug exclusivity does not prevent the regulatory authority from approving competing drugs for the same disease or condition containing a different active ingredient. In addition, if a subsequent drug is approved for marketing for the same disease or condition as any of our product candidates that receive marketing approval, we may face increased competition and lose market share regardless of orphan drug exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because we have limited financial and human resources, we intend to leverage our existing licensing and collaboration agreements and may enter into new strategic collaboration agreements for the development and commercialization of our programs and potential product candidates in indications with potentially large commercial markets while focusing our internal development resources, and any future internal sales and marketing organization that we may establish, on research programs and product candidates intended for selected markets or patient populations, such as rare diseases. As a result, and even as we prioritize our current product candidates and clinical trials, we may forego or delay pursuit of other programs or product candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AEs caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. Certain oligonucleotide therapeutics have been observed to result in injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our future product candidates may induce similar AEs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If AEs are observed in any clinical trials of our product candidates, including those that a strategic collaborator may develop under an agreement with us, our or our collaborators&#8217; ability to obtain regulatory approval for product candidates may be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may withdraw their approval of the product or impose restrictions on our distribution in the form of a risk evaluation and mitigation strategy or comparable foreign strategy; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way the product is administered or conduct additional clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us or our collaborators from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products either on our own or with the collaborator.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third party payers and others in the medical community necessary for commercial success.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The product candidates that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payers and consumers, may not accept a product intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for us to educate the medical community and third-party payers on the benefits of our product, or to provide favorable reimbursement and market access. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy, safety and potential advantages of any of our product candidates compared to alternative treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to offer our products for sale at competitive prices;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the stability, shelf life, convenience and ease of storage and administration compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new treatments and of physicians to prescribe these treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to hire and retain a sales force, or to engage one or more third party distributors for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of third-party payer coverage and adequate reimbursement for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any restrictions on the use of our products together with other medications.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risks Related to Our Business Operations and Compliance with Government Regulations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face competition from other companies that are working to develop novel drugs and technology platforms using technologies similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully commercialize drugs may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Many of our competitors may have greater experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do, and may be better resourced financially. Any product candidates that we successfully develop and commercialize will compete with existing products and new products that may become available in the future. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and recruiting lead clinical trial investigators and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Companies that complete clinical trials, obtain required regulatory authority approvals and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, and our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop and commercialize. Because our products and many potential competing products are in various stages of preclinical and clinical development, and given the inherent unpredictability of drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the competition we face from competing drugs in general, we also face competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of several other companies that are working to develop RNAi therapeutic products and other companies may develop alternative treatments for the diseases we have identified as being potentially treated with our siRNA molecules. To the extent those alternative treatments are more efficacious, less expensive, more convenient or produce fewer side effects, our market opportunity would be reduced.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. Certain of our executive officers are &#8220;at will&#8221; employees and may terminate their employment with us at any time upon prior written notice. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous life sciences companies for individuals with similar skill sets. In addition, failure to succeed in preclinical studies and clinical trials may make it more challenging to recruit and retain qualified personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had 116 employees. In the future we may expand our employee base to increase our managerial, scientific, operational, commercial, financial and other resources and to hire more consultants and contractors. Future growth would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from its day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. Moreover, if our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to introduce new products or keep pace with advances in technology, our business, financial condition and results of operations could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We spend a relatively low amount on technological innovation compared to our larger competitors. There is a risk that competitors will be quicker to develop new technologies, new products for the same gene targets or new delivery methods of nucleic acids into novel cell types, particularly once competitors learn about new gene targets that we or our collaborators have selected for the development of siRNA molecules. We will need to successfully introduce new products to achieve our strategic business objectives. Our successful product development will depend on many factors, including our ability to attract strong talent to lead our research and development efforts, adapt to new technologies, obtain regulatory approvals on a timely basis, demonstrate satisfactory clinical results, manufacture products in an economical and timely manner, obtain appropriate intellectual property protection for our products, gain and maintain market acceptance of our products, and differentiate our products from those of our competitors. In addition, patents attained by others may preclude or delay our commercialization of a product. There can be no assurance that any products now in development or that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we cannot successfully introduce new products or adapt to changing technologies, our products may become obsolete, and our revenue and profitability could suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability and other claims, and, if successful claims are brought against us, we may incur substantial liability and costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims, including claims related to impurities in our products or potential product recalls. Certain single-stranded oligonucleotide therapeutics have led to injection site reactions and pro-inflammatory effects and may also lead to impairment of kidney or liver function. There is a risk that our current and future product candidates, although double-stranded, may induce similar or other adverse events. Product liability claims might be brought against us by consumers, healthcare providers, life sciences companies or others selling or otherwise coming into contact with our products; other claims may be brought against us by third parties with whom we contract, or by current or former employees or consultants, including claims of wrongful terminations, discrimination, other violations of labor law or other alleged conduct. If we cannot successfully defend against such claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, such claims may result in, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impairment of our business reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants with respect to product liability claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs due to related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distraction of management&#8217;s attention from our primary business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to claimants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for our product candidates, if approved for commercial sale. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain product liability insurance relating to the use of our therapeutics in clinical trials. However, such insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and related tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business requires manipulating, analyzing and storing large amounts of sensitive data, and, as a result, we and the third parties with whom we work face a variety of evolving threats that could cause security incidents. Our business therefore depends on the continuous, effective, reliable, and secure operation of our computer hardware, software, networks, internet servers, third party technology service providers and related infrastructure. To the extent that our hardware or software, or the hardware or software of the third parties with whom we work, malfunctions or access to our data by internal research personnel is interrupted, our business could suffer. Cyber-attacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties with whom we work. The regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve, as further described below. Maintaining compliance with applicable security and privacy regulations has in the past and may in the future increase our operating costs. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to a variety of evolving cybersecurity threats, including but not limited to social-engineering attacks (including through deep fakes, which are increasingly more difficult to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify as fake, and phishing attacks), denial-of-service attacks, credential stuffing, credential harvesting, ransomware attacks, supply-chain attacks, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins, software viruses, accidental or malicious insider-action and other similar threats. These events could lead to the unauthorized access, disclosure and use of our sensitive data and information technology systems. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently and may originate from less regulated and remote areas of the world and increasingly involve highly resourced threat actors such as organized criminals and nation states. As a result, we cannot provide assurance that our efforts to address these techniques proactively or implement adequate preventative measures will always be successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remote work has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. We may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party service providers and technologies to operate critical business systems that process sensitive data. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. Certain of our third-party service providers have, and may again in the future, experience a security incident or other interruption that results in adverse consequences to our operations. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We take steps designed to detect, mitigate, and remediate vulnerabilities in our information</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">systems (such as our hardware and/or software, including that of third parties with whom we work). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties with whom we work. A security incident or other interruption could disrupt our ability (and that of third parties with whom we work) to operate our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we (or a third party with whom we work) experience a security incident or are perceived to have experienced a security incident, we could experience material adverse consequences, such as fines, damages, litigation and enforcement actions, additional reporting requirements and/or oversight, restrictions on processing sensitive data (including personal data), indemnification obligations; negative publicity, reputational harm, monetary fund diversions, diversion of management attention, and interruptions in our operations (including availability of clinical trial data). In addition, any sustained disruption in internet systems or network access provided by other companies could harm our business. Similarly, if a security incident were to occur, we may be required, or we may voluntarily choose, to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents, or to take other actions, such as providing credit monitoring and identity theft protection services. Such disclosures and related actions can be costly, and the disclosure or the failure to comply with such applicable requirements could lead to adverse consequences, including reputational damage, investigations and fines from regulators, as well as litigation. Furthermore, if we are required to disclose the occurrence of a cybersecurity incident, the price of our ADSs may be negatively impacted.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, or vendors&#8217; use of generative artificial intelligence ("AI"), technologies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and the third parties with whom we work are subject to stringent and evolving U.S. and foreign data privacy and security laws, regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">contractual obligations, industry standards, policies, and other obligations, and our (or the third parties with whom we work)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class actions); fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, clinical trial data and financial information (collectively, sensitive data).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our data processing activities subject us to privacy and data protection obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, guidance and industry standards govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation ("EU GDPR") and the United Kingdom&#8217;s GDPR ("U.K. GDPR")</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(collectively, &#8220;GDPR&#8221;) impose strict requirements for processing personal data (including health data). Under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the United States or other countries. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom have significantly restricted the transfer of personal data  to third countries, including the United States, whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law (e.g., the EEA Standard Contractual Clauses, the United Kingdom&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the United Kingdom&#8217;s extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework)), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations. The United States is also increasingly scrutinizing certain data transfers and may also impose certain data localization requirements, particularly if we transfer personal data to, or process personal data of residents of, high risk or sanctioned jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) requires covered companies to provide disclosures to California residents,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">including consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for statutory fines and allows private litigants affected by certain data breaches to recover significant statutory damages. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA may impact (possibly significantly) our business activities, should we become subject to the CCPA in the future. Numerous other U.S. states have also enacted comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While many of these state laws, like the CCPA, exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties with whom we work. Failure to comply with federal and state laws in the United States regarding privacy and security of personal data could further expose us to penalties under privacy and data protection laws. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on occasion our employees and personnel use generative AI technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are bound by contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We also publish policies, marketing materials, and other statements concerning data privacy and security. Regulators are increasingly scrutinizing these statements, and if these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, misleading, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security (and individuals&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources, which may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties with whom we work may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third party with whom we work to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others. If we or the third parties with whom we work fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans or restrictions on processing personal data (including clinical trial data); orders to destroy or not use personal data; and imprisonment of company officials.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees, consultants and contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements or insider trading violations, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees, consultants or contractors could include intentional failures to comply with governmental regulations, comply with healthcare fraud and abuse and anti-kickback laws and regulations in the United States, the EU Member States, the United Kingdom and other jurisdictions, or failure to report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including improper trading based upon, information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics and a robust compliance program, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our relationships with U.S. healthcare providers, including physicians, and third-party payers will be subject to applicable U.S. anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations,</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers and third-party payers play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payers and customers may expose us to broadly applicable U.S. federal and state fraud and abuse, transparency, health data privacy, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research as well as market, sell and distribute our products for which we obtain marketing approval. If we are found to be in violation of any of any healthcare laws or any other federal or state regulations, we may be subject to significant administrative, civil and/or criminal penalties, damages, fines, disgorgement, imprisonment, exclusion from federal health care programs, additional reporting requirements and/or oversight, and the curtailment or restructuring of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislative and other regulatory reform measures may have a negative impact on our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been, and continue to be, legislative and regulatory developments regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, require direct price negotiations for certain high-expenditure, single-source prescription drugs and biologics covered by the Medicare program, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. While any proposed measures will require authorization through additional legislation to become effective, Congress and the current administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or successfully commercialize our drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the policies of the FDA, the competent authorities of the EU Member States, the EMA, the European Commission and other comparable regulatory authorities responsible for clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the EU</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recently evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials in relation to which application for approval was made on the basis of the Clinical Trials Directive before January 31, 2023, the Clinical Trials Directive will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans. In light of the entry into application of the CTR on January 31, 2022, we may be required to transition clinical trials for which we have obtained regulatory approvals in accordance with the CTD to the regulatory framework of the CTR. Transition of clinical trials governed by the CTD to the CTR will be required for clinical trials which will have at least one site active in the E.U. on January 30, 2025. A transitioning application would need to be submitted to the competent authorities of E.U. Member States through the Clinical Trials Information Systems and related regulatory approval obtained to continue the clinical trial past January 30, 2025. This would require financial, technical and human resources. If we are unable to transition our clinical trials in time, the conduct of those clinical trials may be negatively impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is currently unclear to what extent the UK will seek to align its regulations with the EU in the future. The UK</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into</span><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UK law, through secondary legislation). On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency, or MHRA, launched an eight-week consultation on reframing the UK legislation for clinical trials. The UK Government published its response to the consultation on March 21, 2023, confirming that it would bring forward changes to the legislation, and such changes were laid in parliament on December 12, 2024. These resulting legislative amendments will, if implemented in their current form, bring  the UK into closer alignment with the CTR. Failure of the UK to closely align its regulations with the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization for the Company's product candidates on the basis of clinical trials conducted in the United Kingdom.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. The HTA Regulation has applied from January 12, 2025, although it will enter into force iteratively and initially apply to new active substances to treat cancer and to all advanced therapy medicinal products (ATMPs), it will then be expanded to orphan medicinal products in January 2028, and to all centrally authorized medicinal products as of 2030. Selected high-risk medical devices will also be assessed under the HTA Regulation as of 2026. The HTA Regulation is intended to harmonize the clinical benefit assessment of HTA across the EU and permits EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA does not apply in the United Kingdom. However, the UK Medicines and Healthcare products Regulation Agency, or MHRA, is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium, or SMC, the National Institute for Health and Care Excellence, or NICE, and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products, including, effective as of 31 March 2025, relaunching the Innovative Licensing and Access Pathway with more predicable timelines and closer involvement of the National Health Service.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation and on April 10, 2024, the Parliament adopted its related position. The proposed revisions remain to be agreed and adopted by the European Council. Moreover, on December 1, 2024, a new European Commission took office. The proposal could, therefore, still be subject to revisions. If adopted in the form proposed, the European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a number of changes to the regulatory framework governing medicinal products, including a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, our development plans may be impacted.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The United Kingdom&#8217;s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our common shares.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following Brexit, the UK and the EU signed a EU-UK Trade and Cooperation Agreement, or TCA, which became provisionally applicable on January 1, 2021 and entered into force on May 1, 2021. This agreement provides details on how some aspects of the UK and EU&#8217;s relationship will operate going forwards however there are still uncertainties. The TCA primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Among the changes that have occurred are that the United Kingdom is treated as a &#8220;third country,&#8221; a country that is not a member of the EU and whose citizens do not enjoy the EU right to free movement. Northern Ireland continues to follow certain limited EU regulatory rules, including in relation to medical devices, but not in relation to medicinal products. As part of the TCA, the EU and the UK recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2023, the UK government and the European Commission reached a political agreement on the so-called &#8220;Windsor Framework.&#8221; The Windsor Framework is intended to revise the Northern Ireland Protocol to address some of the perceived shortcomings in its operation. The agreement was adopted at the Withdrawal Agreement Joint Committee on March 24, 2023, and the arrangements under the Windsor Framework relating to medicinal products took effect on January 1, 2025.  As it relates to marketing authorizations, the United Kingdom has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland continued, until January 1, 2025, to be covered by the marketing authorizations granted by the European Commission but the Windsor Framework provides that the UK MHRA is the sole regulatory body responsible for granting marketing authorizations for Northern Ireland as of January 1, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A significant proportion of the regulatory framework in the UK applicable to medicinal products is currently derived from EU Directives and Regulations. The potential for UK legislation to diverge from EU legislation following Brexit could materially impact the regulatory regime with respect to the development, manufacture, import, approval, and commercialization of our product candidates in the UK or the EU. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of these changes could increase our costs and otherwise adversely affect our business. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may face uncertainty related to pricing, coverage and reimbursement for our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our product candidates in the U.S., if approved, will depend, in part, on the extent to which such products will be covered by third-party payers, such as government health care programs, commercial insurance and managed healthcare organizations. These third-party payers are increasingly limiting coverage and/or reducing reimbursements for medical products and services. A third-party payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#8217;s determination to provide coverage for a drug product does not ensure that other payers will also provide coverage for the drug product. Coverage policies and third-party payer reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for products for which we receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party payer reimbursement or a decision by a third-party payer to not cover any of our product candidates, if approved, could reduce physician usage of our product candidates, and have a material adverse effect on our sales, results of operations and financial condition. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any product candidates will be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange rate fluctuations may adversely affect our results of operations and cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's consolidated financial statements are presented in U.S. dollars. The individual financial statements of each subsidiary is prepared in the currency of the primary economic environment in which the entity operates (its functional currency). Our transactions are commonly denominated in U.K pounds sterling, however we receive payments under our collaboration agreements in U.S. dollars and we incur a portion of our expenses in other currencies, primarily Euros. As a result, fluctuations in exchange rates, particularly between the pound sterling on the one hand and the U.S. dollar and Euro on the other hand, may adversely affect our reported results of operations and cash flows. Our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates between the pound sterling and these and other currencies, any of which may have a significant impact on our results of operations and cash flows from period to period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inflation may adversely affect our operations, including increases in the prices of goods and services required for our operations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">High rates of inflation resulting from global events may adversely affect our operations in the event of increased prices of goods and services, such as energy and other operating costs, labor costs, materials costs and shipping costs, all of which may impact our direct costs. We are also experiencing increases in the cost of services provided by CMOs, CROs and other third parties with whom we do business, including significant increases in the cost of non-human primates required for studies. Such high inflation rates may result in unexpected and unbudgeted cost increases and may require changes to planned investments.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain or protect intellectual property rights related to our current or future products and product candidates, we may not be able to compete effectively in our markets.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our current and future products and product candidates. The strength of patents in the biotechnology and life sciences field involves complex legal and scientific questions and can be uncertain. The patent applications that we own may fail to result in patents with claims that cover our current and future product candidates in the United States, European countries or in other territories. Even if patents do successfully issue, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated and our patents and patent applications may not adequately protect our intellectual property, or our current and future product candidates, and may not prevent others from designing around our claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the patent applications we hold and/or have out-licensed with respect to our product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop product candidates, and threaten our ability to commercialize, future products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. A patent may be challenged through one or more of several administrative proceedings including Inter Partes Review, Post Grant Review, re-examination or opposition before the U.S. Patent and Trademark Office, or the USPTO, or European Patent Office, or the EPO, and by way of similar proceedings in certain other jurisdictions. For example, re-examination of, or oppositions to, patents owned by us have previously been initiated, and while we believe these proceedings did not or will not result in a commercially relevant impact on the individual patents, any successful challenge of patents or any other patents owned by us could deprive us of rights necessary for the successful commercialization of any product candidates that we or our strategic alliance partners may develop. Since patent applications in the United States and most other countries are confidential for a period of up to 18 months after filing, and some remain confidential until issued, we cannot be certain that we were the first to file any patent application related to a product candidate or an siRNA related technology or method. Furthermore, in certain situations, if we and one or more third parties have filed patent applications in the United States claiming the same subject matter, an administrative proceeding, known as a derivation proceeding (previously known as an interference), can be initiated to determine which applicant is entitled to the patent on that subject matter. Such administrative proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications, or those of our alliance partners. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all. Our defense of a patent or patent application in such a proceeding may not be successful and, even if successful, may result in narrowed claims, which may or may not cover our current or future products and product candidates, and at substantial costs and distraction to our management and other employees.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, patents have a limited lifespan. In the United States and many other countries and regions of the world including Europe, the natural expiration of a patent is generally 20 years after it is filed as a non-provisional patent application, or a PCT international patent application. Various extensions may be available, however, the life of a patent and the protection it affords is limited. Once the patent life has expired for a product, we may be open to competition from generic medications. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although each of our Silence Therapeutics GmbH employees either has to assign their inventions to us under German Employee Invention Law, or agrees to assign their inventions to us through an employee inventions agreement, and all of our employees, consultants, advisers and any third parties who have access to our proprietary know-how, information or technology enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or confidential proprietary information, or independently develop substantially equivalent information and techniques. In addition, others may independently discover our trade secrets, proprietary know-how and information. For example, the FDA, as part of its transparency initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change and affect us adversely in the future, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property in Europe and in other jurisdictions outside the United States. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and life sciences industries, including patent infringement lawsuits. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our strategic collaborators are pursuing development candidates and technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to sequences, structures, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates that are broad enough to cover one of our product candidates or use of our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in patents with claims that our product candidates or use of our technologies may infringe. In addition, third parties may have or may obtain in the future patents and assert that our product candidates or use of our technologies infringes upon one or more claims of these patents. If any third-party patents were held by a court of competent jurisdiction to be valid and enforceable and to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate, if approved, unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to be valid and enforceable and to cover aspects of our compositions, formulations or methods of use, including combination therapies, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Parties making claims against us may seek to obtain injunctive or other equitable relief, which if successful could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of our management, other employees and resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including up to treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming, even if we ultimately prevail. For example, in 2017, we commenced patent infringement litigation against Alnylam Pharmaceuticals Inc., or Alnylam. In December 2018, we and Alnylam entered into a settlement and license agreement to settle the litigation, which was related to Alnylam&#8217;s RNAi product ONPATTRO. As part of the settlement, we licensed specified patents to Alnylam, and Alnylam paid us a tiered royalty of up to one percent of its net sales of ONPATTRO in the European Union through December 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the costs and potential distraction associated with enforcing our patents in a lawsuit, in an infringement proceeding, a court may decide that a patent of ours or any future licensor is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing which could negatively impact our ability to develop and potentially commercialize our product candidates, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our efforts in a litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management and other employees. We may not be able to prevent, alone or with our partners or future licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or life sciences companies. We may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our ADSs</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The transition from foreign private issuer to U.S. domestic issuer status effective from January 1, 2025, requires us to comply with the U.S. domestic reporting requirements under the Exchange Act and will result in significant additional compliance activity and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until December 31, 2024, we were a &#8220;foreign private issuer&#8221; as such term is defined in Rule 405 of Regulation C, under the Securities Act and Rule 3b-4 under the Exchange Act. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer are anticipated to be significantly more than costs we incurred as a foreign private issuer because we are now required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive in certain respects than the forms available to a foreign private issuer. We have prepared our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, as opposed to the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. Such conversion and modifications incurred additional one-time costs to present our financial statements retrospectively. In addition, we have lost our ability to rely upon exemptions from certain requirements related to the preparation and solicitation of proxies (including compliance with full disclosure obligations regarding executive compensation in proxy statements) and the exemption from filing beneficial ownership reports under Section 16. We expect the loss of our foreign private issuer status will increase our future legal and financial compliance costs and will make some activities more time-consuming and costly.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We no longer qualify as an &#8220;emerging growth company&#8221; as of December 31, 2024, and, as a result, we will no longer be able to avail ourselves of certain reduced reporting requirements applicable to emerging growth companies.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are no longer an &#8220;emerging growth company&#8221; as defined in the JOBS Act. We have previously taken advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including (i) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (ii) reduced disclosure obligations regarding executive compensation in our periodic reports and (iii) exemptions from the requirements of holding nonbinding advisory shareholder votes on executive compensation and shareholder approval of any golden parachute payments not approved previously. In addition, as an emerging growth company, we were only required to provide two years of audited financial statements and two years of selected financial data in our periodic reports.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because the market value of our ordinary shares held by non-affiliates exceeded $700.0 million as of June 30, 2024, we ceased to qualify as an &#8220;emerging growth company&#8221; as of December 31, 2024, and as such, we are no longer be able to take advantage of any of the exemptions from various reporting requirements that are applicable to emerging growth companies effective as of December 31, 2024. We expect that the loss of our &#8220;emerging growth company&#8221; status and our compliance with the additional requirements that we were previously exempt from as an &#8220;emerging growth company&#8221; will increase our legal and financial compliance costs. In addition, any failure to comply with these additional requirements in a timely manner, or at all, could have an adverse effect on our business and results of operations and could cause a decline in the price of our ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a public company, we will incur significant legal, accounting and other expenses that we did not previously incur as a private company or as an emerging growth company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Once we are no longer able to take advantage of the exemptions from various reporting requirements that are applicable to emerging growth companies, we will be required to comply with auditor attestation requirements, increased disclosure obligations and other reporting requirements which will likely increase our costs in the upcoming fiscal year. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements and will make some activities more time-consuming and costly compared to when we were a private company. For example, as a public company it is more difficult and more expensive for us to obtain director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantial costs. The impact of these events could also make it more difficult for us to attract and retain qualified members of our board of directors.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company&#8221; as of December 31, 2024, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. At such time as we are required to obtain auditor attestation, if we then have an unremediated material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will continue to engage in process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate or increase internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The trading price of our ADSs may be volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading price of our ADSs has been and will likely continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their ADSs at or above the price paid for the ADSs. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, factors that are expected to affect the market price of our securities include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commencement, enrollment or results of our planned and future clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">positive or negative results, or perceived positive or negative results, from, or delays in, testing and clinical trials by us, collaborators or competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license additional product candidates and technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of any of our key scientific or management personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory, legal or tax developments in the United States, United Kingdom, the European Union and other countries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the success of competitive products or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse actions taken by regulatory authorities with respect to our clinical trials or manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">commencement of, or involvement in, litigation involving the Company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes or developments in laws or regulations applicable to our product candidates or technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to our relationships with collaborators, manufacturers or suppliers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">concerns regarding the safety of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements concerning our competitors or the pharmaceutical industry in general; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">actual or anticipated fluctuations in our operating results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in financial estimates or recommendations by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential acquisitions, financings, collaborations or other corporate transactions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the trading volume of our ADSs on Nasdaq; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">coordinated trading in our ADSs by third parties, including market manipulation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publication of information, including in the media, online blogs and social media, about our company by third parties, including equity research analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sales of our ADSs by us, members of our senior management and directors or our shareholders; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic, political, and market conditions and overall fluctuations in the financial markets in the United States, the United Kingdom, the European Union, and other countries, including impact of the wars in Ukraine and Israel and global and regional economic and political disruptions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">stock market price and volume fluctuations of comparable companies and, in particular, those that operate in the biopharmaceutical industry; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">investors&#8217; general perception of us and our business and any failure to meet expectations of investors or equity research analysts. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their ADSs at or above the price paid for the ADSs and may otherwise negatively affect the liquidity of our ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our management&#8217;s and key employees&#8217; attention and our resources. Furthermore, during the course of litigation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future sales, or the possibility of future sales, of a substantial number of our ADSs could adversely affect the price of such securities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future sales of a substantial number of ADSs, or the perception that such sales will occur, could cause a decline in the market price of our ADSs. If our shareholders sell substantial amounts of ADSs on Nasdaq, or if the market perceives that such sales may occur, the market price of the ADSs and our ability to raise capital through an issue of equity securities in the future could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, the price and trading volume of our ADSs could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading market for our ADSs may be influenced by the research and reports that equity research analysts publish about us and our business. As a company admitted to trading on Nasdaq, our equity securities are currently subject to coverage by a number of analysts. Equity research analysts may elect not to provide research coverage of our ADSs, and such lack of research coverage may adversely affect the market price of our ADSs. We will not have any control over the analysts or the content and opinions included in their reports. The price of our ADSs could decline if one or more equity research analysts downgrade our ADSs or issue other unfavorable commentary or research about us. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our ADSs could decrease, which in turn could cause the trading price or trading volume of our ADSs to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentration of ownership of our ordinary shares (including ordinary shares represented by ADSs) among our existing senior management, directors and principal shareholders may prevent new investors from influencing significant corporate decisions and matters submitted to shareholders for approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Members of our senior management, directors and current beneficial owners of 5% or more of our ordinary shares and their respective affiliates, in the aggregate, beneficially owned approximately 45% of our issued and outstanding ordinary shares, based on the number of ordinary shares issued and outstanding as of December 31, 2024. As a result, depending on the level of attendance at general meetings of our shareholders, these persons, acting together, would be able to significantly influence all matters requiring shareholder approval, including the election, re-election and removal of directors, any merger, scheme of arrangement, or sale of all or substantially all of our assets, or other significant corporate transactions, and amendments to our articles of association. In addition, these persons, acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our ADSs by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delaying, deferring, or preventing a change in control; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entrenching our management and/or the board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impeding a merger, scheme of arrangement, takeover, or other business combination involving us; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some of these persons or entities may have interests different than yours. For example, because many of these shareholders purchased their shares at prices substantially below the current market price of our ordinary shares and have held their shares for a longer period, they may be more interested in selling our company to an acquirer than other investors, or they may want us to pursue strategies that deviate from the interests of other shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our ordinary shares (including ordinary shares represented by ADSs) in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should not rely on an investment in our ADSs to provide dividend income. Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be paid. Therefore, we must have distributable profits before issuing a dividend. We have never</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">declared or paid a dividend on our ordinary shares in the past, and we currently intend to retain our future earnings, if any, to fund the development of our technologies and product candidates and the growth of our business. As a result, capital appreciation, if any, on our ADSs will be your sole source of gains for the foreseeable future. Investors seeking cash dividends should not purchase our ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may identify material weaknesses in our internal control over financial reporting in the future. If we experience material weaknesses or significant deficiencies in the future or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will not identify additional control deficiencies or material weaknesses in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if we identify material weaknesses in the future, if we are unable to comply with the requirements of Section 404, in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting when required, the accuracy and timing of our financial reporting may be adversely affected, potentially resulting in restatements of our financial statements, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and applicable Nasdaq listing requirements, investors may lose confidence in our financial reporting, and our share price may decline as a result.</span></p>
  <p style="text-indent:3.307%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</span></p>
  <p style="text-indent:3.307%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, is designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could harm our business and have a negative effect on the trading price of our ADSs.</span></p>
  <p style="text-indent:3.307%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting starting from our annual report required to be filed with the SEC for the fiscal year ending December 31, 2024. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation, which could have a negative effect on the trading price of our ADSs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Holders of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our ADSs do not have the same rights as our shareholders who hold our ordinary shares directly and may only exercise their voting rights with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee as their representative to exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting is convened, if you hold ADSs, you may not receive sufficient notice of a shareholders&#8217; meeting to permit you to withdraw the ordinary shares underlying your ADSs to allow you to vote with respect to any specific matter. We will use commercially reasonable efforts to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#8217; meeting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You may be subject to limitations on transfers of your ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when deemed necessary or advisable by it in good faith in connection with the performance of its duties or at our reasonable written request, subject in all cases to compliance with applicable U.S. securities laws. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to certain rights to cancel ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting, or because we are paying a dividend on our ordinary shares or similar corporate actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, holders of ADSs may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to the ADSs or to the withdrawal of our ordinary shares or other deposited securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The depositary for our ADSs is entitled to charge holders fees for various services, including annual service fees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The depositary for our ADSs is entitled to charge holders fees for various services, including for the issuance of ADSs upon deposit of ordinary shares, cancellation of ADSs, distributions of cash dividends or other cash distributions, distributions of ADSs pursuant to share dividends or other free share distributions, distributions of securities other than ADSs and annual service fees. In the case of ADSs issued by the depositary into The Depository Trust Company, or DTC, the fees will be charged by the DTC participant to the account of the applicable beneficial owner in accordance with the procedures and practices of the DTC participant as in effect at the time. The depositary for our ADSs will not generally be responsible for any U.K. stamp duty or stamp duty reserve tax arising upon the issuance or transfer of ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we do not have any present plans to declare or pay any dividends, in the event we declare and pay any dividend, the depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses, or withholding of taxes. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or impractical to make a distribution available to holders of ADSs. We have no obligation to register under U.S. securities laws any offering of ADSs, ordinary shares or other securities received through such distributions. We also have no obligation to take any other action to permit distribution on the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that you may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may have an adverse effect on the value of your ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Your right to participate in any future rights offerings may be limited, which may cause dilution of your holdings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under English law, shareholders usually have preemptive rights to subscribe on a pro rata basis in the issuance of new shares for cash. The exercise of preemptive rights by certain shareholders not resident in the United Kingdom may be restricted by applicable law or practice in the United Kingdom and overseas jurisdictions. We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless either both the rights and any related securities are registered under the Securities Act, or the distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible, or allow them to lapse. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. We are also permitted under English law to disapply preemptive rights (subject to the approval of our shareholders by special resolution or the inclusion in our articles of association of a power to disapply such rights) and thereby exclude certain shareholders, such as overseas shareholders, from participating in a rights offering (usually to avoid a breach of local securities laws).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are a passive foreign investment company, there could be adverse U.S. federal income tax consequences to U.S. Holders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which (i) 75% or more of our gross income consists of passive income, or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, passive income (including cash). For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on estimates of our income and assets, and certain assumptions with respect to the characterization of our assets as active or passive, we do not believe we were a PFIC for our taxable year ended December 31, 2024. However, no assurances regarding our PFIC status can be provided for any past, current or future taxable year. The determination of whether we are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying interpretation. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If a United States person is treated as owning at least 10% of our ordinary shares, such United States person may be subject to adverse U.S. federal income tax consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For U.S. federal income tax purposes, if a United States person is treated as owning (directly, indirectly or constructively) 10% or more of our shares by vote or value, such U.S. holder will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group (if any). Because our group includes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at least one U.S. subsidiary, our non-U.S. subsidiaries and any non-U.S. subsidiaries we were to form or acquire in the future will be treated as controlled foreign corporations.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A United States shareholder of a controlled foreign corporation will be required to annually report and include in its U.S. federal taxable income its pro rata share of &#8220;subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by the controlled foreign corporations, regardless of whether we make any distributions of such income. Special rules, however, apply to United States persons that are partnerships or other pass-through entities. Certain deductions and credits for foreign income taxes paid or accrued by the controlled foreign corporation may be allowed to a corporate United States shareholder, but will not be allowed to an individual United States shareholder. We cannot provide any assurance that we will furnish to any United States shareholder the information required to comply with the reporting and tax-paying obligations discussed applicable to a United States shareholder in respect of controlled foreign corporations. Failure to comply with such reporting obligations may subject a holder of our ordinary shares that is a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to its U.S. federal income tax return for the year for which reporting was due from starting. Holders of our ordinary shares that are United States persons should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to use U.K. carryforward tax losses to reduce future tax payments or benefit from favorable U.K. tax legislation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a U.K. resident trading entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception. As of December 31, 2024, we had cumulative U.K. carryforward tax losses of $164.8 million. Subject to any relevant restrictions (including those that limit the percentage of profits that can be reduced by carried forward losses and those that can restrict the use of carried forward losses where there is a change of ownership of more than half the ordinary shares of the company and a major change in the nature, conduct or scale of the trade), we expect these to be available to carry forward and offset against future operating profits.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company that carries out extensive research and development, or R&amp;D, activities, we seek to benefit from the U.K. R&amp;D tax credit regime. In respect of accounting periods in which we qualify as a Small and Medium-sized Enterprise, or SME, and in which qualifying R&amp;D expenditure represents 30% (for periods from April 1, 2024) or more of the total (meaning we also qualify as "R&amp;D-intensive" during such accounting period), we may, under this regime, surrender the trading losses that arise from our R&amp;D activities for a cash rebate of up to 26.97% of qualifying R&amp;D expenditure. Accordingly, if we cease to qualify as an R&amp;D-intensive SME, in future, we will either cease to be able to claim cash rebates in respect of our R&amp;D activities, or only be able to receive cash payments or other tax relief (under other provisions of the U.K. R&amp;D tax credit regime) at a significantly lower rate than at present. Further, the regime&#8217;s rules are complex, and if a tax authority were to challenge or seek to disallow our claims (in whole or in part), for example by asserting that we do not (or the relevant expenditure does not) meet the technical conditions to be granted tax credits (or cash rebates), then such challenge or disallowance, if successful, could have a material impact on our cash-flow and financial performance. In addition, future changes to the U.K. R&amp;D tax credit regime may mean that we no longer qualify for it or have a material impact on the extent to which we can make claims (or benefit from them).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event we generate revenues in the future, we may benefit from the U.K. &#8220;patent box&#8221; regime that allows profits attributable to revenues from patents or patented products to be taxed at an effective rate of 10%. As of December 31, 2024, we had 21 solely owned and 2 jointly owned patent families with each family creating rights in current or future patent applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our R&amp;D expenditures, we expect a long-term lower effective rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the U.K. R&amp;D tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments, then our business, results of operations, and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct business in the United Kingdom, Germany and the United States and file income tax returns in multiple jurisdictions. Our consolidated effective income tax rate could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms under consideration or being implemented (such as those related to the Organization for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid, or the stamp duty or stamp duty reserve tax treatment of our ADSs or ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, His Majesty&#8217;s Revenue &amp; Customs, or HMRC, the U.S. Internal Revenue Service or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be a lengthy and costly process and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Protections found in provisions under the U.K. City Code on Takeovers and Mergers, or the Takeover Code, will not apply if our place of management and control remains outside the United Kingdom.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the cancellation of admission of our ordinary shares to trading on AIM in November 2021 and under transitional provisions that apply until February 2027, the Takeover Code will only apply to us if we are considered by the Panel on Takeovers and Mergers, or the Takeover Panel, to have our place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the &#8220;residency test&#8221;. The way in which the test for central management and control is applied for the purposes of the Takeover Code may be different from the way it is applied by the United Kingdom tax authorities. Under the Takeover Code, the Takeover Panel looks to where the majority of the directors of the company are resident, amongst other factors, for the purposes of determining where the company has its place of central management and control.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Takeover Panel has confirmed that based on the composition of our board of directors following Alistair Gray&#8217;s retirement from the board, effective May 1, 2024, we are no longer subject to the Takeover Code. As a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code. We believe that this position is unlikely to change at any time in the near future, but, in accordance with good practice, we will review the situation on a regular basis and consult with the Takeover Panel if there is any change in our circumstances which may have a bearing on whether the Takeover Panel would determine our place of central management and control to be in the United Kingdom.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incorporated certain takeover protections in our articles of association, which apply in circumstances where the Takeover Code does not apply to the company. A resolution was passed at the company&#8217;s annual general meeting held on May 17, 2024, to approve the continued application of these provisions until the 2025 annual general meeting of the company.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Takeover Code provides a framework within which takeovers of certain companies organized in the United Kingdom are regulated and conducted. The following is a brief summary of some of the most important rules of the Takeover Code:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with a potential offer, if, following an approach by or on behalf of a potential bidder, the company is &#8220;the subject of rumor or speculation&#8221; or there is an &#8220;untoward movement&#8221; in the company&#8217;s share price, there is a requirement for the potential bidder to make a public announcement about a potential offer for the company, or for the company to make a public announcement about its review of a potential offer. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When a person or group of persons acting in concert (a) acquires, whether by a series of transactions over a period of time or not, interests in shares carrying 30% or more of the voting rights of a company (which percentage is treated by the Takeover Code as the level at which effective control is obtained) or (b) increases the aggregate percentage interest they have when they are already interested in not less than 30% and not more than 50%, they must make a cash offer to all other shareholders at the highest price paid by them or any person acting in concert with them in the 12 months before the offer was announced. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When interests in shares carrying 10% or more of the voting rights of a class have been acquired for cash by an offeror (i.e. a bidder) or any person acting in concert with them in the offer period (i.e. before the shares subject to the offer have been acquired) or within the previous 12 months, the offer must be in cash or be accompanied by a cash alternative for all shareholders of that class at the highest price paid by the offeror or any person acting in concert with them in that period. Further, if an offeror or any person acting in concert with them acquires for cash any interest in shares during the offer period, the offer must be in cash or accompanied by a cash alternative at a price at least equal to the price paid for such shares during the offer period. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If after an announcement of a firm offer is made, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (i.e. a target) at a price higher than the value of the offer, the offer must be increased accordingly. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors of the offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree company. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All shareholders must be given the same information. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Those issuing documents in connection with a takeover must include statements taking responsibility for the contents thereof. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Misleading, inaccurate or untrue statements made in documents or to the media must be publicly corrected immediately. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actions during the course of an offer by the offeree company which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealings in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#212529;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The rights of our shareholders may differ from the rights typically offered to stockholders of a U.S. corporation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of our ADSs, are governed by English law, including the provisions of the U.K. Companies Act 2006, or the Companies Act, and by our articles of association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See &#8220;Description of Share Capital and Articles of Association&#8212;Differences in Corporate Law&#8221; filed as Exhibit 2.3 to this report for a description of the principal differences between the provisions of the Companies Act applicable to us and, for example, the Delaware General Corporation Law relating to shareholders&#8217; rights and protections.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">As an English company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">English law provides that a board of directors may only allot shares (or grant rights to subscribe for, or to convert any security into, shares) with the prior authorization of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. In either case, this authorization would need to be renewed by our shareholders upon expiration (i.e., at least every five years). At our annual general meeting of shareholders held on April 27, 2023, we obtained authority from our shareholders to allot new shares or to grant rights to subscribe for or to convert any security into shares in the company up to a maximum aggregate nominal amount of &#163;5,402,633.25 for a period of five years from the date of such annual general meeting of shareholders, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution, but not longer than the duration of the authority to allot shares to which the disapplication relates. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). At our annual general meeting of shareholders held on April 27, 2023, we obtained authority from our shareholders to disapply preemptive rights in connection with the allotment of equity securities up to a maximum aggregate nominal amount of &#163;5,402,633.25 for a period of five years from the date of such annual general meeting of shareholders which disapplication will need to be renewed upon expiration (i.e., at least every five years), but may be sought more frequently for additional five year terms (or any shorter period).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years. See &#8220;Description of Share Capital and Articles of Association&#8221; filed as Exhibit 2.3 to this report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Claims of U.S. civil liabilities may not be enforceable against us.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are incorporated under English law. Substantially all of our assets are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and the United Kingdom do not currently have a treaty providing for the reciprocal recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in England and Wales. In addition, uncertainty exists as to whether the English and Welsh courts would entertain original actions brought in England and Wales against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt so that no retrial of the issues would be necessary, provided that certain requirements are met consistent with English law and public policy. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws is an issue for the English court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our articles of association provide that the U.S. federal district courts are the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our articles of association provide that the U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. However, the enforceability of similar federal court choice of forum provisions has been challenged in legal proceedings in the United States, and it is possible that a court could find this type of provision to be inapplicable, unenforceable, or inconsistent with other documents that are relevant to the filing of such lawsuits. In addition, the Securities Act provides that both federal and state courts have jurisdiction over suits brought to enforce any duty or liability under the Securities Act or the rules and regulations thereunder. Accepting or consent to this forum selection provision does not constitute a waiver by you of compliance with federal securities laws and the rules and regulations thereunder. You may not waive compliance with federal securities laws and the rules and regulations thereunder. If a court were to find the choice of forum provision contained in our articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition. This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable results for the plaintiff(s) in any such action.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The deposit agreement governing our ADSs provides that owners and holders of ADSs irrevocably waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including claims under U.S. federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with a jury trial. Although we are not aware of a specific federal decision that addresses the enforceability of a jury trial waiver in the context of U.S. federal securities laws, it is our understanding that jury trial waivers are generally enforceable. Moreover, insofar as the deposit agreement is governed by the laws of the State of New York, New York laws similarly recognize the validity of jury trial waivers in appropriate circumstances. In determining whether to enforce a jury trial waiver provision, New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit agreement and the ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim of fraud or one which is based upon a creditor&#8217;s negligence in failing to liquidate collateral upon a guarantor&#8217;s demand, or in the case of an intentional tort claim (as opposed to a contract dispute). No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of U.S. federal securities laws and the rules and regulations promulgated thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If any owner or holder of our ADSs brings a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under U.S. federal securities laws, such owner or holder may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different results than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="unresolved_staff_comments_item"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1B. Unresolved Staf</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f Comments</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div><ix:nonNumeric id="F_6c63665b-d39a-4006-8455-7d718821e821" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_6c63665b-d39a-4006-8455-7d718821e821_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cyber</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa3fea73-f40d-471a-a47b-6e6accb3525e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3812fad3-515f-4099-9efa-b28a2051dbe9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems and Data.</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function, which is led by our Vice President and Head of Information Technology, known as our Head of IT, and supported by our security management, risk management, and legal teams, helps identify, assess, and manage our cybersecurity threats and risks, including through the use of our risk register. The information security function identifies and assesses cybersecurity threats and risks by monitoring and evaluating our threat environment and risk profile using various methods including, for example: automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats, evaluating threats reported to us, coordinating with law enforcement concerning threats, internal and external audits, leveraging internal and third party threat assessments, conducting vulnerability identification assessments, and leveraging external threat intelligence.</span></p><div><ix:nonNumeric id="F_ea48c297-00d8-4bdc-a951-6b3586834ef4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, vulnerability management, disaster recovery and business continuity plans, risk assessments, achievement of certain security certifications, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, employee training, penetration testing, and asset management and disposal.</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information about our assessment and management of material risks from cybersecurity threats is included in risk management reports as applicable to senior leadership and the audit committee.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dcdcf659-66f0-4667-9ea3-f98b930b1d1c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff6865c3-1924-40a6-b1d6-72554216fdea" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: threat intelligence providers, cybersecurity consultants and software providers, managed cybersecurity service providers, and penetration testing service providers.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business, such as software-as-a-service providers, hosting companies, contract research organizations, and contract manufacturing organizations. Depending on the nature of the services provided, the sensitivity of the critical systems, information and assets at issue, and the identity of the provider, we may conduct a review of security assessments provided by the vendor, review the vendor&#8217;s written security program and/or requested security assessment and security questionnaire responses, and impose contractual obligations on vendors regarding their cybersecurity practices.</span></p><div><ix:nonNumeric id="F_47bc2d7f-0f8d-4b34-b2a5-05600af51c49" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" escape="true" continuedAt="F_47bc2d7f-0f8d-4b34-b2a5-05600af51c49_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fcee8a41-709d-4597-89a0-806b5ca4e650" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks from cybersecurity threats that may materially affect us, please</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including &#8220;Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6c63665b-d39a-4006-8455-7d718821e821_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_47bc2d7f-0f8d-4b34-b2a5-05600af51c49_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.&#8221;</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17d1643a-a69e-4bed-a70a-1e07653f2a7d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93700132-7ea6-41af-bb77-fc9d21d9742b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0e35ebd-d721-4b10-8918-1429c7dd697d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.</span></ix:nonNumeric></span></p><div><ix:nonNumeric id="F_31b33efd-b899-4d2a-9986-d4b356d2a696" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#8217; cybersecurity efforts.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7536a90a-08f6-4d29-a8a4-3f5e28a72418" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd96afec-0262-4ab0-9289-e056e8048480" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Executive Leadership Team, or ELT. The ELT works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit and risk committee of the board of directors, as appropriate.</span></p><div><ix:nonNumeric id="F_3566f23e-065a-4814-820e-df51c8dac5a4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38900dd5-6276-4bb1-ba14-d42d7ac1eab8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee receives annual reports from our Head of IT, concerning our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity threats and risk and the processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have implemented to address them.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 2. Prop</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">erties</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office space in London, England for our corporate headquarters and general and administrative functions, which consists of approximately 4,000 square feet, under a lease with a term through September 2025. We also lease regional offices and laboratory space in Berlin, Germany (two leases: rolling contract basis with either party being able to end the lease upon 11.5 months&#8217; prior notice) and Hoboken, New Jersey, USA (eight leases: current lease end dates of April 2025, June 2025, August 2025, with either party being able to end the lease upon three months' prior notice).</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our current facilities are adequate to meet our needs for the near future and that suitable additional or alternative space will be available on commercially reasonable terms to accommodate our foreseeable future operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 3. Legal Pr</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">oceedings</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings relating to claims arising from the ordinary course of business. We do not currently have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 4. Mine Safe</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ty Disclosures</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_ii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT II</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="market_for_registrants_common_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5. Market for Registrant&#8217;s Com</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mon Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ordinary shares, nominal value &#163;0.05 per share, are not publicly traded. Our ADSs each represent three ordinary shares of Silence Therapeutics plc and began trading on Nasdaq in September 2020 under the symbol &#8220;SLN&#8221;. Prior to that date, there was no public trading market for ADSs. Our ordinary shares were admitted to trading on AIM from 1995 to November 2021.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 21, 2025, there were approximately 1,262 holders of record of our ordinary shares and 104 holders of record of our ADSs. The actual number of holders is greater than these numbers of record holders and includes beneficial owners whose ordinary shares or ADSs are held in street name by brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have never declared or paid any dividends on any class of our issued share capital. We intend to retain any earnings for use in our business and do not currently intend to pay dividends on our ordinary shares or ADSs. The declaration and payment of any future dividends will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions, any future debt agreements or applicable laws and other factors that our board of directors may deem relevant.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, among other things, we may only pay dividends if we have sufficient distributable reserves (on a non-consolidated basis), which are our accumulated realized profits that have not been previously distributed or capitalized less our accumulated realized losses, so far as such losses have not been previously written off in a reduction or reorganization of capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Graph</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The following shall not be deemed &#8220;soliciting material&#8221; or deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or subject to Regulation 14A </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> 14C, other than as provided by this Item 5, or to the liabilities of Section 18 of the Exchange Act, or incorporated by reference into this Annual Report on Form 10-K or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">any of our other filings under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing,</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">except to the extent we specifically incorporate it by reference into such filing.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph below shows a comparison, from September 8, 2020 (the date our ADSs commenced trading on Nasdaq) through December 31, 2024, of the cumulative total return to shareholders of our ADSs relative to the Nasdaq Composite Index and the Nasdaq Biotech Index  over the same period. The graph assumes that $100 was invested in each of our ADSs, the Nasdaq Composite Index and the Nasdaq Biotech Index at their respective closing prices on September 8, 2020 and assumes reinvestment of gross dividends, if any. The graph assumes our closing sales price on September 8, 2020, of $19.50 per ADS as the initial value of our ADS and not the initial offering price to the public of $17.41 per ADS. The share price performance shown in the graph represents past performance and should not be considered an indication of future share price performance.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><img src="img172674775_2.jpg" alt="img172674775_2.jpg" style="width:624px;height:344px;"/></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 6. [Re</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">served]</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="managements_discussion_and_analysis"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7. Management&#8217;s Discussion and A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nalysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes thereto appearing elsewhere in this Annual Report. Historically, we qualified as a foreign private issuer (as defined in Rule 405 of Regulation C under the Securities Act and Rule 3b-4 under the Exchange Act) and prepared our financial statements in accordance with IFRS as issued by the IASB. On June 30, 2024, the last day of our second fiscal quarter, we determined that we no longer qualified as a foreign private issuer under Rule 3b-4(c) of the Exchange Act. As a result, beginning January 1, 2025, we are required to report with the SEC on domestic forms and comply with domestic company rules in the United States. Therefore, we have now become a domestic issuer and are required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP, as opposed to IFRS. The transition to U.S. GAAP from IFRS was made retrospectively for all periods from our inception. The following discussion is based on our financial information prepared in accordance with U.S. GAAP and regulations of the SEC. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis, as well as the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We maintain our books and records in pounds sterling, our results are subsequently translated to U.S. dollars, and we prepare our consolidated financial statements in accordance with U.S. GAAP. All references in this Annual Report to &#8220;$&#8221; are to U.S. dollars and all references to &#8220;&#163;&#8221; are to pounds sterling. Our Consolidated Balance Sheets as of December 31, 2024, 2023 and 2022 have been translated from pounds sterling into U.S. dollars at the rate of &#163;1.00 to $1.25, &#163;1.00 to $1.27 and &#163;1.00 to $1.21, respectively. Our Consolidated Statements of Operations and Comprehensive Loss and Cash Flows for the years ended December 31, 2024, 2023 and 2022 have been translated from pounds sterling to U.S. dollars at the rate of &#163;1.00 to $1.28, &#163;1.00 to $1.25 and &#163;1.00 to $1.24, respectively. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as of that or any other date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221; or &#8220;Silence&#8221;) is a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body&#8217;s natural mechanism of RNA interference, or RNAi, by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced, and its level of activity is lowered. In the field of RNAi therapeutics, this reduction of disease-associated protein production and activity is referred to as &#8220;gene silencing.&#8221; Our proprietary mRNAi GOLD&#153; (</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">G</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">alNAc </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ol</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">igonucleotide </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">D</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">iscovery) platform consists of siRNA product candidates designed to precisely target and &#8216;silence&#8217; specific disease-associated genes in the liver. Using our mRNAi GOLD&#153; platform, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: cardiovascular disease, hematology and rare diseases.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran (SLN124) is our wholly owned siRNA product candidate designed to inhibit </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expression in the liver. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a negative regulator of hepcidin, the body's master regulator of iron metabolism, including its absorption, distribution and storage. Divesiran has shown preclinical potential in several hematological disorders and proof-of-mechanism in a Phase 1 healthy volunteer study. Divesiran is currently being evaluated in the SANRECO Phase 2 clinical trial in polycythemia vera, or PV, patients. We believe divesiran has the potential to be the first-in-class siRNA in PV. PV is a rare, myeloproliferative neoplasm &#8211; a type of blood cancer - characterized by the excessive production of red blood cells, often resulting in elevated hematocrit, or HCT, levels. Elevated HCT above 45-percent is associated with a four-times higher rate of death from cardiovascular or thrombotic events. PV is associated with a range of burdensome symptoms including fatigue, cognitive disturbance and pruritis and additionally, longer term can transform to myelofibrosis and Acute Myeloid Leukemia. The aim of treatment is to maintain HCT less than 45%, a level that is associated with a reduced incidence of thrombosis and CV-associated death. The current standard of care</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">includes repeated phlebotomies to reduce HCT and/or cytoreductive agents to reduce red blood cell production. There are currently no approved therapies that specifically target red blood cells and HCT.</span><span style="color:#003b4c;white-space:pre-wrap;font-size:13.5pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By silencing </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TMPRSS6 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in PV patients, divesiran aims to increase hepcidin production and release by liver hepatocytes, leading to the restriction of iron to the bone marrow and, thus, reducing the excessive production of red blood cells, a process dependent on availability of iron. In December 2024, we presented positive interim results from the Phase 1 portion of the SANRECO clinical trial at the American Society of Hematology, or ASH, annual meeting. Interim results showed divesiran substantially reduced phlebotomy requirements and lowered HCT levels following infrequent dosing in a range of PV patients. Divesiran has been well tolerated to-date with no dose-limiting toxicities. In December 2024, we also announced the first subject has been dose in the Phase 2 portion of the SANRECO clinical trial, which is currently underway. Full enrollment in the Phase 2 clinical trial is anticipated by year-end 2025. The U.S. Food and Drug Administration, or FDA, has granted divesiran Fast Track and orphan drug designations for PV. In December 2024, the European Commission, or EC, granted divesiran orphan drug designation for PV in Europe.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zerlasiran (SLN360) is our wholly owned siRNA product candidate designed to lower the body's production of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a), that has been associated with an increased risk of cardiovascular events.  Zerlasiran works by targeting messenger RNA required to translate the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LPA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> gene into particles of Lp(a), effectively &#8216;silencing&#8217; the gene to reduce Lp(a) production. High Lp(a), defined as 125nmol/L or higher, is a genetically determined cardiovascular risk factor affecting at least 20% of the world&#8217;s population and is associated with a high risk of heart attack, stroke and aortic stenosis. Unlike low-density lipoprotein, or LDL, Lp(a) levels are predominantly genetically determined, typically by age five, and unaffected by diet or lifestyle. There are currently no approved medicines that selectively lower Lp(a). Lp(a) levels can be measured by a simple blood test and while there is no generalized consensus on Lp(a) risk thresholds, growing evidence supports three main levels: Low or Normal (less than 75 nmol/L), Elevated (75 nmol/L to 124 nmol/L) and High (125 nmol/L or higher). A recent US based registry study in over 16,000 individuals showed that there is substantial risk of major cardiovascular events in individuals with elevated levels below the current accepted risk threshold of 125 nmol/L. Guidelines from the European Atherosclerosis Society, or EAS, and Canadian Cardiovascular Society, or CCS, suggest at least one test in an adult lifetime. The American College of Cardiology, or ACC, and American Heart Association, or AHA, recommend testing for those with a family history of premature atherosclerotic cardiovascular disease, or ASCVD, or personal history of ASCVD. In Phase 1 and Phase 2 clinical trials, zerlasiran substantially lowered Lp(a) levels in ASCVD patients with persisting effects following infrequent dosing and was well tolerated with no major safety concerns. We are engaged in global partnership discussions for potential Phase 3 development and future commercialization.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to our wholly owned clinical pipeline, we have a third siRNA product candidate from our GOLD platform in Phase 1 development in an undisclosed indication through our collaboration with AstraZeneca. We believe the potential for our GOLD platform to address disease-associated genes in the liver is substantial and are progressing several undisclosed preclinical programs that have shown promising results. We are committed to maximizing our GOLD platform by advancing a pipeline of both wholly owned and partnered programs.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Developments</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zerlasiran (Cardiovascular Disease)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we presented end-of-treatment data from the Phase 2 clinical trial of zerlasiran in ASCVD patients with high Lp(a) during the Late-Breaking Science Session of the AHA Annual Meeting in Chicago, Illinois. These data were simultaneously published in the Journal of the American Medical Association, or JAMA. Study results showed zerlasiran was well tolerated and produced significant time-averaged Lp(a) reductions following infrequent dosing with effects persisting 60 weeks following the first dose. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter 2024, we received positive regulatory feedback from the FDA and European Medicines Agency, or EMA, on the Phase 3 cardiovascular (CV) outcomes study design for zerlasiran in patients with elevated Lp(a) and at high risk of a CV event.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the fourth quarter 2024, we progressed core Phase 3 readiness activities for zerlasiran, including the scale-up of product supply to enable the full start-up of the Phase 3 CVOT study in the first half of </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025. Partnering discussions for this program are ongoing; timing for Phase 3 initiation is dependent on partnership.</span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Divesiran (Polycythemia Vera)</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we presented additional results from the Phase 1 open-label portion of the SANRECO clinical trial of divesiran in PV patients at the American Society of Hematology, or ASH, Annual Meeting in San Diego, California. Data presented at ASH were consistent with initial results presented in June 2024 and showed divesiran was well tolerated and substantially reduced phlebotomy frequency and lowered hematocrit levels following infrequent dosing in PV patients. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced the first subject has been dosed in the Phase 2 randomized, double-blind portion of the SANRECO clinical trial of divesiran in PV patients. Full enrollment is anticipated by year-end 2025. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the European Commission EC granted divesiran orphan drug designation for PV in Europe. Divesiran also has FDA Fast Track and orphan drug designation for PV in the United States. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2025, we completed follow-up in the SANRECO Phase 1 clinical trial of divesiran in PV patients. Phase 1 data presentations are planned for medical congresses in 2025. </span></div></div>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other mRNAi GOLD Pipeline Updates</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 1 clinical trial of SLN312 (licensed to AstraZeneca) is ongoing.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Phase 1 clinical trial of SLN548, our wholly owned siRNA for complement-mediated diseases, is planned for the second half of 2025.  </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant operating losses and expect to continue to incur significant expenses and operating losses for the near future. These net losses were $45.3 million, $54.2 million and $50.3 million, for the years ended December 31, 2024, 2023 and 2022, respectively. As of December 31, 2024, our accumulated deficit was $474.0 million. We expect to continue to incur significant and increasing expenses and to incur operating losses for the foreseeable future, as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio, as well as hire additional personnel, pay for further accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission, or SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement with AstraZeneca</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2020, we entered into a collaboration agreement with AstraZeneca to discover, develop and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. Under this agreement, AstraZeneca made an upfront cash payment to us of $20.0 million in May 2020. AstraZeneca made an additional unconditional cash payment to us of $40.0 million which was received in May 2021. In March 2020, an affiliate of AstraZeneca also subscribed for 4,276,580 new ordinary shares for an aggregate subscription price of $20.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The collaboration covers five targets initially, with AstraZeneca having the option to extend the collaboration to a further five targets. AstraZeneca has agreed to pay us $10.0 million upon the exercise of each option to collaborate on an additional target. In May 2023, AstraZeneca nominated the first product candidate under our collaboration, triggering a $10.0 million option fee to us to advance development on an undisclosed program. In February 2024, AstraZeneca initiated a Phase 1 clinical trial for this undisclosed program which triggered another $10.0 million milestone payment to us. In March 2024, we completed our obligations for the second product candidate under the collaboration. For each target selected, we will be eligible to receive up to $140.0 million in potential milestone payments upon the achievement of milestones relating to the initiation of specified clinical trials, the acceptance of specified regulatory filings and the first commercial sale in specified jurisdictions. For each target selected, we will also be eligible to receive up to $250.0 million in potential commercial milestone payments, upon the achievement of specified annual net sales levels, as well as tiered royalties as a percentage of net sales ranging from the high single digits to the low double digits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement with Mallinckrodt</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2019, we entered into a collaboration agreement with Mallinckrodt to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. In connection with the execution of this agreement, Mallinckrodt made an upfront cash payment to us of $20.0 million. Under a separate subscription agreement, Cache Holdings Limited, a wholly owned subsidiary of Mallinckrodt, concurrently subscribed for 5,062,167 new ordinary shares for an aggregate subscription price of $5.0 million. Under the agreement, we granted Mallinckrodt an exclusive worldwide license to our C3 targeting program, SLN501, with options to license two additional undisclosed complement-mediated disease targets from us. In July 2020, Mallinckrodt exercised options on the two additional complement targets.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, we reacquired exclusive worldwide rights from Mallinckrodt to the two undisclosed preclinical complement targets. Under the terms of the modified agreement, we did not make any upfront payment to get the two assets back and will potentially pay future success-based milestones and low single digit royalties on net sales if the projects advance. SLN501, the C3 targeting program, remained under the original collaboration agreement. In March 2024, Mallinckrodt notified us that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial. This completion also concludes all required development activities and commitments under the collaboration.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreement with Hansoh</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 15, 2021, we announced a collaboration agreement with Hansoh, one of the leading biopharmaceutical companies in China, to develop siRNAs for three undisclosed targets leveraging our proprietary mRNAi GOLD&#153; platform. Under the terms of the agreement, we retain exclusive rights to the first two targets in all territories except the China Region (Greater China, Hong Kong, Macau and Taiwan). Hansoh has the exclusive option to license rights to those two targets in the China Region following the completion of phase 1 studies. We will be responsible for all activities up to option exercise and will retain responsibility for development outside the China region post phase 1 studies. Hansoh will also have the exclusive option to license global rights to a third target at the point of IND filing. Hansoh will be responsible for all development activities post option exercise for the third target. Hansoh made a $16 million upfront payment to us in December 2021. We achieved our first $2 million research milestone payment in the Hansoh collaboration in April 2022. In 2023, we achieved two additional preclinical milestones and received $4 million from the collaboration. In 2024, we achieved an additional preclinical milestone and received $2 million from the collaboration.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Hansoh notified us that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not have any approved products. Accordingly, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sale of any products unless and until we obtain regulatory approvals for, and commercialize any of, our product candidates. In the future, we will seek to generate revenue primarily from product sales and, potentially, regional or global strategic collaborations with third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our collaboration agreement with Mallinckrodt, we received an upfront cash payment of $20.0 million in 2019 and are eligible to receive specified development, regulatory and commercial milestone payments. We received a milestone payment of $2.0 million during the year ended December 31, 2020. In February 2021, we initiated work on the third complement target which triggered another $2 million research milestone payment. In April 2021, we also received $2 million for the second research milestone related to the first complement 3 target. During the year ended December 31, 2022, we received milestone payments totaling $3.0 million. During the years ended December 31, 2023 and 2024 we received no milestone payments. In addition to these potential payments, Mallinckrodt has agreed to fund some of our research personnel and preclinical development costs. We recognize the upfront payment, milestone payments, payments for personnel costs and other research funding payments over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, we reacquired exclusive worldwide rights to two preclinical siRNA assets under our Mallinckrodt collaboration, which resulted in a modification of the agreement. No additional performance obligations were identified as a result of the modification as there were no additional goods or services to be provided by us and the modification resulted in the partially satisfied performance obligations relating to the two reacquired targets becoming fully satisfied as we were no longer obligated to develop these targets. SLN501, the C3 targeting program, remained under the original Mallinckrodt collaboration through March 2024. We have accounted for the modification as if it were part of the existing contract as the remaining services to be delivered form part of a single performance obligation that is partially satisfied at the date of contract modification. The effect of the contract modification was that the consideration originally received for the two preclinical siRNA assets was reallocated to SLN501. We have recognized the effect of the contract modification on the measure of progress towards complete satisfaction of the SLN501 performance obligation and recognized an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis. We recognized $10.0 million on the contract modification date. In relation to the reacquired targets, the two preclinical siRNA assets were recognized at fair value. The fair value of those assets has been determined to be nil. Under the modification, we agreed to pay future success-based milestones and low single digit royalties on net sales if the projects advance. We will recognize these variable success-based milestones as an intangible asset at cost when triggered. Any royalties payable will be expensed in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, Mallinckrodt notified us that it will not pursue further development of the SLN501 program following the completion of the Phase 1 clinical trial. The completion of the Phase 1 clinical trial also represented the conclusion of all required development activities and commitments under the terms of the Mallinckrodt Collaboration. During the year ended December 31, 2024, we recognized a total of $0.6 million in revenue under our agreement with Mallinckrodt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our collaboration agreement with AstraZeneca, we received an upfront cash payment of $20.0 million and an additional payment of $40.0 million in May 2021. We are also eligible to receive specified development and commercial milestone payments as well as tiered royalties on net sales, if any. During the year ended December 31, 2023, we received milestone payments totaling $10.0 million. During the year ended December 31, 2024, we received milestone payments totaling $10.0 million. We recognize the upfront payment and milestone payments over time. During the year ended December 31, 2024, we recognized a total of $18.0 million in revenue under the AstraZeneca agreement.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a collaboration agreement with Hansoh on October 15, 2021. We received a $16 million upfront payment to us in December 2021. We are eligible to receive up to $1.3 billion in additional development, regulatory and commercial milestones. We will also receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales. During the year ended December 31, 2023, we achieved milestone payments totaling $4.0 million. During the year ended December 31, 2024, we achieved milestone payments totaling $2.0 million related to the Hansoh collaboration. We recognize the upfront payment and milestone payments over time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Hansoh notified us that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration. During the year ended December 31, 2024, we recognized a total of $24.6 million in revenue under this agreement.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, we entered into a settlement and license agreement with Alnylam Pharmaceuticals Inc., or Alnylam, pursuant to which we settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, we license specified patents to Alnylam, and Alnylam pays us a tiered royalty of up to one percent of net sales of ONPATTRO in the European Union. We were eligible to receive these royalties until December 2023. We invoice Alnylam quarterly in arrears based on sales data for that quarter as reported to us by Alnylam. Royalty revenue is recognized based on the level of sales when the related sales occur. During the year ended December 31, 2024, we recognized a total of $0.1 million in royalty income from Alnylam.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of sales</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales consists of research and development expenditure that is directly related to work carried out on revenue generating contracts. This includes salary costs that are apportioned based on time spent by employees working on these contracts as well as costs of materials and costs incurred under agreements with CROs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify our operating expenses into two categories: research and development costs and general and administrative expenses. Personnel costs, including salaries, benefits, bonuses and share-based payment expenses, comprise a significant component of each of these expense categories. We allocate expenses associated with personnel costs based on the function performed by the respective employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The largest component of our total operating expenses since inception has been costs related to our research and development activities, including the preclinical and clinical development of our product candidates. We expense research and development costs as they are incurred and classify them as contracted development, personnel and other.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracted development costs primarily consist of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs incurred under agreements with CROs and investigative sites that conduct our preclinical studies and clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs related to manufacturing active pharmaceutical ingredients and drug products for our preclinical studies and clinical trials; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs for materials used for in-house research and development activities.</span></div></div>
  <p style="margin-left:3.333%;text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our personnel research and development expense primarily consists of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">salaries and personnel-related costs, including bonuses, benefits, recruitment costs and any share-based payment expenses, for our personnel performing research and development activities or managing those activities that have been out-sourced; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consultants&#8217; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our other research and development costs primarily consists of</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">costs of related facilities, equipment and other overhead expenses that are considered directly attributable to research and development; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depreciation of capital assets used for research and development activities.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The successful development of our product candidates is highly uncertain. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect research and development costs to increase significantly for the foreseeable future as programs progress.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress, results and expenses of our ongoing and future clinical trials, preclinical studies and research and development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential need for additional clinical trials or preclinical studies requested by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential uncertainties in clinical trial enrollment rates or drop-out or discontinuation rates of patients; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competition with other drug development companies in, and the related expense of, identifying and enrolling patients in our clinical trials and contracting with third-party manufacturers for the production of the drug product needed for our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of milestones requiring payments under in-licensing agreements, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any significant changes in government regulation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the terms and timing of any regulatory approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to market, commercialize and achieve market acceptance for any of our product candidates, if they are approved. </span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not historically tracked research and development expenses on a program-by-program basis for our preclinical product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, audit, tax and accounting services, public relations and investor relations services. Personnel costs consist of salaries, bonuses, benefits, recruitment costs and share-based payment expenses for personnel in executive, finance, business development and other support functions. Other administrative expenses include office space-related costs not otherwise allocated to research and development costs, insurance expenses, and costs of our information systems and costs for compliance with the day-to-day requirements of being a listed public company in the United States. We anticipate that our administrative expenses will continue to increase in the future as we increase our headcount to support our continued research and development and potential commercialization of our product candidates. We also expect to continue incurring additional expenses as a public company in the United States, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance expenses, expenses related to investor relations activities and other administrative and professional services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Gain/Loss, Net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign exchange losses. Foreign exchange gains and losses relate to cash held in foreign currencies (primarily U.S. Dollars and Euros).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Income, net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income (expense) primarily relates to interest earned on our cash, cash equivalents, as well as accretion earned on our U.S. treasury bills.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation and Benefit from R&amp;D Tax Credit</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to corporate taxation in the United Kingdom, United States and Germany. Due to the nature of our business, we have generated losses since inception. Our income tax credit recognized represents the sum of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">research and development, or R&amp;D, tax credits recoverable in the United Kingdom. The U.K. R&amp;D tax credit, as described below, is fully refundable to us. We have recorded the entire benefit from the U.K. R&amp;D tax credit as a credit to &#8220;Benefit from R&amp;D tax credit.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company that carries out extensive research and development, or R&amp;D, activities, we seek to benefit from the U.K. R&amp;D tax credit regime. In respect of accounting periods in which we qualify as a  Small and Medium-sized Enterprise, or SME, and in which our qualifying R&amp;D expenditure represents 30% (for periods from April 1, 2024) or more of the total (meaning we also qualify as &#8220;R&amp;D-intensive&#8221; during such accounting period), we may, under this regime, surrender the trading losses that arise from our R&amp;D activities for a cash rebate of up to 26.97% of qualifying R&amp;D expenditure. Accordingly, if we cease to qualify as an R&amp;D-intensive SME, in future, we will either cease to be able to claim cash rebates in respect of our R&amp;D activities, or only be able to receive cash payments or other tax relief (under other provisions of the U.K. R&amp;D tax credit regime) at a significantly lower rate than at present. Further, the regime&#8217;s rules are complex, and if a tax authority were to challenge or seek to disallow our claims (in whole or in part), for example by asserting that we do not (or the relevant expenditure does not) meet the technical conditions to be granted tax credits (or cash rebates), then such challenge or disallowance, if successful, could have a material impact on our cash-flow and financial performance. In addition, future changes to the U.K. R&amp;D tax credit regime may mean that we no longer qualify for it or have a material impact on the extent to which we can make claims (or benefit from them).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unsurrendered U.K. tax losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of U.K. taxable profits. After accounting for tax credits receivable, we had accumulated tax losses for carry forward in the United Kingdom of $164.8 million as of December 31, 2024 ($165.1 million as of December 31, 2023). However, in the event of a change in ownership of a U.K. company, certain provisions may apply to restrict the utilization of carried forward tax losses in future periods. These provisions apply where there is a major change in the nature or conduct of a trade in connection with the change in ownership. For the avoidance of doubt, we do not recognize a deferred tax asset in respect of the accumulated tax losses. In addition to our accumulated tax losses in the United Kingdom, we also had $47.0 million of accumulated tax losses as of December 31, 2024 ($54.3 million as of December 31, 2023) related to our operations in Germany for corporate income taxes. We also had $45.6 million of accumulated losses related to trade taxes in our German entity ($52.7 million as of December 31, 2023). We had had a foreign tax expense in Germany of $0.6 million (2023: $0.5 million). Tax losses in the U.S. were negligible.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event we generate revenues in the future, we may benefit from the U.K. &#8220;patent box&#8221; regime that allows profits attributable to revenues from patents or patented products to be taxed at an effective rate of 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Value Added Tax, or VAT, is charged on all qualifying goods and services by VAT-registered businesses. Where applicable, an amount of 20% of goods and services is added to all sales invoices and is payable to the U.K. tax authorities. Similarly, VAT paid on purchase invoices is reclaimable from the U.K. tax authorities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the years ended December 31, 2024, 2023 and 2022</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the results of our operations for the years ended December 31, 2024, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.486%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.722000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.722000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.722000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.722000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.722000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="15" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,615</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,988</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11,810</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,057</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,867</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">596</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,463</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,448</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,672</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,776</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,584</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,192</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,883</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(10,946</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56,937</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,387</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(43,550</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,884</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(662</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(26,222</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(540</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25,682</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(63,319</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,064</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(64,383</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,343</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(61,040</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency gain/(loss), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">646</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,287</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,641</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,935</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,294</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,472</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,669</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,803</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,523</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">280</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Benefit from R&amp;D tax credit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,737</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,788</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,949</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,129</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,820</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss for the year before taxation</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(44,464</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,808</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,272</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,626</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,646</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(845</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(956</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(268</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(688</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(45,309</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,919</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(54,228</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,894</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(50,334</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss per share (basic and diluted)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.33</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.49</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.52</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average shares outstanding<br/>&#160;&#160;&#160;(basic and diluted)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,752,224</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,277,250</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,584,512</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue for the year ended December 31, 2024, was $43.3 million (2023: $31.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million). The increase was primarily due to revenue associated with the Hansoh Collaboration. We recognized $24.6 million in 2024 related to the Hansoh Collaboration resulting from a cumulative catch up as we have now completed all required obligations under the Hansoh Collaboration. This was partially offset by a decrease in revenue from the Mallinckrodt Collaboration as we have completed all required obligations under the Mallinckrodt Collaboration in 2024.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue for the year ended December 31, 2023, was $31.6 million (2022: $21.7 million). The increase was primarily due to the advancement of targets in our AstraZeneca Collaboration and Hansoh Collaboration, resulting in $17.8 million payment to us in 2023, and $13.1 million from the Mallinckrodt Collaboration. In 2023, we acquired exclusive worldwide rights to two preclinical siRNA assets under the Mallinckrodt Collaboration which resulted in a contract modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Sales</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales consists of research and development expenditure that is directly related to work carried out on revenue generating contracts, which decreased to $11.8</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2024 (2023: $12.9 million). The change was due to activity associated with our collaboration agreements, which fluctuates based on the timing of activities and project progression.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales decreased to $12.9 million for the year ended December 31, 2023 (2022: $13.5 million). There were no costs associated with revenue recognized as a result of the Mallinckrodt Collaboration contract modification. The remaining change was due to activity associated with our collaboration agreements, which fluctuates based on the timing of activities and project progression.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our research and development costs for the years ended December 31, 2024, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted development costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(42,902</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,048</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,322</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,503</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,468</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(17,187</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,478</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,421</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,041</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,883</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(56,937</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(43,550</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs for the year ended December 31, 2024, were $67.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million as compared to $56.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the year ended December 31, 2023 and $43.6 million for the year ended December 31, 2022. Contract development costs in the current year increased by $7.9</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million from 2023 as a result of additional clinical trials and an increase in contract manufacturing activities for our proprietary programs. Other costs increased by $2.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million from 2023 associated with the increased shipping and license fees.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses were $26.9 million for the year ended December 31, 2024, as compared to $26.2 million for the year ended December 31, 2023, and $25.7 million for the year ended December 31, 2022. The increase in the current year is mainly due to the cost of additional reporting and compliance requirements in connection with our transition to becoming a domestic issuer and large accelerated filer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign currency gain (loss), net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net foreign exchange gains and losses result primarily from foreign currency (U.S. Dollar and EUR) denominated bank accounts.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income (expense), net</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income primarily relates to accretion from U.S. Treasury Bills and interest on cash accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Benefit from R&amp;D credit</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Benefit from R&amp;D tax credit relates to U.K. research and development tax credits. The higher tax credit in current year due to an increase in R&amp;D expenditure compared to previous year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Taxation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Taxation expense relates to foreign taxation.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have incurred significant operating losses and negative cash flows. We anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development and administrative expenses will increase in connection with conducting clinical trials and seeking marketing approval for our product candidates, as well as costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity financings, debt financings, research funding, collaborations, contract and grant revenue or other sources.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash, cash equivalents and short-term investments of $147.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have financed our operations primarily through the issuances of our equity securities and from upfront, milestone and research payments under collaboration agreements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 15, 2021, we entered into an Open Market Sale Agreement, or the Sales Agreement, with Jefferies LLC, or Jefferies, pursuant to which we may offer and sell, from time to time, our ADSs through Jefferies. On October 15, 2021, we filed a registration statement, which became effective on October 22, 2021, for the issuance and sale of up to $100.0 million of ADSs. In 2024, we raised proceeds of $27.7 million before deducting $0.9 million in placement agent fees and other expenses, from sales of ADSs under the Sales Agreement. On October 22, 2024, we filed a new registration statement on Form F-3, which replaced the registration statement originally filed on October 15, 2021, for the issuance and sale, if any, of up to an additional $100 million of its shares represented by ADSs under the Sales Agreement. As of this filing, approximately $139.6 million of ADSs remained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2024, we entered into a Securities Purchase Agreement, or the Purchase Agreement, with the purchasers named therein, or the Investors. Pursuant to the Purchase Agreement, we agreed to sell an aggregate of 5,714,286 of our ADSs to the Investors, at a purchase price equal to $21.00 per ADS, or the Private Placement. The Purchase Agreement contained customary representations and warranties from us and the investors and customary closing conditions. The closing of the Private Placement occurred on February 7, 2024, and we received aggregate gross proceeds from the Private Placement of approximately $120.0 million before deducting $7.7 million in placement agent fees and other expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Purchase Agreement, we filed a registration statement on Form F-3 (File No. 333-279185), which was declared effective by the SEC on May 14, 2024, covering the resale of the Registrable Securities (as such term is defined in the Purchase Agreement). We have agreed to use our commercially reasonable efforts to keep such registration statement effective until the earlier of (i) the date on which all Registrable Securities covered by such Registration Statement, as amended from time to time, have been sold, and (ii) the date on which there cease to be any Registrable Securities.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, other than operating leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 2 of our consolidated financial statements appearing elsewhere in this Annual Report on for additional discussion of liquidity and capital resources.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating and Capital Expenditure Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not achieved profitability on an annual basis since our inception, and we expect to incur net losses in the future. We expect that our operating expenses will increase as we continue to invest to grow our product candidate pipeline, hire additional employees and increase research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, as a public company, we incur significant additional audit, legal and other expenses. We believe that our existing capital resources will be sufficient to fund our operations, including currently anticipated research and development activities and planned capital spending, at least for the next twelve months.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements will depend on many factors, including but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress and cost of our clinical trials, preclinical programs and other related activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent of success in our early preclinical and clinical-stage research programs, which will determine the amount of funding required to further the development of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs involved in filing and prosecuting patent applications and enforcing and defending potential patent claims; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the outcome, timing and cost of regulatory approvals of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost and timing of establishing sales, marketing and distribution capabilities; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of hiring additional skilled employees to support our continued growth and the related costs of leasing additional office space.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the results of our cash flows for the years ended December 31, 2024, 2023 and 2022.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="11" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash outflow from operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(67,640</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,462</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(57,044</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash (outflow)/income from investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,966</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,294</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,498</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash inflow from financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,087</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,937</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,581</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,481</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,769</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,961</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash outflow from operating activities was $67.6 million for the year ended December 31, 2024, reflecting an increase from a net cash outflow of $49.5 million for the year ended December 31, 2023. This increase in cash outflow is largely due to increased spend in fiscal 2024 associated with additional spend on clinical trials and an increase in contract manufacturing activities for our proprietary programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash outflow from operating activities was $49.5 million for the year ended December 31, 2023, from a net cash outflow of $57.0 million for the year ended December 31, 2022. This decrease in cash outflow was largely due to the 2021 R&amp;D tax credit payment of $8.5 million paid in 2023. No related amount was received in 2022.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investing activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities was $22.0 million for the year ended December 31, 2024, compared to an inflow of $19.3 million for the year ended December 31, 2023. This change was primarily due to the redemptions of U.S. Treasury Bills with maturities over three months of $117.4 million in 2024 partially offset by purchases of $139.2 million. For the year ended December 31, 2023, we had redemptions of $45.1 million partially offset by purchases of $25.8 million.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash inflow from investing activities was $19.3 million for the year ended December 31, 2023, compared to an outflow of $20.5 million for the year ended December 31, 2022. This change was primarily due to the redemptions of U.S. Treasury Bills with maturities over three months of $45.1 million in 2023, partially offset by purchases of $25.8 million. For the year ended December 31, 2022, we had a purchase of &#163;20.0 million with no redemptions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financing activities</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net cash inflow from financing activities was $142.1 million for the year ended December 31, 2024. In 2024, we raised additional proceeds of $27.7 million before deducting $0.9 million in placement agent fees and other expenses, from sales of ADSs under our Sales Agreement. We raised aggregate gross proceeds from the Private Placement (as defined below) of $120 million before deducting $7.7 million in placement agent fees and other expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The net cash inflow from financing activities was $31.9 million for the year ended December 31, 2023, primarily due to the proceeds we received from the Sale agreement.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations and Commitments</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development and Manufacturing Agreements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We enter into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with CDMOs and development and clinical trial services with CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreement. These obligations and commitments are not separately presented.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Collaboration Agreements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See &#8220;&#8212;Collaboration Agreements&#8221; included above for further details on our collaboration agreements. We have not included milestone or royalty payments or other contractual payment obligations under such collaboration agreements as the timing and amount of such obligations are unknown or uncertain and are contingent upon the initiation and successful completion of future activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selected Financial Data &#8211; for the quarters ended 2024 under U.S. GAAP (unaudited)</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table contains selected quarterly unaudited financial information for the year ended December 31, 2024 (in thousands, except per share data). The selected information for each of the quarters reflects our retrospective change due to the conversion from IFRS to U.S. GAAP and includes all normal and recurring adjustments necessary for the fair presentation of our results of operations.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.826%;box-sizing:content-box;"/>
    <td style="width:13.055%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.355%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.355%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.355%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:11.056000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="11" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mar-31</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jun-30</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Sep-30</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Dec-31</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,699</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">755</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,498</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,305</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost and operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(21,280</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(24,145</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(31,496</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(29,657</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net (loss)/income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,312</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,756</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(35,544</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,303</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic net (loss)/income per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.02</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.25</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.09</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted (loss)/income per share</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.02</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0.25</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.09</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we had a net income for the three months ended December 31, 2024, we have added diluted net income (loss) per share. Diluted net income per share adjusts the basic net income per share and the weighted-average number of shares of common stock outstanding for the potentially dilutive impact of the Company&#8217;s stock awards, using the treasury stock method.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Critical Accounting Estimates</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial statements are prepared in accordance with U.S. GAAP. The preparation of the financial statements and related disclosures requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management evaluates estimates and assumptions on a periodic basis. Our actual results may differ from these estimates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition under Collaboration Agreements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, 2023 and 2022, a significant portion of our revenue from collaboration agreements was derived from our agreements with Mallinckrodt, AstraZeneca, and Hansoh.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mallinckrodt obtained an exclusive worldwide license for three RNAi programs, AstraZeneca obtained an exclusive worldwide license for up to ten RNAi targets and Hansoh obtained an exclusive option to license up to two targets in Greater China, Hong Kong, Macau and Taiwan and a third target worldwide.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have out-licensed the rights to some of our intellectual property associated with our siRNA stabilization chemistry technology to AstraZeneca in the context of a Research Collaboration, Option and License Agreement dated March 24, 2020, under which we and AstraZeneca will collaborate to discover, develop and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases. AstraZeneca made an upfront cash payment of $60 million, of which $20 million was paid in May 2020 and the remaining $40 million was paid in May 2021. The upfront payment has been allocated evenly between the ten targets on the basis of a benchmarking exercise that took into account the standalone selling price per target, of similar precedent transactions that had been publicly announced by comparable companies. Subsequent milestones are allocated to the target to which they are related. The upfront and milestone payments will be recognized as revenue as the services are provided. We anticipate initiating work on up to five targets in the early stages of the collaboration, with AstraZeneca having the option to extend the collaboration to a further five targets. Under the collaboration, utilizing our technology, we are responsible for designing siRNA molecules against gene targets selected by AstraZeneca, and for manufacturing of material to support GLP toxicology studies and phase 1 clinical trials. We and AstraZeneca will collaborate during the discovery phase, and AstraZeneca will lead clinical development and commercialization of molecules arising from the collaboration. For each target selected under the collaboration, we will be eligible to receive up to $140 million in milestone payments upon the achievement of milestones relating to initiation of specified clinical trials, the acceptance of specified regulatory filings and the first commercial sale in specified jurisdictions. AstraZeneca has the right to terminate the agreement in its entirety or on a target-by-target basis, for any reason upon specified prior written notice to us. We may terminate the agreement on a target-by-target basis in the event that AstraZeneca begins a legal or administrative proceeding challenging the patentability, validity, ownership or enforceability of our patents. Either party may terminate the agreement on a target-by-target basis upon a material breach by the other party that is not cured within a specified period after receiving written notice, or in its entirety upon giving written notice following the other party&#8217;s bankruptcy, insolvency or similar instance. The license of the intellectual property and the R&amp;D services are not distinct, as AstraZeneca cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, which could not be performed by another party, indicating that the two are highly interrelated. On this basis, we have concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target (i.e., one for the initial target and one for each additional optioned complement-mediated disease target). We recognize revenue over the duration of the contract based on an input method based on percentage of cost incurred.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We granted an exclusive worldwide license to our C3 targeting program, SLN501, with options to license two additional complement-mediated disease targets, to Mallinckrodt in July 2019 to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders, with Mallinckrodt exercising the option for two additional targets from us in July 2020. The license of the intellectual property and the R&amp;D services are not distinct, as Mallinckrodt cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, which could not be performed by another party, indicating that the two are highly interrelated. On this basis, we have concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> one for the initial target and one for each additional optioned complement-mediated disease target). We recognize revenue over the duration of the contract based on an input method based on cost to cost.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement with Mallinckrodt has four elements of consideration:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a fixed upfront payment, which we received in July 2019;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subsequent milestone payments, which are variable and depend upon our achievement of specified development, regulatory and commercial milestones;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments in respect of certain research personnel costs on an FTE, basis, which costs are variable depending on activity under the collaboration; and</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">funding for phase 1 clinical development and certain preparatory activities, including GMP manufacturing, which costs are also variable.</span></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The upfront payment has been allocated evenly between the initial target and the optioned complement-mediated disease targets, because the compounds are at a similar stage of development, on the basis of a benchmarking exercise that took into account the standalone selling price per target, of similar precedent transactions that had been publicly announced by comparable companies. Subsequent milestones are allocated to the target to which they are related. The upfront and milestone payments will be recognized as revenue as the services are provided.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, we reacquired exclusive worldwide rights to two preclinical siRNA assets under its Mallinckrodt collaboration, which resulted in a modification of the agreement. No additional performance obligations were identified as a result of the modification as there were no additional goods or services to be provided by us and the modification resulted in the partially satisfied performance obligations relating to the two reacquired targets becoming fully satisfied as we were no longer obligated to develop these targets. SLN501, the C3 targeting program, remained under the original collaboration agreement through March 2024. We have accounted for the modification as if it were part of the existing contract as the remaining services to be delivered form part of a single performance obligation that is partially satisfied at the date of contract modification. The effect of the contract modification was the consideration originally received for the two preclinical siRNA assets was reallocated to SLN501. We have recognized the effect of the contract modification on the measure of progress towards complete satisfaction of the performance obligation and recognized an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis. In relation to the reacquired targets, we will potentially pay future success-based milestones and low single digit royalties on net sales if the projects advance. We will recognize these variable success-based milestones as an intangible asset at cost when triggered. Any royalties will be expensed in cost of sales.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We granted an exclusive option to license two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of phase 1 trials to Hansoh on October 15, 2021. We will retain exclusive rights for those two targets in all other territories. Silence will be responsible for all activities up to option exercise and will retain responsibility for development outside the China region post phase 1 trials. Hansoh will also have the exclusive option to license global rights to a third target at the point of IND filing. Hansoh will be responsible for all development activities post option exercise for the third target. Hansoh made a $16 million upfront payment to us in December 2021 which has been allocated between the three targets based on geography for each option, amount of reimbursable costs for activities provided by Silence for each target, as well as a benchmarking exercise that took into account the standalone selling price per target based on similar precedent transactions that had been publicly announced by comparable companies. Subsequent milestones are allocated to the target to which they are related. The upfront payment and subsequent milestone payments, which are variable and depend upon probability of achievement of specified development, regulatory and commercial milestones, will be recognized as revenue as the services are provided. The license of the intellectual property and the R&amp;D services are not distinct, as Hansoh cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, which could not be performed by another party, indicating that the two are highly interrelated. On this basis, we have concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> one for the initial target and one for each additional optioned complement-mediated disease target). We recognized revenue over the duration of the contract based on an input method based on cost to cost.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all the collaboration agreements listed above, as there is only a single performance obligation per target, the revenue for each element of consideration will be recognized over the contract period based on a cost-to-cost method, which is considered to be the best available measure of our effort during the contract period. The total cost estimate for the contract includes costs expected to be incurred during the contract period. Other variable elements of consideration will only begin to be recognized when it is considered highly probable that a significant reversal of the amounts will not occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2024, 2023 and 2022, we determined actual costs and forecast costs for the remainder of the contract. We calculated total contract costs across the contract term, including costs that will be reimbursed to us, and costs incurred to date as a percentage of total contract costs. We multiplied this percentage by the consideration deemed highly probable of not having a significant reversal, calculating the cumulative revenue to be recognized. When variable consideration increases due to a further milestone becoming highly probable that a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant reversal of revenue will not occur, a catch-up in revenue is recorded to reflect efforts already expended by us up to that point.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recognition of Clinical Trial Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses related to our preclinical studies and clinical trials. To obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. Examples of our accrued expenses include fees paid to CROs for services performed on preclinical studies and clinical trials and fees paid for professional services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We discuss the effect of recently issued and adopted pronouncements in Note 2.20 to the consolidated financial statements appearing elsewhere in this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See note 2.20 to our consolidated financial statements for the year ended December 31, 2024, appearing elsewhere in this Annual Report for a discussion of new standards and interpretations recently and not yet adopted by us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="quantitative_and_qualitative_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7A. Quantitative and Quali</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tative Disclosures About Market Risk.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market risk arises from our exposure to fluctuation in interest rates and currency exchange rates. These risks are managed by maintaining an appropriate mix of cash deposits in the two main currencies we operate in, placed with a variety of financial institutions for varying periods according to expected liquidity requirements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit and Liquidity Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cash, cash equivalents and U.S. Treasury Bills are on deposit with two financial institutions, one in the US and one in the UK, which management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. We invest our liquid resources based on the expected timing of expenditures to be made in the ordinary course of our activities. All financial liabilities are payable in the short term, meaning no more than three months, and we maintain adequate bank balances in either instant access or short-term deposits to meet those liabilities as they fall due. We do not believe we had any credit risk relating to our trade receivables as of December 31, 2024, 2023 and 2022, which consisted solely of amounts due from AstraZeneca, Mallinckrodt and Alnylam.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currency Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements are presented in U.S. dollars. The individual financial statements of each Group entity are prepared in the currency of the primary economic environment in which the entity operates (its functional currency). Our transactions are commonly denominated in U.K pounds sterling; however, we receive payments under our collaboration agreements in U.S. dollars and we incur a portion of our expenses in other currencies, primarily Euros, and are exposed to the effects of these exchange rates. We seek to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in these other currencies. Where significant foreign currency cash receipts are expected, we consider the use of forward exchange contracts to manage our exchange rate exposure.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash and cash equivalents and short-term investments of $147.3 million. Our exposure to interest rate sensitivity is impacted primarily by changes in the underlying U.K. and U.S. bank interest rates. Our surplus cash and cash equivalents are invested in interest-bearing savings accounts and certificates of deposit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">from time to time. During the years ended December 31, 2024, 2023 and 2022, we have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital preservation of investments with short-term maturities, we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Note 23 to our consolidated financial statements  appearing elsewhere in this Annual Report for additional disclosures about market risk.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="financial_statements_and_supplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8. Financial Stateme</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nts and Supplementary Data</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements, together with the report of the independent registered public accounting firm required to be filed pursuant to this Item 8 are appended at the end of this Annual Report. An index of those financial statements is found in Item 15 of Part IV of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="changes_in_and_disagreements_with_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9. Changes in and Disagreements wi</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th Accountants on Accounting and Financial Disclosure</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9A. Controls and </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Procedures</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosure Controls and Procedures</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this Annual Report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of December 31, 2024, our disclosure controls and procedures were effective.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Exchange Act Rules 13a-15(f) and 15d-15(f) define this as a process designed by, or under the supervision of, our Chief Executive Officer and our Chief Financial Officer and effected by the Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Furthermore, projections of any evaluation of the effectiveness of internal controls to future periods may prove invalid due to changes in our circumstances and the risk that compliance with policies, procedures and controls is not sustained.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has assessed the effectiveness of internal control over financial reporting as of December 31, 2024, based on the Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, management has concluded that our internal control over financial reporting as of December 31, 2024, was effective.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2024, as stated in their report that appears on page F-2 of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was no change in our internal control over financial reporting that occurred during the period covered by this annual report, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b4dd69e-68c7-4865-b38f-18b100c18299" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other Info</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rmation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024, no director or officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9daa9c0c-1bc1-40d4-8564-8845c049accc" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_53c8b60f-1c09-47fc-8fd5-2af6f8fdccd6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aed62cbf-704a-438f-9f22-479781fde2e7" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f4ac5f36-a73a-4ee7-833e-2c0406dba51c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="disclosure_regarding_foreign_jurisdict"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Ju</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risdictions that Prevent Inspections</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iii"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PA</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RT III</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="directors_executive_officers_and_corpora"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 10.	Directors, Executive O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fficers and Corporate Governance</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for our 2025 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted a Code of Business Conduct and Ethics that is applicable to all our employees, executive officers, including our principal executive, principal financial and principal accounting officers, members of our board of directors, and consultants. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, to the principal executive officer, principal financial officer and principal accounting officer or controller or persons performing similar functions from a provision of the Code of Business Conduct and Ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. The Code of Business Conduct and Ethics is available on our website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://silence-therapeutics.com/investors/governance/governance-documents</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91d3cee2-ad0b-41a8-9371-2d73a962532b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> an Insider Trading Policy governing the purchase, sale and/or other dispositions of our securities by our directors, officers and employees. A copy of the Insider Trading Policy is filed as an exhibit to this Annual Report. In addition, it is our practice to comply with the applicable laws and regulations relating to insider trading.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 11.	Executive C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ompensation</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for our 2025 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="security_ownership_of_certain_beneficial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 12.	Security Ownership of Certain Be</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">neficial Owners and Management and Related Stockholder Matters</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for our 2025 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="certain_relationship_and_related_transac"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 13.	Certain Relationships and Rela</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ted Transactions, and Director Independence</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for our 2025 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="principal_accountant_fees_and_services"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 14.	Principal Accounta</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nt Fees and Services</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this item is incorporated by reference to our Proxy Statement for our 2025 Annual General Meeting of Shareholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2024.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_iv"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PAR</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="exhibits_and_financial_statement_schedul"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 15.	Exhibits and Financ</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ial Statement Schedules</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)  Documents filed as part of Form 10-K.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)  	Financial Statements</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Income (Loss)</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Income (Loss)</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Equity</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cashflows</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	(2) 	Schedules</span></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Schedules have been omitted as all required information has been disclosed in the financial statements and related footnotes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(3) 	Exhibits</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following exhibits are filed as part of this Annual Report on Form 10-K or are incorporated herein by reference.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:43%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:10.5%;box-sizing:content-box;"/>
    <td style="width:12.5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference to Filings Indicated</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit Description</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">File No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed/Furnished</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Herewith</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095017023036510/sln-ex4_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Articles of Association</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-273576</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/1/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012321003321/sln-ex41_266.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Deposit Agreement, by and among the registrant and The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 4, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-254021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/9/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1814079/000101915520000240/silence424.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of American Depositary Receipt</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(included in Exhibit 4.1)</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-254021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/9/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Share Capital and Articles of Association</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095017023007992/sln-ex2_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of American Depositary Shares</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39487</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/15/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095017023036510/sln-ex99_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc 2018 Long-Term Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-273576</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/1/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095017023036510/sln-ex99_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc 2018 Non-Employee Long-Term Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S-8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-273576</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/1/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex103_60.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employee U.S. Sub-Plan under the 2018 Employee Long-Term Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4#</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex104_61.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Employee U.S. Sub-Plan under the 2018 Non-Employee Long-Term Incentive Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5&#134;+</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex105_55.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License and Collaboration Agreement, by and between the registrant and Mallinckrodt Pharma IP Trading DAC, dated July 18, 2019</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6&#134;+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex106_56.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Research Collaboration, Option and License Agreement, by and between the registrant and AstraZeneca AB, dated March 24, 2020</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7&#134;+</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000156459022010774/sln-ex47_373.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exclusive Research Collaboration, Option and License Agreement by and between the registrant and Hansoh (Shanghai) Healthtech Co., Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Limited, dated October 14, 2021</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39487</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/15/2023</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:43%;box-sizing:content-box;"/>
    <td style="width:7%;box-sizing:content-box;"/>
    <td style="width:11%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:10.5%;box-sizing:content-box;"/>
    <td style="width:12.5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex107_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Deed of Indemnity between the registrant and its directors</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex108_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Deed of Indemnity between the registrant and its executive officers</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001479615/000095017024030519/sln-ex4_10.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Equity Incentive Plan with Non-Employee Sub-Plan and CSOP Plan</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39487</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.10</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/13/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000119312521299424/d222455dex11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Open Market Sale AgreementSM by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.1 to the Registration Statement on Form F-3 (File No. 333-260265) filed with the Commission on October 15, 2021)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-3</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-260265</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10/15/2021</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000119312524024224/d738907dex992.htm" style="-sec-extract:exhibit;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of February 2, 2024, by and among the Registrant and the investors named in the Securities Purchase Agreement</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6-K</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39487</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">02/05/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1479615/000095012320009257/cik0001479615-ex211_57.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of the Registrant</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">333-248203</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/20/2020</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of PricewaterhouseCoopers LLP</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (incorporated by reference to the signature pages of this Annual Report on Form 10-K).</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1*</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sln-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification by the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001479615/000095017024030519/sln-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc Compensation Clawback Policy</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20-F</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">001-39487</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/13/2024</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#134; Portions of this exhibit (indicated by asterisks) have been omitted because the registrant has determined they are not material and would likely cause competitive harm to the registrant if publicly disclosed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Certain schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350 and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 16.	F</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">orm 10-K Summary</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.96%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46.04%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS PLC</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Craig Tooman</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Craig Tooman</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 27, 2025</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF A</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TTORNEY</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the undersigned officers and directors of Silence Therapeutics plc hereby constitutes and appoints Craig Tooman and Rhonda Hellums, and each of them, their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, with all exhibits thereto, and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary and proper to be done in connection therewith, as fully to all intents and purposes as the undersigned could do if personally present, and each of  the undersigned for himself or herself  hereby ratifies and confirms that all said attorneys-in-fact and agents, or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:48%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Craig Tooman</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Craig Tooman</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer and Director</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Executive Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rhonda Hellums</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rhonda Hellums</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Financial Officer and</span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Principal Accounting Officer</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Iain Ross</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Iain Ross</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Dave Lemus</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dave Lemus</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Davidson</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Davidson, MD, FACC, FNLA</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ James Ede-Golightly</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">James Ede-Golightly</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:90%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#auditors_report"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting firm (PCAOB ID </span><span><ix:nonNumeric id="F_4561052d-b882-44af-afa3-a8928bc66ea4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">876</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-2</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-3</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_income_loss"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Income (Loss)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-4</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_comprehensive_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Comprehensive Income (Loss)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-5</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cash_shareholder_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Shareholders' Equity</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_cash_flow_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cashflows</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-7</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to the Consolidated Financial Statements</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-8</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="auditors_report"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Board of Directors and Shareholders of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2a6f2da-f4d6-4ae5-b4fe-61bbc853c449" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:AuditorOpinionTextBlock" escape="true"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Silence Therapeutics plc</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and its subsidiaries</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Company&#8221;) as of December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 2023,</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the related consolidated statements of income (loss), of comprehensive income (loss), of changes in shareholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the results of its</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations and its</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash flows for each of the three years in the period ended December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the COSO.</span></p></ix:nonNumeric></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinions</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits of the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements included performing procedures to assess the risks of material misstatement of the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accuracy of Management's assessment of accruals and prepayments related to third party research and development contracts</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Notes 2.8, 12 and 14 to the consolidated financial statements, research and development expenditures included within prepayments and accruals and other payables as of 31 December 2024 was $11.0 million and $5.9 million, respectively. Management recognizes expenditure incurred in carrying out its research and development activities in line with their best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal considerations for our determination that performing procedures relating to accuracy of Management's assessment of accruals and prepayments related to third party research and development contracts  is a critical audit matter are (i) the significant judgment by management when estimating the stage of completion of these contacts; and (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the stage of completion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the accuracy of Management&#8217;s assessment of the accruals and prepayments related to third party research and development contracts.  These procedures also included, among others (i) reading new significant research and development contracts; (ii) testing the completeness and accuracy of the underlying data including total contract costs and actual billed amounts for a sample of contracts; (iii) evaluating Management&#8217;s process for determining the stage of completion on a sample of contracts; (iv) evaluating the appropriateness of the methodology; and (v) evaluating the reasonableness of the significant assumptions used by management related to the stage of completion on a sample of contracts. Evaluating management&#8217;s assumptions related to the reasonableness of the stage of completion involved testing a sample of research and development activities and the associated incurred cost based on invoices, external confirmations or other information received from the suppliers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d33137ea-1fc3-4c9a-9359-fe5fa6aa79e1" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c44c9ec-1990-4714-bce7-102b8b2c221d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reading, United Kingdom</span></ix:nonNumeric></span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 27, 2025</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2014.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> balance sheets</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.08%;box-sizing:content-box;"/>
    <td style="width:1.24%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:14.08%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.7%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:13.6%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cada649-14b9-470f-bc9e-e9e533a46f05" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38441d4e-0779-451c-be87-c9f3cc1b88fa" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Short-term investments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a18e2922-a578-4fb6-b193-53a403da1d92" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,004</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;R&amp;D benefit receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0164ad1e-bba8-4a09-85c6-d67b8675b2e8" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:ResearchAndDevelopmentBenefitReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,396</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33d3c0d4-543d-4553-831b-3ebd980343bc" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:ResearchAndDevelopmentBenefitReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,442</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2af90d11-0c18-4372-a1b1-0a44ab917be9" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,664</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed165592-353d-4cef-a201-7424607e4408" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,630</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Trade receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e33dc83-b8d9-44c4-92f6-baf1909c6f44" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3ad840e-c8a1-480c-b984-19d428ec0c55" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf6764cc-0479-4fe0-909b-504ee1605a17" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,366</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bedcf160-6870-4d6a-b915-7cd551592f99" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">103,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bcecd80-205e-4faf-89ed-e666e052dcf8" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,818</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f1438a-8c32-4fe0-b90c-df0fccf86748" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,938</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5da30e31-7e59-4d5c-b502-90fc1f3c72ab" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23470c6e-79d3-4793-a3f4-d9137f6d2a4b" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8bf80f-13b2-4aa0-939b-d6006fdb6fdf" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_377dfe97-02bd-448a-9916-56f3052ec553" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,981</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdce5d68-a546-4c04-bffe-4e0d93eaed42" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OtherIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1b0869b-4f34-4802-9791-cb230821c8a9" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OtherIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da9da5a-d255-4602-8d7c-c7ff5fa74d0c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,590</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee13e042-58ec-43a9-bea9-b376b7e4b42d" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1abaa103-f3f7-437f-bf95-202e6285e7f7" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,635</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09f55380-e132-40cd-ad51-60ad8a3231cd" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3264e12-f8b8-4324-b40b-80b1b41d120b" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c57939d-7274-4b82-864a-4df59aad5a98" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,571</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Trade and other payables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29354654-3983-4edf-bbef-439d9546c661" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccountsPayableOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,399</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3920222f-f24b-482e-9104-34045b28ecb2" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccountsPayableOtherCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,537</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_214e52b5-b083-4f25-ac53-c3dd91450cb3" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a4e3248-734d-4436-8c7f-e4869a5e4e68" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c32e364e-a870-4ae0-a451-5804eef141c3" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,822</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c39024d-b48c-466c-94aa-7a5ab762dffd" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,336</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf3a0e44-b4f2-4ba7-a15c-f10b4dbc3616" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,790</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1923fefc-e6e1-478c-802d-80e8f01355d3" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,001</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, long-term</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9bc3265-3fa3-42eb-b8bc-b9574de7e0b2" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f074fa02-49a0-4cc4-9134-49076bb11464" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,612</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e42b2ca3-2b3f-4dd7-a26e-e46008fbc752" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,455</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_d92f026f-ce71-48af-812d-8e0ff8cabed1;"><span style="-sec-ix-hidden:F_67dabae8-767d-495f-b035-1a9900d294d1;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(Note 20)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shareholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ordinary shares - par value &#163;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_386de441-e369-44a1-a195-e1f0ff453f06" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_U_iso4217GBP_xbrlishares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6add2350-484d-497a-94c2-08e5b8f9f73a" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_U_iso4217GBP_xbrlishares" decimals="INF" format="ixt:num-dot-decimal">0.05</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1d0946d-3aa4-44ad-bd76-e826b28a14f2" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,674,074</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued at December 31, 2024 (2023: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2534482a-409b-430b-8645-6d49e89692ce" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,846,966</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c1f8be-5b0c-4036-b883-15830f1ea915" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,288</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49267d6a-1d2a-4e10-9e32-e20d717f3b2e" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f3aa9d0-f888-4c5c-a4ff-b622bb2c7103" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609,560</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87562ef7-0f42-47be-a611-fd1f30c6e5ce" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">455,765</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85c011a7-af03-4fd3-9006-d8731b803fff" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">474,044</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9148e684-f759-4cf3-83bb-36cf5392b1d5" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">431,894</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41b06106-2f07-4861-9d70-8b8411af5d47" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,781</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_793475a0-ce94-4837-b04d-f316fdb13e5e" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total shareholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16e0635f-80a3-45f9-a43a-eb4e9a1d2306" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,023</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3bf9bac-a752-4597-9663-340b46ae0e77" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities and shareholders' equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f30ad11-6633-49c0-b422-ea3124ef3138" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202,635</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df096ce5-bf51-47a7-96a1-8cf33ab7d2e7" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes form an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_income_loss"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated S</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tatements of income (loss)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands, except for loss per share)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.971%;box-sizing:content-box;"/>
    <td style="width:2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.797%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.498%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.318000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.018%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Note</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddc15893-7405-4f9a-94f9-f152164800dc" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,258</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1af5f9-8c20-4f7f-8854-265ef0ad46ec" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,643</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a24a40cb-53da-4a2f-a60d-f0766b814d8b" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2769a664-1f3b-4af1-a183-da2a340d107f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,810</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d23168d5-2678-4e24-9c4e-9c7d4b985df7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,867</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_567f9362-4939-4865-afd3-8e9e65a57d6d" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,463</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96142dc6-7dd3-454a-9e74-fa9e40765040" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,448</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1870777f-164e-497a-b93f-f4134b1fb6f5" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,776</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432e60cb-538e-4759-9517-0f1fe5f041bd" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,192</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e1046e6-3e5f-42b2-a6f1-9dadbc1de5ba" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,883</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da930b6d-da16-4c4c-8f57-420c8b219939" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,937</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5af2133-0569-4663-b55f-b89750e735fb" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,550</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8d694e4-d5fc-427b-ae64-e2c3515bd590" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,884</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_152787c7-a620-49bb-9d86-381b5c15c878" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,222</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_922bb934-b54a-44b0-a252-3dfc96975c68" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,682</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_958f352c-ba0d-42ee-9a89-5b0749279d66" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,319</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_379f35cf-36c8-4dba-a356-9c6e242ff34d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,383</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4584c9e8-9642-49ab-a409-ff6e3221a58f" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">61,040</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency gain/(loss), net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c1f4bc3-8d86-4cc9-a079-3ad45b594fd8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee69178-cc84-44ce-ba19-6c420a62be21" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,641</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_818e79e5-3819-4207-8cb2-9c8bd7517378" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef386375-b9ce-427b-9310-1121602b18a4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,472</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997d1aad-ead3-4f69-be80-83fdcd8d0af4" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89cf974e-fcbe-43d4-a734-371de6f3d463" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Benefit from R&amp;D credit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce711509-8e06-4dc9-9c89-975bd8866756" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:GainFromResearchAndDevelopmentCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,737</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1458384-e2ef-46c4-8c34-e4bf00ac2fac" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:GainFromResearchAndDevelopmentCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb603e1-9bee-42bb-b07a-6b52bd5bb205" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:GainFromResearchAndDevelopmentCredit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,820</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss before income tax expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c6531ef-de9a-4b03-9813-6d38a08fd7a4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,464</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dde919a-cb47-4bf6-b643-f6ced6fbb3bb" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,272</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7684b55d-a189-48a0-910d-bdbb554801d6" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afbfd5db-fd33-417f-9077-c87afbf6b328" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_773b1a02-5418-484a-a988-a06b06a59377" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8174e9e-ef3b-47b8-b87a-89181ee7b5cb" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6273a348-ef76-4cc6-b2e1-19937d22d33b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7deb037e-df9c-426b-9373-c810d5bc846a" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f1e549f-7c4c-4397-aa9d-438f865c60be" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Loss per share (basic and diluted)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef47ba8a-8663-4f15-b9fd-6955d78b6c70" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a28b619c-6024-4822-8206-da7acffc4e87" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.33</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faeb17c5-5c62-4bd3-8548-0b4897180c2b" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_24b323e6-e8d5-4c63-883e-d7f428aeba2e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.49</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e517c3ca-2f0d-4eaa-a723-dcacc3e33abb" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_715c98f5-f30e-40d5-8a0c-9e305bc1dd20" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.52</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average shares outstanding<br/>&#160;&#160;&#160;(basic and diluted)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4978773e-7464-462d-996f-ab54d4b5c83a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_40bfe501-0b8e-445a-94a8-afc1b32e1428" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">138,752,224</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba793e5f-a534-4ce2-b919-81f353c75493" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_75521240-ffe0-4767-b3e6-27243db55e18" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">111,277,250</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a86fafd8-53e1-40c5-9ef3-d6a984a833ad" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6177a1f1-687d-4876-acea-1ce70794f5fb" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">96,584,512</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes form an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_comprehensive_income"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated statements o</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">f comprehensive income (loss)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1faa9148-69c8-4da9-b567-f4aec8a497fc" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71df3dfe-d9b1-4fdb-a944-5433d2f5e0d6" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2017ab-8846-4c8d-b8d8-e6dd61bc4662" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange differences arising on consolidation of foreign<br/>&#160;&#160;&#160;operations (net of tax)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1112544c-90a7-480c-ab8e-f41339a78717" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,055</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae628588-b471-45a0-a20d-d678b7203b8c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_757416dd-afdb-42d4-b72c-e94bb7c4f59d" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other comprehensive (loss)/income for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c0abc0-694c-40a0-83ba-4d445e9236db" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,055</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f31816-39fa-4e5d-8e16-b9a9b7e840e9" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc9521f8-9338-40ed-9fe8-e5ba0d51bab5" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive loss for the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14431220-ebb7-4ee2-8b5c-4fe674de91d9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,364</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2f2bad0-6c74-4c8f-82f7-f832c39d3066" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,439</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adcf57bc-1715-478e-be7e-03c6672704e6" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,420</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes form an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cash_shareholder_equity"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PLC</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated statements of changes in SHAREHOLDERS' equity</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.786%;box-sizing:content-box;"/>
    <td style="width:1.2%;box-sizing:content-box;"/>
    <td style="width:4.881%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.961%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.981%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.981%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:9.082%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.981%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.981%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ordinary Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Note</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive income</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total shareholders'<br/>equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At January 1, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60bd4205-9b9e-40e8-aa03-7cb1906f7507" contextRef="C_8b1b366e-04b7-442e-aae8-9b9874416e85" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">89,784,720</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c4d3ef1-f512-4cb7-b005-e7bf13907c97" contextRef="C_8b1b366e-04b7-442e-aae8-9b9874416e85" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b7f44a3-7121-4e4f-9f46-e6541d6fc502" contextRef="C_8f5432bd-fe35-4ec3-a327-b8bc31778b49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">346,699</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90d18a7f-370f-4153-a8e2-040b24604a60" contextRef="C_d9492943-8f98-4acc-814a-052f211894d1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,428</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9108ed94-421b-4187-98af-658b78db02a5" contextRef="C_e692684b-2681-444f-8b7c-e8b4ef46529b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">329,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e85955f0-1581-4c90-9b3f-a546d623b50d" contextRef="C_c0f73974-d468-4883-a299-b1954062293c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,374</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3085b7d-1db6-4b02-81a4-89d707a6e033" contextRef="C_0f952a92-9ec0-42dc-8871-ae65f086585b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4efabbb7-5bec-46d7-b65f-b3737da4b5e2" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments (net of tax)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367ecff9-be99-4daf-b60d-42d326e8b89d" contextRef="C_bf66dbc2-8413-43ec-bd18-e8293742fcfe" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a1e615b-3bf5-4921-90f0-921c699f0f20" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of share-based payments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_413f3e0d-f79a-4a95-80f1-8e571d91035b" contextRef="C_27344b07-296f-4272-8c49-e68d36c05499" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,686</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76e15a61-e876-48a0-bad1-fe66fd1ae4c4" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,686</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised in the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b30149-48ff-409c-8bc5-d03b6d5580b4" contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">173,752</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec954ee-1503-48bd-87ca-4adb7af98659" contextRef="C_27344b07-296f-4272-8c49-e68d36c05499" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52446e0d-5d93-4f97-a8e2-f74e20b8c12a" contextRef="C_0f952a92-9ec0-42dc-8871-ae65f086585b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from shares issued</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03c1fad-f9c3-4d99-8354-488faac0dc04" contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,850,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb4ef26-7e74-4f81-a8d8-05e0c14da614" contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a951004-4ff1-47d9-a979-31a217a6dda3" contextRef="C_27344b07-296f-4272-8c49-e68d36c05499" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,495</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b78d2d-51bb-4988-ace3-3a096de86491" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,581</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01829c9e-8603-480a-9b11-e7aaee35d4f2" contextRef="C_c0372b91-8945-4668-a516-80774a76ddde" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">107,808,472</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1facde38-5642-47d0-bba9-cef289c5550b" contextRef="C_c0372b91-8945-4668-a516-80774a76ddde" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,151</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cec66dd-0920-4ede-9207-d3cf1b16ab92" contextRef="C_50fc6d5c-fae9-4564-892e-b943a5104009" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,642</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd890d6c-8d73-48c7-9ec7-8a109be9e913" contextRef="C_58dfc602-04c5-4cbf-99d1-064ead7260df" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,514</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2c457ee-eee9-442d-ac44-3826e40c6203" contextRef="C_62b6b471-c432-4ab7-a3bd-bee9095e34fb" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">380,058</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c45c876-3ba5-4bd3-87a1-c47b08e3513f" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,221</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6268581-7d16-4bc8-9541-77ab749b1984" contextRef="C_97969988-6ccc-4333-8d42-d1661f89dba4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdd92954-8b7f-4349-b0d7-27d6a2dff8d0" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments (net of tax)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e66cc954-603a-4ac5-ad44-3c4db3e9923e" contextRef="C_45b856ba-a9f8-4504-b2af-359c27db06df" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_871a7793-2061-48dd-a911-a0bd4ea382b4" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of share-based payments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df441d9b-7d90-465c-91db-b81373f28942" contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,274</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68c84470-c79f-479e-a7d6-7cfbfbc05767" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,274</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised in the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18/19</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_260dbc9b-8a94-4f7d-b297-acfe6fbefad5" contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">807,927</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_271eb552-ccfa-45d0-be24-8abcecf37c3b" contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34b95401-d722-42e0-bd7d-1e68cbc1597a" contextRef="C_97969988-6ccc-4333-8d42-d1661f89dba4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from shares issued</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b336f7c-0784-4d57-9d0f-a2b4839c77a0" contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,230,567</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e955e3a4-ae31-4ed6-850c-1361af786808" contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1190195c-311f-440b-9b49-750c70ed358b" contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,241</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c757988f-1db2-4480-851a-ae9977cce85b" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,937</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72f18367-5eae-46d0-8884-929446bd6c7b" contextRef="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,846,966</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7310112f-ffd6-45a8-9c6e-fe676496936e" contextRef="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,847</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74ee280a-8579-4602-b637-3f338f493b5b" contextRef="C_2477b135-cd13-49b5-a4d8-b62ae8c75cd6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">455,765</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b02c5ac-54bd-4cd6-8662-5baf16e1b30d" contextRef="C_4d5d0d9e-bfe8-4d5b-9352-c404dd2ac67a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,725</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43a5b4f-9c71-42ea-9213-e752044b7895" contextRef="C_8184c077-a478-46ed-ad2a-22ca667a1dda" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">431,894</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1a99459-4e41-47e7-a9c6-c938321f6897" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,993</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10d6382a-5f68-48ca-b19f-43cfa781542e" contextRef="C_c5dd0282-7233-442b-9081-aa33c6702629" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eca50113-b32a-4c30-86a6-4e4eaf578908" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign currency translation adjustments (net of tax)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d2fa20-44b6-4630-85b2-28da7bf8013c" contextRef="C_2c48633d-504d-4b47-94ba-86f51f5eff2e" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,055</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ae4663-c1cb-41d9-85a4-a2775853b659" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,055</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of share-based payments</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ab8aa1-1713-4a2d-b25d-583570625225" contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,307</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dda6d0d-d316-40d5-8e04-8886d68e29aa" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,307</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised in the year</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18/19</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ba99959-96dd-4325-ba79-c312b7a7dcb9" contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,408,443</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3015d3a-660e-4df1-b2f4-f0f8124e2e25" contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aefc55ba-ac83-4ad5-82af-6a6ab0453fcf" contextRef="C_c5dd0282-7233-442b-9081-aa33c6702629" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from shares issued</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1a39d7f-1edd-4faf-b448-343438c7d98d" contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,418,665</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e86aaabb-a878-4a8f-8fb9-bbc06c1b900c" contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,441</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b2a4426-4e3d-42a1-b808-6560b6b72774" contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">140,646</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee37ba0c-e202-440d-9c03-e6c578796a7f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bbf9481-7d17-46a9-b9dc-6560131f035f" contextRef="C_dffb0a10-ead0-498a-9a65-80ec339f4808" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,674,074</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0900b4ce-014e-4be4-81b5-997290707f4a" contextRef="C_dffb0a10-ead0-498a-9a65-80ec339f4808" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,288</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5171efe-d075-4a55-895d-10a56384b874" contextRef="C_eeb3d142-dc2f-4224-b92c-0c451fa14eb6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609,560</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2ca34ee-e0c6-4a04-8db1-9dde63875b40" contextRef="C_037e26c3-7b8f-42ed-9595-fc5b17699c67" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,780</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6d49beb-4bd0-4484-887d-f7c279656a3e" contextRef="C_2883aa41-3a94-4d8f-bd1b-0dcd31622bf3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">474,045</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_580b777c-56b8-4d06-82ff-30c5af96e60d" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,023</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes form an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_cash_flow_statements"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated statements of cash</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> flows</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.477%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.399%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.776%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flow from operating activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a181edc-cb84-4c77-90e5-a9b2f25e96de" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_552e5ce8-e951-4e5c-878a-9ac942c6d663" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0db2712-cc01-4514-8716-e19eff8c9794" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash (used in) provided<br/>&#160;&#160;&#160;by operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f149c84-b09b-493e-8e1b-7e49e1af96e6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">336</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10cb4804-62b8-4583-9e54-51d8b3eeeb7d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">369</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f10c52-c286-4153-b622-a1e2bbf106ca" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">379</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbb59535-0cc0-444b-8873-77476875ce87" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AdjustmentForAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81326a0d-0d97-4ad6-bdcb-45c5e7c029d5" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:AdjustmentForAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba6f85cc-41e9-4655-be7b-cf7b31584ca3" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:AdjustmentForAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d730f7e5-9256-4027-bae0-e13ce88e4cfa" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,307</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8600c19-e865-40d1-bef4-9e34c8d81e03" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,274</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e71aad2-4f57-4f20-9b9c-08aceaa5b6a8" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,686</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net foreign exchange impacts</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c94727a8-9d5e-4552-a189-45d6b0d779a9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:NetForeignExchangeImpacts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,581</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d07885af-1632-4662-9b72-5b4a6189435f" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:NetForeignExchangeImpacts" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,962</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20552555-0e8e-454a-9bbe-3fb7d306f2ee" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:NetForeignExchangeImpacts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,003</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f33fae15-4f60-4afd-b659-4ab1afa4e38c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,472</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14e73c61-c3d2-4c8a-b955-d3e44dae7625" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84fab173-45bd-4c9d-8edc-03565d326149" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c25e0d30-b722-4bc7-b9bc-3cdbc32bb1ef" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6302002-9611-4261-baca-1757b6d342df" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75b853b8-8d2d-445b-939d-9b028b095a85" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Increase)/decrease in trade receivables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e104cdc-d5a0-412f-8136-c5befcf89cde" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">904</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf462d0c-5a70-407d-92b5-fb7ab714d729" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">392</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbd25819-e037-4002-9273-5472a3eed5e9" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Increase)/decrease in other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbfd5bca-3ab3-4ef8-a330-05d6423f114b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a1baa57-5432-45fb-94b2-d3e49da843c3" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,955</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b766a8d1-5533-411c-8f90-0b7b118ae086" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,199</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase in R&amp;D benefit receivable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17daf8f3-46d6-4254-aa47-5bc55240d830" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,337</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5aef5a8b-e282-4910-a3a8-075a9c29efd3" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0f6d90c-ddc1-4a0e-beee-af7e5470f910" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,821</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease/(increase) in other long-term assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9d60d4e-65ff-4057-8d65-5d2c00a6cb0a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475af9c9-8902-410e-b0c6-1416121d5a99" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increase/(decrease) in trade and other payables</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e657ca07-f6fa-4b48-b1ea-d645d338b12f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:IncreaseDecreaseInTradeAndOtherPayables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39ccbc03-d044-46e8-bff5-16ca422f2db7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:IncreaseDecreaseInTradeAndOtherPayables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">473</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecbe8867-0315-44e2-a1b0-0ded61a73c44" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:IncreaseDecreaseInTradeAndOtherPayables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,024</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease in contract liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c505319d-b88f-49cd-8586-05631a0f7e14" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28,786</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2a93e3b-348d-49e8-890a-74a02f1a35b8" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,323</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95b5ff4f-743e-4c25-bee8-6bf2a0db33ca" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,443</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Decrease in operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69fab691-7d46-4bad-bd59-bca278e87b83" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_612cdabe-044b-4127-a747-412626a757a7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3b53d9f-83fc-40db-8461-5a4aaebc1cca" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">235</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_561e3266-84ef-459f-bc6c-c85d78113ac9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,640</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf8670e-bc60-4298-9e1e-0a3efbe1c005" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,462</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a905074c-feae-4eb9-b9e1-1c2e81ee3b3b" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">57,044</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flow from investing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Redemption of term deposits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d4e31eb-d20f-4b91-8b2d-df8215637be5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:RedemptionOfTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117,412</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0331494-c2b4-4f19-9da7-9c32f59f8c8d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:RedemptionOfTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,121</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of term deposits</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec21ca6-a245-4544-bd42-ebf4e977fc08" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:PurchaseOfTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,167</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfff9cce-9442-4b75-b374-4791da4ccdea" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:PurchaseOfTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,771</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c6ad5b9-57a9-4154-8fc3-a34aba997f79" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:PurchaseOfTermDeposits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,953</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property, plant and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a5efa09-02d3-4db5-878f-a0b8f3bbe2d2" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">211</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1729cb7-cc9e-44b9-a434-7a5df7fda03e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f61b7cb1-e22e-487c-a593-fa812b553749" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of intangible assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_baeffc46-ea17-4e56-a18c-d2c020c31681" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">372</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash (used in) provided by investing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c19c3615-7ab3-4fc6-b215-720271e07c1a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,966</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91338688-931b-4a7a-abc6-699c4eb97ae8" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,294</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfb937ea-43cd-484f-9f69-7380711692b2" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,498</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flow from financing activities</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issue of ordinary shares</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3351b119-1e65-4fab-98d9-a974960cd298" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71863ef6-8053-480b-822b-766ff302d695" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,937</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44fbcf45-30ad-48f8-a3fb-d0ea3fa53d09" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,581</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_560ddec1-2666-4580-b359-ece13b5ca9e9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,087</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20db223f-f9c4-4af5-942c-052889405840" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,937</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f807eaa-710c-47c0-ab5f-f907536a02cf" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,581</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_677f3a26-d9d9-49f7-ae42-76f655ec18f6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,481</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c53be3a-2bb1-4713-82a0-bae1b4d5db6d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,769</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb0895e2-e962-4765-8cae-203f987a0472" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">24,961</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at start of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea937718-a278-4d0b-8203-402ccdbc446b" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7244ca3-7263-4a75-979a-b2d315910c13" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a7239a7-b03f-4ddc-b0b4-9e70482037a4" contextRef="C_c0f73974-d468-4883-a299-b1954062293c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,351</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate fluctuations on cash and cash equivalents<br/>&#160;&#160;&#160;held</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccd37273-b83b-408f-9a60-242abad74b0a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acdda2cd-b77c-47cc-b85a-ce1939462a6a" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">749</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03772c50-6bc0-43bd-98ed-554dd8ee382a" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,119</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d79adb-c8be-4d63-b381-a251c8088558" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,330</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81293dc2-d1cb-4cfe-88ef-c7e53ea7d512" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,789</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f133222-9d8b-45d7-9348-bb174896e4c4" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,271</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosures of cash flow information:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax Paid</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a4a303-448d-4b48-a66d-7a2d6069d751" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">433</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_371c86e2-e30d-429b-9cdd-3593009c67b9" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">801</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes form an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="notes_to_consolidated_financial_statemen"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the consolidate</span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d financial statements</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e356bab4-54c3-43bd-bc0a-fd3a31c8e927" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. General information</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.1. Nature of the business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc and its subsidiaries (together the "Group") are primarily involved in the discovery, delivery and development of RNA therapeutics. Silence Therapeutics plc, a public Company limited by shares registered in England and Wales, with company number 02992058, is the Group&#8217;s ultimate parent Company. The Company&#8217;s registered office is 27 Eastcastle Street, London, W1W 8DH and the principal place of business is 72 Hammersmith Road, London, W14 8TH.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_0433767f-4829-4fc0-af1a-928b452bfc5f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of significant accounting policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12044e2d-e616-4cab-976a-df1c6b650793" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1. Basis of preparation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC"). Any reference in these notes to the applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Group and its wholly owned subsidiaries, after elimination of intercompany accounts and transactions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group previously prepared its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (&#8220;IASB&#8221;)  when the Group qualified as a foreign private issuer under the rules and regulations of the SEC. In connection with the loss of the Group&#8217;s status as a foreign private issuer, the Group is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Group&#8217;s inception.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89a48719-df7e-4741-a494-87ddeb2a4bec" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:FunctionalAndReportingCurrencyPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2. Functional and reporting currency</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reporting currency of the consolidated financial statements is the U.S. Dollars (&#8220;USD&#8221; or &#8220;$&#8221;). The functional currency of the Group&#8217;s subsidiaries reflects the economic environment of their respective operations. All amounts disclosed have been rounded to the nearest thousand, unless otherwise stated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the loss of the Group&#8217;s status as a foreign private issuer, the Group as a domestic filer, changed its reporting currency of the consolidated financial statements from GBP to USD. The change in reporting currency was applied retrospectively. Consolidated financial statements for all periods have been recast into USD and presented to the nearest thousand dollars.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9df30208-8049-4b01-8c37-d0377ba9ff24" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3. Principles of consolidation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial information comprises the financial statements of Silence Therapeutics plc and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d326b1a8-da71-435d-a3ac-00ae53d0faaf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_d326b1a8-da71-435d-a3ac-00ae53d0faaf_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4. Use of estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, the recognition of revenue and research and development expenses. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_1" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d326b1a8-da71-435d-a3ac-00ae53d0faaf_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e13acd15-1e6a-4247-bb28-bc016b7185dd" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:GoingConcernPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5. Going concern</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05b87a8c-58e2-42b9-b003-ddc9769d5b49" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">45.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024. As of December 31, 2024, the Group had accumulated losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_712ffbfa-a980-4b0c-b285-5541f1cc0b53" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">474.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash outflows from operating activities for the year ended 31, December 2024 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44226c9c-6505-42e8-a444-e29b2183dbea" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">67.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group expects to incur operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Group may develop.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Group has funded its operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options to support its continued operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Group raised additional proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_583036d2-7163-4480-a712-7e15d1e6bc8c" contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fdcc719-1fc6-4541-8270-7fcdcea0785c" contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses, from sales of ADSs under its Sales Agreement. On February 5, 2024, the Group announced a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20fc6b4b-f3bd-4638-8e59-c0fe4c5bcaca" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,714,286</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a2543e2-e460-4ad3-82dd-54db06baf60e" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="sln:NumberOfOrdinarySharesDenominatedInTemporaryEquity" unitRef="U_OrdinaryShare" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a4982d9-c079-41b8-a032-7967896d8554" contextRef="C_504e865b-e8c6-4526-9b0b-319762518420" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors (the &#8220;Private Placement&#8221;). The aggregate gross proceeds of the Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb176de-7912-4ac6-ba16-2c40fe84adb8" contextRef="C_9b38472f-f9ad-4927-aa46-e70d32506104" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49678b9b-8e97-44f9-b1ee-ca368d8671ad" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses. In 2024, the Group received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_882e8dac-5760-452f-bcd1-6e210c801574" contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment from the AstraZeneca Collaboration and achieved another $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63fb85ad-cbac-4f89-92ab-ea29eb96f6ee" contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments from the Hansoh collaboration. As of December 31, 2024, the Group had cash and cash equivalents and short-term investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be682d3b-be44-44b6-9c28-1af77cf08612" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">147.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group believes that its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months from the issuance date of these consolidated financial statements. For this reason, the Group continues to adopt the going concern basis in preparing the financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group will need to raise additional funding to fund its operation expenses and capital expenditure requirements in relation to its clinical development activities. The Group may seek additional funding through public or private financings, debt financing or collaboration agreements. Specifically, the Group may receive future milestone payments from existing collaboration agreements which will extend the ability to fund operations. However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur. The inability to obtain future funding could impact; the Group&#8217;s financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75b2bfdb-21b8-4e3a-8545-592f8686964d" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6. Segment reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has determined that its chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Group has concluded that it operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment (see Note 4).</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_690210e3-461c-4bc7-bada-f104a6746e2a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_690210e3-461c-4bc7-bada-f104a6746e2a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7. Revenue recognition</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s revenue for the year ended December 31, 2024, consists of royalty income and revenue from collaboration agreements. To determine revenue recognition for arrangements that the Group determines are within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ASC 606: Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (&#8220;ASC 606&#8221;), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_2" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_3"><div><ix:continuation id="F_690210e3-461c-4bc7-bada-f104a6746e2a_1" continuedAt="F_690210e3-461c-4bc7-bada-f104a6746e2a_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue when, or as, the Group satisfies the performance obligations. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty income</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s royalty income is generated by a settlement and license agreement with Alnylam. Under this contract, Alnylam is obliged to pay royalties to the Group on the net sales of ONPATTRO&#153; in the EU in a manner commensurate with the contractual terms. Invoices are raised in arrears on a quarterly basis based on sales information provided by Alnylam no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ec00f81-c075-43c5-9aac-2e3ecd5c0206" contextRef="C_30137f17-19dd-4a65-a75e-44bd27a45a6c" name="sln:InvoiceRaiseDurationAfterQuarterEnd" format="ixt-sec:durday"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days after the quarter end.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 606, royalty income is recognized at the later date of (i) when the subsequent sale of the commercial partner&#8217;s product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from collaboration agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has considered the Mallinckrodt, AstraZeneca, and Hansoh contracts and assessed whether the research and development services and license of the IP in respect of each target are distinct.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all contracts the Group has concluded the license of the intellectual property and the R&amp;D services are not distinct, as Mallinckrodt, AstraZeneca, and Hansoh cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, and these services could not be performed by another party, indicating that the two are highly interrelated. On this basis, the Group has concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target. The Group recognizes revenue over the duration of the contract based on an input method based on cost to cost.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contracts have multiple elements of consideration (some or all of the following), namely:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments (fixed);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent milestone payments (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FTE costs rechargeable (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recharges of direct costs for certain research activities (variable).</span></div></div></ix:continuation></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_3" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_690210e3-461c-4bc7-bada-f104a6746e2a_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s effort under the contracts continues throughout their entire duration. On this basis revenue is recognized over the contract period based on costs to completion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been calculated on the following ongoing basis for the year ended December 31, 2024:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total contract costs which includes actual FTE and direct costs incurred up to December 31, 2024 and forecast FTE and direct costs for the remainder of the contract</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual costs incurred up until December 31, 2024 are calculated as a percentage of total contract costs (actual and forecast)</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This percentage is then multiplied by the transaction price allocated to the performance obligation in question, thus calculating the cumulative revenue which is then used to calculate the revenue to be recognized in that period. In the case of the upfront and milestones, the consideration that is multiplied is in relation to the upfront and completed milestones only. Consideration in relation to milestones not yet been achieved is excluded from the calculation. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forecast costs are monitored each period, with revenue recognized reflecting any changes in forecast or over/under spend in actuals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details of the revenue amounts recognized in the year ended December 31, 2024 can be found in note 3.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b4266c3-7b37-4261-a531-bd41232c5929" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8. Research and development</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist of salary and personnel related costs and third party costs for the Group's research and development activities. Personnel related costs include a share based compensation charge relating to its stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes expenditure incurred in carrying out its research and development activities in line with management&#8217;s best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion. In all cases, the full cost of each study or activity is expensed by the time the final report or, where applicable, product, has been received. Further details on research and development can be found in note 2.15.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_cc18885c-1042-47ad-9b26-051cd669ab4e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_cc18885c-1042-47ad-9b26-051cd669ab4e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9. Taxation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current tax liabilities are calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company that carries out extensive research and development activities, the Group currently benefits from the U.K. research and development tax credit regime for small or medium-sized enterprises (&#8220;SMEs&#8221;). A benefit receivable arises from the U.K. legislation regarding the treatment of certain qualifying research and development costs, allowing for the surrender of tax losses attributable to such costs in return for a tax rebate. Research and development tax credits are recognized when the receipt is probable. Research and development costs which are not eligible for reimbursement under the U.K. Research and Development Tax Credit scheme, such as expenditure incurred on research projects for which the group receives income, may be reimbursed under the U.K. Research and Development Expenditure Credit (&#8220;RDEC&#8221;) scheme. Amounts receivable under either scheme are presented within the consolidated statements of income (loss) within Benefit from R&amp;D credit. The U.K. R&amp;D tax credit is fully refundable to the Group and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the U.K. R&amp;D tax credit as a benefit which is included in net loss before income tax and, accordingly, not reflected it as part of the income tax provision.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_4" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_5"><div><ix:continuation id="F_cc18885c-1042-47ad-9b26-051cd669ab4e_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Group&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Group assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in consolidated statements of income (loss) in the period that includes the enactment date.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77862921-7478-4a57-98fa-cb407ca41f11" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10. Foreign currency translation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies area remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of income (loss) and comprehensive income (loss) for each respective period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, the consolidated financial statements of the Group have been presented in USD, the reporting currency. The financial statements of the Group&#8217;s entities are translated from their functional currency into USD as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, revenues and expenses are translated at the average exchange rates for the periods presented, and shareholders&#8217; equity is translated at the prevailing historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26f82fa5-0fae-460e-8e46-1f9d9c65c691" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.11. Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group considers cash and cash equivalents to comprise of cash on hand and demand deposits with original maturities of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eef2ae45-2bf7-45e5-9c08-e03d5f4ed1a5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.12. Property, plant and equipment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group only holds equipment and furniture. These are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life of furniture and equipment is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ac2e9195-6dd6-4c77-b0ca-6992cf439655" contextRef="C_16fd02d7-a435-4779-9d74-c3e225640553" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48fa7100-39cb-4fdc-aa88-a275aa4a1832" contextRef="C_c4e5bcd7-a4a8-4fdd-be71-9205e7a10b8e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Estimated useful life and residual values are reviewed each year and amended if necessary.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is assessed for impairment upon triggering events that indicate the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group&#8217;s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_223db406-b6d1-4f49-a9dc-7b4308de83ee" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_223db406-b6d1-4f49-a9dc-7b4308de83ee_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.13. Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group determines if an arrangement contains a lease at inception. The Group currently only has operating leases. The Group recognizes a right-of-use ("ROU") operating lease asset and associated short- and long-term operating lease liability in its consolidated balance sheets for operating leases greater than one year. Its right-of-use assets represent its right to use an underlying asset for the lease term and its lease liabilities represent its obligation to make lease payments arising from the lease arrangement. The Group recognizes its right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments it will pay over the lease term. The Group determines the lease term at the inception of each lease, and in certain cases its lease term could include renewal options if the Group concludes it is reasonably certain to exercise the renewal option. When the Group exercises a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_5" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_223db406-b6d1-4f49-a9dc-7b4308de83ee_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease option that was not previously included in the initial lease term, it reassesses its right-of-use asset and lease liabilities for the new lease term.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As its operating lease do not provide an interest rate implicit in the lease, the Group uses its incremental borrowing rate, based on the information available as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Group recognizes lease expense for its minimum lease payments on a straight-line basis over the expected term of its lease. Its leases do not include material variable or contingent lease payments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with an initial term of 12 months or less are not recorded on the balance sheet. Instead, these lease payments are recognized on the consolidated statements of income (loss) on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to property, plant and equipment, ROU lease asset impairment is assessed upon triggering events that indicate the carrying amount may not be recovered by comparison to the future net undiscounted cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3da53614-4cd7-4f96-a8de-a9e612175142" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.14. Goodwill</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is the excess of the purchase price over the estimated fair values of the underlying net assets of an acquired business. The Group assesses goodwill for impairment annually, or immediately if conditions indicate that such impairment could exist. Impairment testing for goodwill is performed at the reporting unit level. The Group first evaluates qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates potential impairment, or if the Group elects to bypass the qualitative assessment, a quantitative test is performed. The quantitative test calculates the excess of the reporting unit&#8217;s fair value over its carrying amount, including goodwill, utilizing a discounted cash flow method. The test for impairment of goodwill requires the Group to make several assumptions and estimates regarding market conditions and its future profitability to determine the fair value of the goodwill at the reporting unit. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit net assets exceeds the estimated fair value of the reporting unit. Impairment losses recognized for the reporting unit to which goodwill has been allocated are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the reporting unit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All goodwill for the Group is attributed to an acquisition that occurred in 2005 and the Group has determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67fc6ac1-fa02-4586-bdda-4690af7da5b4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_962e7236-c178-4aa6-88e1-6d65cf87b92c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded as of December 31, 2024 and 2023.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_ddd93d49-45e4-4e34-bc33-3a6a61ce80e3" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true" continuedAt="F_ddd93d49-45e4-4e34-bc33-3a6a61ce80e3_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.15. Other intangible assets</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other intangible assets that are acquired by the Group are stated at cost less accumulated amortization and less accumulated impairment losses. Amortization is charged to the consolidated statements of income (loss) on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. Other intangible assets are amortized from the date they are available for use. The estimated useful lives are as follows:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses and software: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5017aa2f-48d8-4edb-b20f-63b1ad0320f4" contextRef="C_0bd98068-47df-4b94-a4e2-24b2b7898f0c" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5216c8d2-963f-4736-a808-f41a38554272" contextRef="C_9db27ca0-901f-4c75-883b-ac5848b73bba" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with research activities are treated as an expense in the period in which they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs that are directly attributable to the development phase of software will only be recognized as intangible assets provided they meet the following requirements:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an asset is created that can be separately identified;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the technical feasibility exists to complete the intangible asset so that it will be available for sale or use and the Group has the intention and ability to do so;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is probable that the asset created will generate future economic benefits either through internal use or sale; </span></div></div></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_6" continuedAt="F_0433767f-4829-4fc0-af1a-928b452bfc5f_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ddd93d49-45e4-4e34-bc33-3a6a61ce80e3_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient technical, financial and other resources are available for completion of the asset; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenditure attributable to the intangible asset during its development can be reliably measured.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Careful judgment by management is applied when deciding whether recognition requirements for software development costs have been met. This is necessary as the economic success of any product development is uncertain and may be subject to future technical problems at the time of recognition. Judgments are based on the information available at each balance sheet date.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf5503d1-812e-4556-8d59-68adcf3ac71b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.16. Fair value measurements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s financial instruments include cash and cash equivalents, trade receivables, U.S. treasury bills, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a752ec57-7de7-4c26-8ba2-6d9485e8e5d5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.17. Share-based compensation expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically the Group has issued equity settled share-based compensation to certain employees (see note 19). Equity settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value so determined is expensed on a straight-line basis over the vesting period, based on the number of stock that will eventually vest and adjusted for the effect of non-market-based vesting conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of the charge is adjusted to reflect expected and actual levels of award vesting, except where failure to vest is as a result of not meeting a market condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancellations of equity instruments are treated as an acceleration of the vesting period and therefore any amount unrecognized that would otherwise have been recorded in future accounting periods is recognized immediately. The Group has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period in which the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is measured using a Black Scholes model. The key assumptions used in the model have been adjusted, based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any payment made to a counterparty on the cancellation or settlement of a grant of equity instruments (even if this occurs after the vesting date) should be accounted for as a repurchase of an equity interest (that is, as a deduction from equity). But, if the payment exceeds the fair value of the equity instruments repurchased (measured at the repurchase date), any such excess should be recognized as an expense.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_0433767f-4829-4fc0-af1a-928b452bfc5f_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8ae650d9-58c7-4c37-994c-049625d3c83f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:StockholdersEquityPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.18. Equity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinary shares is determined using the nominal value of shares issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional paid-in capital account includes any premiums received on the initial issuing of the ordinary shares. Any transaction costs associated with the issuing of shares are deducted from the additional paid-in capital account, net of any related income tax benefits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity settled share-based payments are credited to a share-based payment reserve as a component of additional paid-in capital, until related options or warrants are exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation differences are included in the accumulated other comprehensive income.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated deficit includes all current and prior period results as disclosed in the consolidated statements of income (loss).</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8661e360-7c36-460b-af15-8f5da7b7cfeb" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.19. Loss per share</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic income/(loss) per share is computed by dividing the net income/(loss) attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net income/(loss) attributable to ordinary shareholders is computed as if all net income/(loss) for the period had been distributed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group computes diluted income/(loss) per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, except where the effect of such non-participating securities would be antidilutive. The Group been loss making for each fiscal year and therefore all potentially dilutive ordinary equivalents are considered to be antidilutive.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6694d1d7-e24a-42c1-a517-42410b10ed1f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.20. Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d068121f-6b77-49ec-9e07-b676d008cab3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Group </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92e64978-4b79-4d77-842b-a41faba55040" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the new accounting standard for fiscal year end 2024. See the Segment Reporting policy above and Note 4 below for further detail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards issued but not yet adopted</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures, which provides for improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance is effective for annual periods beginning after December 15, 2024, and the adoption of this standard is not anticipated to have a material impact on the Group&#8217;s consolidated financial statements other than adding new disclosures, which the Group is currently evaluating.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The amendments in this update require disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The amendments are effective for annual periods beginning after December 15, 2026, and reporting periods beginning after December 15, 2027, with early adoption permitted. The Group is currently evaluating the impact to its consolidated financial statements.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_21211ba7-59eb-43a6-ba63-072f7ce0c2a0" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true" continuedAt="F_21211ba7-59eb-43a6-ba63-072f7ce0c2a0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Revenue</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from collaboration agreements for the years ended December 31, 2024, 2023 and 2022 predominately relates to the research collaboration agreements the Group entered into with Mallinckrodt in July 2019, AstraZeneca in March 2020, and Hansoh in October 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue comprised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5457610d-351c-4d34-b970-5822cdf0ccbe" contextRef="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of royalty income (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f61b5faf-cb1d-49f0-9d17-b48ac86d9865" contextRef="C_537e54b5-1a9a-4794-ab29-9db563b5fb50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42830959-f470-4ea4-95f7-fdb18713270e" contextRef="C_00f55fd7-1fe9-443f-8a1a-565e418119ba" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eacbaca5-610f-40ac-a197-7115411c0853" contextRef="C_46a40d66-643e-4949-b548-2f714fd5cbbb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Research collaboration income (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e0ab4f5-41b6-449d-b078-5ae2eac0757f" contextRef="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042f4055-a7da-4bd0-b328-f87ea310679c" contextRef="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span><ix:nonNumeric id="F_031a559c-0f6d-4da9-b2c4-76ff171d40ec" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true" continuedAt="F_031a559c-0f6d-4da9-b2c4-76ff171d40ec_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disaggregation of revenue from contracts with customers is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Arial;"><ix:continuation id="F_031a559c-0f6d-4da9-b2c4-76ff171d40ec_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Mallinckrodt plc</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd40575-4301-492a-88b4-9e2ab6053acd" contextRef="C_993f7efa-93c3-4846-afa1-f47122276cef" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601a9f65-1e49-485b-9c48-7d92134f8066" contextRef="C_add4578b-b18c-498c-9291-73e01f000c88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,149</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f438248f-ad89-49f7-8cb5-d010f021418d" contextRef="C_1936f5c6-4623-4d59-8f5c-fd61504cd85a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,425</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - AstraZeneca</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bc85df5-4f94-487c-b4a4-a1992e3922d2" contextRef="C_23cfb98f-fa5a-4be5-af26-36b14ff411c6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,957</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddeefd0d-3b52-488c-81e3-eac712fb7a2b" contextRef="C_a0234db5-e0d7-409b-9954-5b243a9daa8f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,062</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b388f29b-e7be-4212-bc7a-27eb0ec9f638" contextRef="C_6c632d2c-340e-4b65-8cbb-b51f9c4f1f5d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,287</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Hansoh</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3542e448-7174-46c7-9049-36828725f697" contextRef="C_9467424c-7058-428d-ad9d-47868639fc92" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,573</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ea1da86-e3f5-4ab6-85e4-d130e72fc276" contextRef="C_3429ff17-b505-421b-8d3e-21a87a489736" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b60e6fbc-e3fd-4508-b3c7-1b24a72de0ad" contextRef="C_7e8eb108-56e8-4953-b71b-5050238e0174" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bf688c9-d31f-4d01-83be-f89d4832fedc" contextRef="C_46a40d66-643e-4949-b548-2f714fd5cbbb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,114</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b388016-af64-4448-a58f-724359b70b0a" contextRef="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,933</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb98f0d8-ecf7-42bb-9b55-b117b7efae9b" contextRef="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,940</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb4bdff9-fb01-4b7d-bbe6-d756769315b4" contextRef="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a09cedad-453b-4889-91de-6cb162e3dece" contextRef="C_537e54b5-1a9a-4794-ab29-9db563b5fb50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">710</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee9bebc-62df-4061-ad13-bde2ceb15191" contextRef="C_00f55fd7-1fe9-443f-8a1a-565e418119ba" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue from contracts with customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f7f584-8399-4da2-91e1-8a41a35389df" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16adf59a-ebda-40d3-a990-ec9bfa49fec5" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_657f9292-c6de-4e94-8117-14f5d361bbc6" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under its collaboration agreement with Mallinckrodt, the Group received an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba3f181a-2c76-44fd-a7ab-7b6b3f2b492b" contextRef="C_17e919a1-8144-489c-9e6d-db8d495d267d" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2019 and are eligible to receive specified development, regulatory a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd commercial milestone payments. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1148766b-7084-4762-b17e-66c1d3e23d6f" contextRef="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f" name="sln:MilestonePaymentsReceived" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payments under this agreement were achieved (2023: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2daff004-de8a-4989-b652-b23c5fba45f5" contextRef="C_40b17d20-2184-49db-8942-a7eef127d200" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) during the year ended December 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes the upfront payment, milestone payments, payments for personnel costs and other research funding payments over time, in accordance with ASC 606.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the Group reacquired e</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xclusive worldwide rights to two preclinical siRNA assets under its Mallinckrodt collaboration, which resulted in a modification of the agreement. No additional performance obligations were identified as a result of the modification as there were no additional goods or services to be provided by the Group and the modification resulted in the partially satisfied performance obligations relating to the two reacquired targets becoming fully satisfied as the Group was no longer obligated to develop these targets. SLN501, the C3 targeting program, remained under the original collaboration agreement through March 2024. The Group accounted for the modification as if it were part of the existing contract as the remaining services to be delivered form part of a single performance obligation that is partially satisfied at the date of contract modification. The effect of the contract modification was that the consideration originally received for the two preclinical siRNA assets was reallocated to SLN501. The Group recognized the effect of the contract modification on the measure of progress towards complete satisfaction of the SLN501 performance obligation, and recognized an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis. The Group recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eedb834e-4bb0-4192-8b91-4e8a5edd0f6f" contextRef="C_25d05802-ed6f-4b2e-9cc1-86490d680cb6" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the contract modification date. In relation to the reacquired targets, the two preclinical siRNA assets were recognized at fair value. The fair value of those assets has been determined to be nil. Under the modification, the Group agreed to pay future success-based milestones and low single digit royalties on net sales if the projects advance. The Group will recognize these variable success-based milestones as an intangible asset at cost when triggered. Any royalties payable will be expensed in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, Mallinckrodt notified the Group that it will not pursue further development of the SLN501 program following the completion of the Phase 1 clinical trial. The completion of the Phase 1 clinical trial also represented the conclusion of all required development activities and commitments under the terms of the Mallinckrodt Collaboration. During the year ended December 31, 2024, the Group recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea98a4e3-0e85-4d45-9d9f-a3b572b60cef" contextRef="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1a0f13-1222-4405-ba59-849a6198d663" contextRef="C_e6c9f868-f62a-4111-ba93-f469fcd0d117" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cb11982-86dd-49df-bd9a-db597cae9e7d" contextRef="C_40b17d20-2184-49db-8942-a7eef127d200" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under its collaboration agreement with AstraZeneca, the Group received an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c2d753-841a-408d-a885-41fe83037e6d" contextRef="C_99e52335-f638-4b2b-ac13-630a9a8f63d1" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2020 with a further amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8831e39d-715a-4180-bc7f-d6f7016754a3" contextRef="C_80436ca8-6764-4c9d-a92e-0a804aa65353" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received in May 2021. The Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is also eligible to receive specified development and commercial milestone payments as well as tiered royalties on net sales, if any. The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606. During the year ended December</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_21211ba7-59eb-43a6-ba63-072f7ce0c2a0_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31, 2024, the Group achieved a milesto</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17dab9f6-4e73-49ff-acc9-20b84a7da5fa" contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c865191f-56b8-409f-a117-0ff2923ad7fb" contextRef="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: nil). During the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd8cda8b-204c-4af3-87a5-6beef9ffd884" contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd62dbe-c2c5-417f-80aa-ec705fdab98e" contextRef="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4ac726f-0474-4dab-822c-b0396306b326" contextRef="C_af8fc429-8807-4280-86d7-4bb3e6b0a403" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group entered into a collaboration agreement with Hansoh on October 15, 2021. The Group received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0396b15d-c66a-4f64-9c77-aa2a9f8745ea" contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4072c66c-2b73-4730-9c7e-bb80b7e86e6f" contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850" name="sln:ContractWithCustomerLiabilityNetOfTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of taxes) upfront payment to us in December 2021. The Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is eligible to receive development, regulatory and commercial milestones as well as royalties on Hansoh net product sales. During the year ended December 31, 2024, the Group achieved milestone pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1972bef8-fd50-4aaa-b53c-a5b6cfe4823f" contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f22b1f89-d14a-4b9c-8e35-aa55420efbba" contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cee058e-bb94-4a49-a0d9-7c78211b3b27" contextRef="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Hansoh notified the Group that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration. During the year ended December 31, 2024, the Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a12c4ed-c6da-48b6-8eb6-77578749b643" contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_afd49a1b-1504-427a-a6d7-eaa6e87696ab" contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d94684de-36ac-4fd8-ad9f-56bb78c4a355" contextRef="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, the Group entered into a settlement and license agreement with Alnylam Pharmaceuticals Inc. (&#8220;Alnylam&#8221;), pursuant to which the Group settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, the Group licenses specified patents to Alnylam, and Alnylam pays us a tiered royalty of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68d2c69-9ab4-4384-b2d5-6ffb364693de" contextRef="C_c8c88df3-dd6e-4dfc-995d-d16e951e1d00" name="sln:PercentageOfRoyaltyOnNetSales" unitRef="U_pure" scale="-2" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of net sales of ONPATTRO in the European Union. The Group was eligible to receive these royalties through December 2023. The Group invoices Alnylam quarterly in arrears based on sales data for that quarter as reported to us by Alnylam. Royalty revenue is recognized based on the level of sales when the related sales occur. During the year ended December 31, 2024, the Group recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a33222a8-e4dd-4034-838d-e1bb053335fa" contextRef="C_6aaa0880-d729-425c-8313-d4f3cc099532" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty income from Alnylam (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a8ba9a-34dd-4181-892f-1124bc89674a" contextRef="C_a28de7dc-3a37-4a87-b082-7778b559525a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a11fbb00-f403-450f-b426-38cf449d607d" contextRef="C_67be7eda-a207-4017-be9a-44dc71c47dc1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_83e50b3e-e4cb-48c7-953c-a70102b429ce" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true" continuedAt="F_83e50b3e-e4cb-48c7-953c-a70102b429ce_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Segment reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a86258b-b379-427d-bb4a-51175c4e77f5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fa405555-b8a0-41d6-bcd0-c5ceffcea501;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reviews Consolidated net loss for the year when assessing the Group&#8217;s performance, allocating resources and establishing management&#8217;s compensation. In addition to Consolidated net loss, the CODM receives discrete information for revenue by major customer and geographic location. Consolidated net loss is used to monitor budget versus actual results and is reviewed against the Group&#8217;s peers and competitors as benchmarking. The Group operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd48bea2-d733-49be-b7cb-61d150993659" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment in the specific technology field of RNA therapeutics.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of its operating segment are the same as those described in the Group&#8217;s summary of significant accounting policies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group derives revenues from customers through royalty income and research collaboration agreements, each representing a major customer, specifically related to the development of RNAi-based medicines. Refer to Note 3 &#8211; Revenue for a further description of the types of products from which the Group derives its revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The measure of segment assets is reported on the balance sheet as total consolidated assets.</span></p><div><ix:nonNumeric id="F_10811ab2-8f99-419b-aeb5-c94b6cccb2de" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true" continuedAt="F_10811ab2-8f99-419b-aeb5-c94b6cccb2de_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below provides segment information about the Group:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_83e50b3e-e4cb-48c7-953c-a70102b429ce_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_10811ab2-8f99-419b-aeb5-c94b6cccb2de_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c1822c-7758-40b0-a9f6-ab703a988bad" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd36498b-f66e-41e4-a543-b15e4d6b0771" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f759411-2ffd-4af7-83b8-2aa7a0941df0" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40be5b6d-ca66-4a01-a01c-a70cb0ceaf35" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,810</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17aab1ea-a86f-46e8-a510-75a5b0c76453" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,867</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_997091e2-66ee-491f-a63f-d7b14a830b2e" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted development costs (a)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ed5d897-f1d3-4cce-8ce6-be1e14f87908" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:BusinessDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,902</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_151a73a5-9833-48eb-96b0-8b925ac3cad7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:BusinessDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,048</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_950df6ba-4447-4362-bef2-900a8a155706" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:BusinessDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,322</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel research and development costs (b)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6c376b2-cbc0-4aac-9073-00f9be17b3cf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:PersonnelResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,503</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_029f4cbb-757d-4e88-84c2-1e721a8f5166" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:PersonnelResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,468</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbdf465b-4e61-4a98-9d41-02453b50c480" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:PersonnelResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,187</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other R&amp;D costs (c)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3ad048-6347-4722-9c12-2627bf88c679" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,478</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_801f3eaa-fbf2-4025-be22-02ee158bd261" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,421</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_992f1a7e-0c14-4484-b66f-e9a54bc619d4" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General &amp; administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85dfbdd0-2a7c-46d7-ad4d-c4775fcd3b25" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,884</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a19aae6a-819d-4ae8-a39e-c4c243a2ec29" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,222</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_438141c2-6a35-466a-a2cd-733b4fa8d059" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a018856f-39ec-4936-a7d7-5253eb987d35" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d348d52-f1c6-48fe-8adb-8aad2f7d5fd2" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472df5b6-918a-46d2-950f-d2ba7bf45f83" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items (d)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a4bbb1-7faa-4594-aabd-a0117abf4f29" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,855</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da33f6f7-e3d1-4630-aaab-3605b2e166ef" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,111</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f53758e8-e8ee-4192-bb15-59749d5cc4c8" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:SegmentReportingOtherItemAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,394</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd7ecaf-0861-471b-8443-f7c827992629" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcfed922-0896-45f5-aa7e-641347067582" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b1ae6cd-d4aa-41e5-9bff-b87c1233e536" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel R&amp;D costs primarily consist of salaries and personnel-related costs for personnel performing R&amp;D activities or managing those activities that have been out-sourced; and consultants&#8217; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other R&amp;D costs include associated facility costs, equipment and other overheads that are directly attributable to R&amp;D and depreciation of capital assets used for research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The other segment items include foreign currency gain (loss), net, benefit from R&amp;D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.</span></div></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9f47298-b3d1-4f9a-a46f-68ebd16f95a8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An analysis of the group&#8217;s assets and revenues by location is shown below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.418%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.418%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.418%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.658%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.A.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.K.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21f39027-f4ae-4c62-9f2c-e5877baa02c5" contextRef="C_2e144a57-0ddb-4baf-a9c3-2a52f32e07bc" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,467</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c1a40b9-c543-46c9-88bf-3488af2c3f36" contextRef="C_b8115894-8913-43eb-9042-ef3fc8f7d112" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5cabd21-99c5-46c9-ae03-5a81751b5305" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,298</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0c31db-fdbd-48f2-839c-2e701166742a" contextRef="C_6d523cee-aad8-4ece-86d0-cf54c441dc67" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,103</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ff557a2-1573-4a46-9e4c-8ecaeb828cb6" contextRef="C_8cda337c-0dec-4a91-83cb-e2a5eab87ddd" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,166</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c5ca09b-bd04-44a8-8e8e-a4567a875b5c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,269</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c632918-4242-4371-affb-91ff05055dfb" contextRef="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,940</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd679cde-bf3b-4750-b8e1-9767feffc534" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,940</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d3a9a68-1a90-4dd4-9aa7-ed2287a76337" contextRef="C_c74d2467-009d-495a-bebc-222cee797f05" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8d08ea7-913c-4fa5-b76c-bd27fdd423fd" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af51d196-bb5c-4253-a7f4-6448957ff9a2" contextRef="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,940</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24b7fa77-c439-47e5-8b4d-d5955628cf54" contextRef="C_c74d2467-009d-495a-bebc-222cee797f05" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c18e337e-3079-439d-a93c-3d607d84fd24" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fd18fd3-ea87-458a-8509-14dec665dc18" contextRef="C_95a23c91-e275-4694-9a2b-078f6e447589" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,934</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30c6fc0b-e894-474f-8a03-cd92306933ca" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,934</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd6d5e57-3d44-471d-ac2a-92cf3af9040c" contextRef="C_193e7dca-2118-430b-a24c-39a8be8f2ec5" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_357d358d-f98e-4e28-9579-3db9199c9fe7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86345829-4c8f-462a-92a5-4897aead0c3b" contextRef="C_95a23c91-e275-4694-9a2b-078f6e447589" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,934</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ced3a16-57dd-4c33-be18-53d8476a1a9b" contextRef="C_193e7dca-2118-430b-a24c-39a8be8f2ec5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">709</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a097bf4-826b-429d-a439-b816aee4b267" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,643</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31,<br/>&#160;&#160;&#160;2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26837512-58c1-4b75-91b3-48fe0f87ebdb" contextRef="C_4a556b23-31fe-49a9-90a3-49e389ec6b48" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,114</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d80a3404-094e-402c-a80d-b28b14c28d73" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:RevenueFromContractWithCustomerResearchCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,114</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_523c4f06-634a-4764-98fa-08818088e11c" contextRef="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41ec6126-fe50-4cc9-9dc7-8050adc6a28c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:RevenueFromRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c566bb76-2ade-471f-a230-9de4e896a4c2" contextRef="C_4a556b23-31fe-49a9-90a3-49e389ec6b48" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,114</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7250f64d-854d-49fd-a7a3-25e76b6e81a7" contextRef="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8c92648-0469-486e-b1dc-6699b99f7e44" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df35884c-e688-4b62-9d8c-fc8404ac71e9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:DirectorsAndEmployeeRemunerationTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Directors and staff costs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d52df96-08c5-4c74-b9a0-11f226c56fb7" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:DirectorsAndEmployeeRemunerationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Staff costs, including Directors&#8217; remuneration, during the year for the Group were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0db961ee-71a7-45f4-9a2d-a9972c068363" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,434</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6354bc47-fb22-47c1-9429-cfe49364b27f" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,158</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dcf95ad-6d95-4232-9688-ff3cee7a61ef" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:SalariesWagesAndOfficersCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,264</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4893a2ca-1f06-4e47-81f8-8681fbcde302" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:SocialSecurityCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,744</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb365f8f-9086-4fb7-94a0-d1b19eb76061" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:SocialSecurityCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,901</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46328cd7-a58e-46f4-8f3b-519d738c28b0" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:SocialSecurityCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,774</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other pension costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1c4ba11-db57-4130-ade4-e4fc9fb96821" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:PostemploymentBenefitsPeriodExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c853cfc-76f8-4301-ad3e-36d20fc2c666" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:PostemploymentBenefitsPeriodExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cead5b5c-fce5-4560-bced-e5f4f1966812" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:PostemploymentBenefitsPeriodExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">531</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6e56222-3159-4c67-aeb2-e280ff465def" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,307</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa6da419-9d6d-42e9-9c27-bd441119450c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,274</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_453baa39-58f7-430c-aafd-b64b3bc9a0c0" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,686</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total aggregate remuneration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_098e5947-f5b2-4a5b-a6ff-4c9da2096ef0" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:AggregateRemuneration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e074eb-47ae-4187-b084-6bea59512937" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:AggregateRemuneration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,942</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85b3a556-c7a1-4036-b366-4f8ac0ee8892" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:AggregateRemuneration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,255</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fc23923-f680-42eb-8a55-1c44a4ef45a0" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Other income/(expense), net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53092b32-42d7-4e9c-b174-245750c9f156" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bank interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34192e61-ebe2-479d-aeda-30909f9079d6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:BankInterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4af68bd-e390-4a56-841a-e5e1a8913b16" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:BankInterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a56fcff1-c096-4cc8-b8c5-f9afa2efb194" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:BankInterestReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion on U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cca0c38-93b1-4eb9-b198-b2881a5e43b7" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:AccretionOfSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9891e85-54d6-481a-9f93-8103e631886d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:AccretionOfSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,720</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e448d44d-f8a3-438c-b7f4-9d4295919b6c" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:AccretionOfSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60f1856a-bd7a-462c-87a8-4abfef7cda71" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e892f9e-714b-442d-9411-49cac942d2ce" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0aaa8701-3edb-4649-a998-ada7158f5309" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">280</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_178d3eaf-8caa-40c6-8d11-6888575590ac" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Loss per share (basic and diluted)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing net loss (the numerator) by the weighted average shares outstanding for the period (the denominator). Diluted net loss per share is computed by dividing net income by the weighted average shares outstanding during the period adjusted for the dilutive effects of the exercise of the stock options. In periods when losses from continuing operations are reported, the weighted-average shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_319362a9-55c9-4f0b-a13b-0a560be6c0cf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_319362a9-55c9-4f0b-a13b-0a560be6c0cf_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The computation of net loss per share for the years ended December 31, 2024, 2023 and 2022, respectively was as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_319362a9-55c9-4f0b-a13b-0a560be6c0cf_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.040000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd126128-3052-4f5a-a037-418a3fc49433" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0ddf6c2-82f2-4db2-b098-ec6d20bbc10d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">54,228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8ea20c7-469b-4b35-aebb-c72f1a4ca019" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">50,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23af2cea-c57f-43a5-a659-c16b265a1de9" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6cf70a9c-19ae-4304-9224-9d76265f99bd" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">138,752,224</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ba623df-da37-4197-98a1-e7df2cb4a078" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f4855dc1-323d-413d-a691-3c0dd0eef10d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">111,277,250</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64556d71-97ab-44bc-848c-145e53519387" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7ad5728e-9918-48d8-9ca6-f4586ecd1344" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">96,584,512</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda6a63d-67ae-4c98-a008-938e08e71917" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b23bcbfc-c5d3-4d37-9735-a1ea1a57a492" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.33</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81d2de6c-126d-4fdf-bdd3-1d071bf5f58e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c9f76d3a-7b81-41d0-90c8-cadcf05e708d" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.49</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92b525da-a40d-4b1e-9cff-6faa1903d4a7" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_75537514-8605-4eeb-9bcf-85a90738698d" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.52</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_286cf21f-2c95-4a24-8b36-82f023c04e1b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.52%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Potentially Dilutive Securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd7a71f6-d4fb-4855-84db-1eba17d52e0b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,455,390</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cabdcdd3-bcf4-49dd-a17e-049ec9037eeb" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,853,459</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39f8a5b7-e322-499d-9948-fbafeeffbe6a" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">11,571,487</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48883b26-b200-4530-b957-a9dd25a806ae" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Property, plant and equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_094bb875-0f0e-44e2-a315-3551c01d6ffa" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant, and equipment balances were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equipment &amp; Furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f793ddc-c01f-47e9-95b1-cdd564af0f71" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,343</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e596af4-689f-48c8-bcc0-6ea978f623f5" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,436</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1617ada5-b858-4b66-b21e-8bbda63e9599" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,525</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0174e389-7b0b-4017-9387-2ac69ace4662" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,498</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant, and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d922455-dce7-46ed-a9b3-1821cb0ac518" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,818</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf92625a-50dd-4db2-b188-1761df0f22c1" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,938</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad8833bc-8b86-4673-b77d-4db0a93fe7c1" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dd47f6a-9d99-41ec-98ea-fd9c9e2d2b02" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16354d26-7e48-401c-816d-2022d53b95c5" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized in fiscal years 2024, 2023, and 2022, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d56e1c4f-f5dd-4abe-8bd3-4614ffa04ba4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GoodwillDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Goodwill</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is assessed annually at a reporting unit level, or whenever events and circumstances indicate impairment may have occurred. The Group has one reporting unit and performs a qualitative impairment test (also known as &#8220;Step 0"), and when necessary, a quantitative test. After assessing the totality of events and circumstances as part of the Step 0 test, it was determined that it is not more likely than not (a likelihood that is more than 50%) that the fair value of the reporting unit is less than its carrying amount and therefore a quantitative test is unnecessary. No triggering events were identified during the year.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6c43e52-b94f-4e21-98fb-6716ab5e2e2a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfGoodwillTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in the carrying amount of goodwill:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at start of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46503387-8164-43dd-a2bd-eac4118be16a" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,981</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9f3f78d-c453-4ac0-9f6c-9a3c08471138" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,683</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b44ba554-8433-4507-b95d-89593d90972a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3935dbf7-3d68-4a78-9d00-168f966dd37e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">298</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4dab10bb-07f8-48ff-8aa9-98f1f9b4f5f3" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,392</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9261b033-066d-48a3-80b2-d7a471471c9b" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,981</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_83a3f959-2ae6-40ea-a977-ef5296fbce74" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="F_83a3f959-2ae6-40ea-a977-ef5296fbce74_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Other intangible assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b1b713b-0549-4a1c-808e-706b6eca3645" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of December 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.451%;box-sizing:content-box;"/>
        <td style="width:17.077%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.017%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.017%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36285826-5b3a-4bdc-9047-c895ad3acc6a" contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f315bde4-447a-4e9e-badd-0c63c2034189" contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">547</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9e7c87a-4c2e-408b-ab8d-8dbc77968753" contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">169</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c6dde8f-f969-48d0-b82a-23a3379a7192" contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_490f3c38-3c45-447e-8b98-d8ea80f5fcb0" contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d8d56b8-5ad6-45f4-b562-bdc74be40085" contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intangible assets are amortized beginning from the date of acquisition, over their useful life or written down if they are considered to be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization expense is included in General and administrative expenses, which included on the consolidated statements of income (loss), and was nominal for the years ended December 31, 2024, 2023 and 2022, respectively.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_83a3f959-2ae6-40ea-a977-ef5296fbce74_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_747eb9d1-fa25-4079-a7cd-3b95ad2a36f6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected future amortization expense is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:48.46%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expected Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78214a1b-5028-4ded-ad97-6b29934ada06" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05943c7f-0b45-4c33-ab45-60089c2415d8" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a47b450-40c0-4bff-9d04-38ba9b07dd81" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6422589d-68a5-4471-a88f-940226df93f1" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85435901-f8ef-46e3-96c6-29dd29446355" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f19bb86-3e3f-4e64-8e0a-fe70ce8c3dd1" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af4a5032-0a81-4131-9d11-4a83097f13af" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bfddf3eb-7194-4044-aba2-3e25007538b7" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_887b0d58-a902-496a-9812-fcb9ea225558" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges related to intangible assets were recorded for the years ended December 31, 2024, 2023 and 2022.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d979015-a314-4a9b-8c04-44b7a3e85af3" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e7030e8-8f89-4217-ac28-9c50b13877d4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash at bank and in hand</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b1c797-68bb-49d7-9535-0c4e8b34c33f" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CashAndDueFromBanks" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,590</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_117052b5-148c-4417-89d9-43c0676e78ca" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CashAndDueFromBanks" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,819</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51e57a05-248a-461c-830c-4c9dd7f5667e" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,740</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_015a3425-3b7c-48be-873e-db1ddb94a211" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,970</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3948324c-9f11-47e4-b0e8-b408b4f588bc" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e7dfbec-db89-4eb3-8d15-14622ac89059" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,789</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash at bank comprises balances held by the Group in current, short-term bank deposits, and U.S. Treasury Bills with an original maturity of three months or less. The carrying amount of these assets approximates to their fair value.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6dd7ed1a-3008-41b9-ace9-0560f33c94ed" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OtherAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Other assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78d6535f-5887-4d03-bd73-afb4ee02b1d2" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.76%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.86%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d909e679-427b-400a-a305-e90f42969fa9" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:PrepaymentsAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,124</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8850a48-c635-445a-a891-1f9c06613fde" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:PrepaymentsAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VAT receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45897bf8-4d6d-431e-9979-6b362fbbb7e6" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,540</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6397b8b-b947-4b44-a028-a74c5c896b5d" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ValueAddedTaxReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,245</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dfd3b2db-f281-49de-8183-1fc7fcd21b52" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,664</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c36774-1f8c-4935-84d2-32dc98f7afc8" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,630</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits for properties</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ed92d00-15e5-4aa8-af39-1c30115b52e1" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">356</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa952ac1-26a9-4c60-93de-87b48682d4bb" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DepositsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d532dbbd-8abd-4c87-a4df-b608fbff2c9c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:PrepaymentsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,234</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5904c15-269f-4f2b-ab61-8f1ee1881ff5" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:PrepaymentsAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,284</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f149ff3-acfa-49f5-a5f9-a6fb64bd2700" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,590</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d70ae540-829d-4535-a6cd-ce3885f9478f" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,646</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and 2023, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within prepayments at December 31, 2024 and 2023 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_569ebf76-2e64-41f4-9908-295a70d7de33" contextRef="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19" name="sln:PrepaymentsAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf96ed83-5844-4804-abbc-2dd97617e52d" contextRef="C_1aed09de-bc50-4e87-9680-f6533b6e32a6" name="sln:PrepaymentsAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively, are expenditures relating to research and development.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_aac79947-5e58-4662-9946-4c01b619485a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:AccountsReceivableTextBlock" escape="true" continuedAt="F_aac79947-5e58-4662-9946-4c01b619485a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Trade receivables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_068b9ed5-0d51-4df8-91af-50df5fd623b5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:ScheduleOfAccountsReceivableTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978c1b5a-f08e-44df-af22-013653a97e48" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">972</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e80ef37e-bbce-44ff-9526-0528d43c7776" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of trade receivables approximates to their fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_aac79947-5e58-4662-9946-4c01b619485a_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No interest is charged on outstanding receivables. There were no overdue trade receivables balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has applied an expected credit loss model to the balance and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db6a867-df2f-4023-960a-69a8f1e62f04" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b8f1c3e2-60f3-443f-9a2e-b9e941cd00cf" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance is required for the periods ended December 31, 2024 and 2023.</span></p></ix:continuation></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33d7da59-d1d0-431b-8918-aadfb4e3c710" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Trade and other payables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_de00a1a8-55db-4d3e-b62c-6273fd506314" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faea8a00-f855-4269-9de7-109f1fd14c64" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,697</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0ec4651-3fe2-47b1-8359-61670ef395ca" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccountsPayableTradeCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,348</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5e94b60-2e8a-4aa9-8e2f-15e166d690d7" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:SocialSecurityAndOtherTaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84d47691-52f7-4905-93bd-f274e87aaeeb" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:SocialSecurityAndOtherTaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">734</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e59034a-dd69-4dde-b097-5f14c8cd1b6a" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,361</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d15b6407-bc08-40c6-a48f-cf725e6ad8f6" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bonus accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22521970-f790-4a5a-b0a1-50370ddae33c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,445</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5384962c-8148-4e13-99e6-bf428d2c9535" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccruedBonusesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,134</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b15a0b56-0f52-4e5d-b8db-0131d1e2e189" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fcb7413-254f-4bed-be16-d16fd06160bb" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">474</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e46409-23bc-4024-ab47-e253f064184f" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,399</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a562dd1-80b7-4734-adc7-a9e8f2b0a1d9" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,537</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of trade and other payables approximates to their fair value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within accruals and other payables at December 31, 2024 a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd 2023 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cfdb3b3-e635-454d-98c2-214190aac987" contextRef="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b9b3b99-24c6-4c26-9945-6cc80826e827" contextRef="C_1aed09de-bc50-4e87-9680-f6533b6e32a6" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, are expenditures relating to research and development</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5acb5ab9-39cd-4b49-9fb5-b5de7ecc4708" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true" continuedAt="F_5acb5ab9-39cd-4b49-9fb5-b5de7ecc4708_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34591838-a703-41b9-8821-8eb160cdaaeb" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:NumberOfOperatingLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating lease for office space in London, which was renegotiated upon completion of the original term, with the new term beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb29405c-0b00-4088-b4f0-69bc041f4ab0" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:OperatingLeaseNewTermBeginningPeriod" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Group determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Group recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Group&#8217;s right to use the underlying asset for the lease term. Lease liabilities are the Group&#8217;s obligation to make the lease payments arising from a lease. As the Group&#8217;s lease does not provide an implicit rate, the Group&#8217;s lease liabilities are measured on a discounted basis using the Group&#8217;s incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0619db50-b86b-47c5-904a-72cf1034956c" contextRef="C_cc4a6675-6368-4274-a498-7a1407627000" name="sln:NumberOfShortTermLeases" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term leases in Berlin, Germany and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_047abed3-a636-49e9-b085-37b1e7326606" contextRef="C_edac0d25-e5fa-43db-9447-72b4778d22a3" name="sln:NumberOfLeases" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases in Hoboken, U.S., that have not been recognized as right-of-use assets. Both leases in Berlin are on a rolling contract basis with either party being able to end the lease with a cancellation notice period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f12b097c-c546-4dbb-9333-bcaa4571ebca" contextRef="C_196e5e80-6700-4ee5-83ef-dbd0df792f21" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, while the leases in the United States are on a rolling contract basis with a notice period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9eda33a-c41c-4f3b-bdf8-f0665004dcc6" contextRef="C_c1fd8902-0499-4006-8b7a-f16708af1815" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Expense related to these short-term leases are recorded to the consolidated statements of income (loss) over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adea3861-a285-4c8f-983f-969af54d7740" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents supplemental balance sheet information related to the Group&#8217;s operating lease:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.7%;box-sizing:content-box;"/>
        <td style="width:1.58%;box-sizing:content-box;"/>
        <td style="width:28.44%;box-sizing:content-box;"/>
        <td style="width:1.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.12%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.02%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf1c7359-bb32-4a8d-badb-2cb431cb5055" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50b64087-5132-4f4a-85cf-4069847c2768" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">370</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcb3af80-f943-4f97-8841-f97516789490" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_932e8406-69e8-4cba-87ea-559ad17187fe" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae33b6df-8fd8-4f4c-a7c7-2117067703a0" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_8fe48b28-2976-4613-bf4e-d5f81e6b0c51" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" escape="true" continuedAt="F_8fe48b28-2976-4613-bf4e-d5f81e6b0c51_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Group&#8217;s operating leases at December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_5acb5ab9-39cd-4b49-9fb5-b5de7ecc4708_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8fe48b28-2976-4613-bf4e-d5f81e6b0c51_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:14.883%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:14.883%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4c848435-53a1-4b6b-b0e1-0b7c0f250acd" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_41d5ee42-643c-45df-be1a-07db63b1a462" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5512b6c6-d2e9-4d9e-8034-8fda007eb2d0" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78845f92-b070-43bb-a8a4-f5240988c948" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_856d7e64-c47b-44fa-b68d-e89877ff1e5c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_061ef0aa-a677-41b5-8446-f35854526647" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_432f0dcd-0339-4aed-bb18-b4f6a29a43de" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">242</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_059597a7-911a-462f-b156-b47e85fb50e0" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9744cda3-b763-43be-b6ef-bb9c46d80676" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">736</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a83f8322-df82-443c-896f-70625a8ab346" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">600</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c83cdf-7963-4a8e-bdb8-6459517012af" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c60df7-e241-4d5a-afe0-b1cac9a7208c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">984</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1579900a-f119-4771-953d-9b08165d5f98" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">842</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_372e8425-8127-4bae-a22f-444d5e22de4c" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">587</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3dba137-f0ec-466a-8aa4-7e6ecf203c97" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_c3dba137-f0ec-466a-8aa4-7e6ecf203c97_1"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of the Group&#8217;s operating leases at December 31, 2024:</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.18%;box-sizing:content-box;"/>
        <td style="width:1.38%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:31.44%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd58e4ec-0445-4894-873e-54c4d317099f" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62e2f3cc-28cf-4af3-95dc-e8b22045d00d" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8979070a-c701-40ca-90fb-057d3768f253" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86ab66bd-da9c-45d5-aad7-0b188d270b08" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe7e48f-27f1-4dcd-83a6-7cffe44d2796" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a6d82ad-9619-4828-b903-40d726638505" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total expected lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cb485a7-2d40-45ba-9c5a-82b17f52ee7c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_996a5b03-dd91-4bc8-92e9-1494cb11ce7e" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8af69c6d-de14-4159-a786-f28a1bc40f15" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_c3dba137-f0ec-466a-8aa4-7e6ecf203c97_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_8c96db42-f01d-466f-9b64-138086d46d49" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:ContractWithCustomerLiabilityTextBlock" escape="true" continuedAt="F_8c96db42-f01d-466f-9b64-138086d46d49_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Contract liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities represent the Group&#8217;s obligation to transfer services to a customer for which the Group has received advanced consideration, before the performance obligation has been satisfied. These liabilities are recognized when a customer prepays for services or when the Group has an unconditional right to consideration before the performance obligation is fulfilled.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities comprise entirely of advance consideration received from customers (deferred revenue) in respect of the Mallinckrodt, AstraZeneca plc, and Hansoh research collaborations. The current contract liabilities represent the amount of estimated revenue to be reported in the next 12 months related to amounts invoiced to its partners, while the non-current portion represents everything beyond 12 months. Current and non-current contract liabilities include future revenue from collaboration recharged expenses, upfront payments, and milestones achieved to December 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0d86e13-4ab4-4587-8f2a-54d04f91b403" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faaebc17-0046-42cd-9480-0d57e4b1a7bf" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03948d5c-5474-4e8b-a63b-9d17d5be0af2" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,571</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a379158-57f0-4e3f-9a3d-97d01e8f2b06" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,790</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2459ed9c-623e-4ad1-9c2f-ca60dafb5f41" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,001</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142e57bb-8c72-4e6e-b111-f63abd303638" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce86ed23-b2c7-4a2d-8859-ca49bb99c7de" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,572</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53733a8b-f92f-4e74-a224-5eef8d79bcba" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,572</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b37100-835b-4333-89ce-d62d12148224" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">87,467</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange impact</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b97ef2f8-39fe-4926-8a68-2eb91efe520c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:ContractWithCustomerLiabilityForeignExchangeImpact" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">691</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93042e9d-9e69-44e7-903c-0bf3a7dc4f7e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:ContractWithCustomerLiabilityForeignExchangeImpact" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,428</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51065678-1108-4aa2-b0df-b3371317fb84" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:ContractWithCustomerLiabilityAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,328</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80e52d6e-6d4b-4e97-afdf-89156379b3d3" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:ContractWithCustomerLiabilityAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,611</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue unwound during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83636b50-f315-4057-a281-c387bfce9dbe" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:ContractWithCustomerLiabilityRevenueUnwound" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,113</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb6ddd0-9c6d-431b-a972-f67ec3347ede" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:ContractWithCustomerLiabilityRevenueUnwound" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,934</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bea01076-0255-4ae4-8dae-512062b9023c" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,096</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3d0aeaf-7532-44da-8c5f-fc19db33357e" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,572</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_8c96db42-f01d-466f-9b64-138086d46d49_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023 contract liabilities decreased primarily due to the recognition of revenue in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c72b6cf7-2dcf-48e9-9974-04a39ead2d7c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8752c915-1454-4912-a3f4-f7b33e59c1a9" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, that was included in the contract liabilities balance at the beginning of the year.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Income taxes</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Group operates in the U.K. and is subject to income taxes in that jurisdiction. The U.K. tax rate applied for 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_419c51b2-00d9-444c-ab52-2d38509b8d09" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0907f9cc-4a64-4578-9f26-d51f98788abe" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">23.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for 2023), which results from applying the enacted statutory rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad8afcd4-fcfe-4e9e-89be-0c5cd82d2b5e" contextRef="C_ab13cc0c-5775-43dd-a181-db3338b67deb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from January 1, 2023 through April 1, 2023, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7e61535-ce13-4c47-88de-805924556a07" contextRef="C_a616bd36-1676-406f-a437-69e3e0d34cd4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_682eded1-5f78-4afe-acd7-7d24cdc6a58c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for the remainder of 2023 and 2024. U.K. deferred tax assets and liabilities have been measured at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67678a47-3f01-4f0e-9e92-7d97b228d95a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The entire tax expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76171aa8-01c8-48f9-810a-27e42c345914" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million relates to current tax as shown below. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71683d20-9411-4109-83d0-78659d9ec890" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred tax was recognized in the year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c116dbd4-c27f-4d53-a552-5035d8c85c13" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.611%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.342%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.982%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.062%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df4c913a-d053-4cdc-90d7-8e23e5f250a6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e722f6e-ac45-4d38-b9ee-7001343c0775" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0c66fa0-9df1-4730-8dcc-31012ac37e3e" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in estimate related to prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d72f301d-76b1-43e2-8546-d3aba3906b2f" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">496</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db5cd6e2-5e32-4b2c-a01d-a3bc011539cf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f58d19f-596c-4460-9573-189db530294c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f7d90c8-0150-4238-8996-d5f0fb4d5907" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Origination and reversal of temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses (derecognition of<br/>&#160;&#160;&#160;previously recognized) deductible temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_261f0435-0ae7-4c33-9ee2-cb399bb00495" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ea2069c-8923-4c5c-91c3-501ea893c46c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f79fcfa-f380-418b-99bb-a21342c41444" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da80fd34-9d8a-43c3-a400-e619ad916d83" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of the income tax credit at standard rate of U.K. corporation tax to the current tax credit are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23069a25-f7ac-43ff-952d-542d12e9c31b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">44,464</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e88f1ab-43ae-4707-be5e-619b50f63b90" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">53,272</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1396eae6-44d0-450d-a611-200099353293" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,646</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit at the standard rate of U.K. corporation tax of </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22119616-e1b3-4cd7-9090-7e96267e9b35" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%<br/>&#160;&#160;&#160;(2023: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f842c1f3-ab92-4623-8a35-32b5e91f3419" contextRef="C_a616bd36-1676-406f-a437-69e3e0d34cd4" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%; 2022: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28515016-3de8-402f-9141-24d3ecf88e11" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5718b0fe-c8a2-4799-8159-0bfede0f8acf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,116</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8378b258-9bc0-4b93-a1c9-031974628840" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,530</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e6ed798-4a93-4826-8946-186c0633c221" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,432</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcfd932f-adda-4373-bd8e-6e7ab2999ea4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,356</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daa1186c-7976-4485-a3fa-c265c4a34df2" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,286</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e0a48e8-627e-4c6a-a8a8-a12540ddfef2" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,346</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4cb2efd-e950-49c8-b25b-15243f2628da" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">308</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a337ac6-dbde-4d16-9c43-32049f528729" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bbf868e-d3bb-4858-aba7-ef76116edf1e" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">673</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35c53771-6f07-4b42-b80d-e40176d2d211" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,423</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f6c6282-ab99-4978-84c6-4d4068f09844" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,641</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57a3b885-263b-49c9-a967-f64605ee6548" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,456</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d1c3c15-75e8-4364-a06c-847dcdbb0d50" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">495</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12a5fa5a-02ba-4d50-aec2-7151ebceb194" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:IncomeTaxReconciliationEffectOfOverseasTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">202</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21c7bfe9-c756-4369-ae2b-abcb2a1d75ad" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:IncomeTaxReconciliationEffectOfOverseasTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">465</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d87def8-1a39-4e30-8840-70ace771d03c" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:IncomeTaxReconciliationEffectOfOverseasTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c65a6ac0-5e41-429e-ad07-d40f22ddc2cf" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">845</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a13aef4-5eba-43bc-adc5-45951a4b8c98" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3be669ad-7f7a-4aca-b150-307c20402b4f" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the standard U.K. statutory income tax rate to the effective tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax using U.K. statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de1bfaf8-e22d-4a56-9beb-536d46c2a250" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b53b193-bd1e-486b-9a79-085a5cc051f3" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">23.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f3fccce-3250-4083-b64d-23e6729e6518" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">19.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2055922-f6ba-4c09-be3e-47a9418c256f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64ad15f9-e5e6-4d0d-a524-ce2c7d1100a3" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21bda1a6-3e68-4b5e-b39b-be623b55b901" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f3b851b-b205-4040-9790-d402fa086d09" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c886dec-c174-49c5-af92-262d44b331b4" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a467077c-366b-443e-8f3e-83063566ac9d" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0acdf5e2-e949-46e8-a97e-afa5f5d1c7f8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">34.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbbb7f64-7d1c-42f5-b394-061273b7d1e9" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">29.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d5f9600-7750-4137-9244-8a1fa10fd828" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">23.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d748b6b-8016-429c-94e1-702a451376e6" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_daa63b8a-9cbd-478c-9482-95c286c2b663" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_960a9638-2649-44b1-802b-e49a710918ae" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate for loss from continuing operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_332d5259-9ded-404e-bbc8-468a6bd8744f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9654c233-9941-4470-acb3-5ac20d1e6f2c" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec57e86b-a1cf-416c-a7cc-e49823849c99" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6_1" continuedAt="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61cc3f90-b36a-43b9-b5b3-3b4b05503d20" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7550b65f-42c2-4162-91c6-3aa95444bd42" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any deferred tax liabilities as at December 31, 2024 and 2023. </span><span><ix:nonNumeric id="F_46c2fe0d-90d0-4aa8-b08c-1f6c3f2a7976" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_46c2fe0d-90d0-4aa8-b08c-1f6c3f2a7976_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of the Group&#8217;s deferred tax assets as at December 31, 2024 and 2023 are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_46c2fe0d-90d0-4aa8-b08c-1f6c3f2a7976_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading Losses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c3b9baf-8b05-468b-9c79-830cf81ddc15" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,316</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f045ca95-9039-40d5-91da-1e05384a3b3e" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,563</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe116b0-83f7-424a-9875-5d04dc2e26fa" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f91a4b01-0de2-468e-b128-f27b8be39038" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,670</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_936dd851-2df9-4506-b868-477a040d0228" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,467</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_333825b7-8657-47fe-9e19-dce74644af19" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,506</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17492ded-6d49-4083-932d-f04d5fd87daf" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,446</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1988aab-cb96-45c4-b5d8-08c8a4189e51" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe875719-e82e-484f-bbb7-eb4f98863f4d" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,446</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8963d9c6-13d1-4f89-838f-a2a3da314c48" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_756ab1fa-dab8-400e-ba4e-37bfdf5de1cb" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c40743-c463-4c1b-b880-8ee5e88597a2" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n trading losses is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_916be728-0e74-468d-9ee3-5da8a4435883" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated tax losses as of December 31, 2024 ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd373d48-9080-4b3d-9920-a130bab1037a" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023) related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations in Germany for corporate income taxes and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6c786f8-b845-4a91-b5be-b021e8295011" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated losses related to trade taxes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">German entity ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_263ddbe7-993e-4146-a64d-cf18c023c6a4" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2023).</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bda07c98-a4a9-450f-8766-801528c69a0a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Movements in deferred tax valuation allowance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.16%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.357%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at January 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_224cd5aa-1294-465c-b040-e93d8647c8a3" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a4ed909-5e07-4cfb-b846-fc768a811161" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,703</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Decrease)/increase in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b33ef86-c316-4d2c-a243-240a96ff0a4c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,293</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e22ea9d6-a4a0-4060-a9ad-137ecceff054" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,036</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at December 31</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95441a23-26d2-4ef5-96f0-2d675718691b" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,446</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5ffc665-eb5f-405b-ae3e-a7691dbffd0f" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,739</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Group does not have an establishment or place of business in China, the Group is subject to withholding tax on gross income from dividends, interest, lease of property, royalties, and other China-source passive income. In 2021 the Group entered into a collaboration agreement with Hansoh, a biopharmaceutical company in China and received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39d827cc-47b5-448d-86ca-aad73696f711" contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront paym</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ent, which required withholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96dadcf4-65e6-43ef-b09f-9834c81fd756" contextRef="C_a5aa37ae-e777-4dc1-948b-8abdce9b033b" name="sln:UpfrontPaymentTaxWithholding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In 2024 the Group received a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e7debb7-6812-43fa-be5e-04491de67f7c" contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which required withholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_944ebdc3-f1fa-4315-9494-49d76e724b10" contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4" name="sln:MilestonePaymentTaxWithholding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In 2023 the Group received a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f7143c5-937c-43c9-9b22-aac3a9fc154c" contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0" name="sln:MilestonePaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which required w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ithholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35b6818f-885c-47ff-991f-22c13f122ac7" contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0" name="sln:MilestonePaymentTaxWithholding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year, the Group had not yet received the research and development tax credit related to the prior year. The Group has recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb2a7595-f2d8-4b19-a443-06d8fd1236d5" contextRef="C_84cedcb8-200d-4f11-afb2-0648fda7c636" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in respect of the current year for unfunded projects that are permissible to claim</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the SME scheme (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd04fbfb-9dcd-4f66-8bdc-03f03289c256" contextRef="C_5abd1237-ff52-4950-ac85-db071e0672dc" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06cc70a3-fe8a-47ea-a4c7-e797db7a4680" contextRef="C_dbe56603-c5ad-4050-8b7a-f9ec17240ff0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). In addition, in 2024 we have also recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65701a0-48df-4d84-827a-d3b237f0644e" contextRef="C_3c9aca65-1850-401b-8756-d571e815112f" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the RDEC scheme (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d8cfb909-9a1c-4b94-9e25-bf6e8f777e49" contextRef="C_350c15e1-d957-4be9-aee7-a256f22c97c1" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc9fdf56-9813-4470-925e-e8d9ca7521b1" contextRef="C_38e9b6bf-0e2e-4817-ab67-ec146ae446da" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18. Shareholders&#8217; equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f75838e-e5f7-4bf9-88ce-8ae535358c58" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfStockByClassTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized, allotted, called up and fully paid ordinary shares,<br/>&#160;&#160;&#160;par value &#163;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff0b3bc-da3b-4661-bc71-f4785548f1ba" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_U_iso4217GBP_xbrlishares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_88ee335c-efae-41d2-abc2-1c5774a8fe8e" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_U_iso4217GBP_xbrlishares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a5cbd8a5-c4ce-4e4b-8b5d-3daa638165bf" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_U_iso4217GBP_xbrlishares" decimals="INF" format="ixt:num-dot-decimal">0.05</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09b25e63-f54c-43df-8562-6281a3cd5bdf" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,288</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07c40b9d-d533-4aa5-b1ca-97c6bf760001" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,847</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffe1f95d-f4a5-4bb8-8f59-aed71d9facca" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,151</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ec448d0-bb81-4547-aa62-958f0a2b92dd" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,674,074</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f984d24-f5f6-48b3-ae94-455dbf868b95" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,846,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22c39bd4-3ea8-4739-af79-38967798b483" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">107,808,472</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d90f39-52f8-40c7-8d11-623700dfb3dd" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,224,691</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54b5e016-ac25-49cb-b09d-08f42f334742" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,615,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10d36b5f-1d6b-4236-8f13-cb8d62bb2f94" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,936,157</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has only one class of share. All ordinary shares have equal voting rights and rank pari passu for the distribution of dividends.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2022, the Group announced a registered direct offering (the &#8220;Offering&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb65e939-5b21-454b-8cc7-eee10b512ed7" contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,950,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s ADSs, each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73f706c3-e8d2-4b36-8a70-f15a9cad3ecd" contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8" name="sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e77908e-f782-485a-ba8b-96da8982833c" contextRef="C_daee9f0f-917c-4075-9727-a97e4432d952" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">9.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7757cdbe-013c-486b-8902-5582cfdc5fb4" contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">56.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef5a62c2-c52d-4f9b-845a-6de10bc50dac" contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in underwriting discounts, commissions and estimated offering expenses.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5_1" continuedAt="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 15, 2021, the Group entered into an Open Market Sale Agreement (the "Sales Agreement"), with Jefferies LLC ("Jefferies"), pursuant to which the Group may offer and sell, from time to time, its ADSs through Jefferies. On October 15, 2021, the Group filed a registration statement, which became effective on October 22, 2021, for the issuance and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7859c0-a2cb-4783-b5f4-d234a1f6aac8" contextRef="C_c26bf700-deb8-4a91-a96d-f882b6d529d7" name="us-gaap:EquityRestrictions" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of ADSs. During the year ended December 31, 2023, the Group sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd7997f5-0c5c-4f59-803a-5b9478853a82" contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ADSs for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_185e0502-d2e5-473a-a882-4d9c7d9bc132" contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25d96f8f-030c-4ce2-9216-085ac57e19d8" contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses. In 2024, the Group raised additional proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b94a8735-7699-4f6f-ba58-d0ce2671c10e" contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ca34b1-7c6e-4eb7-a77e-7f83f8387056" contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses, from sales of ADSs under the Sales Agreement. On October 22, 2024, the Group filed a new registration statement on Form F-3 which replaced the registration statement originally filed on October 15, 2021, for the issuance and sale, if any, of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b7d4294-f289-455a-ae55-9c38fbf9bd36" contextRef="C_e965a87f-ea8d-4a71-9f84-acedc7eb6357" name="us-gaap:StockholdersEquityPeriodIncreaseDecrease" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its shares represented by ADSs under the Sales Agreement. As of this filing, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d8b16dc-1898-4cfe-8201-ea8a0c91c65b" contextRef="C_3807dd5f-7db5-4df7-b6df-54b06e17005f" name="sln:StockholdersEquityRemainingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">139.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of ADSs remained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 5, 2024, the Group announced a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d415c9-5048-44df-8368-2f23983c7ec8" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,714,286</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s ADSs, each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d14fa6d-a9ab-4984-a259-84c227285e2a" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0a27740-0f04-49de-902a-bba7e962f6ca" contextRef="C_504e865b-e8c6-4526-9b0b-319762518420" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">21.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_384d062c-8e03-4510-84ea-7dc82ece0685" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">120.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7696006e-6bbf-4dc3-8ad1-f846c2ccb0ed" contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf530f3d-1b06-427e-9a90-33b7319603e8" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the shares issued during the current and previous year are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"/>
        <td style="width:1.48%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:16.3%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d967110a-bb44-44f6-b419-ad87617617a0" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">118,846,966</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3aa4475-230c-420a-aa98-5819a789944c" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,615,655</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issued during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cc9f256-bd6e-4d7f-bebd-8c402be10948" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">21,418,665</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e85aec2-6b3d-4d51-ad2a-e689c6be91fd" contextRef="C_e1e57139-299b-4037-aa4e-2d87f4f5721e" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3c853c8-caa9-4359-9537-58a764c13a5e" contextRef="C_059ba194-dc5a-46d5-b657-d8a5b95f703b" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.07</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2462f0b0-bf55-4acc-87c7-b5f9df7233db" contextRef="C_1945b695-781c-4d0b-a167-a95a2b6c877c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">252,540</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d956889-ea16-4853-8f82-a9c0b22a4d81" contextRef="C_8927c9e3-b70e-49d9-9480-580bb749557e" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c97dd1d-b06a-42e1-8fc7-07f509ee0642" contextRef="C_952f58d5-0f09-4113-8e23-231dd9d6ed60" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9ebc9a5-e2ed-41e6-8e89-4fcc92024fc1" contextRef="C_217d5192-d77e-4113-b140-4e04d06c0567" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">268,791</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d95f41e5-59cd-49de-a044-7e9f9da892c2" contextRef="C_f1deec49-1e4a-4b33-a7be-f5eb5e43b3d0" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64829d9b-08cd-4e8c-a74f-ad92b83047e0" contextRef="C_632ad642-d991-4f1b-8dd8-159d5c4836a7" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dc778d1-26f0-4948-91db-a5e2aa13b6a7" contextRef="C_2375fd1d-98f8-4091-ae30-79225745f3d6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_082dd2a4-fa2d-497f-9417-a24d2ec83283" contextRef="C_54971021-ad19-41ea-9f7b-464afa3961a9" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a4e45f6-3e47-4fa1-b7c2-51ad890e0e08" contextRef="C_a61b329b-79b8-48f7-91c7-c5440305e906" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0782417-b1c8-4423-98a5-14981162db83" contextRef="C_53a85070-3252-4961-9ffb-808312baaede" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c31e067-537e-4920-89e0-390f2583db26" contextRef="C_992c3aa9-ad2c-45d7-abc4-998d7652ae1b" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee24b06-4656-4140-8329-0ab215dc57ca" contextRef="C_0383529a-c338-4296-a791-e865000b7d3d" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">1.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc7416cc-1bdc-46fa-b0d1-bce006149617" contextRef="C_f7e4679a-8036-4192-9419-7bc7f5cca0d9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a006c120-5706-4000-a2fb-c5c5ad08ac88" contextRef="C_238358c8-8861-4cfb-a53e-08e29a69ca49" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.32</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0877b1b9-b9cf-4b94-ba2e-8ed19603f896" contextRef="C_2d238315-cfea-49cf-90a8-194b936a027a" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.44</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_488a0e82-48be-4bda-b1c0-a244b88248df" contextRef="C_5c9bae62-b3d2-43fe-9e77-fe51e795c617" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28eead41-d655-4a27-829d-70068486f28a" contextRef="C_d7a493d2-59ec-46f4-87a1-b9e48f3e1f9c" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02b824b6-09f2-4e29-b653-ae42409838e2" contextRef="C_dc740331-c44f-436b-8d6a-1313f822c913" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.53</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5796e1f-caf8-4014-9837-9fc16b0c2e90" contextRef="C_5f26855a-a871-47e3-a783-ff3eb99970d2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">584,316</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dec44d98-51ba-496e-85f9-ec73b085c159" contextRef="C_7b15e4df-7de8-4272-a954-8f455cf7b864" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">8.20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3c27e44-cf27-4b59-bd09-03b100a1a377" contextRef="C_e1315f97-7497-4c58-b13e-bbae64f85ba2" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">2.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bd13cda-8f2c-42b0-b0b3-e69aaacbaf6c" contextRef="C_049e703a-bbe5-4ce3-afce-99cf7a56663a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">49,998</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34e3ab24-32f6-4ee7-9d14-4254538fb8e3" contextRef="C_ed7dcfe1-421c-4f79-9232-17d734827b7e" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">9.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9a2d75b-9b06-47a8-bc2b-bc5e7e404bd3" contextRef="C_6ad3128e-4140-41e6-b6de-bf526d8f46d5" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.33</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c6e7eda-707e-450f-a508-47f70fd94403" contextRef="C_49d393af-f321-42c7-85a7-7d1ab9d9840c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3918c852-4165-4f06-b5da-f90bccb3a1be" contextRef="C_9cea7a69-a5e3-4fc9-80c0-2433f7e0add4" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">10.68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1e4b665-d8f3-4c27-8fde-44220544a423" contextRef="C_5a53c3f0-bfdd-42e8-9d51-31e9dfd10fb1" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">3.56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_395c31f3-f5b9-4d83-8d57-8eca6c9d0d3b" contextRef="C_216e038d-1b18-4522-bfb1-cfa508cf7c03" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6dc44d2-f8ec-44cd-ab11-02a6f5ebb5f2" contextRef="C_638faea5-e2d8-41ce-a7ed-8338f7223d41" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.81</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e86c693-5863-47de-9c09-9051bba7f1ca" contextRef="C_4ce48f3f-5b8b-44c8-8ccc-45e7cee6a59e" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_798c4372-178e-4ab3-9e65-a8033bbcfa62" contextRef="C_e1f5638a-04f4-4c2c-93a3-b700275c8509" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e37355d0-8521-46ca-abc8-f98d24952784" contextRef="C_e2631f8b-0c37-4dc8-a1cc-38b6a73bdef4" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5f377a3-6dce-408d-9cd9-ea4b5a664225" contextRef="C_11ec3de2-3169-4055-898b-258e9b888703" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5dc0e49-bcea-46ed-9d2e-8513510b4a0c" contextRef="C_74e6c5aa-7ac8-44e0-8882-bd507123cbea" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,841</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eb03a19-2e46-40cb-80e4-05fa33a509b8" contextRef="C_f0b63486-f25b-4b73-b4df-2ac2360a659a" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">13.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_692c9037-aac9-4c81-b949-229ab39570c7" contextRef="C_6a334fb1-6955-4d69-b9eb-b49d579d734d" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">4.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6657535b-7f41-4041-8c4d-f524efd68d62" contextRef="C_51326ac8-4cf9-4ab6-b452-e838538675cd" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,708</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a488f1b9-4852-4a40-b6d0-833287022a1a" contextRef="C_3441304e-2e9f-4e16-88d3-2ba15339295c" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">15.38</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f24a675f-9007-49f9-ae9c-6fee73d37478" contextRef="C_00a18a89-651d-454d-8df8-75896d774647" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.13</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd941800-24dd-4a45-852b-19179d2c0ced" contextRef="C_fc0ec39a-48d9-4919-8064-11ecd22f79fe" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">126,144</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_145b8c70-dd0f-432a-9adb-623cf503de68" contextRef="C_758fbdcc-cc27-4b6a-8f98-eac78abfa599" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">16.64</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_026e0bef-ffb5-4333-8c58-07b25be9273d" contextRef="C_993ce64a-f00f-4229-b0de-9e75b3dd02f3" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">5.55</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5acf69c6-094b-46f1-8732-c7f37f035094" contextRef="C_16908155-fa6d-48d2-86d3-2bd71f67416e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,248</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_507c9dee-ca20-43ac-86bb-318aab58fa54" contextRef="C_e1b8809b-fd1d-4776-97e9-f3f0de39ae40" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">19.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb13cf7d-1415-4aec-80e0-f44a8594f36d" contextRef="C_67267d0e-6a3e-40c0-98fe-e40aa96783a1" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">6.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b62ef0-8044-4e1e-a491-d53cc485085a" contextRef="C_370fbfa4-fb9b-4a15-a3dc-b8d60d44d568" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_898a05c8-ad92-4f3d-9bdd-228d1e1d490d" contextRef="C_6796ff61-ed09-41b6-8d12-60cb26012f20" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">20.41</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_295b4897-757b-4893-b589-8474a3ebd241" contextRef="C_61dbaca8-5fd5-4900-8f20-af4042005ca6" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">6.80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_468d9119-fd9a-42cf-af9a-f0f575cebac1" contextRef="C_fc219a0f-69bc-48c5-8e88-1c1bea1a3b75" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,500</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9811051a-d77c-4bd7-a9af-b280f89e969b" contextRef="C_6697bf60-6fe3-4afc-9808-67be87d95a10" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">22.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a35bd0c-a049-4718-836a-e8f2bb360e38" contextRef="C_608d77f8-a60e-4cd0-baf8-518580ca501b" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9aec78a-5ca9-4569-8bce-89af6034508b" contextRef="C_a004f47b-e1d5-4aaa-929b-464b64c386ef" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">37,545</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fba9965f-3226-4592-a4a3-dee5a57d43c5" contextRef="C_39a561a1-a49b-401a-9662-3894f44c8689" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">23.60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_880542b2-5212-4fad-93bc-589aebc06efe" contextRef="C_b214b1bd-0876-4f24-bab9-83c0ee791a74" name="sln:StockOptionExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">7.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ccf0c8f1-053e-4261-ac63-29336d0f39f6" contextRef="C_3a41af0c-23c8-4e76-9243-d601a6c1bae4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,436</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01dd8feb-5acd-48a2-b224-57d4c536030e" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">141,674,074</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of equivalent ADS in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc27463c-5d1d-4006-96e8-8a41c290d20e" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">47,224,691</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there were opti</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ons outstanding of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e8fa298-5299-410d-888d-563cb84520dd" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,455,390</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_374f1a6d-c66b-4498-93eb-48b0fe3fa7be" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,853,459</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b3a0522-4df3-4f93-ba56-cdd56cf27aca" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,571,487</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) unissued ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffc6c372-b8b9-4d57-a193-0fddf0724ce2" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the options outstanding are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:12.042%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:6.741%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:7.021%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year of issue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average Exercise price (&#163;)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">WeightedaverageExerciseprice($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options expired</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average years to expiry date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_3bcd4912-0249-4d5f-8925-67053d2fe937" contextRef="C_d983b3bf-ce62-495e-8da5-1fec7e50860e" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2014</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbb2bf37-391a-42b8-bbd8-46c2f69b68cb" contextRef="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">3.31</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_319ad786-1010-4386-9561-72b9a03751f8" contextRef="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49a6b996-7364-4020-8961-6327f496b75e" contextRef="C_a401c67e-4a4e-4f35-a3e7-52f49f0af333" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88efba3-b7e9-4a2f-968c-8a4a97127130" contextRef="C_d983b3bf-ce62-495e-8da5-1fec7e50860e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_9e14dbc1-5b73-4a52-92d8-25c270736d4a" contextRef="C_b785019b-0762-4563-980b-1d22109b7cc9" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2015</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59b4860f-ff93-4467-86dc-6152eca49df6" contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">3.31</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e021709-fee6-441d-bb0d-b78e379648da" contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a78d216c-4c02-4e38-b2a1-d964519d3f50" contextRef="C_23dabf2c-86b8-4fd8-9d01-e013311b7293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0e1c204-a71f-4a38-b988-0918ba29f31c" contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_be29c85e-65cf-4cb8-84e5-782902707133" contextRef="C_b785019b-0762-4563-980b-1d22109b7cc9" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_0b5ef63f-9851-4879-bf47-345198506368" contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2016</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ceea0f8c-b164-4b4c-b883-b888125aa338" contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.02</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2defc8b5-4753-4833-971e-cd2ebc67b224" contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.14</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ee5315d-7097-42c3-bb0f-3e236a60b281" contextRef="C_74b750e6-0f2c-44dc-9d32-f425b3eac898" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,857</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_747da366-04de-4f65-883e-8fbbc3c4c75b" contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_962d6085-a00d-4537-80a6-d9506d3aeaac" contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,524</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_725785b1-8e68-4fde-b7ba-7ab51403915a" contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_dc380b0f-45d5-4c2a-ac5f-45ca869f2104" contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8562f03f-b00d-42a3-825a-59fbd76aae17" contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">6.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43393e2e-044b-44de-a74d-fe642957e702" contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a574c74b-7433-4ed2-bcb1-51aaa87c206b" contextRef="C_b68a9405-7a9f-4135-ac8b-98f4d8aa740a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">39,999</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1f8ae2f-20c6-4bff-bdce-e1ea2d391ec5" contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d11d0f86-8bdb-4623-9b5a-d099403f6744" contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,333</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_5ccda493-c3d5-48a7-8863-79aca02457bf" contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.92</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_59e819a2-0ca5-4fc9-b05d-08768dd4a010" contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2018</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf5fe0e-619f-427b-87c6-b5e65fd791ce" contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">0.16</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21500a79-a1fd-4546-9098-66a33e76842c" contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89730130-786c-4ace-8ae5-36750a35499c" contextRef="C_dbbea4f8-6415-4dd5-b5eb-4a147b35a1df" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,596</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b56834a0-aa77-435f-a791-7b95278cb5fb" contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,003</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af46d2d0-a159-46ac-98ab-a3b18b2e02dc" contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">30,593</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_cf4b7efa-7ae8-438c-83eb-11b2690aa56d" contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_a0b8a464-fd98-43cc-897c-f6b9cf63b429" contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3624f262-9d97-4d7c-b3ea-1a1ff64244cb" contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">4.19</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e53a6677-671e-4770-8ac3-df397a74030d" contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.36</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4717a6a5-25f1-43f9-8696-a68856254e0e" contextRef="C_a7b20ad2-f774-44ca-92d9-91406a63fde3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">577,698</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a54f28dd-eddf-4e48-bc4e-1d40e2bee210" contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">347,701</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15aaea55-a913-4225-b5f0-5481eab859e0" contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">229,997</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_aa0bbdf6-c8c6-4ad5-8fad-e189533ee6af" contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.77</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_0d4071e6-462e-4899-9d2b-1494fb53e3d0" contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2020</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc4ea2a8-af69-4250-914b-119d11e3b113" contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">6.44</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d46415e-0876-453a-92ab-bd8ed1acfeb3" contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.23</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ee8b4b9-77be-4a64-9ae1-b114df01b47b" contextRef="C_b902af35-3fe5-4f8a-ac84-e8d236da4c41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">261,207</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d5af7d0-a140-425e-a4b4-fbf3f518caf8" contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">532</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2827161f-1ea9-4c7d-bcdd-dcb551df56cf" contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">26,497</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_047adb86-1350-43f2-a4d9-8e6198d0405e" contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">234,178</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_27a54c9d-c614-43b2-b148-5cefda5291c0" contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.42</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_b13e3ee1-027f-4a4a-b189-e5950d70989d" contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8801919-34be-4048-b0a4-5257bedc6480" contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">17.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd53c3fa-f50d-41b5-a70e-9a664e996856" contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.37</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d4b9f7f-8eec-4659-89fc-6f09bc683293" contextRef="C_21f6c7f3-fcd4-4d89-9f96-a6ce7fcf4b29" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">662,344</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88962d52-60fa-435d-9658-974fc4ff9488" contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,691</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e87ce54c-7cb5-483d-be91-83cd7394b270" contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">62,502</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b61a7f8b-f977-42e9-b02a-731c3622a339" contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,015</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_569341cc-e2e0-4ecd-a31b-b1a0b3b8c7cd" contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">576,136</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_f599f708-0261-465c-acf6-8443dffa44ef" contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_27374314-fd67-44d9-b29d-c911cc79ac07" contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86afa2bc-51e9-4621-b7db-bdc3cefff345" contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">14.46</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88fa6e53-c3b4-4d51-af65-a42da48014f5" contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.49</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95a61320-4282-4a0e-8989-1a32fdbcf2c6" contextRef="C_92ab0815-ca01-49b9-9495-665a702a4024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,419,863</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11fcfbfd-9aff-4375-9ca3-a863aea8e911" contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a77193a0-8ab2-4f7b-9031-ccc881f76f4b" contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">75,037</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac2df501-49ec-40d8-81ee-f1e832dd515b" contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,019</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3b20866-a262-4a0c-9dcb-5aa18ee27fe5" contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,310,498</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_14de4bfe-e0ef-40d1-a37c-f842e1c2de2d" contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.33</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_b6d2d2dd-d7d2-4095-92f5-19ff38b8d2e9" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f337d1cf-3693-4b3f-9454-750b889d5ccd" contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">10.86</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed1b5060-6f13-465a-9506-0c54f1b2e291" contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.88</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb1cf01-89cb-46a5-98a7-bef0590c5346" contextRef="C_c2ca9beb-ad6f-462a-9e3e-0385278c2a72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,269,589</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef707f66-ab11-44ef-a4db-b1d60f1c2506" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64029db5-fd8f-48ad-b40b-bf4d3f7f47d3" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,858</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76dc5b76-ea79-476b-b4fb-766be7e242f0" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,127</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c4e36d4-cb89-4d24-8250-a92eaf4bf0d8" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">42,247</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32372a3c-8e0e-4f92-80b2-29bc98b73633" contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,148,357</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_7c367416-7ae6-4618-9417-ed349c331ab5" contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.20</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_36630d4e-67e4-4f57-b7a5-4e73dcb264a0" contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1" name="sln:YearOfIssuanceOfStockOption"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2db0602-cc96-417d-99e0-705fe405a27b" contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_U_iso4217GBP_xbrlishares" scale="0" decimals="2" format="ixt:num-dot-decimal">14.12</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bef2ec95-2cb8-4f18-b6c1-77e7c15d7507" contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7b2afaf-527a-498d-a023-2d3db6d4edc3" contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,267,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fa402a4-35d9-4510-a460-fdc796a451cd" contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fce9e75a-7520-4a8a-b15e-9eacd57fcbcb" contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,255,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><ix:nonNumeric id="F_654dc77b-3522-4cd5-ae2c-43c47b80488a" contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1" name="sln:OptionsOutstandingWeightedAverageYearsToExpiryDate" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (ADSs)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_911fd7a0-1913-40eb-870d-d402abf63168" contextRef="C_803eaafe-148f-4e2c-a1bf-e54187acd2aa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,284,486</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49055aa5-ea52-4566-8384-ce03fd7c7c89" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,267,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e28ca48-e265-48ac-be30-0d597fef61f2" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,390</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7678e3a-62f1-4d7e-bdd7-f95ebabff037" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">152,666</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70271439-b1cb-41a3-88dd-80e53dfa8ef5" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">469,481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a87784a-21d0-422a-b756-d96531e7c6a5" contextRef="C_201f659a-3cad-42ab-ab6e-27152af749a5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,818,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (Ordinary<br/>&#160;&#160;&#160;Shares)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65501b9b-cf7b-4967-aa43-8f8254eff265" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,853,459</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb7fffed-7e0f-4e9c-929b-32039a435e24" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,802,542</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72c3c608-4012-4a74-a6d2-50b506b2515e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">334,170</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a93cefca-2d1f-4c4e-a150-00c8184b12c3" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">457,998</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_763108b7-20b0-4c25-b9bf-9b6b3092fdff" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,408,443</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a466e56-1d11-49b3-b4a6-f19072433d92" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,455,390</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADSs represent </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8e94dd5-b0d4-48ff-b82d-9e4fb90845f2" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares and the exercise price was also converted to represent an ADS price at an exchange rate equal to the closing current year currency conversion of sterling pounds to US dollars, which was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0a4d116-5559-4299-8111-98fb72f54306" contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51" name="sln:CurrencyConversionRatePerDollar" unitRef="U_pure" scale="0" decimals="2" format="ixt:num-dot-decimal">1.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sterling pounds to 1 US Dollar.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_8d2d60a9-7811-495f-9087-70e013efd712" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_8d2d60a9-7811-495f-9087-70e013efd712_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19. Equity-settled share-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has issued share options under the 2018 Long Term Incentive Plan (&#8220;LTIP&#8221;), 2018 Non-Employee Long Term Inventive Plan (&#8220;Non-Employee LTIP&#8221;), and individual share option contracts, open to all employees of the Group, as well as EMI shares (none of which remain outstanding at December 31, 2024). </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65556a6f-1d05-4d24-bc5d-8c35f96d0e52" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LTIP, Non-Employee LTIP, individual contracts and schemes available, the options typically vest after three years, with the exception of some options granted to certain members of key management personnel. The vesting period for these options ranges from </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bc1d744-0b45-49cd-afe5-d2542564bd71" contextRef="C_424a567f-bfce-4314-a1cc-dcdfd4446d4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9463edd-ec69-4d21-a9ee-d0bf0e8dda63" contextRef="C_30137f17-19dd-4a65-a75e-44bd27a45a6c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_6f332742-f2ab-4d00-8826-4085b59d6a46" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true" continuedAt="F_6f332742-f2ab-4d00-8826-4085b59d6a46_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options usually lapse after one year following the employee leaving the Group.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6f332742-f2ab-4d00-8826-4085b59d6a46_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.421%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:5.881%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_396c10dc-18ca-4b7a-bc95-95a1b8edbb35" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,284,486</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f322f56-3d33-4064-bd14-499e86f79a1e" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eaf2ec8-58ac-469c-a1eb-ee8dc2e3ba10" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,857,162</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9376e3b-38fb-4fe7-af1a-8815757f2004" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4eb31be2-ac20-430e-86bf-acce59f03b86" contextRef="C_53771d0d-7cc8-4b66-b57c-8f18749a5839" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,684,233</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_143ca93d-0eee-474f-bd07-428ef708b9b6" contextRef="C_53771d0d-7cc8-4b66-b57c-8f18749a5839" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.32</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c7d0cd3-ae4a-4fb1-9478-92c0f2e93c8d" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,267,514</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d7e9be-994a-401f-a59e-6d1df182c6b0" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.05</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_033e6cf5-0a04-43e8-b7bc-df56363c925b" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,567,942</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d66750ea-7a7e-403e-9bb3-b9ead9cb624f" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.01</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4aca8f4-1bca-4ac1-8d5c-7ca560d3cf50" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,940,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4fdc3c3-b859-4d84-ab28-c392fba20979" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">22.30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lapsed or forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a65a93-3415-450f-94c9-63705e209016" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">264,056</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f641cc80-60f3-4a74-955f-a65b3839407a" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.82</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcc67c1f-3b56-4d25-b040-a22ba3ec833a" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">871,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3becfe00-95d0-4534-a26e-bf18bf245819" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.50</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43300a75-b12b-4ff5-8f32-7899960cfb6e" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">709,531</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12b54918-986b-4f39-89c0-8db39ae7e5ee" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">29.25</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_227d968f-38bc-4d91-9900-f609f3273b50" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">469,481</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61d42a2-4730-4ea2-bb59-8262ece7e63d" contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.55</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62697272-63ea-4826-95e6-46826fc29a37" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">269,309</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd537ef9-f7e1-4687-bc82-f13f10a597ec" contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.89</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c432e3-e3b5-4159-a8bc-d765f2d817a7" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,917</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b125495b-de40-4445-bac9-b282e771eb3e" contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the year-end (ADS/$)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffeb1e13-630a-491f-8cc4-27ca4043d6bc" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,818,463</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f0c167-252f-48d1-8ece-291002123dcf" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.95</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b51c59c7-58cc-401e-870a-5a0bc1b8395d" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,284,486</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ab5f30-aefb-4044-83e7-3c00831ae3ba" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.80</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3763114-a02f-4b04-923d-097396ca0da6" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,264,060</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_978ed2f1-53d3-4b19-b965-67bf362120c5" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,857,162</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa3ed41c-217e-44ec-a538-59fed76d49c7" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.10</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f271f5d6-e78b-41ac-8aea-fdc85feb1471" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">578,574</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at the year-end</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca9e6883-34c1-4b17-be4a-caed54686cb9" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,870,106</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fd0c13b-3e55-44c4-aa5d-403f02e4c26c" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6e51f57-b986-4fe8-bb80-480d15c88561" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,420,614</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1eebb9-0e12-4221-89df-871a960a68bd" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.34</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52e53983-3f1d-43b0-bc3d-3dc06475dfa2" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,889,460</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44526125-e85d-470a-a823-129992518097" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.24</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table above shows the number of options in relation to ordinary shares and equivalent ADSs outstanding and exercisable at year end, on the conversion ratio of three ordinary share options to one ADS.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options outstanding at the year-end have a weighted average remaining contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29091bec-ead3-4646-a3a7-be9d68e65cb5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years (2023: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a680e1f-353e-441f-afa5-0cb39031dc2f" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9450ee87-b530-45f8-bdc9-433c9bcbb591" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79b1325b-5e60-4c50-bf85-e33a477b6820" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">29.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized compensation cost related to stock options granted but not vested under the Company&#8217;s plans. That cost will be recognized over an expected remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4e501264-0cee-4a37-b8a7-1ba9bf2fd088" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the years ended December 31, 2024, 2023 and 2022 the total intrinsic value of stock options exercised was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab224e0d-2585-4bab-b1db-bfdb4e72659e" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a82f8422-853a-4313-99ed-4ac463b8c607" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8526a0d1-ca26-460b-aa6e-4c4ad354e8c1" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The weighted average share price at the date of exercise of the options during the year was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44dca2d1-2815-48d8-bb8c-74148580f869" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40043ca6-2a44-430e-8408-ea9dd4ba727f" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#894; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3ac726b-e460-4179-944d-e2000d289948" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.06</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8d2d60a9-7811-495f-9087-70e013efd712_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae9f4296-a516-4d77-b73c-8f0f8ba730bb" contextRef="C_2c9a8caf-7853-4084-b2c4-9c763a4f1b1e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,802,542</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share options during the year (2023: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d723a4b-8259-4a0e-868d-cee21f8f56e7" contextRef="C_8fb4cca8-43c3-4e07-8d79-5d79f2a66b76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,703,826</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68c1c85b-6fae-4277-92d7-791c55e5a2f8" contextRef="C_a74d87d0-a1bb-4a4b-a851-11add28ffc71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,821,131</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a28e27d-2488-4ddc-8f55-b695f48d0cb3" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_9a28e27d-2488-4ddc-8f55-b695f48d0cb3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted were calculated using Black Scholes model. Inputs into the model were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9a28e27d-2488-4ddc-8f55-b695f48d0cb3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.162%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.242%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs and assumptions for options granted in the year:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d9b89cc-ac90-469f-bf50-af29f68b42b2" contextRef="C_21a8db84-e973-428f-b46a-6d101573066a" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da7afbad-d0e1-4dc9-a59c-1fb46ae98642" contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">14.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_333914c5-e848-4c2e-a2d1-21c6fdcdcf19" contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe304509-1160-4215-9c02-9ce905f39827" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">18.1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_791a8a4f-214b-4a24-8775-1923d914e2dd" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">14.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78706f1c-c26e-4391-82ce-3fb97655f0a5" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:SharePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">24.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option life (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ddda9de0-4e6a-406a-b6ff-5ae31d3a6db5" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e3704e78-1f08-427f-bc5e-0f2cd20f3e0b" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_31ea69d0-9e35-437e-a6f2-d6c9f3322c66" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01f36c72-8bd1-468f-8d67-ff20bd4abc08" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">74.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e30a640b-68d9-4ac5-9041-e300d4eaf91b" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">78.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_900a5e03-0da3-49c9-a752-0e26f7e21680" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83e2b013-0e03-45a1-a60b-de5271dfd867" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8feec9a3-38f0-4930-b65e-3be348a7d8ee" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">56</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a338ae17-e903-4904-aebc-f82b18a6c753" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dc56286-f48f-4ef9-9527-90e5131d67b7" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.39</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2149665-a833-45ab-8e78-c827c7f8386c" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.97</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60d33dfb-b336-4ed6-a40e-d5ba8784a592" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_402559fc-ee69-4944-b202-12fc260436bc" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.43</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_138208f3-5574-4a62-89b3-7e14f26c6230" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">1.16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e11127-898c-472e-8a62-80676b8ba9c8" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">3.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average grant data fair value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c898583e-09fe-407d-8134-eec9c456fe3f" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:num-dot-decimal">12.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c99be7f6-3181-48c7-8e3c-8548283ce9df" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a4c008d-266a-4759-be1e-d0735ccdb565" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="1" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognized total charges of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d38a4fdf-da67-48a2-adc7-f92d39b78700" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ca29d16-2299-4756-b237-035cb9c22e7e" contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">16.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32243d79-3908-46fa-a28a-f8c35ffb49ac" contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) related to equity settled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share-based payment transactions during the year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group does not bear any responsibility to settle any employee tax obligations that arise on the exercise of share options. The estimated employer tax obligation on outstanding options at the year-end was nominal (2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_732ba615-bab1-43d6-b5a7-79bb8a6fffc4" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="sln:EstimatedEmployerTaxObligationOnOutstandingOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0517a443-72ce-4e0b-8e62-82cb5e334eae" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="sln:EstimatedEmployerTaxObligationOnOutstandingOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p></ix:continuation></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3741a0cd-8fd5-47f9-a7b3-976a294f4903" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock" escape="true"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20. Capital commitments and contingent liabilities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2325ba1-305d-45c8-a9da-f9f36f8d1c32" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="sln:CapitalCommitments" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> capital commitments at December 31, 2024 (2023: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7e7a64d4-569d-4871-a6b1-2ad84515628e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_40e46a58-04d9-4131-ab73-072c46c316bb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65016b21-ed7e-4deb-b5d9-b9074c857792" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:CommitmentsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21. Commitments under short leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Group had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a gross commitment on its office rental and service charge in Berlin, Germany and the Hoboken, U.S. lease equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72a1564e-1dbe-453a-b802-e3ffda17d1a2" contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697" name="us-gaap:ShortTermLeaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c852cdb3-a948-4c87-b280-3c4bf6610373" contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18" name="us-gaap:ShortTermLeaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfe21161-410f-4a09-86c2-70218c282e96" contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d" name="us-gaap:ShortTermLeaseCommitmentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) in the next year. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9705cc1f-1748-4fdf-b2d9-44a091c53480" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:ShortTermLeasePayments" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts are payable after more than one year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Group enters into contracts in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">normal course of business with contract research organizations to assist in the performance of research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancellable contracts and not reflected in the disclosure above.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_cf97fa44-3599-4996-a04e-a5a79ee67bfb" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="sln:FinancialInstrumentsAndRiskManagementDisclosureTextBlock" escape="true" continuedAt="F_cf97fa44-3599-4996-a04e-a5a79ee67bfb_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22. Financial instruments and risk management</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s financial instruments comprise primarily cash and other financial assets and various items such as receivables and trade payables which arise directly from its operations. The main purpose of these financial instruments is to provide working capital for the Group&#8217;s operations. The Group assesses counterparty risk on a regular basis. Board approval is required for adoption of any new financial instrument or counterparty. The primary focus of the treasury function is preservation of capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of these financial instruments approximates to their fair value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of credit risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents and U.S. Treasury Bills. Cash and cash equivalents, term deposits and U.S. Treasury Bills are not considered to be exposed to significant credit risk due to the fact they are held in a financial institution with an &#8220;A&#8221; rating. The Group considers the possibility of significant loss in the event of non-performance by a financial counterparty to be remote.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_cf97fa44-3599-4996-a04e-a5a79ee67bfb_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group regularly monitors the creditworthiness of its collaborators and at the reporting date, no financial assets are credit impaired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital management</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group considers its capital to be equal to the sum of its total equity. The Group monitors its capital using a number of measures including cash flow projections, working capital ratios, the cost to achieve preclinical and clinical milestones and potential revenue from existing partnerships and ongoing licensing activities. The Group&#8217;s objective when managing its capital is to ensure it obtains sufficient funding for continuing as a going concern. The Group funds its capital requirements through the issue of new shares to investors, milestone and research support payments received from existing licensing partners and potential new licensees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest rate risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The nature of the Group&#8217;s activities and the basis of funding are such that the Group has significant liquid resources. The Group uses these resources to meet the cost of future research and development activities. Consequently, it seeks to minimize risk in the holding of its bank deposits while maintaining a reasonable rate of interest. The Group is not financially dependent on the income earned on these resources and therefore the risk of interest rate fluctuations is not significant to the business. Nonetheless, the Directors take steps to secure rates of interest which generate a return for the Group.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit and liquidity risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit risk is managed on a Group basis. Funds are deposited with financial institutions with a credit rating equivalent to, or above, the main U.K. clearing banks. The Group&#8217;s liquid resources are invested having regard to the timing of payments to be made in the ordinary course of the Group&#8217;s activities. All financial liabilities are payable in the short term (between zero and three months) and the Group maintains adequate bank balances in either instant access or short-term deposits to meet those liabilities as they fall due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group only enters into collaboration agreements with large, reputable companies and the creditworthiness of collaborators is monitored on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected loss rates are based on payment profiles of past receivables and the aging profiles of outstanding balances at the reporting period end date. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customer to settle the receivables. At the year-end there were no debts that were past due or are expected to be past due. It was therefore concluded on this basis that there were no expected credit losses for the trade receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade receivables are written off where there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery includes, but is not limited to, a failure to engage in a repayment plan with the Group.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currency risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s transactions are commonly denominated in U.K pounds sterling; however, the Group receives payments under its collaboration agreements in U.S. dollars and it incurs a portion of its expenses in other currencies, primarily Euros, and are exposed to the effects of these exchange rates. The Group seeks to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in these other currencies. Where significant foreign currency cash receipts are expected, the Group considers the use of forward exchange contracts to manage its exchange rate exposure.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SILENCE THERAPEUTICS </span><span style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plc</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS &#8211; (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3b28bc4-2607-45a9-a510-d0b6ccc07dd4" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23. Related party transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, the Group agreed to pay Gladstone Consultancy Partnership, a company controlled by the Group&#8217;s Non-Executive Chairman, Iain Ross, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae3a3997-8b87-4601-a4df-c4e965e5360c" contextRef="C_eb12df02-dc62-4dfe-9745-ea50a6329b7c" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand (plus any applicable value added tax) for consulting and advisory services provided by Mr. Ross. Gladstone Consulting Partnership is no longer being engaged by the Group in 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f5223e2-80ba-4cea-831a-bec8a74e270a" contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24. Subsequent events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>sln-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 4.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="description_of_share"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association, or the Articles, and relevant provisions of the U.K. Companies Act 2006, or the Companies Act. The summary below contains only material information concerning our share capital and corporate status and does not purport to be complete and is qualified in its entirety by reference to the Articles, which are filed as Exhibit 1.1 to the Annual Report on Form 10-K (the &#x201c;Annual Report&#x201d;). Further, please note that holders of our American Depositary Shares, or ADSs, will not be treated as one of our shareholders and will not have any shareholder rights.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were incorporated as a public limited company under the laws of England and Wales on November 18, 1994 under the name Stanford Rook Holdings plc with company number 2992058. On June 21, 1999 we changed our name to SR Pharma plc. On April 26, 2007, we changed our name to Silence Therapeutics plc. Our principal executive offices are located at 72 Hammersmith Road, London W14 8TH, United Kingdom and our telephone number is +44 (0)20-3457-6900. Our registered office address is 27 Eastcastle Street, London, W1W 8DH. Our ADSs were listed on the Nasdaq Capital Market under the symbol &#x201c;SLN&#x201d; in September 2020. In June 2021, we moved our Nasdaq listing from the Nasdaq Capital Market tier to the Nasdaq Global Market tier. Our ordinary shares were traded on AIM under the symbol &#x201c;SLN,&#x201d; but were delisted with effect from November 30, 2021. Our website address is </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.silence-therapeutics.com</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The information contained on, or that can be accessed from, our website does not form part of this summary. Our agent for service of process in the United States is Silence Therapeutics Inc., with a registered address at 221 River Street, Hoboken, New Jersey 07030 USA.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal legislation under which we operate and under which our ordinary shares are issued is the Companies Act.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 1, 2024, we had 139,506,817 ordinary shares issued and outstanding, with a nominal value of &#163;0.05 per ordinary share. Each issued ordinary share is fully paid.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinary Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Articles, the following summarizes the rights of holders of our ordinary shares:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Options</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As at March 1, 2024, there were options to purchase 18,780,849 ordinary shares outstanding with a weighted average exercise price of &#163;4.06 per ordinary share. The options generally lapse after 10 years from the date of the grant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share Register</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are required by the Companies Act to keep a register of our shareholders. Under the laws of England and Wales, the ordinary shares are deemed to be issued when the name of the shareholder is entered in our share register. The share register therefore is prima facie evidence of the identity of our shareholders, and the shares that they hold. The</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share register generally provides limited, or no, information regarding the ultimate beneficial owners of our ordinary shares. Our share register is maintained by our registrar, Link Market Services Limited, trading as Link Group.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our share register. The depositary, the custodian or their nominees will be the holder of the ordinary shares underlying our ADSs. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights see &#x201c;Description of American Depositary Shares&#x201d; filed as Exhibit 2.4 to the Annual Report.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Companies Act, we must enter an allotment of shares in our share register as soon as practicable and in any event within two months of the allotment. We also are required by the Companies Act to register a transfer of shares (or give the transferee notice of and reasons for refusal) as soon as practicable and in any event within two months of receiving notice of the transfer.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, any of our shareholders or any other affected person may apply to the court for rectification of the share register if:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the name of any person, without sufficient cause, is wrongly entered in or omitted from our register of shareholders; or</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">there is a default or unnecessary delay in entering on the register the fact of any person having ceased to be a shareholder or on which we have a lien, provided that such refusal does not prevent dealings in the shares taking place on an open and proper basis.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Preemptive Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The laws of England and Wales generally provide shareholders with preemptive rights when new shares or rights to subscribe for, or convert securities into, new shares are issued for cash; however, it is possible for the articles of association, or shareholders in a general meeting, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder resolution, if the disapplication is by shareholder resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, at least every five years).</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At our 2023 annual general meeting held on April 27, 2023, our shareholders approved the disapplication of preemptive rights in respect of the allotment of equity securities (as defined in the Companies Act) up to a maximum aggregate nominal amount of &#163;5,402,633.25. This disapplication expires on April 26, 2028.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Articles of Association</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Articles were adopted on November 1, 2021.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A summary of the terms of the Articles is set out below. The summary below is not a complete copy of the terms of the Articles. Please refer to the full version of the Articles, which are filed as Exhibit 1.1 to the Annual Report.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Objects</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The objects of our company are unrestricted.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Shares and Rights Attaching to Them</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Rights</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any special rights attaching to shares or class of shares already in issue, our shares may be issued with or have attached to them any preferred, deferred or other special rights or be subject to such restrictions, whether in regard to dividend, voting, return of capital or otherwise, as we may by ordinary resolution of the shareholders determine or, in the absence of any such determination, as our board may determine.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Voting Rights</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any rights or restrictions attached to any shares from time to time, the voting rights attaching to our shares are as follows:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">on a show of hands, every shareholder present in person shall have one vote;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder and the proxy has been instructed by one or more of those shareholders to vote for the resolution and by one or more other of those shareholders to vote against it;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">on a show of hands, each proxy present in person has one vote for and one vote against a resolution if the proxy has been duly appointed by more than one shareholder entitled to vote on the resolution and either: (1) the proxy has been instructed by one or more of those shareholders to vote for the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote against it; or (2) the proxy has been instructed by one or more of those shareholders to vote against the resolution and has been given any discretion by one or more other of those shareholders to vote and the proxy exercises that discretion to vote for it;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">on a show of hands, each duly authorised corporate representative has one vote;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">on a poll every shareholder who is present in person or by proxy or by corporate representative shall have one vote for each share of which he or she is the holder or in respect of which their appointment as proxy or corporate representative is made; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">in the case of joint holders of a share, the vote of the senior holder who votes shall be accepted to the exclusion of the votes of the other joint holders (and seniority shall be determined by the order in which the names stand in the register in respect of the share).</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is (before or on the declaration of the result of the show of hands) demanded. Subject to the provisions of the Companies Act, as described in &#x201c;Differences in Corporate Law&#x2014;Voting Rights,&#x201d; a poll may be demanded by:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the chairman of the meeting;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">at least five shareholders present in person or by proxy and entitled to vote on the resolution;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any shareholder(s) present in person or by proxy and representing in the aggregate not less than one-tenth of the total voting rights of all shareholders having the right to attend and vote at the meeting (excluding the shares held in treasury); or</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any shareholder(s) present in person or by proxy and holding shares conferring a right to vote on the resolution at the meeting on which there have been paid up sums in the aggregate equal to not less than one-tenth of the total sums paid up on all shares conferring that right (excluding the shares held in treasury).</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A resolution put to the vote at a general meeting held partly by means of electronic facility or facilities shall, unless the chairman of the meeting determines that it shall be decided on a show of hands, be decided on a poll.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restrictions on Voting</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No shareholder shall, unless the directors otherwise determine, be entitled to vote, either in person or by proxy, at any general meeting or at any separate class meeting in respect of any share held by such shareholder unless all calls or other sums payable by such shareholder in respect of that share have been paid.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board may from time to time make calls upon the shareholders in respect of any money unpaid on their shares and each shareholder shall (subject to us serving on such shareholder at least 14 days&#x2019; notice specifying the time or times and place of payment) pay at the time or times so specified the amount called on such holder&#x2019;s shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Dividends</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may by ordinary resolution of shareholders declare dividends out of profits available for distribution in accordance with the respective rights of shareholders but no such dividend shall exceed the amount recommended by the directors. The directors may from time to time pay shareholders such interim dividends as they think fit and may also pay the fixed dividends payable on any shares of the company half-yearly or otherwise on fixed dates. If the directors act in good faith, they shall not incur any liability to the holders of shares conferring preferred rights for any loss they may suffer in consequence of the payment of an interim dividend on any shares having non-preferred or deferred rights.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any special rights attaching to or the terms of issue of any share, all dividends shall be declared and paid according to the amounts paid up on the shares and shall be apportioned and paid proportionately according to the amounts paid up on the shares during any part or parts of the period in respect of which the dividend is paid.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to any rights attaching to or the terms of issue of any shares, no dividend or other monies payable by us on or in respect of any share shall bear interest against us. Any dividend unclaimed after a period of 12 years from the date such dividend became due for payment shall be forfeited and shall revert to us.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends may be declared or paid in any currency or currencies and the board may decide the rate of exchange for any currency conversions that may be required, and how any costs involved are to be met.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any general meeting declaring a dividend may by ordinary resolution of shareholders, upon the recommendation of the board, direct payment or satisfaction of such dividend wholly or in part by the distribution of specific assets other than cash, and in particular of paid up shares or debentures of any other company. The directors may, if authorized by ordinary resolution of shareholders, offer any holders of ordinary shares the right to elect to receive in lieu of a dividend an allotment of ordinary shares credited as fully paid up, subject to such exclusions and other arrangements as the board may deem necessary or expedient to deal with legal or practical problems in respect of overseas shareholders or in respect of shares represented by depositary receipts.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Change of Control</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no specific provision in the Articles that would have the effect of delaying, deferring or preventing a change of control.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distributions on Winding Up</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On a winding up, the liquidator may, with the sanction of a special resolution of shareholders and any other sanctions required by law, divide amongst the shareholders (excluding the company itself to the extent it is a shareholder by virtue only of its holding of shares as treasury shares) in specie or in kind the whole or any part of our assets (whether they shall consist of property of the same kind or not) and may set such values as he or she deems fair upon any property to be divided and may determine how such division shall be carried out as between the shareholders or different classes of shareholder. The liquidator may, with the sanction of a special resolution of the shareholders and any other sanctions required by law, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the shareholders as the liquidator shall think fit, but no shareholder shall be compelled to accept any shares or other assets upon which there is any liability.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variation of Rights</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All or any of the rights and restrictions attached to any class of shares issued may be abrogated or varied with the consent in writing of the holders of at least three-quarters in nominal value of the issued shares of that class (excluding any shares held as treasury shares) or by special resolution passed at a separate general meeting of the holders of such class of shares, subject to the Companies Act and the terms of their issue. The Companies Act provides a right to object to the variation of the share capital by the shareholders who did not vote in favor of the variation. Should an aggregate of 15% of the shareholders of the issued shares in question apply to the court to have the variation cancelled, the variation shall have no effect unless and until it is confirmed by the court.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Alteration to Share Capital</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may, by ordinary resolution of shareholders, consolidate all or any of our share capital into shares of larger nominal amount than our existing shares, or sub-divide our shares or any of them into shares of a smaller amount. We may, by special resolution of shareholders, confirmed by the court, reduce our share capital, any capital redemption reserve or any share premium account in any manner authorized by the Companies Act. We may redeem or purchase all or any of our shares as described in &#x201c;Other English Law Considerations&#x2014;Purchase of Own Shares.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preemption Rights</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In certain circumstances, our shareholders may have statutory preemption rights under the Companies Act in respect of the allotment of new shares as described in &#x201c;Preemptive Rights&#x201d; and &#x201c;Differences in Corporate Law&#x2014;Preemptive Rights.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Transfer of Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any certificated shareholder may transfer all or any of his, her or its shares by an instrument of transfer in any usual or common form or in any other manner which is permitted by the Companies Act and approved by the board. Any written instrument of transfer shall be signed by or on behalf of the transferor and in the case of a partly paid share, the transferee.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board may decline to register any transfer of any share:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">which is not a fully paid share, provided that, where any such shares or securities are listed on any stock exchange, such discretion may not be exercised in a way in which the U.K. Financial Conduct Authority, the London Stock Exchange or any other relevant regulator or stock exchange regards as preventing dealing in shares or other securities from taking place on an open and proper basis;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unless any written instrument of transfer, duly stamped (if required), is deposited with us at our registered office or such other place as the board may from time to time determine, accompanied by the certificate for the shares to which it relates;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">unless there is provided such evidence as the board may reasonably require to show the right of the transferor to make the transfer and if the instrument of transfer is executed by some other person on his, her or its behalf, the authority of that person to do so;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">where the transfer is in respect of more than one class of share; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">in the case of a transfer to joint holders, the number of joint holders to whom the share is to be transferred exceeds four.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the board declines to register a transfer of a certificated share it shall, as soon as practicable and in any event within two months after the date on which the transfer is lodged, send to the transferee notice of the refusal, together with reasons for the refusal.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholder Meetings</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Annual General Meetings</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with the Companies Act, we are required in each year to hold an annual general meeting in addition to any other general meetings in that year and to specify the meeting as such in the notice convening it. The annual general meeting shall be convened at such time and place and with such additional means of attendance and participation (including at such other place(s) and/or by means of an electronic facility or facilities) as the board sees fit, subject to the requirements of the Companies Act, as described in &#x201c;Differences in Corporate Law&#x2014;Annual General Meeting&#x201d; and &#x201c;Differences in Corporate Law&#x2014;Notice of General Meetings.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Notice of General Meetings</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The arrangements for the calling of general meetings are described in &#x201c;Differences in Corporate Law&#x2014;Notice of General Meetings.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Quorum of General Meetings</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No business shall be transacted at any general meeting unless a quorum is present. At least two shareholders present in person or by proxy and entitled to vote shall be a quorum.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Class Meetings</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The provisions in the Articles relating to general meetings apply to every separate general meeting of the holders of a class of shares except that:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the quorum for such class meeting shall be two holders in person or by proxy representing not less than one-third in nominal value of the issued shares of the class (excluding any shares held in treasury);</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">at the class meeting, a holder of shares of the class present in person or by proxy may demand a poll and shall on a poll be entitled to one vote for every share of the class held by him or her; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">if at any adjourned meeting of such holders a quorum is not present at the meeting, one holder of shares of the class present in person or by proxy at an adjourned meeting constitutes a quorum.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Directors</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Number of Directors</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless and until otherwise determined by an ordinary resolution of shareholders, we may not have less than two directors on the board of directors but are not subject to any maximum number of directors.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Appointment of Directors</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the provisions of the Articles, we may, by ordinary resolution of the shareholders, elect any person who is willing to act to be a director, either to fill a casual vacancy or as an addition to the existing board. However, any person that is not a director retiring from the existing board must be recommended by the board of directors, or be proposed by a shareholder not less than seven and not more than 42 days before the date appointed for the meeting in order to be eligible for election.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without prejudice to the power to appoint any person to be a director by shareholder resolution, the board has power to appoint any person to be a director, either to fill a casual vacancy or as an addition to the existing board but so that the total number of directors does not exceed any maximum number fixed by or in accordance with the Articles.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any director appointed by the board will hold office only until the following annual general meeting. Such a director is eligible for re-appointment at that meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rotation of Directors</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At every annual general meeting, there shall retire from office any director who shall have been a director at each of the preceding two annual general meetings and who was not appointed or re-appointed by us in general meeting at, or since, either such meeting. A retiring director shall be eligible for re-appointment. A director retiring at a meeting shall, if he or she is not re-appointed at such meeting, retain office until the meeting appoints someone in his or her place, or if it does not do so, until the conclusion of such meeting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#x2019; Interests</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The directors may authorize, to the fullest extent permitted by law, any matter proposed to them which would otherwise result in a director infringing his or her duty to avoid a situation in which he or she has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with our interests. A director shall not, save as otherwise agreed by him or her, be accountable to us for any benefit which he or she derives from any matter authorized by the directors and any contract, transaction or arrangement relating thereto shall not be liable to be avoided on the grounds of any such benefit.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the requirements under sections 175, 177 and 182 of the Companies Act, a director who is any way, whether directly or indirectly, interested in a proposed or existing transaction or arrangement with us shall declare the nature of his interest at a meeting of the directors.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A director shall not vote in respect of any contract, arrangement or transaction whatsoever in which he or she has an interest which is to his or her knowledge a material interest otherwise than by virtue of interests in shares or debentures or other securities of or otherwise in or through our company. A director shall not be counted in the quorum at a meeting in relation to any resolution on which he or she is debarred from voting.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A director shall be entitled to vote (and be counted in the quorum) in respect of any resolution concerning any of the following matters:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the giving of any guarantee, security or indemnity in respect of money lent or obligations incurred by him or her or by any other person at the request of or for the benefit of our company or any of our subsidiary undertakings;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the giving of any guarantee, security or indemnity in respect of a debt or obligation of our company or any of our subsidiary undertakings for which he or she has assumed responsibility in whole or in part under a guarantee or indemnity or by the giving of security;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any proposal concerning an offer of securities of or by our company or any of our subsidiary undertakings in which offer he or she is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting of which he or she is to participate;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any contract, arrangement or transaction concerning any other body corporate in which he or she or any person connected with him or her (within the meaning of sections 252-5 of the Companies Act) is interested, directly or indirectly and whether as an officer or shareholder or otherwise howsoever, provided that he or she and any persons so connected with him or her do not to his or her knowledge hold an interest (within the meaning of sections 820 to 825 of the Companies Act) in one percent or more of any class of the equity share capital of such body corporate or of the voting rights available to members of the relevant body corporate;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any contract, arrangement or transaction for the benefit of employees of our company or any of our subsidiary undertakings which does not accord to him or her any privilege or advantage not generally accorded to the employees to whom the scheme relates;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">any contract, arrangement or transaction concerning any insurance which our company is to purchase and/or maintain for, or for the benefit of, any directors or persons including directors;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the giving of an indemnity in relation to another director; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the provision of funds to any director to meet, or the doing of anything to enable a director to avoid incurring, expenditure of the nature described in section 205(1) or 206 of the Companies Act.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a question arises at a meeting of the board or of a committee of the board as to the right of a director to vote or be counted in the quorum, and such question is not resolved by his or her voluntarily agreeing to abstain from voting or not to be counted in the quorum, the question shall be determined by the chairman and his or her ruling in relation to any director other than himself or herself shall be final and conclusive except in a case where the nature or extent of the interest of the director concerned has not been fairly disclosed.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Directors&#x2019; Fees and Remuneration</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of the directors shall be paid a fee in such sums as may from time to time be determined by the directors provided that the aggregate of all such fees so paid to directors shall not exceed &#163;500,000 per annum, or such higher amount as may from time to time be determined by ordinary resolution of shareholders.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each director may be paid all his or her reasonable traveling, hotel and other expenses properly incurred in attending and returning from meetings of the directors or committees of the directors or general meetings of the company or separate meetings of the holders of any class of shares or debentures of the company or otherwise in connection with the business of our company.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any director who is appointed to any executive office or who serves on any committee or who devotes special attention to the business of our company, or who otherwise performs services which in the opinion of the directors are outside</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of the ordinary duties of a director, may be paid such extra remuneration by way of salary, percentage of profits or otherwise as the directors may determine.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Borrowing Powers</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board may exercise all the powers to borrow money and to mortgage or charge our undertaking, property and assets (present or future) and uncalled capital or any part thereof and to issue debentures, debenture stock and other securities, whether outright or as collateral security for any debt, liability or obligation of us or of any third party.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board must restrict the borrowings of the Company and exercise all voting and other rights or powers of control exercisable by the Company in relation to its subsidiaries so as to secure that the aggregate amount remaining outstanding of all monies borrowed by the Company and its subsidiaries shall not at any time, without the previous sanction of an ordinary resolution of the shareholders, exceed a sum equal to five (5) times the aggregate of:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the amount paid up on the issued share capital of the Company; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">the total of the capital and revenue reserves of the Company and its subsidiaries (including any share premium account, capital redemption reserve and credit balance on the profit and loss or income account) in each case, whether or not such amounts are available for distribution;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all as shown in the latest audited consolidated balance sheet, subject to certain adjustments.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnity</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Every director or other officer of our group may be indemnified against all costs, charges, expenses, losses and liabilities sustained or incurred by him or her in connection with the actual or purported execution and/or discharge of his or her duties (including those duties, powers and discretions in relation to any members of our group) including all costs, charges, expenses, losses and liabilities suffered or incurred in disputing, defending, investigating or providing evidence in connection with any actual or threatened claims or otherwise. Every director or other officer of our group may also be provided with funds to meet, or do anything to enable a director or other officer of the Company to avoid incurring, expenditure of the nature described in sections 205(1) or 206 of the Companies Act.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exclusive jurisdiction</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Articles will provide that, unless we consent in writing to the selection of an alternative forum in the United States of America, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Save in respect of any cause of action arising under the Securities Act, by subscribing for or acquiring shares, a shareholder submits all disputes between him or herself and us or our directors to the exclusive jurisdiction of the English courts.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other English Law Considerations</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Mandatory Purchases and Acquisitions</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Sections 979 to 991 of the Companies Act, where a takeover offer has been made for us and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the shares to which the offer relates and not less than 90% of the voting rights carried by those shares, the offeror may give notice to the holder of any shares to which the offer relates which the offeror has not acquired or unconditionally contracted to acquire that he, she or it wishes to acquire, and is entitled to so acquire, those shares on the same terms as the general offer. The offeror would do so by sending a notice to the outstanding minority shareholders telling them that it will compulsorily acquire their shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Such notice must be sent within three months of the last day on which the offer can be accepted in the prescribed manner. The squeeze&#x2011;out of the minority shareholders can be completed at the end of six weeks from the date the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notice has been given, subject to the minority shareholders failing to successfully lodge an application to the court to prevent such squeeze&#x2011;out any time prior to the end of those six weeks following which the offeror can execute a transfer of the outstanding shares in its favor and pay the consideration to us, which would hold the consideration on trust for the outstanding minority shareholders. The consideration offered to the outstanding minority shareholders whose shares are compulsorily acquired under the Companies Act must, in general, be the same as the consideration that was available under the takeover offer.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sell Out</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Companies Act also gives our minority shareholders a right to be bought out in certain circumstances by an offeror who has made a takeover offer for all of our shares. The holder of shares to which the offer relates, and who has not otherwise accepted the offer, may require the offeror to acquire his, her or its shares if, prior to the expiry of the acceptance period for such offer, (1) the offeror has acquired or unconditionally agreed to acquire not less than 90% in value of the voting shares, and (2) not less than 90% of the voting rights carried by those shares. The offeror may impose a time limit on the rights of minority shareholders to be bought out that is not less than three months after the end of the acceptance period. If a shareholder exercises his, her or its rights to be bought out, the offeror is required to acquire those shares on the terms of this offer or on such other terms as may be agreed.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Disclosure of Interest in Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Part 22 of the Companies Act, we are empowered by notice in writing to any person whom we know or have reasonable cause to believe to be interested in our shares, or at any time during the three years immediately preceding the date on which the notice is issued has been so interested, within a reasonable time to disclose to us particulars of that person&#x2019;s interest and (so far as is within such person&#x2019;s knowledge) particulars of any other interest that subsists or subsisted in those shares.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Articles, if a person defaults in supplying us with the required particulars in relation to the shares in question, or default shares, within the prescribed period of 14 days from the date of the service of notice, the directors may by notice direct that:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">in respect of the default shares, the relevant shareholder shall not be entitled to vote (either in person or by proxy) at any general meeting or to exercise any other right conferred by a shareholding in relation to general meetings; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">where the default shares represent at least 0.25% of their class, (a) any dividend or other money payable in respect of the default shares shall be retained by us without liability to pay interest and/or (b) no transfers by the relevant shareholder of any default shares may be registered (unless the shareholder is not in default and the shareholder provides a certificate, in a form satisfactory to the directors, to the effect that after due and careful enquiry the shareholder is satisfied that none of the shares to be transferred are default shares).</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase of Own Shares</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, a limited company may only purchase its own shares out of the distributable profits of the company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, provided that they are not restricted from doing so by their articles of association. A limited company may not purchase its own shares if, as a result of the purchase, there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may purchase our own fully paid shares pursuant to a purchase contract authorized by resolution of shareholders before the purchase takes place. Any authority will not be effective if any shareholder from whom we propose to purchase shares votes on the resolution and the resolution would not have been passed if he, she or it had not done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is to expire.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Distributions and Dividends</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Companies Act, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves (on a non&#x2011;consolidated basis). The basic rule is that a company&#x2019;s profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under the laws of England and Wales.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is not sufficient that we, as a public company, have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only make a distribution:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:3.06%;box-sizing:content-box;"></td>
    <td style="width:93.88%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:11pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#149;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of the net assets to less than that total.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">City Code on Takeovers and Mergers</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK City Code on Takeovers and Mergers, or the Takeover Code, provides a framework within which takeovers of companies subject to it are conducted.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the cancellation of admission of our ordinary shares to trading on the AIM market of the London Stock Exchange in November 2021 and under transitional provisions that apply until February 2027, the Takeover Code will only apply to us if we are considered by the Panel on Takeovers and Mergers, or the Takeover Panel, to have our place of central management and control in the United Kingdom (or the Channel Islands or the Isle of Man). This is known as the &#x201c;residency test&#x201d;. The way in which the test for central management and control is applied for the purposes of the Takeover Code may be different from the way it is applied by the United Kingdom tax authorities. Under the Takeover Code, the Takeover Panel looks to where the majority of the directors of the company are resident, amongst other factors, for the purposes of determining where the company has its place of central management and control.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Takeover Panel has confirmed that based on the composition of our board of directors following Alistair Gray&#x2019;s retirement from the board, effective May 1, 2024, we are no longer subject to the Takeover Code. As a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code. We believe that this position is unlikely to change at any time in the near future, but, in accordance with good practice, we will review the situation on a regular basis and consult with the Takeover Panel if there is any change in our circumstances which may have a bearing on whether the Takeover Panel would determine our place of central management and control to be in the United Kingdom.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incorporated certain takeover protections in our articles of association, which apply in circumstances where the Takeover Code does not apply to the company. A resolution was passed at the company&#x2019;s annual general meeting held on May 17, 2024, to approve the continued application of these provisions until the 2025 annual general meeting of the company.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Controls</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by us to non&#x2011;resident holders of our ordinary shares or ADSs representing our ordinary shares, other than withholding tax requirements. There is no limitation imposed by the laws of England and Wales or in the Articles on the right of non&#x2011;residents to hold or vote our shares.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Differences in Corporate Law</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The applicable provisions of the Companies Act differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#x2019; rights and protections. This summary is not intended to be a complete discussion of shareholder rights under the laws of Delaware and the laws of England and Wales.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of Directors</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.011in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#x2019;s articles of association.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.011in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Removal of Directors</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days&#x2019; notice of the resolution has been given to the company and its shareholders. On receipt of notice of an intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act must also be followed such as allowing the director to make representations against his or her removal either at the meeting or in writing.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, shareholders may effect such removal only for cause, or (b) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his or her removal would be sufficient to elect him or her if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he or she is a part.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vacancies on the Board of Directors</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, the procedure by which directors, other than a company&#x2019;s initial directors, are appointed is generally set out in a company&#x2019;s articles of association, provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (a) otherwise provided in the certificate of incorporation or by-laws of the corporation or (b) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Annual General Meeting</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, a public limited company must hold an annual general meeting in</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">each six-month period following our annual accounting reference date.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">of directors or as provided in the certificate of incorporation or by the bylaws.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General Meeting</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, a general meeting of the shareholders of a public limited company may be called by the directors.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholders holding at least 5% of the paid-up capital of the company carrying voting rights at general meetings (excluding any paid up capital held as treasury shares) can require the directors to call a general meeting and, if the directors fail to do so within a certain period, may themselves convene a general meeting.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Notice of General Meetings</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subject to a company&#x2019;s articles of association providing for a longer period, under the Companies Act, at least 21 clear days&#x2019; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company&#x2019;s articles of association providing for a longer period, at least 14 clear days&#x2019; notice is required for any other general meeting. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 clear days&#x2019; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#x2019; consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting (excluding any shares held as treasury shares).</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Quorum</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Subject to the provisions of a company&#x2019;s articles of association, the Companies Act provides that two &#x2018;qualifying persons&#x2019; present at a meeting (in person, by proxy or authorized representative under the Companies Act (provided that the proxies and/or authorized representatives, represent different shareholders)) shall constitute a quorum for companies with more than one shareholder.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one-third of the shares entitled to vote at the meeting. In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proxy</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#x2019;s voting rights as a director.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preemptive Rights</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, &#x201c;equity securities,&#x201d; being (1) shares in the company other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution, referred to as &#x201c;ordinary shares,&#x201d; or (2) rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authority to Allot</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, the directors of a company must not allot shares or grant rights to subscribe for or to convert any security into shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, if the corporation&#x2019;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liability of Directors and Officers</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the Companies Act, any provision, whether contained in a company&#x2019;s articles of association or any contract or otherwise, that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, a corporation&#x2019;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company against any liability attaching to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he or she is a director is also void except as permitted by the Companies Act, which provides exceptions for the company to (a) purchase and maintain insurance against such liability; (b) provide a &#x201c;qualifying third party indemnity&#x201d; (being an indemnity against liability incurred by the director to a person other than the company or an associated company or criminal proceedings in which he or she is convicted); and (c) provide a &#x201c;qualifying pension scheme indemnity&#x201d; (being an indemnity against liability incurred in connection with our activities as trustee of an occupational pension plan).</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;text-indent:36pt;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any transaction from which the director derives an improper personal benefit.</font></div></div></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Voting Rights</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or our articles of association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act, a poll may be demanded by (a) not fewer than five shareholders having the right to vote on the resolution; (b) any shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution (excluding any voting rights attaching to treasury shares); or (c) any shareholder(s) holding shares in the company conferring a right to vote on the resolution (excluding any voting rights attaching to treasury shares) being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company&#x2019;s articles of association may provide more extensive rights for shareholders to call a poll.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy, who, being entitled to vote, vote on the resolution. Special</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting. If a poll is demanded, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders in person or by proxy who, being entitled to vote, vote on the resolution.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shareholder Vote on Certain Transactions</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Companies Act provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations, or takeovers. These arrangements require:</font></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval at a shareholders&#x2019; or creditors&#x2019; meeting convened by order of the court, of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the class of shareholders or creditors, or class thereof present and voting, either in person or by proxy; and </font></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval of the court.</font></div></div></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#x2019;s assets or dissolution requires:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval of the board of directors; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</font></div></div></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Standard of Conduct for Directors</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, a director owes various statutory and fiduciary duties to the company, including:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to act in the way he or she considers, in good faith, would be most likely to promote the success of the company for the benefit of its members as a whole(and in doing so have regard (amongst other matters) to: (i) the likely consequences of any decision in the long-term, (ii) the interests of the company&#x2019;s employees, (iii) the need to foster the company&#x2019;s business relationships with suppliers, customers and others, (iv) the impact of the company&#x2019;s operations on the community and the environment, (v) the desirability to maintain a reputation for high standards of business conduct, and (vi) the need to act fairly as between members of the company);</font></div></div></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;text-indent:36pt;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to avoid a situation in which he or she has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the company;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to act in accordance with our constitution and only exercise his or her powers for the purposes for which they are conferred;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to exercise independent judgment;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to exercise reasonable care, skill, and diligence;</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not to accept benefits from a third party conferred by reason of his or her being a director or doing, or not doing, anything as a director; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;text-indent:0;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a duty to declare any interest that he or she has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the company.</font></div></div></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-kerning:none;min-width:fit-content;">best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;text-indent:18pt;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholder Suits</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under the laws of England and Wales, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an irregularity in our internal management. Notwithstanding this general position, the Companies Act provides that (1) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the company) in respect of a cause of action arising from a director&#x2019;s negligence, default, breach of duty or breach of trust and (2) a shareholder may bring a claim for a court order where our affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:</font></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#x2019;s failure to obtain the action; or</font></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">state the reasons for not making the effort.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:17%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:42.88%;box-sizing:content-box;"></td>
    <td style="width:1%;box-sizing:content-box;"></td>
    <td style="width:38.12%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">England and Wales</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid #ffffff;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid #000000;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.007in;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">approval of the Delaware Court of Chancery.</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Exchange Listing</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ADSs were listed on the Nasdaq Capital Market under the symbol &#x201c;SLN&#x201d; in September 2020. In June 2021, we moved our Nasdaq listing from the Nasdaq Capital Market tier to the Nasdaq Global Market tier.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ordinary shares were traded on AIM, a market operated by the London Stock Exchange, under the ticker symbol &#x201c;SLN&#x201d;. On October 15, 2021, we announced our intention to cancel the admission of our ordinary shares to trading on AIM, subject to shareholder approval which was obtained. The final day of trading of the ordinary shares on AIM was November 29, 2021 and the delisting took effect at 7:00 a.m. on November 30, 2021.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrar of Shares, Depositary for ADSs</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our share register is maintained by Link Market Services Limited. The share register reflects only registered holders of our ordinary shares. Holders of ADSs representing our ordinary shares will not be treated as our shareholders and their names will therefore not be entered in our share register. The Bank of New York Mellon has agreed to act as the depositary for the ADSs representing our ordinary shares and the custodian for ordinary shares represented by ADSs is The Bank of New York Mellon, acting through an office located in England. Holders of ADSs representing our ordinary shares have a right to receive the ordinary shares underlying such ADSs. For discussion on ADSs representing our ordinary shares and rights of ADS holders, see &#x201c;Description of American Depositary Shares&#x201d; filed as Exhibit 2.4 to the Annual Report.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>sln-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">Exhibit 19.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approved by the Board of Directors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 13, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Introduction</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the course of your relationship with Silence Therapeutics plc (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), you may receive material information that is not yet publicly available (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">material nonpublic information</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) about the Company or other publicly traded companies with which the Company has business relationships. Material nonpublic information may give you, or someone you pass that information on to, a leg up over others when deciding whether to buy, sell or otherwise transact in the Company&#x2019;s securities or the securities of another publicly traded company. This policy sets forth guidelines with respect to transactions in the Company&#x2019;s securities and in the securities of other applicable publicly traded companies, in each case by our employees, directors and consultants who are advised that they are subject to this policy (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">consultants</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and the other persons subject to this policy as described below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statement of Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is the policy of the Company that an employee, director or consultant of the Company (or any other person or entity subject to this policy) who is aware of material nonpublic information relating to the Company </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may not</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, directly or indirectly:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.6018025222343497%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engage in any transactions in the Company&#x2019;s securities, except as otherwise specified under the heading &#x201c;Exceptions to this Policy&#x201d; below; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.6018025222343497%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recommend the purchase or sale of any the Company&#x2019;s securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.6018025222343497%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons, such as family, friends, business associates and investors, unless the disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company; or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:7.463%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.6018025222343497%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assist anyone engaged in the above activities.</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prohibition against insider trading is absolute. It applies </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">even if</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the decision to trade is not based on such material nonpublic information.  It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) and also to very small transactions.  All that matters is whether you are aware of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> material nonpublic information relating to the Company at the time of the transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The U.S. federal securities laws do not recognize any mitigating circumstances to insider trading. In addition, even the appearance of an improper transaction must be avoided to preserve the Company&#x2019;s reputation for adhering to the highest standards of conduct. In some circumstances, you may need to forgo a planned transaction even if you planned it before becoming aware of the material nonpublic information. So, even if you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting to trade, you must wait.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is also important to note that the laws prohibiting insider trading are not limited to trading by the insider alone; advising others to trade on the basis of material nonpublic information is illegal and squarely prohibited by this policy. Liability in such cases can extend both to the &#x201c;tippee&#x201d;&#x2014;the person to whom the insider disclosed material nonpublic information&#x2014;and to the &#x201c;tipper,&#x201d; the insider himself or herself.  In such cases, you can be held liable for your own transactions, as well as the transactions by a tippee and even the transactions of a tippee&#x2019;s tippee. For these and other reasons, it is the policy of the Company that no employee, director or consultant of the Company (or any other person or entity subject to this policy) may either (a) recommend to another person or entity that they buy, hold or the Company&#x2019;s securities </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">at any time</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or (b) disclose material nonpublic information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons (unless the disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company.</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, it is the policy of the Company that no person subject to this policy who, in the course of his or her relationship with the Company, learns of any confidential information that is material to another publicly traded company with which the Company does business, including a customer, supplier, partner or collaborator of the Company, may trade in that other company&#x2019;s securities until the information becomes public or is no longer material to that other company.</font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are no exceptions to this policy, except as specifically noted above or below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Subject to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy applies to all transactions in securities issued by the Company, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#x2019;s securities. Accordingly, for purposes of this policy, the terms &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">trade</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">trading</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; include not only purchases and sales of the Company&#x2019;s American Depositary Shares (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADSs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or shares in the public market but also any other purchases, sales, transfers, gifts or other acquisitions and dispositions of ADSs, common or preferred equity, options, warrants and other securities (including debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons Subject to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy applies to you and all other employees, directors and consultants of the Company and its subsidiaries. This policy also applies to members of your family who reside with you, any other persons with whom you share a household, any family members who do not live in your household but whose transactions in the Company&#x2019;s securities are directed by you or are subject to your influence or control and any other individuals or entities whose transactions in securities you influence, direct or control (including, e.g., a venture or other investment fund, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> you influence, direct or control transactions by the fund). The foregoing persons who are deemed subject to this policy are referred to in this policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.&#x201d; You are responsible for making sure that your Related Persons comply with this policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Material Nonpublic Information</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material information</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It is not always easy to figure out whether you are aware of material nonpublic information. But there is one important factor to determine whether nonpublic information you know about a public company is material:  whether the information could be expected to affect the market price of that company&#x2019;s securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or to be considered important by investors who are considering trading that company&#x2019;s securities. If the information makes you want to trade, it would probably have the same effect on others. Keep in mind that both positive and negative information can be material.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by relevant enforcement authorities with the benefit of hindsight. Depending on the specific details, the following items may be considered material nonpublic information until publicly disclosed within the meaning of this policy. There may be other types of information that would qualify as material information as well; use this list merely as a non-exhaustive guide:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial results or forecasts, and any changes, revisions or withdrawals thereof;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">status of and new developments related to product or product candidate development or regulatory approvals;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical data relating to products or product candidates;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timelines, progress or results for pre-clinical studies or clinical trials; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communications with the U.S. Food and Drug Administration, European Medicines Agency, the Medicines and Healthcare products Regulatory Agency in the United Kingdom or any comparable foreign government agencies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential mergers, amalgamations, acquisitions or dispositions of assets, divisions or companies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public or private sales of debt or equity securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the capital structure of the Company, share splits, dividends or changes in dividend policy;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the establishment of a repurchase program for the Company&#x2019;s securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">major contract awards or cancellations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishment of, or developments in, strategic partnerships, collaborations, joint ventures or similar collaborations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gain or loss of a significant licensor, licensee, customer or supplier; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes or new corporate partner relationships or collaborations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notice of issuance or denial of patents, the acquisition of other material intellectual property rights or notice of a material adverse change in intellectual property or patents owned by Company; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">board, management or control changes;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee layoffs; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a disruption in the Company&#x2019;s operations or breach or unauthorized access of its property or assets, including its facilities and information technology infrastructure; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tender offers or proxy fights;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">accounting restatements;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation or settlements; </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">events of default under financing or other agreements; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">impending bankruptcy or financial liquidity problems.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">When information is considered public</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prohibition on trading when you have material nonpublic information lifts once that information becomes publicly disseminated. But for information to be considered publicly disseminated, it must be widely disseminated through a press release, a filing with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), or other widely disseminated announcement. Once information is publicly disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. Generally speaking, information will be considered publicly disseminated for purposes of this policy only after two full trading days have elapsed since the information was publicly disclosed. For example, if we announce material nonpublic information before trading begins on Wednesday, then you may execute a transaction in our securities on Friday; if we announce material nonpublic information after trading ends on Wednesday, then you may execute a transaction in our securities on Monday. Depending on the particular circumstances, the Company may determine that a longer or shorter waiting period should apply to the release of specific material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Quarterly Trading Blackouts</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because our workplace culture tends to be open, odds are that the vast majority of our employees, directors and consultants will possess material nonpublic information at certain points during the year. To minimize even the appearance of insider trading among our employees, directors and consultants we have established &#x201c;quarterly trading blackout periods&#x201d; during which the Company employees, directors, consultants and their Related Persons&#x2014;regardless of whether they are aware of material nonpublic information or not&#x2014;may not conduct any trades in the Company securities. That means that, except as described in this policy, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Company employees, directors, consultants and their Related Persons will be able to trade in the Company&#x2019;s securities </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">only</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> during limited open trading window periods that generally will begin after two full trading days have elapsed since the public dissemination of the Company&#x2019;s annual or quarterly financial results and end at the beginning of the next quarterly trading blackout period.  Of course, even during an open trading window period, you may not (unless an exception applies) conduct any trades in the Company&#x2019;s securities if you are otherwise in possession of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this policy, each &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">quarterly trading blackout period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; will generally begin at the end of the U.S. business day that is on the last trading day before the end of each fiscal quarter and end after two full trading days have elapsed since the public dissemination of the Company&#x2019;s financial results for that quarter. Please note that the quarterly trading blackout period may commence early or may be extended if, in the judgment of the Chief Executive Officer or Chief Financial Officer, there exists undisclosed information that would make trades by Company employees, directors and consultants inappropriate. It is important to note that the fact that the quarterly trading blackout period has commenced early or has been extended should be considered material nonpublic information that should not be communicated to any other person.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Company employee, director or consultant who believes that special circumstances require him or her to trade during a quarterly trading blackout period should consult the Chief Financial Officer. Permission to trade during a quarterly trading blackout period will be granted only where the circumstances are extenuating, the Chief Financial Officer concludes that the person is not in fact aware of any material nonpublic information relating to the Company or its securities, and there appears to be no significant risk that the trade may subsequently be questioned.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Event-Specific Trading Blackouts</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, an event may occur that is material to the Company and is known by only a few directors, officers and/or employees. So long as the event remains material and nonpublic, the persons designated by the Chief Executive Officer or Chief Financial Officer may not trade in the Company&#x2019;s securities.  In that situation, the Company will notify the designated individuals that neither they nor their Related Persons may trade in the Company&#x2019;s securities. The existence of an event-specific trading blackout should also be considered material nonpublic information and should not be communicated to any other person.  Even if you have not been designated as a person who should not trade due to an event-specific trading blackout, you should not trade while aware of material nonpublic information.  Exceptions will not be granted during an event-specific trading blackout.</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The quarterly and event-driven trading blackouts do not apply to those transactions to which this policy does not apply, as described under the heading &#x201c;Exceptions to this Policy&#x201d; below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions to this Policy</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy does not apply in the case of the following transactions, except as specifically noted:</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Option Exercises</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This policy does not apply to the exercise of options granted under the Company&#x2019;s equity compensation plans for cash or, where permitted under the option, by a net exercise transaction with the Company. This policy does, however, apply to any sale of ADSs or shares as part of a broker-assisted cashless exercise or any other market sale, whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes.   </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Tax Withholding Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This policy does not apply to the surrender of ADSs or shares directly to the Company to satisfy tax withholding obligations as a result of the issuance of ADSs or shares upon vesting or exercise of restricted stock units, options or other equity awards granted under the Company&#x2019;s equity compensation plans.  Of course, any market sale of the ADSs or shares received upon exercise or vesting of any such equity awards remains subject to all provisions of this policy whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;word-break:keep-all;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.2%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Automatic Trading Programs</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), and as permitted by the Company, employees, directors and consultants may establish a trading plan under which a broker is instructed to buy and sell the Company&#x2019;s securities based on pre-determined criteria (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">10b5-1 Trading Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). So long as a 10b5-1 Trading Plan is properly established, purchases and sales of the Company&#x2019;s securities pursuant to that Trading Plan are not subject to this policy. To be properly established, an employee&#x2019;s, director&#x2019;s or consultant&#x2019;s Trading Plan must be established in compliance with the requirements of Rule 10b5-1 of the Exchange Act and any applicable 10b5-1 trading plan guidelines of the Company at a time when the Company was not in a trading blackout period and they were not otherwise aware of any material nonpublic information relating to the Company or the securities subject to the Trading Plan. Moreover, all 10b5-1 Trading Plans must be reviewed and approved by the Company before being established to confirm that the 10b5-1 Trading Plan complies with all pertinent company policies and applicable securities laws. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font></p>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.2%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inherently Speculative Transactions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No employee, director or consultant may engage in short sales, transactions in put options, call options or other derivative securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to the Company&#x2019;s ADSs or shares.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.2%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Hedging Transactions.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds. Such hedging transactions may permit an employee, director or consultant to continue to own the Company&#x2019;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership. When that occurs, the Company employee, director or consultant may no longer have the same objectives as the Company&#x2019;s other shareholders. Therefore, Company employees, directors and consultants are prohibited from engaging in any such transactions. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.2%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Margin Accounts and Pledged Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities held in a margin account as collateral for a margin loan may be sold by the broker without the customer&#x2019;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in the Company&#x2019;s securities, Company employee, director and consultants are prohibited from holding the Company&#x2019;s securities in a margin account or otherwise pledging the Company&#x2019;s securities as collateral for a loan.  </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:3.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.2%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Standing and Limit Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Standing and limit orders (except standing and limit orders under approved Trading Plans, as discussed above) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction when a Company employee, director or consultant is in possession of material nonpublic information. the Company therefore discourages placing standing or limit orders on the Company&#x2019;s securities. If a person subject to this policy determines that they must use a standing order or limit order (other than under an approved Trading Plan as discussed above), the order should be limited to short duration and the person using such standing order or limit order is required to cancel such instructions immediately in the event restrictions are imposed on their ability to trade pursuant to the &#x201c;Quarterly Trading Blackouts&#x201d; and &#x201c;Event-Specific Trading Blackouts&#x201d; provisions above. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-Clearance and Advance Notice of Transactions</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;" id="ole_link1"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the requirements above,</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">officers, directors and other applicable members of management who have been notified that they are subject to pre-clearance requirements face a further restriction: Even during an open trading window, they may not engage in any transaction in, or enter into, modify or terminate any contract, instruction or written plan or arrangement in, the Company&#x2019;s securities without first obtaining pre-clearance from </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Company&#x2019;s Chief Financial Officer </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or his or her designee at least two</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business days in advance. The Chief Financial Officer or his or her designee will then determine whether the transaction may proceed and, if so, will direct the Compliance Coordinator (as identified in the Company&#x2019;s Section 16 Compliance Program) to help comply with any required reporting requirements under Section 16(a) of the Exchange Act. Pre-cleared transactions not completed within five business days will require new pre-clearance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons subject to pre-clearance must also give advance notice of their plans to exercise an outstanding stock option to the Compliance Coordinator or Chief Financial Officer. Once any transaction takes place, the officer, director or applicable member of management must immediately notify the Compliance Coordinator and any other individuals identified under the heading &#x201c;Notification of Execution of Transaction&#x201d; in the Company&#x2019;s Section 16 Compliance Program so that the Company may assist in any Section 16 reporting obligations.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Short-Swing Trading, Control Stock and Section 16 Reports</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Officers and directors subject to the reporting obligations under Section 16 of the Exchange Act should take care to avoid short-swing transactions (within the meaning of Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule 144 under the Securities Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms 3, 4 and 5), which are described in the Company&#x2019;s Section 16 Compliance Program, and any notices of sale required by Rule 144.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy&#x2019;s Duration</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This policy continues to apply to your transactions in the Company&#x2019;s securities and the securities of other applicable public companies as more specifically set forth in this policy, even after your relationship with the Company has ended. If you are aware of material nonpublic information when your relationship with the Company ends, you may not trade the Company&#x2019;s securities or the securities of other applicable publicly traded companies until the material nonpublic information has been publicly disseminated or is no longer material.  Further, if you leave the Company during a trading blackout period, then you may not trade the Company&#x2019;s securities or the securities of other applicable companies until the trading blackout period has ended.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individual Responsibility</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons subject to this policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in the Company&#x2019;s securities or the securities of other applicable public companies while aware of material nonpublic information, as more specifically set forth in this policy. Each individual is responsible for making sure that he or she complies with this policy, and that any family member, household member or other person or entity whose transactions are subject to this policy, as discussed under the heading &#x201c;Persons Subject to this Policy&#x201d; above, also comply with this policy. In all cases, the responsibility for determining whether an individual is aware of material nonpublic information rests with that individual, and any action on the part of the Company or any employee or director of the Company pursuant to this policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this policy or applicable securities laws. See &#x201c;Penalties&#x201d; below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Penalties</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone who engages in insider trading or otherwise violates this policy may be subject to both civil liability and criminal penalties. Violators also risk disciplinary action by the Company, including termination of employment. Anyone who has questions about this policy should contact their own attorney or the Company&#x2019;s Chief Financial Officer, at compliance@silence-therapeutics.com. Please also see Frequently Asked Questions, which are attached as </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendments</font></p>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is committed to continuously reviewing and updating its policies and procedures. the Company therefore reserves the right to amend, alter or terminate this policy at any time and for any reason. A current copy of the Company&#x2019;s policies regarding insider trading is posted on the Company&#x2019;s intranet at </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://silencetherapeutics.sharepoint.com/</font></font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adopted by the Board of Directors: 	December 13, 2024</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effective: January 1, 2025</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">7</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit A</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insider Trading Policy</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frequently Asked Questions</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is insider trading?</font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Generally speaking, insider trading is the buying or selling of shares, stocks, bonds, futures or other securities by someone who possesses or is otherwise aware of material nonpublic information about the securities or the issuer of the securities. Insider trading also includes trading in derivatives (such as put or call options) where the price is linked to the underlying price of a company&#x2019;s shares. It does not matter whether the decision to buy or sell was influenced by the material nonpublic information, how many shares you buy or sell, or whether it has an effect on the share price. Bottom line: If, during the course of your relationship with the Company, you become aware of material nonpublic information about the Company and you trade in the Company&#x2019;s securities, you have broken the law and violated our insider trading policy. In addition, our insider trading policy provides that if in the course of your relationship with the Company, you learn of any confidential information that is material to another publicly traded company, including but not limited to a customer, supplier, partner or collaborator of the Company, you may not trade in that other company&#x2019;s securities until the information becomes public or is no longer material to that other company.  For example, if you learn of nonpublic information during the course of your relationship with the Company that could affect the stock price of a competitor, you may not trade in that competitor&#x2019;s stock until the information becomes public or is no longer material.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why is insider trading illegal?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If company insiders are able to use their confidential knowledge to their financial advantage, other investors would not have confidence in the fairness and integrity of the market. This ensures that there is an even playing field by requiring those who are aware of material nonpublic information to refrain from trading.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is material nonpublic information?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information is material if it would influence a reasonable investor to buy or sell a share, stock, bond future or other security. This could mean many things: financial results,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical or regulatory results, potential acquisitions or major contracts to name just a few. Information is nonpublic if it has not yet been publicly disseminated within the meaning of our insider trading policy.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who can be guilty of insider trading?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Anyone who buys or sells a security while aware of material nonpublic information, or provides material nonpublic information that someone else uses to buy or sell a security, may be guilty of insider trading. This applies to all individuals, including officers, directors and others who don&#x2019;t even work at the Company. Regardless of who you are, if you know something material about the value of a security that not everyone knows and you trade (or convince someone else to trade) in that security, you may be found guilty of insider trading.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Does the Company have an insider trading policy?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes, the insider trading policy is available to read on our intranet or upon request.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I work in the UK or another office outside the US?</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">8</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same rules apply to U.K., U.S. and foreign employees and consultants. Because our American Depositary Shares, or ADSs, representing ordinary shares, trade on a U.S. securities exchange, the insider trading laws of the United States apply. The Securities and Exchange Commission (the U.S. government agency in charge of investor protection) and the Financial Industry Regulatory Authority (a private regulator that oversees U.S. securities exchanges) routinely investigate trading in a company&#x2019;s securities conducted by individuals and firms based abroad. In addition, as a director, employee or consultant of the Company, our policies apply to you no matter where you work.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t buy or sell anything, but I tell someone else material nonpublic information and they buy or sell?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That is called &#x201c;tipping.&#x201d; You are the &#x201c;tipper&#x201d; and the other person is called the &#x201c;tippee.&#x201d; If the tippee buys or sells based on that material nonpublic information, both you and the &#x201c;tippee&#x201d; could be found guilty of insider trading. In fact, if you tell family members who tell others and those people then trade on the information, those family members and the &#x201c;tippee&#x201d; might be found guilty of insider trading too. To prevent this, you may not discuss material nonpublic information about the company with anyone outside the Company, including spouses, family members, friends or business associates (unless the disclosure is made in accordance with the Company&#x2019;s policies regarding the protection or authorized external disclosure of information regarding the Company such as the Company&#x2019;s Corporate Disclosure Policy). This includes anonymous discussions on the internet about the Company or companies with which the Company does business.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I don&#x2019;t tell them the information itself; I just tell them whether they should buy or sell? </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">That is still tipping, and you can still be responsible for insider trading. You may never recommend to another person that they buy, hold or sell the Company&#x2019;s ADSs, shares or any derivative security related to the Company&#x2019;s ADSs, shares, since that could be a form of tipping.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What are the sanctions if I trade on material nonpublic information or tip off someone else?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to disciplinary action by the Company&#x2014;which may include termination of employment&#x2014;you may be liable for civil sanctions for trading on material nonpublic information. The sanctions may include return of any profit made or loss avoided as well as penalties of up to three times any profit made or any loss avoided. Persons found liable for tipping material nonpublic information, even if they did not trade themselves, may be liable for the amount of any profit gained or loss avoided by everyone in the chain of tippees as well as a penalty of up to three times that amount. In addition, anyone convicted of criminal insider trading could face prison and additional fines.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What is &#x201c;loss avoided&#x201d;?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you sell ADSs, shares or a related derivative security before negative news is publicly announced, and as a result of the announcement the share price declines, you have avoided the loss caused by the negative news.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I restricted from trading securities of any companies other than the Company, for example, a licensee, customer, partner or competitor of the Company?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes, you may be restricted from doing so due to your awareness of material nonpublic information. U.S. insider trading laws generally restrict everyone aware of material nonpublic information about a company from trading in that company&#x2019;s securities, regardless of whether the person is directly</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">9</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">connected with that company, except in limited circumstances. You should be particularly conscious of this restriction if, through your position at the Company, you sometimes obtain sensitive, material information about other companies and their business dealings with the Company. Please also refer to Question 1 above and our insider trading policy with respect to restrictions on trading in the securities of other public companies.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">So if I do not trade the Company&#x2019;s securities when I have material nonpublic information, and I don&#x2019;t &#x201c;tip&#x201d; other people, I am in the clear, right?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not necessarily. Even if you do not violate U.S. law, you may still violate our policies. For example, employees and consultants may violate our policies by breaching their confidentiality obligations or by recommending the Company&#x2019;s ADSs or shares as an investment, even if these actions do not violate securities laws. Our policies are stricter than the law requires so that we and our employees and consultants can avoid even the appearance of wrongdoing. Therefore, please review the entire policy carefully.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">So when can I buy or sell my Company securities?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are aware of material nonpublic information, you may not buy or sell our ADSs or shares until two full trading days have elapsed since the information was publicly disclosed. At that point, the information is considered publicly disseminated for purposes of our insider trading policy. For example, if we announce material nonpublic information before trading begins on Wednesday, then you may execute a transaction in our securities on Friday; if we announce material nonpublic information after trading ends on Wednesday, then you may execute a transaction in our securities on Monday. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if you are not aware of any material nonpublic information, you may not trade our securities during any trading &#x201c;blackout&#x201d; period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our insider trading policy describes the quarterly trading blackout period, and additional event-driven trading blackout periods may be announced by email.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If I have an open order to buy or sell the Company&#x2019;s securities on the date a blackout period commences, can I leave it to my broker to cancel the open order and avoid executing the trade?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No, unless it is in connection with a 10b5-1 trading plan (see Question 27 below). If you have any open orders when a blackout period commences other than in connection with a 10b5-1 trading plan, it is your responsibility to cancel these orders with your broker. If you have an open order and it executes after a blackout period commences not in connection with a 10b5-1 trading plan, you will have violated our insider trading policy and may also have violated insider trading laws.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I allowed to trade derivative securities of the Company&#x2019;s shares?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. Under our policies, you may not trade in derivative securities related to our ADSs or shares, which include publicly traded call and put options. In addition, under our policies, you may not engage in short selling of our ADSs or shares at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Derivative securities&#x201d; are securities other than shares that are speculative in nature because they permit a person to leverage their investment using a relatively small amount of money. Examples of derivative securities include &#x201c;put options&#x201d; and &#x201c;call options.&#x201d; These are different from employee options and other equity awards granted under our equity compensation plans, which are not derivative securities for purposes of our policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Short selling&#x201d; is profiting when you expect the price of the shares to decline, and includes transactions in which you borrow shares from a broker, sell them, and eventually buy them back on the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">10</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market to return the borrowed shares to the broker. Profit is realized if the share price decreases during the period of borrowing.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why does the Company prohibit trading in derivative securities and short selling?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies with volatile share prices have adopted similar policies because of the temptation it represents to try to benefit from a relatively low-cost method of trading on short-term swings in share prices, without actually holding the underlying shares, and encourages speculative trading. We are dedicated to building shareholder value, short selling our shares conflicts with our values and would not be well-received by our shareholder.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I purchase the Company&#x2019;s securities on margin or hold them in a margin account?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our policies, you may not purchase our ADSs or shares on margin or hold it in a margin account at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Purchasing on margin&#x201d; is the use of borrowed money from a brokerage firm to purchase our securities. Holding our securities in a margin account includes holding the securities in an account in which the ADSs or shares can be sold to pay a loan to the brokerage firm.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Why does the Company prohibit me from purchasing the Company&#x2019;s securities on margin or holding them in a margin account?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Margin loans are subject to a margin call whether or not you possess material nonpublic information at the time of the call. If a margin call were to be made at a time when you were aware of material nonpublic information and you could not or did not supply other collateral, you may be liable under insider trading laws because of the sale of the securities (through the margin call). The sale would be attributed to you even though the lender made the ultimate determination to sell. The U.S. Securities and Exchange Commission takes the view that you made the determination to not supply the additional collateral and you are therefore responsible for the sale.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I pledge my Company shares as collateral for a personal loan?</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> No. Pledging your ADSs or shares as collateral for a personal loan could cause the pledgee to transfer your ADSs or shares during a trading blackout period or when you are otherwise aware of material nonpublic information. As a result, you may not pledge your ADSs or shares as collateral for a loan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I hedge my ownership position in the Company?  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  Hedging or monetization transactions, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds are prohibited by our insider trading policy. Since such hedging transactions allow you to continue to own the Company&#x2019;s securities obtained through employee benefit plans or otherwise, but without the full risks and rewards of ownership, you may no longer have the same objectives as the Company&#x2019;s other shareholders. Therefore, our insider trading policy prohibits you from engaging in any such transactions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">11</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Can I exercise options granted to me under the Company&#x2019;s equity compensation plans during a trading blackout period or when I possess material nonpublic information?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes. You may exercise the options for cash (or via net exercise transaction with the company) and receive ADSs or shares, but you may not sell the ADSs or shares (even to pay the exercise price or any taxes due) during a trading blackout period or any time that you are aware of material nonpublic information.  To be clear, you may </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> effect a broker-assisted cashless exercise (these cashless exercise transactions include a market sale) during a trading blackout period or any time that you are aware of material nonpublic information</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Am I subject to trading blackout periods if I am no longer an employee or consultant of the Company?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">It depends. If your employment with the Company ends during a trading blackout period, you will be subject to the remainder of that trading blackout period. If your employment with the Company ends on a day that the trading window is open, you will not be subject to the next trading blackout period. However, even if you are not subject to our trading blackout period after you leave the Company, you should not trade in the Company securities if you are aware of material nonpublic information. That restriction stays with you as long as the information you possess is material and not publicly disseminated within the meaning of our insider trading policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What if I purchased publicly traded options or other derivative securities before I became an employee or consultant of the Company?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The same rules apply as for employee share options. You may exercise the publicly traded options at any time, but you may not sell the securities during a trading blackout period or at any time that you are aware of material nonpublic information.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">24.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May I own shares of a mutual fund that invests in the Company? </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">25.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Are mutual fund shares holding the Company&#x2019;s shares subject to the trading blackout periods? </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. You may trade in mutual funds holding the Company&#x2019;s ADSs or shares at any time.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">26.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">May I use a &#x201c;routine trading program&#x201d; or &#x201c;10b5-1 plan&#x201d;?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A: </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes, subject to the requirements discussed in our insider trading policy and any 10b5-1 trading plan guidelines. A routine trading program, also known as a 10b5-1 plan, allows you to set up a highly structured program with your stock broker where you specify ahead of time the date, price, and amount of securities to be traded. If you wish to create a 10b5-1 plan, please contact the Chief Financial Officer for approval. Please also see the &#x201c;Rule 10b5-1 Trading Plan Guidelines,&#x201d; which are attached hereto as </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">27.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">What happens if I violate our insider trading policy?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Violating our policies may result in disciplinary action, which may include termination of your employment or other relationship with the Company. In addition, you may be subject to criminal and civil sanctions.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">12</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:4.533%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">28.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Who should I contact if I have questions about our insider trading policy or specific trades?</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A:  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should contact our Chief Financial Officer at compliance@silence-therapeutics.com.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">13</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Trading Plan Guidelines</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This document lays out guidelines for any Rule 10b5-1 trading plan covering publicly traded ADSs and shares of Silence Therapeutics plc (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">the</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). In addition to honoring these guidelines, all 10b5-1 trading plans, along with any amendments or modifications to those plans, must comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participants.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s directors and executive officers are strongly encouraged to adopt a 10b5-1 trading plan to govern all trades they make involving the Company securities. The Chief Financial Officer has the power to allow additional Company employees to adopt a 10b5-1 trading plan. </font></div></div>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan Adoption and Approval</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must be in writing and signed by the participant establishing the plan. The Company may keep a copy of each 10b5-1 trading plan. The Chief Financial Officer or an individual designated by the Chief Financial Officer must pre-approve, in writing, each 10b5-1 trading plan, including any amendment, modification or termination. Participants must enter into a plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 of the Exchange Act. In addition, all participants that enter into a 10b5-1 trading plan must act in good faith with respect to such plan. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Representation/Certification. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must include a representation certifying that, at the time of adoption, the participant: (i) is not aware of any material nonpublic information about the Company or its securities and (ii) is adopting the 10b5-1 trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Exchange Act.</font></div></div>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Timing and Term of a Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are limits on when a 10b5-1 trading plan can be adopted, so plan ahead. In short, a participant can only set up a 10b5-1 trading plan when the participant does not possess material nonpublic information about the Company. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy may only adopt a trading plan during an open trading window. Each 10b5-1 trading plan must have a term of at least 6 months but no longer than 24 months. That said, a 10b5-1 trading plan may provide for early termination at any time after 90 days following the termination of the participant&#x2019;s employment or directorship. </font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Timing of a Plan Amendment or Modification.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All participants must pre-clear any modification of a 10b5-1 trading plan with the Chief Financial Officer or an individual designated by </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Chief Financial Officer. In addition, all participants must promptly notify the Chief Financial Officer or an individual designated by the Chief Financial Officer following any pre-approved modification of a 10b5-1 trading plan and provide a copy of such modified plan. Each 10b5-1 trading plan may be amended or modified to change the amount, price or timing of the purchase or sale of the securities underlying a 10b5-1 trading plan (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Modification</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) only when the participant does not possess material nonpublic information about the Company. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy may only enter into a Material Modification during an open trading window. Any Material Modification must include the representation set forth under &#x201c;Representation/Certification&#x201d; above. A Material Modification of a 10b5-1 trading plan may not be entered into more than once in any 12-month period. If a participant enters into separate contracts at the same time with different agents to execute trades that are collectively compliant with Rule 10b5-1, such contracts may be treated as a single plan and a Material Modification of any such contract will be considered a Material Modification of the other such contracts.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> All participants must pre-clear any termination of a 10b5-1 trading plan. In addition, all participants must promptly notify the Chief Financial Officer or an individual designated by the Chief Financial Officer following any pre-approved termination of a 10b5-1 trading plan. Participants are discouraged from terminating a 10b5-1 trading plan while in possession of material nonpublic information. In addition, participants that are subject to trading windows under the Company&#x2019;s Insider Trading Policy are discouraged from terminating a 10b5-1 trading plan during a closed trading window.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delayed Effectiveness of First Trade.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The first trade under a 10b5-1 trading plan cannot occur until the expiration of the applicable waiting period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Waiting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as follows: (i) if the participant is a director or Section 16 officer of the Company, the later of (A) 90 days following the adoption of the 10b5-1 trading plan or (B) two business days following the disclosure of the Company&#x2019;s financial results in a Form 10-Q or Form 10-K for the fiscal quarter in which the plan was adopted (subject to a maximum of 120 days after adoption of the plan), and (ii) for all other participants, at least 30 days. Following a Material Modification of a 10b5-1 trading plan, a participant may not trade under the plan until the expiration of the applicable Waiting Period measured from the date of the Material Modification. </font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Relationships with Plan Broker; No Subsequent Influence.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> If the 10b5-1 trading plan allows a broker discretion regarding the details of trading (e.g., timing, share amounts), the participant cannot communicate any material nonpublic information about the Company or the securities subject to the plan to the broker, or attempt to influence how the broker exercises its discretion. In addition, any individual who is authorized to exercise discretion in executing the participant&#x2019;s 10b5-1 trading plan must be a different individual from the person who executes trades for the participant in other securities. </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Plan Specifications; Discretion Regarding Trades.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 10b5-1 trading plan must specify the amount of ADSs or shares to be purchased or sold, or specify or set an objective formula for determining the amount of ADSs or shares to be sold. Other than plans providing for nondiscretionary sell-to-cover transactions to satisfy tax withholding obligations arising exclusively from the vesting of restricted shares or restricted stock units (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Qualified Sell-to-Cover Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), 10b5-1 trading plans that are designed to effect the open-market purchase or sale of Company securities as a single trade may only be entered into once per 12-month period. Transaction types such as market, limit, and VWAP orders are allowed. Each 10b5-1 trading plan should specify the timing of trading or allow for the broker to exercise its discretion regarding the timing of trading. While the Company generally will not comment on the specific trading instructions proposed to be included in a 10b5-1 trading plan, the Company may, in the exercise of his/her discretion, refrain from approving a proposed 10b5-1 trading plan on the basis of the proposed trading instructions. For example, the Company likely will not approve a 10b5-1 trading plan if the trading instructions provide for trades on a frequent (e.g., weekly) basis for an extended time period.</font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Trades.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading the Company&#x2019;s securities outside of a participant&#x2019;s 10b5-1 trading plan could, in certain circumstances, jeopardize the validity of a participant&#x2019;s plan. Therefore, except as may be approved in advance by the Chief Financial Officer, no participant entering into a 10b5-1 trading plan may make open-market purchases or sales of the Company&#x2019;s securities while a 10b5-1 trading plan is in effect.</font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only One Plan in Effect at Any Time.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A participant may have only one 10b5-1 trading plan in effect at any time. However, a participant may maintain two separate 10b5-1 trading plans at the same time so long as the first scheduled trade under one of the 10b5-1 trading plans does not occur before all trades under the other 10b5-1 trading plan are completed or expire without execution; provided, however, that if a participant terminates the earlier-commencing plan prior to its completion or expiration on its terms, the participant&#x2019;s trades may not commence under the later-commencing plan until the expiration of the applicable Waiting Period, measured from the date of termination of the earlier-commencing plan. This restriction on overlapping plans does not apply to plans providing for Qualified Sell-to-Cover Transactions. </font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Hedging</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Individuals subject to the Insider Trading Policy are prohibited from engaging in any hedging or similar transactions designed to decrease the risks associated with holding the Company&#x2019;s securities. Likewise, before adopting a 10b5-1 trading plan, the participant may not have entered into a transaction or position that has yet to settle with respect to the securities subject to the 10b5-1 trading plan. The participant must also agree not to enter into any such transaction while the 10b5-1 trading plan is in effect.</font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mandatory Suspension or Termination.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must suspend trades or terminate if legal, regulatory, or contractual restrictions are imposed on the participant, or other events </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0.1pt;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;visibility:hidden;word-break:keep-all;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">occur that would prohibit sales under such a plan. For example, trading would need to be suspended or the plan terminated if these guidelines were amended to preclude the particular sort of trade contemplated by the plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <p style="margin-left:4.173%;font-size:10pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compliance with Rule 144</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must provide for specific procedures to comply with Rule 144 under the Securities Act of 1933, as amended, including the filing of Forms 144, when applicable. If you need additional information on Rule 144 and Form 144, please contact the Chief Financial Officer. In addition, participants must indicate on Forms 144 that the trades were made pursuant to a 10b5-1 trading plan.</font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Broker</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligation to Provide Notice of Trades.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must provide that the broker will promptly notify the participant and the Company of any trades under the plan so that, where required, the participant can make timely filings under the Exchange Act (i.e., no later than the close of business on the day of the trade).</font></div></div>
  <p style="margin-left:2.507%;text-indent:-1.739%;padding-left:1.667%;font-size:10pt;margin-top:0.9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Required Exchange Act Filings.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each 10b5-1 trading plan must contain an explicit acknowledgement by the participant that all Section 16 filings required by the Exchange Act, as a result of or in connection with trades under the plan, are the sole obligation of the participant and not the Company. In addition, the Company is required to disclose certain information on a quarterly basis on Form 10-Q and 10-K with respect to the adoption, Material Modification or termination of 10b5-1 trading plans by any director or Section 16 officer. Directors and Section 16 officers must, in any Section 16 filing reporting a transaction effected pursuant to a 10b5-1 trading plan, check the appropriate box to indicate that the transaction is pursuant to a 10b5-1 trading plan and provide the date of adoption of the plan. By entering into a 10b5-1 trading plan, the Company&#x2019;s directors and Section 16 officers are deemed to understand, and agree to cooperate with the Company with respect to, such disclosure obligations, including by notifying the Chief Financial Officer of information relevant to the preparation of such disclosure.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Not Party to the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  The 10b5-1 trading plan may not have the Company as party to the plan, although it can have a representation by the participant to the effect that the Company has reviewed the plan.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:1.602%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:1.6435489166119504%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exceptions; Waivers</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All requests for exceptions to or waivers of these guidelines must be reviewed and approved by the Chief Financial Officer or an individual designated by the Chief Financial Officer.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A-</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sln-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-248682 and No. 333-273576) of Silence Therapeutics plc of our report dated February 27, 2025, relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP<br>Reading, United Kingdom<br>February 27, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sln-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.39in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Craig Tooman, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Silence Therapeutics plc;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:36.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.72%;box-sizing:content-box;"></td>
    <td style="width:1.78%;box-sizing:content-box;"></td>
    <td style="width:84.5%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</font></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Craig Tooman</font></p></td>
   </tr>
   <tr style="height:17.3pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Craig Tooman</font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.39in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:36.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.72%;box-sizing:content-box;"></td>
    <td style="width:1.78%;box-sizing:content-box;"></td>
    <td style="width:84.5%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sln-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.32in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION REQUIRED BY RULE 13A-14(A) OR 15D-14(A)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Rhonda Hellums, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Silence Therapeutics plc;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:28.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.4%;box-sizing:content-box;"></td>
    <td style="width:2.26%;box-sizing:content-box;"></td>
    <td style="width:80.34%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 27, 2025</font></p></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rhonda Hellums</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rhonda Hellums</font></p></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.32in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:auto;width:28.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.4%;box-sizing:content-box;"></td>
    <td style="width:2.26%;box-sizing:content-box;"></td>
    <td style="width:80.34%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:11.5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sln-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.2in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Craig Tooman, President and Chief Executive Officer of Silence Therapeutics plc (the &#x201c;Company&#x201d;), and Rhonda Hellums, Chief Financial Officer of the Company, each hereby certifies that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.998%;box-sizing:content-box;"></td>
    <td style="width:1.996%;box-sizing:content-box;"></td>
    <td style="width:97.007%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:0.998%;box-sizing:content-box;"></td>
    <td style="width:1.996%;box-sizing:content-box;"></td>
    <td style="width:97.007%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>Dated: February 27, 2025</font></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Witness Whereof</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the undersigned have set their hands hereto as of the 27</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day of February 2025.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:auto;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.299%;box-sizing:content-box;"></td>
    <td style="width:12.99%;box-sizing:content-box;"></td>
    <td style="width:43.711%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Craig Tooman</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;border-bottom:3pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Rhonda Hellums</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Craig Tooman</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rhonda Hellums</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Tahoma',sans-serif;font-kerning:none;min-width:fit-content;">&#xfeff;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Silence Therapeutics plc under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.49in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img172674775_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img172674775_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'Y!)8# 2(  A$! Q$!_\0
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M^&K/V7?^CDO@'_X>'X>?_-%1_P -6?LN_P#1R7P#_P##P_#S_P":*M/J]?\
MY\5O_!<__D?-?>8_7<'_ -!>&_\ !]+_ .3/?**\#_X:L_9=_P"CDO@'_P"'
MA^'G_P T5'_#5G[+O_1R7P#_ /#P_#S_ .:*CZO7_P"?%;_P7/\ ^1\U]X?7
M<'_T%X;_ ,'TO_DSWRBO _\ AJS]EW_HY+X!_P#AX?AY_P#-%1_PU9^R[_T<
ME\ __#P_#S_YHJ/J]?\ Y\5O_!<__D?-?>'UW!_]!>&_\'TO_DSWRBO _P#A
MJS]EW_HY+X!_^'A^'G_S14?\-6?LN_\ 1R7P#_\ #P_#S_YHJ/J]?_GQ6_\
M!<__ )'S7WA]=P?_ $%X;_P?2_\ DSWRBO _^&K/V7?^CDO@'_X>'X>?_-%1
M_P -6?LN_P#1R7P#_P##P_#S_P":*CZO7_Y\5O\ P7/_ .1\U]X?7<'_ -!>
M&_\ !]+_ .3/?**\#_X:L_9=_P"CDO@'_P"'A^'G_P T5'_#5G[+O_1R7P#_
M /#P_#S_ .:*CZO7_P"?%;_P7/\ ^1\U]X?7<'_T%X;_ ,'TO_DSWRBO _\
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MJS]EW_HY+X!_^'A^'G_S14?\-6?LN_\ 1R7P#_\ #P_#S_YHJ/J]?_GQ6_\
M!<__ )'S7WA]=P?_ $%X;_P?2_\ DSWRBO _^&K/V7?^CDO@'_X>'X>?_-%1
M_P -6?LN_P#1R7P#_P##P_#S_P":*CZO7_Y\5O\ P7/_ .1\U]X?7<'_ -!>
M&_\ !]+_ .3/?**\#_X:L_9=_P"CDO@'_P"'A^'G_P T5'_#5G[+O_1R7P#_
M /#P_#S_ .:*CZO7_P"?%;_P7/\ ^1\U]X?7<'_T%X;_ ,'TO_DSWRBO _\
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MJS]EW_HY+X!_^'A^'G_S14?\-6?LN_\ 1R7P#_\ #P_#S_YHJ/J]?_GQ6_\
M!<__ )'S7WA]=P?_ $%X;_P?2_\ DSWRBO _^&K/V7?^CDO@'_X>'X>?_-%1
M_P -6?LN_P#1R7P#_P##P_#S_P":*CZO7_Y\5O\ P7/_ .1\U]X?7<'_ -!>
M&_\ !]+_ .3/?**\#_X:L_9=_P"CDO@'_P"'A^'G_P T5'_#5G[+O_1R7P#_
M /#P_#S_ .:*CZO7_P"?%;_P7/\ ^1\U]X?7<'_T%X;_ ,'TO_DSWRBO _\
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M_:>9?]##'?\ A77_ /EGDON/*?\ A1'P/_Z(U\*?_#=^$/\ Y3T?\*(^!_\
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MLNR[.L;EF%>%I1KXE8C'X:C5PM!X:A*%:O[2K'V-*4:E3E@TS\\?^%$? _\
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M'_"B/@?_ -$:^%/_ (;OPA_\IZ]6KU#QY\&?B5\,O#WP]\5>./#?]B:!\5=
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M8IRE*R2;L>*_\*(^!_\ T1KX4_\ AN_"'_RGH_X41\#_ /HC7PI_\-WX0_\
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M]>K44?V=E_\ T 8+_P ):'_ROR7W!_:>9?\ 0PQW_A77_P#EGDON/*?^%$?
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M]##'?^%=?_Y9Y+[CRG_A1'P/_P"B-?"G_P -WX0_^4]'_"B/@?\ ]$:^%/\
MX;OPA_\ *>O5J*/[.R__ * ,%_X2T/\ Y7Y+[@_M/,O^AACO_"NO_P#+/)?<
M>4_\*(^!_P#T1KX4_P#AN_"'_P IZ/\ A1'P/_Z(U\*?_#=^$/\ Y3UZM11_
M9V7_ /0!@O\ PEH?_*_)?<']IYE_T,,=_P"%=?\ ^6>2^X\I_P"%$? __HC7
MPI_\-WX0_P#E/1_PHCX'_P#1&OA3_P"&[\(?_*>O5J*/[.R__H P7_A+0_\
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M>)KT\3C,)1K8>A4HX>K1KU85:D94Z-2G5FHPG&3_ #A_X41\#_\ HC7PI_\
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M%>(KXC#<=RQ%>M7E&OD\8RK5)U7&/L\6[1<Y2:5];+0]GHHHK^4C^Z@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_S]O^#L[_D_+X!?]FC>&O\ U<GQHK_0)K_/V_X.
MSO\ D_+X!?\ 9HWAK_U<GQHKZS@K_D>TO^P?$_\ I!^:>+7_ "1N*_[#<!_Z
M?1_+11117[(?RD%%%% !1110 4444 %%%% ']87@?XO?%GX(?\&Q7A+QS\%_
MBA\1/A#XUC_;#U32H_&'PO\ &OB7P!XICTO4/&6OB_TU/$'A34])U9;"^$,0
MO+-;L6]R(HQ-&^Q<?0G[.7B[XD_M=_\ !'3]D_Q/^W=-=?&;48O^"N7[./@O
MX#>*OC4%\9:Y\4OAC?\ Q>^'OA/Q5::UJWBF75K[XD6,\VO?M!> ]67Q&]]]
MM\/^&+C1;^&YL?#UN]?CI^PS_P %[_VP?^"?W[/VC?LW_!OX;_LU^)? ^A^(
MO$_B:TU7XF^#_BAK/BN2_P#%>HG4]1AN+[PK\8O!FD/:0SG991Q:%#-'#\L]
MQ<O^\KSC]J[_ (+8_MK?MB_&7]GKXN_%2Z^&VF:;^S)\1_"?Q;^&GP:\#>'/
M$FA?!^3XA^$M>TO7;?Q/XMTN^\9ZSXT\4ZA?C1[71Y)-2\=,-!T2YUNS\$CP
MI-XF\2W6K_&RRC,*F(KP6%PM.G+-Z^9T\P]NGB73:ER8>%*-)2@ZCM&<I5^2
M-.4TX-VO^K4^*,CHX/!57F.8UZT.&<#P_6R3ZG*. 5>$J7ML?4Q$\3*G55",
M9SI4X8/VDZU.BU5C&]OWCG\)_P#!+CX(_P#!5K_@J+\*/BAX%_8H^%'Q7G\-
M? W0_P!B;PY^U+\(=.;]AWPEJEQ^S=X>\=>/8O%'A?18O#OPQ\"R:_XGM/#\
M^H^*->NO#FN-)J=U:?#[4=0\1^)M?\.^)U\#?\$Y?A+^TA_P4Z_99/Q]_8H_
M9@^#WPGUG]FGQO\ &9O%/[&_QIL?%O[%/[<FO_##2OA#96WBSX7^"=$\,^$=
M3^%/@;0=4^)6GZCXD\*7L5T_C6UBL9M4U7QGI%SJOBCQI^'NF_\ !<K]KRV^
M/O[37QNU[P+^S=\0?#/[7=GX,@^-_P"S-\2OAGKWCK]F3Q'?^ /!OAKP+X8U
MZW\!>(/'EWXEL]8MM#\,68U!F\<SZ?KMS-NUS3]1MM(\,6N@XGCW_@MS^VSX
ML^.'[.'QJ\&-\(/@+:?LI:/J/A[X,?!/X$?#MO!7P&T'0/$-O:Z;XRT.\\!W
M^N^(;K4M'\9:%I^FZ!JFF3:^EEHNGZ=9S^"8/"FL1'5&E91G,6O95/9U)993
MPTZ]3'5I>SK0R^G0?L(THTW3<L1!.2J+$TU>>*I3A7E&,-7Q3PI+F=?#^VH4
M^(JV84L'1R?"TG7PE3/:F-2QE2O/$1K*& J2C3EAWE]:7+1R[$4JF"IU)U_V
M&_;;_9V_8Y_:"_93N;J%_P#@D3#^VOH/[3GPPT#]G7X/?\$D_CY\.?"FL?&S
MX2_&#XD_#/X977PC\:Z?XAT"TMO$?Q)M)_$FK>(8?B9+X$N=%\*V^B66OV^D
M>'/#*>/M \4_H/J7[&_[&'Q \ ?MS?LB_%#]GC_@FE\._B-\#_V6'\8^"?A;
M^R+X&\=_$+]I/X':'X9\"Z9<>"/'_P 7?V\_%OA+X:7_ (J^*5_XY\/76JZG
M\/+_ .&]AXNU?PC>>'-5^*NM?$KPOX]UI/$?\M7Q^_X+1_M7_&GP]X+\(^!O
M!7[-_P"R1X4\)_'73?VFM5\.?LC?"!/A?H_Q,^//A_4M UGPM\2OBO::_P"(
M?'*^.=;\-ZQX;TO5[>UU QZ-KVK6>D:IXTTOQ1J'A7P7<^&_HS4?^#C3]L>^
M\3>/?%=M\ /V&-"U7XQ> M4\!?':Z\.? ;Q)HNL?'B";0]*\,>%O$/Q7\9V?
MQ13X@>(=?^&_AJUU[P_X AM/%VE>&=+TGQMXFM=3\-ZR(/"K>&<JF3YTZ%"%
M.;BZ=2M6II8Z?/AY.IA)0A=P=-PE&C7E%04JL:E6SKPIU*L5M0XJX1CB\75K
MTHU(U\/A,+7D\GINGC::H9C3JU;*HJZK4YXK"0JNK*&&J4,-=8.M7HT)R_5#
M]BFU_8 ^)/['G[*7@_\ 9(^!/_!*O]I#X\:=\/-4T#]JG]FC]L:TL_AC^V9\
M;/C-/\-(]>U;1_V8_C7\0M+\27*:MJ7C9]1A\.7C>$]<^%]CIES:Z?H_C[X9
MMX<U3^R<;]C3]@;X/_ K]D#]H_\ :1\7_ S_ ()Z_#+]I'7?VR?B9\$?#/@C
M_@K'X^N/$_[.?[-GPX\*>)86A^$?]L7%I?:7\2_BG%%H>I'P]\0]-M_#NI>,
MO#=];^(=.UD^'+;4-*\7_CU\%O\ @N_^U7\)/ ?P4\(>)/@I^QK^T/XE_9PT
MM- ^ _QH_:)^!=]XX^-WPH\/6MGI]AI&B^"_'NA^.O"$NDPZ)::78PV6I)I[
M^(+M;:W&N:QJXMK80^7?!#_@LG^UK\*(?V@-(^(N@? ;]KWP5^TU\1)/B_\
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M<0914C*C7X0P%7#SSS_4/AO+Z&/PLL-4P"HM<59?F^*Q*S'ZW05?$PQF78?
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M;#YE@Z5"C[?$72E"-:I[-SEX71117W)^9A1110 4444 %%%% !1110 5]_\
M_!,7_D\3X??]@3Q[_P"H7K5? %>P? GXU^*OV?/B5HWQ2\&:?X?U/Q!HEKJ]
MI:6?B>UU&]T:2/6M+NM)NFN+?2M5T6]=X[:[D>W,>H1*DZHTBRQAHV^;XRRO
M%9WPGQ+D^!4)8W-,CS3 82-6:ITWB,7@ZU"BIU&FH0<YQYI--15W;0^O\/LZ
MP/#G'7!V?YG*I#+LEXFR3-,=*C3=:K'"8#,</B<0Z5)-.I45*G)P@FG*5E=7
M/VM\0?M2?LP_ /Q!\8O%6E?M(_M%?&[Q\]IXT\+P?!#QIKGC'4? >G^)+_7X
MC);Z+'KG@70_#N@VGA^_L7TN/5DUK5VT[PK)JT6D:=K][+9VMQPOC;XH:!\+
MOV/OV&;_ %?X3?#;XL2ZXEEHAT_XH:&_B71-,T.XM8'UZ72=*DNHM/M_$UZ5
MTV'3->OK/5%TFWBU")-/G34)D/XE>*?$-[XN\3^(_%>I16L&H^)]>U?Q#?PV
M*2Q64-[K6H7&I745G'//<SQVL<]S(ENDUS<2I$$62>5PTC>V^-_VF_'GC[X9
M_![X5:QI'A&V\/?!*19/"MYIEAK,.M:@RQPQ >(+BZU^\L;L;8$)_LW3M).2
MQS@@#\K_ .(/4,)4X=GAJV.S*7]IT<7Q'7S#,*.'K+#83AW-LNP>%P3RK"Y9
M%4:.-S&7P0^LU:=:H\1B*U.$(1_;_P#B8'%8^EQ9#%X?+,HC_8M? <(X;*LK
MQ&*P\L9C^+<AS;,<;F*SS&YS4>(Q&793"WM*GU2A6P])87"T*LZE2?ZNZW^S
M3X%\!_M0_M$ZYX0^#WP1O/!/ASX=>$_%Z7WQS\07.D_!3X5:WXR35UU2:/P7
M;>%_$2>)X;V72;K5].\/_;O"^C^&+>.\TS2=4T.*]\-6UESOQU\+?L<^$_B7
M^Q/\7?%_ASP);_"KQ]X=^(>I^,M4^'_PWU_P1X"\6MX;TCPQJ/@75KSX4V4F
MK:Q9Z8=?\1ROJ&F3Q:MJ>IVCV>E^)Y-7T6T>U3XT?_@HS\<+GQ[XZ\<:EX6^
M$>M67Q)\(:+X-\8_#S7/">LZO\/-8L?#YOUTR^GTB^\53:LU^MIJVK6%W"VN
MOHVI6>H2)J.DW4MKITUEDZU_P4'^/>KZI\+-=M[?P!X<UKX/ZCXED\(W_ACP
MQ<:/%_PC'BAH(;[X>ZEHT>L2>';GP1:Z18:-H.G6-OH]GJUO8Z!HU])K4_B*
MU?7)O%P? 7B0\;EF(S#%U9QP^0/)\95P?%>*PF)Q,:W!>)RE^UKUL)F3HXO#
MY_*GBZ6-PM&6'IWIYC4R_,<P=6K1^CQ_BCX/K+LYPN58&A3EBN*8Y_@*&8<#
MX+'8/!SP_B+@L]2H87#8_)XXC 8OA>%; ULNQN(CBZUJV44LVRC*50H8C[$_
M:#^$WAOXB^&=-_X1;X5?LM:SX'E^-GA[PO9?M!?LH^)=$\.-\/O"_BWQ7X0\
M.:=H?Q5^']K9ZA!KGB75H-<B:*ZLO$>J:=HMU<6\RV>DQ2,?$/T!XZ^"7[+F
ME>(O&?P/\9+^Q'\-?A;8>!+;1?#^K/XYTW0?VK]!\</9:/JND^)/$>N:[%:L
MECF>YN5T^^U#4[C6;)M*NM3N-1T;4;[P\WY0_$C]N#XG^/O FK?#K1/!?P@^
M#OAWQ'X@L_$WBH?!?P5<^"M0\4:K87-O?VMQK5])KNK2231ZC96-^][9K9ZG
M/-96\5Q?2V?FVLO2:Y_P4/\ CIK?A[5;(Z'\*=)\>Z[X+C\ :S\<M#\#G3?C
M5J'ADR6KWMD_B^/5VL[4ZBMJ@F;3]$LTL+@IJFA1Z3K-II^I68_#[Q%J8/*,
M/'%QP=+!8O,E2I8?B'&TL3A)XJIDM3!YUB*D_KN"6*PT\+F<71RW#QP]&E6I
MU<-E[Q6-S&4G'Q5\)*689]BZF >85\PP.3.M7Q7"F7U<'CJ6"I<0T<PX<PE&
MG_9V8O!8NGC,FDL3G&*EB\16H5J.+S7ZEEN4QCYG^Q/_ ,G8? ;_ +*#I/\
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M9)*4LTQ5*%6-OW=!RK.ZBT?)%%%%?KI^"!1110 4444 %%%% !1110!]N?\
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M>GAL++$U%AL5C%BZBPW[D^)?^0Q_P5^_[%/X9_\ J"^.*^/OV]O^2,?L!_\
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M_P#ES7^-S11_Q#^E_P!#2I_X21_^7A_Q&_$_]$[0_P##G4_^8O7^EK_LC?\
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MO_AQ_!W_ ,N:/^%^_ G_ *+5\)?_  X_@[_Y<U_C<T4?\0_I?]#2I_X21_\
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M0_X@GFW_ $.\N_\ !&)_R]?Z>G^1]17^N#_P[,_X)R?]&$_L;?\ B-'P;_\
MF-H_X=F?\$Y/^C"?V-O_ !&CX-__ #&T?Z_X/_H7XK_P92_KO_3T/^()YM_T
M.\N_\$8G_+U_IZ?Y'U%?ZX/_  [,_P""<G_1A/[&W_B-'P;_ /F-H_X=F?\
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M_P#DRC_A.O!'_0X^%?\ PH=(_P#DROZV_P#AV9_P3D_Z,)_8V_\ $:/@W_\
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M];?_  [,_P""<G_1A/[&W_B-'P;_ /F-H_X=F?\ !.3_ *,)_8V_\1H^#?\
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M0Z1_\F5_4#_P[?\ ^">W_1C'[(7_ (CA\(/_ )D*/^';_P#P3V_Z,8_9"_\
M$</A!_\ ,A1_Q--2_P"B/J?^':/_ ,Q^O]/0_P"))<;_ -%[A?\ PRU?+_J-
M]?P\S^7[_A.O!'_0X^%?_"ATC_Y,H_X3KP1_T./A7_PH=(_^3*_J!_X=O_\
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MM_T8Q^R%_P"(X?"#_P"9"C_AV_\ \$]O^C&/V0O_ !'#X0?_ #(4?\334O\
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M_P#S'Z_T]#_B27&_]%[A?_#+5\O^HWU_#S/Y)/\ A.O!'_0X^%?_  H=(_\
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MY)/^$Z\$?]#CX5_\*'2/_DRC_A.O!'_0X^%?_"ATC_Y,K^MO_AV9_P $Y/\
MHPG]C;_Q&CX-_P#S&T?\.S/^"<G_ $83^QM_XC1\&_\ YC:/^)IJ7_1'U/\
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MR_ZC?7\/,_DD_P"$Z\$?]#CX5_\ "ATC_P"3*/\ A.O!'_0X^%?_  H=(_\
MDROZV_\ AV9_P3D_Z,)_8V_\1H^#?_S&UYYKO_!-K_@GC#JMU'#^PI^Q_%&O
MD;8X_P!F[X/HBYMH6.%7P> ,L2QP.223R:/^)IJ7_1'U/_#M'_YC]?Z>A_Q)
M+C?^B]PO_AEJ^7_4;Z_AYG\L_P#PG7@C_H<?"O\ X4.D?_)E'_"=>"/^AQ\*
M_P#A0Z1_\F5_4#_P[?\ ^">W_1C'[(7_ (CA\(/_ )D*/^';_P#P3V_Z,8_9
M"_\ $</A!_\ ,A1_Q--2_P"B/J?^':/_ ,Q^O]/0_P"))<;_ -%[A?\ PRU?
M+_J-]?P\S^7[_A.O!'_0X^%?_"ATC_Y,H_X3KP1_T./A7_PH=(_^3*_J!_X=
MO_\ !/;_ *,8_9"_\1P^$'_S(4?\.W_^">W_ $8Q^R%_XCA\(/\ YD*/^)IJ
M7_1'U/\ P[1_^8_7^GH?\22XW_HO<+_X9:OE_P!1OK^'F?R_?\)UX(_Z''PK
M_P"%#I'_ ,F4?\)UX(_Z''PK_P"%#I'_ ,F5_4#_ ,.W_P#@GM_T8Q^R%_XC
MA\(/_F0H_P"';_\ P3V_Z,8_9"_\1P^$'_S(4?\ $TU+_HCZG_AVC_\ ,?K_
M $]#_B27&_\ 1>X7_P ,M7R_ZC?7\/,_E^_X3KP1_P!#CX5_\*'2/_DRC_A.
MO!'_ $./A7_PH=(_^3*_J!_X=O\ _!/;_HQC]D+_ ,1P^$'_ ,R%'_#M_P#X
M)[?]&,?LA?\ B.'P@_\ F0H_XFFI?]$?4_\ #M'_ .8_7^GH?\22XW_HO<+_
M .&6KY?]1OK^'F?R_?\ "=>"/^AQ\*_^%#I'_P F4?\ "=>"/^AQ\*_^%#I'
M_P F5_4#_P .W_\ @GM_T8Q^R%_XCA\(/_F0H_X=O_\ !/;_ *,8_9"_\1P^
M$'_S(4?\334O^B/J?^':/_S'Z_T]#_B27&_]%[A?_#+5\O\ J-]?P\S^7[_A
M.O!'_0X^%?\ PH=(_P#DRC_A.O!'_0X^%?\ PH=(_P#DROZ@?^';_P#P3V_Z
M,8_9"_\ $</A!_\ ,A1_P[?_ .">W_1C'[(7_B.'P@_^9"C_ (FFI?\ 1'U/
M_#M'_P"8_7^GH?\ $DN-_P"B]PO_ (9:OE_U&^OX>9_+]_PG7@C_ *''PK_X
M4.D?_)E'_"=>"/\ H<?"O_A0Z1_\F5_4#_P[?_X)[?\ 1C'[(7_B.'P@_P#F
M0H_X=O\ _!/;_HQC]D+_ ,1P^$'_ ,R%'_$TU+_HCZG_ (=H_P#S'Z_T]#_B
M27&_]%[A?_#+5\O^HWU_#S/Y?O\ A.O!'_0X^%?_  H=(_\ DRC_ (3KP1_T
M./A7_P *'2/_ ),K^H'_ (=O_P#!/;_HQC]D+_Q'#X0?_,A1_P .W_\ @GM_
MT8Q^R%_XCA\(/_F0H_XFFI?]$?4_\.T?_F/U_IZ'_$DN-_Z+W"_^&6KY?]1O
MK^'F?R_?\)UX(_Z''PK_ .%#I'_R91_PG7@C_H<?"O\ X4.D?_)E?U _\.W_
M /@GM_T8Q^R%_P"(X?"#_P"9"C_AV_\ \$]O^C&/V0O_ !'#X0?_ #(4?\33
M4O\ HCZG_AVC_P#,?K_3T/\ B27&_P#1>X7_ ,,M7R_ZC?7\/,_DB^/_ (S\
M'W7P'^-EM;>*_#5Q<W'PC^)$%O;P:[I<T\\\W@W68XH88H[II)999&5(XT5G
M=V"J"Q K^Z_]G#_DWCX#?]D8^%W_ *@^A5^0?[=G[ ?["W@[]B']LCQ=X2_8
MT_99\+^*_"O[*O[0WB3PQXE\/_ +X6:/KWAWQ#H?PC\7ZGHNNZ)J^G^%K>_T
MK5])U*UMK_3=2L;B"\L;VWANK::*:)'7]=?V9[:VLOV</V?K.SMX+2TM/@C\
M*;:UM;:*."VMK:#P)H,4%O;P1*D4,$,2+'%%&JQQQJJ(H4 #\@\5?$F/B3')
ML;'*I95_9CQF%]F\4L5[7VRP];GYE2H\G+;EM:5][K8_>O WP?K>$&)XBRVM
MG=+.WG%#+L<JM/"3PBH>PJ8J@Z;C*K6Y^9MRYDXV22L[W7MU%%%?CQ_1 444
M4 %%%% '^/9^V)_R=Q^U-_V<;\;_ /U9GB>OG*OHW]L3_D[C]J;_ +.-^-__
M *LSQ/7SE7]%8?\ W>A_UYI?^D1/X1QW^^XS_L*Q'_IZ84445L<H4444 %%%
M% !17];/_!!3XL_ S]HRV^#_ .Q#?_\ !'_]F/X_ZY\/;7QEXA^.W[:/Q1L/
MA;JVH:)X*U[Q]XK\4Z9K7B?2_$?[.7BO6];US3[+7=)^&G@+PG)\1[F]\0OH
MUE(EYX:\*:;K5[X7\]_:O^!'[,7_  5B_;Y\9?"O]A+PW^R[^R-^QM^Q1\(O
M%?BO]H/]JWP-\+?"WA#P7K>G:1JPN/'GQ"CL? ,'A31O'VA:);V*:=\-Q?7^
MBV.JZ3X>\>^-8O'+>%M7T=;7PGG?L\=B,)B<'4P]+"TY5JN+=:C5IQH\[A0G
M*G0E4J0GBI)>QP\HK$24KJFTF?9QX0^L9/@,SP&:X?&XG,:]/"8;+%A<7AL1
M4Q:I0K8VE"MBX4</4HY="4OK>.ISE@J;A9UTY)'\M%%?O0O_  1/\/>.?'/[
M%6M_LZ_ME^'?CW^R-^V9\3_$?P1TS]I;3O@EXG\ >)/AM\6_"UGXSU34/"WB
M?X!^.O&>F>)KFSU72?!>K7OAC5QXJTU]272M=FU33=!TS_A"]3\=_J)_P3M_
MX)5?L,?L]_\ !3EOV<?'W[2WPN_;I^+?A+PS\4=(^)W[-7CC]C[4X/ G@;2X
M/#^G^(O#OCN]\9_$37/&_P ./$7BBWL[[PM:S^&/#=IJE]X<U;Q'KFGR>(/,
M\-7+ZI6)X@R^A2JSA*M6JT\/6Q#P\,-BHU(PH3G3J*MS4$L*XU(2IR6)]DXR
M<4TN>'-& X(SS&8G#T:M/"X3#XC&X7 K&U<PRZ="=7&4:6)H2PGL\8Y9C&IA
MJT*]-Y?]852FIN$G[*KR?QIT5^ZW[.O_  2U^ O[5'C3QM<^.?VY?AS^S[XN
M\??M+_$GX5? O]FGX2?!CQ!^U5\=];M/#6K^,[_5O$'B7X*?!SQ5I7B[X/\
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M8_Q=]- _+Q-_\U%'_#8_Q=]- _+Q-_\ -17\O?\ %3'Z*_\ T.N-/_$,QO\
M\TGZ5_Q+EXG?] >3_P#AXH__ "L_8NBOQT_X;'^+OIH'Y>)O_FHH_P"&Q_B[
MZ:!^7B;_ .:BC_BIC]%?_H=<:?\ B&8W_P":0_XER\3O^@/)_P#P\4?_ )6?
ML717XZ?\-C_%WTT#\O$W_P U%'_#8_Q=]- _+Q-_\U%'_%3'Z*__ $.N-/\
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ML?XN^F@?EXF_^:BC_BIC]%?_ *'7&G_B&8W_ .:0_P")<O$[_H#R?_P\4?\
MY6?L717XZ?\ #8_Q=]- _+Q-_P#-11_PV/\ %WTT#\O$W_S44?\ %3'Z*_\
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M/-Y_P5$T7Q_\>?'WP_\ @+XE^'EQ\.O!7_!/S]HK]IS6/$GQ8^&WQQ\'>+/
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MU\4X48P_LOVRJTX?NWI'[37P0U[P7\<OB'I7C;[5X/\ V;?%'Q,\&?&G6/\
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MV,94/Z#OA]XC\:^+?%W_  =AZ-\4[[4KC2].\&?%B\TG1]4NIYM)MAX6TO\
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M?]&A_P#-_P#"_P#^C4/^(]^$W_15_P#F"XE_^<Q^<=%?HY_P[^_ZJU_Y8?\
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M,6_]5*_\L[_\*J/^*>GTP/\ HT/_ )O_ (7_ /T:A_Q'OPF_Z*O_ ,P7$O\
M\YCX7HK[H_X8M_ZJ5_Y9W_X54?\ #%O_ %4K_P L[_\ "JC_ (IZ?3 _Z-#_
M .;_ .%__P!&H?\ $>_";_HJ_P#S!<2__.8^%Z*^Z/\ ABW_ *J5_P"6=_\
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M_P##.C_AW]_U5K_RP_\ \,Z/^*>GTP/^C0_^;_X7_P#T:A_Q'OPF_P"BK_\
M,%Q+_P#.8_..BOT<_P"'?W_56O\ RP__ ,,Z/^'?W_56O_+#_P#PSH_XIZ?3
M _Z-#_YO_A?_ /1J'_$>_";_ **O_P P7$O_ ,YC\XZ*_1S_ (=_?]5:_P#+
M#_\ PSH_X=_?]5:_\L/_ /#.C_BGI],#_HT/_F_^%_\ ]&H?\1[\)O\ HJ__
M #!<2_\ SF/SCHK]'/\ AW]_U5K_ ,L/_P##.C_AW]_U5K_RP_\ \,Z/^*>G
MTP/^C0_^;_X7_P#T:A_Q'OPF_P"BK_\ ,%Q+_P#.8_..BOT<_P"'?W_56O\
MRP__ ,,Z/^'?W_56O_+#_P#PSH_XIZ?3 _Z-#_YO_A?_ /1J'_$>_";_ **O
M_P P7$O_ ,YC\XZWO#?AO5?%6JP:3I,!EGE(,DA!$-M"#\\\[]$C0<\\L<*H
M)-??W_#O[_JK7_EA_P#X9UZ1X<_9[T?X=0RZ/INL&ZN,0-?:I-I:QW-]*T$<
MA9D&H2>3"K.?+@61U0=69OFK]>\$?V:7C5Q)QWEU#QHR->'G &#<<;G..P_$
MG"F>9OG%*E4A_P (F3T.',YSN6#Q>-3<:F8YA3HX;!8=5:U)8K$QI86I\IQG
M](O@[+LDQ%3@_&_V_GM6]'!T*F7YI@L)A)23_P!LQ<\PP>"56E1WCA\/*=2M
M4Y82=*FY58^3^"/!&E>"-*6RLE$MY*%?4-0=0)KN8#D ]4@0Y$40. /F;+$F
MNTKTC_A7W_47_P#)#_[MH_X5]_U%_P#R0_\ NVO^@;A'AOA/@+AK)^$.$,KP
M60\.9#@J6 RK*L!0G2P^&P])?X7.M7K3<JV)Q5>=3$XK$5*N)Q-6K7JU*DOX
M.S;,,USS,<7FV;8FMCLQQU:5?%8JO-2J5:DK+NHQA"*4*=."C3I4XQITXQA&
M,5YO17I'_"OO^HO_ .2'_P!VT?\ "OO^HO\ ^2'_ -VU])]:H?\ /S_R6?\
M\B>?[*I_+^,?\SS>BO2/^%??]1?_ ,D/_NVC_A7W_47_ /)#_P"[:/K5#_GY
M_P"2S_\ D0]E4_E_&/\ F>;T5Z1_PK[_ *B__DA_]VT?\*^_ZB__ )(?_=M'
MUJA_S\_\EG_\B'LJG\OXQ_S/-Z*](_X5]_U%_P#R0_\ NVC_ (5]_P!1?_R0
M_P#NVCZU0_Y^?^2S_P#D0]E4_E_&/^9YO17I'_"OO^HO_P"2'_W;1_PK[_J+
M_P#DA_\ =M'UJA_S\_\ )9__ "(>RJ?R_C'_ #/-Z*](_P"%??\ 47_\D/\
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M0BXYW64E9_V50?1Z/%XA=/1GL]%%%>.>V%%%% !1110!_CV?MB?\G<?M3?\
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M\\_P?8^8Z*^G/[(_8S_Z*!^TY_X9_P"%?_S\J/[(_8S_ .B@?M.?^&?^%?\
M\_*CV\?^?=?_ ,$5?_D?ZL_*Y]3G_P _L)_X5X?R_P"GGG^#['S'17TY_9'[
M&?\ T4#]IS_PS_PK_P#GY4?V1^QG_P!% _:<_P##/_"O_P"?E1[>/_/NO_X(
MJ_\ R/\ 5GY7/J<_^?V$_P#"O#^7_3SS_!]CYCHKZ<_LC]C/_HH'[3G_ (9_
MX5__ #\J/[(_8S_Z*!^TY_X9_P"%?_S\J/;Q_P"?=?\ \$5?_D?ZL_*Y]3G_
M ,_L)_X5X?R_Z>>?X/L?,=%?3G]D?L9_]% _:<_\,_\ "O\ ^?E1_9'[&?\
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M\\_P?8^8Z*^G/[(_8S_Z*!^TY_X9_P"%?_S\J/[(_8S_ .B@?M.?^&?^%?\
M\_*CV\?^?=?_ ,$5?_D?ZL_*Y]3G_P _L)_X5X?R_P"GGG^#['S'17TY_9'[
M&?\ T4#]IS_PS_PK_P#GY4?V1^QG_P!% _:<_P##/_"O_P"?E1[>/_/NO_X(
MJ_\ R/\ 5GY7/J<_^?V$_P#"O#^7_3SS_!]CYCK^U#_@S^_YR'?]VE_^_,U_
M*7_9'[&?_10/VG/_  S_ ,*__GY5_2__ ,&Z$OQOT>Z_;)'_  3ML?A5\1;.
MX@_9T/Q:;]M+5/%WP8NM(NHI/CS_ ,(2/ATGP.T?X]1>(X+^*3Q4?%+>)7\+
M2:3)9^'QI*ZTNI:B=*\#BB2KY%CJ2O3<OJOOUXRHTHVQF&E[U2:48WLTKO65
MHJ[:O]KX=0>#XRR;$3<:\8?VA>EA)PQ6(ESY5C8+DH492J3Y7/FGRQ?+",YN
MT8MG]TM%?F1_;_\ P66_Z)-_P3(_\2%_:H_^ABH_M_\ X++?]$F_X)D?^)"_
MM4?_ $,5?D7U&7_03@?_  KH_P#R7]6?E?\ J'^V*?\ T 9O_P"&S%^7]SS_
M  ?8_3>BOS(_M_\ X++?]$F_X)D?^)"_M4?_ $,5']O_ /!9;_HDW_!,C_Q(
M7]JC_P"ABH^HR_Z"<#_X5T?_ )+^K/RN?VQ3_P"@#-__  V8OR_N>?X/L?IO
M17YD?V__ ,%EO^B3?\$R/_$A?VJ/_H8J/[?_ ."RW_1)O^"9'_B0O[5'_P!#
M%1]1E_T$X'_PKH__ "7]6?E<_MBG_P! &;_^&S%^7]SS_!]C]-Z*_,C^W_\
M@LM_T2;_ ()D?^)"_M4?_0Q4?V__ ,%EO^B3?\$R/_$A?VJ/_H8J/J,O^@G
M_P#A71_^2_JS\KG]L4_^@#-__#9B_+^YY_@^Q^F]%?F1_;__  66_P"B3?\
M!,C_ ,2%_:H_^ABH_M__ (++?]$F_P""9'_B0O[5'_T,5'U&7_03@?\ PKH_
M_)?U9^5S^V*?_0!F_P#X;,7Y?W//\'V/TWHK\R/[?_X++?\ 1)O^"9'_ (D+
M^U1_]#%1_;__  66_P"B3?\ !,C_ ,2%_:H_^ABH^HR_Z"<#_P"%='_Y+^K/
MRN?VQ3_Z ,W_ /#9B_+^YY_@^Q^F]%?F1_;_ /P66_Z)-_P3(_\ $A?VJ/\
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M='_Y+^K/RN?VQ3_Z ,W_ /#9B_+^YY_@^Q^F]%?F1_;_ /P66_Z)-_P3(_\
M$A?VJ/\ Z&*C^W_^"RW_ $2;_@F1_P")"_M4?_0Q4?49?]!.!_\ "NC_ /)?
MU9^5S^V*?_0!F_\ X;,7Y?W//\'V/TWHK\R/[?\ ^"RW_1)O^"9'_B0O[5'_
M -#%1_;_ /P66_Z)-_P3(_\ $A?VJ/\ Z&*CZC+_ *"<#_X5T?\ Y+^K/RN?
MVQ3_ .@#-_\ PV8OR_N>?X/L?IO17YD?V_\ \%EO^B3?\$R/_$A?VJ/_ *&*
MC^W_ /@LM_T2;_@F1_XD+^U1_P#0Q4?49?\ 03@?_"NC_P#)?U9^5S^V*?\
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M-_P3(_\ $A?VJ/\ Z&*C^W_^"RW_ $2;_@F1_P")"_M4?_0Q4?49?]!.!_\
M"NC_ /)?U9^5S^V*?_0!F_\ X;,7Y?W//\'V/TWHK\R/[?\ ^"RW_1)O^"9'
M_B0O[5'_ -#%1_;_ /P66_Z)-_P3(_\ $A?VJ/\ Z&*CZC+_ *"<#_X5T?\
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M_H;*/[=_X*_?]$L_X)M_^']_:>_^ALH^HR_Z"<#_ .%='_Y+^K/RN?VQ3_Z
M,W_\-F+\O[GG^#['Z245^;?]N_\ !7[_ *)9_P $V_\ P_O[3W_T-E']N_\
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M] &;_P#ALQ?E_<\_P?8_3>BOS(_M_P#X++?]$F_X)D?^)"_M4?\ T,5']O\
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M/TDHK\V_[=_X*_?]$L_X)M_^']_:>_\ H;*/[=_X*_?]$L_X)M_^']_:>_\
MH;*/J,O^@G _^%='_P"2_JS\KG]L4_\ H S?_P -F+\O[GG^#['Z245^;?\
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M **** "BBB@ HHHH **** "O[4/^#/[_ )R'?]VE_P#OS-?Q7U_:A_P9_?\
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M==U]Z-2BLO\ MS1?^@QI?_@PM/\ X]1_;FB_]!C2_P#P86G_ ,>HY)_RR_\
M 7_D%UW7WHU**R_[<T7_ *#&E_\ @PM/_CU']N:+_P!!C2__  86G_QZCDG_
M "R_\!?^077=?>C4HK+_ +<T7_H,:7_X,+3_ ./4?VYHO_08TO\ \&%I_P#'
MJ.2?\LO_  %_Y!==U]Z-2BLO^W-%_P"@QI?_ (,+3_X]1_;FB_\ 08TO_P &
M%I_\>HY)_P LO_ 7_D%UW7WHU**R_P"W-%_Z#&E_^#"T_P#CU']N:+_T&-+_
M /!A:?\ QZCDG_++_P !?^077=?>C4KQ>O5/[<T7_H,:7_X,+3_X]7C/]LZ/
M_P!!73?_  .M?_CM')/^67_@+_R"Z[K[T:5%9O\ ;.C_ /05TW_P.M?_ ([1
M_;.C_P#05TW_ ,#K7_X[1R3_ )9?^ O_ ""Z[K[T:5%9O]LZ/_T%=-_\#K7_
M ..T?VSH_P#T%=-_\#K7_P".T<D_Y9?^ O\ R"Z[K[T:5%9O]LZ/_P!!73?_
M  .M?_CM']LZ/_T%=-_\#K7_ ..T<D_Y9?\ @+_R"Z[K[T:5%9O]LZ/_ -!7
M3?\ P.M?_CM']LZ/_P!!73?_  .M?_CM')/^67_@+_R"Z[K[T:5%9O\ ;.C_
M /05TW_P.M?_ ([1_;.C_P#05TW_ ,#K7_X[1R3_ )9?^ O_ ""Z[K[T:5%9
MO]LZ/_T%=-_\#K7_ ..T?VSH_P#T%=-_\#K7_P".T<D_Y9?^ O\ R"Z[K[T:
M5%9O]LZ/_P!!73?_  .M?_CM']LZ/_T%=-_\#K7_ ..T<D_Y9?\ @+_R"Z[K
M[T:5%9O]LZ/_ -!73?\ P.M?_CM']LZ/_P!!73?_  .M?_CM')/^67_@+_R"
MZ[K[T:5%9O\ ;.C_ /05TW_P.M?_ ([1_;.C_P#05TW_ ,#K7_X[1R3_ )9?
M^ O_ ""Z[K[T:5%9O]LZ/_T%=-_\#K7_ ..T?VSH_P#T%=-_\#K7_P".T<D_
MY9?^ O\ R"Z[K[T>P>'O^0/9_P#;Q_Z53UM5R7A[6]%&CV8.KZ6#_I'!O[0'
M_CZG_P"FM;/]N:+_ -!C2_\ P86G_P >HY)_RR_\!?\ D%UW7WHU**R_[<T7
M_H,:7_X,+3_X]1_;FB_]!C2__!A:?_'J.2?\LO\ P%_Y!==U]Z-2BLO^W-%_
MZ#&E_P#@PM/_ (]1_;FB_P#08TO_ ,&%I_\ 'J.2?\LO_ 7_ )!==U]Z-2BL
MO^W-%_Z#&E_^#"T_^/4?VYHO_08TO_P86G_QZCDG_++_ ,!?^077=?>C4HK+
M_MS1?^@QI?\ X,+3_P"/4?VYHO\ T&-+_P#!A:?_ !ZCDG_++_P%_P"077=?
M>C4HK+_MS1?^@QI?_@PM/_CU']N:+_T&-+_\&%I_\>HY)_RR_P# 7_D%UW7W
MHU**R_[<T7_H,:7_ .#"T_\ CU']N:+_ -!C2_\ P86G_P >HY)_RR_\!?\
MD%UW7WHU**R_[<T7_H,:7_X,+3_X]1_;FB_]!C2__!A:?_'J.2?\LO\ P%_Y
M!==U]Z-2BLO^W-%_Z#&E_P#@PM/_ (]1_;FB_P#08TO_ ,&%I_\ 'J.2?\LO
M_ 7_ )!==U]Z-2O,?$/_ "&+S_MW_P#26"NZ_MS1?^@QI?\ X,+3_P"/5YGX
MAUK1SK%X1JVF$?Z/R+^U(_X]8/\ IK1R3_EE_P" O_(+KNOO17HK-_MG1_\
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MY)_RR_\  7_D%UW7WHTJ*S?[9T?_ *"NF_\ @=:__':/[9T?_H*Z;_X'6O\
M\=HY)_RR_P# 7_D%UW7WH^3?^"B'_*/_ /;G_P"S._VFO_5*^-J^Q?V</^3>
M/@-_V1CX7?\ J#Z%7Q9_P4*U/3;C]@3]N*WM]0L9YY_V/_VEX888;NWEEFEE
M^"_C5(XHHTD9Y))'941$4L[$*H)(%?:?[.'_ ";Q\!O^R,?"[_U!]"KLDFLN
MIW37^VUMTU_RXH=SR8M//JUG?_A(P_\ ZFXH]GHHHKA/7"BBB@ HHHH _P >
MS]L3_D[C]J;_ +.-^-__ *LSQ/7SE7T;^V)_R=Q^U-_V<;\;_P#U9GB>OG*O
MZ*P_^[T/^O-+_P!(B?PCCO\ ?<9_V%8C_P!/3"BBBMCE"BBB@ HHHH ****
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MJ-<_^3JXRBC_ (B7XC_]' XV_P#$JSW_ .;P_P!7.'O^A%DW_AKP/_R@[/\
MX6/\0_\ H?/&?_A4:Y_\G4?\+'^(?_0^>,__  J-<_\ DZN,HH_XB7XC_P#1
MP.-O_$JSW_YO#_5SA[_H19-_X:\#_P#*#L_^%C_$/_H?/&?_ (5&N?\ R=1_
MPL?XA_\ 0^>,_P#PJ-<_^3JXRBC_ (B7XC_]' XV_P#$JSW_ .;P_P!7.'O^
MA%DW_AKP/_R@[/\ X6/\0_\ H?/&?_A4:Y_\G4?\+'^(?_0^>,__  J-<_\
MDZN,HH_XB7XC_P#1P.-O_$JSW_YO#_5SA[_H19-_X:\#_P#*#L_^%C_$/_H?
M/&?_ (5&N?\ R=53_A./&G_0W^*/_!_JW_R77+T4?\1+\1_^C@<;?^)5GO\
M\WA_JYP]_P!"+)O_  UX'_Y0=1_PG'C3_H;_ !1_X/\ 5O\ Y+H_X3CQI_T-
M_BC_ ,'^K?\ R77+T4?\1+\1_P#HX'&W_B59[_\ -X?ZN</?]"+)O_#7@?\
MY0=1_P )QXT_Z&_Q1_X/]6_^2Z/^$X\:?]#?XH_\'^K?_)=<O11_Q$OQ'_Z.
M!QM_XE6>_P#S>'^KG#W_ $(LF_\ #7@?_E!U'_"<>-/^AO\ %'_@_P!6_P#D
MNC_A./&G_0W^*/\ P?ZM_P#)=<O11_Q$OQ'_ .C@<;?^)5GO_P WA_JYP]_T
M(LF_\->!_P#E!U'_  G'C3_H;_%'_@_U;_Y+H_X3CQI_T-_BC_P?ZM_\EUR]
M%'_$2_$?_HX'&W_B59[_ /-X?ZN</?\ 0BR;_P ->!_^4'4?\)QXT_Z&_P 4
M?^#_ %;_ .2Z/^$X\:?]#?XH_P#!_JW_ ,EUR]%'_$2_$?\ Z.!QM_XE6>__
M #>'^KG#W_0BR;_PUX'_ .4'4?\ "<>-/^AO\4?^#_5O_DNC_A./&G_0W^*/
M_!_JW_R77+T4?\1+\1_^C@<;?^)5GO\ \WA_JYP]_P!"+)O_  UX'_Y0=1_P
MG'C3_H;_ !1_X/\ 5O\ Y+H_X3CQI_T-_BC_ ,'^K?\ R77+T4?\1+\1_P#H
MX'&W_B59[_\ -X?ZN</?]"+)O_#7@?\ Y0=1_P )QXT_Z&_Q1_X/]6_^2Z/^
M$X\:?]#?XH_\'^K?_)=<O11_Q$OQ'_Z.!QM_XE6>_P#S>'^KG#W_ $(LF_\
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MAK7@C6[;7-#N##<0L%G@8DV][;D@R6MS&#AXI!T/WD;#H01S_7?T2OIP<<^
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MO_) YS_V6./_ /5)P\%%%%?YBG](A1110 4444 %%%% !1110 4444 %%%%
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MG\6U^FG[.'_)O'P&_P"R,?"[_P!0?0JSS#_D7X?_ +#,1_Z8PQQX?_D=5O\
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MQ5\.'TSQGX/A72O'</Q7\(?%>$230ZIX,M_!VL:?'J$OG.B?MV^ =._:4?\
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MIRC"*_M*\I248J^48]*[;25VTEKJVEN?W"T5XK_PTG^SI_T7WX*_^'3\#?\
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MO_T87P7_ /%6\#__ #B/6_XB'Q__ -%SQA_XDV=?_-I\X_\ #)/[/G_1/_\
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M_P#1A?!?_P 5;P/_ /.(/^(A\?\ _1<\8?\ B39U_P#-I\X_\,D_L^?]$_\
M_+K\;?\ S24?\,D_L^?]$_\ _+K\;?\ S25]'44?\2W_ $=_^C"^"_\ XJW@
M?_YQ!_Q$/C__ *+GC#_Q)LZ_^;3YQ_X9)_9\_P"B?_\ EU^-O_FDH_X9)_9\
M_P"B?_\ EU^-O_FDKZ.HH_XEO^CO_P!&%\%__%6\#_\ SB#_ (B'Q_\ ]%SQ
MA_XDV=?_ #:?./\ PR3^SY_T3_\ \NOQM_\ -)1_PR3^SY_T3_\ \NOQM_\
M-)7T=11_Q+?]'?\ Z,+X+_\ BK>!_P#YQ!_Q$/C_ /Z+GC#_ ,2;.O\ YM/G
M'_ADG]GS_HG_ /Y=?C;_ .:2C_ADG]GS_HG_ /Y=?C;_ .:2OHZBC_B6_P"C
MO_T87P7_ /%6\#__ #B#_B(?'_\ T7/&'_B39U_\VGSC_P ,D_L^?]$__P#+
MK\;?_-)1_P ,D_L^?]$__P#+K\;?_-)7T=11_P 2W_1W_P"C"^"__BK>!_\
MYQ!_Q$/C_P#Z+GC#_P 2;.O_ )M/G'_ADG]GS_HG_P#Y=?C;_P":2O,?^&:O
M@I_T)?\ Y<?BS_Y?5]N5XO1_Q+?]'?\ Z,+X+_\ BK>!_P#YQ!_Q$/C_ /Z+
MGC#_ ,2;.O\ YM/"_P#AFKX*?]"7_P"7'XL_^7U'_#-7P4_Z$O\ \N/Q9_\
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M )<?BS_Y?4?\,U?!3_H2_P#RX_%G_P OJ]THH_XEO^CO_P!&%\%__%6\#_\
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ME_\ _)5=117UGMJO_/VI_P"!R_S/*Y(?RQ_\!7^1R_\ PAGAK_H&_P#DY?\
M_P E4?\ "&>&O^@;_P"3E_\ _)5=111[:K_S]J?^!R_S#DA_+'_P%?Y'+_\
M"&>&O^@;_P"3E_\ _)5'_"&>&O\ H&_^3E__ /)5=111[:K_ ,_:G_@<O\PY
M(?RQ_P# 5_D<O_PAGAK_ *!O_DY?_P#R51_PAGAK_H&_^3E__P#)5=111[:K
M_P _:G_@<O\ ,.2'\L?_  %?Y'+_ /"&>&O^@;_Y.7__ ,E4?\(9X:_Z!O\
MY.7_ /\ )5=111[:K_S]J?\ @<O\PY(?RQ_\!7^1R_\ PAGAK_H&_P#DY?\
M_P E4?\ "&>&O^@;_P"3E_\ _)5=111[:K_S]J?^!R_S#DA_+'_P%?Y'+_\
M"&>&O^@;_P"3E_\ _)5>:>(/"'AU=7NP-.P!Y'_+W??\^L)[W->YUYCXA_Y#
M%Y_V[_\ I+!1[:K_ ,_:G_@<O\PY(?RQ_P# 5_D<#_PB/A[_ *!__DW??_)-
M'_"(^'O^@?\ ^3=]_P#)-=)11[:K_P _:G_@<O\ ,.2'\L?_  %?Y'-_\(CX
M>_Z!_P#Y-WW_ ,DT?\(CX>_Z!_\ Y-WW_P DUTE%'MJO_/VI_P"!R_S#DA_+
M'_P%?Y'-_P#"(^'O^@?_ .3=]_\ )-'_  B/A[_H'_\ DW??_)-=)11[:K_S
M]J?^!R_S#DA_+'_P%?Y'-_\ "(^'O^@?_P"3=]_\DT?\(CX>_P"@?_Y-WW_R
M37244>VJ_P#/VI_X'+_,.2'\L?\ P%?Y'-_\(CX>_P"@?_Y-WW_R31_PB/A[
M_H'_ /DW??\ R37244>VJ_\ /VI_X'+_ ##DA_+'_P !7^1S?_"(^'O^@?\
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M/C-XEUGXJ>-K;3/!]YX?^%=UXST+2_&_C+1_#>I6U]XFO-6\2:QXU\+:A#J
MT.SM/$]I937\]CK?MO\ [(7['WQ$_P""8?[,O_!1S]D?]F_Q=^R9XH^*_P"T
M#J?P$N/V?9OC)XW^.VA^/+6/4/BKIEIXG\%^(?'MG)XQUWQ0=;^']MIJ:?H]
MOHFDK WB#3VT6]U'1(-9U;VB?X&_L+?MU_\ !</]K_Q]^TI^UO\ L_\ @O\
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M?#C_ ,+CPS_\M*\;_B)'AW_T7O!?_B4Y'_\ -QZ7^KV?_P#0CSC_ ,-F-_\
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M'D1_Y'U;_L48?_U-Q1[/1117$>N%%%% !1110!_CV?MB?\G<?M3?]G&_&_\
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M^"NNX^&7PN^''C6:^TG6]'\:^"M0\.^%M&UM-,T_Q;8ZM%JXTC^T8^F\2_\
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M2P499;]6Q.#P"X86+Q52=2A+&0G1_L_%M4HXNC*H\+#V="HJL57_  (\,_\
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M"O@\?@GX9\#>/O&47PAN+2]^$WACXW?&;3O&.L#XA^&?!U]I>C7=U:Z'\//
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M>7XO*LUPE''9?CJ,J&*PM>//3JTY='UC*+M.G4@XU*=2,:E.49QC)?K?X/\
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M $0;XS_^&N\<?_*.CVU+_G[3_P# X_YA]5Q7_0-B/_!-3_Y'S7WGC%%>S_\
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MA?\ B2OP9_\ FTH_X>#?L$?]'O?LA?\ B2OP9_\ FTH^J8O_ *!L1_X)J?\
MR(?VGEO_ $,<#_X5X?\ ^6'U[17R%_P\&_8(_P"CWOV0O_$E?@S_ /-I1_P\
M&_8(_P"CWOV0O_$E?@S_ /-I1]4Q?_0-B/\ P34_^1#^T\M_Z&.!_P#"O#__
M "P^O:*^0O\ AX-^P1_T>]^R%_XDK\&?_FTH_P"'@W[!'_1[W[(7_B2OP9_^
M;2CZIB_^@;$?^":G_P B']IY;_T,<#_X5X?_ .6'U[17R%_P\&_8(_Z/>_9"
M_P#$E?@S_P#-I1_P\&_8(_Z/>_9"_P#$E?@S_P#-I1]4Q?\ T#8C_P $U/\
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MZ_&W_P TE'_#)/[/G_1/_P#RZ_&W_P TE<A_P\&_8(_Z/>_9"_\ $E?@S_\
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MX/\ _P V-'L<P_Y]8S_P"O\ Y!_:.5?]!V7_ /A3AO\ Y,^C?^$1\/?] _\
M\F[[_P"2:/\ A$?#W_0/_P#)N^_^2:^<O^&]OV&/^CT/V3O_ !(OX/\ _P V
M-'_#>W[#'_1Z'[)W_B1?P?\ _FQH]CF'_/K&?^ 5_P#(/[1RK_H.R_\ \*<-
M_P#)GT;_ ,(CX>_Z!_\ Y-WW_P DT?\ "(^'O^@?_P"3=]_\DU\Y?\-[?L,?
M]'H?LG?^)%_!_P#^;&C_ (;V_88_Z/0_9._\2+^#_P#\V-'L<P_Y]8S_ , K
M_P"0?VCE7_0=E_\ X4X;_P"3/HW_ (1'P]_T#_\ R;OO_DFC_A$?#W_0/_\
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M_P"CWOV0O_$E?@S_ /-I1_P\&_8(_P"CWOV0O_$E?@S_ /-I1[',/^?6,_\
M *_^0?VCE7_0=E__ (4X;_Y,^E?^$,\-?] W_P G+_\ ^2J/^$,\-?\ 0-_\
MG+__ .2J^:O^'@W[!'_1[W[(7_B2OP9_^;2C_AX-^P1_T>]^R%_XDK\&?_FT
MH]CF'_/K&?\ @%?_ "#^T<J_Z#LO_P#"G#?_ "9]*_\ "&>&O^@;_P"3E_\
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M:/8YA_SZQG_@%?\ R#^T<J_Z#LO_ /"G#?\ R9]&_P#"(^'O^@?_ .3=]_\
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M_ ;_ ,-!\/?_ )GJ]YHH^L5_^?\ 6_\ !D__ )+R7W!]2P?_ $"8;_P12_\
MD#P;_AE?]F'_ *-Q^ W_ (:#X>__ #/4?\,K_LP_]&X_ ;_PT'P]_P#F>KWF
MBCZQ7_Y_UO\ P9/_ .2\E]P?4L'_ - F&_\ !%+_ .0/!O\ AE?]F'_HW'X#
M?^&@^'O_ ,SU'_#*_P"S#_T;C\!O_#0?#W_YGJ]YHH^L5_\ G_6_\&3_ /DO
M)?<'U+!_] F&_P#!%+_Y \&_X97_ &8?^C<?@-_X:#X>_P#S/4?\,K_LP_\
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M] F&_P#!%+_Y \&_X97_ &8?^C<?@-_X:#X>_P#S/4?\,K_LP_\ 1N/P&_\
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M;S\#?_#2^ ?_ )GZ]RHH^L5_^?\ 6_\ !D__ )+R7W!]2P?_ $"8;_P12_\
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M_9J_Z-Y^!O\ X:7P#_\ ,_1_PS#^S5_T;S\#?_#2^ ?_ )GZ]RHH^L5_^?\
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M_P"S#_T;C\!O_#0?#W_YGJ/^&5_V8?\ HW'X#?\ AH/A[_\ ,]7O-%'UBO\
M\_ZW_@R?_P EY+[@^I8/_H$PW_@BE_\ ('@W_#*_[,/_ $;C\!O_  T'P]_^
M9ZC_ (97_9A_Z-Q^ W_AH/A[_P#,]7O-%'UBO_S_ *W_ (,G_P#)>2^X/J6#
M_P"@3#?^"*7_ ,@>#?\ #*_[,/\ T;C\!O\ PT'P]_\ F>H_X97_ &8?^C<?
M@-_X:#X>_P#S/5[S11]8K_\ /^M_X,G_ /)>2^X/J6#_ .@3#?\ @BE_\@>#
M?\,K_LP_]&X_ ;_PT'P]_P#F>H_X97_9A_Z-Q^ W_AH/A[_\SU>\T4?6*_\
MS_K?^#)__)>2^X/J6#_Z!,-_X(I?_('@W_#*_P"S#_T;C\!O_#0?#W_YGJ/^
M&5_V8?\ HW'X#?\ AH/A[_\ ,]7O-%'UBO\ \_ZW_@R?_P EY+[@^I8/_H$P
MW_@BE_\ ('@W_#*_[,/_ $;C\!O_  T'P]_^9ZC_ (97_9A_Z-Q^ W_AH/A[
M_P#,]7O-%'UBO_S_ *W_ (,G_P#)>2^X/J6#_P"@3#?^"*7_ ,@>#?\ #*_[
M,/\ T;C\!O\ PT'P]_\ F>H_X97_ &8?^C<?@-_X:#X>_P#S/5[S11]8K_\
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M^J_V5_:O]E?;O[-_M34OL/G_ &7[?>>5]HD_4O\ ;$_X(T_$C]EO]@O]EO\
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MT\?:?XN_LWPWXHNI;&_O)?A]9^&M?N-*T>;1O[?\0Z/XJN=>\(>&?H+X9_\
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M@_A;%0R?A?CGB?(,JAB<10Q3Q&(CE^59IA,)&O7<8NM65%5*KC%SE)I']R^
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M%%U3_P  -#_^55>"T4?\3)_2+_Z/[XU?^+3XY_\ GZ'_ !#OP_\ ^B%X._\
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M7_T?WQJ_\6GQS_\ /T/^(=^'_P#T0O!W_B,9)_\ ,)[U_P -/_'C_HHNJ?\
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MG](O_H_OC5_XM/CG_P"?H?\ $._#_P#Z(7@[_P 1C)/_ )A/8O\ AH#XP_\
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MR<*E*K3FE.%2$TXSA)*49)II-&E_;.L?]!74O_ ZZ_\ CM']LZQ_T%=2_P#
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M07?=_>S4_MS6O^@QJG_@PN__ (]1_;FM?]!C5/\ P87?_P >K+HHY(?RQ_\
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M*Q'_ *>F%%%%;'*%%%% !1110!_9K_P2A\+?\%%=-_X)V?"ZR\-?LH?L8?\
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M,TO@SP[J\GA?6=4\,ZM.UY;:Y%$G@[0-0FTBRL=5^)NJK:>!/Y-O^%T_&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/=<_Y"EU_VP_\
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M^[2__?F:_BOK^U#_ (,_O^<AW_=I?_OS-?-\7?\ )/9A_P!RG_J=AC[[PO\
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M<O&?_E#_ /E77W311_Q)I]%S_HR7!/\ X1XG_P":P_XB]XE_]%EG/_@ZG_\
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M+_,\W_X5]_U%_P#R0_\ NVC_ (5]_P!1?_R0_P#NVO2**/K5?_GY_P"2P_\
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MO\SR_P#X5M_U&O\ RG?_ '=1_P *V_ZC7_E._P#NZO4**/K5?_GY_P"2P_\
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M=^5CZS1_Z%^#_P# \?\ _-W]7?E;Z=_X5/\ LZ_]'8:9_P"&6^)W_P CT?\
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MG_9U_P"CL-,_\,M\3O\ Y'KYBHH]E4_Z":__ (#AO_F?^KORL?6:/_0OP?\
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M_P"D4VL_^)K_ +./^%?IO11];H?]"S _^#,R_P#GA_5WY6/[-QO_ $4&;_\
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MLW&_]%!F_P#X)R'_ .<A^9'_  U9_P %%O\ I%-K/_B:_P"SC_A1_P -6?\
M!1;_ *13:S_XFO\ LX_X5^F]%'UNA_T+,#_X,S+_ .>']7?E8_LW&_\ 109O
M_P""<A_^<A^9'_#5G_!1;_I%-K/_ (FO^SC_ (4?\-6?\%%O^D4VL_\ B:_[
M./\ A7Z;T4?6Z'_0LP/_ (,S+_YX?U=^5C^S<;_T4&;_ /@G(?\ YR'YD?\
M#5G_  46_P"D4VL_^)K_ +./^%'_  U9_P %%O\ I%-K/_B:_P"SC_A7Z;T4
M?6Z'_0LP/_@S,O\ YX?U=^5C^S<;_P!%!F__ ()R'_YR'YD?\-6?\%%O^D4V
ML_\ B:_[./\ A1_PU9_P46_Z13:S_P")K_LX_P"%?IO11];H?]"S _\ @S,O
M_GA_5WY6/[-QO_109O\ ^"<A_P#G(?F1_P -6?\ !1;_ *13:S_XFO\ LX_X
M4?\ #5G_  46_P"D4VL_^)K_ +./^%?IO11];H?]"S _^#,R_P#GA_5WY6/[
M-QO_ $4&;_\ @G(?_G(?F1_PU9_P46_Z13:S_P")K_LX_P"%'_#5G_!1;_I%
M-K/_ (FO^SC_ (5^F]%'UNA_T+,#_P"#,R_^>']7?E8_LW&_]%!F_P#X)R'_
M .<A^9'_  U9_P %%O\ I%-K/_B:_P"SC_A1_P -6?\ !1;_ *13:S_XFO\
MLX_X5^F]%'UNA_T+,#_X,S+_ .>']7?E8_LW&_\ 109O_P""<A_^<A^9'_#5
MG_!1;_I%-K/_ (FO^SC_ (4?\-6?\%%O^D4VL_\ B:_[./\ A7Z;T4?6Z'_0
MLP/_ (,S+_YX?U=^5C^S<;_T4&;_ /@G(?\ YR'YD?\ #5G_  46_P"D4VL_
M^)K_ +./^%'_  U9_P %%O\ I%-K/_B:_P"SC_A7Z;T4?6Z'_0LP/_@S,O\
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M *1=ZQ_XF3^SS7Z244?6Z'_0LP/_ (,S+_YX?U=^5C^S<;_T4&;_ /@G(?\
MYR'YM_\ #4/_  4%_P"D7>L?^)D_L\T?\-0_\%!?^D7>L?\ B9/[/-?I)11]
M;H?]"S _^#,R_P#GA_5WY6/[-QO_ $4&;_\ @G(?_G(?FW_PU#_P4%_Z1=ZQ
M_P")D_L\T?\ #4/_  4%_P"D7>L?^)D_L\U^DE%'UNA_T+,#_P"#,R_^>']7
M?E8_LW&_]%!F_P#X)R'_ .<A^;?_  U#_P %!?\ I%WK'_B9/[/-'_#4/_!0
M7_I%WK'_ (F3^SS7Z244?6Z'_0LP/_@S,O\ YX?U=^5C^S<;_P!%!F__ ()R
M'_YR'YM_\-0_\%!?^D7>L?\ B9/[/-'_  U#_P %!?\ I%WK'_B9/[/-?I)1
M1];H?]"S _\ @S,O_GA_5WY6/[-QO_109O\ ^"<A_P#G(?FW_P -0_\ !07_
M *1=ZQ_XF3^SS1_PU#_P4%_Z1=ZQ_P")D_L\U^DE%'UNA_T+,#_X,S+_ .>'
M]7?E8_LW&_\ 109O_P""<A_^<A^;?_#4/_!07_I%WK'_ (F3^SS1_P -0_\
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MFUG_ ,37_9Q_PK]-Z*/K=#_H68'_ ,&9E_\ /#^KORL?V;C?^B@S?_P3D/\
M\Y#\R/\ AJS_ (*+?](IM9_\37_9Q_PH_P"&K/\ @HM_TBFUG_Q-?]G'_"OT
MWHH^MT/^A9@?_!F9?_/#^KORL?V;C?\ HH,W_P#!.0__ #D/S(_X:L_X*+?]
M(IM9_P#$U_V<?\*/^&K/^"BW_2*;6?\ Q-?]G'_"OTWHH^MT/^A9@?\ P9F7
M_P \/ZN_*Q_9N-_Z*#-__!.0_P#SD/S(_P"&K/\ @HM_TBFUG_Q-?]G'_"C_
M (:L_P""BW_2*;6?_$U_V<?\*_3>BCZW0_Z%F!_\&9E_\\/ZN_*Q_9N-_P"B
M@S?_ ,$Y#_\ .0_,C_AJS_@HM_TBFUG_ ,37_9Q_PH_X:L_X*+?](IM9_P#$
MU_V<?\*_3>BCZW0_Z%F!_P#!F9?_ #P_J[\K']FXW_HH,W_\$Y#_ /.0_,C_
M (:L_P""BW_2*;6?_$U_V<?\*/\ AJS_ (*+?](IM9_\37_9Q_PK]-Z*/K=#
M_H68'_P9F7_SP_J[\K']FXW_ **#-_\ P3D/_P Y#\R/^&K/^"BW_2*;6?\
MQ-?]G'_"C_AJS_@HM_TBFUG_ ,37_9Q_PK]-Z*/K=#_H68'_ ,&9E_\ /#^K
MORL?V;C?^B@S?_P3D/\ \Y#\R/\ AJS_ (*+?](IM9_\37_9Q_PH_P"&K/\
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M_0LP/_@S,O\ YX?U=^5C^S<;_P!%!F__ ()R'_YR'YM_\-0_\%!?^D7>L?\
MB9/[/-'_  U#_P %!?\ I%WK'_B9/[/-?I)11];H?]"S _\ @S,O_GA_5WY6
M/[-QO_109O\ ^"<A_P#G(?FW_P -0_\ !07_ *1=ZQ_XF3^SS1_PU#_P4%_Z
M1=ZQ_P")D_L\U^DE%'UNA_T+,#_X,S+_ .>']7?E8_LW&_\ 109O_P""<A_^
M<A^;?_#4/_!07_I%WK'_ (F3^SS1_P -0_\ !07_ *1=ZQ_XF3^SS7Z244?6
MZ'_0LP/_ (,S+_YX?U=^5C^S<;_T4&;_ /@G(?\ YR'YM_\ #4/_  4%_P"D
M7>L?^)D_L\T?\-0_\%!?^D7>L?\ B9/[/-?I)11];H?]"S _^#,R_P#GA_5W
MY6/[-QO_ $4&;_\ @G(?_G(?FW_PU#_P4%_Z1=ZQ_P")D_L\T?\ #4/_  4%
M_P"D7>L?^)D_L\U^DE%'UNA_T+,#_P"#,R_^>']7?E8_LW&_]%!F_P#X)R'_
M .<A^;?_  U#_P %!?\ I%WK'_B9/[/-'_#4/_!07_I%WK'_ (F3^SS7Z244
M?6Z'_0LP/_@S,O\ YX?U=^5C^S<;_P!%!F__ ()R'_YR'X=_MO?M&_MRZY^Q
M=^UYHOBW_@G'JO@?PKJ_[+_Q^TOQ-XTD_:P^!7B*/PAX?U#X4>++36?%$GA_
M2/\ B;:ZF@:=-<ZLVC:7_P 3'5%M#967^DSQ5^W_ .S1)++^SC^S_+/ UK-)
M\$OA3)-;-)'*UO*_@306D@:6)FBD:)R8S)$S1N5+(Q4@U\@?\%$/^4?_ .W/
M_P!F=_M-?^J5\;5]B_LX?\F\? ;_ +(Q\+O_ %!]"K6O5A5R^DX8>CATL963
M5&6(DI?N*&K^L5Z[O_A<5Y'+@\/6P^>8A5<=BL<Y93AFI8J&"A*"^N8E<L5@
ML'@XM/?WXSE=Z22LE[/1117F'T(4444 %%%% '^/9^V)_P G<?M3?]G&_&__
M -69XGKYRKZ-_;$_Y.X_:F_[.-^-_P#ZLSQ/7SE7]%8?_=Z'_7FE_P"D1/X1
MQW^^XS_L*Q'_ *>F%%%%;'*%%%% !1110 4444 %%%% !1110 4444 %%%%
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M^=66ZL[G] M%?S]?\+'^(?\ T/GC/_PJ-<_^3J/^%C_$/_H?/&?_ (5&N?\
MR=7X7_Q5J\./^C2\;?\ AYR(^V_XE8XA_P"BIR;_ ,),<?T"T5_/U_PL?XA_
M]#YXS_\ "HUS_P"3J/\ A8_Q#_Z'SQG_ .%1KG_R=1_Q5J\./^C2\;?^'G(@
M_P")6.(?^BIR;_PDQQ_0+17\_7_"Q_B'_P!#YXS_ /"HUS_Y.H_X6/\ $/\
MZ'SQG_X5&N?_ "=1_P 5:O#C_HTO&W_AYR(/^)6.(?\ HJ<F_P#"3''] M%?
MS]?\+'^(?_0^>,__  J-<_\ DZC_ (6/\0_^A\\9_P#A4:Y_\G4?\5:O#C_H
MTO&W_AYR(/\ B5CB'_HJ<F_\),<?T"T5_/U_PL?XA_\ 0^>,_P#PJ-<_^3J/
M^%C_ !#_ .A\\9_^%1KG_P G4?\ %6KPX_Z-+QM_X><B#_B5CB'_ **G)O\
MPDQQ_0+17\_7_"Q_B'_T/GC/_P *C7/_ ).H_P"%C_$/_H?/&?\ X5&N?_)U
M'_%6KPX_Z-+QM_X><B#_ (E8XA_Z*G)O_"3''] M%?S]?\+'^(?_ $/GC/\
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M'M_[G_DW_P!J?2%%?-]%'U#_ *>_^2?_ &X>W_N?^3?_ &I](45\WT4?4/\
MI[_Y)_\ ;A[?^Y_Y-_\ :GTA17S?11]0_P"GO_DG_P!N'M_[G_DW_P!J?2%%
M?-]%'U#_ *>_^2?_ &X>W_N?^3?_ &I](45\WT4?4/\ I[_Y)_\ ;A[?^Y_Y
M-_\ :GV]X>_Y ]G_ -O'_I5/6U7R3H?_ ""[7_MO_P"E,U:U'U#_ *>_^2?_
M &X>W_N?^3?_ &I]045\OT4?4/\ I[_Y)_\ ;A[?^Y_Y-_\ :GU!17R_11]0
M_P"GO_DG_P!N'M_[G_DW_P!J?4%%?+]%'U#_ *>_^2?_ &X>W_N?^3?_ &I]
M045\OT4?4/\ I[_Y)_\ ;A[?^Y_Y-_\ :GU!17R_11]0_P"GO_DG_P!N'M_[
MG_DW_P!J?4%%?+]%'U#_ *>_^2?_ &X>W_N?^3?_ &I]045\OT4?4/\ I[_Y
M)_\ ;A[?^Y_Y-_\ :GU!17R_11]0_P"GO_DG_P!N'M_[G_DW_P!J?4%>8^(?
M^0Q>?]N__I+!7EM>>ZY_R%+K_MA_Z30T?4/^GO\ Y)_]N'M_[G_DW_VI[U17
MS?11]0_Z>_\ DG_VX>W_ +G_ )-_]J?2%%?-]%'U#_I[_P"2?_;A[?\ N?\
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M^&]QXE\+ZO::=XQT+PSX9^'_ (DU#P-H7C;PAH5OK6H:_=U\@?\ !./XH_\
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M\(_#W4]+&MKH6KVT/B.7Q5>^)4?^R?$]GIFG_6W[#7[&'[//Q&_9U_X)H_\
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M5]?VH?\ !G]_SD._[M+_ /?F:^;XN_Y)[,/^Y3_U.PQ]]X7_ /)<Y'_W4_\
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M2A*48U8I<M6IAY2MB*5.=#EJ.HJ<^2T7]ACX)?L8_%F+]J;]GSQ!+^S5\$_
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M_ ?_ *%O5/\ PI=<_P#DVC_ACGX#_P#0MZI_X4NN?_)M'_%*'Z0__1:^"O\
MXD/'?_TMP_XFBX!_Z$W&/_A!DG_T0GXTT5^RW_#'/P'_ .A;U3_PI=<_^3:/
M^&.?@/\ ]"WJG_A2ZY_\FT?\4H?I#_\ 1:^"O_B0\=__ $MP_P")HN ?^A-Q
MC_X09)_]$)^--%?LM_PQS\!_^A;U3_PI=<_^3:/^&.?@/_T+>J?^%+KG_P F
MT?\ %*'Z0_\ T6O@K_XD/'?_ -+</^)HN ?^A-QC_P"$&2?_ $0GXTT5^RW_
M  QS\!_^A;U3_P *77/_ )-H_P"&.?@/_P!"WJG_ (4NN?\ R;1_Q2A^D/\
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MT?\ "!Z/_P _.I?]_K7_ .0Z/KE'O+_P%A[&?E]YY+17K7_"!Z/_ ,_.I?\
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M/R^\\EHKUK_A ]'_ .?G4O\ O]:__(='_"!Z/_S\ZE_W^M?_ )#H^N4>\O\
MP%A[&?E]YY+17K7_  @>C_\ /SJ7_?ZU_P#D.C_A ]'_ .?G4O\ O]:__(='
MURCWE_X"P]C/R^\\EHKUK_A ]'_Y^=2_[_6O_P AT?\ "!Z/_P _.I?]_K7_
M .0Z/KE'O+_P%A[&?E]YCZ'_ ,@NU_[;_P#I3-6M7IF@?#[16TBT8W6J9/G]
M)K3'%U,/^?+VK8_X5YHO_/UJG_?^T_\ D*CZY1[R_P# 6'L9^7WGC=%>R?\
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MW^M?_D.CZY1[R_\  6'L9^7WGDM%>M?\('H__/SJ7_?ZU_\ D.C_ (0/1_\
MGYU+_O\ 6O\ \AT?7*/>7_@+#V,_+[SR6BO6O^$#T?\ Y^=2_P"_UK_\AT?\
M('H__/SJ7_?ZU_\ D.CZY1[R_P# 6'L9^7WGDM%>M?\ "!Z/_P _.I?]_K7_
M .0Z/^$#T?\ Y^=2_P"_UK_\AT?7*/>7_@+#V,_+[SR6BO6O^$#T?_GYU+_O
M]:__ "'1_P ('H__ #\ZE_W^M?\ Y#H^N4>\O_ 6'L9^7WGDM%>M?\('H_\
MS\ZE_P!_K7_Y#H_X0/1_^?G4O^_UK_\ (='URCWE_P" L/8S\OO/@7]N+_DR
M#]M;_LSO]J7_ -4/X_K],?V</^3>/@-_V1CX7?\ J#Z%7PE^W_X2TW3/V"_V
MX+ZWGOGE@_8[_:>V+-) T9\WX(>.H6W!+:-CA9&(PX^8 G(R#]V_LX?\F\?
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M\H]?Z>GS'17TY_PT1X0_Z--_9C_\ /CA_P#/SH_X:(\(?]&F_LQ_^ 'QP_\
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M/^C3?V8__ #XX?\ S\Z/^&B/"'_1IO[,?_@!\</_ )^='M*O_0/4_P# Z/\
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MZOA/^AA2_P#"?$__ "OU_IZ'U_,O^A'B?_"W+O\ YI/TXHK\Q_\ AW+\0O\
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M(7_24/\ X*9?^')_9J_^A6H^KX3_ *&%+_PGQ/\ \K]?Z>A]?S+_ *$>)_\
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M\+<N_P#FD_3BBOS'_P"'<OQ"_P"DH?\ P4R_\.3^S5_]"M1_P[E^(7_24/\
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MU?\ T*U'U?"?]#"E_P"$^)_^5^O]/0^OYE_T(\3_ .%N7?\ S2?IQ17YC_\
M#N7XA?\ 24/_ (*9?^')_9J_^A6H_P"'<OQ"_P"DH?\ P4R_\.3^S5_]"M1]
M7PG_ $,*7_A/B?\ Y7Z_T]#Z_F7_ $(\3_X6Y=_\TGZ<45^8_P#P[E^(7_24
M/_@IE_X<G]FK_P"A6H_X=R_$+_I*'_P4R_\ #D_LU?\ T*U'U?"?]#"E_P"$
M^)_^5^O]/0^OYE_T(\3_ .%N7?\ S2?IQ17YC_\ #N7XA?\ 24/_ (*9?^')
M_9J_^A6H_P"'<OQ"_P"DH?\ P4R_\.3^S5_]"M1]7PG_ $,*7_A/B?\ Y7Z_
MT]#Z_F7_ $(\3_X6Y=_\TGZ<45^8_P#P[E^(7_24/_@IE_X<G]FK_P"A6H_X
M=R_$+_I*'_P4R_\ #D_LU?\ T*U'U?"?]#"E_P"$^)_^5^O]/0^OYE_T(\3_
M .%N7?\ S2?IQ17YC_\ #N7XA?\ 24/_ (*9?^')_9J_^A6H_P"'<OQ"_P"D
MH?\ P4R_\.3^S5_]"M1]7PG_ $,*7_A/B?\ Y7Z_T]#Z_F7_ $(\3_X6Y=_\
MTGZ<5YCXA_Y#%Y_V[_\ I+!7PK_P[E^(7_24/_@IE_X<G]FK_P"A6KS_ %O_
M ()Y>/X=4NHS_P %-/\ @I),5\G][-\1?V<6D;-O"WS%/V7D4[<[1A!\H .3
MDD^KX3_H84O_  GQ/_ROU_IZ'U_,O^A'B?\ PMR[_P":3]$**_-K_AWOX^_Z
M28?\%'__  XG[.?_ -##1_P[W\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_
M  GQ/_ROU_IZ'U_,O^A'B?\ PMR[_P":3]):*_-K_AWOX^_Z28?\%'__  XG
M[.?_ -##1_P[W\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_  GQ/_ROU_IZ
M'U_,O^A'B?\ PMR[_P":3]):*_-K_AWOX^_Z28?\%'__  XG[.?_ -##1_P[
MW\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_  GQ/_ROU_IZ'U_,O^A'B?\
MPMR[_P":3]):*_-K_AWOX^_Z28?\%'__  XG[.?_ -##1_P[W\??]),/^"C_
M /X<3]G/_P"AAH^KX3_H84O_  GQ/_ROU_IZ'U_,O^A'B?\ PMR[_P":3]):
M*_-K_AWOX^_Z28?\%'__  XG[.?_ -##1_P[W\??]),/^"C_ /X<3]G/_P"A
MAH^KX3_H84O_  GQ/_ROU_IZ'U_,O^A'B?\ PMR[_P":3]):*_-K_AWOX^_Z
M28?\%'__  XG[.?_ -##1_P[W\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_
M  GQ/_ROU_IZ'U_,O^A'B?\ PMR[_P":3]):*_-K_AWOX^_Z28?\%'__  XG
M[.?_ -##1_P[W\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_  GQ/_ROU_IZ
M'U_,O^A'B?\ PMR[_P":3]):*_-K_AWOX^_Z28?\%'__  XG[.?_ -##1_P[
MW\??]),/^"C_ /X<3]G/_P"AAH^KX3_H84O_  GQ/_ROU_IZ'U_,O^A'B?\
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M^3N/VIO^SC?C?_ZLSQ/7SE7T;^V)_P G<?M3?]G&_&__ -69XGKYRK^BL/\
M[O0_Z\TO_2(G\(X[_?<9_P!A6(_]/3"BBBMCE"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O[4/\ @S^_YR'?]VE_
M^_,U_%?7]J'_  9_?\Y#O^[2_P#WYFOF^+O^2>S#_N4_]3L,??>%_P#R7.1_
M]U/_ -4^8']J%%%%?B9_704444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%07%U:V:"6[N;>UC9Q&LEQ-' A<A
MF"!Y652Y568*#DA6(& <4O[<T7_H,:7_ .#"T_\ CU-1D]5%M=TFQ77=?>:E
M%9?]N:+_ -!C2_\ P86G_P >H_MS1?\ H,:7_P"#"T_^/4^2?\LO_ 7_ )!=
M=U]Z-2BLO^W-%_Z#&E_^#"T_^/4?VYHO_08TO_P86G_QZCDG_++_ ,!?^077
M=?>C4HK+_MS1?^@QI?\ X,+3_P"/4?VYHO\ T&-+_P#!A:?_ !ZCDG_++_P%
M_P"077=?>C4HK+_MS1?^@QI?_@PM/_CU']N:+_T&-+_\&%I_\>HY)_RR_P#
M7_D%UW7WHU**R_[<T7_H,:7_ .#"T_\ CU']N:+_ -!C2_\ P86G_P >HY)_
MRR_\!?\ D%UW7WHU**R_[<T7_H,:7_X,+3_X]1_;FB_]!C2__!A:?_'J.2?\
MLO\ P%_Y!==U]Z-2BLO^W-%_Z#&E_P#@PM/_ (]1_;FB_P#08TO_ ,&%I_\
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M^.T?VSH__05TW_P.M?\ X[1R3_EE_P" O_(+KNOO1I45F_VSH_\ T%=-_P#
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MI45F_P!LZ/\ ]!73?_ ZU_\ CM']LZ/_ -!73?\ P.M?_CM')/\ EE_X"_\
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M==U]Z-2BLO\ MS1?^@QI?_@PM/\ X]1_;FB_]!C2_P#P86G_ ,>HY)_RR_\
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MO_QVCDG_ "R_\!?^077=?>C2HK-_MG1_^@KIO_@=:_\ QVC^V='_ .@KIO\
MX'6O_P =HY)_RR_\!?\ D%UW7WHTJ*S?[9T?_H*Z;_X'6O\ \=H_MG1_^@KI
MO_@=:_\ QVCDG_++_P !?^077=?>C2HK-_MG1_\ H*Z;_P"!UK_\=H_MG1_^
M@KIO_@=:_P#QVCDG_++_ ,!?^077=?>C2HK-_MG1_P#H*Z;_ .!UK_\ ':/[
M9T?_ *"NF_\ @=:__':.2?\ ++_P%_Y!==U]Z/DW_@HA_P H_P#]N?\ [,[_
M &FO_5*^-J^Q?V</^3>/@-_V1CX7?^H/H5?%G_!0K4]-N/V!/VXK>WU"QGGG
M_8__ &EX888;NWEEFEE^"_C5(XHHTD9Y))'941$4L[$*H)(%?:?[.'_)O'P&
M_P"R,?"[_P!0?0J[))K+J=TU_MM;=-?\N*'<\F+3SZM9W_X2,/\ ^IN*/9Z*
M**X3UPHHHH **** /\>S]L3_ ).X_:F_[.-^-_\ ZLSQ/7SE7T;^V)_R=Q^U
M-_V<;\;_ /U9GB>OG*OZ*P_^[T/^O-+_ -(B?PCCO]]QG_85B/\ T],****V
M.4**** "BBB@ HK_ $!?^":/@/0OCY_P;_?!K]D?5Y-'@U7]JGX=_MO?#CX>
M7.LP)>0V_P 4M&^)OQM\<>"+Z.Q=E^V-H%YX<NO%OEP%+V)O#<=S:3VTD!G3
MHOV6OAAIW[-O_!OS\9/@)J-M9V/Q2\6?\$S?VKOVJ/B9IS6::1KUC%\<_ 'Q
M.O\ X?/K^DNS:A'?)X2L(_"$UUJ:QSO/X"FM8XX1;2:?IWR=7BF%*>(I?4W*
MM0S19>J?UBWM*/M*U)XWF]@^6*J490=*TO><5[74_3<-X;U<12P.)6:J&%QG
M#G]MRK?4N;V.,]A@\2LIY/KB=2;H8VE56)O!>S4Y?5URV?\ GL45_0!^U9_P
M2H_9Y^!G[5O_  2=^!?A+QE\9]1\)?MVZ;^SI>?%S4?$7B'P/=^(_#DOQ=^)
M'@[P?XD7X<7>F?#O2-,TB.QTSQ#>SZ&/$VD>+VMKZ*UEOVU.W26UG_67X!_L
MT_";]CSX _\ !QK^S5X<U;XB:Y\'?A1X?^%6B'5M;O\ PUJ?Q+O?"VH?"+QA
MX@UZ07]CH/ACPO<Z^L>L:E%I#G0=.TY7CLDO(G59YI>^MG^%A0I5J,*E:594
MIP@[TKTIYA1R^<G)QG:4*M7F4+>^HVYHI\R\7!\%9C6Q>(PV+K4<)#"RQ%*K
M6BUB+8BEDF)SRE34%.E>%;#X=PE5Y[4I2OR3<>67\35%?WM?M0_#']CG3?BS
M_P $$O /P)O/VB/@1X\UJS\*:G^S-K_P_P##/[.>F:!X;^&?B^Q\*>*/'WB_
MXIZ'KG@GQAX9NOCYKVI:MI'B&XO=*\$^(O!.M>*M6\:ZOXAL[ZYO;.Y?XF_:
M#_X)J_L9^-M7_P""J_[:/[<?[17[6U\/V7?VM?#_ (#UGQ5X%L_@5-XP^)6A
M:EX0^!\EGIDO@[1/@YX/\'+\2/&&M^/QX,T#7-)C\#^ O#4EUH_B+Q1HDFDZ
M/X@NK[GH<2T*GLI5<-6HQJP;A!*=6O*<L=]1I1C2C2491G.UY*KSQJ<U)4Y*
M/M'VXSP_QN'>(AA\?A<3/#5(1K59.CAL'3I+)HYQB)U,34Q+G3E1I.2C&6'5
M.I14,0Z].4_81_C^HK^OO]CS_@G[^S?\'?VQ_P#@D'^WA^Q%\3/BWX[_ &6O
MVFOB1\2/!C:!^T!8^&;3XN^ ?B;X4^'WQ9M=3TK5[OP9H^@>&M0M)KKPMXMT
M2XM=/TN6TTO4O"$FIZ/XK\:^'_%6E7^FX7CG_@E5\.?VE/VB_P#@JA^VS^T)
M8?M=^/?A3\/OVXOBK\&_!/P(_86^&>E^/_VD?B'XYF\7^&=3UGQ;81^*M(US
MPW#X"\'Z+XOC_M2!M+634IH=:N?^$FT2[\+VOA[QIL^(L'&LX2C4C25",W*4
M91K+$O&5,$\)+#N"<*D*E-N4Y5%%*[=H+G?-'@3-9X6%6G4HU,1/&3I*G"5.
M>$> CE.'S>&:0QT*LHU*%3#XB"A3A1=1RM&+E5E[%?R0T5^JG_!67_@G78?\
M$]_C+\-]/\!ZU\1/$GP-^/OPJT;XP?"/4?BWX4E\%?%/P[8ZC/+!K/PU^)_A
MNZTWP]>Z?\1/!*R:-/XEAN?"GA26V_X2*PL+SP_I.L66K:=9_P!<?_!'O_AM
M7_AR/^R;_P ,+?\ #+G_  M3_A9_QK_X2;_AK/\ X6Q_PK__ (5__P +A^,_
M]H?V%_PI[_BH_P#A,?\ A(_^$8^Q?VA_Q)/[$_M[S_\ 3O[/IX_/:.%R_"YC
M0A#$4L77A1A[6L\)&'/"M*4JDW1K.+A*BZ<H.%U)O56UC).#,5F>>9ED>-K5
M<#B<LP5;&55AL)',JE;V=;"4X0H4HXK"QJ1K4\7&O3JQK-.FDU%\]X_YY%%?
MWZ_M[?L;?L\_\%#/VZ/^"?W[,G[5'BOP1HG[8,_P"^..O_M@ZC^QGJNBZ/=:
M;=^'?"/PT\0_#;3+Z^^)WA?QQXIM_"\VIW7BRY^&UGXYT9_$4OA&\UB]E%A;
MZAI$DGXI_#O_ ()=?\$XOV@OC9\;-#^#_P :?VO/ 7[.W_!/SPO\4?%/_!0#
MXT_&/2?@_K%QXG3P%KITS1-/_9A\-?#K3[O7M+LO%VE^ _C)XCBUSQWH/C+5
M=/LM.\)Z=%X)U36[F33=5SPO$F$K4(5:U&O0E[!8BI&-.=>G3ISKUL/1<:L8
M0=18FI1Y</RTE*K[2G:*YFUMF' 6987&5,/A<5@L936,>"H3J5J>#KUJU/!X
M3'8N,\-4JU(T'@,/BN?'.=>4,.L/B.:HW!*7\VU%?T!^-_\ @E9^RY^TS^RY
MX._:T_X)=_%?XXZEX87]H[X<_LM?%+X3_MDV7@C3?'WA7Q[\6?''@_P)X)\3
MVOB;X1:,?#+^&Y]8^)/P\-UIFGZ=XGE.D:[J&J)X@BUK0M1\&)]P>#/^",/_
M  28US]NO0/^":UY^TO^VEJO[3G@?P%%XL^-/B33-)^#N@_"#QAKEM\-[?Q1
MJO@CX77E_P"$-=\4>"?%D8UO1OB,+77]/^)WA>R\#:;K_@B?QM=>.BFH6'14
MS_ 4XS<EB>>E'$2KT5AJKJX>.%5-UI5X)6IQ7MJ7+*[C)5(RBW'F<>.CP5G=
M>I2C!Y>J6)G@:>"Q4\?AXX;'5,Q=986G@ZCE>M4E]6Q//3454INA4A.*J<D)
M?R.45_35>?\ !,+_ ()=? ;]A+P[^VI^UK\2_P!M]++7/VG_ (X_L[6'@SX#
MZA\$-6UOQ#>^ _BW\9/!O@YM)M?'/P^TO3=)N(_!?PJNO$?C#5]:\3_V;>7U
MO>6NB6&GW.IZ/I(]E_82_P""(W["7[7G@+X3:M W_!3#7]4^+'AG7OB!JWQ0
M\+?#_P "?"K]G'X(Z'>75P?"/@GQ%X^_: ^%7A"Z^/?BW23Y/ACQ%XB_9GA^
M(6@Z]XBL-5U>#2?!?A3R-16:G$& I4JM><<2J-&M/#SJNA)4_:T^?VD8S;47
MR\EM_>E*,(<TWRET.!\ZQ&(PV$I3R^6*Q6$HXZGAEC:;KK#XGV/L)SI1C*<7
M4]LG;E?)"%2K5Y*,/:/^3"BOZ8/AW_P21_8*^&O[&O[5G[4O[9?QB_:FEC_9
M._;8^*O[+>N0_L\V_P ++:7XC:3\/_&GACX>Z/=>%?!_Q"\.:H-#\3^(M<U^
M36+JZUOXC7.AZ/HMK+;FUO+J$7%S]9:W_P $)/\ @E[X)_;$^$7[)'BK]I3]
MLK6/&7[87@36/B1^S'IOAK1_@]96WPX\+>#/A]J?B/6Y_CQXQU3PO=/XPN_&
MVJZ!XFN_ L'@?X?>"8=*LO#U]X=\37+WD^G^)KI3XBRZ$JD?]JDJ?M[SAA:L
MH2^K4Z=;$<LDO^75"K&M-R44H75W-Q@ZI<"9]6A0FGET'7^I6IU<PP].K3_M
M&O7PF"]I!RO?$XO#U,+34.=NJD[*DI58_P =M%?U,_LV?\$-OV:+G]G'XA?'
M+]H#6_VV_P!H75/!W[6?Q)_9EU;P-^P#X-^&NO>,?AK9_#'XC>(?AMJ7C[X@
M_#[Q?IOCSQYXBTV_N-+T;Q;?Z-\/M(U+Q?X4\*^)]&U%O"?B71WU'Q#I?\^?
M[6OPX^"7PF_:'^)W@']G3XMZM\;O@SH&O&'P1X]\1^!/%WPU\62V,UK;W%YX
M;\8>#_&WAWPKKEAXJ\%ZI+?>$M=O?[!TJPUV^T:37M.TS2+74H]&T_LPF:83
M&UZV'P[JSE0<E4J.E.-+FBXJ4?:-64KR3C&:@ZD5*=-3A&4EY.9<.9EE&#PF
M-QT<-2AC5"5&BL51GB7"I&<H5'0C)RE3:IR4ZE)U(T9N%+$.E5J0A+YRK^U#
M_@S^_P"<AW_=I?\ [\S7\5]?VH?\&?W_ #D._P"[2_\ WYFO,XN_Y)[,/^Y3
M_P!3L,?0^%__ "7.1_\ =3_]4^8']J%%%%?B9_704444 %%%% !1110!R.M?
M$'P%X:\4^"O _B+QOX0T#QK\29]?MOAUX/UKQ+HVE>*?'USX4T=_$/BBW\%>
M'[Z]@U;Q3/X;T"*77-?BT.TOY-'T>-]3U%;:R1IPWQ%\0_ 'A#7/!OACQ;XY
M\'>%_$OQ%U6]T/X?>'O$7B;1=$USQWK>FZ=-J^HZ/X-TG4[VVO\ Q/JMAI-O
M/JE[I^B6]]=VNG0S7L\,=M&\J_EW^VG_ ,I1/^"+?_8Z?M[_ /K(&MUG_P#!
M1'_D^/\ X(W_ /9TGQF_]9Z\65Z=+ PJ2P:=22^M8#&8R5DO=EAIYA&,%WC+
MZE&[>JYY6V1\_7SBK2CFK5&F_P"S\[RK*H7E+]Y3S&GD4YU9=ITWFU11BO=:
MHPO\4C]A**_FED_:+_X*+ZE^Q'^U7^W79?M>:9I3_LP?%_\ :FLO!GP7/P&^
M$%[X.^)GP[^!GQP\8:1_9/Q7\2R^&1XTAUJ3PU8R^#O#E_\ #;5? /V/3O#V
M@ZOXF?Q5XBU/7]7N/L[PU\8OVKOVS_VF_P!HGP7\#OC_ &7[+GPP_95T'X&:
M2EAI_P *? GQ7U3XM?%OXP?"G3/C#JD7CJ_^(&FM=Z;\,_!6F>(-!\+C3? /
M_"%>+?$U_P#VWJ5OXQTBVBT\2W4RBK3]I*6)PGLZ$JL*]1/$.-&=*>&IN,E]
M6]I)RGBJ,8NE"I'63DXJ$FLZ/$V&KNA"G@,R]MBX8:I@Z#C@E4Q5+$TL=6C5
MIR>.]C3A3I9?BIU5B*M"=HP5.%256FI?IYH7QP^"WBF3P5#X9^+_ ,+O$<WQ
M)O?&^G?#J+0O'_A/5Y/'VH?#.\O=/^)%AX*33]6N&\4WOP_O]-U&Q\;VNA"_
MG\*7EA>VVO1V$UK.D?J%?RZ?L$^//B3X>\ ?\$CM%T[PSX!U;Q?XL\:_\%G[
MW4]&O/#7@W5KEO&?ACXJ?&S6=,T3P9\2_%'AV[\9_#W2=1\2.=,UC4O"&L^&
M&\2:(T-IXM35-,@2QC]'_9 _;J_: \9_&[]GWP)\:/VRW\#_ +1'C+QA/HG[
M0_["/[5W[,%G^SUI&FZ;/H.LRZE;_LC?$_0/AG:ZK\0?$OAKQ1#HVG^%+'Q=
M\4_&MKX_T&:^U6[E\/W=QH.GZOO7R2K"6(]C5A.&'6(<N;VDZDHT<7CL,I<M
M&C44(M8.\JE1QHQE.*=5<UH\>"XNH5J>"^M8>K3JXYX&$.1T*=&%3%Y9DV.=
M-U,5BJ,JM12S91A1H1J8J=.C4<</+V?-/^D2N5\/^._ _BW5?%NA^%?&7A3Q
M-K?@#6X?#7CO1_#_ (ATC6M5\%>([C2['7(- \6Z?IMY<W?AO6Y]%U/3=7AT
MK68;*^DTO4+'4$@:TN[>:3\;/A%XK_X*-?MJ_#GXA_M6_ O]ISP5\#]*?XR?
M%KP?^S?^SAXG^$?@/Q)\(_%G@7X*?%/Q)\*;B_\ CY\0IO#WB;XV6FO^/M8\
M&^)9[RY^&FN>&;7P@%TV73]#\06S2)=?+-G^T1\7?@U\<?VV?AQ\(=0\*>%O
MCM^UE_P5=^!W[.F@>,M9T:X\8^&?A=%XC_9#^&OBKQ_\1;/0KQM'M_%=UX5\
M/^$]2@\*:+K,EE;:OKVIZ-+JMC)ID&J6Z90RB<Y8BE]8H2KT(WJ4X2J/V$XU
MJ%.M'$.5**M2C4J.4J'MDY49QBY-)2Z*W$]*G#!8CZEC(8/&5+4:]6-!/&4J
MF%Q5;"SP4:>)F^?$U*%&$*>+6%FH8FE*<8*3</Z8Z*_$CXA_&7]O;]D'XNW?
MP ?XB)^W)KOQU_9*_:6^*W[,6K>,OA]\-/AC\0]+_:$_9RT;POJ-W\/?$5G\
M)]*\#^"O$W@+QC;^//#L^AD^'-&\1PZW&N@SZ]+93W6M6ODO[$G[=GCKQ?\
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M2_$?_HX'&W_B59[_ /-Y_1'^KG#W_0BR;_PUX'_Y0=G_ ,+'^(?_ $/GC/\
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M5DZ'_P @NU_[;_\ I3-6M0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_:KV]><H5*TJ=6E^E/[</_!13X%?&_\ X)]^ ?V*_ ^C?$67XC_#3]N/X_\
MQ[U+QG?Z1X6B^%^N^!O'_P 0OVAM=\/IX9UJS\97_B>\UA]/^*7AV2YM]1\'
M:5IZ-;ZJ(-3N$@LWO_T8^&7_  7=_8/_ +&_X)\_$7XQ?!+]L&W^-O[$/@'0
M_AKI_P (_A-XM\ Z=^R.CP>'?^%3ZE\7=$\,ZIXLTS6]7\<:+\+)M8OO OAB
M\T#PM8:9<^(KOX9:WXRUO0M+TWQ^/Y(:*[JF18"K1C1FJW+&MB:W-&M.$W+&
M1E'$Q;C;W*L9-.*2<5I&23=_(H<9YUAL54Q=*6$<YX7+L)R5<+2JTXPRF=.I
ME]2,9IOVV'G2C)3;<9RNZD)-1Y?Z#_VCO^"J?[,OQ/\ V#?VY?V5/ WA;X[#
MQG^TS_P4 ^(?[6G@+7O%GA#X?Z/X8T;P)XZ^)'A+Q['X<\7W.C_%3Q'JMIXM
MTN+2=4TMX]&T;6M&OI(["\74[-;VXM=.]U^(G_!:_P#97\7?\%/O^"?G[:NF
M^ /V@8/A9^RC^SYKGPG^(F@7WA7X<Q?$#6?$6I^!_B[X9@O?!>E0?%:Y\.ZC
MHJ7_ (^T>::YUSQ5X<OEM+;4Y$TV2:&UM[S^7NBFLBP"C*/+5:E'&1E>J[OZ
M]AZ6%Q#T2UE2HPY?Y97DEK9+_7+.O:0J*>&4J<LJG!+#JR>38[$9C@M')MJ.
M)Q-5U+M^T@XP?PW/Z&_@W_P4<_X)Y67C7]I'QUXS\._\%'_V7/BA\3/VE?B9
M\7-$_:,_8&^/=OX1^)/QB^&OCOXF_$CQUH/PW^/_ ,,/B%\1I/@[X?B\!6OB
M3PU;VX\#Z=XF3Q+=63K>7^E#3=8O?B'\ ?\ !5C]N'PG_P %"_VSOB!^TGX'
M^%,/PG\+ZOIF@^$-$L;MK"7QIXPT;P5!/HN@^//B;<:7OTP^.]:T"/2K&\TS
M3[S6;'PMH>D:!X-M/$GBFW\.1^)-5_..BMZ&587#XKZW#VTJRI2HQ=2M.I&%
M.?LN>,%)MJ+=&#46W"FERTHTX>Z<6,XCS+'9=_9=7ZK#"O$0Q514,)1H3K5J
M7M_95*LJ<8IS@L364JD8QJUW+GQ,ZU3WPK^U#_@S^_YR'?\ =I?_ +\S7\5]
M?VH?\&?W_.0[_NTO_P!^9KS.+O\ DGLP_P"Y3_U.PQ]!X7_\ESD?_=3_ /5/
MF!_:A1117XF?UT%%%% !1110 4444 ?%_P"V-^QY!^U-:_"/Q1X5^*GBGX"?
M'O\ 9X\?3?$CX%?&[PCH^B>)[WP?K>J:)>>%_%6B>(/!WB1#HGC/P/XT\-7\
MVE^*/#-U<:8VI+;V .II8QW^GZEX]\+_ -A'XOW?[0WPR_:5_;#_ &LIOVHO
M&GP'TSQG:_ GPIX8^"7A_P" /PR^'VM_$'1AX:\5^-[SPQI/C/X@:GXO\97?
MAI[O0M/U'6?$:Z=HUE>33:=I$.H+#>Q_IC177#'8JG1]A"<534*M.+=&A*K"
MG6YE5ITZ\J;KTJ=13FIPIU(QE[2I=?O)\WF5<GR^MBOKE2C4=9U</7G&.*Q<
M,-5KX5P>&KU\'"O'!UZ]!TJ3I5JU"I4@Z-'EDO8TN3\R[7_@G1]F_81_:8_8
MH_X7%O\ ^&BO$'[3&N_\+,_X5[M_X0__ (:*^('BGQU]E_X0S_A.&_X2#_A#
M_P#A)?[+\_\ X2O1/^$@^Q?;O)T3[3]C@;XF_8+^+GAKXI>*?BY^RM^U>?V>
M/$OQ<^'7PN\ ?'NRUCX':!\8=!\=W_PB\+MX)\'?$[PCI^K>-O"<OP_^)^G>
M#S#X;75+R[\;^%KO2]+T&+6O!^L2Z/!*_P"FU%6LQQB=1NK&7M:E2I4C.C0J
M0J3JNDYN=.=*5.2<J%&2BXN,)TXS@HR5S.6197*-&*P]2#PU&A0P\Z6+QE&M
M1I8:.)A15*O1Q$*T)1AB\33E4C452K3K3IU93@^4_(WX ?\ !*N/X&>$?V)/
M"#?M#^*/%47['+?MK(WB5?"+^'/&GQ'C_;"U7QCJ)U%?$5GXUOI/!/BCX>+X
MMWCQ%:VWB!_%.K6']K06/A-KE;2TGT;_ ()R?'?Q'J'[./AO]H_]N'6?VA?@
MS^RU\6?A]\:/AUH.L_ [1?#WQO\ %7C7X132WWPON_C!^T%/\0_%-WXX.A:J
M+'4?$5_I'@#P;KWCV2P \5:Q>R7VI3W?ZUT54LTQTI2G*K"4Y.HW-X?#N<95
M:N(K5)4Y.ES4I2J8JO+FI.$ES\L6HP@HYPX=RBG3ITJ>&J0I4E0BJ4<;CHTY
MPPV'P6%HPKTUB>3$TX4,NP=/V>(56$O9.4XRG5K2J?C]XH_X);>.)?#/QP^
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M **** "BBB@ K^U#_@S^_P"<AW_=I?\ [\S7\5]?VH?\&?W_ #D._P"[2_\
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MO_FDH_X9)_9\_P"B?_\ EU^-O_FDKZ.HKYC_ (EO^CO_ -&%\%__ !5O _\
M\XCTO^(A\?\ _1<\8?\ B39U_P#-I\X_\,D_L^?]$_\ _+K\;?\ S24?\,D_
ML^?]$_\ _+K\;?\ S25]'44?\2W_ $=_^C"^"_\ XJW@?_YQ!_Q$/C__ *+G
MC#_Q)LZ_^;3YQ_X9)_9\_P"B?_\ EU^-O_FDH_X9)_9\_P"B?_\ EU^-O_FD
MKZ.HH_XEO^CO_P!&%\%__%6\#_\ SB#_ (B'Q_\ ]%SQA_XDV=?_ #:?./\
MPR3^SY_T3_\ \NOQM_\ -)1_PR3^SY_T3_\ \NOQM_\ -)7T=11_Q+?]'?\
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M'P]_T#__ ";OO_DFNDHH]M5_Y^U/_ Y?YAR0_EC_ . K_(YO_A$?#W_0/_\
M)N^_^2:/^$1\/?\ 0/\ _)N^_P#DFNDHH]M5_P"?M3_P.7^8<D/Y8_\ @*_R
M.;_X1'P]_P! _P#\F[[_ .2:/^$1\/?] _\ \F[[_P"2:Z2BCVU7_G[4_P#
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M]_T#_P#R;OO_ ))KI**/;5?^?M3_ ,#E_F')#^6/_@*_R.;_ .$1\/?] _\
M\F[[_P"2:/\ A$?#W_0/_P#)N^_^2:Z2BCVU7_G[4_\  Y?YAR0_EC_X"O\
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MO\_+\^[/YJ?^(5?_ ()J_P#0Y_M7?^'/^'W_ ,YZC_B%7_X)J_\ 0Y_M7?\
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M ()J_P#0Y_M7?^'/^'W_ ,YZOH_]GW_@@K^SI^RE_P )=_PS?^U+^WG\%_\
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M^5^7Y]V']A97_P! \_\ PJQ?_P O\OS[L_,?_AVIJG_21?\ X*<?^)'^$/\
MYS]'_#M35/\ I(O_ ,%./_$C_"'_ ,Y^OTXHH_M'&?\ /V/_ ()H?_*_+\^[
M#^PLK_Z!Y_\ A5B__E_E^?=GYC_\.U-4_P"DB_\ P4X_\2/\(?\ SGZ/^':F
MJ?\ 21?_ (*<?^)'^$/_ )S]?IQ11_:.,_Y^Q_\ !-#_ .5^7Y]V']A97_T#
MS_\ "K%__+_+\^[/S'_X=J:I_P!)%_\ @IQ_XD?X0_\ G/T?\.U-4_Z2+_\
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M_P#"K%__ "_R_/NS\Q_^':FJ?])%_P#@IQ_XD?X0_P#G/T?\.U-4_P"DB_\
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M'_P30_\ E?E^?=A_865_] \__"K%_P#R_P OS[L_,?\ X=J:I_TD7_X*<?\
MB1_A#_YS]'_#M35/^DB__!3C_P 2/\(?_.?K].**/[1QG_/V/_@FA_\ *_+\
M^[#^PLK_ .@>?_A5B_\ Y?Y?GW9^8_\ P[4U3_I(O_P4X_\ $C_"'_SGZ/\
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M**/[1QG_ #]C_P"":'_ROR_/NP_L+*_^@>?_ (58O_Y?Y?GW9^8__#M35/\
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M^5^7Y]V']A97_P! \_\ PJQ?_P O\OS[L_+7_AUY_P!9"O\ @IA_XD9X/_\
MG/T?\.O/^LA7_!3#_P 2,\'_ /SGZ_4JBC^T<9_S]C_X)H?_ "OR_/NP_L+*
M_P#H'G_X58O_ .7^7Y]V?EK_ ,.O/^LA7_!3#_Q(SP?_ /.?H_X=>?\ 60K_
M (*8?^)&>#__ )S]?J511_:.,_Y^Q_\ !-#_ .5^7Y]V']A97_T#S_\ "K%_
M_+_+\^[/RU_X=>?]9"O^"F'_ (D9X/\ _G/T?\.O/^LA7_!3#_Q(SP?_ /.?
MK]2J*/[1QG_/V/\ X)H?_*_+\^[#^PLK_P"@>?\ X58O_P"7^7Y]V?EK_P .
MO/\ K(5_P4P_\2,\'_\ SGZ/^'7G_60K_@IA_P")&>#_ /YS]?J511_:.,_Y
M^Q_\$T/_ )7Y?GW8?V%E?_0//_PJQ?\ \O\ +\^[/RU_X=>?]9"O^"F'_B1G
M@_\ ^<_1_P .O/\ K(5_P4P_\2,\'_\ SGZ_4JBC^T<9_P _8_\ @FA_\K\O
MS[L/["RO_H'G_P"%6+_^7^7Y]V?EK_PZ\_ZR%?\ !3#_ ,2,\'__ #GZ/^'7
MG_60K_@IA_XD9X/_ /G/U^I5%']HXS_G['_P30_^5^7Y]V']A97_ - \_P#P
MJQ?_ ,O\OS[L_+7_ (=>?]9"O^"F'_B1G@__ .<_1_PZ\_ZR%?\ !3#_ ,2,
M\'__ #GZ_4JBC^T<9_S]C_X)H?\ ROR_/NP_L+*_^@>?_A5B_P#Y?Y?GW9^6
MO_#KS_K(5_P4P_\ $C/!_P#\Y^C_ (=>?]9"O^"F'_B1G@__ .<_7ZE44?VC
MC/\ G['_ ,$T/_E?E^?=A_865_\ 0//_ ,*L7_\ +_+\^[/RU_X=>?\ 60K_
M (*8?^)&>#__ )S]'_#KS_K(5_P4P_\ $C/!_P#\Y^OU*HH_M'&?\_8_^":'
M_P K\OS[L/["RO\ Z!Y_^%6+_P#E_E^?=GYAP_\ !,Z_MXUAA_X**?\ !3:*
M),[43]H_P@%7<Q9L#_A3_=F)/N34G_#M35/^DB__  4X_P#$C_"'_P Y^OTX
MHH_M'&?\_8_^":'_ ,K\OS[L/["RO_H'G_X58O\ ^7^7Y]V?F/\ \.U-4_Z2
M+_\ !3C_ ,2/\(?_ #GZ/^':FJ?])%_^"G'_ (D?X0_^<_7Z<44?VCC/^?L?
M_!-#_P"5^7Y]V']A97_T#S_\*L7_ /+_ "_/NS\Q_P#AVIJG_21?_@IQ_P")
M'^$/_G/T?\.U-4_Z2+_\%./_ !(_PA_\Y^OTXHH_M'&?\_8_^":'_P K\OS[
ML/["RO\ Z!Y_^%6+_P#E_E^?=GYC_P##M35/^DB__!3C_P 2/\(?_.?H_P"'
M:FJ?])%_^"G'_B1_A#_YS]?IQ11_:.,_Y^Q_\$T/_E?E^?=A_865_P#0//\
M\*L7_P#+_+\^[/S'_P"':FJ?])%_^"G'_B1_A#_YS]'_  [4U3_I(O\ \%./
M_$C_  A_\Y^OTXHH_M'&?\_8_P#@FA_\K\OS[L/["RO_ *!Y_P#A5B__ )?Y
M?GW9^8__  [4U3_I(O\ \%./_$C_  A_\Y^C_AVIJG_21?\ X*<?^)'^$/\
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MXD?X0_\ G/T?\.U-4_Z2+_\ !3C_ ,2/\(?_ #GZ_3BBC^T<9_S]C_X)H?\
MROR_/NP_L+*_^@>?_A5B_P#Y?Y?GW9^8_P#P[4U3_I(O_P %./\ Q(_PA_\
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M":'_ ,K\OS[L/["RO_H'G_X58O\ ^7^7Y]V?EK_PZ\_ZR%?\%,/_ !(SP?\
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MLI5:GUB<L11J7PU&-*I[>*I14J,Z\76C3PL^>NIPC#WIS2?72S/-ZF$S"I+
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M4(_$&MW6K>)==NM(\*^%+Z;4?L'1?V[?V6_$/Q$MOAGI7Q$U:;5;_P"(-_\
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M^*].U?PYJ_A[PUXH\":MIZWEM=^+=.U:./2YOU$D^$OQ(/\ P4=L_CLF@O\
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MBKX@^-_'&@_$V%?"?C&":Y\1ZA!XE-QK/AW5/$_@6&T\93^R2?LJ_M2?#O\
M:G^(_P"UGH/PFU3XE:;X+_X* ^-/C#X4^#6C_$/X;:'XD^*_P6^,W[&'PG_9
MN\4?$+X=7/BOQ?I'@72OB%\/O%6@W-_!X2^*GB;X8-XG\&Z/XQMK3Q%97]YX
M2M/$?74P&51FX0Q3DU1=9-XS".,Y^UG"&$YHTW3IU)+V;E6=25.FG*I*FZ:N
MO.H9SQ'.C&M5RZ$5+%0PDX1RO,U.E3^KT:M;,E3G6C7K8>G)UU#"1HTZU>48
M4(5U7]V?VW^Q5^V/<?M;>/OVQK'3H-)7X?\ P%^.WA[X6?#R\3P?XZ\"^-+C
M3[CX.?#SQEXJL/B=X7^(3V?B+0O'?AKQ]XC\4>%M8T#4/"G@K5/#C:,N@Z]X
M=@UW3M1N)^GM/^"A?[)%ZWQIFB^)&OPZ%^SOK/Q$\+_&7QS?_!WXW:9\,/!'
MC3X6>+(O _C/X?77Q7U+X<VGPUU7XEV_B>YL-/T#X:Z!XKU;QWXVBU?0M2\$
M^'O$6E:]HU]?>5?L#?#;XZ>&_BA^WI\6/C7\&KOX(P?M$?M)^'?B5\-O">I>
M,?AYXQUJ7P+IGP-^&/@.TO?$DWPW\4>+="TCQ4U]X5NX_%>C0ZOJ-A9>(UU2
M+P_K_BWPXNE^+-:^:KK]BO\ :%N?V6OCEH&G>"]!B^*VB?\ !5/XG_MX?#'X
M>>(O%/AZVT+XV>#?"O[9DGQ_\!^$]6\4:+=Z_IWA23XL>"=,M=/TN;Q/ LWA
MK5[W2+?QGINAV]MJ$FGXRP^7RQ-2,JBITT\NIP]EB:#BG5HP^M3E44)PJ^SF
MI*I."A"-23E*T5RG53QV>4\OH5*="5>O*.>5ZWUC 8R,Y+#XNI_9]*%!UJ57
M#^WHSC*C1J^UK5*5.-.GS3;F?=FE_P#!0C]DW4H=3-W\0?%'@_4="^(GPL^%
MWB/PO\3_ (*_'7X2>.O"WBGXW:G;:'\);KQ;\/OBA\-?"'CCPGX'\?:Y=1Z'
MX=^*/B/P_IGPQO-:2ZTC_A+TU&QO;:W[;QW^V-^SE\-M9^)WASQ=\09[7Q'\
M(+_X2:)XV\.Z1X)^(7BK7QXG^.SZ@OPE\$^$-%\*>%-;U/XE_$+QJNFSW&G?
M#SX:VOBWQO;64^EW^IZ!8V6M://?_G;\8/V8/BE^VAXN_:L^+/Q@^%OB']D_
MP9JW[%;?LW?"[3/B;XZ^$6L?$F7QUHOC[_A?>D_'G7KGX._$+XG_  V\#^&_
MA=X]T?PH?!<=U\1]6U^\U#2_$^NZSIOA/38]+.L>,_ #PG^VS\0/^">_AC]I
MGP1;^-],_:/_ &W/VBM%_:>_:%MOA5=?!:S^.NG?LZ^,] 3X:>$/#?P#\3?M
M'V^G_"#1/&GAOX"^&O@_=:/=^,%\/:?8:*WCB'PH=,\2ZEI-Q-:P& E",_K'
M+^]H49PEBJ+A3J5XTZL;XFG0G3=-4Z>,C4J1@U2J?5XR3]]2R>=9S&K*B\%[
M1>PQ>*HU*>6XR%6MA\'4K8>IRX"MBZ=>-:5?$97*C1J5(/$8?Z[.FTO92A]L
M_$[_ (*.>"KNP^'T?[/MU)JWBK_AM/\ 96_9D^-7@?XT_"#XU_"'Q]\/_#W[
M0NNZ6?[4F^&_Q4T'X2^/=(U/5O!^IIK7@+Q1J6@ZCX0U.2.Z>*VUY=/U"SM\
MCX$?\%(_#'Q]\1IIIN[GX)$_MO?$O]E?POX9^)7[/7[0T^J_%^R\!^$O'6I:
M=IGAWQ3K^C_"O1OAQ\1-8'@#Q!X[\41^)]%\46WPNTG3X_A5XU\-VWC;7="\
M2W7YZ>#/V'/VL9?CEX_\<P_ 'XN^$?AWXL_;(_X)>?&;PE;?'#]JS0/VA?BG
MIWPZ_9I\6_$6U^,FK_$;QEXO^./Q-UB/Q=I>G7>B^*O^$.\+^,/&GAR/0M;T
MCP_X!UC7=2TK5=&TKVWP]^R-^TY_PN'P-IVH?!WQ)HWA/P+_ ,%=?VD?VLKW
MXGV_COX1+H.J_ [X[_#']H;3O#_BGPG9V?Q$O/B!%KWA?6O%WA31?$F@Z]X%
MT/6;75=>LKWP[9>)=#T_7=7TGIGA,IA3G"%:G*<:2J0JRQ.%E4C*6&A5G3E&
M//2JRC6E[%1IKGC:3A)M2D<%+,N):M>A6J82M&G/$^QK8>&7YC3H2A#,98>G
M7IRJ.EB<-"6#B\7*5=^RG>*JTU"4:;_3;PK^W7^R[XT\<:/X"\/?$+6+B[\3
M^--=^&_@SQK?_"[XNZ%\$_B%\1/#5SKUEK7@#X:?M#:]X#TSX#?$KQO9WOA3
MQ;9+X3\!_$CQ%K]U>^$?%EI9Z?<7/AC7HM/E^%_[<G[,OQD^(&E_#7X?>.O$
M&IZ_XFA\<7/@/6=8^$WQB\&_#7XL6_PXU&'3?&<_P2^,GC7P!X>^$7QPAT@S
M'54E^$7CCQHFJ>%[>_\ &.CMJ'A/3=0UJV_*;]E/]A3QK\*_#O[+?P%^*/[(
M_P"T1XYUO]G7XD_#^YN_CIKW_!1[XJ6_[&K:?\%]>DU_P3\</AY^S_;_ +3/
MC?Q$WC&=]$\-ZMH7P%UK]E'P7\.K'Q;J&I^&;_QOHG@FPC\1:CZA^S3\!?VG
M_AA^T)\(O^%1?!;]HC]D;X)Z7J/B>Q_:2^#WQ!_:J^%'[2G[$>M^$-'L_BN-
M ;]DO0-5\4>.OVC_  !XQ\5^/O'7@OQ9I;:5X1_91^&6G> ? LFC>+_A@^O&
MVT'4^:K@LL2Q"HXBI*5.G.5&=7%8"-*HX^V::5*=6LW44(.%%4HSYGR5)T_:
MPDN_"YOQ!-X%XK T81KUZ5/%4L/EN<RKX>-3ZHI)RQ-+#86,:$JM;VV*>)G3
M]G'VE"CB'AZU.7[>T445X1]B%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '%?$3X:_#KXO>#M8^'?Q9\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img172674775_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img172674775_1.jpg
M_]C_X  02D9)1@ ! @$"6 )8  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M185V&43$Q48E1PFD92;_V@ , P$  A$#$0 _ +S)V'P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ235YV=45.K7+Z4Z%[A.%2*G!IQ?"M*(S4IU*4W3JQ<9K6FL&NHSE#D<
M
M
M
M
M
M
M
M
M
M
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MEP+0
M
M
M
M
M
M
M
M
M
M                                                        #C,U
MF<5KF'RFP9R]7QF&PF/N97*Y&T[P5J..H026KEJ=R(JI'!!$YR]$5>B>A%4X
MSG&G%SF\()8M] YTZ<ZLU2IINI)I)<;971[C>?=U[I^3*F*P%3+R:O%ETP_'
M&CU6NEM6IK4R4J^3N4ZZ*VSL6:5R*J*LB5F/]2QRM1SWPB^O*N85TH)\GCA&
M/[N%_<,G97EMOE%HYU''EMG&<^EIP3_!79UOH2E]J'93K7#-+&[KOM2EL?*\
ML45J-TO@N8C1Y'(KTJ8-J^*O:S$:.1)L@J.5KVJVLK6>)\T@R[*H6J56LE*X
M[$>ET>CUNC$<YSZK?2="V;A9ZN)SZ?0XH]?B6^Q>2.   $(7F\>;%DNP.+CK
MC_A7'\<[MSOM]E^Q[#K^_4]BS.#U'C6&"[3JY')4-7V74;\>:V?/-:S'^*]X
M6UZ-ITD*H^!Y<K"Q5TW*IBJ2XN%]7$M&:YG[@C&-+9=>3U/'0N/0UPZ%IX^(
M^CR;?,DYR\PVCW#6>:=5XHUB3B6UQ9!KB<7X/;\*RZS=X>0I,LN;3;-ZW5;+
MJZZG6]S^H6LC$?)X_6=6^#YF%G2M'!4W)[6.O#@PXDN,93F%:_C.5913BUA@
MGPX\;9-J6XNX  !B+F3A'C_G35I=8WK$1V?5LF?ALY6;'#GM<NS-:GNW#Y!6
M.?"KG1L66%WBKV$8C96/1$Z4UU:4;NGR=9=)\*Z3_<F5MCF%SE];E;>6'&N"
M2XFO-UK@( .6N*>4.T/EC&R5<M:IV:=I^:T'>L2BP0YBC!)ZMSUB<LT<-R*.
M7U&0H3>L9TD5J^M@E8^2&W%O<9;<+!X-:8R7#^[A7F&2;*\M,ZLWC%--83@^
M!]SABUV&FE.7VO\ <+B.XCCN+88XZ^.VW"20XO=L# YRQX_*NC<^"]1;*]\Z
MX;,Q1NEK*Y7*QS9(5<]T+G++,OO8WM#;U55HDNCQ])\'6X#'V;Y9/++GD]+H
MRTP?&N)]%</4?";(E>6H
M
M
M
M
M
M
M
M
M
M
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M/&6CJI\!8])R8N
M
M
M
M
M
M
M
M
M
M
M     *X/>OL%O=.Z/D.&-72MQF3P^GXNNZ1')$F(Q>/H30L=U\+&SYAUB7IZ
M/"Z5>OIZD&S2;JYA4Z#45U%AVS*.0TE0RBDWPIR?5;?:P74+">BZG0T32]4T
MO%LC90U;7L1@:ZQ1I$V5N,HPU'V7-3XLUN2)99'+U<^1ZN<JJJJ36C35&E&E
M'5&*76,:7%:5Q7G7GX4Y-]=XG:SL.D   JQ<J>13RQW8]^O<!S?S%NN*XJX
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M,:DDNEB\.P9,*@I
M
M
M
M
M
M
M
M
M
M
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MLNBX6-)/\!/KZ?-(;F\U/-*\EJY1KK/#S#/A6EM
M
M
M
M
M
M
M
M
M
M
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M00M3T(B>CXA.X05."A'P8I)=0Q74G*K4E4GX<FV^FWBSDSD<
M
M
M
M
M
M
M
M
M
M
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MKZ-\?',+RE=N#IJ2V<=>'#AQ-\1RRG+ZUA&<:SBW)K#!O@QXTB;4MQ=P
M1!=_/=K2MU,GP/QMDV6DEE6KR1L-";Q0-;!)^B:;C[$:^&9[YF_^])['>%J-
M]S=7*Z=C8SG&8J2=I0?C->A[O6XR;;N9+*,EF-TL/P(OT3_T>OQ'T>7%V[6*
MSIN?MMH.A66"WB>-ZEJ-[)5BL-=5S.V-8Y&](IX'/HU'+U1['V'^'HL+U^Y'
M9/'W9470CYK\Q=7H'S>C,T__ .-HOB<WV5'S7U.B2ZDE(4
M
M
M
M
M
M
M
M
M
M
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MDY2;<F\6WPL^H^G$
M
M
M
M
M
M
M
M
M
M
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M7PC&O2]9_0/@
M
M
M
M
M
M
M
M
M
M
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M6,8QJ(UK&M3HB)Z$0K]6A:BUMMO%ZS^P?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6C96MZ-99G+,2$
M
M
M
M
M
M
M
M
M
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MW.I8W=-;4H/#H8/M8G51S*QKO9IU8[6.&#QB^IM)8DBQ2%<
M
M
M
M
M
M
M
M
M
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M?,1LKG[!98^.AEN1-PUC):KA=9QSE\/NZ[C\+G[>3LJSQ,J-@@];X76($?\
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MA.;=G6>."QBWT-<?-70QX,"VH6(DP
M
M
M
M
M
M
M
M
M
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M#(<9#
M
M
M
M
M
M
M
M
M                                                  ,+]R'WO'/7
MV%^4?H'SIV4O58^,NV<9^ ^DSS'.%_KQ<3_9+T3Z*<43*KZE+Q7VC'%I[ZI>
MN1[:/5+(29)/.,\WS_B3]V?V0L?]!NL$NR_WG3Z7FL@.<?*57IKT*+E_DN_\
M,?M5^=W??Z7>02.YA[\J=/S$2_*_D^EXA!M^,[?76[3_ +'O)7T2:T7/)O J
M=->:63>3PJ/2E_HF9/Q8#^*?>3\\7!_S-Y2.O.O#I])^8=^[GJ%3QUVA^,__
M ,4^S;YXN</F;Q:,E\.ITEYHWC]0I^.^T:P?BS7WT?<#]@*+^D34SNSGU*'C
M>84V[?JM7Q8]MEQ'DKCG3.7M W#B_D/!4]ETC?-?R>L;-A+\;9(+V*RM9]:P
MUJN175[4'C26O.SPRUYV,EC<U[&N2P0G*$E.#PDGBB53A&I!PFL8-8-= \V;
MOO[/=V['NY#=>$-L9<NX:K8?G^-=ML5O<\&]<;Y2W;;K>QP(QSX6VT;6DIY"
M%CG-K9*K8B1SFL:]TOM;B-S152.OA7$S'N86<[*Y=)X[&N+XUW5J99._%Z._
MZ?>-5O\ 8_RAF5FV70,79V+@C)795?8S&BP236-FT.2Q--XY;>F2S-N8V-J/
M<N+EGC3U<5"-'6?-K78E[IAX,M?3X^KV^F2/(;YU:?N2H^_@N]Z,>+J=KI$G
MWG1?\,?NJ^=W0OZ7>/BBR_WY3Z?F,N6:?)]7Q"G=Y+__ !-^U3YY-Y_HEW\D
M&8^\I])=M$1R;Y2I?OO0R/05Y6XPTKFKC;>.)>1</!G]'Y#UG+:ILN+G:Q5G
MQF7J2599JDKXY%IY.B][9ZEEB)+5M11S1JV1C7)%83E3FIPT23Q1.ZD(U8.G
M-8PDL&N@SS3>\WM6WCLR[BN0> ]Y9+/+K&0]V:KL*PI%5W/1<LZ2SJFVT? Z
M2'P93'(C;$;'N]R7HIZSU]9"]$F-M7C<455CPZ^@^%&.[ZTE97,J$M6M/C3U
M/N]$Z7VQ_?)]O?V<>)_H]P!RK^HS\5]HXV?OREZY'T2/41SN;Q.LX3,;)G[]
M?%8+7\5D,WFLI;<K*N-Q.)J37\C?LO1'*VO3IUWR/7HO1K5(6DV\%K9DAM)8
MO4>8EWA]P65[I^YSFGGS*OLHWD3>,IDL%4MRR338K3Z'J\-I.$<^1&N_]XNI
M8VE5]#6IUB54:G7H3*WI*A0C27 NSP]DQS?7'NJZG7^];T=):%V">SAK\6JV
M7D?B7C;D'<>[!G'6S[SI&M;=F=";P)+LS].N;%B:N776[>=EYDUIV1R.(CMM
M@LO2C Q+#'M8CFHCW6RIG$83<8T\8IX8[6&/8+W3W<E.G&4ZNS-I-K9QPZ&.
MTL<#)?\ 9=__ (^/_9G_ -X$X?'7_=?E?ZIS^;7_ 'WY'^L0'^8'V4[/V$=Q
M>8X(SVRR;UBVZWK6W:=OZZQ+J$.XZ]GZ*ML7X,!)FMC;1]D[-1R&,>C+]IKY
M**O\35?ZMETM+F-U1Y5+!XX-8XX%DO[*5A7Y&3VHM)IX88]33P]%EL'\7E[H
M6\P=H.5X*SEQ9MQ[:=D7"U&R.C66WQIO-C)[#IUE7K,L\TN,S,.8QRM2-(X*
ME2HGB<KU1MBS6AR=QRB\&:QZJU^8R4Y%<\O9\E)]_3>'4X.YU"?HM9>C%_-G
M*F,X-XDY%YBS>N;9MN#XRU+,[KG<!HU+%9+;+N#UZI)D<R_"T,WF=>QERS1Q
MD$MAT<ER%71Q.1BN?X6.YTX.I45--)MX:=1PJU%2IRJM-J*;P6O1Q=$KFQ_C
M$O;/S1M6G<2<E=J$[N(N0=OPNK<B;!ROM6JY[5=5U;*92K4DVO,Z2ND['3VB
MCA/6I:MU'RP*R&)SHY)'HUJW;XIKTXNI"??I8K#'%OBQQ+$L_M*LXTI0?)R>
M#<L,$GPO7CT=6@W[Y?\ (Z\M[G1B[!A>,LCQ3<S<<N1CV'@G<;&O8RY7RB);
MJV<7K64BVSCFG2C299*WN+$PPK&]&]'1MC:VEIYE>4M#EM+\98]G7V2MK9/E
M];3L;+PUQ>'8U=@I;=_7;+K'9[W5\G]OFH<B-Y/P6BRZ^E?9I*U.GDHILYK6
M)SUS YRKCK5RC#F]>M9)]2QZMZ(]8D>Z.%[G01R*UK2N*"JR6RV0_,+6%G=2
MH4Y;44ETUCP/HEM3RHM%WKG+R4<_Q)G76)4Y%TON>XOXXGRLC6QKKNTR;?KF
M.=!:F:BMHX_<,ED(HGN<Y($@\+5:R-C6V*^E&EF/*1X'%OIZ&2K*X.OE"I3Q
MPE&<>HVU_P!A2QX]RU;BWF/1\[O.I4L[3XYY,UG+;AHFT86CF,=F:VH;32N;
M!J6Q:]F(Y,;E*60BQ\U.W2M,=!.Q[XI45KG(2*:Y2FU!Z91>#716AD-IX4;B
M/++1":VD].IZ5AP\1Z,?'7:5Y</+6BZKR5QUVG]G.VZ/NN%I;!K6PXCM[X;M
M4,EC+T:/BD8]FGJL4\+_ !13PO1LM>=CXI&MD8YJ1*=>[A)PG4J*2?X3[I/X
M6EA4BIPI47!K%-1CW"*GFOO3\C'@;FWD3@K=.S?A^]L'&>1APF=V?4^T+@;8
MM*MY]*T$N6P6(R-:*/,SY'6[<SJE_P!?0KPQVX9(XY)?!U*ZG;YG5IJK&I+"
M7'-XENK7.24*TJ%6G34HX8ODTUTM"X.$F,[,,_VH[QPCB>2NS?0M,T3A_D#(
MY'+0Q:3P^G"^.S6>QDB:YFK]K74U;4VY6]C[>(7'29".*Q7E?36.*Q*R)%2W
MW"KQJ;%PVZBXWCYK+I:.VE152TC%49:=$=G'@QPP7%K//Y\R7AW)\%=]?=#H
M.0QL^+IKR[MNWZQ#+U>R73.0<E-O.H35['K)FVHDU_8*\;G^)7)+&]CT;(U[
M&RFSJ*K:PDM>RD^FM#(-F=%T;^I%ZG)R72EI\W#J%XGRD.Y/3NX_L5X(L8+-
M8NUMO%6@ZOQ!R/KU:PBY77-AX_Q,.K8^;+4GO=- S:L%AZ^4KRIUAECM*UBH
M^.2..-WU&5&YDFN];;72?<U$TRVXC<V<)Q>,E%)]!I8/N])D:OXQQW5:/KO
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MHPX\2?4M9>0
M
M
M
M
M
M
M
M
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M+6ETB&7>49A5NJE2%/&$JDFN^CJ;;7WQ<*[)>.MRXB[0>VGB[D/#^][>N/\
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M>:R<@MI=P
M
M
M
M
M
M
M
M
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MP\&90.!V
M
M
M
M
M
M
M
M
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M2#QN>QJ2(Q[*W+Z-.O<J%18QP;ZQ;\TN*MK93K47A46"3Z;P*QOD4;AM>_\
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MXG#8BG#C\9C*%:)&QUZ="E79%%&U$:QC$1/0A$FVWB];)^DDL%J.6/@
M
M
M
M
M
M
M
M
M
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MRVD8R6W-XHG>7+NJSG]XM"70^Z3VPLXV5LJ*TSUR?&^YP+H$A!2E:
M
M        ?XJHBHBJB*Y>C45417+T5W1/[J^%JK_Z$/F*6OA/N#>K@/\ 3Z?
M    ?XBHY$<U4<UR(J*BHJ*BIU145/0J*A\34EBM*9]::>#UG^GT^      '
M^=4ZJWJGB1$54ZIU1'*J(JI\5$56KT_]!\Q6.'#^[N'W!X8\!_I]/@
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M/$J*J-ZIU5&JB.5$^*J(KDZ_^D^8K'#A/N#PQX#_ $^GP
M                                                    '^*J-17.
M5&M:BJYRJB(B(G5555]"(B'QM)8O0D?4FW@M+9_I]/@
M                           !_B*BJJ(J*K5Z.1%15:O1'=%_N+X7(O\
MZ%/F*>K@/N#6OA/]/I\                               !_BJC45SE1
MK6HJN<JHB(B)U555?0B(A\;26+T)'U)MX+2V?Z?3X
M                                                #_%5&HKG*C6M
M15<Y51$1$3JJJJ^A$1#XVDL7H2/J3;P6EL_T^GP
M                        _P 5414151%<O1J*J(KEZ*[HG]U?"U5_]"'S
M%+7PGW!O5P'^GT^
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M4D=TJDK><:.FHU@N#M] A5A.A3O*<[AX48O%ZWJ3PT+3KP+P?X<KRM?A0_\
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MT+,<T,C%5KXWHY%Z*0]IQ;B]#1D---8K2F<P?
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MBN"*X%YN+)ASHY58Y+1RS+LN@H6T*=;IMXT\92?#)\+[221L$98,1@
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M\*/#X4=&*C>=_=PJF05)9IE<7+)9/2M+=%MZGPNFWHC)ZO!EIV92SB9-,8
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MKVZVIU;)8-RFM;J6JPQVFW.BO#VH)U%+R;*FE@
M    !J#Q'RXN'6MJ^T65=B7*V'%Y29RJN+55\+*EM[O2N-5?0QZ_WO\ $7]#
M_P"KU^W!W^>7.&2YU/'+WHIU'_LN*,G^CXG]YXG@["\X'-^LQ4\\R.'_ /(:
M75I)>J\<X+])QK_::UW_ (>WJ*CD1S51S7(BHJ*BHJ*G5%14]"HJ&P":DL5I
M3->VFG@]9_I]/@  !TC>MZQ.BXE;UY4GO3H]F,QC'HV>].U$ZJJ]'+#5A5R+
M+*J*C45$1%<K6K&=Z-Z+'=BQ]TW/?W4\53IIZ9OS(K[Z7!J6+:3D^ZVZU_O3
M?^Y;7O+6&#JU6N]A'S9/3LQQTZWA%2DL:<&9_*;-8W;,9>RZS<M7,0JJOHCA
MB2+(^JK5X_S,->%J]&M3_P!*]5556&\V.:7N<ULRS#,)N=Q.I2Z26%3",5P1
M7 O-Q9-.='*K'):.69=E\%"VA3K=-O&GC*3X9/A?F)(V",L&)   "(3OT\R;
M%\.)F.(>#+U'.\KM2?';+MC6QWL'QS+\=%8I56N1];,[G7]*+$OCJX^3T3^L
MF:^NW6KG=Y\:&[W*[L[H3C5SY8QK5UA*%L]3C#@G77#KA2>B6U-2C'=3[._V
M7+O?9T-]><"G4M]S]$Z%N\8U;U:U*6J5.V? ]%2LO V8.-243G:9W]<J]N.\
M9"_L&4S?(V@;CFI<OO\ K>:RL]_*V\I=?(Z[M>!RF3FF?4VB627UEA7N]5D4
M:C)U1R130Z[\WG.WO#N/FT[BO4J7F47-5SN:52;E*<I8[56$Y8N-;3C)O14P
M2GCA&4=Q>>/[.NY_.?D%.VRZC0RS>.QH*G9UZ5-0IQIQPV;>K3@DI4$EA!);
M5'%RIZ'*$[3/%7+&@\UZ1B.0N-MAI['K.8CZQ6:SD;9H7&1QOM8C+TG+[HQ>
M8H+*U)ZTR-D9U1>BM<UR^@.[F\F3[UY33SK(ZT:UC46M>%"22;A..N$XXK&+
MXTUC%IOR-WPW.WCW#S^MNUO3;3M<UH/3&7@SBVU&I3EX-2E/![,XMIX-:&FE
MD4OA&   "+COP\TGB7LTL2:%B<6O*?-\]".Y[R<?DX\=AM1KWH%DQU[>LXR"
M[)0FLQN;/#C((GW;%=6O>M:*:&=\\W3W#S#>9>ZZDO<^5IX;;6+GAK5..C'#
M4Y-[*>COFFBVWV9T;+O/"K<2\U\';*_>[>=;WZ;1DK=S7]XTKC>G.]%KXC4>
M-]3R52E&U6]&1V-_H;MD9G.:WXYTDSNJJJM1OH1,OVO-ANE0@HUJ56O):W.I
M--]2FX+K(C]3/+Z?@.,5T%CV\3HWX8'S%?A#_P#Q)>#/ZLBK^KC<SR/^.K_K
M3J^.,Q_2?DQ]*/PP/F*_"'_^)+P9_5D/JXW,\C_CJ_ZT?'&8_I/R8^E,J\<>
M=[WNZAEJ=K=,SH?+.(8YC;^)V72,)KD]F!.B2NJ9/0JVKNI77)U5DCX;$+7>
ME87)\:6^]YK=UKFFXVT:UO4X'&<I8=-5'+%=5/HG?2SV\@URFS./#HP?77<+
M'?9%YA'#7>[@,@W5([6E<EZY5BN;9Q=L%ZK;RU&E*]D*9S7LE!'5BVG66VI&
MPOM1P5YJ\SF-L5X/70++A;>G<_,MUJR]T85;&;PA5BFDW^#):=F6&G#%IKP6
M\'A([*_HWL,:>BHM<7K7=71-]")%:               :]=R'<SQCVOZ-+N7
M(F35UJTD\&KZECGUY-EV[)0^J1]/#TYI8FI7J^Z&.M6I%;!5C<BN57NCC?"=
M^=_<AW!RIYEG$\:\\51HQ:Y6M)88J*>J,<4YS?>Q3X9.,99+YK^:G>SG9W@6
M1[M4L*,,'7N)IJA;0>.$JDDGWTL&J=..,ZDD\$HJ4HU=>6>^?N!Y2YFPW,\>
MW7M-RVFWII^/,#KUA_L+3*D[(X;52O3MMEKYA^8KQ(S)R7(Y6Y!BK'(Q*Z,@
M9H+O#SI;X;P;STMZ97,[>\MIMVT*;:IT$\$XQB\5+;2PJN:?*KO9IPPBO6G<
M[F YM]T=QJ^XLK*G?6=]32O*M:*Y6ZDFW&4I1PE3Y.3QH*G*+HO"49<IM5)6
M!.R'OVTWNFP\&J[$E#4.;,5263*ZLD[FX_:JU.!BV]BT^2=$=+ [XZ2QCW/D
MM4FHY>LL+?7+N-S4\\&7;_6\<LS'8MMZJ<.^IXX1K**[ZI1QZKE2Q<H+%IRB
MG)><'/Y]G;.^:.]EG&5\I>[AUJF%.OAW]O*3>S1N4M3U1A624*KP6$)O8)"S
M-1K4                           :/=ZO?OPUV2:K2O;N^SM._P"QUYY]
M+XOP%FO%L&<AA>L#\MD[<[9H-:UB&TBQOO3LD=(]KV5H;$D<C&RG=C=+,]Z+
MAPM<*=I!]_5DGLQZ"7WTOQ5JUR:311WE]1LH;533)ZDM;^YT2MYR?YX?>IN6
M7M6-#N:%Q!A%];'C\7K^GXK:LA% [UGJ9,EE]\K[##?R$2/3K)#4IP.5B?H"
M)XD=FNQYJ]V+:FE=JM<U>%RFX+J*GLX+IMOHD<JY[=S;Y-1A'I8OKO1V##_X
M8'S%?A#_ /Q)>#/ZLBY?5QN9Y'_'5_UI3_'&8_I/R8^E'X8'S%?A#_\ Q)>#
M/ZLA]7&YGD?\=7_6CXXS'])^3'TIW33?.I[]]9R=2[G=_P!.Y$IUY5?8P^V\
M:Z;CZ-Z-5],,\^A8O2\I$C4_,NBL1N1?B]?B%+<\V&Z5>#C2HU:,FM#A5FVO
M9'-==';3SN^AX3C+IKN8$^/8=YK7%7>!D:O&VU89O%'-[JDDU36K.3COZONS
M:==DEV72LU.RI:]J,1LL[\39B]T1UF^**:TC)G1XDWLYO\PW<@[VWE[HRO'3
M)+"4,=6W'2L-2VT\&]:CBL;]8YK1O'R;6Q7XN/I/AZ6LE?,?%T
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M;W$90KPDXRC).,HRB\'&2>#333336*>AG[G,Z@
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MS7M:]CD<QR(YKFJCFN:Y.K7-<G5%147T*8AU%]/Z
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MMTFFL5I3//5IIX/0T?Z?3X
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M\&]$Z_D)XN,U=T3_ *552]_5QN9Y'_'5_P!:4GQQF/Z3\F/I1^&!\Q7X0_\
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M47H
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M^N53_P!DM,GT.+IO4NOP&3O-8[",CV&]RN3UG!4K\G"'(Z7]OX3S5J6Q<2/
M^Z8VY?2+N1LOEFM9O0KMN.M(Z61\\]&6I9D7QV%1.%C=*ZHXOU6.A]WJG;FM
MA[AN,(>H2TQZ'&NIVL.'$FP_%[/,+;D\9)V)<L9V-,AB(LGG^W?*9*619\AB
M_':R^U\8K:D>YLDN)5TN4Q#'(CO<JW($?X(*L26W-;3!^Z8+0_"\Q]TO.0W^
MW#W%5??Q\'HKBZG!T.D6KRR$D
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MA",-*3&)G8 $QW81YE%_BQ<-P[S[D[N7XT18<=JV]676+^7T"-$BKU,7EO\
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M&4_)5M\'I^@1KUFWRK<_"*GHV<J7 MX
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MO)9M^9WL)1]S47CCX37:[O6+ODF65*4_==PL'AWJ>O3POBT:%_V$S7G'=O\
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M@\#XT9 L;N%[;JM'7J:XGPKN= WG*8JP
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M@UOWKR?ZDTR!S7_2VGZS4]"8\YT_HC4]>I>B-XS9HU@*Y7?QYE64Y FSO"_
M.1O831(I+.)V_?H/=..S>Y>K=&RUB<"DD=:_@];;+')%/(OALY!G5G2.NKFS
MZ0\[W/C<9]*KNSNC.=+(\7"K76,:EQJQC#%*5.ECBGJE46B6S!N,O3O[.OV6
MK3=N%OOUSBTJ=QO"U&I;6CV9TK;'%QJ5<'*%6O@U*"TPHO3WU1)TX8#6@WF
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MF<YE-UN9W)/<F51]T9_7BO=5Y.*52LUIV(K%\E1B_!I1? I3<Y]\:DF/3,H
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ME2X%O
M     .F;SQSQ[R?A7ZWR5HFF\AZ[(LSI,!O.KX3;<*]UBI8H6%?BL_1R%%RS
MT;<L+^L?QT4KV+U:Y47E&<H/&#:?0T'&4(3CLS2<7P-8HQ3IO:%VF\=9RKL_
M'W:]V[:+LE&6O-2V'3>%.-=8SE.:G<KY"I+5RV$UFC?KRU;].*>-S)$5DT3'
MIT<UJISE7KS6$YS:Z+;.NG;6U)[5*G",N-12[2-B3J.X         PAR/VS=
MM_,65@SW+O;[PARGG*T3H:V9Y'XHT/>,K7A='7B=%!D=FP.4N11.BJ1-5K7H
MBMB8GQ&IT[(5JU-84YRBN@VNT=52WH5L'6A";7&D^VCN''W$_%G$N,DPO%7&
MN@<98:9*[9L3Q]INNZ9C)6U/7^Y4DH:YCL;5D2M[ID]7U8O@]8[IT\2]>,IS
MF\9MM]%XG.$(4X[--*,>)+!=@YK;=,T_?\#=U;>]4UK==8R36LR.N;;@L7LF
M!OM:O5K;N(S-6[C[36JOH1\;NA\C*47M1;3Z!]<5)822:,3Z%VI=KG%><BV?
MC#MLX"XXV6!.D&PZ%P[QWI^<A1$>U$BRVO:[CK\:>&1R>B1/0Y?[IV3KUJBP
MG.4ET6V=5.WMZ+QI4X1?0BEVD9].H[@     "GUMWXQ7W8<0\G;_ ,9<G]M_
M"61S''?)>U:;G*F'M;_I]QE?5=@LX6YC)$R>Q;DR#,(ZA*U;?A?!XW-<E;PM
M\+[]'*:-2FIPG+!Q3X'KZQ%ZF?UJ%:=&I2BW&;6AM:$^KU^P37]HWG!=F_<M
MQ)BMYWCE[B'MRY :^U7V_B;E3EO7<!?UNTW*96KC4Q&R[I3T"EN]')8JA%<6
MQCJSFU?=+89TCE3HZWU["XHU-F,93CP-+7UL<"[6V:V=Q152<X4Y\,922:Z^
M&/3(%O/^[]NWGN7J\+<*< [[1Y0;QULVV[=O>VZRZ>QI5;)6:-;7L%A<)G'-
MCH;5:]2EVQ-:I>OHQPR0)#8E=+,R*YY5:UJ+E4JK9Q6"3U_<++GM];UX0H4)
M*;4L6UI2T8)8\.LRM^+)<09UVS]S//=JC+!K5? :KQ'A,E(R5L64S=[)+N.S
M4Z<GJ_4R/P=+&8E]A/$CF>[X>B*CE5.&<U%A"E]]I?F=T[=W*4DJM9^"\$NI
MBWVT6Z2PDG,=<B\0<3<OX^#$<M<7<=\HXJJVPRKC.1=)UK=L?69;DIS6VP4M
MEQF3K0MM38ZN^1&M1'N@C5>JL;TYPJ3IO&$G%]!X'&=.G4CLU(J4>)I-=DZ%
MI/:5VJ\:9F'8^..V;M]X_P!AK2UYZ^>TGAGCC5,S7FJ3-L59H<I@M;H7HI:U
MAJ/C<UZ*QZ(Y.B^DY2KUYK"<YM=%MG73MK>D\:5.$7T(I=I&P1U'< #7K=^T
M?M1Y,V"SMG)';'V]<@[3=16W-EW?A?C?:]@MHLTUA4LYG/:U?R,Z+8LR2?'R
M+\?(YWQ7*J]L:]>"V83FH]!M'34MK:K+:JTX2EQN*;[*,N:?HVD\>8:/7- T
M_5M&UZ&59XL#I^OXG6<-%,L,-=9H\7A:E*BR5:]:-GB1B+X(VM^(U$3KE*4G
MC)MOHG:HQBL(I)':3X?0 4^MN_&*^[#B'D[?^,N3^V_A+(YCCODO:M-SE3#V
MM_T^XROJNP6<+<QDB9/8MR9!F$=0E:MOPO@\;FN2MX6^%]^CE-&I34X3E@XI
M\#U]8B]3/ZU"M.C4I1;C-K0VM"?5Z_8)K^T;S@NS?N6XDQ6\[QR]Q#VY<@-?
M:K[?Q-RIRWKN OZW:;E,K5QJ8C9=TIZ!2W>CDL50BN+8QU9S:ONEL,Z1RIT=
M;Z]A<4:FS&,IQX&EKZV.!=K;-;.XHJI.<*<^&,I)-=?#'ID"WG_=^W;SW+U>
M%N%. =]H\H-XZV;;=NWO;=9=/8TJMDK-&MKV"PN$SCFQT-JM>I2[8FM4O7T8
MX9($AL2NEF9%<\JM:U%RJ55LXK!)Z_N%ESV^MZ\(4*$E-J6+:TI:,$L>'696
M_%DN(,Z[9^YGGNU1E@UJO@-5XCPF2D9*V+*9N]DEW'9J=.3U?J9'X.EC,2^P
MGB1S/=\/1%1RJG#.:BPA2^^TOS.Z=N[E*256L_!>"74Q;[:+=)823F).2> >
M".9GUY>8.%.).5I:D->O5DY)XXT[>7UH*DMR:K!7?M&&RCH8:TV1L/C:WHUC
MIY%1$5[NO.%6K3]3E*/2;7:.NI1I55A5C&2Z*3[9QW'?;3VY<09%<OQ-P!PG
MQ=EG+(YV4X[XJT72<BKI:\E255NZU@<9959:DSXG?'?'1N5J^A50^SK5:FBI
M*4ET6V?*="A1]2A&/227:,V'6=H       /BR6-QV9QU_$9>A2RN)RM*UC<I
MB\E5@O8[)8Z]!)5NT+]*U'+6N4KE:5T<L4C71R1N5KD5%5 FT\5K&O0]1K3:
M['>RJ[DYLU=[/^URWF;%Q<A/EK7;_P 3V,G-?=+ZYUZ:_+J3[4EQ9OCUE5ZO
M\7IZ]3N]TW"6"J3P\9]TIW:6CEMNE3<\<<=E8X]/ V,P.OX'5L33P&L83$:Y
M@L<R2/'X7 XVGB,30CEFDL2QT\=CX:].JR2Q,][D8QJ*]RN7TJJG4VV\7I94
M))+!:CESX
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M4OGYV[]4H&%=^_EY^LP\TDF6>]5XS-'/.\_\L?\ XT?^TG-$OM4_^0_^-_\
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M^%[6N143*MKS)<Y][:T[RVRMNWJTXSBW<6L6XR2E%N,JZE%M-:))26II/08
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M1I5FWRK<_"*GHV<J7 MX
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M(XHF62K5G6FZE1XR9):-&G;TU1HK"FC-IUG:
M
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MSA_0JO\ P/MD#5SFX^G%O_#>U5"- UE-HS:[MM_O+;?V5A_U+(&=.9WWO?\
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MH^UQ/UX[_CWJ/[_XS]M1E7NE])[#X72]$BDWO^BV8?!*OH62+&W9IZ4]=_\
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MC(RB2:8+_$>&_>K'?M2$W-RGY*MO@]/T"-*LV^5;GX14]&SE2X%O
M
M
M
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M2665Z-:U$555>B'*,93DH03<V\$EK;>I(ZZM6G0I2K5I*-*$7*3;P226+;?
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M^V5#2O?_ ./>Z_/;LGS9NF$]X/EZ]^%UO;)&<MW?H_8_ Z/M<3-7:I]<F_\
M.ED_FGA2;<U'TFJ?!)^CID&YW/HQ3^&0]!5'=7]<FA\Z6,^:>:'.O])J?P2'
MHZ@YH_HQ4^&3]!2-9S&1E$D4XY_B'J7[PX_]0:;<[G_1:P^"P[1I]OA]*<P^
M%U/1,K6^;_\ ?9T_L3Z=\U=I-*/M'?XC/X#0[<SU%^Q7_@W+^V+GT% BR,"F
MW!8H\CCA!8,?RSW#96FB/O35N*]-GD8Q'I6J>XMCW2S%X^LBQ6+$F)A9(U&M
M\5>9G5RHY&[=?9CW9T7^]]>/%:T7H_%J5GQ_H4FM'AK3IP\Z/MS;\;=QE/-W
M:3T0B[ZX2;URVJ-LGP8I*O)IXO"4'@M#>@??3W09G.>8#FN5=1R#IH>"=TUO
M6-%?#>=+5<WBW*I/DFP6&M? _&YG;TR4RHQCH9(+/1?6(JN?B;G/WUN;WG5K
M9]E\\5EMS3IV[QVDO<LM+3U.,ZRJ36"P:GPXXO8#F)YKK*P^S]0W4S>FHSSZ
MRK5[I..$O]^IX0Q6O;IV_(QTM24H?>M)*>;O[X^Q/=?V)9O:M.B=E9Z&K:]S
M[QZ^+U,L]B#&X5^:M1Q-C=)ZZS?T?+7X611.5SYY&-;XEZ(NT_.QE=#?WFJG
MF>7)SE"A3OZ&K%QC#;DNBW0G46RGBYX)8ZC0GF WAN^:;GXH93G+5*G4NJV5
M7>.*2<ZG)Q;QPPC&YITI.4E@H)MX:U3M//<]C39?LT^^O[=_LO:-\WJ9->;?
M_$#)/[4MO;H&*^?'_![>;^Q;OVJ1<]/4 \,C6_N/_P 2ZU^^EO\ :C3#G/#\
MGV7KT_0HS-S-_*-[ZS#T3-1C IG\DO[?/K+X/_O)\V\H;-<WGT*H?PWMDS5S
MG'^G%Q_ ^U4R- UE-HS<WM!_OK??V/K?ZIG#-',]ZKF'BT>W5,(\\WJ67>-7
M[5(PKS_]=[<OV1BOF!BB$\X/TPO?&A[53)SS=_0RR\6I[=4,.$-)J2>X_P#O
M"E^Q*WZBPW5M/>E+UN/:1I%=>^JGKDNVR GS6/OAM-^PQKWT<<B&:N;WY%J_
M"I>UTR+YM[YCXB[;(RB=EK+8'?'#'KG9)RUC\"_U5+'Z3K>$I+7<KF>R%V#6
ML2Z-CFN=XH9<9(YBKU5%8OQ50P)NNW6WGMYU?"E5E)X\>S)]LE-[WMG-1_![
MA4_,]D6   ,^=J_WR7!GV4M+^;E,M&\'R'=_!Y^A94VGOJGXR+$O>A]YWW8?
MZ-/.W]%VTF%=V?I)E_PZA[; D5[[SJ^M2]"SSY#<(Q\7"/Q=?%8:'M8YJSD'
MJ??#D>?[F*RGA_OCV-AN.M#N8+UOI_ZGW;GLCX/0GQWC^+^1KQSP5*CSVVI/
MU%6B:Z;J34NQ&)+L@2]R3?#RC]#$KH>9#D,KD^_'NOLYB2:6W'S7N>/A=.KU
M>F*Q&0=BL'&U9'.=ZF'"4J[(TZ]$C:U$1$Z(9@W,A"&ZM@J?@^YH/JM8R[+9
M8<T;=_5QU[7F(D-[+_)'^Z\[:>-NXC[IOZGOU0O?C_\  ?\ 48]]GLCWI[]M
M.C_Q@^JQK7N_W?[VO=7]XP>J]?ZOX_P>L=$=Y.<WYO9U6R?W%RW(['?\ML8[
M=.,_!Y*6&&UAX3QPQT8X%99Y-[KMHW'*;.UCHV<=3:U[2XN(RCSA^+^_49X5
MY?Y@^ZT]\GU*>+N0.2?>[]0;V/[>]XNIY;:/8OM;ZLV4]E^U/9?J/=/N6SZC
MUGC]5)X? M#E?.S\99E;Y=\7['NBO3I[7+X[.W-1QPY%8X8XX8K'5BCMK9#R
M-&=;E<=F+>&SKP6/X17(,QD>+AGD/_>5[#]GG>?H4X]-;N=CZ41^"4_15"9Y
M'[Q7C,F9R']X7?V)9_47F*KOWI5];EVF7^U]]4_7(]M$81I4;NFS':I]<F_\
MZ63^:>%,F\U'TFJ?!)^CIF+N=SZ,4_AD/051W5_7)H?.EC/FGFASK_2:G\$A
MZ.H.:/Z,5/AD_04C"N@?Q[TKY[=;^;-(A.[_ ,O67PNC[9$G.\7T?OO@=;VN
M1NIW9_Q$U_Y[:_S&S)FSG<^0;?X6O:ZA@WF>^D%S\#E[93(_37PV*-PNW+^+
M&=_?[_V7U#8+F@^1KKX5_)Q->.>+Y<M?@G\I,QQYA'WH/+O_ '!_I/THV"W-
M^DEM_">U3,*9C[SGU/1(K+&=B,%BKR><?1BX#Y'RL?@]I7>7[V/MJCD]9[AQ
MFEZ=9Q_C;XE5&)/E[/A7HG5>OI7IZ,/<XLY/-J--^ K=-=-SFGVD2#*4O<\G
MP[?F(AJ[R+5FYW4\^S6Y'R2LY0VJJQS^OB2M1R,E*E&G7T^"*G7C:W\CPHAD
MC=R,8Y%:*.KD(/JM8OLEHO&W=5,?PF:U%Y*8   L_=B'WIG#O[U;#]&>R&!=
M[OI%<^-'T$24V/O2'2\UF O-M^] RGV0='_;-XU@^TA_ATOA]'T-0VY^QG_C
M52_LRZ[4"K":#'KF;,=G?"DG<'W*<3<6OKNL8?,[16R.V(B)X&:;KC)-@VI'
MR/5L<3K6%QLU>)7=46>:-J(YSD:LQW W;EO;OC89#@W0K5TZO!A1IXU*KQU)
M\G&27')I:6TC&7/'OM'F]YM,WWI4MF\HVLH4.C<5FJ5#0M+V:DXREA][&3Q2
M3:GP\Z[F./3. ](X5Q%EE;(<K;0R_EJ=:=(_#I6@>Y,@ZM/3A1/!7M[1<QCX
M5?TC7W%(C6N5JK'M3]I7>*.7;KVF[%LU&I?5]N<4\/S-#!J+BN"565-QQT8T
MG@FUWN@GV)=S99UO]?;[7D7*WRFUV*<I+'_>;O:AM*3^^C0C64L-/YV+;2>$
MNQ^3!S(F_=M6=XJR=KW3E^&=JL4:T$TK)G^\S=G7,_A/$U_Z-ZMF<9EX&M<C
MF,BB8UJ]$\#*W[-V\7QIN=7W?KO:K9=7:BGAZC7VIQ7&_P XJVO4ME8\"MWV
MTMS/B#G+M]Z[6.S:9U:*4FDU_O-MLTJG0Q=)V\FU@W*4FUCI=>[O&X3D[>^Y
M3ECBZ.K)5PN(V:QD]2\:(K)=-V)C,]JZQ2L_0YO<V)R$=>56^AL\,C%1'-<U
M-2=_]VI;I;XW^0X-4*-=NECIQHS[^D\=3?)RBGAJDFM#31Z%\S>^\></FTRG
M>F4U*]K6JA<="XHXTJ^*>E8U(.<<=<91:Q33>LI#C)Q<8["?O/. ?G&A^:>1
M/2?F:_PQRCX/+VVH>)'VBO\ &W>/X>_:X$9WFO?7KX\^Q;6^BS9S:SF\^2ZW
MPA^@@:[YMZM'Q?-(M2?EI+8'?'#'KG9)RUC\"_U5+'Z3K>$I+7<KF>R%V#6L
M2Z-CFN=XH9<9(YBKU5%8OQ50P)NNW6WGMYU?"E5E)X\>S)]LE-[WMG-1_![A
M4_,]D6   ,S]N'WPW WV9^+OHXP9;,[^1;SX+5]KD=]M[YI^/'MHMH&NI+2L
MMYA'WWW+O_<'^C#2C.VYOT;MOX3VV9&,Q]^3ZGH480[>\?1R_/G!^*R?@7&Y
M/E_C3'Y!)'(V-:-W=,+6M^L<KF(UGJ)7=5ZIT3\DN^;SE3RFZJ0\.-O4:Z:A
M)HZ+=)W$$]6W'MHL ^;+:LU^U:O#!(]D5[E#4*MUK>OAEK,QVR761R=/1X$N
M4XG>GT>)J&)=P(Q>>MO6J$VNGC%=ILOV:-^Y='X2\TK/F:B-@  &\?ES_?9Z
M!^]6\?09G"*;[?1VMXU/T<2ORWWVND^T65#!I)2/WESZXVT?LNM\SZ9JCO[]
M+[[UR/H(&V?-_P#0ZQ];E[9,QP1 F1)?W!_67SG_ ';^;>+-FN</Z%5_X'VR
M!JYS<?3BW_AO:JA&@:RFT9)?V^?67P?_ 'D^;>4-FN;SZ%4/X;VR9JYSC_3B
MX_@?:J9&@:RFT9F;@;ZX-;]Z\G^I-,A\U_TMI^LU/0F.>=/Z(U/7J7HC>,V:
M-8"B/L_\9=A_?S+?M^P>2%S[XJ>/+ML_0CE/R7;?!Z?H$<55JV+MFO3IP2V;
M=N>&K5K0,=+/8L3R-B@@AC8BODEEE>C6M1%557HAUQC*<E"";FW@DM;;U)%9
M5JTZ%*5:M)1I0BY2;>"22Q;;X$EI;+B.R^Y>P+RXK-"K-7H;1Q]Q.S#59Z]F
M*!]KEW>G^Y9\A2DKJ^2UZG>MCEN(D;G/]R0*OC1K%D;Z#WJCS3\S,J,&H9C;
M6.PFI)/W7</!RBUX6Q6J.:PT[$-:2VEXYY9ROV@/M(QN*L95,KS#-N4DG%M1
MR^U6TH23P4<;6C&F\4ERDUWN+V7$1Y*7-#M1[@=OX@R5Q[<7S!JDEW%0RSM\
M#]ST1MO,5DCCE7T26]7MY59',7QO6"-'(Y&HK, _9MWC>6[WUL@JR:M\QMWL
MK1ARU#&<=?\ W;JK1K>SH?!M[]MG<I9QS>V>^%M!.ZR>[49M+3[FNMFG+%K@
MC7C0P3T+:E@TVU+]?.MX1=IW/&I\U8VFYF'Y?UMF.S5EC6K&FZ:+!2Q4JS*Q
M$]2MW59L;ZI'^F5U:96JOA<C>7VDMVGEN]M'>.C%^YLQH)2?_?4%&$NEC2=)
MK'6U/#'!X<?L3;\+.=PKO<JYFG>9/<N=./#[FNG*HL,=>S75;:P\%3@GABL8
M637(W5)ZO)#_ /,Y_P""_P#[5@V[^RM_Y]_X+_[L\[_M[_\ ZI_ZG_\ CS?S
MS./O"^YCYP8_HBP9O-N-]+;'U[_1D><=_P"\JOK;[10\-LB %ZKR1<5AL=Y<
MW#MS%^I]VY[8N6,KL?JOS?MF'D_:L'![H]*_HWO>PU#I\3]#\/\ Z5U<YS:E
M2>^-Q&?@PA24>ER<9>B<B<9,E\74_P!]Z)E(SDS(97+\D<@97.2339O)[OM>
M0S$MA7NL2Y6[GK]G(23ND<^19GVY'JY7*J^)5ZKU-F;&$*=E1ITO4XTH)=)1
M6'8(=<-NXJ-Z]N7;98 X/_%_?JS<*\0<P?=:>]OZJW%W'_)/O=^H-[8]@^_K
M4\3M'L7VM]6;%^U/9?M3U'NGW+6]?ZOQ^JC\7@3$V:<[/Q;F5QEWQ?M^YZ]2
MGM<OAM;$W''#D7ACACAB\-6++U1R'EJ,*W*X;44\-G5BL?PC%W>AY(_W(?;3
MR3W$?=-_5"^I[[SO_@/^HQ[T_:_OLW[5M'_C!]5C9?<'N#WR^ZO[QG];ZCU?
MQGC]8VNW;YS?G#G5')_<7(\MM]_RVWAL4Y3\'DHXX[.'A+#''3A@=5YDWN2V
ME<<IM;.&C9PUM+7M/CXB!DRJ6,NJ^2S]X)QU\^')OT:90UBYSOI=6]:I>@1-
MLF^3X=.7HF2/<I?6^VK]ZW_JL1A/?GZ)7WK/^E$R#N+]+K#U[_1D1Z&IIMP;
MF]H/]];[^Q];_5,X9HYGO5<P\6CVZIA'GF]2R[QJ_:I&%>?_ *[VY?LC%?,#
M%$)YP?IA>^-#VJF3GF[^AEEXM3VZH. /KO:;^R,K\P,J.;[Z867C3]JJ#G$^
MAE[XM/VZF9J[OO[ZT+]C[)^J8,FW/#ZKE_BUNW2(-S,^I9CXU#M533(PN9N-
MZ^#?K<XK]EY;YH3FSW-E]$*'KE7T;-6^<_Z8W'K=+VN)I/YMOWH&4^R#H_[9
MO$"^TA_ATOA]'T-0S;]C/_&JE_9EUVH%6$T&/7,V8[.^%).X/N4XFXM?7=8P
M^9VBMD=L1$3P,TW7&2;!M2/D>K8XG6L+C9J\2NZHL\T;41SG(U9CN!NW+>W?
M&PR'!NA6KIU>#"C3QJ57CJ3Y.,DN.32TMI&,N>/?:/-[S:9OO2I;-Y1M90H=
M&XK-4J&A:7LU)QE+#[V,GBDFU/AYUW,<>F<!Z1PKB++*V0Y6VAE_+4ZTZ1^'
M2M ]R9!U:>G"B>"O;VBYC'PJ_I&ON*1&M<K56/:G[2N\4<NW7M-V+9J-2^K[
M<XIX?F:&#47%<$JLJ;CCHQI/!-KO=!/L2[FRSK?Z^WVO(N5OE-KL4Y26/^\W
M>U#:4G]]&A&LI8:?SL6VD\)=C\F#F1-^[:L[Q5D[7NG+\,[58HUH)I63/]YF
M[.N9_">)K_T;U;,XS+P-:Y',9%$QK5Z)X&5OV;MXOC3<ZON_7>U6RZNU%/#U
M&OM3BN-_G%6UZELK'@5N^VEN9\0<Y=OO7:QV;3.K12DTFO\ >;;9I5.ABZ3M
MY-K!N4I-K'2Z]W>-PG)V]]RG+'%T=62KA<1LUC)ZEXT162Z;L3&9[5UBE9^A
MS>YL3D(Z\JM]#9X9&*B.:YJ:D[_[M2W2WQO\AP:H4:[=+'3C1GW])XZF^3E%
M/#5)-:&FCT+YF]]X\X?-IE.],IJ5[6M5"XZ%Q1QI5\4]*QJ0<XXZXRBUBFF]
M92'&3BXQV$_>>< _.-#\T\B>D_,U_ACE'P>7MM0\2/M%?XV[Q_#W[7 XWN*_
MCMB_G6I?-;-D#YW/I)0^ P]MK$EYG_HU7^'3]JHF!#%AE8DO_P#+9_X2?_"R
M;-?_ --/_2/Y$U<__J?_ .L_RY&@:RFT9(%VF?Q$V#Y[;'S&PQL'S1_(-Q\+
M?M=,UUYX?I!;? X^V5#2O?\ ^/>Z_/;LGS9NF$]X/EZ]^%UO;)&<MW?H_8_
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MA4_,]D6   .VZ!_'O2OGMUOYLTBGN_>E7UN7:9SI^J1\9=LN%&M1,36_N/\
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M%O
M
M
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M(J>C9RI<"W@
M
M
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MC(QB5IU%C#RROO8*7S\[=^J4#"N_?R\_68>:23+/>J\9FCGG>?\ EC_\:/\
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ML:$B&8UU-SBXQV$_>>< _.-#\T\B>D_,U_ACE'P>7MM0\2/M%?XV[Q_#W[7
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M)R)-,%_B/#?O5COVI";FY3\E6WP>GZ!&E6;?*MS\(J>C9RI<"W@
M
M
M
M                       %=3SJOKJ\+?8^SGT1N-)OM0?2C+O@#]NF>FWV
M$_H=GO\ :=+VA$*QK&;U@     '>N+_KE\>?/SJ7S?QY<,I^5+;X13]&BP;U
M_1?,O@%Q[3,O-'K*?G](MC2(WE       !M=VV_WEMO[*P_ZED#.G,[[WO\
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M&P9$P       6,/+*^]@I?/SMWZI0,*[]_+S]9AYI),L]ZKQF:.>=Y_Y8_\
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M%ST]0#PR-;^X_P#Q+K7[Z6_VHTPYSP_)]EZ]/T*,S<S?RC>^LP]$S48P*9_
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M_C;O'\/?M<",[S7OKU\>?8MK?19LYM9S>?)=;X0_00-=\V]6CXOFD6I/RT@
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MM\'I^@1P9TEP      )ZO)#_ /,Y_P""_P#[5@V[^RM_Y]_X+_[L\[_M[_\
MZI_ZG_\ CS?SS./O"^YCYP8_HBP9O-N-]+;'U[_1D><=_P"\JOK;[10\-LB
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MHUJ)B:W]Q_\ B76OWTM_M1IASGA^3[+UZ?H49FYF_E&]]9AZ)FHQ@4S^
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M?O5COVI";FY3\E6WP>GZ!&E6;?*MS\(J>C9RI<"W@
M
M
M
M             %=3SJOKJ\+?8^SGT1N-)OM0?2C+O@#]NF>FWV$_H=GO]ITO
M:$0K&L9O6      =ZXO^N7QY\_.I?-_'EPRGY4MOA%/T:+!O7]%\R^ 7'M,R
M\T>LI^?TBV-(C>4       &UW;;_ 'EMO[*P_P"I9 SIS.^][_QZ/:J&!^>;
MWQE_B5NW3,D\X_64Y@^Q;R!]">7,\Y3\J6WPBGZ-&#JWJ,_%?:*C1L:0\
M    %@+RI_O>=R^S/L/T#\=F'><+Y:I?!8^V5"0Y3[VEX[[2-W>>OK&<T?8G
MY%^@_,$4RGY5MOA%/T:+C/P'TF>=,;G&-P       6O_ ,7[^]YYO^S-!]!&
MO&OW._\ +%K\&?HY$MR#WK/USS$30<T_6SV7_P!\WS?Q1K7SC_0R\_@?;Z1E
M?FV^FME_#>T530@U9-JP       2 <0_6XU?]BV_FG=-K.;_ .A]EXD_;)FI
MO.%],;[QX>U0.A=V?WM'.'V-]F_:$ADO=SY=M/7X]L@EW[UJ>*RJ<;!D3
M    !8P\LK[V"E\_.W?JE PKOW\O/UF'FDDRSWJO&9HYYWG_ )8__&C_ -I.
M:)?:I_\ (?\ QO\ ]H>D/V"/_P!K_P#3/_R! J:B'H@      <YK'\9=>_?S
M$_M^N=UM[XI^/'MHM^;?)=S\'J>@9>X/6\_/<0Q^;K_Y?/\ Q7_]IJ9/YN/_
M *W^!_E2RYQ_L_WW^B0R&3BR@     '*X+_'F&_?7'?MN$ZZWJ4O%?:.4/#7
M31<B-9B9%2_N/^^&YY^S/RC]'&<-BLD^1;/X+2]KB1*Y]\U/'EVV88+F=
M   !+%Y37UR^5OG&Q?S?B,><XGO"W]>?H67?*/5)^*NV3JF)2^D6QI$;R@
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MT]0#PR-;^X__ !+K7[Z6_P!J-,.<\/R?9>O3]"C,W,W\HWOK,/1,U&,"F?P
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MZ17/C1]!$E-C[TATO-9@+S;?O0,I]D'1_P!LWC6#[2'^'2^'T?0U#;G[&?\
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M?!Z?H$<&=)<      ">KR0__ #.?^"__ +5@V[^RM_Y]_P""_P#NSSO^WO\
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MJ)B:W]Q_^)=:_?2W^U&F'.>'Y/LO7I^A1F;F;^4;WUF'HF:C&!3/X
M)/<?_>%+]B5OU%ANK:>]*7K<>TC2*Z]]5/7)=ME:?SFOOH-#^P+J_P#2%RB:
M/?:<^GMI_9%+_B+H]3?L-_X39C_[BK_\'8$1YKF;F      &>^U7[Z#MO^SU
MP_\ TA:Z2_F^^GN2?VO9_P#$4S'?.]_A-O1_[=S+_@ZQ=9/48\(CS3C=XQJ
M      "SM^+S_P 6>ZC]_>(?F?R(8*YX_?%AXE7MTR5;O^HU/&7:)M.XW^+&
M"_?[_P!E]LT[YW_D:U^%?R<C/W,[\N77P3^4@:>FOIL.       "33!?XCPW
M[U8[]J0FYN4_)5M\'I^@1I5FWRK<_"*GHV<J7 MX
M
M
M
M            !4*_&.NZC(\#<_\ ;UKM33:6RQ9GA[-9I;-C,SXR2O)[]<A1
M= D<>/NME8K:J.1>K5155/20S>/[.V7\\UY#.+S-*UA*SIJBHPHQJJ2<I3VF
MY5(8:\,,.#'$S)S;_:NS'[.^55\GL<EH9I',KCEG*I<RH;')PC!12C1J;6..
M.+:XL"N=^$;S7\U.+_E9;_@$C_\ D2R/^\5W_5*?ZXR+_P#)QO!_=&S_ *_4
M_P"5'X1O-?S4XO\ E9;_ (!'^1+(_P"\5W_5*?ZX?_)QO!_=&S_K]3_E1^$;
MS7\U.+_E9;_@$?Y$LC_O%=_U2G^N'_R<;P?W1L_Z_4_Y4?A&\U_-3B_Y66_X
M!'^1+(_[Q7?]4I_KA_\ )QO!_=&S_K]3_E1^$;S7\U.+_E9;_@$?Y$LC_O%=
M_P!4I_KA_P#)QO!_=&S_ *_4_P"5.9UOS-<]KFQ8'88N(L19EP.:Q>9BK2;?
M<CCL28N]!>9!(]N 5S&2N@1JJB*J(IWVOV&<DM;JG<K>&[;IU(RP]RTUCLM/
M#'EN' H<T_\ [E6?9GEEQELMT[.$;BA4I.2OZC<54@XXX>Y=.&..!,Y_:R>7
MO@;<;_;7V?Z43:3ZM[?RJ?G%Z8T3^L>?D:]E_FS6W^T<\C?!<TG[96=^E4PW
M_E6RG]L7'L$/UAFG_-9?_L6C_69?J1_:.>1O@N:3]LK._2J/\JV4_MBX]@A^
ML'^:R_\ V+1_K,OU(_M'/(WP7-)^V5G?I5'^5;*?VQ<>P0_6#_-9?_L6C_69
M?J1_:.>1O@N:3]LK._2J/\JV4_MBX]@A^L'^:R__ &+1_K,OU(_M'/(WP7-)
M^V5G?I5'^5;*?VQ<>P0_6#_-9?\ [%H_UF7ZD?VCGD;X+FD_;*SOTJC_ "K9
M3^V+CV"'ZP?YK+_]BT?ZS+]29-X^_&A>4^/X<I%4[2- R*922K(];'*.Q0K$
MM5L[6HQ(]3=XD?Z]>O7^X37=+F)L-U*=>%',:U;EW%O:I1CAL[6K";U[1!][
M^?>YWMJ4*E;+(4>04TL*[ECMN/'26&&R=AW/\:EY9W+3]KU"QV@<=TJ^U:WG
M=;GN0\J;++-4ASF+M8R6U%$_4FLDD@9:5[6JJ(JIT4FUKS?4+6YIW*NIMTZD
M98;"T[+3P\+AP(9/G%G.#A[C6E->J\?\&19_A8-F_F8P7\LLA_ !D#8?'V/N
MEH^>$O)UY_\ U!^%@V;^9C!?RRR'\ #8?'V/NCYX2\G7G_\ 4'X6#9OYF,%_
M++(?P -A\?8^Z/GA+R=>?_U!^%@V;^9C!?RRR'\ #8?'V/NCYX2\G7G_ /4'
MX6#9OYF,%_++(?P -A\?8^Z/GA+R=>?_ -0?A8-F_F8P7\LLA_  V'Q]C[H^
M>$O)UY__ %#>;ME_&0>2>VC0\MHF'[6]'VFMEMNO[:_(9+DG/4)X9[^&P&'=
M39#5U>:-T4<>!:]'*O55D5.G1$(GGVZ-+/;R-W4KRIRC34,%%/5*4L=+7X78
M*^TW_E:TW3]RJ6,L?5,.!+\!\1F/=_QJ+EC=M,V[3;/:#QW1K[;K&?UB>[!R
MGLLLU.'/8JWBI;4,4FIM9)+79;5[6N5$54Z*6NUYOJ%K<T[F-U-NG4C+#86G
M9:>'A= J7SC3::]QK2OTO\V0$_=<Y'_,>E_EV?\ @PR_\=3_ $:Z_P!PC?SF
MG^A7GO\ 5'W7.1_S'I?Y=G_@P?'4_P!&NO\ <'SFG^A7GO\ 5'W7.1_S'I?Y
M=G_@P?'4_P!&NO\ <'SFG^A7GO\ 5'W7.1_S'I?Y=G_@P?'4_P!&NO\ <'SF
MG^A7GO\ 5'W7.1_S'I?Y=G_@P?'4_P!&NO\ <'SFG^A7GO\ 5'W7.1_S'I?Y
M=G_@P?'4_P!&NO\ <'SFG^A7GO\ 5)/>Q?S[M^['-"W+1->[<M/WZON.W,VV
M?(9G?\UAIJ4S,-0PZ4H8*.N6V2Q*R@C_ !N<B]7=.GH('O9D$-ZKNE=U:KHN
ME3V,%':Q[YO'%M<9=LOWZE8TG2]RJ6,L<>4PX$OP'Q&WFW_C4O+&W:[D->L=
MH''=.'(>Y/'9AY4V622/W)>K7F^%C]21J^-U9&KU_(4QYO!S/6>?Y16RFI?5
M*<*NQC)4XMK9G&>IR6O9PZI*=W>>&MN_G%'-Z=A&K.CM]ZZS2>W"4-:IO5M8
MZN PC_:.>1O@N:3]LK._2J8T_P JV4_MBX]@A^L,G_YK+_\ 8M'^LR_4C^T<
M\C?!<TG[96=^E4?Y5LI_;%Q[!#]8/\UE_P#L6C_69?J1_:.>1O@N:3]LK._2
MJ/\ *ME/[8N/8(?K!_FLO_V+1_K,OU(_M'/(WP7-)^V5G?I5'^5;*?VQ<>P0
M_6#_ #67_P"Q:/\ 69?J1_:.>1O@N:3]LK._2J/\JV4_MBX]@A^L'^:R_P#V
M+1_K,OU(_M'/(WP7-)^V5G?I5'^5;*?VQ<>P0_6#_-9?_L6C_69?J3.6J_C5
M/+.K8#&X"#L_X[MQ8Z.6-EB7E398Y)4EL36%5S&:DK6JBS=/1^0AD[(N:&TR
M/*:.54[VI4A132DZ<4WC)RU*71P,6Y]SO5<]S>MFU2PC3G6:;BJS:6$5'6Z:
MQU8ZC@^4/QH[E7D_CO<N/;O:-Q]BJNXZ_D<!8R57E'8[%BE%D8'0.LPP2ZFR
M.62)'=4:Y41?[I(LOW"H6%[2O8W,Y2I34L'!+'#@\(LE7G$E5I2I^Y$MI8>J
M_P V1E_A8-F_F8P7\LLA_ !.]A\?8^Z6KYX2\G7G_P#4'X6#9OYF,%_++(?P
M -A\?8^Z/GA+R=>?_P!0?A8-F_F8P7\LLA_  V'Q]C[H^>$O)UY__4'X6#9O
MYF,%_++(?P -A\?8^Z/GA+R=>?\ ]0?A8-F_F8P7\LLA_  V'Q]C[H^>$O)U
MY_\ U!^%@V;^9C!?RRR'\ #8?'V/NCYX2\G7G_\ 4-^NW7\95Y,[>..(>.<5
MVJZ+LE2'-97,ID\AR7L%&PZ3*.@<^#U%;5I8T9%ZA.B]>J]2'YWN;2SJ^]VU
M*\J<MA1P44]6/"Y=$N-MS@2MJ7)>Y$].OE,/Y,PUWC>?EOG>']3GV_VX:CI?
MU._??[D]C\A9G)^TO?=[V/7^Z/=NLP>H]Q^]AG@\/7Q>M=UZ=$,)<YWV9,MY
MR_</NG-J]I[BY;#9H0GM\MR6..-2.&SR2PUXX] V%YCOM@9CS)?&GN+(J&8?
M&?N;:V[J5+D_<WNC##9H3VMKEWCCAALK7CHTE_"-YK^:G%_RLM_P"8J_R)9'
M_>*[_JE/]<9]_P#DXW@_NC9_U^I_RH_"-YK^:G%_RLM_P"/\B61_WBN_ZI3_
M %P_^3C>#^Z-G_7ZG_*C\(WFOYJ<7_*RW_ (_P B61_WBN_ZI3_7#_Y.-X/[
MHV?]?J?\J/PC>:_FIQ?\K+?\ C_(ED?]XKO^J4_UP_\ DXW@_NC9_P!?J?\
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M^5'X1O-?S4XO^5EO^ 1_D2R/^\5W_5*?ZX?_ "<;P?W1L_Z_4_Y4WG[///\
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MLA_ !>MA\?8^Z4WSPEY.O/\ ^H/PL&S?S,8+^660_@ ;#X^Q]T?/"7DZ\_\
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M*0C-=QJ.:9A4OYW$H2J-/!032P26O:Z!=*'.'*C2C2]R)X+7RO\ -G2.Z/\
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M=>J>@MN;Y3#-[&=A5FX0FXO%+3WK3X7T"HMM]JMO557W/%X)Z-MK7^]9OO\
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MJKUZHG6Q[P<V%MSN9?\ -.[NZEE2VU7Y2%-5'C3Q6SLN45@]O7CHPU$RYO\
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M$R@?3I
M
M
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M_>2'UE?T+^._FA]6_P#3?XG^=']DB_Y@/^RG_O)#ZROZ%_'?S0^K?^F_Q/\
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M_P#3?XG^=']DB_Y@/^RG_O)#ZROZ%_'?S0^K?^F_Q/\ .C^R1?\ ,!_V4_\
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M_COYH?5O_3?XG^=']DB_Y@/^RG_O)#ZROZ%_'?S0^K?^F_Q/\Z/[)%_S ?\
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M_-#ZM_Z;_$_SH_LD7_,!_P!E/_>2'UE?T+^._FA]6_\ 3?XG^=']DB_Y@/\
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M &4_]Y(?65_0OX[^:'U;_P!-_B?YT?V2+_F _P"RG_O)#ZROZ%_'?S0^K?\
MIO\ $_SH_LD7_,!_V4_]Y(?65_0OX[^:'U;_ --_B?YT?V2+_F _[*?^\D/K
M*_H7\=_-#ZM_Z;_$_P Z/[)%_P P'_93_P!Y(?65_0OX[^:'U;_TW^)_G1_9
M(O\ F _[*?\ O)#ZROZ%_'?S0^K?^F_Q/\Z/[)%_S ?]E/\ WDA]97]"_COY
MH?5O_3?XG^=']DB_Y@/^RG_O)#ZROZ%_'?S0^K?^F_Q/\Z/[)%_S ?\ 93_W
MDA]97]"_COYH?5O_ $W^)_G1_9(O^8#_ +*?^\D/K*_H7\=_-#ZM_P"F_P 3
M_.C^R1?\P'_93_WDA]97]"_COYH?5O\ TW^)_G1_9(O^8#_LI_[R0^LK^A?Q
MW\T/JW_IO\3_ #H_LD7_ # ?]E/_ 'DA]97]"_COYH?5O_3?XG^=']DB_P"8
M#_LI_P"\D/K*_H7\=_-#ZM_Z;_$_SH_LD7_,!_V4_P#>2'UE?T+^._FA]6_]
M-_B?YT?V2+_F _[*?^\D/K*_H7\=_-#ZM_Z;_$_SH_LD7_,!_P!E/_>2'UE?
MT+^._FA]6_\ 3?XG^=']DB_Y@/\ LI_[R0^LK^A?QW\T/JW_ *;_ !/\Z<CC
M_P 4GQ4;Y%RO?ID+L:M1(FX_MFK8Q[']?CG226>>\NV5JM^(B-8J+^2OQ#A/
MG)J/U.S2Z=5OM4T=M+FYH)OE[J<EP;,%'MRECV#E?[);IWPY-E_U?\7_ %O'
M7]9%QY+#S[]*=_U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'GWZ4?5UE
M_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39
M?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'
MGWZ4?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM'N#^
MR6Z=\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO
M#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^
M45NM'N#^R6Z=\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_
MU?\ %_UO#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>?
M?I1]767^45NM'N#^R6Z=\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[)
M;IWPY-E_U?\ %_UO#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/
MK(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y1
M6ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5
M_P 7_6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_ !?];P^LBX\EAY]^
ME'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'GWZ4?5UE_E%;K1[@_LEN
MG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_ !?];P^L
MBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'GWZ4?5UE_E%;
MK1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_
M !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+CR6'GWZ4
M?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM'N#^R6Z=
M\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\ %_UO#ZR+
MCR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_P 7_6\/K(N/)8>??I1]767^45NM
M'N#^R6Z=\.39?]7_ !?];P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\
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M/[);IWPY-E_U?\7_ %O#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_Q?\
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M/[);IWPY-E_U?\7_ %O#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_Q?\
M6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_%_P!;P^LBX\EAY]^E'U=9
M?Y16ZT>X/[);IWPY-E_U?\7_ %O#ZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV
M7_5_Q?\ 6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_%_P!;P^LBX\EA
MY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\7_ %O#ZR+CR6'GWZ4?5UE_E%;K1[@_
MLENG?#DV7_5_Q?\ 6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?]7_%_P!;
MP^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\7_ %O#ZR+CR6'GWZ4?5UE_
ME%;K1[@_LENG?#DV7_5_Q?\ 6\/K(N/)8>??I1]767^45NM'N#^R6Z=\.39?
M]7_%_P!;P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\7_ %O#ZR+CR6'G
MWZ4?5UE_E%;K1[@_LENG?#DV7_5_Q?\ 6\/K(N/)8>??I1]767^45NM'N#^R
M6Z=\.39?]7_%_P!;P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U?\7_ %O#
MZR+CR6'GWZ4?5UE_E%;K1[@_LENG?#DV7_5_Q?\ 6\/K(N/)8>??I1]767^4
M5NM'N#^R6Z=\.39?]7_%_P!;P^LBX\EAY]^E'U=9?Y16ZT>X/[);IWPY-E_U
M?\7_ %O#ZR+CR6'GWZ4?5UE_E%;K1[A;(XMTB/C+C+CKC>+(OS$7'VB:CI$6
M7DJMI292/5-?Q^!9D9*39[3:C[S:"2K$DLB1J[P^)W3JN.:]7EZ\ZV&&W-RP
MXL7B9"C'9BH\2P.]G4?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(WN;RJV=S0ARE6.$,>-/M-G"WS&SNJG)4)[4\,<,)+1U4C?0I2M
M
M
M
M
M
M
M
M
M
M
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M)/O(=ZNIK[./4P-/>U7GK.]L'<7P]SWKWKGW.--XP^?NTH)'Q/S&NK*M':\
MYT<L"^JV#6+END]/$B*V=>OH*BO25>C*D^%=G@[)1V=P[6YA76J+T]+4^P>G
MQJVSX'==8US<M6R4&9UC;<#B-GUS,5FRMK97 Y['U\KB,E7;/'#.V"]C[<<K
M$>QKT:].J(OH(8TXMQ>M,R.FI)26IG/'P^@
M
M
M
M
M
M
M
M
M
M
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M=ZI),DN>7LE!^'3[WJ?>]C1U"=,MI>
M
M
M
M
M
M
M
M
M
M
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M0O53D^\J+9ZOWO9T=4]!(BQ.
M
M
M
M
M
M
M
M
M
M
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M$L[A75M"NOOEIZ>IKKFX)T%2
M
M
M
M
M
M
M
M
M
M
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M4-$;A=)^9YI4;NW/AVDO&7:?F/KEO L)*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R
M2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^
M0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<
M;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3
M^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O
M7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]
MSC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3
MJ?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2
M]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23
M?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'
MZ=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:
M0'O7R'Z=3^23?N<;2 ]Z^0_3J?R2;]SC:0'O7R'Z=3^23?N<;2!WLX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*-:EZK"4>FFNV=B.9U@
M
M
M
M
M
M
M
M
M
M
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MIW%,
M
M
M
M
M
M
M
M
M
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M/0ET.)]1X:,9!B[$?
M
M
M
M
M
M
M
M
M
M
M         !U+?-WUSC;3=DWS;KS<=KFJXFUF,K:5&ND]169U96JQ.>SW3?O3
MN9!7A1?%-/(R-OQSD.NK5A1INK4>$(K%G=0H5+FM&A16-2;P7[N):WQ(K"\G
M<B\L][O.]*''8^W>R.>R3\'Q]I=>Q(_&ZO@?6.E1LDKU2O"L5.%;65ON;&UZ
MQOD<C(F,CCA=:M7S*Z6"Q;>$5Q+]VELR=:VUIDE@W)I1BL9RX9/]VB*ZFLGN
M[5.T31.V?6H7P04]@Y,RM)D>U[U+ JSR+(K9I<+KK9T63%:]!,U$\+49+<<Q
MLD_56QQQ2FQL*5G#CK-:9>8N)=OA(%FN;U\SJZ<8VR?>Q\U\;[6I<..W)7EH
M !U/=]^T7C+6LCNG)&Z:GQ]IV'8V3+;9N^QX?4]:Q<;W>%DF1SN>N4,728YW
MH1996HJG*,)3>S!-RXEI.,YPIQVZC48+A;P779&/L'GE^59K.7MX/)=V>&LW
M:7N?UTVO\8<X[;B'^Z:L-N/W)L&J\99K 9#PQ6&I)ZBS)ZJ5'1O\,C'L;6++
M+Z2Q5-X=.*[;+=+.<MB\'56/04GV4L#=W@3NT[:.Z*A>R';[S=QWRLW%Q1SY
M?'ZIL-2SL&%@F6-L-C-ZQ8=6V/#5YWR(UDEJK$Q[^K457(J)35:%:@\*L7'I
M]TK*%U;W*QH3C+#B>GK:S8<ZCO   .F<@<>Z;REJF5TG?,#1V/6\Q"L5O'WH
M_%X)$1WJ+M*=JML4,E3>[QP6(7,FA>GB8Y%.NK2IUZ;IU4G!G=;W%:UJJO0D
MXU%PKM/C7&GH*VG=GVL[=VF;_C<WKN2RUK1,IE$R''^ZUGS5<KA<G2E]VP83
M*WJ;8&T]EQ7JO6P3Q*Q+<4?KHT8YLL4,/O[&I855*#?)-]Z^%=!]%=G69)RG
M-:.;6[IU4E72PG'@:>C%+B?"N#4^!N:+L>[J(^Y'CJ6ML<M>'E'2&U*&X5XF
M0UF9JK.U[<9MM"K$C8XX,DD+H[4<;49!;C=T:R*2%%D66WWNRCA/U>.OH\3Z
MO#T>H0O/,J>6W.-/'W+/3'H<<7TN#C713-W"Y%D
M
M
M
M
M
M
M
M
M
M
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M04X/HX8KK^"^FRT\3<Q8
M
M
M
M
M
M
M
M
M
M
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M>8TE1OZU*/@JK+#I8O#L&92H*,
M
M
M
M
M
M
M
M
M
M
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MH8['4*\=2C1I58&LAK5*E:)L<<;$1K&-1$1$0B;;;Q>LG:2BL%H2/N/A]
M !7<\U;8H,MW&X/#5YFR)JO&6OX^[$WPJZ#)9+,['G'M>[PHY%?B\C4<C554
M1%ZI\52)9Y-2O%%?>P7;;[6!D3=6FX9;*;^_JMKI))=M,FD[5,*_7^VS@W&R
MQ^JE3C'4+\T2K(KHYLQAZV8F9)ZUK7LE9)?5'MZ=&.ZM3JB(I([&.S9TD_P%
MV5B0O-9\IF5>7!RLEUGAYAG\JBW@
M
M
M
M
M
M
M
M
M
M
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MK7I4ZT2*D=>I5B9!7@C15549%#&C4_Z$)PDHK!:D8JE)RDY2TR;Q9]1]/@
M
M
M
M
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M6%2C3A"2D\4VWWL6^'I%K4QV9
M
M
M
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M^X:#QHP??-<,N+I1[?21*P7PB@
M
M
M
M
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M^[F7Y]/>F^I3O;*A<."LZ4E!UJ4:CBI<NL=G:PQP6.&.".D_@\^'?\Z^2_\
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MG@?YK+O]B4_ZT_\ EQ_E3R[]M5OZM']</[.'HWPJ]K^U3B/IX'^:R[_8E/\
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MN9E$
M
M
M
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MO>&.#M,OEBWHE-=E1]-UN-3;HB-1&M1$1$1$1$Z(B)Z$1$3T(B(20A)_H
M
M
M
M
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MATI=IES'N?\ O:>X?[!G+7T [ :XY'\M6?PJE[9$E]S[VJ>)+M,IN&QI$0
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M\TK,C%#/SG_^)7W)?^#W] ?%AM3S;_0NR_AO;ZI!\X^4:G[WT,2+LG);
M  "6SR0/^(MQ+\Z_*W]'&R&/^<[Z'W'CTO;(EUR;Y0ATI=IEZ0U=)L
M
M
M
M
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M7C?F+@[?1(;F.>7N88P;Y.W_  8\/C/6^PN@;GEQ+*
M
M
M
M
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M]NF4=_.?_P")7W)?^#W] ?%AN!S;_0NR_AO;ZIB7./E&I^]]#$B[)R6P
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M]I%9_P#&0/XZ]J/SK\M?-;0C:'F;][7_ *Y2[50Q9O#X=+I2\PK/F:B.
M  &4>#_KT\0?91T#Z+,24.9_)MQZQ4]"SMH^K0\9=L]+\TK,C%#/SG_^)7W)
M?^#W] ?%AM3S;_0NR_AO;ZI!\X^4:G[WT,2+LG);      "6SR0/^(MQ+\Z_
M*W]'&R&/^<[Z'W'CTO;(EUR;Y0ATI=IEZ0U=)L
M
M
M
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MBTYWY+I'N<OY*E;3H4:.BE",>DDBUUKJYN'C7J3GTVWVSO9VG0
M
M
M
M
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MQF)K;+H_"N6PFH7(Z\]/;>1;V/X_P^0K6W.2O<P]?8YZF>S]"1D;G^Z*%*U
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M)=<F^4(=*7:9>D-72;
M
M
M
M
M
M
M
M
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M^(MQ+\Z_*W]'&R$+YSOH?<>/2]LB5^3?*$.E+M,O2&KI-@
M
M
M
M
M
M
M
M
M
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MC_ ?2_?Q#]:?C#['>E?0UC#U:W?^0;+X)1]KB> .]_TLS3^T;GVZ91W\Y_\
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MR;Y0ATI=IEZ0U=)L
M
M
M
M
M
M
M
M
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MNS_B)K_SVU_F-F3-G.Y\@V_PM>UU#!O,]](+GX'+VRF1^FOAL427_P#EL_\
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MZ38
M
M
M
M
M
M
M
M
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M]F7D_P"C;.'ECOA]+<T_M&Y]NF>]O-Q_AYD/]BV7_#4C#1'"9DB_E>=P>*X
M[I\!8VS/4-<X_P"1,-E-#W'+9B]3QV&Q+;;&977<SDKV0FK4:%:EL>,K12V9
M)&-KU;,SE7P]47+G,GO90W3W[H5KZK&CE5W3E;UI2:C"*EA*G.3DU&*C5C#:
MFVMF#D\<,4]<OM1\WMUS@<U5Q3RFWJ7.\&75H75O3IQE.I4V7L5J<(P3E.4J
M,YN,$FYSA!)8X-6:;/=7V8Z@S=-UI<_\ S93)U4SNR+@>6./LGL6R2:Y@V4J
M%6I1K[+):R>09C*#*]2M$G5\BHUK?&]57=2IOSS;98KO-J6:Y4[FI'E*O)W5
M"=6KR5/9C&,54QE+9BHP@M;T)8MX^8]+FIYZ<X=EDE?=_>"-K2GR5'E;"[A1
MHJM5VIRE)T5&$'.;G4G+4M+>$5A2]Y3Y"S7+/).]\F[$_P 6:WS:\YM-]OB\
M3*\N9R$]UM*#HUJ-JT(I6PQ-1$1L4;41$1#SBSG-;G/,WN<YO'C=75>=67%C
M.3DTN@L<$M2221[3;J[O66Z6[5ANSERPLK"TI4(<;5."CM/\:33E)ZVVVSH)
M;"_DVOD:??"<M_8:E^C?5#9;[,7TNS#^SG[=2-(OMT?X>91_;2_X:N6!.ZG[
MV#N/^P+S!_1[L1OAD/RY9?"Z/MD3RUNO>U3UN7:9YM)N:8[/V@GGJSPV:TTM
M>S7ECGKV()'PSP3PO22*:&6-6R12Q2-1S7-5%:J=4])\:4DXR6,6?4VGBM#1
M+9PQYW'?IP_BJF#R&YZCS-B\?4GIT6<SZS:V'*Q,EDKR1SV]KUG-:=N&<MU7
M12(R7(Y"X]6SO1ZO1L*18_S+FRW5S&HZL*=2VFWB^1DHKJ1E&<(I\48K5HX<
M;M2SN^I1V6XS\9:>PUV=)VCDWSW^_3D'$.Q."R7%/$7KJENG:R?&6B6ER]B.
MVZOUE;<Y%V/D/V?;@AB?'%-3;6DC2=[T=ZUL,D719<UFZMI4Y2K&O<8--*I-
M8:.A3C3Q7&GBGAQ8I\JF>WTXX1V(OC2T]EM=@B&VO;-HWK8\SN&Z[#FMLVO8
MKTV3SVR;%D[F8S>8R%A46:[DLG?FGN7+$G1$5SWN7HB)\1$,A4+>A:T8V]M"
M-.W@L(QBDHI<22T(M,YSJ3<ZC;F];9UX[C@7*OQ>'[ROD_\ THMU_HGX3-<N
M=[Z2T/@,/;:Q+\@]YR]=?H8DM_<E]:3._LW!_->F:V\Y?T1N/'I>V1,N<V'T
MQM_6ZOM<B-2O8GJ3P6JL\U:U6FCL5K->1\,]>>%[9(9X)HW-DBFBD:CFN:J.
M:Y$5%ZFLU.I4HU(U:4G&K%IIIM--/%--:4T]*:TIFT-2G3K4Y4:T8RI2BU*+
M2:::P::>AIK0T]#1S66VW:L_!'5SNS;!FJL,R6(JV6S.1R4$4Z,?&D\<-RS-
M&R9(Y'-1R(CO"Y4Z]%4KKO-\US"FJ5_=7%>DGBE4J3FD\&L4I2:3P;6.O!LH
M;/)\HRZHZV7VMM0JN.#E3I0@VL4\&XQ3:Q2>&K%(_G7-9SVVY.'#Z[C+.4R$
MW5R0P(U&1QHJ(Z:S8E='7J5V*J(LDKV,151.O54..6Y7?YO=*RRVE*K<2X%P
M+CDW@HKHR:71/N9YKE^3VDKW,JL:5M'A?"^**6,I/H13?0.;R^<Y&P#;.H9K
M.[?C(*E?V98UZWF<M%291]5ZEM1*"VO<DF/DK^AC6M6%\:IX>K5*Z\OMY,O4
MLGO:]Y2A".PZ,JE114<,-G8VMEP:U)+9:U:"ALK#=G,7'.;&WLJM2<MM5HTZ
M;DYXX[6WL[2FGI;;VD]>#.C%B+\ "5CA;ZU>D?O+%^K3&V&Y/T4L?6%VV:C;
M\?2V_P#7WVD5G_QD#^.O:C\Z_+7S6T(VAYF_>U_ZY2[50Q9O#X=+I2\PK/F:
MB.&0^+>6>2N$MTQ?(G$VZ[!H&ZX;UK<?L.MWY*-UD%AJ,M4K"-\5>_C;L:>"
M>K89+7G9\;(QS?04=]8669VTK/,*4*MM+7&2Q6C4^@UP-8-<#.VC6JV\^4HR
M<9\:)>=.\_WOJUC#-QF;Q? _(EULWK5V+<>/]@HYE[/<]>'W.Z#C_>M%U](?
M60.FZI123UDST\7JTC8S'MQS3;K5ZFW2E=48X>#"I%K^,A.70\+@X\6[M'/K
MU+!JFWT4_,DC7;N&\W7OB[C<'F=1S_)5+CW2<_[IBRVI<1X9NEU+V/MU'4;.
M$M["^WE=ZMX&S5FE9/2FRTE>VR9S;#96I&C+QE'-]NQD]6-Q2HNM<PPPG5>V
MTT\=I1P4%+'#!J&*PT8:<>BXS>]N([&TH1>O9T8]7%OK/ID9A-BUF4>#_KT\
M0?91T#Z+,24.9_)MQZQ4]"SMH^K0\9=L]+\TK,C%#/SG_P#B5]R7_@]_0'Q8
M;4\V_P!"[+^&]OJD'SCY1J?O?0Q(NR<EL-W^V3S%.[?M(QC];X?Y0LU])DLR
M7':#M6,Q^W:A!9FE]?9FQ>.S,$]G7GW)55TZXV>GZ]SE=)XG=%2,9WN?N_O!
M/ELQH)W.&'*1;A/#HM>%AP;2>' 5]KF5W:+8I2QI\3TKNKJ,WRSGXP=WOY;%
M7<=0T[MRUFY:C:R#.X/1-\L97'.;(QZS4H=DY3V'!OD>UBL5+%*=GA<O1J.Z
M.2*TN:3=BG44YU+R<5][*<,'T]FE&76:*UY_>?@T^L_3$6/<+W4\_P#=3L\&
MV<\<F9[?<A0;+%AJ%KW'C-;UZ&9(TFBU[5<)6QVN85;#88TGDKUF365C:Z9\
MCD\1.LHR+*<BH.WRJA"E!ZVL7*7C2;<GT,7@N!(MEQ=W%W+:KR;PU+4ETEYN
MLU\+N4Q+9Y('_$6XE^=?E;^CC9#'_.=]#[CQZ7MD2ZY-\H0Z4NTR](:NDV
M
M
M
M
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MY75"E&HIM/6EAH6/!)DS1;R[
M
M
M
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M3\[^ZG.]D*S;()\GF-)15S:3:Y:WF^!Z%MTY8/DZT5LS6*>S4C.G#5<@IE4
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M/T^EB6J<K/\ Z9BFU?-M)/<RS2UIUD_9ZC[31!,X7_\ (U/WOH419DZ+6
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M>A%^+?RT#/3T_-&/>="<8;H5HRURJTDNGMI]I,NV2IO,(M<$9=K O*&KY-0
M
M
M
M
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M15V_%[O^*+PU\YG,O]&&REZS;WE+IKMD<R/Y1ATI=IGHBD3)V
M
M
M
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MK>6U_FT+FTG&I0E;PP:Z<M#X4UPIX-<*.W+J<Z5!PJ)J2F_,)"2(%> "*+S
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MG(;24(RNYK#:6$>EPOJO5TF64##!(@
M
M
M
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M;P<,.K'NE7+.\M2Q51M\2C+S4BDMYE_>73[\>[SD'N!P>M9#4=.R-+7M4T/
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M2[3/1%(F3L
M
M
M
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M^@
M
M
M
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MX23Z^CS2M+^+W?\ %%X:^<SF7^C#92\9M[RETUVR/9'\HPZ4NTST12)D[
M
M
M
M                                              !@'N-[EN*NUSC^
MUR!REFVTX%];7U_7*+J\^S[?E6)'TQ6MXN6>!UV:/US'3RJYE>K$[UDSV-Z*
ML4WPWSR+<?*99MGE79CI5.G'!U*LM'>TXMK%Z5M/1&*TR:1D#FXYL]Z^=+>"
M&[^ZU!SJ:'5K2Q5"W@\?SE::3V4\&HQTSJ26S",F5 >[GO(Y3[OMX38=UL^Q
M]1P\UAND<=XVS))@=4J3LBBEE5[F0OR^=O,A:MJ],U'R.^,C;%"C(6>?&_\
MSB9[S@YG[KS*7)Y?3;Y&WB_S=)/!-\&W.6'?3:Q>I*,<(KV$YHN9K=7F?R/X
MNR2/+9O6BO=-W.*56O)8M+6U3I1;>Q2B\$M,G.;E-X^[>.XSE'MBY#H<C<6Y
MMV/OQ>JJYS#6O'/K^VX-+,5BS@-BQZ/8EJA96+XU[',L5W])(9(Y$1R6C='?
M#/-R<WAG&1U=BJL%.#TTZL,4W3J1X8O#6L)1>F+3TDAYQ.;C=;G/W=J;N;TT
M%4MWC*E4C@JMO5P:C5HSP>S...E/&$UWLXRBVBX#V@=Y7&'>!HGO@U"=,)N>
M$@J,WSCO(66RYG5K]AJM2>"7U==,UKEV6-WN3(11M;(B>"5D,[7PL]">;[G%
MR3G"ROW7E[Y+,J27+V\GC.E)\*>"VZ<GCL5$L'JDHR3BO'GG@YF=Z.9[/OB_
M.(\ODM>4G:W<(X4Z\%P-8ODZT4URE*3;6N+G!QF]O#(!B  '4<WO.LZWF\-@
M<YD8\9<S\5E^+FM](J,TE62"-]9]MSDCKV)%L-]6DGA:]?C47Q*C5L]]GN69
M;?4+"_J*E6N%)P<M$6XM)Q<M2;Q6&.">I/'!.\V&09IF=A7S"PI.K1MW%5%'
M3-*2;4E'6TL'CABUK:PQ:[<7@LP     !U':]ZUG3&4O;N19!9R=F&IC<?$G
MKLA>FFF9"GJ*S51WJ8WR)XY7*V-GQ%=U5$6SYMGV69*H>[ZBC5JR4806F<FV
MEHCQ+'3)X17"\<"\Y1D&:9W*I\7TG*E2BY3F]$())O3+C:6B*QD^!88G;B\%
MF,.:#SWQ=R1MV\Z!K>RUEWGCK8,OKVSZED590SL$N'N/I392A2DD<[*X*=[4
M5EJNLC&>-K)?52+ZM+C=Y3?65O2NZT'[EK04HS6F.E8X-\$N@^IBM)TTZ]*I
M.5.+[^+P:X?^PS&6X[@     ##.$Y_XLV;F#+<&ZULD&P;]KNKY7:MEJXA&7
M<9KM7$YG 8.?&9;*1R>YX\_)=V&/_LD?K9(6PR^O]2[U;9+E5RF_H9='-*T'
M"TG448MZ')M2EBE^#A'7HQQ6&.G#IC7I2K.A%XU$L7T-2Z^DS,6T[B-OS*?,
M)UKL.XJH7Z%#';;S3R M^AQAI5^29,;'[ACC]I[GMB5)ZUQNJX"2S"Q8(I8K
M.1M2L@B?&Q+%FM,]R]T:V]5^X3;IY;1P=6:UZ=4(8XK:E@]+344FWB\(RMV8
MW\;&EBM-:7@KS7T%V>RJ0W/'<KSGW,[;9W3F[DG9=\RTUF:Q2J9*\^+7L R=
M&M=3U?6*GJ,!K=%&,1/54Z\+7JGB?XGJYR[-Y5DN5Y);JVRRC"E3PTM+OI=&
M4GWTGT6WT-!#*]Q7N9[=:3D^PNDM2ZA@PNAT   &\/9]Y@W<=V8[3C+W'>XY
M+-\>LNLDV3A[9LC<OZ#L%"65'WV4\=,^=NJYR=OQT>3QS8;+96M]<D\'C@DB
M^\6Z63;R4)1O*<8W>'>UHI*I%\&+^^CQQEBL-6#P:K;2_N+.2=-MT^&+U/N/
MHHO5]KO<KQQW:\+ZIS9QA;E?@]ABEJY/#7G0^VM2V:@D;,WJF?A@?(R'*8J>
M1J]47U=BO)%8B5T,T;G:N9YDMYN_F53++Y?G8:4UX,XOP91Z#[#Q3TIDVMKF
MG=456I>"^NGPIFPA:"H.HZCO.L[Q3EMZ]D66759%AO4I$]3D,?,USF+';JN5
M7L17,7PO;XHW]%\+E+/D^>Y9GM%ULNJ*3@\)1>B<'Q2CP=!K&+X&R\YSD&:9
M#65',J3BIK&$EIA-<<9</13PDN%([<7@LP    "JB)U7T(GI55^(B '4=>WC
M6MJRF>Q.OY!F3FUOV>W)V:W22@V;(K?2*O6MM<K+4D7LY_K%9U8WJB(Y5\2-
MM&79[EF;75Q:9?456=ML;<HZ88SV\%&6J36P\<-"Q2Q;Q2O&99#FF46EO>9C
M3=*%UM[$9:)X0V,7*.N*>VL,=+P;P2P;[<7<LYA[B_GGBWF"YM.(T?9ZE[8M
M(S>7P&V:O:5*6QX.[ALI8Q%B:SBY7++-BY[59?47(5EJR]4:C_6(]C;C?95?
M9=&G4NH-4:L5*$EIC)-8Z'QX/2G@UQ8:3II5Z59M0??1>#7"C,);CN
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M\M>U6GC<CF2,<YKFJBHJH4,X3IS=.HG&I%X--8-/B:>IG8FFL5I1]IQ/H
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M.)]
M
M
M
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M;>\I=-=LL.1_*,.E+M,]$4B9.P
M
M
M
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MUNK^K3\9]LE\?!72.=.HY
M
M
M
M                                   Q7SAPQH'<1Q'R!PCREB'9O0.2
M]:O:QLE"*9:UM*EQK7P7\;<1DCJ.8Q%Z**W2L(URU[<$<B(JMZ'.E4G2J*I#
M1.+Q.JM1A7I2HU%C"2P9YZ?>/Y0_?!V+<EV,YJFD[]R?QS@=AIYCCKGSA?#Y
MW)RT%K9."?6LEL%/5_=>R\9;=CKZUF^.PD=5N1\*4;EGXQZRRWO[:YAA)J,V
MM,7]W6OW,@UWE=Y95,8J4J:>B4<>ICAI3\W4SA/PS_FKV]?;Q='W5;Y)%/X-
M>CAKZ+QDWD&2TZZUL=2+=Z^@-Y)7,ON=(DD;D?=CNOJO%X5\)]^+K'';V%UW
MAUL<#Y\;9DX\GRLN+4L>OACV3(G8MY.7>)WQ<I8_:N5]/Y$XFX9R.R3YSDSF
M3E3&Y3#;3M,<]Q<AG&Z3C-N9#L6[[1L=F65GM589L97M++)9L/FC]SR\+G,+
M>VALTVI5,-"6I=/#4NAK.=EE5U>5=JJI1I8XN4M;X\,=+;X]1Z&6F:AKG'VG
MZIH6G8NO@]1TC6L%J&K82IXO<N'US6L75PV#Q=;QN>_W/C\92BA9U55\+$ZJ
MI$Y2<Y.<M,F\7U2=0C&$%"&B*22Z2/.K\P+L<[UMS[YN[[;M/[/^Z3:]4V;N
M1YDSNN;/K7;]RSG=>V#"93?<Y<QF8PF:Q>I6L;E<5D:DS)8+$$LD,T;D<QRM
M5%);:W-M&VIQE4@I*"T;2XNF0.^L[R=Y5E"E4<74DTU&33TOH%[SR_=:V/3.
MQGM!U'<-?S>J;7K/;=PW@MCUC9<5?P6PZ_F\7H6#IY/#YO"Y2"KDL5E<=;A?
M%/7GBCFAD:K7M1R*A&+IJ5S4E%IQ<WIZI-+&,H6=*,TU)4XIIZ&M"*+/F.=D
M'>EO'?EW<;AI7:%W0;AJ6R<]<BYC7=IU;@'E?8-<S^(O;!;FI97"YO$ZG;QF
M5QUR%R/BG@EDBD:J*URH2:SN;>-K3C*I!245H<EW2&W]G=SO:LX4JCBYO!J,
MFGIZ1=8\J+2MRXZ\N_M6TGD'4MFT3<]>X\L4L_J.Y8'*ZQL^#N.VG8;"5,Q@
M,W4HY7&6EKSL>D<\3'^![7=.BHI';Z49W<Y0:<6]:TK42[+(3IV%*$TXS4=*
M:P:TO@)"RD*XH:><-Y.G,?$G<S>Y"[1>".2^4N$^:Y<IMM;5^(./]KW^UQ1N
M7KX9MMU;(XC4,/EI\'JF0NWVWL&][(J[89I:,2=*/B?)\OS"G4H[%Q*,:D=&
M+:6*X'IX>/K\)"\URJK2N.4M82E1GIPBF]E\*T<'%UN WC_%]MD[V.VK?MG[
M6^?>USNET_@ODY]O;-)W#=^".6L#J?&?)6-H/DR=?)9S,ZI3Q6!USD##TVQR
M23RM@CRM.KX4:ZW.]U-FJMJT%7I3@ZL=#2DL6NOP=HK,CE>6\W;5Z=549:4W
M&22?3PT)]O#C.I?C'?;'W)\X]S_!>P<*=O7./,&!Q' K</ELWQ;Q-OO(&(Q>
M7^J%N-WV5D<EJ> RU.ED?<=J*;U$KVR^JD:[P^%R*O+**U&E1DJDXQ>UPM+@
M7&<<_M[BM<PE1ISG%0X(M\+XD2%?BY7"_,7!_:%S'K7-/$_)?$&QY3N1SF=Q
MNO\ *.B;1H&;R.$FXQXOQ\68HXK;,5B;]O%2W\?/ VQ'&Z%TT$C$=XF.1*3-
MZE.K<1E3DI+8X&GPOB*[(:-6C:SC6C*$G4;P::X(\98&G@ALPS5K,,5BO8BD
M@G@GC9+#/#*Q8Y89HI$<R2*1CE:YKD5%1>BEJ+YK//E\T7R>>X+@CNKV]G;#
MV^\O\N\"\C/L[_H,O$7&&X[_ $^/X\Q?LNR_&>;9I^&RZX5^J9'Q-QONA&I9
MQ$E9S7R3,LI'*[+,*56@N6G&-5:'BTL>CIX^'HD&S'*J]&Y?N>$YT):5LIO#
MH/#BX.@2K_BU_;EW"\%;UW8W.;^!^9N'*FQZEQ-6UZURKQ?N_'M?/6,;F-ZE
MR-?#3[=@\1%E)J$5R)TS(%>Z)LK%<B(YO6ASBM2JP@J<HR:;U-/BXBY[OV]>
MC.JZT)P34<-I-8Z^-&AWG>\;]\G=[WU[KD-([1NZS:^(N'<3C>(^,LSK_;[R
M_EM;SU3"OGR>W;5A\AC]0GQ65JYW=,K>;7OUGRQ7<;5IN;(^-(^E5EL[:WM4
MI5*:J2TOOEU%KXNR46<4[RZO6X4JKI06RL(RP?&]7"^'BP)L_P 7E[*]U[7^
MV#?N1^7] V;CKESG7?'.M:OO&M9/4]QP/'W'K+>#U6CF,#GJE+.8F;)9^_F;
M[630P^OIV*LJ-5JL>MMS:YC6KJ%-ITXK6GBL7K\PN^16D[:VE4JQ<:LY:FL&
MDM6AZ=>+ZQ8&+47PZYN.IX#?=1VG1=KQT.7U;=-<S>I[+B;+4=7RF V/&6L/
MF<=.U45'0W<=<DB<GY+7*?8R<9*4=$D\4<9QC.+A+3%K!])GF<\U>5UWQ\7<
MN\F<=8#M/[FN0M?TK>-EUS7]\T_@CE#9]8W+ 8O+6JN$V?"9[ :I<Q&1HYS%
MLBLM=#(J-]8K51KFJU)E3O;:=.,W4@FTM#DDUT-9CZMEUY3JRIQI5)13:346
MTUQXI'H&>7+R7RYRIV8\%9_GOC_D3C7F?#ZC7TCD?7N4M0V32=NN[%H\DFL/
MVZWB-HQV,R,D6\4,;!ETF;$D+GW7L;T5CFMBMW"G"XDJ33IXXK!XK3IPT<6H
MF]A4JU;2$J\91K)8---/%:,=/'K-W2F*PT\[[NS?0N^WMLW7M^WJP[$29=U7
M/Z1MT-=+=S1N0<&RPNN;35JK)$EJ*%+<]2Y!XV+9QUNQ"U\;I$D;46MQ*UK*
MK'JKC7"BDO;2%[;NA/1CI3XGP/\ =P'GB\Z=I7>_Y:7,U/.;5J_('%VR:%G$
MR.B<ZZ"N8?H^4<V9:=/,Z?R/BZ\6->S)UK;638^T^O?CAM)7O5(G2NA664J]
MM>4\(M236F+U]5?NZ!!:UK>9?6QDI1E%Z)+5U'YFOC1N[Q[L'G*^<E3U?@_+
M\@\B;AP<_(U)=AWC-Z?K_&?"F.JXNUZKVAOFTZ'I>M0\BV\5=QCI*V.G?E[[
M[T"R10I*Q\K*::R_+\:J257BQQ?43;P[!64Y9MFR5%RDZ/"\$H]5I+'I:6:O
M]SOE9=VW$G/O*7&?$_;#W6\L<=Z1M$^NZKR7A^WSD[,8G>L?CZU:)^S8W(:[
MJN0PDU'+6_62Q-K6+$<3'(Q)9/"KW=U&]H5*49SG3C-K2MI:.AK*>YRVZI5Y
M4Z5.K*FG@GLO3T="/1&[5L/E]=[8.V_7]@Q61P>>P? O#^'S>$S%&SC,OA\O
MC./==I9+%97&W8H+F/R./N0/AG@F8R6*5CFN:CD5")UVG6FUI3D^V3JV3C;4
MXR6$E"/:14M\XSR.>7J7*V[=T?9IHV1Y,T?D3,93<.1>&]0ILM[OHNV9227(
M9[+Z/K%=4O;AJFQ921\[<;C(I\EC[5AT<-5]-&NKWW+\RIN"H7#V9)8)O4UT
M7P/ID9S7)ZJJNYM([4)/%Q6M/AP7"GQ+2N+ AXXV\R[S*NT;29. -/YXY.XQ
MU;&XU*%/1-RT_6,ME]3Q-^K*^O4U>QR5IV:VK1Z+J]Y9:S,9/29$KFRP^%R,
M<EPG9V=>7*RC&4N--Z>G@\&6JGF&86L.0A.48K@:6CI8K%=0[GVG>6%WR^8;
MRV_/975.0=<U?:L\[8N3>X[F;%;%4Q4C,K99?S69HY'8VU,GR9MUYEKUD5.A
M),^66:-UF:K7<ZPSC7O;:TIX)IM+1%8?N2.=KEUY?5=IJ2BWBYRQ\W6ST/.W
MO@K0>V7A/C7@7C"C+0T?B_5Z6M85MET<E^^^)TEK*YW+2Q1PPSYO9,U:LY"]
M(QD;)+EJ1S6-14:D3JU9UJCJS\*3)U0HPMZ,:%/P(K#[O5ULIP^;7Y%?-&B\
MK;CS[V9<>97E/AW?,K=V?-\3Z/3GRW(/%^PY*1;>;I8'4ZZ29/;]+R63FDGQ
MT>)CL7<>V5:LE9((([,T@L,SIR@J5PU&HM&+U/J\#Z9%,TR:M"JZ]I%RI2>.
MRM:?07"N+#5J(P^,/-#\SKL]U?'<*:CSQR-QSK^LX^A5PVB\C<?:1M=S6<+'
M'(_%8["U^7]$V7-8#!1UY^E:M6?#5;"C&L8C&,1M;.RLKB7*2BFWPIM8]9HM
MU/,<QM8\C&<HQ7 TGAYY/!'':5VT>9%YHG+M7<9=1YAYDV39JF+AN<S\EU\O
MB..L%K3)%;1=+O>;J4]4Q>!I16)K%;&8Q7SSM2=U.I-)XT7[*M9V5/9QC%+@
M6O'I:^J^J?(6]_F-7;PG.3^^>I+IZL.@NHB_IY>O97J?8/VP:9V_ZWDF;%F*
MEK(;9R+N+*BT??GR+L+*B9[.1TU?(ZKCZU2A5QU"-RK*S'4*Z2N?*CWNBUW<
MRNJSJRT+4EQ(FUC:1LK94(Z7K;XV]?<70*@_G>]GO=ORQYE'.^]\6=K?<9R7
MI&8Q/$,>)W+C_A'DS<M5RDF,X=T3%Y*/';#KNL9+$77X_)4YJ\Z13.6*>)\;
MNCVN1+_EMQ0IV<(SG",ECH;2>M]$BV<6MU5S"<Z=.I*#V=*BVO!7"D6;_)"X
MXY"XG\M?@C1.4]#W/C3=\/EN7I,MIO(&KYS3=JQ<>3YCWO*8V3(Z]L5'&Y>D
MS(8VY#8@66%J2P2LD;U8YJK9<RG"I>3E!IQ>&E/%:D2+)Z=2EE\(5(N,UM:&
ML'X3X&:T><_Y/EOOPI8?G/@6?"83N6TK"-U^]A\U99BL#R_J%6=]G'86_F).
MM7![=KKYY_9MV9J5[,4RU;<D<3*\];NR[,/<N-*KBZ+?6?<*?-LJ=ZE6H8*X
M2PZ$EYC7!UF5/]-[,/-Y[:]]R>&XGX)[XN*=OR3Z.#R^P\(87EC%8?*0RS?]
MDKW>2>*Y':CD<37ELJYTKLG)4K]7.>YB(Y4OLKBPK1QJ2I2C^-AVGI[!&86F
M:6\VJ4*T9/1C':[:T=DSYSOY2O<YQ%V8\S]]7>EL>=P_*,F:XYI:EQ_G-GAW
M??\ +3[=N>NX'(;;RML[K^>CK/9K]IT=/&MN39%LSD6XZJZNM6;JI7]&I<1M
MK=+8P>+PP6A:DO-.^MEEQ2M)WEVVJF*P3>+TM+&3T\'!KX\-1^?XO:USO-$X
M<5K7*C-*YD<]4151C5XRV-B.<J?F6^-Z)U7\E409M[RETUVSYD?RC#I2[3+>
MOG6<>[]RKY9?<MH7%^C[AR1O6>^HW[#TO0M:S6X;9F?9?<!Q5F<G[*US7J61
MS&1]G8?'6+<_J87^IK022OZ,8YR6#+IPA>0E-I16.EO!>"R4YO3G5RZI"G%R
MF]G!)8OPH\"*IWDW=FG=_P 7^91VQ[WR7VI]R7'FD8#+<BR9W<MYX,Y/U+5<
M+'>X<Y$Q=*3+;#G]7Q^(QK+F2NPUXEFF8DD\S(V]7O:BWS,+BWG9SC"<')X:
M%)-ZUT2-93:75/,*<ZE*I&"QQ;BTO!?"T7_R+$W//(\U#LI[R>0_,*[K-UT#
MM*[FMXTW8N3K%_7]MT_@;E/9M9SM!V%P\27<-GL+JMW%9.HLL3FI)!*]GB:J
M=>J*2RQN;>%I",ZD%)1U.23[9!<RM+NI?59PI5)0<M#46T^K@70O*\T[;N/_
M "^^U#2]\U;8])W'7.)L1C=AU/;L)D];V7!9&*Y?=)0S."S-6EE,7=C:]%=%
M/$QZ(J=4])';V49W5246G%RUHEN70E"QI0FFIJ.E/0UU"M1YQGD<\O4N5MV[
MH^S31LCR9H_(F8RFX<B\-ZA39;W?1=LRDDN0SV7T?6*ZI>W#5-BRDCYVXW&1
M3Y+'VK#HX:KZ:-=7O&7YE3<%0N'LR2P3>IKHO@?3(_FN3U55=S:1VH2>+BM:
M?#@N%/B6E<6!#QQMYEWF5=HVDR< :?SQR=QCJV-QJ4*>B;EI^L9;+ZGB;]65
M]>IJ]CDK3LUM6CT75[RRUF8R>DR)7-EA\+D8Y+A.SLZ\N5E&,I<:;T]/!X,M
M5/,,PM8<A"<HQ7 TM'2Q6*ZAW/M.\L+OE\PWEM^>RNJ<@ZYJ^U9YVQ<F]QW,
MV*V*IBI&96RR_FLS1R.QMJ9/DS;KS+7K(J="29\LLT;K,U6NYUAG&O>VUI3P
M33:6B*P_<D<[7+KR^J[34E%O%SECYNMGH>=O?!6@]LO"?&O O&%&6AH_%^KT
MM:PK;+HY+]]\3I+65SN6EBCAAGS>R9JU9R%Z1C(V27+4CFL:BHU(G5JSK5'5
MGX4F3JA1A;T8T*?@16'W>KK97_\ /+\GS<NZO)1]V7:_A:^:YMQ&!I8;E'C9
MEFM1O\HZ_@*WN;"['K%B[+!3L;WKN*B93?2EDC7)XVO#'77W57C@MW7+,PC0
M7(5WA3QT/BZ?0?898\YRJ=R_=5LL:R6E?A):FNBNRNCKJO<"=T_F =@&X9OC
MSAK;^6^"=MV?*U8LWQ5L&B5[S\IL,KW8*G--Q9R;JF<H+LLTD?N-D[<:EU[H
MFQ(Y5C8UM[JT+6ZBIU%&45PX^:GYI&Z%S?6,G3HN4)-^"UPZM33T]0D/N>6O
MYD'>UQ/SSWV]W,/-.P;MA- 27A[CG*ZKEKW,G*N<ER>/AQ&,U3BC#X2.;1^,
M\/5RUO(,JT\;46W*G6I4]3--;;2*\L[:I&UH;*CCI>.A=-\+ZI7_ !??WE*=
M[=;;FH]ZL.^D^A'@7#JZ2X3O7D8=H7=EQ'YCG$^\<K=KW<3QCI6.U+EBMD-P
MY"X4Y*TO5J%C(\=;#1Q]>[L&R:SC<35FOW9F0PL?,UTLKVL:BN5$.&9W%"I:
M2C3G"4L5H33>OIG/)K6ZI7\9U:=2,,):7%I:GPM%[PC),P
M
M
M
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M
M
M
M
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M<KBLC4F9+!8@EDAFC<CF.5JHITM.+<9)J2X"HC*,XJ4&G%K%-:4SFSX?0
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MB.2.:..:&1DL4K&212QO:^.2-[4<R2-[55KV/:J*BHJHJ*4Y5']@
M    '&+FL,F99KBY;&)L,F,DS3,$M^JF9?AHK4=&7+,Q?K?=KL9'=F9"Z=&>
MJ25Z,5WB5$/N#PQX#YBL=G%;6&HY,^'T
M
M
M
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MJ>C9,*'J,/%7:(P_.0^MIPU\_.?^8$9..;GW[<^M1]$6W-_4H>-YA7[,M%A
M!D74>(.6N0*DU_0^+N1=VHU_5^Z+FHZ3LNR5(/6R688O76,-C+L,7K9J4S&^
M)4\3HGHGI:[I27&89?:24;NO1I2>I3G&+X.-KC771V0HU:BQA&4ET$V=>VC3
M=OTC(OP^Z:KLFHY:-51^+VC!Y/ 9%BHV-ZH^EE:M2RU49,Q?2WXCD7\E#MH7
M-O<PY2VJ0J4^.,E)==-H^2A.#PFFGT5@=;.XX  N\ZO_ !:UW]XL3^T*YK'7
M]6GXS[9,X^"ND<Z=1R
M
M
M
M                                                         (9?
M/0[4.?N\;LZU3BOMPT+ZHV^XWGS2]UNX'WTZ7J/J=9Q.E\DXG(9/VIO>QZQA
MI/<^0S]2/U++#K#_ %OB;&K6O5MQRRO2M[ASK/".PUJ;TXKBQ+3G-M7N[54[
M>.U-33PQ2T8/C:XR+OR+_+%[XNSGO%VOE3N/X1^ISH62X#W32J6>^J5Q#MWK
MMFRVZ<;9;'XSV7HF_;/F8_=&/P%N3USZ[:[/5>%TB.<Q'5N9WMM<6ZA1EC+;
M3U-:,'QI%NR;+KRTNG4N(;,'!K'&+TXKB;XBS_W"<@7>)^ N<.4\:UCLCQIQ
M!R7R!0;)$V>-UW3=+S6QU6R0/^,F8L^-;U8OH<GH4LM*"J58P>J4DNNR15ZC
MI4)U5KC!OK+$\KW7<5O_ '&\V:]@+&:L;)R?SER=A<"N?V6_/-8S6[\C[15Q
MD>3S>1>V>=SKN:RZ23R^%SD1RJB+\0FS<*--O#"$8]A(QO%3N*RCCC4G+#%\
M;9<J[,_Q=2SVJ]RO G<5F^Z3%<FMXMVCWU9[08^&[.J0S9"+5,[%BWX3:YN2
MMG=<=AMRL496K/BZBSU8WR=8949$Z/7&;<O1E14-G:6&../#Q8+@Z)*[3(?<
MUQ"O*HI;+Q:V<.!\.+X<. B@[W?)<\R[E[O%[H^5..^VSWPZ%R-SYRMNNFY[
MZL7 6)]L:SLNZ9C+87)^R\YRIC,SC_=N/M1R>IM5X+$?B\,D;7(J)7VV8V=.
MWA"<\)*"3T2UI=(MEYE&85;JI4IT\82G)I[4=3>C[XN:=D7'6Y<0]G7:YQ7R
M)A_>]OO'/ ?%.E;E@?:&*RWL?9M:TO#XG-8SVI@[V3PV0]Q9"K)'ZZK8GKR>
M'Q1R.:J*L=N9QJ7$YPTQ<VUTFR6V=.=*UITZBPG&$4UT4M)M$=)4
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MO79Y[4WA:CGJUK42T5:M2M-U*K;FR_T*%*WIJE1BHTUP?NULS(=9V@
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MH1\E0
M
M
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M]SUG3^]UKI&NY=RG+O.K_P 6M=_>+$_M"N:QU_5I^,^V3./@KI'.G4<@
M
M
M
M
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MSWNBE_2IT;N=*DL(+#!=1/A)UE=>K<6,*U9XU'M8O!+5)K@P6I$CQ1E>
M
M
M
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MG(?6TX:^?G/_ # C)QS<^_;GUJ/HBVYOZE#QO,*_9EHL);!XBADX^\OW4[V
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M>+UGS'T^%WG5_P"+6N_O%B?VA7-8Z_JT_&?;)G'P5TCG3J.0
M
M
M
M
M -&O,PX_W/E+L#[L]$X]J6LAN&<X6VWV/BZ/1;V87%UF9F]A*4:M?Z^[FL9C
MYJL42)UEDF1B*BN14J;.<875.4_!4D4>80G4LJL*?AN#/.,[-^Z+9^S+N/XW
M[D-/U?5]SSW'5O,RUM<V^O-+B,A5V#7LMJ^38VQ5?'=QF19C,S,ZK;A57UYT
M:Y6R,1T;Y=<4(W%%T9-I/BZY K2YE:7$;B"3E'@?16!<.X7_ !EKLDY/H)@.
M?^,.4>$;.5J.J9I;&*QO,/&RTKJTJ%ZC9R>O14-PR43X;UA\L;M6]5)3KO\
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MJ>Q[/E-FS#<]J6<@@P.X9-+F;F]3:;E<0[U<,<4J2N<L[.-[E;N:CK4YX3?
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M?G?J5/QGVBEW;]6J^*NV75".DN
M
M
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M/@:YS?%(L%A,@K4ZIU<K8L>JKT]/H_N=387G.K0M]TI4<<.4K4X+HX/;[4.
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MF<?!72.=.HY
M
M
M
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MGXS[12[M^K5?%7;+JA'27
M
M
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MD<Z=1R
M
M
M
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MV/Y 7_"M[=_WYYL_IQY#+%FGOZ?4]"B39)\FT^G+T3*G'G^_\5+N(_>;A/\
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MJ[HIXI8:>FB;6%T[VUC<-)-MZ.+!M=HWF*8K
M
M
M
M     :)^9C]XSW!?.]KGT>:H8NYZ?\,,V]9I^WTC._V9/\==WOA%;_A:Y2X/
M-\]J0       7!?*,^\9XU^>+D?Z.\Z>A/,!_AA9>O7'M\SQX^UY_CIF?P>S
M_P"%I&3>[S_&.C?L+/?J^+*3G@]\V'B5>W C_,U[VO\ UREVJAIP89,U@
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M1_(&ZAFPP:4O^>/KX\R_96Y$^B_,&R65?)=M\'I^@1#Z_JT_&?;,4E>=0
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M;S"OV9:+"       "[SJ_P#%K7?WBQ/[0KFL=?U:?C/MDSCX*Z1SIU'(
M
M
M
M
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MNN9?U7IT:VP9K6Y6Z<5X,%AU>'LZ.H2G([?D+%3?AU'M=34NQIZI.$6TO
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M$5W1K42DJ5*E66W4;E+C97TJ-*A#DZ,5&"X$9..!V
M
M
M
M          T3\S'[QGN"^=[7/H\U0Q=ST_X89MZS3]OI&=_LR?XZ[O?"*W_"
MUREP>;Y[4@       N"^49]XSQK\\7(_T=YT]">8#_#"R]>N/;YGCQ]KS_'3
M,_@]G_PM(R;W>?XQT;]A9[]7Q92<\'OFP\2KVX$?YFO>U_ZY2[50TX,,F:P
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MW]2AXWF%?LRT6$       %WG5_XM:[^\6)_:%<UCK^K3\9]LF<?!72.=.HY
M
M
M
M
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M2E4KO:J*+P7 M'9[1%+C/:E>M&C:K8I.23?WST]A=GHHN<D>)8
M            "DGYJ?DR]^W-_?=SOS-V^\)4>1>+>3\KK6TX3-U>4^)=8LP9
M"32]<QVS4,GA]]W?4\M7MQ;-C[CV+'#-7?7?&YLJN5S&2.QS&UIVL:=66$XX
MK4WPZ-2? 1#,LIO:U[.M0AM4Y-/PHK@6.MKA/F[*?Q;/N#V7?M5VSO2R&J<8
M\68F]3RFQ<9:SM=3;>2=MCJR).NKSY?5G7M.UK%7W,2.W>K96[:;"KFP1M>Y
MMB+[<YQ24'&WQE/C:P2Z.G3V!9Y!7E-2N\(TUK2>+?0T:%UR[+B<3B\#BL9@
M\)CZ6(PN%Q]/$XC%8VM#2QV,Q>.K1TZ&/H4Z[(X*E*E4A9'%$QK61L:C41$1
M".-MO%ZV2Y)12BM"1R!\/H  !1W\[K'=_/8[W'NW/CCO"[O:';ASO;RFP\=1
M8[N/YL]F:'LT"PV-MXRE5-R]50KXZQ;2YAHU5&OQ4R0QJ]U*PK9)EKM;FCLS
MIT^6CK[U:5P/5U^CTR'YPKVSN-NG5J^YYZ5W\M#X5KZW0Z1M9^+^^:KO'(>X
MYSLY[H^3MKY!V[:;&0V[@WDCDK;<OM>SY3(5J:V=GXORNR;+D+^5R#G4:CLE
MA&RRN5GJKE='+XJL2=.:V,815Q0BE%:))+!=!^8^H5.1YE.I-VES)RF],6WB
M^BL7UUU>@6D^8N6]#X&XMWWF3D[-PZ[H7&^LY/:]GRLRL5\6/QD#I?<M*!SX
MUO9;)6/!5I56+ZVW<FCAC19)&HMDITY59JG!8S;P1(ZM6%"G*K4>$(K%GG&]
MS_FV=[?/G.O(G*6I=R//_#&G;'G9UTSC#C/F3D#1M7T_4J72GK^+3#ZEL6*Q
M-G,IC(8WY&[ZKUEV\^6551KFM;+J-A;4J2A*$)22TMI-M]4@5SFEY7K2J1J3
MA!O0E)I)<&I]<LP<.^3CO7=KY>N%PG?CSISQL/=)O5V#E'0MSY/W_<.5LIVX
M17,;)6P6E4-=W39;$:4MDQ$\5G<,;%8H37;:5H7RQSXFI-'9JF81H7;=K&*H
M+0TDEM='0NM]UDAI95.ZL4KV<W<O2FVWL=#!OA^^6C@XD0D\L_BY?F0:#?NQ
M:'KG%W.6,9D4KXZYHO)FOZS>M8V5+4D.2O8[EB7CZ"A+!'#&RS!':LK'/,C8
M7V(VNF2Y4\WLY+OG*+Z*Q[6)9ZN0W\'WBC-=!I>BP,=ZM^+]^:;L&5;CLMP)
MKFC4W0R2KGMIYIX;MXICV.8C:SH=)WC<,XLTR/56JVDL:(U?$YJ]$7G+-;)+
M%2;Z2?FI'7'(\RD\'!)<;E'S&RRYY4GD>ZSV';;'SWS+NV&Y8[AH<3<Q>LMU
M>GD*O'O%\69H/QVPSZY:S,-+-[7L&2HSS5&Y.U4QK8J-B6)E-KWNE6S7V92N
MH\E36S2X<=;[G2TDARS)XV4N7JM2KX:,-2X\.-]'1TB?DM9>P
M
M
M
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M6'O_ /MS./Z[<_K!]V_WI?"][H?M_P#*_P!-@^KS<#]AY/\ U*V_5CZP]_\
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MA^W_ ,K_ $V#ZO-P/V'D_P#4K;]6/K#W_P#VYG']=N?U@^[?[TOA>]T/V_\
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M1W,ZCM
M
M
M
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MR4./]K>POJ%X+VM[B]=X_4>[*WK.G3UC?BGVOE'(T95>4QV5CAL_ZQ\ML_\
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M #LUUE]W4NJ=F26'NFM[HJ+\S3?7EP+I+6^H7W"+DU
M
M
M
M                                           !T3DSC#COF;1M@XRY
M8TO7.0^/=LKUJFRZ9MV*JYO7<[5IWZF4JP9/%W8Y:MN*OD:,,[$>U4;)$UWQ
M40[K>XKVM:-Q;3E"O'5)/!K@T/I'57H4;JE*A<1C.C+7%K%/ATKIFEWX)?RR
MO@)=K_VH=1_@XNGSCS[RRX\^RU_-W(O)*'G$/P2_EE? 2[7_ +4.H_P</G'G
MWEEQY]CYNY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^
M65\!+M?^U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO\ VH=1_@X?.//O
M++CS['S=R+R2AYQ#\$OY97P$NU_[4.H_P</G'GWEEQY]CYNY%Y)0\XA^"7\L
MKX"7:_\ :AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_  </G'GW
MEEQY]CYNY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^6
M5\!+M?\ M0ZC_!P^<>?>67'GV/F[D7DE#SB'X)?RRO@)=K_VH=1_@X?.//O+
M+CS['S=R+R2AYQ#\$OY97P$NU_[4.H_P</G'GWEEQY]CYNY%Y)0\XA^"7\LK
MX"7:_P#:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_!P^<>?>67
M'GV/F[D7DE#SB'X)?RRO@)=K_P!J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65
M\!+M?^U#J/\ !P^<>?>67'GV/F[D7DE#SB'X)?RRO@)=K_VH=1_@X?.//O++
MCS['S=R+R2AYQ#\$OY97P$NU_P"U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*
M^ EVO_:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_!P^<>?>67'
MGV/F[D7DE#SB'X)?RRO@)=K_ -J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\
M!+M?^U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO_ &H=1_@X?.//O++C
MS['S=R+R2AYQ#\$OY97P$NU_[4.H_P '#YQY]Y9<>?8^;N1>24/.(?@E_+*^
M EVO_:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_ +4.H_P</G'GWEEQ
MY]CYNY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!
M+M?^U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO\ VH=1_@X?.//O++CS
M['S=R+R2AYQ#\$OY97P$NU_[4.H_P</G'GWEEQY]CYNY%Y)0\XA^"7\LKX"7
M:_\ :AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_  </G'GWEEQY
M]CYNY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!+
MM?\ M0ZC_!P^<>?>67'GV/F[D7DE#SB'X)?RRO@)=K_VH=1_@X?.//O++CS[
M'S=R+R2AYQ#\$OY97P$NU_[4.H_P</G'GWEEQY]CYNY%Y)0\XA^"7\LKX"7:
M_P#:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_!P^<>?>67'GV/
MF[D7DE#SB'X)?RRO@)=K_P!J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!+M
M?^U#J/\ !P^<>?>67'GV/F[D7DE#SB'X)?RRO@)=K_VH=1_@X?.//O++CS['
MS=R+R2AYQ#\$OY97P$NU_P"U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EV
MO_:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_!P^<>?>67'GV/F
M[D7DE#SB'X)?RRO@)=K_ -J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!+M?
M^U#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO_ &H=1_@X?.//O++CS['S
M=R+R2AYQ#\$OY97P$NU_[4.H_P '#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO
M_:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_ +4.H_P</G'GWEEQY]CY
MNY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!+M?^
MU#J/\'#YQY]Y9<>?8^;N1>24/.(?@E_+*^ EVO\ VH=1_@X?.//O++CS['S=
MR+R2AYQ#\$OY97P$NU_[4.H_P</G'GWEEQY]CYNY%Y)0\XA^"7\LKX"7:_\
M:AU'^#A\X\^\LN//L?-W(O)*'G$/P2_EE? 2[7_M0ZC_  </G'GWEEQY]CYN
MY%Y)0\XA^"7\LKX"7:_]J'4?X.'SCS[RRX\^Q\W<B\DH><0_!+^65\!+M?\
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M
M
M
M
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MB>F5-X=36NYU">@M9>@  "GY^- \#\'XEW!7<53V#&X#N VZ];XXRVFPQ?\
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MTM#X\=./5UFR1TE0
M
M
M
M
M
M
M
M
M
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MHYYDTK"LWJV'V="[)Y_/E=?\17LM_P!(SC#Z)*9*KWWI4\1D'R[W_1]<7;+
M7XU>S(^Z.QF5?&N)2'N/9'X6_H;,BK^"W3>M<C?0^6LC/5HYR^AC_"B?'=;5
MD>'YWC[W_2+YO+C^9XN__P!$@B\O[@_S).9K'*WX/'-<LX>WK<.E?59^I5W"
M8;@>Q8KYA^U^\GVS[4Y+X[EVJ&&7%Y7U/JO=C:+G/\?JEL,];<[JK9T]GW6H
MZ<<,8[7%CP/#@++8T<PJ[7N!R6&&ULRV>/#A6/#TB27[A_\ &6?\]>[_ /\
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M/$BVB6(DX
M
M
M
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MJWM=T*Z@GLXQP36K6M+?!VF642SD@
M
M
M
M
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MZ!O@4I6@
M
M
M
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MG&<%..F+2:Z3.S'$Y
M
M
M
M
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M*-A-SHRJ/:6#3:PZ>B*THE)*(N0
M
M
M
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M_BO7WD_./^E+L']$W$A0YU[YCXB[;+ENY[SGZZ_0Q(SOQHW[[;MZ_P!'-O\
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MK_'.<]4;9LWH<E<\HO!FL>JM?F/JDAR&YY:TY&7ATWAU'I7FKJ%@PM1?
M
M
M
M
M
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M!DV55;>?NJY6%3#"*X5CK;ZFC#IXEI LA(P
M
M
M
M
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MH[3PIS[U]75V<.IB>C<1$GH
M
M
M
M
M
M
M
M
M
M
M !\.4FR%?&9&?$4J^2RL%&W-C,=;O.QE6_D(Z\CZ5*SDF4\@['U[5EK8WSI7
MG6)KE?ZM_3PK]6&.G4?'CAHUE,SDC\9Y[E=?VS.:Q0[1N+-#R.M[G/AL_@-V
MVO=-LS>&K83+RT-DUJ[)BV:'"FS5UK2UTN+"V""PWQ.J2-3U:R&&2T7%2=23
M37 DNZ1.IO%<1DXJE&+3TIMM]%<&G]V!8TQG'/ER^9MQO@>89.,>".X#$;1A
M\;DO?-=US6Y^2=<=D:36+K^QYW%+%O.H9Z@E1:UNA+;ADBFJ>%6KZIJI:'.[
MLINGM2@UP<'<9?U3L,QIJKLPFFM>"Q70;UI] I"><IV]]F';9W1XK0NRW:*N
M6U6;0Z>7W_5<7NT_(V%X^W:QG<W$S7L?MER_E\FY\NOPU)YJ%R[=MTW/1TDW
M2=L<<DR^K<5J&U<+OL=#PPQ72(?FU"TM[E0M'C'9TK''!XZL>EP%BS\5^U[;
M,;V<\W9[*1VJ^I;)W#77:G'8]<R*W=Q&@:;1V;*THI%2*2K-*M2HL\:='S4I
M(U55A5&VC.G%W$4O"4-/79?MW8R5I.3\%U-'66)%W^-"_?L<'?Z+6O\ ]+/+
M979+[VEX[[2+;O'[\AZTO12)2_Q7K[R?G'_2EV#^B;B0H<Z]\Q\1=MERW<]Y
MS]=?H8D9WXT;]]MV]?Z.;?Z3-X*S)?4)^/YB+?O'[ZI^M^:S=?\ %8?K.=V_
MV3.-OH6V I\[]4I])]M%7NWZC5\9=IEF/F;B'0^?>*M^X8Y.P[,]H7).LY/5
M=EQKE8R9]#)0JQMNA.^.7W%EL79;':I66M5]:W#'*WXYB%FIU)4IJI!X23Q1
M(:M*%>E*E46,)+!GF$][W:)R#V/=R&_=OG(+76Y==MMR>G[/' Z"AO/'V8DG
MFU/<,>B]6-;D:43HK<+'2)3R5>S55[GP.4F=M<0N:*JPX=:XGPHQW>6L[.XE
M0GP:GQK@?[N'06[OQ=SS"Y^=N&[_ &@<IY]MSE3@3#U[7&M[(6(DO[;PG$ZM
MCJ>+:CU];=R7&5^6.D]_Q5Q5JBWPJZ":1UAS:TY*I[H@N\EKZ#^[V\249%?<
MM1]RU'^<@M'1C]SM8&2_QE;_ (=6)_TC.,_H;Y#.&3^^_P!X_,.S>#W@O7%V
MF0:_BRO_ !!]Y_T6N1?Z1N'BY9S[T7CKM,L^[WOZ7K3[<2[KSYPAH/<EPSR/
MP5R?C&Y;1N3M7OZSG*Z)'[IJI81D^-S6,DD9(RMF]=R]>OD*$_A5:]VM%(GI
M:A'*56=&HJL/"BR7UZ,+BE*C46,)+!_NXUK1Y?'=QVP\A=G7<)R1V]\EUG)G
MM#S<E?'YF*O+!C-OU:ZB7-7W+"+*GZ)BMCPTT5AJ=5=7E5]>7PS0R,;-*%:%
MQ256&IKK/A1CJZMYVE>5"IX47UUP/JFW7DI_\47M%^?/;/Z,-Y.C,?>53I>:
MBJRCY1I=-]IEWWS=NZ=.T;L+YLY!QV0]G[QN&)^I#QD]CV1VO?QR-6NXJ*_0
M5\D?6[K.N19+,L1/$O\ [S5^-5.J$:L*'+W48_>IXOI+NZB89I<^Y;*=1>&U
MLKION+%]0\^/L@[9LGWA]UO"7;I0FR%*GR+N=.IM67Q;8W9# Z'B(;&P;[G:
M2V*UNFS(8K4,5<EJ^O8Z%]ML3'^AQ*[FLK>A*L]:6CI\'9(-9V[NKF%!:I/3
MT%K;ZQ<._LP/8-_.[W?_ ,ON&/Z@"/\ QU=?@T^L_3$J^;ME^%5Z\?2G\N_%
M@.PA6N1G+W=ZUZM7PN=OG#+VH[I\:KFIP$Q7-1?BHBIU_NH/CJZ_!I]9^F'S
M=LOPZO7CZ4I3<V\3[IVX\W<D<.;;[HQV[<0[]G=1OVZWK*3WW]:RLM>GG,7)
M'*^2.IDX8(KM.9DCO%!+&]CE14<LCIU(UJ:J1\&2QZY$:U*=O6E2EX<)-=;A
M/2W\N+NEA[R.S'@WG6>S7GVO-ZI#K_)$,#FHM7DO3I7ZUNKGUFL8M&++9C'/
MR-:%R*K:5V%4<]JH]T.NZ'N>XE2^]3T=)ZC(-A<^Z[2%;[YK!]-:'W3> IBL
M
M
M
M
M
M
M
M
M
M
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M0NY1G24E-+!XI:N#4WT2JRFQNK",Z=:4'3;36#>AZGK2UZ.L3=EM+P
M
M
M
M
M
M
M
M
M
M
M
M                        <+7V/ 6\S>UVKF<;8SN-KPVK^(AN029"I7L+
MTBEGJM>LL;5]'7JG5J/8J]$>WJP>O@!S0
M
M
M
M
M
M
M
M
M
M
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M)XFLZY1PTK4?3:$X
M
M
M
M
M
M
M
M
M
M
M                     '1-_P"2-3XUQ"Y?:,@V#QH]M#&U_!-E<K,Q$58<
M?35['2^%7)XY'*R&/Q)XWMZIU^I-Z@:'W\YRUW39U^*PU=V!T6E:;Z^/ULK,
M-CV)T>R?,W6M8_-Y=6*BQP,;T:JHK61M\<AV=[#IGPW2XNX;U'BO'^JP]=+V
M:L1HS);'>BC7)7%]"OA@Z>),?0\2>B"->B]$5[GN3Q'6Y-](^FJO&7WW&[?O
MAN_ZLIV2\ ^&3N;NVNCN"VMMT1D&&V]JK:M8Z-6U<;GYFN61TK7-5C,;F9%]
M*3)TBF>GZ(C7.=,G&,L-#U'TZ3Q%W'Y/7\A]3[F5+5&[1G;CH-CR<;XK=*5B
M-8RILS9&^-S%3IX;OI7HJ.EZM594^RCPQ/AO1%+'-''-#(R6&5C)8I8GMDCE
MCD:CV21O8JM>Q[5145%5%13K/I_8
M
M
M
M
M
M
M
M
M
M
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M$U,YK^1K97%7F>.O;JO\3'=/0^.1JHV2">)WQKXWHU[')T<B*=6H^G,@
M
M
M
M
M
M
M
M
M
M
M                                                     '1N2<!G
MMGTG/X36,W8U_.7*;DH7ZSTA5\D;DD6C+81JSU:]]C5B?+$K9(T?XD5416N^
MII/2#!W#?;-@](]R[%N*5MBVUO@G@KN:D^%P<Z*CVNJQ2L3W?D(G>GW1(GA8
MY$6-C7)XW<I2QT+4#:HX    C\XR^^XW;]\-W_5E.V7@'PD#.H^@ Z;O.@ZQ
MR)@YL#L^/9;K.\3ZMIGACOXRTK?"VYCK7A<^O89^3\5DC?C7M<U5:OU-K4#!
MW!_!^U\5;3L\UK:G6]3G8R+%8RJJMCR\LB(Y,EE:<K9(Z%O'Q-]4GJ7*Z557
MX]&-1KN4I)KH@VC.
M
M
M
M
M
M
M
M
M
M
M                     !'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                                                           !
M'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                                     !'YQE]]QNW[X;O^K*=LO /A
M(&=1]
M
M
M
M
M
M
M
M
M
M
M               !'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                                                     !'YQE]]
MQNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                               !'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M
M         !'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                                               !'YQE]]QNW[X;
MO^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
M                         !'YQE]]QNW[X;O^K*=LO /A(&=1]
M
M
M
M
M
M
M
M
M
M
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MON8IB34[%F)(*V>K1KX+EC$>)WK9&4Y%;XFR-C>]CO&QKF(Y6\G%I8L&83B
M
M
M
M
M
M
M
M
M
M
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M)U; QR_$17N>Y/$=;DV?3+)\
M
M
M
M
M
M
M
M
M
M
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MKD8GBL6["M:V2Y>L*GK+5N;PIXGN7XB(B=&HB)UMMZSZ=G/@
M
M
M
M
M
M
M
M
M
M
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M=2&.O6K5X6HR*""")K(HHHV(B-:U$1$.L^GT@
M
M
M
M
M
M
M
M
M
M
M                                           'X6JM:]6GIW:\%RI:
MBD@LU;4,=BM8@E:K)89X)6OBFBD8JHYKD5%1>B@&"<%VV\8Z_N4^X5,;-.O5
MD^-P-V1EG!XB]XG.EN5*\D:RRJGH6&.9\D<#O$K$Z^K]7RVFU@#/IQ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX5KB]#Q33<YWTW+NMU[KE:6U4RBI+\W4X8O7L3PU27 ]4UI6#32S238@P
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MI[N;TT=BNEM4JL<71N*>."J49M+:CP232G"7>SC&2P,]$J("
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MMY83A-8:."<'JG3FN^A4BW"<6I1;3._%U+
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M)-/IZ=:? UH? RZ4ZM.M#;I24H/A1WTI#L
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MD]3>#C+Q9Q;C+#A2>*X<"Y4+JWN8[5"2DNRNFGI1L&6@J
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MN2JQ37*4I-N+TQ<Z;C.6W1D Q"
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M-*$Z-5ZMI:'T8R6,9+HQ;1=*%Q0N8[="2E'H>:M:ZIFPMAW
M
M
M
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M+1.'C+BXI)N+X\=!T;P;L9MNU<\AF-/\VWWE2.FG/Q7Q\<6E)<6&D[X7\CX
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M_@/OEP;239.][.;[--W'*[M\;C*$_#2[Z"_[R*U8?AKO7P[+:1G@GIC\
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M*15B3LSG(,PR2KLW4<:#?>U(Z8RZO _Q7IXL5I.-O=4KF.,'WW"GK-FBR%2
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M;RC&WNZMO#%PA4E%8Z\(R:6.K3HXCD2I*8
M
M
M
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M3XI-\HW,RG+)*M53N+I:I37>I_BPU=5[33U-%LKYC7K+97>0XEW?^PT3U?\
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MR$]R?=7*<G:JTHNI=K[^>EKQ5JCTTMK@;9:[B^KW&AO"'$O-XS'_ &???2\
M?96TSYLUBKWB^0KOX//T+.%I[ZI^,BT-W9[/E])[5NYC<\!9?3SVH]OW,VSX
M2W&YS7U<O@..=DRN-LL<U4<U\%RHQR*B]45#!V04*=SGME;55C2J7=&,EQJ5
M2*:ZS))=2<+6I./A*G)KJ)GFX&Y9CP       %XWR,-TR&V>7[IF,OVY;?O
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M%XJ46TTUJ::TIFVM:C2N*4J%>,9T9K"49)--/6FGH:Z9N9Q7W-?WK@>1U_\
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MB8O6OXN8#]Y,5^T8#<K+/DVW]8I^A1I5F?RE<>OU/1LYLKBA
M
M
M
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M*DU:S"OI1?2CXY&*BLF@F8JMDC<BL>Q5:Y%12LL+^[RR[A?6,W3NJ;Q37:?
MTUH:>AK0]!1YAE]GFEG.POX*I:U%A*+[#3UIIZ4UI3TK299Y.YSV/DC'X_#O
M@CPF)A@KR92E2FD>S+92-$<^Q.]R->VA%*GBAKJKT8[XY[GN1BLEN]&_>9;R
MV].S<50M(Q3G&+;Y2:UM\.RGIC#3@]+<FEA#]U=P<LW8N*EZI.O>2DU"4DER
M=-ZDN#;:T2GHQ6A**;QP>08G@ -X>T/_ !=O/[-P/ZAE#.?,_P"]K_QZ7:F8
M&YY??-AZW5[=,SCSQ]8[F7[%/(GT(9@SKE7RI;?"*?HT8/K^HS\5]HI?FR1#
MP       6/O)_P#O:=X^SGLOT \9F&^<3Y:I?!8^V5"0Y3[VEX[[2)!^<?K*
M\P?8NY ^A/+$0ROY3M_7Z?HT5]?U&?BOM'F@&ZACD       %P+\76^]@YO^
MSU+_ $>Z6:\\\'RY:_!/Y29+=W_>T_'\Q$TG<1]9W</^[_T4X0UMYQ?H;>?P
M7M](ROS;?36R_AO:*I&":N&U8 ,C\:<EYSC3.-R6-<MG'65CCS.&DD5M;)5F
MJO3T]')!=@1RK#,B*K%545',<YKI+NQO/?;LWWNFV[ZVE@JE-OO9Q\R2^]EP
M:GBFTXSO3NM8;T6#M;I;%S#%TZB7?0EYL7]]'AUK"237X<B\BYWDC.OR^7?Z
MFK#ZR+$XF*1SJF+J.<B^KCZHWUMF7PHLTRHCI7(GH:UK&-ZMX]X[_>6_=Y>/
M"DL53II]["/$N-O[Z6N3XDDEV;M;M9?NQEZL[-;566#J5&N^J2XWQ17WL=45
MQMMO'Y'R1  E+X'^M)IG["O?-?(FU.X/T1LO$E[9,U-YP?IC?>N1]K@=-[P?
MO6N?_L4[G\QK)DG=WY=M/A$/1(@MW[UJ>*RGP;$$2       !9W\JS[TK$?/
MUNO[<K&$-_/I!+UJ':)+EGO1>,S1_P ]S9-@HX+MLU>EFLI4US8;W+.2SV"K
M7K$.*S-_76<9,P-S)T8Y&U[T^';F[GN9TC7+#[ID5O17*:/?:DO+NE:Y-8TZ
MDXV=:5U*<%)J,Y4_<VPY1U2<-N>SCJVGAK/1/[!V6Y?7O]Y<TKT*4\RMX6$*
M55Q3J4X5O=KJQA)K&*J<E3VTFMK8CCC@BN6:>GHZ      =YXRS^<U7D31]A
MUK+Y' YW$[5@[>,R^)MST<A1LLR-=J2UK5=\<T3E8Y6KT7HYJJU>J*J%SR6[
MNK'-[:[LJDZ5U3KP<9Q;C*+VEI36E?N18]YLOL<UW=OLNS.C3N+"M:U8SIU(
MJ4)+8>B47BGQ]!X-:47^CU>/S]D&GG0?^6W_ ,8O_:6&4>;;_P"M_@?Y4LN<
M?[/]]_HD&AE L@     !SFK_ ,9==_?W$_M^N==?U&?BOM'*/A+IEWHUB)F4
MW.Y_[Y;N'^SGRU]'VP&QN1_(MG\%I>UQ(C<^^:GCR[;,&%T.@      F1\F_
MZY?,OSBX'YOO,<\XWO*V]=EZ$O&4>J3\5=LL"F)"^D*YI,;R  Y/#YC)Z_DZ
M>9PUR;'Y+'S-GJ6X'>&2.1O5%145%9)%(Q5:]CD5CV*K7(J*J%59WEUE]U"]
MLIRIW-.6,9+6GYJ>IIZ&L4TTREO;*US&UG97L(U+6I'"47J:\QK6FM*>#331
MF/DSGC8N1,3C\&VNS!XUE>!^:KU)WO\ ;.2CZ*Z21ZM:Z/&QO:CXJZJ[H_TO
M<]6L\,SWGW^S'>.SIV*BJ%LHKE5%X\I-<+XH)Z8PTZ=+<L%A"=UN;[+=V[RI
M?N3KW3D^2<EAR<'P+CFUHE/1HT14<98X)($9  !O#VA_XNWG]FX']0RAG/F?
M][7_ (]+M3,#<\OOFP];J]NF;6;-8GIZWL%NM(Z&S5PF6L5YF>A\4\%"Q+%(
MU5ZIXF2-14_Z4,NWLY4[.K4@\)QI2:?$U%M&(LLIPK9E;TJJ4J<J]--<:<DF
MNJCS_,YG<UL^9RFQ;'ELCG<_F[]K*9C,Y>Y8R&4RF2NS.L6[U^]:DELV[=F9
MZN?(]SG.<O55/)ZZNKF]N)WEY4G5NJLG*<YMRE*3>+E*3Q;;>EMGZ![&QLLK
MLJ679;2IT+"A3C"G3IQ4(0A%81C",4E&,4L$DDDCBCH*L      LL^1AM.QY
M3C;G/5\EF\E?U[5]ITNSKF(MVI;%+!RY_'[))F?9<,KG)2BR,N,ADDC9TC61
MJO\ #XG/5VYWV8+Z\KY-FEC6JSG:4*]%TX-MQ@ZD:FWLIZE)Q3:6C%8X8MX^
M9_VZLJRVUWER+-+:A2IYC=6MS&M4C%*554IT53VVO"<%.23>G9>SC@DEF[SO
M_P#AU<M?/1Q3_2/KAO%S8_3"W];J^UR//K.OD^73CVT46S:,A(       /0=
M\K__ (?_ &K_ &+J/S3R9J1OQ]+;_P!??:1/<M]X4O%,W=SOUK+?[]X?]6D,
M(<Z'T4GZ_3[;,J\U?TMAZQ4[2(W#6HV= !G7C#GG9^/DBQEM'[#K+?C6XJU8
M<VQCV_D+B;CDE6M&U?2L+FNA7T]$8JJXGFZ^_P!FF[V%K6QN,K7^SD],/6Y:
M<%^*TX\23>) -ZN;[*MX\;JCA;9J_P#:16B?KD=&T_QDU+C<DL#K_)'+VU\D
MVE;D9_9V#C?XJFOT99$I1^%>K);CU\+\C<3T?HDB(UJ]? QB*J%NWEWPS;>6
MKA<2Y.Q3[VC%O97$Y?ARZ+T+[U1QP+ENQN9E&[%+&VCRM^UWU::6T^-1_ CT
M%I?WSE@8J(H2T $LW$WUL]$^=?$?M.,VWW2^C%A\%I^A1I_OA]*<P^%U/1,K
M.^=CL^Q7>Z'5M3MYG(SZS@>*=?RF'P+[,BXK'9/.9K9(\OD:U)%2!E_)18VN
MR:;HLCXX(VJOA8U$TY^TK>W=3?>A85*DW94K"G*$,7LQE.=3;DEJVI*,4WK:
MBEJ2/3+[$F5Y=0YKKK-J5&G',[C-JL*E517*3A2IT73A*6O9@YS<8ZDY2>&+
M;(<#78W*      -Q?+_V?8M6[QNWZ;7<SD<,_-\D:WK&8]GV9*[<KKN?R5>C
MF,-D(V*D=S'7Z[^CXI$<WQM:].CV,<W(G-/?7ECSB93*SJ3INK>4Z4]EX;5.
MI)1G"7'&2UI\.#UI-8;^T#E>79KS-[PPS&C3K1H9;6KT]N*?)UJ4'*G4@]<9
MP>J2P>#<7WK:=VX]+3Q#-1>[G^+NH?OU>_:+3$'._P#)UGZ_+T)F3F<^4[SU
MB/HS1$P*;   V/XZ[C]HTZF[%9Z!^V8R*NYF.6U;6#)49&,5((/=[HK#K-'J
MB-5LC7/C;T\#D:U&+DG=SG)S7)J+M+^+N[51[S:EA.+2T+;P>U'@P:;2U/!;
M)C+>7FRRG.JRN\ODK.Z<N_V8XPFF]+V,8[,^'&+2;UK%[1BS>^2-JY$R'NW8
M;WBKQ/<ZAB:J.AQ>.:[JGAK5_$Y72JU>CI9'/E<GH5W1$1(KGV\N:[QW'+YC
M4_-I]Y3CHA#Q5Q\<FW)\>&@EN[^[&4[M6W(9=3_.-=_4EIJ3\9\7%%)17%CB
MSH98"0  F;QO^+J'["J_J$9NE;>]J?B1[2-(KKWS4]<EVV5SO. ^^6T?[!FM
M?1]R89LYN_D6K\*E[73(OFWOF/B+MLBG)X6L      V/[/OOI> /LK:9\V:Q
M9MXOD*[^#S]"RIM/?5/QD69>^'[RON^_T7>?_P"B?;3">['TER[X=0]M@2.]
M]YU?6I>A9YR)N,8]       !=2\@#[Q;+_9ZY ^AS0C6OG9^E,?@E/T50F.0
M^\GZX^TB;')?XNO_ +"M?J$ABJY][5/$EVF2&U]\T_7(]M$,AI:;N@ [YHG(
M^T\=Y'W=K]Y6UY7-6]B;7CFQ>18G3T6:R/;X941.C98U9,U/0CNBJBW_ "'>
M3-=W+GE\NJ?FV^^IRTPGXT>/BDL)+@>&*<?W@W9RG>6V]SYC3_.)=Y4CHJ0\
M67%QQ>,7PK'!K*7(G<AM.XT68G!P.U/'35V-R2U+CI\E>D?'TL0)?;%7=6H>
M)51&QM;)(W\V[PN5B2K>/G*S7.:"M+&/N2V<>_V98SD\-*V\%LPZ"2;6MX/9
M(GNWS8Y3DM=WE_)7ERI/8VHX0BD]#V,7M3Z+;2>I8K:-<3&QDP &_G:5_$O9
M/GH=\R<<; \T7R)<_"OY.!KQSP_+EK\$_E)G1?,F^\KYG_\ #K^EC1#8#<OZ
M2VW\)[5,PKF/O.?4]$BJ>9Y(N       "V;Y?7WG7"'[Q9WZ,MD,!;W?2.Z\
M:/H(DJL/>D.D^VS"_FV[5LFI]F&WSZSG,G@;&9VK3]=REG$VY:-FY@\I?E]I
M8J2S7<R=*61C@;'.QKD2:)71OZL>YJZY\_M]>6'-Q<2LJLZ4ZE>C3DXMQ;A*
M3VHXK3A+#"2X5BGH;1M+]D;*LMS;GILZ>9T*5Q3HVEQ6@JD5*,:L(+8FD\5M
M0;QBVN]EA)822:I^GGL>PP     !_J*K51S55KFJBM<BJBHJ+U145/2BHI]U
M:5K/C2:P>HO!=B^R9_;NT3@+8]IS.2V'/Y/C_'RY+-9BY-D,GD)H;%NLR>[=
MLODL6I_40-:LDCG/=TZJJKZ3TTYL+R[S#F_RF\OJDZUU.TBY3FW*4FFUC*3T
MMX):7I/#GGURW+\HYWMX,MRNC2M\OI9A-0ITXJ$()J,FHQ6"BL6W@DDN!$1W
MG$?7QXQ^Q3']%^RFSG-U\EU_A'^A$P/F_JT?%\UD11D$M(     !G/M@^^6[
M>/LY\2_1]KY:\\^1;SX+5]KD=]M[YI^/'MHN1FN1+BJ=YDWWZG,__AU_1/HA
MGG<OZ-6W\)[;,B^8^_)]3T*-&B4%$      2!>6%]^+Q_P#O%OOT&YDB6_'T
M<K>-3]'$K\M]]QZ3[1:4,%DF(M.>/KM[G^S:/S(QQJMO]]+KWQX^UP-LN;[Z
M'6/K<O;)F(B'DR.5PV;RVNY*ME\'D+.,R51_C@MU)%CD;_[DQZ>EDL,B>A\;
MT<Q[55'(J*J%597UWEUS&\L:DJ5S!XJ47@^ET4^%/%-:&FBDOK"SS*VE9W].
M%6UFL'&2Q73XTUK36#3TIIFRMONKVR?5V8ZOBJ%39W>.&QL+%\=9($8U&6:N
M*D8Z./(/55\2O>^%JMZHQ?%X69-K<[&;SRI6U.E3AFCT.LM*PX'&FU@IOAQ;
MBL,5'3A'%]'FCR>GFSN:E:I/*EI5%Z)8\,95$\7!<&"4GC@Y:,9:Q9#(W\M=
ML9')W+.0OVY%ELW+DTEBQ/([XKI)97.>Y?R$]/H3T)Z#%UQ<W%W6E<W4Y5+B
M;QE*3;;?1;,J6UM;V="-M:PC3MX+",8I))=!+0?$=)WFPG;']=2I^\N9_48S
M(G-?]*X>L5.TC''.I]$I^OT^VR20V5-8B@1RALFP;?R-N^R;3FLIL6?RNS9B
M?)9G,WK&1R5V5EV6")UBY:DEGD2&O"R.-%7I'&QK&HC6HB>4>=WEWF&<7-Y?
M59UKNI7FY3G)RDWBTL6\7H227$DDM"/T!;KY;E^3[N6.6Y50I6V7TK6FH4Z<
M5"$4XIO",4DL6VWPMMMXMMG0RU%^      +&7D0[#G;N#[E=:N9C)6M>P-[B
M3)83"V+D\N,Q-_8&<FQYRYCJ3WN@ISY=F$J)8=&UJR^YH_%U\*&X/V6[NZJ6
MV=652I.5I2E:RA!MN,)5/=.VXK4G/8AM8:]E8ZCSC^WEEUA1OMV<SHT:4<QN
M(7\*M112G4A2=DZ49R2QDJ;JU-A-O9VY8:R0[S0/^'_W4?8NO?-/&&[>X_TM
ML/7UVF>=N9>\*OBGGQ&VY @       7I/) _X=7$OST<K?TC[&:N<YWTPN/6
MZ7M<2;9+\GQZ<NVR1SFGZU>[_O++^K0F%]]OHI?>L/MHR!N/]+;#U]=ID4YJ
M>;<@ ROQMS#M?&UED=&=<E@'RJ^WKUV5RTW^->LDU*3H]^.MN^+XXT\+EZ>L
M8_HB)+=VM\<VW:JJ-"7*Y>WC*C)]Z\=;B]+A+HK0_OE(B&\^Y>4;STG*O'DL
MQ2PC6BN^6&I26A3CT'I7WKB<YR?SOL_(2RXVKXM?UAWQOLFK,K[%]$_];+76
MMC=9:J]52%J,A1.G5'N1'E=O3O[FF\6-M2QM\K_1Q>F?KDM&/BK"/&FUB4&Z
MG-_E6[>%U5PN<U_226"AZW'3L^,\9<3BG@8,((3X $F/;;]:3!?LW.?->X;.
M<VGT1M_'J^V2-6^<_P"F-QZW2]KB:B^;;M6R:GV8;?/K.<R>!L9G:M/UW*6<
M3;EHV;F#RE^7VEBI+-=S)TI9&.!L<[&N1)HE=&_JQ[FK%.?V^O+#FXN)656=
M*=2O1IR<6XMPE)[4<5IPEAA)<*Q3T-HRU]D;*LMS;GILZ>9T*5Q3HVEQ6@JD
M5*,:L(+8FD\5M0;QBVN]EA)822:I^GGL>PP     !_J*K51S55KFJBM<BJBH
MJ+U145/2BHI]U:5K/C2:P>HO!=B^R9_;NT3@+8]IS.2V'/Y/C_'RY+-9BY-D
M,GD)H;%NLR>[=LODL6I_40-:LDCG/=TZJJKZ3TTYL+R[S#F_RF\OJDZUU.TB
MY3FW*4FFUC*3TMX):7I/#GGURW+\HYWMX,MRNC2M\OI9A-0ITXJ$()J,FHQ6
M"BL6W@DDN!&)N['ZXN%^<K'?-W8S&?.W](Z'P&'MM8FW-!]&J_PZ?M5$U@,7
M&53]ZMJS2L0VZ=B:K:K2LFKV:\KX9X)HW(YDL,L:M?'(QR=45%144[*56K0J
M1K492A5B\5)-IIK4TUI3.NK2I5Z<J-:,9T9+!QDDTT]::>AHV@P7=1MF-URQ
MC<IBZ>;SL4;(L7G)WNKL\/14=)EJ4#&I>FC3IX5C?!X__7ZKU5V4;#G6S:VR
MV5M=4H5[])*%5O#JU(KPFN#!QQX=.EXIS#FERBZS.-S:59T,O;;J4DL>I3D_
M!3X=I2PX-&A:Z[%LN=VS*39G8<E9RF0GZ-6:PY/#%$BN<R"M"Q&PU:T:N7PQ
MQM:Q%55Z=54QSF.9W^;W4KW,:LJMQ+A? N)):(I<"22Z!DO+<KL,GM(V66TH
MTK:/ N%\<F],I/A;;;XS@B@*\R%Q-]<S1/GHQ'[<C)%NE])[#X53]$B-[X?1
M;,/@E3T+)9C;<T_*47)_UR^0_GYVWYOY V7L?>5'UJ'H40ZKZK+QGVSHQ5'6
M      37>3/_ !EY\_>+C_\ ;^UF-.<CU&T\:IVH%YRCPJG27FD]!BDOAYH'
M.'UZ>7_LH[_]%F6-U,L^3;?UBGZ%&.:WJT_&?;,7%<=0     !9@_%O_ ..O
M==\Z_$OS6WTPKSR>]K#URKVJ9(]WO#J]*/FEI79?XN9_]Y,K^T9S7G,_DVX]
M8J>A9-LL^4K?U^GZ-$.1IH;K  []H7)6U<=9#W9@+J^Y9GM=?Q%I7RXO((WH
MG_:*R/9X)T:G1LL:ME:GH1W1519!D&\V:[N7'+9?/\TWW].6+A/IK'7Q26$E
MQX:"/;P[KY3O+;<CF-/\ZEWE2."J0Z4L-*XXO&+XL=)D[D;N-VC<Z:8G"0.U
M3%2PL;D$J7'SY._(Z-/7POOMCKK7H^-51&1M:^1OYMRHY6))]Y.<C-<ZH^Y+
M&+M+1Q6WLRQG-X:5MX+"./ DFUX3P>RHKNSS9Y3D=;W9?25Y=J3V-J*4(+'0
M]C&6,\.%MI/P5BMIZYF.#)8 -_.TK^)>R?/0[YDXXV!YHOD2Y^%?R<#7CGA^
M7+7X)_*3-K#+!B(HTFT)"@       3T>3/\ Q:Y\_?WC_P#:&UF*N<CU:T\6
MIVX%\RCP:G37FG=/.LV+/8'M)UJMA,SD\17V;FW5]=V&''7;%-F;P,NC\D9:
M7#9-M>2-+N,ER6(JSO@D\4;I*[%5%\*&F/VD[RZM=P*,+:I.G"MF=*G446UM
MP=&XDX2PUQ<H1DT]#<5Q&['V)\NL+_G<N:M]1I5JEKD=>M1<XJ3IU5<V=-5(
M8I[,U"I.*DL&E.23TE48T0/6$      ^JE=N8VY4R..MV:&0H68+M"_2GEJW
M*5RK*R>K;J6H'QSUK-:>-KXY&.:]CVHJ*BH<Z=2I1J1K492A5A).,DVFFGBF
MFM*:>E-:4SJKT*-S1G;7,(U+>I%QE&24HRC)82C*+Q3BTVFFFFG@R^IP3E<E
MGN#^&\YF;UG)YC,\5<>97*Y*[,^Q<R&2R.HX>Y>O6YY%5\UFW:F?)(]RJKGN
M55^*>J.ZU>M=;LY==7,I3N*EA;RE*3Q<I2I0<I-\+;;;?"SP/W\M+:PWYSJQ
MLJ<:5G1S:[ITX16$80A<5(QC%+0HQBDDEJ2(IO.8_BUP'^_O('[0U0S3S;^K
M7?BT^W,QWF_@T^F_,(%S*I8P       7EC5XFI OYS'\9> _WBY _;^J&5N;
M?U&[\:GVIECS?PJ?2?F$*)DLLP     !WGC#ZY?'GS\ZE\W\>4M][RK>M3]"
MSLI>JQ\9=LNNFM!,347NY_B[J'[]7OVBTQ!SO_)UGZ_+T)F3F<^4[SUB/HS1
M$P*;   V/XZ[C]HTZF[%9Z!^V8R*NYF.6U;6#)49&,5((/=[HK#K-'JB-5LC
M7/C;T\#D:U&+DG=SG)S7)J+M+^+N[51[S:EA.+2T+;P>U'@P:;2U/!;)C+>7
MFRRG.JRN\ODK.Z<N_P!F.,)IO2]C&.S/AQBTF]:Q>T8LWODC:N1,A[MV&]XJ
M\3W.H8FJCH<7CFNZIX:U?Q.5TJM7HZ61SY7)Z%=T1$2*Y]O+FN\=QR^8U/S:
M?>4XZ(0\5<?')MR?'AH);N_NQE.[5MR&74_SC7?U)::D_&?%Q1245Q8XLZ&6
M D  )F\;_BZA^PJOZA&;I6WO:GXD>TC2*Z]\U/7)=ME8GSQMFV&;N+XQTV7-
M9)^J8_A7#;-2UU;<WLBML.8WGD/%93-1T?%ZA,E=QN"IP/EZ>-8J[6]>G7KI
M3]IR]NY;X6672J3=A#+85%3Q>PJDZ]Q&4]G5M.,(1;UX12/3_P"PSEF70YN<
MTSF-&FLVJ9W4HRK;*Y1T:=K:3A3<M>Q&=6I)1U;4V]9">:UF[0     !M)V2
M[/L.J=W/;A<UO,Y'"6<IS3QIK&2FQUF2LZ_KVT;GA<%L.&N>K5$L8[+XF]+!
M-$Y%:YC_ .ZB*DXYM+V[L-_\FJ6=2=*<\RMJ<G%M;5.K6A"I!\<9PDXM/0TS
M%G/=E>79MS1;R4<RHTZ]*EDE[7@IQ4MBM0MJE6C4CCJG3J1C*,EI37%B7CST
MY/#(\N\WB,:        M8?BW_P#$ONO^>CB3YD[Z8'YY/?-AXE7MTR4;O>!5
MZ<?-)M.[7^)>M_/0WYDY$T]YW?D2V^%?R<S8#F>^7+KX)_*0- S7XV' !L9Q
MQW&[/IE5<5G(9-KQ$4#VT&VK:P9*C(UB^HA9D'Q6'3T5>B-5DC7NC:OQB]&H
MQ<C[M\Y&:9+2]R7T7=V:B]C:EA.+PT)3:>,<=&#3:7@O!;+QIO-S9Y5GE7W7
M825G>.2V]F.,)K'2W!..$L-.,6E)^$L7M+&6^\E;5R+D$N;!=_[+"]SJ&(J^
M.'%X]KNJ?H%=7N]9.K5Z.FD5\KD]"N\*(B1C/]YLUWCN.6S"?YJ+[RG'1"'2
M7"^.3QD]6.&")3N]NOE&[5OR.74_STEW]26FI/IO@7%%816O#'%OH!'R1  F
M-UK^+F _>3%?M& W+RSY-M_6*?H4:4YG\I7'K]3T;.;*XH0
M
M
M
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MT;U5&2QJ^PW6]&06<^3KW-/;Q:PBI3P:UI["EAU>BN!E7"RNJBQC!X='!=O
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MFYSYKW#9SFT^B-OX]7VR1JWSG_3&X];I>UQ-)O.-^\KS?V1-!_;ULA/VB/\
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MRN*$
M
M
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MJMO]]+KWQX^UP-LN;[Z'6/K<O;)F(B'DR)+^X/ZR^<_[M_-O%FS7.']"J_\
M ^V0-7.;CZ<6_P##>U5"- UE-HR2_M\^LO@_^\GS;RALUS>?0JA_#>V3-7.<
M?Z<7'\#[53(T#64VC-A.V/ZZE3]Y<S^HQF1.:_Z5P]8J=I&..=3Z)3]?I]MD
MDALJ:Q'GW;=_&O9_GAS7S2LGDSF'O^OZ]/T3/T'Y1\DVOP>GZ")UTI"XECWR
M.>$UQ^M<K]P63J.98V&[6XQU*=_A:[V/B'5,_ML\:=%>^M?RTN-B:[JB))0D
M3HJIZ-P/LQ;M.G;YAO;6CWU1JUI/\6.S4K/HIRY%)ZL826G@\WOMS;[^Z,RR
MGF]M9IT[>#O;A?\ >5-JE;I\"<::K2:UX58O1PRA\,<U<?=XNB<[:Y%%6N:]
M@]_Y.X,V*K!(]OMO6$AEQE3-QQ6&NDBI[+KN3ZQN5%:Y[)/0U6NC9FW=G>?*
M><G*,VL<(NSIW=S9347IG1:<85$GI2JTY/#%:U+0L'%:M[Z;D[P\S>?9#F4G
M*&8U\OLLSI2DE^;KXJ<J3<=#E1K0TK'%)QTO%2=,+EKCK,<1<G[]QAGVJF6T
M/;,YJ]N141K;7LF_/5@OP]%5%K9&LQD\2IZ'1R-7\D\YL[RFYR+.+K);SWS:
MUYTI<3<)..*Z#PQ3X4TSVCW2WCL][]V,OWHR]_[G?VE*O%?@\I!2<7T82;C+
MB::,>%K)$6&O(8_\U?\ X&_^UA-N?LL?^>_^"_\ NSSO^WM_^J?^I_\ X\DF
M\T#_ (?_ '4?8NO?-/&&\>X_TML/7UVF><.9>\*OBGGQ&VY B?;R1?+]T[N+
MVG9^XOFK7:VS\8<6YNIKVEZAEH/7X'<.2(X*>9N6MAIS1NK9C7]/QENJ]]&3
MQ5[MN[$DR/AAE@FQ/SF[VW.3T(9/ELW"^KQ<IS7A0IZ4E%ZU*;3[[6DGAI::
MD&2V$*S=S66,(O"*?'Q]3@Z/2)%_,"\[+'=L/(^<X$[=^/M8W_>-%F9B=SVS
M<+.1;H6LYJO6>V?4,7KVNVL1D\_D,/(^)EV5,C1@IS1256LED1[X8?NES:3S
MRSCFV<5ITK6KIA"&'*26/AN4DU%/3@MF3::EH6AW"_SB-K4="C%2J+6WJ3XN
MCT=*XNEKWVF_C >V[=RIKFE=U/'/'.MZ7M>5KX1G(/%U;:L0FFV\C)!6QV2V
M+ [/L^XORV!9=?TNS5K5>:M7>LS(IEB6*6[9_P TMO;V$[G(JU:=S3CM<G5<
M7MI:6HRC&&$L-2::;T-K'%4]GGKJ553NHQ2D\,5C@N+%-OKX]0XGS[.#NW&S
M0P?/_'NX\7XKG2AMT>D\JZ-A-HU2':]TQMNK.M?9,IJ];)-S-K9]/R%2*K;E
M2LZP^E=:MAR,JQ].SFJS3.5.64WE.O+*W3VZ4Y1ELP:?@J36"C--M+'#%:/"
M8SVWH."N(N*K)X/2L9+I<+7:Q*QAFXBY>D\D#_AU<2_/1RM_2/L9JYSG?3"X
M];I>UQ)MDOR?'IR[;)'.:?K5[O\ O++^K0F%]]OHI?>L/MHR!N/]+;#U]=ID
M4YJ>;<FYO:#_ 'UOO['UO]4SAFCF>]5S#Q:/;JF$>>;U++O&K]JD85Y_^N]N
M7[(Q7S Q1"><'Z87OC0]JIDYYN_H99>+4]NJ#@#Z[VF_LC*_,#*CF^^F%EXT
M_:J@YQ/H9>^+3]NIF:N[[^^M"_8^R?JF#)MSP^JY?XM;MTB#<S/J68^-0[54
MTR,+F;B3'MM^M)@OV;G/FO<-G.;3Z(V_CU?;)&K?.?\ 3&X];I>UQ-)O.-^\
MKS?V1-!_;ULA/VB/\-JOPNAZ)F:OL;?XUT/[.N_01*CAH">NP +>W:?@L=V1
M^7)#O6PU8ZN:K:#L'.&SU+2._P"W[3M&,CO:S@YXX%CDCMRXZ+#XES5>BI,S
MTO:GI;O[N#;TN;/F:^.+M)77N6I>S3QPE5JQ7(P:6E.450I-8Z)8XM<'D#SL
MWUQSW_:/>0Y=)RLI9A2RRC*/WM"A-QKU4WBG%3=Q73P\%Z$^'E.\O5<1WF>7
MSDMQU2NV[=LZ+KO/&CPPR-FEK97!XA<UDL4U'1L>_(NUZYD\8L?1DB69?"J(
MJ*T[^<>SH<X_-#+-;%*57W-3OJ23QV94X;52'1DJ<JU/#0]O1KT%)S,9K=\S
M'VA:>39M+8HQOZV5W+:P3IU:G)PJ:'HART:%;'2MA8K0TRGJ>?9[$@ NT^7K
M]Y7VZ?8\I_-#('I9S2?X;9/\#CZ*1XB_:&_QKWC_ +1EZ"!T#NQ^N+A?G*QW
MS=V,QYSM_2.A\!A[;6)3S0?1JO\ #I^U436 Q<95)+__ "V?^$G_ ,+)LU__
M $T_](_D35S_ /J?_P"L_P N1H&LIM&2!=IG\1-@^>VQ\QL,;!\T?R#<?"W[
M73-=>>'Z06WP./ME0TKW_P#CWNOSV[)\V;IA/>#Y>O?A=;VR1G+=WZ/V/P.C
M[7$Y3B;ZYFB?/1B/VY&5>Z7TGL/A5/T2*/?#Z+9A\$J>A9+,;;FGY2BY/^N7
MR'\_.V_-_(&R]C[RH^M0]"B'5?59>,^V=JX X?RW//,&C<58B22J_:<NV+)Y
M)D;9/8^OT89<EL.7\$CF1/DQ^&J321,<YJ33(R-%\3T.C-LQIY5EU6_J:53C
MH7')Z(KJMI=!:3E;T77K1I+A>GI<)8YYMYAX?\NOA+6-;TK3()[N2DMX[2-/
MJ3LI2YW)4JU3VWM>V9KU,UJPE=)JZV[*LELV)I8H6(QB^.'#F69=F.^.9SKW
M51J$<'.;T[*>.S"$>O@M26+>+UR&M6I6%%1@NDN/C;(\=*\XCE&/:ZC^1.,M
M NZ/):<R]6TR/8L5M5.E*YS66*M_-[)F\3D;-)CD<Z)U:LVRK5:DD'B\3)?<
M\W5B[=^XZ]976&ASV7%OHJ,8M)\>+PXF6^&;5-O\Y&/)]#''MFR?F.:;P3S'
MP33YAPVVZ%C>2,+KNO[CJ-VWGL-B,_NVBYR&*XW .HVKM:]DG6L=<6YC8UBE
MG2Q"L,*-]?(BV7<VXS7+LU>75:=9V4IRA-*,G&$XZ-K%)I:5A+2E@\7J14YA
M"A5H<JG'E$DUIUKB[A7>,OD?)KO)G_C+SY^\7'_[?VLQISD>HVGC5.U O.4>
M%4Z2\TGH,4E\/- YP^O3R_\ 91W_ .BS+&ZF6?)MOZQ3]"C'-;U:?C/MFRWE
MV=H=CO3[G=2XGN37:.B8RM9W?E++8]WJKM'0\#8IQ7ZF/LNBFBJY38<E?JXV
MM*YKT@DM^N5CTB5BV3?#>%;M9)4OXX.ZDU"DGJ<Y)X-KA44G)KAPPT8E7EMI
M[LN53EZFM,NEQ=7NEK?O4[X^!_*HXJX_XCXLXNPM_;LG@;2<;<38"PS7==U_
M7Z*OHOW3<LE%7OY*>M:S#7=55),CG;<=ETEECTFLMP-NUNQFN_E_6S"^KR5O
M&:Y2K+OI2D].Q!8I:%^]@FL(M81)1>7M#+*480CC)^#%:%@N%\7;;ZK(>-0_
M&*>Y2MM=.QOO"7!V:T?W:U;^(U"OONL[7[/=:C5S:>Q9G=]MQ'NV*EXVHK\7
MX))>CNC&]6KD2XYG\EE0:M+JZC=8:'/DY1QPX8J$'AC^-JXRT0W@K[?YR$'3
MZ&*?7;:?66/0)3>_JEV<=^?8W7Y8DY XVU+;+?&F2Y2X"V[>]@U/2MSIY#$N
MN-O:/=]N9:G,N.S>>Q-C 9*LV:>G%DF^MB=)+!$]8+NI/>/=7>=Y>J5:I;JN
MJ5>$(RG!IX836RGIC%J<7@FXZ'@FT7:]IVM]9<HW%=[C&3P6'5>I/4^Z4FS9
M@A!9@_%O_P".O==\Z_$OS6WTPKSR>]K#URKVJ9(]WO#J]*/FEI79?XN9_P#>
M3*_M&<UYS/Y-N/6*GH63;+/E*W]?I^C1#D::&ZQLQVJ?7)O_ #I9/YIX4R;S
M4?2:I\$GZ.F8NYW/HQ3^&0]!5'=7]<FA\Z6,^:>:'.O])J?P2'HZ@YH_HQ4^
M&3]!2,*Z!_'O2OGMUOYLTB$[O_+UE\+H^V1)SO%]'[[X'6]KD;J=V?\ $37_
M )[:_P QLR9LYW/D&W^%KVNH8-YGOI!<_ Y>V4R/TU\-BC?SM*_B7LGST.^9
M..-@>:+Y$N?A7\G UXYX?ERU^"?RDS:PRP8B*-)M"0HS'P!P_EN>>8-&XJQ$
MDE5^TY=L63R3(VR>Q]?HPRY+8<OX)',B?)C\-4FDB8YS4FF1D:+XGH6[-LQI
MY5EU6_J:53CH7')Z(KJMI=!:3NMZ+KUHTEPO3TN$L<\V\P\/^77PEK&MZ5ID
M$]W)26\=I&GU)V4I<[DJ5:I[;VO;,UZF:U82NDU=;=E62V;$TL4+$8Q?'#AS
M+,NS'?',YU[JHU".#G-Z=E/'9A"/7P6I+%O%ZY#6K4K"BHP727'QMD>.E><1
MRC'M=1_(G&6@7='DM.9>K:9'L6*VJG2E<YK+%6_F]DS>)R-FDQR.=$ZM6;95
MJM22#Q>)DON>;JQ=N_<=>LKK#0Y[+BWT5&,6D^/%X<3+?#-JFW^<C'D^ACCV
MS9/S'--X)YCX)I\PX;;="QO)&%UW7]QU&[;SV&Q&?W;1<Y#%<;@'4;5VM>R3
MK6.N+<QL:Q2SI8A6&%&^OD1;+N;<9KEV:O+JM.L[*4Y0FE&3C"<=&UBDTM*P
MEI2P>+U(J<PA0JT.53CRB2:TZUQ=PKO&7R/D]'DS_P 6N?/W]X__ &AM9BKG
M(]6M/%J=N!?,H\&ITUYIS?GA?>H<??Z0VI_T;<LFE/VFOH':?VO2_P"'NC>7
M[#?^+.8_^W:__&6!5?-&#U4/LH4+F5OTL9CJTMS(9&W6H4:D#?'/:N7)F5ZM
M:%B>E\L\\C6M3\E5.=.$ZLXTJ:<JDFDDM;;T)+HMG3<5Z-K0G=7$E"WIP<I2
M>J,8IN3?023;+EV4VC5?+G[)=!9E8(;<?'..T#5KE"-9'KG=HVG8J,V\V*+J
MK/1+)/D\ODV>AR(V)?1(O1K_ $1N+^TYF^:^S5:,9U+2%"FX8O\ .5JM12N-
MEKQJU2/!A'[[4_&2URO-?M'<]^82M92A+,:EW7C/0N2H4*,E:J6T]24+>B]6
MF7WJTK7_ ,X7A^KRQVJXKEC7VQY/(\/YNEM=2]3DCG9:T3<6T</L+JCF]?70
M/G=B[[GM=T2"FYW14]*17[1&04\^W&H[Q6>%2>7U8U%)/%.A7V83:X\9<C/%
M:-F+?160/L=;X5=T^=:MNEF&-*WSBA*A*,DTXW5MM5*2EQ/#EZ6#7A5$M'#5
M%-%3UA !?.[<_O>^"/L-<7_01@SU.W/^B.5_V=;>TP/!/G'_ ,0\^_MJ]_XF
MJ1;><Q_%K@/]_>0/VAJAF_FW]6N_%I]N9C+-_!I]-^80+F52QD]?E;=IVM1:
ME7[E=_P]?)Y[)Y&['QA6RD44U/ 8K#6GTK6WQ5YO$UN:NY>K/%5E>U'58*R3
M1+UG1S<5;]9_7=P\EM).-)17*M:Y-K%0Z233:X6\'JP+[EEK%0]T37?/5T%Q
MG6>=?-TV##[IE<!P1I.GY76<+>FQ[=MWN/.9+WR.JOEAGOXG$X'-ZZN-QDTS
M46L^:Q/)+"B/<R-7^KC[LKYOJ-2VC5S6K4C7DL=BGLK9QX&Y1EB^/!))Z-.&
M+XU\UE&;C0BG%/6\=/46!M1VD]\&F=VNM;KHW+6LZOK&QX/6Y\EM>.NV89M"
MVC3[%F/&Y'(PPYZ6:3&UL?->KP6ZUN:PU/7QR,F<CW,BL6\&Z]SN_7I7673J
M3HRGA%I?G(SPQ2[W7C@VFDM36'"ZJTO87490JI*26GB:ZO9((^[3C/2.)^=M
MTU7C;9<!L^B26(<UK%C7\]2V&'$8[+L6P[6[]RE=OK'?U^UZRMX9Y%L/KLBF
M?Z94,IY!>W5_E5*O>PG3NL-F2E%QQ:T;232T26G0L,<4M18[NG"E7<:;3AK6
M#QPZ'4-;B\E,7EC5XFI OYS'\9> _P!XN0/V_JAE;FW]1N_&I]J98\W\*GTG
MYA"B9++,3U^5MVG:U%J5?N5W_#U\GGLGD;L?&%;*1134\!BL-:?2M;?%7F\3
M6YJ[EZL\565[4=5@K)-$O6='-Q5OUG]=W#R6TDXTE%<JUKDVL5#I)--KA;P>
MK ON66L5#W1-=\]707&=9YU\W38,/NF5P'!&DZ?E=9PMZ;'MVW>X\YDO?(ZJ
M^6&>_B<3@<WKJXW&33-1:SYK$\DL*(]S(U?ZN/NROF^HU+:-7-:M2->2QV*>
MRMG'@;E&6+X\$DGHTX8OC7S649N-"*<4];QT]18&U':3WP:9W:ZUNNC<M:SJ
M^L;'@];GR6UXZ[9AFT+:-/L68\;D<C##GI9I,;6Q\UZO!;K6YK#4]?'(R9R/
M<R*Q;P;KW.[]>E=9=.I.C*>$6E^<C/#%+O=>.#::2U-8<+JK2]A=1E"JDI):
M>)KJ]D@C[M.,](XGYVW35>-MEP&SZ))8AS6L6-?SU+88<1CLNQ;#M;OW*5V^
ML=_7[7K*WAGD6P^NR*9_IE0RGD%[=7^54J]["=.ZPV9*47'%K1M)-+1):="P
MQQ2U%CNZ<*5=QIM.&M8/'#H=0Q/QA]<OCSY^=2^;^/*^^]Y5O6I^A9U4O58^
M,NV7736@F)J+W<_Q=U#]^KW[1:8@YW_DZS]?EZ$S)S.?*=YZQ'T9HB8%-@"2
M_M\^LO@_^\GS;RALUS>?0JA_#>V3-7.<?Z<7'\#[53(T#64VC-S>T'^^M]_8
M^M_JF<,T<SWJN8>+1[=4PCSS>I9=XU?M4C"O/_UWMR_9&*^8&*(3S@_3"]\:
M'M5,G/-W]#++Q:GMU0PX0TFI,WC?\74/V%5_4(S=*V][4_$CVD:177OFIZY+
MMLJV>>%]]?Q]_H\ZG_23RR:0?::^GEI_9%+_ (BZ/4W[#?\ A-F/_N*O_P '
M8$-AKH;F&U79/PFO<#W/<2\;V:CK> M;)!G]P9\:D?O/U9KL_L$,SWHYL:9*
ME06FQ51?T:RQ.B]>A-N;K=I[V[Z9?DDH[5M4KJ57UFG^<JZ>#&$7%?C22TZC
M%7/;OO\ 5[S7YOO+3FH7\+9TK?C]T5_S5)I+7L2ERCU=[!Z2WMR'W(ZMQ[W#
M<%\ Y)]9<QS3BM]NP3R/DB?B9M9HT[FOME>O_9U9LTT&0JPL7XY\]=$16JK6
MR>@F<[ZV63[Y95NE5V>6S*G7>+;3@X).ET'RLE4@EK<HK5H4O'_=WFUS7>+F
M[S[G ME+W'DE6UBTDFJBK2E&M@M?YA.E.3U*,V\&L7&!7SM>$UU;FK1^;\94
M<W&<JZW[ V&=OA<WWX:-%5I033JB(Z-<AJ=JC%$B]?%[/D5%]'1-5_M*[M/+
M]Z;?>2C'\QF%#9F_^^H)0ZF-)TDL=>Q+I+?C[$6^_P :[DWVX]S-.ZRFYY6D
MOZ/=.4FEQ[%>-64L-7*QT<+A)-;3=TV'[1?OK^V'_2&X5_I)UHEW-_\ 3S)/
M[7L_^(IF.^=[_";>C_V[F7_!UB]8>H9X1GEWF\1C0WG\NSM#L=Z?<[J7$]R:
M[1T3&5K.[\I9;'N]5=HZ'@;%.*_4Q]ET4T57*;#DK]7&UI7->D$EOURL>D2L
M6+;X;PK=K)*E_'!W4FH4D]3G)/!M<*BDY-<.&&C$N&6VGNRY5.7J:TRZ7%U>
MZ6M^]3OCX'\JCBKC_B/BSB["W]NR>!M)QMQ-@+#-=UW7]?HJ^B_=-RR45>_D
MIZUK,-=U54DR.=MQV7266/2:RW V[6[&:[^7];,+ZO)6\9KE*LN^E*3T[$%B
MEH7[V":PBUA$E%Y>T,LI1A".,GX,5H6"X7Q=MOJLAXU#\8I[E*VUT[&^\)<'
M9K1_=K5OXC4*^^ZSM?L]UJ-7-I[%F=WVW$>[8J7C:BOQ?@DEZ.Z,;U:N1+CF
M?R65!JTNKJ-UAH<^3E''#ABH0>&/XVKC+1#>"OM_G(0=/H8I]=MI]98] E-[
M^J79QWY]C=?EB3D#C;4MLM\:9+E+@+;M[V#4]*W.GD,2ZXV]H]WVYEJ<RX[-
MY[$V,!DJS9IZ<62;ZV)TDL$3U@NZD]X]U=YWEZI5JENJZI5X0C*<&GAA-;*>
MF,6IQ>";CH>";1=KVG:WUERC<5WN,9/!8=5ZD]3[I2;-F"$%K#\6_P#XE]U_
MST<2?,G?3 _/)[YL/$J]NF2C=[P*O3CYI-IW:_Q+UOYZ&_,G(FGO.[\B6WPK
M^3F; <SWRY=?!/Y2!H&:_&PY(%VF?Q$V#Y[;'S&PQL'S1_(-Q\+?M=,UUYX?
MI!;? X^V5#2O?_X][K\]NR?-FZ83W@^7KWX76]LD9RW=^C]C\#H^UQ,U=JGU
MR;_SI9/YIX4FW-1])JGP2?HZ9!N=SZ,4_AD/051W5_7)H?.EC/FGFASK_2:G
M\$AZ.H.:/Z,5/AD_04C6<QD91)C=:_BY@/WDQ7[1@-R\L^3;?UBGZ%&E.9_*
M5QZ_4]&SFRN*$
M
M
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MM'F@&ZACDN$?BZ^*PT/:QS5G(/4^^'(\_P!S%93P_P!\>QL-QUH=S!>M]/\
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MBAEQDCF*O545B_%5# FZ[=;>>WG5\*564GCQ[,GVR4WO>V<U'\'N%3\SV18
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M6*?H4:4YG\I7'K]3T;.;*XH0
M
M
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M#*<W:HT;JO5RNZ3;PC4E4V*>/!WMU3IIR>A0<]*3;*>AY\GL46&O(8_\U?\
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M.,)RC"-O1Y2>S"3QVGLMMFIWX<+M0_F^[AOY)\;?ULD(_P S6X?DF;^Q6_\
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MGZ%&E.9_*5QZ_4]&SFRN*$
M
M
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M&DFN)XNH^FTT\-6#TBIO#4<<*5.,9=%X]C!$(G/W<QSGW0[>F[\Z<C9W?LW
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M1I3F?RE<>OU/1LYLKBA
M
M
M                                                    *T7GJ?78
MX)^QWL?T2L-,/M0_+V5_!*GMB/3+["7T3S[^T:/M+(*35TWN      ,A\1?7
M7XQ^R'I?T28TO&[_ ,O6/PRC[9$CN]_T3S3^SKGVF9?P/5D\ 2%<TF-Y
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M 'RW</\ 9SY:^C[8#8W(_D6S^"TO:XD1N??-3QY=MF#"Z'0      3(^3?\
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M-SPT-1>[G^+NH?OU>_:+3$'._P#)UGZ_+T)F3F<^4[SUB/HS1$P*;
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M$N?A7\G UXYX?ERU^"?RDS:PRP8B*-)M"0H       $]'DS_ ,6N?/W]X_\
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M&ZU_%S ?O)BOVC ;EY9\FV_K%/T*-*<S^4KCU^IZ-G-E<4(
M
M
M
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M\/SLI_UJ."_I[/2[XBSOR.Z]BJ>E/$'X\R7RRU]EI^F(C/NW^RWX7O:]]O\
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M^^FZ?_5\O_Y@?5OX7_G>XO\ Y?ZI_"P^J+G8_NQO%_TV\_4CZ^N8S^^FZ?\
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M]4CCO_/W2_Y4X/\ =QL=[JM?TE/SR[I$/=]C^FI>?CW1]4CCO_/W2_Y4X/\
M=P]U6OZ2GYY=T>[[']-2\_'NCZI''?\ G[I?\J<'^[A[JM?TE/SR[H]WV/Z:
MEY^/='U2.._\_=+_ )4X/]W#W5:_I*?GEW1[OL?TU+S\>Z/JD<=_Y^Z7_*G!
M_NX>ZK7])3\\NZ/=]C^FI>?CW1]4CCO_ #]TO^5.#_=P]U6OZ2GYY=T>[[']
M-2\_'NEYGRY^_P#[#]'['^VS4]T[V.T?4-JP7'-*CF]9VCN0X<P&P8:ZW(9%
M[J>5PV6W.ID<?::Q[56.:-CT147IZ35_?'*<TNMY[VXMK:XJ4)UFXRC3G*+6
M"TII--=)DUR_.<GA94X3N[924=*=6"?HC,/<3YB7E^YOC:S1PO?1V=9>\[+X
MJ5M/%]S?"E^TZ..619)$KU-VEF5D:+\<O3HGY)A[G&W6WFOMVI4+++K^M7Y:
MF]F%O5G+!-XO",&\%PF2N;7>C=FPWGA<7V8V-&@J-1;52XI0CBTL%C*:6+X-
M)H!]V_V6_"][7OM_\4?38:^_5YO_ /L/./ZE<_JS8KZP]P/VYD_]=MOU@^[?
M[+?A>]KWV_\ BCZ;!]7F_P#^P\X_J5S^K'UA[@?MS)_Z[;?K!]V_V6_"][7O
MM_\ %'TV#ZO-_P#]AYQ_4KG]6/K#W _;F3_UVV_6#[M_LM^%[VO?;_XH^FP?
M5YO_ /L/./ZE<_JQ]8>X'[<R?^NVWZP?=O\ 9;\+WM>^W_Q1]-@^KS?_ /8>
M<?U*Y_5CZP]P/VYD_P#7;;]8/NW^RWX7O:]]O_BCZ;!]7F__ .P\X_J5S^K'
MUA[@?MS)_P"NVWZPGNX$V/7MOX6XNVC4\]AMHUG/Z1K^5P6Q:[E*.;P6:Q=S
M'PS5,EB<OC9[./R5"U"Y'QS0R/C>U45JJAL?NY:W5CD-G9WM.I1NZ5O",X3B
MX3A)12<91DE*+3UII-&L^\UW:WV\%Y>652G6M*MQ.4)PDIPG%R;4HRBW&46M
M33:95D\\?DGCO4^]#%XO:=^TO6LF[A/1K3<=G]IP>&O.JRY_=6164J9&]6L+
M!*^)R-?X?"Y6JB+Z%-4^??<+?G>7?:&8[NY+FV89>K&E#E;:SN*]/;C.JW';
MI4Y1VDFFXXXI-8K2CT/^R7SH<VFY_-;4RG>W>+(LKS5YK7J*C>7]K;573E3H
M*,U3K583V).,DI88-Q:3T,AS^K?PO_.]Q?\ R_U3^%C"_P!47.Q_=C>+_IMY
M^I-G?KZYC/[Z;I_]7R__ )@?5OX7_G>XO_E_JG\+#ZHN=C^[&\7_ $V\_4CZ
M^N8S^^FZ?_5\O_Y@?5OX7_G>XO\ Y?ZI_"P^J+G8_NQO%_TV\_4CZ^N8S^^F
MZ?\ U?+_ /F!]6_A?^=[B_\ E_JG\+#ZHN=C^[&\7_3;S]2/KZYC/[Z;I_\
M5\O_ .8'U;^%_P"=[B_^7^J?PL/JBYV/[L;Q?]-O/U(^OKF,_OING_U?+_\
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MR[RBAY^/='W17;[_ #Z\.?;.TG^&Q@Q\9Y=Y10\_'NC[HKM]_GUX<^V=I/\
M#8P8^,\N\HH>?CW27CRFN]3LWXXV'FR;D/NT[9M#ARN&T>+%R[GSQQ9J\62E
MJ7MF?:CH29S:J++DE9D\:R)&KE8CVJO3JACW?^QO;RC:JSHU:KC*>.Q"4L,5
M'#'93PQ+KE>;Y53E/E+JWCBEKJ07'QR)J_PE/ES_  _.RG_6HX+^GLQI\19W
MY'=>Q5/2EY^/,E\LM?9:?ICSV.8N5N+LGRYRGDL;R3H.0QV0Y&W>]0OT=QUV
MW2O4K>S9.Q5N4[5?(R06:MF"1KXY&.<Q['(J*J*BFW.77%"&7T(3G!35&":;
M2::BL4UCH:(%6S"P=635>CAM/[^/'TS''U2.._\ /W2_Y4X/]W%9[JM?TE/S
MR[IU^[[']-2\_'NCZI''?^?NE_RIP?[N'NJU_24_/+NCW?8_IJ7GX]T?5(X[
M_P _=+_E3@_W</=5K^DI^>7='N^Q_34O/Q[H^J1QW_G[I?\ *G!_NX>ZK7])
M3\\NZ/=]C^FI>?CW1]4CCO\ S]TO^5.#_=P]U6OZ2GYY=T>[[']-2\_'NEA3
MR!^[+M8X;V[N9L\O=R_;_P 55L]KG&$&#L<D<R\=:-!FI\?D]UDOPXF79]CQ
M<>1EI1VXG3-A5ZQI(Q7=/$G7$?.Q;W&8V]E'+X3KN$ZNUR<7/#%0PQV4\,<'
MACKP+]D6:Y71G4=6YH132PQJ07'QLLA[!YDGEV38#-PP]_'99+-+B,E%%%%W
M3<&R22R24IF,CC8S>E<][W*B(B(JJJF"LQR#/IY?7A"RNW-T9I)4:C;;B\$E
MLZ6R7Y=GV1PS"A.=[:*"K0;;K4TDE)8MO:T)$4?W;_9;\+WM>^W_ ,4?38:F
M_5YO_P#L/./ZE<_JS;SZP]P/VYD_]=MOU@^[?[+?A>]KWV_^*/IL'U>;_P#[
M#SC^I7/ZL?6'N!^W,G_KMM^L'W;_ &6_"][7OM_\4?38/J\W_P#V'G']2N?U
M8^L/<#]N9/\ UVV_6#[M_LM^%[VO?;_XH^FP?5YO_P#L/./ZE<_JQ]8>X'[<
MR?\ KMM^L'W;_9;\+WM>^W_Q1]-@^KS?_P#8><?U*Y_5CZP]P/VYD_\ 7;;]
M8/NW^RWX7O:]]O\ XH^FP?5YO_\ L/./ZE<_JQ]8>X'[<R?^NVWZPW<[8?,+
M[ \!J.P5L]WQ=GV$L3;&Z>&OE^Y?A?&SRP>S*$?KHHKFZPR21>L8K?$B*G5%
M3\@SCS7;I[U9?E%Q2O\ +,PH5)7.*52WK0;6Q!8I2@FUBL,3!'.KO9NMF.<6
MU7+\SR^O2C;8-T[BC-)[<W@W&;2>#QP-E_PE/ES_  _.RG_6HX+^GLR;\19W
MY'=>Q5/2F+OCS)?++7V6GZ8IN?=%=OO\^O#GVSM)_ALV-P9$?C/+O**'GX]T
M?=%=OO\ /KPY]L[2?X;&#'QGEWE%#S\>Z/NBNWW^?7AS[9VD_P -C!CXSR[R
MBAY^/='W17;[_/KPY]L[2?X;&#'QGEWE%#S\>Z/NBNWW^?7AS[9VD_PV,&/C
M/+O**'GX]T?=%=OO\^O#GVSM)_AL8,?&>7>44//Q[I-5Y37>]V7<<:]S9#R'
MW>=K^AS97,Z/+BXMSY^XHU>7)15*.S,M24(\YME%]R.L^>-)%C1R,5[47IU0
MQIO_ )??WE:U=G0K55&,\=B$I88N.&.RGAB7G*\WRFG&?*75O'%K74@N/CD<
MQYQ7?'V4\G=LNC8'C;O [6^0L[4YVUG+V\+H_<#Q-MF6JXFOQ_R=2GREC'8'
M;;]R''0W+\$3YW,2)LL\;5<CGM1=1/M#[E;Y9WN5:VN393F=W=1S2G-PHVM>
MK-05"Y3DXPIR:BG**<FL,9)8XM&Y'V.-_P#<3=CG.OK_ 'ESO*,NL)Y#6IQJ
M7-Y;T*<JCN[*2@IU:D(N;C"4E%/:<8R>&">%;3ZM_"_\[W%_\O\ 5/X6--?J
MBYV/[L;Q?]-O/U)Z4_7US&?WTW3_ .KY?_S ^K?PO_.]Q?\ R_U3^%A]47.Q
M_=C>+_IMY^I'U]<QG]]-T_\ J^7_ /,#ZM_"_P#.]Q?_ "_U3^%A]47.Q_=C
M>+_IMY^I'U]<QG]]-T_^KY?_ ,P/JW\+_P [W%_\O]4_A8?5%SL?W8WB_P"F
MWGZD?7US&?WTW3_ZOE__ # ^K?PO_.]Q?_+_ %3^%A]47.Q_=C>+_IMY^I'U
M]<QG]]-T_P#J^7_\P/JW\+_SO<7_ ,O]4_A8?5%SL?W8WB_Z;>?J1]?7,9_?
M3=/_ *OE_P#S!=3X$\Q?R^,/P7POB,OWV]FV*RV*XFXYQN3QF2[GN$J.1QV1
MHZ?AZMVA?I6MXBLT[M.S$Z.6*1K7QO:K7(BHJ'I)NKNYO#;[KY;;W%A>TZ].
MPMXRC*A5C*,HT8)QDG%------8IZ&>*&_P#O+N[>;]YU>6>8656TJYO>3A.%
M>E*$X2N*DHSA*,G&491:<9)M---/ C?\V7O>[+N1]>X3AX\[O.U_?)L5F=XE
MRD6F<_<4;1+C8K='6659+\>#VR\^G'9?!(D:R(U'JQR)UZ*9AW R^_LZUT[R
MA6I*488;<)1QP<L<-I+' Q[FF;Y34C#D[JWE@WJJ0?%Q2(5?NBNWW^?7AS[9
MVD_PV9+P99OC/+O**'GX]T?=%=OO\^O#GVSM)_AL8,?&>7>44//Q[H^Z*[??
MY]>'/MG:3_#8P8^,\N\HH>?CW1]T5V^_SZ\.?;.TG^&Q@Q\9Y=Y10\_'NC[H
MKM]_GUX<^V=I/\-C!CXSR[RBAY^/='W17;[_ #Z\.?;.TG^&Q@Q\9Y=Y10\_
M'NER/\)3Y<_P_.RG_6HX+^GLUR^(L[\CNO8JGI27?'F2^66OLM/TQ"IYLO>I
MV;\C[#PG-QYW:=LV^0XK#;Q%E)=,YXXLVB+&RV[VLOJQWY,'M5YE.2RR"18T
MD5JO1CE3KT4R7N!8WMG1NE>4:M)RE##;A*.."ECAM)8X%FS3-\JJ2AR=U;RP
M3U5(/BXI$0_W17;[_/KPY]L[2?X;,A8,M7QGEWE%#S\>Z/NBNWW^?7AS[9VD
M_P -C!CXSR[RBAY^/='W17;[_/KPY]L[2?X;&#'QGEWE%#S\>Z/NBNWW^?7A
MS[9VD_PV,&/C/+O**'GX]T?=%=OO\^O#GVSM)_AL8,?&>7>44//Q[IW+CKN4
M[=*/(.B7;O/O"M.G3W+6+5NW:Y4T6O6JUJ^;HRSV+$\N=9%!!!$Q7/>Y4:UJ
M*JJB(4UY"<K.K&*;DZ<DDEI;V6<Z>9Y:JD6[BAAM+_:1X^F6\?PE/ES_  _.
MRG_6HX+^GLU[^(L[\CNO8JGI25_'F2^66OLM/TQJ[W1>83V#;!@=6AP/?!V@
M9N:OE[DMB+$=RW#&2D@C=3:ULDS*6ZS.B8YWH17(B*IBSG3W2WKS"PM86&69
MA7G&M)M4[:M-I;.MJ,'@NF97YJ-[=U<NS&[GF&9Y?0A*C%)U+BC!-[6I.4UB
M^D:7?=O]EOPO>U[[?_%'TV&%/J\W_P#V'G']2N?U9G'ZP]P/VYD_]=MOU@^[
M?[+?A>]KWV_^*/IL'U>;_P#[#SC^I7/ZL?6'N!^W,G_KMM^L'W;_ &6_"][7
MOM_\4?38/J\W_P#V'G']2N?U8^L/<#]N9/\ UVV_6#[M_LM^%[VO?;_XH^FP
M?5YO_P#L/./ZE<_JQ]8>X'[<R?\ KMM^L'W;_9;\+WM>^W_Q1]-@^KS?_P#8
M><?U*Y_5CZP]P/VYD_\ 7;;]8/NW^RWX7O:]]O\ XH^FP?5YO_\ L/./ZE<_
MJQ]8>X'[<R?^NVWZPEGQ_F3^72RA18_OZ[*V/94K->QW=/P8US7-A8CFN:N]
MHK7-5.BHOQ#;BWR'/(V\(RLKM-0C_L:G$OQ33VYSW))7%24;RU<7.7^UI\;_
M !BM_P"<5W:=JO)W<UHV>XV[F>WWD+!5."=9Q%O-:/S-QSMF)JY:OR!R==GQ
M=C(X'9+].'(PT[\$KX'/25L4\;E:C7M5=._M#\W7.#G>^MK=9-D6<W=K'*Z<
M'.C97-6"FJ]RW%RA2DE)*46XMXX23PP:/2/[''.OS6[L<V-]8;R[RY!EU_//
MJU2-.YS"TH5)4W:645-0JUH2<'*$HJ26RY1DL<4\(G_JW\+_ ,[W%_\ +_5/
MX6,#?5%SL?W8WB_Z;>?J3;/Z^N8S^^FZ?_5\O_Y@?5OX7_G>XO\ Y?ZI_"P^
MJ+G8_NQO%_TV\_4CZ^N8S^^FZ?\ U?+_ /F!]6_A?^=[B_\ E_JG\+#ZHN=C
M^[&\7_3;S]2/KZYC/[Z;I_\ 5\O_ .8'U;^%_P"=[B_^7^J?PL/JBYV/[L;Q
M?]-O/U(^OKF,_OING_U?+_\ F!]6_A?^=[B_^7^J?PL/JBYV/[L;Q?\ 3;S]
M2/KZYC/[Z;I_]7R__F#.O:YW#< Z_P!S7;KGL]SCP]A,%A.=N(\OFLUE^3-+
MQN)Q&)QO(&OW<CE,ID;N;AIX_'8^G"^6>>5[(HHF.<YR-15)3N/S5<Z%IOKD
M]U=;MY_2M:6:6DYSGE]W&$(1KTW*4I.BE&,4FY2;223;>! ^=/GNYE\PYL=X
M["PWOW7KW]?(<PITZ=/-;&=2I4G:58PA"$:[E.<Y-1C&*<I2:23;+F_X2GRY
M_A^=E/\ K4<%_3V>C7Q%G?D=U[%4]*>+_P >9+Y9:^RT_3'G(_5(X[_S]TO^
M5.#_ '<;B^ZK7])3\\NZ8^]WV/Z:EY^/='U2.._\_=+_ )4X/]W#W5:_I*?G
MEW1[OL?TU+S\>Z/JD<=_Y^Z7_*G!_NX>ZK7])3\\NZ/=]C^FI>?CW1]4CCO_
M #]TO^5.#_=P]U6OZ2GYY=T>[[']-2\_'NCZI''?^?NE_P J<'^[A[JM?TE/
MSR[H]WV/Z:EY^/='U2.._P#/W2_Y4X/]W#W5:_I*?GEW1[OL?TU+S\>Z66O(
M'[P.TOAO4>YFMR]W1=NO%5G/;'QA/@J_)'-G&FC3YJ#'XS=H[\V)BV?9L7)D
M8J4EN)LSH4>D:RL1W3Q)UPOSL6EUF-Q92R^E4KJ$*NUR<7/#%PPQV4\,<'AC
MKP)%D6;971C4Y6YMXXN.&-2"QU\;)?>Y[S"^P//ZCK]; ]\79]F[$.QMGFKX
MCN7X7R4\4'LR_'ZZ6*GNLTD<7K'HWQ*B)U5$_)-5>='=/>K,,HMZ5AEF85ZD
M;G%JG;UIM+8FL6HP;2Q>&)G#FJWLW6R[.+FKF&9Y?0I2ML$ZEQ1@F]N#P3E-
M)O!8X&D?W;_9;\+WM>^W_P 4?388.^KS?_\ 8><?U*Y_5F=_K#W _;F3_P!=
MMOU@^[?[+?A>]KWV_P#BCZ;!]7F__P"P\X_J5S^K'UA[@?MS)_Z[;?K!]V_V
M6_"][7OM_P#%'TV#ZO-__P!AYQ_4KG]6/K#W _;F3_UVV_6#[M_LM^%[VO?;
M_P"*/IL'U>;_ /[#SC^I7/ZL?6'N!^W,G_KMM^L'W;_9;\+WM>^W_P 4?38/
MJ\W_ /V'G']2N?U8^L/<#]N9/_7;;]8/NW^RWX7O:]]O_BCZ;!]7F_\ ^P\X
M_J5S^K'UA[@?MS)_Z[;?K"Q)IEZED]/U3)8VY5R&.R&M8*]0OT;$5NE>I6\7
M5L5;E.U7?)!9JV8)&OCD8YS'L<BHJHJ*;/6%.I1L:-*K&4:L:4%*+33344FF
MGI33T-/2F:K7]2G6OJ]6E)2I2K3<9)IIIR;336AIK2FM#1V4JRD
M
M
M
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MQ4@
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR.9RK65U;PY2K'"&/&GVFSA;YE9753DJ$]JIACAA)=M(D *4K@
M
M
M
M
M
M
M
M
M
M
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M3Q.2K+(R.1:]ZA:CE9XFM7PN3JB*0AIQ;B]:9DF,HSBIQTQ:Q729S9\/H
M
M
M
M
M
M
M
M
M
M
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MX>[U229%<\O9\G)]_3>'4X.YU">0M9>@
M
M
M
M
M
M
M
M
M
M
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MG>OIO5V='5/1((F3L
M
M
M
M
M
M
M
M
M
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M=Y%[:O*VK1JQX-?17"B:7EK"\MY4)\*T/B? _P!W!H/,5WW2N4NVGF+;>/\
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M&*L,NJ+M[B5+@3T=+@[!D2RN%=6L*ZUM:>FM#[)N$4Y5
M
M
M
M
M
M
M
M
M
M
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MXD1\E0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#VID?EVS\E?^6,$![4R/R[9^2O\ RQ@@/:F1^7;/R5_Y8P0'M3(_+MGY*_\
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M ]J9'Y=L_)7_ )8P0'M3(_+MGY*_\L8(#VID?EVS\E?^6,$![4R/R[9^2O\
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M/R[9^2O_ "Q@@/:F1^7;/R5_Y8P0'M3(_+MGY*_\L8(#VID?EVS\E?\ EC!
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M![4R/R[9^2O_ "Q@@/:F1^7;/R5_Y8P0'M3(_+MGY*_\L8(#VID?EVS\E?\
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M?EVS\E?^6,$![4R/R[9^2O\ RQ@@/:F1^7;/R5_Y8P0'M3(_+MGY*_\ +&"
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M#VID?EVS\E?^6,$![4R/R[9^2O\ RQ@@/:F1^7;/R5_Y8P0'M3(_+MGY*_\
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M_P"6,$![4R/R[9^2O_+&" ]J9'Y=L_)7_EC! >U,C\NV?DK_ ,L8('P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             '#2[%K\$LD,V=PT,T,CXI8I<G2CEBEC
M<K)(Y(WSH]DC'HJ*BHBHJ=%.#J4T\')8]-'8J51K%1EATF??4NTK\7KZ%NK=
M@1ZQ^NJ6(K,7C:B*YGK(7O9XVHY.J=>J=3DI*2QBTT<91E%X233Z)]1].(
M
M
M
M
M
M
M
M
M
M
M
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M-:&-+\*.F/7UKJI&Q!7%K
M
M
M
M
M
M
M
M
M
M
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MT\4\TCNB(G7HA?*-M;VZPHPC'I+3U]9%[B\NKM[5S4G/IO1U%J741D([RE
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M<U45%Z$I34EM1:<606491DXR34D]*>M'TGTX@
M
M
M
M
M
M
M
M
M
M
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MW?VZ_/Q7?)??17#TXKKKI(F^)80
M
M
M
M
M
M
M
M
M
M
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M0V5*\M0
M
M
M
M
M
M
M
M
M
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M\5%3U?Y/7XV@W?J::M)ZM#[:?F%UWOHK"A76OOHOL->:2^DF(2
M
M
M
M
M
M
M
M
M
M
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MHFC)20,
M
M
M
M
M
M
M
M
M
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M=2786A=G$H-Z;I5K]4(^#2CA^^EI?8V20XO9&0
M
M
M
M
M
M
M
M
M
M
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MQ;4J3K5)5:CQJ2;;?&WK.6.1U@
M
M
M
M
M
M
M
M
M
M
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MM
M
M
M
M
M
M
M
M
M
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M+?"0FZN[B]JNM<R<I]A+B2U)=([X=Q3
M
M
M
M
M
M
M
M
M
M
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M%FK5ZUQ+;KSE.?')M]L[$=AU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M
M
M
M
M
M
M
M
M
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M4R;$MQ=@
M
M
M
M
M
M
M
M
M                         #0CS1MCVK5/+V[MLUI<MN#/1\.[!CTL4?6)
M;JX;.25,%M%N"2)DDM=U36,E<D]:WPNA1OC1S%;XVU-FHRNJ:EJVD4E_*4;*
MK*&B2IR[1Y^G:!L7;KJ?<;QAL7=?J6>WC@3%9BY9WK6===(M[(,]CY%F"DL5
MH+^+LY'$4-D?3L7:L=F)]JI%)%\>CEC?*KA5I49*@TJO 02RE;0N8RNTW06O
MS,5PK'6O^PNEZ?H'D5=Y.A2<>\8X'LY>_,TXL-C8=2UW4N%><JL\M>KBL=DL
M6S)8?2^69KT=O+UVLFGAL0V;[F,G2:7JPCLIYG;RVINIHX\6O-1,:=/)KN.Q
M2C1>*X$E+#L27=(J-'_%MNY/7.1:&SUNZ+BW1ZFL<A19K3-EUS$;IM&X8K"8
M/,P9'5]G?1L8[1\?%N=5*\<TE&*ZE6*Q&B,NN:OB;72S>E*&RX2>,=.I+H\>
M@M=/=ZK"KRD:JCLSQCHQ>">*;U:>-:NB7 L=%>AQ]&'*6Z]_)Q4ZL61O5*;L
M=5NWHX&-MVZV/?;OOHU[-A'/9"L\ZQ-<C5D?T\2V!X8Z-1*3S./,,^_S[SO]
M*+G7^DO9"8VGO6GXB[1CO,O?];UQ]LO^>6[]X%V;_P"CAQ+]!N*(M=^^JGCO
MMDZL/>-'UJ/H44%/,@^_\[R?])'EWZ-<N2BR]Z4_$1!\T^4*OCF1>'/-I\P3
M@#C34^'N).?_ 'I\<Z/2L8[5M=^I5PGGO9=.WD;F5L0^U]FXWS.=N^LOY":3
MQ6+4ST\?A14:C43C4L+2K-U)PQF]>E]TY4LVS"C35*G4PA%8);,=751W+8?.
ML\SS9\/<P>2[J,U6I7O<_KI]>XWX8U',,]S6H+D?N/8=4XXPN?Q_BEKM23W/
M9B];$KHG^*-[V.XK+K)/%0[+?;9S><YDUAROY,?2F$>W[LF[S.^K?_=N@\><
M@;M8W'-2Y/:^:=];G(-+BMY2>2YE=DV_DW88YJ^3O3*Z6S(R.:[E+KD=ZF&>
M54:O95N;:VAA)I8:DM?22_<CKH6-[?5-I1D]K2Y2QPZ>+U]3%GH#=D/:=J79
M3VV\?\ ZG<?F)-<K6<IMVSRQ)!-MN\YV;W?L^?6#XM:I-<<D%*%5<^OCZ\$3
MGR.8Z1T6N:\KBLZLN'5T%P$YM+:%I;QH0U16OC?"^N55OQF#[[W@W_1NQO\
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MC><E+P*BPZJTKS5U2_81<FP
M
M
M
M
M
M
M
M
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M1QZ3X5U'H-I#I.\
M
M
M
M
M
M
M
M
M                               &FO?_ (SN8R':=RU-VA[7E]5YYPV&
MBSNI)@L/KF:RVS4L;9CDV;4<97V3$9B*OFLWK;K28Z:HR&^S),KI#*Q7+UJ+
M5T57CRZQI8Z=?7T%->*X=M/W*\*^&C4^IIT:5H*3/;;YP/>/Q#W&\;\I<R\U
M<P\S:#JV0NXK>N*=@W7+,P>P:SF*MO%9=R:[[KHX&?;,"EOW=BY[<7BCO58F
M/>V%TC5D=;+[>I1<*<8QF]3P_=HXR'V^<7E*YC4N)2G36*<=6CI:%BN#'I8K
M$M%Y'SY_+%R''EW,Y#DO;,K<OXJ>*_Q+:X;WVUM-^"Y*ZA;PEN6Y@/J8V5L4
MI'22-DSRU7UU5JO5Z^J6RK++U2P45T\5W<>P2/X[RW9QVWTMF7<P[)1\YQVO
M <V]PW)^X\3\=KIFN<H\J;+F>/\ C'!48'RX6AM>R69]>U;&8G"PI29::V[%
M#'4I1I R5WJH&^K1B$DI1=*C&-1XN,=+Z1#;B<;FZE.C'!3EH73\U\1Z/W8[
MPQF^WGM"[=>&-G<Y=IT+BK5L9M42RQ3LI;5:HMRNRXN"Q#)+#9J8G.9"Q5AD
M:Y6R10M<G3KT2(7-15:\ZB\%R>'2,@VM)T+:G1EX48)/II'GK>89]_GWG?Z4
M7.O])>R$KM/>M/Q%VB!9E[_K>N/ME_SRW?O NS?_ $<.)?H-Q1%KOWU4\=]L
MG5A[QH^M1]"B@IYD'W_G>3_I(\N_1KER467O2GXB(/FGRA5\<O)>3I_PTNT_
MYR=A_I#W$C5_[\J>,37+?>%+Q$;1]V7;)Q]W@<![_P !<DP^#"[GC/#C,[!4
MKVLKIVTT'I;UO<,&DZL\&3P62C9)X$?&EJNLM:1WJ9Y&KTT*T[>JJL-:[/0.
M^XH4[JC*A4\&2ZW$UT4>:QW <%<A]M',>_<'<IXA^&W;C[.SX?)Q='^Y,C5<
MR.WA]@Q$TC&+;P6QX>S!>HS=$];5L,<J(JJB3"E5A6IJK#P6C'=S;U+6M*A5
M7?1?77 UTR[_ .1[WZ)W:=M4/%N^YM+G.?;SC\-JNP/O31)D]QX^]2^CH^[-
M\3_=.3MUJM'V9EI^CY/=E>*Q8?X[S/%&\RM>0K;<5^:GI70?"NX33)[[W9;;
M,W^?AH?1XGU>'HD+'XS!]][P;_HW8W^D[D@N.3>H3\?S$6C>/U>GXC[9)!^+
M/?>B\Y_Z1^0_HRXZ*3./?$?$\UE=N[[SGZZ_0Q)D>]3M2TGO1[<^0.!-U]74
M78J'M'3MD6%DUG3-_P 3'-/J>U56JQTCF4+SUBMQ1JQ]K'3V*Z/8DRN2WV]>
M5O656/!KZ*X47>ZMX7="5"IJDNL^!]0\U+E3C+<N%^2-XXFY#Q,F#W?CS9\O
MJ6S8R15>VOE<-<EISOJSJUK;>/M>K2:M88GJ[%>1DK%5CVJLPISC4@JD-,6L
M3'=:C.A5E1J+"<7@_P!W$]:+)?XL3]=;NP^Q[QK]$FREGSGP*?3?F$BW;\*M
MTH_Z1\7XR?W/>^7E+B3M-U[)MEQ7&N&7E+D2K7EF\'OWW"":AJ&*R$3G-B6[
M@-,9+=C5&.3U.?;\=U\36LGHX0E7>MZ%TEK[/:&\5SC*%I'4N^?:7F]@Z1^+
MU=DG'7/>Y<W\Y\W<::9R=QYH6'QG&^I:SR)JN*W#5;V][--!GLUF4PN?H7\-
M;R6IZWC8(6^N8]8DSB/:U'HQ[.>;7,Z48TJ<G&;TO!X/#[OF'7D-E3K;=>M&
M,H+O4FDUCK;P?4Z[+3WW _8K\"WM,_U<^'OI.+)[JN?TE3SS[I)/<-E^AI><
MCW#6/O-\KWM:Y<[7>:M$XA[9NW_C?E7)Z5?R''.W:!PQQUJ&T4]SUR6#9->Q
MM/8-=P.(RM"GLF2Q,>,N*R9&NIW)4<V1JJQW=;WM>G6C*I.;ACI3;:PZIT7.
M6VM6WG3ITZ<:CCH:BDT^#2ECKU] H \3\E;?P7RSH'*^H32XO=.+=WP&XX59
MX_ L68U?+U\C'2OUIXWMDJV):JP68)6.9)$]\;VN:JM64U(1JTW3EX,EAUR"
MT:L[:O&K'1.$L>MK7F,]07AWE+5^;^*...8=*LI:U7DW2]<W?!O];#+-!1V/
M%5LFRA=6![V19/&NL+7M1*OBALQ/C<B.:J)#*D)4YNG+PD\#)%.I&K3C4AIA
M))KI,R0<#F5I/QFG[VSMT^SCE/H"S9>,F]6GXOFHL&\7O.'KB]#(J_\ 9'W-
M;_V9<_:5W-:9@;.P8K1LM%K^ZXMZ35\/L&N;GC\K5R&I7LLVO8KXS)9K%8VW
M8QTCVO6.W02=(Y&P/8MZN:,+BDZ,G@WI737"1JPN:EG75S%-P6B72?!V,5TB
MX9LGXPIY?>,XC3?-=S7(NS\B6<;-+3X.70=@PFVU<NL-SW)1V#;KM&7C*CC7
M6Z\26+=#,966&"PU\=>=[7PMCZRJ[<]EI*/'BL.MK[!+)9[EZI[:E)SP\'9>
M/2QPP[)2TV[8.6.\CN2V#9(L)-M/+_<)RC?R577-<J3R-M;+NN;DEJ83"U7O
MGF@Q>.6TRO!ZQ[O45(461_1KG$BBJ=M12QPIPCVB(3E6OKIR2QJU):O,Z278
M1Z2G:;P-0[8>VSA;@.A:AO\ U,="PNO93)5ED6MEMD]4[(;9F*B2PUY65,OL
M]VY9B:]C7LCE1KDZHI$*]5UJTJK^^>)D*WHJA0A16E1BEUCSLO,,^_S[SO\
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MQ8R3
M
M
M
M
M
M
M
M
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MZVS"O;0Y.&RXXXZ<='6:+;>95:WU15:KE&:6'>M+'IXIZOW<!W?L3\KCM_\
M+WV#D+9.&-PYBV:]R3AL'@\[%R?L&E9JI4J8"[>OTY,3'JG'VES06)9L@])5
MFDG:YJ-\+6JBJO&ZO:MVDJBBMGBQ\ULYV.6T+!R=%S>UACM-<&/$EQFMG/\
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M8ZVL'BL-.$430%N+L
M
M
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M??<']JO[U_@_]K7^2>6?ZTQ]7.6_IZ_Y'I1]8UUY+3\^^X/[5?WK_!_[6O\
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M\^^X/[5?WK_!_P"UK_)/+/\ 6F/JYRW]/7_(]*/K&NO):?GWW!_:K^]?X/\
MVM?Y)Y9_K3'U<Y;^GK_D>E'UC77DM/S[[@_M5_>O\'_M:_R3RS_6F/JYRW]/
M7_(]*/K&NO):?GWW#?3RQ_Q@/NB[W.^'A'M@Y%X?X#U;3>3?JD^V,]I6/Y#@
MV:C[R^(M^Y"Q_LR7.[]FL4WW5E=3@AF];5EZUY)$;X7^%[;/G^Y5CE.4U<PH
MUJLJE/9P3V<'M3C'3@D]3+MD>^EQFV:4LOG0A"-3:TJ3;6S"4M6'0P+;1C<R
M"
M
M
M
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M2S.5B33>)[8XFN2-O3<4E1K2I)XJ+P*BVK.XMX5FL'.*>'%B;2'2=X
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MM!0V694[ZM.%%-4X):7PXX\' M'3Z1+T4!<@
M
M
M
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MT;/.:-Q"<G*.WH>'#3DO-/0--;3*0
M
M
M
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MMD?59'*L:NC5S.CEZ*M*=&;IU%A-=)]HJZ-:G7IJM2>-.6IX-=AI,RV=9V
M
M
M
M                        P)W%?Q)Q?STTOF3FS%G.Y]&Z'PZ'M58RMS/_
M $EK_ 9^VT33$UU-CP       24ZG_%;6OW@PWS.K&X^0_(=E\$H^UQ-,<_^
M7;WX76]LD1&^=)]8SBC[+"_0?L)KO]J'Z,Y;\.E[5(W*^PK]/LY_L=?\31*W
MII0>H        +NO;Y]83A#[$/&OT&84]3=Q_H5D_P#9=I[13/!/G)_Q$S_^
MVK[_ (FJ4]_.7_X@W+_[Q<6_T9:H;D<V?T/M_'J^V2,+YW[_ 'XJ(M2?%H
M    )+?)^_XBO;Q_XM?T&<FD'YQ_H9>?P/M](N>3_*-/]]Z&1<RYQ^LIS!]B
MWD#Z$\N:TY3\J6WPBGZ-$SK>HS\5]HJ-&QI#P       6 O*G^]YW+[,^P_0
M/QV8=YPOEJE\%C[94)#E/O:7COM(DU((7,IA=Y?WU_<1]E[>?F]</+_G(_Q
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M./\ 0R\_@?;Z1<\G^4:?[[T,B\(:LDW
M
M
M
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MCH/2U>OCI<YIQPA57A:5W"NW<JS<:E%OO%@UT,<<>TC87\9I^]L[=/LXY3Z
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MMVRY5<Z2Q.][G.<Y56&U:CJU)5):Y-LR)2IQHTHTH>#&*2ZAEPX'8
M
M
M
M                  # G<5_$G%_/32^9.;,6<[GT;H?#H>U5C*W,_\ 26O\
M!G[;1-,374V/       !)3J?\5M:_>##?,ZL;CY#\AV7P2C[7$TQS_Y=O?A=
M;VR1$;YTGUC.*/LL+]!^PFN_VH?HSEOPZ7M4C<K["OT^SG^QU_Q-$K>FE!Z@
M        NZ]OGUA.$/L0\:_09A3U-W'^A63_ -EVGM%,\$^<G_$3/_[:OO\
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M+S^!]OI%SR?Y1I_OO0R+PAJR3<
M
M
M
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ML606_*WCK/P:<<>J]"[&/6+Z)&":@
M
M
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MS^!]OI%SR?Y1I_OO0R+PAJR3<
M
M
M
M                                        Q[RY]:GD[['NZ?0WDCE#
MPUTT?)>"^D>58BJU4<U5:YJHK7(JHJ*B]45%3THJ*3@Q>>D-Y<'?EQ=WN\!:
M1G,-MV'?S+K^IXJAS%QW8R=9-NP6SXFM2QF:V%</)(S(6M2V#)/;9HY%C'UG
M-LM@>]MF.6)D/N[:=M5::_-MZ'P8=TR+8WM*]H*I!K;P[Y<*?[M3X2O3^,2=
M[?&',66XC[8N(MSQ.]U>-LSE^0N3\WJ^5J9G5:NW7<9[!U/6:N5QT\]'(Y[
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M>K&Q_-:W*7.PO!@L.KK?<ZA+<CM^1L5-^'4>UU-2[&GJD[Q;"\
M
M
M
M                 &!.XK^).+^>FE\R<V8LYW/HW0^'0]JK&5N9_P"DM?X#
M/VVB:8FNIL>2?<A96YQ[PI9GP3O<-[$8# 8?'R1HU5J.L38W$NFB54<WUT$$
MSWL=Z?CT13:+>&ZK[N[CRG8OD[BC;T:<6OO<7"FVNBDVT^/2:J;N6E#>3?J,
M+]<I;UKBM4FG]]@IU$GT&TDUQ8HC/DR>1EO+DY<A=DR3I$F=D)+4[[SID1$2
M5;;I%L+(B)T\7BZ]#6.5S<2K^Z95)NY;QVW)[6/'M8XX]'$VDC:VT*'N6%."
MM4L-A12CAQ;.&&'0P)+^-\G=WWA.G+G)79"[E,#L&'OS6$:^2VE>?)XF.2=S
M_"DTTU6%BO<[TN>JJY5554V;W:N:^?[CPE?2=2O5MZU.3>#<L'.FF^-N*6+>
MMXMO'2:N;SVM#=[?N<;"*IT*5Q1J02T*.*A4:7$E)O!+4L$EAH(PC5XVJ !)
M3J?\5M:_>##?,ZL;CY#\AV7P2C[7$TQS_P"7;WX76]LD1&^=)]8SBC[+"_0?
ML)KO]J'Z,Y;\.E[5(W*^PK]/LY_L=?\ $T2MZ:4'J 6X/*GY6QG.W9I6XYVA
M8<M=XRDS'$VQXVR^97W]-O4WV=:]>B/1S*,NN9)^,9X'-7ICW].G1#??F'SR
MAO3S<O(LPPJ3LG.UJ1;>,J%1-T\>*+A*5)8-/"GU3R+^U=NI=;A\\TMY,JVJ
M-#,U3OZ,UAWES"25;#1X2K059XI^JK6=:V/L[\GO3LYD=9VZ7A35=DQ$R5LM
MK^Q]TNVX/.8NPZ..9M?(XG)\Q5;]*9896O1DL;7>%R+TZ*A3W?-[]GG+[F=E
M?O+*%Y3>$Z=3,ZL)Q?%*,KM2B^@TF7++>>/[8N<V-/,\H6=W66UH[5.K1R.W
MJTIK%K&%2&72A)8IK&+:Q31N#VN]N/:-Q+3R?(7:S@=6]E[W39B[>XZIR%L'
M)&(S=+!9*Y%)3QN:R^V;7CXXZ>6CECL-IR,\4\/AEZNB:C<A;D;F\WV0PGG&
MXU*AR5S#8=:E<5+B$XPD\8QG.K5CHFFI;#7?1PEIBL,/<Z7.1SO;VUJ6[W.I
M7NO=5A/;C;U[2C9U*<JL(M2G3IV]";<J;BX.HGA&6,,%-MU8/,3YL7G;NWY5
MV2I;6WKFKY7ZF^H*V9T]9,!I$D^*DLTGNZ)[CS6?]W9%B(B)_P!L7\GJJZ+<
M[6\SWJW]O\PA+:LJ53D*.G%<G1Q@G'\6I)3JX<<V>JGV=-R%N'S1Y5EE6&QF
M5U2]V7&C!\K<I5%&7XU.ER5%^MFD1C<S>7=>WSZPG"'V(>-?H,PIZF[C_0K)
M_P"R[3VBF>"?.3_B)G_]M7W_ !-4I[^<O_Q!N7_WBXM_HRU0W(YL_H?;^/5]
MLD87SOW^_%1F3R#?O\O_  6Y$_;VK%%SK?13_P 33[4CLR'WZ_6WVT3)>;IP
MMYD'.FQ:'IW:)!MMOAE^F6'\A8[5>3>.^-6Y3<),[=\-3-3[!N&H[+FZ#<+#
M5<VOXYL<U_5WA];XE,<\WV9;FY72JW&\+IK,>47)N5.I4PALK2MF$XQ>..G1
M+J%XS6GF%79A9X[&G:P:6G@TMI]8JJ[3KW<SV*\XV->RV0VCA'F_2EPV4M^]
M;=,7:R%&/,XRKF\8D^:TK.YC!Y2GDL5D6+-6=8GADBF=#/&J*^,SM0K9)O3E
M:K4U3NLLJ8I;4&D\'@^]G%2336AX)XK%/4R+R5W85MEMPK:'H?;P;3Z3+H?9
MWRS@/,W[ 'Q\QXJE=O;GAMHX?YBJTJE*&J[:\/%#'[YL'7<VS7QF2GI7<;G*
MBI$SV?D)&^I;X88W+K=O%E]7<G>S_P#CI-1IRC6HMMX[+^]D]&*Q4H/\*.O6
MR8VM6.862E52[Y-271U/NKB*,/*.@Y;BKDSD/C#/=%S?'.\[9HF8<U$1CLGJ
M6>OX"\]GA<]O@?9Q[E;T<Y%1?0JIZ3:&QNZ=_94;ZEZE6I0FNE.*DNV0BM3=
M&K*D]+C)KK/ WR\G[_B*]O'_ (M?T&<FD2YQ_H9>?P/M](KLG^4:?[[T,BYE
MSC]93F#[%O('T)Y<UIRGY4MOA%/T:)G6]1GXK[14:-C2'FZ793W0:;VK[GM>
MY;'QO?WK+9O 5\#A,E0SU/%S:[56Y[KS$4=.YB+K;3\RZ&LBS-L0.@97<SP2
M),JQQO>7([C/K:G;4:RI4XSVI)Q;VGA@M*:PPTZ,'CCCHPTUME<PM9N<HN3:
MP70/V[S.\39NYW>K2X;(;-@>(<=%1@U?1LC/#3\<T5:M)?S6R4,5<M8[(9BQ
ME&R.A<^6=*M=&,C5%]8Y_P W;W=H9':KE%">82QVIK3PZ(Q;2:26&.A8O%O@
M%Y>2N9]ZVJ/ O-9]78UW/;SP=S)H^"]\>2FXPV_9,7K.V:K<M3V<'6J[!D&4
M4V''T9'21XW)X>Y<;:=+7:R2>-CXG^)KU0X[T9':YIEM6KL1]W4X.4))=]C%
M8[+?"I)88/0M? ?;&YG1K1CB^2;P:Z?"27>;UQ)B<OQEI7,]6O'%LNH;%6TW
M)VF1=)+VJ[%'D+=6*S,BJKDP^?K-6NU4Z)[OG7JBKT6%<WF85*=[5RV3_,U(
M;:Z$HX)X=.+T^*BXYK24J2K+PHO#J/[O;*]YEPL!8"\J?[WG<OLS[#] _'9A
MWG"^6J7P6/ME0D.4^]I>.^TB34@A<RF%WE_?7]Q'V7MY^;UP\O\ G(_Q SO^
MU+GVZ9[F\QW^#V[/]BVGM424[R/>;4Q&\\H< Y2VUE/<<5!R%J<,KWHWWPZX
MD6+V.I6:BJQUG*8"U7G=U1%]5BU]/Y!FW[,N\ON7.;W=6O+"E=4E7I)_I:6B
M<4N.=.6T^A2U\>KWVY-R'>9%E?.!:PQK655VE=K#U&MC.C*7#LPJQG%?C5UH
MX22KGWM,\M-V^Y/>.XBAQCJ>]\B6[6?MW-VYWVCC>;9+,?J*][)4,,[DK6\;
M(ULG@29U2LUGK7=7_'N55S3O3N#S++-:F8[VPL;?-;N4JDG6OJMNZC;[Z<8>
MZ:<=>MQBECKTLUHW YV_M,+(*61\W53-+O(<NA&E&-ME="\5&+Q<83J>XZTU
MHQV54FWLK!:%H^CM][2O+<BWFCR'VY8OC7;-TXWN5,I#E-)YPVCDQ-7NY*#(
M5<;<R>*^J/LV(@DM,AL^Y76ZZ_HD+GQ?'Q>)O/=3<#F:^,X9MNA3LKC,;.<9
MJ5&]JW/)2>*A*4?=%2*QPEL[<=:;6F.*Z^<+G<^TG+(JF[O./5S.TR7,H2@X
M7.64++EXP<)3C"I[CHU&HXPVU3GJDHR[V6#C2\\3FQ<KNG%G &+MJZEJF*L<
MD;9!%,YT3\_L"V,-K%:S#Z&,N8C!U+DS57JJQ99.G3JO7"OVFMYG<YO9;J4)
M?F;:FZ]5)Z'4JXQIJ2_"A3BY)\58V9^PUN0K3),UYP+J&%>[JJSH-K2J5'"I
M6E%Z]FI5E3B_QJ#UD"IJV;[DN'DR_?0;Y]@7:/Z0N+C8S[,?T]N_[(J_\1:F
MF?VY/\)LN_\ <5#_ (._+!G/7UC.:/L3\B_0?F#?G*?E6V^$4_1H\J)^ ^DS
MSIC<XQN>B1S=6YYN]D>8I=L2SISO<XCTZIQTZI<UC'6V92S7UV"_)5R&YV*F
MMT;4>#?:='-9EC]6]$=&Y)48IJ!ELLJCO/&6=X?%2N9NIBI-8)RPQ4,9-8X:
M$M/#HQ,AUN6]S2Y#U;8[W5KPZ.CKE+KNS[,^_P#X>Q7U>^[75-JAK9?9Z&O+
MOVT\O:'R+G+.R92+*9>A4<_ \@;5L3%ECQEJ5LBQM@B<SHKFN<U%V1R#>3=+
M,:GQ5D%2FY1@Y<G&E4IQV5@F^^IQCPI:\60VZM,QIKW1=*6AZW)/M-LEO\C#
MOZY3V7DRQVB<N[?FMYU[+ZKE<YQ%EMDOS9C/ZSE=4K-OY/3X\MD+#\C:UBWK
M$-BQ6@D?,F/?02.!K(97HS'_ #H[J6-&R6\&7TXTJT:BC545A&2D\%/!+!24
ML$WHVMK%XM:;MDE_5J3=K6;EHQBWKZ*QX>-<72U:S^??VVX3B/N;U/F75L?%
MC,-W%:_E\OG:M:*O!4=R-I,^*Q^V9&""NR-(G9O%9S%7++GM5]B_+9F<]SI'
M>&]\U.<U<PR2IEM=[52SFE%\/)SQ<5^]<9)<44EP%-GUO&G<1KQ_VB>/36&G
MJIKK$$IE,L):_P#Q?O[WGF_[,T'T$:\:_<[_ ,L6OP9^CD2W(/>L_7/,1-!S
M3];/9?\ WS?-_%&M?./]#+S^!]OI&5^;;Z:V7\-[15-"#5DVK-[^T?'QQZYM
MN52-OKK6;J8]TOH\2QX^@VRV/^ZC6NR2K_T]?^@SUS0V\8Y=>7>'?3KQACT(
M1QP_+-?^>.YE+,[.TQ[R%"4\.C.>SC^0:T<R[AF]GWS9X,A?LRX[$9[)XO%8
M]9GI2J5L9;L489(JJ*D+;$[(U?(_IXW.>J*JIT,8[YYQ?9IG]U"XJ2E;T;B<
M*<,7LQC"3BL(ZDVEBWK;>LRCN3DUAE6[UK.VIQ5S6MX5*D\%M2E.*FTY:\$W
M@EJ26HS)VI;3F';)F-4L7[,^&?@9LI5IS2OEAJ7:=_'5D=5:]7>YF35[KT>C
M/"URL;U151.DSYILTO'F=;*:E24K)V[G&+>*C*,H+&./@XQD\<,$\%CJ6$*Y
MW<ILEE='-Z=.,;Y7"IRDE@Y1E"<N^P\+!Q6&.+6+PULZ5W/48Z?*4\[&-8N3
MP6(O2JU&IZR1C;&.\;O#Z5=ZO'M3JOI]']SH63G0H1H[U2J)8.K0IR?1>#A_
MH<)?.:JXE6W3C3D\52N*D%T$\)]N;->#'9D@D XA^MQJ_P"Q;?S3NFUG-_\
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M(:LDW
M
M
M
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M-XF2HQC"*A'1%+!=0[B<3Z
M
M
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MW\T[IM9S?_0^R\2?MDS4WG"^F-]X\/:H%?#\8@_\H'_V0'_M$S:#F;_\R_\
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M_P 17MX_\6OZ#.32#\X_T,O/X'V^D7/)_E&G^^]#(O"&K)-P
M
M
M
M
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M(*W./>T?7%VI%LW=]^R]:?HHEWXC9,@
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M1XEH
M
M
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M](N>3_*-/]]Z&1>$-62;@
M
M
M
M                                           TH[EO+J[,^\#;L-OO
M<3PK2Y!W# :_%JN+S\>Y\CZ;?CUZOD+^4K8NT[0MPU:/)5ZM_*V9(O=+9G1+
M.]&*B.5"IHW=Q;Q<:,L(MXZD^VF4ES86EW)2N(*4DL,<6GAU&C\.!/+=['>V
M3.U]JX6[<M&UC:Z4CIL;M>7EV#?MIP\SW>)TV#V3D7-;9F\'.J*K?'4GA=X%
M5O7PJJ"K=W-985)MQXM2ZRP%"QM+9XT*<8RX];Z[Q?9-WBF*L
M                QOR9PYQ%S5B*.O\ ,?%?&_+.!Q>2;F<9A.3-'UC?,1CL
MNRK9I,RM'&[3B\K2J9)M*Y-"D\;&RI%*]GB\+G(O.%2I3>-.3B^@VNT==2E2
MK1V:T8SCCC@TFL>J=7XT[9.VWA?.V]HX=[?.#^)]FOXF? 7MBXTXGT/1,[=P
M5JY0R-G"V\OJV Q60LXFSD,55GDK/D6%\U:)ZM5T;%3E.M6J+9J3E*/1;?;.
M-.VMZ,MJC3A&6&&*BD\.HC.!U'<
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M,3KZ$*-MR>U)MMEP245A%8)'.'P^@
M
M
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MC_0R\_@?;Z1<\G^4:?[[T,B\(:LDW
M
M
M
M
M
M
M
M
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M1S-<]V]',[G3N,M;N=W:\T[FSG+"G526&W!X/DJT5X-2*[Y)1J*<4DJI/.?
MW)?;MO=[C_DW!28K*5^L^,R4"33X'9L4KU;!FM;RCX88\EC9E3HJHC98)4=%
M,R.5CV-\^-Z=T\\W-S:>39]1=*ZCIC)8NG4AP5*4\$IP?&M*:<9*,U**]@>;
M_G#W6YS-WJ>\FZEPJUI+1.#P5:A4PTTJ]--N$UKUN,HX3A*4)1D\-D;)P
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MNAL03,=T<R6&5BM<B^E%0W3C*,XJ<'C!K%/C3U&.))Q;C+1),^8Y'$
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MKIJI&?:@R[9+!ROXR7WL9/L8>:78C5\F@
M
M
M
M
M
M
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M%)Z"KS7++K)[^>77J2NJ>SM)/%)RC&6&.IM;6#PQ6*>#:TG+EP+>
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ML[O+KNI87]*I0O:,W"I3G%PG"<7A*,HR2<9)K!II-,Y [RF
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MY6U;AO=]]H8K<=F56SJYT3L+J*SP1SXE-WS#IF5M;7/>M:E7UOB\+7-EG]3
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M;M;TVT[7-:#TQ>F,XO'9J4YKO:E.>#V9Q;3P:T232R,7TBX
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MPV]2TSBUJ.%6E-82C+7K3<91DFI0G%N$XM2A)Q:;[67(LX
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M+1;SF
M
M
M                                                        1?=]
M/F)ZSV[5,CQOQA/C=KYMLUWPV51T-[ \<-GC>UMW8$8][+FRLZM?6Q;DZ-14
MEM>&/U<5C '.USUV6YL*F0[NN%QO2UA*6B5.VQQ6,^"59:XTGH7A5-&$)[:?
M9]^S-FO.96I;T;V1JV>X<98QUPK7N#7>T<4G&@]*G76O3"EC+:G3K&[7M>R;
MSL>9V_<,UD-BV;8;TV2S.:RMA]F]D+LZIXY9I7_$:UJ(QC&HV.*-K6,:UC41
M-%+^_O,SO*F89C5G6OJTW*<YMN4I/6VW^Y+0M!ZMY/D^5Y!EE#)<EH4K7*K:
MFH4J5.*C"$5J22Z[;Q<FW*3;;9)+V)>8EL7;O;QO&?*-C(;-PE9LMAJS=)KV
M;XU6=\KY+F"C3Q37]=DL3(^UCD\3H_CI:J)(LD5C-G--SS7^Y-6&29VYW&ZD
MI:M,IVV+>,J7'3;>,Z73E3PDY*>KOVA/LSY9SF4:N]6Z<:=IO["&,EHA2OL$
ML(UGJA626%.MH3T0K8QV9T[..L[/KVYZ_B-KU/,X_8=;S]&#)X;-8JS';Q^1
MHV6^**Q6GB56N:OQ%3T.8Y%:Y$<BHF^67YC8YM8TLRRVK"O85H*4)P>,91?"
MGV&GI3332::/*/-LIS+(LRKY/G-"K;9I;5'"K2J1<9PG'6I)]=/4U@TVFF<Z
M5A;@ 1VZ+O66T7+-O47+/2G5C,GC'O5L%Z!JKT]/1R0VH4<JQ2HBJU55%16J
MYJZC;L;SW^[%^KJU>U;RP52FWWLX^9)?>RUI\<6T]O\ >C=>PWHL':W2V;F.
M+IU$N^A+S8O1M1QP:TK"236^NM[)B=JQ-?,8>PD]6=/"]CNC9ZL[419:MJ)%
M<L-B%7)U3JJ*BHYJJU45=I<GSBPSVPAF&7SVJ$M:^^C+AC)<$EUFL&FTTWJK
MG.37^0W\\NS&&S7CJ?WLH\$HOAB^!ZT\4TI)I<Z70M0  !K3R[R[[A]U:KJM
MK_MWQ\&7R\#_ .\OBMDH4)&K_?OQ4EE1?T'\RW]$ZK'AG?\ W_\ <^WD>1S_
M -XTQJU8OP..$'^%P2DO!U+OL7'-/-]S?>ZMC/L^A_NNB5&C)>'PJI43^\X8
MQ?AZWWF"G^7;;_>>V_LK$?J60./,[ZA?^/2[50Y\\WOC+_$K=NF9_P!FV"AJ
M>M[!M652=<7K6#RVP9)*L;9K*T,-0L9&XE>)SXVRSK7K.\#5<U'.Z)U3XIFV
MA1G<UX6]/#E*DU%8ZL9/!8]5F$I248N3U)8G <<\FZ+RSK%/<./MCQ^R8*Y\
M;[HI2_H]*RC6ODQ^4I2(RYB\C UZ*^"=D<B(J.Z>%S57NO;"[RZN[:]A*%5<
M>IKC3U-=%:#C3JTZT=NF\8G>RD.8    /FN7*>.J6;^0M5J-&E!+:N7;D\5:
MI4K0,=)/8LV9W,A@@AC:KGO<J-:U%55Z'*,93DH03<V\$EI;?$D&TM+U&.N+
M>8-"YFQNQ9OCK,+G\)K6UW=.M9B.O-!0O9?'XK#9:W)B9)VLDNXZ.+-Q1ML>
M%L<KV/6/QQ^"1];F&6WF5U(4KV.Q5G34U''2DW)+'B?>O1P:,=.*772K4ZR<
MJ;QBGAU?W,R<4!V$'7FG>:+?[:+<O / D]*3FVWCZ=_<-QM5ZF3H\8XO*5TM
M8W'T<=92>K>W?*TI([2):B?6HTI8I%CFDG9ZC*>X.X<<\BLWS=/XK3:A!-IU
M6G@VVM*@GBM#QE)-8I)XV7-,T]R_F*&#N&M+_!^[_P!K*H.[[]O')FQW]OY$
MV_9-XVG)O1]_8-KS60SV7L^%/#&R2]DK%FQZF%B(V.-'(R-B(UJ(U$0V"M;.
MUL:"MK*G"E;QU1A%12ZB[?"1.I5J5I[=63E-\+.HE2=8 /\ 456JCFJJ.145
M%1>BHJ>E%14]**BGP^DNG8AYL/,G;7LN TWEW8=@Y6X$L3U\=DL9G+<^;V[1
M,>[PP,RND9B_.Z])5Q3/"YV'L2OIRP,6.O[FD<DJ8ZWLYOLMSNA.YRV$+?-T
ML4XK9A4?%-+1B_PTL4]+VEH+S89O6H35.X;G0?'I:Z*>MKH=8N0ZUL>"W'7<
M%MNKY6GG-:V?#XW/Z_FL?*D]#+8;+TX;^,R-.9.B25KM.PR1B^CJUR&ME>A5
MMJT[>O%PKTY.,HO6I)X-/HIDOC*,XJ47C%K%,Z1S3];/9?\ WS?-_%$#YQ_H
M9>?P/M](G?-M]-;+^&]HJFO/%'*\VIS18/.2R3ZU/)TBE7Q22X661W5TT+4Z
MO?1>]>LL2=5:JJ]B=?$U^)-Q=^JF0U%EF9MRR:3T/6Z+?"N%P;TRBM7A1TXJ
M67=_-PZ>?TY9IE<8PSJ$=*U*LEP/@4TM$9/7X,M&#CNG!/#9ABL5Y8YZ\\;)
MH)X7MDBFBD:CXY8I&*K'QO8J*BHJHJ*;'TJM.M3C6HR4J4DG&2>*:>E--:&F
MM3-;*M*I0J2HUHRA5A)J46L&FM#33TIIZ&F?J<SK !^%FS7I5Y[=N>*M5K1/
MGL6)WMCAAAC:KY)))'JC6,8U.JJIU5Z]&VHRN+B484(1;E)O!)+2VV]21VT:
M-:YK1M[>,IUYR48QBL6V]"22TMMFDO*G*EC<K#\1B'RUM9K2^A/CHYLQ-&[J
MVU::O1S*K')UAA7_ *'O3Q>%K-;-^-^*V\59V%@Y0R6$NDZK7WTN**UQB_&E
MWV"CLQN)N)1W<HK,,P49YW./35%/7&+U.36B<UXL>]Q<]F.(?K<:O^Q;?S3N
MF9^;_P"A]EXD_;)F%><+Z8WWCP]J@<]O.Y87CS3]CWC8W668'5L5:S66?3KK
M:M,H4F>LL/@K(YCIWLC15\*+U7IZ/23FTM:M[<PM*&'+5)**QT+%]$A52<:<
M'4EX*6)_FD[UI_(^NT=MT;8L9L^NY)GBJY3%6$GA\:-8^2M9C5&6*-ZNDB)+
M7G9'/"Y?"]C7>@75I<V-=VUW"5.M'6GVUP-<36*? Q"I"I';IM.+.V%.<@
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M*E7N(-4*T(RA):8M2BI)8\$DGI3T]32==.M3J-Q@^^BVFN'1H,HEO.P
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MD7O=W=S/-[<YH;O[N6U6[SBYGLTZ=-8M\;;U1A%8RG.34(13E.2BFRKCWO\
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MXP5K$555&-5_#KWJUJ>A.JJO]U5)6N=S>3#U&Q\Y5_7%O^(+/\*IUX^E/Y_
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MRL8]R(U9!8V-QF-U&SM4G<34FDWACLQ<FL>-I/#'1CPHLU6I"C!U)Z(+#LO
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MN^^XV\O-YO!6W9WJMI6^94M*X858-M1JT9ZJE*>#V9+2FG&2C.,HK*)(2(@
MQ/R+S;QOQ-F](PG(6P0ZPO(%G+4<!ELBWU."9>Q#<8Z:KELHKO4XCW0W*,]5
M-/X*_P :Y'R,7PHZXV657V8TJM6RARG(I.27A8/'2EPX8:4M/$F=52M3I.,:
MCPVM7$95CDCFC9+$]DL4K&R1R1N:^.2-[4<Q['M56O8]JHJ*B]%0M[33P>L[
M3^SX     8LY<YHXYX.UB3;.1]BKX2@Y9(<=3:BV<QG+L;$?[/P>+B5;.0M*
MCF^)41(H6N1\KXV=7)<,MRN^S:O[GL8.<^%ZHQ7')ZDNR^!-G55K4Z$=NJ\%
MV^D93+>=IBK<.:^-^/\ =M1T'<]CK:WF]ZJ9"SK$V5_[+B,A-C;%.M+C7Y5Z
MI4IY&=]UGJ&3K&V9?C&.616L=<;;*KZ\M:EY:P<Z5)I2PTR6*;QPUM:-.&.'
M2TG5.O2IS5.;PE+495+<=H     !B3E3G'C/AJ#$.WO8ZU#([#D*>,U_7ZWA
MN;#F[5RU'38ZABHWI.M*"65/769/5UH?0CI$<YC77++\IO\ -)25I!N$$W*3
MT1BDL=+X^)+%OBUG55KTJ.'*/!MZ%PLRV6T[3KV=VG!ZU+C&9NXVA'E;$E6K
M:F14JLGC8U_ALS_F:S'H[T/=T8G_ *RH6C-,]RS)JE"&95%2C<3<8R?@II)]
M\_O4\=;T+A:+QE>19IG4*\\LINK*W@I2BO":;:[V/WS6&I=\^!,Y]KFO:U['
M->Q[4<Q[51S7-<G5KFN3JCFN1>J*GQ2[1E&<5*+3BUBFM37&BTRC*,G&2:DG
M@T]:9_1].(    ."V'9<+JV/?DLY>BI5V]4C:Y?%/9E1.J05*[>LMB9?[C47
MHGI7HB*J6O-\YRW([1WF9U8TZ7 M<I/\&,=<GTM6MX+277*,ES//;M6664I5
M*W"]48K\*<M45T]>I8O!',Q2-FBBF9U\$L;)&=4Z+X7M1S>J>GHO12XTYJK3
MC4CX,DFNJL2VS@Z<W3EX46T^IH/T.9P !$EWX>9'A^$F9;B?A&[C]AY>\,M'
M.[*Q*V2P'&LJHK)8ECD98I9O<8%7HE1R/K4I/[Y1[VNK+K?SN<^%ONSRF[FZ
M4X5MX=,:E982IVSX8K'&-2LN&+QA3>B>U)."W,^SS]EV]W\='?'?VG4MMR\5
M*E0>U"M?+@>*PE2MG^D6$ZJ]2V8M556MSF<S.S9C)[#L.4OYO.YJ[8R66R^4
MM37LCDLA;E=-9N7;=A\D]BQ/*]7.<Y5554TAN;FXO+B=W=SG5NJDG*<Y-RE*
M4GBY2D\6VWI;>EL]2K"PL<JLJ66Y;1IV^7T*<84Z=.*A"$(K",8QBDHI+0DD
M2O=A7F0Y;A>7$\2<X9"_G>(W+%1P&T2I9R.<XW;X(X*M5S&K+8RFEPHQ$6LU
MKK%%J^*#QQM2NNP/-%SV7.Z<J>[V]$IUMV7HA4TRJ6O L%I<J"X8+OH+33QP
MV):>?:(^R_9[]0K;Y;@TZ=OOFL9UJ"V84KW6Y2X%3NGCX;:A5>BILR?**RAB
M,OBL_BZ&;P62H9G#96K#>QF5Q=N"_CLA2LL22O;I7:LDM>S7FC<BM>QRM<B^
MA3>6UN[6^MH7EE4A5M*D5*$X24HRB]3C)8II\:9Y;7ME>9;=U+#,*52A?49N
M%2G4BX3A*+P<91DDXM/6FDT<B5!2@ AR\T/S,F]H^/BXBX@]P93G_9L3'DI<
MG=KULEA^,,!>62.IF<ACY_65\GM.12-S\=1G8ZO'&B6;+7Q+%!9R3N'N/\XI
MO,<RVHY13EA@L4ZLEK2?!%??26G'O8X/%JT9IF7N.*ITL'<2742X^Y^Y.HMR
M)R?R+RYLMO<>3]WV??=GO.<L^:VK,WLS=2-SW2)6K/N32MI485=TBKPI'!$W
MHUC&M1$-BK*PLLNH*VL*5.C07WL(J*Z;PUOC;TOA(C5K5:\MNM)RET7VN+J'
M1"K.H   E#[(O-)YV[5-CPV!VW/Y[E;@N2>&GF]#V+(S97*:YC7S^*7)\<Y;
M)6%GPF0H^L?(F/=+[+N>)[7QQ2O9:A@>]&X64Y_1E5MX0M\UPQC4BL%)\51)
M=\G^%AM+@;6,7=K+-KBVDHU6YT,=*>EKI/S-72UET'0M[U+D[2]8Y"T3-T]D
MT[<<+1S^NYN@YRU[^,R$+9X)/!(V.>M8C\2LF@E8R>O,UT<C&2,<U-9;NTN+
M&YJ6=W!PN:<G&47K37[M#6AK2M!,H3C4@IP>,&L4S[L[L^%UKV<[-W&T(<G<
M]P5[,J+[F986&29J694ZI7C<V-4\;NC$7\TJ)Z2Q9IG>79+R+S*HJ5.M4V(R
M?@J6#??/[U/#6]"X6EI+QE629EG3K1RRFZM6C3VY17A..*3V5]\].I:7P)O0
M<ZQ[)&,DC>V2.1K7QR,<CV/8]$<U['-56N:YJ]45/0J%SC*,XJ<&G!K%-:4T
M]33X4RURC*$G"::FG@T]#36M-<#1_1R.(    .$S^QX75\>_)YR_#1JM7PL\
M:JZ:Q+T54@JP,1TUB9R)U\+$543JJ]$152V9MG&79):.]S.K&G16K'7)_@QB
MM,GT$NB\$FRZ93DV99Y=JRRRE*K7>EX:HK\*4GHC'HMZ]"Q;2.4JV([E6M;B
M1R16H(;$:/1$>D<\;96(Y$5R([PN3JG5?25UO6A<T(7%/'DZD%)8Z\)+%8]'
M!E#<49VU>=O4PY2G-Q>&K&+P>'51^YVG2
M
M
M
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MAA+HK7HVE)+ S?O/N9E&]%+&YCR=^EA&M%+:7$I+5./0EI6G9E'%LW1TW?\
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M!4JJY5<Y5<YRJJJJ]555]*JJKZ555-4CT#226"U'^ ^@ DN[&?,(VGMJOT=
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M6O#7)_A2EKE)\;Z2P22)(<?_ 'A2_8E;]18;AVGO2EZW'M(TUNO?53UR7;9
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M]\R',%NUS.Y9R\=B\WQKTTKB\<<,%K=&WB\73HIZWHG6:4JFA0A3T>,7&?
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MV]W5RZ&5[NVEG!)25",I=&<UM3?GF^I@0+,*LJU[4E+@DTNDM'W35 D)1
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M[U8[]J0FW64_)5M\'I^@1I]FWRK<_"*GHV<J7 MX
M
M
M
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MUF)D5+^X_P"^&YY^S/RC]'&<-BLD^1;/X+2]KB1*Y]\U/'EVV88+F=
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MZU>OQJ1JG5;5O7SH5KC:L-V\:=#4Z[T3EZVGX"_&??<2@UB[MNES6T;?9O\
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M@E/T50F>1^\5XS)F<A_>%W]B6?U%YBJ[]Z5?6Y=IE_M??5/UR/;1&$:5&[H
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MQ.*<%'%HV!\SC[PON8^<&/Z(L&;=;C?2VQ]>_P!&1I1?^\JOK;[10\-LB
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M\TF[,5%\/.,Y6^NCR3\_VX_1%D3=++_>%#UF'H48]NO?-3UR7;9T$K"G
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MT_0(TJS;Y5N?A%3T;.5+@6\
M
M
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M!WV1[=]H>U\%_BKW-[L]U>Y/:?N[^]OCO!ZKUGY'AZ^@D_S.WD^+/CCW-_\
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M&P9$P       6,/+*^]@I?/SMWZI0,*[]_+S]9AYI),L]ZKQF:.>=Y_Y8_\
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M'_;-XU@^TA_ATOA]'T-0VY^QG_C52_LRZ[4"K":#'KF       "XQV$_>><
M_.-#\T\B>D_,U_ACE'P>7MM0\2/M%?XV[Q_#W[7 C.\U[Z]?'GV+:WT6;.;6
M<WGR76^$/T$#7?-O5H^+YI%J3\M( ,\\6=L'/_-4,5SC/BO:=DQ<TLL$.>?7
MK8/699X(9YYH8]GV*SB->?+$RNJ.:EGJU[F,7X^2-KK5?YYE.6/9O:].$TO!
MQVI<7@QQEV.-ZDSOI6U>MIIQ;7'J77>@[AOG9#W6<;8U^8VOA7:&8R&O/;LW
M->GP>[14JM;P^Z+.0]Y.6V%V.@A:[Q.?.D;48CG=?"URI3VF\^0WL^3M[FGM
MMX)2VH8M\"VU''J8G.=E=4UM2@\.A@^UB:K%]*4S/VX??#<#?9GXN^CC!ELS
MOY%O/@M7VN1WVWOFGX\>VBV@:ZDM*RWF$???<N_]P?Z,-*,[;F_1NV_A/;9D
M8S'WY/J>A1IB2<HCZ:=*YD;=:ACZEF_>N31UJE*G!+:MVK$SD9%!6K0,?-/-
M*]41K6HKG*O1$/DI1A%RFTHK6WH2/J3;P6LV]UKR_N\/:\8S+8O@_8*M5[VL
M2+9<SJ&F9-'.KP645^%W#8L%F&,]79:BN= C4D1T:KXV/:V/5][=W;>?)U+J
M#E^*IS7%X4(R7!Q]'4T5<;"[DL5!X=%I=MHP9R9PAR[PW;AJ<H<>;1I:V9YZ
MU*YF,9*S$Y&>LYZ3Q8O.0>OPV4=&C/$ON>>7XQ4?^9<U5NEEF>7YC%RL:U.K
M@L6D]*QXXZUU4CHJT*U%X58M?NX]1BPKCJ-X_+G^^ST#]ZMX^@S.$4WV^CM;
MQJ?HXE?EOOM=)]HLJ&#22D?O+GUQMH_9=;YGTS5'?WZ7WWKD?00-L^;_ .AU
MCZW+VR9C@B!,@     #,W WUP:W[UY/]2:9#YK_I;3]9J>A,<\Z?T1J>O4O1
M&\9LT:P%$?9_XR[#^_F6_;]@\D+GWQ4\>7;9^A'*?DNV^#T_0(X,Z2X
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MTEU7R6?O!..OGPY-^C3*&L7.=]+JWK5+T")MDWR?#IR]$R1[E+ZWVU?O6_\
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M$UO[C_\ $NM?OI;_ &HTPYSP_)]EZ]/T*,S<S?RC>^LP]$S48P*9_
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M?O5COVI";FY3\E6WP>GZ!&E6;?*MS\(J>C9RI<"W@
M
M
M
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MU4R- UE-HS<WM!_OK??V/K?ZIG#-',]ZKF'BT>W5,(\\WJ67>-7[5(PKS_\
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M*6KH= T%)64!8P\LK[V"E\_.W?JE PKOW\O/UF'FDDRSWJO&9HYYWG_EC_\
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MA4O:Z9%\V]\Q\1=MD91.RUD]?E;=IVM1:E7[E=_P]?)Y[)Y&['QA6RD44U/
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MM7&6B&\%?;_.0@Z?0Q3Z[;3ZRQZ!*;W]4NSCOS[&Z_+$G('&VI;9;XTR7*7
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M-G*EP+>
M
M
M                                        5U/.J^NKPM]C[.?1&XTF
M^U!]*,N^ /VZ9Z;?83^AV>_VG2]H1"L:QF]9;#\I'BG'<)]H-_EK:E9B;?*5
M[+\B9G(6FN1<?H>JP6\;KZV&Q,>]:K:=*]DXU3QN6+()^3\:F]O,!D=#=GF^
MJ[R9AA3E?2G7G)X][;T%*,,5AJ6%6HL,<8S1Y-?:YWKN=]^>"GNCE6-:EE5.
MG:4X1^_NJ[C.KAB_"VI4J+QP6U2ZIH'Y;G=K?V;S ^5LALEKW)C.Z>SM$M>G
M/))##1SV$MWMET.EZ9)8E3':U#=Q==KW.>Y]AC4>KEZ/Q/S-;^UKKG9O*]]+
M9HY[*KWK>$8U%)U:*X<=F*E1@F\>_23;U[ ?:3YI+?+/L^95;Y;';NMU8T$Y
M))N5*I&-&ZEJ3[^LZ=>;2P2A)N."QC_?G><)IKO*W'?.V+J)'C^1M?DU#9I8
MD<J+M>FHUV-NVG.16MFRFKW8:\:(O168IR]$7JJ]GVE]VO<6\5IO/0CA1OJ/
M)U&L?5J&"3? MJE*$8X?HGU>/V']]_C'=/,=P[J>-QEMPKBBG^@N/#C'H0KQ
ME-]&NM.I*#4UF-YSO7%_UR^//GYU+YOX\N&4_*EM\(I^C18-Z_HOF7P"X]IF
M7FCUE/S^D6QI$;RG;M _CWI7SVZW\V:1=]W_ )>LOA='VR)9]XOH_?? ZWM<
MC=3NS_B)K_SVU_F-F3-G.Y\@V_PM>UU#!O,]](+GX'+VRF1^FOAL427_ /EL
M_P#"3_X639K_ /II_P"D?R)JY_\ U/\ _6?Y<C0-93:,VN[;?[RVW]E8?]2R
M!G3F=][W_CT>U4,#\\WOC+_$K=NF9)YQ^LIS!]BWD#Z$\N9YRGY4MOA%/T:,
M'5O49^*^T5&C8TAY*+Y1V/HW>Z#.V;?@]?B.(-KR&,\;D1R7I=ETK%2>K3Q)
MXG^S<G8]'1?C>J]/1U2#<X,Y1R.,8ZI7$$^ELS?;2+GE23N7T(/MH[MYQ5JR
M_FGBRD^1ZTZ_%[[4$2]?5LLW-KSD-N1OY'CDBHPH[\GHQ"FYNHQ^+*\OOG7P
MZBA'#MLYYNWRL%P;/FD0AD(M(  !8"\J?[WG<OLS[#] _'9AWG"^6J7P6/ME
M0D.4^]I>.^TC=WGKZQG-'V)^1?H/S!%,I^5;;X13]&BXS\!])GG3&YQC<LS?
MBWV*PTVV]V><G]3[X<=KO#V*Q?B_OCV-F<GR+<SOJO3_ -3[MP..\?H7X[P?
M$_)PISR5*BM\OI+U%SK-]-*FH]B4B2[NI8UGP][_ *1HIYY60RMWS#N1JV0D
MF?4Q&D<6X_!ME5ZLAQ4FEXW*S1UT<Y6MA7-Y.X]4:B)ZQSEZ=>JK*.:^$([H
M47#PI5:KET]MKM)%'GK;OM.K87FG->7AY2'W>W"NS\P?= _4I][?*.:XV][O
MU*??U[M]CZGI.T>VO:WU2=.]S^Z/?CZCW-[ED\'N;Q^M=ZSP,Z][^<#YJ9E#
M+O<GNC;H1J;7*[&&,YQPPY.?X&../#AAHT_,ORKW=1=;E-G"36&SCP)\:XS?
M/^S:?_'G?[.O_P!'4BOUS?\ ^M__ ,C^8*[YN_\ ??D?ZQ5W,XD9+7_XOW][
MSS?]F:#Z"->-?N=_Y8M?@S]'(EN0>]9^N>8B:#FGZV>R_P#OF^;^*-:^<?Z&
M7G\#[?2,K\VWTULOX;VBJ:$&K)M627]OGUE\'_WD^;>4-FN;SZ%4/X;VR9JY
MSC_3BX_@?:J9&@:RFT9N;V@_WUOO['UO]4SAFCF>]5S#Q:/;JF$>>;U++O&K
M]JD85Y_^N]N7[(Q7S Q1"><'Z87OC0]JIDYYN_H99>+4]NJ&'"&DU) .(?K<
M:O\ L6W\T[IM9S?_ $/LO$G[9,U-YPOIC?>/#VJ!T+NS^]HYP^QOLW[0D,E[
MN?+MIZ_'MD$N_>M3Q653C8,B983\G/5ZM7B'EC=&QQ^[L[R15U>:5&-]<M75
M-8Q>6K1K)U\:QI-N<JHWHB(JJOIZ^C$7.-7E+,+>V^]A1<NK.37^@B_Y1%*C
M*?"Y8=9+ND3G?+M.4VWNPYONY6Q)._%;KD-6HL>Y596Q>JI'@*%>!GYF*/U-
M#QJB(GBD>YR_'.55G^Z]"G;Y!:QIK!2I*3Z<^^?;+7?2<[J;? \.MH-;]3VK
M8-&V? ;EJF3FPVRZOEZ&=P64@9!+)1RF,LQVJ=CU%J*>I9C9-$GCBFCDAE9U
M9(QS'.:MYN*%&ZH3MJ\5*C.+C)<::P>K2NFM*X"FA.5.2G!X23T'?>3.?.9^
M9(ZU?D_DG:]RI4KLN2IXS+9*1</3OS-E8^Y5PU9*^*K6&Q3OC8]D+5CB>K&>
M%B^$I++*LMRYMV-&G3DU@VEI:XF];Z^O2=E6O6K>JR;1B(N!TEC#RROO8*7S
M\[=^J4#"N_?R\_68>:23+/>J\9FCGG>?^6/_ ,:/_:3FB7VJ?_(?_&__ &AZ
M0_8(_P#VO_TS_P#($"IJ(>B!.1Y(G"?OCY8Y#YURE578[C? 1ZEK,TB(C'[7
MN;95R=FL[HJK+B=8I2PRHJHGARC/B_D;,?9HW:]W;Q76\]>/YFQH\G3?_>UT
MTVO%I*:?KD31G[<&^_Q;NEEVXEK/_><RN'<5DOT%MAL1?0J5Y1E'7IH/5P_-
MWV=X%C5_,LX[VO#W%FUOMCR.L:Q>CJ^Z&MNMR3W7N586JU5F6W9Q.P38B3PM
M\"K33HQZ=5?T\Z7.#4M.>:VS*UEC:9)4I4FHXK:T[5RN/%JI.C+!880U-:7V
M\Q',]3S3[,^8Y3>PV<RWGIUZ\7+9[W86S8OBV8SI1N(XO'\X],7X,A_F\</U
M.7NTJ/DO -@R64XAR^.WO&Y"H_U_NS2M@BAQ&S1TWQ^.*2G+!;HY)[_TK'=4
M7HJHN7_M![OTMX-PH9]9[-2ME]2-:,D\=JA5PA4V<-#3QI5&_P &GBGQZZ_9
M!WPK;G\[;W9S#:I6N<49VLX26&S<TFZE%R3TJ2<:M%+\*M@UPJIB:''K6<YK
M'\9=>_?S$_M^N=UM[XI^/'MHM^;?)=S\'J>@9>X/6\_/<0Q^;K_Y?/\ Q7_]
MIJ9/YN/_ *W^!_E2RYQ_L_WW^B0R&3BREH7RN-7JX#M#U/+P1QMGW;:=XV6\
M]C&M?)/2V*WIT:RO15=(YM35(T15Z=&]$_(ZK@[?JO*KO#4IO52IPBNK%3[<
MB399%1M(M<+;[.'F%;?E3:<IN_)>_P"WYNQ):RNR;CL68NRRN5SO6W<K:F2)
MOY#(:[')'&Q.C61M1J(B(B&9[&A3M;*E;TEA3A3BEU$B.U9.=64WK;9^?'')
M6\\1[;0WKCK8;6L;7C(,C6I9:K!2M/BKY;'V<7?B?5R56[0L-FIVWHGK(G^K
M?X9&>&1C'M^WEE:YA;NUO(*="33:>*U--:4T]:X^@]#%.K.C/;IO"1]?(G+G
M)W+=ZAD>3-[V?=[>+@EK8M^Q9:UD(\;#8=$ZRS'UI7K6I):= Q95B8U958U7
M]?"G3C9Y?99?%PLJ5.E&3Q>RDL>GQX<&.H5*M6J\:DG)KC.H8+_'F&_?7'?M
MN$[ZWJ4O%?:.,/#731<B-9B9%2_N/^^&YY^S/RC]'&<-BLD^1;/X+2]KB1*Y
M]\U/'EVV;C>5#J]78.ZQF4LQQODTGC?;]HI>L8UZQVK%G!Z?ZR)7*GJY$J[9
M*GB3JO153\GJD>W]KRHY#L1U5:T(OI=]/MP*O*XJ5UB^"+?:7FF:?..VG*3\
MC<0Z4MB1,)C-*RFTQU6N5(I,IG,[9Q,UB5B=$DDAJ:\QL:NZ^!)'^'IXG=;;
MS<T*:LKBYP_.RJJ./0C%/MR9W9O)[<(<&&/[NL0TF1BSF?M@[INX?:-/J\?Y
MKES<9]+JZWCM1;KE2^S%8VSKF*HLQM7%Y.+$PT79>)]&-(YWVUFEMHGZ.Z1?
M26JCD644+AW=*WIJY<W/::Q:DWBVL<<-.K#!+@P*B5U<3AR<IO8PPPZ'FF 2
MZE.2Q>4U]<OE;YQL7\WXC'G.)[PM_7GZ%EWRCU2?BKMDZIB4OI%L:1&\IV[0
M/X]Z5\]NM_-FD7?=_P"7K+X71]LB6?>+Z/WWP.M[7(W4[L_XB:_\]M?YC9DS
M9SN?(-O\+7M=0P;S/?2"Y^!R]LID?IKX;%$E_P#Y;/\ PD_^%DV:_P#Z:?\
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M[7WU3]<CVT1A&E1NZ "2_N#^LOG/^[?S;Q9LUSA_0JO_  /MD#5SFX^G%O\
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MFY>U(JHB]4?U3HGQ$P)>-UM[YJKJ>8;.GB579781*:?>V"V=?)?Z)4_,]D6
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M7'AQCT(5XRF^C76G4E!J:S&\YGOM5^^@[;_L]</_ -(6NDOYOOI[DG]KV?\
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M-,%_B/#?O5COVI";FY3\E6WP>GZ!&E6;?*MS\(J>C9RI<"W@
M
M
M
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MW[U8[]J0FYN4_)5M\'I^@1I5FWRK<_"*GHV<J7 MX
M
M
M
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M.FW&3IS<4Y0<H.49.#QBW%N+PQ3:P9.OY(?_ )G/_!?_ -JP;;?96_\ /O\
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M[K7-&AX6C%C=>Q'*,&6NYO6L?5@9!0QN$VW$93&YAV+HQQ,CAK7EO105VI%
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M*O;IDJW?]1J>,NT3:=QO\6,%^_W_ ++[9IWSO_(UK\*_DY&?N9WY<NO@G\I
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M4]&SE2X%O
M
M
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M?)\.G+T3)'N4OK?;5^];_P!5B,)[\_1*^]9_THF0=Q?I=8>O?Z,B/0U--N
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M/FY]5N_%I]N9C+-_ ATWYA"<92+&       "YN:Q$T(1/-L_C3PK^\&Y_-'
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MX%O
M
M
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M'*?>TO'?:1N[SU]8SFC[$_(OT'Y@BF4_*MM\(I^C1<9^ ^DSSIC<XQN
M  "U_P#B_?WO/-_V9H/H(UXU^YW_ )8M?@S]'(EN0>]9^N>8B:#FGZV>R_\
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MAW]ZMA^C/9# N]WTBN?&CZ")*;'WI#I>:S 7FV_>@93[(.C_ +9O&L'VD/\
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M]\5/'EVV?H1RGY+MO@]/T".#.DN      !/5Y(?_ )G/_!?_ -JP;=_96_\
M/O\ P7_W9YW_ &]__P!4_P#4_P#\>;^>9Q]X7W,?.#']$6#-YMQOI;8^O?Z,
MCSCO_>57UM]HH>&V1         75?)9^\$XZ^?#DWZ-,H:Q<YWTNK>M4O0(F
MV3?)\.G+T3)'N4OK?;5^];_U6(PGOS]$K[UG_2B9!W%^EUAZ]_HR(]#4TVX
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MO
M
M
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M>'S4W6_9N7_U>CZ0?//?#]K9E_6J_IQ]TKW&?S_<U_;4WK^'A\U-UOV;E_\
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M1CGYU;P>55/R>X=*W#O[[V.0_9WO^[I^<]V]D>Z_9/OMY%V/8O9GM#W+[O\
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MY[^PH5J&*>S/:DL5J>#>&**RRW_WPRZM[IL+ZK1N,&MJ"A&6#UK%1QP9U_\
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MY$V_Z%;_ *LR-#[1//Q3@J=/?#>.,(I))9A<I)+0DERFA(_/[I;GK^=3;O\
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MI.JE5JMRJ2TMO2VWI;;X6WK,V'0?0
M
M
M
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MKZ<?V?GRB?@D_P#Q>NYO^N<?/3>;RG^+I>D'S,W:\F_C*OIQ_9^?*)^"3_\
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M)NI-XSDVV^-O2R[I)+!:D<R<0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)RCQX:N'4D=&79W6NKI4*Z@HR3PP3U\&N3Z/5P+4I9"2
M
M
M
M
M
M
M
M
M
M
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M?WK_ .SL&1+>M&XH0KQU2BGW5U'H-B3J.X
M
M
M
M
M
M
M
M
M
M
M             POW(?>\<]?87Y1^@?.G92]5CXR[9QGX#Z3/+RU+;-ET/:->
MW;3<UD-;VW4\SCMBUG8<3.ZKE,'G<1:BO8O+XVTSX^KD,==A9+#*WHZ.1B.:
MJ*B*3248SBXR6,6M)C.G4G2FJE-X33Q3+7?;%^+AZ1NO"F'W;N@YCY5P/,6]
MZW4V6+5N/X]7QV)X[R.:JVKM?%;C-M>O[-E=XR]9MFK)D&5I,(D-EMBLR69/
M!;6QULWE&ILT(QY-/#3CIZ6&&'9)30W>IRI*=U.?+/2\,,%CTT\>F5D.XSA;
M.]M?/?*_!F=R=?*YGBC?,[J+\YCV25:^7BQ%Y[<;G*L#WOFIMRN/6&RV)SG/
MA]9X%55;U+S1J*M2C56J2Q(W=4)6ES*@WBX/7V4^L33^6GY4VR^9Q6W+NI[K
M>9.2(-&R&QWM7IY'#Y.ADN5.2MBPF+IUKF7FVW<*.T4,-K^N.?6J-];CKTMU
MT,L+/<S86R/MUY?1LL*%"*VL.HNHL.V7FPRR69)W=Y.6RW@L,,7AHQQ>."6K
M##K<.E7FK^7QCO+TYYP&C:GNN5WGCCD/4Y-TT?([)6I0;7B*U?-7\-D-;V2?
M%P4\5F,ACGU894OUJU**RRRB>YHE8J.J+&[=W2<I+":>#PU%%FN7JPJQ4).5
M*2T8ZUAK3X.KHZ7'85_%L>:=LW?MJYEX?V'*VLIA^%>0L';TJ.Y)-,[!Z_R5
MC\QD[> I/D>YD>+CV37KUUD343P3WYG?$>B):LXIQC7C-:Y+3U"0;OUIU+25
M.3QV)8+I-8X=?$CE_&8/OO>#?]&[&_TG<D%7DWJ$_'\Q%OWC]7I^(^V:B^6%
MYKGX.#7.7=?^H+]67ZJF;U/,>Z_JI?4\]A>]>AFZ7N;U'U.MY]J>[O;/B\?C
MK^J]7T\+_%U;47MA[KE&6WL[*XL?-11Y=FOQ?3E3Y/;VI8^%AP8<3)2_[41_
M\8Y_M,?[OQ1?$O\ WOY/^L7'YR_]S^7_ *I!]Y@/F1<V^8;M>F9?DS%:QINJ
M<=X_(5-,T/36Y-<31O9WW _8L_D[V6NW;V7S>5?C((T>OJH*]6"..*)'K/+/
M<K2SIVD6H8N3UMEGS#,JN826VE&G'4EVWQ]#1H+ OXNOV.[[QGCM_P"\+D[
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MHU$=39Q0PE&X6IZ'YG[N@5F[USM4Y6LGIB]I=)Z^L^V6K2R$D
M
M
M
M
M
M
M
M
M
M
M                            ,+]R'WO'/7V%^4?H'SIV4O58^,NV<9^
M^DSS"N+\9!FN2^/,-:1KJN6WG4L99:]JO8Z"_G\?5F1[$?&KVK'*O5/$WJGY
M*$SJ/"G)K7@^T8WMDI7-.+U.<>VCU72$&2CSB?-YCCB\R7NT;%&R-J\BU)%;
M&UK&K)-J.M332*C41%?+*]SG+\5SE55]*DNR_P!YT^EYK(#G'RE5Z:]"BY-Y
M*%&MC_+#[6XZL:,;/B>2;TR]&HZ2S?YFY&MV)'JUK?$JR2JB*O54:B)U]!'L
MQ>-Y/'C7:1+LIBHY=22_!QZ[;(0OQG;ZZW:?]CWDKZ)-:+EDW@5.FO-++O)X
M5'I2_P!$S)^+ ?Q3[R?GBX/^9O*1UYUX=/I/S#OW<]0J>.NT:F?C,'WWO!O^
MC=C?Z3N2#OR;U"?C^8BEWC]7I^(^V8E\G/RO> ?,)U/G3.\S[?S!K%OC'8M'
MQ.!CXPS^EX6M;K;+C=BN7WY=FU\?[K+8GBEQ$:0K"^NUK7.\2.545O9F%[5M
M)QC346FN''S&CIRG*[>_I2J5G-.,L-#7%CPIG0?-*\H';.P"E@.4-&V_(\K<
M"[+E?>_8SN3Q,..VOC[9)F.FQF*V^/'N?B\AC,_!')[BR==M=CK$4E>:O Y:
MS[7*RS"-TW":V:JZSZ1UYGE#LHJM2;E0QP>.M=/#@?'U#HGE-]T/:;P#S=B\
M3W8=O_&6]:GM.8IPXCFK:<%+L^=X?S4KHZ]',6L#F[&2UBYJ,,_A?8GKT(<K
MC55UJ*6;U?N=W*_H5ZM/&A*2:7@KA^[VSYE%W:T*JA<PA@WHFUIB^CCP=%88
M=KT)ZENID*E6_0M5[M&[7AMTKM2:.S4MU+,;9J]JK8A<^&Q7L0O1['L56O:J
M*BJBD5U:&3@C#\Z+_AC]U7SNZ%_2[Q\5F7^_*?3\QE!FGR?5\0IW>2__ ,3?
MM4^>3>?Z)=_)!F/O*?27;1$<F^4J7[[T,B;C\8?[!G[%@\=WT\8X1),SK%7&
M:GW TJ$3W6LEK375<5I7(;X(F?HTNM/>S$Y*7JZ3W!)2?T;#3F>EMRFZV9>Y
MIO0],>GPKJ_NUEZSZQY2'NRFN_BL)=%<?4X>ATB"+R]>]_)]J%[G7C[/V[4W
M#O<?PQR%QQN&.8R:TW#;A>TG9,?QUNM*M'(SU<^.SN4]PWG?'(N+OSO5DDD$
M'AN=Y;<NHSCZI"2:Z6.E%FRN^]R3E3J/\Q433Z#PT/S']PU3[8_OD^WO[./$
M_P!'N *BOZC/Q7VBCL_?E+UR/HD>I,0HR04'?/K[GUY\[X\]Q[A<@RWH_;7B
M_J5XIM=9O<TV[/ECRO)U][)7N\.0J[&]F%G5K6,<F$8J(OYM\HRNCR5MMOPI
MZ>IP=WJD)SZYY:\Y*/@4UAU7I?F+J&/_ "Q?-"UKRX<7RLYG;4SF3<>4[^N-
ML[?+RQ%H4F$UK6*^06CK=*@[B_>)GLM93+V+5J9MJ%MA6UVNBZUV/7E>V4KQ
MQ[_9C'@PQT\>M'5EN9QR^$ER>W.3U[6&A:EJ?1,P>8OYS&L^8/P+6X<S':6W
MCC.X/=,)N^H\@LYMBW&?7\ACH;N-RE1V#7AW5IKU#.8'*V:\D;<A7:V;U,[D
MD6!K%X6F72M:O**IBL,&L,/-9W7^<1OK?D)4MEXII[6.#70V5P8K61R=B'<I
M>[1^[/A/G>&Q9BPVI;?4J;Q7JL;-)D>.]D9)KN^46UI&216;#M8R=F2LCF]6
M6XXI&*U[&/;5W5'EZ$J7"UHZ:U%!E]S[DNX5OO,<'TGH?6U]0]-''Y"AEJ%+
M*XJ[4R>,R=2MD,;DL?9AN4,A0N0LLT[M*Y6?)7MU+=>1LD<D;G,D8Y'-545%
M(:UAH>LR(?8
M
M
M
M
M
M
M
M
M
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MMKP):5YO9)CD]S[IL8X^J0[U]35V,.J3&E 70
M
M
M
M
M
M
M
M
M
M
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MPRG+KNPJ2=64'2DM2;QQ6K6ET2PP6HOH
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M)E/E-_Y^+]<&* ]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H#V)E/E-_Y^+]<&*
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M)E/E-_Y^+]<&* ]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H#V)E/E-_Y^+]<&*
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M)E/E-_Y^+]<&* ]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H#V)E/E-_Y^+]<&*
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M)E/E-_Y^+]<&* ]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H#V)E/E-_Y^+]<&*
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M)E/E-_Y^+]<&* ]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H#V)E/E-_Y^+]<&*
M]B93Y3?^?B_7!B@/8F4^4W_GXOUP8H&2C@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTK46YIIX/6?V
M
M
M
M
M
M
M
M
M
M
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MO4=*O%PJ+@:P_<NCJ9VDYG4
M
M
M
M
M
M
M
M
M
M
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M7RVOR-;3%^#+@DN[QK@Z6#>P!5EO
M
M
M
M
M
M
M
M
M
M
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M<U4)K2J0K4U5IO&$EBC%]>C4MZTJ%585(-I]3S.+C1VDYG4
M
M
M
M
M
M
M
M
M
M
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MGH67).4XY%7<J<[>7WKQ72>OL]LY[V6BA7IWD5X:V9=..I]5:/WI+N7\B
M
M
M
M
M
M
M
M
M
M
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MB7F.
M
M
M
M
M
M
M
M
M
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M*]DC616M0JV\]BLL)-8ZT]'4QXB<6UU0NX.I;RVH)X8X-:=#X4N-&QYTE0
M 8 [JMKJ:5VX<UY^V]C&LX[V3$U5DZ^K7*;+0DUK#1O1/2YLN7R\#>GHZ]>G
M5/BE+?35.SJ2?X#75>A=EEPRJDZV94*:_21?4B]I]A,A6\J[7;65[C\IFF->
ME/5^.-AN6)OB1K8R>1PF'J57+X'=9)F7)I&IU;U2!R]?1T6.9'!RO'+@C!]G
M!$UWJJ*&6J'#.HNPF^YURQ02TQT
M
M
M
M
M
M
M
M
M
M
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M/8*#>F\5>\C;0>,*2T^,]?66"Z>))V7HC
M
M
M
M
M
M
M
M
M
M
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MH6(C(J]:O$UC&HG1K6HB$S244HQT12,92E*<G.3QDWBWQMGVGTX@
M
M
M
M
M
M
M
M
M
M
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M':=
M
M
M
M
M
M
M
M
M
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MA=B.ZS^P
M
M
M
M
M
M
M
M
M
M
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MQ5Z[(XHVHUJ(B(B>A#O245A%8(I)2E-[4FW+HGV'T^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>EGUG5J1I1C5VI226*CPO#\(G^+47L
M
M
M
M
M
M
M
M
M
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MW3N5)H[-6W5LQMFKV:UB%SX9Z\\+T>Q[%5KFJBHJHITZM#UE0FFL5J/H
M
M
M
M          !PVQ;%@M2P66V;9LM1P6OX*C8R>8S&3L1U:&/H58UDGLV9Y%1K
M(V-3_P!*KT1$551#LHT:MQ5C0H1<ZTW@DM+;? CY*481<I/"*.G\1<IZQS5Q
M]@N3-,=:DUC99,VF'ENQ-@M3U\+L&5U]]F6NU\CJRV9\2^1(GJDL2.1LC6O1
MS4J<PL*^67D[*YPY>&SCAJ[Z*EAT<,=>I\&@X4JL:U-5(>"^[@9)*([
M                                             =0R&]:UB=IQ^GY2
M^VAF,M0;?QGNI&Q4[J/LSU4J0VG/\#;RR0+X8WHWUG5$8KG+X4L]QGV66F:T
M\FNJG)WE:GMPVM$9=\X[*E^%BM">&.*4<7H+S;9!FEYE-3.K6GREE1J;$]G3
M*/>J6TX_@8/2UCA@W+!:3MY>"S      '\N>QB(Y[FL17,8BN<C45\CVQQM1
M55$\3Y'(U$^*JJB(?')16,FDL4NOH77>A'U1<GA%-O!OK:7UEI9_1]/@
M
M
M                                  !U?/[EKVKWL%0SM^/'/V*U8IXV
M>PK65%LUXXY%CL3N<C:_K?6M:QSOC%>J-5454ZVK,,ZR[*J]"A?U%3E<R<8-
MZ([22>#?!CBDF]&.C%8HNV79)F6;4+BXR^FZD;:"E-+3+9DVL4N'#!MI:<,7
M@\&=H+J6D
M
M                                        &)N?/K%<T_8FY&^@_,G9
M2]5CXR[9U5_49^*^T>6!P!R]D^W_ )QXCYRPN(HY_,<0\B:CR/B<)E)K%?&9
M7)Z=FZ>>H4,C-4Z6F4;-JBQDWJE;(L:JC7-7HJ3:K356G*D]"DFNN8WH570K
M1K)8N$D^L\2;'#^4_P":YYH&(M=Y?*FVZ/6O<CXY-FTJ'G#=\]K^>V;5KK;E
MS#0<?Z=J^G;3B=&U&9D;4Q=2\N#JO@L16(FK7E]T+;7?6-D_<\$\%H>"U/HM
MM8OCUEW669GF*]UU''&6E;3P;7023P7%C@0W8+9.?NRSG^Y:P&7VCASG;A3=
M,C@LI[.NK4R6&V'6LJZGF,'DDJRRX_.82U9I.BLUI%L8_(U55KDEAD^.N+5*
MXI:<)4I(M495[2OWK<*T'AU5^[I,EZKZCYG/XP5R/G]OK7]7UOB'C:Q%0H0;
M+L&>T_MYXZV-</%*F&P>-Q>-V_9-DW[-U)EL6[C,?DK=>&S$RS8JU'TXBW[5
MEE4%'2ZCXM,GVDEUNV711S'/*CEH5*/&VHI]EM]1]'!8$9'>#V9]POE^<TU>
M+N::5'#[3'1H[CI.Z:1G+.1UC:,,S(V:M+:-.SRU<1F*SJ>8Q<L:Q6ZM#)59
M8FO?!&U\+WUMO<4KJGMT_!U-/6N@RW75I7L:W)UM$M::U/HI_P#8R[MY"_>U
MR#WB=H.2QO+V6M[-R?P+MT?'.6W/)6GW,SNFKW,16S6G9_8K4KEGM[##6DLX
MZS8?UDN)CV6)7R6)IG+&\TMH6]QC3T0DL<.)\),,EO)W5KA5>-2#PQXUP-]'
M@ZA'O^-2_6\[-?GSYF^8?'A59)X=3I+S2AWD]3I=.7F$6_D(=Z';3V6<X<Y;
MAW,<D_4UUS<>*<5K6N9'WG;]N7M'-5MOQ^4FI>Y- U;:KU3P48'/]9/%%$O3
MPHY7*B%=FEO6N:48T5BU+'6EP=%HMN27=O:5ISN);,7'!:&^'H)EI+\/3Y3_
M ,*S_P"(9W)?U/%D^*[[\#\J/=))\=99^E_)GZ4@5\[7SE.WON^X0Q7;'VPL
MV;;,)=WW&;?O?)FQ:U=U7"3XW4I<O%@L'J.)SON/:+%G+Y*2'(3V;M&BE:G'
M%"C))IYVU+IEN7U;>KRU;!/#!+''7Q\!9,WS:A=45;V^+6UBVUAJX%CIZ/[M
M&K7XNOV][;REY@FL\OT\;D&Z)VZ:MN.U[/GFPN;BVY[<]1S_ !]J6M2W%:K$
MR>4?L5N_%"BHY]?%SN_,M7KWYM5C"T=-^%-I+J/%_NZ)39#0E4OE57@4TVWT
MTTEV>P6PO.L_X77=U\YFI_TGZ,6++O?M/I^8R39O\G5>DNVCSR.VWM_W7NBY
MAU[@_CA*\N][=A.0,AJM"SZ&YO,:1QUMF_U=;@D5\<<%[9W:M[.K2R.;#%8L
ML?(J1M<I+*U6-"FZD_!36/5:6/4Q(+;T)W-54:?AM/#HX)O#JX8';NT?N8Y(
M[)>Y7CWG?2F7:FQ<=;&ZOL^K6WV,='L^L6'NQFZZ)L%:1B.CAS&+=- OK8W/
MIVVQ6&-2>"-S>-Q1A<T72EJ:T/B? SG:W%2SN(UH>%%Z5QKA3/2.W'F/0^X3
ML-Y$YLXQRS,WHG)G;'R-MFN7D\#9VU,CQUGW38[(P,>_W%F<-=;+3O5G+ZRK
M<@EA>B/8Y$B$:<J5TJ<]$HS2[)/Y585[*5:F\82IMKK/]S/-:[/?OMNUO_2,
MX1_I,UDF%?U"?B/M&/[7WU3]<CVT>K40<R4:W=W_ '"87M3[8^;.X/..J+%Q
MCH.;SN(I7I$CKYG;984QNE:ZY5E@57;%MUZE11&N1W6?T>D[K>DZ]:-)??/L
M</8*>ZKJVMYUW][%OJ\"ZK/,BX7XYWOO![H-!XX9>MY7?>X'E['T,UGI&MEL
M)?W78UN[9MEU.B-6+&5K5O)65Z=$CA>O1?B$RJ3C;T7/[V$>UJ1CRC3G=7,:
M?W]2>OIO2_-)R?QC7LKUW@#E/M^YGXQU^+"<<;SQ=@^&<A1I01,JXC9.#\%B
MM<U-)Y(VQ(U<KQBF/IUV>%?C<#*O7HJ-2VY1<NK"=.;QFI8]26E]GMEYSZTC
M0J0K4UA3E'9ZL="[&'6-M/Q8'NO22KS;V9;-EOT2L]G.7%-2W,SXZ"9<=K/)
MV%HOF\+_ -!F3#9""I$YW7UM^PC&])GK3YU0\&X7BOMKS>P56[MSHG:2?XT>
MT_,?7+>)824   %!;SO_ #4N2.Y+G'D#MDXFW')ZWVT<3;'E-(R]/7,A8QZ<
MR;CKUB7%[1F]JN49VIF],QV<KSUL/0\<E"Q% W(/;)++"E:49;8PHTE6J+&M
M)8])<&'1X^L0G.,RJ7%:5O2;5O%X:/OFM>/0XEJX37;L^\CSO@[SN+,?S/I-
M3C/C3CS/LLSZ=F.9=FV+7+.[4JTZU7Y/7</JVF;MF/9,]ACVU[5V"G7M-C5\
M+Y(U8]W=<9E;6\^3EM2FM>"U==HZ+7)[R[I<M#9C3>K:;6/2P3,#]WT_?!VX
MZ?CO+T[K'9FOJO%NYT.3N-L)L%WWR4\30FPVQ:U4O<6[=%;GK6N,]BK9*>1*
M<:NAJ7ZSF)%3M-O0O[;?W-6E[KH>%)8/[JXU^['0=-U[LMX*QN<=F+Q6.GC6
MA\3[?$\263\5R^^V[A?]'-W])FCE!G7J$/'\QESW<]]5/6_-1-QYWGF?9OL,
MXEUSCOAJU1C[CN:ZF676\O<K0Y"+C+2,>K:.6W_V;9BFI7L]9R$Z4\+#98^J
MMF.>Q*R9E1:\]NRVR5U4<ZGJ,>R^+NEWSC,794E3I>^)ZN@N/I\7W"GGVG]B
MO>?YIW)N^[%H]M^V9.M=@R/*/.G-6W9QN!KYO*QN6C7S^U24=GVC8-@O5ZO5
MM>E4OV(8&-=(V.+P.6_U[FWLH)2T+@BEYFA$5MK*[S*I*4-+X92;PZKTMOKG
MZ=V'8IWI^5?R3H>R;K=EU/(7+<M[C3G3A+;<^NOS9S&)X[='"[8S'ZMLN V&
MG7>DBUKE2E/-7<KXVR1I(K5"ZMKZ#C'2N&+7F:4?;FRN\MJ1E/0^"46\.OH:
M9<3\D3S-<YW[<+['H_,-FE+W%\',PU7;LO5@KX^'DG3<PVQ7U[D%F-K15ZE+
M.I;H34LW!58E5EI(+,;86765H(_F5FK6HI4_49:N@^+N?<)5D^8RO:+A5]7A
MKZ*X'W?NFR_FL]^=;R_>U//<H8>+&Y/EC<,C'Q_PU@\FU)Z4VYY2E;MR[%EJ
M+9(Y[6!T[$TYKUAB=&3SMKU7/C]TM>G38VONJNH/U-:7TONE1F=[[AMG46#J
MO1'I\?4UGGZ:7IO=KYEG<PS"XVWMO/'/?)-JQD<MG=DRS%CQV'I.:Z]F,UE;
MKX,1J6DZU7G:R.*)L%.I&L56I#XG00.E4I4+.CB\(TE^[JMD'A"ZS"XP6,Z\
MN%_NT)?]A)1R;Y0_FA>6=AZW=WQYMVIW;7&3/;^?VCMRW?9\KL^B8*MX+.2R
M.U:]M>DZ:[8],C;"UN7K009B@M3QNNPK2;.]M'"_LKQ^YYI]]P22P?2P;T\6
MKH:2X5,KS'+U[JIM8QTMP;Q2Z*:6*X]?1T$0'<1S=LG<ES9R/SMN./Q6+VSE
M'89=KV2E@V6(L-%G+U:LW)OQ<%J:Q9JT;%R)\L4+Y970L>C%D?X?&MPI4U1I
MJE'P8K!%KKUI7%:5:>"E)XL],_@3[P;A?_1 XZ_H8PY#:GOJ7KC[9D*A[RAZ
MTO0GF)\+\DVN&N8>)^7Z.+KYR]Q5R7HG)-/"V[$E2KF+6C;1BMGKXNS;ACEF
MJU\A-BTB?(QCG,:]51%5.A,ZD.4IRIO0I1:ZZP,=T:CHU8U4L7&2?6>)G'>=
M>[TN]79>1^Z7-<8\[<WRYS,W,EO')VL\:;UMFH826)O2+$.S>#PN0P.M87 4
M6,K5*/KHH:52)D;&M8U$.J+MK:*H*48X:EBD_NG=.-W=RE<N,YXO2TFUV-"P
M+B'EC7L+Y:WDGW>YOD:G;FN;'A]M[C)M?M6+,+LK;W:SC=3X;UG'26W*VE4W
M7&T,#*U\4;8F29:29&O^.>^/WB=YF7(PX,(];2^MIZQ*LN:R_*/=%36TY8=/
M1%=71URH[EMG[RO-<[J\3B;^5SW,7-/)>8R,6L:]+DEQVG:3A8X),ED:>OT+
MUM,%H>B:UB*#II_ K$<R%9976+4CGRWY1M[&ABL(TUKXWW61ARN\SN4FW.M)
MZ%P+I<"2_=I-]>:?Q=KO_P"%^*MFY6ER'!')-34,)<V/.Z=QIO.WWMX@PF+Q
MMK+9FY3H;=QSIN$RTN*J5'^.M4R$]RP_HVM%.Y>A2T\VM:DU3[Y8O6TL.PV5
MM;(KZC2=7O))+%I-X]E+M](P-Y0W?MS#V@=U?$VKX;;<K9X/Y;Y'U+0^5>-\
MC?FL:I/CMTS>/UM^ZXW&3R.JXG;M5?=CNPW*WJ)K,=9:DSW5Y7M.V_M:=Q0E
M)K\Y%-I\.C@Z3.C*[VK:W,8IOD922DN#3HQZ:^X>D'DLC0P^.OY?*W:N-Q>+
MI6LCDLC=GCK4J%"C!)9N7;=F9S(J]6K7B<^1[E1K&-557HA$$FW@M9/FTEB]
M2/-Q\TGS0.5^_P"YAV.K1V3.Z]VS:MG;U'B;B^I9N8O%9+$T+;HL?OF]8J.5
MD6:W;.Q0MLI[J25N(CE]RUO#TFEL3"RLJ=K36*3K-:7YBZ';(#F68U;ZJTFU
M;I]ZO-?1[6HS-P9^+Z^8+SIQ%B.8*=#B;C>ALF"@V/5]*Y4W'8<!R!G\3>JO
MN8J9F%PFE;-C<#-E:WJWQ0YB]C9F),SUS8OCO#UU<UM*53D^^DT]+2T=M=C$
M[:.1WU:DJJV8IK%)MIOL/#JM&AO=_P G=W5JUH_;'W@S;,_=>U!^U:;@J6^.
M=D-XP&'VA-;O)KV0V=+UZ+:=9IU\+6GP=MLMF-U"TGJ+,U-:K8JFWA0P=:WP
MV:F#T:NMP/C[I1752ZQC;W6.W2Q2QUK'#1CPKBZ'#A@68/Q5KZWG>5\^?#/S
M#Y#+-G?AT^D_,)#NWZG5Z<?-.A_C#_F9<FZGR'7['.!]VS&C8W%:WBM@Y^V/
M5LA8Q&QYK(;16ARVN<<09NA/#D<9@:^M2P7\I' ]BY),C#7D7U$4\4_/*;.$
MH>Z:JQ>/>X]#AZ^HX9[F-2-3W'0;BDL9-:].I8\6&OCQP(C.S+R1.]7O<XII
M\UZ#]2OCGCC-V+T.I9SF':-EP,NZ0XR[-C+^1UW%ZAI.]95<57R-::!+%R&I
M%,^%_J5D:GB6ON,RMK:?)RVG-:\%JZ[1:[3)[N\I<M#9C3>IR;6/2P3-6.[O
MLP[F?+CYEP&F\MI5UO;'U6;CQUR'QOL]RWA,[2QV4FI1;%I^QP083/XR[C\E
M3ZK%:K8_)5NL4CX6-DB<[OM[BC=TW*GICJ::[?[L"FNK2XL*RA5T2UIIZ'T4
M]?:9=U\BGO<Y([T>SV_9YFRR[)RGPKO=CC'-;=/ZOVKNFNMU_"9W4]FV%T21
MMFV%U;)6,?:G\'CN.QZ697/GGF<1O,[:%O<?F]$)+'#BXT2_)KRI=VOYUXU(
M2PQXUABF^CP=0J#>:EV/]T/;IW \T\X<R<8>\[B_G+N5YLRG%NS^_7CS8??1
M0SFZ['MV+G]BZKMN<V'">ZM>O16/#D:E1[/%ZMZ-E16)?[&YH5J4:5.6,XP6
M*P>C1APHB^96=S0KSK58X4YU);+Q3QQ;? \=7&:I]K'9/W.=ZV=VO6NV7C/Z
MI>;TC$T<[M%+WY\?Z;[,Q62N/H4K7NGD#:]4J7?76XW,\%>2:1O3JYJ-])WU
M[FC;).M+93U:&^TF4MM9W%W)QMX[32Q>E+MM%XKMVX%Y8[8O(?Y"X.YQU3WD
M<HZ1VM=['OHU?V[K>R^S/?+E.=]OPO\ [VM0S&?UV[[MUW/U+'_9[<OJ_6^K
MD\,K7L;&JM6G6S15:3Q@YPP?G5PDPH4*MODLJ-985%2J8K%/7M/@Q6IE'+L:
M^_8[/?\ 2E[??Z6=1)+=>]JGB2[3(?9>_*7KL?1(]2_;MLUS0M3V?>=QR]37
M]1TO7LUMFTYZ^Y[*&$US7,;9S&<R]U\;)'MJ8W&4Y9I%1KE1C%Z(I"8Q<I*,
M=,F\$9'E*,(N<WA%+%OH(\Z7S*/-B[@?,%Y)S>HZUF=FTGMOBSK\1QSPOKEJ
MY7DVRHRW[EQ6P<BPXU63;=MN>?X)HZ,GKJ6+61M>LQ\C9;5F6V=C2M8*32=;
M#2^+I<2()F&9U[ZHX1;5OCHBN'HOC;XN#LF:>/OQ<WS&-\XSI\B6Z7#/'N3R
M./;DZ/%G(.^9W&<F25IZM>W3CN4<)I6PZE@\A;CL>%:F1S%2U5E8^.U' ]OA
M.N>;VD9['?-<:6CMX]@[:>0W\Z?*/8B^)O3VFEU7TS2?@SN3[U?*A[C,QA,7
M8VGC3<-+V.O3Y7X+W">Q8T;<H6,J3R8_:M=KW)<-DX<MAG1NQ^<Q\GNIE2=E
MBA<1DC7NJ:M&VOJ*;P<6M$EK72[G7*2C<7F65W%8QDGWT7J?37::ZC/1([->
M[#COO7[=] [AN-6S4L1M]*:#-:U>LPVLMI>WXF7W'LVHY::!D3)K.(R#5]5/
MZN)+E22&RUC&3-1(G<4)VU5TIZUP\:X&3JTN:=W0C7IZGP<3X44Z/QG[[_GB
M+_1 T'^F?G\D&2^]9>N/M1(KO%[]CZTO12-/NU7>N_;O$X&T[RR^T'%9'&Z3
MA[>]\B<NW\/L'O8J[11V?.-<]W).W3RTJ^)X^Q%>6O6AP['2.RM^5[GLM.2M
M#7[Z\;6WJN]N/"T)=##B7'T> I+:=[=45E]KCL+%RTX8XOA?%T.%G6>^;R=.
M[_L#T3$\H\KIQIO''&0RM3!9'<>(MDV'8,;JV9R3IV8JALU/:]/TC-T6Y1U=
M6PV8JD]+UKF1.F;-(R-W*VS"WNI;$,5/B?#TL&SC>95=6,%4J[+IXX8Q;>'3
MQ2?F&]_XO!WX\F\<]T6M=G^V;?E<UPCS51V6GJFN9J[8O4- Y'PF#R6UXK(:
MNMF65<)1VFOB+6/MTZZ-@M7;5:9S4?&KG4N;6L)T'<16%2.&/16K3TBMR*]J
M4[E6LFW1GC@N)Z]'%CJ+V)&29@
M
M
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M@@G=RLZL959X.I+:@TUCJBGCALQP6K'%Z22 V4-9
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M3TJJ]$.,IQ@DYM)-I:=&EZ$NFWH1RC"<VU!-M)O0L="TM])+2WP'Z'(X@
M
M                       &C7=WD/69;2\4CE_[+CLOD',]/1?=]FG68Y?R
M%5/9KD3^YU7^Z8*YX+C:N[*T_ IU)^?E&*] S/?,U;;-G?7>'AU*</.1E)^C
M1\/"O<'-@_<NJ;W:ELX;XROB\_,KYK.)3KX65<D]5=)8QC4Z(R3TOKHG1?%'
MT]7T;D\X<['8RG/IN5EH4*KQ<J?%&?"X<3UPU:8^#W[\\W$+_;S?=^"C?:74
MHK!1J<<H+4I\+6J>O1+PM[X9HK$44\$L<\$\;)H9H7MEBFBE:CXY8I&*YDD<
MC'(K7(JHJ+U0SU"<*D%4IM2IR2::>*:>E--:T^!FO\X3IS=.HG&I%M--8--:
M&FGI33UH_0Y'$ '\O>R)CY97MCCC:Y\DCW(QC&,17/>][E1K6M:G557T(A\E
M*,8N4FE%+%MZDN-GV,93DHQ3<F\$EK;XD:^;?W$:IB<A#K^JHFV9ZW<@Q\4E
M1_3!UK5F9E>-9;[>JW_!)(B^"LCFOZ*WUK%,>9QSC93:7$<ORG_>[^<U!.+_
M #492>"QG]_@WJABGJVDS(^3<VV;WEM+,<W_ -SR^$'-J2_.RC%-O"'WF*6N
M>#6O8DC84R(8W
M
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M.;OZ3-'*C.O4(>/YC*3=SWU4];\U&GWXP;R'DMX\S_F#!VYW38_BO3N)>/,
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M7M-,HR>3_P#\3#L[^RS6^86;)+F'O.IXI#LJ^4*7C>8>FB0TR$
M
M                                    #_%5$]*JB)U1.JKT]+E1K4]/
MY*JO1/\ I#:6L)-ZC_0
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M*Y?&Y[DZ)X?3AWG$I[.;T:O!*W2ZJG/S&B092\:$H\4_,1+,0 NH
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M
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ML:.&*5Q&?4IXU'V(G/?6Z]Q;J7];'!NWE#JU,*:[,B5XVS-0P
M
M
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MYN#4VT\,4EAHXM)7TL@O:M.-12II22>#;QT\?>LR'_9@>_G^=WM _E]S/_4
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MSJ>*0S*OE"EXWF'IHD-,A
M
M        TD[F.4+4&:Q.FZ[>EJS8"U3SN6MU9%8]F7C\-C$U.J(B*M"-4L.1
M?$Q7R1_$=&I@_G.WIJPO:.39=4<9V\XU:DHO_:+33C^\7?O6L7'AB9VYK=U*
M-2QK9WF5-3A<0E2IQDM#IO14E^_?>+4\%+@D;'\4<AU.2-3J9=JQQ9:KX:.>
MI,]'N;)1L172QL555*EUGZ+$O5>B*K.JN8XR3NEO%1WERB%XL%=P[VK%?>S2
MUI?@R\*/6QQ3,9;W[MUMV,XG9O%V<^^I2?WT&]3?X4?!EU\,&C)A)R+
M
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MSG(I83M*RX54B^IL-=ME[RB6BI'I/MDWQC$O0
M                          (RNX^9LO+NQL3Q=:];!0OZ_$\3L%C[">'T
MK\;X9T_]OU-8><F:EOA<Q6N,:2_BH/S3:;FR@X[FVTGJE*J_XV:\PP800GP
M    !FOMWA]=R_J:JQ'LA3.3/Z]%1G@UW+)&_HOY+9W,Z=/2BDWYNH;>^-IH
MQ4>5;]AJ8/KX$&YR:FQN9>:<)2Y)+JUJ>*ZV))Z;1&J@
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MV]\;/%8I<J^EA1J8/KX$(YR*G)[F7F#PD^273QK4\5UL23\VC-4P
M
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MTYU[KW/NKR">FO<4X8<:6U4ZV,%V"1LV1-9@
M
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MWU*<Z52,%+2W%I+JX'H;D3)T
M
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MHO0U)/!I]%/0?2=AU
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MU+'+K>M^#6<?/1;_ -$NF4/\[./''M/[I85,0E_
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M1JQ7WU:DORL?,)*39@U?
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M$3XO5JUU_P#DF">>":=[94^%4JCZ\HKS#/G,U!JROJG ZM-=:,GYII\8<,T
M     &?NV>%)>5\6_P 73W/B\U,B=.OB5U%]?PKZ?1Z)^O\ [8R#S8PVM[:4
MOP:51_DM>:8[YTI[&Z%6/X5:DORD_,)*C9@U?
M
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M5T<M6IZ74I1II.*DZ=2I)*,I<S/YJ&
M
M                                                         ?C9
MLUZ=>Q<N6(:M2K#+9M6K,K(*]:O QTL]BQ/*YL4,,,35<][E1K6HJJO0:]"U
MC5I>HU-K>8!V'7+%>G3[V>T>U;M315JM6MW(\-SV+-B=[8H*]>"+<W2S332N
M1K&-17.<J(B=3O\ <MTM+IU,/%?<*7W=9/0JU+'QX]TVX.@J@
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MGP^@
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MNP9O,%@
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M[<?](N.5O"ZPXXON^86;3"1)
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M&QIK4
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M!H.
M
M                            #IG(_P!;S?/G,VCYAWCE#PUTT<*GJ<ND
MSR<../KAZ'\^>K_-RB3F?@/I,QG3]4CTT>N$00R>
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MM_Z.?"/]&>LD,K^KS\=]LR':^]:?K<>TC8PZCO
M
M              /DR&0H8FC<R>4NU,;C<?6FN7\AD+,-.C1IUHW2V+=RW8?'
M7K5H(F*Y\CW-:UJ*JJB'*$)U)*%-.4V\$DL6V^!+A9\;26+T(AL[K?.^[4>
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MBR6 SM%LS'2U;44<OJY&2-1T4D;WX0S3*<PR6\E8YE3E2N(\#U-<$HM:)1?
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MQQTQ;_"@]#XULR^^,K$L(B
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MNX=-]IEL,P&2D
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M@=XGUJ=1?Z1O^;!FNP
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M)>>&;606U/[UWB?6IU%YK) 38,UU
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MEH5*35)X)TG*8HV'-.
M
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M\P]WT'*:2K1>#PU=!KI^82U% 7,
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M:XHW=O"ZMI*=O4BI1DM336*9J1<VU>SN)VMS%PN*<G&47K33P:ZY]AW'0
M
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MAACGDFE8V-/A=:H^M&*\TWI,[F @
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M$KNZ^G\E/_;9AYH(-WU[4X%1@NO)OS&89YY)I6%C3X76J/K1BO-1O29X, @
M
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M?Y/I-S[*W5I9TK2/@TJ48>=BEYAI->W+O+RM=R\*K5E-_OI.7FG)%24H  !
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M%X([[4<DMM\LVMMVHRCN]3S*YA;)R<VJ$:TXTN^>E]XEABV\-<I/&3R<7LC
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MI6U*IMV]26&-6VJ-NC4T8+:<>]J8:%5C./WIL<3$QN
M
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M)WE-4KJ=->"I:.D]*[9.\OK.O94ZLM,G'3TUH?91O&4Q6  \I7O"^^V[I/\
M2,YN_I,V8G%#U"'B+M&-;KWU4]<EVV9N[S^_KDKNYU;MYXLMNMZUPSVU<-\;
M<::-HT=E'09'9=4T+7]5VGD;8?4KZJ_GM@MXE[*;7*YF-QOAAB1));<MCKM[
M6%"4YZZDY-M]!O%+]W"=MW>U+J-.D]%*G!)+HI)-OHOL+JEEG\7%[#^#:?$\
M7?7E,[@>2^9,WF-KT;5\=#%)-7X$BQ$[\;G,?+7N1QJSDC:L5:@LRW/!_P!F
MP=^&*J_P6[3IK-F]U5V_<J3C3P3?XWW%VR0Y!9452]VMJ55MI?B\?5?:>C66
MHRR$D/+(\PC[_GO@_P!+_N6_IGW4FUI[UI>MQ[2,;WWOVMZ[/T3+Y'DA]OVC
M<&>79P-E=:PM2KM/-.KUN7N0MB]16]K[)F-LEM7<)'?N0L222CKNM35:-.!5
M\,,<;G=$EEF<^,9E5E5NY*3[V+P74[I-,GH0HV$'%=]-;3?'CW%H(@/QISB_
M6HL9VF\RT\/5K;;9R?)''&>SL%=S;67P4-+6]CUG'9&RWXR1F#N>TWU6N^/3
MW=-Z51.C:_))O&I3Q[W0^WCYA:]Y*<<*55+O\6F^AH:\WKF(?Q6*W99S5W9T
M63RMIV>+N/+<]9'JD,UFEMF9AJ3R1_F72UXK\S6*OI:DKNGQ5.S._4Z;_&?:
M.K=M_GJJX-E=LV#_ !HSN#SN&TGMP[8\+;L5,-O&5V?ES>V1/]2W)0Z=[BUS
M1L;*K/T2U1]H9S*6IH7JD7NBI5D\+GQM6/JR6DG*=9ZU@EU=?F'?O'7DH4[=
M:I-R?4T+S35S\6=[0M'Y1Y7Y?[I>0,%1V&7@E=3UCBBEE:D-['X[?]I9ELKE
MMSC@G8YC,]J&%Q%:+'2*C_4R95\[$9/!!(WNSFXE"$:$'AM8M])<'5\PIMWK
M6%2K*YFL=C!1Z;X>IP=,NG[/K&N;KKN;U';\%B=GU;9,9<PNP:[GL?5RN&S6
M)R$#ZU[&Y/'78YJEVE;@D<R2.1KFN:O14([&3BU*+PDB6RC&<7&:3BUI3/,+
M\R/MIQG9_P![_/\ P/K++-?4=1W"ME]"9/9DMV*FD;KA,3O.I4'7Y'NGN383
M#;##2?.]RR/EK.5_Q_4F=G6=Q;0JR\)K3TUH9CS,+=6MY.C'P4]'2>E=LNR=
MOO?+M.=\D%.[_)96;(\H:%VQ\D8VYF+"];U_E'BZ+9..,+G<J]SI6NN[!L."
MI9*S(WT.6VY[6-ZI&D<JVT5F7N=> YKK/3]PEU"\E+)_=3>-2--]=8K'JO24
M5NSKAZOW,=W7;[PSLMF[8Q7+',VE:]N-Q+<Z9.;6\IL-6?<K45U7K8]IR8%E
MM[)5=XEF5%5W7TDFN*G(T)U(ZXQ>'F$-M*7NBZA2EJE-)]+'3V#U.-6U;6](
MUO!:?I^"Q6LZKK.*I8/7M>P=*OC<1AL1C:[*M#'8ZA59'7JU*M>-K&,8U$1$
M(3*4I2<I/&3,CQC&$5""2BE@DBO_ -V'XO'PCW3=SO)_<*_FG8>*,1R8[%9>
M[QQH?'V#2"END="M4V?9W;!DL]/7M-VVW66]8KQXNLYMZ>:59I/6*B76AFU6
MA1C2V5)QX6^#@74Z99+K(J-S<2K[;BI<"2U\+QQX=>K63(=I?;9KW:'V_<>=
MNVI;IO>^ZQQO1R&/P>?Y&O87([-[BR68R&<=C76L%@]?IMP^*M9.2#'P+"^2
MI19% LLC8FJ6^O6=Q5=:22D^(NMK;QM:$:$7*48\+U]A+J'F1]X7WVW=)_I&
M<W?TF;,3*AZA#Q%VC'MU[ZJ>N2[;,W=Y_?UR5W<ZMV\\66W6]:X9[:N&^-N-
M-&T:.RCH,CLNJ:%K^J[3R-L/J5]5?SVP6\2]E-KE<S&XWPPQ(DDMN6QUV]K"
MA*<]=2<FV^@WBE^[A.V[O:EU&G2>BE3@DET4DFWT7V%U2RS^+B]A_!M/B>+O
MKRF=P/)?,F;S&UZ-J^.ABDFK\"18B=^-SF/EKW(XU9R1M6*M069;G@_[-@[\
M,55_@MVG36;-[JKM^Y4G&G@F_P ;[B[9(<@LJ*I>[6U*JVTOQ>/JOM/1K+49
M9"2&H]GS .PZG8L4[G>SVCU;=6:6M:JV>Y'AN"Q6L0/=%/7L02[FV6&:&5JM
M>QR(YKD5%3J=_N6Z>E4ZF'BON%+[NLEH=:ECX\>Z?Q'Y@G85-)'##WN=HDLL
MKV1Q11]R?#3Y))'N1K(XV-W17/>]RHB(B*JJI]]R77Z.IYU]P>[K+]-2\_'N
ME;_\:=Y9S#/N2^"Z=R:'7['U1>6=AQZ._P"SY#,4_8>GZ;<<Q']/78BE?SS&
MJK?S-Y>B_%0N^24U^<J\.A>:_,+!O)5?YJBO!TR?:7FF*OQ8WM7T??>1^;^Z
M3=<)2S>9X:]ZND\4^T*J6J^#V?<*>=O;7M-1)%]5#G,9@*-6G5E\+W1Q9.PJ
M>!W@<<\YKRC"-"+P4L6^DM2.O=VVA.I.YFL7#!1Z#>.+Z>';+?7.'"W'?<1Q
M/O7"W*VOTMFT3D'7[VOYS'7((9GPMM1*E3+8R2:.3W!G<)=2.W0MQHDU2W#'
M+&J/8BE@IU)T:BJ4WA),E%:C3KTI4:BQA)8?NZ7 >4MR7I5OC;D;?^.LA-[H
MOZ#NVU:5=L>J=!Z^WJV=OX*S-ZE_5\/K9J#G>%?2WKT4G$);<%-:FD^N8UJ0
M=.I*F]<6UUG@>DQ?YON=MGE+X+G7%QLESG&78WH>RZU%+'%-7DVR'AW 5M39
M;BF;)$^D[9+-5)D<UZ>J\7QKOS*Q!4N6ON2>J51KJ8Z2?NL[?+%67A1HIKI[
M*P[)YXW:[Q#E>[+NNX8X=R^:R;[O-O+^MX+;-FDG6[FH\=L6?BL[ILJSV_7+
M=RU7#NN7.LJN]=.SX]?2JDLKU%0H2J)>#'0NTB"VU)W5S"DWIG-8OIO2SU)^
M,^--#X<T#4^+N,=7Q.EZ#H^&JX#5]9P=5E3'8O&U&KX6,8WJ^>U9F>^:S8E5
M\]JS))-,]\LCWNA,YRJ3<YO&;>EF1Z=.%*"ITTE"*P2*HOXSAV@:/B-?XD[S
MM.UVCA-MS.Z-X?Y:N8N"&JFV>TM>RVPZ'L68@@;&V?,8B+5LA0ENN1TT]>>I
M#(Y6UX42^Y-<2;E;R>,4L5T./MD:WAM8*,;N"PDWLRZ.C%/L-=8Q7^*\=PN<
MQG+W/W:YD<G-+JFVZ'7YHUC&6'.=6QFV:=F\'J6R.QJ(]$AM;+@=JIOLHK7)
M(S#1*BL5BI)SSJDG3A77A)X/I/3V,.R=6[E>2JSMF^]<=I=--)]=/L'1_P 9
MW[=VZ9W)<-=R.)I.CQG-N@W--VBQ#$BQKN_%,]&&O<NRLB;ZNQE=,V3'UX$>
MY72,Q,GA]#'=.62U=JC*B]<7BND_NKLG#>*AL7$+A:IQP?37W&NL2I_B\G<_
MA\OY<&Y:UN&0?5A[2MPY 9E9Y)/=+ZW&V;IVN6:647JV-[&0W\EG*T<2N=X8
MZ+>CD:J,90YM1:O$X_[1+KZNX7+(KE.P<9_[)OK>%W>L4MMGM\E]WG/O+>]T
M,98SF^<D97F[GC/T('.EDBQ^#PNY<R[PZLC(_CHL-K.$NN@B8U$5L+(F-3JU
M"114+>E&.J$<(]I+LD2EREU7E-:9R<I/J8R?8)R?Q9+FSWD]Y/)W"]VSZG&<
MX\06KE"#UWA]U[GQ9E&9[$1^I<]K)?5:AFMADZHCGL\/H3PJ]4MN<T]JWC46
MN,NP_NX%YW>K;%W*B]4X=E:>UB8#_&%^?7\Q^8EMNET;TUG6^WW3-4XIQT/H
M;2]O2U'[MN-J"-'N5UIF:VI<?/(YK'.7&M;T5C&.7MRFER=HI/7-M^8NT=&>
MU^5OW!>#!*/FOMX=0M:>1QV\IV]>7%PA#>H^XMIYCAR//.U^*!D$D\O(RUIM
M0?(WU,5A7Q<:8[!QO]:KW)(Q_149X6ML>95>5O)?@Q[U=37V<22Y-0Y"PACX
M4^^?5U=C H>>81]_SWP?Z7_<M_3/NI)[3WK2];CVD0N^]^UO79^B9?(\D/M^
MT;@SR[.!LKK6%J5=IYIU>MR]R%L7J*WM?9,QMDMJ[A([]R%B224==UJ:K1IP
M*OAACC<[HDLLSGQC,JLJMW)2?>Q>"ZG=)ID]"%&P@XKOIK:;X\>XM!$!^-.<
M7ZU%C.TWF6GAZM;;;.3Y(XXSV=@KN;:R^"AI:WL>LX[(V6_&2,P=SVF^JUWQ
MZ>[IO2J)T;7Y)-XU*>/>Z'V\?,+7O)3CA2JI=_BTWT-#7F]<Q#^*Q6[+.:N[
M.BR>5M.SQ=QY;GK(]4AFLTMLS,-2>2/\RZ6O%?F:Q5]+4E=T^*IV9WZG3?XS
M[1U;MO\ /55P;*[9=,(Z2T
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MBX/0HMO>0SJ8$
M                       !$EYPF!]U\$<<[$R-7R83E6MC7N:CU6*KGM4V
M2621W3XQL:V<+"Q57T^)S43XJF0.;NKLYK6H\$K=OJQG'S),M6;1QH1EQ2[:
M976,PD?      .R:=F?>YM^J["DGJ5P6R8/,I+^C?H7LO)U;WK/^S_H_QGJ.
MOQGQ_H]'IZ'3<T^6MZE'\.$EUTT<H2V9J7$TR[D:R$S
M                                !#%?F2S>NV&N<]L]NQ,CW=?$])9G
MO1SO%\=XG([JO7TFEEQ-5*\ZB>*E-O'IMLW>MX.E;PIM8.,(K#I)(^0Z3N/]
M:YS7(YJJUS51S7-54<UR+U145/2BHI]3:>*UAI-8/4?M-9L6/#Z^>:?P=?!Z
MZ5\GA\73Q>'QN=X?%X4Z]/B]#E.I4J>')RPXVV<(4Z=/U.,8X\22[1^!P.8
M-U.T"#ZX%E6?YL01R?Y?DF8G_P#35?\ VQFWF=A\H5&OT"3]E;7:,&\\\_DZ
MDG^G;7L*3[9NH9L,&@
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MZQFTP8
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M<6>6UYTGJ_/;#C16/!C5E!<>G0F]!>_/4D\&0
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M$9#,<@
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MK]1M_(VKV0O-K8FM"Q)IYYII?#XGO>Y5<LAI.4J492\)Q6/3P(I7C&-><8>
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M]6J^*NV75".DN
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M<43!?.ONV[6\CO%:Q_,5\(U</O:B7>RZ"G%8>-''7(P/W!<>+I.YRY"C!ZO
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MFK:KR-?'(Q5:]CD5%5%().$Z<W3J)QG%M-/0TUH::X&BYIIK%:F?8<3Z
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MG&[&>Y#IS2VG3I-X*>B4'Q+;BW'%\";3Z!=;>]M;KU":<N+4^L])M66$J@
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M57-5B/)SS;V_NC?"UQ6,8<I-]2G/#\IK_M+9G$]G+Y\;P797F%#<VI(.
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M?AA97M3CJTUUHR?FF N>2>-]8T^*E4?7E%>8;@F8S#
M
M        (^N[#(>OWS"X]J]6X_6*\COB?&SW<CD7O3ITZ_\ 40Q+\7\GXG]W
M7KG:N.4S^A;K53M4^K*<_,438SF@M^3W?KW+UU+IKJ1A##LN1JX8K,L
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MF1S&@
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M:G!=K3V3S<?,(^_Y[X/]+_N6_IGW4E]I[UI>MQ[2(!?>_:WKL_1,]%_RV?\
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M6'R3R(DDJM;T8C42'3EMS<\$L7C@M2Z",@TH<G3C3;<FDEB]+?1?3._'$Y@
M\I7O"^^V[I/](SF[^DS9B<4/4(>(NT8UNO?53UR7;9Z6O9AB<7GNQ+M/P>;Q
M]++X7-=I7!6)R^*R5:&[CLGB\CP[JU._C[].PR2"W2NU)GQRQ/:YDC'*U45%
M4A]RVKJHUK527;9D"T2E94HO2G2CZ%'GH>9_V6YCL+[P=^XGI5\A#QYD[+.0
M.$\[*Z=?:''6P69[&)JQWWKZVQD].R4-C#VY%5)'V:"S=$9+&YTKLKE75NJC
M\/4^G]W60;,;1V5U*E_LWIB^@^YJZA=]\FOORC[Z>T37LIM679=YSX=]G\<<
MT033-?D<KDJE-_O5Y#F8LCIGP\A8*HMB:96QQNS%;(11M\$**L;S"U]S7#45
M^:EI7FKJ=K F&4WONVU3D_ST-$O,?579Q*%_F$??\]\'^E_W+?TS[J2>T]ZT
MO6X]I$*OO?M;UV?HF>B_Y;/_  ^.R;_1:X-_HYUXB5Y[[J>/+MD]L/>-'UJ/
M:1"%^-+_ 'O7:Y]F7:_H(>7+)/59^*NV6;>3U"GX[[1J!^*R_7U[K?L3:-]&
M%X[\[]2I^,^T4N[?JU7Q5VRQ#YK_ &$Q>8+VIYGC'!6,;BN6]*S$'(?#>;RC
M_<V.;M^,I7:%O6LS=CBDGKX'<,'D+%.5R=8Z]M:MM[)$JHQUIL;KW)7VWZFU
M@^E]POV9V7NZV=-:*J>,>GQ=)_=*$'"',_=?Y67=0_:,7@,KQES#H<M_5MWX
M\Y!PUQF'VO6;5N!V5U?9L;'8INS6J9N7'0V*MVA9:U[H8+E&RCF13$HJ4Z%[
M0V6]JF]*:X'QKH_N9":-6YRVYVDG&K'0T^%<3XUTNFF37\P?C0W.&X<87M6X
ME[;-/XBY)R>);CI^3LER-<Y&IXBW/7CAO9G5]'L:)JM:CD&2+))2;D,AE8*S
ME9ZZ.TC'));J>2THSVJDW*'%AAUWB_,+O5WCK3I[-*FH5,->./66"[+?5(J?
M+I\O#F_S+N>WK([9:O%=/:'9WGSG3*I/;922_9]L9G&T<QDO6LV'D[:ULK[G
M@ZSRQOL^[+34KM>YU==W=*SI<&WAWL?W<"^X6VPL:V85^'DL<92_=K;^ZST@
M\+QQI&O<=8OB3$:WC*?'&&TRGQ[CM1C@3V/7TRCA8]=K:\E=5Z+CV86-*_A5
M?3'Z%(@YR<^4;[_'''HD^5.$::I)?FTL,.AJP/-Q\S#R[^5O+M[@,MAYL;G;
M/#&Q;!=S7 _+%9MEV/RN#]TR9#':]?S5?HS'\AZ?"C8+U=[H;$CH6W86>YIX
MGK+[.[IW=+'1RB7?+]W R YA85;"NUIY%OO9>9TU]TE7X3_&?N<=$XGQNF\M
M]NFK<S<C87#)B:?*=;DJ_P ?MS$U6FZMC\SN.H1Z-MD68RSY6QRWG4<ABHK;
MD?X&5U?XFT53):4JFU3FXP?!ACUGBO-+E1WBK0I;%6FIU$M>.'76#[:(1]PV
M+NB\T+N^R>P0Z_;Y*YZYPV&G%4UW5:$E3"X3&4*E/$8RA3CL6)Z^M:/IN!IP
MLEN7;'JZ]:%UBW8?(Z69]QBJ%E;X8[-**X?W:6RSSE<YC=.6&U6F]2X.XDON
MGHV]BG:I@NRKM5XA[<\-;K96WH^ONEV_8:D<L<.S[]L%RQG]VST"66MMIC[F
MQ9&=M%DW62#'QP0KZ(T1(C<UW<UY5GPO1T%P$]LK:-I;1H+2TM+XV]+?7[!Y
MIO>%]]MW2?Z1G-W])FS$QH>H0\1=HQ_=>^JGKDNVSTM>S#$XO/=B7:?@\WCZ
M67PN:[2N"L3E\5DJT-W'9/%Y'AW5J=_'WZ=ADD%NE=J3/CEB>US)&.5JHJ*I
M#[EM751K6JDNVS(%HE*RI1>E.E'T*//0\S_LMS'87W@[]Q/2KY"'CS)V6<@<
M)YV5TZ^T..M@LSV,35COO7UMC)Z=DH;&'MR*J2/LT%FZ(R6-SI797*NK=5'X
M>I]/[NL@V8VCLKJ5+_9O3%]!]S5U"[[Y-??E'WT]HFO93:LNR[SGP[[/XXYH
M@FF:_(Y7)5*;_>KR',Q9'3/AY"P51;$TRMCC=F*V0BC;X(458WF%K[FN&HK\
MU+2O-74[6!,,IO?=MJG)_GH:)>8^JNSB2SE 7, $2OG*]@^3[]>TVWKNA5ZL
MG-O$V9=R-Q/'8DCKIL%N+'SX_9M!?=GDCKTV;?AY$6!\BMC3)TJ?K'QP^L<E
M?E]TK6OC+U.6A]WJ=K$M>;63O;79AZM%XQZ/&NKV\"B3VD=V7<)Y;_<>_D31
MZ%K7]SUF;*:/R?Q;O6.RN-H;'B([K(\]H^[8-[L?EL==H9.BR6)_Z%:H7ZS'
M]%1KXGR:O0I7E'8EIB]*:[:(;:W5?+[CE(:)K0T^'C3_ ':&3,=Q'XP3W3]Z
M?'\7;!VR=M\O%/(/,,3M#R^7T[=,SROR)LE3.5?<61P?&N-I:1ITFHWLQ"Z:
M*6V[VI:K4Y'K!)7F8VTRWTLJH6T^6K3VH1TZ5@ET]+Q[!=:^>7-W#W-;T]F<
M]&A[3>/%H6'9\TKS\X\-[EV^<L[SPMR'%CZ^]<<YIVN;95Q=V/)4*.=KUJ\V
M1Q\&1A1*][V?8G6!TL2NAD?&KHW/8K7+=:=2-6FJD/!:Q18ZU*="K*C4\.+P
M?3/4([3\=0S'9QVU8C*TJN2Q>4[9^&\=DL==@CLTK]"]Q;KE:Y2MUIFOBL5;
M5>5S)&.16O8Y45.BD+KMJXFUKVWVS(MLD[2FGJ=./:1Y_?FD>6+RKY?G,V>L
MT,!F\YVV[7GK^0X@Y/J0V\CC\?B[5M9Z&B[IE(XU;AMXUZ*9M=%L+$W+1Q>Z
MJW7K-%7E5E>PNJ:Q:59+2O-70[1",RRZK8UFTF[=OO7YCZ*[.LD4[:?QFCGG
MB7BC$<?<W<$8'N%VC6L54PN#Y.;R3>XWV+)TJ,$T%:UOU+WC[U2VO-M9ZEDE
MRJ[$OL,A5TZ2V))+"TE;)J52IMTY.$7P88];2L.R5UOO#7I4E3K05226AXX/
MJZ'CV")CNL[L^Z?S5^Y/6\CG,!;VC;\K+[RN&N%N-L9DKN,UK&6[4EWV/KN+
M=+<O9'*WE9[IRN4L.66QZGQR+#5KPPUZZA0H6-%I/".MM\/[N!%LN;JYS*X3
MDL9/1&*X.EYK\PO%>3]Y=+?+U[;I<)N+\=D.>.6KV.W'F')XYU>S5PUBI1?7
MUOCK&9*OU9DL5I%:W9\<[7/CL9*[<EB<L#X42-9A=^ZZV,?4HZ%YKZO:P)CE
M5A[AM\)^K2TR\Q=3MXDH&YZE@M_T_:]$VFFW(ZSNNM9W4MBQ[E\+;^"V/%VL
M/EZ;G=%\+;6/N2,5>B]/$449.$E*/A)XEQG&,X.$O!::?29Y0/./%&?X)YEY
M3X7VEKV[!Q9R!MFA961\*P):LZOF[N(]WPQJYZ)5R,=5MB%4<YKHI&JBJBHJ
MSFG456G&I'5))]<QI6I2HU949>%&376+Q_XMEP9+QMV'9CE7)T9:V7[@.5]D
MV6A9F9ZI]C2M'BKZ%@(TC55>L3-CQ.<F8]R-\;+**U/#X7.C><5=NZV%JA'#
MJO3W"8;OT>3LG5>N<F^HM"[.)7T_&(."9N)?,3VC>:F.]QZYW :-IW)F.EA\
M/N-^<QV-;H6W0,\*>)EV3*ZFV_8:[JJNR*/Z]'HB77*:O*6BCPP;7FKMECSV
MCR5^YKP9Q3ZNI]K'JF;/Q9[MV^J+WA[YS]E*?KL)V[<<V(</9=#XFP\@\L-R
M.K8AS)7L6-/5Z11V)'(U4D1TD:_F57KU9S5V+=4EKF^PM/;P.[=ZAREU*N]5
M./9EH[6)>S(R3,\LCS"/O^>^#_2_[EOZ9]U)M:>]:7K<>TC&]][]K>NS]$ST
M7_+9_P"'QV3?Z+7!O]'.O$2O/?=3QY=LGMA[QH^M1[2(0OQI?[WKM<^S+M?T
M$/+EDGJL_%7;+-O)ZA3\=]HU _%9?KZ]UOV)M&^C"\=^=^I4_&?:*7=OU:KX
MJ[9=4(Z2X
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M_P *WLA^PIC/FQF37?>GZ0W?KK[2-@MV/D"U]:7;9*"6 OP
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MMWAWNLY76\=U.ZN:-38A*2BL(;,7AWL8XZ6VV\6\=>@LMD:+\
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MM,<.G4FL>KL]@VK,L&(P
M                                             4!/-T\X+O0X#\R#
MN2XBT'.Z+'H7&NR:I@M;PV?T+&Y&?V=+Q[J69FCNY)MBODK#+&1RL\K7MEC=
MX'M3T?$)7;\S&X^^%C2SO.*=R\QK0PE*-:44MF3BMF.F*T+B>.LL-3GKWUW,
MNZF0Y.[-Y?1GBE.EM-[<8S>U)2BVTWAP888<!'U'Y^G?<R2-[J_"$S6/:YT,
MG'N52.5K7(JQR+#N$4J,>B=%\+FNZ+Z%1?2=;^S7S<--)Y@GQ\O'S:>!VK[3
M7.*GBZ>6->LU/UQW/^T-]Z7\V/:]_(OE?^NLM_\ E>W \LSCV6V_Y0J_\T6_
M_D>3^Q7/_-G/1_C$G=8D<:2\,]OCY48U)7QX[D>*-\B-3QNCB=R%,Z-CG=51
MJO<J)Z.J_%*9_9<W,Q>S?YGAXU#]2NT5T?M3;V**VLNRYRPTX<LECT%RCPZ6
M+Z9SM7\8L[A601MN<!<,SV41?6S5<CN]2!Z^)518Z\N9NR1(C>B*BROZJG7\
MGHE//[+6ZSDW#,LP4.)JBWU]A=HJH?:IS]12J959N?"U4J)=9IX==G8<=^,:
M\M10.;ENVCCJ[965RLEQV\;+BX&P>!B-C=7LXK,2/E21'*KTE:BHJ)X4Z*KJ
M:K]E?(W+&AFUW&&&J5*G)X]-2CHZ&'5*FG]JO-%'\[DUO*6/!<3BL.DZ4NWU
M"=WR'O-*V?OU[@>9=#S_  ABN/8M(X<9MU?9L+N.1ST#Y)]VUO#/P5VA<UNA
M&V;(MN)8AF2RU6-I2-]5(C_'%U1YF;+FWK+-K:^J74Z\71<9TXPP3<9XIJ<L
M? P:PX5I7#\N.>>YYR;=Y36L(6D:$XUL8U74VGA*&#3IPPPV\<<>H6E"H+:
M  = Y7W:#C7B[D?D2TK?<^B:)MNX2H[HJ/;K>!OYCU:-<J(]TJT_"C?_ %E5
M$_)+3GV90R;([S-Y^!:VM6L_X.$I]G D&Z>25-YMZ<MW<I>J7]_;VZ_AJL*>
M/4VL6^#64$9YYK4\UFQ*^:Q8EDGGFD<KY)9I7K)++(Y?2Y\CW*JJOQ54\II2
ME.3G-MS;Q;XV];/?VG"%*$:5-*-.*226I):$ET$B83RA^T?ZL/+,O.VYXSUW
M'?#>1J38"*W"KJNR<FM1EW$Q1^)/!-6TZ'U>0G]/HM/IMZ.:Z1&[ \P&X'SD
MWA>\N8PQR;+9IQ36BI<^%"/15)85)?C<FFFI,T[^U]SN_,[=);AY+5PWBSFG
M)57%]]1LM,:C?"I7#QHQ_$59Z&HXRE]V?FKZ'VO<T.X@K\=6N39\3AJ-S<LM
MAMOJ8635\SD/'9KZ^VA/@LK#E+K<4^"Q-ULU?4>O:Q4>[Q(S.._W/QENY.\C
MW>HV3OI4J<76G&LJ?)SEB^32Y.:DU'9<N^CLM[.EIX:L<TGV4<^YT=RUOA4S
M&&5PK5I1MZ=2WE45>G#"+J[:JTW".VI0CWD]O9<M"PVNLZEYP'9=R!D, _=M
M6WK3\Y0OQOQN1VW2,%L%/"7Y4?&R]B\S@<OG,C33PO\  Z9*U=[5>O5/ BN*
M"R^T+S;YK5HSS:TNJ%W3EC&=2C3JQIRT]]"<9RFNFH1>GBTESS?['O/5N_;W
M$<CN[&\L*E-[<*%S5HRJP6EQG3JTZ<)<:CMS3P6G'0<KYSW'K=K[2*^X0U72
M7>,.1M7STEN-CGN@PNP-NZ=D()%Z^&.M9RF=H/<[HJ^.%B=415ZU7VD<H5]N
M'3S*$<:ME>TY.7X-.HI4I+B2<Y4M/&DN$I/L6[Q/*>=R633FE0S3+:])1;PQ
MJ4=FX@UQR4*55)<4I/6D5.S1 ]9BT/Y(7&?O=X!Y&Y/M5_57>2N068FE*K?3
M9US0<:E:E.UZ]%\/O@V'*1*B>A%BZ]?3T3=[[,V2^X]U+S.YK"K>W>PGQTZ$
M<$_9*E5=0\N/MP[S_&/.!ENZ]*6-#+,O=22XJUU/&2P]:I4)?OB:PV3-)@
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M=8R4HJ4=,6CE3K/H
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M4+2VME^8A&/16OKZS9HZ2H !K/N797V<<B[/F-VY![3.V?>]SV&TEW/[=N7
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MR1QS.>QCU5R(B^D^SK5JJPJ3E)+C;?;.-.WH46W1A"#>O!)=I&:CK.X
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M+3AACWS? M2T&U9;BX
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M%]' LN$6)&
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MG7S[/XRVZ%3,*E.D^.C;X6]%]6E2@^J;0$W,7
M               Z+R?R!A.*>.=YY+V-RI@]#U3.[9DV,>UDMBM@\;8R#J=9
M7([Q7+SH$AA:B*KY9&M1%540M>=YM;9#D]UG5Y[UM:$ZLN-J$7+!=&6&"XVT
MB^[K[OWV]F\=CNSEJ_WZ_NZ5"'"E*K-0VG^+'':D^"*;;10NW?;\WR#N6V;Y
MLMGW9L6Z;)F]JSEI$\+9\MG\E9RF0D8SXD<;K5IWA:GH:WHB>A#RPS/,+G-L
MQKYI>RVKNYK3JS?'.I)REV6SWOR/)['=[)K3(<LCL9=96U*A2CQ4Z4%""Z+V
M8K%\+TG5RA+H;(]K/;%R#W7<J8OC;1J[JM1/!D-PVVS6EGP^F:VR1&V<OD58
MZ-)K$J_H5.JCV26[+FL16L222.7[D[EYOOUGM/)<JC@GWU6JTW"C33[Z<L.M
M&.*<Y-16&.*QMSJ<Y^[W-/NI5WESV2E5TPM[=22J7-9KO:<->"7A5)X-4X)R
M:;V8RWX[QO*6S_;EQ[M7,FC\IXS<^/\ 4H*%S-XC9L5/@=OHU\AE:V'B2C-C
M?:>&SZLMWX%<YWLY?"]W1B^!/'E/G%YA;[<S**^\67WU.ZRB@HN<9Q=.M';F
MJ:PPVX32<HXO&F]+[W1IP#S-_:WR_G'WAM-S<\RJK9;P7<I1I5*,U5MY.%-U
M'M*>Q4I8QC/!+EM*7?=]HAV-?3<< &?NUOABUW!]P/%?$<$<SJ6V;52CV&:!
M7MEIZCBTDS.W7HY&]/5S5=;Q]IT756HZ9&-ZHKD4E>X^[E3>W>RQW?BGR=Q7
MCRC6M4H]_5ETU3C)KHX+A,?\Z>^E+F]YOLUWOFX\M:6DG13U2N)X4[>+7"I5
MIP4M>$<7@\"]E'&R&..*)J,CB8V.-C?B,8QJ-8U/^AK4Z'J+%**48Z(I'A#*
M4IR<Y/&3>+Z;(PN?MH]\_)N=6*3UE+!*S7:7I141,8Z1+RIT^-5'Y66=47\E
MO0U<YP,U^--Z*[B\:%#"C']YCM?QCGU,#:KF[RGXJW5MU)85[C&M+]_AL]:F
MH=7$PN0HG      !]%2K/>M5J5:-9;-RQ#5KQ-_-23V)&Q11I_TOD>B'92I3
MKU8T*2QJSDHI<;;P2ZYUUJM.A2E7JO"E"+DWQ)+%OJ(F!UK"U-5UO#8*!S&U
M<)BJE)9EZ1L?[EKM;/:D5>B-6>1KI'JOY+E4W&RJPIY9EU#+J.F%&E&'3:6#
M?3D\6^BS2_-<PJ9KF5?,JWAUJLIX<2;Q2Z45@ET$4_>YKE%>9N>^4^1X[#[6
M.V#;+[,!*_XJZOB/!A-73P^%J,5,!CJ_B3I^:5>O5>JKLYDEC\6Y30LFL)PI
MK:\9]]+\IL@-S5Y:O*IP-Z.EJ78) ?+W[^*O$T5'A'F?)/CXYFM2)IFY65EF
M]XUJY+ZQ^%S'@21ZZC<MO=)'.B*N.FD=ZSK6=XJT2WNW3E?MYGEL?]\2[^"^
M_2^^7XZ6M??+5WWA5]A?*E^9K>I\#XNATNUTM5ABI;J9"I5OT+5>[1NUX;=.
MY4FCLU+=2S&V:O:JV(7/AGKSPO1['L56O:J*BJBF()1E"3A--23P:>AIK@9?
MTTUBM1]!\   !\=G(4*4M."Y>IU)LC8]R8^&S9A@EO6TBDG6M3CE>Q]JPD,3
MG^!B.=X6JO3HBG*,)R3<4VDL7@M2XWQ'S%+6?8<3Z
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MB[=G\+$EM6)'(UK51J1VK5G6J.K4>,VR74*-.WI1HTEA"*T?NZ)F$ZSM
M
M
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M4M+ZOW,#=LC)6@
M                  JX_C&W+#EL]MW!E.TB-C@V_EC8J/C57.=-)5T_3+2Q
MIT1J,2#/,1R]?%XE1.G1>N<N9VP[V]S22X84HOKSFO:R,[PU=-.@NC)]I>:0
ML=F_8!W#][N?MT^)\#3QVG8.W%4VOD[;9[&+TG7II&1S+02W!6MWLWG5K2->
MVC1@GF:U['S>IB<DJ9)WCWLRC=FDI7\W*YDL84H:9RZ.&A1CC]])I<6+T%IL
M\OKWK_-Z*:>F3U=3C?0Z^!.)B/Q;[ IB(4SW=CEWYU\-=UA^(XAIQXBO87Q.
MM0PQ7.09;EV%B.1D<KGP.=X5>L:>+U;,85.>2MRCY&PCR6.C&J\<.#53P72T
M\6/"7N.[U+9[^I)RZ"276T]LTK[F/(;[G^%]>RNX\3[/KO<1K^&C?8N8;7L1
MD-3Y*=2B9ZR:[0TJ[<SN.R[8&-=XJ]++V+[UZ)%7E55\,FR7G4R/,JT;:_A.
MSK2U.34Z>/$YI1:Z;@H\;117&17%*.W1DJB7!A@^HL6GU^EB0;R1R0R212QO
MBEB>Z.6*1KF21R,<K7QR,<B.8]CD5%14ZHID]--8K46-IIX/6?P?3X6=/Q<K
MB/UN;[CN>+E7P^X,7JG$>N7?!U];[6MR[ENM7UBHG@]S^Q< _HG7Q>MZKT\+
M?%A'GBS#"E9Y5%ZY2JR726Q!_E5.L23=^EWU2N^)17;?:1:<,%DG
M
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M[#*Z<J5A3Y.G.6TUC)Z<$L>^;PT+4M!M(6\KP
M
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M1?
M
M
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MDWI)>E@L%J/V/@
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MR>ER5A%\,VY=?0NPD2L$#+H
M                           #YZENI?JU[U&U7NTK<,=FI<J31V:MJO,Q
M)(9Z]B%SXIH98W(YKFJK7(O5%/LHRA)QDFI)X-/6@FFL5J/H/@      .$I[
M)K^0SN:UBCF<;<V'7*F'O9_"UK<,V1PU38?:*X.;)U8WNEI-RK<38= DB-61
MD2N1/#T5>V5&M"E&O*,E1FVHMK0W'#:P?#ABL>F<5*+DXIK:6OJZCFSJ.0
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M+PUX+6\,5CAJQ.:IU)0E5C&3IQPQ>#P6.K%ZEC@\,=>!^QS.
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M57U#4'[:F\_Q/S44L@I2PKYMF%*FUQT:&-Q-]2K"@OWQ:Y-[SR>
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MT:;Y./2AH?4<MIKH,E-A2Y&VBGX3TOJ_<P-SB-E8
M
M
M
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MNF_N=LL$F(R_
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M,143T)^0:6WEU4O;NK>UO5:U24Y=.<G)]EF1J<%3IQIQ\&*2746!W$ICF
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M0J2HUXRA6BVI1DFFFM::>E-<*9^YS.L
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ME&QMZ,5&G"-7!)8)+\VDDETCCE+E+E)R>+;CYI-<8S+R
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MN"J2DHN:C!3<<')1ACCLHN-D )F
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M7%&,;&UK&-:QC&HQC&(C6L:U$1K6M1$1K6HG1$3XAKIKTO62X_H
M
M
M
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MXWB^B9 R[(<IRI)V=&*JK[]]]/SSQ:QXE@N@;^EF+P
M      ?%DLA4Q..OY7(3-KT,92M9"[8?U5L%2E ^S9F=T15\,4,;G+T_N'*$
M)5)JG!8SDTETWH1\;26+U(I0;UM5W>MVW#=LBKUR&X;1G]HN^-WC>EK/Y6WE
M9T<[HB.5LMI4_N&S%K0C:VM.UAX%.G&*Z44EYA#IR<YN;UMM]<[5P;R!%Q3S
M%QER/8@?:I:9NVO9[(UHD3UUG%4LE _*UX%<UZ-L38U96QNZ+X7JB]/0=&:6
MCO\ +J]G%X2JTI13XFUH[.!RH5.2K1J/4FF6*O,!X+RG=+V_:WL7$KZ^TYS5
MKM??-7K4+3'1[=JV8PTC<A6PKE;ZNUD;=62M:JM5[/7)"Z)O621C3#VZ6:0R
M+-YT<PQITJBV)8KP))Z'+B2>*?%CCJ3)#?T'<T$Z6F2TKHK#@*[&!X*YFV;;
M8M$PW%V]6=NEM)4?@Y=9RU*Y3E]9)&]^3]W5:T>*JP.A>LLUET4,36.5[D1J
MJF8:N:9=0M_==6O25OACM;2:?2P>E\26+9'XT*TI["C+;Z1(GW#^6+]1S@Z+
ME;'\H8WVOJ.K4+_)6#V5BP8F[FY?5QVX=&S%*KZ]SI,C9CITZ=ROX[;U1ZV(
ME<D*0[)]]_C+-'83H2Y.I-JG*.EJ/!MIOB3;:>C5@]9<+C+52H\JI=\EIQU=
M0B5)^6DM?^7OQ1]2;M9X]J6JWN;.;Q!-R3GT='ZJ5UG;606,.R>-?T1D]35*
M^/@D:_XYLD3NJ-_,I@3>Z_\ C#/:THO&E2?)QZ4-?7EM/JDHL*7)6L<?"EI?
M5^Y@;KD9*T
M              $:7F]<LNXD\O[GFY4L^Y\OOV(Q?$V)9ZQ(_=3>0\K5P>RU
MO%U\2_\ P#R95_A:CE=X.B]&JKDFG-[E_P 8;VVD9+&G2DZKZ')IRB_/[);L
MVJ\E83:UR6SU]?8Q*%^%S&2UW,XG8,-;DH9C!9.AF,5>A5$FIY+&6HKM&W$J
MHJ))7M0->W_I0VJJTX5J<J-18TYQ::XTU@UUB#PE*$E..B2>*Z:+TG%W)W;Q
MYPW99F-%V/(5*>S9?7\90Y,U6A+%!MG%?)F-BAL4=MP-&U++/-A&9N+W5B[2
MK)5NU'/J3N]8EJ!FKM]99OS=[RQNJ*;H1FW3D_ JTWKA)KAPT26M/OEHV63B
MG4M\ULW%ZFL)+AB_N/2F0-[[^+^]Y> VM<7HNR<1;_JEBS(E':I-FR.J6*M/
MQSI#+L.OY3#V+-*VZ.-JOBH392-JR-1)'='>'*EISL[N5;?E+J%Q2KI:8[*E
MB_Q9)X->,H](L4\@NE+"G*#AQO%=C!]LGB\J[R[]I[!=,Y1AWS>M8W/=>6,G
MJ%K*Q:?C\C'@<%1TRIL$6/IU<UF:^.RV<=8L;/:>YTE*HR)$3PL57/4Q7OWO
M?0WKN:#M:4Z=M;QFEMM;4G-QQ>RL5'1%<+QZB+YEM@[&G)2:E.33>"XEJZ/#
MW"J-YI.[-Y \P'N@V&.S7MQ0<@Q:I!8J2UYZ\E?0-;P.AU_!+6:V%ZMAUIK7
M?%=XD7Q*YW5RYZW&MO<FZ5C1::;H[6#XYRE-Z_&(OFLE+,*C7&EUHI'?O)ZX
MC^JYW_\ "45FK[IPW'%K,<N9EW@\?N7WB8V6YK-KHJ>%/!O=G$MZJJ>'Q]4]
M*(BTG.)F'Q?NG=.+PJ5DJ2Z.V\)+SFV?<II<K?PQU1[[K:NS@7UC50G(
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MC:[XBOB98C5R?D(]/[IBGG(:Y>T7#L3[<>X7W*/ GTUYI-48T+P
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M_GV&-SJ%SFV;[]W+@ZEK3C9T(XIM2JX5:\]G7%J$:4(RX54J(KJFFYZ2
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M;+PK7"5&/\)CM_Q:GU<#</NBY2;PSV_\J<B,LNJY'"ZI>K:_*QR-E;M&=6/
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M#I,O64TO"KOI+MOS"= Q:7L
M
M
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MJ3R6MHJX][%8:IP<FDY1X4L6XMK#'!J+[R9CD]"CLW-:$;R.J*[Z72:6+2?
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M<FY2>,F])+TL%@M1^Q\
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M75>TALY)FZ=[1P7>J523]T4T]6,:RE-16&S3J4UAA@2.F8C6\
M                               I8\QTO9O+W*F.];Z[V?R1O%+UW@]7
MZWW+L^4@];ZOQR>K]9ZOKX?$[IUZ=5-E<MEMY=;SU8T8/KQ1#JRPJR7XS[9C
M<K#K-S^W_L,[@>X?&5]FUS"XW5-)MN<E/<=XM6L1B\HR/UK99<)3J4<CF<Q
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MEYQO?MMZU+T1?LH]2GXWF$R1C@NX
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M<
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M6VM+D;>-/APT]-Z6;#%H*@
M
M
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MCG$O^3M:.6P??5).<O%CH2ZK>/[TN^4TL:DJSU)8+IO[G;+ !B4OP
M                                                          !1
M>\[?EEW)W?YR%B(;'NC$\1:SIO%N+<V1'1I)0Q:[9L#$:U5:R6MM6W7J[_\
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M;X#5S[6W-X]]>:VKG%G#:SG(I.[A@M+H;.%U#I<FE6?"W0BEK9;Q/0(\@@
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M#X/_ *<B_P"4>HR\;S$2[&/2[
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MM#,8K&=O7V7T(5%@_P J,%U2_9!6V+F5%ZIQ[*^XV7"C7<EH
M * _FT[<NZ>8?W-9-)DEBQNVX+4849*V2*%-(T?5]1GAC1DT[(E2YA972-14
M5)G/\36N5S4VQW M_<VZ%E#AE3E/S\Y3[4EU""9K/;S"H^)I=9)$<Y,2WEMS
MRY_*$X6XLXLPO<GWI8;#9[;[FOQ;U%HO(DU7'<;\1ZW'"S,U\AO=#(SP8S,9
M^+%1^NR,>85V,QT<CH9*RS0NF37_ 'QYPLROKZ62[MRE"W4]C;IXNI5EJP@T
ML5''1'8[Z6M/!X$MR_*:-"FJ]VDZN&.#U1\QOCQU<'&\[Y;SJ_+9XSMY/C?4
M,1M^8U&*Q9H6K7&_$F%H<>WTG8VCD)(,?E,KJUG(49((_ ^1N.<RQ"U/!ZQB
MMZVJGS:[YWL8WMQ*G&XP37*56ZBX5I2E@_WVA\3*B6<9?"3@I-KH)X?=ZAD[
M>NT'R]O,^X.EY%XIP^D8_(YJ+)0:]S)Q?KM'4-QUO;V006Y,;O>'@H8N;-34
M9[,+KN+S,"S^YIU?6EKNFCLE%:[P[W;D9I[COY57"+6U1JR<X2AJQ@\7AC@]
MF4'ABM*>#1V5+6QS*CRD4GBM$EH:_=Q,I4<Q<5;9P;RGOW$.]58ZFV<=[1E=
M6S3(7^MJS6,99=%'?HR_^[L=DZW@LUW^CQP2L=T3KT-E<NO[?-+&EF%J\;>M
M!2CQZ5J?13T/HHAE>C.WK2HS\*+P^[U5I)$?)2U5-F\Q7A:U)'ZVMJ.(Y,VJ
MPQ7-:G6#CC9\-1D55FBD7U&5S=>1$8CU5S4ZM\'B5(?SEU^0W/N8KPJDJ<?X
MR+?8B_\ M*[)H[680? DWV&7M35HFY'IW7S))R-B8FN<J5]/QS'M7KX6R/R^
M=E56HOHZNB>SJJ?^C\@UVYV9J6\E&*?@V<.NZE5]K V0YH8..[5:;7A7LWU%
M3I+MIFM%>%;%B"!'>%9YHH4<J=4:LCVL\73JG7IXC&5.'*5(PU;32ZYE&I/D
MZ<JFO93?61L-R+V\W^/=6N;//L]3)QU)Z4"TX<9-6>];EF.LCDF?<F:U(UDZ
MK\:O7H9$WCYN[C=W*IYI4NH58PE%;*@TWM-+6Y/48WW:YR+?>/-H953M)TI3
MC)[3FI);,7+4HK7AQFN9C@R69^PG;UL^=TVONM?-8&''V,59R[:LSLA[L;!5
M;.]\;D92?#ZUR0+T^/Z>E/23^QYO<TOLD6>4ZUNK:5*539>WM81QQ6B+6/>Z
M-)CR^YQ\JL,[ED56A<.YC6C3VEL;.,L,'IDGAITZ,3 ) #(9M)VF1.7?\[.G
M3P1Z?<B=Z?CO%-FL$]G1.GI3I [K_P"V,J<TD&]X+B?WJLY+KU*7<9B?G@FE
MN[;T_OG>Q?6I54^VB00V%-<P
M                                      #$/+7;]P1SWBEP?.'#'%?+
M^)]0M=E#DS0-5W>O7B5TCV^Y&[)BLBM.2*25SV/B5CXY%\351WI*FVO;RSEM
MVE6I2E^+)Q[3137%G:7<=BZI4ZD?QHJ7;3(@N=/Q<+RK^:/=]O#\0;9P3G;_
M (G29OA#D#-X..&5?$K7U-3W%-YT&A&U7?\ 5U\3"Q43XGY));3?C>&UP4JL
M:T%P5(I]F.S)]5D<N]RL@NL7&G*E-\,)-=B6U'K(ALYT_%$\[$Z]D.V?O Q-
M]CFR>S=2YTT&YB70N:O6%+W(F@7<VEELJ.Z.6/5XO5^'JB/\7A9*+3G)@\(W
M]LUQNG+'\F6'HR,W?-S/2[&Y3XE4CA^5''T)#1SC^+W>:KPA[JM?<[?5>P57
MUW_O>X.VW7M_]T>I\:_]EU)+>)Y&E];&SQ,_]XJ>+JC?S?QI*+3?3=Z[P7+\
ME-\%1./9TQ_*(S=[G;P6NGD>4AQTVI=C1+\DB5Y"XJY6X<SS=>Y6XWY"XKV>
M)TCVX/D+3]DT?/1OJRM9*]N,V3'8O(,=6F5$<O@ZL=T1>BDBI5[6\IMT9TZM
M%K![+4DT^!X8K26"=*[L:R=2-2C<1>*Q4H233T-8X--/A6IG8M5[@^:M+]6S
M7^2-GAKPN1T=+(WO;N/9T_\ 59C\ZS(TV,=^2C6(B_\ I,;[R<RW-3O;MRSW
M(<NJ5YK!U(4U0JO^%H<G4Q7 ]K%&9-T/M'\^FXNQ#=S>?-86T)8JE6J^ZJ*Z
M"HW2K4TGPI12>O7I)&^R_P WOD7M7YMT[F'=.'M)YO\ >8N3EQ^$ES.2X^N/
MNY/&6L0[(+EZ-'9L6RS2IWI75NN*>V*=6RJCG,;TQ;EGV3.;;=_>:AO1N[5O
M[>YH*6Q1G4C6H*4HR@I)3BJNTE)X;5:2QP:2:Q,Q[R?;FYWM]-Q[K<;>NCE=
M>TNW3V[BC2G;W#A"I&HX-QJ2H[,W"*>S1@\-J+<HRP5K'@S\:R[#=^6M1YJX
MWYPX!RDK6+9R+L-BN4](JJK4]8WVQJ-RKN<[F2=>GAUQ$<U.O5%7PI.;OF\S
MBCIM:E*M'BQ<)=9][^483M.<#**VBZA5HRX\%./77??DFQNS^9IV2=T^\P/X
M>[G>*]DHT\9C:&#Q>4V#WD;%DGW&+=M3U=/WZ#5]I?,EJSZB5$I^)BQ,1Z(K
MF]=5^=C=3?7X[Y>OEE[\5T:2C&I&G*I3_"G)SIJ48Z7L]\UBH8K%(VQYHMY-
MSGD2H6V963S:XJ2G*DZL(U4O @MB3C-K!;6A:'/!X-F2F/;(UKV.:]CVH]CV
M*CFO:Y$5KFN151S7(O5%3XIA!IIX/69O336*U']'P     _IC'R/;'&USY'N
M:QC&-5SWO<J-:UK6HJN<Y5Z(B>E5/J3DU&*;DWH1\E)13E)I12Q;? 2[Z#K;
M=1TS6]<\+6RXO%5HK?@Z>%V0E:MG)2-Z*J=);\TCOBK\4W W?RU9/DMMENC:
MI4HJ7COOIOJS<F::[PYF\YSRZS/3LU:TG''\!=[!=2"BBKEYAG*2\I]U?(MB
M"PD^'T:>OQI@_#(LK(Z^HNGAS"1OZ(UT4VV6LC,WPIX?#*G17?FEV3W0L?<&
M0T4UA4JKE)?O]7Y"BNH8^OZO*W4N*.A=3[N)I*28HB83RZ>^W6^),0G!G,N1
MDQ>E.R-N]HNY3)+/1U:SE;#K61U_-QQ,?)6P-_)2R6H;36JE:S/+Z[]!D22#
M'F^.ZM;,*GQIEJVKG92G#ADEH4H\<DM#7"DL-*P=WR^^C2CR%9X1QT/BZ#-U
M-P\LSM3YCSK.1M+V#8-;P>PVG92U2XSV#7+^E91L\KI;4VONM8K.18IMJ5SN
MC:LSJ<2+X8H(VHB$9M]]L^RVE[CN80G5@L$ZD9*:XMK3''#HK%\+963RVUK2
MY2+:3XFL/-.2[C]4[*>VWMEM<2[OK>)FPGN:>]JNFX_(5G<H;)N$D;8F[50R
M\K9\I1RCYHVI;RTK/<<%9/<WJWP+%3?PR:OO-G6=K,+:<E4QPE-I\E&'X+6I
MKBBM+>G%/&2Y7$;.WMN2J);/ N%OCZ?1_P"PK+.\*N<K$5K.J^%KG(YR-Z_&
MHYR-8CE1/BKT3K_<0S81HW#[#.(4YE[GN.\)<JI;U_5[C^0=H8]OCA7$:E)!
M<JP68U14DJY/89*-.1J]$5EE2.[UYA\6Y'6JQ>%:HN3CTYZ'AT5'::Z166-+
MEKF,7X*TOJ?=P+:1@ E(
M
M
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M;ZKTDVH4*%M35&WA&G26I122ZRT'>SI.T
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MOL^KO[RE+DET-C0_R]I]4GF6Q@K.$X-.,UM8K2FI:4T^E@;QD:*X
M                                                        '0N5
M.0<1Q+QAR/RKGV.DP/&>A;AR#FXV31UWOQ&F:]D=CR3&SS?H,#G4\:]$>_XU
MJ^E?0AW6U"5S<4[:'AU)QBNG)I+MG57K1MZ$Z\O!A!R?22Q\P\L/E7OWPO,'
M*W)/*NRZOLM7+<D[_MF\Y**&?&7_ '-/M>>O9N>O&^2U21S*;KRQQM1&L1C$
M1/"GH3;?+;ZVR^PHV$(2Y.C2A!88:HQ4<>#2\,?-,-U-Z+:M5E5G3J*4I-\#
MUO'C1U>MW3<:S]/6U=II]7*U?=.+I.\*=$^/7W)E;7QJ_P#1U7_H*_XXM>*?
M67=.4=X<OEK51=-+S&SG*W<AQ-/X?6YR]3\7BZ^Z<'EG>#HB]%=[DJ6NOCZ>
MCP]?B^GIZ3LCFMF];:Z:?F8G:L]RQZYM?O9>8F<Y6YTXGM(U8MSH-\2*J>Z:
MF5IJB(O1?$ENA K%]'H1>BK^0=BS*R?W_8EW#NCF^6RU58]7%=M(YNORIQM:
M1%BWO56]6H__ +1FZ%->B]/0J6YX%1WI_,_FO^@[(WMI+54AU7AVSM686#U5
MJ7GDNVS(N@>RN2MTU#0]6V+7K^=W;9]>U/"PP9G'S^NRNSY:IAL7'TALN<J3
M7+C$3I\7KZ#A<9A:6]O4N9U(.G3A*3PDM44V^'B14TJM&M-4Z<X.4FDL&GKU
M'IP:/J.(X_TK3]"P$7J,#I.K:_J.$AZ-;ZG$:WB:F&QL7A;\:WU=.DQ.B>A.
MAIC=7%2[N:EW6TU:M24Y=.3;?99DR$%3@J<?!BDEU#M)T'(            J
M,>;CP [A[NCR6[XJE[GU#G2K/ON/DC;)[GCVZ*6&IR!1]9(GQ]N7,31965$5
MS6IEF(G1$\*: <_^Z?S>WXGF=".&7YI%UX\2JII5X]-S:JOUU+H'KQ]D3G 6
M^/-92R.ZGM9QD4U:S3PQ=NTY6DL%JBJ:E0CPOD&WQN+,P:;4  NJ=E'#?"7'
MW;#PULNO\=Z+J^1Y)X9XSS.\9E<;5DO[+E-YT_7[64IY;-YJ2[E+]'*Y;)*R
M*E-8?71TJ1QQIXNB^D'-MNSNMD^Y&77UO9VE&M>Y;;2KU'%.565>E3<XSG4V
MI.,YRP5-RV,7LQCIP/%'GLWSWXWAYT,ZRS,,QO[JWRS.KVG;4]N2C1A:W%:,
M)4Z5)1A&5.G#%U8P4\([4I:,2$WS*/+7M<)VLOSKP5B)[G#UR>2[M^H4HY+%
MKB^U8D\4EZC&WQRSZ'/*_P!"^EV+<J,>JUU:Z/6KGDYFZFZU2IO-NS3E/=N<
ML:E-8MVK;Z[H-ZGKIOO9:,&;M_9J^TK2WWI4=Q-^ZT8;XPBHV]Q)I1OHI:(R
M>A*Z26E:JZ[Z/YS%2A=-=#=,^FG;M8^W5OT;$U.[2L06Z=NM(^&Q5M5I6S5[
M$$T:M?%-!*Q'-<U45KD14.=.I.E4C5I-QJQ:::T--/%-/@:>E'76HTKBC*WK
MQC.A.+C*+6*E&2P::>AIIX-/6B\CV>\]5>Y3MUXVY626NN<RN&;BMTJ5U8B4
M-VP#EQ6RPK7:YSJD-R_66Y6C>OB]QV87>E'(J^G/-YO5#?/="RS[%>Z:E/9K
M)?>UJ?>U%AP)R6W%/3L2B^$\,>>+<&KS:<XV9[IM2]PTJW*6TG]_;5?SE%X_
M?.,'R<VM'*0FM&&!LR34QB
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M>!7+&WU<EV5>J(BKXO2J]$Z8<YQ)/XYI1X%;1?7G4[B)#E*_W>3X=M]I$KY
M2Z                                                        B^
M\XWB=W*_E_<U-JU4M9CCAF Y8Q'5BO6LW2\O7EV6TWIZ6+%HUW*_'?D(J]?1
MU)QS=7_N#>VVVGA3K;5)]';7>KSZB6W-Z7*V$\-<<)=;7V,2HWY9?'.-Y5[\
M^V/3\Q2IY+%KR+%M5['Y!E>6C>K\>X7+\@R5+=>T]E>W7L)J_A?"_P 39T7U
M?@D\7@=L#OM>3L-U;ZXIMQGR.RFM:=22IXK#5X6O@UXK61;*X1J7]*,M*VL>
MLFUV46 /QB3D_;=:X/X*XPPN3L4-8Y.WC:\KN->M*Z%<S'Q_C]>GP6+NJQ$6
MQC&Y+9EMNA<O@6S4@>J*Z-JMQ+S065O6S2ZO:D4Z]"E%0;X.4<MIKHX1PQXF
MUPE^S^I*-M&$=4I:>HL>V5<^$N!.8.X[<W<>\(Z)E^0MQ9BK&=FPN'?0@DJX
M:I<H8^UE;MO)W*&/I8^O=RM>-\LTS&-=,U%7TF<LSS7+LGMO=>9U8T;?:V=I
MXZ6TVDDDVW@GH2X",4+>M<SY.A':GACP+1U<.,F%XZ\AWOGY$H8.IRKN_'G%
MVO:]&^EB,%L>Z97?<K@:.2MRY3)1:]@]3K9;5JD#\A8DFFB9E:K9K+W/^.\2
MR&.[SG4W7LYRE84JU>M/2Y1@J:DTL%M2DU)Z-"[UX+K%XIY'>5$HUIQC!:EB
MY88\2T+IX,BV[P^VG,=H?<1R!P#FL_'M<^DR8&2GM,.,7"P;#C-BUK$;)0R4
M6*7(95:'6#+)$^+W3-ZN6)S?&O3J3K=W.J>\.3T<VI0Y-5=K&...RXR<6L<%
MCJUX+06N\M79W#H-XX8:<,,<5U>D<KV+<PNX%[P.WCE1]E*>/UWDW 4MAM.<
MK$@U#:Y)-.W23Q>)J=4U/8+O1%5&JOH7T=3KWHR[XUW>O+!+&<Z$G%?CQ[^'
MY<4+*MR%W3J\"DL>D]#[#/1@-/#(              /-J[J=N7?^YSN)W=95
MF9MG.'*NP5WK(LC6T\KO.<N4H87>Z;B)6K5)61Q-;+(UD;6M:Y6HBFYF16_N
M3)+.UU.G:TH]50BGP+AUZ$8[NI\I<U)\<Y/LL[;V.Z'@^3N\+MIT39H/=>N[
M#S-H=?-TE56LR&+K9ZI?O8V1S?CFPY&O4= ]6JCD9(O147HJ4^]%W5L=W;VZ
MH/"M"VGLOB;BTGU,<3NRZFJM[3A+5M8];3YA:/\ Q@#EW-Z+VBZAQY@<A-CG
M<Q<HT,1L7N>X^O-?U#5</DMAR&+=#$K9)ZEG8&XITW5W@\,?@<UWK$Z8-YIL
MOI76\%2\JI/W-0;CBL<)R:BGTU':PZ?0)+GE65.SV8Z-N23Z6#?F=8J*<4<-
M\I<Y[2[2>(=&V#D+;68NWFEU[6::W\HN*H25HKMYM9KFO?!6DMQH]4ZJGCZ_
M$ZJ;!7^8V.5T/=68584;?:2VI/!8O'!8]' B="WK7,^3HQVIX8X:-75)(>$^
M*/.$[6-:W77^#N).XCCS"\AVL+8VN'7.-:F8R-VU@H<E#C+%&[9P>:S6!ECA
MR<S99<?)569/ DKG)'&C89F>8<W>>UJ5;-+BSK5:*DH[51I)2PQQ6*C+4L%+
M'#3AK9=*%#.;2#C0C*,6\7X+[I'[W#)SVO+>SV.YJ'?XN:;K,-:VU>4*^2K;
MM+&["8Z+ 29:++QQ7TA;KL51E1'HC6TV1-C1(VL1);D_Q3\7P62.E\6K%0Y+
M!P\)[6&&CPL<>CCCI+==*XY9NZQY=X8XZ]6CL$QWXO#JB9+NSY8VZ5BOAU;@
M3*XZ%?CFMBR6S;WHZ5YE<VPQ7+[.PMMB,='(Q?6*Y5:YC.N.^=ZOL9!;VZUU
M+M/J1A/S6BZ9!'&ZE/BI]MHN+FNI+B.#N@F=+RC*QWAZ5\!B(6=/B^%R6;"^
M+TKU=XYU_N>CH:V<Z4W+>IQ>J-O37;?FFS?-3!1W34E]]<5'Z%>88+P3&RYO
M#QO3Q,DRN/8]O54ZM?;A:Y.J*BIU1?R/20*S2E>4HO4ZL?1(G]])QLJTH^$J
M4W^2R1+N:F6+BJ^SP]?=&7PT*KUZ>!&VO='B3T>GJL'3_P!N;&<Z%38W4G'#
MPJ]-=ER\PUKYK*>WO=3ECX%"J_R=GS2-@UJ-GB3O1V)3X#QJRO3P-T'(V7N1
M%7PQS4+MKXB(KE5C).B]/BJAL]D<>1YO8;3T?%]274<9R[&)JOGTG7YQ*FPM
M+S&$>JIPCV6B,0UA-J#;?M'A1VS;;8\+E=%@JD*/]/A:D^0:]6K_ .KXGK61
M4Z^GXU>GY)E[FA@GFEW4PTJA%8].>/F=@P[SQS:RNSIXZ'<2>'2AA_I=DWQ,
M]FOH
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M!&KO<;/K?%THTZT5^!)8]:6R^HL2'+FOM,[G^V^W+4Y[[?.8^(5BE2)MW?\
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M*L]<G@NDON]HF&,=%V
M
M
M                                                      *S7FX=
MC7O!S]WNCXLP_@TG;,FB\KX3'P=(=6V_*6&LBV^"*)O2+";==F\-SJB-KY5Z
M.\3DN-9%I9S_ '-A\4W<M^,CIX99<3_WJ$5HI59/1526J%63[_\ !JO'_:)1
M]-OLB\^GQ_E\.:W>JMCG=I2_W"K-Z:]O!:;=MZZMO%8T^&=!-8)T6YP8FL)O
M4=CT_:,GI&W:MNF$D]5F=0V/";1B9?$]GJ\G@,G5RM"3QQN;(WP6JC%ZM5%3
MIZ%ZE58WE?+KVCF%J]FYH585(/BE"2E%Z.)I%MSC*[7/,HNLEO5C97EM5H5%
MH>,*L)4YK3HTQD]>@NA=RG/.\ZGVG0]S7!\.)RRXK":+RJ_ YVLE['[/QQG8
ML?9S>.EL4Y63TI*^!SB9!EJM*US'4T],D:NCD]&M]=[,VL>;^&_&ZZA)PIV]
MTZ=2.TJEO54=N#PP<<(U%4VHM-;&MIM/Q:YM-P<BS;G:ES8[\NM256O=6*JT
MI;,Z%Y2<U3FE)823JTN2<)Q::J?>R2E'%7"?=CVD>8GI$_&VX8' KLM^M))F
M>%^1?<5C*I-!%*K\KI>61M1<TM*)'21W<:M?)4VIZQ\==>BK8MVM_N;_ )X,
MM>1YK1I*_FL96=Q@Y8I/OJ%3".VTL6I4]BK!8MQBM+E>^_-+SN_9TSR.\N37
M%Q\64Y)4\QL]J,,&U^;N:??<GM/!.G6VZ-1]ZI5-*(QN[GR;-MU)<EN_:U;M
M[QKC5?:L\79JU"FZ8F+]$DE][68G=7I[53A:G1E:98<BB(C6+;D<85W_ /L[
M9GEFWF>Y$I7ECI;MIM<O!:WR<M$:T5P1T5-22J/%FSW-#]LS*,W5+(^=.$+'
M,GWL;ZG%^YJCT)<M36,J$GPSCM4=;?(Q1![D<=F]8S%G&9:AE=>V#"W5@N8_
M(U;>)S&)R-21%=#9J665[M"[6E;Z6N:R1CD_(4UHJ4KBTKNE6C.E=4Y8--.,
MHR3U-/!Q:?2:9O';W-CF=G&YM*E*XR^M#&,X2C4IU(26M2BW&46N%-IHN ^6
MOWC0]U'#$.+VK(Q/YDXR@H8/>H99$2UL>/6-T.#WN&-?3(F:BKNCO>'JD>1B
MD56QQS0-7T)YF><2._.[BH7\T]XK)1A73UU(ZH5UQ[:6$\-51-X)2BCQZ^TM
MS-SYJM]'=933:W,S.4JMJTN]HSQQJVK?!R;:=+'71E%8RE";4A>8Q-#/8K(8
M7*0-LX_)U)Z5N%W3X^&=BL<K7=%5DK.OB8Y/CF/1')T5$,LWEI;W]I4LKJ*E
M;U8.,ET&L.HUK3UIX-:37FRO+C+[NG?6DG&YI34HOB:>/57 UJ:Q3T$2^]:A
M?T7:<MK-_J]]"PON6SX?"V[CYD];1NLZ=6IZ^NYJN1%7P/\ $U?2U34?/LGN
M,AS6MEEQI=.7>O\ "@],9+IK#%<#Q6M&X.09S;Y_E-'-+?0JD>^C^#-:)Q?2
M>.#X5@]3.L5;5FE9@N4[$U2W6E9/6LUI7PV()HW(Z.6&:-S9(Y&.3JBHJ*BE
MKI5:M"I&M1E*%6+34DVFFM336E-<:+K5I4J]*5&O&,Z,TU*,DFFGK33T-/B9
MF2'N&Y;@IMIMVA'HR/U3;,V)PT]SP_$176):#G22(G_KN\3E^*JJOI)E#G$W
MOIT515UBDL,73IN7GG!MOHO%]4A4^;?<ZI6=9VF#;QV54JJ/64TDN@L%U#%6
M9SN9V*Z_)9W*7LM>D1&NM7[,MF5&)^9C8LCG>KB9_P"JQO1K4^(B$4O+Z]S&
MN[F^JU*U=_?3DY/I:=2XDM")=96%EEM!6UA2IT;=?>PBHKIZ-;?"WI9Q)2%6
M #)G$W(%CCG<*.9\4C\59\./SU5G5WK\7/(Q9961HJ(ZU2>U)8OB*KFJWJB.
M<2?=+>&INWG-.]TNTEWE6/'!O2TOPH^%'HK#4V1;?#=RGO+DM2RT*[CW]*3X
M*B3P3?X,O!ET'CK2)+=IY!T+1=2M[]O&ZZGI>BX^C%D\AN6W;%B-:U;'XZ9C
M9(KU_/YNW1Q5*I)&]%2265C>B_%-LK5.^4'9IU542<=A.6TFL4TECCBM*P-1
M+K"QE.-XU2=.34MIJ.RT\&GCJP>AE2[S@?.X\N?<-0KZ)PGD=B[B.;=+S"RZ
MYN6B8GV/Q=BH;*QQ;!@\OO\ L3*=G/8S(P,BEB?@\?E:JV(&.]T,1'M?EG<O
M(\_RVXE<7,8TK&I'"4)/OFUX,E%8X-:?":>#>C4UC_/-[\EC'DK7:KW$7H<5
MA'I.3UI\<5)%1GEWON[@N5_=5&/9O>!K=A'QK@-#6QAW2P.:L;H[^?6:78+B
M31.5LL:6(JTG5?T%$]"9+4%PZ3'M[O%F-WC&$N2I<4-#ZLM?6P70,1<'=N?/
M_=%NJ:+P#Q)R%S+N4[X9KN-TC7,GL$F.BNSNC9E-CR->%^.UW%/G1WCO9&>M
M58J*KY$Z*IT7=]9Y?2Y:\J0I4N.32QZ"6MOH+%ELM;.]S"MR=I3G5K/7@F]?
M"WP=-Z"S3V=_BH_<%OR8K:.\[EO7^!]>E=7L6N-.-78_D;E*:OXO^TX_)[,D
MOU.=2N.9T6*>K+LS$^(^)J^@@69\XEE1QIY73E6G^%+&,.HO"?5V>F3G+>;Z
M\K85,SJ*C#\&.$I]5^"NIM%J[L[\HGL"['5Q>7X6X&U^]R)BVUWQ\P<E>'D/
ME)+T#?![3Q>PYZ&2IIUR=/\ K6Z_4Q$#_P F,QYF>\N<YMC&ZK25!_>1[V'2
M:7A?OFS(&6[N9/E6$K6BG67W\N^GTTWX/[U(DL+$7P
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MC1]SV5&WU;%*$?.Q2\PS>4A5
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MHK]MOF[^--V[+G'L*>-YELU;W+2TNVK2_-2D\-5*N]E:5[X;X"S*;I'F2
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M&JGI5JLH([JOY+E,,<X,MK/(+BMHK\J;\TD65+"V?1F^TB4@@I<P
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M%3BC177=5^881YYIX4LNI\<J[ZRI+S3=LS@8)
M
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M+6E+:C&K"#>.&&+G!0G)X/[Z3PTX88LD?Y:_&>MB[C^$OJ/<L]L-/3+^3V#
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M=18+J$OHTU1I1IK@7_:9-*$[0
M
M
M
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M=:ZJ3J5GPR;;Z[)M;VUO:4E1M80ITEP122ZR,C'0=X
M
M
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M$W"32E'CC-83@^&,DUH9WTNI8
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MS6J<7Z+K7;IW;9#+U->U2M'A>.N98ZV0S[,3KT'JXL3J.\8VC!<S/L_!P?\
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M7>Y\\HYC%80N:&#Z,Z;P?Y$H+J$NR"MMVTJ+UPEV']U,GZ,3E]
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M3JO#IN"QZNSV#<8S*85
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MME;/[XE.3SH7M=5:$XSIPTMQ:>G@6CAX>H6O3!I*P
M
M
M
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M
M
M                              0<^=CV^>^OB[3>X?!T?69GC&_'J6Y2
MPP]99M&VBZB8B[:FZJ[U.O[=,R*-B)T_][$KE5$;Z=8_M*;I>[\CMM[K6.-Q
M925*LTM+H59=Y)OBIU6DE_WS? ;S?8DYPOBK>F]YN[Z>%EFE-W%NF]"NJ$?S
MD8KCJVZ<F\?_ *>*PTE9(TJ/3HN!]C/N'*>6+HT+[[*M*?BCEW'V\@DC(V44
MCV3D&C>F=)*K(XUHR1O\2N5&M5B]5Z'H!S9JG6YBZ,)2V:;L+Z+EJV?SMRF]
M/%IZQX]<^?+VOVH+Z:IN5:.;9?.,,,=K&C:2BL%I>TFL,-.DI^'G^>PI]=&]
M>Q=VIDL;<M8[(T+$-RC?HV)JEVE;KR-EKVJEJN^.>O8@E:CF/8Y'-<B*BHIS
MIU)TIJK2DXU(M--/!IK2FFM*:>IHZJ]"A=49VUS"%2WJ1<91DE*,HM8.,HO%
M--:&FL&M9^$LLMB66>>62:>:1\LTTKW22RRR.5\DLLCU<^221[E5SE5555ZJ
M<6W)XO2V<X0A3@J=-*,(I))+!)+0DDM27 C\SX<BRUY)7<+[X=!WCMOSU]'Y
M70+,F]:+!-(JS2Z;L%UD&S8^JS\RVK@-JLQ67=?CG/S7HZHWT;G?9IWN]UY5
M=;G74_S]I+EZ">MT:CPJ170IU6I=.MQ+1YG_ &W>;SXNS^QYR;"GA:9A%6MT
MTM"N*46Z,Y/\*K04H+@2MN-Z9V3:,T/
M          *?'>#]]+S_ /96W/YLV38C=WY"M/@\/0HB=W[ZJ>,S7 O)3
M   %GSRL()H>T? 22QN8RUNF[SUW+\26%N396=(S^ZU)Z[V_^EJF#]^VGO!-
M+6J4.UB27+/>BZ;)&B'%P
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MHOQ>KEL+_P#(,_<T4$LHNJG"[E+K03\TU[YXIMYQ:4^!6S?7G)>8;9&6S#X
M
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MA7JU6\))II12BL4].M2ZY9'(*34
M
M
M
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MT-1.+:UMK.DJ-K3A3I+@BDEV.'HZS*)3G>
M
M
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M/5['M;@O?F+CO%5QX84W^0EYA.,CNJ%YET:]M+:I.4EC@UJ>G6DR44B!=P
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M*"?3Y2J^TT;.&4#%8
M
M
M
M
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M9D#+=V,FRO"5"DIUU]_/OI=-8Z(_O4B5<CI(
M
M
M               "LKYV7;ZFJ\G:5W#X.DD>(Y-HIJ.Y200HV.'=]7I,7#7K
M<J-:U9]AU.-(8V_'.Z8:1R_%0TK^TKNDK'.[;>ZUCA;WL>2K-+56I+O)-\=2
MEH7K+9Z<_8CYPGFN[%[S=WT\;O*Y^Z+9-Z7;5Y/E(Q7%1KO:;T+_ 'B*6H@V
M-8C><*J(BJJHB(BJJJO1$1/2JJJ^A$1#ZDV\%I;/C:BL7H2,'[QW(\(\>),S
M8^0\#[NA\378G#3NV'+)*GB1(9:&#9?FJ/<YO3K/ZIB+\5R)Z3*FZ_,ESI;W
MN,LIR>ZC:RP_.UTK:E@\.^4J[AMI)X_FU-\2;T&$M]OM'<RFX"G#>#>"Q=[!
M/\Q;2=W7VECWKIVRJNFVUA^=Y.*X6EI-/]W\Q[7*JRUN/-!RF8D3JR/*;5>K
MX:JUS5_ZUF+QOM2U;A?T]"/L57]%ZJB+Z#8K=?[&&:UMFMOCF]&A'AI6D)59
M-<7+5>3C%\>%*HN!/A-1M]?_ .XGD%MMV_-]D-S=SU*O?5(T()\:H4>6G.+X
M,:U&7"TM1J!NW>EW ;HLT4>V1Z?0E\7_ &#2Z3,,K.J*B+'EY7W=A8Y&K_ZM
MQ$Z^GIU1.FQ.['V:^:/=E1F\N^,+N*PY2]FZ^/3I81M_XG'@QPQ-2-]/MD<_
M>^3G3AFRRFPD_4LNIJWPX-%=NI=K1_2,,=.&*6&O-.ING(VRU<=0K;/O>X9V
MQ[GHT:<.5VC9<S:\+Y?45:T+;V4R%CP-<[PL:]W1%7I\4S=:VECEEK&VLJ5&
MWLJ:P4(1C3A%=",4HI=)&M=_F.:9U>ROLTKW%WF-1XRJ59SJU)/HSFY2D^FV
M>KIY.6>YBS'EK=J.,Y\X[W_B[E30>.8>+<]J?)>K9S3]I9B.-,E?TW1LQ9Q.
MQ4,9EG19[0,/B[B32PHZ1\S^KGN17NQ=G4:*S.L[>49TI2VDXM-8RTO5Q-LR
M#E,JKRZDJ\91JQCLM--/1H6OC6!)H6LN(
M          /.F\Q_R1O,^Y0[X.ZWF7C7M5S&W<:<J]P/*&[:-L.)Y-X4GES.
MO[+M&1S./RDV"DY*BV/"QW*]I'MCOTZLK.OA<QKD5#-N1[UY!;Y3;VM>X4:]
M.C",DXST-))K'9P?4;,,9YNOGUQFMQ=4+=RH5*TG%J4-*;T/#:Q752-'OP#7
MFW? PW;^6W$/]89=OG?NWY5#SL_2EI^:6\7DL_/0],/P#7FW? PW;^6W$/\
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M?9[5N;2:J4'&&$EJT12?9,N[I6ES8Y'3M[N#IUU*>*>O3)M=@F((R20
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M9QWO?<R[1O5ZMNF^9N-21L4C&NC8]&^GIU77C>/8>>W<H-2@ZTFFM3QT^:;
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MO^$S[\;7?XO6^Z??G%?\5/K/TP^ZDY+_ $C6/\E6_P"$Q\;7?XO6^Z/G%?\
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MX=8
M
M
M
M
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M?6QU+H+03FVM+6RI\C:4X4Z7%%)=?#6^B])EHIBH
M
M
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MISGT4M'7U=DGM[<_Q47ONY*]P9+N!Y%X@[9\)8]5[NQ7M"7F;D;'>/U;I?\
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M]NMFA",%T$E_VF=BG.\
M
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MO*:OG8C^R*]NGPO>:_Y#:+^OCZR;[R:EYZ0^KJR\IJ^=B<#E_P 4,X;FDA7
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M=F/X6&&'!K)EN]DGQ#92L^5Y7:JN>.SLX8QC'##:E^#CCCPZB4$L!?@
M
M
M
M
M
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M67;G6$XJVJVM:ZX)2JTYR;Z"QP3\6*98H(23,
M
M
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MP^IZ>K]5^A^'IX?01R6UB]K':X<2_1V<%LX;/0.4/A]
M
M
M
M
@                                      !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img172674775_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img172674775_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (]! X# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKS;7_C+\(/"GC7P]
M\-O%/Q5^&WAKXB^+O('A3P#K_CGPQHWC7Q.;J:2VMAX>\*ZCJEMKNM?:+B*6
M"#^S;"Y\V:.2*/<Z,HN)\5?A?)X_E^%$?Q(\!/\ %*WL%U6?X:IXP\/-X_AT
MM[9;U-2E\'+J)\11V#V;I=K>/IRV[6SK.)#$P<@'>T5P7@3XJ_"_XI1:Q/\
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MO+N8]<\-I&68QJ_A74Y'5"3M5Y%\91J[!<!G$<88@D(@.T-^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
M"2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:
MB@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR
M_P"@]X9_\)+5?_FUH^R>,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM
M5_\ FUH^R>,O^@]X9_\ "2U7_P";6NFHH YG[)XR_P"@]X9_\)+5?_FUH^R>
M,O\ H/>&?_"2U7_YM:Z:B@#F?LGC+_H/>&?_  DM5_\ FUH^R>,O^@]X9_\
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M7LA8&%M.TNYTM$3'S+)'<ZOJ[2L6Y#K)"%'!1C\U:-% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT'O#/_A):K_\VM'V3QE_T'O#/_A):K_\VM '345S/V3QE_T'O#/_ (26J_\
MS:T?9/&7_0>\,_\ A):K_P#-K0!TU%<S]D\9?]![PS_X26J__-K1]D\9?]![
MPS_X26J__-K0!TU%<S]D\9?]![PS_P"$EJO_ ,VM'V3QE_T'O#/_ (26J_\
MS:T =-17,_9/&7_0>\,_^$EJO_S:T?9/&7_0>\,_^$EJO_S:T =-17,_9/&7
M_0>\,_\ A):K_P#-K1]D\9?]![PS_P"$EJO_ ,VM '345S/V3QE_T'O#/_A)
M:K_\VM'V3QE_T'O#/_A):K_\VM '345S/V3QE_T'O#/_ (26J_\ S:T?9/&7
M_0>\,_\ A):K_P#-K0!TU%<S]D\9?]![PS_X26J__-K1]D\9?]![PS_X26J_
M_-K0!TU%<S]D\9?]![PS_P"$EJO_ ,VM'V3QE_T'O#/_ (26J_\ S:T =-17
M,_9/&7_0>\,_^$EJO_S:T?9/&7_0>\,_^$EJO_S:T =-17,_9/&7_0>\,_\
MA):K_P#-K1]D\9?]![PS_P"$EJO_ ,VM '345S/V3QE_T'O#/_A):K_\VM'V
M3QE_T'O#/_A):K_\VM '345S/V3QE_T'O#/_ (26J_\ S:T?9/&7_0>\,_\
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MI:-!#/?W-_*MC^O?V3QE_P!![PS_ .$EJO\ \VM?SO?\$U8-?_:6_P""IO\
MP4E_:_74=)N+#P'JEG^SUX)UF\T6]O=(U#3;358O#BWWAZQC\16[:<1X=^#>
MBWTK-?7$HM_&$F\>;J%X:\/.\1B5++,OP6(GA<1F6-]E*O3C3G4I8.A0JXC%
MU*:JPJ04^6$*<92@^5U$U9VO\EQ7C,?&ID.395C:F QN>YM]7J8NC3H5*^'R
MS!X3$8W,:U!8FE6HQJJ%*E1A.=.7)*LG'WN4_0S_ ()H?\%#K#]MO]G_ ,6>
M-_B7I_AOX7?&'X+ZYJOAWX^>$(WU#0=#\(-9C4+_ $[Q1Y'BF]NM2T#P[J&D
MZ=J274>O:I<3Z/K'ASQ/97=X\.G+<2?HYX6\5^%_''A_2O%O@KQ)H'C#PKKM
ML+W1/$WA;6-.\0>']8LR[QB[TK6=)N;O3M0MC)')&)[2YFB+HZ!]RL!_/9^U
MA_P0S\9?M ?M7>.OBKX _:%L?@O\%OC[IT.J?M$>$/"5AXKLM7\3^-=/N3?F
M2R\*QZS/X6\1:3XHUB"T\1ZM<>*->3^P?%$^JZYI^A:Q)=Q6T'>?\&]/C_7)
M/V5?BO\ LZ^+Y$@\6_LP_'GQCX,N=&!=I=)TCQ-/)KQ21WD!Q+XZB^(421K;
M0*OV1Y2\LDTB0<>6YEFM#&X7*,VPJ3G2QE.AF?M8/^T:F"E2G&HL/!7I*KA*
MBJ3<Y)RK0JJ$5&+MY>19[Q#A,UR_AGB3+TI5*&:4,)GZQ%-_VU7RJ5"K"O'!
MTXWPRKY;6C7JNI.\\53KPIP4:<U']]J***^J/T,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**R=>U_0O"VBZIXD\3ZUI/ASP[H=C<:GK6O:]J-GI&BZ1IMI&TUWJ&J:IJ$U
MO8Z?8VL2M+<7=W/#!#&K/)(J@D)M)-MI))MMNR26K;;T22W8I2C&+E)J,8IR
ME*32C&*5VVWHDEJV]$M6:U?QQ?\ !PE\7O'EW^VG^S_X=^%S:A<:W^RM\)(O
MCP;W3%,\GA+Q#K/CV#5+C6Y8D8/&NDV'@3P+JUU. !';W$$K$1PNZ?L%JO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_PK=5_^8JC[7XR_Z /AG_PK=5_^8JNFHK[T_83F?M?C+_H ^&?_  K=5_\
MF*H^U^,O^@#X9_\ "MU7_P"8JNFHH YG[7XR_P"@#X9_\*W5?_F*H^U^,O\
MH ^&?_"MU7_YBJZ:B@#F?M?C+_H ^&?_  K=5_\ F*K5TZ75I4D.K66G64@8
M"%=.U2YU1'3'S-))<Z1I#1,&X"+',&')=3\M:-% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+E3E*$FXR:91116AL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%;JO_P Q5 '345S/VOQE_P! 'PS_ .%;JO\ \Q5'VOQE_P! 'PS_ .%;JO\
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MQ5#,70Q-95*=.4,FS7"U\NSBSJ2BI_[-751TX\TYJFU3A*IR(^_/@5\)M ^
MWP8^%?P7\+J@T'X6^ ?"W@;3Y5C\MKU/#FCVFFS:G."69KS5;F";4[Z5V:2:
M\NYYI&:1V8^K5S/VOQE_T ?#/_A6ZK_\Q5'VOQE_T ?#/_A6ZK_\Q5?24Z<*
M5.%*G%1ITX1IPBMHPA%1C%>2BDEZ'W=&E3P]*E0HP5.C1IPI4J<5:,*=.*A"
M$5T48Q44NR.FHKF?M?C+_H ^&?\ PK=5_P#F*H^U^,O^@#X9_P#"MU7_ .8J
MK-#IJ*YG[7XR_P"@#X9_\*W5?_F*H^U^,O\ H ^&?_"MU7_YBJ .FHKF?M?C
M+_H ^&?_  K=5_\ F*H^U^,O^@#X9_\ "MU7_P"8J@#IJ*YG[7XR_P"@#X9_
M\*W5?_F*H^U^,O\ H ^&?_"MU7_YBJ .FHKF?M?C+_H ^&?_  K=5_\ F*H^
MU^,O^@#X9_\ "MU7_P"8J@#IJ*YG[7XR_P"@#X9_\*W5?_F*H^U^,O\ H ^&
M?_"MU7_YBJ .FHKF?M?C+_H ^&?_  K=5_\ F*H^U^,O^@#X9_\ "MU7_P"8
MJ@#IJ*YG[7XR_P"@#X9_\*W5?_F*K5TZ75I4D.K66G64@8"%=.U2YU1'3'S-
M))<Z1I#1,&X"+',&')=3\M &C1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1S30VT,MQ<2QP6\$4D
MT\\SK%###$I>6661RJ1QQHK.[NP5%!9B ":3:2;;225VWHDENV^B0TFVDDVV
MTDDKMMZ))+5MO9$&H7]KI=A?:G?3+;V.G6=S?WD[\)!:VD+W%Q,Q[+'#&[M[
M*:_B$_X(._&S4[+_ (*6>(#KDDMNG[47P^^+_D6]P^$OM;M_$#?$]+V,D_OK
MBU3P1XLL4;<P(GOAAF(9?TV^-7C/QI^T?\(OVA_VI?BO^T)9_"_X(?"_Q-K.
MF?"3P9KEW'H.@>)]6L536=)\-6D+:AI,%_XKNO#[6-KI<K6VN^(-8\1W\D-M
M'96=G+;G\R/"^C> /V8O&7_!*[XZ^ ]14IX3_:?^(WPX^+\K*MO+H>@>.OB!
MH.N^'8(YE+"^TZ;X9^./&=O97CF**XGT6_M0SM#=/%R>#7BOE/%N+XBX0JY'
MF&5?ZZ9%C,7P)FV/K8:=#B;#Y!3S:693H8>@YO!5J&)CE^)PV&KUIXG&8#$+
M&QI4*5/]Y?T@?!C-^"</PKQOA>*,GSRKX:\1Y9A?%#A[*Z>)CC>"Z_%U?(Z>
M1QQE;$<GU[#8["K.<'B,=0PU+!X+,\%5R_V^*K3DJ/\ </111789A1110 5_
M-_\ M<NW_!0'_@K[^SU^R'IRC6O@K^QK8_\ "Y_CDD9,^DWOBA_[#\13Z'J9
M@0P7EO*#\./ TD3W*W%A<>*/&=JHM[BUO$<_;(^,G[6/[:G_  42T[]B?]AW
MX[>(_@9H?[.7@K6_%?QH^)OAS5==L-"D\<7%O9N-$\3KH/EGQ!I^B7-[X:\)
MV>A74MQ:IXCUCQ9=W>GW3>' (ON/_@F!_P $_/B!^QM;_'GXB?'[Q]X;^+7[
M1G[07Q D\1>,_'_AZ76+^VE\/V<M[?V%J=0\0Z/H>HG5=8U_6]?U[Q&EMIEG
MI[22Z-81?;(]$MKIOO\  82APM@:F<XO'X;^V\7DLGE&50C6^N826;.6'I9A
M6G[/V,'#+GB,31@JCJ1E5H<\8\T>;\JS/,,3QQF=+AW 99C'PWE_$45GV>5)
M8?\ L_,(9"H8NME6'@JOUBHJF;+"X6O4]DJ4H4,3[.<N6:CYQX\_X)/1>(O^
M"JGPX_;W\/Z_X0TWX<Z<D'C#XD> [F/5H_%.J?%SP_X8U+P[X:U[PY#;:;+H
M TN\N$\*^(->GO-2L+]-9T34[F*TU*XU][NP^9OAIXL\+?LO_P#!>_\ :TL_
M&WB7P_X'^'GQY_9[TGQQ;ZOXIUG3O#FAV^MVND_#35[K4+[5]6N;/38D;4_#
MGQ%5&FEBRUX%\PR12>;_ $>U_-5_P<!?!;]D:P\->&_VA?B1:>.?$/[47BGP
MQ%\#?@1\.O"WB&*PT+QE=VNL:AK">)?%6A6FBW?B#4;7P"_BV[N-^BZQI3ZU
MJ6I^&?"MZ)H[^TGL?-PW&.&H4,9+BO&XF.44>%JN11JX:A3K5Z%"EB*.*P7)
M1E4HQKUXUZ4*-)SJ1G-NE3<K:J>+^'L+P]EE3B'(</@\/BLOXKAQECHXS$U*
M%#%5JF$K9?CJ$*D:=:=/ZY#$)4\/2IR]IB*C5*#J5(Q?U]^U1_P6S_9K^ OC
MO2?A'\(?#/BW]K[XJ:YH=CKEAH_P"O\ 0/$_A.--4MVO-,TVZ\8:1>:[/=ZO
M?:<8=66S\,>'/$PMM+N8+F^EM9)H;>7Y!^//_!=K2_''[#]GXR_9BL)O 7[8
MWCKXKZ/\%K'X/Z[;Z;XU\4?#C7)[F74+_P 30:=JNCV>F>+=)U#2;6WT'PY?
MWN@1V[>*O$$=C>Z+)<:%JEHOGW_!NSX6^'_P>/[:_A/XG^%[3P'^TM\)/%FG
M:7\2]<\674%A>:!\,+*WU"&[T-;B]=+/2](\/^,?"?B#5O%FIVURME?QW?A:
MZU">2UTW2)E^_M._X)4?LD_%?]MCX=?\%(?A=X[TC5?"\]\/B9)X(\#1:#XF
M^&?Q"^*=G)=+HWQ1T?Q?IFKSV>GK::TD'B'5M*TFPO8=6\9Z1'K+:EI]Q-K%
MKJ'Y;F^5<;TE)RM@(XYT8O+ZE*E#$93@,SI4\5@L4\?3G^]S&G@9QJUJ,)1B
MJDZBHT_:45;SL'F''G%&3X7,\MS;+:"SR>+P6(R>C1CA<3D&#AC7E^)S+#8V
MK.GCL1C\NG2J*O"2A&,ZR5"E*M"E?\_;7_@IO_P5L^+4]O\ L1> ?V2(OAU^
MV]H<EI9_%#XO:M86\OA+PAX1+Z?!8?$S_A&M=TO4O 6B1:VQNY9O$-YJWB_P
M3JT2;O 7A[5[O6]+TK1NU^)5_P#\'%?[,7AK7O$NM^)?@[^V3HVN>'=9T-],
M^$W@K1;_ ,6?#_4;_3KRTTSQ9HF@>&?A=\$/%^M:MIM_/;7UO:V&F^.].?[(
MD5_I5K%++=)ZO\=O^"M8^,OQ-^,_[)_[+GAKQ$FK^&_%/A+P!I?[07ASQ5;I
M#XB\2SZ[)I_B'0/".GV>G1W=DAU:W.AZ'XIM/$%XNLVS:QJ%E;:9!_9-_J7W
M!^RW^UQXCTOQ'?\ [-'[6+1>#?C3X,B>WTKQ7KEQ!::1\0=(LX&F@NYM5E:*
MPDUA["(WEKJJ2+9>)[)6N4:/5X[F"[^'S;.L'D?&U3@;B'/>)<%FD,)E7L<W
ME5HX3)L)CLXPL\PRG(,?*@Y8>.>8W*G3Q\(YA"G/%PJ1I15'%<E&7[;D'@%Q
M7Q9X:S\2LJX^SW.Z'US.\-@,!EF.>!S99!PUC891F/$=')*6'CA^(,KP&<2J
MY7FF;0AB)RK498J,:6%BZ]+Y,_8F\$:/_P $F?V!-$\6_%W0+W6/VB_CMXAC
M\>^//"MWJ2V?BK5O&&NPB;2O"&IZK<)JUQ:0> _"^Q_$MX]MJ$=KXKU'7C''
M-=:W;1S?>1_:S_8V^.'P#_X2CXO:C\.KGP+K033/%WPP^*.DZ3XPG@UJ&)9K
MC1+WP+=:=K,WB=(P3<6-Y8:'?6U[9%;I$AD6YM[;YH^"NF7/[=/[57B']H?Q
M1;3W/P)^!NICPW\(-%O[<KIVNZ]:.+RWU*>VD8H\\#FW\7:NLB"47%[X3TF9
MKBSTZ:%?J+5O^"=7[+&N_$7Q#\1M5\%7US/XC$\MSX2AUB?3?!-EJ5W%)'>Z
MQIFCZ5%8WEM>W;RO=-;R:I/I%O=D7%CIEI(JD>'E&:>(V=0JYIP-1X9J\%N=
M;(,BR_B2.)H/&T, YTZW&<\5@:,\5B,-C\?#$8>EEK]FL5@XT<9!T)U9U9_N
M=+@#P2\..'LE\.^.%Q;3XKRK*L%FO$..X:^H8U4*F/I4ZBX$KX',ZM/+X9C1
MP-6CF.8YRX5?8YMB<;A*L<33IPP\/Q-_:^TKX*?\$_\ _@H5^P!^W3\!O#WP
M_P#AQ^S!\9M+OOA-\3X_A?X:T+PE\.[;3M2:2QO_ !??:-X<T_3+&WEF\,^-
M++Q+-%!:)>27GPLFDNH/MT4T5PO[2'Q1E_X+:_MA^"/V-_V??%VJO^Q+\$&L
MOB5^T+\5O#HU#2K?QQJ"NMO'9:,=8TV-9GM'EF\*^ OMVFSVUWKMYXJ\;K8Z
MUH'AO3+FOK/P+^S5\,M;^,WCG_@G+^TWX8T[XV? JPNHOCG\'+?Q!?\ B'1]
M3T+Q%:6ZRVIT[4?#>JZ'J-J;KP_K_B.T\0VUG>1Z9?:CINIR)9_8]<U*"7]?
M?@K^SQ\"_P!G+P]=>%O@3\)O ?PIT/4)K>ZU6T\%>'=/T6;6[NTB:"UO=?U"
MWA&I:_?V\#O!!?:S=WUW%"S1),L9*U[W!]3&\69?C)8BCA\GPRSFM@^)\B@Y
MSQ&#S[*53PV:Y;AZU/\ V=Y7B\12H8RE6ISG4K82O%7@Y5+_ ,Z^)/@WB^$N
M+\QR++<[P&-\,N*99/QOE%7#T,1ALQSC(LTP-&IA\/.BH4:.7T<94PM..;4(
MVK1Q-#%X>E&G2ES5-CX/_!GX6? 'P!H?PM^#/@7P_P##OP#X=C=-*\-^'+3[
M-:)+,P>ZO[R>1YK[5M7OY1]HU/6M6NKW5M3N2USJ%[<W#M(?3:**_680A2A&
MG3A&G3A%0A"$5"$(15HQC&*48QBDDHI))*R5CNI4J5"G3HT*=.C1I0C3I4J4
M(TZ=.G!*,(4Z<$HPA&*48QBE&*2222"BJM_>V^FV-YJ-T_EVMA:7%[<O_<M[
M6%YYGY('RQQL>2.G45^2W_!)/_@I1K/_  4/\ ?%F[\?>&?!_@GXF?"_QI9V
M]SX>\&R:M_95SX!\56<]SX.U<Q:[J6IZ@^IQWFD^(M&UJ>*X%C/-IUG?P6NF
MC4UTZV]+#Y7C<5E^89G1I<^#RR>#AC*G,DZ3QTZE/#OD?O2C*I2<)25U"4H7
M^)'FXK.\NP6:Y5DN)K.GF&=4\?4RZER2<:RRRG1K8J+FERPG&E6C.$9->TC"
MIRW<&C]<Z_._]O#_ ()E?L[_ /!0T_#FX^-.J?$KPQJ_PP_X2*'P_K_PNUSP
MSH6K7>F^)O[+?4='UIO%'@[QG8W^G1W6CV=[8".QMKNPN6O#;W:PW][#/^B%
M%>/B\)AL=0J87%T88C#U>7VE*HKPER3C.-UH[QG&,DTTTTCIS'+L#FV#JX#,
ML+2QF#K\GM</7CS4YNG4C5IMJZ=X5(0G%IIJ44S^=[_@@)>:A\-+7]NW]CK5
M]2OKNY_9K_::U.'3H-4G\RYCT[6YM?\ !%RUHFV*)+2;4?A3-JEPEA!#9"^U
MF6^$,<FJ;YOZ(:_G7_9T_P"+#?\ !?\ _:^^&S_Z)X<_:6^">F_$KP_!_JOM
M_B:WT_P-XGOKG9]R;9?6WQ5^9<N?OD@B93^_EYX^\"Z=XQT;X=ZAXT\)6'Q
M\1Z5J&N^'O MYXCT>U\8Z]HFD,J:KK&C>&)[Q-;U32M,=E34-0L;&>TLF95N
M9HB0*\3AF2I96\'.24LMQ^.RR\G9/V.,J+#Q3;UYJ%2BH+>5U9:V/E> ZD<-
MD$LLJS499'G.;Y#><K76%S*NL%"+D]7+"5L+&FEK-./*M4CK****^C/MPHKD
MO'OCSP=\+O!?B?XB?$+Q'I?A'P1X,T6^\0^)_$NLW MM-T?1]-A:>[O+F3#.
MVU%V0V\$<MU=W#Q6MI!/<S0PO^,WP9_X+M_LX_'[]KSX>_LS_#7P!X[N/!GQ
M'U75O"V@_'/Q+-:^&=(O?&%GH]QJFEZ9I_@JZL[C6Y]+UVXCM=&M=0U/4=%U
MFVU35=+6Z\,):7+747!B\TR_ U<-0Q>+I4:V+J0I8>E)MU*LZDU3C:$5*48.
M<E%U9J-*+=I31X^9<09-E&(P6$S+,</A<3F->EA\%AYRE*M7J5JL:--JG3C.
M<*3JSC3E7J*%"$I)3J1/W&HHHKO/8"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***IZAJ%AI%A?:KJ
MM]9Z9I>F6=SJ&I:EJ%S#96&GV%E"]S>7U]>7+Q6]I9VEO%)<7-S<21PP0QO+
M*Z(C,!M)-MV2U;>R7=B;23;:22NV]$DMVWT2+E%?F;^VK_P5"_9X_99_9PU#
MXT>"_'GP\^-WB;Q%<2^&/A#X3\ ^-M \66?C+QG- 7C:\O\ PQJ6H"W\+Z!&
M\>I^)]0AE61+7[/I=F_]L:QI4,]__@E[^WFW[?/[/EWXY\4Z'HO@WXR> /%6
MH^!OB_X'T./5+73M&UR%FN]&U72]/URZOM9L='U[2'4Q6VHWU]/9:SIVOZ2U
M]=MI;3OYL<WRZ>81RR&)ISQD\.\3&G!\T?9JS2]I&\/:2@_:1I\W.Z2=2W)9
MOPX<2Y)4SJGD%+'T:N9U<'+'0HTG[2#H1::3K0O2]M*FW7A0YO:/#QE6Y53Y
M92_2.BBBO2/="BBB@ HHHH **\B^.?QX^$O[-?PT\0?%WXV>-=)\!^ O#<2M
M?:QJKR/+=7<JR&ST?1=-M8Y]2UW7M2:-XM,T32+2\U.^D5Q;VSK'(R?@_:_\
M%6_^"B'[7T^KS_\ !.C]@L:G\,&UO4M"\._&[XVZD;?1M8@T^X-M=:K';W/B
M#X>^#]*U*SY-SHMIXT\=-87">1<"\N2^GCR\?G&!R^I3H5I5:N*JQ<Z6#PE"
MKB\74BG;G5"A"<HPO[JJ5.2FY>ZI-IH^?S?B?*<EK4L)B:F(Q.8XB#J8?*\M
MPF(S',:U-/E]HL+A*=2=.DY>ZJU?V5&4DXQFY)I>Q?\ !7[]JOXUP^,?@)_P
M3W_9!\4W'AS]HK]J+6$3Q/XDT:Z^R:OX%^%UU)>:7]I75K42ZGX8&LRVNNZW
MJ/B+28UUK1O"O@G7IK!X9]0M9JYOQ-_P0+_9=\/_ +'7Q2^&/A#2;OQ_^TUK
M7A#5M6T#X_\ C2[NXO$U]\2;!X]?T:UT_3(]4;0/"?AG6M6L(_#M[;PQ7^HI
MH.K7\FKZUKM^#>2>B_\ !/7_ ()_?M+>#?VFOBQ^W9^WMXO\"^./VB_'WAZQ
M\*>"-)\%W,U_IGP]T*2TMM/UEB$TC1]"TN^&CZ7I7AG1K'PXNIVUMH\FOW5[
MK5_J/B&]*_MU7D87*89Q+&YCG6#GS8MU<-@,'BTG/+\O4?9*4:3<X4,9BI*5
M>K4C>I3O3A&<4I)_-9?PY3XFGFN=\5994Y\R^L8#*,LS&,95<FR54_J\9PH.
M56EA,SQ\U4QF(K0YJU'FHTZ=6*C)2_B,_9H\9_&'_@K7\1OV$_V)_BAH^LVW
MPJ_8Q\,:AXF_:0N-3-R)/&#> =>N/"_AZV\017-LUQ%JMSX.M?!_PU/V^X.K
MR:IXG^(6N/D1E8?[;H((+6"&VMH8K>VMXHX+>W@C2&"""%!'%##%&%CBBBC5
M4CC151$4*H"@"O#/A1^S%\ _@;XT^+7Q$^$WPQ\/>"/&GQS\2)XM^*FOZ3]O
M>Z\6:]&]W,+J6.]O;NUTFW>\U'4=2FTS0;?2]*N-7U+4M8GLI-4U"\NY_>*[
M,@RBME5"L\9B%C,=B)P5;$J_O4,+36'P5).2B[4Z$%*=U_&JU7S3NIOU.#N&
ML5P]A,3+,\;',\WQM6C'$X]*2Y\'E]&."RO#KGC"5J.$I*I4O&[Q5?$2YZM_
M:3***Q_$.N:?X8T#7/$NKR^1I7A[1]3US4Y^/W.GZ393W][+\Q5?W=M;RORR
MCY>2!S7T"3DU&*;<FDDMVV[)+S;T/L)2C&,I2:C&*<I2;LE%*[;?1)*[9L45
M_-I^Q=_P7K\0?%SXA_#7P'^TU^SO=?#C1?CU\0E\!?!CXL_#]-<N? U[KE[K
M]EX=MO#VO0^*)'-[+H^JZQH>G>(_$OAW6[D:=/JMG>ZGX2T73;A+E?Z2Z]C.
ML@S3A_$QPV:8=4*E2,ITIPJTJ]*K&$G"I[.K1G.#E3J)PJ0;4Z<U:<5=7^?X
M<XIR3BO"3QN28MXFE1G"G7IU*-;#5Z$ZE-5:2JT,1"G44:M*4:M&HE*E5IM2
MISDD[%%%%>,?0A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\/X[AWAKC+'\29?QIA<+E/&/^L^->)QF58RO+"X7%\:<+8BM4B\KQ&$RNC+
M4,IP<X4\+AJ."G@*=3$X=\_T.59]X(\0\4Y;Q;Q=P!EG"6;>'N-QN>< O@W
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M$/Q!J6IW?BGQ-:Q1:K\,_"%K9ZOXMT+5;4M;:T;RWU+4]'L+/1;>]B=M+O\
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MC(.I@\SPDU:I@\SP<G0QV&FNGLZ\9.F].>C*G422F@HHHKTCW0HHHH ****
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M_P"U65[9>)FL_ UCH-K)X>\8:GX;N1%I&FV?CVSM8=-UG39O$5KXAN[/4/\
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MOH^JVD-_IFIZ=>6[/!=V-_93P75I<PN\,]O+'+&S(ZD_Q<?M+?M:?M4_$_\
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M# X5156R2EBJF(G[UU)E%%%>\?7A1110 5\/?\%+/B'_ ,*M_8%_:U\7I/\
M9;E?@CXT\+Z?=!MKVVK>/]//@'1[B)N@GAU3Q-9R6^<@SK&&5@2I^X:_#3_@
MX5\?R>$_^">]WX0MY':Z^+_QE^&?@-;*#<\]Y!I4^K?$IE6",&22-+SP#8 D
M*5%S+:1_ZR6)6]WAC"?7N(LDPC5XULTP2J+?]S'$0G6=MG:E&;UTTUT/F>-,
M?_9G"7$F.3M/#Y+F+HN]O]HGA:E+#J^^M>=-::ZZ79^/W[0WPMNO@A_P1G_X
M)??&G3[)_P#A(OAY\?K;XGW,\:A+EK;XL:CX]^)>EWS,=BK&+?PMX+TR)PP+
M 6#'=\\@_M!L+ZTU2PLM3L)DN;'4;2VOK*XCR4N+2[A2XMYDR =DL,B.N0#A
MAQ7XC?\ !5GX#1^'_P#@C/K'PTM+6,W?[/\ \//V>$TR"-5,<*_#G6O G@_5
MI$9 P46_AJ?6Y Z APFPE4D9U_1O]AGQU_PLO]C+]E?QR\WGW?B#X ?"BXU2
M3=OSKEMX+T>PU]-_5O*UJTOXMQ 9MF656)4?0\28MYQD.$S6]_9\4<34&]_<
MS&6#S6BO**=2OR):?$EL?)<'8#_5_BC'Y&URJMP3P9BXQV_>933QV1XE^<FJ
M.&]I?WM(-_%=_5-%%%? GZF%%%% !1110 4444 %%8EOXE\.7>NZAX6M=?T2
MY\3:39VNHZIX=M]5L9M=TW3[XD65]J&D1SMJ%G9WA!%K=7%O'!<$$0NY!K;J
M(5*=52=.I"HHSG3DX3C-1J4Y.%2G)Q;2G3FG"<':49)QDDTT:5*56BXQK4JE
M*4Z=.K!5(2@Y4JL%4I58J23E3JTY1G3FKQG"2E%N+3"BBN?\2^+/"O@O31K/
MC'Q-X?\ ">D&ZM[(:KXEUG3M"TTWEVQ6UM!?:I<VMJ;JY966WM_-\V9E(C1B
M"*56K2H4YUJU2G1I4XN=2K5G&G3IP6KE.<VHQBEO*3275CHT:V(JTZ&'I5:]
M>K-4Z5&C3E5JU9R=HPITX*4YSD]%&*;;T2.@HJEI^I:=J]G!J.E7]EJ>GW2>
M9;7VGW4%[9W$9X#P75M)+!*A/&Z-V7WJ[51E&<8SA*,H22E&46I1E%JZE&2N
MFFM4TVFM41.$Z<I0G&4)PDXSA.+C*,HNTHRBTG&2::::335F@HHK!U?Q3X8\
M/WNB:=KWB/0=$U#Q-?G2O#=AJ^KZ?IM[X@U,('.G:):WEQ#/JM^$97-G81W%
MP$(;R\$&IJ5:5&#J5JE.E34H1<ZDXP@I5)QITXN4FES3J2C""O>4Y1C&\FDZ
MI4:U>:I4*52M4<9R5.E"52;C3A*K4DH04I.-.G"=2;M:$(RG)J,6UO4445H9
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q%\??A_H<7[
M3G[$7Q->[\1W7B2?X^^+/!UK:W?BG7Y_"VD:+)^QM^UUJNHG1O!SZA_PC.GZ
MKK5[I^E/K.NQ:6=:OH=(TVT>_6SMS;O\-?'C7OV>O%7[3?B[P_\ LX>*/@_X
M._:K^'5_\1?%'B_XCZK\1-(A^-7Q"^+&L?!KQCX,\'?LU_#?3]5\0/\ $+Q1
MI']L:EH&N^*_#^@JGPZ\$7?AVRT+0-#N_'&H:Q'X;_<*B@#\F/V!O^%6?\+*
MT_\ X9V_LG_A6W_#(WPB_P"%Q_\ "+>7_9G_  T#_P )%K.[_A8&W]Y_PN_^
MQ?\ A(?^$_\ [5_XK3R_[*_X3;Y_^$?K]9Z** .;>Z\7AW$>A^&WC#,(V?Q5
MJ<;L@)VL\:^#9%1BN"R"20*20'<#<6_:_&7_ $ ?#/\ X5NJ_P#S%5TU% ',
M_:_&7_0!\,_^%;JO_P Q5'VOQE_T ?#/_A6ZK_\ ,57344 <S]K\9?\ 0!\,
M_P#A6ZK_ /,51]K\9?\ 0!\,_P#A6ZK_ /,5735\C_MK_M=> ?V+/@9K?Q?\
M<7NG)<&[M?#_ (1TB_N981KGB?4A(;6 PVJ3:C<6=A;Q7&IZDFGV\MR]I:-;
MPM%<7,$@XLRS#"93@,7F6.J.EA,%0GB*\XTZE6?)!7Y:5&E&=6O6J2M3HT*,
M)UJ]64*5*$ZDXQ?3@\+/&XFCA:=3#495I\KQ&-Q>&P&!PU-)RJXK'8_&5:&#
MP."PU*,\1C,;BZU'"X3#4ZN(Q%6G1ISG'Y9_X*"_$KQYXPN_AW^Q_P""H](T
M_P 9_&C5;"Z\2S:7X@O;X:9X*M;N4A=9:31M&>RTN\N;*\UC4Y$-SNT/PSJ4
M,\!@O%$OY1?'O]JSX5?\$OOB+XINO@!\8OA[\3Y?&/PLU;PEJGP]\+_$G2?B
M'KN@_$*RTQK31]3\32Z%IEK%X?N;'7IK3Q5;1ZI9VI2RN?$6AVYCCN+-&^._
MC/\ $'Q-^W?X_P#A+\#?@Q\7[;XJ?M!?MFZL)OBWXH\.IJ4OAOX)?!BQO4GE
M\,ZJ(HK22UN4T[1=0\1^,M L1:_\(_X&\-Z;X84ZB_CO4(%_<GQ/_P $Y/\
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M?^)+RVLYR1;RZ@GA7X6ZVNEM<J/-MH-2:UN+FW*W,$4ENRR'EOVH?V,U^/\
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M4]0_;W_:H^ ]I\._!6K7WPG^!WB&^\4>(/$5_P#VG:^%-3U&WFT[75:_OY=
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M77+W3;[4K#06L?!(5H;;PUJ<4D47BC0?%]T)Q=9:XU"Y0Q1B,9_=G[7XR_Z
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M_?W[7XR_Z /AG_PK=5_^8JC[7XR_Z /AG_PK=5_^8JNFHK[$_3SF?M?C+_H
M^&?_  K=5_\ F*H^U^,O^@#X9_\ "MU7_P"8JNFHH YG[7XR_P"@#X9_\*W5
M?_F*H^U^,O\ H ^&?_"MU7_YBJZ:B@#F?M?C+_H ^&?_  K=5_\ F*H^U^,O
M^@#X9_\ "MU7_P"8JNFHH YG[7XR_P"@#X9_\*W5?_F*H^U^,O\ H ^&?_"M
MU7_YBJZ:B@#F?M?C+_H ^&?_  K=5_\ F*H^U^,O^@#X9_\ "MU7_P"8JNFH
MH YG[7XR_P"@#X9_\*W5?_F*H^U^,O\ H ^&?_"MU7_YBJZ:B@#F?M?C+_H
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M+2V9-3UK1O"T_A=-<U32=.=62_U&RL9[.S966XFC((KU6OXQOVXOVK;KP?\
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M,?,TDESI&D-$P;@(L<P8<EU/RUHT5]D? !1110 4444 %%%% !1110 4444
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M#<1G_&?!V2YSAL3EN4Y_C,/CL1C<;3JX"A4X8PM2MB,[S;#8JO&E3G@\+EV
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MG549<\54A&:C/EE'FBI)I2Y92CS*SY925[-I_P ;^A?\$I?VX=7_ &AO&O[
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M]3TW4/!-M9V^MPZ5H4L]SH]WJ&F:CK6LW.J:7JB6GAB2TMENY?C/0?%&C_\
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M=TDC8DO-0O) WV/2-(L]RR:AJVH2*8K.SB(+D/-,\-K#<7$7Y4:'^U+_ ,%
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MD4,2)'&BHH LT45]CML?3I))))))626B26R2Z)!1110,**** "BBB@ HHHH
M**** "BBB@ HIDDB1(\LKI'%&C2222,$2-$!9W=V(545069F("@$D@"ORC^/
M?[2WQ(_:*\?S_LO?L::E')<!)5^)WQIL;R6'0O#VE@F"\M-%\16,5TUI91.W
MD7?B'2Q-J.HWI33/"WF,);R;Y;BOBW+N$\%2KXJ%?&X_'5XX/)LDP$%6S7.L
MPJ?P\)@,/=.5KJ>(Q$W&AA:*E5K3BN52^SX)X'S;CC,:V&P53#9=E>6X>6/X
M@XBS.;P^2\/972UJX[,L59J-[.&%PL.;$XVNXT</3D^:4/IOXV?MV_LY_ C6
M1X9\4>++G7_%,-\EEJOASP/91>(M2\/GS$CN)-?D^V66F:8]F'\RYTV;4#KG
MEJQ@TJ=L(?6?B!\6O#MC^SU\0?C;X2UZQUCPWHOPE\:_$/1]?TVX$MG<6?A_
MPKJNMI=12C:T;P-8,L\,JQW%I<12V]S%#<0RQIXM\&?V"OV?OA/X/U#P_JOA
M33?B9X@\1:?>V/BWQKXWTVVO]7UB/4DVWT&FQ2-.OAJQ8DFWCTF==20K'/=Z
MM?7T:WE?FO\ MV?L$_ ']E_]E7X[?M!>&_$'Q.N]6\ >%Y-2T?P[KNO^&+KP
MS>W>N:SIWARST*_C@\&6FKS:7=RZW'I\@;5WN9()-MQ-=,T@E^9RO&>,L<RP
M5>MPIPKGU'-JN'IT>&L#Q!4R?'Y+6EB*<:6%KYSC<'C<#G%?%4ZOLJ\Z5# X
M6CB:2=*I]7;G4^OSK _1_>49CA\/QMQKPU7R.ABZM?B_,N%Z6?99Q!0AA*LZ
M^,PW#^7X_+LRR'#X*K1]OAZ=;$YCC*^$JM5J3Q25.E^8W_!,C_@D/>?M._LL
M>$OVAO#'[5/QA_9VUOQYXE\<^&/&&E^ H9)M-\9^!?#.O3:+9V<<VG>(_"=Y
M8W+:K9:JMX^K3>*-(F6& 0Z+;3K/-/\ JU\+;#X<_P#!-C1+G]C']ACPQXG_
M &@OC?XP\3:AXN\?^(O%U[:ZS-I?B6ZTS3=,C&N?\(YI^@Z?Y&BZ?86['15N
M-'TKPK:&>_\ $6MW&IWVIO+SG[$_[$7Q.^*W[*'P.\;:?^T[\0?A!\._B3X*
MM/'"?!#P5::Y;^%M LO%]Y>>(9K;339^/-'T%GUBYU"37[VZ_P"$-A6XU#5+
MJXN+>YN9);N;]9/V;_V3_A;^S'I>K0>"H]4UKQ'XBE$OB+QMXIFL[[Q-J<:L
MLB:<MS:65C!9:1%<![E+&W@#3W#BXU"YO[B*&:/ZGC/C?QHX_P ;CN'JN3XC
MPTR6KFE669YCB,YX9SS-</A,-6J6R_**63+%T*^+<K8>EF69UZE'!TE4KX;"
MSK1P[C\1X>>&_P!'KPOR[+.*Z&?87Q=XAH9'AXY/E>%R#C#AS)<5CL9AZ#GF
MF>5L_E@,3A<"X\^*K91E&%IXC'UG1P^+QE.A+%*7QAX*_;#_ &@?V??'^C?#
MO]N?PM96&A^.+LR>%?BUH$&E1:-IDDPLEN-.U(Z$%T:^TC19;N&+5+F);;7M
M#$@O+Z'6=-O+.]B^.O\ @H#X'^,W[$'[<7A;_@JU\"O *?%;X4>*/!>A_#7]
MIKP;X<DN3K\NG72V.@1>)Q]@CD1]*U31]*\"+HVLK%?V6F>+O"NG?V_ =.UF
MU>OW2^./P8\'_'WX:^(/AGXUMV;3=8A$MAJ4"1MJ/A_7+99#I>OZ4\@*I?:=
M-(QVDB*[M);K3[H/9WEQ&_YM^%/^";WQ?\5Z;X?\(?M$?M*:[XA^&'@Q8]/\
M.?#WP3=ZLUE-I-A-_P 2L7-[KT-M9:?-!;I'"L;:!KMS8V^VQT[5X8+:"0_,
MY#G'B1X99KBLKR_*,9XIY#FV K8?+\3G6;X/+\;@:5>489AE/$^;S5.MB<(K
MTL?EF:87"5LQC4ISPLJ&(]E3FOL>*.'_  E\8LDP6<9IGV \%N)\CS3#XO,\
M+P]D>89I@,QKX6,JF59YP?D<)5</A,<[5\MSC)L9C</E4Z5:&-CB<-[:K"7F
M?_!3;_@HAX"/_!-35?'WP#\37NH^)OVG9X/@=X&L((;O3/&_AK5?$EH\GQ&T
MK7?#R#^VO#_BOPWX2CU31I[-O)N;#7]=\.7EC<75K?Z9<7WR;^UW_P $Q-)^
M"/\ P1S\'67@?P_;:1\??V;YO"_[3/CKQ1I$;1>(=5\9R:?;1?%\R:M&TLTM
MEX4T6[2ZTN7=$D6F_#71# EJ_G+)P'@[_@GIX>T7_@J5\)_"WQ1\86^F^$?A
M=XKN/B5H&B:_YAT[XOWFCQVFH?"J2PM?-&AP>(+VZT_3$\3+/!*FK6WA&X\)
MQ^?/!8PM_5G?6-EJEE>:9J=G:ZCINHVMQ8ZAI]];PW=E?65W"]O=V=Y:7"20
M75K=02207%O/&\,T+O'(C(S*?UO@7Q*P>/X9X=Q.4T:V S?+\[QE?C?(ZU2]
M;+.(,MQ#R^MP]7KJ,5B<+2PU*MB,-B5!4\7@LSP^*]G2JSG1I_A?B3X/YCEW
M&'%F$SZO0S'(LSX<P&#\..),/22P^<\+YMA8YM1XKPV&=2<L'C:V,KX?"XW!
MNI[7 YADV*P7MJ]"%+$5?Y+O ?\ P7(_:MUOXL_L]?''X@?#4?#W]A#6M?\
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M8M+.M7T.D:;:/?K9VYMW_.;XI?;?^%A_%K_A77V7_AX#_P -<_$K_A'/[/\
MM'_"U/\ AG[_ (4QXB_X0;=YG_$\_P"%(?\ "%_\([Y7E?\ %%_\+!Q_8_\
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MT ?#/_A6ZK_\Q5'VOQE_T ?#/_A6ZK_\Q5 '345S/VOQE_T ?#/_ (5NJ_\
MS%4?:_&7_0!\,_\ A6ZK_P#,50!TU%<S]K\9?] 'PS_X5NJ__,51]K\9?] '
MPS_X5NJ__,50!TU%<S]K\9?] 'PS_P"%;JO_ ,Q5'VOQE_T ?#/_ (5NJ_\
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M/X3\%>%M1:Z@MK*]M1'!<V2+<)"8_E_]DS_@L7X;\<_M:_!3]D?]G;]G70?
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MV.M:19:WHYL?M%K:3U]DZO\ \%%OV:M$OI=.O?B;X&FN(<;Y-(?XI>(+$Y)
M\K5-!^#^I:9/T.?(NY,#!. 1GZ7*?$W(IK,,)Q=6R[@3/<IQ=/"YAD^?YYEE
M)6Q%".)PF+R_'U*N'P^8X'%T9-T:]&,9*I2K4JM*G*'O?(9WX/<24WE>.X&P
M^:^)/#6>8&KC<KS[ACAW.*[OAL1/"8[ YIEE*CB\5E.8X'$1C&OAL1*<)4ZU
M"K1K585'R_>M%> _#'X_^$/C-#<3?"_Q-\,?&4EG!'=7UAI7CW4AK.GVTKB.
M*XU'0KKP3;:UI\$DA\J.:]L((WE!B5C(I4>L?:_&7_0!\,_^%;JO_P Q5??X
M+'8+,L-3QF78S"X_"5DW2Q6"Q%'%8:JDVFZ=>A.I2FDTTW&3LTT]3\QS#+<Q
MRG%U<!FN QN68Z@TJ^"S#"U\%BZ+DE**JX;$TZ=:FW%J24X1;336C.FHKF?M
M?C+_ * /AG_PK=5_^8JLG7O%.K^%]&U+Q%XDM_!&A:#H]I-?ZKK&K>.+ZPTW
M3K*!=TUS>7ESX.C@MX4'5Y'49(498@'>I4A2A.K5G"G3IPE4J5*DE"%.$$Y3
MG.<FHQA&*<I2DTHI-MI(Y:5*I6J4Z-&G.K6JSA2I4J4)5*E6I4DHPITX13E.
M<Y-1A"*<I2:23;2/SV_X*,^+O%'BK4_@=^RKX#UN^TC6_CCXNC7Q7-ILLD<D
M?@R.XAT=8-46*6&2XT.[N;[4=7U"U#!+F#PI+#.WDL\4WW%\$?@+\,OV>_"$
M?@WX9: FE63NEQJVJ73K>>(/$=^BLHU'7]6,<<M]<@/(((42#3[".1[?3;*R
MMB(1^:7[.^MZE^U+^W-\3?VC-'TW3M7\$_"+PY;>!_ -S>ZCJEEI;7-_;7>D
M6]_I=_<>');JXCOK9_&FN+:SZ1IMY:0>(].:\BMIR$N/UJ^U^,O^@#X9_P#"
MMU7_ .8JOR;P_P /A.)<\XJ\1JM.EBWCLWQ&0\)XV:5>.'X:R&*RV=?+*LN;
MV%'.<UAF6+K2H\OUBG[%RDXVC']P\4,3CN$.'."_"BA6Q&!66Y%A.)>-\O@Y
M8:6*XOXED\WIX7.*,.7ZQB,@R:IE.!P\<0IO"U/;J$8RO.735^+7_!?OQB?#
M'_!-OXB:.)?*;XA?$'X4>#@ VUIA:^+[3QV\0Y!.Z+P2[.HSNC1P05W5^O\
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M55 "@   "G?:_&7_ $ ?#/\ X5NJ_P#S%5\Y7JRKUJU>?Q5JM2K+_%4FYO\
M%L^OPM"&%PV'PM/^'AJ%*A#I[E&G&G'3II%'345S/VOQE_T ?#/_ (5NJ_\
MS%4?:_&7_0!\,_\ A6ZK_P#,561N?-_[6W[*GAC]I;P7B,QZ!\4_"MO<7OPY
M\<6[/:7FG:I#FZMM'U2[MT:YD\/W]ZD9GV"2YTFX8:MIB_:8YK>\^</V;_VX
M(=,^ GQ*_P"&B-5&F?%S]GF6_P##WBS3=9EMK/7_ !?<V[7MIX;M[>W#@ZAX
MEO=4L+CPSJAMDD7[?:Q:S?S10:B\Z?H_]K\9?] 'PS_X5NJ__,57P-\5_P!@
M'PK\7OV@--^-_B/3M$BTYX+.7QE\/K37;^+3/&NM:7&(=/U*]U>+PK!<V$$]
MO%:6^O6,%E/)K*6B.M]833W<MQ^4<7\-<28'/*'%WA[A\#_;N84I9+Q'@L;B
M%A,MS'!UJ,J>79[C4KQK8[AO%1I58NG3GC,9ED\3@*<G>E _;>!.+^$LQX=Q
M/ OBIBLR_P!6LKK0X@X4S'+\*\?F^4X_#UX5,VX;R]NTL/EW%N"=6A*-2K3R
M_ YO3P>958Q7MZAG?\$P_ FK6WPG\;?&[Q9&[>,/CWX\U?Q3=WLT+Q37>BZ;
M>W\-K<$2DS;+WQ#?^*M1B<L8[BTN[29#(C+*_P"F%<C9CQ/I]I:V%AX7\(V-
MC8V\%G965GXFU"VM+.TMHEAMK6UMH?!"0V]O;PHD4$$2)%%$BQQJJ* +'VOQ
ME_T ?#/_ (5NJ_\ S%5]GPAPY1X2X:R?AZC6>)_LW"1IU\7*+A+&XVK.>)S#
M&R@Y3<)8S'5L1B91E4J2BZO*YS:YG^?\=\5U^-^+L^XIKX=8/^U\=*KAL#&:
MJ0R_+Z%.GA,LR^%10IJ<,!EV'PN$C.-.G&:HJ2IP3Y5^;7_!77]COPW^U9^R
M-X]U:VT667XR_ WP[X@^*?P:\1:4YM?$%GK/ARP&LZUX8M+F("6XLO&&E:4^
MG#3FDCB.O0Z!JJ217>E6TJ=[_P $K?VF+_\ :M_8;^"GQ+\1:Q/KGCW2=(N?
MAU\2=1O9OM&IWOC7P%<'0[O5]7GRWFZGXITB+1O&%W)\ID?Q"'9(V9HU^YGG
M\7R(\<GA[PO)'(K))&_BO4W1T<%61U;P45964D,I!!!(((-?QV^ _$__  42
M_8.^.G[;O[!O[$7P5O?%6H^(OB0GQC\">(+3P^?$=E\+_AW=Z9<:E!K7A^+Q
M)9V?@?5KKQ!X5G\%>#HM2\1Q26;Z]X4NO#VG>'M3\1ZA9VFE?L&18:?$G#^-
MR)XG"T<5E.+H9MEU?'XB.'P]# XB?U3-J<J]2ZHX>G.>$QLX03<YQFX0E4ER
MS_ N)\93X/XKR[B=83&XC Y]@,5D6;X?+,)4Q6*Q.982"QV0U88:C9XC%U*=
M''9=3J5'%0I3IQG4C2@Y4_[.J_E5^'/[*WPB_P""F?\ P5N_X*$ZW^T-9>)/
M&_PT_9]U#PO\/-#\-V'BS7/#^FP:UH-Q_P ();Z5+>:)=V>JV>E>=\/_ !OJ
M$VFZ-J.DK/K.I:CJ<LC7<UQ))^NG_!-K]NO5/VU/V6](^)^JV7A"U^(G@-I_
M!OQNT^;7KO0I--\8:!8Q7-UXA_L.#PUJ(TO1/%.F-#X@L%2XDM+::75-&@D>
M;1+M(_@G_@@''XH\9> ?VR?VE8M'TNXN_CS^U'KMQ=W&JZU>Z9=3'1=//C%B
MBP>'M5^T6Z7_ ,5-2B6=Y82;I+N/R049C>4T<PX:P?&N(<JN"S3+J. R:G6I
M3E"I2K8[,J<ZLJ%:/+)<^%P-65.I!KFIRC.+Y9(SSW$95QEF'AQA8PI9CDF;
MU\TXBJX>O3A5HU\/EF3U*="GBJ$^:#=/&YG1A6HU%)1JPG3DN:#2YGQ+\-?
M/[)/_!=_]C;PU\+O".A?#WX6_$S]F#5? ]GH/ARPBTW2K2^T_0OC!806HAC
M:\O;S4_#'@VYU+4;N6?4=3O]2FU+4;F[OY9IY_Z4J_G-_P""O<^O_#K]M?\
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MJ*YG[7XR_P"@#X9_\*W5?_F*H^U^,O\ H ^&?_"MU7_YBJ .FHKF?M?C+_H
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MC\+BZF%E3C7Q'/S'[3W@CQ#^QI_P18_:+T7QA;6VB_$+QSI\ND^(-,M+^SU
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M/&TLSS_,,#B,OAG,XU:%'ZEA\#1JSJ8'"5'6KTJ^(=6>(E[-1CY#^P/\7_\
MA?/[%_[,_P 59;G[9J/B7X0^$(/$-SO\SSO%OAK3T\*>,6W]?^1JT/6!M8ET
MQL<LZL3]=5_(O\'_  #_ ,%SO^"=7[/-H/#W@[X<ZC\!_P!G_P 3:YXKUOX5
M6=SX&\?^+/'7@_4_$5UKOBRYLI]%CUGQ+;>%P]SJ&LN-#U3PYXLTFTO;C4I=
M'F%K?6\/] _[%G_!0;]G']N7P/IOB#X4^,=-LO',>FV]QXS^#^NZA;VOQ!\%
M:CY*-?03Z5-]GFU_0X9BRV/B[0H+K0M0BVJ\]EJ<=]I5CY7$G#=3"5L=FF6X
MC!9KDLLPQ488G*L0L9# PG5E4PU''^SC;#SG1G#DE>=&4DX*ISKD/<X/XPHX
M^AEF29SA<RR/B.&58&4\'GF$>7SS.K3H1HXROE?M9N6+IT\33J<\'&GB(Q<:
MCH^S?.?<-%%%?'GZ"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4X13=E=W=D%%%%<YUA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7_H2O$W_ (%^#?\ YK:Z:B@#F?[>U7_H2O$W_@7X-_\ FMH_M[5?^A*\3?\
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M[TYG^WM5_P"A*\3?^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMKIJ* .9_M[5?\
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M  +\&_\ S6UTU% ',_V]JO\ T)7B;_P+\&__ #6T?V]JO_0E>)O_  +\&_\
MS6UTU% ',_V]JO\ T)7B;_P+\&__ #6T?V]JO_0E>)O_  +\&_\ S6UTU% '
M,_V]JO\ T)7B;_P+\&__ #6T?V]JO_0E>)O_  +\&_\ S6UTU% ',_V]JO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P";GP."S&E%^G]G59)>KZ']#-%%%?)'WH4444 %%%% !1110 4444 %%%%
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MH(+SPO<#P/9BZTWP5XQTVRCF\0)96]_KGBCQ1X>T?Q/HGBS5)/%Z-'I_[!_
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M ,EDCQ^!J_UG@OA2M>[EP[D\9OO4IX"A3J/_ ,#A(****\ ^J"BBB@ HHHH
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M\3?^!?@W_P":V@#IJ*YG^WM5_P"A*\3?^!?@W_YK:/[>U7_H2O$W_@7X-_\
MFMH Z:BN9_M[5?\ H2O$W_@7X-_^:VC^WM5_Z$KQ-_X%^#?_ )K: .FHKF?[
M>U7_ *$KQ-_X%^#?_FMH_M[5?^A*\3?^!?@W_P":V@#IJ*YG^WM5_P"A*\3?
M^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMH Z:BN9_M[5?\ H2O$W_@7X-_^:VC^
MWM5_Z$KQ-_X%^#?_ )K: .FHKF?[>U7_ *$KQ-_X%^#?_FMH_M[5?^A*\3?^
M!?@W_P":V@#IJ*YG^WM5_P"A*\3?^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMH
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M1_;VJ_\ 0E>)O_ OP;_\UM '(?&KX(?"G]HKX<:_\)/C5X+TSQ]\//$ZV?\
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M)7B;_P "_!O_ ,UM']O:K_T)7B;_ ,"_!O\ \UM '345S/\ ;VJ_]"5XF_\
M OP;_P#-;1_;VJ_]"5XF_P# OP;_ /-;0!TU%<S_ &]JO_0E>)O_  +\&_\
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M-17,_P!O:K_T)7B;_P "_!O_ ,UM']O:K_T)7B;_ ,"_!O\ \UM '345S/\
M;VJ_]"5XF_\  OP;_P#-;1_;VJ_]"5XF_P# OP;_ /-;0!TU%<S_ &]JO_0E
M>)O_  +\&_\ S6T?V]JO_0E>)O\ P+\&_P#S6T =-17,_P!O:K_T)7B;_P "
M_!O_ ,UM']O:K_T)7B;_ ,"_!O\ \UM '345S/\ ;VJ_]"5XF_\  OP;_P#-
M;1_;VJ_]"5XF_P# OP;_ /-;0!TU%<S_ &]JO_0E>)O_  +\&_\ S6T?V]JO
M_0E>)O\ P+\&_P#S6T =-17,_P!O:K_T)7B;_P "_!O_ ,UM']O:K_T)7B;_
M ,"_!O\ \UM '345S/\ ;VJ_]"5XF_\  OP;_P#-;1_;VJ_]"5XF_P# OP;_
M /-;0!TU5;ZRM]2L;S3[M/,M;^UN+*YCX&^WNH7@F3)!'S1R,O((YZ&L/^WM
M5_Z$KQ-_X%^#?_FMH_M[5?\ H2O$W_@7X-_^:VFFTTUHT[I]FA-)IIJZ:::>
MS3T:?J?@S_P;BWMQ:_L>?&GP5?/NO?!?[5'C:S9,%?*M[OX??#!-FPDE<ZC8
M:H__  /;C*DG^@ROYT?^"%FIWOA;Q5_P4=^'$'A[6+X^#_VK=0DEM+*?0(VT
MU[O4?'&A>1<C4-<L(S*3X2,6ZS:Z@)MV FVA"W]!']O:K_T)7B;_ ,"_!O\
M\UM?6<=)?ZUYQ-*RK5</B=/^HK!8;$W^?M;_ #/A/#)O_47A^F]\/0Q6#=]6
MG@LPQF#L_3V%OD=-17,_V]JO_0E>)O\ P+\&_P#S6UJZ=>W-ZDC7.D:CI#(P
M58]1ETF5Y@1DO&=)U35(PJGY2)I(GS]U&7YJ^2/O#1HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2 ;OP#XNT;Q9KZ6&N>)3H#,T4UE=^(=6TN;QCX.O;:]\-S6=W=^+-)'AC4M
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MX+:UMH(Y)KBXFD2*&)'DD=44L/XK?CW^TE^V'^T-^TE\>?\ @J'^R_>ZG/\
M C]B#Q=X?^%OA*VBO[X:=XA^&-R=2M?&NHV^CV\LL&KZ3KXEMO%GCYA%#?:-
MX8\8^%M3=U_X16*ZT_VS2OVGO^"EG_!5CX$^ OV.OA]\%M:^&/AW['HOP_\
MVL_VH?$9UBRL=?30+Q]*U^&234;?P_;V,FHV5C'J7Q \$:'-X@\5>(]:DN=
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?ST?\
M!)?_ (I?_@HO_P %D/!!'EIJ?QXT_P 8VT!P!'#-\2/C=?YB7^%##XOM%X&-
MB0CL*_H7K^>C]B7_ (I?_@N?_P %,/!?^K_M[X<>&O''D]-_G-\(M5\[;W_Y
M'W=N_P"FW^U7]"]?6<9^_G%#$_\ 09D?#V)OWY\DP,&_FZ9\'X<_N^'\3A-O
M[/XEXLP5GNO9\19E4M\E5"BBBODS[P**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /YU/VQY8OV5/^"VO[$_[1K2)I'@G]I[P==_ OQW>W#K;V
M5[XC@>7P/#=7]\QB@M[:P'BSX0WKFY<I"GA^2:240'%O^*>C_$OX\Z3\=?B=
M_P %KO B7>K_  S\*_MNZIX%\1:- L\<^H?#;Q38A%TNZN)+F*%M%?P+K/AK
MP$LLZ2+8^(M<\.7JJLL"B+^@'_@X,^#&H>/_ -B+3_BOX<M;Q_%'[.OQ0\+^
M/H[[3HI)=0LO"^NM+X/\020B%'FB@M-4U;POX@O;I-JV5KX?>\N&CM;>>1/<
M?^"9G[(OA#0?^"77PH^!?Q:\&VNLZ7\:? &L>-?B?X9UZR:)]0_X6W=7'B.R
MM[^VE2*ZTW6-%\,7GAFPMYU^SZKHVIZ+;7EO+::E9Q20_LF7<08#+N%,MSG$
M488S%5O8\'9AA7RN57)\)6Q>-Q2C=JTYX#%8/#QDVN62I-OE24?YZS?A7-,W
MX[SCA["XBIEV"PSK^(.58V+ERT<_QV'R_+L'*?+>].GFF"S#%3A%-RA.O9<[
MO+QS_@M/\>/"'BO_ ()-^*/&WP^\0V6N^$OCYJ/P8T_PGKFGSQ2PZEI.J>,-
M%\>E8WB=Q'.VF>$KVTU"T8^?:R)>V5RD<T4R)^H7[(_@D?#;]E7]FSX?F'R)
M?!OP'^$OANZC*[7-_I'@/0;/4)91Q^^GOHKB><X&9I'.!G%?SG^$O^")G[5N
MK?%2+]D[XF_&76)_^"9'PY^).I_&?P9]D\1:(WB+Q;?:W"MO'X-M- @>37?#
MWB6SM;B_LM:UK4;*V\'6$VI>)?%/A&TN=<\37EF/ZLH88K>**""-(888TAAB
MC4)'%%&H2..-% 541%"JJ@!5    KY'B.658#*,NR3*<SI9I3>8YAG-6O14D
MJ='&4,%0R^CB.9)1QL,/0J?6J"N\/4:A*TFTOO.$(YYFN?YOQ)GN35\DJQRC
M*N':.&Q$HMU<1@,1F&*S7$85)R<\NJ8O$TE@<2[+%4HNI&\8J3DHHHKXD_23
MX#_;V_X)Z?!#]NOX5^)/#GBSPQX<T;XN1:)<I\,OC-'I*KXJ\&^(((S)I2WV
MHV#6NHZ[X1N+A%M-<\+ZC<76GSV%Q/=:?!9:[;:7JEC\@_\ !&+]@3XT_L@>
M&_CUX_\ VG(8)/CI\8/&FG:;)=OXNMO'>H2> _!EO=G3-5N_$EM>:@'N?%FM
MZUJVHSVLUV^H?V9IOAY]7CM-0233K']NJ*]VEQ)FU+),5P_[?VF6XJI2J.%5
M2G4H*E4A5='#5'/]U0K5:5&I6H\KA*=*,HJ#E5=3YBMP?D5;B7!<6/"^RSC!
M4<1152CR4Z6)=>E.A&OC*2A^_P 3AZ-6O2P]=RC.-.O.$W4C"BJ11117A'TX
M4444 %%%% !1110 4444 %%%% %/4-/LM6L+[2]1MX[S3]2L[G3[^TF!:&ZL
MKR%[>ZMY0""8YX))(G ()5B 17\]_P#P;_:X? /A;]LO]D/6M3B;Q-^S[^TS
MXG=-+N[B%-572[Y1X%U&6&S++.UC:>(/AQ=O>2QPF&UO]85)G1[R!&_H<K^?
M#_@I3_P3+_:#U[XU6W[7/_!.K5_^$#^-_P 0-)U?X9_'3P[H_B/1_ D/B;P[
MXSTQ]!U3XAVVJ:I=6&EQZC!I[(WBZVC9]9OK[3]"\:>&8)/&^E2SZC]=PS6P
M6)PV;\/8_&TLMIYQ'!5<+F&)_P!TPN.RZK4JTOK+NO9TL11K8B@ZR?[N<X.4
M91V^"XRP^98/&Y!Q7E>7U\WJ\/SS&AC<JP:;QV-RS-Z-&C7>#C:7MJ^$Q&'P
MN*CAVKU80J*$HRTE^S/P@_:;^ GQ]\1?%'PI\&_B?X;^(.O_  7\16WA3XFZ
M?H$EY*?"^N7C:G':6\MU<6EO9ZG:W4^BZS:VVJZ+<:EI,]YI.IV<5\UU87<,
M/NU?RW_\$9_@_?\ [&7_  4>_;4_8RU7Q OB+4-!^"?PP\4WFLQV[V-KKM[H
MMOX%U6XU*PLY6:6&P,GQCG.FQ3/)<Q6$D2W$CS+,Y_J0KBXGRG"Y-FKPN Q%
M7%X"K@LOQN#Q5:*C4KT,;@Z.(]HXQC!1C*I.IR1Y>:,%&,W*:E)^CP7GV.XB
MR18W-,)1P&9T,QS7+<PP5"4ITL-B<NS#$85T5.4ZCG*-*G2]I-2<9U7.<%&$
MHQB4445\\?6!1110 4444 %%%% '-^,O%_AKX?>$/%7CWQGJ]KX?\'^"/#FM
M^+O%>O7HE-GHOAOPWIESK&N:M=B".:<VVG:99W5W,(899C'"PBCD<JAXOX-_
M'/X3?M _#'0OC+\'O&^E>-OAIXCM[^YTKQ39QWVG6S)I5W<V&J17]CK=IIFK
M:-=Z;>6=S!?V.LV%A>V;PM]HMXU*D_"/_!9[XE#X9?\ !-O]I.^AG\G4?%^@
M^'?AKIL8;8UT?'WB_0O#VM0*<@G;X6N]?N749WQV[H1AB1_-+\-?VCOCQ_P2
M>^"7QG_9E^)FB^(]8\'_ +8/[*OA_P"+/[/GB32(L6/@7XG?%OX;Z5IFOW*'
M4KS3X([?P_\ VQ?Z1XN2P?4M0M?$O@3PEJ%MHTNE>);JZ;[K(.#99_DM3&8;
M$.&9RS183!X.<H1ABL)0IX6685::E%2E5PT<;1KZ5$G1HUXJG*=G'\QXI\1(
M<*\24<NQF$4\EADKQV89A3A5G5P..Q57&PRJC5Y)2C"AC)9=7PUY47)8C$8:
M3JTZ=XU/U]_X(H0R_'[]H#_@HA^WMJ44EQ;_ !9^-$_PX^'5]*CJ;3PCI=[<
M>++W2UEE!>:.#PY?_">R3:8Q%_8["1&,B+!;_P""LG[-WC[]G/XD:%_P5E_9
M-N8- ^*'PHET:+]H?PJ9YX=(^)W@%Y--\,+JVI64<BKJ 336T_PQXPTY3&UU
MX>BTKQ/ITEAKWA,WM_\ =7_!(+X&3? +_@GO^SWX:U/3IM-\2^,?#EU\6/%,
M%W;O:WW]I_$N_G\3Z;#?VLB)-;7NF^%+SPYHMQ;SHMQ"VF>7.B2JZ+]J?'OX
M6Z?\</@A\7O@YJ@B%C\4?AKXU\!2RS E+5_%/AW4-&M[Y6 +1S:?<W<-[;S1
MCS8)[>.:(B1%(TQO$$<'QKB\70<9Y72K0R.MAYI5,/BLBPD*66U</.G\,Z5;
M#8?VT5;W:O)524XHRRSA.68>'& P&*4X9W6PT^),/C(/V6+P7$V.J5LXHXNG
M5^*G6P^,Q7L)M/WJ"J4)-TYN]7]GCXT:#^T7\"_A-\=/#-I+IVC?%7P'X<\:
M6VDW%S'>76ASZSIT-QJ/A^\NX8X8;J]T#4C>:->7$,4<4UU8S21(J,JC5^,_
MQG^&/[/7PS\5?&+XR>*[3P1\-O!5M97?B7Q->66JZE%IT6IZK8:'IR)IVAV&
MJ:QJ%UJ&L:GI^FV5CIFG7E[=7EY!!!;R.X%?D#_P;\_%+4/%/[#^H_"'Q%Y]
MKXJ_9R^+_CSX=7VDWK!KZPTG6;V/QS8B?YG*QQ:YXC\4Z-#&S$P_V')!&%MX
MH!6#_P '#7C34+3]C?X>_![P_NN/$GQX_:!\">$K73$8JU_IFAV6M>(G "Y9
M]OBFU\&P"/8PW72R9#1HK\/^K<)<:OAN4IT\*\XEAG4A*/M(Y<JCK>VA.:G'
MG^H+VL9SC.*=I24E=/T_]<*L/#>/&,84JV-7#]/&*C4A)49YNZ4<.\/4ITW3
MFZ?]J-T9TZ<J<W%.$)0DTU\T?\%:/^"J_P"QA^T9^PE\5?@_^SO\;X/'7CGQ
MIX@^&EA=Z%_P@WQ/\'W?_"/:5XYTCQ?J5[;W/CGP7X8M+N&)_"]M:WD-C=3S
MB*\5)H?(F;=_09^RYX%'PP_9H_9Z^'!A^SOX#^"/PK\(SQ;=K"Z\/>!]#TJ[
M:4'DS27-K++.[9=YG=W)=F)^9KG_ ()3_P#!/[7/"7@7PUXI_94^#5_=>"=+
M\/V@UWP_X4@\":QK^H:'96=N^I>)]3\"R>&]0\5/J<]H;K4X?$MQJMOJ<D]P
M-0AN5N)Q)^AX      & !P !T '8"LLZS/)9Y3@<GR*EF=/#X?,<?F&)GF<\
M+4J5:V(HX/#472J86%*,HQI8:;DIT*<H<\8J5362UX<R7B2GGV9\0\3U\EJX
MO%Y3E>58.GDU/&T:5##X7$8_&8F-:GC:F(E&<J^+@HNGB:L:G)*3C2]V+***
M*^4/NPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /YZ/AS_Q2?\ P<9?'O\ Y9?\+-_9.T;V^T?8/"WP7_[ZV_\ "O?P\C_9
MK^A>OYZ/BI_Q2?\ P<8?LV-_JT^)?[*&NHS=%F:Q\+_'H!2>A8-X#B 4\Y6,
M8^9<_J5XH_;R^ 'A+]L;P!^PUJ.H^(;CXW?$/PQ?>)[!M/TNRN/!^A+;:+K?
MB.RT+Q/K<FK07NF^(M<T/P_J&I:/I]MH]_#+;OIWVV[L9-7TN.\^VXCP>*QS
MX?GA:%7$.'!66XNM[*#E[+#9>L5AJ]>I;X:=*.&]Z3LEI'=I/\WX0Q^"RQ<6
M4\=BJ.%C/Q'SC X=UIQ@JV,S:6!QF&PU*_Q5:\\;[D%=N\I/1-K[-HHHKXD_
M2 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ[6[^.FH_M[?"3
MQWX^^$_C?PKXP\2>#/VIO!_PXTO7?$GPGU3X;^%_AUX<_P"%=GP5?NO@WXH:
MSXAO+[6=0N7\6_%#4Y]%M/$*R^*=!\'>&[#6](\#IJB?L)10!^.7[ '_  KG
M_A.O@+_PJC[+_P )/_PQGXJ_X;4_LO;_ &K_ ,-*_P#"=?!'^QO^%U[?])_X
M6_\ \)'_ ,-*>7_;?_$U_L;[?]A_XI;_ (1ZOV-HHH YM]<U-'=5\'>))55F
M59$NO" 20*2 Z"3Q5'(%<#<HDC1P"-Z*V5#?[>U7_H2O$W_@7X-_^:VNFHH
MYG^WM5_Z$KQ-_P"!?@W_ .:VC^WM5_Z$KQ-_X%^#?_FMKIJ* .9_M[5?^A*\
M3?\ @7X-_P#FMH_M[5?^A*\3?^!?@W_YK:Z:B@#F?[>U7_H2O$W_ (%^#?\
MYK:/[>U7_H2O$W_@7X-_^:VNFHH YG^WM5_Z$KQ-_P"!?@W_ .:VC^WM5_Z$
MKQ-_X%^#?_FMKIJ* .9_M[5?^A*\3?\ @7X-_P#FMH_M[5?^A*\3?^!?@W_Y
MK:Z:B@#F?[>U7_H2O$W_ (%^#?\ YK:/[>U7_H2O$W_@7X-_^:VNFHH YG^W
MM5_Z$KQ-_P"!?@W_ .:VC^WM5_Z$KQ-_X%^#?_FMKIJ* .9_M[5?^A*\3?\
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M\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6UTU%24<S_ &]JO_0E>)O_  +\&_\
MS6T?V]JO_0E>)O\ P+\&_P#S6UTU% ',_P!O:K_T)7B;_P "_!O_ ,UM']O:
MK_T)7B;_ ,"_!O\ \UM=-10!_.O_ ,' 'B76_'?PL_9+_9CT[1];T76OC]^T
MYX?MK..>?0);C5+?0=.?PM]AMH].UO4E;;KOQ-\.79%TMO%]IM[,><%,BG]\
M]+NY]&TS3M'TWP%XCM=-TFQM--T^UCNO!OEVUE86\=K:6\8/BTX2&"*.-/15
M%?@=^V#<Q_M$?\%Q_P!@WX'Z4'U?2_V:?"=_\9_&QB DM_"^O,-2\?6(OE))
MAEG_ .$.^%?ER!,&;Q'I"AOO-'_1-7UV?+ZKD/".7/2H\#C\XJQ6FN:XZ4*#
MDN[PF!H2C?7EDFO=DK_ \+VQO%/'V;+WJ2S/*^'Z$GJDLDRRG4Q4(OM''9EB
M8RMISP<7[T7;F?[>U7_H2O$W_@7X-_\ FMH_M[5?^A*\3?\ @7X-_P#FMKIJ
M*^1/OC^:W]COQ4O[&?\ P6+_ &SOV</%&AZSX=\.?M?O8_&?X0Z9<SZ!;6VL
M:_<7>O>-H[+29KK7H-'AA?\ X2?XF^'[9+/4'-QJ7@Z+1(H9+B.SA3<_X*4Z
ME>_'/_@JC_P2Y_9R/A[5WB\$:[J7QZUSPW)-H$MQJVFV?B&+Q+)YXM=<N-/%
MNFD_ S7H2+Z^M&2VN[XJ LZL_P!A_P#!6G]AGX@?M3?#OX=?%K]FY4TW]KC]
MG#Q=IWC'X0ZK;:KH_AO4=;LEU.POM2\,KX@UJ2STFUO['4M/TSQ3X7N-=U"W
MTFSU33+ZPEFM(/$6H7(^6/V)?V:/^"A7Q(_X*/WW[;W[?'P:\$?">7PK\";S
MP#X*M_!?BSP;K6DW'B"9K+0;.'2]%T#XF?$W5M.#^']5\;:GK5]J6J6EHVHZ
ME%!IMN(KJ2"S_5<)C<MQ$%Q=+,,%0S/"\-8[+<3@*^*I4\=6SFAEJRG XS#8
M>3C5Q%+%X2M3JSE3A)4:U&M%RT3C^&XW+<WP=27 4,IS/%9-CN,LKSG!9KAL
M#7JY9A^'L3G']NYGE^-Q=.,J&$KX''X>K1I0JSBZ^'Q&'FHW;4OWT_M[5?\
MH2O$W_@7X-_^:VC^WM5_Z$KQ-_X%^#?_ )K:Z:BORH_<CF?[>U7_ *$KQ-_X
M%^#?_FMH_M[5?^A*\3?^!?@W_P":VNFHH YG^WM5_P"A*\3?^!?@W_YK:/[>
MU7_H2O$W_@7X-_\ FMKIJ* .9_M[5?\ H2O$W_@7X-_^:VC^WM5_Z$KQ-_X%
M^#?_ )K:Z:B@#F?[>U7_ *$KQ-_X%^#?_FMH_M[5?^A*\3?^!?@W_P":VNFH
MH YG^WM5_P"A*\3?^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMKIJ* .9_M[5?\
MH2O$W_@7X-_^:VC^WM5_Z$KQ-_X%^#?_ )K:Z:B@#F?[>U7_ *$KQ-_X%^#?
M_FMH_M[5?^A*\3?^!?@W_P":VNFHH YG^WM5_P"A*\3?^!?@W_YK:/[>U7_H
M2O$W_@7X-_\ FMKIJ* .9_M[5?\ H2O$W_@7X-_^:VC^WM5_Z$KQ-_X%^#?_
M )K:Z:B@#F?[>U7_ *$KQ-_X%^#?_FMH_M[5?^A*\3?^!?@W_P":VNFHH YG
M^WM5_P"A*\3?^!?@W_YK:/[>U7_H2O$W_@7X-_\ FMKIJ* .9_M[5?\ H2O$
MW_@7X-_^:VC^WM5_Z$KQ-_X%^#?_ )K:Z:B@#^9+_@IM\6]'_9Z_X*R_L(_M
M*>-='UK1O#7@KX+?$A]>1WT.74+W1O#>G_%2;4(-.%CK%[;37,EOXPDM[>UE
MN(I[BXN(X8(99)HU?\AO#5[\;])^.?[)W_!6_P"+@U&VM?VA?VX-2:XMF:U2
MRB\ :'K?A?28[31[J>>VN8;$Z#%\0_!&CIJ%M#91Z+X.TJZCN9HY[A5_:C_@
MNS^Q9\<?VMOBQ^PYIGP8\">)?$EM?ZS\1_A_X[\8:/HM[JF@?#33?$.J_#6?
M3/$OC>[M0L6C^'X;%/%5\]Y>SV]O<?V1/I\4QU"\L;:Z]-_X+5_LT^%_"G_!
M*#3?!OP^TH67AS]E77O@MJOA6WA2,7MMHNCRK\))+J22".-Y[R6R\<R:KK-V
M%$EU<I=:I=%I%DE'[AD6<Y;0R_@S!J5&KC\^P]7AW,=83GA<J6/S2A3I25^:
MC+%XO'X>JN:W/3PB:5FF_P":>*.'LXQ.;>(F8.%>CE?"^*P_%N4VC4I4\;GD
MLKR/%5:\)64*\,!E^5XJA+EO[.KCI*_,FE^Y?]O:K_T)7B;_ ,"_!O\ \UM:
MNG7MS>I(USI&HZ0R,%6/49=)E>8$9+QG2=4U2,*I^4B:2)\_=1E^:OQ2^.'_
M  65^&?P3_9]_9YE\&:%J/Q\_:M^/OP9^&?C+PA\&/"*76H7>GZQX[\(:;J%
MG?>.WTF"[U&S276+F6*S\*Z3:W/BWQ'+&(;*UTW3KG^W[7Z0_P""8G[?5S^W
M7\)/%UUX[\*V7P[^/WP<\62^"?C7\/=.M-7L+#1M3N9]2_L'5]-L-=N;_5M,
ML=632=8TR?2-6U&\U32M?\.:]9W,LEO'97-S^7XGA?.\)EM7-L1@ITL#1Q'U
M>52<HQF[U94%75%M5OJKKQ5&.(<%2E5G"$92;T_;,'QKPWC\XH9#A,RIULSK
MX1XN%&G&<J:2HPQ+PTL3&+P_UV.&F\3+"*HZ\*$)U)PC%*_Z74445\^?5!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;[+9NLNH:;I_AH?%/6!Y4D1NK:U\J":,2RRQ_3G_  2,_;,\<:W8_$#]@_\
M:ON5T+]J+]DK[3X=DO->U-I;WXA_#7P](MC!KS:E?./[9O\ PG;-IL-YKBR;
M?$7A'4O"WBM9+Z:YUS4!^6/_  0Q\$?%CXN_MS^(?&?QP6_GU;]A7X #]G_1
MK75(LZAX/U?^W=<\"^&O"ERV^2*)M"\,0_$_156(J?+MD0;PL\DG[.?M]_\
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M%[K]W;PZS%!=7EOX8\5I)XJ\07%[$;HZV/!7A&YGU*R\*ZG#'XF R#(:<_\
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MUM']O:K_ -"5XF_\"_!O_P UM '345S/]O:K_P!"5XF_\"_!O_S6T?V]JO\
MT)7B;_P+\&__ #6T =-17,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP
M;_\ -;0!TU%<S_;VJ_\ 0E>)O_ OP;_\UM']O:K_ -"5XF_\"_!O_P UM '3
M45S/]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6T =-17,_V]JO_
M $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;0!TU%<S_;VJ_\ 0E>)O_ O
MP;_\UM']O:K_ -"5XF_\"_!O_P UM '345S/]O:K_P!"5XF_\"_!O_S6T?V]
MJO\ T)7B;_P+\&__ #6T =-17,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O
M_ OP;_\ -;0!TU%<S_;VJ_\ 0E>)O_ OP;_\UM']O:K_ -"5XF_\"_!O_P U
MM '345S/]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6T =-17,_V
M]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;0!TU%<S_;VJ_\ 0E>)
MO_ OP;_\UM']O:K_ -"5XF_\"_!O_P UM '345S/]O:K_P!"5XF_\"_!O_S6
MT?V]JO\ T)7B;_P+\&__ #6T =-17,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0
ME>)O_ OP;_\ -;0!TU%<S_;VJ_\ 0E>)O_ OP;_\UM']O:K_ -"5XF_\"_!O
M_P UM '345S/]O:K_P!"5XF_\"_!O_S6T?V]JO\ T)7B;_P+\&__ #6T =-1
M7,_V]JO_ $)7B;_P+\&__-;1_;VJ_P#0E>)O_ OP;_\ -;0!TU%<S_;VJ_\
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MEBDKRG*4I.UY2DY.[;9TU%<S_;VJ_P#0E>)O_ OP;_\ -;1_;VJ_]"5XF_\
M OP;_P#-;4EG345S/]O:K_T)7B;_ ,"_!O\ \UM']O:K_P!"5XF_\"_!O_S6
MT =-17,_V]JO_0E>)O\ P+\&_P#S6T?V]JO_ $)7B;_P+\&__-;0!TU%<S_;
MVJ_]"5XF_P# OP;_ /-;1_;VJ_\ 0E>)O_ OP;_\UM '345S/]O:K_T)7B;_
M ,"_!O\ \UM']O:K_P!"5XF_\"_!O_S6T =-17,_V]JO_0E>)O\ P+\&_P#S
M6T?V]JO_ $)7B;_P+\&__-;0!TU%<S_;VJ_]"5XF_P# OP;_ /-;1_;VJ_\
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MK_T)7B;_ ,"_!O\ \UM']O:K_P!"5XF_\"_!O_S6T =-17,_V]JO_0E>)O\
MP+\&_P#S6T?V]JO_ $)7B;_P+\&__-;0!TU%<S_;VJ_]"5XF_P# OP;_ /-;
M1_;VJ_\ 0E>)O_ OP;_\UM '345S/]O:K_T)7B;_ ,"_!O\ \UM']O:K_P!"
M5XF_\"_!O_S6T =-17,_V]JO_0E>)O\ P+\&_P#S6UJZ=>W-ZDC7.D:CI#(P
M58]1ETF5Y@1DO&=)U35(PJGY2)I(GS]U&7YJ -&BBB@ HHHH **** "BBB@
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M);I7_/IXF_\ "*\9?_*&NFHH YG_ (2W2O\ GT\3?^$5XR_^4-'_  ENE?\
M/IXF_P#"*\9?_*&NFHH YG_A+=*_Y]/$W_A%>,O_ )0T?\);I7_/IXF_\(KQ
ME_\ *&NFHH YG_A+=*_Y]/$W_A%>,O\ Y0T?\);I7_/IXF_\(KQE_P#*&NFH
MH YG_A+=*_Y]/$W_ (17C+_Y0T?\);I7_/IXF_\ "*\9?_*&NFHH YG_ (2W
M2O\ GT\3?^$5XR_^4-'_  ENE?\ /IXF_P#"*\9?_*&NFHH YG_A+=*_Y]/$
MW_A%>,O_ )0T?\);I7_/IXF_\(KQE_\ *&NFHH YG_A+=*_Y]/$W_A%>,O\
MY0T?\);I7_/IXF_\(KQE_P#*&NFHH YG_A+=*_Y]/$W_ (17C+_Y0T?\);I7
M_/IXF_\ "*\9?_*&NFHH YG_ (2W2O\ GT\3?^$5XR_^4-'_  ENE?\ /IXF
M_P#"*\9?_*&NFHH YG_A+=*_Y]/$W_A%>,O_ )0T?\);I7_/IXF_\(KQE_\
M*&NFHH YG_A+=*_Y]/$W_A%>,O\ Y0T?\);I7_/IXF_\(KQE_P#*&NFHH YG
M_A+=*_Y]/$W_ (17C+_Y0T?\);I7_/IXF_\ "*\9?_*&NFHH YG_ (2W2O\
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M7_/IXF_\(KQE_P#*&NFHH YG_A+=*_Y]/$W_ (17C+_Y0T?\);I7_/IXF_\
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MNFHH YG_ (2W2O\ GT\3?^$5XR_^4-'_  ENE?\ /IXF_P#"*\9?_*&NFHH
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MY\!:7\1]*T.;QOXJ\':=J\A\(:7XDETO4C9:?K:-ZA\6/C)HOQ<\(_'SP%\
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MQ8:CX,\90W6C^$O&&HZ>UT-#TSQ1)%?-IU[?:2UT <_XX^*NC_'_ %*+X/\
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MWPMIFD7FJ:;9%_%%B >R?LI?&+XG3>.+_P#9]^)MYX1\;WN@^!=;^(NA^/\
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M'XEZ5?Z;J5IXH@\8>'9?"MN_C:?0="\8_KQ#,EQ#%/&)52:*.9%FAFMIE21
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MX;N8-,^'WQ7\-K8_&'X3:;9V=Q\-OBI?6MMIY\%?$*VM[2>U'A3QSX?AL;6
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MLM+L]7U<W,=UI]AJ&HZ>+_2]+\07<=U##I%W+'D_%[]H?X8?#2^'P_U+XG^
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MK:VM[.W@M+2"&UM+6&*VMK:VB2"WMK>!%BA@@AB58X888U6.**-52-%5$4*
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MBY:&;7/$6JZGJ]U&LS(+J]F9?O'/245\U_&S]H'P/X,DU3X4:+\7?ACX)_:
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M^"O@>ZT'0[7X@#XOQWGPT\+_ !*^)=SXC_:ML?C7X;T[QGXQOOB!XQ>QNV\
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MWVEVU_\ VG;?-O@37?BKXO\ CGX"U+Q1X.M?!_[0WP@MKSX;?M!Z/82W-O\
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M7'B :=J4 !])?#7XO^)/%OBKPS\'_P!N#X0^#_!?COQ7JVO>-_@-=SP6FO>
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M\26^EZIIL,VJ?>\<:1(D42)'%&BQQQQJ$2-$ 5$1% 5450%55 "@   "GT4
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MQN;.];P+X1\:2:-:?V59R:ZNO^(8],\*BTT30;+Q!;>%],DGT_1;>1OM"B@
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M/I5]+INJZ6VIZ9=_3%% 'QS^RY\'-?\ ".B_% ^.OAQX7^''A;QG\8(?B=X
M^!MEJ^E>/=%^%EW%H_A2ZU?4M,U>WTNQT?3[OQ#\3](UWXCZ?HN@VC:=X6U3
M4QJ>EWEOJ&H75CI?V-110 5YC\9_A9HOQM^%?CGX4^(;W4=+TOQOH%UHTFK:
M1(D6JZ-=LT=SIFMZ:TJ20&^T;5+>SU2TCN8I;6:>T2&ZAFMWEC;TZB@#\YO
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M_P 1*G["W_1*/VLO_"%^#_\ \_>OH/\ 43B__H08_P#\ A_\L/E?^(G\ ?\
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MW\,^/+CXG^)O!FK?'+PO\'X?&FC^*Y?'MIX4T#Q/H+>-]#O)/#M[X3UW2O%
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M9]8U[PI\3/V;YO"/CC6O%6@6WB+X0Z;IFE6?AFW\-^-9- U/3O'?AJZ\-:%
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MT[7K'0?'/B[P9X*\5_%.&^N$*:7J\_PYUO4_B)'JT"V_]F7DXU+36LC;VKP
M'Z]45^?.K?LG_LD? GQ!\"?'G@<67[/WB^S^*7@[PMH?C+P;->KX@^-M]XF&
MLVR?#'XEZFYU&Y^)5MXY6]O+BYUCQ@VK:MILUA:ZKI^LZ9_9T4T7"_#S]KSX
M]:[X8_9L^/?B?2_A$WP0_:@^*^A?#KP]\.]!T'QE:?%?X>:9\0+K7K3X>^(-
M:^(%_P"--1\+^-M1CETBV;QOX<LOAEX*&B17MV]CK.H?V1.+@ _4"BOR%\.?
MM<?MC>)/!?[.OQ%M;3]FB+2/VC_CKXS^ 'A_PQ<>%/BE%J/A74M#L_B]<:3\
M1-8\4Q_$.YMM5L6?X0ZP-1^'EEX4LIYUO=,6V^(UJ;JZ?2]G1OVMOVI=>^)?
MASX!V,7P!C^(C_M,?'+X!^)_B%=^"OB(G@N30_AC\$_ /QNT3QSH/P]A^)TV
MN0:K=:)XW72M4\&ZA\1;FSNM5LV2T\9:;:$7D@!^L-%?EGX3_:__ &@/'WC#
MPS^SSHVG_!_P]\<!\8_VB?AIXT^)^K>%/'FM?"?^P_V>=#^&WB&_\2>$_ADG
MCGPSXHO-5\86GQ@\&V5GX=NOBY+::!<Z5XMN)?$6N+8QVL>[J'[6'[0UQ\$-
M?U7PUX!\(ZU\8OA[^U!K'[.7Q%NO"_A?Q+X\\,KI?ADS7VM_$_P#\)X?'7A#
MQUXV<Z+/H\R_#33?'S^(;"\GUI1K.K6_A^YEN #]+Z*_%S7OVE?B5\4X/@-J
M&DZQ\,XOB9-KG[97@B/QYI_A7X^>%K#PM?\ P\^#%WXDAO-4^!.O?$OP!KWA
M;QG>645K9ZMX-^)NH>,[SP7<SQZKX9UI)KA;RYT/!O[6'Q]^'G[/'[ 7AS7_
M !/I'C7XD_M*?!FS^(5Q\4K?]F_]H'XWWGAGP3X0^$OPPUNYM?%7PJ^$?COQ
M+\0_B?\ $G7-=\>:8FM_$6W\3_#WPK<?\3?6[GPKI,@M]-N0#]DZ*^(-*^*/
MC?XO?L4_&'Q;\1O ^L^ O%\/@#X^^&]2T[5_!7CCX>0:Y;>&;/Q?HVB^-_#_
M (/^)=AI?C[0O#?CC0K33/%&DZ7XMTZUUO3(]3DTR\^U/9?;KKXR^%G[2'[3
M6D?!#Q-I?PLB^!-AX2_9._8H_9D^*<@^('ACX@>(/$7CTZ]\ /\ A,]2\'I<
M^'/'?A?3/"P>V\):LEEXQ:S\1?89[G3K.?P7JD?VG4HP#]K**_(#XT_M"?';
MX^_"O]LJR^&%K\)/"/PP^%O[-NG7/BG1O'NB>,=?\?>-KOXO?LXV_P 6]8M?
M#_BG0/%FA:#X%M/#/A#QA96&EZI?^"/B$GB'Q/97UG/9Z+9(]W!?O_VK_B-X
M 3]G[X#_  UL8-,O+/\ 8X^%?QBUSQ5??LV?M(?M.PZFVNQR>#_"_@RU\,_L
MY+:ZKX(CFN/".O7NM>.?$UYJEI;17&E6VD^%=8NA=( #]<**_*3PS^W!\===
M^*7P4^"NO?#[P5\-O'_[0>@_"[XB^';;QSI'B73+GX4^$9_#/BC5/C)\/_BC
MX3U#Q9HWB>X^*_\ ;'@+7K+X+K:P^'+'Q?I&LMK&KZ'8-\-_&-E?_0?[1ER/
M$7[27[$?PJU0"?PIJ_CGXI_%_5].9 8=6UWX'^ HKWP#!=N'21;?0_&7C+2O
M'%JB95M>\(Z)),&AA>*0 ^V**_%_]G#]GGX"_M%?L=W'[27[1FFVEQ\;O'UE
M\5/'?Q(^/5]JMT_Q*^#7B30O$WCFTN8/ /BRQN$U#X;:?\(K6T_LW3?#'A)M
M'T2 >';8:GI%Y+&X;KOA)\/?AC^UA^T?\=+#X\#3_P!HOP=\&_A=^R_I'P.L
MOB1:VFJ^&=;\&?$OX.?\)CXB^,\WP]N+6UT&;Q;\0/%.I:M:2^*-3T%]5T@^
M&;;3]#N-)2Q6WA /URHK^=SXL>!CXK\,?%?]D[1_$GBFT^"7@C_@IM^S=\-O
M@_XSLM<U:^UOX=MX^\#^%?%GB_P3X1UO4;ZYO$3X,^/?$ES<^&[6>\F;1Y+Z
M#2V<:9:V=G;][\4M3_:<^+/C#]DCQ#^T#X6USX:V'[/?[7W[/7PPNM.:)],T
M'X[?&Z^\<3V/BKXW^';.-H8;GX:6O@K3]+?X<2I;-;#4OB7X[TIYS?>%&CB
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M+.]\;7C,TBW*+" ?<-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ6I1WEPMY?U]4T44 %%%% !1110 5PWC;X;>"_B++X+F\9:+_;$GP\\<Z/\
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MB2'Q%\9OB]\9/&GP]^'WABPT.#2?@1X'\8?$GP/!XF^)FG^)KNU\4IXH\?\
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M)^QQ^S9X;\,WWA'0/AC::/HU_P"(_AYXM#:=XB\8VNM:7X@^$]IHVG_#B_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>sln-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-02-27T11:19:49.2231+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://silence-therapeutics.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:sln="http://silence-therapeutics.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails2" id="DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails2">
        <link:definition>100020 - Disclosure - Leases - Summarizes of Maturities of Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails2" id="DisclosureSegmentReportingSummaryOfSegmentInformationDetails2">
        <link:definition>100030 - Disclosure - Segment Reporting - Summary of Segment Information (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss" id="StatementConsolidatedStatementsOfIncomeLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>100070 - Statement - Consolidated statements of Changes in Shareholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation" id="DisclosureGeneralInformation">
        <link:definition>995467 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" id="DisclosureSummaryOfSignificantAccountingPolicies1">
        <link:definition>995477 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>995487 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3" id="DisclosureSegmentReporting3">
        <link:definition>995497 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts" id="DisclosureDirectorsAndStaffCosts">
        <link:definition>995507 - Disclosure - Directors and Staff Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1" id="DisclosureOtherIncomeexpenseNet1">
        <link:definition>995517 - Disclosure - Other Income/(Expense), Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted" id="DisclosureLossPerShareBasicAndDiluted">
        <link:definition>995527 - Disclosure - Loss Per Share (Basic and Diluted)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipment">
        <link:definition>995537 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill" id="DisclosureGoodwill">
        <link:definition>995547 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets" id="DisclosureOtherIntangibleAssets">
        <link:definition>995557 - Disclosure - Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents" id="DisclosureCashAndCashEquivalents">
        <link:definition>995567 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets" id="DisclosureOtherAssets">
        <link:definition>995577 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1" id="DisclosureTradeReceivables1">
        <link:definition>995587 - Disclosure - Trade Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables" id="DisclosureTradeAndOtherPayables">
        <link:definition>995597 - Disclosure - Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995607 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities" id="DisclosureContractLiabilities">
        <link:definition>995617 - Disclosure - Contract Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1" id="DisclosureIncomeTaxes1">
        <link:definition>995627 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1" id="DisclosureShareholdersEquity1">
        <link:definition>995637 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation" id="DisclosureEquitysettledSharebasedCompensation">
        <link:definition>995647 - Disclosure - Equity-Settled Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities" id="DisclosureCapitalCommitmentsAndContingentLiabilities">
        <link:definition>995657 - Disclosure - Capital Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases" id="DisclosureCommitmentsUnderShortLeases">
        <link:definition>995667 - Disclosure - Commitments Under Short Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement" id="DisclosureFinancialInstrumentsAndRiskManagement">
        <link:definition>995677 - Disclosure - Financial Instruments and Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>995687 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995697 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995707 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>995717 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995727 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables" id="DisclosureDirectorsAndStaffCostsTables">
        <link:definition>995737 - Disclosure - Directors and Staff Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables" id="DisclosureOtherIncomeexpenseNetTables">
        <link:definition>995747 - Disclosure - Other Income/(Expense), Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables" id="DisclosureLossPerShareBasicAndDilutedTables">
        <link:definition>995757 - Disclosure - Loss Per Share (Basic and Diluted) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" id="DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>995767 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables" id="DisclosureGoodwillTables">
        <link:definition>995777 - Disclosure - Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables" id="DisclosureOtherIntangibleAssetsTables">
        <link:definition>995787 - Disclosure - Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" id="DisclosureCashAndCashEquivalentsTables">
        <link:definition>995797 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables" id="DisclosureOtherAssetsTables">
        <link:definition>995807 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables" id="DisclosureTradeReceivablesTables">
        <link:definition>995817 - Disclosure - Trade Receivables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables" id="DisclosureTradeAndOtherPayablesTables">
        <link:definition>995827 - Disclosure - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995837 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables" id="DisclosureContractLiabilitiesTables">
        <link:definition>995847 - Disclosure - Contract Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995857 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables" id="DisclosureShareholdersEquityTables">
        <link:definition>995867 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables" id="DisclosureEquitysettledSharebasedCompensationTables">
        <link:definition>995877 - Disclosure - Equity-Settled Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>995887 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" id="DisclosureRevenueAdditionalInformationDetails">
        <link:definition>995897 - Disclosure - Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails" id="DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails">
        <link:definition>995907 - Disclosure - Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>995917 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails" id="DisclosureSegmentReportingSummaryOfSegmentInformationDetails">
        <link:definition>995927 - Disclosure - Segment Reporting - Summary of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails" id="DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails">
        <link:definition>995937 - Disclosure - Segment Reporting - Summary of Group's Assets and Revenues by Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails" id="DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails">
        <link:definition>995947 - Disclosure - Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails" id="DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails">
        <link:definition>995957 - Disclosure - Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails" id="DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails">
        <link:definition>995967 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe" id="DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe">
        <link:definition>995977 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" id="DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>995987 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>995997 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails" id="DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails">
        <link:definition>996007 - Disclosure - Goodwill - Schedule of Change in Carrying Value of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" id="DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails">
        <link:definition>996017 - Disclosure - Other Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails" id="DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails">
        <link:definition>996027 - Disclosure - Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails" id="DisclosureOtherIntangibleAssetsAdditionalInformationDetails">
        <link:definition>996037 - Disclosure - Other Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" id="DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails">
        <link:definition>996047 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" id="DisclosureOtherAssetsScheduleOfOtherAssetsDetails">
        <link:definition>996057 - Disclosure - Other Assets - Schedule of Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails" id="DisclosureOtherAssetsAdditionalInformationDetails">
        <link:definition>996067 - Disclosure - Other Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails" id="DisclosureTradeReceivablesScheduleOfTradeReceivableDetails">
        <link:definition>996077 - Disclosure - Trade receivables - Schedule of Trade Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" id="DisclosureTradeReceivablesAdditionalInformationDetails">
        <link:definition>996087 - Disclosure - Trade Receivables - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" id="DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails">
        <link:definition>996097 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails" id="DisclosureTradeAndOtherPayablesAdditionalInformationDetails">
        <link:definition>996107 - Disclosure - Trade and Other Payables - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="DisclosureLeasesAdditionalInformationDetails">
        <link:definition>996117 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails" id="DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails">
        <link:definition>996127 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails" id="DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails">
        <link:definition>996137 - Disclosure - Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails" id="DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails">
        <link:definition>996147 - Disclosure - Leases - Summary of Components of Total Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails" id="DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails">
        <link:definition>996157 - Disclosure - Leases - Summarizes of Maturities of Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails" id="DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails">
        <link:definition>996167 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails" id="DisclosureContractLiabilitiesAdditionalInformationDetails">
        <link:definition>996177 - Disclosure - Contract Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996187 - Disclosure - Income taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails">
        <link:definition>996197 - Disclosure - Income Taxes - Schedule of Components of Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails">
        <link:definition>996207 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails">
        <link:definition>996217 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails">
        <link:definition>996227 - Disclosure - Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
        <link:definition>996237 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails">
        <link:definition>996247 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails" id="DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails">
        <link:definition>996257 - Disclosure - Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails" id="DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails">
        <link:definition>996267 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails" id="DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails">
        <link:definition>996277 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" id="DisclosureShareholdersEquityAdditionalInformationDetails">
        <link:definition>996287 - Disclosure - Shareholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails" id="DisclosureShareholdersEquityDetailsOfSharesIssuedDetails">
        <link:definition>996297 - Disclosure - Shareholders' Equity - Details of Shares Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails" id="DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails">
        <link:definition>996307 - Disclosure - Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails" id="DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails">
        <link:definition>996317 - Disclosure - Shareholders' Equity - Schedule of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails" id="DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails">
        <link:definition>996327 - Disclosure - Equity-Settled Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails" id="DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails">
        <link:definition>996337 - Disclosure - Equity-Settled Share-Based Compensation - Summary of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails" id="DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails">
        <link:definition>996347 - Disclosure - Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails" id="DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails">
        <link:definition>996357 - Disclosure - Capital Commitments and Contingent Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" id="DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails">
        <link:definition>996367 - Disclosure - Commitments Under Short Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>996377 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sln-20241231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="sln-20241231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="sln-20241231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss" xlink:href="sln-20241231.xsd#StatementConsolidatedStatementsOfIncomeLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="sln-20241231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:href="sln-20241231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="sln-20241231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="sln-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation" xlink:href="sln-20241231.xsd#DisclosureGeneralInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" xlink:href="sln-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue" xlink:href="sln-20241231.xsd#DisclosureRevenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3" xlink:href="sln-20241231.xsd#DisclosureSegmentReporting3" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts" xlink:href="sln-20241231.xsd#DisclosureDirectorsAndStaffCosts" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1" xlink:href="sln-20241231.xsd#DisclosureOtherIncomeexpenseNet1" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted" xlink:href="sln-20241231.xsd#DisclosureLossPerShareBasicAndDiluted" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment" xlink:href="sln-20241231.xsd#DisclosurePropertyPlantAndEquipment" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill" xlink:href="sln-20241231.xsd#DisclosureGoodwill" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets" xlink:href="sln-20241231.xsd#DisclosureOtherIntangibleAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents" xlink:href="sln-20241231.xsd#DisclosureCashAndCashEquivalents" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets" xlink:href="sln-20241231.xsd#DisclosureOtherAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1" xlink:href="sln-20241231.xsd#DisclosureTradeReceivables1" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables" xlink:href="sln-20241231.xsd#DisclosureTradeAndOtherPayables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases" xlink:href="sln-20241231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities" xlink:href="sln-20241231.xsd#DisclosureContractLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxes1" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation" xlink:href="sln-20241231.xsd#DisclosureEquitysettledSharebasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities" xlink:href="sln-20241231.xsd#DisclosureCapitalCommitmentsAndContingentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases" xlink:href="sln-20241231.xsd#DisclosureCommitmentsUnderShortLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement" xlink:href="sln-20241231.xsd#DisclosureFinancialInstrumentsAndRiskManagement" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="sln-20241231.xsd#DisclosureRelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="sln-20241231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sln-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables" xlink:href="sln-20241231.xsd#DisclosureRevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="sln-20241231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables" xlink:href="sln-20241231.xsd#DisclosureDirectorsAndStaffCostsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables" xlink:href="sln-20241231.xsd#DisclosureOtherIncomeexpenseNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables" xlink:href="sln-20241231.xsd#DisclosureLossPerShareBasicAndDilutedTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" xlink:href="sln-20241231.xsd#DisclosurePropertyPlantAndEquipmentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables" xlink:href="sln-20241231.xsd#DisclosureGoodwillTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables" xlink:href="sln-20241231.xsd#DisclosureOtherIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" xlink:href="sln-20241231.xsd#DisclosureCashAndCashEquivalentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables" xlink:href="sln-20241231.xsd#DisclosureOtherAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables" xlink:href="sln-20241231.xsd#DisclosureTradeReceivablesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables" xlink:href="sln-20241231.xsd#DisclosureTradeAndOtherPayablesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:href="sln-20241231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables" xlink:href="sln-20241231.xsd#DisclosureContractLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables" xlink:href="sln-20241231.xsd#DisclosureEquitysettledSharebasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureRevenueAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails" xlink:href="sln-20241231.xsd#DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails" xlink:href="sln-20241231.xsd#DisclosureSegmentReportingSummaryOfSegmentInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails" xlink:href="sln-20241231.xsd#DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails" xlink:href="sln-20241231.xsd#DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails" xlink:href="sln-20241231.xsd#DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails" xlink:href="sln-20241231.xsd#DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe" xlink:href="sln-20241231.xsd#DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="sln-20241231.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails" xlink:href="sln-20241231.xsd#DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:href="sln-20241231.xsd#DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails" xlink:href="sln-20241231.xsd#DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureOtherIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" xlink:href="sln-20241231.xsd#DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:href="sln-20241231.xsd#DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureOtherAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails" xlink:href="sln-20241231.xsd#DisclosureTradeReceivablesScheduleOfTradeReceivableDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureTradeReceivablesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" xlink:href="sln-20241231.xsd#DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureTradeAndOtherPayablesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:href="sln-20241231.xsd#DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails" xlink:href="sln-20241231.xsd#DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails" xlink:href="sln-20241231.xsd#DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails" xlink:href="sln-20241231.xsd#DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails" xlink:href="sln-20241231.xsd#DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureContractLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails" xlink:href="sln-20241231.xsd#DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityDetailsOfSharesIssuedDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails" xlink:href="sln-20241231.xsd#DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails" xlink:href="sln-20241231.xsd#DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails" xlink:href="sln-20241231.xsd#DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="sln-20241231.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails2" xlink:href="sln-20241231.xsd#DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails2" xlink:href="sln-20241231.xsd#DisclosureSegmentReportingSummaryOfSegmentInformationDetails2" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OpenMarketSaleAgreementMember" xlink:label="sln_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThirteenMember" xlink:label="sln_OptionsExercisedThirteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityNetOfTax" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithAstrazenecaMember" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityRestrictions" xlink:label="us-gaap_EquityRestrictions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_InvoiceRaiseDurationAfterQuarterEnd" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SmallOrMediumSizedEnterprisesMember" xlink:label="sln_SmallOrMediumSizedEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesTable" xlink:label="sln_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RedemptionOfTermDeposits" xlink:label="sln_RedemptionOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationAstraZenecaMember" xlink:label="sln_ResearchCollaborationAstraZenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesTable" xlink:label="sln_TradeAndOtherPayablesTable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixteenMember" xlink:label="sln_OptionsExercisedSixteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AccretionOfSecurities" xlink:label="sln_AccretionOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityTextBlock" xlink:label="sln_ContractWithCustomerLiabilityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInTradeAndOtherPayables" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DirectorsAndEmployeeRemunerationTableTextBlock" xlink:label="sln_DirectorsAndEmployeeRemunerationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearElevenMember" xlink:label="sln_OptionsIssuedInYearElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFiveMember" xlink:label="sln_OptionsExercisedFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_BankInterestReceivable" xlink:label="sln_BankInterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityAdditions" xlink:label="sln_ContractWithCustomerLiabilityAdditions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesLineItems" xlink:label="sln_TradeAndOtherPayablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NetForeignExchangeImpacts" xlink:label="sln_NetForeignExchangeImpacts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityRevenueUnwound" xlink:label="sln_ContractWithCustomerLiabilityRevenueUnwound"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_WeightedAverageGrantDataFairValue" xlink:label="sln_WeightedAverageGrantDataFairValue"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentBenefitReceivableCurrent" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="us-gaap_CashAndDueFromBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sln_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityCosts" xlink:label="sln_SocialSecurityCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearThreeMember" xlink:label="sln_OptionsIssuedInYearThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockOptionExercisePrice" xlink:label="sln_StockOptionExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicenseAndSoftwareNetMember" xlink:label="sln_LicenseAndSoftwareNetMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityForeignExchangeImpact" xlink:label="sln_ContractWithCustomerLiabilityForeignExchangeImpact"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock" xlink:label="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AggregateRemuneration" xlink:label="sln_AggregateRemuneration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSixMember" xlink:label="sln_OptionsIssuedInYearSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSeventeenMember" xlink:label="sln_OptionsExercisedSeventeenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTenMember" xlink:label="sln_OptionsExercisedTenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSevenMember" xlink:label="sln_OptionsExercisedSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock" xlink:label="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OperatingLeaseNewTermBeginningPeriod" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromRoyalties" xlink:label="sln_RevenueFromRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedOneMember" xlink:label="sln_OptionsExercisedOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RoyaltyIncomeMember" xlink:label="sln_RoyaltyIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineMember" xlink:label="sln_OptionsExercisedNineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourteenMember" xlink:label="sln_OptionsExercisedFourteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearEightMember" xlink:label="sln_OptionsIssuedInYearEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NonExecutiveChairmanMember" xlink:label="sln_NonExecutiveChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ScheduleOfAccountsReceivableTableTextBlock" xlink:label="sln_ScheduleOfAccountsReceivableTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RegisteredDirectOfferingMember" xlink:label="sln_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityAndOtherTaxesPayableCurrent" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfLeases" xlink:label="sln_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentBenefitReceived" xlink:label="sln_ResearchAndDevelopmentBenefitReceived"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GeneralInformationAbstract" xlink:label="sln_GeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOperatingLease" xlink:label="sln_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PurchaseOfTermDeposits" xlink:label="sln_PurchaseOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesLineItems" xlink:label="sln_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxReconciliationEffectOfOverseasTaxes" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedElevenMember" xlink:label="sln_OptionsExercisedElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GainFromResearchAndDevelopmentCredit" xlink:label="sln_GainFromResearchAndDevelopmentCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithMallinckrodtMember" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSevenMember" xlink:label="sln_OptionsIssuedInYearSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwoMember" xlink:label="sln_OptionsExercisedTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsTable" xlink:label="sln_OtherAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixMember" xlink:label="sln_OptionsExercisedSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThreeMember" xlink:label="sln_OptionsExercisedThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfShortTermLeases" xlink:label="sln_NumberOfShortTermLeases"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sln_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsNoncurrent" xlink:label="sln_PrepaymentsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GoingConcernPolicyPolicyTextBlock" xlink:label="sln_GoingConcernPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicensesAndSoftwareMember" xlink:label="sln_LicensesAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PersonnelResearchAndDevelopmentCosts" xlink:label="sln_PersonnelResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates" xlink:label="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AccountsReceivableTextBlock" xlink:label="sln_AccountsReceivableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTwoMember" xlink:label="sln_OptionsIssuedInYearTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentExpenditureCreditMember" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DirectorsAndEmployeeRemunerationTextBlock" xlink:label="sln_DirectorsAndEmployeeRemunerationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_YearOfIssuanceOfStockOption" xlink:label="sln_YearOfIssuanceOfStockOption"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationMallinckrodtPlcMember" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EstimatedEmployerTaxObligationOnOutstandingOptions" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTenMember" xlink:label="sln_OptionsIssuedInYearTenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CurrencyConversionRatePerDollar" xlink:label="sln_CurrencyConversionRatePerDollar"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromContractWithCustomerResearchCollaboration" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFourMember" xlink:label="sln_OptionsIssuedInYearFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwelveMember" xlink:label="sln_OptionsExercisedTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationIncomeMember" xlink:label="sln_ResearchCollaborationIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FurnitureAndEquipmentMember" xlink:label="sln_FurnitureAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentTaxWithholding" xlink:label="sln_MilestonePaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFiveMember" xlink:label="sln_OptionsIssuedInYearFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationHansohMember" xlink:label="sln_ResearchCollaborationHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssets" xlink:label="sln_PrepaymentsAssets"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CapitalCommitments" xlink:label="sln_CapitalCommitments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFifteenMember" xlink:label="sln_OptionsExercisedFifteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_JefferiesLLCMember" xlink:label="sln_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsLineItems" xlink:label="sln_OtherAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearOneMember" xlink:label="sln_OptionsIssuedInYearOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearNineMember" xlink:label="sln_OptionsIssuedInYearNineMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEightMember" xlink:label="sln_OptionsExercisedEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineteenMember" xlink:label="sln_OptionsExercisedNineteenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEighteenMember" xlink:label="sln_OptionsExercisedEighteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PercentageOfRoyaltyOnNetSales" xlink:label="sln_PercentageOfRoyaltyOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock" xlink:label="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockholdersEquityRemainingValue" xlink:label="sln_StockholdersEquityRemainingValue"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_UpfrontPaymentTaxWithholding" xlink:label="sln_UpfrontPaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsCurrent" xlink:label="sln_PrepaymentsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SettlementAndLicenseAgreementWithAlnylamMember" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourMember" xlink:label="sln_OptionsExercisedFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Market Sale Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Open market sale agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OpenMarketSaleAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open Market Sale Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Increase)/decrease in trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit at the standard rate of U.K. corporation tax of 25% (2023: 25%; 2022: 19%)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit at the standard rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credit at the standard rate of U.K. corporation tax of 25% (2023: 25%; 2022: 19%)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThirteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $13.80/ADS or $4.60/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThirteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Thirteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThirteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised thirteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Movements in Deferred Tax Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Net Of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability, net of tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payments received, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With AstraZeneca [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with AstraZeneca</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with AstraZeneca.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityRestrictions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Restrictions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityRestrictions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum value of shares to be sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Invoice raise duration after quarter end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Invoice Raise Duration After Quarter End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Invoice Raise Duration After Quarter End</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SmallOrMediumSizedEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SME scheme</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SmallOrMediumSizedEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Small Or Medium Sized Enterprises [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SmallOrMediumSizedEnterprisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Small or medium sized enterprises.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Exercisable at the year-end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ADS in issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RedemptionOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redemption of term deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RedemptionOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redemption Of Term Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RedemptionOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redemption of term deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration AstraZeneca.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Astra Zeneca [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration - AstraZeneca</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Other Segment Item, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other segment items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease Commitment, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_TradeAndOtherPayablesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Payables [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_TradeAndOtherPayablesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trade and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $19.50/ADS or $6.50/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Sixteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised sixteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Lapsed or forfeited during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income not taxable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income not taxable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccretionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccretionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccretionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion on U.S Treasury Bills</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free rate, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with Customer, Liability,</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(decrease) in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Trade And Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in trade and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standards update [extensible enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deposits Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deposits for properties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hoboken, U. S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase/(decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss per share basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Decrease)/increase in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors And Employee Remuneration [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors And Employee Remuneration [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Staff Costs Including Director's Remuneration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Eleven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year eleven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity settled share-based payment transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payments charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Accumulated losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding at the year end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">USA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $5.81/ADS or $1.94/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash outflows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease contract notice period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant, and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution, Domestic [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionDomesticMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hoboken, U. S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_BankInterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_BankInterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bank interest receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_BankInterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary shares - par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer, liability additions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Contract liabilities, beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Contract liabilities, ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_TradeAndOtherPayablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Payables [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_TradeAndOtherPayablesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trade and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NetForeignExchangeImpacts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Foreign Exchange Impacts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NetForeignExchangeImpacts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net foreign exchange impacts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NetForeignExchangeImpacts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net foreign exchange impacts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityRevenueUnwound_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue unwound during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityRevenueUnwound_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability Revenue unwound</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityRevenueUnwound_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with Customer, Liability revenue unwound</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_WeightedAverageGrantDataFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average grant data fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_WeightedAverageGrantDataFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average grant data fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Benefit Receivable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development benefit receivable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D benefit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax expense related to current tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability - non-current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised in the year, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable at the year-end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General &amp; administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">General and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndDueFromBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Due from Banks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndDueFromBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Due from Banks, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndDueFromBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash at bank and in hand</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Information Related to Operating Lease [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental balance sheet information related to operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Balance Sheet Information Related to Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free rate, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise price, Lapsed or forfeited during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Social security costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Social Security Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Social security costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive (loss)/income for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2016</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockOptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of stock option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockOptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockOptionExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock option, exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss for the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares in issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits, Period Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other pension costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicenseAndSoftwareNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Software, Net [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicenseAndSoftwareNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and software, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicenseAndSoftwareNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Software, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityForeignExchangeImpact_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Foreign Exchange Impact</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityForeignExchangeImpact_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability foreign exchange impact.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ContractWithCustomerLiabilityForeignExchangeImpact_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange impact</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments And Risk Management Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instruments and risk management disclosure.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments and Risk Management</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AggregateRemuneration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Remuneration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AggregateRemuneration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate remuneration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AggregateRemuneration_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total aggregate remuneration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Derecognition Of Recognized Tax Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax derecognition of recognized tax losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of previously unrecognized tax losses (derecognition of previously recognized) deductible temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2019</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Seventeen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised seventeen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSeventeenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $20.41/ADS or $6.80/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Ten [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised ten.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $10.68/ADS or $3.56/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $7.60/ADS or $2.53/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Goods and Services Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Goods and Services Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositaryShareADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Share (ADS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositaryShareADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American depositary share (ADS).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositaryShareADSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Commitments and Contingent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Contingencies and Guarantees [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Disaggregation of Revenue from Contracts with Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes of Maturities of Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term and Weighted Average Discount Rate [Table Text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease weighted-average remaining lease term and weighted average discount rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds of offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease New Term Beginning Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease new term beginning period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease new term beginning period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate fluctuations on cash and cash equivalents held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option life (years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement agent fees and other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of overseas tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effect of overseas tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from royalties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $0.20/ADS or $0.07/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with Hansoh.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Hansoh [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with Hansoh</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Germany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DE_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GERMANY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RoyaltyIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RoyaltyIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RoyaltyIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RoyaltyIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Settled Share-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Trade, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised nine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $9.98/ADS or $3.33/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Period Increase (Decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in maximum value of shares to be sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $15.38/ADS or $5.13/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Fourteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised fourteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised in the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised in the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NonExecutiveChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Iain Ross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NonExecutiveChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Executive Chairman [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NonExecutiveChairmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Executive Chairman.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Components of Total Operating Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ScheduleOfAccountsReceivableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Trade Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ScheduleOfAccountsReceivableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ScheduleOfAccountsReceivableTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Accounts Receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of stock options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other R&amp;D costs (c)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of share options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Goodwill [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Carrying Value of Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Berlin, Germany</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicDistributionForeignMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Distribution, Foreign [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registered Direct Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Registered Direct Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Registered direct offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment &amp; Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Social Security And Other Taxes Payable Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Social security and other taxes payable current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Social security and other taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Fair Value of Options Granted were Calculated Using Black Scholes Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Group's Assets and Revenues by Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment in respect of prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment in respect of prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Taxes and Tax Credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Taxes and Tax Credits, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Income Tax Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-lived intangible assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Effect Of Overseas Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation effect of overseas tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of overseas taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effect of overseas taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income not taxable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income not taxable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inputs and assumptions for options granted in the year:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Benefit Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development benefit received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentBenefitReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D benefit received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">General information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease for office space in London</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate for loss from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Effective tax rate for loss from continuing operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other R&amp;D costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of ADS remained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PurchaseOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Term Deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PurchaseOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of term deposits.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PurchaseOfTermDeposits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of term deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Bills</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Securities, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at start of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Estimate Related To Prior Years Current Tax Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in estimate related to prior years current tax expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in estimate related to prior years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized compensation cost granted but not vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of overseas taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Effect Of Overseas Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation, effect of overseas taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effect of overseas taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Eleven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised eleven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $12.81/ADS or $4.27/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GainFromResearchAndDevelopmentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain From Research And Development Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GainFromResearchAndDevelopmentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain from research and development credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GainFromResearchAndDevelopmentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit from R&amp;D credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Expense Origination And Reversal Of Temporary Differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax expense origination and reversal of temporary differences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Origination and reversal of temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) In Research And Development Benefit Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) R&amp;D benefit receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase in R&amp;D benefit receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Contract Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment in respect of prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment in respect of prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with Mallinckrodt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Mallinckrodt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration Agreement with Mallinckrodt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with Mallinckrodt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearSevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, All Other Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant data fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total liabilities and shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss per share diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $2.40/ADS or $0.80/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OtherAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OtherAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the grants has been calculated using volatility assumption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from shares issued, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period for options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedSixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $7.32/ADS or $2.44/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Trading Symbol Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $4.23/ADS or $1.41/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American Depositary Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American Depositary Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AmericanDepositarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">American Depositary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfShortTermLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Short Term Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfShortTermLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of short-term leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfShortTermLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of short-term leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based payments charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Translation adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GoingConcernPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GoingConcernPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Going concern.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_GoingConcernPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going concern</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicensesAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicensesAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses And Software [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_LicensesAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses and Software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share (Basic and Diluted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PersonnelResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Personnel Research And Development Costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PersonnelResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Personnel Research And Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PersonnelResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Personnel research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PersonnelResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Personnel research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issue of ordinary shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Tax Rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation allowance deferred tax asset change in tax rates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares per ADS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Ordinary Shares For Each American Depositary Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares for each American depositary share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccountsReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccountsReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_AccountsReceivableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, weighted average remaining contractual life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2015</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RDEC scheme</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenditure Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenditure credit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Directors And Employee Remuneration [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Directors and employee remuneration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DirectorsAndEmployeeRemunerationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Directors and Staff Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Options Outstanding Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_YearOfIssuanceOfStockOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of issuance of stock option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_YearOfIssuanceOfStockOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Issuance Of Stock Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_YearOfIssuanceOfStockOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Accumulated Tax Losses Related To Trade Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset, accumulated tax losses related to trade taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated losses related to trade taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shareholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration - Mallinckrodt plc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Mallinckrodt Plc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration - Mallinckrodt plc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated employer tax obligation on outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Employer Tax Obligation on Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated employer tax obligation on outstanding options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated tax losses related to corporate income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Accumulated Tax Losses Related To Corporate Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax asset, accumulated tax losses related to corporate income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options issued in year ten [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year ten</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearTenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected remaining weighted-average period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Increase)/decrease in other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus accrual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Recognition Of Unrecognized Tax Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax recognition of unrecognized tax losses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of previously unrecognized tax losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Salary and Wage, Excluding Cost of Good and Service Sold, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wages and salaries</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CurrencyConversionRatePerDollar_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currency conversion rate per dollar</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CurrencyConversionRatePerDollar_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Currency conversion rate per dollar.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Amounts of Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contracted development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Trade and Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Options Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finite-lived intangible assets, accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at start of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Research Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from contract with customer research collaboration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research collaboration - total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax using U.K. statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.K. tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.K. corporation tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Ordinary Shares Denominated in Temporary Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary shares denominated in temporary equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares in American Depositary Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability - current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2017</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments (net of tax)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign exchange differences arising on consolidation of foreign operations (net of tax)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Other Income/Expense, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income/(expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $12.94/ADS or $4.31/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Twelve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised twelve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of overseas tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Effect of overseas tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise price, Exercised during the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Details of Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders Equity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration income.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Income [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FurnitureAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Furniture And Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease/(increase) in other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Tax Withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment tax withholding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_MilestonePaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment, tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2018</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration Hansoh [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Collaboration Hansoh [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_ResearchCollaborationHansohMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research collaboration - Hansoh</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other long-term assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VAT receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CapitalCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CapitalCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital commitments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_CapitalCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of preparation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares - par value 0.05 per share; 141,644,488 shares issued at December 31, 2024 (2023:118,846,966)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Authorized, allotted, called up and fully paid ordinary shares, par value 0.05</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Ordinary shares - par value &#163;0.05 per share; 141,674,074 shares issued at December 31, 2024 (2023:118,846,966)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFifteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $16.64/ADS or $5.55/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFifteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Fifteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFifteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised fifteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Expected Future Amortization Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_JefferiesLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OtherAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OtherAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Intangible Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2014</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued in year nine.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued In Year Nine [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsIssuedInYearNineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued in 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 20)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of significant accounting policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Eight [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $8.20/ADS or $2.73/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total expected lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options outstanding weighted average years to expiry date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Outstanding Weighted Average Years To Expiry Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average years to expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $23.60/ADS or $7.87/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Nineteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedNineteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised nineteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with customer, asset, cumulative catch-up adjustment to revenue, modification of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss), Foreign Currency Transaction, before Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net foreign exchange impacts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency gain/(loss), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Eighteen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised eighteen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $22.01/ADS or $7.34/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PercentageOfRoyaltyOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PercentageOfRoyaltyOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PercentageOfRoyaltyOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income and Expense [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income/(Expense), Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Functional And Reporting Currency Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Functional and reporting currency.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Functional and reporting currency</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash flow from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise price, Outstanding at the year-end</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding at the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockholdersEquityRemainingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Remaining Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockholdersEquityRemainingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity remaining value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_StockholdersEquityRemainingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of ADS remained</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_UpfrontPaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment tax withholding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_UpfrontPaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Tax Withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_UpfrontPaymentTaxWithholding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment, tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments Under Short Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Valuation allowance at December 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Valuation allowance at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments assets, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_PrepaymentsAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement And License Agreement With Alnylam [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement and license agreement with Alnylam.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement and License Agreement with Alnylam</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Exercised Four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options exercised four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="sln_OptionsExercisedFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised at $4.24/ADS or $1.41/ordinary share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Other, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for expected credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OpenMarketSaleAgreementMember" xlink:to="sln_OpenMarketSaleAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedThirteenMember" xlink:to="sln_OptionsExercisedThirteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ContractWithCustomerLiabilityNetOfTax" xlink:to="sln_ContractWithCustomerLiabilityNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_CollaborationAgreementWithAstrazenecaMember" xlink:to="sln_CollaborationAgreementWithAstrazenecaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityRestrictions" xlink:to="us-gaap_EquityRestrictions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_InvoiceRaiseDurationAfterQuarterEnd" xlink:to="sln_InvoiceRaiseDurationAfterQuarterEnd_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SmallOrMediumSizedEnterprisesMember" xlink:to="sln_SmallOrMediumSizedEnterprisesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_IncomeTaxesTable" xlink:to="sln_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_RedemptionOfTermDeposits" xlink:to="sln_RedemptionOfTermDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchCollaborationAstraZenecaMember" xlink:to="sln_ResearchCollaborationAstraZenecaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_TradeAndOtherPayablesTable" xlink:to="sln_TradeAndOtherPayablesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedSixteenMember" xlink:to="sln_OptionsExercisedSixteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_AccretionOfSecurities" xlink:to="sln_AccretionOfSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ContractWithCustomerLiabilityTextBlock" xlink:to="sln_ContractWithCustomerLiabilityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_IncreaseDecreaseInTradeAndOtherPayables" xlink:to="sln_IncreaseDecreaseInTradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DirectorsAndEmployeeRemunerationTableTextBlock" xlink:to="sln_DirectorsAndEmployeeRemunerationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearElevenMember" xlink:to="sln_OptionsIssuedInYearElevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedFiveMember" xlink:to="sln_OptionsExercisedFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionDomesticMember" xlink:to="us-gaap_GeographicDistributionDomesticMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_BankInterestReceivable" xlink:to="sln_BankInterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ContractWithCustomerLiabilityAdditions" xlink:to="sln_ContractWithCustomerLiabilityAdditions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_TradeAndOtherPayablesLineItems" xlink:to="sln_TradeAndOtherPayablesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NetForeignExchangeImpacts" xlink:to="sln_NetForeignExchangeImpacts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ContractWithCustomerLiabilityRevenueUnwound" xlink:to="sln_ContractWithCustomerLiabilityRevenueUnwound_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_WeightedAverageGrantDataFairValue" xlink:to="sln_WeightedAverageGrantDataFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchAndDevelopmentBenefitReceivableCurrent" xlink:to="sln_ResearchAndDevelopmentBenefitReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndDueFromBanks" xlink:to="us-gaap_CashAndDueFromBanks_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SocialSecurityCosts" xlink:to="sln_SocialSecurityCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearThreeMember" xlink:to="sln_OptionsIssuedInYearThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_StockOptionExercisePrice" xlink:to="sln_StockOptionExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsPeriodExpense" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_LicenseAndSoftwareNetMember" xlink:to="sln_LicenseAndSoftwareNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ContractWithCustomerLiabilityForeignExchangeImpact" xlink:to="sln_ContractWithCustomerLiabilityForeignExchangeImpact_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock" xlink:to="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_AggregateRemuneration" xlink:to="sln_AggregateRemuneration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" xlink:to="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearSixMember" xlink:to="sln_OptionsIssuedInYearSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedSeventeenMember" xlink:to="sln_OptionsExercisedSeventeenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedTenMember" xlink:to="sln_OptionsExercisedTenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedSevenMember" xlink:to="sln_OptionsExercisedSevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_AmericanDepositaryShareADSMember" xlink:to="sln_AmericanDepositaryShareADSMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock" xlink:to="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:to="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OperatingLeaseNewTermBeginningPeriod" xlink:to="sln_OperatingLeaseNewTermBeginningPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_RevenueFromRoyalties" xlink:to="sln_RevenueFromRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedOneMember" xlink:to="sln_OptionsExercisedOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_CollaborationAgreementWithHansohMember" xlink:to="sln_CollaborationAgreementWithHansohMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_RoyaltyIncomeMember" xlink:to="sln_RoyaltyIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedNineMember" xlink:to="sln_OptionsExercisedNineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="us-gaap_StockholdersEquityPeriodIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedFourteenMember" xlink:to="sln_OptionsExercisedFourteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearEightMember" xlink:to="sln_OptionsIssuedInYearEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NonExecutiveChairmanMember" xlink:to="sln_NonExecutiveChairmanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ScheduleOfAccountsReceivableTableTextBlock" xlink:to="sln_ScheduleOfAccountsReceivableTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionForeignMember" xlink:to="us-gaap_GeographicDistributionForeignMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_RegisteredDirectOfferingMember" xlink:to="sln_RegisteredDirectOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SocialSecurityAndOtherTaxesPayableCurrent" xlink:to="sln_SocialSecurityAndOtherTaxesPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NumberOfLeases" xlink:to="sln_NumberOfLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" xlink:to="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchAndDevelopmentBenefitReceived" xlink:to="sln_ResearchAndDevelopmentBenefitReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_GeneralInformationAbstract" xlink:to="sln_GeneralInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NumberOfOperatingLease" xlink:to="sln_NumberOfOperatingLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillDisclosureTextBlock" xlink:to="us-gaap_GoodwillDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PurchaseOfTermDeposits" xlink:to="sln_PurchaseOfTermDeposits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" xlink:to="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_IncomeTaxReconciliationEffectOfOverseasTaxes" xlink:to="sln_IncomeTaxReconciliationEffectOfOverseasTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedElevenMember" xlink:to="sln_OptionsExercisedElevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_GainFromResearchAndDevelopmentCredit" xlink:to="sln_GainFromResearchAndDevelopmentCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" xlink:to="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" xlink:to="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_CollaborationAgreementWithMallinckrodtMember" xlink:to="sln_CollaborationAgreementWithMallinckrodtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearSevenMember" xlink:to="sln_OptionsIssuedInYearSevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedTwoMember" xlink:to="sln_OptionsExercisedTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OtherAssetsTable" xlink:to="sln_OtherAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_MilestonePaymentsReceived" xlink:to="sln_MilestonePaymentsReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedSixMember" xlink:to="sln_OptionsExercisedSixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedThreeMember" xlink:to="sln_OptionsExercisedThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_AmericanDepositarySharesMember" xlink:to="sln_AmericanDepositarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NumberOfShortTermLeases" xlink:to="sln_NumberOfShortTermLeases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sln_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PrepaymentsAssetsNoncurrent" xlink:to="sln_PrepaymentsAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_GoingConcernPolicyPolicyTextBlock" xlink:to="sln_GoingConcernPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_LicensesAndSoftwareMember" xlink:to="sln_LicensesAndSoftwareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PersonnelResearchAndDevelopmentCosts" xlink:to="sln_PersonnelResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates" xlink:to="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" xlink:to="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_AccountsReceivableTextBlock" xlink:to="sln_AccountsReceivableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearTwoMember" xlink:to="sln_OptionsIssuedInYearTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchAndDevelopmentExpenditureCreditMember" xlink:to="sln_ResearchAndDevelopmentExpenditureCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DirectorsAndEmployeeRemunerationTextBlock" xlink:to="sln_DirectorsAndEmployeeRemunerationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_YearOfIssuanceOfStockOption" xlink:to="sln_YearOfIssuanceOfStockOption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" xlink:to="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchCollaborationMallinckrodtPlcMember" xlink:to="sln_ResearchCollaborationMallinckrodtPlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_EstimatedEmployerTaxObligationOnOutstandingOptions" xlink:to="sln_EstimatedEmployerTaxObligationOnOutstandingOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" xlink:to="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearTenMember" xlink:to="sln_OptionsIssuedInYearTenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" xlink:to="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_CurrencyConversionRatePerDollar" xlink:to="sln_CurrencyConversionRatePerDollar_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDevelopment" xlink:to="us-gaap_BusinessDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_RevenueFromContractWithCustomerResearchCollaboration" xlink:to="sln_RevenueFromContractWithCustomerResearchCollaboration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" xlink:to="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearFourMember" xlink:to="sln_OptionsIssuedInYearFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedTwelveMember" xlink:to="sln_OptionsExercisedTwelveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchCollaborationIncomeMember" xlink:to="sln_ResearchCollaborationIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_FurnitureAndEquipmentMember" xlink:to="sln_FurnitureAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_MilestonePaymentTaxWithholding" xlink:to="sln_MilestonePaymentTaxWithholding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearFiveMember" xlink:to="sln_OptionsIssuedInYearFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_ResearchCollaborationHansohMember" xlink:to="sln_ResearchCollaborationHansohMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PrepaymentsAssets" xlink:to="sln_PrepaymentsAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_CapitalCommitments" xlink:to="sln_CapitalCommitments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedFifteenMember" xlink:to="sln_OptionsExercisedFifteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_JefferiesLLCMember" xlink:to="sln_JefferiesLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OtherAssetsLineItems" xlink:to="sln_OtherAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearOneMember" xlink:to="sln_OptionsIssuedInYearOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsIssuedInYearNineMember" xlink:to="sln_OptionsIssuedInYearNineMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedEightMember" xlink:to="sln_OptionsExercisedEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" xlink:to="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedNineteenMember" xlink:to="sln_OptionsExercisedNineteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedEighteenMember" xlink:to="sln_OptionsExercisedEighteenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PercentageOfRoyaltyOnNetSales" xlink:to="sln_PercentageOfRoyaltyOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock" xlink:to="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_StockholdersEquityRemainingValue" xlink:to="sln_StockholdersEquityRemainingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_UpfrontPaymentTaxWithholding" xlink:to="sln_UpfrontPaymentTaxWithholding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_PrepaymentsAssetsCurrent" xlink:to="sln_PrepaymentsAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_SettlementAndLicenseAgreementWithAlnylamMember" xlink:to="sln_SettlementAndLicenseAgreementWithAlnylamMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sln_OptionsExercisedFourMember" xlink:to="sln_OptionsExercisedFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentBenefitReceivableCurrent" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="sln_ResearchAndDevelopmentBenefitReceivableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Goodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GainFromResearchAndDevelopmentCredit" xlink:label="sln_GainFromResearchAndDevelopmentCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="sln_GainFromResearchAndDevelopmentCredit" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_10"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RedemptionOfTermDeposits" xlink:label="sln_RedemptionOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PurchaseOfTermDeposits" xlink:label="sln_PurchaseOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentBenefitReceived" xlink:label="sln_ResearchAndDevelopmentBenefitReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NetForeignExchangeImpacts" xlink:label="sln_NetForeignExchangeImpacts"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInTradeAndOtherPayables" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sln_RedemptionOfTermDeposits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sln_PurchaseOfTermDeposits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="sln_ResearchAndDevelopmentBenefitReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentForAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sln_NetForeignExchangeImpacts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="sln_IncreaseDecreaseInTradeAndOtherPayables" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherIncome" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GeneralInformationAbstract" xlink:label="sln_GeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_GeneralInformationAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DirectorsAndEmployeeRemunerationTextBlock" xlink:label="sln_DirectorsAndEmployeeRemunerationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="sln_DirectorsAndEmployeeRemunerationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock" xlink:label="us-gaap_GoodwillDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AccountsReceivableTextBlock" xlink:label="sln_AccountsReceivableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sln_AccountsReceivableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityTextBlock" xlink:label="sln_ContractWithCustomerLiabilityTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="sln_ContractWithCustomerLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock" xlink:label="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock" xlink:label="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock" xlink:label="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GoingConcernPolicyPolicyTextBlock" xlink:label="sln_GoingConcernPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sln_GoingConcernPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DirectorsAndEmployeeRemunerationTableTextBlock" xlink:label="sln_DirectorsAndEmployeeRemunerationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="sln_DirectorsAndEmployeeRemunerationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ScheduleOfAccountsReceivableTableTextBlock" xlink:label="sln_ScheduleOfAccountsReceivableTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="sln_ScheduleOfAccountsReceivableTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" xlink:label="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithAstrazenecaMember" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OpenMarketSaleAgreementMember" xlink:label="sln_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sln_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicensesAndSoftwareMember" xlink:label="sln_LicensesAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_JefferiesLLCMember" xlink:label="sln_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FurnitureAndEquipmentMember" xlink:label="sln_FurnitureAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sln_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_InvoiceRaiseDurationAfterQuarterEnd" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithAstrazenecaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OpenMarketSaleAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sln_LicensesAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sln_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sln_FurnitureAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sln_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="sln_SummaryOfSignificantAccountingPoliciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_MilestonePaymentsReceived" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_InvoiceRaiseDurationAfterQuarterEnd" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithMallinckrodtMember" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RoyaltyIncomeMember" xlink:label="sln_RoyaltyIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithAstrazenecaMember" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationIncomeMember" xlink:label="sln_ResearchCollaborationIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityNetOfTax" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SettlementAndLicenseAgreementWithAlnylamMember" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PercentageOfRoyaltyOnNetSales" xlink:label="sln_PercentageOfRoyaltyOnNetSales"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithMallinckrodtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_RoyaltyIncomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithAstrazenecaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_ResearchCollaborationIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_ContractWithCustomerLiabilityNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_SettlementAndLicenseAgreementWithAlnylamMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_MilestonePaymentsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_PercentageOfRoyaltyOnNetSales" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationMallinckrodtPlcMember" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationIncomeMember" xlink:label="sln_ResearchCollaborationIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationAstraZenecaMember" xlink:label="sln_ResearchCollaborationAstraZenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RoyaltyIncomeMember" xlink:label="sln_RoyaltyIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationHansohMember" xlink:label="sln_ResearchCollaborationHansohMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationMallinckrodtPlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_ResearchCollaborationIncomeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationAstraZenecaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_RoyaltyIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationHansohMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PersonnelResearchAndDevelopmentCosts" xlink:label="sln_PersonnelResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_BusinessDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="sln_PersonnelResearchAndDevelopmentCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromContractWithCustomerResearchCollaboration" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromRoyalties" xlink:label="sln_RevenueFromRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AssetsNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="sln_RevenueFromContractWithCustomerResearchCollaboration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="sln_RevenueFromRoyalties" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityCosts" xlink:label="sln_SocialSecurityCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AggregateRemuneration" xlink:label="sln_AggregateRemuneration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="sln_SocialSecurityCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="sln_AggregateRemuneration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_BankInterestReceivable" xlink:label="sln_BankInterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AccretionOfSecurities" xlink:label="sln_AccretionOfSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="sln_BankInterestReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="sln_AccretionOfSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:label="us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillForeignCurrencyTranslationGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_Goodwill_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicenseAndSoftwareNetMember" xlink:label="sln_LicenseAndSoftwareNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sln_LicenseAndSoftwareNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="us-gaap_CashAndDueFromBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndDueFromBanks" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsCurrent" xlink:label="sln_PrepaymentsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsNoncurrent" xlink:label="sln_PrepaymentsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="sln_PrepaymentsAssetsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="sln_PrepaymentsAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsTable" xlink:label="sln_OtherAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsLineItems" xlink:label="sln_OtherAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssets" xlink:label="sln_PrepaymentsAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_OtherAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="sln_OtherAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_OtherAssetsLineItems" xlink:to="sln_PrepaymentsAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_OtherAssetsTable" xlink:to="sln_OtherAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityAndOtherTaxesPayableCurrent" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sln_SocialSecurityAndOtherTaxesPayableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesTable" xlink:label="sln_TradeAndOtherPayablesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesLineItems" xlink:label="sln_TradeAndOtherPayablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_TradeAndOtherPayablesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_TradeAndOtherPayablesLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sln_TradeAndOtherPayablesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_TradeAndOtherPayablesTable" xlink:to="sln_TradeAndOtherPayablesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOperatingLease" xlink:label="sln_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OperatingLeaseNewTermBeginningPeriod" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfShortTermLeases" xlink:label="sln_NumberOfShortTermLeases"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfLeases" xlink:label="sln_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_GeographicDistributionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfOperatingLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomesticMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_OperatingLeaseNewTermBeginningPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfShortTermLeases" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfLeases" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_3"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityForeignExchangeImpact" xlink:label="sln_ContractWithCustomerLiabilityForeignExchangeImpact"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityAdditions" xlink:label="sln_ContractWithCustomerLiabilityAdditions"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityRevenueUnwound" xlink:label="sln_ContractWithCustomerLiabilityRevenueUnwound"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="sln_ContractWithCustomerLiabilityForeignExchangeImpact" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="sln_ContractWithCustomerLiabilityAdditions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="sln_ContractWithCustomerLiabilityRevenueUnwound" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesTable" xlink:label="sln_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SmallOrMediumSizedEnterprisesMember" xlink:label="sln_SmallOrMediumSizedEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesLineItems" xlink:label="sln_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentExpenditureCreditMember" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_UpfrontPaymentTaxWithholding" xlink:label="sln_UpfrontPaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentTaxWithholding" xlink:label="sln_MilestonePaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sln_SmallOrMediumSizedEnterprisesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sln_ResearchAndDevelopmentExpenditureCreditMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesTable" xlink:to="sln_IncomeTaxesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_UpfrontPaymentTaxWithholding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_MilestonePaymentsReceived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_MilestonePaymentTaxWithholding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxReconciliationEffectOfOverseasTaxes" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_IncomeTaxReconciliationEffectOfOverseasTaxes" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" xlink:label="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates" xlink:label="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_3"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RegisteredDirectOfferingMember" xlink:label="sln_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_JefferiesLLCMember" xlink:label="sln_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OpenMarketSaleAgreementMember" xlink:label="sln_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityRestrictions" xlink:label="us-gaap_EquityRestrictions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockholdersEquityRemainingValue" xlink:label="sln_StockholdersEquityRemainingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CurrencyConversionRatePerDollar" xlink:label="sln_CurrencyConversionRatePerDollar"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_RegisteredDirectOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sln_JefferiesLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OpenMarketSaleAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityRestrictions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityPeriodIncreaseDecrease" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_StockholdersEquityRemainingValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_CurrencyConversionRatePerDollar" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedOneMember" xlink:label="sln_OptionsExercisedOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwoMember" xlink:label="sln_OptionsExercisedTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThreeMember" xlink:label="sln_OptionsExercisedThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourMember" xlink:label="sln_OptionsExercisedFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFiveMember" xlink:label="sln_OptionsExercisedFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixMember" xlink:label="sln_OptionsExercisedSixMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSevenMember" xlink:label="sln_OptionsExercisedSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEightMember" xlink:label="sln_OptionsExercisedEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineMember" xlink:label="sln_OptionsExercisedNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTenMember" xlink:label="sln_OptionsExercisedTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedElevenMember" xlink:label="sln_OptionsExercisedElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwelveMember" xlink:label="sln_OptionsExercisedTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThirteenMember" xlink:label="sln_OptionsExercisedThirteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourteenMember" xlink:label="sln_OptionsExercisedFourteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFifteenMember" xlink:label="sln_OptionsExercisedFifteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixteenMember" xlink:label="sln_OptionsExercisedSixteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSeventeenMember" xlink:label="sln_OptionsExercisedSeventeenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEighteenMember" xlink:label="sln_OptionsExercisedEighteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineteenMember" xlink:label="sln_OptionsExercisedNineteenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTenMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedElevenMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwelveMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThirteenMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourteenMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFifteenMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixteenMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSeventeenMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEighteenMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineteenMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedOneMember" xlink:label="sln_OptionsExercisedOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockOptionExercisePrice" xlink:label="sln_StockOptionExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwoMember" xlink:label="sln_OptionsExercisedTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThreeMember" xlink:label="sln_OptionsExercisedThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourMember" xlink:label="sln_OptionsExercisedFourMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFiveMember" xlink:label="sln_OptionsExercisedFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixMember" xlink:label="sln_OptionsExercisedSixMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSevenMember" xlink:label="sln_OptionsExercisedSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEightMember" xlink:label="sln_OptionsExercisedEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineMember" xlink:label="sln_OptionsExercisedNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTenMember" xlink:label="sln_OptionsExercisedTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedElevenMember" xlink:label="sln_OptionsExercisedElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwelveMember" xlink:label="sln_OptionsExercisedTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThirteenMember" xlink:label="sln_OptionsExercisedThirteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourteenMember" xlink:label="sln_OptionsExercisedFourteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFifteenMember" xlink:label="sln_OptionsExercisedFifteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixteenMember" xlink:label="sln_OptionsExercisedSixteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSeventeenMember" xlink:label="sln_OptionsExercisedSeventeenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEighteenMember" xlink:label="sln_OptionsExercisedEighteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineteenMember" xlink:label="sln_OptionsExercisedNineteenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_StockOptionExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTenMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedElevenMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwelveMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThirteenMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourteenMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFifteenMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixteenMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSeventeenMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEighteenMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineteenMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearOneMember" xlink:label="sln_OptionsIssuedInYearOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_YearOfIssuanceOfStockOption" xlink:label="sln_YearOfIssuanceOfStockOption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTwoMember" xlink:label="sln_OptionsIssuedInYearTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearThreeMember" xlink:label="sln_OptionsIssuedInYearThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFourMember" xlink:label="sln_OptionsIssuedInYearFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFiveMember" xlink:label="sln_OptionsIssuedInYearFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSixMember" xlink:label="sln_OptionsIssuedInYearSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSevenMember" xlink:label="sln_OptionsIssuedInYearSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearEightMember" xlink:label="sln_OptionsIssuedInYearEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearNineMember" xlink:label="sln_OptionsIssuedInYearNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTenMember" xlink:label="sln_OptionsIssuedInYearTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearElevenMember" xlink:label="sln_OptionsIssuedInYearElevenMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_YearOfIssuanceOfStockOption" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearFiveMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearSixMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearSevenMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearEightMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearNineMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearTenMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearElevenMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EstimatedEmployerTaxObligationOnOutstandingOptions" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sln_EstimatedEmployerTaxObligationOnOutstandingOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_WeightedAverageGrantDataFairValue" xlink:label="sln_WeightedAverageGrantDataFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="sln_WeightedAverageGrantDataFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CapitalCommitments" xlink:label="sln_CapitalCommitments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sln_CapitalCommitments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeasePayments" xlink:label="us-gaap_ShortTermLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NonExecutiveChairmanMember" xlink:label="sln_NonExecutiveChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sln_NonExecutiveChairmanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="sln_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SummaryOfSignificantAccountingPoliciesTable" xlink:label="sln_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithAstrazenecaMember" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OpenMarketSaleAgreementMember" xlink:label="sln_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicensesAndSoftwareMember" xlink:label="sln_LicensesAndSoftwareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_JefferiesLLCMember" xlink:label="sln_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_FurnitureAndEquipmentMember" xlink:label="sln_FurnitureAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" xlink:label="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_InvoiceRaiseDurationAfterQuarterEnd" xlink:label="sln_InvoiceRaiseDurationAfterQuarterEnd"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithAstrazenecaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OpenMarketSaleAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sln_LicensesAndSoftwareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sln_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sln_FurnitureAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_MilestonePaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sln_InvoiceRaiseDurationAfterQuarterEnd" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithMallinckrodtMember" xlink:label="sln_CollaborationAgreementWithMallinckrodtMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RoyaltyIncomeMember" xlink:label="sln_RoyaltyIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithAstrazenecaMember" xlink:label="sln_CollaborationAgreementWithAstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationIncomeMember" xlink:label="sln_ResearchCollaborationIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ContractWithCustomerLiabilityNetOfTax" xlink:label="sln_ContractWithCustomerLiabilityNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SettlementAndLicenseAgreementWithAlnylamMember" xlink:label="sln_SettlementAndLicenseAgreementWithAlnylamMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PercentageOfRoyaltyOnNetSales" xlink:label="sln_PercentageOfRoyaltyOnNetSales"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithMallinckrodtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_RoyaltyIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithAstrazenecaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_ResearchCollaborationIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_ContractWithCustomerLiabilityNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_SettlementAndLicenseAgreementWithAlnylamMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_MilestonePaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="sln_PercentageOfRoyaltyOnNetSales" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationMallinckrodtPlcMember" xlink:label="sln_ResearchCollaborationMallinckrodtPlcMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationIncomeMember" xlink:label="sln_ResearchCollaborationIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationAstraZenecaMember" xlink:label="sln_ResearchCollaborationAstraZenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RoyaltyIncomeMember" xlink:label="sln_RoyaltyIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchCollaborationHansohMember" xlink:label="sln_ResearchCollaborationHansohMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationMallinckrodtPlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_ResearchCollaborationIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationAstraZenecaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="sln_RoyaltyIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_ResearchCollaborationHansohMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromContractWithCustomerResearchCollaboration" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DE" xlink:label="country_DE"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromRoyalties" xlink:label="sln_RevenueFromRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="sln_RevenueFromContractWithCustomerResearchCollaboration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="sln_RevenueFromRoyalties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_LicenseAndSoftwareNetMember" xlink:label="sln_LicenseAndSoftwareNetMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="sln_LicenseAndSoftwareNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsLineItems" xlink:label="sln_OtherAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OtherAssetsTable" xlink:label="sln_OtherAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssets" xlink:label="sln_PrepaymentsAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sln_OtherAssetsLineItems" xlink:to="sln_OtherAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_OtherAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_OtherAssetsLineItems" xlink:to="sln_PrepaymentsAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesLineItems" xlink:label="sln_TradeAndOtherPayablesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_TradeAndOtherPayablesTable" xlink:label="sln_TradeAndOtherPayablesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sln_TradeAndOtherPayablesLineItems" xlink:to="sln_TradeAndOtherPayablesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_TradeAndOtherPayablesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_TradeAndOtherPayablesLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="us-gaap_GeographicDistributionForeignMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomain" xlink:label="us-gaap_GeographicDistributionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOperatingLease" xlink:label="sln_NumberOfOperatingLease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicDistributionDomesticMember" xlink:label="us-gaap_GeographicDistributionDomesticMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OperatingLeaseNewTermBeginningPeriod" xlink:label="sln_OperatingLeaseNewTermBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfShortTermLeases" xlink:label="sln_NumberOfShortTermLeases"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfLeases" xlink:label="sln_NumberOfLeases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionForeignMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_GeographicDistributionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfOperatingLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeographicDistributionDomain" xlink:to="us-gaap_GeographicDistributionDomesticMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_OperatingLeaseNewTermBeginningPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfShortTermLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="sln_NumberOfLeases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesLineItems" xlink:label="sln_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxesTable" xlink:label="sln_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SmallOrMediumSizedEnterprisesMember" xlink:label="sln_SmallOrMediumSizedEnterprisesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CollaborationAgreementWithHansohMember" xlink:label="sln_CollaborationAgreementWithHansohMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentExpenditureCreditMember" xlink:label="sln_ResearchAndDevelopmentExpenditureCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_UpfrontPaymentTaxWithholding" xlink:label="sln_UpfrontPaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentsReceived" xlink:label="sln_MilestonePaymentsReceived"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_MilestonePaymentTaxWithholding" xlink:label="sln_MilestonePaymentTaxWithholding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_IncomeTaxesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sln_SmallOrMediumSizedEnterprisesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="sln_CollaborationAgreementWithHansohMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sln_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="sln_ResearchAndDevelopmentExpenditureCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_UpfrontPaymentTaxWithholding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_MilestonePaymentsReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="sln_MilestonePaymentTaxWithholding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sln_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RegisteredDirectOfferingMember" xlink:label="sln_RegisteredDirectOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_JefferiesLLCMember" xlink:label="sln_JefferiesLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OpenMarketSaleAgreementMember" xlink:label="sln_OpenMarketSaleAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" xlink:label="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityRestrictions" xlink:label="us-gaap_EquityRestrictions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockholdersEquityRemainingValue" xlink:label="sln_StockholdersEquityRemainingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_CurrencyConversionRatePerDollar" xlink:label="sln_CurrencyConversionRatePerDollar"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_RegisteredDirectOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sln_JefferiesLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OpenMarketSaleAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EquityRestrictions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityPeriodIncreaseDecrease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_StockholdersEquityRemainingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_CurrencyConversionRatePerDollar" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedOneMember" xlink:label="sln_OptionsExercisedOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwoMember" xlink:label="sln_OptionsExercisedTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThreeMember" xlink:label="sln_OptionsExercisedThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourMember" xlink:label="sln_OptionsExercisedFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFiveMember" xlink:label="sln_OptionsExercisedFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixMember" xlink:label="sln_OptionsExercisedSixMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSevenMember" xlink:label="sln_OptionsExercisedSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEightMember" xlink:label="sln_OptionsExercisedEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineMember" xlink:label="sln_OptionsExercisedNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTenMember" xlink:label="sln_OptionsExercisedTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedElevenMember" xlink:label="sln_OptionsExercisedElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwelveMember" xlink:label="sln_OptionsExercisedTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThirteenMember" xlink:label="sln_OptionsExercisedThirteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourteenMember" xlink:label="sln_OptionsExercisedFourteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFifteenMember" xlink:label="sln_OptionsExercisedFifteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixteenMember" xlink:label="sln_OptionsExercisedSixteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSeventeenMember" xlink:label="sln_OptionsExercisedSeventeenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEighteenMember" xlink:label="sln_OptionsExercisedEighteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineteenMember" xlink:label="sln_OptionsExercisedNineteenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedElevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwelveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThirteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFifteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSeventeenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEighteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineteenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedOneMember" xlink:label="sln_OptionsExercisedOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_StockOptionExercisePrice" xlink:label="sln_StockOptionExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwoMember" xlink:label="sln_OptionsExercisedTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThreeMember" xlink:label="sln_OptionsExercisedThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourMember" xlink:label="sln_OptionsExercisedFourMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFiveMember" xlink:label="sln_OptionsExercisedFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixMember" xlink:label="sln_OptionsExercisedSixMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSevenMember" xlink:label="sln_OptionsExercisedSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEightMember" xlink:label="sln_OptionsExercisedEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineMember" xlink:label="sln_OptionsExercisedNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTenMember" xlink:label="sln_OptionsExercisedTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedElevenMember" xlink:label="sln_OptionsExercisedElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedTwelveMember" xlink:label="sln_OptionsExercisedTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedThirteenMember" xlink:label="sln_OptionsExercisedThirteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFourteenMember" xlink:label="sln_OptionsExercisedFourteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedFifteenMember" xlink:label="sln_OptionsExercisedFifteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSixteenMember" xlink:label="sln_OptionsExercisedSixteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedSeventeenMember" xlink:label="sln_OptionsExercisedSeventeenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedEighteenMember" xlink:label="sln_OptionsExercisedEighteenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsExercisedNineteenMember" xlink:label="sln_OptionsExercisedNineteenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_StockOptionExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedElevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedTwelveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedThirteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFourteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedFifteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSixteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedSeventeenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedEighteenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sln_OptionsExercisedNineteenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositaryShareADSMember" xlink:label="sln_AmericanDepositaryShareADSMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearOneMember" xlink:label="sln_OptionsIssuedInYearOneMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_YearOfIssuanceOfStockOption" xlink:label="sln_YearOfIssuanceOfStockOption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTwoMember" xlink:label="sln_OptionsIssuedInYearTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearThreeMember" xlink:label="sln_OptionsIssuedInYearThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFourMember" xlink:label="sln_OptionsIssuedInYearFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearFiveMember" xlink:label="sln_OptionsIssuedInYearFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSixMember" xlink:label="sln_OptionsIssuedInYearSixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearSevenMember" xlink:label="sln_OptionsIssuedInYearSevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearEightMember" xlink:label="sln_OptionsIssuedInYearEightMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearNineMember" xlink:label="sln_OptionsIssuedInYearNineMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" xlink:label="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearTenMember" xlink:label="sln_OptionsIssuedInYearTenMember"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_OptionsIssuedInYearElevenMember" xlink:label="sln_OptionsIssuedInYearElevenMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositaryShareADSMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_YearOfIssuanceOfStockOption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearSixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearSevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearNineMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearTenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sln_OptionsIssuedInYearElevenMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EstimatedEmployerTaxObligationOnOutstandingOptions" xlink:label="sln_EstimatedEmployerTaxObligationOnOutstandingOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sln_EstimatedEmployerTaxObligationOnOutstandingOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AmericanDepositarySharesMember" xlink:label="sln_AmericanDepositarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_WeightedAverageGrantDataFairValue" xlink:label="sln_WeightedAverageGrantDataFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sln_AmericanDepositarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="sln_WeightedAverageGrantDataFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NonExecutiveChairmanMember" xlink:label="sln_NonExecutiveChairmanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sln_NonExecutiveChairmanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="sln_ResearchAndDevelopmentBenefitReceivableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ResearchAndDevelopmentBenefitReceivableCurrent" xlink:label="sln_ResearchAndDevelopmentBenefitReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="us-gaap_OtherIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_BusinessDevelopment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="sln_PersonnelResearchAndDevelopmentCosts" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_SegmentReportingOtherItemAmount" order="7" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDevelopment" xlink:label="us-gaap_BusinessDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PersonnelResearchAndDevelopmentCosts" xlink:label="sln_PersonnelResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncome" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="sln_GainFromResearchAndDevelopmentCredit" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_GainFromResearchAndDevelopmentCredit" xlink:label="sln_GainFromResearchAndDevelopmentCredit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="sln_RedemptionOfTermDeposits" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="sln_PurchaseOfTermDeposits" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentForAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sln_NetForeignExchangeImpacts" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherIncome" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sln_IncreaseDecreaseInTradeAndOtherPayables" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="16" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RedemptionOfTermDeposits" xlink:label="sln_RedemptionOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PurchaseOfTermDeposits" xlink:label="sln_PurchaseOfTermDeposits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_NetForeignExchangeImpacts" xlink:label="sln_NetForeignExchangeImpacts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" xlink:label="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncreaseDecreaseInTradeAndOtherPayables" xlink:label="sln_IncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="sln_RevenueFromContractWithCustomerResearchCollaboration" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="sln_RevenueFromRoyalties" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromContractWithCustomerResearchCollaboration" xlink:label="sln_RevenueFromContractWithCustomerResearchCollaboration"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_RevenueFromRoyalties" xlink:label="sln_RevenueFromRoyalties"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="sln_AggregateRemuneration" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="sln_AggregateRemuneration" xlink:to="sln_SocialSecurityCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="sln_AggregateRemuneration" xlink:to="us-gaap_PostemploymentBenefitsPeriodExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="sln_AggregateRemuneration" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AggregateRemuneration" xlink:label="sln_AggregateRemuneration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityCosts" xlink:label="sln_SocialSecurityCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PostemploymentBenefitsPeriodExpense" xlink:label="us-gaap_PostemploymentBenefitsPeriodExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="sln_BankInterestReceivable" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="sln_AccretionOfSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_BankInterestReceivable" xlink:label="sln_BankInterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_AccretionOfSecurities" xlink:label="sln_AccretionOfSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndDueFromBanks" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndDueFromBanks" xlink:label="us-gaap_CashAndDueFromBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="sln_PrepaymentsAssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="sln_PrepaymentsAssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_ValueAddedTaxReceivableCurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsCurrent" xlink:label="sln_PrepaymentsAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_PrepaymentsAssetsNoncurrent" xlink:label="sln_PrepaymentsAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="us-gaap_ValueAddedTaxReceivableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="sln_SocialSecurityAndOtherTaxesPayableCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_SocialSecurityAndOtherTaxesPayableCurrent" xlink:label="sln_SocialSecurityAndOtherTaxesPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" xlink:label="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" xlink:label="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" xlink:label="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" xlink:label="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxExemptIncome" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sln_IncomeTaxReconciliationEffectOfOverseasTaxes" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:label="us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_IncomeTaxReconciliationEffectOfOverseasTaxes" xlink:label="sln_IncomeTaxReconciliationEffectOfOverseasTaxes"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="sln-20241231.xsd#sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" xlink:label="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="sln_AggregateRemuneration" name="AggregateRemuneration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_MilestonePaymentTaxWithholding" name="MilestonePaymentTaxWithholding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_RedemptionOfTermDeposits" name="RedemptionOfTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_AmericanDepositarySharesMember" name="AmericanDepositarySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" name="DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_InvoiceRaiseDurationAfterQuarterEnd" name="InvoiceRaiseDurationAfterQuarterEnd" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_RevenueFromContractWithCustomerResearchCollaboration" name="RevenueFromContractWithCustomerResearchCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OtherAssetsLineItems" name="OtherAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsIssuedInYearTwoMember" name="OptionsIssuedInYearTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_GainFromResearchAndDevelopmentCredit" name="GainFromResearchAndDevelopmentCredit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_BankInterestReceivable" name="BankInterestReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsIssuedInYearFourMember" name="OptionsIssuedInYearFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ResearchCollaborationMallinckrodtPlcMember" name="ResearchCollaborationMallinckrodtPlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_NonExecutiveChairmanMember" name="NonExecutiveChairmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_UpfrontPaymentTaxWithholding" name="UpfrontPaymentTaxWithholding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsExercisedSevenMember" name="OptionsExercisedSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ResearchCollaborationIncomeMember" name="ResearchCollaborationIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_CollaborationAgreementWithAstrazenecaMember" name="CollaborationAgreementWithAstrazenecaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses" name="DeferredTaxRecognitionOfUnrecognizedTaxLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsIssuedInYearThreeMember" name="OptionsIssuedInYearThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_StockOptionExercisePrice" name="StockOptionExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsIssuedInYearTenMember" name="OptionsIssuedInYearTenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsIssuedInYearSixMember" name="OptionsIssuedInYearSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_RevenueFromRoyalties" name="RevenueFromRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_NumberOfShortTermLeases" name="NumberOfShortTermLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_PrepaymentsAssetsCurrent" name="PrepaymentsAssetsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" name="DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" name="ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity" name="NumberOfOrdinarySharesDenominatedInTemporaryEquity" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_TradeAndOtherPayablesTable" name="TradeAndOtherPayablesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare" name="NumberOfOrdinarySharesForEachAmericanDepositaryShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock" name="FunctionalAndReportingCurrencyPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_ContractWithCustomerLiabilityRevenueUnwound" name="ContractWithCustomerLiabilityRevenueUnwound" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" name="EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_PersonnelResearchAndDevelopmentCosts" name="PersonnelResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_OptionsExercisedFiveMember" name="OptionsExercisedFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsIssuedInYearEightMember" name="OptionsIssuedInYearEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedFourteenMember" name="OptionsExercisedFourteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedSixteenMember" name="OptionsExercisedSixteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ResearchCollaborationAstraZenecaMember" name="ResearchCollaborationAstraZenecaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_EstimatedEmployerTaxObligationOnOutstandingOptions" name="EstimatedEmployerTaxObligationOnOutstandingOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsExercisedTwoMember" name="OptionsExercisedTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedFifteenMember" name="OptionsExercisedFifteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_CollaborationAgreementWithHansohMember" name="CollaborationAgreementWithHansohMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedSixMember" name="OptionsExercisedSixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsOutstandingWeightedAverageYearsToExpiryDate" name="OptionsOutstandingWeightedAverageYearsToExpiryDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_GoingConcernPolicyPolicyTextBlock" name="GoingConcernPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_StockholdersEquityRemainingValue" name="StockholdersEquityRemainingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_PrepaymentsAssets" name="PrepaymentsAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_OptionsIssuedInYearElevenMember" name="OptionsIssuedInYearElevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_GeneralInformationAbstract" name="GeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsIssuedInYearNineMember" name="OptionsIssuedInYearNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedOneMember" name="OptionsExercisedOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock" name="FinancialInstrumentsAndRiskManagementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" name="SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsIssuedInYearFiveMember" name="OptionsIssuedInYearFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_PercentageOfRoyaltyOnNetSales" name="PercentageOfRoyaltyOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_MilestonePaymentsReceived" name="MilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_ResearchCollaborationHansohMember" name="ResearchCollaborationHansohMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ResearchAndDevelopmentBenefitReceivableCurrent" name="ResearchAndDevelopmentBenefitReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_ResearchAndDevelopmentBenefitReceived" name="ResearchAndDevelopmentBenefitReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_SettlementAndLicenseAgreementWithAlnylamMember" name="SettlementAndLicenseAgreementWithAlnylamMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedEighteenMember" name="OptionsExercisedEighteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DeferredTaxDerecognitionOfRecognizedTaxLosses" name="DeferredTaxDerecognitionOfRecognizedTaxLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" name="DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" name="IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_AccountsReceivableTextBlock" name="AccountsReceivableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_CurrencyConversionRatePerDollar" name="CurrencyConversionRatePerDollar" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsExercisedTwelveMember" name="OptionsExercisedTwelveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ContractWithCustomerLiabilityNetOfTax" name="ContractWithCustomerLiabilityNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_SocialSecurityCosts" name="SocialSecurityCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates" name="ValuationAllowanceDeferredTaxAssetChangeInTaxRates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_AmericanDepositaryShareADSMember" name="AmericanDepositaryShareADSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_LicensesAndSoftwareMember" name="LicensesAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" name="OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_PrepaymentsAssetsNoncurrent" name="PrepaymentsAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_NetForeignExchangeImpacts" name="NetForeignExchangeImpacts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsExercisedSeventeenMember" name="OptionsExercisedSeventeenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ScheduleOfAccountsReceivableTableTextBlock" name="ScheduleOfAccountsReceivableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsExercisedFourMember" name="OptionsExercisedFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OperatingLeaseNewTermBeginningPeriod" name="OperatingLeaseNewTermBeginningPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_PurchaseOfTermDeposits" name="PurchaseOfTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_FurnitureAndEquipmentMember" name="FurnitureAndEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedElevenMember" name="OptionsExercisedElevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_CollaborationAgreementWithMallinckrodtMember" name="CollaborationAgreementWithMallinckrodtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_RoyaltyIncomeMember" name="RoyaltyIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_JefferiesLLCMember" name="JefferiesLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_NumberOfLeases" name="NumberOfLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_ResearchAndDevelopmentExpenditureCreditMember" name="ResearchAndDevelopmentExpenditureCreditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OtherAssetsTable" name="OtherAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_YearOfIssuanceOfStockOption" name="YearOfIssuanceOfStockOption" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_LicenseAndSoftwareNetMember" name="LicenseAndSoftwareNetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ContractWithCustomerLiabilityTextBlock" name="ContractWithCustomerLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsExercisedEightMember" name="OptionsExercisedEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedNineMember" name="OptionsExercisedNineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedTenMember" name="OptionsExercisedTenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_CapitalCommitments" name="CapitalCommitments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_OptionsExercisedThirteenMember" name="OptionsExercisedThirteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_SmallOrMediumSizedEnterprisesMember" name="SmallOrMediumSizedEnterprisesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DirectorsAndEmployeeRemunerationTableTextBlock" name="DirectorsAndEmployeeRemunerationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_OptionsIssuedInYearSevenMember" name="OptionsIssuedInYearSevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_IncreaseDecreaseInTradeAndOtherPayables" name="IncreaseDecreaseInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_OptionsExercisedThreeMember" name="OptionsExercisedThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsIssuedInYearOneMember" name="OptionsIssuedInYearOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_ContractWithCustomerLiabilityForeignExchangeImpact" name="ContractWithCustomerLiabilityForeignExchangeImpact" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_IncomeTaxReconciliationEffectOfOverseasTaxes" name="IncomeTaxReconciliationEffectOfOverseasTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_AccretionOfSecurities" name="AccretionOfSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_WeightedAverageGrantDataFairValue" name="WeightedAverageGrantDataFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="sln_SocialSecurityAndOtherTaxesPayableCurrent" name="SocialSecurityAndOtherTaxesPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="sln_TradeAndOtherPayablesLineItems" name="TradeAndOtherPayablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_DirectorsAndEmployeeRemunerationTextBlock" name="DirectorsAndEmployeeRemunerationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="sln_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="sln_OptionsExercisedNineteenMember" name="OptionsExercisedNineteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067129040">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Silence Therapeutics plc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">0001479615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">001-39487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 737.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">72 Hammersmith Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">W14 8TH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">+44 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3457 6900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Portions of the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#8217;s fiscal year ended December 31, 2024.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Reading, United Kingdom<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Silence Therapeutics plc</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and its subsidiaries</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Company&#8221;) as of December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 2023,</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the related consolidated statements of income (loss), of comprehensive income (loss), of changes in shareholders&#8217; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our opinion, the consolidated</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and the results of its</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations and its</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cash flows for each of the three years in the period ended December 31, 2024</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control - Integrated Framework</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2013)</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issued by the COSO.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,674,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">American Depositary Shares, each representing three ordinary shares, nominal value &#163;0.05 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">SLN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Ordinary share, nominal value &#163;0.05 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327066876464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 121,330<span></span>
</td>
<td class="nump">$ 68,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">26,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ResearchAndDevelopmentBenefitReceivableCurrent', window );">R&amp;D benefit receivable</a></td>
<td class="nump">24,396<span></span>
</td>
<td class="nump">22,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">14,664<span></span>
</td>
<td class="nump">11,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">972<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">187,366<span></span>
</td>
<td class="nump">103,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">1,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">9,392<span></span>
</td>
<td class="nump">9,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">202,635<span></span>
</td>
<td class="nump">119,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(6,571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Trade and other payables</a></td>
<td class="num">(16,399)<span></span>
</td>
<td class="num">(15,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="num">(16,822)<span></span>
</td>
<td class="num">(22,336)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="num">(51,790)<span></span>
</td>
<td class="num">(75,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="num">(68,612)<span></span>
</td>
<td class="num">(97,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 20)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares - par value &#163;0.05 per share; 141,674,074 shares issued at December 31, 2024 (2023:118,846,966)</a></td>
<td class="num">(10,288)<span></span>
</td>
<td class="num">(8,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="num">(609,560)<span></span>
</td>
<td class="num">(455,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">474,044<span></span>
</td>
<td class="nump">431,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">11,781<span></span>
</td>
<td class="nump">10,725<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="num">(134,023)<span></span>
</td>
<td class="num">(21,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="num">$ (202,635)<span></span>
</td>
<td class="num">$ (119,448)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ResearchAndDevelopmentBenefitReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development benefit receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ResearchAndDevelopmentBenefitReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327058507776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance sheets (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares - par value</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="nump">141,674,074<span></span>
</td>
<td class="nump">118,846,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067234768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 43,258<span></span>
</td>
<td class="nump">$ 31,643<span></span>
</td>
<td class="nump">$ 21,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(11,810)<span></span>
</td>
<td class="num">(12,867)<span></span>
</td>
<td class="num">(13,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,448<span></span>
</td>
<td class="nump">18,776<span></span>
</td>
<td class="nump">8,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="num">(67,883)<span></span>
</td>
<td class="num">(56,937)<span></span>
</td>
<td class="num">(43,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(26,884)<span></span>
</td>
<td class="num">(26,222)<span></span>
</td>
<td class="num">(25,682)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(63,319)<span></span>
</td>
<td class="num">(64,383)<span></span>
</td>
<td class="num">(61,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency gain/(loss), net</a></td>
<td class="nump">646<span></span>
</td>
<td class="num">(2,641)<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">4,472<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_GainFromResearchAndDevelopmentCredit', window );">Benefit from R&amp;D credit</a></td>
<td class="nump">13,737<span></span>
</td>
<td class="nump">11,949<span></span>
</td>
<td class="nump">9,820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(44,464)<span></span>
</td>
<td class="num">(53,272)<span></span>
</td>
<td class="num">(49,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(845)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share basic</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding basic</a></td>
<td class="nump">138,752,224<span></span>
</td>
<td class="nump">111,277,250<span></span>
</td>
<td class="nump">96,584,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding diluted</a></td>
<td class="nump">138,752,224<span></span>
</td>
<td class="nump">111,277,250<span></span>
</td>
<td class="nump">96,584,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_GainFromResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain from research and development credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_GainFromResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327068960768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange differences arising on consolidation of foreign operations (net of tax)</a></td>
<td class="num">(1,055)<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss)/income for the year</a></td>
<td class="num">(1,055)<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss for the year</a></td>
<td class="num">$ (46,364)<span></span>
</td>
<td class="num">$ (53,439)<span></span>
</td>
<td class="num">$ (50,420)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067194208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of Changes in Shareholders' equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 12,374<span></span>
</td>
<td class="nump">$ 7,065<span></span>
</td>
<td class="nump">$ 346,699<span></span>
</td>
<td class="num">$ (11,428)<span></span>
</td>
<td class="num">$ (329,962)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,784,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments (net of tax)</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of share-based payments</a></td>
<td class="nump">12,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised in the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised in the year, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares issued</a></td>
<td class="nump">52,581<span></span>
</td>
<td class="nump">$ 1,086<span></span>
</td>
<td class="nump">51,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from shares issued, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">27,221<span></span>
</td>
<td class="nump">$ 8,151<span></span>
</td>
<td class="nump">410,642<span></span>
</td>
<td class="num">(11,514)<span></span>
</td>
<td class="num">(380,058)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,808,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments (net of tax)</a></td>
<td class="nump">789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of share-based payments</a></td>
<td class="nump">16,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised in the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised in the year, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares issued</a></td>
<td class="nump">31,937<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">31,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from shares issued, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,230,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">21,993<span></span>
</td>
<td class="nump">$ 8,847<span></span>
</td>
<td class="nump">455,765<span></span>
</td>
<td class="num">(10,725)<span></span>
</td>
<td class="num">(431,894)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,846,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments (net of tax)</a></td>
<td class="num">(1,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Recognition of share-based payments</a></td>
<td class="nump">$ 16,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised in the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised in the year, Shares</a></td>
<td class="nump">1,408,443<span></span>
</td>
<td class="nump">1,408,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from shares issued</a></td>
<td class="nump">$ 142,087<span></span>
</td>
<td class="nump">$ 1,441<span></span>
</td>
<td class="nump">140,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from shares issued, Shares</a></td>
<td class="nump">21,418,665<span></span>
</td>
<td class="nump">21,418,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 134,023<span></span>
</td>
<td class="nump">$ 10,288<span></span>
</td>
<td class="nump">$ 609,560<span></span>
</td>
<td class="num">$ (11,780)<span></span>
</td>
<td class="num">$ (474,045)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, Shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,674,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327063006480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">16,307<span></span>
</td>
<td class="nump">16,274<span></span>
</td>
<td class="nump">12,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NetForeignExchangeImpacts', window );">Net foreign exchange impacts</a></td>
<td class="num">(2,581)<span></span>
</td>
<td class="nump">3,962<span></span>
</td>
<td class="num">(1,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="num">(4,472)<span></span>
</td>
<td class="num">(1,803)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase)/decrease in trade receivables</a></td>
<td class="num">(904)<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="num">(723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">(Increase)/decrease in other current assets</a></td>
<td class="num">(1,330)<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="num">(5,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable', window );">Increase in R&amp;D benefit receivable</a></td>
<td class="num">(2,337)<span></span>
</td>
<td class="num">(3,403)<span></span>
</td>
<td class="num">(9,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Decrease/(increase) in other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncreaseDecreaseInTradeAndOtherPayables', window );">Increase/(decrease) in trade and other payables</a></td>
<td class="nump">499<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in contract liabilities</a></td>
<td class="num">(28,786)<span></span>
</td>
<td class="num">(10,323)<span></span>
</td>
<td class="num">(5,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liabilities</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(67,640)<span></span>
</td>
<td class="num">(49,462)<span></span>
</td>
<td class="num">(57,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_RedemptionOfTermDeposits', window );">Redemption of term deposits</a></td>
<td class="nump">117,412<span></span>
</td>
<td class="nump">45,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PurchaseOfTermDeposits', window );">Purchase of term deposits</a></td>
<td class="num">(139,167)<span></span>
</td>
<td class="num">(25,771)<span></span>
</td>
<td class="num">(19,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(21,966)<span></span>
</td>
<td class="nump">19,294<span></span>
</td>
<td class="num">(20,498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares</a></td>
<td class="nump">142,087<span></span>
</td>
<td class="nump">31,937<span></span>
</td>
<td class="nump">52,581<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">142,087<span></span>
</td>
<td class="nump">31,937<span></span>
</td>
<td class="nump">52,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">52,481<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
<td class="num">(24,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at start of period</a></td>
<td class="nump">68,789<span></span>
</td>
<td class="nump">66,271<span></span>
</td>
<td class="nump">99,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate fluctuations on cash and cash equivalents held</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="num">(8,119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">121,330<span></span>
</td>
<td class="nump">68,789<span></span>
</td>
<td class="nump">$ 66,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Tax Paid</a></td>
<td class="num">$ (433)<span></span>
</td>
<td class="num">$ (801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) R&amp;D benefit receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_IncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_IncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NetForeignExchangeImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net foreign exchange impacts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NetForeignExchangeImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PurchaseOfTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PurchaseOfTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_RedemptionOfTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption of term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_RedemptionOfTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163809584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163641072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p id="other_information" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9B. Other Info</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rmation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the three months ended December 31, 2024, no director or officer of the Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060754848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067070784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 1C. Cyber</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">security</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Risk management and strategy</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems and Data.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our information security function, which is led by our Vice President and Head of Information Technology, known as our Head of IT, and supported by our security management, risk management, and legal teams, helps identify, assess, and manage our cybersecurity threats and risks, including through the use of our risk register. The information security function identifies and assesses cybersecurity threats and risks by monitoring and evaluating our threat environment and risk profile using various methods including, for example: automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats, evaluating threats reported to us, coordinating with law enforcement concerning threats, internal and external audits, leveraging internal and third party threat assessments, conducting vulnerability identification assessments, and leveraging external threat intelligence.</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, vulnerability management, disaster recovery and business continuity plans, risk assessments, achievement of certain security certifications, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, employee training, penetration testing, and asset management and disposal.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain information about our assessment and management of material risks from cybersecurity threats is included in risk management reports as applicable to senior leadership and the audit committee.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to assist us</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: threat intelligence providers, cybersecurity consultants and software providers, managed cybersecurity service providers, and penetration testing service providers.</span></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business, such as software-as-a-service providers, hosting companies, contract research organizations, and contract manufacturing organizations. Depending on the nature of the services provided, the sensitivity of the critical systems, information and assets at issue, and the identity of the provider, we may conduct a review of security assessments provided by the vendor, review the vendor&#8217;s written security program and/or requested security assessment and security questionnaire responses, and impose contractual obligations on vendors regarding their cybersecurity practices.</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks from cybersecurity threats that may materially affect us, please</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including &#8220;Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.&#8221;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.</span></span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#8217; cybersecurity efforts.</span></p></div><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Executive Leadership Team, or ELT. The ELT works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit and risk committee of the board of directors, as appropriate.</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee receives annual reports from our Head of IT, concerning our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity threats and risk and the processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have implemented to address them.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></p></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Systems and Data.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For a description of the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks from cybersecurity threats that may materially affect us, please</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including &#8220;Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">related </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.&#8221;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.</span></span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#8217; cybersecurity efforts.</span></p></div><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Executive Leadership Team, or ELT. The ELT works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit and risk committee of the board of directors, as appropriate.</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee receives annual reports from our Head of IT, concerning our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity threats and risk and the processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have implemented to address them.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, vulnerability management, disaster recovery and business continuity plans, risk assessments, achievement of certain security certifications, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, employee training, penetration testing, and asset management and disposal.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#8217; cybersecurity efforts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The board of directors&#8217; audit and risk committee receives annual reports from our Head of IT, concerning our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant cybersecurity threats and risk and the processes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we have implemented to address them.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060536224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_GeneralInformationAbstract', window );"><strong>General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">General Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. General information</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.1. Nature of the business</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Silence Therapeutics plc and its subsidiaries (together the "Group") are primarily involved in the discovery, delivery and development of RNA therapeutics. Silence Therapeutics plc, a public Company limited by shares registered in England and Wales, with company number 02992058, is the Group&#8217;s ultimate parent Company. The Company&#8217;s registered office is 27 Eastcastle Street, London, W1W 8DH and the principal place of business is 72 Hammersmith Road, London, W14 8TH.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_GeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_GeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060015296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Summary of significant accounting policies</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1. Basis of preparation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC"). Any reference in these notes to the applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Group and its wholly owned subsidiaries, after elimination of intercompany accounts and transactions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group previously prepared its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (&#8220;IASB&#8221;)  when the Group qualified as a foreign private issuer under the rules and regulations of the SEC. In connection with the loss of the Group&#8217;s status as a foreign private issuer, the Group is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Group&#8217;s inception.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2. Functional and reporting currency</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reporting currency of the consolidated financial statements is the U.S. Dollars (&#8220;USD&#8221; or &#8220;$&#8221;). The functional currency of the Group&#8217;s subsidiaries reflects the economic environment of their respective operations. All amounts disclosed have been rounded to the nearest thousand, unless otherwise stated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the loss of the Group&#8217;s status as a foreign private issuer, the Group as a domestic filer, changed its reporting currency of the consolidated financial statements from GBP to USD. The change in reporting currency was applied retrospectively. Consolidated financial statements for all periods have been recast into USD and presented to the nearest thousand dollars.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3. Principles of consolidation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial information comprises the financial statements of Silence Therapeutics plc and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4. Use of estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, the recognition of revenue and research and development expenses. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5. Going concern</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024. As of December 31, 2024, the Group had accumulated losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash outflows from operating activities for the year ended 31, December 2024 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group expects to incur operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Group may develop.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Group has funded its operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options to support its continued operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Group raised additional proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses, from sales of ADSs under its Sales Agreement. On February 5, 2024, the Group announced a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,714,286</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors (the &#8220;Private Placement&#8221;). The aggregate gross proceeds of the Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses. In 2024, the Group received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment from the AstraZeneca Collaboration and achieved another $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments from the Hansoh collaboration. As of December 31, 2024, the Group had cash and cash equivalents and short-term investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group believes that its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months from the issuance date of these consolidated financial statements. For this reason, the Group continues to adopt the going concern basis in preparing the financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group will need to raise additional funding to fund its operation expenses and capital expenditure requirements in relation to its clinical development activities. The Group may seek additional funding through public or private financings, debt financing or collaboration agreements. Specifically, the Group may receive future milestone payments from existing collaboration agreements which will extend the ability to fund operations. However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur. The inability to obtain future funding could impact; the Group&#8217;s financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6. Segment reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has determined that its chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Group has concluded that it operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment (see Note 4).</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7. Revenue recognition</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s revenue for the year ended December 31, 2024, consists of royalty income and revenue from collaboration agreements. To determine revenue recognition for arrangements that the Group determines are within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ASC 606: Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (&#8220;ASC 606&#8221;), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue when, or as, the Group satisfies the performance obligations. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty income</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s royalty income is generated by a settlement and license agreement with Alnylam. Under this contract, Alnylam is obliged to pay royalties to the Group on the net sales of ONPATTRO&#153; in the EU in a manner commensurate with the contractual terms. Invoices are raised in arrears on a quarterly basis based on sales information provided by Alnylam no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days after the quarter end.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 606, royalty income is recognized at the later date of (i) when the subsequent sale of the commercial partner&#8217;s product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from collaboration agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has considered the Mallinckrodt, AstraZeneca, and Hansoh contracts and assessed whether the research and development services and license of the IP in respect of each target are distinct.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all contracts the Group has concluded the license of the intellectual property and the R&amp;D services are not distinct, as Mallinckrodt, AstraZeneca, and Hansoh cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, and these services could not be performed by another party, indicating that the two are highly interrelated. On this basis, the Group has concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target. The Group recognizes revenue over the duration of the contract based on an input method based on cost to cost.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contracts have multiple elements of consideration (some or all of the following), namely:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments (fixed);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent milestone payments (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FTE costs rechargeable (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recharges of direct costs for certain research activities (variable).</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s effort under the contracts continues throughout their entire duration. On this basis revenue is recognized over the contract period based on costs to completion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been calculated on the following ongoing basis for the year ended December 31, 2024:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total contract costs which includes actual FTE and direct costs incurred up to December 31, 2024 and forecast FTE and direct costs for the remainder of the contract</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual costs incurred up until December 31, 2024 are calculated as a percentage of total contract costs (actual and forecast)</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This percentage is then multiplied by the transaction price allocated to the performance obligation in question, thus calculating the cumulative revenue which is then used to calculate the revenue to be recognized in that period. In the case of the upfront and milestones, the consideration that is multiplied is in relation to the upfront and completed milestones only. Consideration in relation to milestones not yet been achieved is excluded from the calculation. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forecast costs are monitored each period, with revenue recognized reflecting any changes in forecast or over/under spend in actuals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details of the revenue amounts recognized in the year ended December 31, 2024 can be found in note 3.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8. Research and development</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist of salary and personnel related costs and third party costs for the Group's research and development activities. Personnel related costs include a share based compensation charge relating to its stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes expenditure incurred in carrying out its research and development activities in line with management&#8217;s best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion. In all cases, the full cost of each study or activity is expensed by the time the final report or, where applicable, product, has been received. Further details on research and development can be found in note 2.15.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9. Taxation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current tax liabilities are calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company that carries out extensive research and development activities, the Group currently benefits from the U.K. research and development tax credit regime for small or medium-sized enterprises (&#8220;SMEs&#8221;). A benefit receivable arises from the U.K. legislation regarding the treatment of certain qualifying research and development costs, allowing for the surrender of tax losses attributable to such costs in return for a tax rebate. Research and development tax credits are recognized when the receipt is probable. Research and development costs which are not eligible for reimbursement under the U.K. Research and Development Tax Credit scheme, such as expenditure incurred on research projects for which the group receives income, may be reimbursed under the U.K. Research and Development Expenditure Credit (&#8220;RDEC&#8221;) scheme. Amounts receivable under either scheme are presented within the consolidated statements of income (loss) within Benefit from R&amp;D credit. The U.K. R&amp;D tax credit is fully refundable to the Group and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the U.K. R&amp;D tax credit as a benefit which is included in net loss before income tax and, accordingly, not reflected it as part of the income tax provision.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Group&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Group assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in consolidated statements of income (loss) in the period that includes the enactment date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10. Foreign currency translation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies area remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of income (loss) and comprehensive income (loss) for each respective period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, the consolidated financial statements of the Group have been presented in USD, the reporting currency. The financial statements of the Group&#8217;s entities are translated from their functional currency into USD as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, revenues and expenses are translated at the average exchange rates for the periods presented, and shareholders&#8217; equity is translated at the prevailing historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.11. Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group considers cash and cash equivalents to comprise of cash on hand and demand deposits with original maturities of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.12. Property, plant and equipment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group only holds equipment and furniture. These are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life of furniture and equipment is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Estimated useful life and residual values are reviewed each year and amended if necessary.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is assessed for impairment upon triggering events that indicate the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group&#8217;s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.13. Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group determines if an arrangement contains a lease at inception. The Group currently only has operating leases. The Group recognizes a right-of-use ("ROU") operating lease asset and associated short- and long-term operating lease liability in its consolidated balance sheets for operating leases greater than one year. Its right-of-use assets represent its right to use an underlying asset for the lease term and its lease liabilities represent its obligation to make lease payments arising from the lease arrangement. The Group recognizes its right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments it will pay over the lease term. The Group determines the lease term at the inception of each lease, and in certain cases its lease term could include renewal options if the Group concludes it is reasonably certain to exercise the renewal option. When the Group exercises a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease option that was not previously included in the initial lease term, it reassesses its right-of-use asset and lease liabilities for the new lease term.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As its operating lease do not provide an interest rate implicit in the lease, the Group uses its incremental borrowing rate, based on the information available as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Group recognizes lease expense for its minimum lease payments on a straight-line basis over the expected term of its lease. Its leases do not include material variable or contingent lease payments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with an initial term of 12 months or less are not recorded on the balance sheet. Instead, these lease payments are recognized on the consolidated statements of income (loss) on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to property, plant and equipment, ROU lease asset impairment is assessed upon triggering events that indicate the carrying amount may not be recovered by comparison to the future net undiscounted cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.14. Goodwill</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is the excess of the purchase price over the estimated fair values of the underlying net assets of an acquired business. The Group assesses goodwill for impairment annually, or immediately if conditions indicate that such impairment could exist. Impairment testing for goodwill is performed at the reporting unit level. The Group first evaluates qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates potential impairment, or if the Group elects to bypass the qualitative assessment, a quantitative test is performed. The quantitative test calculates the excess of the reporting unit&#8217;s fair value over its carrying amount, including goodwill, utilizing a discounted cash flow method. The test for impairment of goodwill requires the Group to make several assumptions and estimates regarding market conditions and its future profitability to determine the fair value of the goodwill at the reporting unit. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit net assets exceeds the estimated fair value of the reporting unit. Impairment losses recognized for the reporting unit to which goodwill has been allocated are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the reporting unit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All goodwill for the Group is attributed to an acquisition that occurred in 2005 and the Group has determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded as of December 31, 2024 and 2023.</span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.15. Other intangible assets</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other intangible assets that are acquired by the Group are stated at cost less accumulated amortization and less accumulated impairment losses. Amortization is charged to the consolidated statements of income (loss) on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. Other intangible assets are amortized from the date they are available for use. The estimated useful lives are as follows:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses and software: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with research activities are treated as an expense in the period in which they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs that are directly attributable to the development phase of software will only be recognized as intangible assets provided they meet the following requirements:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an asset is created that can be separately identified;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the technical feasibility exists to complete the intangible asset so that it will be available for sale or use and the Group has the intention and ability to do so;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is probable that the asset created will generate future economic benefits either through internal use or sale; </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient technical, financial and other resources are available for completion of the asset; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenditure attributable to the intangible asset during its development can be reliably measured.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Careful judgment by management is applied when deciding whether recognition requirements for software development costs have been met. This is necessary as the economic success of any product development is uncertain and may be subject to future technical problems at the time of recognition. Judgments are based on the information available at each balance sheet date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.16. Fair value measurements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s financial instruments include cash and cash equivalents, trade receivables, U.S. treasury bills, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.17. Share-based compensation expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically the Group has issued equity settled share-based compensation to certain employees (see note 19). Equity settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value so determined is expensed on a straight-line basis over the vesting period, based on the number of stock that will eventually vest and adjusted for the effect of non-market-based vesting conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of the charge is adjusted to reflect expected and actual levels of award vesting, except where failure to vest is as a result of not meeting a market condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancellations of equity instruments are treated as an acceleration of the vesting period and therefore any amount unrecognized that would otherwise have been recorded in future accounting periods is recognized immediately. The Group has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period in which the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is measured using a Black Scholes model. The key assumptions used in the model have been adjusted, based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any payment made to a counterparty on the cancellation or settlement of a grant of equity instruments (even if this occurs after the vesting date) should be accounted for as a repurchase of an equity interest (that is, as a deduction from equity). But, if the payment exceeds the fair value of the equity instruments repurchased (measured at the repurchase date), any such excess should be recognized as an expense.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.18. Equity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinary shares is determined using the nominal value of shares issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional paid-in capital account includes any premiums received on the initial issuing of the ordinary shares. Any transaction costs associated with the issuing of shares are deducted from the additional paid-in capital account, net of any related income tax benefits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity settled share-based payments are credited to a share-based payment reserve as a component of additional paid-in capital, until related options or warrants are exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation differences are included in the accumulated other comprehensive income.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated deficit includes all current and prior period results as disclosed in the consolidated statements of income (loss).</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.19. Loss per share</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic income/(loss) per share is computed by dividing the net income/(loss) attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net income/(loss) attributable to ordinary shareholders is computed as if all net income/(loss) for the period had been distributed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group computes diluted income/(loss) per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, except where the effect of such non-participating securities would be antidilutive. The Group been loss making for each fiscal year and therefore all potentially dilutive ordinary equivalents are considered to be antidilutive.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.20. Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d068121f-6b77-49ec-9e07-b676d008cab3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Group </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the new accounting standard for fiscal year end 2024. See the Segment Reporting policy above and Note 4 below for further detail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards issued but not yet adopted</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures, which provides for improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance is effective for annual periods beginning after December 15, 2024, and the adoption of this standard is not anticipated to have a material impact on the Group&#8217;s consolidated financial statements other than adding new disclosures, which the Group is currently evaluating.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The amendments in this update require disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The amendments are effective for annual periods beginning after December 15, 2026, and reporting periods beginning after December 15, 2027, with early adoption permitted. The Group is currently evaluating the impact to its consolidated financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163775744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Revenue</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from collaboration agreements for the years ended December 31, 2024, 2023 and 2022 predominately relates to the research collaboration agreements the Group entered into with Mallinckrodt in July 2019, AstraZeneca in March 2020, and Hansoh in October 2021.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue comprised $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of royalty income (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Research collaboration income (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disaggregation of revenue from contracts with customers is as follows:</span></span></p><div style="font-size:10pt;font-family:Arial;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Mallinckrodt plc</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - AstraZeneca</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,062</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Hansoh</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">30,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue from contracts with customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under its collaboration agreement with Mallinckrodt, the Group received an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2019 and are eligible to receive specified development, regulatory a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd commercial milestone payments. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> milestone payments under this agreement were achieved (2023: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) during the year ended December 31, 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes the upfront payment, milestone payments, payments for personnel costs and other research funding payments over time, in accordance with ASC 606.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2023, the Group reacquired e</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">xclusive worldwide rights to two preclinical siRNA assets under its Mallinckrodt collaboration, which resulted in a modification of the agreement. No additional performance obligations were identified as a result of the modification as there were no additional goods or services to be provided by the Group and the modification resulted in the partially satisfied performance obligations relating to the two reacquired targets becoming fully satisfied as the Group was no longer obligated to develop these targets. SLN501, the C3 targeting program, remained under the original collaboration agreement through March 2024. The Group accounted for the modification as if it were part of the existing contract as the remaining services to be delivered form part of a single performance obligation that is partially satisfied at the date of contract modification. The effect of the contract modification was that the consideration originally received for the two preclinical siRNA assets was reallocated to SLN501. The Group recognized the effect of the contract modification on the measure of progress towards complete satisfaction of the SLN501 performance obligation, and recognized an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis. The Group recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the contract modification date. In relation to the reacquired targets, the two preclinical siRNA assets were recognized at fair value. The fair value of those assets has been determined to be nil. Under the modification, the Group agreed to pay future success-based milestones and low single digit royalties on net sales if the projects advance. The Group will recognize these variable success-based milestones as an intangible asset at cost when triggered. Any royalties payable will be expensed in cost of sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, Mallinckrodt notified the Group that it will not pursue further development of the SLN501 program following the completion of the Phase 1 clinical trial. The completion of the Phase 1 clinical trial also represented the conclusion of all required development activities and commitments under the terms of the Mallinckrodt Collaboration. During the year ended December 31, 2024, the Group recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under its collaboration agreement with AstraZeneca, the Group received an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2020 with a further amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million received in May 2021. The Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is also eligible to receive specified development and commercial milestone payments as well as tiered royalties on net sales, if any. The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606. During the year ended December</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31, 2024, the Group achieved a milesto</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ne payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: nil). During the year ended December 31, 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group entered into a collaboration agreement with Hansoh on October 15, 2021. The Group received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, net of taxes) upfront payment to us in December 2021. The Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is eligible to receive development, regulatory and commercial milestones as well as royalties on Hansoh net product sales. During the year ended December 31, 2024, the Group achieved milestone pay</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ments totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Hansoh notified the Group that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration. During the year ended December 31, 2024, the Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2018, the Group entered into a settlement and license agreement with Alnylam Pharmaceuticals Inc. (&#8220;Alnylam&#8221;), pursuant to which the Group settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, the Group licenses specified patents to Alnylam, and Alnylam pays us a tiered royalty of up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> percent of net sales of ONPATTRO in the European Union. The Group was eligible to receive these royalties through December 2023. The Group invoices Alnylam quarterly in arrears based on sales data for that quarter as reported to us by Alnylam. Royalty revenue is recognized based on the level of sales when the related sales occur. During the year ended December 31, 2024, the Group recognized a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in royalty income from Alnylam (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163850192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. Segment reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fa405555-b8a0-41d6-bcd0-c5ceffcea501;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CODM</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reviews Consolidated net loss for the year when assessing the Group&#8217;s performance, allocating resources and establishing management&#8217;s compensation. In addition to Consolidated net loss, the CODM receives discrete information for revenue by major customer and geographic location. Consolidated net loss is used to monitor budget versus actual results and is reviewed against the Group&#8217;s peers and competitors as benchmarking. The Group operates as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment in the specific technology field of RNA therapeutics.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of its operating segment are the same as those described in the Group&#8217;s summary of significant accounting policies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group derives revenues from customers through royalty income and research collaboration agreements, each representing a major customer, specifically related to the development of RNAi-based medicines. Refer to Note 3 &#8211; Revenue for a further description of the types of products from which the Group derives its revenues.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The measure of segment assets is reported on the balance sheet as total consolidated assets.</span></p><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below provides segment information about the Group:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,867</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted development costs (a)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,048</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel research and development costs (b)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,187</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other R&amp;D costs (c)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General &amp; administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items (d)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,855</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,111</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">50,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel R&amp;D costs primarily consist of salaries and personnel-related costs for personnel performing R&amp;D activities or managing those activities that have been out-sourced; and consultants&#8217; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other R&amp;D costs include associated facility costs, equipment and other overheads that are directly attributable to R&amp;D and depreciation of capital assets used for research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The other segment items include foreign currency gain (loss), net, benefit from R&amp;D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An analysis of the group&#8217;s assets and revenues by location is shown below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.658%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.A.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.K.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,269</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31,<br/>&#160;&#160;&#160;2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163670544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Directors and Staff Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_DirectorsAndEmployeeRemunerationTextBlock', window );">Directors and Staff Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. Directors and staff costs</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Staff costs, including Directors&#8217; remuneration, during the year for the Group were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,264</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,744</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,901</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other pension costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,686</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total aggregate remuneration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">38,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">37,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_DirectorsAndEmployeeRemunerationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors and employee remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_DirectorsAndEmployeeRemunerationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060803136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income/(Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other Income/(Expense), Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. Other income/(expense), net</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bank interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion on U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,720</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">280</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163795072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Basic and Diluted)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share (Basic and Diluted)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. Loss per share (basic and diluted)</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing net loss (the numerator) by the weighted average shares outstanding for the period (the denominator). Diluted net loss per share is computed by dividing net income by the weighted average shares outstanding during the period adjusted for the dilutive effects of the exercise of the stock options. In periods when losses from continuing operations are reported, the weighted-average shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The computation of net loss per share for the years ended December 31, 2024, 2023 and 2022, respectively was as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.040000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,752,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,277,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,584,512</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Potentially Dilutive Securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,455,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,853,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571,487</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163842544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. Property, plant and equipment</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant, and equipment balances were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equipment &amp; Furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,498</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant, and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized in fiscal years 2024, 2023, and 2022, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163851936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. Goodwill</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is assessed annually at a reporting unit level, or whenever events and circumstances indicate impairment may have occurred. The Group has one reporting unit and performs a qualitative impairment test (also known as &#8220;Step 0"), and when necessary, a quantitative test. After assessing the totality of events and circumstances as part of the Step 0 test, it was determined that it is not more likely than not (a likelihood that is more than 50%) that the fair value of the reporting unit is less than its carrying amount and therefore a quantitative test is unnecessary. No triggering events were identified during the year.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in the carrying amount of goodwill:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at start of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060536032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Other intangible assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. Other intangible assets</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of December 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.451%;box-sizing:content-box;"></td>
        <td style="width:17.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">362</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intangible assets are amortized beginning from the date of acquisition, over their useful life or written down if they are considered to be impaired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amortization expense is included in General and administrative expenses, which included on the consolidated statements of income (loss), and was nominal for the years ended December 31, 2024, 2023 and 2022, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected future amortization expense is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:48.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expected Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment charges related to intangible assets were recorded for the years ended December 31, 2024, 2023 and 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060531632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash at bank and in hand</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">121,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">68,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash at bank comprises balances held by the Group in current, short-term bank deposits, and U.S. Treasury Bills with an original maturity of three months or less. The carrying amount of these assets approximates to their fair value.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059969184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">Other assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. Other assets</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VAT receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits for properties</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024 and 2023, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within prepayments at December 31, 2024 and 2023 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million respectively, are expenditures relating to research and development.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327170457168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_AccountsReceivableTextBlock', window );">Trade Receivables</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. Trade receivables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of trade receivables approximates to their fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No interest is charged on outstanding receivables. There were no overdue trade receivables balances.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has applied an expected credit loss model to the balance and determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowance is required for the periods ended December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_AccountsReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_AccountsReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163529904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Trade and Other Payables</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. Trade and other payables</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,697</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bonus accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,445</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,134</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of trade and other payables approximates to their fair value.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included within accruals and other payables at December 31, 2024 a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nd 2023 is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> respectively, are expenditures relating to research and development</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060798368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating lease for office space in London, which was renegotiated upon completion of the original term, with the new term beginning in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Group determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Group recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Group&#8217;s right to use the underlying asset for the lease term. Lease liabilities are the Group&#8217;s obligation to make the lease payments arising from a lease. As the Group&#8217;s lease does not provide an implicit rate, the Group&#8217;s lease liabilities are measured on a discounted basis using the Group&#8217;s incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> short-term leases in Berlin, Germany and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eight</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> leases in Hoboken, U.S., that have not been recognized as right-of-use assets. Both leases in Berlin are on a rolling contract basis with either party being able to end the lease with a cancellation notice period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months, while the leases in the United States are on a rolling contract basis with a notice period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Expense related to these short-term leases are recorded to the consolidated statements of income (loss) over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents supplemental balance sheet information related to the Group&#8217;s operating lease:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.7%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:28.44%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Group&#8217;s operating leases at December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">507</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">984</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of the Group&#8217;s operating leases at December 31, 2024:</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.18%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:31.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total expected lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163856032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ContractWithCustomerLiabilityTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. Contract liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities represent the Group&#8217;s obligation to transfer services to a customer for which the Group has received advanced consideration, before the performance obligation has been satisfied. These liabilities are recognized when a customer prepays for services or when the Group has an unconditional right to consideration before the performance obligation is fulfilled.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contract liabilities comprise entirely of advance consideration received from customers (deferred revenue) in respect of the Mallinckrodt, AstraZeneca plc, and Hansoh research collaborations. The current contract liabilities represent the amount of estimated revenue to be reported in the next 12 months related to amounts invoiced to its partners, while the non-current portion represents everything beyond 12 months. Current and non-current contract liabilities include future revenue from collaboration recharged expenses, upfront payments, and milestones achieved to December 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;">&#160;</p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange impact</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue unwound during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,113</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024 and 2023 contract liabilities decreased primarily due to the recognition of revenue in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, that was included in the contract liabilities balance at the beginning of the year.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ContractWithCustomerLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ContractWithCustomerLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060769392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17. Income taxes</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">he Group operates in the U.K. and is subject to income taxes in that jurisdiction. The U.K. tax rate applied for 2024 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for 2023), which results from applying the enacted statutory rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from January 1, 2023 through April 1, 2023, and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for the remainder of 2023 and 2024. U.K. deferred tax assets and liabilities have been measured at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The entire tax expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million relates to current tax as shown below. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> deferred tax was recognized in the year.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.611%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.342%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.062%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in estimate related to prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Origination and reversal of temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses (derecognition of<br/>&#160;&#160;&#160;previously recognized) deductible temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of the income tax credit at standard rate of U.K. corporation tax to the current tax credit are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit at the standard rate of U.K. corporation tax of </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%<br/>&#160;&#160;&#160;(2023: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%; 2022: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,432</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,286</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,456</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the standard U.K. statutory income tax rate to the effective tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax using U.K. statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate for loss from continuing operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t have any deferred tax liabilities as at December 31, 2024 and 2023. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of the Group&#8217;s deferred tax assets as at December 31, 2024 and 2023 are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading Losses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n trading losses is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated tax losses as of December 31, 2024 ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023) related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations in Germany for corporate income taxes and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated losses related to trade taxes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">German entity ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2023).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Movements in deferred tax valuation allowance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at January 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Decrease)/increase in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at December 31</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the Group does not have an establishment or place of business in China, the Group is subject to withholding tax on gross income from dividends, interest, lease of property, royalties, and other China-source passive income. In 2021 the Group entered into a collaboration agreement with Hansoh, a biopharmaceutical company in China and received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upfront paym</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ent, which required withholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In 2024 the Group received a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which required withholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In 2023 the Group received a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which required w</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ithholding tax of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year, the Group had not yet received the research and development tax credit related to the prior year. The Group has recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in respect of the current year for unfunded projects that are permissible to claim</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">under </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the SME scheme (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million). In addition, in 2024 we have also recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million related to the RDEC scheme (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060792464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18. Shareholders&#8217; equity</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized, allotted, called up and fully paid ordinary shares,<br/>&#160;&#160;&#160;par value &#163;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,674,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,846,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,808,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,224,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,615,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,936,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has only one class of share. All ordinary shares have equal voting rights and rank pari passu for the distribution of dividends.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2022, the Group announced a registered direct offering (the &#8220;Offering&#8221;) of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,950,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s ADSs, each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in underwriting discounts, commissions and estimated offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 15, 2021, the Group entered into an Open Market Sale Agreement (the "Sales Agreement"), with Jefferies LLC ("Jefferies"), pursuant to which the Group may offer and sell, from time to time, its ADSs through Jefferies. On October 15, 2021, the Group filed a registration statement, which became effective on October 22, 2021, for the issuance and sale of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of ADSs. During the year ended December 31, 2023, the Group sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million ADSs for net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses. In 2024, the Group raised additional proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses, from sales of ADSs under the Sales Agreement. On October 22, 2024, the Group filed a new registration statement on Form F-3 which replaced the registration statement originally filed on October 15, 2021, for the issuance and sale, if any, of up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of its shares represented by ADSs under the Sales Agreement. As of this filing, approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of ADSs remained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 5, 2024, the Group announced a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,714,286</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s ADSs, each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the shares issued during the current and previous year are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">118,846,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">39,615,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issued during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,418,665</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,791</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.81</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.32</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.44</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,998</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.98</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.68</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.56</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.81</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.38</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.13</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.64</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.50</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.50</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.01</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.34</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.87</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">141,674,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of equivalent ADS in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47,224,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, there were opti</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ons outstanding of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,455,390</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,853,459</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571,487</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) unissued ordinary shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the options outstanding are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:12.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year of issue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average Exercise price (&#163;)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">WeightedaverageExerciseprice($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options expired</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average years to expiry date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2014</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2015</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2016</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,524</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.92</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2018</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577,698</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">347,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.77</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2020</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">532</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,178</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.42</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.37</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662,344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,419,863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,037</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,310,498</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.33</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,269,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,247</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,148,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.20</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,255,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (ADSs)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">111,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">152,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">469,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,818,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (Ordinary<br/>&#160;&#160;&#160;Shares)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,853,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,802,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">334,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">457,998</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,408,443</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,455,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ADSs represent </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares and the exercise price was also converted to represent an ADS price at an exchange rate equal to the closing current year currency conversion of sterling pounds to US dollars, which was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sterling pounds to 1 US Dollar.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060813200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Settled Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity-Settled Share-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19. Equity-settled share-based compensation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has issued share options under the 2018 Long Term Incentive Plan (&#8220;LTIP&#8221;), 2018 Non-Employee Long Term Inventive Plan (&#8220;Non-Employee LTIP&#8221;), and individual share option contracts, open to all employees of the Group, as well as EMI shares (none of which remain outstanding at December 31, 2024). </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the LTIP, Non-Employee LTIP, individual contracts and schemes available, the options typically vest after three years, with the exception of some options granted to certain members of key management personnel. The vesting period for these options ranges from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> months.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options usually lapse after one year following the employee leaving the Group.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.881%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,857,162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,684,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,940,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lapsed or forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">871,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">469,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the year-end (ADS/$)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,818,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,264,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,857,162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">578,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at the year-end</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870,106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,420,614</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,889,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table above shows the number of options in relation to ordinary shares and equivalent ADSs outstanding and exercisable at year end, on the conversion ratio of three ordinary share options to one ADS.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options outstanding at the year-end have a weighted average remaining contractual life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years (2023: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of total unrecognized compensation cost related to stock options granted but not vested under the Company&#8217;s plans. That cost will be recognized over an expected remaining weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In the years ended December 31, 2024, 2023 and 2022 the total intrinsic value of stock options exercised was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The weighted average share price at the date of exercise of the options during the year was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#894; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.06</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,802,542</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> share options during the year (2023: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,703,826</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,821,131</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted were calculated using Black Scholes model. Inputs into the model were as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs and assumptions for options granted in the year:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option life (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.39</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.97</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average grant data fair value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognized total charges of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) related to equity settled </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">share-based payment transactions during the year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group does not bear any responsibility to settle any employee tax obligations that arise on the exercise of share options. The estimated employer tax obligation on outstanding options at the year-end was nominal (2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060803920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock', window );">Capital Commitments and Contingent Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20. Capital commitments and contingent liabilities</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> capital commitments at December 31, 2024 (2023: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7e7a64d4-569d-4871-a6b1-2ad84515628e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; 2022: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_40e46a58-04d9-4131-ab73-072c46c316bb;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nil</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments, contingencies, and guarantees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 460<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/460/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060807904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments Under Short Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Under Short Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21. Commitments under short leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At December 31, 2024, the Group had</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a gross commitment on its office rental and service charge in Berlin, Germany and the Hoboken, U.S. lease equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (2023: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million; 2022: $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) in the next year. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> amounts are payable after more than one year.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the Group enters into contracts in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">normal course of business with contract research organizations to assist in the performance of research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancellable contracts and not reflected in the disclosure above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060790416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock', window );">Financial Instruments and Risk Management</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22. Financial instruments and risk management</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s financial instruments comprise primarily cash and other financial assets and various items such as receivables and trade payables which arise directly from its operations. The main purpose of these financial instruments is to provide working capital for the Group&#8217;s operations. The Group assesses counterparty risk on a regular basis. Board approval is required for adoption of any new financial instrument or counterparty. The primary focus of the treasury function is preservation of capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Directors consider that the carrying amount of these financial instruments approximates to their fair value.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concentration of credit risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents and U.S. Treasury Bills. Cash and cash equivalents, term deposits and U.S. Treasury Bills are not considered to be exposed to significant credit risk due to the fact they are held in a financial institution with an &#8220;A&#8221; rating. The Group considers the possibility of significant loss in the event of non-performance by a financial counterparty to be remote.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group regularly monitors the creditworthiness of its collaborators and at the reporting date, no financial assets are credit impaired.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital management</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group considers its capital to be equal to the sum of its total equity. The Group monitors its capital using a number of measures including cash flow projections, working capital ratios, the cost to achieve preclinical and clinical milestones and potential revenue from existing partnerships and ongoing licensing activities. The Group&#8217;s objective when managing its capital is to ensure it obtains sufficient funding for continuing as a going concern. The Group funds its capital requirements through the issue of new shares to investors, milestone and research support payments received from existing licensing partners and potential new licensees.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest rate risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The nature of the Group&#8217;s activities and the basis of funding are such that the Group has significant liquid resources. The Group uses these resources to meet the cost of future research and development activities. Consequently, it seeks to minimize risk in the holding of its bank deposits while maintaining a reasonable rate of interest. The Group is not financially dependent on the income earned on these resources and therefore the risk of interest rate fluctuations is not significant to the business. Nonetheless, the Directors take steps to secure rates of interest which generate a return for the Group.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit and liquidity risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Credit risk is managed on a Group basis. Funds are deposited with financial institutions with a credit rating equivalent to, or above, the main U.K. clearing banks. The Group&#8217;s liquid resources are invested having regard to the timing of payments to be made in the ordinary course of the Group&#8217;s activities. All financial liabilities are payable in the short term (between zero and three months) and the Group maintains adequate bank balances in either instant access or short-term deposits to meet those liabilities as they fall due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group only enters into collaboration agreements with large, reputable companies and the creditworthiness of collaborators is monitored on an ongoing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected loss rates are based on payment profiles of past receivables and the aging profiles of outstanding balances at the reporting period end date. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customer to settle the receivables. At the year-end there were no debts that were past due or are expected to be past due. It was therefore concluded on this basis that there were no expected credit losses for the trade receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trade receivables are written off where there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery includes, but is not limited to, a failure to engage in a repayment plan with the Group.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currency risk</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s transactions are commonly denominated in U.K pounds sterling; however, the Group receives payments under its collaboration agreements in U.S. dollars and it incurs a portion of its expenses in other currencies, primarily Euros, and are exposed to the effects of these exchange rates. The Group seeks to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in these other currencies. Where significant foreign currency cash receipts are expected, the Group considers the use of forward exchange contracts to manage its exchange rate exposure.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial instruments and risk management disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327167505024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23. Related party transactions</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, the Group agreed to pay Gladstone Consultancy Partnership, a company controlled by the Group&#8217;s Non-Executive Chairman, Iain Ross, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand (plus any applicable value added tax) for consulting and advisory services provided by Mr. Ross. Gladstone Consulting Partnership is no longer being engaged by the Group in 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060023456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24. Subsequent events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327063171280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.1. Basis of preparation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC"). Any reference in these notes to the applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of the Group and its wholly owned subsidiaries, after elimination of intercompany accounts and transactions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group previously prepared its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (&#8220;IASB&#8221;)  when the Group qualified as a foreign private issuer under the rules and regulations of the SEC. In connection with the loss of the Group&#8217;s status as a foreign private issuer, the Group is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Group&#8217;s inception.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock', window );">Functional and reporting currency</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.2. Functional and reporting currency</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The reporting currency of the consolidated financial statements is the U.S. Dollars (&#8220;USD&#8221; or &#8220;$&#8221;). The functional currency of the Group&#8217;s subsidiaries reflects the economic environment of their respective operations. All amounts disclosed have been rounded to the nearest thousand, unless otherwise stated.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to the loss of the Group&#8217;s status as a foreign private issuer, the Group as a domestic filer, changed its reporting currency of the consolidated financial statements from GBP to USD. The change in reporting currency was applied retrospectively. Consolidated financial statements for all periods have been recast into USD and presented to the nearest thousand dollars.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.3. Principles of consolidation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial information comprises the financial statements of Silence Therapeutics plc and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4. Use of estimates</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, the recognition of revenue and research and development expenses. The</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Group </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_GoingConcernPolicyPolicyTextBlock', window );">Going concern</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.5. Going concern</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has incurred recurring losses since inception, including net losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2024. As of December 31, 2024, the Group had accumulated losses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and cash outflows from operating activities for the year ended 31, December 2024 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group expects to incur operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Group may develop.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Group has funded its operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options to support its continued operations. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, the Group raised additional proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses, from sales of ADSs under its Sales Agreement. On February 5, 2024, the Group announced a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,714,286</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Group&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS, with new and existing institutional and accredited investors (the &#8220;Private Placement&#8221;). The aggregate gross proceeds of the Private Placement were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million before deducting approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in placement agent fees and other expenses. In 2024, the Group received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million milestone payment from the AstraZeneca Collaboration and achieved another $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in milestone payments from the Hansoh collaboration. As of December 31, 2024, the Group had cash and cash equivalents and short-term investments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group believes that its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months from the issuance date of these consolidated financial statements. For this reason, the Group continues to adopt the going concern basis in preparing the financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group will need to raise additional funding to fund its operation expenses and capital expenditure requirements in relation to its clinical development activities. The Group may seek additional funding through public or private financings, debt financing or collaboration agreements. Specifically, the Group may receive future milestone payments from existing collaboration agreements which will extend the ability to fund operations. However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur. The inability to obtain future funding could impact; the Group&#8217;s financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.6. Segment reporting</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has determined that its chief executive officer is the chief operating decision maker (&#8220;CODM&#8221;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Group has concluded that it operates as a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">single</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reportable segment (see Note 4).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.7. Revenue recognition</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s revenue for the year ended December 31, 2024, consists of royalty income and revenue from collaboration agreements. To determine revenue recognition for arrangements that the Group determines are within the scope of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ASC 606: Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, (&#8220;ASC 606&#8221;), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">revenue when, or as, the Group satisfies the performance obligations. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty income</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s royalty income is generated by a settlement and license agreement with Alnylam. Under this contract, Alnylam is obliged to pay royalties to the Group on the net sales of ONPATTRO&#153; in the EU in a manner commensurate with the contractual terms. Invoices are raised in arrears on a quarterly basis based on sales information provided by Alnylam no later than </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> days after the quarter end.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under ASC 606, royalty income is recognized at the later date of (i) when the subsequent sale of the commercial partner&#8217;s product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from collaboration agreements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group has considered the Mallinckrodt, AstraZeneca, and Hansoh contracts and assessed whether the research and development services and license of the IP in respect of each target are distinct.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For all contracts the Group has concluded the license of the intellectual property and the R&amp;D services are not distinct, as Mallinckrodt, AstraZeneca, and Hansoh cannot benefit from the intellectual property absent the R&amp;D services, as those R&amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, and these services could not be performed by another party, indicating that the two are highly interrelated. On this basis, the Group has concluded that there is a single performance obligation covering both the R&amp;D services and the license of the intellectual property in respect of each target. The Group recognizes revenue over the duration of the contract based on an input method based on cost to cost.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The contracts have multiple elements of consideration (some or all of the following), namely:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments (fixed);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent milestone payments (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FTE costs rechargeable (variable);</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recharges of direct costs for certain research activities (variable).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s effort under the contracts continues throughout their entire duration. On this basis revenue is recognized over the contract period based on costs to completion.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been calculated on the following ongoing basis for the year ended December 31, 2024:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total contract costs which includes actual FTE and direct costs incurred up to December 31, 2024 and forecast FTE and direct costs for the remainder of the contract</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Actual costs incurred up until December 31, 2024 are calculated as a percentage of total contract costs (actual and forecast)</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This percentage is then multiplied by the transaction price allocated to the performance obligation in question, thus calculating the cumulative revenue which is then used to calculate the revenue to be recognized in that period. In the case of the upfront and milestones, the consideration that is multiplied is in relation to the upfront and completed milestones only. Consideration in relation to milestones not yet been achieved is excluded from the calculation. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forecast costs are monitored each period, with revenue recognized reflecting any changes in forecast or over/under spend in actuals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details of the revenue amounts recognized in the year ended December 31, 2024 can be found in note 3.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.8. Research and development</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development costs consist of salary and personnel related costs and third party costs for the Group's research and development activities. Personnel related costs include a share based compensation charge relating to its stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group recognizes expenditure incurred in carrying out its research and development activities in line with management&#8217;s best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion. In all cases, the full cost of each study or activity is expensed by the time the final report or, where applicable, product, has been received. Further details on research and development can be found in note 2.15.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.9. Taxation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current tax liabilities are calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a company that carries out extensive research and development activities, the Group currently benefits from the U.K. research and development tax credit regime for small or medium-sized enterprises (&#8220;SMEs&#8221;). A benefit receivable arises from the U.K. legislation regarding the treatment of certain qualifying research and development costs, allowing for the surrender of tax losses attributable to such costs in return for a tax rebate. Research and development tax credits are recognized when the receipt is probable. Research and development costs which are not eligible for reimbursement under the U.K. Research and Development Tax Credit scheme, such as expenditure incurred on research projects for which the group receives income, may be reimbursed under the U.K. Research and Development Expenditure Credit (&#8220;RDEC&#8221;) scheme. Amounts receivable under either scheme are presented within the consolidated statements of income (loss) within Benefit from R&amp;D credit. The U.K. R&amp;D tax credit is fully refundable to the Group and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the U.K. R&amp;D tax credit as a benefit which is included in net loss before income tax and, accordingly, not reflected it as part of the income tax provision.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Group&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Group assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in consolidated statements of income (loss) in the period that includes the enactment date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.10. Foreign currency translation</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies area remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of income (loss) and comprehensive income (loss) for each respective period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For financial reporting purposes, the consolidated financial statements of the Group have been presented in USD, the reporting currency. The financial statements of the Group&#8217;s entities are translated from their functional currency into USD as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, revenues and expenses are translated at the average exchange rates for the periods presented, and shareholders&#8217; equity is translated at the prevailing historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#8217; equity.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.11. Cash and cash equivalents</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group considers cash and cash equivalents to comprise of cash on hand and demand deposits with original maturities of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.12. Property, plant and equipment</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group only holds equipment and furniture. These are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life of furniture and equipment is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years. Estimated useful life and residual values are reviewed each year and amended if necessary.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant and equipment is assessed for impairment upon triggering events that indicate the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group&#8217;s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.13. Leases</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group determines if an arrangement contains a lease at inception. The Group currently only has operating leases. The Group recognizes a right-of-use ("ROU") operating lease asset and associated short- and long-term operating lease liability in its consolidated balance sheets for operating leases greater than one year. Its right-of-use assets represent its right to use an underlying asset for the lease term and its lease liabilities represent its obligation to make lease payments arising from the lease arrangement. The Group recognizes its right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments it will pay over the lease term. The Group determines the lease term at the inception of each lease, and in certain cases its lease term could include renewal options if the Group concludes it is reasonably certain to exercise the renewal option. When the Group exercises a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lease option that was not previously included in the initial lease term, it reassesses its right-of-use asset and lease liabilities for the new lease term.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As its operating lease do not provide an interest rate implicit in the lease, the Group uses its incremental borrowing rate, based on the information available as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Group recognizes lease expense for its minimum lease payments on a straight-line basis over the expected term of its lease. Its leases do not include material variable or contingent lease payments.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Leases with an initial term of 12 months or less are not recorded on the balance sheet. Instead, these lease payments are recognized on the consolidated statements of income (loss) on a straight-line basis over the lease term.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similar to property, plant and equipment, ROU lease asset impairment is assessed upon triggering events that indicate the carrying amount may not be recovered by comparison to the future net undiscounted cash flows.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.14. Goodwill</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is the excess of the purchase price over the estimated fair values of the underlying net assets of an acquired business. The Group assesses goodwill for impairment annually, or immediately if conditions indicate that such impairment could exist. Impairment testing for goodwill is performed at the reporting unit level. The Group first evaluates qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates potential impairment, or if the Group elects to bypass the qualitative assessment, a quantitative test is performed. The quantitative test calculates the excess of the reporting unit&#8217;s fair value over its carrying amount, including goodwill, utilizing a discounted cash flow method. The test for impairment of goodwill requires the Group to make several assumptions and estimates regarding market conditions and its future profitability to determine the fair value of the goodwill at the reporting unit. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit net assets exceeds the estimated fair value of the reporting unit. Impairment losses recognized for the reporting unit to which goodwill has been allocated are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the reporting unit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All goodwill for the Group is attributed to an acquisition that occurred in 2005 and the Group has determined that </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> impairment was recorded as of December 31, 2024 and 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Other intangible assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.15. Other intangible assets</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other intangible assets that are acquired by the Group are stated at cost less accumulated amortization and less accumulated impairment losses. Amortization is charged to the consolidated statements of income (loss) on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. Other intangible assets are amortized from the date they are available for use. The estimated useful lives are as follows:</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Licenses and software: </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> - </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with research activities are treated as an expense in the period in which they are incurred.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs that are directly attributable to the development phase of software will only be recognized as intangible assets provided they meet the following requirements:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an asset is created that can be separately identified;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the technical feasibility exists to complete the intangible asset so that it will be available for sale or use and the Group has the intention and ability to do so;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">it is probable that the asset created will generate future economic benefits either through internal use or sale; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sufficient technical, financial and other resources are available for completion of the asset; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the expenditure attributable to the intangible asset during its development can be reliably measured.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Careful judgment by management is applied when deciding whether recognition requirements for software development costs have been met. This is necessary as the economic success of any product development is uncertain and may be subject to future technical problems at the time of recognition. Judgments are based on the information available at each balance sheet date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.16. Fair value measurements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group&#8217;s financial instruments include cash and cash equivalents, trade receivables, U.S. treasury bills, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.17. Share-based compensation expense</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically the Group has issued equity settled share-based compensation to certain employees (see note 19). Equity settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value so determined is expensed on a straight-line basis over the vesting period, based on the number of stock that will eventually vest and adjusted for the effect of non-market-based vesting conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The value of the charge is adjusted to reflect expected and actual levels of award vesting, except where failure to vest is as a result of not meeting a market condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancellations of equity instruments are treated as an acceleration of the vesting period and therefore any amount unrecognized that would otherwise have been recorded in future accounting periods is recognized immediately. The Group has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period in which the forfeiture occurs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value is measured using a Black Scholes model. The key assumptions used in the model have been adjusted, based on management&#8217;s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any payment made to a counterparty on the cancellation or settlement of a grant of equity instruments (even if this occurs after the vesting date) should be accounted for as a repurchase of an equity interest (that is, as a deduction from equity). But, if the payment exceeds the fair value of the equity instruments repurchased (measured at the repurchase date), any such excess should be recognized as an expense.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.18. Equity</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ordinary shares is determined using the nominal value of shares issued.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional paid-in capital account includes any premiums received on the initial issuing of the ordinary shares. Any transaction costs associated with the issuing of shares are deducted from the additional paid-in capital account, net of any related income tax benefits.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity settled share-based payments are credited to a share-based payment reserve as a component of additional paid-in capital, until related options or warrants are exercised.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foreign currency translation differences are included in the accumulated other comprehensive income.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accumulated deficit includes all current and prior period results as disclosed in the consolidated statements of income (loss).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.19. Loss per share</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic income/(loss) per share is computed by dividing the net income/(loss) attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net income/(loss) attributable to ordinary shareholders is computed as if all net income/(loss) for the period had been distributed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Group computes diluted income/(loss) per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, except where the effect of such non-participating securities would be antidilutive. The Group been loss making for each fiscal year and therefore all potentially dilutive ordinary equivalents are considered to be antidilutive.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.20. Recently Issued Accounting Pronouncements</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently adopted accounting standards</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the FASB issued </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d068121f-6b77-49ec-9e07-b676d008cab3;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This guidance expands public entities&#8217; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#8217;s financial statements. The Group </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> the new accounting standard for fiscal year end 2024. See the Segment Reporting policy above and Note 4 below for further detail.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounting standards issued but not yet adopted</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes (Topic 740): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures, which provides for improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance is effective for annual periods beginning after December 15, 2024, and the adoption of this standard is not anticipated to have a material impact on the Group&#8217;s consolidated financial statements other than adding new disclosures, which the Group is currently evaluating.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The amendments in this update require disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The amendments are effective for annual periods beginning after December 15, 2026, and reporting periods beginning after December 15, 2027, with early adoption permitted. The Group is currently evaluating the impact to its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Functional and reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_GoingConcernPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_GoingConcernPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060541488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Disaggregation of Revenue from Contracts with Customers</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disaggregation of revenue from contracts with customers is as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Mallinckrodt plc</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,149</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,425</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - AstraZeneca</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,957</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,062</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,287</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - Hansoh</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,573</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">722</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration - total</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">30,933</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">710</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue from contracts with customers</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060776976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below provides segment information about the Group:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,810</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,867</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contracted development costs (a)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,902</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,048</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,322</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Personnel research and development costs (b)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,503</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,468</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,187</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other R&amp;D costs (c)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,478</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,421</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General &amp; administrative expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,884</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax expense</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other segment items (d)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,855</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,111</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,394</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">45,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">54,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">50,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Personnel R&amp;D costs primarily consist of salaries and personnel-related costs for personnel performing R&amp;D activities or managing those activities that have been out-sourced; and consultants&#8217; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other R&amp;D costs include associated facility costs, equipment and other overheads that are directly attributable to R&amp;D and depreciation of capital assets used for research and development activities.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The other segment items include foreign currency gain (loss), net, benefit from R&amp;D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Summary of Group's Assets and Revenues by Location</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An analysis of the group&#8217;s assets and revenues by location is shown below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.418%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.658%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.A.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.K.</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Germany</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">As at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">As at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,103</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,269</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,940</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">715</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,643</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue analysis for the year ended December 31,<br/>&#160;&#160;&#160;2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research collaboration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,114</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">43,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163855536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Directors and Staff Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_DirectorsAndEmployeeRemunerationTableTextBlock', window );">Schedule of Staff Costs Including Director's Remuneration</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Staff costs, including Directors&#8217; remuneration, during the year for the Group were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Wages and salaries</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,434</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,158</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,264</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,744</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,901</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,774</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other pension costs</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">609</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments charge</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,307</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,274</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,686</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total aggregate remuneration</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">38,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">37,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">33,255</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_DirectorsAndEmployeeRemunerationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors And Employee Remuneration [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_DirectorsAndEmployeeRemunerationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163710384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income/(Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Income/Expense, Net</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bank interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">704</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accretion on U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,720</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other income</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,803</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">280</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163740896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Basic and Diluted) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The computation of net loss per share for the years ended December 31, 2024, 2023 and 2022, respectively was as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.040000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares outstanding (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">138,752,224</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111,277,250</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,584,512</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share (basic and diluted)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.33</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.52</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.52%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Potentially Dilutive Securities</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,455,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,853,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,571,487</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163856032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant, and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property, plant, and equipment balances were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equipment &amp; Furniture</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,343</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,525</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,498</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant, and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,818</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163830928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the changes in the carrying amount of goodwill:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at start of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,683</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Translation adjustment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,392</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">9,981</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327058852912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets as of December 31, 2024 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.451%;box-sizing:content-box;"></td>
        <td style="width:17.077%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.017%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">547</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated Depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">169</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and software, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">312</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">362</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Future Amortization Expense</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expected future amortization expense is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.54%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:48.46%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Expected Amortization</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060455104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash at bank and in hand</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,819</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">US Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,740</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,970</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total Cash and cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">121,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">68,789</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163875808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.76%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.86%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></td>
        <td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,124</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">VAT receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,245</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">14,664</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,630</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deposits for properties</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,234</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,284</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term assets</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,590</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163750576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ScheduleOfAccountsReceivableTableTextBlock', window );">Schedule of Trade Receivables</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">972</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">290</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ScheduleOfAccountsReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accounts Receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ScheduleOfAccountsReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060023456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Trade and Other Payables</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,697</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,348</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Social security and other taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">244</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">734</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,361</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bonus accrual</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,445</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,134</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate income tax payable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">652</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">474</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total trade and other payables</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">16,399</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,537</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327171747280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock', window );">Summary of Supplemental Balance Sheet Information Related to Operating Lease</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents supplemental balance sheet information related to the Group&#8217;s operating lease:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.7%;box-sizing:content-box;"></td>
        <td style="width:1.58%;box-sizing:content-box;"></td>
        <td style="width:28.44%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.12%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.02%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classification</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-current assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">370</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">228</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liability - non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock', window );">Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Group&#8217;s operating leases at December 31, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:14.883%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average remaining lease term</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.75</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.75</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;years</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Total Operating Lease Cost</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">242</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">600</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">507</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease cost</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">984</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">842</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">587</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summarizes of Maturities of Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the maturities of the Group&#8217;s operating leases at December 31, 2024:</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.18%;box-sizing:content-box;"></td>
        <td style="width:1.38%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:31.44%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fiscal year</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total expected lease payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease weighted-average remaining lease term and weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information related to operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327167729808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Liabilities</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">306</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,571</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,790</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,001</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total contract liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">At January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign exchange impact</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,428</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additions during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,328</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,611</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue unwound during period</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,113</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,934</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">52,096</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">81,572</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060500720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Tax Expense</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.611%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.342%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.982%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.062%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">&#160;</p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current Year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in estimate related to prior years</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">496</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred Tax Expense</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Origination and reversal of temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Recognition of previously unrecognized tax losses (derecognition of<br/>&#160;&#160;&#160;previously recognized) deductible temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Taxation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Credit</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reconciliation of the income tax credit at standard rate of U.K. corporation tax to the current tax credit are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss before tax</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,464</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,272</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,646</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit at the standard rate of U.K. corporation tax of </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%<br/>&#160;&#160;&#160;(2023: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%; 2022: </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,116</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,530</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,432</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,356</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,286</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,346</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">673</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,423</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,641</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,456</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">495</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">202</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">465</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">845</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">956</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">688</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the standard U.K. statutory income tax rate to the effective tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(%)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax using U.K. statutory rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income not taxable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowances</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustment in respect of prior year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of overseas taxes</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate for loss from continuing operations</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Components of the Group&#8217;s deferred tax assets as at December 31, 2024 and 2023 are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$000s</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading Losses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,563</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payments</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,670</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital losses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,467</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,506</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross deferred tax asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n trading losses is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated tax losses as of December 31, 2024 ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023) related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations in Germany for corporate income taxes and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated losses related to trade taxes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">German entity ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2023).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Movements in Deferred Tax Valuation Allowance</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Movements in deferred tax valuation allowance:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.16%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.357%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at January 1</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,703</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Decrease)/increase in valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,293</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,036</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at December 31</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,446</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,739</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060516304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares Outstanding</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Authorized, allotted, called up and fully paid ordinary shares,<br/>&#160;&#160;&#160;par value &#163;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.05</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,288</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,847</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,151</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,674,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,846,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,808,472</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,224,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,615,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,936,157</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Details of Shares Issued</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the shares issued during the current and previous year are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.22%;box-sizing:content-box;"></td>
        <td style="width:1.48%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:16.3%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">118,846,966</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of ADS in issue at December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">39,615,655</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares issued during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,418,665</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.07</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,540</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.40</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">268,791</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.24</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.81</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.32</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.44</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.53</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">584,316</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.20</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.73</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,998</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.98</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.33</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.68</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.56</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.81</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.27</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.31</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,841</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.38</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.13</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126,144</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.64</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.55</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,248</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.50</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.50</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.41</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.80</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,500</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.01</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.34</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,545</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Options exercised at $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.60</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ADS or $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.87</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/ordinary share</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,436</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of shares in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">141,674,074</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of equivalent ADS in issue at December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">47,224,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Options Outstanding</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Details of the options outstanding are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:12.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:6.741%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:7.021%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year of issue</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average Exercise price (&#163;)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">WeightedaverageExerciseprice($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>January 1, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options granted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options expired</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options exercised</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">At<br/>December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted average years to expiry date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2014</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2015</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.31</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.51</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2016</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.14</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,857</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,524</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.19</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2017</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,999</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,333</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.92</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2018</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.16</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,596</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,593</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.26</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2019</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.36</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">577,698</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">347,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,997</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.77</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2020</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.44</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.23</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,207</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">532</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,497</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,178</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.42</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2021</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.37</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662,344</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,691</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,015</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">576,136</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.25</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.46</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.49</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,419,863</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,037</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,019</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,310,498</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.33</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.86</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.88</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,269,589</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,858</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,127</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,247</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,148,357</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.20</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.12</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,255,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (ADSs)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">111,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">152,666</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">469,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,818,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total (Ordinary<br/>&#160;&#160;&#160;Shares)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,853,459</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">3,802,542</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">334,170</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">457,998</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,408,443</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">17,455,390</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163850192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Settled Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Options</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The options usually lapse after one year following the employee leaving the Group.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:23.745%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.421%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:5.881%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of<br/>ADSs (1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Options</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,857,162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,684,233</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.32</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267,514</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.05</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,567,942</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.01</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,940,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lapsed or forfeited during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">264,056</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.82</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">871,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.50</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">709,531</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.25</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">469,481</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.55</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269,309</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.89</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,917</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding at the year-end (ADS/$)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,818,463</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.95</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,284,486</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.80</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,264,060</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,857,162</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">578,574</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercisable at the year-end</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,870,106</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,420,614</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.34</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,889,460</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.24</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary Fair Value of Options Granted were Calculated Using Black Scholes Model</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of options granted were calculated using Black Scholes model. Inputs into the model were as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.162%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.242%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2022</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs and assumptions for options granted in the year:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average ADS price ($)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Option life (years)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.9</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74.4</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78.6</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk free rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.39</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.97</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.43</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.16</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.57</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">nil</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average grant data fair value ($)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.6</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067687456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>USD ($) </div>
<div>OrdinaryShare </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,309,000)<span></span>
</td>
<td class="num">$ (54,228,000)<span></span>
</td>
<td class="num">$ (50,334,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,044,000<span></span>
</td>
<td class="nump">431,894,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,640,000)<span></span>
</td>
<td class="num">(49,462,000)<span></span>
</td>
<td class="num">(57,044,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting standards update [extensible enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate202307Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement | American Depositary Shares | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Placement agent fees and other expenses</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued | shares</a></td>
<td class="nump">5,714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity', window );">Number of ordinary shares in American Depositary Share | OrdinaryShare</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds from private placement</a></td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember', window );">Collaboration Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember', window );">Collaboration Agreement with Hansoh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Licenses and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_InvoiceRaiseDurationAfterQuarterEnd', window );">Invoice raise duration after quarter end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">75 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Licenses and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_InvoiceRaiseDurationAfterQuarterEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Invoice Raise Duration After Quarter End</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_InvoiceRaiseDurationAfterQuarterEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares denominated in temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sln_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sln_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sln_LicensesAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sln_LicensesAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sln_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sln_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327066939376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,258,000<span></span>
</td>
<td class="nump">$ 31,643,000<span></span>
</td>
<td class="nump">$ 21,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,096,000<span></span>
</td>
<td class="nump">81,572,000<span></span>
</td>
<td class="nump">87,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithMallinckrodtMember', window );">Collaboration Agreement with Mallinckrodt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">13,100,000<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Contract with customer, asset, cumulative catch-up adjustment to revenue, modification of contract</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember', window );">Collaboration Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">17,100,000<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember', window );">Collaboration Agreement with Hansoh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,600,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ContractWithCustomerLiabilityNetOfTax', window );">Upfront cash payments received, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_SettlementAndLicenseAgreementWithAlnylamMember', window );">Settlement and License Agreement with Alnylam | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PercentageOfRoyaltyOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember', window );">Royalty Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">710,000<span></span>
</td>
<td class="nump">715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember', window );">Royalty Income | Settlement and License Agreement with Alnylam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember', window );">Research Collaboration Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,114,000<span></span>
</td>
<td class="nump">$ 30,933,000<span></span>
</td>
<td class="nump">$ 20,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ContractWithCustomerLiabilityNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ContractWithCustomerLiabilityNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PercentageOfRoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PercentageOfRoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithMallinckrodtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithMallinckrodtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithAstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_SettlementAndLicenseAgreementWithAlnylamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_SettlementAndLicenseAgreementWithAlnylamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327050468464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">$ 43,258<span></span>
</td>
<td class="nump">$ 31,643<span></span>
</td>
<td class="nump">$ 21,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationMallinckrodtPlcMember', window );">Research Collaboration - Mallinckrodt plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">13,149<span></span>
</td>
<td class="nump">14,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationAstraZenecaMember', window );">Research Collaboration - AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">17,957<span></span>
</td>
<td class="nump">17,062<span></span>
</td>
<td class="nump">6,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationHansohMember', window );">Research collaboration - Hansoh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">24,573<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember', window );">Research Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="nump">30,933<span></span>
</td>
<td class="nump">20,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue from contracts with customers</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 710<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationMallinckrodtPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationMallinckrodtPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationHansohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_ResearchCollaborationHansohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sln_ResearchCollaborationIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sln_RoyaltyIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163779008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">The CODM reviews Consolidated net loss for the year when assessing the Group&#8217;s performance, allocating resources and establishing management&#8217;s compensation. In addition to Consolidated net loss, the CODM receives discrete information for revenue by major customer and geographic location. Consolidated net loss is used to monitor budget versus actual results and is reviewed against the Group&#8217;s peers and competitors as benchmarking. The Group operates as one reportable segment in the specific technology field of RNA therapeutics.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067839184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Segment Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 43,258<span></span>
</td>
<td class="nump">$ 31,643<span></span>
</td>
<td class="nump">$ 21,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(11,810)<span></span>
</td>
<td class="num">(12,867)<span></span>
</td>
<td class="num">(13,463)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Contracted development costs</a></td>
<td class="num">(42,902)<span></span>
</td>
<td class="num">(35,048)<span></span>
</td>
<td class="num">(24,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PersonnelResearchAndDevelopmentCosts', window );">Personnel research and development costs</a></td>
<td class="num">(20,503)<span></span>
</td>
<td class="num">(19,468)<span></span>
</td>
<td class="num">(17,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other R&amp;D costs</a></td>
<td class="num">(4,478)<span></span>
</td>
<td class="num">(2,421)<span></span>
</td>
<td class="num">(2,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(26,884)<span></span>
</td>
<td class="num">(26,222)<span></span>
</td>
<td class="num">(25,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax expense</a></td>
<td class="num">(845)<span></span>
</td>
<td class="num">(956)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">18,855<span></span>
</td>
<td class="nump">11,111<span></span>
</td>
<td class="nump">11,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PersonnelResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel Research And Development Costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PersonnelResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327066803024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Group's Assets and Revenues by Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">$ 15,269<span></span>
</td>
<td class="nump">$ 16,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_RevenueFromContractWithCustomerResearchCollaboration', window );">Research collaboration</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="nump">30,934<span></span>
</td>
<td class="nump">$ 20,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_RevenueFromRoyalties', window );">Royalties</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">43,258<span></span>
</td>
<td class="nump">31,643<span></span>
</td>
<td class="nump">21,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">UK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">4,103<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_RevenueFromContractWithCustomerResearchCollaboration', window );">Research collaboration</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="nump">30,934<span></span>
</td>
<td class="nump">20,940<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">43,114<span></span>
</td>
<td class="nump">30,934<span></span>
</td>
<td class="nump">20,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">11,166<span></span>
</td>
<td class="nump">11,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_RevenueFromRoyalties', window );">Royalties</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_RevenueFromContractWithCustomerResearchCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from contract with customer research collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_RevenueFromContractWithCustomerResearchCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_RevenueFromRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_RevenueFromRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327058548848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Wages and salaries</a></td>
<td class="nump">$ 19,434<span></span>
</td>
<td class="nump">$ 19,158<span></span>
</td>
<td class="nump">$ 18,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SocialSecurityCosts', window );">Social security costs</a></td>
<td class="nump">1,744<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsPeriodExpense', window );">Other pension costs</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payments charge</a></td>
<td class="nump">16,307<span></span>
</td>
<td class="nump">16,274<span></span>
</td>
<td class="nump">12,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_AggregateRemuneration', window );">Total aggregate remuneration</a></td>
<td class="nump">$ 38,151<span></span>
</td>
<td class="nump">$ 37,942<span></span>
</td>
<td class="nump">$ 33,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_AggregateRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate remuneration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_AggregateRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_SocialSecurityCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Social security costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_SocialSecurityCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period expense related to postemployment benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067848832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_BankInterestReceivable', window );">Bank interest receivable</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_AccretionOfSecurities', window );">Accretion on U.S Treasury Bills</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Total other income</a></td>
<td class="nump">$ 4,472<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_AccretionOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_AccretionOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_BankInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_BankInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060444432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,309)<span></span>
</td>
<td class="num">$ (54,228)<span></span>
</td>
<td class="num">$ (50,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding basic</a></td>
<td class="nump">138,752,224<span></span>
</td>
<td class="nump">111,277,250<span></span>
</td>
<td class="nump">96,584,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding diluted</a></td>
<td class="nump">138,752,224<span></span>
</td>
<td class="nump">111,277,250<span></span>
</td>
<td class="nump">96,584,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share basic</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share diluted</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.52)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060537216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">17,455,390<span></span>
</td>
<td class="nump">15,853,459<span></span>
</td>
<td class="nump">11,571,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059979968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment &amp; Furniture</a></td>
<td class="nump">$ 6,343<span></span>
</td>
<td class="nump">$ 6,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(4,525)<span></span>
</td>
<td class="num">(4,498)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">$ 1,818<span></span>
</td>
<td class="nump">$ 1,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327251901712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 336<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059976816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill - Schedule of Change in Carrying Value of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at start of year</a></td>
<td class="nump">$ 9,981<span></span>
</td>
<td class="nump">$ 9,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Translation adjustment</a></td>
<td class="num">(589)<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of year</a></td>
<td class="nump">$ 9,392<span></span>
</td>
<td class="nump">$ 9,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163626768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Intangible Assets - Schedule of Intangible Assets (Details) - License and Software, Net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 481<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated depreciation</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sln_LicenseAndSoftwareNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sln_LicenseAndSoftwareNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327068004512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163880256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327169454032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndDueFromBanks', window );">Cash at bank and in hand</a></td>
<td class="nump">$ 56,590<span></span>
</td>
<td class="nump">$ 31,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_USGovernmentSecuritiesAtCarryingValue', window );">US Treasury Bills</a></td>
<td class="nump">64,740<span></span>
</td>
<td class="nump">36,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total Cash and cash equivalents</a></td>
<td class="nump">$ 121,330<span></span>
</td>
<td class="nump">$ 68,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndDueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndDueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_USGovernmentSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_USGovernmentSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327063595408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets - Schedule of Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PrepaymentsAssetsCurrent', window );">Prepayments</a></td>
<td class="nump">$ 13,124<span></span>
</td>
<td class="nump">$ 10,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">14,664<span></span>
</td>
<td class="nump">11,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits for properties</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PrepaymentsAssetsNoncurrent', window );">Prepayments</a></td>
<td class="nump">3,234<span></span>
</td>
<td class="nump">3,284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">$ 3,590<span></span>
</td>
<td class="nump">$ 3,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PrepaymentsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments assets, current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PrepaymentsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PrepaymentsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments assets, noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PrepaymentsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327169630416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OtherAssetsLineItems', window );"><strong>Other Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_PrepaymentsAssets', window );">Prepayments assets</a></td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_OtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_OtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_PrepaymentsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_PrepaymentsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067117968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade receivables - Schedule of Trade Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables</a></td>
<td class="nump">$ 972<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163818928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Receivables - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for expected credit loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059010336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables - Schedule of Trade and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">$ 3,697<span></span>
</td>
<td class="nump">$ 3,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_SocialSecurityAndOtherTaxesPayableCurrent', window );">Social security and other taxes</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accruals and other payables</a></td>
<td class="nump">8,361<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Bonus accrual</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">3,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Corporate income tax payable</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total trade and other payables</a></td>
<td class="nump">$ 16,399<span></span>
</td>
<td class="nump">$ 15,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_SocialSecurityAndOtherTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Social security and other taxes payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_SocialSecurityAndOtherTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327066801008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Payables - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_TradeAndOtherPayablesLineItems', window );"><strong>Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accruals and other payables</a></td>
<td class="nump">$ 8,361<span></span>
</td>
<td class="nump">$ 7,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_TradeAndOtherPayablesLineItems', window );"><strong>Trade And Other Payables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accruals and other payables</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_TradeAndOtherPayablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_TradeAndOtherPayablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060010896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Lease</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfOperatingLease', window );">Number of operating lease for office space in London</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OperatingLeaseNewTermBeginningPeriod', window );">Operating lease new term beginning period.</a></td>
<td class="text">2022-09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember', window );">Berlin, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfShortTermLeases', window );">Number of short-term leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease contract notice period</a></td>
<td class="text">11 months 15 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember', window );">Hoboken, U. S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfLeases', window );">Number of leases</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease contract notice period</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NumberOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NumberOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NumberOfShortTermLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of short-term leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NumberOfShortTermLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_OperatingLeaseNewTermBeginningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease new term beginning period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_OperatingLeaseNewTermBeginningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=us-gaap_GeographicDistributionDomesticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060763776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060889008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327169612560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Total Operating Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 242<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060886912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summarizes of Maturities of Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total expected lease payments</a></td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060519776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities - Schedule of Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current</a></td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 6,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current</a></td>
<td class="nump">51,790<span></span>
</td>
<td class="nump">75,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">52,096<span></span>
</td>
<td class="nump">81,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, beginning</a></td>
<td class="nump">81,572<span></span>
</td>
<td class="nump">87,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ContractWithCustomerLiabilityForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(691)<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ContractWithCustomerLiabilityAdditions', window );">Additions during period</a></td>
<td class="nump">14,328<span></span>
</td>
<td class="nump">20,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ContractWithCustomerLiabilityRevenueUnwound', window );">Revenue unwound during period</a></td>
<td class="num">(43,113)<span></span>
</td>
<td class="num">(30,934)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities, ending</a></td>
<td class="nump">$ 52,096<span></span>
</td>
<td class="nump">$ 81,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer, liability additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ContractWithCustomerLiabilityForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability foreign exchange impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ContractWithCustomerLiabilityForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ContractWithCustomerLiabilityRevenueUnwound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability revenue unwound</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ContractWithCustomerLiabilityRevenueUnwound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059018144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liabilities - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of revenue</a></td>
<td class="nump">$ 43.1<span></span>
</td>
<td class="nump">$ 30.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327062376416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.K. tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Tax expense related to current tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 845,000<span></span>
</td>
<td class="nump">$ 956,000<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,572,000<span></span>
</td>
<td class="nump">52,096,000<span></span>
</td>
<td class="nump">81,572,000<span></span>
</td>
<td class="nump">87,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=sln_SmallOrMediumSizedEnterprisesMember', window );">SME scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=sln_ResearchAndDevelopmentExpenditureCreditMember', window );">RDEC scheme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember', window );">Collaboration Agreement with Hansoh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_UpfrontPaymentTaxWithholding', window );">Upfront payment, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_MilestonePaymentTaxWithholding', window );">Milestone payment, tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_MilestonePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_MilestonePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_UpfrontPaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment tax withholding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_UpfrontPaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=sln_SmallOrMediumSizedEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=sln_SmallOrMediumSizedEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=sln_ResearchAndDevelopmentExpenditureCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=sln_ResearchAndDevelopmentExpenditureCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sln_CollaborationAgreementWithHansohMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059982048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Tax Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Current Year</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense', window );">Changes in estimate related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Tax Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxation</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimate related to prior years current tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327063611856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="num">$ (44,464)<span></span>
</td>
<td class="num">$ (53,272)<span></span>
</td>
<td class="num">$ (49,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax credit at the standard rate of U.K. corporation tax of 25% (2023: 25%; 2022: 19%)</a></td>
<td class="nump">11,116<span></span>
</td>
<td class="nump">12,530<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Income not taxable</a></td>
<td class="nump">3,356<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of overseas tax rate</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="num">(15,423)<span></span>
</td>
<td class="num">(15,641)<span></span>
</td>
<td class="num">(11,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment in respect of prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_IncomeTaxReconciliationEffectOfOverseasTaxes', window );">Effect of overseas taxes</a></td>
<td class="num">(202)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (845)<span></span>
</td>
<td class="num">$ (956)<span></span>
</td>
<td class="num">$ (688)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_IncomeTaxReconciliationEffectOfOverseasTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation, effect of overseas taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_IncomeTaxReconciliationEffectOfOverseasTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060516016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.K. corporation tax</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059959104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax using U.K. statutory rate</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(25.00%)<span></span>
</td>
<td class="num">(23.50%)<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Income not taxable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effect of overseas tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.70%<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="nump">23.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax', window );">Effect of overseas taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for loss from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation effect of overseas tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060019360">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities', window );">Trading Losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 55,316<span></span>
</td>
<td class="nump">$ 57,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,663<span></span>
</td>
<td class="nump">3,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">2,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,446<span></span>
</td>
<td class="nump">63,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(61,446)<span></span>
</td>
<td class="num">(63,739)<span></span>
</td>
<td class="num">$ (61,703)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included i</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n trading losses is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated tax losses as of December 31, 2024 ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023) related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations in Germany for corporate income taxes and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated losses related to trade taxes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">German entity ($</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of Decem</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2023).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060796432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes', window );">Accumulated tax losses related to corporate income taxes</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes', window );">Accumulated losses related to trade taxes</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, accumulated tax losses related to corporate income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset, accumulated tax losses related to trade taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060005168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at January 1</a></td>
<td class="nump">$ 63,739<span></span>
</td>
<td class="nump">$ 61,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">(Decrease)/increase in valuation allowance</a></td>
<td class="num">(2,293)<span></span>
</td>
<td class="nump">2,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at December 31</a></td>
<td class="nump">$ 61,446<span></span>
</td>
<td class="nump">$ 63,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327167495344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Shares Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized, allotted, called up and fully paid ordinary shares, par value 0.05</a></td>
<td class="nump">$ 10,288<span></span>
</td>
<td class="nump">$ 8,847<span></span>
</td>
<td class="nump">$ 8,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares in issue</a></td>
<td class="nump">141,674,074<span></span>
</td>
<td class="nump">118,846,966<span></span>
</td>
<td class="nump">107,808,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Number of ADS in issue</a></td>
<td class="nump">47,224,691<span></span>
</td>
<td class="nump">39,615,655<span></span>
</td>
<td class="nump">35,936,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163818432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
<td class="nump">&#163; 0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327058512032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,455,390<span></span>
</td>
<td class="nump">15,853,459<span></span>
</td>
<td class="nump">11,571,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare', window );">Number of ordinary shares per ADS | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease', window );">Increase in maximum value of shares to be sold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockholdersEquityRemainingValue', window );">Value of ADS remained</a></td>
<td class="nump">$ 139,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,818,463<span></span>
</td>
<td class="nump">5,284,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_CurrencyConversionRatePerDollar', window );">Currency conversion rate per dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_RegisteredDirectOfferingMember', window );">Registered Direct Offering | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare', window );">Number of ordinary shares per ADS | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement | Jefferies LLC | Ordinary Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityRestrictions', window );">Maximum value of shares to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement | Jefferies LLC | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare', window );">Number of ordinary shares per ADS | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_CurrencyConversionRatePerDollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Currency conversion rate per dollar.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_CurrencyConversionRatePerDollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares for each American depositary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_StockholdersEquityRemainingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity remaining value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_StockholdersEquityRemainingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the amount of equity that is restricted to use by regulation or agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in stockholders' equity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sln_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sln_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067419776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Details of Shares Issued (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Number of shares in issue</a></td>
<td class="nump">141,674,074<span></span>
</td>
<td class="nump">118,846,966<span></span>
</td>
<td class="nump">107,808,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during the year</a></td>
<td class="nump">21,418,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,408,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Number of ADS in issue</a></td>
<td class="nump">47,224,691<span></span>
</td>
<td class="nump">39,615,655<span></span>
</td>
<td class="nump">35,936,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">469,481<span></span>
</td>
<td class="nump">269,309<span></span>
</td>
<td class="nump">57,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember', window );">Options exercised at $0.20/ADS or $0.07/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">252,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember', window );">Options exercised at $2.40/ADS or $0.80/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">268,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember', window );">Options exercised at $4.23/ADS or $1.41/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember', window );">Options exercised at $4.24/ADS or $1.41/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">9,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember', window );">Options exercised at $5.81/ADS or $1.94/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember', window );">Options exercised at $7.32/ADS or $2.44/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember', window );">Options exercised at $7.60/ADS or $2.53/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">584,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember', window );">Options exercised at $8.20/ADS or $2.73/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">49,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember', window );">Options exercised at $9.98/ADS or $3.33/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember', window );">Options exercised at $10.68/ADS or $3.56/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember', window );">Options exercised at $12.81/ADS or $4.27/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember', window );">Options exercised at $12.94/ADS or $4.31/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember', window );">Options exercised at $13.80/ADS or $4.60/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">3,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember', window );">Options exercised at $15.38/ADS or $5.13/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">126,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember', window );">Options exercised at $16.64/ADS or $5.55/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember', window );">Options exercised at $19.50/ADS or $6.50/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember', window );">Options exercised at $20.41/ADS or $6.80/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember', window );">Options exercised at $22.01/ADS or $7.34/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">37,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember', window );">Options exercised at $23.60/ADS or $7.87/ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327062218720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember', window );">Options exercised at $0.20/ADS or $0.07/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember', window );">Options exercised at $0.20/ADS or $0.07/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember', window );">Options exercised at $2.40/ADS or $0.80/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember', window );">Options exercised at $2.40/ADS or $0.80/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember', window );">Options exercised at $4.23/ADS or $1.41/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">4.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember', window );">Options exercised at $4.23/ADS or $1.41/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">1.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember', window );">Options exercised at $4.24/ADS or $1.41/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">4.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember', window );">Options exercised at $4.24/ADS or $1.41/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">1.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember', window );">Options exercised at $5.81/ADS or $1.94/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">5.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember', window );">Options exercised at $5.81/ADS or $1.94/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">1.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember', window );">Options exercised at $7.32/ADS or $2.44/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">7.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember', window );">Options exercised at $7.32/ADS or $2.44/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">2.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember', window );">Options exercised at $7.60/ADS or $2.53/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember', window );">Options exercised at $7.60/ADS or $2.53/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">2.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember', window );">Options exercised at $8.20/ADS or $2.73/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember', window );">Options exercised at $8.20/ADS or $2.73/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">2.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember', window );">Options exercised at $9.98/ADS or $3.33/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">9.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember', window );">Options exercised at $9.98/ADS or $3.33/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">3.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember', window );">Options exercised at $10.68/ADS or $3.56/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">10.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember', window );">Options exercised at $10.68/ADS or $3.56/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">3.56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember', window );">Options exercised at $12.81/ADS or $4.27/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">12.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember', window );">Options exercised at $12.81/ADS or $4.27/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">4.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember', window );">Options exercised at $12.94/ADS or $4.31/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">12.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember', window );">Options exercised at $12.94/ADS or $4.31/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">4.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember', window );">Options exercised at $13.80/ADS or $4.60/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember', window );">Options exercised at $13.80/ADS or $4.60/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember', window );">Options exercised at $15.38/ADS or $5.13/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">15.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember', window );">Options exercised at $15.38/ADS or $5.13/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">5.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember', window );">Options exercised at $16.64/ADS or $5.55/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">16.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember', window );">Options exercised at $16.64/ADS or $5.55/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">5.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember', window );">Options exercised at $19.50/ADS or $6.50/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">19.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember', window );">Options exercised at $19.50/ADS or $6.50/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember', window );">Options exercised at $20.41/ADS or $6.80/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">20.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember', window );">Options exercised at $20.41/ADS or $6.80/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember', window );">Options exercised at $22.01/ADS or $7.34/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">22.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember', window );">Options exercised at $22.01/ADS or $7.34/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">7.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember', window );">Options exercised at $23.60/ADS or $7.87/ordinary share | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember', window );">Options exercised at $23.60/ADS or $7.87/ordinary share | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_StockOptionExercisePrice', window );">Exercise price of stock option</a></td>
<td class="nump">$ 7.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_StockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option, exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_StockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sln_OptionsExercisedNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327067022000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Schedule of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#163; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">15,853,459<span></span>
</td>
<td class="nump">11,571,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">3,802,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(334,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="num">(457,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(1,408,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">17,455,390<span></span>
</td>
<td class="nump">15,853,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">5,284,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">1,267,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(111,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="num">(152,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(469,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">5,818,463<span></span>
</td>
<td class="nump">5,284,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearOneMember', window );">Options Issued in 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTwoMember', window );">Options Issued in 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 3.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">6 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearThreeMember', window );">Options Issued in 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">9,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(3,333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">9,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFourMember', window );">Options Issued in 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">39,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(16,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="nump">39,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFiveMember', window );">Options Issued in 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">36,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(6,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">30,593<span></span>
</td>
<td class="nump">36,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSixMember', window );">Options Issued in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">577,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(347,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">229,997<span></span>
</td>
<td class="nump">577,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">4 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSevenMember', window );">Options Issued in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 6.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">261,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(26,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">234,178<span></span>
</td>
<td class="nump">261,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">5 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearEightMember', window );">Options Issued in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">662,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(7,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="num">(62,502)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(16,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">576,136<span></span>
</td>
<td class="nump">662,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearNineMember', window );">Options Issued in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 14.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">1,419,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(27,309)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="num">(75,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(7,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">1,310,498<span></span>
</td>
<td class="nump">1,419,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">7 years 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTenMember', window );">Options Issued in 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">2,269,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(63,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired</a></td>
<td class="num">(15,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(42,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">2,148,357<span></span>
</td>
<td class="nump">2,269,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearElevenMember', window );">Options Issued in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_YearOfIssuanceOfStockOption', window );">Year of issue</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price | (per share)</a></td>
<td class="nump">&#163; 14.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">1,267,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">1,255,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate', window );">Weighted average years to expiry date</a></td>
<td class="text">9 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_OptionsOutstandingWeightedAverageYearsToExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options outstanding weighted average years to expiry date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_OptionsOutstandingWeightedAverageYearsToExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_YearOfIssuanceOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year of issuance of stock option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_YearOfIssuanceOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositaryShareADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sln_OptionsIssuedInYearElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327068164848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Settled Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting rights</a></td>
<td class="text">Under the LTIP, Non-Employee LTIP, individual contracts and schemes available, the options typically vest after three years, with the exception of some options granted to certain members of key management personnel. The vesting period for these options ranges from 3 to 33 months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options granted</a></td>
<td class="nump">3,802,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity settled share-based payment transactions</a></td>
<td class="nump">$ 16,307<span></span>
</td>
<td class="nump">$ 16,274<span></span>
</td>
<td class="nump">$ 12,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_EstimatedEmployerTaxObligationOnOutstandingOptions', window );">Estimated employer tax obligation on outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost granted but not vested</a></td>
<td class="nump">29,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Expected remaining weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Exercised during the year</a></td>
<td class="nump">$ 20.99<span></span>
</td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="nump">$ 11.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of share options granted</a></td>
<td class="nump">3,802,542<span></span>
</td>
<td class="nump">7,703,826<span></span>
</td>
<td class="nump">5,821,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for options</a></td>
<td class="text">33 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for options</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_EstimatedEmployerTaxObligationOnOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated employer tax obligation on outstanding options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_EstimatedEmployerTaxObligationOnOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327060166992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Settled Share-Based Compensation - Summary of Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">15,853,459<span></span>
</td>
<td class="nump">11,571,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">3,802,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(334,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(1,408,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">17,455,390<span></span>
</td>
<td class="nump">15,853,459<span></span>
</td>
<td class="nump">11,571,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Exercised during the year</a></td>
<td class="nump">$ 20.99<span></span>
</td>
<td class="nump">$ 10.26<span></span>
</td>
<td class="nump">$ 11.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the beginning of the year</a></td>
<td class="nump">5,284,486<span></span>
</td>
<td class="nump">3,857,162<span></span>
</td>
<td class="nump">2,684,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted during the year</a></td>
<td class="nump">1,267,514<span></span>
</td>
<td class="nump">2,567,942<span></span>
</td>
<td class="nump">1,940,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Lapsed or forfeited during the year</a></td>
<td class="num">(264,056)<span></span>
</td>
<td class="num">(871,309)<span></span>
</td>
<td class="num">(709,531)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised during the year</a></td>
<td class="num">(469,481)<span></span>
</td>
<td class="num">(269,309)<span></span>
</td>
<td class="num">(57,917)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding at the year end</a></td>
<td class="nump">5,818,463<span></span>
</td>
<td class="nump">5,284,486<span></span>
</td>
<td class="nump">3,857,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at the year-end</a></td>
<td class="nump">2,870,106<span></span>
</td>
<td class="nump">2,420,614<span></span>
</td>
<td class="nump">1,889,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at the beginning of the year</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted during the year</a></td>
<td class="nump">18.05<span></span>
</td>
<td class="nump">14.01<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Lapsed or forfeited during the year</a></td>
<td class="nump">19.82<span></span>
</td>
<td class="nump">18.5<span></span>
</td>
<td class="nump">29.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Exercised during the year</a></td>
<td class="nump">6.55<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise price, Outstanding at the year-end</a></td>
<td class="nump">15.95<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at the year-end</a></td>
<td class="nump">$ 15.94<span></span>
</td>
<td class="nump">$ 14.34<span></span>
</td>
<td class="nump">$ 13.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,264,060<span></span>
</td>
<td class="nump">$ 578,574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327059214144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Inputs and assumptions for options granted in the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price</a></td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 24.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option life (years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">74.40%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">78.60%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free rate, minimum</a></td>
<td class="nump">3.39%<span></span>
</td>
<td class="nump">3.16%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free rate, maximum</a></td>
<td class="nump">3.97%<span></span>
</td>
<td class="nump">4.43%<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant data fair value</a></td>
<td class="nump">$ 12.6<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Inputs and assumptions for options granted in the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Weighted average share price</a></td>
<td class="nump">$ 18.1<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sln_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163790032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Commitments and Contingent Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sln_CapitalCommitments', window );">Capital commitments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sln_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sln_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sln_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327169618960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments Under Short Leases - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Gross commitment</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Lease amount payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45327163716096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sln_NonExecutiveChairmanMember', window );">Iain Ross</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amount paid</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sln_NonExecutiveChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sln_NonExecutiveChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MIU>*#<F6^MLB4R8E2_7/!<$QX>H$.#YC3*XVU 6J#^"<_P]02P,$%     @
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M3X)D]&0'K?BBP<I)A'KHAC8H&<$6M]AB-S:N2'[!]L7#C8DC'/8?L<7,PS"
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M0:CC@D;T8>&&[VKK%H(B;]D.UF"_MRN-LV!@J7@#TG EB8;M@EY$9\O4Q?N
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M+':O'];XOH)V ;B_5<H^3%P+#R]V\1=02P,$%     @ RX-;6G")!/?T!
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MHYV0)?N8)7M<EE[WC]I%V3)BMRO&VWJ7I/1ZPI^2FE9W=#+_]1?LH=]U(^$
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MB<--PW;=-_N_LJ9AV^YR0Y.,5JT!_WS%6//CIOVQP/'W*O/_ %!+ P04
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M?6@LK;+^?9^[]Y&9]V&"?I:5WBKT?97S_-C RG3^P( \,_A,G!93GGU$%']
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M- OAR"(/&4R28";GD4&"$;<$&],RZ< D ?WT >T*UB@O4[/XWWNQ:S:%0)J
M9B)XNDB$4-;"! +A:([>H+Z(6WV-Z8E*FV6*,+77H4;<]MX\_4^Z-44@I3=:
MT![[:%!PQ*W@7B@,KTZ<@$@C. FG51[ X80DTUT0T)SG)S.+53+(-!*]I2YL
M1,6J[!7TG.+OS8%Q2FOIJ:P=>W30A,2M":]KF7&>J[[0*K5OYYNL<^/;^@FI
M9D,-=BJPU^43+[;2I(VC.)DNA5( %ASM6AT3'(0A>7GSK)TAXWGQZL"QY1S,
M$=A,@SC:, ='.LA#ZI:',ZN7EG93"-J+IAK<LZ+Y1@!^&+*U7$!\:]<0@.'(
MVIP&4$OB)^$<TT$84O>>V]4<)<0T4IK5NBV&O!8R!UE">VA1/%VF0;"06)4=
M@"4)#>98#F*-NL7:]YL-SUHFA^U>H^^YR7S[3._;#6V%I&. T987,'];KX53
M]0]@(M\:81NTC#&>V7*AHZ^:;JDV.\ ?$&^6X<[!M866D:+VIA*  X(@[6'1
M;! <4QQD&_6=1>QFO]L5[==S5J!<J*R0:F^2;$,N.Q0X475G-<Q8@QNOU*D-
MW_PE]Y36TE-9.W;P(!RI6SA^98_HF@DX1@+@<RZETP@!4+%G3?^3?F]<C<YF
ME+R^:\^X*)3)?:6[0PZ'IX=S-)_:TR.3YY_Q>=J=AAG,=(=S?F;UG3"IH^ ;
M8]+[&!D"=7?>I;O1<M>> +F56LNRO=QREO.Z 9C_;Z34SS?-"PZGCM;_ E!+
M P04    " #+@UM:+$HC=V,"  "(!@  &    'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;*U586^;,!#]*Q:KIE9::P(D[3*"U(15J[1.4;-NGQVX!*M@,]N$
M]M_/-H0E%8FBJ5^"S[[W[NZ9/,*:BV>9 2CT4N1,3IQ,J7*,L4PR*(B\XB4P
M?;+BHB!*AV*-92F I!94Y-ASW1$N"&5.%-J]N8A"7JF<,I@+)*NB(.)U"CFO
M)\[ V6X\TG6FS :.PI*L80'JJ9P+'>&.):4%,$DY0P)6$^=V,(X#DV\3?E&H
MY<X:F4F6G#^;X#Z=.*YI"')(E&$@^K&!&>2Y(=)M_&DYG:ZD >ZNM^QW=G8]
MRY)(F/'\-TU5-G%N')3"BE2Y>N3U-VCG&1J^A.?2_J*ZR1T.'9144O&B!>L.
M"LJ:)WEI==@!#$8' %X+\-X"@@, OP7XIP*"%F"EQLTH5H>8*!*%@M=(F&S-
M9A963(O6XU-FKGVAA#ZE&J>B.7E%&XGF(.PKQ!) ,95)SF4E %VBIT6,SL\N
MT!FB#/W,>"4)2V6(E:YM&'#2UIDV=;P#=08>>N!,91)]92FD^P18-]UU[FT[
MGWI'&6-(KI _^(0\UPMZ&IJ=#O=[X/'I<._(-'YW#[[E\__G'OKD;NB"?CIC
M%F-9D@0FCG8#"6(#3O3QPV#D?NF3ZCW)XG<BVY,QZ&0,CK%'/[11WK.$%X#.
MOW,I+_JD:RBN+86QQ4UT&0Q]]W.(-[NB]*0- \^[V4^+^])<WP^ZM&80O/,?
M+4"LK==)E/"*J>:E[W8[.[VU+O)F?ZIMMG'%?S2-1S\0L:9,HAQ6FM*]NM:N
M)AK?:P+%2^L$2ZZTK]AEIC\5($R"/E]QKK:!*=!]?**_4$L#!!0    ( ,N#
M6UI8TEK\\P(  &,(   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULG59M
M;]HP$/XKIU2J-HF2$%Y*6T""=M/0U*VBW?;9)!=B-;$SVRGMO]_9@91-(9TJ
M ?'+/<\]=V=SF6RE>M0IHH'G/!-ZZJ7&%)>^KZ,4<Z:[LD!!.XE4.3,T51M?
M%PI9[$!YYH=!,/)SQH4WF[BU.S6;R-)D7."= EWF.5,O"\SD=NKUO/W"BF]2
M8Q?\V:1@&[Q'\Z.X4S3S:Y:8YR@TEP(4)E-OWKM<C*V],_C)<:L/QF C64OY
M:"?+>.H%5A!F&!G+P.CQA->899:(9/S><7JU2PL\'._9/[O8*98UTW@MLU\\
M-NG4&WL08\+*S*SD]@ONXAE:ODAFVOW"MK+M7W@0E=K(? <F!3D7U9,][_)P
M !@'1P#A#A ZW94CI_*&&3:;*+D%9:V)S0Y<J Y-XKBP1;DWBG8YX<QL2>F-
M4<&#8C$7&Y@KQ<0&*>U&3WQ#'JR='^W8%A5;>(2M%\*M%";5\$G$&/]-X).T
M6E^XU[<(6QEO,.I"O]>!, @'+7S].MZ^X^L?X6N*LP/K%UB*F#_QN&194]@5
MZ:"9U%Z<2UVP"*<>W0R-Z@F]V>E);Q1<M4@>U)(';>RS6V90<9;! ZI<@TR:
MBM4DNI6V6?328 X7BRY\-RF=BJ5()-BS;R_03:FL4]J@KT*$O"HUVE(#%0KS
M-6'VQ>J D!!S1==/*K"?).$1VJ?CN)9YP<0+L%@6A@C(@N*D(\[LC,'IR3@,
M@ZM5F2'T@O7PK =F%S=[C=M9]:XL>@<04IR] >KL48S4LRAUCH%K>YTI2S%P
M 2X3@V#\@7VTBE>X*;,J#_=G7[O04M=A7==A:UT/11Y4$N950IHJVDZ8L$QC
MB[!1+6S4RO/MGPS^I[AVTK?$G=?BSM^5M8?Z[#1I:^=\2]NXUC9^=^+:];7S
M'M7G'_SQYZ@VKKUIB&0I3-4#ZM6Z@\ZKQO%J7K7?6Z8V7&C(,"%HT#VGLZ:J
MEE9-C"Q<&UE+0TW)#5-Z"T!E#6@_D=+L)]9!_5XQ^P-02P,$%     @ RX-;
M6CRE,S@1 @  W00  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULI53;
MCM,P$/T5RT@\H3I)+Z"21&IW0:S$2M4NEP?$@QM/$VM]";:S6?X>VTE#0=T*
MB9?88\\Y<X[C<=YK\V ; (>>I%"VP(US[9H06S4@J9WI%I3?.6@CJ?.AJ8EM
M#5 605*0+$E61%*N<)G'M9TI<]TYP17L#+*=E-3\W(+0?8%3?%RXXW7CP@(I
M\Y;6< _N<[LS/B(3"^,2E.5:(0.' F_2]781\F/"%PZ]/9FCX&2O]4,(;EB!
MDR (!%0N,% _/,(5"!&(O(P?(R>>2@;@Z?S(_CYZ]U[VU,*5%E\Y<TV!WV#$
MX$ [X>YT_P%&/\O 5VEAXQ?U0^YRCE'56:?E"/8*)%?#2)_&<S@!I*MG -D(
MR*+NH5!4>4T=+7.C>V1"MF<+DV@UHKTXKL)/N7?&[W*/<^6-/UX&!GTRE'%5
MHYT6O.)@$54,[8RN@'4&;$Z<+Q8@I!J)MP-Q]@QQFJ%;K5QCT3O%@/U)0+S*
M26IVE+K-+C)>0S5#\_05RI)L<8%O/EF?1[[Y_UE'WSYZ(+IQ(.WW<^<P5%F<
MKQ*::FU;6D&!?==8,(^ RY<OTE7R]H*'Q>1A<8G]GSULF&[=WW]AD'^Y@#,=
MG--)3JZ<!%/'QK*HTIURP^V;5J?>W0Q7]G?ZT/BWU-1<623@X*')[/42(S,T
MTQ XW<8+O-?.MT.<-O[] 1,2_/Y!:W<,0H'I12M_ 5!+ P04    " #+@UM:
M%.X,R>0+  #1.@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6SM6UN/
MVS86_BO$%.B3,S-VKLUE@,DDV09(T2"9;1^*?: EVN:.)*HD9<?]]?W.(47)
M'EO.).T&71AH.I9$\MR_<['U?&7LC5LHY<6GLJC<BY.%]_73LS.7+50IW:FI
M584G,V-+Z7%IYV>NMDKFO*DLSB;GYX_.2JFKDXOG?.^]O7AN&E_H2KVWPC5E
M*>WZI2K,ZL7)^*2]\4'/%YYNG%T\K^5<?53^W_5[BZNS=$JN2U4Y;2IAU>S%
MR>7XZ<OQ#[2!5_RBU<KU/@L296K,#5V\S5^<G!-'JE"9IR,D_BS5E2H*.@E\
M_!X//4DT:6/_<WOZ&Q8>PDRE4U>F^%7G?O'BY,F)R-5,-H7_8%8_JBC00SHO
M,X7C_XM57'M^(K+&>5/&S>"@U%7X*S]%17S.ADG<,&&^ R'F\I7T\N*Y-2MA
M:35.HP\L*N\&<[HBJWST%D\U]OF+J_546:>RQFJ_%A^TNQ$_R0KV@.;]2&"I
M]&J^%K+*Q;_,4ME*5IEZ?N9!FTXXRR*=EX'.9 ^=\43\9"J_<.)UE:M\\X S
M,)TXG[2<OYP,GOA*9:?B_G@D)N>3!P/GW4^:N,_GW?\Z38RV5"%^>X>#Q%NO
M2O>?77H)5!_LIDI!]]35,E,O3A!53MFE.KGX_KOQH_-G S(]2#(]&#I]6";Q
MWII,.:><0'2+2_KD=#4?B;<Y'NO9FB](7-Z$*W&]0.A[)WZ[5I^\>%F8[&:G
MT,-LD;+$^.I4,']BD\&R8Y!(N]8#?U5B(9=*Z+(N^+'*>0%!C\<_L916F\8)
M706PHJ!/1]=)UEPY/:^PV1NAHZ"0DJ4?Q1.) _SQRFI9" NVH"-K2I%M*-1'
M;> DTUB1X:;.L"$S9=U@LZB49WP=8:FVN:BEQ;:%<<0\&5N#J1&M+YL*6XEG
M)]S:D3>-(*_-5]*JH @S\W01>-R@ER/R1Y [*YJ<K 2% .: >PT>0O):@2R1
MJ69!8MSN:\DOI!?:\5*KE0<\CUK%ZTS .4@BY34A*':*2OIF@Q-8F#GQK#"Z
M;54A2<K &XYXVR/X,4C("PFV3L7/.&6GX69-Q?@]$JN%SA;$9H%CIVLF_ L4
M"#^&2?/687Y$;A)FMD'O6F6+RA2&PO>F,BMD \?[T^+K((QKZMI8WQ%(?)0]
M++";?AJV%FI."E"2+:>*V@V[%^MMISNQ^LCG^C;%0]/,%_BK1.,4,4TG,"L6
M9H)"[2GB4PVKL>5)JT G,(:+ ZR0/DI3:6\L<4/WU5(6#<C@DC@)6X2JEMJ:
M*L4O,PC'FNF"&*?5;:"6RB],[CHA1PQ$ZI.D$'\J9(/LQT[D#=(<7+*9.CC]
ME/5A(#;9*C#9!E/TY:CXW5*1&62Q_H..:<^ .M/3GF"M'L*R !H-1ZRQX#@L
M6FF_$(5<07;PGP7L0K!E2!&]0T8<E\@:(4  H/$"LM/30B&G!)C=6-B'CJCD
M8#6BP[Q4>9,Q)\NFJ'#&5!<D;FOJ@"N;FX+')H*)F4@@((B>*PAQ*EXI%('L
MA0P6:L/(L%@ +$1H#YUW8[.G0"2D&(EZL7;A$Z.(G<M*_\&<@HU220>$ :,)
MN F1L!*0&"Q>FT)G>@O08VPQ;:#5'-YS=QP?0JK17F_%_0!"N?)MR<DXZ&J
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M^*XN_[(M(5^E 4&'30?=>)C<<19QG$4<9Q''6<1Q%G&<11QG$7_O+&(\Z8J
MR9<5 5>=Z:WXV$P[:3]LX<@=*H1A7KY]63"DTNYWH./!GV3N4FGLX5A=H3DF
MS_T;%3W,X3<O?H;TW/TV=7SG'Z=^, 5#56\:<%!5PT2./UTZ_G3I'_33I:'
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M5!M.O3)JA0S7(:R45)@5VLV :T=)/PKL):ZX031<[L[+>OAR[L-[%<-7M0U
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MVA7K 7!%(T.Q=4@!&$//XQ_ET&]:6+]$85;$C11E*%: I(@#P]F AZ8JNRH
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MQ0[D40L4677M=F+OP.H@T&#:.4A:D,SOAV8IA&4<*V. *$*ILB=H)KX6S#Z
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M5&6&(_@C8U;M2H_&8UE57DS9""FQTL6+^8O(K0N'? '81>SCZM\59_,?XL]
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M$F,5,#)E)M"W[Z(B?_/;VU]RY8C?H$>)N<\C4944R$$RY4*-Q,^\^.1".W2
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M)H.9^M2SA!?-,D\(ON8X>2;%V<7\_!E*M!\ Q^57QL0;04%??D5[E&Q,&[>
M[^D[ (R\-F,U\2SF1RZ<B@4D]%VIY;-)#DN (N8\L2:K!#6,P3Q10!C8<]O
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MOSGJL4W'WU2V>F:85!1($72R>4KJ,W$%V[!Z$X21M3&8QN*DM"TK]&@XDE,
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MX?D=!;\;@"W<W=H>BM0=UY+3''%8"U*$YGM>^HG#.8,\1QT5_0?^L$BC)96
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MY29\7G@D#Q]IWJ,(XG6%U6*#H_'L=#%E)GSX" ].M_YCPUH[C,?^EHJ-,$2
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MV?4\ -V_0OW&JL9W_IVR]([X944/-VHG0-]+I>QAXPR,OP*;_P!02P,$%
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M[.<69\*6('0!H7-^U\A[H5 [.XL=X[U1G.]1RQ:5O8)*,[@PVI46SG6!Q=^
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M9.:3S/P2^RB3O;@-E]%).H=3AMD_R#2@VQ*@A&*SHRE*ZLPEU64VF[V*X]B
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M;(T 2$N  O[KG.M\ARL'T+72Y+/;3>L1:9(PC&DO L@#2#:J!(#,F4?%[?^
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MH(ZZ$] 8<A_,HGEGT6.GV1PU#EJ;I\$B78Y^?PPAJD6_QI6E6T<LZ)K=4&#
M:LAS-!!/:%(K6PJ,9*"_SK'.,-3>"U1 MIL2D"&^7K=5V_77??OA+GV/4W+R
M@IVB#'H!QY>EDV'+E@2%/08!_Q\%CCZ &4&V9VMQ."12ZE^P.2#_A*V=G0,]
MY.Q@QB2U7I$;F.R6;%\,! YL9P?&ASA_W N?9@@Z2-Z16G\:CGL('LLO(+\;
M./O\(N.+*!V=0 Q.PT9,IHB*NWJ":(C"@F1)9)8$43I_2M/ KD/HL3>\QD'9
M,5/AIK]['%+A21?JGF-Z7" OC58?_?G717#3VM;W<,>Q@X6YL$@ CA.YG_C1
MN0%!(N2*NGXI/PE,0'A4>Y8N?%_?XKA:EL@)C.$E#48ANUH#*(3E<AL<)]S]
M_ S[[B4E@PCT&.&$[+VDN-@]!2KA#>LHD&9/>"--X0(#G#8E3F?D[HJ:D3 .
M&M<%ALA@(.?PV/,@;5&HTI6@FT1J=N?XH(.Z8^I<DK%U;@+<1KR@.6"E2[EK
M#U0Z%DYKM>4ED; _@"@HU=Z ET:U&L8U\([2Y:73H8W %P_,$TX!S?6PCJ/V
MRI*O^EF)WVGA<4!VLY]X;50!96PE50,*K!" ULHUS=H@>2K@/@3=#+T64(]C
M"RHWGJ,']Y76-O 4<HD\R8;]:>V/5I(]CP)%QYEXSS.]+]G EX$ZK$+4T'5Z
M>O8"DKT)WZ8Q"I,O-:;_E<;L.8WLN,ILK_(&)^+NN$H#P1!8!<\=/K>@^IT=
M_NR)$4%#D2^X>YSKFNJ+F7U(DMBR'SG"P110'![]$/]T'XXOAI;AV<"-+L3D
M;;UI'0=V_&!\05/O;H@& $[B!SJ1EEQ6K'4G9A+U_LTM<V\&06<4\S-H7V),
MZ93W0SO=7/0W)RY#/,_=^8AJIWM)(+H:+HTZ]"?"R'=X/-Y%Y-W-[?4C"^(P
M?FQ!O!<R"8^]FID.7IM50M^YEX,&%=/6UK]!V]W=O7^\\J_=]LO]R\LW7..0
M:D &&VS%%#H;,^U?"/H?5C7N)=Q*6:LJ=UD(-$%-"_!\HY3M?Y""W5O9RS\!
M4$L#!!0    ( ,N#6UJ.3=4LQ@D  . 9   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;+U9:V_C-A;]GE]!N$$W 32R2%&O3"9 9C+3[:+3#)IVB\5B
M/S 2;0LCBRXEY;&_?L^E9%N.[0RZP"X"V*;$>^[[0>;RT=BOS4+KECTMJ[IY
M-UFT[>IB.FWRA5ZJQC<K7>/-S-BE:K&T\VFSLEH5CFA93440Q-.E*NO)U:5[
M]L5>79JNK<I:?[&LZ99+99_?Z\H\OIOPR?K!+^5\T=*#Z=7E2LWUG6Y_6WVQ
M6$TW*$6YU'53FII9/7LWN>87[R7M=QO^7NK'9O2;D2;WQGREQ8_%NTE  NE*
MYRTA*'P]Z ^ZJ@@(8OPQ8$XV+(EP_'N-_LGI#EWN5:,_F.KWLF@7[R;IA!5Z
MIKJJ_<4\_E4/^D2$EYNJ<9_LL=\;)A.6=TUKE@,Q)%B6=?^MG@8[C C2X B!
M& B$D[MGY*2\4:VZNK3FD5G:#33ZX51UU!"NK,DI=ZW%VQ)T[=7=0EF],%6A
M;?,7]O&/KFR?+Z<MD.G]-!]0WO<HX@@*%^RSJ=M%PS[6A2YV :80:2.76,OU
M7KR*>*-SGX7<8R(0\A6\<*-GZ/#"8WJV)O_Z0D_VLVDU^^?U?=-:1,>_#NG=
MH\K#J)0Q%\U*Y?K=!"G1:/N@)U???\?CX.TK,LN-S/(U]!>^T4=]\SH*3WTV
M1OK^NU3PY.V =_(/K2S3Y#4&F^OEO;9D]Q.R.QD_I ]Q<MVU"V/+?^O"8ZJJ
M3-O2KQP_0=BMF*H+-NNJZIFM5%DP8XNR1I*SAC@W'@O\(&(\\$2:LM1+98)/
M'O&3GSO'<>=K_=#,!G)6UJQLFDXS+KD7)](+$LDX)Z#8R^(8R(F7!JDG$S&B
MOKZYVY+*Q!-">G'&69AY,8^\.(I8&'E9&$.4A/VZT.P':Z#,0C7,U-#%U)KE
ME6J:C2P^NZZJE^J!X$&3057%'DQ;UG-FJ1HTSBQ6U5]A%5OB Y(P5%+6@E=1
M(N[*^\Y5)^ 7Y4-9P!.-SVYK=MW-D?U0TJ6 \!Q)+YZJ:]/5.0RO4!?G@-$6
MBZ*T*'5 FFE+(IP1!7E;!&]OAX=NR=^>$S]H'@5>$ 2TV* /X=&0\> WK?(%
MF+CHKIUF[<)JO>]@U4*:E2US37"G+/.C@*W@!^!X*&KM@M6HT600_021":JL
M\=TZ \!R]$KE.50I$5QX^:!1_BS,09Y1\SET54C8N35PR,J:7.NB60N_UI ]
MPAC@'\5^A()9563=>PVCP^*ZZ'+'^91)GV]>(T8Z9(!]M*5["\_DL' +M7*S
M7")^L*MW)D0JT0L@W\;.^@D=LM&]VV[SUE#T(;S(;WSL-QC0.:JL6P,P=@LZ
M]EG9K^B]=ZK2[!HJ:G2\MO?=A!XVVZ>3\\&0?]..-][]]-,'=C;9K&G'JK--
MIX !)H^+$N[;2K!4S[W<3A?TQLIC,VN6#$II(J!OCY5M[W[RM>GF(X;?U'%6
M5J.XM,H%=]/"8J2!-TATKW,%AH3JNC(2;8-*L=ZCKA.%\E<AWGNAR5#P.7A!
MWE-D/DK+QI-]TD/,F\[VP:K9\^$*YXK;6/0&]9&%OMR .1.0$#4<-(XWM<+J
MR<4!BL0I"X4OUE3>H6#C(Q$1;*L*+</Y&7,//F=:]]%E((T=!=2/M>M_8RFM
M*ANR<($LZ?-F+-DI$XF?O!;W@9_]%Z(,8=*X@!R,W.>,$^U%H.Y$R>!/>2A*
MJ"(<CA2*"!J[V*<WX1 TJ$(D;.%PCE&A[J(N41_J>9A#X7HTL!#Z\&[][&TC
M#'DZLK6+MW&T4:H,36!3)<'V_OF;)KH>2E?9D*APCK<75SS,_/AE;(,/#=NZ
M<%;^I.]M1W4XVK?RN$^@,C]0\=SZVW6 A$NTY/A_T@$$HO[_V@*^##I^V>@X
M] (NQC7B0%*,<^;/Y.>-;E59;0183RLT;Z ?;TM0WEGKX( !0SZ4IFOZN@0"
MIJC*8*9Z;"Y>&7U@WKWR-9Z!CLT]!^FV$]#)W3&AG7Q(%PD><1R=W*Y:UP;U
MD[9Y7X1:5U!$P*;$$EE%RR!AT]W@8"(27B2#8Q#"E[L0:; /$:=>DO%C$-*'
M5EL([DN^!\$%33NO(,AO(61>EF7' "(_Y3L F=P#").C=DS\4(S(89,#Y,%K
M&B1^'.P@1.$>0I1*+^3Q,8ATUYG"3_8A)%DA/8:0^5DZ0@C]<!]!X$!QA)P'
M?KQ+'\7[C@R\Z+@9N-AU!!R['Y'\&PB9W$$(]V-!(/&.AB,/70R/$.+]D Z]
M)#AJ1Q[YX=@0D<_W#<D%CBY2'L6(_5CN8.#$LV\)(8]+X<;X+4+LEB\0DO1X
M9@<NC4;T!U+[=7<*X0=C".3)H;Q"?3F:6B+<S8S$3_<C(O)D&/^Y^BO'Y]$1
M*1VM']#O4?&_58KE^%QZ?>"]:^@0S[4R _T8*6BZ%D-/75"M!D.>>#**O# +
MV!G5]PL:=M(HQ-.,O74'R LZ2D8)RCET/\=@,A3\%VU\KZ>9P:1CCB^;EKM#
MH&'(:?F[NPDCVS]HBP;*/@[>&(:#,[H@"7$&76\<]JVWN5UGI^=DCK5#YSA$
M$^1ZC0X^T^7X"9IR:7?6ZQ  S)Y(U-L:&N\<V3,K,#><B(!+*EB\[R;2G8W?
MN+^S875.*]H8C3:&7H@B]V;XZU>!'W':%V-+("A[);I'&B4;P'[?.8N]B +)
MYQGM3Y B88 Z'$34I-%N-@0\1AN.02%Z4A0I020IF(&/Z\,AT+)X0Q)#:.*!
MOA%E$-07,5%D=/K-(%08LRA)$'OI5BS$8X*$ QM!_!/L31*Z#@H@&GI22BJ+
M&&4C2!Q%A+YU[GZA&LDL<1)*CR<I.$@247!$*%4.Y'((#6/AA4 BDL0%_CG)
MBA$A$.XG-"4+GT,XU#<(&?LB(AR!A/-ES'CJRXS1: *;QF'///'"('/T2>0%
M8=+_]$C=<^P-468D%$7]"$_ZX0F#1NQ*=8IJ+N+,B]*LMUL(5Z6]+)''18\E
ML4DZ]5!T4R^$,ZE?G@R5P.>"!(/CWE!1C5&2X/2S8>SH0X=>(%'I1>8'\<FO
MIL78>T:3-K3%*"Z1G_$N.?*6$KL71@PQ &D@KTS)=DAUC&@R#M=PM^N<'E4!
M:!30$";(Q\X]/:2,$FKG/;PGZ0Y-4LB,2LIPZAA. (?'?S?:4KW0N\G^B#JA
MJL:PW&"8MY2#R+HMF'+'[&&S<FO]E"]4C22U-,SWMVIT-4%S=&4:*D#K>=J-
MJ/TB?QY8-,-9B6[%Z%C%5C@$%2[9?[MC!6H64G]]$4'B<037H=V<]M^X_?ZA
MV]SIZ-9]J>W<_6^A8>[FJ+^ WSS=_/OBNK^UWV[O__?Q65D<6QM6Z1E( S^)
M)OT-XGK1FI6[P[\W;6N6[N="*YPM:0/>SXQIUPMBL/FGSM5_ %!+ P04
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MXV&?JOIC1'UCU-)^ )@H8U1A+Q=28,;P CR?*67:&U;0?1&Z^0]02P,$%
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MF+ZT1MD)#S;(<R5L+_/(7>TI<92.#\IUSZ//ZOUK](G'4G/%#6[8=)+^<IF
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M",=9%AY(XLD(G(Q<\*0.F&BQ:ZD0:=")59F#- /V@!SQZB$]P)\.ED6&D/Q
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M08X+5@LW4ZNON,WGQ/,R)6SXA57CVR?GK+9.5=M@4E!QV8QLO;V'O8#SY(V
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MPA3Q@SJ3_]"8TMP@NC; A74C=&-;X$.0P3?LH:SP-+D#38H.2C#[UK99=WM
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MC=!?T^^O%*<DHM^;5=-AY/;)*;_E507J=XWG.$4MKO]D]FSQ>+9\_G38]9!
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M!UD)$.;I0&-^9(:S74H2UB\Y3&%X;>QNL-W+>5;93@^!%@(E\%28%N%7*M]
M+*)[!5"Q9/&_?S!/]<^HUY/:ELIOAIV?7V%1P.47."728XACL&WD@P\J%R4Y
M!#X!+  XH'@&YV]&3'HOQ6(N$41\^,A.*F6M*>:(/-OFS=9PIJ@@EV[=LK>>
MD[Q54,8M+=/?!S.J)*8[#C3"G0'Z-9OVZ?M\?WCY-H)4<E2Z.P5)[XDIC EB
M.J@R&QM%B$8@6#F*APP 07MRSF00OLZ)QV7!+@$7-<8[EB@TW3;$J?FH(!*K
M'=$I;HC9)2]E*09:'CD*. "I3SUB=86"P;XF'U?90*2C!+J0;(^H1 KKI;4P
M:7LK%KS=[LHCY[PI6H&%&[]7+"DE*39I4W,FS$;6] A'$IK(;:U%_)TBMOH&
M\AFEW-CJ\-(IF,-T6Y3\[4X2WT3:09[F&!T\=*"B@='J(O:97,L&BVM]1:#P
M!=4%[,&_P5H'<,!#84*J:\\')),W0,$XK?*]*8\O.-3[]&7VN9^>.-_8KR"'
M7OHGKH-T'0B1G*O.C]YX_\<[.@.)\1UBCXR"H4<_R0-TDL(VB'=^%<T<C:\$
M,1026&&U^8"BYY11G*;UF(S"@!SPJCNB-]N0$=>$*^R1K+_K5#_YF_<W+3G6
MY%X=7^P>;D]L%5G,ZX9U7JXEQ2<&07 <DGSRO5RO<,-_U&T>)*P PUI,K#*7
MB;6 %T<2)[X(GQH%PH<SG.Q$;V HGVJ+!I=0@!N#K0YX)7WF4& E]WRZ,QJ_
MY=#FF"P/F"/_&_ /G-[F6^;UH?.?RXECV!\$E.&=1ZMP.*92_K.AXG3 D/5:
M?]);0D$#3.4XI]SN.N>/H?:OI'S19PQN$UV;@*/:PI]?D,S/:LV")U32"GGK
M"T4^B%V?!YFHR<HT1SD;\'HX\N%BE-B3X'1_2:%_DR1 T87CLK;(ITK7B9Y&
MQ70TK5A8FH-!!^RKZ ^OG3T^D=W>*X'R_5/PJJYL6R-]J5,!:)$T6B_(\ \*
M8E'%#&6JJF-<H>&)'T-3( T>LMAQ&#CF8F>D-4Q.= UI4'#&<UOZA)DOBY&Z
MG_Z=37,Z&@1XT[[T'8OJLT>3X:6HP65Q1WAIV  <C#%-+[6</Z>0XK!!.?H'
MOB^)(R'&P,3'I"@%^<!UQH+J,A,C0V^7-+YM"K95>E*(-,6_3<2KX]3)QY$M
MU*'-.3LKPAX)'&P,,4U(LPDA<_8'8[Y R.LODFJG,"7KKY+48!LBE$P=_4.(
M^/<IGQ:K<4X2_AU6"7&16/(T9O5+;=L B[\&[PC/%)U^IE6A%^&MMBL(&7=<
M$N)!DEDDB55^CYA.<8K+BWHL> *WE(Q65,R3B87('(#WD."8>T/)@S<(5HA;
M#5S$UEFB:%JN\""DD5!P7,B("6G5(%C="0@YDI'% !SGK#*\/NV)'ZY]&SW$
MND'QH'@/V:<V%DR4M.0H$(,788^$L3<D8K2'G@ 7G=Y+GDU7EB?FB9&C]P\I
M,1I7#^%1LL5.M6YLZGRHV,G+G>H2OZ\WLD]WLRX0DVI;NS<^'5MJAT/=S-!I
M;>(.HIFZ^+. %RT"&)##U?CU#$K7Y7SQ9%+ +H. 74Y*Q3_RKZ/ESW>\NIS_
M %<L[V=OY ;:_"M:YV1QQU$<^#W]#O!"/FQD0_(JT1^YV,^7%]'O<JV"#UI)
MPC4^(XYUA#D8)1C:%'6,84ZS=]QAM!;71*Z5R1:%AL)6-UH.0M!74MIQI" 5
MUUD#Z312[Y%LX->J#-GC0RO.$R0EA;NI%8D)TBT]U$@]&/&7K\RN6 Q@-%<#
MQ-3:HG\0<I4J[XP[A%&P4%PW][TUM"Z*.X0!I1TEL!U;?'?*O*2V@0^&P3L.
M4D3%%)_G_S$?7P]/R?5 F+=&!D/2<'OR'QOP40O;[2\<62.8+VRD5MXW^/WZ
MSH7DXY4/DC"WT27D_$8*4 F;.1&/6$[4%"'N:_*VGV+G;JRCY/DFM-",+/#;
M*%(.EX3(4;<#KY[K$_,6M.>J:S73C+D^KQ&P\Z)K)+7$M&!6=(6C6C"@,M3>
MBAWG XN$ED.2@KA3K[+5K_$K RX$\<>&2@WL?M4UCODON+N$XF39M]&RP.[9
M&[YSZE0'<4EGST>4<BP? >J_4]TG;N]KB+$4+-19.6'V&=4[D!<B8!;WAO%=
M!(C JB3WZ>V[T*[)!P#*"\:STAUO92S)"WY.^VPE]1TE I,D<-KZ(9+K',GF
M@;[S.@X&:LR);Y_M'3Z>_"'B,K3@.@SZ@D,!$"KQ!5XF0<>>3E)\HCH6\"[U
M(2KE&$ 1+IP&9^'P1@3-+G>A$ER376BU]B.:8T"37ZU/>R_4:LP.]:(40VM=
MGR -UZ!^+N[XQ%C><49GBSH0:/TXW16]3+D&1W;$6VP )C,-%QUIP4CY3D6
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M,6?=2GB)6CT(PT@0V#KA*%QN1 YP2VQ\90)2SQH/)8&D#%$,8%"3<(7'Q@N
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M?WABX>ROOIJMC+W37?C$DI3%274REY -K8@&LM@>!LR[^HAC>FGN'77.+7X
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MQQ[HIALV"ZO6=0=:*$LRZVE./Q#4SH#.5TK9_<(Y:'])R1]02P,$%     @
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MN'_J?<#Z+:1A%<R1-!R<8ZIH_WSR$ZMJ]V29*8L/(#>D.@F:#N#^7"F[FY"
M[@T[^0]02P,$%     @ RX-;6E0Z0#H% P  508  !D   !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL?57;;MLP#'W/5Q#NT&V 5U_C7)H8:-I=^E"L:+H5
MP[ 'Q69LH[+E27+3_/TH.TE3+,V+)<KDX:%)'4]60CZJ'%'#<\DK-;5RK>NQ
MXZ@DQY*I,U%C16^60I9,DRDS1]426=H&E=SQ73=R2E945CQISVYE/!&-YD6%
MMQ)44Y9,KF?(Q6IJ>=;VX*[(<FT.G'A2LPSGJ'_4MY(L9X>2%B56JA 52%Q.
MK0MO/ N-?^OPL\"5VMN#J60AQ*,QKM.IY1I"R#'1!H'1\H27R+D!(AI_-YC6
M+J4)W-]OT;^TM5,M"Z;P4O"'(M7YU!I:D.*2-5S?B=4WW-33-WB)X*I]PJKS
M[9-STB@MRDTP,2B+JEO9\^8[[ 4,W3<"_$V W_+N$K4LKYAF\42*%4CC36AF
MTY;:1A.YHC)-F6M);PN*T_%5(>G["*F 52G,-5LNX5(HK>##/5MP5!\GCJ8\
MQMM)-IBS#M-_ ]/SX494.E?PN4HQ?0W@$,$=2W_+<N8?1;S"Y P"SP;?]<,C
M>,&NZJ#%"][ NQ0E3;5B[6#<(6<:TTW9OR\62DL:EC^'"N]@P\.PY@*-5<T2
MG%IT0Q3*)[3BTQ,O<L^/D YWI,-CZ/&<+F3:< 2Q?-6HZRKA35I4&6R;^5Y1
M4653H6PK/%3(T52'"^ER)B:G#<5_2=7IR=#W!N=T55]2VY VTGCI'&&-3 +I
M2&M\E:*I8842@2DZY20/:MS[97S0C U0T[%<H#2-[YG&F^X'YN'WWKFNJV#O
MV7L@">F&6#'.9$&&-[+#(#2+UQ^"-[3]*.S-15(P#@H3(J;773W@V8.0/.V1
MZYG](.Q])Y(2ZHW\=%Y1%$'DCJ ?>+UYSB1^,H*00LW6I%/DD-!AAN!%=N .
MS.(/"-6WHV'4NQ>:\K(LDYC1O+WZ3! ,B:,'P< >A3X$@>WW^W!H9IR]JUXB
M)3."1HE%4^GNUN].=YIYT4G%BWLGN#?$M:@4<%Q2J'LVZ%L@.Q'K#"WJ5C@6
M0I,,M=N<=!^E<:#W2R'TUC )=G^2^!]02P,$%     @ RX-;6D[H/ZZ. @
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M3G/\C4 :!3S/A-#;A7'0_V_Q7U!+ P04    " #+@UM:SL=WC'("  !S!0
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M3V@0SJ[3: NO- =W9C@8TU\(XZ"S6$MENBZE#8.H/X)1$, PB#H/KW-_/Q[
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MTPYWT>*B%W!A!%=$S#6\%QEFSP$^:>L%1CN!%]%1XB6F9Q"''D1!E!SAQ7W
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ML-0Y%_LD2?PD2\@ AFGL1^/(#I.IGR49&6#)6G&@>\^+!=Y'*7EI+Z^M-R=
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M#*794)H#I;E0F@>E^5!: *6%*)I8*)VI;*E-944'I,X<7 E0Q[BE]>]H/NJ
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M!=8ML-OM8M@%8QU;0B52)6D[^_<C)5EQ9-KS17,1B]1[#L]S^'4TV0OY5>4
M&CU7)5=3+]>ZOO-]M<JA8NI6U,#-F[60%=.F*3>^JB6PK#&J2I\$0>Q7K.#>
M;-+T/<K91&QU67!XE$AMJXK)?Q^@%/NIA[U#QZ+8Y-IV^+-)S3:P!/VE?I2F
MY?=>LJ("K@K!D83UU+O'=RDFUJ!1_%G 7AT](XOR),17V_B83;W 1@0EK+1U
MP<S/#N90EM:3B>-;Y]3KQ[2&Q\\'[S\W\ ;FB2F8B_*O(M/YU$L\E,&:;4N]
M$/M?H0.*K+^5*%7S'^T[;>"AU59I477&)H*JX.TO>^X2<62 XS,&I#,@0P-Z
MQB#L#,)K#6AG0)O,M"A-'E*FV6PBQ1Y)JS;>[$.3S,;:X!?<SOM22_.V,'9Z
MMH2-F46-%E +J0N^03=HV:X!)-;H\/HC;Y>8G:IW*6A6E.J]D7Y9INC=F_?H
M#2HX^IR+K6(\4Q-?F]#L /ZJ"^.A#8.<"0,3]$EPG2OT$\\@>^W -TP]&#F
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MVRC/&7D-5#QHU<5U1KY3HXZB!'64H#L*?4*YR+!QO8*6+^@WO;<QH=-8T=B
M@0.S[[#V';ZP!+J;FER'AIJ[@\;S,VVC/!CX7L-Y&^7"8'#"^[#V/NST_OBG
MR78GY_\VEC[%XI[$CFHUJFLU^H'->M1G3?L4BWL2.ZHI=/;#B]-#NZY$CMXD
MZ#1>D:D)Y0=AXT7J-G1IX(-I#?;4L2NAEUJV 6;JV0981].&[CZ/>VG[JY@O
M!FC#C ':L*X ^QD,=HXCT7LLWV'R9 S0ZXC5JUK<E]IQU?93%O1_8#>$/<U,
M56'[5(O[4CLN['Z@@]T3W9D-L3VH00B#H/EJF6!##S9?K4Y+ET;>#W[P.R8_
M>,[H9P"U9S\3Z-3P!_?3'[QX_*N88;?U-LA@W0!J6;</]A *S)9Z+X;+WYD-
M$>5_V/75>K_G1N]R-*[?JGT@O3>QERDWD3XBMLP(!SE>2$GG*I0/#BOW9<H3
M0==ZIV).A:"%/EQAE&*F /+[!:7B^43=H-X=B_X#4$L#!!0    ( ,N#6UJ!
MW^L02P,  /H)   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;*U6R6[;
M,!#]%4(MN@!MM%I24EM 8K5H#T6#N,NAZ(&1QA91251)*F[^OD-)5FR%-G+H
MQ>8R[W'>#,69^9:+W[( 4.1O5=9R815*-1>V+;,"*BK/> ,U[JRYJ*C"J=C8
MLA% \PY4E;;G.*%=459;R;Q;NQ;)G+>J9#5<"R+;JJ+B_@I*OEU8KK5;N&&;
M0ND%.YDW= ,K4-^::X$S>V3)606U9+PF M8+Z]*]2&-MWQE\9["5>V.BE=QR
M_EM//N4+R]$.00F9T@P4_^Y@"66IB="-/P.G-1ZI@?OC'?N'3CMJN:42EKS\
MP7)5+*S8(CFL:5NJ&[[]"(.>F>;+>"F[7[(=;!V+9*U4O!K Z$'%ZOZ?_AWB
ML =PPR, ;P!X4T!P!. / /^I@&  !%UD>BE='%*J:#(7?$N$MD8V/>B"V:%1
M/JMUVE=*X"Y#G$I2)C #7$A"ZYRL%%VOR9)+)<E;LL([EK<E$+X^V/E49V6;
MLWI#=NB7DMQ U=8@:)?-5RDHRDKY&EF^K5+RZOEK\IRPFGPM>"OQ)#FW%7JO
M?;"SP=.KWE/OB*>N1S[S6A62O*]SR \);)0]:O=VVJ^\DXPI9&?$=]\0S_$"
M@T/+I\-] SQ].MP[H<8?,^EW?/X1OB6O\"V0?0)NH*0*\B%A/R]OI1+XB?TR
MA;VG#<RT^MFYD W-8&'ANR)!W(&5O'CFALX[4\C^)UGZG\@.PAF,X0Q.L2<_
M\-'K/PI)2RH8&*]LSQ%U'/J%O4O<\\#'RW2W'Q23E3N+#ZU2@U7LA0]<!S)F
MHXS921DKGC%:$@E9*YBZ)YF^$"8E/4VX?WH43(48C,X==Z+#Q!0=D1&.,L*3
M,KZH @1IAG)S5$3XZ.@P#"<:##;.^43"8YN9[YH51*."Z'0B"BK@K2Y1.6GH
M/59._# S7-R 24GT.(BA[T03+28K+YID+358>6$<FO7$HY[XI)ZO7.&]HIN-
M@ T^-=@"/+S_)D'QH]OMQ^YL<G>6!JOH// F@@Q6OC>;3039>U6Q HRS[BXP
MYKRM55\DQM6Q@;GLZO9D_0H;F[X/>:#INZ+/F#Y62U+"&BF=LPCOON@[C7ZB
M>-/5WENNL))WPP*;,Q#: /?7G*O=1!\PMGO)/U!+ P04    " #+@UM: T<,
MQN@"  !."   &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6RM5EUOVC 4
M_2M65DVMU)%/ NL@$I1.ZT.WJK3;P[0'DUR(5<=FM@/MOY_MA(R/%/%0"1';
M.>?DGFOGW@S67#S+'$"AEX(R.71RI997KBO3' HL.WP)3-^9<U%@I:=BX<JE
M )Q94D'=P/-BM\"$.<G KMV+9,!+10F#>X%D6118O(Z!\O70\9W-P@-9Y,HL
MN,E@B1<P!?6TO!=ZYC8J&2F 2<(9$C ?.B/_:A(;O 7\)+"66V-DG,PX?S:3
MVVSH>"8@H) JHX#U90770*D1TF'\K36=YI&&N#W>J'^UWK67&99PS>DODJE\
MZ/0=E,$<EU0]\/4WJ/UTC5[*J;3_:%UC/0>EI52\J,DZ@H*PZHI?ZCQL$?SX
M#4)0$X)]0O0&(:P)X:F$J"9$-C.5%9N'"58X&0B^1L*@M9H9V&1:MK9/F-GV
MJ1+Z+M$\E?Q0.0ATRU)>@'M^\Z*/DX2+2_1=G[A/:*I/65920'R.=I UL,*=
M3T!A0N6%9CQ-)^C\[ *=(<+08\Y+B5DF!Z[2L9HGNFD=U[B**W@C+C] =YRI
M7*(;ED&V*^!JDXW38.-T'!Q5G$#:0:%_B0(OB%H"NCZ='K;0)Z?3@R-NPF;?
M0JL7GK!O2*<8U3LBT>_13"JAWZ<_;5FO5*-V55-CKN02IS!T=!&1(%;@)!\_
M^+'WI2UC[RDV>2>QG6Q&33:C8^K)&+-G?6 5:&FEJUD*9(5G%-HR6"GUK)(I
MJJNDY^GSM-I.S"&F'^Y")H>0X',#V3'1;4QTCYH8I:D 6TSU[ZDS18^Z#\A2
MO*(QH;3U':P$XZT@PE[<WS-S"/)[@;=GYQ 4=/UV/W'C)S[JYY$K3!&W!YW8
M@]YF(3[(8Q3U@CT+AR"_[^WOR"$HZ'M[%MRM2EN 6-B.)5'*2Z:J4M2L-DUQ
M9'O!WOI8-\NJM_V7J3KM'18+PB2B,->27J>G4RNJ[E5-%%_:>C[C2G<'.\QU
MPP=A /K^G'.UF9@'-)\0R3]02P,$%     @ RX-;6NS>7N S P  0PH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULK59=;],P%/TK5D ()+8D3M)V
MHXVT+B"0 $V4P0/BP4MN&XO$#K;3CG^/[:2AZ]RJ"%Y:?YQS<L_UUYUNN/@A
M2P"%[NN*R9E7*M5<^K[,2ZB)/.<-,#VSY*(F2G?%RI>- %)84EWY. A&?DTH
M\]*I';L1Z92WJJ(,;@22;5T3\6L.%=_,O-#;#GRBJU*9 3^=-F0%"U"WS8W0
M/7]0*6@-3%+.D(#ES+L*+[.)P5O %PH;N=-&QLD=YS],YUTQ\P(3$%20*Z-
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M)ICUM3"2=A/[@?X&S/X!4$L#!!0    ( ,N#6UI&R'.^@P(  )T&   9
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*U574_;,!3]*U:&$$B%?+84:"-!
M.[0]3*KHV!ZF/;C);6/AV,%V6OCWNT[2M'2!\;"7Q!_WG)QSXMR,-E(]Z@S
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M=WZ!+*INAO7$R*+J)PMIL#M5PPS_'Z!L >XOI33;B6U1[1\I_@-02P,$%
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M_+:T+Q8H%V#]A93F8+BA&-[ ]"]02P,$%     @ RX-;6I*U8%XC @  !P4
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MX.;NEA+=CEWK6%7[SMTHBW/@S0)?*M N />W2MF3XX:A?_O2?U!+ P04
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MC%$GBB^<]=\NZ2Q<&,SU]SH'%,!']<"VH$[T@B4X]*AB-*H5>O'K5V$W>-=
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M,/)[EIQ5(#23@B@H9MYY>#:?V'R7\(/!5N^LB76RDO+6!I?YS NL(."0&<M
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MMHGX:6G;/&KG8/>72M&CX3I)_^/(_@!02P,$%     @ RX-;6I^)35+  @
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MFX/0 +6_X!RW$WU \_\@_ M02P,$%     @ RX-;6F)C%I>8 @  LP<  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#$N>&ULC95O;YLP$,:_BL6JJ96V\B<)
M)!E!6AM-J]1J5=-NKQTX@E5C,]LD[3[];$-9MI&$-^ SON?W'.!SO./B618
M"KV4E,F%4RA5S5U7I@646%[R"IA^DG-18J5#L7%E)0!G-JFD;N!YH5MBPIPD
MMG/W(HEYK2AA<"^0K,L2B]<KH'RW<'SG;>*!; IE)MPDKO &5J">JGNA([=3
MR4@)3!+.D(!\X7SVYU>^3; KOA/8R;TQ,J6L.7\VP4VV<#SC""BDRDA@?=O"
M-5!JE+2/GZVHTS%-XO[X3?V++5X7L\82KCG]03)5+)RI@S+(<4W5 ]]]A;:@
MB=%+.97VBG;-VFCFH+26BI=MLG90$M;<\4O[(O82@N! 0M F!-9W [(NEUCA
M)!9\AX19K=7,P)9JL[4YPLQ762FAGQ*=IY);T"5)]!&M[&<AOW3 <W2'52V(
M(DWTK0*!%6$;U"X_7X+"A,H+=(8(0X\%KR5FF8Q=I3T993=M^5<-/SC 7T)Z
MB4;^!Q1XP1@]K9;H_.SB;QE7E]35%71U!59W=$#W7\M]SAJ%<;^"V0YS6>$4
M%H[^WR6(+3C)^W=^Z'TZXF_4^1L=4T]TN9,^3TU69+/,CMHFOA_%[K8'->Y0
MXU.HL _59(5[**\?-.E DU.@J \T&0H*.U!X"C3M X5#05$'BDZ!9GV@:"AH
MVH&F1T&/!>B>FBL0?;CI4-RLP\V.X[C"%,%+I7LC9(B:+8(J_*K;K>K=*K/_
M'!S\+7WO3^OQCKJX!2GGZ*:L:F.",%T]2-7;0[RA;\#?:WS^@'?0E$X)7A-*
MU&LOW!^P)]V]%FR.LSLL-H1)K9_K+.\RTIM -"=$$RA>V:Z\YDKW>#LL]*D*
MPBS0SW/.U5M@&GUW3B>_ 5!+ P04    " #+@UM:3!M4;CT#  !."@  &0
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MD>?5?SXN-SECY3?6/I9;])EF@F^U-H%6L4!I!)3F@]("4%H(16OGSJ%ZAEW
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M,)25FS5-=3,1M-9MYI(*V;3J82X_1( I@+R_HE0\3=0#ND^;V;]02P,$%
M  @ RX-;6J1RV_"\ @  ^P@  !D   !X;"]W;W)K<VAE971S+W-H965T.#<N
M>&ULK99M:]LP$,>_BO!@M+#%C\G6SC&D<<+**(1VW5Z,O5#L2RPJ6YXD)]FW
MGR0[;AI<-["\L?5PO[].)W&G<,OXD\@ )-KEM!!C*Y.RO+9MD6208S%@)11J
M9L5XCJ7J\K4M2@XX-5!.;<]Q1G:.26%%H1E;\"ADE:2D@ 5'HLISS/_> &7;
ML>5:^X%[LLZD'K"CL,1K> #Y6"ZXZMFM2DIR* 1A!>*P&EL3]WH>:'MC\(/
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MUX 38"I /D\I%?N":J#]2C+]%U!+ P04    " #+@UM:)BC(RM(#   (#0
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M5 &A W!\R[EZ:>@)VH^?Q?]02P,$%     @ RX-;6LVUK#]P @   08  !D
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MN+F5ZR_0^#FS?)GDVCW)NHD-/))5VLBR :."DHGZ39^:/&P!PN050-0 HGU
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MI,&6ZH8%7GJ@; !^GTMI-A/[@_8:37\#4$L#!!0    ( ,N#6UK#_00J&P,
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M]*40A0'HYPO.U7W'7".&:V;R#U!+ P04    " #+@UM:N<9Q@%("   8!@
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M/HPIT6T?:B>H:G\SEPKM/??#PK9NT"[ [J^4/2?=Q%WV_<<@^0-02P,$%
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M)&(0CP#QB'MOZ"$)_DT) VA&W#0;EP1/)38DD;/9"2/&-I  *4D65!TQX$<
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MA]\\RX;6 WT&1GRF'R14=!>"CORXEN7R+M\$F=P6U;)NV#ZX/88R[V Q5T9
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M?)R3X%-1U\5Z]^NCS!>R;#=H_GY?%/7^1=O!<U%^WH5]\W]02P,$%     @
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MYV#WUTKAP7 =H_^C9'\!4$L#!!0    ( ,N#6UIPMBX F@(  *T'   :
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MIZ!<@'V^D-)L-RY!=T-G?P%02P,$%     @ RX-;6G?+FKI' @  7@4  !H
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MRUZ^2M<KV6.A/LWU<H3I0ZW06TDSMC#]1=88P-1#7)V4)5]^Y&PJ<FH7OW?
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #+@UM:%+/;/ED'  "%0P  #P   'AL+W=O<FMB;V]K+GAM;,6<6W/:.!2
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M;NL"  "&/   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=N];N)
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MY9^E-S\!4$L! A0#%     @ RX-;6@=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #+@UM:KR3O5^\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ RX-;6C&'WC]8 @
MO04  !@              ("!71H  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( ,N#6UIPB03W] 0  -D2   8              " @>L<
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #+@UM:P$O>
MDD8#  "^"@  &               @($5(@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ RX-;6BO]."\Q!P  NS(  !@
M ("!D24  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ,N#
M6UKV@GTDC <  ($D   8              " @?@L  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " #+@UM:+$HC=V,"  "(!@  &
M        @(&Z-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( ,N#6UI15'\$D"<  "E^   9              "
M@2M,  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ RX-;
M6@[)-X^B"0  @AT  !D              ("!\G,  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " #+@UM:*6&YT=$'  ")$@  &0
M        @('+?0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( ,N#6UJK5G1@[P(  $D&   9              " @=.%  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ RX-;6CW%9D.# @  C04
M !D              ("!^8@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " #+@UM:U>X]D 0$  "\"0  &0              @(&SBP
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ,N#6UH%<%>T
MOP(  $(&   9              " @>Z/  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ RX-;6FG=$#F_ P  %P@  !D
M ("!Y)(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #+
M@UM:8Q1'VY@#   6"   &0              @(':E@  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ,N#6UH+0GEFX@(  $\&   9
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M970R-BYX;6Q02P$"% ,4    " #+@UM:'*4Z1-0$   3"P  &0
M    @('TK0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M ,N#6UJ1 >=OLP@  *$5   9              " @?^R  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ RX-;6HY-U2S&"0  X!D  !D
M             ("!Z;L  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " #+@UM:@E)J][,'   =$@  &0              @('FQ0  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ,N#6UKN^=$%1@(
M &$%   9              " @=#-  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ RX-;6E33_L!M P  <@<  !D              ("!
M3=   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #+@UM:
M/%/$]7 )  "D%P  &0              @('QTP  >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,N#6UHVY$4UPP(  !@&   9
M      " @9C=  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ RX-;6C%E-B8  @  J 0  !D              ("!DN   'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #+@UM:(7;^CQHI  !KB
M&0              @(')X@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( ,N#6UK<,62.X (  )X&   9              " @1H, 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ RX-;6C7IZ/TL
M!@  SPX  !D              ("!,0\! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " #+@UM:5#I .@4#  !5!@  &0
M@(&4%0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ,N#
M6UI.Z#^NC@(  ($%   9              " @= 8 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ RX-;6M^<RZF- P  >0@  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( ,N#6UI+?G63E0(  (\%   9
M  " @< J 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MRX-;6I"G; PR @  ^00  !D              ("!C"T! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " #+@UM:%7>IDZ,"  #.!0  &0
M            @('U+P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( ,N#6UHH6;3'(@0  ,D+   9              " @<\R 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ RX-;6L&DU&#? @
M0@8  !D              ("!*#<! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " #+@UM:[HS5*1L&  !C$   &0              @($^
M.@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ,N#6UKA
MX<0V9@8  'D1   9              " @9!  0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ RX-;6O^\3/NR!   R H  !D
M     ("!+4<! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
M" #+@UM:3%2XF#T)  #H3   &0              @($63 $ >&PO=V]R:W-H
M965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( ,N#6UK]J7@ML @  /)E   9
M              " @8I5 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L!
M A0#%     @ RX-;6H*I*%T[!   51@  !D              ("!<5X! 'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #+@UM:^T$FJK4#
M  "%"   &0              @('C8@$ >&PO=V]R:W-H965T<R]S:&5E=#4W
M+GAM;%!+ 0(4 Q0    ( ,N#6UJ><<)ER0,   H-   9              "
M@<]F 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ RX-;
M6O.MM\3S P  *1,  !D              ("!SVH! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " #+@UM:@=_K$$L#  #Z"0  &0
M        @('Y;@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( ,N#6UH#1PS&Z (  $X(   9              " @7MR 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ RX-;6NS>7N S P  0PH
M !D              ("!FG4! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " #+@UM:L=R*P[$"   -!P  &0              @($$>0$
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( ,N#6UI&R'.^
M@P(  )T&   9              " @>Q[ 0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ RX-;6A36G[1\ @  L 8  !D
M ("!IGX! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #+
M@UM::].YN,0"   K!P  &0              @(%9@0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( ,N#6UH<N_5AC0(  ,X&   9
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M970W,2YX;6Q02P$"% ,4    " #+@UM:\]D'J4@"   )!@  &0
M    @($LD@$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (
M ,N#6UI'&S4&(0(   \%   9              " @:N4 0!X;"]W;W)K<VAE
M971S+W-H965T-S,N>&UL4$L! A0#%     @ RX-;6I*U8%XC @  !P4  !D
M             ("! Y<! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"
M% ,4    " #+@UM:@EG<-M@"  !G"   &0              @(%=F0$ >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( ,N#6UI(>AB1?P(
M ,H'   9              " @6R< 0!X;"]W;W)K<VAE971S+W-H965T-S8N
M>&UL4$L! A0#%     @ RX-;6G#/AP 5 P  5PH  !D              ("!
M(I\! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " #+@UM:
M&#*%38,"  "U!@  &0              @(%NH@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<X+GAM;%!+ 0(4 Q0    ( ,N#6UH%$O)U6@(  $0&   9
M      " @2BE 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%
M  @ RX-;6I^)35+  @  *P@  !D              ("!N:<! 'AL+W=O<FMS
M:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    " #+@UM:8F,6EY@"  "S!P
M&0              @(&PJ@$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+
M 0(4 Q0    ( ,N#6UI,&U1N/0,  $X*   9              " @7^M 0!X
M;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ RX-;6CL3YQ!O
M @  SP4  !D              ("!\[ ! 'AL+W=O<FMS:&5E=',O<VAE970X
M,RYX;6Q02P$"% ,4    " #+@UM:EV9L46H%  #<*   &0
M@(&9LP$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( ,N#
M6UJH)DPM! ,  '$*   9              " @3JY 0!X;"]W;W)K<VAE971S
M+W-H965T.#4N>&UL4$L! A0#%     @ RX-;6EQJU1GE P  Y@P  !D
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M=#DP+GAM;%!+ 0(4 Q0    ( ,N#6UH39@(CR0(  %('   9
M  " @3;. 0!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @
MRX-;6L/]!"H; P  <@H  !D              ("!-M$! 'AL+W=O<FMS:&5E
M=',O<VAE970Y,BYX;6Q02P$"% ,4    " #+@UM:N<9Q@%("   8!@  &0
M            @(&(U $ >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4
M Q0    ( ,N#6UK)B7;>1 @  &U6   9              " @1'7 0!X;"]W
M;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ RX-;6D7CN " "
MX50  !D              ("!C-\! 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX
M;6Q02P$"% ,4    " #+@UM:KK'_FJ0(  #\4@  &0              @(%#
MZ $ >&PO=V]R:W-H965T<R]S:&5E=#DV+GAM;%!+ 0(4 Q0    ( ,N#6UJ$
M-.<:1@T  'N'   9              " @1[Q 0!X;"]W;W)K<VAE971S+W-H
M965T.3<N>&UL4$L! A0#%     @ RX-;6N6+^%3M!0  N1P  !D
M     ("!F_X! 'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q02P$"% ,4
M" #+@UM:U97]S;T%  #]&P  &0              @(&_! ( >&PO=V]R:W-H
M965T<R]S:&5E=#DY+GAM;%!+ 0(4 Q0    ( ,N#6UIG\S1F&00  -8/   :
M              " @;,* @!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+
M 0(4 Q0    ( ,N#6UJWI:JV1P(  %T&   :              " @00/ @!X
M;"]W;W)K<VAE971S+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( ,N#6UIPMBX
MF@(  *T'   :              " @8,1 @!X;"]W;W)K<VAE971S+W-H965T
M,3 R+GAM;%!+ 0(4 Q0    ( ,N#6UIWRYJZ1P(  %X%   :
M  " @544 @!X;"]W;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    (
M ,N#6UJD/S6-7 ,  ,H5   -              "  =06 @!X;"]S='EL97,N
M>&UL4$L! A0#%     @ RX-;6I>*NQS     $P(   L              ( !
M6QH" %]R96QS+RYR96QS4$L! A0#%     @ RX-;6A2SVSY9!P  A4,   \
M             ( !1!L" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,N#
M6UH*2%)NZP(  (8\   :              "  <HB @!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,N#6UJ$=9N'8P(  &$Z   3
M          "  >TE @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !O &\
*A!X  ($H @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>368</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss</Role>
      <ShortName>Consolidated Statements of Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated statements of Changes in Shareholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Consolidated statements of Changes in Shareholders' equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995467 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Directors and Staff Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts</Role>
      <ShortName>Directors and Staff Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Other Income/(Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1</Role>
      <ShortName>Other Income/(Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Loss Per Share (Basic and Diluted)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted</Role>
      <ShortName>Loss Per Share (Basic and Diluted)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets</Role>
      <ShortName>Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Trade Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1</Role>
      <ShortName>Trade Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables</Role>
      <ShortName>Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Contract Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities</Role>
      <ShortName>Contract Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Equity-Settled Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation</Role>
      <ShortName>Equity-Settled Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Capital Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities</Role>
      <ShortName>Capital Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Commitments Under Short Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases</Role>
      <ShortName>Commitments Under Short Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Financial Instruments and Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement</Role>
      <ShortName>Financial Instruments and Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Directors and Staff Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables</Role>
      <ShortName>Directors and Staff Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Other Income/(Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables</Role>
      <ShortName>Other Income/(Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Loss Per Share (Basic and Diluted) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables</Role>
      <ShortName>Loss Per Share (Basic and Diluted) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables</Role>
      <ShortName>Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables</Role>
      <ShortName>Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Trade Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables</Role>
      <ShortName>Trade Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables</Role>
      <ShortName>Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Contract Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables</Role>
      <ShortName>Contract Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995877 - Disclosure - Equity-Settled Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables</Role>
      <ShortName>Equity-Settled Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995887 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995897 - Disclosure - Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995907 - Disclosure - Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails</Role>
      <ShortName>Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995917 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995927 - Disclosure - Segment Reporting - Summary of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails</Role>
      <ShortName>Segment Reporting - Summary of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995937 - Disclosure - Segment Reporting - Summary of Group's Assets and Revenues by Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails</Role>
      <ShortName>Segment Reporting - Summary of Group's Assets and Revenues by Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995947 - Disclosure - Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails</Role>
      <ShortName>Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995957 - Disclosure - Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails</Role>
      <ShortName>Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995967 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails</Role>
      <ShortName>Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>995977 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe</Role>
      <ShortName>Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>995987 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>995997 - Disclosure - Property, Plant and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property, Plant and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Goodwill - Schedule of Change in Carrying Value of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails</Role>
      <ShortName>Goodwill - Schedule of Change in Carrying Value of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Other Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Other Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails</Role>
      <ShortName>Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Other Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Other Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Other Assets - Schedule of Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails</Role>
      <ShortName>Other Assets - Schedule of Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996067 - Disclosure - Other Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails</Role>
      <ShortName>Other Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996077 - Disclosure - Trade receivables - Schedule of Trade Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails</Role>
      <ShortName>Trade receivables - Schedule of Trade Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996087 - Disclosure - Trade Receivables - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails</Role>
      <ShortName>Trade Receivables - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996097 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails</Role>
      <ShortName>Trade and Other Payables - Schedule of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996107 - Disclosure - Trade and Other Payables - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails</Role>
      <ShortName>Trade and Other Payables - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996117 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996127 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails</Role>
      <ShortName>Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996137 - Disclosure - Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996147 - Disclosure - Leases - Summary of Components of Total Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Components of Total Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996157 - Disclosure - Leases - Summarizes of Maturities of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails</Role>
      <ShortName>Leases - Summarizes of Maturities of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996167 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails</Role>
      <ShortName>Contract Liabilities - Schedule of Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996177 - Disclosure - Contract Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Contract Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996187 - Disclosure - Income taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996197 - Disclosure - Income Taxes - Schedule of Components of Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996207 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996217 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996227 - Disclosure - Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996237 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996247 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996257 - Disclosure - Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996267 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>996277 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>996287 - Disclosure - Shareholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Shareholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>996297 - Disclosure - Shareholders' Equity - Details of Shares Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails</Role>
      <ShortName>Shareholders' Equity - Details of Shares Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>996307 - Disclosure - Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails</Role>
      <ShortName>Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>996317 - Disclosure - Shareholders' Equity - Schedule of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails</Role>
      <ShortName>Shareholders' Equity - Schedule of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>996327 - Disclosure - Equity-Settled Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Equity-Settled Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>996337 - Disclosure - Equity-Settled Share-Based Compensation - Summary of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails</Role>
      <ShortName>Equity-Settled Share-Based Compensation - Summary of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>996347 - Disclosure - Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails</Role>
      <ShortName>Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>996357 - Disclosure - Capital Commitments and Contingent Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Capital Commitments and Contingent Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>996367 - Disclosure - Commitments Under Short Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails</Role>
      <ShortName>Commitments Under Short Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="sln-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>996377 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sln-20241231.htm">sln-20241231.htm</File>
    <File>sln-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img172674775_0.jpg</File>
    <File>img172674775_1.jpg</File>
    <File>img172674775_2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="825">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="42">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sln-20241231.htm": {
   "nsprefix": "sln",
   "nsuri": "http://silence-therapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "sln-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "sln-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 313,
   "keyCustom": 55,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 13,
   "memberCustom": 50,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://silence-therapeutics.com/20241231": 2
   },
   "contextCount": 217,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 653,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 825,
    "http://xbrl.sec.gov/dei/2024": 42,
    "http://xbrl.sec.gov/cyd/2024": 16,
    "http://xbrl.sec.gov/ecd/2024": 6
   },
   "report": {
    "R1": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100040 - Statement - Consolidated Balance sheets (Parenthetical)",
     "shortName": "Consolidated Balance sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_U_iso4217GBP_xbrlishares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss",
     "longName": "100050 - Statement - Consolidated Statements of Income (Loss)",
     "shortName": "Consolidated Statements of Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
     "longName": "100060 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
     "longName": "100070 - Statement - Consolidated statements of Changes in Shareholders' equity",
     "shortName": "Consolidated statements of Changes in Shareholders' equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_c0f73974-d468-4883-a299-b1954062293c",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c0f73974-d468-4883-a299-b1954062293c",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "995457 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation",
     "longName": "995467 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1",
     "longName": "995477 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue",
     "longName": "995487 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3",
     "longName": "995497 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts",
     "longName": "995507 - Disclosure - Directors and Staff Costs",
     "shortName": "Directors and Staff Costs",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:DirectorsAndEmployeeRemunerationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:DirectorsAndEmployeeRemunerationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1",
     "longName": "995517 - Disclosure - Other Income/(Expense), Net",
     "shortName": "Other Income/(Expense), Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted",
     "longName": "995527 - Disclosure - Loss Per Share (Basic and Diluted)",
     "shortName": "Loss Per Share (Basic and Diluted)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment",
     "longName": "995537 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill",
     "longName": "995547 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets",
     "longName": "995557 - Disclosure - Other Intangible Assets",
     "shortName": "Other Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents",
     "longName": "995567 - Disclosure - Cash and Cash Equivalents",
     "shortName": "Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets",
     "longName": "995577 - Disclosure - Other Assets",
     "shortName": "Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1",
     "longName": "995587 - Disclosure - Trade Receivables",
     "shortName": "Trade Receivables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:AccountsReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:AccountsReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables",
     "longName": "995597 - Disclosure - Trade and Other Payables",
     "shortName": "Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases",
     "longName": "995607 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities",
     "longName": "995617 - Disclosure - Contract Liabilities",
     "shortName": "Contract Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:ContractWithCustomerLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:ContractWithCustomerLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1",
     "longName": "995627 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1",
     "longName": "995637 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation",
     "longName": "995647 - Disclosure - Equity-Settled Share-Based Compensation",
     "shortName": "Equity-Settled Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities",
     "longName": "995657 - Disclosure - Capital Commitments and Contingent Liabilities",
     "shortName": "Capital Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases",
     "longName": "995667 - Disclosure - Commitments Under Short Leases",
     "shortName": "Commitments Under Short Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement",
     "longName": "995677 - Disclosure - Financial Instruments and Risk Management",
     "shortName": "Financial Instruments and Risk Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:FinancialInstrumentsAndRiskManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:FinancialInstrumentsAndRiskManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "longName": "995687 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents",
     "longName": "995697 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995707 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables",
     "longName": "995717 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995727 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables",
     "longName": "995737 - Disclosure - Directors and Staff Costs (Tables)",
     "shortName": "Directors and Staff Costs (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:DirectorsAndEmployeeRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:DirectorsAndEmployeeRemunerationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:DirectorsAndEmployeeRemunerationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:DirectorsAndEmployeeRemunerationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables",
     "longName": "995747 - Disclosure - Other Income/(Expense), Net (Tables)",
     "shortName": "Other Income/(Expense), Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables",
     "longName": "995757 - Disclosure - Loss Per Share (Basic and Diluted) (Tables)",
     "shortName": "Loss Per Share (Basic and Diluted) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables",
     "longName": "995767 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables",
     "longName": "995777 - Disclosure - Goodwill (Tables)",
     "shortName": "Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables",
     "longName": "995787 - Disclosure - Other Intangible Assets (Tables)",
     "shortName": "Other Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables",
     "longName": "995797 - Disclosure - Cash and Cash Equivalents (Tables)",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables",
     "longName": "995807 - Disclosure - Other Assets (Tables)",
     "shortName": "Other Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables",
     "longName": "995817 - Disclosure - Trade Receivables (Tables)",
     "shortName": "Trade Receivables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:ScheduleOfAccountsReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:AccountsReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:ScheduleOfAccountsReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:AccountsReceivableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables",
     "longName": "995827 - Disclosure - Trade and Other Payables (Tables)",
     "shortName": "Trade and Other Payables (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995837 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables",
     "longName": "995847 - Disclosure - Contract Liabilities (Tables)",
     "shortName": "Contract Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:ContractWithCustomerLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "sln:ContractWithCustomerLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995857 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables",
     "longName": "995867 - Disclosure - Shareholders' Equity (Tables)",
     "shortName": "Shareholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables",
     "longName": "995877 - Disclosure - Equity-Settled Share-Based Compensation (Tables)",
     "shortName": "Equity-Settled Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "995887 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "sln:GoingConcernPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
     "longName": "995897 - Disclosure - Revenue - Additional Information (Details)",
     "shortName": "Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_76502e8d-3af9-4b0f-a654-bea5116a3a5f",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
     "longName": "995907 - Disclosure - Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details)",
     "shortName": "Revenue - Schedule of Disaggregation of Revenue From Contracts With Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_993f7efa-93c3-4846-afa1-f47122276cef",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
     "longName": "995917 - Disclosure - Segment Reporting - Additional Information (Details)",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
     "longName": "995927 - Disclosure - Segment Reporting - Summary of Segment Information (Details)",
     "shortName": "Segment Reporting - Summary of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:BusinessDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails",
     "longName": "995937 - Disclosure - Segment Reporting - Summary of Group's Assets and Revenues by Location (Details)",
     "shortName": "Segment Reporting - Summary of Group's Assets and Revenues by Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails",
     "longName": "995947 - Disclosure - Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details)",
     "shortName": "Directors and Staff Costs - Schedule of Staff Costs Including Director's Remuneration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sln:DirectorsAndEmployeeRemunerationTableTextBlock",
       "div",
       "sln:DirectorsAndEmployeeRemunerationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:SalariesWagesAndOfficersCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "sln:DirectorsAndEmployeeRemunerationTableTextBlock",
       "div",
       "sln:DirectorsAndEmployeeRemunerationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails",
     "longName": "995957 - Disclosure - Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details)",
     "shortName": "Other Income/(Expense), Net - Schedule of Other Income/Expense, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:BankInterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:BankInterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "div",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
     "longName": "995967 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details)",
     "shortName": "Loss Per Share (Basic and Diluted) - Schedule of Computation of Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R63": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe",
     "longName": "995977 - Disclosure - Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Loss Per Share (Basic and Diluted) - Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "995987 - Disclosure - Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "shortName": "Property, Plant, and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "995997 - Disclosure - Property, Plant and Equipment - Additional Information (Details)",
     "shortName": "Property, Plant and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails",
     "longName": "996007 - Disclosure - Goodwill - Schedule of Change in Carrying Value of Goodwill (Details)",
     "shortName": "Goodwill - Schedule of Change in Carrying Value of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_2170fa2b-c003-47f8-8bf3-4833d45e9e18",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_08dd2d55-0e01-4e62-95a4-087adff7660d",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "us-gaap:GoodwillDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails",
     "longName": "996017 - Disclosure - Other Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Other Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails",
     "longName": "996027 - Disclosure - Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)",
     "shortName": "Other Intangible Assets - Schedule of Expected Future Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails",
     "longName": "996037 - Disclosure - Other Intangible Assets - Additional Information (Details)",
     "shortName": "Other Intangible Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails",
     "longName": "996047 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "shortName": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CashAndDueFromBanks",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CashAndDueFromBanks",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails",
     "longName": "996057 - Disclosure - Other Assets - Schedule of Other Assets (Details)",
     "shortName": "Other Assets - Schedule of Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:PrepaymentsAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "div",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:PrepaymentsAssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "div",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails",
     "longName": "996067 - Disclosure - Other Assets - Additional Information (Details)",
     "shortName": "Other Assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_81c24346-1f04-45a3-900d-ddb8e8aa6c19",
      "name": "sln:PrepaymentsAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_81c24346-1f04-45a3-900d-ddb8e8aa6c19",
      "name": "sln:PrepaymentsAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails",
     "longName": "996077 - Disclosure - Trade receivables - Schedule of Trade Receivable (Details)",
     "shortName": "Trade receivables - Schedule of Trade Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails",
     "longName": "996087 - Disclosure - Trade Receivables - Additional Information (Details)",
     "shortName": "Trade Receivables - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails",
     "longName": "996097 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)",
     "shortName": "Trade and Other Payables - Schedule of Trade and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails",
     "longName": "996107 - Disclosure - Trade and Other Payables - Additional Information (Details)",
     "shortName": "Trade and Other Payables - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_81c24346-1f04-45a3-900d-ddb8e8aa6c19",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "longName": "996117 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:NumberOfOperatingLease",
      "unitRef": "U_Lease",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:NumberOfOperatingLease",
      "unitRef": "U_Lease",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails",
     "longName": "996127 - Disclosure - Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details)",
     "shortName": "Leases - Summary of Supplemental Balance Sheet Information Related to Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails",
     "longName": "996137 - Disclosure - Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)",
     "shortName": "Leases - Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails",
     "longName": "996147 - Disclosure - Leases - Summary of Components of Total Operating Lease Cost (Details)",
     "shortName": "Leases - Summary of Components of Total Operating Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails",
     "longName": "996157 - Disclosure - Leases - Summarizes of Maturities of Operating Leases (Details)",
     "shortName": "Leases - Summarizes of Maturities of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails",
     "longName": "996167 - Disclosure - Contract Liabilities - Schedule of Contract Liabilities (Details)",
     "shortName": "Contract Liabilities - Schedule of Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "sln:ContractWithCustomerLiabilityForeignExchangeImpact",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "sln:ContractWithCustomerLiabilityTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails",
     "longName": "996177 - Disclosure - Contract Liabilities - Additional Information (Details)",
     "shortName": "Contract Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996187 - Disclosure - Income taxes - Additional Information (Details)",
     "shortName": "Income taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_ab13cc0c-5775-43dd-a181-db3338b67deb",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:DeferredIncomeTaxesAndTaxCredits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails",
     "longName": "996197 - Disclosure - Income Taxes - Schedule of Components of Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Components of Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails",
     "longName": "996207 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails",
     "longName": "996217 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Credit Amount (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_ab13cc0c-5775-43dd-a181-db3338b67deb",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R88": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails",
     "longName": "996227 - Disclosure - Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Standard U.K. Statutory Income Tax Rate to Effective Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_ab13cc0c-5775-43dd-a181-db3338b67deb",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails",
     "longName": "996237 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails",
     "longName": "996247 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails",
     "longName": "996257 - Disclosure - Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details)",
     "shortName": "Income Taxes - Schedule of Movements in Deferred Tax Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_2170fa2b-c003-47f8-8bf3-4833d45e9e18",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
     "longName": "996267 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Details)",
     "shortName": "Shareholders' Equity - Schedule of Shares Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CommonStockValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_08dd2d55-0e01-4e62-95a4-087adff7660d",
      "name": "us-gaap:CommonStockValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails",
     "longName": "996277 - Disclosure - Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details)",
     "shortName": "Shareholders' Equity - Schedule of Shares Outstanding (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_U_iso4217GBP_xbrlishares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_08dd2d55-0e01-4e62-95a4-087adff7660d",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_U_iso4217GBP_xbrlishares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
     "longName": "996287 - Disclosure - Shareholders' Equity - Additional Information (Details)",
     "shortName": "Shareholders' Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9f0adb4a-3977-49bd-bd43-31874b535e51",
      "name": "sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
     "longName": "996297 - Disclosure - Shareholders' Equity - Details of Shares Issued (Details)",
     "shortName": "Shareholders' Equity - Details of Shares Issued (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1945b695-781c-4d0b-a167-a95a2b6c877c",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
     "longName": "996307 - Disclosure - Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)",
     "shortName": "Shareholders' Equity - Details of Shares Issued (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "C_e1e57139-299b-4037-aa4e-2d87f4f5721e",
      "name": "sln:StockOptionExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e1e57139-299b-4037-aa4e-2d87f4f5721e",
      "name": "sln:StockOptionExercisePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
     "longName": "996317 - Disclosure - Shareholders' Equity - Schedule of Options Outstanding (Details)",
     "shortName": "Shareholders' Equity - Schedule of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "C_2170fa2b-c003-47f8-8bf3-4833d45e9e18",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
     "longName": "996327 - Disclosure - Equity-Settled Share-Based Compensation - Additional Information (Details)",
     "shortName": "Equity-Settled Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4981ab38-3780-4326-a492-3b5aa602b56e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
     "longName": "996337 - Disclosure - Equity-Settled Share-Based Compensation - Summary of Options (Details)",
     "shortName": "Equity-Settled Share-Based Compensation - Summary of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "C_2170fa2b-c003-47f8-8bf3-4833d45e9e18",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_53771d0d-7cc8-4b66-b57c-8f18749a5839",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "unique": true
     }
    },
    "R100": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
     "longName": "996347 - Disclosure - Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details)",
     "shortName": "Equity-Settled Share-Based Compensation - Summary Fair Value of Options Granted were Calculated Using Black Scholes Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:SharePrice",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails",
     "longName": "996357 - Disclosure - Capital Commitments and Contingent Liabilities - Additional Information (Details)",
     "shortName": "Capital Commitments and Contingent Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:CapitalCommitments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "sln:CapitalCommitments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails",
     "longName": "996367 - Disclosure - Commitments Under Short Leases - Additional Information (Details)",
     "shortName": "Commitments Under Short Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:ShortTermLeaseCommitmentAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d5ab5df5-07a8-4cbf-9fc9-f75571272697",
      "name": "us-gaap:ShortTermLeaseCommitmentAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "996377 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "C_eb12df02-dc62-4dfe-9745-ea50a6329b7c",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_eb12df02-dc62-4dfe-9745-ea50a6329b7c",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sln-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting standards update [extensible enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r194",
      "r195",
      "r196",
      "r256",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r300",
      "r301",
      "r304",
      "r428",
      "r429",
      "r430",
      "r431",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r464",
      "r465",
      "r466",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r489",
      "r490",
      "r506",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r968"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Trade and Other Payables",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r58",
      "r1004"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "totalLabel": "Total trade and other payables",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Other, Current",
        "negatedLabel": "Trade and other payables",
        "terseLabel": "Trade and other payables",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r53"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesScheduleOfTradeReceivableDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "terseLabel": "Trade receivables",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "sln_AccountsReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "AccountsReceivableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivables1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Receivables",
        "label": "Accounts Receivable [Text Block]",
        "documentation": "Accounts receivable."
       }
      }
     },
     "auth_ref": []
    },
    "sln_AccretionOfSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "AccretionOfSecurities",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Of Securities",
        "documentation": "Accretion of securities.",
        "terseLabel": "Accretion on U.S Treasury Bills"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bonus accrual",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and other payables",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "terseLabel": "Accumulated Depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r153",
      "r597"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "terseLabel": "Accumulated other comprehensive loss",
        "negatedLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r68",
      "r161",
      "r592",
      "r626",
      "r630"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r17",
      "r468",
      "r471",
      "r528",
      "r621",
      "r622",
      "r957",
      "r958",
      "r959",
      "r965",
      "r966",
      "r967",
      "r969"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r965",
      "r966",
      "r967",
      "r969",
      "r1012",
      "r1061"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization",
        "totalLabel": "Amortization, Total",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Recognition of share-based payments",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r357"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "sln_AggregateRemuneration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "AggregateRemuneration",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Remuneration",
        "documentation": "Aggregate remuneration.",
        "totalLabel": "Total aggregate remuneration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r877",
      "r910"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r880",
      "r913"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r905",
      "r914",
      "r918",
      "r926"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Equity settled share-based payment transactions",
        "verboseLabel": "Share-based payments charge",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r397"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for expected credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r259",
      "r272",
      "r273",
      "r274",
      "r1028"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sln_AmericanDepositaryShareADSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "AmericanDepositaryShareADSMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American Depositary Share (ADS) [Member]",
        "documentation": "American depositary share (ADS).",
        "terseLabel": "American Depositary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sln_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Shares.",
        "label": "American Depositary Shares [Member]",
        "terseLabel": "American Depositary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfOutstandingPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareDe"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r107",
      "r157",
      "r186",
      "r220",
      "r229",
      "r244",
      "r247",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r457",
      "r461",
      "r491",
      "r587",
      "r681",
      "r774",
      "r775",
      "r809",
      "r834",
      "r998",
      "r999",
      "r1019"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r164",
      "r186",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r457",
      "r461",
      "r491",
      "r809",
      "r998",
      "r999",
      "r1019"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Non-current assets",
        "label": "Assets, Noncurrent",
        "verboseLabel": "Non-current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r457",
      "r461",
      "r491",
      "r998",
      "r999",
      "r1019"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "sln_BankInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "BankInterestReceivable",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Interest Receivable",
        "documentation": "Bank interest receivable.",
        "terseLabel": "Bank interest receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of preparation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Development",
        "terseLabel": "Contracted development costs",
        "negatedLabel": "Contracted development costs",
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "sln_CapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "CapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital commitments",
        "documentation": "Capital commitments.",
        "terseLabel": "Capital commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r151",
      "r759"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r590"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashAndDueFromBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndDueFromBanks",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Due from Banks",
        "totalLabel": "Cash and Due from Banks, Total",
        "terseLabel": "Cash at bank and in hand",
        "documentation": "For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "terseLabel": "Cash and cash equivalents and short-term investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents at start of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r78",
      "r183"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase/(decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r147",
      "r193",
      "r256",
      "r261",
      "r262",
      "r263",
      "r268",
      "r269",
      "r300",
      "r304",
      "r429",
      "r438",
      "r439",
      "r447",
      "r448",
      "r450",
      "r464",
      "r465",
      "r474",
      "r475",
      "r489",
      "r490",
      "r506",
      "r523",
      "r524",
      "r546",
      "r547",
      "r619",
      "r620"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r147",
      "r256",
      "r261",
      "r262",
      "r263",
      "r268",
      "r269",
      "r270",
      "r300",
      "r304",
      "r429",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r463",
      "r464",
      "r465",
      "r466",
      "r474",
      "r475",
      "r476",
      "r479",
      "r489",
      "r490",
      "r506",
      "r523",
      "r524",
      "r546",
      "r547",
      "r619",
      "r620",
      "r950"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "sln_ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Estimate Related To Prior Years Current Tax Expense",
        "documentation": "Changes in estimate related to prior years current tax expense.",
        "terseLabel": "Changes in estimate related to prior years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r158",
      "r159",
      "r160",
      "r186",
      "r209",
      "r210",
      "r212",
      "r214",
      "r222",
      "r223",
      "r260",
      "r310",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r491",
      "r634",
      "r635",
      "r636",
      "r637",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r669",
      "r690",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r949",
      "r961",
      "r970"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r222",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r634",
      "r635",
      "r636",
      "r637",
      "r788",
      "r949",
      "r961"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "sln_CollaborationAgreementWithAstrazenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "CollaborationAgreementWithAstrazenecaMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration Agreement With AstraZeneca [Member]",
        "terseLabel": "Collaboration Agreement with AstraZeneca",
        "documentation": "Collaboration agreement with AstraZeneca."
       }
      }
     },
     "auth_ref": []
    },
    "sln_CollaborationAgreementWithHansohMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "CollaborationAgreementWithHansohMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with Hansoh.",
        "label": "Collaboration Agreement With Hansoh [Member]",
        "terseLabel": "Collaboration Agreement with Hansoh"
       }
      }
     },
     "auth_ref": []
    },
    "sln_CollaborationAgreementWithMallinckrodtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "CollaborationAgreementWithMallinckrodtMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement with Mallinckrodt.",
        "label": "Collaboration Agreement With Mallinckrodt [Member]",
        "verboseLabel": "Collaboration Agreement with Mallinckrodt",
        "terseLabel": "Collaboration Agreement with Mallinckrodt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 20)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r98",
      "r589",
      "r668"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsContingenciesAndGuaranteesTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCapitalCommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Commitments and Contingent Liabilities",
        "label": "Commitments Contingencies and Guarantees [Text Block]",
        "documentation": "The entire disclosure for commitments, contingencies, and guarantees."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r995"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments Under Short Leases",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares",
        "verboseLabel": "Ordinary share",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r826",
      "r828",
      "r829",
      "r830",
      "r831",
      "r965",
      "r966",
      "r969",
      "r1012",
      "r1060",
      "r1061"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued during the year",
        "label": "Ordinary shares - par value",
        "terseLabel": "Ordinary shares, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Number of shares in issue",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r669",
      "r687",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares - par value 0.05 per share; 141,644,488 shares issued at December 31, 2024 (2023:118,846,966)",
        "verboseLabel": "Authorized, allotted, called up and fully paid ordinary shares, par value 0.05",
        "negatedLabel": "Ordinary shares - par value \u00a30.05 per share; 141,674,074 shares issued at December 31, 2024 (2023:118,846,966)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r591",
      "r809"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss for the year",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167",
      "r169",
      "r175",
      "r581",
      "r603",
      "r604"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r763"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract Liabilities",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Contract with customer, asset, cumulative catch-up adjustment to revenue, modification of contract",
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities",
        "periodStartLabel": "Contract liabilities, beginning",
        "periodEndLabel": "Contract liabilities, ending",
        "terseLabel": "Upfront cash payment received",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r349"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities:",
        "label": "Contract with Customer, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ContractWithCustomerLiabilityAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityAdditions",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions during period",
        "label": "Contract with Customer, Liability Additions",
        "documentation": "Contract with customer, liability additions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities",
        "negatedLabel": "Contract liabilities",
        "verboseLabel": "Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r349"
     ]
    },
    "sln_ContractWithCustomerLiabilityForeignExchangeImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityForeignExchangeImpact",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability Foreign Exchange Impact",
        "documentation": "Contract with customer liability foreign exchange impact.",
        "terseLabel": "Foreign exchange impact"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ContractWithCustomerLiabilityNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract With Customer Liability Net Of Tax",
        "documentation": "Contract with customer liability, net of tax.",
        "terseLabel": "Upfront cash payments received, net of tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities",
        "negatedLabel": "Contract liabilities",
        "verboseLabel": "Non-current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r349"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Recognition of revenue",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "sln_ContractWithCustomerLiabilityRevenueUnwound": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityRevenueUnwound",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilitiesScheduleOfContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revenue unwound during period",
        "label": "Contract with Customer, Liability Revenue unwound",
        "documentation": "Contract with Customer, Liability revenue unwound"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ContractWithCustomerLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ContractWithCustomerLiabilityTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureContractLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Liabilities",
        "label": "Contract with Customer, Liability, [Text Block]",
        "documentation": "Contract with Customer, Liability,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Cost of Goods and Services Sold, Total",
        "negatedLabel": "Cost of sales",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r544"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r319",
      "r323",
      "r534",
      "r541",
      "r586",
      "r760",
      "r762"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "sln_CurrencyConversionRatePerDollar": {
     "xbrltype": "pureItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "CurrencyConversionRatePerDollar",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency conversion rate per dollar",
        "documentation": "Currency conversion rate per dollar."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "terseLabel": "Current Year",
        "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax",
        "terseLabel": "Tax expense related to current tax",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r963"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Tax Expense",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r932"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r933"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r931"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r934"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r936"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r940"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r935"
     ]
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "DE",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax",
        "terseLabel": "Deferred tax expense",
        "verboseLabel": "Income tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r117",
      "r963"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Expense",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Taxes and Tax Credits",
        "totalLabel": "Deferred Income Taxes and Tax Credits, Total",
        "terseLabel": "Deferred tax expense",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated tax losses related to corporate income taxes",
        "label": "Deferred Tax Asset Accumulated Tax Losses Related To Corporate Income Taxes",
        "documentation": "Deferred tax asset, accumulated tax losses related to corporate income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "sln_DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset Accumulated Tax Losses Related To Trade Taxes",
        "documentation": "Deferred tax asset, accumulated tax losses related to trade taxes.",
        "terseLabel": "Accumulated losses related to trade taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital losses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax, net",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based payments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsUnrealizedLossesOnTradingSecurities",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss",
        "terseLabel": "Trading Losses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodEndLabel": "Valuation allowance at December 31",
        "periodStartLabel": "Valuation allowance at January 1",
        "negatedPeriodEndLabel": "Valuation allowance at December 31",
        "negatedPeriodStartLabel": "Valuation allowance at January 1",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "sln_DeferredTaxDerecognitionOfRecognizedTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DeferredTaxDerecognitionOfRecognizedTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Derecognition Of Recognized Tax Losses",
        "documentation": "Deferred tax derecognition of recognized tax losses",
        "terseLabel": "Recognition of previously unrecognized tax losses (derecognition of previously recognized) deductible temporary differences"
       }
      }
     },
     "auth_ref": []
    },
    "sln_DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DeferredTaxExpenseOriginationAndReversalOfTemporaryDifferences",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Expense Origination And Reversal Of Temporary Differences",
        "documentation": "Deferred tax expense origination and reversal of temporary differences.",
        "terseLabel": "Origination and reversal of temporary differences"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net",
        "totalLabel": "Deferred Tax Liabilities, Net, Total",
        "terseLabel": "Deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "sln_DeferredTaxRecognitionOfUnrecognizedTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DeferredTaxRecognitionOfUnrecognizedTaxLosses",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Recognition Of Unrecognized Tax Losses",
        "documentation": "Deferred tax recognition of unrecognized tax losses.",
        "terseLabel": "Recognition of previously unrecognized tax losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits for properties",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32"
     ]
    },
    "sln_DirectorsAndEmployeeRemunerationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DirectorsAndEmployeeRemunerationTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors And Employee Remuneration [Table Text Block]",
        "documentation": "Directors And Employee Remuneration [Table Text Block]",
        "terseLabel": "Schedule of Staff Costs Including Director's Remuneration"
       }
      }
     },
     "auth_ref": []
    },
    "sln_DirectorsAndEmployeeRemunerationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "DirectorsAndEmployeeRemunerationTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCosts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors And Employee Remuneration [Text Block]",
        "documentation": "Directors and employee remuneration.",
        "terseLabel": "Directors and Staff Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Summary of Disaggregation of Revenue from Contracts with Customers",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity-Settled Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r359",
      "r390",
      "r391",
      "r392",
      "r798"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863",
      "r906"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "terseLabel": "Net loss per share basic",
        "verboseLabel": "Loss per share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r207",
      "r209",
      "r212",
      "r213",
      "r214",
      "r219",
      "r445",
      "r454",
      "r483",
      "r484",
      "r582",
      "r605",
      "r765"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Loss per share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r209",
      "r212",
      "r213",
      "r214",
      "r219",
      "r445",
      "r454",
      "r483",
      "r484",
      "r582",
      "r605",
      "r765"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r216"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDiluted"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share (Basic and Diluted)",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r215",
      "r217",
      "r218"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate fluctuations on cash and cash equivalents held",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate for loss from continuing operations",
        "negatedTotalLabel": "Effective tax rate for loss from continuing operations",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r799"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Income tax using U.K. statutory rate",
        "terseLabel": "U.K. tax rate",
        "verboseLabel": "U.K. corporation tax",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r405",
      "r432",
      "r799"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowances",
        "negatedLabel": "Change in valuation allowances",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r799",
      "r964",
      "r1006"
     ]
    },
    "sln_EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Effect Of Overseas Tax",
        "documentation": "Effective income tax rate reconciliation effect of overseas tax",
        "terseLabel": "Effect of overseas taxes",
        "negatedLabel": "Effect of overseas taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Effect of overseas tax rate",
        "negatedLabel": "Effect of overseas tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r408",
      "r799",
      "r964",
      "r1006"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Adjustment in respect of prior year",
        "negatedLabel": "Adjustment in respect of prior year",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfStandardUkStatutoryIncomeTaxRateToEffectiveTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "terseLabel": "Income not taxable",
        "negatedLabel": "Income not taxable",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r964",
      "r1006"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost granted but not vested",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r144",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r195",
      "r201",
      "r203",
      "r205",
      "r221",
      "r265",
      "r271",
      "r301",
      "r336",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r482",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r508",
      "r528",
      "r602",
      "r621",
      "r622",
      "r623",
      "r644",
      "r714"
     ]
    },
    "us-gaap_EquityRestrictions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityRestrictions",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Restrictions",
        "terseLabel": "Maximum value of shares to be sold",
        "documentation": "Disclosure of the amount of equity that is restricted to use by regulation or agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r877",
      "r910"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "sln_EstimatedEmployerTaxObligationOnOutstandingOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "EstimatedEmployerTaxObligationOnOutstandingOptions",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated employer tax obligation on outstanding options",
        "label": "Estimated Employer Tax Obligation on Outstanding Options",
        "documentation": "Estimated employer tax obligation on outstanding options."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "sln_FinancialInstrumentsAndRiskManagementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "FinancialInstrumentsAndRiskManagementDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureFinancialInstrumentsAndRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments And Risk Management Disclosure [Text Block]",
        "documentation": "Financial instruments and risk management disclosure.",
        "terseLabel": "Financial Instruments and Risk Management"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful lives of intangible assets",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finite-lived intangible assets, accumulated depreciation",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r275",
      "r291",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1063"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfExpectedFutureAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r545",
      "r548",
      "r755"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total",
        "terseLabel": "Finite-lived intangible assets, gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r291",
      "r548",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r291",
      "r293",
      "r294",
      "r297",
      "r545",
      "r755",
      "r787"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r294",
      "r755"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Finite-lived intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r992"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total",
        "negatedLabel": "Net foreign exchange impacts",
        "terseLabel": "Foreign currency gain/(loss), net",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r711"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r914"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "sln_FunctionalAndReportingCurrencyPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "FunctionalAndReportingCurrencyPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional And Reporting Currency Policy [Policy Text Block]",
        "documentation": "Functional and reporting currency.",
        "terseLabel": "Functional and reporting currency"
       }
      }
     },
     "auth_ref": []
    },
    "sln_FurnitureAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "FurnitureAndEquipmentMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and Equipment",
        "label": "Furniture And Equipment [Member]",
        "documentation": "Furniture And Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "GB",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "UK"
       }
      }
     },
     "auth_ref": []
    },
    "sln_GainFromResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "GainFromResearchAndDevelopmentCredit",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain From Research And Development Credit",
        "documentation": "Gain from research and development credit.",
        "terseLabel": "Benefit from R&amp;D credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General &amp; administrative expenses",
        "negatedLabel": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r693"
     ]
    },
    "sln_GeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "GeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General information.",
        "label": "General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r583",
      "r584",
      "r783"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Domain]",
        "terseLabel": "Hoboken, U. S.",
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r583",
      "r584"
     ]
    },
    "us-gaap_GeographicDistributionDomesticMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionDomesticMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution, Domestic [Member]",
        "terseLabel": "Hoboken, U. S.",
        "documentation": "Allocation of business activity identified as domestic."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r784"
     ]
    },
    "us-gaap_GeographicDistributionForeignMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicDistributionForeignMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Berlin, Germany",
        "label": "Geographic Distribution, Foreign [Member]",
        "documentation": "Allocation of business activity identified as foreign."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r583",
      "r584",
      "r785"
     ]
    },
    "sln_GoingConcernPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "GoingConcernPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern Policy [Policy Text Block]",
        "documentation": "Going concern.",
        "terseLabel": "Going concern"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Balance at start of year",
        "periodEndLabel": "Balance at end of year",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r277",
      "r579",
      "r775",
      "r786",
      "r802",
      "r809",
      "r981",
      "r988"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r283",
      "r786"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Other intangible assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r296",
      "r299"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r279",
      "r282",
      "r786"
     ]
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillScheduleOfChangeInCarryingValueOfGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation adjustment",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r278",
      "r280",
      "r283",
      "r786",
      "r802"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r73",
      "r106",
      "r186",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r491",
      "r767",
      "r774",
      "r972",
      "r974",
      "r975",
      "r976",
      "r977",
      "r998"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r863"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total",
        "terseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r286",
      "r296"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before tax",
        "verboseLabel": "Loss before income tax expense",
        "totalLabel": "Loss before income tax expense",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r102",
      "r106",
      "r584",
      "r599",
      "r767",
      "r774",
      "r972",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r305",
      "r486",
      "r487",
      "r488",
      "r616",
      "r618",
      "r698",
      "r755",
      "r803",
      "r1030"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r486",
      "r487",
      "r488",
      "r616",
      "r618",
      "r698",
      "r755",
      "r803",
      "r1030"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxes1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r401",
      "r405",
      "r412",
      "r413",
      "r414",
      "r415",
      "r421",
      "r433",
      "r435",
      "r436",
      "r437",
      "r639",
      "r799"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfTaxExpenseDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Taxation",
        "negatedTotalLabel": "Income tax expense",
        "negatedTerseLabel": "Tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r120",
      "r204",
      "r205",
      "r220",
      "r232",
      "r247",
      "r404",
      "r405",
      "r434",
      "r607",
      "r799"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxation",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r402",
      "r403",
      "r415",
      "r416",
      "r420",
      "r425",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowances",
        "negatedLabel": "Change in valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r799",
      "r1006"
     ]
    },
    "sln_IncomeTaxReconciliationEffectOfOverseasTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "IncomeTaxReconciliationEffectOfOverseasTaxes",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of overseas taxes",
        "label": "Income Tax Reconciliation Effect Of Overseas Taxes",
        "documentation": "Income tax reconciliation, effect of overseas taxes.",
        "negatedLabel": "Effect of overseas taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Effect of overseas tax rate",
        "negatedLabel": "Effect of overseas tax rate",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r408",
      "r799",
      "r1006"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax credit at the standard rate of U.K. corporation tax of 25% (2023: 25%; 2022: 19%)",
        "verboseLabel": "Tax credit at the standard rate",
        "negatedLabel": "Tax credit at the standard rate of U.K. corporation tax of 25% (2023: 25%; 2022: 19%)",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r799"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Adjustment in respect of prior year",
        "negatedLabel": "Adjustment in respect of prior year",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1006",
      "r1007"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxCreditAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount",
        "terseLabel": "Income not taxable",
        "negatedLabel": "Income not taxable",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r1006"
     ]
    },
    "sln_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Tax Paid",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r182",
      "r422",
      "r423"
     ]
    },
    "sln_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "(Increase)/decrease in trade receivables",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Decrease in contract liabilities",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r960"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Decrease in operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r960"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase)/decrease in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease/(increase) in other long-term assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "sln_IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) In Research And Development Benefit Receivable",
        "documentation": "Increase (decrease) R&amp;D benefit receivable.",
        "negatedLabel": "Increase in R&amp;D benefit receivable"
       }
      }
     },
     "auth_ref": []
    },
    "sln_IncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "IncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase/(decrease) in trade and other payables",
        "label": "Increase (Decrease) In Trade And Other Payables",
        "documentation": "Increase (decrease) in trade and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r905",
      "r914",
      "r918",
      "r926"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r841",
      "r930"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Other intangible assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r295",
      "r298",
      "r754",
      "r755"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sln_InvoiceRaiseDurationAfterQuarterEnd": {
     "xbrltype": "durationItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "InvoiceRaiseDurationAfterQuarterEnd",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Invoice raise duration after quarter end",
        "label": "Invoice Raise Duration After Quarter End",
        "documentation": "Invoice Raise Duration After Quarter End"
       }
      }
     },
     "auth_ref": []
    },
    "sln_JefferiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "JefferiesLLCMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jefferies LLC [Member]",
        "documentation": "Jefferies LLC.",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r808"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Total Operating Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r521"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r521"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Summarizes of Maturities of Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expected lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease contract notice period",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "negatedTotalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r186",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r458",
      "r461",
      "r462",
      "r491",
      "r667",
      "r766",
      "r834",
      "r998",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "negatedTotalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r99",
      "r594",
      "r809",
      "r962",
      "r979",
      "r1014"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "negatedTotalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r150",
      "r186",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r458",
      "r461",
      "r462",
      "r491",
      "r809",
      "r998",
      "r1019",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "sln_LicenseAndSoftwareNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "LicenseAndSoftwareNetMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Software, Net [Member]",
        "documentation": "License and software, net.",
        "terseLabel": "License and Software, Net"
       }
      }
     },
     "auth_ref": []
    },
    "sln_LicensesAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "LicensesAndSoftwareMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses and software.",
        "label": "Licenses And Software [Member]",
        "terseLabel": "Licenses and Software"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r354",
      "r398",
      "r485",
      "r542",
      "r615",
      "r617",
      "r631",
      "r659",
      "r660",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r752",
      "r753",
      "r782",
      "r788",
      "r797",
      "r804",
      "r805",
      "r806",
      "r807",
      "r819",
      "r1000",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "sln_MilestonePaymentTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "MilestonePaymentTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone Payment Tax Withholding",
        "documentation": "Milestone payment tax withholding.",
        "terseLabel": "Milestone payment, tax withholding"
       }
      }
     },
     "auth_ref": []
    },
    "sln_MilestonePaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "MilestonePaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments received",
        "label": "Milestone Payments Received",
        "documentation": "Milestone payments received."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r354",
      "r398",
      "r485",
      "r542",
      "r615",
      "r617",
      "r631",
      "r659",
      "r660",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r752",
      "r753",
      "r782",
      "r788",
      "r797",
      "r804",
      "r805",
      "r806",
      "r819",
      "r1000",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "General Information",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r121"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Net cash provided by financing activities",
        "verboseLabel": "Cash flow from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flow from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Cash outflows from operating activities",
        "totalLabel": "Net cash (used in) provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "sln_NetForeignExchangeImpacts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NetForeignExchangeImpacts",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Foreign Exchange Impacts",
        "documentation": "Net foreign exchange impacts.",
        "negatedLabel": "Net foreign exchange impacts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r80",
      "r103",
      "r148",
      "r165",
      "r168",
      "r173",
      "r186",
      "r194",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r211",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r445",
      "r454",
      "r484",
      "r491",
      "r601",
      "r689",
      "r712",
      "r713",
      "r832",
      "r998"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "sln_NonExecutiveChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NonExecutiveChairmanMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Iain Ross",
        "label": "Non Executive Chairman [Member]",
        "documentation": "Non Executive Chairman."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r881",
      "r905",
      "r914"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "sln_NumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NumberOfLeases",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of leases.",
        "label": "Number Of Leases",
        "terseLabel": "Number of leases"
       }
      }
     },
     "auth_ref": []
    },
    "sln_NumberOfOperatingLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NumberOfOperatingLease",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Lease",
        "documentation": "Number of operating lease.",
        "terseLabel": "Number of operating lease for office space in London"
       }
      }
     },
     "auth_ref": []
    },
    "sln_NumberOfOrdinarySharesDenominatedInTemporaryEquity": {
     "xbrltype": "integerItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NumberOfOrdinarySharesDenominatedInTemporaryEquity",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Ordinary Shares Denominated in Temporary Equity",
        "documentation": "Number of ordinary shares denominated in temporary equity.",
        "terseLabel": "Number of ordinary shares in American Depositary Share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_NumberOfOrdinarySharesForEachAmericanDepositaryShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NumberOfOrdinarySharesForEachAmericanDepositaryShare",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ordinary shares per ADS",
        "label": "Number Of Ordinary Shares For Each American Depositary Share",
        "documentation": "Number of ordinary shares for each American depositary share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r768",
      "r780",
      "r973"
     ]
    },
    "sln_NumberOfShortTermLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "NumberOfShortTermLeases",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Short Term Leases",
        "documentation": "Number of short-term leases.",
        "terseLabel": "Number of short-term leases"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OpenMarketSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OpenMarketSaleAgreementMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sale Agreement [Member]",
        "documentation": "Open market sale agreement.",
        "terseLabel": "Open Market Sale Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating loss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r767",
      "r972",
      "r974",
      "r975",
      "r976",
      "r977"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummarizesOfMaturitiesOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating Lease, Liability, Total",
        "terseLabel": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability - current",
        "negatedLabel": "Operating lease liabilities, current",
        "verboseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability - non-current",
        "verboseLabel": "Operating lease liabilities, long-term",
        "negatedLabel": "Operating lease liabilities, long-term",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "sln_OperatingLeaseNewTermBeginningPeriod": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OperatingLeaseNewTermBeginningPeriod",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease New Term Beginning Period",
        "documentation": "Operating lease new term beginning period.",
        "terseLabel": "Operating lease new term beginning period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeaseDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r808"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfWeightedaverageRemainingLeaseTermAndWeightedaverageDiscountRateForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r808"
     ]
    },
    "sln_OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Weighted-average Remaining Lease Term and Weighted-average Discount rate for Operating Leases",
        "label": "Operating Lease Weighted Average Remaining Lease Term and Weighted Average Discount Rate [Table Text block]",
        "documentation": "Operating lease weighted-average remaining lease term and weighted average discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r49",
      "r50",
      "r95"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedEightMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Eight [Member]",
        "documentation": "Options exercised eight.",
        "terseLabel": "Options exercised at $8.20/ADS or $2.73/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedEighteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Eighteen [Member]",
        "documentation": "Options exercised eighteen.",
        "terseLabel": "Options exercised at $22.01/ADS or $7.34/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedElevenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Eleven [Member]",
        "documentation": "Options exercised eleven.",
        "terseLabel": "Options exercised at $12.81/ADS or $4.27/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedFifteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedFifteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $16.64/ADS or $5.55/ordinary share",
        "label": "Options Exercised Fifteen [Member]",
        "documentation": "Options exercised fifteen."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedFiveMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Five [Member]",
        "documentation": "Options exercised five.",
        "terseLabel": "Options exercised at $5.81/ADS or $1.94/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedFourMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Four [Member]",
        "documentation": "Options exercised four.",
        "terseLabel": "Options exercised at $4.24/ADS or $1.41/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedFourteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedFourteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $15.38/ADS or $5.13/ordinary share",
        "label": "Options Exercised Fourteen [Member]",
        "documentation": "Options exercised fourteen."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedNineMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options exercised nine.",
        "label": "Options Exercised Nine [Member]",
        "terseLabel": "Options exercised at $9.98/ADS or $3.33/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedNineteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $23.60/ADS or $7.87/ordinary share",
        "label": "Options Exercised Nineteen [Member]",
        "documentation": "Options exercised nineteen."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedOneMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised One [Member]",
        "documentation": "Options exercised one.",
        "terseLabel": "Options exercised at $0.20/ADS or $0.07/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedSevenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Seven [Member]",
        "documentation": "Options exercised seven.",
        "terseLabel": "Options exercised at $7.60/ADS or $2.53/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedSeventeenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedSeventeenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Seventeen [Member]",
        "documentation": "Options exercised seventeen.",
        "terseLabel": "Options exercised at $20.41/ADS or $6.80/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedSixMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Six [Member]",
        "documentation": "Options exercised six.",
        "terseLabel": "Options exercised at $7.32/ADS or $2.44/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedSixteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $19.50/ADS or $6.50/ordinary share",
        "label": "Options Exercised Sixteen [Member]",
        "documentation": "Options exercised sixteen."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedTenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Ten [Member]",
        "documentation": "Options exercised ten.",
        "terseLabel": "Options exercised at $10.68/ADS or $3.56/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedThirteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedThirteenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $13.80/ADS or $4.60/ordinary share",
        "label": "Options Exercised Thirteen [Member]",
        "documentation": "Options exercised thirteen."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedThreeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Three [Member]",
        "documentation": "Options exercised three.",
        "terseLabel": "Options exercised at $4.23/ADS or $1.41/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedTwelveMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised at $12.94/ADS or $4.31/ordinary share",
        "label": "Options Exercised Twelve [Member]",
        "documentation": "Options exercised twelve."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsExercisedTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsExercisedTwoMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Exercised Two [Member]",
        "documentation": "Options exercised two.",
        "terseLabel": "Options exercised at $2.40/ADS or $0.80/ordinary share"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearEightMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year eight.",
        "label": "Options Issued In Year Eight [Member]",
        "terseLabel": "Options Issued in 2021"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearElevenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Issued in 2024",
        "label": "Options Issued In Year Eleven [Member]",
        "documentation": "Options issued in year eleven."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearFiveMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year five.",
        "label": "Options Issued In Year Five [Member]",
        "terseLabel": "Options Issued in 2018"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearFourMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year four.",
        "label": "Options Issued In Year Four [Member]",
        "terseLabel": "Options Issued in 2017"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearNineMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year nine.",
        "label": "Options Issued In Year Nine [Member]",
        "terseLabel": "Options Issued in 2022"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearOneMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year one.",
        "label": "Options Issued In Year One [Member]",
        "terseLabel": "Options Issued in 2014"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearSevenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year seven.",
        "label": "Options Issued In Year Seven [Member]",
        "terseLabel": "Options Issued in 2020"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearSixMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year six.",
        "label": "Options Issued In Year Six [Member]",
        "terseLabel": "Options Issued in 2019"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearTenMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options issued in year ten [Member]",
        "documentation": "Options issued in year ten",
        "terseLabel": "Options Issued in 2023"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearThreeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year three.",
        "label": "Options Issued In Year Three [Member]",
        "terseLabel": "Options Issued in 2016"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsIssuedInYearTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsIssuedInYearTwoMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued in year two.",
        "label": "Options Issued In Year Two [Member]",
        "terseLabel": "Options Issued in 2015"
       }
      }
     },
     "auth_ref": []
    },
    "sln_OptionsOutstandingWeightedAverageYearsToExpiryDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OptionsOutstandingWeightedAverageYearsToExpiryDate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options outstanding weighted average years to expiry date.",
        "label": "Options Outstanding Weighted Average Years To Expiry Date",
        "terseLabel": "Weighted average years to expiry date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r809"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Disclosure [Text Block]",
        "terseLabel": "Other assets",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "sln_OtherAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OtherAssetsLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Line Items]",
        "documentation": "Other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "sln_OtherAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "OtherAssetsTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets [Table]",
        "documentation": "Other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total",
        "terseLabel": "Foreign currency translation adjustments (net of tax)",
        "verboseLabel": "Foreign exchange differences arising on consolidation of foreign operations (net of tax)",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r602"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss)/income for the year",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r12",
      "r166",
      "r169",
      "r174",
      "r201",
      "r498",
      "r499",
      "r504",
      "r580",
      "r602",
      "r957",
      "r958"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r691",
      "r732",
      "r733",
      "r734"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Other intangible assets",
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetScheduleOfOtherIncomeexpenseNetDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income, net",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNet1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "terseLabel": "Other Income/(Expense), Net",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Other R&amp;D costs",
        "negatedLabel": "Other R&amp;D costs",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r879",
      "r912"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r872",
      "r882",
      "r915"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Placement agent fees and other expenses",
        "verboseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchase of intangible assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "negatedLabel": "Purchase of property, plant and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "sln_PercentageOfRoyaltyOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PercentageOfRoyaltyOnNetSales",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Royalty On Net Sales",
        "documentation": "Percentage of royalty on net sales.",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "sln_PersonnelResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PersonnelResearchAndDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personnel Research And Development Costs.",
        "label": "Personnel Research And Development Costs",
        "negatedLabel": "Personnel research and development costs",
        "terseLabel": "Personnel research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "us-gaap_PostemploymentBenefitsPeriodExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PostemploymentBenefitsPeriodExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits, Period Expense",
        "terseLabel": "Other pension costs",
        "documentation": "Period expense related to postemployment benefits."
       }
      }
     },
     "auth_ref": []
    },
    "sln_PrepaymentsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PrepaymentsAssets",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments Assets",
        "documentation": "Prepayments assets.",
        "terseLabel": "Prepayments assets"
       }
      }
     },
     "auth_ref": []
    },
    "sln_PrepaymentsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PrepaymentsAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments Assets, Current",
        "documentation": "Prepayments assets, current",
        "terseLabel": "Prepayments"
       }
      }
     },
     "auth_ref": []
    },
    "sln_PrepaymentsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PrepaymentsAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepayments Assets, Noncurrent",
        "documentation": "Prepayments assets, noncurrent",
        "terseLabel": "Prepayments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Gross proceeds of offering",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds from sale of stock",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r634"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r544",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r757",
      "r790",
      "r818",
      "r819",
      "r820",
      "r822",
      "r823",
      "r996",
      "r997",
      "r1002",
      "r1029",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r544",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r757",
      "r790",
      "r818",
      "r819",
      "r820",
      "r822",
      "r823",
      "r996",
      "r997",
      "r1002",
      "r1029",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r165",
      "r168",
      "r180",
      "r186",
      "r194",
      "r201",
      "r204",
      "r205",
      "r260",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r445",
      "r454",
      "r456",
      "r459",
      "r460",
      "r484",
      "r491",
      "r584",
      "r600",
      "r643",
      "r689",
      "r712",
      "r713",
      "r800",
      "r801",
      "r833",
      "r959",
      "r998"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r112",
      "r115",
      "r116"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "terseLabel": "Equipment &amp; Furniture",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r152",
      "r598"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment",
        "totalLabel": "Property, plant, and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r520",
      "r585",
      "r598",
      "r809"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r112",
      "r115",
      "r596"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Plant, and Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of property, plant and equipment",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "sln_PurchaseOfTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "PurchaseOfTermDeposits",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Of Term Deposits",
        "documentation": "Purchase of term deposits.",
        "negatedLabel": "Purchase of term deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r352",
      "r354",
      "r385",
      "r386",
      "r387",
      "r398",
      "r485",
      "r539",
      "r540",
      "r542",
      "r615",
      "r617",
      "r631",
      "r659",
      "r660",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r752",
      "r753",
      "r782",
      "r788",
      "r797",
      "r804",
      "r805",
      "r806",
      "r807",
      "r819",
      "r826",
      "r994",
      "r1000",
      "r1013",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r352",
      "r354",
      "r385",
      "r386",
      "r387",
      "r398",
      "r485",
      "r539",
      "r540",
      "r542",
      "r615",
      "r617",
      "r631",
      "r659",
      "r660",
      "r724",
      "r726",
      "r728",
      "r729",
      "r731",
      "r752",
      "r753",
      "r782",
      "r788",
      "r797",
      "r804",
      "r805",
      "r806",
      "r807",
      "r819",
      "r826",
      "r994",
      "r1000",
      "r1013",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r874",
      "r907"
     ]
    },
    "sln_RedemptionOfTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "RedemptionOfTermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption of term deposits",
        "label": "Redemption Of Term Deposits",
        "documentation": "Redemption of term deposits."
       }
      }
     },
     "auth_ref": []
    },
    "sln_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered Direct Offering",
        "label": "Registered Direct Offering [Member]",
        "documentation": "Registered direct offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r353",
      "r532",
      "r533",
      "r588",
      "r595",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r686",
      "r688",
      "r723"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Amount paid",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r532"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r353",
      "r532",
      "r533",
      "r588",
      "r595",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r686",
      "r688",
      "r723",
      "r1018"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r533",
      "r535",
      "r640",
      "r641",
      "r642",
      "r696",
      "r697",
      "r698",
      "r720",
      "r722"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r319",
      "r323",
      "r534",
      "r541",
      "r586",
      "r761",
      "r762"
     ]
    },
    "sln_ResearchAndDevelopmentBenefitReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentBenefitReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Benefit Receivable Current",
        "documentation": "Research and development benefit receivable current.",
        "terseLabel": "R&amp;D benefit receivable"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ResearchAndDevelopmentBenefitReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentBenefitReceived",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development Benefit Received",
        "documentation": "Research and development benefit received.",
        "terseLabel": "R&amp;D benefit received"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ResearchAndDevelopmentExpenditureCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchAndDevelopmentExpenditureCreditMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RDEC scheme",
        "label": "Research And Development Expenditure Credit [Member]",
        "documentation": "Research and development expenditure credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Other R&amp;D costs (c)",
        "negatedLabel": "Research and development costs",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r755",
      "r774",
      "r1027"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "sln_ResearchCollaborationAstraZenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchCollaborationAstraZenecaMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration AstraZeneca.",
        "label": "Research Collaboration Astra Zeneca [Member]",
        "terseLabel": "Research Collaboration - AstraZeneca"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ResearchCollaborationHansohMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchCollaborationHansohMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Collaboration Hansoh [Member]",
        "documentation": "Research Collaboration Hansoh [Member]",
        "terseLabel": "Research collaboration - Hansoh"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ResearchCollaborationIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchCollaborationIncomeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration income.",
        "label": "Research Collaboration Income [Member]",
        "terseLabel": "Research Collaboration Income",
        "verboseLabel": "Research Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "sln_ResearchCollaborationMallinckrodtPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ResearchCollaborationMallinckrodtPlcMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration - Mallinckrodt plc.",
        "label": "Research Collaboration Mallinckrodt Plc [Member]",
        "terseLabel": "Research Collaboration - Mallinckrodt plc"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r875",
      "r908"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r876",
      "r909"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r873",
      "r883",
      "r916"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "terseLabel": "Accumulated losses",
        "verboseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "negatedTerseLabel": "Accumulated losses",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r91",
      "r593",
      "r625",
      "r630",
      "r638",
      "r670",
      "r809"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r190",
      "r191",
      "r192",
      "r195",
      "r201",
      "r203",
      "r205",
      "r265",
      "r271",
      "r301",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r467",
      "r469",
      "r470",
      "r472",
      "r482",
      "r506",
      "r508",
      "r621",
      "r623",
      "r644",
      "r1061"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue from contracts with customers",
        "totalLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r220",
      "r230",
      "r231",
      "r243",
      "r247",
      "r251",
      "r253",
      "r255",
      "r347",
      "r348",
      "r544"
     ]
    },
    "sln_RevenueFromContractWithCustomerResearchCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "RevenueFromContractWithCustomerResearchCollaboration",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer Research Collaboration",
        "documentation": "Revenue from contract with customer research collaboration.",
        "terseLabel": "Research collaboration - total",
        "verboseLabel": "Research collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r351"
     ]
    },
    "sln_RevenueFromRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "RevenueFromRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Royalties",
        "documentation": "Revenue from royalties.",
        "terseLabel": "Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r756",
      "r764"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sln_RoyaltyIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "RoyaltyIncomeMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty income.",
        "label": "Royalty Income [Member]",
        "terseLabel": "Royalty Income",
        "verboseLabel": "Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "totalLabel": "Salary and Wage, Excluding Cost of Good and Service Sold, Total",
        "terseLabel": "Wages and salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share",
        "label": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Payables",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "sln_ScheduleOfAccountsReceivableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ScheduleOfAccountsReceivableTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade Receivables",
        "label": "Schedule Of Accounts Receivable [Table Text Block]",
        "documentation": "Schedule of Accounts Receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Tax Expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Credit",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r799",
      "r1006"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r291",
      "r293",
      "r294",
      "r297",
      "r545",
      "r755",
      "r787"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r991"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIncomeexpenseNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Schedule of Other Income/Expense, Net",
        "terseLabel": "Other income/(expense), net",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Summary of Group's Assets and Revenues by Location",
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r69"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary of Segment Information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Options Outstanding Details",
        "verboseLabel": "Summary of Options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Fair Value of Options Granted were Calculated Using Black Scholes Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r87",
      "r89",
      "r90",
      "r91",
      "r158",
      "r159",
      "r160",
      "r222",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r634",
      "r635",
      "r636",
      "r637",
      "r788",
      "r949",
      "r961"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares Outstanding",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r61",
      "r62",
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Options Outstanding",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Details of Shares Issued",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r993"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r656",
      "r657",
      "r658",
      "r725",
      "r727",
      "r730",
      "r735",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r758",
      "r791",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r821",
      "r826",
      "r1002",
      "r1029",
      "r1031",
      "r1032",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r773",
      "r781"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r770",
      "r778"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReporting3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r233",
      "r234",
      "r235",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r252",
      "r255",
      "r768",
      "r771",
      "r772",
      "r774",
      "r776",
      "r779",
      "r780"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment items",
        "negatedLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r234",
      "r235",
      "r247",
      "r774"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r250",
      "r253",
      "r769",
      "r770",
      "r777"
     ]
    },
    "sln_SettlementAndLicenseAgreementWithAlnylamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SettlementAndLicenseAgreementWithAlnylamMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement And License Agreement With Alnylam [Member]",
        "documentation": "Settlement and license agreement with Alnylam.",
        "terseLabel": "Settlement and License Agreement with Alnylam"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "verboseLabel": "Stock-based payments charge",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period for options",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting rights",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Inputs and assumptions for options granted in the year:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted average exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Fair value of the grants has been calculated using volatility assumption",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable at the year-end",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable at the year-end",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, Lapsed or forfeited during the year",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of share options granted",
        "terseLabel": "Number of Options, Granted during the year",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant data fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding",
        "periodStartLabel": "Number of Options, Outstanding at the beginning of the year",
        "periodEndLabel": "Number of Options, Outstanding at the year end",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average Exercise price",
        "periodEndLabel": "Weighted Average Exercise price, Outstanding at the year-end",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at the beginning of the year",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise price, Exercised during the year",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise price, Lapsed or forfeited during the year",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted during the year",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r363",
      "r382",
      "r383",
      "r384",
      "r385",
      "r388",
      "r393",
      "r394",
      "r395",
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "terseLabel": "Weighted average share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Option life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected remaining weighted-average period",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning balance, Shares",
        "periodEndLabel": "Ending balance, Shares",
        "terseLabel": "Number of ADS in issue",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r955"
     ]
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCommitmentAmount",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease Commitment, Amount",
        "terseLabel": "Gross commitment",
        "documentation": "Amount of short-term lease commitment."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesSummaryOfComponentsOfTotalOperatingLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r808"
     ]
    },
    "us-gaap_ShortTermLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCommitmentsUnderShortLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Lease Payments",
        "terseLabel": "Lease amount payable",
        "documentation": "Amount of cash outflow for short-term lease payment excluded from lease liability."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r184"
     ]
    },
    "sln_SmallOrMediumSizedEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SmallOrMediumSizedEnterprisesMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SME scheme",
        "label": "Small Or Medium Sized Enterprises [Member]",
        "documentation": "Small or medium sized enterprises."
       }
      }
     },
     "auth_ref": []
    },
    "sln_SocialSecurityAndOtherTaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SocialSecurityAndOtherTaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Social Security And Other Taxes Payable Current",
        "documentation": "Social security and other taxes payable current.",
        "terseLabel": "Social security and other taxes"
       }
      }
     },
     "auth_ref": []
    },
    "sln_SocialSecurityCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SocialSecurityCosts",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureDirectorsAndStaffCostsScheduleOfStaffCostsIncludingDirectorsRemunerationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security costs",
        "label": "Social Security Costs",
        "documentation": "Social security costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfSharesOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r158",
      "r159",
      "r160",
      "r186",
      "r209",
      "r210",
      "r212",
      "r214",
      "r222",
      "r223",
      "r260",
      "r310",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r491",
      "r634",
      "r635",
      "r636",
      "r637",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r669",
      "r690",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r949",
      "r961",
      "r970"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r144",
      "r171",
      "r172",
      "r173",
      "r190",
      "r191",
      "r192",
      "r195",
      "r201",
      "r203",
      "r205",
      "r221",
      "r265",
      "r271",
      "r301",
      "r336",
      "r427",
      "r428",
      "r441",
      "r442",
      "r443",
      "r446",
      "r453",
      "r454",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r482",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r506",
      "r508",
      "r528",
      "r602",
      "r621",
      "r622",
      "r623",
      "r644",
      "r714"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r656",
      "r657",
      "r658",
      "r725",
      "r727",
      "r730",
      "r735",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r758",
      "r791",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r821",
      "r826",
      "r1002",
      "r1029",
      "r1031",
      "r1032",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r221",
      "r508",
      "r544",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r692",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r827"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r221",
      "r258",
      "r508",
      "r544",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r692",
      "r693",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r714",
      "r827"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r868",
      "r878",
      "r911"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued during the year",
        "label": "Proceeds from shares issued, Shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r91",
      "r634",
      "r714",
      "r737"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryOfOptionsDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Options exercised in the year, Shares",
        "negatedLabel": "Number of Options, Exercised during the year",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r91",
      "r369"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Proceeds from shares issued",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r91",
      "r644",
      "r714",
      "r737",
      "r833"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options exercised in the year",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised in the year",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r91"
     ]
    },
    "sln_StockOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "StockOptionExercisePrice",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of stock option",
        "label": "Stock Option Exercise Price",
        "documentation": "Stock option, exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "negatedTotalLabel": "Total shareholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Value of ADS remained",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r82",
      "r671",
      "r687",
      "r716",
      "r717",
      "r809",
      "r834",
      "r962",
      "r979",
      "r1014",
      "r1061"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Shareholders' equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r185",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r336",
      "r473",
      "r718",
      "r721",
      "r741"
     ]
    },
    "us-gaap_StockholdersEquityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPeriodIncreaseDecrease",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Period Increase (Decrease)",
        "terseLabel": "Increase in maximum value of shares to be sold",
        "documentation": "The increase (decrease) in stockholders' equity during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91",
      "r715",
      "r740",
      "r833",
      "r1059"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Equity",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r719"
     ]
    },
    "sln_StockholdersEquityRemainingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "StockholdersEquityRemainingValue",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Remaining Value",
        "documentation": "Stockholders equity remaining value.",
        "terseLabel": "Value of ADS remained"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r538"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityDetailsOfSharesIssuedParentheticalDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "sln_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "sln_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of Movements in Deferred Tax Valuation Allowance",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "sln_SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Information Related to Operating Lease [Table Text Block]",
        "documentation": "Supplemental balance sheet information related to operating lease.",
        "terseLabel": "Summary of Supplemental Balance Sheet Information Related to Operating Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesScheduleOfTradeAndOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate income tax payable",
        "label": "Taxes Payable, Current",
        "totalLabel": "Taxes Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "sln_TradeAndOtherPayablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "TradeAndOtherPayablesLineItems",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables [Line Items]",
        "documentation": "Trade and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "sln_TradeAndOtherPayablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "TradeAndOtherPayablesTable",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureTradeAndOtherPayablesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables [Table]",
        "documentation": "Trade and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueAdditionalInformationDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureRevenueScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSegmentReportingSummaryOfGroupsAssetsAndRevenuesByLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "USA",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentSecuritiesAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentSecuritiesAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury Bills",
        "label": "US Government Securities, at Carrying Value",
        "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "sln_UpfrontPaymentTaxWithholding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "UpfrontPaymentTaxWithholding",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment tax withholding.",
        "label": "Upfront Payment Tax Withholding",
        "terseLabel": "Upfront payment, tax withholding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r110",
      "r111",
      "r113",
      "r114"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "(Decrease)/increase in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "sln_ValuationAllowanceDeferredTaxAssetChangeInTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInTaxRates",
     "crdr": "credit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureIncomeTaxesScheduleOfMovementsInDeferredTaxValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in tax rates",
        "label": "Valuation Allowance Deferred Tax Asset Change In Tax Rates",
        "documentation": "Valuation allowance deferred tax asset change in tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureOtherAssetsScheduleOfOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "sln_WeightedAverageGrantDataFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "WeightedAverageGrantDataFairValue",
     "crdr": "debit",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureEquitysettledSharebasedCompensationSummaryFairValueOfOptionsGrantedWereCalculatedUsingBlackScholesModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant data fair value",
        "documentation": "Weighted average grant data fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r214"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureLossPerShareBasicAndDilutedScheduleOfComputationOfNetLossPerShareDetails",
      "http://silence-therapeutics.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "terseLabel": "Weighted-average shares outstanding basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r214"
     ]
    },
    "sln_YearOfIssuanceOfStockOption": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://silence-therapeutics.com/20241231",
     "localname": "YearOfIssuanceOfStockOption",
     "presentation": [
      "http://silence-therapeutics.com/20241231/taxonomy/role/DisclosureShareholdersEquityScheduleOfOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of issuance of stock option.",
        "label": "Year Of Issuance Of Stock Option",
        "terseLabel": "Year of issue"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "460",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/460/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(5)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(1)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)(Instruction 5)",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subparagraph": "(Instruction 5)",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-8"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0000950170-25-029129-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-029129-xbrl.zip
M4$L#!!0    ( ,N#6UH]&<M#/\D! '>] @ 2    :6UG,3<R-C<T-S<U7S N
M:G!G[+P'5%-KNRX:*P(BTCM1$>D@"M(B^14! 2$"TDL4%AU$1"1B($KO+$%
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M,WFY#I4^D6LPBE,G!QZGVU'S"_L$P<<4*0P9'UL;LL4+[I= B/BXBHW^+)1
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M"%"&!9$M)(LPGK(@$!9DS:YDZIGMKQB<P4,R5  ,[@OSMVU:TQ>=:DX[_LD
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M?@S#Q_4E!K^Z XW$&Z\558)LD;F4!B7UW;E#2(&CGBYQKX<E4@:,MQ82I(5
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M)&?8N5AYTT4"R!@^N03RJVR3SHF?6[R,+L(N/%9E$3>FD6]MD/B+:#OIO#6
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M"I:7[NUM&EBW3_KGFG:.?].4DK#L!GY$7*=?9;3KRX%[KW/:B+4"/9@C^L?
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MTST )9H=4)X0@GS<?:Z5D83C "(77F?MWO437TG=:(;.S%I04X:G6[IX!>?
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M[RKTNPK]KD+_5U*Y)\.+"9DS8.4$@Z+.<V@=O1BQ8EPIWRW"G9H,'XY/.^W
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M_N^O(*56Y&H,_TLLH=FD4#^!M!=8PIA(8;-HX$.]B5L\H %<XM_:YV0!;^&
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M<!F'(7Y:Z8#!D>N5:\H$AWM"$1;L=Z#3G<7??N%Y/TK2^-#_H=_DLS>K>O8
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ME']M#A--R&NKOUCW+5G4Z:GV>0C%UNT^6TIO)6-KOTS[TKQ_AII,*W(*\)?
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MZ A">UO?S_@ !AO^$_^<GD\0X8;>4S\JO@/5!&V3G?871;@_N^.+V3K=13A
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M144G<3N7'I$Z%%?DY/BD1L_^,,6^86!1W%!#Y5!TE8=?-L73T,BV:\;+:[V
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MNQ%ETV0=:M-.VN7$@E.X,C'>52:#3.GA/O=+TT[U00(3#]:ZH?;)*O4!B[3
M'$I2BW.J6H%DN?F^M&N11#>G2JW$;5V)!J5WK"F/6J5BYIM6A4>JDNUS9/TZ
M<HP/GK64??9,9;V+:I-]@K3GG(M\RIAUQE9*<#+T)NZZBEN RN YLM5+7]^B
MV 9U;X\._X*>QMU6"<!#X<,""\*38),)7<C(!2(W:\8$VR?6=&$TWUO12) B
MRO)R'+ RX]/X&JR3Y9##^PXY#C5XZPE(0S]'V_)D$*7*8VWOPDKJ+CA.1#&>
M_/'Z?MF>BZ]I-W7 _A+C3M"3+D71F"3#8!;U^3P9D6IAFTPP<Q"'GNVZDRN]
MK!R0?7 :SZ1^UC&[.A>.MNV8GE"NW4'!UU8J/EZ6ED<Q,>,IWLYS]G2W[3PJ
MIZ#:_)G60"_SJ0-Z&8,FR#HZGP+3\T8K-2=DN(PD>GE/4LWZT#4I]1F;07GD
M$$1N8D56'@)65OD-CIEMEYO3I2_RW/QV@!+=.!_TI!V1R1P)OE_""<\YZJC4
M.N0XV:!@Q#ZFJ,1#;T$V=<Q2<U8T,/@.?.,X&*K ZXDZ&^HQ",KTOT.\X+3L
M@8I$HI)[MN=LQA8H)5J=H4&TYSA+=O_Q=M11(SK$:VDW7;T@U['R*%$R_X-%
M@=TQ%7:659VJ;^Z#:W8>KZPBY*O=UW>>MWWLG-%^/(83UWY#87^YW,[ZIG(E
MPG*M GWKV^*G= 84JW=;9/WR^%Q;^O VX?%GRO(J^S1GW0<GD;5^6-/(XRG5
MDW]$Y9$C71K4GRC< UT!D[C3U!VP.2^3?098,^V--T]S[)K1Q'J31LUHZ@IH
MML'+?,\O%72GRI1:N?*J36TGPHXR.<=('<YBM9K]K7Q[869H0 #$'<QI<'9M
M'MCZH)RW=CXAU:>N-1YK,=N'H(S"/LV8TC#[YOF>BZ6L11[4K>V3#2Z!$3-X
MR7Y*JIG:.VV[BO93[67>._F3T+(A[DP/)HW[;5!Q\UQG:C^Z3/C /TR3_QMO
M2[6050OTMAR"32 9MG),P.1%$4[R3*GFC_08&3T7S6X&,9"3[52M5X\NJH'#
M/?),[\'6 NMN(MX[5R.92"AB0OM7&C2U\!=!AB^S[JV;E6,VX_LUK;JVQNF:
M:D[>%3XD$4>TWKW;(7O#O\._VJ#QY)D'Y0\K8A2*<]=S/[_0P"\?ZY=JU=VW
M(T<UB?0JR_%6@IMJ1O_BJ()MN8.#G8:),I/E^1:K=AH\//O3"^U#M;\^?K!\
M[8>$/,?2;2J5G3LZ=ZK^%DG(_PB/&QI<S4L[DE 0YB6U-K=)(T)5]0I@BS58
M<U,3_WXIX@?F.L"+-K=;4Q%\S"8+C8B&Y-(9N%APS!V5DVBF?Z+8;\ T=(1V
M_;N@H?2IY@VN"?0I37X1^-P 2A%F6&R8 YMD.7AD%_V*D#!-%N&NBG"[,,UM
MM$.$ZWKU<^@[K$U$YN@#&[]X?NC_+X>CW)$"\"ZYWS/8[<6-BO*'XAM3M2__
M.%IH0#Q+LM___&&Z8E/)\/VJ98!"LNN#H(RC"0T?YI+(L7<2G[I"=J/'BV\2
M3\G=\SK.<SAF++NO:(7Q\@>1CKIY%KHJG0GNLBJ;7Q2\SHS-M%\9FV51HUBM
MW\;85ZIDG>QIMXEMG>SH9R&5LUM/MLZTR<I;IX,T _OQY.J;Y2@F6GUC-XH9
M_86!KI0-8?F=4BF76M67.6[=XY0@-UV)?()THV,U$=.<G,A4A[(#64>/?-BY
MJ2QBS<<6?U;@N.#\9I,_?E.X*+D?V#=Q(Z#BTMD,_;,WUM_XZ'"X>>VU""OM
M1GGM4M^JM%MK;L?E+3\:\TR$R_;Y'6C?DT3]C;K>594WN>JCSE3&R@;V^8-5
M@1MT#61EY)@GWN>WE^2T-*Q7]<T15IN([W-8=6:_C(Q%MF*VUF NF(YU:B%7
MS\E(6B49WSS^(?SE2%>3B5+ %AN%:XX>NUM-E2\R5,Q&=Q;HNG2.MOOFR:F6
M?KP;IR:H0G[^SQY2.^?'QWK&:ZK"!\!X#W :+[1%MS,Z+'OK47/NH)[P"BV2
M-1\^;#>7(O %GR53WQ#X7O12,30?7-<SDC/.%N&V\B!Y](_FNDGAWFG55@QM
M5Z@$M%Z+,.^ZPA?[]_L )[31'YC1>#P^;65,<7_T[]\"!&GN$[$BG+*OP ;L
M;4)\,)C>X@3//:])_.H5N>DC!.% M# H2X2[]PNZIAFLX0+C:FM$N)QL;+0S
MYR/76OV\%#L([<"$V*!@,AJ SK8B4AU/R?C2ES_#U_A%0D9H$(_0G J&<VHR
M!!R]&)T"$2YN8 7D$I_G\*:A E6J1IL[2 I]1T]G]WT6ZT:T[E7?LY=)/7O+
M'SP]P^S/&4R9L.<Y#6;3L,8Y'^NIL+ZJ5F'A:3V?AT6XE:@T+,_WY&E&U"CA
M+RINA^]PS7)+)Y=06LGP2@9"XBG76\805GT*=66TL-^4$6(""8OO\33BLS'B
M$]]2<RMGY(C!1,[4,^4)<8C+]4%6AYC 8B /J"7] $\)EJ'=\_8-P \4*0>>
M^?TK7%H<4[Q&BP6_/*N)RHTX)@_<SJ6$.T.,!GRL ;^$$V^Y-/&LCSB%7+>K
M4H2+*?+_(]0HAT4[ WN)<&('P%HS9!$DV ?M?WP/?4E?5Q8F^8K_G!S+DJR1
MI[RD_C368CCSX65BTQ,1;OD4AU8_N?B8RVE^X*X^P^2NE,OJ6VN*V\<_(?OZ
M!JI)186CX)J8%JV;N79\!TI7P^&7VJ<^$'\YUV'5V)GEF/#8BZU%.6.A2/$Y
M+G=]R/S9MCJ=CT56)OP5^#5N1P..Z75K==0/%J?KUR_7&?DU)RG3X);S\C=G
M[/1LEMYRNQ6U6,&$,/.LC7&P,B++H,NK_9I_6,XPX6*-'!( &P\R8 /@*;F4
MT6"^F#/4E*C-%GNJ8-/(DD*TV6$2M7)DFG>5/?2$VQ-?M863 H%1_K=E]D*O
MB@LI:L[0Q%#,M.'.5Q0=UAJS_+[;9/(-%=UW9G-_8$&U$.&>'P*/6PH,%AJZ
M^9L>R=.6XRF8<G\EK !/TN.8I4--$UHD2<0;SA(X>1'P :SXFNWP$-MG[6C*
MSE'"BHDJ5U?V'?9M@)V35"-S&B5T<#JJ/!9PZ[HWQSQSI/+(-;90L[Y<;BL]
MNZRL^3&"L7HX380[B^^30M>RD*WTY2*<FZ$VNA9LID?32X$($8XM P&-_9H3
M>#E$!WV#UK4CQL("7HNC@!SY280KO\\L*RQEC=]V!#58X\'OHIX1!_H<B/VK
M>-.DO,@B2P6CE>(<#XYK=*3J]<^%I%4Y)76%>X1]10<MTFWSMI@W;KM7&+0^
MO2?*M_B9+TWGQ8.RSV=.D<J(*T-KL@WN;XJD*C5]+"45WR)Z4M^Q?76Z@I,R
M-CXO=5?6KP@4NGEF+(=U!8%@[3[B%EY*+?0&=O_'<YF/4-O[4NIH\8['S98\
M@1,%>Q!3R#W6IVI-7O.>@?BFCFDL5JE1>7<,WP_VCLUK-@H-6GX)X.V_%$!N
M:9TPY=$P@7U9A/.DPRI /1B[BUEV-DV$6_(['"N@(/;1_$J>WG@7%/XT,#6K
M)VZP1^=(&U'7E=??7/-C91M1F_%V] 9KQ8D:R** )V;2/F.X^$C(T5(S!GSP
M??P16(;-0*1%./Y#V%00M+ [Y^4(BF(/.^D6SXDKZ;6.*4E5)%WB/$8EX)P#
MW3K5.UL$DH)Z!M>7NWY<I]K2Z'65Y3U++^ZPKI<Y:%HQI:L_[77;TH0Y2I+!
MZ. T9C,MBK4:]&2N'27]($PG:2!ZPH=$OR+$'&X1:(>>A<EY6/#2/U$W>AE\
M2BZBK1LFK63RDBMBU<M6ZOO'>V\=Z+'F91??\S3P#PY%-W<$O/.JIZ[N)AH^
M"_^C&%:I&(?@2JVG;)7#68[Y-O5=B92>AJ9$TWV>NMNZDSUA@R)=\8-K/L;%
M>76\W-VRY>5PDT:Y]O9&VU=^1 MMJ:CZY[:^CX)^_7#YJ6WCZTA/ZSPCF8B<
MR-J/CQR>'2S<Z,A0OVTB"[H35I5*+'Q$5'N4Z"2P')L?N!4$S7("$4FS^M3)
M\1QP4!#FM1^F9X:NIS63UG<A@2$<-?.0PUUGSU*W>O3U).G$)VHW0+KIIG?@
M@KUMFQ\:E&54&S9_[!FG0VE\=U@ C:'B2H*CH1*03R.SMV*0FBP(&\WXH0LX
M05]/[0"QV)P&+\KI-6Q7.@!S.99+0FVA7;=Y^T;G.P[!%XFNF2/VY#Y'BTOL
M]4?(Z[R@^#V)%KU51AS\D+8S%LL7Z+O@H8D2-J&_FAC$GI#@I%SR=ZA:PZ;]
M0 'KBW)"91[ ^\]^NC]#N-P!2Y>I?)JQC ZN9[F8A@F+.!*3LGOSRF]SO)6:
MY,CQ5?ILG]6G@["$1Z2;^7>%]WZ'9>]Z9"C"\@)MBAC?#X[TXL6S[>M:>YW8
M"60)=,,P778<V9M/N<'B=/:M*BBBU(4PY9KSO0PBQI1&Q>^(,W35>'<2G8[U
MS*RT5SUF>,NHM]8N4I>X2S%AU&B-S=6(;>SBZUN,V9U*EFNL7082N#&^UI'&
M+O["E%+/''/J'O;\_;*CQPN.\/6CM*7W1QZ3%G.2M9>Z>1)^<^).8K)I]].V
MZ,[BZZ._*EEU%.US,- =4'K39 O\/AD]H,1CQ"]\_B=V?)BU=K),+5'3 G)O
MC'^I;-*ED9-F6JZXKAWS>1B>O:[ V]TWF']C/J%F%<2\R"E^''OUHY?S'K-(
M[U[U[>H_(>\7+B\>[45^Q7XN7!+<R/1825U&CB'A>/A&R]XHB38-;L@@8:57
M!@")<-';S_Z8>*AM1,Z]UEQ,H+\AAQ_B&5RX1KR=G0.HHATLZ!B^;XJ?":LM
M9'MP:SC@3HC8!<II5JF$"/:&[H<E((Q*V+.-/GUK81.3BK;Q[34:\$-09HS?
MUU4T?L3 U=/K[C"JF!JBL N_O+_5:Q#+Q+H>] K&U@?@":CE9V$"5IYO+MS6
MB'$L%8!D&IR!0<U:"7H"*%\FPD4.Z$"MM"HI+UX+=]T=,'],49S60%W3-;-R
MTU@#5:Q+ PD(9.S/_;BMRCOK>O75#S/KCX_6N\&5ZPMK[%3V)7IP<SO/90(>
MRQV.K3-3EW97R6W<$E,PWGG<W4TU,/19UD=N256)[ UW?PA.?5.HNR%->J]=
M8[NMV@F_#?WQ'J?@ S;W1FVO9TC@)]X=3'^FW_0D(FB+K!ET/VX;XP&@_A_7
M7?[]0#N!P=;)N3\"A7UD%'D)2L]\<1_%7(T&)OM#, GVV%)H44\(8X-(BCY!
MV"G"S5C>)/1A$HD<2^_9^_]%P9/C"67-2+H,#7@+,= [&8J,OF"XA#,T#HIP
M$C:<5=5<)NP OB'W>V7AQQGP+\PR4HOP5J;'_'[J.TS@[+H]%"3"_2HP08(:
M/P35V$\2F;HB7!1PFA">H02S!IFK('HDHH^6\):)-52EQ&@=!?DU1E<%ZIGB
M]<3C*1PMT)&SH4.EUK*7JWUL*:&@HZ%5&O"9V+C?-N_(;: /$>-\4AQ\M>.%
MG\66%T#).6G83_9B%GGTYK@[2>.^^_43*NU\AQ6[5$N#<ME>K7T'4^]5T]6S
ML[;M)U^SM1\>0O8(T/P>U %$91<VS$!%N'P,'3<(F(4!Z!ZPT9!TDS!]&IP"
M(:8(EVDSWX,JL2)8TW8BW$>)6'#N!=6WC9Q)AR8GYPO(<\=%.-C=Y,]#KIV>
M_Q5LNR/"O13AZD0X--'H^PC?1_B71CA&1K1\A+8,I(2)J&:B*B/33S$L&HEP
MF"Z*%.&$<M&("5.<.8SU-"]D)$6XJ9NP2YP@$UU?@>;;HT=9J+25"+?"282S
M4Q/AU"<Q:9^+=3_!83N X=?8K!C/8IF\'S-IS62=S[PJ-L#2!B;RD21SMP;K
M;J*V8SF!]3LW K'9;,'Z=5BW=E"$:]F#V9\/<#+HA_#S.L <$R:+<&VY8$,(
ME(;&,9%:7TT13I\6.<RH!-CQX&@6^.$V-I,= 6IDSE@S/[_"J#F?!N?D="Q&
M$_&H#XJICFE/ D\1V2K"W66(<#N.F8EPKUS9P6J?:/ )UGP>><X=A.U,OOOB
M_Q)?O!;NX8L+PM+U0*BLBJ'W0LA"?JHYQ=*PC\=,J3MQZ]5+EK_K[B%9/9#-
M8LT<87ZNQ]STZAO<-)44)]R 21 0['+$#,*+</4&P/<QOH_Q'V-45.FQJ^T;
M'0OE+*XMNA%T8.>!O:O[]^%;B9-M2GM;B<5UN9M[6*S_F8-=KK!;>R=-X( 5
ME:2T0OF"A)][^N[U.3;[A:GMW1!Y:]D=Y6O+2^@:2Z]TB1TY-5<P,[D$/)62
M>,RT.2@ +[=3ESV$^_6M[^-7>_ -Z2H9I^8:5>TVBG _WC)<M>&5W^-?>93.
MMYZG]",-=I]9IV!79'JB6"LK,N]SNOMT_.#XD\T-MH.(#Q\-.3)]SE_5;2Y;
M0CSB^C41[DQCZX[:P61'V\ D EZEL\CFAJ1_WF,[VC58J5;._K).UL.'5MO?
MWR$?[E3X.?73K_JXF0.KWQNOWKWXXYGBK4\.3M-@>]8,YJ-G>'0B$Y6>%1J+
M<)\Q^GCBA5YZ9!(%6UY\Y*7,7K7Z.704O^KD;E6'%06J3P_?5B?)XTW!R%=E
MP1WGBV(;[6\?LE!;8WU?6>I(47"9JAF\9]<+[6-36HT?>\NWEN_1:CZ2''I$
MM:HSWRY/36-4*V+3=96.RXD&MEPY?^[Z_5HN/L;!)HC:Y'R\"/<^6H2[@-7(
MY0+TK@@WAWGH7=DTW1%C( #X?!0S3ID^G@]J<@E3Q(&XOS?_]'P7?FX.T\.M
M(MP5O)O-'+A>A+OU<=K^'EA7(\+E,M$#X*PW 6(P1S$NNDH0]IMTYX*MK<@-
M$(D)4:6WP,U(J][=:J4_#8JQ7)@(9P4BOXEPG_I(948H%7Q?@AEMU&N+DIN
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M7UDA_F%3*;V"'OJ70GMHA%I3 4 +.](0=V!2%XZ>:Q#V%9JC6',.!<EEN0$
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MJC?#8:^E^,\IW#YSBG^^65!O<Q<*M1&Z/"RMK9D[XV<4]P/S#@YT/K4+N"8
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M976>%,D71UW?DA8>1TP2HAF@??"K8U;UHEO4RT(K2*&5^9"QH#;)W@QOAHQ
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MQ4I-A#P]I\$79<RR4KN3J3@)L,_YE.FQFR4.S@'/SX?=\DRWTO7[$.H0:WS
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M^_!=VU97*E,J]]5**=?H*EARL^@;((]>F\&:!1/.N>(V X/;N5_>3S."#'A
M$K.*]KB$JMG_8:4WF? -?B=5370/D9X^?.BS@O<N%%N7>"(LUPFO6+/]>)8C
MWR[F[MS$]I<\OU@%[Z&:QV_3S\0.,8_X%XKRKH>#0^]GGG'VY"A:I&CJ#3J[
MN]S:H7XT^[*?47>O3?/EP'L3-E?=3K#6V[I>"U6W.ATPV,8-<7YC&1\G+Y?N
MY>NQY*SA4&CE&/&.7A67B9.BA'(BKA'\>^GLJD^PK!9'C&DK: +M;@CUJ<?
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MZ%9X,2=S< I!31NYA-'U+*!:H9T@3XG@_ 1=GGQ"$.YNO[(?TK@;,+$+OW=
MST1WZUQ#?5(MZ;K*3GYN-<#M)K89C %),I:#IKH1'"CL7D4!$D$-1EVQ&WK"
M#W6$ LMANV%D]\1L\SJH _#7W42:B6!(G=>A;80=^\(6(JWZSJ/VQ67&(II:
MG%YI<O/.X?(FQ\G>)"98WR1==*1DO)CUY7';[4*L[8'/?M> R7(%O((HCW:
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M,TT5O@P%3S*W4R*$CNY]A#I8OQ*ZV<%R&0!J89-[,TH?L@2-5@5)"YD6Q3[
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M O?.@LUSOZ78].[<-#3B-))R[]Y-RTVN<?^T(MX3[L<\HS3J#2$JF,TD"BU
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M'T1H4&JJ[(%(7WR'<4Y/A>0%E7 I\4ZB[\#^Y)HP#BX!HZP[PI=*V=9)UOI
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MV%UOK.A:8G/\0KZ)T+H^J63G%%ZFQD7H1GZKMA<:PYTC)'HI057"[R$IS@I
MD:0GQ$]4:S!9<70CL%(0&W)%@8)5(#E"5\#/YKI,_(ONV0.&_-RK/& 5"==A
M<*=$/8WY9<@+BOLX7-\#(<RZ<B_DQJ,JB[X'J4GP&G(/!C5+&<0X>JH(R-!-
M/HL3E[#X#*W"7$N.\DQ#Q/ZK>8&F"C?,W&A$AP8U#7 N]F,YQU.*6Q2/Q4RH
M;:VXRNW>_5COIPK<9K@+5E[LX<PNPJQA!*-70-)U:EAQ+B(%'&3);_>)3*"=
M2$#CL:[-3L<R-M--R)V"W+W=HDL:-PQE%!K<+_!'ZQ=_Z#W8^0/D&U0(=8TR
MOTQD+O"@6Z.V5=V3M+M)?EQ& R.1587<8]($O%/'*IN?PH!!;M IH3O<!E1D
M3BWCXI#\3\JP/98E Z.)@(#8-X3(KEB1 D_FTIL.>!<QJ;%Z)+8HFJ0L04E_
M%CD4R,@YO^@SO#.EVV54A4VLZRA6(QV[,%[^\8;V>&] 9]RJ#?7=Q3858TT]
M'P(KM_#<<PPG>VWLDWW6SIFSUGPD/C(3WUI5:,[QF1SW9>'S/!3<C$K<]I98
MR<7F)Q2W7C]YVGQU=^[FVH#(<%O9+:?'7>J\$>_YL191UK^*5I2#12GPSF80
M(ZCNP:XCJ4-)/'RL!*5,WQ_ 6FNF'08.<:02D/ N[0Q%EMAR2]JA4]9<'>#H
ME<D*"4KN60'8SB1C*19@U?5939%7KG(?ZT1'!2,/JPG4_8.N*,)"E0^0Q(F
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M= Q2 4>M^XM21QLQ*[ :T %.9F*-&Z_].E8=/$9>"\0C+E8HL[T>W@QZ%3V
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MV!S'IU,D[O;>MU8&&>T4><OS+*("9/VH>\$\NFDK\",NVW=P=H$H=K!D:L?
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M VLIW'G>^3K!I49]_J:X'B&J=A"2#=\+,HZSQ[I:G4 -(E5?BG?N"9A9CON
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MF<C?'3[BGG-H75=$1JP0]22VA;+\7(.:L"6,*3 7R4](/K=*77^6A+]]4<-
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M=B5P;E*(6I+K!4#302$JI;L#-YX!?[]V7. YK5[9R26(^QKA"@<]C86H=64
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M6F>KVQ&MKJ4XQG8Q,P^KBCY)MI;;!<7M=(Q6L'_9G9A^XJH<_[=N0@D5="%
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M7/&2 X$6K(1_Y&$.+JZJBVQ[>GK& TH.SIU<U7M8_6E@85KJ8O#RK1I$\4B
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M$<ST!!IXDZ@A1#5[B0A1::K4OU/3Z6*:O1 EA6T!5O=M"12BXEVN"E%=S']
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M@P;I$&<TAKQURC2F9-C\#CN $,OMW%#!$6O)'.^U8(OK-Q_/:EFYG+GW^IA
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M-<JQI6$3=+9F9"M!DBC1UGX4[&^M_YQ6>^MQ.?$3,!4PAFN:W^1/!5UP$O"
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M:\-^*#!OBKP/2BZGM=[U/MX;<N*SF4\)L>?3B(J>MIYR^^&*7G6B7(,L8B(
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MS"-,(U$,D08#,N;(UC+JXA ]M+< 'D<]8SH*X[$"WMQN9$  G45PC,\EG(G
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M-P/T[RP81C,H_;-/X^QXN1SZ0UD3;9OT$/4JK%H/F42";'_H"#'3GGP3>47
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M%3N Z*RB/+6<FOP9]P_4+;+?!*A;U&*\7R@W"/)5EAI9E-X_X-T('E"BL?T
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M>'7A)<(P$$N6APV(BCK\HM-Q!WIC.MNL"02&DXS7D2#M&1.%,V!X.6IO*G9
MYOU4<4-P&YJM6=:TAJMQ2;D]KBHF! +P4#Q0BV%CHXUP5X%]7.! )5ES^M"E
M4;4[YXQJ$$C4()4#,D()1BY[HX)=8O@N8.GBD"1O>*>/+N89+@BI#F-M=MCW
MYWG(,&KAS3RY]BQ@)V3G44AJ1.P8)$> S7&>&@;;,O@AVRV2^:#<#FPY<%1*
MB_JQHN(ZY8;34;R9WY_$DS52"WFTZ22$&D+SX5+"%TR$-Z85YU%(1Q++K4N<
M>*L.34PVO8&>VA/.M=7:10+ZB&G0W8['Y8/8;<)X4N!D.&A,^:'5BVVM-A7%
M%&^%7H$5Z;13K:N&OXRE[<J2Q[/C]J!8$_8"0C93,ERC3$5KC1P0U^0L' OE
M&%)!N FD"C\@4ZOIFW"9XX96H6N81&("[(&:WUNR36([4[242@DI@(PY3K;D
M#AR[W<A#EA79))>8Y_G.I$1(!$["Y5INJJE%A 'LK_QLS?I@#@6Y:]I]PV;B
MN@^VGL.4\DUBF4J%E%G]*!1K[Y]!2 9HR7.7Q3;ETK3\J-\ &QT5+]-<@O/I
ME)06NFZJPVA(DX:WJH/?7E0)6YLR004)&B\8N ($W5R7_+ !Q5#.SS>29Q=B
M41%*&G4&6&#8IBOJF.E.H)BVA81PD3ZG1!1%11'%6<"ZM8WUY)[?4.('7@F8
M-::%GVK\J%<88M-,UF"9SJ#QU*G=2 3+ZCFXF [5F<STA*W&SFA6'#%,YC9G
MP:*A*YL)IR)8,= 0/ 4GGKKT@\%ZM5KX6$ONTCXZ:WLT*J+SJ<-P!N^X.$+D
MM1E>FX!B;Y=9PMF&"SRC0KIX<]9KT<VTW4(\;C"J-![<T#1=-MK%I@DY#!M%
MS0ZQ,J'8'LN*+;L%R:_2A%R&((E/Q?6VR;7[/K>GFNO9TX0QBGS1&-9NA;VB
MNT5[XPQE>^RZY&  +3PW+LG1%%(=)LZ$=C!:N94:H;7N1<ND.UDKU-:#)3CU
M 10_40%<W2L<!&!!%H(SH5N,>TMBG/*65#I++I5Z3-ZUP(D0:)C"(FMG&]Y2
M(49U&]B2YGUWW&<9=S;RLAAS *YM "!IR\2JK<&2U$MSVVQBV+"GJCFU'.,T
MOAX1D@)/.W %LUVQN95AF"BQA.&%F)I$5K"C^<2!5UBM\L#NPLOQ;*P.P%2:
MS'"QXK!P!IDKU"\Q<QCS%42$U<X@QR9<0:*RO34!.J8R8P!'9E:GQ4,B*A=T
M+K>MJ$(CWYTXZ"Q(L9$6#,>*HD2#B8V0?EH. *2076,ZE3A1@-NL7\?FR&!;
M0T.,X*7!&S-UQ'N<6E3<LK?T?9[-8TSB\)DW#YAE.&_UT=Y_ZCEM%X+^<^=J
MR=4*KM"B:$;Z S0IM* EQW"I%O?NR>W4^Q4&_N!#ZS='6 $U"&A@M%&P,1BT
M((YT58OPJ+[!HQM@5$<TA+<-;[.RN6$':I\/>0LW^<A2II0K%OZL#C#JN&XV
MXU:*1=C+&%J1E2!.,P:W:+-9!84*M7I4&QN-55E&^N:RMUVJ\@8,RZ,)HFQ@
M7^C.8GK9T?!EE>0)8L?M %Q90,HL&$&"41\;4%(9R32*>=AH55!\O#*!5E;7
MLT<:@K#5APU'UW)?,?3VJI?9;"O1NW7?2'J$@BAMS@)&!L?KQI*;:;H^C<NN
M:-EI@XVKC(Y7CM3U&&@X6S2HK#:,6QE"F.)/FWJK6BQ(1YRIIMYN$<)H1,)4
MQ!=QN"':O--$W(%I%%A K 78&C1GNBA/(!B)X20OVRHRS=?)*-AN?\C(1M8S
MT?>RKKF<CB&P$932:..+W?:FP3N^YL]"'HN*&3<*S*JIFV)33MK6T)[CSHJ%
M%I*Z+E/94UUJ?# *F"V7)1/,^\),S3)\([NZQ;=";@BWQD N[RSXC!HYW,@$
M(9Z*2WD\B1 NML+:P7$B)99713SK90BNIWIS%[":!A7)-^T=C;M$R8X;>+7S
M6A(EGJ4-4H'PS2*!PXW%I.W1.@EB1UDDV9A*5[S;0,(-B*)X8;C-S; K;LUH
MADM I6,(L3%R".@EC:4&RFO61$:YWPD7\USU];$XS=M5(X!H1!^J\^FZ0\^6
MI(M."3'"AU@Q!L(1AKO;1=UL-)X;F FI*]H0"&TP&:Q;RSY$425;MT-.I"FZ
M&(P);P)G<%"N@R#1$RH'Y@NTV- 0!"[J'FT7"2@[PGP[;!*F-:@4'IZYO+(<
MVDPK*%T=9H&)/$F(::GK0A]MR9X,C!J1W+2MB4_Z+J"&C"].QE ?)4L%:FB*
MD3+;-0<1[KESS5FN/58-7:GT%'[#$CCL6U- [,5-D#6P(I=7PE#RY819]^D2
M#",Y'WCQ A^'%M+EPK)G%;R=;9TEH?;>1=?2T2ALS(*5ICA3GLL++<O:8:AU
M+9*T*HOI^19AM.A 3]I+G%,':G/)R:/$FO?$/@;0S3XN&_)V8#/^SIB;K>BF
M%L_J5BW%(:^83BD43EE*I3AB,ZDV?L9\MB**3I.K[&$P%MQ28+(RD^/2X^8=
MW36D=FTPMDNF&]5JXF9)RZ8ZHOU@% _9S733QLA>/&\16C6G.O8(H->;%3S@
MIMUY(S+SH4<J\['K-$ML#8W7>4\U^Z-H:U,L0^; !<;H&IJN6L1DAND>.E.[
M/J[.D)&/J@QE*Z$+</)F[',(E$K37NBYC0SLQE0O8WH&OS)6Q=!%B.W2/3T8
MM?P@6,F]KDJF@1T91G_@4?5T]M 2B\NHCE[4%%>T3!_V1VI;DL3:[">H)"^0
M7J^>SD6H+KVUN#+S[8*D2_DVZ:_J&8%@M3;*:Q'*IB.U%=:$AU4N:KC-8(,B
M+]9*&,M&-LZGX^6F6H9=:3"?09:\XG*_+-=](=A.O1)LJJ7%XPI,1(XQTJ&)
MS.BVO$*CX7K2S5+;[7EK3>JK:(@FY118S3:ZCV%67U[0(#XS4(6;<L/"#C1I
M&SPN'\#*#R!>*#8]61UF)$M$I>:WI:H70X4Y+WAZTTZ%H1478@6-\@4Y%^F.
M1V\]6+[JC+5X0T^K8%(,'$<IV# U:@4 =;",R%E3ZZYD*/"*X6(-$A8Z5=E\
MHH-V.QU(A<KEA# W>TFRR6N_9:N^BF*P&N5#HX\LO6R>,DRW-N]*.YOX15<"
M(T=, WU4Q]-\H<-&0@;,CJ7F.LQZI5.@:8'3B0JI6H]WZ>U,0:9XA]E0H>E3
M,C;G4%U?M[J2T$%Z2.TTI7(UD3U2=)8+4L\3>S##R0HI=1M7UPMU"=2.%9=.
MVLZR#@0WVVA4*]H2D<.]67\1D$0<>*YC39=H;7K")1TP'AJ(+C <5G+'&EI"
MTR'L=12MJLFH2N>6$%#K("5]:C8<CH?@MLD\0740N]_RY:'+DI,9I-9N"T D
MDBQN"J/*^/:8L^K0-PU;RA*O-5 !>\%D(>2-?BW_*=<0VOE =8@\!+:+:7@5
MCU4.RD8#M5%-:ODE:@RF0[PSG$JHHVTF3#CAZW$$5# 1PH*EJ0%KN!.O.5_D
M:<('ZU:;R+DHE?WML)GQ?<OCFQG@N"Q7\YM 4&*\5?7PL>B-)I!D)DU^G+:\
M*AT6ZF(R*^:APU@L0EO58JS(I<BV\'5&8T9CZ\&VP-6DC]  1<=Y'HQ'/(XT
M)F:GK;N#_EKD0G&%!YI'S!LJBM8.<FOLZZG:*X:KSLS"VY,ZDM>(>8?HEN%T
M:^A=83$!!D751Q4^7C(#26WE0Q]D8\4C,03U\)4UPXLFQ2!(V\<X?[6$NA6)
M9;T)[=-5895.8,$$2,P8?AO1^SD> R[%M.B!4GOS6-4JU_R8F_E]Q6I(_$!9
M$!*(^)UJ!0[6(W,3MH0D[9H5CK;4N*0FD*'T6C*[ICQRNXY--:BIO!Q,.#\9
MS (/8[R\ERL@Z>>]QH;+-M:B7*GP5(*:_5"CAXSKVB'5ZZ]3"0B =5O5ERIF
M.HX((N)R%[ 89NZHB7<KW,3:7-*K!X(KR;JB D.ZDNI0%B3GQ7Q8.^( -D9K
M#<O'E(?/J:K2=8Q/V0#?&%FO,4$";3NP8=_-,!2C&W 3L>%X)"L0$R (4BEQ
M7XCP5>V]!0,4&-93QLK!H)P6'#YO(7YNQFX=2E#=4($BJN4SI=??.IQ=JC4L
M(@VF1UR)R@S!VWK<,W2,(3)#(X9:W:,4T\=*,;40UNMT_24)Z^T%PC:]SA#J
M;S;3MDA%M,Y;RB[@..'IWD2E/3=-O+)4:[\=39K1SD*:XHP'^6^2O56P_UL0
M]\S>KL[=G2:9H*ID;E1L 0A.*$]*89P5'7:,LEK<U55GL B]UK!VU+*94T=O
MFD\.Q;';C.!(6RG8%K #3:?FHMTJ&<UVI*2"3+?RDK%8*O'B/UNUN_=C&YH]
ML/-?ZV]@9*=1:MC3JFG8D@^-XD6/SDI!B/IZ"$_)?C3H=,6,[LGM=+:=>B@Y
MRTR%F;&$KZ1U>"-R:R4;K+QT0B(-T&TE$!-/G!R64*I$JS# &S9G9[.)+QDC
MWM*R//+G2S%Q5M[ VZJOLC.4@YQ44ZC'T_1"+@?9LF%U@PUM^\V>)?)FGR'8
M/KKT6*LQKS)UMO ]3\6T24.5"Z&+$@-"ZA?%IMRZ<]X*Q<R)&,<LG;'#4*BD
M02)4 S!)>XQA:R0S@AN]H$052]I(_,:#-@J;JB*FY?0\L&>3/+6*47\U4KK^
M]O )6N(+WL/!T<BU-^XT87F%<#?W%Z1)B#+C'->P^68/MX>=00\+I)1&922A
M1'C-=K=FU)$HDU@7K %B1M8>BU'F:!B]R'!LP,G#(%]%(<\I.5"2&-\F"C#N
ME:U(%IMJ;3I6,[,OH(Y3U2ZJM3"V1SLZFPTV#H>#,-.,O(!]/Y38HM'R!V'(
MMXV,U@+<L6=LLE+-23;N=)(X1RDGF&$$,W>PWH(;\1 OVU(&I-NYO)Q8(\PD
MW"+5"+>**UJQ?+9G$ZX@;F2#O=^]I^V#F8V6OB?,1AS'.4G,:-O-5BCH%6P7
M$WUN30TI,Y'&#(-1(+.>@W,7;#E H&)L(<7YD'6[4GND:H8JEEFTZ=&KE%+;
M8&,G&)@LVIW%UNJQ)E&@>EH#58%:NY(@RQ03'VU) TY%4C5+<#++&WQ7L2BU
MU9!GF#V7*&,BZCJOUO\"=#'WF$$G6%%LYV!H%GMES^D.>\ .=B\O4KXYGA9-
M65C(HT'MD_2G<%0,0G2ZQ'"TKLR\[334&=OP'&UH. B83=J3[MRWJJU+W)^V
MU/9@/FH1@[E--OTZH6U3:DDV&M?1O 3385X59M/8>/6,0->TIX-,=R4F42 7
MY3 1BY#N:&(P2'ATN^F?VS[81<5N'75CA(<P#DD0QLPHI=50:X:A0(.HXO7T
M-JO646R0=)UHW9LM47W%.4Q%\0[*9:[@FIV-N#7TD]"-DTHCFL(J74U#F43[
M;L>) LJH57_7MI+0Z<]:4!8RW1+U1X"WE#:<;ZPGPV%S/5_Z)&=-I5)5],UD
M.U,V54N4!YD8]@>"ZQ2PW0?DIJ1IK-\>%5DS+.8X0+6@F*?RJ>FWIHLQ.2T)
M3J>8*=#+M&@S)*B<+IGJKHU"SNHM#98GM67HAWP?R5 H(3P(5AVD[E)]KH\4
MQFY+6$Z+H8[-.P7NKVJWN U6).1V9-24FET;7 [@0MMJ&\KUIV+*5)U9H*KF
MN@EM!CVZR\VQF9F#<BEY/M?9M)%-)PF6O%7$]2N6U)5UYCA!I8W%P&]'&MM*
MUIYQ,'ALA$:J8$P5K$E *QQ<EJ:ZZ)6X:4(S/FBL.)98-R9X$\G7!)E.H:5D
MC#%/:BUZYF ]%V3!=8%BALR&Y-;06XV^R:^2EM=7\7Y9P<TQ"P=A=]-/&0I;
M6@0TJ<B.U2QC<F/"Y+*_(KA1SBB%:2UT1O?S%FVU%SX_G/GQ]C >'/L.1(A!
M5Q41?@D"PG)5<(S,CN:FE>5%4X7GVJ99>\LVDC$QN$+Q< P:?0K0TC(VP]%
MHOR!T\$'4KG=RJR<R&<,@\$ B5]-IW,KM)9-L_:Z_ QR-X#D)(B-F(*0&1.
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MFVXE#^79J+>T^RU,CZ((7S>69J1%:[\5K\V@Y%GOX.YMK'25)K;H, Z_"#8
MC>0JWQW3;MN8-"+-6<)UOV #QK3;D2',PX4]3TA*ANJ><26CXZ7IF,R&,*)A
M6\^!5<,,2=>!;,L"..H0Y<[:@*JM!R5=(4E_)35TO )SJ "$N8;1"<)U2CBU
MS(78G>I&:Y+V9V0QC%V^DVU7B;NT/29%8F/T8CC6G'"2P:L1.?.'AM#E)(Q%
MTYP2"C9;5$SBA(+G^8(T%F1#K\VLV)B,U$91R:F&M3)T&R^7+&T+E3#NSWQC
MH?=$=Y3G"AI5]*C8]'DI-QS= MD)%D,RV:T!9(CA% /*8IV!J4YWW./;<[,.
M3.74WZY]6:9/S8-YX2,;<HK82WXR\=@>J1OCJE&$K!F Y+CK<RT9L%.I?E)M
M;"> WUFOP>-\;,[B1G>.D#B(][8>[%WZL5=B:18!X'+,LKH*PF,T#.:VW(\'
M(VG4LP,<C,/AP(JH:@0.@2FVXH2JSXEJQ=!-<$VDS8VS]1Q2?2,AEL)9/H?$
M"]Q09"&/1992+-MHR^[,HEG#'.AS']HTS96MSVLIMKI+RQ;%ID>V+=T?,[Z*
M8R!H;#=;(6C4"\A)LUHW!@JK]?HD5[7Z=6@?"BI55XI7UQX_YT<;RYE7<NDP
M@Q1W;*;!3T:T[VNL63'2:BR5.U_%;+>0IB,!\U',FN9CU)*L3A=4[,7T 5:3
ML&(V68:TS'.KP+-GDY'9P]C1J*4+0N!O >=3R.43J/9S>7R5,D+$I-IRHC4Z
MP5B8-Y(10'4(F[;HX7S,="G1IWA'AN &#"PVD]KX#PI["MD-E61"=SN790Y<
M1EK<S;!J9GM-A$2Z"-/*%FR!1%0K(QRE="F[:LX82N]Z4RX@<D<H!DC0'/,D
M#0NCLMLI"[;2X_46L &JOA/+OEUU(]YD-E5?7$54W'/TC"XR=15%PP&IK4,O
MU)2JZ.IK5=5HVJ7=F$PR Y^N@W4@=<TXJ\? ]C!>ALL^S0U:$Y]"";A6A6!B
M6&'BY*)OCF)QW*H5]\ZN\Z!VUY=AR*M]2.()2E1-JVI.35W"&LE*GU;9>K*U
M>@6.+CR"SH*HHL0D ]6\=HRHTERJ*4W2"!F0=B!VV&Z0Q<T5X4TZ"\W508&;
M>.VRJ'I\T].,?"SX_1ZY7>&<S+"&G(TWV#3Q68*7+1+1"MZOJG4^R=,^DD]<
MIX6AOF^TA=Y$R*-IM!ZCN@&.]95D(+;-4-UY?YVBVE9C=WF&RS-)0H"FN*KU
MBC8>PY[;R,>;!3R!9HK#^[+03Z#^1$_@V.L%#66UG";K-FFJP[KI7#5P!B D
MH6Z^G7I,5&N4-6[,:".K YE4:72Y;-UB01A!D W;:I50U@@\2"@PCU99?C1>
MLG0O 2 -GFL&L@2KMJ;US+A68-LC1D#L15UYEA+L&&[0;8%9!H0:;'0;,XLP
M+[1&F_"ZAM@.L,ZP0XB85<BDJF =S($-H-,6:GGY6"SR@SS9?N;97,1DD(R6
M0WVR&FS@U1JMUD6>MC,;B/N:KX&E+YCMC90Q("*9(W,HI_90@Y0@<+T>U:Y#
M*Y=J5?) ]\WMCD_6JZ79Q?%J9/.)W/2FS3KJ23<C:Z:FU6@8PB)"]U=&;0&@
M1I>PD3&LT++ %K,"RY617D=5=I+D$[&E(5M#3V]:0\QS<W+BKG1<9+NVZ?9J
M7WTFMG2QJ?BS]6(Y)MD.#FV&=647@F58'@-K%J8M -(_X9??8&\_L+[/=^6_
MP4?^#_CA^O&[USSL9Y:KS%A:#M,Y4+\XSG7M_2:,(XC1A/8UFQ"R#R=1=!]I
M&N0^: ;#( GB&(H0N\#W9+\/=">R\IW;+0Y"VS7T#+<= FYB^V 'A_;!"&KO
M,\@FO@^V8=0A0-P"(>@NZ+NQWP=ZG+IS=VD$=Z/)\QH?Z\ @0<(HB;1ZG18$
MD1!*$1@)=A ( XGV+ZI]/_SW*4-TEK:[<[='.S!6JP-Q&D6SG8L@[L*X5_Y]
MF^^D;N'8O30*?\T; ([?O3]CO_M+F6X;11JV >/VOB8(V?M0$'?V$3/3WH>
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M+%4?-E#TC+F^.24TK=^.Y*X,S[T/[,E0PEG+"1KC6?4I&R<RU=NK 4#[1_Q
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MM_GR;9C]-#J.YQM ^9CRFEH565I+^?07'C3&FK1R_U';P'%;W[G3Y8%J+T7
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MSP%QR4:H/-DU_&P&7K(!QE6,HG53&%[W%.7R?BDJ\XN,UBHN43DV S@>)F:
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M-]4/$WDCJ>6B%!%UUP8=]3+$@G([0XEKNM-4&Z1;)-F_-C\44+64;M%YN2F
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M%V:GS^UCG"'+&:^9(]*3S_-/8&(;FR+%=A5/'36]>A3XI?M?[2FCA*\!G0&
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M5/#VOG8I7+HT_^UP8H-.FUEC>QV"XUSHVU6W:/."!-:SR__W#,#E[)/7H;*
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M_D//_!4<EB.A$#L3&APIT-N,4JDD#67798>=FT@T"J7'!=R:'(9!R V61AW
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M1NT[^N FJJ6>K>FE=54#XBP% QC-M%7>0V-E?KI@$X9D;UZ57/LVMXCI!FP
M[5:Q,(2?Q*+4W-+-X*CP-T?FU*>+%3/Y<\%RCRW%!X.M_+]@/&I[S,+ME^H"
M^]A4@6C(WY.D,V?"O/N8F?D<ID]K]'Q#:N#Z1A'K>7^R%!:<GN>T)A)S;0\8
M,7W:5P%@@Y<JA&GL7V;P?DKUF^$(Z\%W=<+?YDJ[@+JNY+"IZC$?LZ3H/."H
MEJ45UC*Q,D8E-K!7XIG)*ZT^.F'[12U>H=>C.Z%^B/=H<9,0%H.$,G/)9I90
MGT)Q0TA&<"Q\NNO(\?M\U73K0_J*K<;^(.M(ZVZ'*G,15<7; .RBUV2,U])^
M>C]3@2;6)N<^8(K1$,50X<#P^,<G[7J2N*7 !E\5$&)^^E_+N__$?PU>:.66
M$K..!><3&H?).13<\<NI\//P@4B K0>5EC2K.DP9.1:^IFF@"A OPPV:KFE>
M'!/#U#BL:H9]#Y(HFCU#0_$5\N?\>8H46_026=\X96:L&B+_[GA[C]%[6:W\
M3AMQ>!.YB]W,VRU4.E8_SZ>"YW;;;%VF*(.[PW,"US0W5<]5JK<P<^1=JFU3
M6$3#TL6K3'9VX>1.!_HGKIWYGW^Y!^OW28!.KWB/0>271K#Z*I*.8<UM]STG
MYFK5#"F1E[@V@ ?#?DA>D_#FG6-VRA226HK\>$V#6!L?)C7$8J]I3I"@XZWS
MAT;$0+*83BG,ARJ^%U"]LY1@TK(RQTHM@"BWH:L3%K:W3ZHZ87]Z()_GGON)
MM<O3\N*4-.1/K)LE_/TA8DNGNYTZJTN-YG"9]-&N&&2U@7D[X:O;BIBD@LHK
MU;O3D-P@WO!H_+09(%A^'5)_FD8>UT$B!2=_^)<6;^K&7^V$_QK'44A,BR0Y
M*I=GQE%M!7T\/#WS>#(IM[T=?%'2V1$J*174^E;QA.,S L=VA-R]+2.2^M^@
M(@A-S,F.BK(G7U6^"\@ ?+>H]6QKBW+72;<%*PGOZ^Y;HE3_J%H_4A2Y0-M6
M#TNH=@J.K"#FXLYT/ZWCT9!CY51L%IY=T/96<,;="GO.E)G3CU[#4F95&4!O
M57BE><5*S21>9A^N>!DU6#RVO+@DT$5('^D)L$B-"P:Q=BA[IWDZM2@6K0:_
M.)LD-T<?(@)0)-/^9AE,QXK('0;?B)?R?QNDKM0=P>-&SH1<MZ/I6A3.K#F>
MS(Y6BVD%6S*MF3NEU!I-1:9I,OCOX.^!;5P/S<PQ*PI=6WJ6UBW.%ZS>1]SI
MYPG:*KD.S:8CA2<"1,VY8K>,2S4W0J,ON/^=;+RE1"+A1(1+!^/<U*KU,+-K
M$I;48_,G":I'5Y$(WV>BM2YR$$[7U)9'B])AYG3>UL*?R1;!^DKJ9/)3WNT,
M#PJT/&!9Y71(#A1;5(I:I7N*4/?)R/9M/8Q\ZC9MBLWM>T]]RF[D,?;GH'N
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MN(7&[-[&>/[N[6E0ZZPG8EF941BA4N&@W>)>GLVVVU_R73T,N?LN.K[JPW
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M.^ H#FG2;/_-N*Q6D\POCA1CN#GOUN<)K+!M<+J3*?I,(M>BHH>3"6/Q7LE
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M+LOZ=_[@_W>RHS=35V&4&&\SEBG4HJKQJ=>9&UYPL/5R'=W"^842;9LHCDZ
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M[('.%GGK*CKZ!J_L40F4Q\)7TBL7:A MMV3I:X;U&M(]S"RXPSTH="_@S/]
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M8KR?X#(;[9D$DCYC92:1"4B%LA$$-P/O^!!?J&'*/-W*UGECO4FC]9+6U/Z
M1\AQ=F$%7>)<XF,I5<)-;^&#73.,2'56K48PJ[?V'5TVL;W@ZT='UK<\01M<
MYLY%%:[.SM3-:3QLWO%;40Y[7U6B?LZ/NKK !9:3+HOG\UC6M&Y+/01M[TY-
M526N&<>Y+SK\4Y.+)VP&!Y(4&*ML$&IQY.ZUETEY6; 54PRS7*@ /K7D[>%%
MZ107"_W/#;<OP4KW]=<]T '#PRJAJ0X1DO<-F(<@$:/3X,NU7B9L]00^Y@%6
MIVE<MR]WN(:;!3G/)%C+HU5(]IHP4$GJR+9N<IT&6J*U[^EAUC?&4M"E"O/:
M/X/B5>8Z&MV(0[AE-_1M[M_[YA,L%_&RGH^IC>EK,]4:WV !=$X;;Y?L^;O(
M^P;%-\8T7#9<JC9-AWPT=4DC7)';KY ?Y83DB,>MNZM':%;G M]PURL!GVDY
M >A[M%^5%%JT&,4"^4=Q\8&Y^<@>.2&A(,/<3)VF)6H3SEM8HO, NRZWZ_ V
M:F;LHN-84O;H76ZO0?KL@=ZH:.W^AJCUM *LB_C$., ::NG>^6+LJJPWWE,0
MQI=CU?FGJ_HU P3KN]O8H_AV>L.?<IN8MN.@+<YSAP1PQO>BC)NKDHI(WYI:
MJB'*Q^D!W!9?G]7L+E/B)K\,*Q2(L4[=6EOK.H @O<HTS1.?QC?&=6S<_U2<
MR:AZ F,M./JV+UFQ:C^<J8J!@U=1Y94)WBR3@2*49(IBGM&1*>?7F^WI9&>_
M6@D:5(5=.<_NEH/;D8&03\N=)QC26O@1'90F>ECD%&ZIT><9&;!BE*]?8[ZF
M32X)X<^2(+X'67D+)/Z(*Z%#>ZMN8$G!QEMT_5S)]MT=VR6US+3.FCB@;_3,
ML?"$IV#[1_AZB_BK 3\94,+H))BH]-1%#6[19*G2+UW29JC.?^'6S/3#[C@!
MY%.CW-Y<-RRI^0#% RYSE1+O*W2DUENF*GI7R:6.RYV^\YV06*H^M3&EMO@$
MO[T(*! 1S.F'R"KR*B09)<'CX)Y\)HS"2O1H#J\A^-V0SB?.'D_2K 1.R;$^
MUBI&44A%:MZLQR/IYP;Q?\Z<J2'ZCAVIJ#_VHJ>.Q#U_T,37+]SAX6FJ!);D
M'27QL;$BS*^)0[4308VO\K\;OZBRRS%;!#(J;@3*BMJTIIG@$O3G._0Q\YD
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M![%;AYZ(+A^,#U(LKAA48&1ZW/E]YP31]Y&J<1P3^<RU(2,#^DGBH2GV2;-
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MDFS:-A?+OA]@MNW;WJ(>,P4[WT,G6S;S<QT(!B73$,5NKCE2Q0*X<\^+W7H
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MJD2/A96J-B/Q!$BJ*@N4L?9]9+O#QZ?+(N61^):QS;)+%+NHWM67KJ/>&CJ
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M>\^QBQY$0"ER! 'I4D.H5Z4(2) 22FA*E= D]!*X%E!"DY+0X5!#$D(/(4!
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M6G^^&,:_=YCVV.*V%1?GR>\11MT\7DMSS=28_&*"GKS_,G-K?Y ,WE C43<
MV)=F@6,<:Y'>DU_SZ1V>.>5^9'%P+UPSJ=&35!"BE-KH5XS4<?\KPY_LK=T0
M',86&BD9Z\I?IB-=P1?K-Q_KMQ"0\W<%#:6!_5LQJ#=@<G[E5P'M73)2")R"
M,P*!GVRY5-#<?M7/MI*P:?*>CBW(I_D#B%^J8**:?)E\/V(2*SGHG\T.B@2.
MXUY_[ X>& LJ,^A+W$E3R9)1\D_( D2,9IO<G/?96@#'S]THJQ'_ >08T;DG
M*#+C?79\UW.V+" !Y^E,"/N1$S-<]WF8)@)34PR?+OON8.09544J6[ZK,'XX
M[C" JU;(!@ZT;7W 6=BP)["71$AH&2[;(/QS]=ZCNC@BR HG\F<H/,"5]62O
M1U3(AZ-A$&H&44H:J&AE8T=^@(5 #F6>BC[+VCT8NN<Y_>_ASW[_O@PR<95?
M$_UN?3I(-7[LGE?O\(\2Z\EALHU'1G3G+.J]/>%+3_]6J4@>Z_&/P>1KQVP-
M4= *]9(U\OK^E@,'/IG2 Y,?R(9KTB&YG 8?4KU ]^I=U);\]W(&#>   >^C
M'Q/'- )9MH_4*2S&Q8Q69(^$&%!!!1(!4N8NTC/S;,YBW0$_!JM)?47V[I5'
MA+7%-Z]UE%\,6<;I&+ %B'5]FI64<XX;B9EJ6"#'V/5E(T7^M63%B=^5-(4S
M+M2EXNZX;X>-&^0MV>]7,Y%R<ULDTX>;ECLW,I7"I#."KZ;:(493+YUK:]+K
MQ:3(&;2-EQ% H2Z@0ZMG^FVN_OUQX"OP)\K-<M(K09E)'2W)SY2G+W%'R>2M
M?8[QSNR Q/G976M2E!&VU/R<%?@ .Z1FU,XQ5*C[#0]6VWTXZXY2H-E$+]?U
MQWS<.)LW'IYZG]E?8?N?QIXKU--$-PAQ_JSYNTF2W=>'I=LA[")&)??(IL!;
M[]J567$0Q)S7^)<!+QAVSQ]M^>U;<GV/,R_71N%,>4<:_[%X'&+MB<ZV6]PT
M)2'+%@%+&#Z!GM&#5TH>& <%A5GY]Q[K25Z=.1,KWMO8M=7(Q.2-<U% 4]Y<
M/(M%36/&E)@E>B).:/FI.>@;HC <*R)UJ*<HV8+W]U0%&^U!VX@!_E(N8Y7S
MS@*1-Y3/X\L;X#+U8H(:U^K#3= <DZ)#'8#DJ=BNQR%-QGY&\D(O<PYM6A_:
M<,DM^<I4R0/XZ+0F1CM3_:AW!<:F#6,QM<MN(?*U6K&>-FY&NN$SUKS)&2E.
M_IDE*66U?J =@S?98MH2VK79 E/OAW_N"K9FE1?5(F2J_0'"@ E$(7BV8[[[
M@)"5WOM<QW$DX?E2<(#@VQY=MTFO,_Z$*@_6N(E[$CWHR,*"N,=>!MB@SS=)
MM==CVOL'E,PX@@0LR4Q.Q,]^VVDTXGS9C7-_[1HT)Y?F+DJ>C3.=R=QWZ:E/
M@-<.?)XT!UL)3M*MPXB Y3SG0Q.:62+2:YXUX\4G20IO)_D]C9[L!['$^M*G
M5]IJT5CQ%FUOUP@X_<89E4<"=X0"8/>H2HM3KVE^6#FC0)1YND0N6_9?"[O
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M#CPI7DB0B]97RJ%C(OF5Q>.D=7?W)/'?5L(L1-">8-*[J:CEHN\07CEQ5/F
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M(Z %)\@D-:%E\+E4OSJ+)*0T.(D>>\7 '90XOTW^H1V4=41")ZKW8-KBY/W
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M.DY[E9WWR&D*'UX@)PWJ_NE)K 'TQ :)$LQGK! H#]27_%]CB;_#"O-:/PJ
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M<==33+->/\;:[MK@)[,>/2K+A&O!M=9(R *CMXCF^D%IU0Z*C;#1H%N?0IU
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M4UXVIK/8=R_N6%4Z;54D=RV[ 7N6I.B98W@@7?W@K769BC+2_'4O3OE<\R4
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MD_X@-/_G,IFFE_9Q"V"SMKS<T,+"U[X)$\-UY/M-_:6^]8_5TNEK^-M_Y'$
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M2A7L$KBFV<D6&_'=U).UNVO('HS]B40>QAO%#H9X\9-D!S4^XDA^LG#9Y;S
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MD)%+MGBFX\_65Y>/W7F C:J.;Z'1:TDK'$D?L>!2<+6*VDM1S T>]Z]N=E<
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M@,V1^:2_1T<[[;>HSMSS:[/7VL/<L":L>"("(W_H1:XW8@?=^W(4Y\ZN$Y?
MA"U6^>R]8A:U:YF-QKQ'^$X': =YX+0F[^+R"C 3_N)-\]]G[-M+]GT_\(G!
M&)N&4X&#5,F>+*V%Z']G'@W&H5%SQ.(,8@?$9% PBS8<;J >-\ VG7#OT>H(
M89BW"6[<[R(/8\)VM[E8\Z0.D7++^VG<[2FP=_B&67TM*2V27;^<AXUF $7+
M]@NVR/UQ,B-E!/2.>A<!VD=7$>+IK-6W=(M*^,:"]UEN8Z9L3'R_8N6Y!Q;5
M\X*@:W?CR;% \]C@(KWO.QSP^W<3;6!.]T)#/=-UPL*,WGC[.$C4DLC$AAU\
MIU3[@Z-%I.F8;!4$CHR[VYI3H'*0.NAW*_5C_<I^YZLUREY)0HVV8UQ7Z6Q/
MA5\;UFQ\I:QX+=/0AW6@05PF=^3I@1E#PAGB]92W]&ZV4I:>M=MXJFA2M^FP
M+>3O'H>ZK 2JO9J#IK-G'U>P>Z<;ICQ(MOKC8&@?LV=X4WVE.P*285(FJR-F
ME+#OT07V\3&<K/&0+?'>:#^V6O-$:NC4:J/U?(Y]<* 1F#RSSYU6]#8]NZOU
M>D(V8W^W,4<ONR<*WC&--7<J7,W+T5ETM8,-*1P,6KYI6^M\(-)LFQAI60DT
MNVC"ST#!VC/V'55#,GF*_5+:71>[$U;>H[B,_5"9QSG2)3K2IH)-R\?%I\'[
MY.37^@.&+KL_5(^&N2ZVIB,2J"_^N1<T+IS/KAKUI+1GX<MF2.5W.P]LZ'7C
MG>BBRYDV\ W""[J2/5/1!HC#CRI]!6 OBW2V#?S;],.H(U[B'UZ>$_L6N[WT
MYD<+C>PU4T-FHX%WO&>VK+0B9ZEY16Q<9)<;*MXBOEJ>-OX68;JP:@WM[$V(
M\?C\Q1Q'J,W,H2REBZ"S/=<@[@Q7T$%:5&DRB@KV"WWDKQD3\0%']W('>E4I
M[M&TVF+%4M/3ZFY9.K%I[;F^SH&&EK49Q^4T5<&Y&4;SF007["H^[4D/K/,U
M;:7/!I+S6&S7H=RL[]S'<?V+% 98GP,L$9H4H4$X'H1+.F[TW1O$,*N;F.71
M23.CZSPP-N=&09WJYC*BD3:I3LB;4'8G(5W1#!$3BRJRBTK-3L#M92?5BZKD
MR&5TL1)Q_;O6%@+Z2'U]9AG@[ZM%SQN5S#JZ7-W2CE5HP,\ %M8=@3V519Y<
MUPBW%0/M,]@5X+9O4O3 +(C[27@AMGN>= JA-MW-6T,?;Y-&:CR\"H=R"<->
MJKK(_=B-/\ 8CZTQ2MBXJ/:9FPATFLD#)N"5RV/?!-="Z&,.OX',@W+.Z/6B
MV006'C4.51VDC97PNQ1H94S+9T]Z MB]%4]+[UN"&IZ"(7X5E429$-E43QSS
M@P?F-)VLQ5F2CA5O>Q$X5CVQF_#P*"04_A4G2A&GR<+R>^'><XD7\&T%!-0?
M%.K_L#3N0^N1\AW'MWV34+*[O(OGM7?XFM//[C55H7CUIN3@,4S#);-?-2YL
MWE*(8?YXJS6C_@ B)$@)&DL-]MGH^?P@71J48P]+"%12($V#[_1AZ!QS6(:3
MUO:<#+4,":LU%+>@3\L5@'=;F=^A.%@!,=BN_"V;?@=TN#&D(P(M-VY)31]L
MU9D*DJT%6O05QSEG\[NT*I8HKA[DSM6D*VH JTXZ$@IK>G[!X7])G:POL7^^
M#"5?+R]N8@_'+%E[6D](YH;TY72G?ICQX8AAL9FN5=B1&XGJ'1UP]+.(T:EU
M%-<*8@/"Q&KXV'AU[_;PHC4^A.E@^ 6S#VC9"Y9&S14WC2L4^$E/)N*7+&3@
M:"N92C9.Y*_ZE04/<XU'QZ9IWK2E)HZ=D2ZB%JM4OO+9P\/%AO J+66OL D*
M:5:CGC& K\2IK4.5MFM[!6A2&XM)<_$8.I?WH LT#B8XJ]+SC4>+]!SB+%?C
M?GN<XK:6G/SB]BO_E &11$VM!X8US/]F='X7J6YJ:O=)>U;;X>B)X?9H0T;L
M8L0?RPO?6[W[#O0/=?@]98]#0ZI>SSA$-<R1*TO6)W5:^+'2)>YNSS$./QZ
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M/P7C-Z1OA>8T70&>UT;NM!JXE@8+#!N<?O[9@'C81_Z8XG4<PM*UVK&8UBL
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M^M&J#DE97@  'DH<]-.F!</H9&+Y:XFJ"WK;A3.WVY,!X%:;L^MZWOJEQ16
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M+,;L&==U38>6Y\H-4MP?LN._TSU=O%ZE]2<X%J0P %EPCROR/S>/$*US%@+
M+C-A%$N/(:7 /:YB]("H*%!?NK)<[\TW4)C",O5:%AQ<6:DZ,BEO+%]:I'+>
MWP I)GW $LN6;INA6P+I"?X-?$_#M[4%U_;VDFJ >"I?#J%^(R\='H.L]MOC
MQH@;BU#_Z%ZRAS5PZD''0[?EC\(:3BT?Z)NKAK#B3C,+Q28.:])'B0L@1/9J
MW_#K OW+F$H;1\9FL7A_ 4-W1#S\IN/74?@;^9@]F&?$4R?% 9.RR19DNBTI
M3GL8(?"0TOE;]UJ>H*+VF[]S@L$F9)43(%3.OLX @T5%UE*AAZ'9LFM$^I]]
M:@VBZ);KPNL]=.X%KQUK+"C9;V+R6B>O-2WI"G!OVQZ3<04 R73F[M/SG;8G
MCIX.S@W1BR#;$D>O)AW_F4U/N22JUIZJT?H.O9ZZX^7SGW^-9"2GROKE1B)8
M>+[33*7^O=K,+8Q&8E#$Z7/B5G:GC!]PJSDV7@METJ%R&)IA2S(G&TE4JUT$
MH<1G6*NS6 OO#S--,!#9N:=>Y1X&'4D-=)61IVXKO- N$VBZ NS=LJ\1CBCL
M#/  ;NKB2 3-9%O(%J)*M['WYJ$%;:F>^*T;?>33&P-:.UFQPM[*;)AX?(;"
M."Z+S?(^S<NHG>:B='(WSPB(.NZ+'YO4G.NC/A0WS%6YU+*\P=6(01/!><LQ
M_XVXMXQJ,^W;?KFG-BT%AE+<I@6*0Y'@,BT%"A12)%B0(L$A0/ @4P&*%PN%
M0!B*! U% @0M&BQ0",$)[NX29/=Y]E[O^WQ[[[WVO=:^/IWK^GK:<?SE_%G8
MQ]N6@]1M+T%JOWDT^-:BR+[!@J 4E!)<,J32$$Z>(&CNP<.!_2?J?U/=4O$K
M/^WQ=)S0T3G'O:F&WNOV#[OWZW[713<7G757B =Q!\[Z<:\1!V:'_(9M+"<N
MM-(N%2)K?B1:40;*RW1^5@U^F>;A9O[]TC+8F(UK5+Y$_E[1:7OB*N5K*3J2
MLC@^[J'P<^==$Q1]C9[!;25\_)G-N7C6DEC.L6=4>#CE AP!?7,MV-#5J6!)
MVGHO[JV[=Y#PLP,3F4ZK)IR\BZ^GR$<]0TP'C^$6YWTVCH-L*UCOV7[WPMK#
MLC9LV@PPW<3R5W%EKU[I?7:@Z?_TI+[F0?;''2>5$M.^R@D; KO_L=<8=N6I
M&ES\0)-2KNB\Z+&@LMY2M$NBGOVU./YU0Z6?$(+J/D6WN"NH[G_<J"B#M\Q<
MGS21KA;O%1]?ER]><E4,<2ZMRJZ<^(+Y3YE%N[?\+VNZ%'T65>\E(5C<;>:5
M//$:<HR(0-GZ[5RO7K=MNUQ'3MTRN$[,YUZE^;.6%GT4X_+U.TJ9\D&(=D##
M%WE^\NX(^_@U^32F:+DFP98"WB"DG%ACE=,VE(D[8)7<T8 K(Q3W;S^7@[<N
M(>G@Y5GF+?BW)@6X1;.B(DP?3ZMN%R$W'XTW%M@N^W(@[0A.Q3N(SE>5WTF8
M9^R68N428UU2/4W=4G7,6ETS3-#U6+5;?Q5Z'SAD]"R0N]$DMB>].RS \BK*
M\9CY:_$N.37$P[+ >COD&#C&,_7*ALW(8[V*LSC$&WJY;G_M//\&^;^.7-L=
M?Y58PS-[Y3OZ,]9CSR('$%(K*"=8^5%&=NN3M0U:I^M8HS/[JSL\#];^=_+H
MT\X-5=^H-77N=B*_8N=1*&7.MPFCL>'O>/EJ[!KN>MG5GUZ5-?C%_9JI"9/S
M,1!U\0*V)P^'2*KJ!LL(3(M-M\2PSL[N7J6-R%!GT"5BFADO,W4#5F.6^ZP_
MA E*<01^"EE3:KBA\@S+NQ(8%R5<:+E?\F/?M*4G-*Z.'+TNK<CZW&I;SI\9
MPE)'EWA0<::<[Y^V:[==+*_L6.>5897ER+T(C0*Q)"]OG9E\\[5J3EU?:Y]>
M& #*Y.J>/9@!$&$9(7FO)5.:!OG;:U>>LC5T8QU6?94H !PW;^DR37$)QW4S
M;YDF#Y^0/MH:^$'(=]$UC*?MLWW<=*Q=HKG QM*?%V6V%+YO^[6^AMQM#ECF
MI*]45")7XY'D]/:6)C#=$*K[G>7.A3IL4?/GJY1QRC"G.. K-:%V]Z_>D"\^
M85.R<>\HK\,B=>:/0FC4/$*[PA9!XEM]F)$'WS,>!JVXX1V#!?D]0WJ]9)F:
M&TIM#A75W>+'/T?-.2 QDKH?732[C]V\%$:9V0$!J3/ZCADRW^0'-$KQGK(>
MX*EF&59:FI]EE@J-+/KH..UR3JT#KR0+;V=G=QY6&+YY:.44^68VR*@&*C#9
M^UA!EC$C7^WE\(F+GB2"&\ZJ9*!;M'>(69$[&K@U+&="#TFMY"BKEKPVSW(>
M5J5-_0>>_.<&D1C.T&I%'H*QG(&N>*R]7L>YIA97; ,G30)RTSR:"K;  +8T
MTLGJX[U+PD.VF.BY5#-#+[R&-.H^EKS&/YX&@V1!CT\H5NJ]LX+8<;2@2!C9
MXR2G.N_Z0IK'3(=&-2O&G?]3 W?R/<EG5U/&_M&5?DW$M/FLXDZVG[K"S\(:
M"1-C4F= !NL+V1('K_0 MC&>K]W?[,R;&'[TSE;Y[0<[XTBGH0V396DF+H+S
M&X 3-&/7#95<B>M(C;'2@YF3X>G!S_)]M>0&TZU)1^-H V? ]:%[E39:C5EK
MJ@?[T3L%:;KNN[/+_FEI>Q>G9[JPMM%C0OUYHM3^6)SM::6EK*V=U&1]I["J
M&G)Z//.3[[+Q!;N2I(0^QQ@ P!]VZ@+.;Y8]IZ5YFVM9;[K>%4NY '+J'GA'
M![@DN:KI<H4?RC;OK](AWZ"#( #AR=%B9D[J:+GA\N@@8\"?JQR^7?JNCXE!
MO6JQF?\Y'F3-O6!//,9/J\_TDOH*)!*:7#8O^,L!IV^%CP-*=7+M,E8#<M)8
M>;Z6D/1-6QC?_D!B9MQ7:[.L'X @_ E<_=EN*>33&IC^)=>\X:%RXCLJJO\$
M<=&&EKQ_Y'UYWGI6FOW>"Z=BO?@F] 6OMPP@U]^G;;1VDP-C"T!],_&U*AI2
MY6U8.4Q5*MC(4Y*;&G$MR'D6'^.3U<% JN6:%+FUTN="""65M-].L#?!J;TM
M\2W;G$=424SQC6KR S7?BQE&D;,UHPIM+7_$6@5-C1;J8E 2E@5])TZS.)_0
M1X?:@^F%<7]3W=T_AUV=!-W;-=X_8LU\BMP^\JN- PYUE/>%G-0#J\W>MN:E
M)) M+A;=N2LW@P<+7.*OK\2;C[LO?F=W)-Q0_=SD!J?5O,'?_BO]WXR8_YL)
M]'3D^^8Z0$O005B1='?PV)4H>A.@?#\^D'C!8SA6%,030,@ _/U-9? 2,AX6
M)CE;N\7UVH*R@$X0FU)]*0_L\9N]AUZC[P3]FQYXC*77^^T'#_>YI-&ID40S
MXS*%Q_GFU2G.+\4,?OW389J:TW)VJXOOV['ZT5A7^K,$$,2NR>VE^)SD6.X@
MP.V:YH^F((+#!85+EK ;_F7QX,^)N,%3W@?-TJY,&A=T0;D$52G)W+LY7Z=,
MMY[E)9]:MK?VB@: &8OE2Z6WU,QUG -6$=XM3G35L1Y"72#)QG:99=Y,L'[?
MMO'PI^16379SB8)]+>]DRQUQ2(=F4IJTHO[./>C"PU1\+7,_6UZ:U]L^Q6"Z
MZ2.-J7[CUXNI(8_ I.UE8TV)8*@ICR9/8F'I#U6'F<5 C]/1;J&>DN"NF:TR
M%N\1B4S?&ZJ9^A*-VJJ</??=*4=OA!=A&W4&?J%8BMK6<!=56:F?0(N8S\4%
M_&Q5IG8QE9XRN K>#%"?]%=R"2;%%:S8G(>!'10!D#B7+F1!S!T1HQ+)"H:1
MLAEC-VBQY@7$USFUN)F9)S DK]9YN6%*,V"MDX*4^"<E^^KX#HM.?AR_5JDO
M5DFB=1Z_I=M"+3\MW-2+R_!/5^[+DMNC9*SW?FOGA -([J5*C'+\$<(L9H#N
M&8.@QB\W5(>_%MF'&RJ*,4T#13AL=?9,_'KKL&5[]X9J(_N_:K\39 _[%W>I
M=^Q6[ZI^$V%MG(H[JL'_%VIOE?.&JK'X8FK[L9),]]_,Q0?JG3859(MI11CS
M1L@4:AQG)UQQ44Z@.' !)[][PG.'6W+AY/:WZ_NJ:GLW5.N6%JLR^5J[<1V.
M<VV/4X(L,B%KF5%=;](Z1WXYK;7TUP-ONB'>EXG=K!9+R;K(GAV*E9J$:#B\
M5">U =7B^(1W)W$PT2$$QX4Q$2J/,BD^EG'H^@,-T<@2-XP3X!O6-_7[W;?=
M8R$WZ&1Y"O*WG.I^6&CIM' '1^NI.7SJHL3+G_L V#1;*%NC_'%WT[!CFZOS
MI):$9-X&0BB&(W#T-+8IK&3_HO#2ZG;'!%I1E6G%A-6_DQ*Z6FZ &A./&.V8
M]FI/#/BELVSW2#'B1MY<YK'"WG7NZDHROK85ESS,_CE+":=/3H@]RATAQ# C
M\:+=QMWK6]>Y7$=7Y;M5H:3JL,5[)#O(Z;TZY0-*":4K#+RA;-T5<&7G6@O-
MG,V4)W%D3ULDB-;.'DP%N!FF7')IRRU617[ZCN>4>^=K94]>JDG%"V*K(N(R
M =78;165IW??%)OV%9^+7,UE^A[.][1HI*N9X@8N+,&C14&W=2NAR?/$M&_V
M"=YIHQ27J\VPC0H68&AHE'70X(6^).W"E=CW7^[=7C.GJ&":_?][M<T_<W28
M$R2%1_CPEI!\\X4-9!$X64SKI1)A=59]59^>T=!\??&SQ6XKN_A=3ZV22DG:
M&;;!Y[.LE$K^U[,119"NY',<,FYS;K9L0/C$"KSR:640!CEZ&8D!';F1FF'7
M7Z>#9L1=H_*N_T?/\E_-P]SSPV<AW&IO"2UVJOO%:2>0,9<[IKIWE6$R=E7-
MCY/K5);ED#'6EJ//S[.^U6BZO7JU)Z4[QOJL%<NS%%0CE^5*'9?1J+U36$5@
MU^=8Y3&VJV.O%=V>97\8>7?-&)-E]5" V)5O$I]W+M<C)B]=79,8BUN<=3J$
M$PJ@34)@V11WR -.]FB"04Z.,QS SZI#UQ2+$GPV<A8X!N,(<OS7.H?PY\K>
M"5KC2=8P4;WJ=>Y([9_*/5]\G=?;HN;*H4ZXV&"AZ\3RNCP-;"_)] 2]+=RH
MWU=K1?03S8C3V:# H@-"'2)HU#L]M4N+ZA9SV8"W)W=]&+9T<)4#M1>4D/*G
MR]"4R2W#%(3JKBS\[:1!6 @;?6E^1/9 9TURFV5"S\=TAM#M$L5.,T6K];Z]
M 9)MG-.SU&15LL/69OHE?U3Y%3NI2JZ_D<8UL=]>7Z+,*FH. IUH"&B6GMZ@
MM%AN&_>58!_O';-1#*,7PS)!V VP,-<=#XJSAV,'Q_+4KF6IG[M4B;J@=,:O
MNZAF(M\P)R9O>VFR%:>M6^I3?^H?U^;M=SJ-%O'R\;4O">]P&Y4,2HNC-Q-#
M5DBD;UO:IF;G$';<]%XJ')2$T*!860KC73,RDELH6-'A6?;+R+N%^I@9$9]%
MC9 K_OB"<WEU)8 6(*<@X>4Y<C;@,))08-@DF9&Z[0JBC@_OY' VZ5069OL"
MBU=8%,!&.S=!GG3IB4F, \F!/U3E?EX2NU')AX!KEF7N>VDU(TJO*>IA<0WX
MO=-M3SGR0DO\>$N6BS6@RIXN:S O1>46G7NI5F#V!<!ZGGA2_.RVA$UJE/@O
MQ^)X_2ALK])M[(:*"+SB.6<P4;U&WU!MJO;]]^LR]N_]TB]?C:O W8*[VMGO
M$;B[9;FI0\?>C%D%A'X!!].J3+P=;OH?\+VOP  5JZ8S2ZA;8F:M_]I5PH\U
MB@5P+/[7Z1N4L'LM=3("L5H/X?]^9BG^*EKW_P7%+TEBF3,AU[_^X38RE,[Z
M\P)-^9/8?1Q]3Y!EFG:GU@:Q \5/D>6W&QH*E2T^.O)][2\GE>(MUZ60[W7[
M BP54AT3892,"_E=95*Q-A-4(KZ"$LD[YZK>W(=OOWAT?.Q6!7,=4//0N-:,
M?UW8%G^)BGV)1!;B%WH/**O6M-\^>6Y7H3QFA>^T5JTD_F[_=)B*ZM'Y,O^E
M\THYF49J)3ZXZW(13A[#9[OP+0KLK0Y;.<LZ"(E'9CH*A_@$\J]2O"Z>=B/S
MTRAMD:7M/W.Y9N K_Q4 Z7L<*GHB3",S-8/R#C/<C>3$[)T(,R]<GYW(./)W
MUTHUE_S?N7!:1?R:=?Q>,+"G@^/ J+#LX$)GQ&)3EJB=D6!K(-Y0CP!DT\&O
M$[^A LT>ELT^W]$H^Y+D.-+AS %.:*T!!55R&&58R0I+^PX-&-<P$I9VE/4+
MHS8YEM?'BDMS,\Y>*N:HM[>EFF,L_SOC'[CI0=$K"U_)'$N+3(F<V6YK4'T>
M\E/5(!L>G)NQ"(6W&&2'66V?J*#SMKDF?UTT_'JGJO7*9Q<),#@"> _7&(HE
M5_T8:-I=O;52 'G8,(U:F\IA0UI@NE@&O-II]<+>Q\OMS4?$J4I>ELR,6'H8
M.MX'1 PHW=_'2 7?4%4YWU#ALZX'6JXX7Y>/R?Y:AF$W5#SG'QI6=J].E\)*
M0=,#O/85P(63,.Z&]//!Q00D6#\B<.$T*P$S<B3!BVR:!ZUK7CT=")S=YW(\
M+>&A&-A9'D*3,*%TAC\EW5,N2]SWHD/CZ!'.B?4%_7Y%QSTMA_G)Y^AP22B
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M)(Y_^H4,$UN?@5J:$EVTX^0, YR'$41+31%NAD[7C@R8M:,!T:=([YN7;_'
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M))T18TM <>=<AFNNQVF:F9D!7S5.T2E9 396 V;;(MU*W:J<\' >=@7J"?J
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M>&%F;9F[4:2MLE35R<=B"R"60R]65;4#R9USVDX;R\J5-^3?VHE7HO?'!)-
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MUX-C!'3X_-@?=M8)=O:=L49-/KJP&G7-*^]9,I]P\5;TX/PV8S?@4S;&*?J
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MD7K#GZSX5C;E0,VTWV'']!MYP !Q".EY%.>?+_O6 .HP= 8(;A!+W!(C\ZP
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M?^?!H@'(I!A)I*.&!KZW)EL_,47Q!._^]$F4F=EB.R$JX]Z^Q^H98(3Y+XV
M<3__J 99;Y5N=.89X%4 ]>W4DZ16*$\E\Y^_F.WA9-=.YODY3*"DI\=ZHN 5
MB\O$RBXHX'8P<IR0O?JA*?T\*CRZ.O]Z I$<3K./>D@$7'3U'^EIUGD"2G<U
M!F+[;7_R$7--,[,=+&&J#%O690GGD'GF;8,(^M-L1O73Z.A*Q*#B@\MEBEQ'
MVM&@_.?/.#*=(WAP^V(>W#UIV:IRE^\?*6LB54P#Q[FQ8F2=ZAF@:Z$%CS_H
MSB7$3WMT45Y$>SZ]F>J^1M6JR;M,@V6UFW0D<TBY:P:*9V1^P!RVD%MS2]/>
MR3(&;54#,5A^KJT6:H#U:?GBX*:V(@9R3G^!NAV8;Y4?'/B-RU1\V*[,!<9]
MB.C[1(DW6H+V^IHNG\O ^UN(O?--J=!P!G@305S)7-/-.-^T_F@)YH,'B2>>
MT+G6?S;[_7>WQLYV$ EUVTAA7M1S=*/K,'Z#$#G=5^L79 /M,\O+%7HR\F1=
MF99S,V&"1[GGVAF (2UL=$;2]]H#G.6OL\4-NA[V#7SQ,N'W/2MV4I'4:#I/
M%'Y#1SB=_[O-79:?S*GL,E/4I4(7-?<[9TJ71#:9/KO,B+L^6-J;"(X7U6>+
MFDXL-@$'1HU$%R]Z6-H?$0,%5G;=9&PREZDJ4Q)''[>5=@IJ+4Q.I-D4=CM,
MM!<I>WEET$\ATC3ZUL<52M:P^-(J)6S;J['"9D.]C;DG4;A('X8Y> ZIL@JA
MG"?\EVU\*_/OYP-@M5L7YG(?!S8^_52;>=GP,:G"9>M7TNLS@$CB&:#"]@R@
MG[BA^-<A91.+K8"U?#+OF$N85RK/?2A>YDU!T@ORX "K'XUP9JV.U[H6--XQ
M']>!+)<[>O\OJA1**#X>E:XJ?BU0?TT*N-CH8I&=(*J7&"^JMQ3/7B$2J"N0
M$E-3%":FKKCT,+:2S]9)4#HO4EL-E_M"0_6QI(OJ(@>OLC'C+<-,MV9=F;Y-
MZU$>5C6/%&>N*CLS*B;G%*2.9.3=.""]5+P/,!+/)],X*<9L7K0M25;\R8)=
M-\Y3BOJQ?/3;;Y*]3U0**R4L0YA&Z9>?FV['\"#>%.B9##5']"YS@31;6WG>
MS.V&L9NXL.O$%1*B>7.#B\X H@JF?^4#-=P%]Y3]C^(>3.D,E$XW5LI[\:/W
M*M5D:5BE5K!(?&^>^L-NR&6&.[&<:XS',O).!GJ#T;X?UII]RS29T[>=>#8(
M,S7GI%-[_XV&NHXTG_&]1:?^2[!"5Y,E=;46T-VE7I%9L<R$DUGFD=4I4KV]
MI.G(#@8*EXGJTD_+K&[&0\:/R&MXYZJK!7CFYB!O:1D_DYH97W>YZV[I.$N4
M#PI_M\'-'I>QL%P^\>4Z=G\Z07Q14]QQ7^6V]^(W49JDG=HK%KV)G1D+7076
MS'2$5 ?G#2TXT V2?4O45MW!(=%[,8B!VT12.'$W8@61DF:Z7XG9O1Z*Z$I0
M)"TTD@O5CSK/P\^E16]@@R@4O0'MB6H32R';NT![4- _68DAEM!9;L1&W!G
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MYX.("#]-I2ZD1<]J<B#>:'F]PZCP46Y4D_TKKZ89Y/>M., 9@Y?5[E36:%?
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M9KY!?-6L21XB6?$BJ]4;0#6-%7$LIWQ?F9/_UF%XBD^/=$@"R_&K3-5N-R0
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M?7LL+]>6]^MV<#%BAA6]-FMRW%#KPAE(A;&T'J&9-0YQL(O![1Z(*C8BV<Y
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M"$C(XV(I86\I<0JV9R^'8+\QU;94#FK:/DBU;HG#KQX"S%;TR[7WM;>*C6;
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MX9GC+AY$T&'I<'H8N2U)<8.:,"BPDCYMVR\\%#;K<<\6;M2_+29S7E7H $5
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MQ5)PSF42 '6HW^*$]<8=ID1\L]W"? I]LJ,0M'$HP=N$%4?R^9/=:9=Q4H#
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MV^;S'DB;^/,>QO5A5ENLFKI(B*W?Q%?BWF'U%=78K M]#L6!EH1R55.D8 X
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M-E&"-YXG\\=@HHS-EV- JTWC!'I,D2=#X#7 F^CKFV8UU0-D2UGK>,RF%5A
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MC8<QU)R4CFI.P*1Y-'>B7!-WRL:>U\;6/%O*331?A\L7%:0"D!.;(Q4%BXF
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M8<. *%O<C8P0_ZYQ95RX5^]JD?*+@/&\*OU'D=(H=1%?G A[&XKM@LECJWE
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M;AT:R5M[PG>4WW_=UW8Y7@#V4 A[X_XOO9D,8E"[PZXYTOH%X,OEH%H\S&S
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MK/TKD@&6C& Y\O73,GZND\#8?'[6[#=)G>E.]V ]L$GH5](("A@>@?T@+\Z
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M=LVZZTWVSAM5^:?&MOWKX9$>0N2A^NI1J"E5\9CXJO208"+H9>H!D-;(&ZY
M"@61CWTNC$9G)LC;W HR@/U?BH9QS8@T*[ZJ7PS+KL]G!>W8&IS4G1%C(IQ"
M8S9Y0<RP92D!/9(2'QQG#W_-#6L:$S=H-G0:K]6CZCR PVI*!MC3>#W -GB<
M@0$CXT,IM#;F?F6.C62$LU:70:*K06* ],AP.HP-9C0XH%-DEN/[BMFT*D+'
M]:OAI\71O.<]0%8-'<;G/=(CN@5(X9?[G$[.-#0@=^8%O;?;/W]],0WN;* V
MQX"(W>-:ZY,\$M_> 1VCA=.N8IY-+'U^_!$/.RXE\1X&9$Y,Q"/>4D(N_$[
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MJ'//Y1+MX'..\!GCQ&#=G;JM,+],L0DW=*#48!?X:![5Q[BF[Z,777!VNV&
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M=_:C?T_U^2!&8(I1P@>Y]V#C0!]'&-9Y8AREOI.2-@!7\RFZDRQ)U[KT/:?
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M^'H$EK<GVT(TL8I=[LF9E)4Z2#'#T!;&.GR1+(>AYL/5C)@?OLN]1=#0G$T
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MS@_)7/C(5"\VVNC1#TIM=9=_!D3&XU2NF^G[B1$HN72)@3R^S&;H='#!U*L
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M_>.AW-NO"T= S^9%F\EU=5/SVR*Q;(*8<%81Z.]_4,)81W(C27Z[ZK__\1+
M%7;+RDJ=\06952J>#&"-@?VZZA$#MW:%AG7.=_.#SEVF&P=Z&P?M=D#B%N]R
MXI:X..N#SHK6@V RCSH OY(.45DP>_/D4=)NP^ @@:]6N.QZO/% ]E;KI/FS
M>8"Q62*#4(R_X+)GYHC?\>J;!7>H79V"IKN")B1@L&3%? C#</NEUXPSNO.Y
MRK(P1J7HHT!,T%N/0ZEDZ);\QU/MRND%[VS62=Z.]X1K7V2DSP&V;?Z8/RZR
MG PMNU<#/I:8V#2L8<"*T1""G+BT-O1?;R@$J"!;3(,.YFZZ0(%',]@(KC0
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M?](IWJ7-E _29+#V^MTF*4=D+=-V(E?)6E</QAK$SH/@=DT1P]YU&"HMS_2
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MA2;USRJFI7>]&X\]A?X'<>_YU :R]/^R9X^SL1>3H]=$DTT0.:S!@,D+B"1
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MB)WU_O;64S]AAW5JJ>/9DLRC45_VW,B(/([K/(FI?7WS-=R_YD=Q=O&P;JM
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MQV;A0-2/??K@[!/CDR.;L %0-R6\8&].*@.AXT(B%1_G)R96>[)YN4&6WXQ
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M5ZM74M/DSRSG #\&F%G<;/M>IA8+=3<ZF3M32U]M;Y^)OD[,Q\3P7H)H1:A
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M'PN0,VGZD(Q%:V"WB&EI?JP.3ZF"A_'0Y##CX<@%>HXX1Q@[,V_39;JAARE
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M0N;7&:_^2WG74G2.$Y1,]Z07VX)RP]O]L7![_UE6ULVK3_P^U@=E2U6GK0]
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MDC 3+X3!6Y_A<1  ^=Y/3&A T8-T0R76,B[5?& R=9B-LUARTY"U&3_>Y .
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MIJ NP;1AA!T_$R$S*/#8!I*?F@!.1?KV'&0-!1X(FK< @'Z2;!)=]%#T]S$
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MQI8$CHG[H]N*)JG.$S&+'_-YI]S.%/P%S@OLN3*<UA$OOE-9WGI_734K?2Q
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MT/I-?2XW[Y__*]O'_[0YY:0G$"5GF0>/&PZ#2UFP\)S=#IFCC/#YUX,W5 Z
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M#YX);Y8QC&0[! -5:/-R+.)R%*_/@A]4$4>\(=SWW/6=+V=ZLM+*G8$JP5[
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M=\5.NF9/M9&7[:V&N9;F630,]N^;Z?=6#;IS5BN_)(3R=MK097/Y4ASRD@5
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MM3R4*]%%1\;)]JK8A"2Q*(N$UQ+EUS=:5CWO>!O.PEXQ\]4K<MBNP6T:G4&
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MV>3/SZ<'MSB\AC:<=USW0G:>3X 2TIPL*D")X[<ORYM<*6XG=J3GVKG8\G6
MQUN F+.XC^E>A8F)F+^9DONV8MOFKO!0>'M+D2)=O*K_%EXZRTML*LD*GQ?L
M;&*Z7X77N9W7Z(O]3V2&7R)$F6N@$J=/7VCWL#DDXP3YMDD'P?MC1CS&2@A,
M;^YM1F7WBH%;0EO'SO2:56G^[0'6>#-7)VG^M7]VEO$-<[\'YR)_S?\1MMYQ
M1(OE"]-Z]"(+8/[7!NP(['A)??GGKDRC\=8?X;Y^L,'K!C]":[>YO>8R&I]9
MV>XU^IT9[6+LV-T?LG'@7TT)S7HC->Y7!Z@.>25Y]@C[A#R;'=PA*0UL; ]K
M;7]XX'XGJ!Q^=[&+,U8,R<<S+F4-GWP"R/ X\%[*_5.=;7M<@@IB"$"@4X>8
M9J.[+R2QU9MJ<^Q8:NOT3)5C[?F<Z;>4II"BYU1E+S7A=*Z_8CK$/P_Q@O7Q
MZGVFHIAEI/N-W#YDSCJ\GVB4OF#\&*YF%Z&HH2[I-=M]4BG:6U.N*?1Q=Z"Q
M1IJ>FJ9(-TT)U?C9(0UE=7_3OX5CEH77;%JZY.'M-0+<ZI!?LF?A=7=)]6(>
MSX39E^+MS^"FW)06[.1)J+MZ8O_K]Q\:+4L3+"+F(_:[KJ$K/)8HWVN_T6#>
MAN3/R4IS$GR"-RQ'S5^_SO[?GDIX?Q3V?E=M5RTD\..H#]6+A(%%RW9#X9H9
MNCODG.,JGQ0!MVZ\B[<=N6SZ/K?]R"]E"5:/L$[1KWCQ<$P]DI9%M?H-H6C%
M^J[5 @80WK<W]D^'\*2AWI9TP@<N9Q_A?FQ]LT^EK-*SQD.W[YZ_J@IYNX>[
M;9D_S:LEZY)-5?62-NK$>/4$M()$=5*/OVOR\R%=D@(MGKJ&8XI\(;SY!A4)
MXWS0]39V$:3C5,14K(T$9:(I_\-XU[L]^7#HW6VAS0V!H99#$ Z]J#)ZJNV^
M 7]8Y^PPX!ZB>J#H$A7(@B9ESX9YZ6D5[&D9/(1Y5-1/)(/67?1T&550+7&_
MQ@'16R"ZLV+L6)(?;&N\I''\^[Z!1Q=[LG=RJE325CEBL32&D^ 9&DJ5*=F[
MH>2N0DQE2-:L)7>.ECJ+.,N#^?E_"%@_VN+DK;'!)4(]5JII>P<3D2>\H&+;
ME<BHDB)6XW^SFDI44R0_'L^JC!7D=UW?2P<JU4:8^_)QR#PWY8PW"M4KO#U<
MJ$2VC^3_Q89YQM!AS?JG%*2]U::8S#[DC-H<WR_VRB5V. @5JJ7\Z_\TF/2_
M);^L-?D@;S?Z@M"@+![ :E/ "K84:54&'&V!<'A-YP[&WMY[W@.=.];#?*VL
M_!0#^EBME-ZS*0&9G<_@A*^%%=2EXSH<"!L:S%33AU [OV(CVFS3LV7^0*_C
M^Q>E;N2JO=(0>[V>&P:%-(P6IY ^_YUT+0-(BWX5?-\W9\YNO+.:[RN2JV&*
MSTA@4XAA:_QQTFI]XC5*2N5Q7J2O.U_$R#\?G!'W_34ZFCNPDG%\73VSWQP]
M=1HA^I]]9+?L7(Z==6S'"-A># 8H%O$8,V)X=& ]+W\/P=/F'O&E>6R(+OH9
M^AK&GK#M!)1PX9PX&I_)6]<0M%VDN"AY7H"50TJ'9%>/6XMH7?:4;O7@%B5-
M<\JW[?/&D9IEL)',NZ'765SU.A2 2U6TH*>J!#"1^.M^'QNUI[E?86N\8U$\
MP$$OT=(52&Z4]6'_Z]Q8L6-6_RNG^P^:=L L<D]0TX'8%=]W@.+PY(T*Y 3,
MJ871$X7B8^;YQ66L57>)4\-$QZS)2X':4D O*5CG(]5\&3*</LFMX&($G%MO
M_!A:TB]V'&8JOW,6=9FRUSZ6W2RSX>[S6*GMI&))OR$)!MWM;\/)Z(SH^TH5
MKC'WXO\(\48O>).P1CL!2[" B2Q7@Y(8S2^>7'A1#^+I^!53R%*C=\2L!T\;
MO(\YKRW37"B<D[DR?HOB6[/O\!Z:/6195_9D<WFI!?'FXLG$%9,6'<5>?6;+
MX+80DN<.],5UMY1?QRU[^>"RBG,4O":^$RI3K+7:6&^$C'R\!QBJ0:R;U)C\
MJ)&:ZV*Y W;,G*%F!I#CMZ!BX2M4<;9E4X2+THA"T0RLAZ_*#EC7]_==O]N_
M1<^"N-B<'7YL;O(U(:T'(N&&M PXTH'%_C3\+'7%))^>G'FN(MW_:$;!'BT>
MYN=TQ212@"H.0:9-_1B'IF!"..O+9XP^-19(CI@4;1%-NR(X!+H'=71,?U4=
ME.IE6SH^UI[5<@TP(7#Y.>$D+PI[B')?YRKJ_[;"J[BRORR5M#N.&9+ WN:?
M5TZ1\L(FCUS+_Y[QSB+(P5D40;>UYP/,HD45/(O&0JSO6I7K_P"#)\HF$H],
MK;? HZ%YZL"=Q(H4+@]R%Y\UQQU$71^ 7M\,"+'S=D2G<&DHTJ6+2H/;ZW.O
MF(AK/P?:=Q]8_ B_8@H^ V]F12NU[UXQ"5TZ^T#O_P#;XA[O-,5?%,7@YBOE
M3SN].W;&?OXE-:&)8YDG4MQBG%@C?5>3D;)1JZB&EFA.]+;$I?4[C=O+:9D,
M6U3+6\-4T=@IGI"ZB?$E>UT 7']'/8<:@+-369_IXK, GA0+WBMI3WY1O?)F
MN>U[**=UQ,)!A+(XY*D=!.#L8WVM>*(>7M5_M#D]+V*<P*F7. I*CC9IXPRJ
M[!-N%->/>W#ARG&@>Y!9P<!)A5@'#14GM+<XK='F=E7H7L\'IR0"ERY',?R3
MC9).AZ?&%=<O[@D5+N;QP(\;&TUO!R>/H[O;/S_=&EXZV1B)N8YS&,>%K&+5
M&DXM3%$)A\P.R_4*_EQ;9UYE7]_2_(.0+@'*7G@AE$GR$T&W6<0R6,>/A&(K
M6I/I]A2'"^>'2;ED-<!ES(5V4R+)&DUG5H1_%I7.,N[5KXXH3-8>-=V!6R3[
M&'ERSL1C?":6(ZTJG.]Y4C'V_:-4+]9&!F':7#=/&&:_+?,P95+U[=(XN;ND
M(G?:LD.OVC\R0CWLWNSI$'CO=/3O$Y;27EKD*'[@"VN_=S+Z[/]UM4K_N)#Y
M!B;_0%SX3NZ_\LHUSJ@;UOSF;+.BAV$<\LF\X#=."<Q"ZK7TP#]75CYD;_94
M'L^8J&R;46E(A-N92-A]SEXN\M)PK47_:P6D13ZH'?A%H>C9Q E?5OA"/NGY
MD*]S23KVSJ09M_,4(;. I%<H.*D6\2#'V+NCQZ_\7V(#3M4NI\+%MD48RYJ)
M/@M$&G$F=H7Y^ W.<,6#5Q$*D-+IV[)];R5>;^,>JX>MT;4,!+#??(QDM<VP
M,';"\*"I^I&S%2>%Z/6(4'^-490_*#I]?5M54^EN#'_]D+[0"VO#J!D,5#F^
MTZ4VXLBL+^K)PDE67F*(J\U6Q S725-;%B9B/Z"44X0?!I[]9D%J;6S,= 1Y
MRL%5G%-O0"I=I%EV3/^ PK^!9DZ9<\(NX'O3^?<FADQ+MZ>ID]77$,M8?D,*
MAW3K5A:I&FS(9F";_>;=E*,[,EZ0IY3T$:CX%I]7YP][$%CJ_WQ)W5*46Z3[
M..@T525:7OI<5; M94V9/O]F^L#</P13OWK<QC'ZN=TC&&FGU[,L:=:S7+E$
M704X9'A4_2+C*MVB'6139)G8G;6 >F!^H?[6SLS,J!UBM.B[X_>;).&@;*6[
M0O2L82]AP:CEU&"6+K/O+&NGEXC8Y2<'-LZB5I4B'XNJ!B:J0._]05P^5EK>
M3\5M%S0]],8TMH:\4+:"^,D-2+RY'/HU:R5%=;M1SYB_IBV )LISSU@4N7?,
MP5]_",%5OK9HR3=&75=YN]D*U5$_&SRIZ(#EAD8;Q4"C>ESK@+$2GQ223ARQ
MLXE"]2L[=+OKUI[8 /K6S*VB:="VFEG\GZ2$UKL)CW&3U:GI!M+<L(@FCA](
M,+/'D<);*5L,AM>H1N^]Y^U;&V$;89>=).W$HJFF@1=F5IBOJ)4V8.#DO7OV
MRT-33JK]Q7FA[[X66A_<^ZUN]>>/*''A&=:^+4*:=;'V_"DB]-[%4&?T]U !
MSFK4W-/-\\?Z\NV9E4&EZV9>T;_+G%J=[%X<#A6/ISZ$2X[/CV]&/#"H-\WP
M.%I9S[5(_1_UJ?]-7R_P?U*?<;8>TE@X> 8+@%7KJ<KX%K"L8TDF-@M!3<+(
M\HGFV4/N?W8F.M+;B:0 <[GK0NG0K*K/357 U?K^'\E4_SW7N;::FCZ&:B-#
M-RG/X8?ZR@1INKO*>HG!T$^BK[5Y*&JV*X-O$%OI1%Y021'^SP#]A)ZU8Q[Y
M Q9D/E[M)?%?ZZ4D%*TT--;JM+XRQ3/X.&WN$,B":9RPDD\T197\W'G'U[L#
M8![*;14;EM+*&\,9![_<6,:GAO^=-=H<2E7?OY\L)+9H+7RI0+Q&/TB-DFYC
M-.G'CM=9";F<%+)H6W?8(!PVZ_&U4Y65&^Q(:W8_,TRCP>G3V*+/XZ0GXH:A
MI&1B%\)"'["^)30^$-],LENLD:85"8U7*94C"$ M9 FD5L@LQ4?0HG.LXWM0
M.]\Q+!XR!ED)+%C3TE<=!@  -JX&+1G!(HL&320Y?G'_4A.%D@6"F'3)GR8W
MWC =3A_.[Y:F723OLJ6'B=<0TXE[OCYVH!<IM6K&S"=_=:TV(3TV4N:4C>$9
M_.R1C1&:< E+,2TK?.9;*\@;/2VH:9XUW.YY<DM5W)I;'?&OXT=W"T&6S2U9
M?-'RQ@O9O$#*.JWTB[=V=MS2#G#'/59EJSEJ$8N2(D9$BR[47?A4$#6"WQ'F
MJ/1-;KM[MEUK<A=%4=!FR5]GMMDX>H!U3@&&O37/).ME]_L LYSA34)F8V5\
MKIPQOE::,BT)^7SQ5+/DB$/_)+B82 6+!NACPKKVTRFP!LNW"\C!Y;2Z.^WG
M_"9]#$0YHN]JXM<8R>7&&4[3@HF]GC;>49-?*R>[(<V$\]YZN<K71 N7#%-1
M2YN9.WZ,E29 3>::]=V[CN\W,L]ZDO%)B,Y8E0:*]])<M1I?1-K3Z(3O4Q6^
MA6.://.\V QS2.&HAN'4QA.D)VZI"H@"Q9_Q6U^4M:L?VX2A&AV4?2?$P[8:
M=*Z8:"(;6/[ 0=M\]KPQM&"O!B>!PB)'>@\V4W/RWB8']]I*Y*1))8QO.;@D
M5U82C'BS*Y)O;Q<96N7X(;1V\^SD3U7FZ9KF[V&853;\:0,U\0,9^LNT@F&C
MHW%,XME <$D.\3.JQ3:%(IMW,OIAX.5P9;SU0RE<%BWTOW#WGE%-KMVZ,.MU
MJ4NQ+$5 ^E*:=.D=EB@@(" !0@?I)00D].JR $J5+H0B-4 (2$D@0$! $CH"
MDI $@A Z)!!*Z'A<[_N=[^S]_=CCG&_L<_889_YXGA_W>*XQGS'G/<L]YKQG
M*7REKT"3#TC,?X!=-7IEYI!\?CUT3<RZ1>:R?'0^ER*F?SOF>FQ;Y!+%ABCW
M._7^='@O=(3H-[TV:<HO8-]G5P6\/4TXKJ =UZ1@PFP)'>&+;F!0_H(N:NQU
M%5 !WRR4B.G5U7NS-FCA,OMLNXJ:6LL?O[,,/YDN,5[^KI4AB]2V2#7F3Z4\
MQU!I?&G,!QC("P'3J](FT_(M6B)4>^1;HOI]=2WJ!>!,08KX=J\"AQPW$_ZJ
MWZ&BWW8%N'$C M^A$.3W=I')0*.?%OV5+5/6HK9PK-B659!?_7"2Q\SAPD%$
MXLW8TQQFUE"'V\S7GB\'4H.UY(;Q*=6+:>':,9V94YZ]SV0S+)[0"?EY(+9E
M)7OD- J(L"ZUB09#<P3W&GH%:O)4-7LC0H)4]=HFBX5)=X#9R$#60D.9CC 4
MI8!7BI%=_NT%![GAC.MK2 $U%RV?H]HF7^6=.[0W0,<D4*]I%]IS<&@@$_T_
MKZ>Y*8MO1.?[KL[M#]6X&UWN91CQ^&8;>'*RBY2:R";X5QP7O#+B?36>R;LV
M8.[M^J4IB*.PWY@RPTW8O]CU)-)V23U7I;<6E,9+4"2CKOY\1I0@S:+O/09%
M9+9;D>X&:3KRJ]$*&X1N]</2^'$GSJ,Q)XO:_B:FP%).([O5PI:(94;DN>/A
MQ-/27\Y%#!7S&96%W\B8X.1OLQVT'0YT<N7&RWYX8FZ++U%$@+S^3 ;9%MS@
M?EOXY@]3.[FD*/9QL>2#"2<GQV\=7\BC8[$W'Z9'9)ERA;S-WHY RK SASM/
M@*F8]5;M1NFJW=][2O^EXY9^LY46#((7-.7@0+21?ZEE>-J8<D'_0?&;EPTT
M6[K5,\KS/(Y9F&W=K;T%LJ+FJ],C(",YX1YE\/)"=NR'J7IB@C6I1@HUZ7=O
M-+,9QV=;;_IQL'>1QR@A*@L_PHV7N= J=K:(!3[,>L&1 I[XY:)PB/S,+-_V
MK(!O\-+ ZB3ZQI9:BNFU?A[>:U^V]SD:?2;W+_G6!,HVXMY@+0T^X-'#H,*#
M386=Y)SZ0&,LR)$/]]HA1+^:?C8=;J16GZ4,%WA2;UKS5H>^.>C4'H.K'AO>
MO_@%?Y\;:"=[[=REOKRSP//-7H?VO7DY,D!LA=,O[]%: H(^**7!.7C&J^2J
M7%M]',^'V9O3B$TI>A @6ZX'6&%#;SAN4TP.F[NP9:Q <!W^G"_36[HIFE&R
M9#S:*%7G/.@;90>EGBS?#1A1EWB?MQ-T%0[LFR/F]J[7-.UK"]2"5>R;F)*6
M[R@E$M]R)0,4F>#'QWX!_M>,[76=%;:B;QW'4D/I:Y#:<>-6/Y7:U_8.%\ Y
M5*/338?:Z-R0SH_Q!5RBU:.]#@VP<$V=HI1CO8\Q$C($0NMLO5+RKG/8YLBI
M85'2L:XT[0CIQ!XR6'UCW/Z_^ECC/Z0+[PX_G%(UNZ(V047Z><6)Z-4?+%?D
M_6U@M-VD3:;;#Q:^T,@Y]LXY4&:+QJQFE6A=HXR\'T'=DM9C.?\N2-IGR"\H
M&EU$VE89?J&;>AXZ'1@JVK3_,*VQ[ZD;3S+<..L>3GVEK&.YFE C3D<XE"_-
M%A;T36L.EZ893LA6Y8D"RFWT;EFJXJ%ASJ).WKJZ.CSVA2KZ?-F[W-=']8F)
M!=+!Z/Y62I_30B;$9MNB4B?8K\ 6N#M?6G&CZ3DYL\"P5KQV9)ID;F3X.AGG
M,^1OYS?6YJOD$*C=O*%:4*0,ID?.>$H5]A$'W$2M!I;[-FW\)@C4+*N)57,;
M_SH_>0D2,7DAG[X^66#0OYZY+"JFG,H#A@YG+ +#.<Q Z>YC3P<W:*M?8>RO
MS&"&EW^WEN1XV^NC'<T6,,18HE5NMM+B)T>]H=)LWCVC/#,\I7W?&RP;@M4P
M&,O;J_"[JFKB$I9F9F81O WKQ_EU]XMSB?U8.J5)_ 'C[X'9ZV7!RVC%;(9;
M3NX%5W9U5K)/D[A(/9;]V9P4GYC72D8JQ3,7YS,SP5QM9BAPBRK/H\BT+\N*
MO-GF#F-LK/'DK>QY)- H5&Q;$TX9;CQ78YX--$]_]&JP<*K]<;*2?WY*1"A/
MS+Y6ARZ/_4"AV[0X(+-J;"K66B.HWU[5MP7=A8G;RE97R9,?PA'C"QQ]T+A&
M"G%V(1B2$%4N\58'21 #4,KLW4JY;+#JWAL620Z/4!\S"KD?7U6TG^W^WF%6
M%#;*?<* :(]1@G9%/US?ZAXDU&IV>*8*@$89$_('FD4G4H(B^^%GLF.=SIZ=
M5KV9^5N12SU?X.27 DL@"N$,;81\.O'Z2FY-?[[G@,V9[,!@X.VI35=_(=^!
MN9J^@W4'7T<92TE(?5VPW?O222YQQ9D;EKP$T8\9=.R>!T]=R#II3MW[>[5Y
M1K=<CSENTZU%^/6\-^)7IXA04VD*7%=GG3M4@1&TUNMZCXI0W!\+DW1-F"R&
ME9'%'4C>-ZU #6KT2>!X]<%<.<?=TQ!8:0EJZ/");ZJE8R>'D-S,M5 Y57/L
M$HG.'E92-1R^K*+=?_\TQK-QZIL/:6D\*(RWX+&V6M5PC+D:D#;CF^-E6UPZ
M)^7J^8GP98CB8;CN4^.?S-U@B9V,SJ.A4B '_(<+KAKWJG'!*V3^\)$OZU\+
M.O1U+&#"K^!FB,H*)/9&KUB LIAP'"PE<4EW^-8]>QVJ5MWE3XF]XQ6%0WD1
MY:J^_;CD>[WM4<)Q!:KI!B)IVP/[@Y)U0>D&@OF'0FET*\W-R"S[?<Q =35\
MTJ('D%DN*J:T0)'"@'-K99/N%O^:">@2+A9JN3'T;TIK_&RVDSOK)G8?EPQK
M/4'O)12^S.#VLRD7UE+O.EX-_\&R@4"?$!M\]>@GL=Y;81&W'M%/]\RQ'BV<
MZ1_21B8U<.&BS4E2FJR>/8T9+91$*+\@3Z"HB+S;9'5U9Z_YN;Q@$,,T(=F-
M@<JJ=,2'F;T?=$BH?-A(&VX8$6]KO;D@XXC*ELW1,^OU7H&->>?PV'>7MX>K
M(JJCL\:%=/Q5'%G\Q"8>X#1Z1 *GC=-:5NM)%K?+^X[*K"Q#W*'EB<EE&7L^
MUOO_P%@7R@ 2.F[%U_KM^)E?M)U-QSG*XZYI%B3)KH"##7^P)".VMCQ3S5OU
M<D(ZGMDG3T]RKGZ8MH@*[:WR895?5V@ +#0<"^WQ]HL/(CW2+]^P@YW_,![F
MU>-X[VY.]RJ?,T-7PJ.MLQ48+H294(40IIR;\)=5UHDI^?S<O% PPEIDS*^M
MLPJ"NDDL[^T^BAXA?OSUT\?_M*%?%67O2T5V&CK5*1 :S**+X2_ALQ5(X 8%
M2\P'YVYZ"A/0;)8]0)]>*S8[S^@KO0Z)UQ/C2\7QG4XSOW=C/P\&?.XK3;V]
M*:-DXQCL:(5G"\EI!/??HYEG1%!&Q'H[.#E?1]C;];;1"D.!;RS5UOU8S8\7
MVBFX)UD?7MS.: I]-E^O?7V?A[^OI<)82817@&OT=:I*T]BV:\F44__DYG""
M^UF]TAJ52[[XE-VGM%/G,<_2ZS!5>_;>(D%DG4\%?D2-&2XIVV/"8^U:"GJ#
MCGKA&?_:G#\S6I;_="#FOHPJ1$3DK)Y,X'-N41:(@:Y.3>]P 3>AQ]&![F[X
MYX8GC@(V^'+K13U%)W-A#3]/1(H79>'Q(E%& >U0H.NDC)"H@J5TV]WZP1)=
M/N 0!JN"]3P,+/J6%X!*&:!&.-D!-MY?^C#DCN+M,-<N[)\=]@S,Y2$FX3TE
M(-B'8MF#;AN#H8(9_4[-0J@ZITY(Z*#"N.JXD>#DWTF=W+!:T,I$LKB96?FM
M=(-GZ4:_IMO>--+1?06 ^ '"^MOM1,T983&G)J8_6'1G"$?6<_(<.YA=G_B>
M8IIE(O[!9G_$Q*Z9M 4H3>9.AO"9;.>Q$F%MF]LN<#.O4*/-=X;L%&F^U\),
MVY;=3*:E*ZNFNN8Q-5. F%2?TKPE='4"0=&\6CS"S"1SVC;3\:9M[O1X>D Z
M5L96F56?7HM5%S#G:7,&NY?7X'4VEJ2];NY]L"Z\%=T>7?[J$J)$%/>82#7@
M'$?HKL$_-$@'KY'MNLD:Q6KC*:Q9K^W  0,WNU0#,)74[OKQK8[H83YUZ+L9
M-\LY/;FP;4NV*=,$^10I_7<J@]<T%*0/_=N,V=]K?@NF-0QG;AW<:;[ GWG-
MI&J>,14O$Z,7Y%^N]H@.7]F- CRP*QA*4" WH]JR',\+FTB,BF> 1AJT]7,W
MSBQOMJ ;DZ4Y.0&F59PFEPX7?%Z(;J->9&P_M>[#\:NS/\2+R+ "]0?/.]E6
MK8O6JY-P]FV"MLE!"7A%;DJR:T1;K3 E>7U(N61-T0\  YGRF^0[BJNL@U=(
M&5^A75+<-R=2'&<<Q@:; 7@+&K0JU/P:H";[FK6/@62(2U-3O3]GA:G>[?;$
MFXW_.;4I+NGM:T*!2%-9B@&-RFJJ0]S:6* KERSAWF*G^_N3B(H^U74,B\]+
M!;8GYO.E-AK@<A].9.$M-SF"2_7O&\>!OHT)M?0W:%8"HCS)?2PSP#9";-?6
M'4NX7^7/;P+R*7(/>O<[=(3S+YZ$H*\!H_?[\_?9W/S4?$.R+HA!M*K8)QUR
M/59=J-Y"I[;9FI_K@**)WTKJ8N^L0]O)F5WXYH5Z0A*C)]73]4H$CP.@DPJ*
MTN"B?J.GE<_4?> 4#%74/?)09A?@8_C8OAHZ&I;,1$MV]&OJRQDVT&S*7KT!
MKG9Y*!1RWR<D_%:^U:IO'65F2*S=I&<5&L@$C=@CF;?!BJ]2U)BNL(MQ\2)D
M$/!2DUWMYIH]X@W*.^!Y1U$@RNL7R7N7TK;]CQ9W9$:D+RX=#P6.*+<C,"&.
M;]K=^:NTV4.&"3N!Q]APB>7$%*V4+;W"P!\L9[<=C_8ZFS^3_1L$#E:SH_AW
MSCBJ3$M'7:<@$<=R.TJT0*3CM*+CO1R=I1KLLCXY][1.,(FP:[UE@\$I0R)-
M@U1Y-&(O/&@A-1$!28$="4;T"$1$=^W:),D1?+@ZG=PS35*]A9#GSBT)%K?,
M=-8U+_!NCKL9S,RTL+B#[*>^"2#Z/_AXLAO] 3V^;)</16S$GAGH"Q<)&[X1
M!:Y.EON;B*LY\^A?11M\JYZOWJ -ERLT5:I,A]1@]U T'E2/.T'^.*8GE[@3
M0EG&X"'$C>3\"IW@J-JHE+ULFF:,JF6T5I9B]A&3*H=!?* 8C- Q-M_R"]$F
M$$A&& -%;"=J67JFN7.@11S8KW2,4 HN!U@+<P=]+#[_JLLK"5BZ/Z;,.\KO
M1THYKIV*MF?F-LPIY6LP,&.M&BFLPC^M$)P\:9:2UR"845*"M&1GYRP>E.Y$
M#^Q<YBK(S_>CK>N4"=PJ%K[7T:KO&)EAX\]A$/[>0];\$P8%URD!\3H#K]T<
M&\].>:=RNA2>'X*8T?:#OF![4!(8(P'NF#8)-.MW_QERW6^)[KSD)V'IU@PI
M$B1A-LCWU7I5W=U5A1Y+HFF)7]Y.>!SV+<,"FC<#UQ?,D$-52\;=Y6*&!7QO
M+5__="0]V8.)^3Q3_I=<&]^5:@Q%?PB?7(+G1VK2"L[TK>[!!@ M;R0<(%E2
M:[I80]FL?%=48>_CWF]&/I=4Y\K^FK </I&>6%S?SV*N,C5@.P__B+ 9%CT
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M]G7V6WKX>\_01Y;=LV:V?V]<JA1RGN]VDL9,HPT6TT<AFNO'<:=?_NG*2.,
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M;QX9E"75_P5U@(+Y4!YJ(_%C<&Q-;7-",IG+',218/K6.7W52_CU &<KV,A
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MJE_-;E"(]D ZTHK>?/U=JZ Y1V8;ETYC!-2[9R?$JUGF,SAU)E>T(;/&!B]
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MHJ\;:%HSC1(5.D'Y-G>O;MJPY<]O%BE"#=MJZK1-*QC"XZZ[A)GK$TD/KAK
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MWQ+T5QDLZY-TGP*:K=6/0E5]%\&OI>ZC15L0D8_-P2+EHO.E?()'-HL*OPR
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M.+ @D\CNE'5;#NWB::YW?*5"\3IF=E$;G?A13%(+*4)L3!9=K!5NKX2UH-7
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M!=N%6PS>T4O5GJILZ@+&#R!L/S4VWGR23WG1FN$^;)0:6V!?/^LNQ9);%YU
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M)T$&GG]=:^;8L:EOTOD[4^ QSS]3R93?QT>)_AZG7+;G&3%M19C"LV2Y824
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M"YY]63:[\/SBC(W],L[BBN8 W>MTQD.M;0Z8?&D;>'%RS\(F]F7QI=#8C/Z
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M1YMQO\REC$<-X?D!.Y<D4!%H E_/*G<%-]5DEV+XI5M;R4X71M5];A5-3[.
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MX:J5ZL+$I^3GT)Y^VTK][Z"^H.=4OF7N 2OS[AR!IAU(U=NAX\]25A@]PXD
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ML'UPR:78'CLJ1:IV=/A.0_/[^8(8?@%RL3-]10,PPMK\LO-)LNR41I46 #=
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M2)(MP'1!U5Y4&1P,J?S/&W!W44L<5L1 ^/TZ2:,SN(@S7Q-]E4EJS*?N+B(
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ML5AJ6TH_RJCCVE9AF"7J$0!=H'8'Y##+N6PH$VAR;I4T](<74<%?G"CT^C,
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MI8JEH"/Z!U6F1@=0NVTA(=91I>#GN-$4221%RR](RNQ:%6<K9SSS?%S?8LC
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MJM:F<+RG\ZF)7\,%,AM7K>+\LD 8\(N==EK%OZ/R-=Z,?F=RDZF!=L4R*4V
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ML@YZ>]Y%[O_)B;KO_YL33O^?.1&?^F?H7C!'@U.I@7+2,NJQ,4Q%+GCG(D*
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MK:^*DY1Q87)@)M9<]NSN? 1/2S.JN"[#Q-IN%EB)PUGNPFTN.<R*(6[XMSR
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M.]M\FG8P#8$*XTB/6GPEBA DZZED60!HCQR'257=KLL4!PPVZ-$+,V(3[J\
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M5*-@:[P<<FPE6W0YH3*WT?>[?K#R+Y,&0VK498.!VH)QA4QX&EUNJ)5_MR-
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M].1ZVF\K-4-[-7D75NT53DTC0<^IC. C5&9-IX0]:@C+"?S<ZK@#QT3>Y:L
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M9Y%;@D7*9])W_KWL_4NO\G7IAB1"6N_D2%A0Q(AJ]+W%$83T+Y9K*RDX(H:
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M%]=#3/^!MDU*VDU7."#@^Z;F1::F3VZZI"^RMH^42PM7%K\Y!OT7VV:G2UD
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MK\%52_]:*;;LW/[(K&<4Z!!D-XH7GKB'*,Z.<XE3T;'!.S<D:4;%.\SW-,E
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M*DYCNZ.R)[Y*_.U>3C\9TG^#6)U; ZF768A59%G)L$*;@]61;2PKL2HZK X
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M/^*D [9=B=],!ROK\4 3.T$N%9VR;<TV2),AU7[,[-%HPX '4&4,DH4E<^J
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M1E&S*NAU(%AQ-ZB9^<6(W&Q_"J5,>T,FE2SF<NG03FQ;62$I4BM#J/W21T8
M/2[38<.QK1D..4Q;6[)WYZUB3BL= =^&0+DM86B_"%2XC-P9:!2P/H.=UK2P
MJ\;.E#]M76>[M#4C3'Q;<@_Z*!;OHU=C3"%C5VU4 DK5LYLRR2):L^_\ZN=
MFUEP"23C'=$VB8:><D&[L'OZFQE PPZIMH<%U>VUC70J="FC?@XN&9;/GQ"6
M>BQ'.ITMM!6F)T"1_/Q(6:1X!>7@O(F86O2VQ>3(#_CG"M"HJ+S4G*)X9W<L
M126DNY@<WW;]GG^G2B/<QT [[VZS1$.?UR,[NWM&F_E!DAV2G=?G][N_EMYN
M%+O;*5G5XU'TQ?G!_/K*#%:47U32743=.&EX>##'8A%WJ3J^+_C*>?33H7%E
M;.6JT.:YS19H#/R[!:AVO(9!P@QG>=),;\N<7ZZQ LST//3^K.C=]W57'XT8
M"+OM4!6A>AT9P5(: !Y\-5_?F>1U!R6:72.*\M@X2GD40592Y7"(4Y(P4ZS.
M>E*96FETS+VF51C:VKAGRP/1G[ZX7[G#OY$D*Y_)72A/Q7.#WQ*#6L[(^"N:
M=6/\>4>E8];DB1]QYE_[+]]-GI&+HGJ"V?^E_I___Z@<I1.SD!6+^)Q2RN&"
MPQ]>2\.WX2-*ZJFB1WD[:7\U!5_1G)A<T71*7.1W1%V@KFAV)<Z]KFA<X4\/
M;U_1'#9?2%_1=#$NR++L_YO&<X#SQ.<HI6=,O[ZKCIM.)YV(Z[F=3-DE>@4[
M? A]P;6"C%!RB_DA;VT&JC969!8%RP:0-7V"X)@^Z'QF1CJ7M_1Y99QW\D)_
MF0U(R61Q;?RYFSU9259$T\T^FZ7=OKK$6+=5J?,P=M'%9Z\^:V)@#_D<4(W"
MF*5C&XLQR@^\QY$014B)F9)T@++]MANR7+F]M2'KFQ(V6W&AS\KFN3?J.7=R
MZ@,!@]MI]G.[GTM&("U)%*AEL$9M(=@Z"F,!QVS .&>"K$<^;=W;= $6IQ$$
M!Y:5@CONQV3*Y:HP6+2CC).GB=9& <K&+84QD?CZC;KS:<<$JLI@G7F:S*K^
MG;QPJY!S+H;H<%=C%%-UP"N+P@*,GGPT[2-A):;\<S!9->!-LTPQ8V!8\S)\
M7X5!;+2Y6][V%FJ9#_Y'=A5WSN]TRLMJN^-7-#&V9SIW\_M^>O; <_I=9*K"
M3^-\MK7_4D;JK:,:&3L L^@HSE[0Q)9JP#*7)'[^ZZ/1Z*8/;&]Q;"\<.$>A
M7)+X6/"'0[^Y@G?8+X*CD&D9?V"IM\N1;)3L47!'O?,^ ZZND9N6:R1VJ-&4
M5=3]C(Z\[\@$FU^;((ZWE_ @E=G(V:T(3E#4M).U:!E:U.'6QQ<WQK]U3A2-
MVRIMYW,[)!TWNY(PO1A.C?YN,X[":EPAF)/.&<("V(7O)_7&+W?(]>![XM0U
MS/ ,96V*/54J3+(K(]DLZW,?*N9&$0SKG+Z0XB&BF9BXZKVZP=>[BSX<B^7G
M3I2P,&^UFK4LWPO-4)$-COP9\33_?(O(-+W^I<L3SYG+_F#L?D@%.WO">;3+
MMA6(PL +VTK/5J[W: D?7%8"I>5Y-D1GEI>Z6A6VU"ZMG_M89,$>^$OX\FBH
M)_8.#D<XE>M?!U7V"48\SB -P*RBBC3Z2-@L0:O5 J%A:RDW\0%Z!G+_FR+%
MQ-'"C-1_C_F?!/@G]BJZ<+9::A14LR8<W!VK9I7F6DIDZO]! <6#_4(D\CD^
MK38M'AG;DJ+95!B1D5ZAFXJ9J77YV#@N.EW)'9S?F^6YC_<4&&V9J79Q'7'I
M&PZ1:*!G&FX90+#JWRI9\A6+2)0EOQEG$M[DYG\(]3TP%M/9;I$N[H\UC=/,
MZ^0-$3,UT JMP=?4%Q2/ZS,^;C2*UO,=TE'0S\0YIZ>JK[WP_I;&+7!%4V8K
M=3X['>K5T*D\%]0S3G%:UNDP7$W:,?>H$(JD7?F;+ E3O&Q.'8/N;RL(9V\2
M'#E%W$T.#M"G2T]!OS0^7A8^=/SZ;?_Q4DVY?N2*R;,:"<*6-+#+PN)Y<OU7
M:J]WC'<+0$7*7>29EXX&D\.7T04YXU[IV[M^/MMC" 8$"Y8Q3ZA[Q<W5H 0&
M#..&G#[X*NWQ/4AH5'/4]^%1J/A1.43VK:B$-60\DKD8*'H^];$\>HB2MU_:
M+Q^DT,6IL#@2*&BJX]+\ 3/:QOV[4=M=LP;9Y<=0F[GNFG 3A $088+S.^OY
MW ;FS+DGV<F9^M-ZZG^QU!E-DN/BFH>8TZJV95-"6CZ6;GK9PL:.14#TO@.,
M\)_:"6ZIQ)2U)I"&6K;?7R/!>803@SMA-4G"E0B',$CW:*<+*S09&4'4<HV9
MJ,;5*CH"Q:;T1ONV\A$+1\K(=5Q%O*"9PGJ18.&K&!\^:E-"3%>+D/S':K4=
MO[TS^6NG$:_Z@P?.QGXJ1^18VEO\PE'?QU+2!E$NU>M2:(-;"=^<AM.M^1+4
MVEPR,%C%,']%(V)USI.3'[DT$2@5^O[;3>,9*N/\9NADL3?E_NKPQEEL'>O=
M HLONP&ZT@^XH\,%&CV#L]L3O]L+:]!:CV@@VABW8!93#R;(I5O^-3!%:DD_
M0/7ITPEGZ9B"7.P?KE$=>CT%N=<3YQ+;IQ%B!1K^A) :VXSS1&!GXY'V@$#X
MRZ<C;XJ-FS-:)5_EWTGAH^;<I+^>F7U;#L>>H%P7U#.;)6@_;[,7@6Q=&<NZ
MT>/!ZNK?)-G7S!GO,?2<']L!/BLSEW!^;"-MIA'1$,VNV#C)0@'PCP[(*,\Z
MLCIYS,D1LD3K/OBA]<QQV3WMHGYNY.2Q]I(WT2UN 7RC<4>P#?;>_D,7OW'\
M9Q?M)IB_L7V*/#A(QS- +K_&;.PA,4!9KA 3H&$_9J 5X^$\_9M#,P_W;!%4
M35G9;4\>)O]@O6;K[A*EM)'.H6^K)K5G'+L=-/7"P\,EZXKF7!$/7LJ/"BL(
M>4/M]PC] CR=M 4G+(%\=X/KO#?RHIV'/G_^K9'#>"%WRE]F[G7OLDKUUNZL
MV-Q<SV#/!N'MG+*? :?B]Y2-6<]=D(MA*2*"( ">M>I/)7]OPF191,U'VVZ5
MK3E5^6QNN4$CIT?DT#+'Z85%$1P*,^^'2LJ+$+:DN!$WPKTX6MS0"70 41.B
MS!M3E3$O/BZ_6FNEL$!PE&9#3P?R,D9WRFGE(\A WH[1+%RV4,K%\RQABV#]
M*/%$%;9.6<)A6X@\4#H=Z1:D->)U'8G5JQDT?<B^;%>Z;*6A6WF9[%>D-S/8
M<I@A\R;Y(<VU0?^>*YI+[HOBB^BOY\3N](1F;AVOBY##!!5"R(Q.N[0_K-F*
M$-8<$$8J>/)1D5M#<&W_S*.G@70A]K'$9(-'GLY=SJ=+,95I*ZB/EE4%>&-#
M6Q92]V'OS(!.AS3F^.2'#ZB<]S-*NNZY7?0LV+0I.PN>E_<2&DL:J!ICJ.OY
M"JU^I((X7.F\_3J;1=\;GCZ,N Y3H/9-=8GS@C.LH:9+=-4X81V66;)"*X,5
M<9"J*,LI\N@96?QBPNFX46/=MUY&_.E<G*VQ>\% N;V$)>U\A(&YC'NV * /
ME&5HJL*?.!L.M-K#EN' Q,Q\_J@ ;;%"C$71>RLB^%/3N+5A?4V1K^?A5],/
M+LSO+3JT9+;=9*/ S[5V\M-),A?Q_MU:GT@[5&)7NQ%PU_S(A@W$5D&X+J6S
M5LF$_G<3JZBD\N,MAH-]0750"EY?+\TE57Q I*AGXBM %LMRA"J@2B>;X:H=
M(I]G+%DZ/W<OAUDUI%2EOPN23@TFNMG]T;T:38Q@DXTM-_BQ'Y,<$)O/N=X;
M@^5IY@SS':J?+9:I:N-HJN=VG[@]FUA/;"W;$330]C%9[:OT(/#BS0*1JMH+
M+5IB7PF-D(*=#P78HGP.3<,LI[2#XL8>]"ZNQY-NO5]E5PO[88X9K://XD;V
M3?QA<]MYUJLT.W*O_--%$2ON#+EOWS9=?7%'YHHF6#5YD9L6M9QF0:\8UDS+
M>L@VW.2YJ9EZ41#V_7&8B^&^;_RKT':UZ0W;C>(<]QH>F6\W)_]#=]86"#HB
M5MCM6*[;WM"1DY:/S4_MU%/C]190#71U1+=#,Y->=7EAO893#A;=ZUAGXUQ)
MP1(_/:3(%$A@XI+J(3EK 6<VV6CEG0FLQ49[)QI%>Z?X/L:E#_$5_&K(2P.Z
M^'H22=@2_F&SA)8W$>[)'*YJ3C?^D.F8G M^K"60S1"3":K%I3NG[]Y[6[,#
M6L'L+%Z$I]I,^(HFU\:^IY5-E[=]=B[F,,EFTV%5'X=_,)=0'N<J@&"UF(=Q
M+**%XJJLRZYH^'K!3@"DO,Z3FJ\S1G1%5?RE#DRSE ?1WF!MB+)N7_UX2]*6
MF0ZDX?]B[[VBVMJV;4'V\?;VQB8X 29OFV2R3<X<!\"  9-!)(/(0H  D83@
M;&-R,MDDL8D"1!8YVF ADL@(D,@B@Q YB5 ^IV[5?56MO=?N;>VVJFJOWM?Z
M63]KKCG'Z'V.T?LPOPV%)%N-&0L:Z:?X+I[Y.CT9$G\\'EO ^I,GZGST69ZW
MUBG9@5&^DU$[ WF7<R6ZS;4W-/=K;<AL7'%/4+GB>WX!G37N[65JR\,ZP_3T
M_Y&K>WL<+**9W;7K>_4B=,%O:8>*G+ \Z;A;E3";/&"-O4+LZK877S3G>06:
MY01"=4M*"G/%9LDK.+>"K],67FE>A"[+HN>D6D(@G[0HO0I#(O-@X[BO5\RF
M0W/8L ",,QO8-YG&KJGI$LO'*8BL*@9*O-#272^!G"QTM%"EE33JK6+ 3M9Z
M?LL;%^&SYF,MQWU6Q4D7F/(;FD'_%G^XL@+2 J_7.M,3O*4A6-#?HJ5H=<D3
MCI?S]XJ76SP&HC3MAQH3^.=6=<TQ[FK&A&F*D!YGMDS;[P-T,FD_D[*<5:C-
MP-8,["L'6<]SM68WJF$K\ +?KHVL8BI)GAK/Q+@H?="="@+-C5>I'>7GJ7UU
M.,TP7MD17^J;&P>YRO68V:6D?6UDR4/FU;:*#;H=@IX[L@:=:RM\W1F@U>!@
MC_FYA^J*ZXKP<G:1%?_#$H$E18ZQPT*#^AO(1F/VJ^.0^[4::J\49B4AG@5;
M4WE&KA7L6P*I9/I4VH/Q>0FECE?;R1J (B%/;=<YU"-YUL=,J+]C<4IC[?IL
M^/SF_O8'C$DIMBR"=?GUC7D\6SIMS&@/:)7X[MY)&U!BNH-Q6F@21O@1XS"X
MQ>:HP[&U9ZX6S.(Y76T>+CDYXRJ<\S=I7@UU% E(F#Z&D^>( 0=0L;]6S\J\
M+:T?\_!]QXY.C)JRWVL6,>+B9$X'%_SFY?2[%X6>&(Y\#ED;+:K(6*_06@.R
M"K^49]V6WU0R:UOAZJ1/\7$>?DA%! 2_U+^AR? V=D\S1]A\Q?3WU"LTB0#T
MM+#Q"E/&//D5=R>LF>RF=DD3=EU-6S*J:$I'^C]4^@E.N$Q,EG_'Z]8SI:M[
M0F#E8[T>M0S8$K6?VG%#HS8?<AUU,DZ[BQVS;%V:4&[X-?YT'@IWM0Y#>/&3
MGAS1N'7^[@N9X_9Z\,;C\YELR,*+PQ7E%!PBGA.2"91X?H(5U69O"+0T*3!Q
M'?(2Z1/%!X:7*>C=,RVU'SQ-X.E###E!M5+?ULQXL"YA:S@<]Q='D?] Y3GX
M>364=.DJ!:9;+<:%$X,*VC!UY6_0 8CI!E@=41%4KI VU4.\ML$K"!9KR/Z2
M[Y[%'S#"\X>72*DY4 ,%J-10CMQ6ZY1CS_4V3$;";XNH7#,)5BG+J2N_AVQ+
MMJ^RQIJ(96UC3C*XY<DARF5K7H"UT<\#VS &KHD4KS.1$YDU;LGHUKOYVGI\
M,;UOK,GL^D*7/EXU51XK>6)%@-1 UWI:=1_[FI\06[HG<V3J76/_P\_9CIE)
MBX&L/S@C'FY9_YW;O\%FY[B7^TWF@XJ@G2O!A.^"%T*?L4]/DX^QA+?3*YV8
MJ1L:6\#5ZS=,EE0",DILG%>FXQRYG4C.9Z47E?79(13GUNR>"[YDZU D!#PI
MTP[6NMXNT.XV8?T8K@GW?3WYCJ6;+UP@C'/9NN/S1LS8>LK*3%J U\Y!2U!%
M?VBRA7Y"8*8.25X-!%*72VM;4!B08#>&94ZN5&1//)K);EW+TOY=7<_(.OO%
M:#DX,!A;:%_P _R$XFCO4,ITMDVMC%M@,B]"/%D]GJ::+.H]3IU',/E%*00:
MYB--P,F.YIS]:)S@@:G874VPNM4V6""6CZ]"^<FR1.RVR'"%U:ZQ:6J#H:>'
M(X22I%,N\*3= .#9K8L.PX[4IW1JL[X6MX'QN-??]?0GQ4P!&B6%IV+P[\^6
M$O ZSP2B=D&&5<9&>IIJ'J\K)OT!(Q;&6[HOHS$B#OQ)9FT/,>W@HAY3RUG]
MNL92J.>)L\%GI$"HO[I@PYYFXR>]USK[/"WD-HOVC0GAE9-LEMH-0@/AOAY9
M27K!W&4/9UL3V.;[>A:W3>]7%853OU" ;I7$P'"GIBJ])>K;TGE]'[)/#(E(
M$8=0?UO:OBT];3-FD5R8;(AJ4VJE(:1_ZK,,8;J4@R?:C"3W<UE?^V]. )>5
MWN$N_QLK]6DNYXZWS6>F!Y[2) 1WNF@P[67A4,R:SFGJX3_[#+79GE:SIQ^E
M$<_T7#/"O+D#ADLW$HT.E1(]?T'XHQL80M9*[)I[@DSK=KXV%Z7][CU<97&G
M?$#I_K#2"!:]8P)A.UR-2IWDF$!/5GD_Z>3F!4/+;FB4^KVP:)AU-G]Z:/Q$
M4]L3DAB6?2)C08O0#I9:)I F6BBO9F6'>F'E)#?0(;O-73)=SQMKF*\[:'SQ
MU+G4N&+I5"T[HBV[H6O'YW[]O("*3US)#^^6,\"J%DQGO=?#J8_XD^G_$V72
M62Q:N,H=OY0?ZM_*)*1P<=)Q@QX9QVQJT8AFK1Z?YGA&4)C]-@;L7S"?PGE:
M]@LVGFF5*V\R))/1UDJDX(.VA9E'KZ[:W? )=1IG8-,E'^5',E,[X&OID>NA
MUJ,'0G+.M-O5-#/N=W=N:)J&5FL"+A=H]W^T%@N;=9JR9+6UJJ17O#)\ZMM*
M_FX@36Q0^MM\^NS@?KMP8>E#^0Y5QCB$8-JV=T@[=5.K'DY ^TDY:[W,6GT^
MKMDGD[[N:DCP%[$>DG/&TIG(#0>?+ZV1LA11,-'3P=34N4EYW92 >YE#'V+T
MO8+7"TP=[/8L8(IFRMF>_O)3Z&N2H@MF43)H!OMPT[\"<55N_?# [<)ZX'9;
MF-!.H[(FB_[TX;:ZC;=JSX_J1-Z2*7\EZSMG%N.XZ]-=*R'ITS0<4;]*4)TQ
MI4!?]G&636:IH</BOH49$$GGZ2_[",'E+C_8TE0[&]MG/4<8C]W"?FG.)]'*
M,O'M1DLUI G?J:E'1Q.ZF>+KOHSST]RK.P^\6H6WP!,$+T=ZN=*\-:_9[6]H
M;B7D)RZ+$]@O0?.J9-; WQ_HKS\XWB=QU[P/4:,*UK7-!:7;+'%OO)TJ7Y@L
M6#XOCRSX(RUY$ZFUIC[G^N0BS6.^60I:9H#\M:&"4".9F/@*4$<7-(X3GGSP
MSYFFJ-'[YX+J#[RRM(0M A^J%!*_@V1. 0?7%$90CZ1HS.+5IPK3]O)W#99#
M><7VHT-5MU-,E_SH8VY_!2I;I>4WC_ 8O/5Q[9!1KD@PG9^;:\P5,-ABL(E&
M2F.67DM8<L Y=9@@U:U)F%=+HRZ^A!=._)X18GMS3:Y>$5Q@-L ,(G"BTO%E
M$OI1(@*-2,;$#+W:WIO14(_=%V]>3R<Q<9^G2YML.F2LGL=:EH,,49\PA4?E
M_J0*J(&"T$B%VI*):/"NLKJ(<'R!_/_%&[O^__3&IOPGO+'9I+3N\J1_VYZY
M0HEJ_U+^\9"=RX]/Z%5\UR*DT9L5=%CU(SQ-D9L^)JW(IA?T9%5A"U_T.@ME
MK1_VO$),A[<%O*'QO,<0]E)G((K=+_9@CR(@&ALC:OJY-M$X ]V>:']2<>=>
M\MLJD>K>I"5O12NZ00;O)>.XJLHI+0SH:SPH$\5=VDYMUD4*")>0Q9Y/)(V?
MC<8D.&G0FM12>VH^[%1NEA,IK%[<S*O [P<RJ6@7>?,E"R97MZ^P)J15>70<
M-/,A(%S.BRGS>*_\2XLZST6]:9D02ZLV47$KJ"+'S+@808]!AB[[N\(E,HN$
M4A"X=TT=4:/1R>5?Q$7$.UD2;FC\&Q?^FNU[N)!0D-KF&AS/%VQ!:3K*=:[+
M^]3WDCE[_Y@X>T/C.'J>&"]M$=*1;GVV?]+$[H ['=GFMDAO>/_CK5(&Z_\+
M145^T*QR+]&$F3[B5B6UD]%I3B5_O7[/."AX!0$X4=TY]8*292=Q]Y+'?FR/
MET'5U'C/?=<]^$$.'#U=Q!1T&O[AJJ &9]KXJ&"IL\N>3V2#0T<6.L5&6W10
M+$!Q>H?$I5M>3=#2?F_[?%-'&2[)FOC)P$W +<1**[>M.7<"*"$@?4.CM?1/
MH1268PO^,+=JG%RK29\J'7FX2^R,@ZD.,X#64I/[LKL7CJ\"@Z-R_[HL6,FR
M"1T_>J"P^<[R/;*[3;AO]JK5A%3),UE$/&7WD6!]5_-R9>^K([\JRUV=P-ES
MY1B^R!]&T<S-)3&BX<+S:S4= LT5%O,4]S5HNWFV5]"GT*9!)U;--Z[W1YEB
MLU(U7]/R8?EBOHM8O(NFI%'=.V7/>1L38+NI")V[7T)+EDR0(;*?[?+4F80T
MVU7HN&CEE1Z"W62?!?B<IF(4=#&]K>OTVF'C]0KW4J8E1BA!P*Q@1:Z9_'!M
M4.S4J66E]>"'%L?R&/H 9ADHK.5EI9<V&N$<\*-7HG^F!YRN8 []G6R46056
M3HTVVQFO$*R/,5MB^32VIXGFW%TGR&;D[ R1&[W_&$H-6MLMQ@BYXT_29O?
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MCH5IZ%C,X;L>81V:/^29T-;5S'@1M'\;TY%-D)]JJ 23D2]#OQTZ)H@E)\]
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M0I\5EH[/&$2#F.H%!44KS# :[1/$P(YYI^Q4#2V"D*XX/1+%Q?&PFPNA'!?
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M;#6Z6%DX'^N['.]*=G=5238ZX[WBE* ?6A^-#J&+^*M,$76Q,G(^UA,TCF.
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M.P0P:VD$%;'0<;%4> $W:<Y"Z1N4)WD86L(MH9GHM3B,Y9M*RL^0S@]Q_U[
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M9@V\'%6;/(EU PTHOTNVK+*.9K,T2C*YK6>?9[XT2?-%>6?>&C9_'!=PUT9
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M\S?VY)SV#>4T62,H"+ $4H$KWW79F/BWIE4N1OV$0^T-">T@Y>\*[=NC?52
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M?]@7AP0'._;*,1*66969.,U*5( -ANY3'^Y9?-S_N^8<-QFTO2\^ #EJ:SJ
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M#]V\N5MC5H)+ZQ_,MZ0%OMY9;%S+R(EDU?<:%_(1*W,T\U]*@)7T=#:]:Y/
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MZ"J^LKY $]T[;GZ,) HW&?35@49]1=-C=+<HL$C_$*?P.QJ=[W3*2^J7\]F
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M:YKRXY"K<QOX,GYZ 9(J-Z]>'NP!FI*Z?^_ X9\DO/\<1/D7F9C)ZZ#=;6I
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M;?3L!V;$7[?J["GL,70.[>Q?)@">4PAAG2XW0%T?J7:F],]EP=1"]W_6AOQ
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M00&'AR5!\_BD.L(!:MOH2&2G<*MJ/]6]81-UO6,,M(N(:H@@C9.F125HE*@
M 8OS"]RM-(7,,_W#"9Z-@?M/!;]=3ST^(Z>V4@$$8$: NA.VZ9Q1_13JGE:6
MN7PI7W]%,UT2_R=8L-9I[?CC);GY"O\3D1D/LN:GD4SZE2U5&HKNKV>,59/8
M6MSBPP)^GLLX;$AW9]!?G?>RWX5\!9U^/RYU6,]HR4T!B0(]BM^VL>EI9W11
M 5'%(6UEYZ%.FU;PZ9S/7"/2D=OS,BI>-AB3FB%:4N4RZ2A@C HHR+:0_DB4
M.3H8I3Q.O= 8WH+^@%[P]R-.&!&G2K^RW_&6>UJE%8__383ERF*775CO_DD1
MJC/0_4#BTQ'*:-:*:]-)G-N"29B)MZ.MART&&MG4O[6JQ>.[O8-O5!0_:6[R
M1[G@N*,,:Y8O;^NY[$UDR0<,'Z_-QS1&(S,:M3=";<AM>MLIX^P.IQ+:9HE
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M.^K+Q"P>VPE=! U4^I!> ('OXVP_13IFNXH+C@SLNJ^+\%E^\+3V>#!63W@
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M@DM89'4$:LEX=#BR&M;>6=[OXA9A?2J6U6Z+91(Q+EFV0VKZFBZ4L:-R.,N
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M<3'L*Y3-2DL$S5;U'O_E)%9M[G[DL86P*,Q:P>0A#LDI,Q+;S=_YL] O*22
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M%1/[H5I:G6_%@7SXQC./EA@0L#FWZQ]T6JD[%@>-VAHI__LZDUCH1[CEIM&
M%%'A<OY^(:I'9QUF,7Y7_0^"UJ2,WH<F6P-U83T&_>E?H,/@[91/P5(!"],[
MV%[:]$I$Y=SHH94:V&:PXJ=SSP+Z5,'P?E@YAL\>WYT*(^SI;(J]+!4W-(S]
M'$L24[O4V 'NKBI:"8PV08 K0[6EAF;K/[Q](VC)<6GM_'O);HO,:%EZ6"+M
M1O;V_@R*>Z.2W.5JN<*RAS=DWK31*L,8>VKT/Z\I_8/ Q5_G(GFB9ZCR</P3
M9?K2>277<*@>\P^LK^1MU2;GS<UZZ]SQBG6FO4<06/7KSO%FET??,WOC;7_4
MC5G$.&*EK- .JJVCOJC3)Y?_V@'NNP!IW+C[W6FC,ZY#D67#!=\P$H],O.NS
MTT<J8UNE]"Q_UE9P+IZ\6E6$$VU/0P[IR],76ELC<"9,8M;=6 R7PC2?R5 J
M3[M/=E4V8H(B'214S!/,]6SY(OF4(;9H&0IVB26*/=*:HV>D!CH->?0F%>CL
M=V]19'1_X8XT>,W,W245+@UA/4@PPTX^SXG.Y%B(/*XLU8[34Z64V,(FR2=W
M':TX;X\Z# R43T2$P5#C/P=)L9U:B:?!PCCU4G&>=&RWN_':AX \*3L*GFA4
MM?PBB_W&4+_;BS:/O)\^1R8 S<M7X4A$YW6AE,:-;X&.Q]36JV7')MB6,V#5
M:YW[X;_;IJ"/<UW5D19G?M=E,>6W)&5*!:W=TTZ;[A1&?1Q^="JOGXMQT)9"
MCGA20?TBN832!5^@\)@R*#8'J"@?XF>FX!7 #+CTMG>\BRN=-/LVVY@I("P>
MHN>LXR/G/GND@FKN9]#;^()X3L9XI^/JB1R)#U"3<:%N%3<TJ[,UNKYF1WY=
MK\5%3R<U_S6E1+'I+59WQDYWZ'%?/!^P^.LWW4.[!%_KL3*QI.*[#=/7J[7U
M <-5I.R4-C;3U)\7HCZ&2OZFUB+L)\.AIZ #FG7KQ>0C:$NIB=Q*K;LWRH3J
MQVBPX3';=&M8)C2X\Y!:(R,>MGFN2KK\HB/G7K^1@-:M]9E**ZOL.-'0@(3P
M9?R5N+:LJ?EZ@#,BQ0:VLZNK7&"&-<.*5AM4'*A*Z^AL& A[JDG=]UNGBM_H
M?Q (I: ZV9<-1O,-4UVI19?GGKH&5*@;:0O'X4UU=:M?G( S]+@<9FJ)DC+%
M.XR>4.U8S3U[:BS=\8F+%V4ZY^IY.UDS7ZW%R!>G>N:@X;S<E%"5((/,'EQ.
MKMW+P4VTUI^'5<8_U[FQ,4VD+*$!+;Z3)<C4__0FR0M5CW/FO5FZ9B7>,97U
MWB0NY1<I]-/A8=W5W'=.*<==477"PY>?_>W,,^(OG8.W$C/WLQFGHZ,:/!1,
M<DOAT(;B<9_NH]AH1DCYQH-NRV/7TX8*SF>$'?W/XR2'BB5WL086W$J/2];2
MJ&=).;0(_4>G\'I;\9B(7_^E:'=4NXO4'VMA)FZ 3E5#&B)Q1/[!ZX6O92Z!
M:ASI&KG4CS,!+[Q'X.N@2T9ZN(Y)6GR"3+N8FFO:UM^E=.-]B]X4OE>8GOZ5
M8.!CTO^;C@UL#C7DN3F6< [5V?#Z@$Z(!U&<6:KK/^9(R"9"_L06G.C,\)S6
MF8P^F4>>6OG'O5\E5L(F^Z&FH_M?I'?T%,M79>6@IC6V% _?P31@^W#!LY==
M7"L%2UC<ZG><YTP;"0U@^=QJG)WWV-B ,-HBR1('$*]P44/&2,992C9[I]GN
M7FILRT:2;5.<>J"PCH-;53A[>35'E_$#XO-,@]50:U4??W%GZ8<I?!'-W)M?
M7DA\>5W>PU-,*>7:/\M9^ C;V5L]SPW^/IP[FKTJHBNCJ\NT3_UYI/.._'V]
MC:5*GS0S"1JLFX3>17^$:DD53D'"XZLM=2H.7'[)'*[NLO+^FIOL=>O7+ID,
M&E5]*Z6L'65:1!D*N6]B]U#N@??%T<%O.IIV^(5X#V=I>BC*:Y/I^IYTGQ<P
M+_[2*3Y8/M#NW]L1Y! Y(B7-0YO+%\@0-.#8.YOVI'.3A&7GR)20=6A4G>,R
M7]= X7;H&767H@D>\36-QE7^;P*5SAFL#P.G<:9IR[6D-^@*O5L8YHX3Q!*!
MR%2OEVO@A]NI$RK(T?QD$4$:%4SLA_:\2D)D?X?F4 .N/T<X+>586)QB&EVE
M::6OA(CN9RAV\3I.15P7W'U4AE.2?7S+(ATUFRXUZB=>49%^ZY6"PLIBF,?!
M&R.AOJ)YB GB;2Y#B<[/;$AT&NO'H(TX:B,#(;#O8"/#TB(_ LL<80T%M44P
MTSJ_:;RX>[*[,E=BE1(?I*>YZ_5YGZ:_11,+HG#W6\P;W.H/&:AY'N ;?'^F
M-SJOH&'IN-0\5J^:MG&1]G4YI.TA<%E\0&GEUX+Z3N_&<@9C_'-#W31WE!B[
M< E:>3[.RX7!"RA>-5C75S C*EK+ H")Q7'YZ)S29YTX?COD?11 I((L?*8(
MN,6,XRN%@-G?=,3EDZN.=1A"V1/SHLH4FS1UHBBI+:% _M UEB^.1_Q$NHL]
M3=J3421;*R;L2O;*=I\JRPOH2647E+9H:+PK9*,\Y:9WU^F2"/$KVG_=.I8#
M NY'!7N:Z^E1F_[&ASV<L8ZMO;QQX5?^.^15NYCW4*]BYM64V3$>D@5!/VGG
M]),%FE>NMJ+GRGK@UP$DW+4?VN]RX-E9;G8DCH+DB8#_0];U&2[W8\91[826
M@8]=!G@ G=^P?^UTJGI$ZM>2'A-$IF^^7#9_O0D8R>H0^E6;X"Z$UCE5(*9N
M*U:DNNLYRY?VY[UBJ2MHJ!"15!A,#!ZH+@UN,(?HJIKDFS#STK<HLJL7I'C%
M"/8.3^-9/3DEP:Q$J"7M4'JLC<B8G*_91'[*2O*T(?U1XJYXA$!F$JVI'F].
M"ZK4%0N.!:=7=NJ@F;8F?0?=)CBV0;-5-G'G.HB(B/!F,L(RL)[P<; HXM"N
M,=/0PL5"L$^T(Q)MEQJY6O#073HN+KUDOB9!I@5@FW.+:\'VR>RNE\KR57I-
M1JM#96;V>X?KWF5ZRV)QRQYC&]T]S0!A%X($ICVI0&O\65 #"?2Y[$O?T/35
MKR:$I^W*&(%>ESG?!(Z]:VKY4M=2@#\[N[+E72X%K*-03)YO0C2_>D(BUC44
MVNXTWAV.=#.4YY&-2Y"@$IB9]H,(V#_BW-A1Y/CR^VWN2G)I6/<.PQ7S'WQI
MMA,BHZ>< @C&'V-= JM\YN]%"3/J?#%XU7&_T9R<6&A:FHX9]-.=3HA"@Z2!
M>% N1^:=%7A_82.EV>W &,WAMJ<HXBF7IZ&I2(WM!,F]:Q$,_;^1G*S04ZWN
MTN%M!.=@6:^DZ8:@NRHV4#:=8D.B; ;I-26J(HZCA;,;]1ZQXR09/MOE6')2
M2<6:I2)*(A>:8EY74%61G,K*58AY@+)$#XMN8459'V536/./=8H.N;95(3LO
MWHXH,\8ZE.9,'[E;W4*PT/M/7+<9]Z"A6_H270*Z0!FEGC_+CPLLJOXN)2K=
MG_0,>3;EZWNA+$_54[VR]S3'*04Q@E27<4*E3;?25:3=][^"NA?N^=7VJZ6^
MK(BC"?DA9FEZ9A'1BC.0,8G+W-D6,E099V31\:].DOAL37;O(,ZP+V2_:D#+
M',QH^#F&GM\W*RZY@ICWC$ ,?+"2N@?BNZL%#]715!BWN%D/$M^K)F6?*/ W
M2+QKN&XU1S1OWZ[M?[P=8I B@2-S?N?H($2.'"/S[+JG6R&*.?O>V]21JJ_M
MZOH)#ZX"*_YU5:?QN$8\).N@R+=S(3#V+IG<EK<2O,IGB #Z9J.%NT2$33M9
M(P8%/N[R8>Z#J#*K@6Y0K2FW<L'TNSBVID3/M%\R7?9"A5UY9X2!O&9*^.4K
MJ+2%,@_.;6%D^Z\F" ^#8=:AH=< _>[;Q=VCZ)'?=(4P*SG,MOS1@^%+VXPK
MM4%*LWWSOHOT;[HIPF^Z1?%[^*SG(24@WR['R,:E@,L:WUN&>65]OH*]9_LF
M/?]4,!LZBI&TW]^)U?X5VV$[L>4TNV1$+Y"@9+,_PU&\=YUUZK*P/58_J[O?
MNO@<5W-K_)*#C2IWC"NK*!8SG8@;+GPHUC0YM;N_JJ1 SH$"/*JAUN[\1XCB
M9:VB?3VMYP4E:!RU&ZJ5"B<EJO(,5[&'%@O(]0=V%TOQ(;@R <"JSI2% Q'=
M7D+R+P4H &W2/B+);UO-JL-DY ?3].5H-!;%AJ&)]Y!N0T!:^8C3V(@;N+[G
M=K0T;!G 0X@U8G!C"@AW, R ;8O8D*>C4["&LA,Y"(*2IZ9:)MJ1'\/EG6R2
M; #@!.F/3[EDSGGE#,*1/'R#A!VS\8#X7#[IC(X^RCN">(#@Q;M-@:GZBY/G
MJOT]OI/J QXU5145$^G"_!M'</F*9%B@VE1A$VU;;;9'>&ZP"7NW6[)61.OQ
M1%QJ0;;8" (LTA58;\^* 3ZO@#?U<LW[@AM&%<EJ]=T5,@WFI<-9=5@?E:1E
M2 T[ 3@6'Z!PXC")2I=)> 1ER9_KSXBT*3QEP/O>4D@I;/%5J'GLM"6C4,0P
M<_39;5[&P\[L\P1PEB@H"CP;Y)8K54VRF0_\9-,T.%5]@-O'Y TFL&2F,4T-
M?I+0U,H>HP?*G8LX7(DHJZD8=%PR>[4.!)/KIR\S,>'),VJ1LWF^UB2SB&&\
M<S6>FX./.ZJ0.5X^ZP!F_[\S^-FJL,<K_1CFM!U+9%S>&J^IVI]](52T-<%>
M;$9 &'8WK596)VF/\M33]@-M$GVSEH$&QC/&)6=7EJ:A!Q?GL*##>VYE\EG9
MD+^**R=M ,!QG2-V_IY-+0*1_TJXG&/-._"._ZIM"^+3@LV46-3XV2)\J5'G
MU#G%<K+6(%"$4/WKF96 _PNH<8LY&4&?]I$E2)P*T$<*:%K.\<.0.]])MB=.
MYU'E[J,XPZ@.[B,7 2[>!P\,1"0%Z^5_[FL6-$9110ALI%<?T(FNLX9MH62<
M$4]?XZE:I__PP\R62WJ3Q>O\%(VL6*MJ><_92;B\^P3^R[C$N+.RZ AR-V%X
ML4HUMT-V5.5-W;%7I&E4A;;505+ZR(9VR\A0K*>\ (:U)1\:-&_CF-$H2TJ(
MKM0YN;CI'XA&[S5S'9Z,%WI[! L3PB!?%GVE;7K[<DHM8#K;$WT.>T0)ZO;-
MCG>+N1RB4[)3.>)CF3:R%QB=A&WK%8M, ]7R89>,W+3( '!T/%?R8'QMSTN]
M6[7/YH+OR6W6O^V$0(<3\NK=D]Z+T/=P4 S>L!Y^_26SQ[O+^N3]W.A]7%]S
MR<S9R*6I>'!SE%'152N3?KI5G%RPY\$LKC>G"K@0VIAU$J"NVKETE(.Z(=>=
MCG>C64R?L)@(7Q2.<ZI+;E;M^%J7=96IELGS\L;=\\JULY,8X+$WD->J,8VO
M9QKCU,/$3JZK1_!GAKF.U2WE13%'V#QX,/^ LCDAY7VE1X9X-_RFXX)99Y2J
M;PU!.8$Q%<L*=7;M>OP5F&UW)5&BESV\\N7 'U\Q,4E%)5C.)>1@(XU5;+8W
M[SD!"2*4_JAO:XI?*HR8;^E""[2/WZ+P"-=:5-:C%0I9A;WEJK8YNR:\,OQ+
M%VG$IM7ZG0;[0Z47]N[6X;4RKK+&>@I:./*4H18.S'S L=RPU2D 2FK<GPP-
M$/*=Z C!Z+#,XO9BO0G?-]5-9"9SWIRI9!D;%!?5+IS)27AQB97#3XL#I7^,
MW56?^U="Q5%M$^MB[OO)(QA#H@ +OKR:"^8L1LJL(8AN=ZF1V<MM69;K&[]]
M[>7R;=,$.R-\T5G#8L7A9NO2,]CL[D,1C'^6Q\'A4&5"C_=@1#)(.CW35>?=
M6"1X]ZE63N ]MBU<B,_PZ7W6#E[K)L#Y^4B3UV(/^I2"#1FYIE<1"2D/A4Q)
M-D UI/]_-N;_)]F8P & 5%-S8O/@JNFOY&"GH8>UX\,]1ENQ=ONLVJ5_ X$]
MU-] 8-K\-]W/K3O>L2(>>DQ_:O(/]_$]BV;[NBZ0;L45GR!<Z*!\H,,W_?D_
M;<'E1X6$/@[12*;9(BTC)2/V3%.>/Y-!8,\-O:@,@T71"Z]W-@F;+*<-XYEQ
M"TA&[JS9^9;1? 47OGI/=M$36;_]?9MF) 9^W4BV!_F'A95DE;^9Q+L_\SL*
M?)9@TZ<H/R+F/)B%AGARI(TP6<^X#QOZ@$UB4TF@[.R HEKA<A,='E$O-?W5
M[1L#.:-<T68S8Y[A*L"*\N+2UME(#HR(4BL\GL]+.S6WEW]_$B%1YQ[XWY4\
M=_Z[DL?EORIY9OI'5:D+ZH?^?0,2'6<X,KO=VZZAEBTE@TOFCX5)H<%EC%9H
MS[1*U(.!EQUB3[I/GAIQ]84T43ZO#3:QJO+O2"F1&_LU<:/ZN3GM3[V$6XO$
M6K,\S4Q\@EZB+>M[G/7TC-@H0#;'2.6Q%2_$>49O.4XQF9 #RDA% Y%@4!KD
MYGJ7EC$<JQ69^G-:H$#"7I@@[J.;/S/I77O=%,C:?66R<:@1/QZ 3=G800UM
MJ@1XLF>/E(>,'2>X5-QX:I.,M2AT<9QLY!J7!US.Y4SGKGMY_M+@'Q5E7NY:
M1#?([*YU-2D:&GO%+! *QV?=%,?RE*RGEU4GT.PVUI.:%FV[,)%%W7E[G"20
MT:?3VAI$E9M;G92:LYMZ>/'*&W^4@N,B-5\$)X=#:7]_^:;*OHV_&+VT?\WT
M-O_<9"U7>P7@ Y#[%J3S)=0-;,9_JK[;F45*[ J 'W5RC4;8RDX<*J+?2%_L
MN'=H%>OI3^ -3SN90]XZ;R(^M@^1GN+ ?.*[9AXV)O_H5W]E 9@Y%3-;#O:4
M-!&!)K>44GT:<\\E/*F2C_=3;,00N)@UC+']Z,\=?YW"PZR#'TNVJS(<JSXV
MS0Y/:,I"YJ/7Z[N@^P'N;[NV)YL$._0DHOLVX=99!/WHGFC_2^;EXE-TW+$-
MO1@6_>%+'Y)4/P<&)#-V';HI69GEC@A%N#\.$F*W1VO^S%4IV/=ZY6ES&-J
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M[X&)S10E*'V2O.W=WV)8=ZJJK!;#83WIN-PRIG5H]\6/)C'K]\.79'?.#A+
MLCR.*Q40I"4T5;";N##OLVC \5OD^"=6-SL<I3BQ 1>3>"4_H3[V)?[8]1AR
M?\B70W#017,Y+*79WY;8KT.[OZV@S-.EJ"!&M_I:$J/!/R30Y;&U17U[0U-]
M-N VM7^-T?X1"_LU9?.&YL)]I&GE9#XTW#9 +6NP"]*@G56&!)'%&JZ!7] J
MJH8P-RE@/39F']>0N;&O=N]1^2I@1GXUHZ_\ *&;NW_XF+X).Q@4.VP>CB8G
M^6B9/POH?%OZ:[X=P,FV<DQ)0VBYXG2NLD.+-:Y\PP+%YJH:.+_!;=)+;9Z8
M;Q6M[M_!HV/H!404W%JDB?#S8)YOM7BT?M/)9I,=F*YF4SAXY8:&6K/+X:B8
MNGXG9E!FF&_ L.4^AVOQ&\_L0*V>X/PWRK)7]OYAVY:]'*_\;9^G7!9!MXZN
M6(2VSF,N3>841FDGQ?LN7BH<.T8,.1=@')HJ1ZPZZ928?V0QY2=H/Z@LM8LR
MS7<!EKODUAJ4!.C&"O Q"]N.H&KV02R\(UAKQ>N=4]]'7_ X,>82ZEV,;7X>
M4ZT,L,I/YTTJDU6GU48>[V%4XI!K.&X]CV2_#1?C<N,U'A BJS7(D!1(B*'%
MGR9I3BX!&</EGG]"D2(^5^PY@XL<)*(Z7G6 F@EDK%1>M9E@Y(?-8),"']K2
MN1L:YCL?<)%><LK.<\1FI%G:FIU/BW6_NRE\6NU-HLJV*%>\EU9\^H$00Q7/
M26TQ7A6<THNN&%US)P+$&UHS-VQ*I PY+"<1EUDH?6KX$G%L@A1:\N5?%,P@
MN(&R;RXJ!,?](K!>ZBTV1:)]EK@Y1^M,2C_$F\O.;)OW;^M\(]_0S*X,+/0.
M/5(Q;F;'FSQ?D4=^I>R2)<YE%VS"2F5J#?+"VOA)'16YV8^=&P;+RZ>&U%*4
M>')\K8T04IKW_O'#.AI-K8"%SFY:KU.U .2L1ZDB(7<O\_O<=R_F0I33(O,I
M7%OR]:$_G5!NYG-TT_(5;=/U?<(&LW4&M+#.NB-05?^%MH5TV84'3N@T^E@B
MK1$VUJN'A N:EQ_'.?'&!M1N>X8>,#"5 !GT]/2,'EY $"?>2]X0H$%]$3>)
M>\^YG-[+@F!.-!^>VGR,<M,7E8B!"Q1]OZ'QB76:*V/R:620&_S\'E^)PZ6S
MFE$:9-;:M80(8XR0QPV%QK<")Y;SW2*;@_F_9(4)F<)PZ7J%.6ESXQBIBKD8
M).\BJSF ,>MC5(\Q2XQ&&DP1;EQ"3K7$Y]S>GTUF,$RE"S0DWM_/S&(A3(6:
MM>Q4GVRVL-U&Q768!D$=&W97"H<:^!K;8^&_FVD]H5.2/EY/Y(XU\3)253'&
M$"B^,);)3(D+34-!J:G)PLV:T_'9PDI+!IZXIV52RG"VX=5)%]2:3 ID0ELQ
M[:5^SS<B7CULW;5)O(U4X%)G(I0P;.=N?T#E:TULE2\SQ]H0@0XI5XI"ZVJU
ML2Y<H*E<0*P*1(_E2V24>WDYM-S1UQ=HB$,)V_.A6Q=R>')$[O\6@W5V=K-Q
MNR\OJX9$RRX]16N$[(@TBRP3W#+]=0SI_BUJ:C3<11\51OT)7RI.ATP@>5]6
MAZSI^H]1@2M87W;L9$\;IU?.;8*9:& )=WDYF+M5YVCLR);KREP1U'YHV=-?
MS9)8_VT5:F6*K4H*"PI\]*C/0U?W?B?NW>#6N*:DIH=%P/G5A/+VM2?!NRFT
M=,*/R^+[:D#K-:%Z%ZB(Y5@RS4HHJA8'49(<2_F,<0.4UCA;(;W'1FP$[8?N
M(B0%=_<BN2"]CV%;.&V?AV<.!Y"FPJ3UIJ!.53&10PXN&'P)XK^RD#C5DU7Y
M1/#[!C,MZ&F9EVZBYFF9DG39A_%N4FF#B: ZZV,KJIP&PX'BKA=5;*#LH-$;
M KYU3TN7%1J++6C)UG 2\8888A0;,,Q/.]%RT?\.\;+C+MUX='+W[,!HJE 4
M)B3S3,&"*95928N#X<M*XRNV1)/Z^C-W8TB>ZP9]*5UCUP]?W7N;1LP&L:;]
M-1;K*#[^HJJ5RO'D"C_I&G!8A]4CO775>5'!.7R1LYY^8PJ07[O'[94;@+D>
MS%[+%.8Q%S?UU+:R,\UJ16$! \O^A]L\<^F>B+MH:9WM/N@R_10HM"@D'K!Z
M__1"1IS^18+'2>43LX2>42H=SM7/%B-T+FZY9+S->P:[, B0T6G9G+'7JRBP
M^F?$7/VJM'.[GOOCCSD:(@4,C^[?8IQZ^F,*"7,[>953WWCEW.I?'BH\A2X
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M7$"/*9>KYFW"Y06K?B8K*:G"&U-Z<?,D(\M1O^%\2^M?9/MUM:9>E[L,2U/
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M\2A$EVTDJV2VN\>6:&+K?4?Y>H37BJ+F%,!9NTXIP3UZ/K_]V3<4F#K6O?6
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M)DZ&Z(@)%XF ,A,A5INZ7*\6AD"V[@:9\;E#;T>=0)-4!L$N0*[XNYYO1,F
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M0C8VRQW",\:)%G8XN/Y[DG1\B6E\T:V!9[XIOGIW<'JRL2$<,]&G=.L2%!*
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M6&)TL)]\!=#M$506\^QX+/MM:6BUCKY!.1$.NN-GY:?DHZK^0<4@IW [,W]
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M4^,B]<4158;%N6)#?8EI2.^I$=1( [>_-^N=__08/L38U[VV<?*M&C[OQLG
M1D8RR[NO7OPB4QLJZ1!/C8K'W-&4;V->/O>FRP9@[F66N3H8ZQ2>^Q1*"X^[
MSL_Z_'NR:565][,Q%6@Y>>>E]_OS8ZLS'EB*(JP &Z\G9J"3W M@JC7IG%/2
MI 7"!GUY2@P 63V>%Z_/>:5T=BW;&%)<9!.G<<A=$PE,VWA2(($G26=E+35@
M+G V%4A80Q(LG^ <,:ZY'\4TA]2S1W(N;%>S#LL?T'S_<_4XW=2+F:22<3_
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M$OW(2GL]>P^/F">8ZW#)PB5'\,%ZTVLMY<'Y/UN5/0/A,[2C^> B+B$_ J&
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M W%M*TD4G$Y[J1,#__7%0+XQ:%[R@1_P-QUWMWPO'=R+I7P>%"*J. MX3OK
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MU@E\PPBK72E=]O>Q>19[NP4FON[Z$)9[%;"LY[C-"R8NJUH@P'54*?Q[9::
M/3VG3GS]Y>&.5@5]3]-HY!,M+$6>\S2]1TE>?PSMD)F/)7&):J\MSUPP5:I.
MB95'32N5W/\TX<B]M0JB/-';"5[I, SRU"OX07IK\]M4]#"T[*&6U'[_A,RO
M5@C-5S/21O2KRI\)M$F%A.C+<35=3GNW*<C>R8^<8F*VNOV.'FF+Z8I)'.^;
M1$SU\]1VW8]SBZ13) .QTMBM>72WN,],$1Y3Z2GF<OX*,1[D2/C!7^JG'>$[
M>\PI\3A[)F%5)N)EOYS*/7U+Z1>?A[_V>-D(BAP3^RMLVJ6"._:)(DZ;AS\B
MGK:G,;_;3S:A0\XW3,NJ*%[K(NF#:=)WR&IJ?#8W;[Y>\FPYQ6/\2:R^)+EE
M>4U/DY1=;'#0E^+N;X'F)15TP)R)(()01XD6BT\.-B<*VA(L8M;L]$UC3=^A
M#08S(KE>:Y08*Z([RC6NB5!U\[TU[0LB"D*GEY_V-0_8?M7' E=!;39%@BZV
M%TS8U<0:NYV>X(U?UZ;/^%0REI39G^+.]DPZ$96!]AL\FD3!1['70_]?T=FG
M_XK.OEWX5W0V--1N7Y^V(7ODN[^8.\>@'O+ZTVK6 1KK*7Z]OK:99ZM2DO"%
M07. >? GV3\\EX,DB(XQ*96K+A[/H;>_#BU9>$M[B4]2'OD;&0_'M6(_I5M8
MCID22L0'2N=^$+P 7,.MK VVOE.6:2?L\\^UM]J&Y"KWA[OWQ5Q*&"<I\VN^
M"W3(96(ZO1<)Z9DC^\6G9:]F6G%.K,H/ZKY,UEU *<9XT1 ;]?8$D^$BFC5B
M )CK7-;GCN4XWY!NG5W6O.04EJDQ7L-@G0H4&(:_'\-Z\-VN<W*#6H?6>(#S
M'"Z86#RRKN6 ;SVD09,ED?3GY#INB/L.T*&U^W#MT1*T)%UW,'-4N]@&!K@>
M!Z&?D"M18A37:QC]C 3E0JE5T&O-MS]FE]T;[O*+MM^_8/KOF/I9Y7]B:M'_
MRM8^T^*$;SQ=U-I-_!JA;1U@["IPF!BS4-D0C%C4L@F/$I$-G=G_C3'0$!<A
MM70G#?\%V.HLKR[ *D'0'H/H"$LV]4\J1(!M$J*BY(9(0%240\T]*=U2#)MU
MJ@AL0JX'9YLHIF46[>RC)7LV,)@W>I+=7"^.[QU"N/G@<,3A66& &T,_=!+N
M,7L^%N16W.T^H?A5O6FQ,XM9"94]PL;]U>+TL1*+]OT2_\(XYIO!-^LDL(DM
MY54?2+,KB0Y*E0K"/-MX?K]8$+K%"A6LENY;G9]V;;;@(=8&\?3OB/]G/M>8
MFGO(?NS=*Y-#FC%?UCD3:K5U ?:1JI$]JE7IKZ8#6?H\_0RXXB=O;)LW[#V9
MRCZ]TO"A2,0 ##NSEZ1DP<.>@Q\F)/$LU!GI&^0)V,XJ3+]%RA03#YC/SCKK
M/,6L-I+[!V%<3CNV\&GA21&D_QP\]X#,  ,W_#"YBZK=98NJX)_GKIEN##*G
M4W]$+YRYK[EWT++%?J_QJI_9EH54!$=BB[UOH(H.*<BL8]97\>Y'Y$?+N#:<
M.15EV"#L$&B;X,XN(U7IS<4B4R2][&_9YY1^O3214R!U0'I6/6TA?[7N]@3^
M&SP00?\@TN*H2-N_KPB4 :6/B-VH 7.S=/-(-Y3/>EF4]7@E2/9<6JOGK%1^
M1FCGM3313E#[8[2X(DIEU9L4\]37WW8%!;"U,FF]X:.O8R0MY_-S1 K6<VY]
M\[.B>IQ<;D^T95RRVA\IIO$+8O!=8;X@X31G%\FJ1Z-"HPHQV^%$BJY(>H=F
M\:NI6)QGE?)'DJXY9'83(78 =]X)Q@4!]$9 Y.SV@)&F^G4N.^'BVG\;!=XX
MA4"'_MQ0SUP&2=Z>D]GOKY &)@-X);>&YAC2R6MFP]U(>%*BXT3'GAF4HSOO
M3EE::$OX8MR/\1UN[\D.<K\18K\S!]4K/:)S+70Q8M'7D=>5PEQO*6MLFHSQ
MWGH::@,:/D[M,OV!>X#)2CA'WVY:C9.YL5Z [X3M1L31ZY-[28*^CP42"YV8
MU8X,\1N(&_I.1^RF7X>VOZS/4T=,8Z=T,K%TX;1M]6''X@7<PP0TG_<%TZ=8
M:)(! #*5X*>[RK:#,&_/FF'09KZO"YDDEU:.A9PK%SK?/VW5O&#2W&D>B,N+
M*"9_2(+ 1PK>-SS1DCLX\[9&5%XPY5LUAW"Y7# MS;0U/ZPME K>*,M77T_!
MW KIW_MTS!YZ=+!UL!=<<IZ.Z(AXKAXC03P@:EDENOT!V @?V:,=WX/]<O1J
M*"HC8\/UP6>DMA8))U>SP=:HOUK),PS8Y^#JW\(X]-2+S8D]$:)F>_W'K2)(
M\E^WBF-/I,/EBWWQ?P1A) AQ %6Q#W2GV"%+7K[L#I8!6?SR+%0DP  L!..
MY(4+<=W(&7:=Q='<IK1@K52-#O>(V6[$YED7(G)32X==+WYQZ"-=LU^_(9S?
M-C5L<.O4I>R =R+:RSP?=_#;A' &WE)-JY71/3YEJ]^--!=QGX^:#/^$- /I
MF!I^*NLBZX7+K;/,[>E96^C7)&!.+>(""MK/QHP2'/<3$ =QZV/NBJRF)<&V
MX_:=F.G!MJ5)(+,FN]TC"754NTF1ZMXS39:,<0F2+][?U%H]W$&*SU+WVCQ^
MHG>TA_]K\&7'WSLZHPIRZFP]'M]94(WOT&]R+7@8'^#IX05UKWL?._3$]##F
M>_;WSJ0HM7WPJXZ#_!-,%,[8-B8_^>S_(_@9\*_@)P=^XX)I"T8Z_?:GES6)
MIFUE^A4ZKOEHH=WU35!Y(90[3,!.U'Y$[@Y#B_;3:,;5JGKV'D&'NBW;3]X(
M?L]Q"(#^T0A9(+PP9;"U([9WP#[(Z3DYM+$9EF<C7UHF,?IJ_RRL=O,[.#'[
M1(Y!(NESSB[@INM ?Z$-]9-T*YP5)=.P:L$O8)5TPDG3/<FH@K2HYB?^Q1C8
MJS.KT5V[2Z/S#29U'ZV&%CF/8;"QGLM0WIX(,Y1(,C4*@"/8I%0'-4^C LD%
MKK)UFG_,K^<PORUQD[2FE[>?P*_><16&EP1FTQ"\P@[/Y4[0-2)/JRS3\"V5
M@!D">YY +G3L>ZV%:6QG8C3.C]@KO<XS5[JO=7DYT>HM^O42B"88,';!%$JN
M](WVR>2Y/2,Z00A:]1@;E\26C"@#(^Y"+U?/L+H24W2-^8C71%$B"4XI1MG7
MS-"KOV,I5[TAI@57G7W8>O0S)\<[9GG8TW%B:%R14NV2!-/5'*WLZ-,G#>03
M!8^",P-C.\<-O7!Q)LJY$6;0-I(K?#OA@BEJPTW+4>>,S>,WKY/I0 T'UPQX
M2R*VLQH<MY5=-N7J2ZZ=3!)<&^<3R\(8=7>Q*I)!\.Z>#]I BR35=3P,'W.[
M>Z&05"8$,*-:YPRAZ-+]+Z>>A_[G5UEQ:H%1H6XI!P[-6I )5X5\R3D4P_PZ
MV9H]+%+2^"L9=HR"E 1_.>(WZM3V3P1<_5)YXFS.4&2XQT6G[MQ^Y=?[# 2<
M!JJ/-DRY(EK5N8'PFUB=]Y_F2LKW]8:Z36>P5W@?Z(IX^9NW/QO[ZN2]4!3F
MWBFD6O8.(VE@V2F@/.[$"_0-C:\8*>*#A00_D!*<$TWL&MCNFUG>9DDC5C9X
M2\\]F"(R_&WBO477,A?K.27PZ!B_T1,[GKS;-L/3QY/F/=D*&Z+1K.M"NO]W
M-#EUI6^OV(?/:1X@82?,VXG?-0/62E8(6QD>=*U?=K,69%J_/X6F']94KV]]
M<4RJ?G_/-8:RU2Y-B4=J'V9B?YZ3?BA34]/3-\[@H9+9IGZD%&(/1!4>URE[
M?4U.=Y%[X>B"B35\[?RKQ073/Y,O,YS/=U #.Y:_]&D:_^N%26U#'+GG$\8P
M%AT$#'YCP]31Z!,^)>/HNJ[ I_<QLV%(L,2IF9F9G2Y_+_#(I+3A6<9\A-C
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M)>J"J7%-<GG&;&_4%9] \3<2H9D)&$ZGAK-/ 9]B* AC[H*);9+[FTUQ7,_
MR9V@9ZWKB8TX^HDR95U=S/,TT@Y9U9 O@61S[%;7H9,[AM<,-<<W1CXR'ZR#
MW)X[1P1IC>BEL=ZR7=!9#0O':;%X0F'*UR1ZV(ENT.I^:$UC797G>(]SSXT
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MAG[_IV-UW$68Y>V7+U:WD/@/[:#8;E6AJ-^R)U>E-P%)&X$73(#:-'=I#MY
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M;5%N@<DT9N]5JJB\H@.7&$&67'0MQ0*+!JV@UGO))>+7$55S9S!V<9R5O7&
MF/(C!4S[G0#W.:/W2944M>@S.1HNNV$K%P A-/"TNE$ESJ':C>]G#RDJW6LI
M;AZ6&%Z1A\E%E;[:J,P\6Z'5K*!RG3"VNID0Q#[TWG!3>9V;+S"G2.@&I]3U
M'5IUS)1@+1;U8#N0FXIDJ]K08G&R26B@&V4ZPC'/&5X>$^VI4N[81L=2#UQ@
M1-]?JGTWGSIT0!JFWX?TPX5_XJ0JC*FC7B2EEWV\HL/^%<OJ$OX;GINH/2XF
M6>D!'!C,X\#&Y-H[ZH>Z:9]F"MBPWM\Q !N5Y[\>V22IP52!-$6$O&'4?*7U
MIF^PW2^T,ZLU*--B)S%P&FM;)_#P;9_CWKYON&),JS]+:J?S4KR%EL<ME@XX
M:/(0VV-J(XNV3RU2:G?9YPLHP/:@4.)B^T6F$!"J@E><44F+Y:\V"57_W0]E
M_Z_V+!/1^HG]T8GW8=L7_UCFU5.F=0S-]@"Y8S!MR4^<])P3GY-#0'M5(Q#1
M5@<5EXT1LAB'8:1V9_A6[%B?M(5X>J5G:N ND'/3454_;O W&+L:*$:I[(F2
MNY%.>/?E[K*YK#B'W6AQN9ZYV6,(RC<-,SQ_J#<4Y=&*CWIW10=V6,BSOJSM
M61X?M#D-^ZD*5Y_K3 "(*:-[6PV:6 =*:]O/*J)WC22NZ("@M67)"_6H[OV"
M]0?K/>XG1]-\9/26PX\K.C+Q1"0C"B5SX)]QF=>Z$&9\  M<J#T_V[Q+LSQ"
M;T?1P.>I?9H3GTX;^Z*,'';5'YUV->T"(R..Z ^19\1CS4/LI>YB_OJ+"-O%
MUA+T"6]:!,@N5%)3X^S=F?G%^CG?&?"*3G!WZ*!8H])O=I1XGJ2G@:ELSLC/
MCVB[*+\\N+Q[@8I*"74['>6S5/9>7;_4*>*S(MKK&PVU_+@<C_J9%OWE1&N/
M6LV%>Q(24;]_<$4G,))4 48+E2S/^OR?H"#\*Q+_!.*?0/P3B'\"\4\@_@G$
M/X'X_S00C/N[A/-7&BNXZ:W8]]!7"_9\/]1M#!9FRXWJY,@6FA]_D$K/^N8E
MSSYB+OLS55M=,09'%I:F;SGQ$.LP8LHS[^A+]KJA_$USN&G:>/^C":18VJ&/
MD1L]5HE@>$O]!<X9NNJ;XYI6??+]O8 I6"\5XOG-9#SVZ2]3VHJRO_YW"\C_
MH 5"EI6]K4>">5+>!R[AT1Y3-_W2+$B"Z4+U<1U3K?:JQNV2H?EV>Y;/PF2U
ME8'(X>Z6M#/6Q)1P"<6W'46HNUTOM_+&UP(+Y_-&4U39D%\/7&']O^X[C\HJ
MBIM/KRWH\*L.C[.JI(BD3@G!QPV;]@M5N-JAHH\:1MI:1,.<-IU]/OWM_SV^
MOSSONZ)+_#RK;D,4U^E4+Y$(I%F]B;_@^L2ZUNT:#K$4#QTOK33S+OG"'R@(
M%JD#\Y3G!JX^#SB*.93U-2YZ&VZRWTE\S+[4^Z,J2Y\Q+D/6*A%R0KJM7%4-
M3IO#B#N!9P6F6!SX"XQM%Y\=E[?>A^/O_N*$Y6[<_K^+Y;I;,&D)3;ZB<PI9
MGXRH43W06DKRZU00>%^;@'4C-5O,A=>B-I4M%;JDGW[K&88'9*H%%\8\2T&I
M/H^/LX:X %>IK-$:BLBRKI?V2PH3QN?4KI+K%JT-3=)E<1A\VMX$M/%RHL$_
MO\Y36,!FP"^FT1]4_Z9-8Z&A^1DXOV^X2+OYY%9)O?OVRQ)F?;GT.'F*2)U2
M]@(,KW@__<%(89Z8]"]?R#4-]=&N5?[Q(;Y.D(<CP?\'N);> \L#K0V77W'O
MOROEQ,I7WB,%#B!CJL[C/N)ZPBA'60-/L[N]SI:P *!%H)?NZ&M" H3''D<F
M3*28I>^*=:,LL)E@AMN*9H@U9>&BF$2ES <NL0H#4A+BVKFL])PZ/*([V*_#
M]927$<=^6U'GK#W<N?UARUSKUC3-#,CKD%Z$VP?2]F3<SF_NI\5?^Q21--68
MY2#;E)G!_O'P(/Z$<4#<VOGS996\RXE<E/EM2"T5CE":9=:R-X=:G%+,P8_*
M1+$%W(_;--B.>^XLM03__>.6+Y*$_:,>@A'>A2#N;K>!#8L9]J9*/6(3MRL?
MEX6J<OBE4Y^ 7Z<>#,JVJ-UHS96,'$G)54EWP1@H\K>@@ &OULQ3$MD9!**J
MM@"YT-;+A<986$-KTB983:OS/,+2L0.28UL^,Q78;T,6G1LYJZJMT$T8/S@<
M3=&*KTVQ;91%"J7HK<]7I&=:R&(+. >H)D8F8[7W%:S35==&H^^/*PD5;5.3
MZ'\9'EUEWG_)_OM_*F7_\^U7Y!YT VV_55^'%_AP:+ L1]@/I/A.-/)*#-YE
MT9'S&FC6CNX)ZP_I$9NML>!8'V":%43R*]O"H\M&"])-IK*]+X84V=;5L'4E
M@285X_2W>MJ$!-<@3JDA);H2*M(?< NX-RZ#@+%J_;/XNC%WT\"QLM*Z:5OW
M#:PD!\"\1<U$//D"4?GH^,4NWRZ+S26'A.92B?)%,F1C=/]]_CER<YFF/ZNL
MWZ!9D][)=ROOZ>43<%3[M?.Q9<UJ27QVY,>H](CIBS+HLF@P_:%?0\&<7'=4
MMX'W\:NH;,3RH59]C='(W5TT+A\K';XH]>-RT/)^N'#HW9-;J"NZ.W?W3!&7
MW76'[J=_7)H?^1\6;2&*IOE(O?-)[X<>7M$]!+3.O;GT\,\GL5$&-)]K]K9L
M1H[A]])P[\Z4;8VWLQ8T%X3KSQ]K#ACZG_%/D4I6Z4\L9X;(F2U^F3[D.SKS
M!3X31BP)/:K-3 ;1I#N!XH-QS:!R/+]-X)<J3 '1V:.1HSI@?5AE7\[581!V
M0(MF( %-$I'&[[?)J>U>8E:@V)O"3/VAU;V>_K</C1L:TUY/(%BVV%29?0F,
M<&X9^=D6Z<ZU><IP ,]3_\[@AZV;HYY34?BX1\[RL& &UN?XA)3>,U3J1-]L
M 'KGI78(*\H0ODX<_MZ%V+@HD(OTDD7:=HU*U#7E=K87CZT9WA*BES U#L%S
M<+9O7!Q:S[2$'L&/!%L'I"O<R=9^:V9S>@6IBXY&+F6/"JLRE/9_[3[G4;'<
M@]5>T:7L:&:\RM\C-K=62415F._'3$;M9#7,4L*G3O&M 9%,N>(G7>2HGI#\
M/KYE=&C4*ZLK.BOD*OT5'6<.[.)G8T).'>G\6!UI14!*SC/CSC&784>9AS>2
M#N);/O[W.=*=H>9W.LW-K"<%J%.\:"?2/ K48H\SLX;C!J(EAI4SB%N(NSF-
M6G41+V+86]E0H8,$5FH?K.2&<7E_]*^)0BQ86#=OK'P+MD@#*Y7UE#;54A7O
M;X]D3-S:S@OQUI'/4MC:4@!]'&EL+#/L.IV?,=@0$=*N6"V3_S+B9]Q9N._T
MA "E6#ZP=(\@>(5S?EB,*/'_7$X]$,=X*DO<%&'QHM89V-S#Z/4\,J_WX["Q
M>)'=,:[+,Z\=DOD%_6Q@JGRQ65E2;:+R_K*)J8VH4T8_(K"^/4:006:&2U4_
M4SL=6,DA4N+&HRX(>W&6$CB[AP-<7M/9[6'OP%P(K$>,O%L:;UT5F7BZJ4N,
M&MP@'C/R]?$Q$_:34$<Z \BH$:.*V.G4RBNZ7!)Z^X%FAH90TBJ?S692CL45
M76&^]=U&$;LK.M4:AQ_R41+A^GPC&O4S? H_V::K4<WG9XB[#'9M_?KZTNHX
M0[,PPKM) V)SF1+A#.%SH5@UN07:]>W4_[+8:.0VNG.VW,H7X!FRP20N[L^S
MY? 'N5X);\"@4-:FV;1,M+G6;*+XC63>,VY\SY-KB-.9DR><G&HNH@_Z%?L6
M:OZ0T7T; AH3EU T'%S;O"]F7OI9(M"3^EGQ6S[[/47<UGRESV;.E\V<</7I
M7;N30 ,C$(F_0.2!QW<=OQ>\O$O&Z8*YN/OPZ P><PZT=B,P@?CE_"F;]=Z;
MT,!@/=+4B%[1<P)/V6MRBM6!C""K,K[WLZ&)>:6,+MYG_[WBY6T#EI.IJ:AN
M#N\984-RYE/4D3[[ )?TR/AYWH_S^]DB>_5U5W0?'\\V:8\U\?Q$X#4I,@.]
M<$3_HW!8,Q=??_XFYF)$H>C[>L3PGG;?/C9*I$'SAG#<.8W6NG!'<3,9*Q7[
M$^UL!8<BY(EZV[&HO-&R-^2*[G?'U@!868#*;$#X</6%I$//YMTVW2]1JE#O
MDVN,9X40_<\39P5+L,Q5CTLCGV2OX2CV:_'03U1/RE'*IO]'K/*.:I>^B:L*
M_!UJD3];C(,'+#M5B='PRB$))@VI )P QLSR]BUY<;<H!K3&;O1G=\-$,6VS
MM!T(RB_-9WC^4+\(/N]2+Y^KEXXL+HJ!Y0D=HQ/)41L(GZ%VEM26\5/TJ"C?
M*0&_ZV$?IN4V3C$_!<.;U1_^RCVU:/395UK:SXC3?#$7![!Y.KUW6L$)YI
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M@GE+(,A7\OVT,"5:*$;=C+Q>[?KI\'F7+M>4H!\ #9I<\.<E\"NC0=GE1,"
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MWQN%-68< HCS9>Y]:Y7/ED)( @7!AJ6+WEKB%G8A$R,QB4K4&<F1@=WC@=%
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M"3F\53L_:$&%>PT#+@WG(7TW6E_;&!@%O3J$!%&]0)O:Q";1'U&?,T2=1:U
MGVLLVOEK+()41 N<8?XF4TJ&"(1P=LH/:?FU)Q6L>A"]NZ;:,IL@7"3E3&WL
ML<VR;_.; ]5Q!;L4=9U;Z4=E.!J%-NG2Y>PO0[UH_[)NHZ%7G\ 5AQ%!97/\
M,+*<LSQ&3*!='K!Z"<YI@00Q$YG>U\J7UJ(+6?7C/-N: 8HE#K^$:XO]B)*-
M[,9E')U>\BY7"/OELZ\;;W*_RR !(J[H8(]5BC&21<59%77M/:=Y.>]B$B3X
M"Z8SN#$E!/4'L[J#J-P!;N7GM0O;0%-"!8GH'>4>4+AB +B1\'V")Z !=G/!
MNTMH]V(X"$S>9,I7W<7JR?;<IB'\_P0;KRL4Q:USC20B8EM?<^)D0I+#98OX
M3 4BE>'^YJP>G]-F#)7PG_:Y1B=??$;F6YED] <M#\</D\"\GQ_:?3EY&X2F
M'&J*B/SB)Q$*2?V+L1^7".^&U9G*X!7=&P(44VN=5H->N*=>%!,P^E<X'IY!
M>^1<<]^DCWOK0%?7?@)?<[[6IL'S&EV'KVLVF.I1P*(, GGS*@L">OU*=\/Z
M?B9>G=^B&.79:VA1-"(#,S++3#QS0S+EG+\<CPS:CI)=^Q@:8E3LO%A*O%Q5
M_4ZKJ;'34\<U\+[H<!_HUG$)'+"_:?5S*XN('\;WV5B-R<B0!YP%K(<_]OCN
M=,)*)#!GY?UWPM1H!=[ >1OY@B3W )+1SV/ISMBT:VR7.:*OS_]6LTMK0_2D
MJ%-5>S-(3/1C2GZ+KM(5'9QX&YLE]\7+^O>$3.=)?+[<@Q0 \@]) >X/*\!+
ME-X57;Q4%8$#U)FP^0HXL6VEO#%GZL83(J$2MK,!^BZ45,>TIPK>XK+ 8(-.
M>I4,*&I@\-D<T;RN"E>,!'R87-*J=C\I?;2,^=YDJ?((=9KY'2MH(N2^I*W<
M\P>0@FVN\^BL'%V57?<.] YD;&(VL4L?!0[7TNM2M&),!^O[Q!GRNM<Y-18O
M!A =B[0?U?<C"^R^&FR&HQA20+3Q(X-(L0Q$2_F"H1LL144Q8 UNL6^"=2'"
M((]^:D?UD1F)6>G$&4735J,["BYHRQ]9UYJ-Y".'H ^[H9.+M/6'60O114Q:
M2DBXC 3YJ.$UN4RHUT*V2C^8M7)=]V.< +"_=^%UCV,J00(2(+;*U47IG5\$
M&00CO)]<S A4;\G45@\#[2XY-E#2FX$^ )OH*SH.^KZ]S$,R,,94J+=97,&P
M_S[F9--E#+!A6*:.Y!7NY&D^3&WR3O?Q">O0;AG4F0X4V.%OL:CO6-@L2Y\Q
MA8^0,G57-PI-O@]NB/>!./]H_68EU021JKS^(5B1@H;P_+E26W\9M,@MC($-
M$#,@.HQ)!U-L4\W=O2VK<$E-ZV^RFT:2]M[<+P*WKH?T5N8)85U_I22)OIZ:
M:,CH?%1W'))ID'[$;G%8M2C>HZW^+V>B[R_'A(@WK@IBQR_@V.G(,ECV%+*G
M?OEXRP!3.19='<)\$4]N%=[( 96KM_+&L4E9GVNRR0=WI:,?-1EW*BEV)A"J
M4S8RNI</F?/ZIO1A*)Z8V5<YAA*+7DI+-!:'A4WAZ2J;P^C:L2/7NZY$+X4E
MC04(]$L>_2FG4\:3]!@5+H"GK#C #?0E6^$Y$2!9\WZUYYM[F=0O>X:%8FUF
MQ6-_'L@[L\1UQ[6LJ*U!?Z.YN7>O9 TL.RW"EF\)IA\R.KQ__.EBX)@+8U5B
M_\+5R+7/+1#&VAC"UM'GA+"VAI@&ZA;4<,N%?2JJ_)QI9PD?T9,)E]:9V6";
MJB#W3ABRI*9KM;$FK*]8[7,1JAQ;),X=C:3M=88FVMPJ_?F89&=BS-^I]H;=
ME'G,6V>U$&!8$PQ7H&C_G.JC (P*^+?.^U[)/ )9S!K:06:]E3\P-K*K&FLZ
M!MR'WY!MC7]0C_H&#(K&OV;/>+L0%2681#S&Y(X-D%9#P^]$WDX>-*.XE^@!
ML.I9'L\8$9G$O E- >UV=J10C$[7_OZ7,B_WSHT>^>%@ UU1K1(V1\-%7,4/
MC:%]6R.A(]:6""-YQ-+44^W.)?SZ)M2[J0Z1QZ>>7Y1PZ 6KW""]5H\4L<9+
MHU-N6GB7;C<]@U+!9X^^(WTEX\4YA>"UM8$^5!4OJ5+@'V8-&?U<[:9A 2W7
MC[/BE*[U)U5'KDAL 7ZNES)0,=_B\HO9"#QB+/0N?)M<5W3G<CE?/7W(S^)S
MJ:,383QU5"ZE/4.8'[\RP=^H*D:V?=F>#N<RNE&DYF!<4TFY'%D'?\Q3%6?_
M7*&R^D"D-S]1<G&O:TH+#Z:7EMOC-G/+QL)RXO=?W,]N&K)+OW RPW?GH'GM
M>OY:HW=,4O<8M4Q_!:4F#ZN("I:5I-L-JAJYJBN65&5IV:A7%4FF+6JROEZO
MPZPY0:[HW%I>S^0%XY(-'#XH]AW#=8[N9 G-MVAU%)?@#?3P2I64'-9K4BX
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MF#-+L3/PQL::O3?JW*!AS]LH*/BK/BHSY?.45X$_V'K#],B<WH^-RCAC^:Q
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M)&6>*ME$,/NRG19"O+VI4;9Z[5MX?9D_\9YOJ_SKC(CQ,K^@G#?35?%''6<
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MG%K'QE,="4N8@=H\WNHSE1N&>3?6]1&C\'XQ- .WV@@N6-R@/(UKBXU12B)
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MQ+:>=F&*VOR?M*_!F^Z';.D:WL'E3C5"/E(\P>$T!>44:M6K('\_RXC?D\-
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M10EKP;[ )\NM:XK/^@,7E YQZ^A@/[V1&QK)M-C83#CPF#W$[OY;?TAA1D"
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M-[2]5R2"3'\>$Z>)6PP/$;Z9L0*Y^X^W:U@"ADO/CG%SGJ&Y_BJL4(-=+V7
MRGE8O![QV&.VJ+^M]B4:?)J+.8]=(#LQ1@C#=@#7A9U&$CD@+F(R&R7D^"*;
MWN-L=)W.W3C19\MNL:_@AJ9_;.@$+P^>QYGED+7$5RN]V ')#LFF*.C3A5F7
M(6-J@1]C3M*H#FJDCU_!_C5@FC73*;E35'71,Z>Q!DT4#>5@XK#AJLNVE;K[
M8GYWJC=+G^2[,S'=^RBNBT/_CTO[PH,0JVS!E:C%TZR@'P=,#LERG.G!JQ$#
ML#18+L;'4N0TU\(F&)BBF%PXILQ?E'RO3B^*!43VB8KE2-BQY?,U79,[?@H'
MNM_&/.":U^Q@#H"R 'N@LJ(@#K;G>E H;$:)3!B>?]\Y&,QN-,EC6?315\X^
MH?BTZ#>;0SK&+_1A(6&:_(.I876V*09%:7YCD;I<TB2.8.\9X=J/X1Z+Y/_*
M"9SD_IT3F/WGL[ID?'_IQ;%B^A5SD/>6PZ?A#N(2Y5<CL*+ZXV55O4<UL:]7
M)(3X3]'145#:&YKBO:8K4?]_XQVZ(DMPC[S2^'_Y6"V >\#O@[9/G7N0D?K+
M3QG!G[DZ.3?3!J I:7P[4S\*K  W-(Q&D5S)787YC=Z HOAVEU$BM5K5?\0Y
M_5J,:SRVGVHXIH31$$PJRUP(T15<?H8;-*L*EU1[X-MK/6C:-YDSFB=HCU *
MGL^L/RUZ\D?G-OX?BJ.P,9. =Y@RB><EBT.:@"HFS%3\KORB>/"'N>?*6N)=
M_I:C!#E1L9:%Y'+;W]*@6?T+:4E#%*I#W5?4J'WI.#2JNEXW*:S:7VM=N22W
M(G4]-T3U(42@,+.B'$7D.YEL\U:A1 >PZ IQL>? 4T(NRCZGFI??T* "5Q(8
MPW8Z?D],ER]>@ %O4Q0!K9;,Q0%'@U)A6-.U%SL)_0%%BZ1450)B'O:@8CMM
M/E*V+!"C:D^/U&OSI&:V!Y*:6E2N<HHJ@^:NW]JX[:5R7)!6(^,AH35MJYL7
M]^I0EL=NYW@V3!UO29)1PHI>IA(]%!@(0:[,[4' L^DU[KKSQ%B5L-9.3J>_
M6\<)U).U8^[=U,L&2/GPA:&?<B1IU-%<>-[Y$VS(VWA2R#)EIJ%:1\Q\>'5E
M<^/T[V%)@%%80\,EID7(O[Z#152I#>]?H>>G'*75KW\:R#5K8KSKMIW>8?7@
M^W_W-.3_H=X9$+J_*'07YMI*^3N+;OAO+M)]TEBH8K7*N:$IA5_?4O<L=OM2
M6XY*BQRTM,H/_P%QZ5'&R3>P/+S#S<WG.@-,;I"3?[Q5#-"6GWUQ>SR<<^OT
M2%,N(<2K:F^/.!PDD=Y:XJV5#[S 60LAVH3DIHB3X/(]X-LE_?-$B5DA;R !
MK@.ES@E-ZQRQZ\CVQ_.JO2G4LD*G9ST->I->JE/P-6V:W+&52O\8@-AB^C'X
MN4 %)-Y)^TN>]U5=E ,$]JQ0GD,D!Q0\6>'(5RY-#O'SVYZ%R0>X'FWLDY)/
M3&,L=C^_IUW+#RWB0PSRD4,V7]LSON^RA!]::'7IN8$B"@44!?TOA62F +'Q
M5.7)C<JJ3 ! /V^Q*O?LFOC#?#)09*:EQD!_&5?O7YY']!*R7VI)\.84J/56
MK:%=PB,'?@@7W#=_ GXA=E^APM3-EU]@7\^XAS_NP_,DD%P%C8X!]-(,TQWR
M'"]=Q9[R]?*3T[ZNVBS#&_\;FBSO*&8K+-\K[P)!C'2\&OK!$7=]+OGDV[DT
MY%()-,/KU_6CV["I:#?PAH;A5<U6V=V*WUI58&=6K&.+N6;$@F]V:!NBD#2'
M?@/1H\LI\DKN6'X>TQG&.S%2(HY,BY(LO"L;YH"?@KZ2QV='',0='?H=B/;>
M3V_TA\.8EJ2^&<D;<CUKU36%T*H('1OR7,]@88&M$8=ZH5(UE3+2L@;7B1C.
MM1&^3 ^9$-UF1I?XJ$IX@;O#+GF(;##F&%C0!GHR$_3FU9"56-UNY"2I565=
MO+<DV7EVD. 7T6]V)01A!1XY-L"7F'F.-BM,%@_#3T+1>RY.40?#S!E+#% 3
MZ:I[_11=J7;CA$V9'#]T*/'"?D-.YE#EFTNPI:<KR:1*F[>E2M>=J2'VM=/D
M1XA0M?U"OXP7G7MGZTE27_-!1.S"V%VS$Q!5/[L]/!DV:'67SUXZH-Y2)%7'
MD#T73<H#J2ELK95 E&FAO"HFO2M95<5@^:=>6NN'D5]_A X0C;\-6??:8<I\
MC0D,B7R41!<EN$.Q&\Q#%J]]SRV^E\Z_;$Q;&8L%0LC^,-#.HAD#-JGS?Y#W
MGD%M95O;(-UNVVV;T [DU#8&3#9!B,RU,6# @ DB2 2#R"! B"A2VQ@PV>0,
M)@B9(+(D1&R21,8$ 2*:G$7.:?J]5>]7<ZMF:N:K^:IFJN;YO<^I<\[>>ZUG
MK[/6L_PUI;T$>LJ>C:)ULIONX05=1>GS?=5,VF]+SY@H=)Q5^4TU!($H@A (
M<J4B^3QSXSXE6]'F;\='NI$)_?P-^?YQ@-P3;]4O7R)N:%PLNS=*\Z>WW21G
M,5<M?4]%2@5!LO?EX&;9'!^R@ID*DS;F2=+(XF//Z="Z@*%E4UL3%SMCPR8*
MO.!NSS1*3\TR1B>55_6<4J@&E/3SL9A3JLQZ>OQTT?);G\"&Z^+5_>X;FNIM
MQ?STG[FRR@M\P5?8P'_6D"&ZY3\B]].Q_QVY5V/^=Q&>G>Z?<RV]-S2W"8^/
MC\OT$)A#@W\NT\7RU#P]V3S"3[WI]JMWQZ??E7,!<V5//F>'-;,&I5M=AL:2
M_8"QIV2"=MN[[3FZ=Z,7=^:_;Q'JZ=K:0?T5BYD<XT<^X6.G222%.3M(9O)P
M*;Q1-*//3[6;8%!L\+L+1LCN<;2%S/J0:)YOO^,*H[>5?2PQNXP-["N%RS4I
M*1^I\)&<J)"9&*^FT!5\]FO1-)/6GVN"C3 [/U53&) H=V-)7*DMHT+O)J$3
M.FU,:HR\(N83!+)I]TJ$%B6Q]RE\A\M.6(#.IG!Q).2]HP(70U.68:*V@R]_
M9*?BNZAN\PDC"JP-%YYWO M32A0-I\P)_U3HOZ )""!%HKR/5\,F98+32H:+
M-=G*)W?W5+B;73A]I/L#[#21QG!"3V2\).7L'OL&9#X,*(IW8[(T]O"IN:%9
M+!QU[ %\Q\W*B^W8'%I7Z8=<OM@<ZX[!F*PP:8+T=Q+US3EUZ^LB7^['AJ0L
ME+];4GHYZ&DVQ[$C;Q>1AM![&-N]8;IY^F#0/G30[>,QG&ITB(C7"[Q?O"X=
M1J1F7R6S;UB@P$E\]0:1"=M?(T=GV*H+#^NZRVO^GA/CWSF-/-Z[H8FR_&'/
M%R\*OPZS"+ZU?1BYE;O,%MQ\*"%J.Z!LJO/A@FG_[H\<L[$L]+*6VV>#0X?T
ML2/6TXI:0X>)82[75%O%'XY-I51_B^6JO::K39',OXW_GI<PE!S=0SACC5;K
M#QZJZZP\VX0I2ZPY/^N;^D/NCC%"X='SGBKB22I/W2"F>$JOK-@@^K@P"S+I
M^Z&VJ+)=)YI+9K& #H S?HG-S,I?FFSU9)AJ'-B3=EWU*=4*ZW*9X'I*4E6C
MLU3K&J13YA@RPO!>CG6K,'J,R3]-JTIRB0T=3/$L-6?I(C./R=[0 -U\'&R\
M2Y/>YU@)>Q?5[JY%0S0*4UC63!HA/YE3$PBYR,F"OQO' LUC?!0;=WTD'$[%
M OP$ZMK=*.+( 4K)-%8QB].IX<ZK) ,KTE#\L'I,]SS5#(;6,B]+\)TXS5UP
M)M/+#\5/KJ3#P T/3[QD9%]K^$QT0JOG[B>8?#@4";@[Q9X^A&%9../;=4:W
M:?ADCC^R]KBT12$4P7N=U1OLC# @OV.\9\)Q:97Z5[R1D.2S$L++L_-^\+;A
M6LY.-C*_0C44X9=FB/8W%DF\['\+*_]<\,G7<^'P]'O=2FU2L6!O6U3[]^L=
MEPJ_U >_?! 3#&Y:];B0W%+^UZ6WU:Q[,QBU:W)A^UHEZ6+20G[[F?;;IPB!
MT%G+.<MI=8J_WUF3^_X-35;<WBWYZU'"\7K.R@'G-8/KX+$(&OLF:8=G%O9.
M[:"'XU82;LQ@&O[>@PE-6X$$SM'7Q5L?RR5G1)9Y917]2O:;(3\,-!()5/YJ
M-U<CNG^1*MLT ]YO2R;S6B0$HU#Y<*U8S^7:\R?8O8V3J40/SA75Y(./SK3.
MIB#OY,GV46>HG$0J?9\@$6X98^XP_[PTU__=_HCW1>*L_)<\HES.25?*MOWV
M] QASF'1#Z<E?AYY4FWX<F )X\;. ^'_R.>EV6^/\3&^]$\VEMK1^7D@7 -.
MCSUN(\X!&I)*-,::2UTWI"_6B5SK:$[DM'6*W&$-&'@KNZ6VK4O )F#&L%]T
MGZ/^(8IERM93C)&ET<Q*+F<1 RC@3-:';94QA1:L;9_45HATX3,4PJ=2Q&*\
M^T=BJ(8]*DG#?NT.2QUDZM*W+A!QNGNA^?N%]+-[(A+L2LM>]9OGST4#++F9
M(QI/#-QE,TX'6'%K!M5U?2ZKK,5Z3:6(;HV%/ 'U&<9G56T0>?A8)A@:N;GZ
M('NP-JM:,+-A0-%L8(2W+^^%C-ERDC#!M[7-(%K0/S9&K2!:FBR[D1#=0/FP
MJ#7X.)-9J!YN3V.]75KLE%;*$8][]63 4W=PZP&4KLRHAB$OFO"E=90@"4*6
M=*;H9,M5F D=9\S:(S(IKJA[07:3F14@_KS1TFC'8K&V4!D"?Z<));=R;$GH
M72)@]=<-%N.&DK(UZ=H20_=BL![RV F4+--"_';T5=")TKQ4YR=Q=<B^.L'L
M</VUKFYBL(9[9*IE*[)ECZDH_8J@W.;2<$,#?W]#$](BS#IH:3+@</%X7^Q'
MT(>Y?PP)Y-^&9#\_Z-:ZY$#:]")[3@3'#"3']5@]#37U:"!K!_'E<"/+<R,5
M$.V%LQ4>'__0PFL6MFI=A%<;]05.>B),4Y2-#M75EI)9BK[95O<4-.ZE^(1W
M:JZX%@EJ?\BJ[%1A!<2R/1II+WC\=&RYJ5]4A8R3GP'OKJUM)M53!VN4;FA.
M_1F/_*GCAI-YF%3*FG-O"TRA*6]?U&.@.RE*(#5/;_#O_3OD*G';.%8GHZXJ
MW.]9 Y$KA'Y5"D>('U!+O'C/Z)5^9M*'Y6YBLB:<8L)WL0&/NP_>LY'>&!$O
M:AKR1.5M>NC63O&V=+6WE!M0_"1(#ED-^!5\MK]8R3(B2S6%(M:?-K@I:ZY?
MX[9T>+I/><#0-3DFLOG'1!7X'K<$=.X5S\>R,.,"\1L:.?EBJ%JWVQU+':E2
MM?P8$.-GF\)=@U;A)TF5VFN3DYT+8YDXC6"CPAF,W7(!"[XBOVI^T<Q<!#RX
M.C?E^OC+1>;H6:H1J3.ZW8>Q8GG_;!*;7W%;W4,Z44F(&V?SX5,#S]OLS$Y[
M<6-APK;Q1(M(>M:)G+JO6\#H*@!!FU $,=\VK,G0"U#(VH-;-L$3S/0TW)]0
MCAH=I]4:@R?YX[2MT"49FW]HVDJT@6]H]H*N3W+<+B1?'3ZL8+L:N*'I96JY
M$Q3[!O_G2=D5HN_-#X3NV*#M#<T<L/]2#Q.P>$7;>'UW:IW5,M.M"&?9[J]J
M\)K.5+IL]GIH;X]4#B,8QC37C[D6*0Z?*VAQ*86XX)2I!>"MA(HKQ> UR7$I
MZ;U8<S^?\$"YO3#%W]4YE(7'KWVIML(# R-<^T]X%>0D<P:4OSJK2U!9FW(#
M*#^[+&M$Y1_F="_LF1REKVNB7&P;GE@E"'XO?N"BTT7>5T;'#"#S2] J+#LY
M\, ,^Y/W=<4"D*&Z+(%VYAJ6-AVAWS>T45'(*61? 4$6$ 9J&*O!H1D1X%E&
M0=W;6 $=09BL<ROP$S@!'-T]F3*2YMV=1A:VK%%B/66M3G;L%UH.0TWZ[)'C
MR> C'T(ZP+]"O4!!Q*.J20_TN' PPV5X;\6K.B.95XC?=94%'QE=\$(8&A<2
M;;/7_MNNR8;):\),CTN*L3H0K2/>;'P_JS"%7B^)7_2"X<%=QC 9;%0[1,X8
M,0I%]Q@,$ %1B:W68IH8-719?$Q5[%Y#^[HQLM'?H.0\D'MZS53V1QZ;/%DP
MXL/&#S3_D*],<%Z;I6Q)73)L)$96 204^=7\M]U<5Y?Q$,[T/[_2/SV?=KJA
MJ8)=CM3#[($W-"I;C1H7-OW:JP_68T[B&)P^6C(0_[RAZ;E[0V-S]WI(TD$V
M\X:FKV7WG\E/R_4-GKB^H;EZ]$B>Z^)(_M4-C:8HS74*@$? 37FHC/03<%5B
MF] [E]3DK13!;'<@-NY/FFIP#S?="G/9=@7U[9RR97)B[)U'I0(_X3GXF.UR
M :+\SE,'X(.7N-0/X4_(J=P>'*FEB$RV<U3:6$P/I@%W-BC6."7:)E6X@&(=
M$"T2IQ!?1N-2!L8B^+D491XKM)KW4(B#7*;8XL+=^=;&E]M)!*HE=F#G0F-"
MJK^F;MOMPP]<N4KFAYKO6]7[1J@Z%]8HML\R]RF4<<E"*D1)[?/$Y 4GR]!8
M8>BPA!NMYB%T*),W836SJ?&)$V1I)!3\Q-M[L7O@(<1?1X[_=W14-):_5*=6
MA>I@,=EO6#<9HP$-F=1>:^<4P+=% <^>G9"[. ?A-S1/W5NDMX! I=<+,B_/
M7/@6L])/:BZ"0G,SMEFM)JA]U5JIO4X4S:%V7LKX.+@"^5N\38(L;]#C5: 7
M1D*K7C;%]+;F\#SVA?H;*WT9I2-W 1$9D7N=\Y\<'[W+.$:1!0S*]HIII?;0
MI"$3[TCJ6='Q<LAV5)..X9 7&WRQ%A9S.J Y7/7US5?C#BN@+_=7[&?T Y I
M$_!656=0LEI^A6;RXN;Z1D0JGEFF-)M*?E :'C,JC@:27CCH![*JVS9'V88
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M6P@C#&[9>Z!GGR5'?W&KB;(]NK!= >UP,@LIJA\]Z)E6DK>BE$.]./&6>8\
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M;DF"]B92+,$K_*5&I5FSFQ<;0,/%^TX:Q5 TO6B(K9)!BG%EL>R8NY.>EDI
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MC &HZI)S9I#%(-^*=Y:T-%&:6!/?5DWK.5F>29C,V ?CQH5LPUBNP(*G9"3
M;\+< %LL,*J-YI"R(@TY;/:[E,R]CQ$4%=3T72=%E/]VVF^Q'[*?2I6LY/)>
M"M)=41P)E3:[,]^1<BALJR0Y<5(V8$W;&4/2GS"U.PI$QTKUZ$'U4^[8E2Y6
M"3=C^W2-,,:R3>,GHZ[%Q">CB?HD'0[S.ST!:.$**WU$V<_1_)2PTW.!Q\[3
M=W^!^R :M?"[:/'->)=ZOE55P;G232:<"J=W8TQ-U."':A%G5*?];NJB;22.
M)>IG?#;7.'&U:FP#9*^67ZP]_]Q"2 \-UQXJJ4+SHH*HK3I<2S<TS 8- XH4
M"<GC]911^8]#_ FCIV]%7%AT9)<T7TIWVH1P5D*]+R::Y#I37L'T4C9LR2GZ
M9=5*3:H!+YM?J0/S &=+\Z+U6XY;#X5BY@B?,W%.[C]UW]2;F9L9:[ PJ._3
M'XA-'GCM^5T_&Y49^%QC%&N>Z+4\"^B:WR!)]4>:+F-(\GQ7E4IR\)+N9^JJ
M.XC'!0^I:R,X4U26D:".[K?<S(]#NL_Z^':SH+>'$FYHU!^-69@V&RO8+R]_
M7ZY^UX>/]QM'$@WS6CP,TVYH[$?049$F8N7)A="E!'^9&2..).$4/UOD9,_$
M)X$5%^W8)J=C^5[*3&]DQFCC^! O:Y"Y9AN=ZC8HA> 7%<$]F(F'7E;-S<'J
M=>EWJ>VDC-E^S$$8OMNGPL,"8M/^$]5J=:BD22X;+;8W&L4+?TYWE&!/-B:Q
M;Y#NMW.45&/[H=S';2O9&'O]?%=1&8=U=-OXPW9 =6F@&YN4F6'2R$@LRX?_
M\I2?S[3/%'W$)\(1E""GY9G53\?_)7CY&(;DD))9M)O;O[CE<39]G9M<; =N
M4&9U8EE9A%94]%&X4F8$%?O4B$O&0DYN!_>!AB Y)TV(QKI600=%-=D6R 04
MQ9J^ZFS%T"W&"NRB.DR?U#[Z]?_[]@6R QSD';"E&F1)!@X=$_BJ*ET@1>P/
M&)[M>?L =4&]-M**T%MW;G'GCDK*^H#(-J[0N^$HBW[GL>_(AGA,G/DS7?[O
M#1-V4FLCAD+6^3GA%9;<][CZJY&I(/-^'$<!V& H]H$:@Y%<2A;SF^@<2D#"
M91_6U7=!<0?8?M["/KHXJ[VXO3QUA]P;8)54\*O3E"N_S!FTF'2AMI.1H=F?
MM\E8;% :+P?LV'D%L92H219XI8%;&/M\:JS^ZXQCHMW#NE"-3K6761;I_,6+
M!;1:=_UJS][I[QR'-71G02L_' 8M2+D(87N,O=6FXO27.%7QPC9.F_* :=B[
M,!6ZX'O(H_0JRN^EIF].WF%7(X::!4HFR]RR2]TS7!,WT<0HJF,R\5K0W0GX
M$,P^.O[X@/M.]FV;Q*Z0OCU$<[?%KVVX\/H9R-SK WY:_P>C^17OP@E3S0VV
M)SSU2/:M'4]DH/A3O]/A7EKO' 43I17.!-D]+BB^IH8S1Q$5[L;5RE\_MS"Q
M!6B SA9,$(SUND\0.:DF57E"'A FH<^'<IX'I^LX%R-[ 6.3GFV(FHIX^04F
MIF[:3-RH^BNQBV/0U.I05T:GNDWLJ\DB\;3^0;E90<,$N%M38Z;Q)=(;2JR;
M5?#UDCG )^.3Q)"!GT]TXU9$&K[Z(R9D5F51,+F[3^<]MP<315UPNWYA^GT+
M95;%]C+^M[_4(+CQFZ<4LT0SS V-K49\Q48SLY?%W-3,^Z6%HJ(,YR<-C>K>
MQLD6)M/[-<E [<ZBQ!0%QY\+*5A26__FP:<MAK3&O^OB(J6XV"B^(Z9]#HTQ
M"+=>RM+TP$@8<8(X,>8A8_0J-A,TXB-O8*%E-+GL4MG.7:IJR5:AA@&$DN7!
M"=EO)N'M:AR!3)'38SV8H]^'\Q<*T;%9OAD_=:/)NB_<!.@7+WZE/@Y>SH'.
M^*K;CDN7L_7!9Y52V5PR9^T!],Y/&];\A:7+QR9]I[0+N$1JO?QI$10[#7UC
M8@0;UFS%9VYNJ+XP3UL#(.PYWW&:*>"15;[05EMBY Y/<O\QQQ8@P/1<A/>T
M?"YS,"D<?G5]<N^;QR"]:R,/QCFC@L[J=.>I5L*Q]@Y=1B8@;N:D/\79L-1I
M&D;02V3:D%?U!NS4<)0*/5>-88M!4,>8#V&.,H;ZL%Y.%KBH=!0]+'G:<BQ&
M4_2^>"P;9-'MHZ1;X[<+AN79OV6$$F1(:<=*0 IB*EQX<DX\Y710K&8%_H<U
M_\B1=F!RA<FDYY7$ENGSAD_I/5V;O<PE".8QW^1^F.(56;ZDQ'-$0YU.!M[,
MU]-8TH.):2PV@GL@W-1DK#Z9"<!9@_M(5?5-U\>#7^<GT\_94@X^4O;,/A(;
MI,$/)*W68'5(TW>:0X/2GPUL#&YEMJZZ@K)_5!NW/H\W>5OD21=QY>TC.H87
M"!-WOE-_U]O*GGW31[61-U9@#W BKJJ 4%*YMO?MV\Y2%;W=NF5R*MSY&T2-
M/5W&B9:QJ]!%)["'?$RW<[M&NO;!,^RZM)Q LLG. XX<1L^/=BG:UDLC"ZTG
M+[?B!6S\(G-Z/L$7]4V\P8&?9J\-LW$'0,? -(=&S@%'3'O=)H3O++XT;DQ2
M* <=U>HRI7H5B1)*9QHIU7\7.=<-3M\N7U]PYK5&=@;'E%5:&J$MYLGHV%XM
MRU>/^G"S*%26 ZC=56:#C,+_6!3'9^]P.OK?T*3LR,],P_Y9BK',>DOF\@+*
MX2B1$?9:J->EN4G\;&BN+:IZLEUR7\]#T6#X2[A"O4?HDK2OIU(J==B]?[VM
MR-+ 3>T!XPBX_KP>==<7$B7-Y;Y,E9COUP=J5'D$G90ZU*4^=^01FJ+42.V)
M-%DQ[HDG[?75U@R<-$7'LDRORF)4#9- WXL-DC6<(ET^30TE=_KJQ1(T1#<W
M1/B_DSC7,G:8'>1TV9P YEJ@Q6TM\V%L?=R1%F\ 5U5$<6@G2?);6*-8=FVQ
M)'&%V($XKPB5.WSJD9B5M3P/C$@H8&D3?#CTI-)<I2Y+]]O_VY'9_W/\\E$^
M\OKYPC72,:"[/ZTF>[# 4XF3P:G,UM7^.F'\E/8*%U'$5Y_)I1'L'FP:L'HU
M=8:/DG;.4LX#W=!\/.YB(_231J*"YYM*\MCN5&>J:02[Y9H&<%\MG>&3I)TS
M!_,,E<..NS,( \HC47$_ TO2_SV*YCG:X%K(V;*1Q2V='$/J"E*I/N7E=HXH
MDKVAZ<6W/,!L)SP##B1NLG9RVX:>,TQH^UR\OV+M#>(4<XHG6%I9HBF#QW(W
M-!'Y1H?#(:._FC5F$II\YPB]9HX)#=1 GTPLI5([4H.;TW/Z* P\L(&S.2S3
M>EX;B%9[;KBQ7B'^T&!!7O$J!YB[8'YZFE];6=VW+F<"_;1<O"@GLM=BB.:*
M,=!3HOC''21F_KX#J)6N$8Y=!G4^GR.4N@Q7,+9_2N4Q,M,KG#(3>G[VPUU:
MG7-:G</#&QN5,T=NN:UK5,5!%SK8T++Q6*]U+*0C!P--Y2FWJ7K?1@F6WJ@6
M,OM.=A;C=KB:*'5NEB8LE[''VJN^F@\A-G%F^'J*HP0%H)CB#[-T+\8G:H)A
M5+_Z/CQ4HI0E0-T"-.)[@L/?!T'F.U_7"O5 Y)(6(SO1 M[+96/*50QB#4GN
M8PNE&8M! AUK&?W?A841EDN!8;^_A*\45X3)\E4VJ!D%-,9 P<5/]&4?QCB=
M(JYWS0Q6*C*87T]J,J?@Q/.TBS_,]%L<C<8]<"I<A=QN92X680NMES;FN+S*
M>VJQ3^]MF@+3WZ@U@^O5Y,]8Z("'S4)EIHJF=E",J":I09"Q(*&G')$,&@#]
M XN2DM)U$$AA6S%+@_?3:/!?Y^;C^,$R_M\#O_B.KTG>1V;6W="\K@[>:M!U
M*/+E'] ]C<B]H8%9!G>0!7;^4[0>R/,_1.M##UJ"6QC96BB#7AP%E!L:B?'E
M(.ZQ(Y$:+T*%K6=)FO8@0Y4]W+O4Q5M\(%D(ZA48;MJKFV3Z76U"01K49/:]
MB@"2>PN,>E8URX&=L),LUJ%H:_?0BSO;<[&J:=')>7IIR@N5C"43-.]I%IA\
M&$'N+C@N?DN)R1T,[P-JA-^U1VP??/)BNP"PLRJZ!N9&RK;_0M\:4QQ$%)Q5
MORMJG"8H*:*&T\DB%V;<3I#6?;P(4L=V?;W/0::&]B;@&NJ__]Q-Z0=+4&#6
M297YNS"IW0"&1YL*F^*H< '-AR0C\002*OH+@II*,-]LB'6B$*82Q.52'KM.
M%F^.5K-L/XN%LI>K,&'_(CG7FFL6^2M6+RTF@$VZ9B2:E[ZL@WI&G4%LZ<S/
MNF$^P2)AQK:""?B01!V8K,^PAV\=40@R5*#G4%]?[&><4I*0<L^!1,<IW6L3
M)'9<D3%^P3IH*X%U,4(U'!Q?U#HGZ-)625"9<,6D#$]<2?T;M4%SR?/DM4:7
MC4'3QU-G175_!VR-HR%(GOLP6?U:-*LG%UGCYPV-OTRU0?RK-I+C1M*4>>@*
MX[L=7:<.UZLY'V7<3SY8%E=PSIDESQ<<L935AUUZ.^.$<P40),ONW0 1]%IK
MXEY_8_DJ!^@4JF4^6X4OS2\3<>2KRVGK] (\S#PKGB4GD'$7#+=L&G-;%H2F
M2-<BP:^R,DS^AT2)_/^,.-748;/RK!^W.-.M5Z/2BKV2DHM0^.0LU[5UGR-_
MC#Z$KN"W;J,:T\>S9[9&;XCB XAXC =*L7\&DZUD1"T4&#:3<!0=:(X?>+)A
MZ"\UXO8MX"(GM1:^,I@R C03:?)W:-5E#&AF.RDY ;$686YWI0NV/A\2[#;J
MY8H<%Q0R"Q=RSF#VY$' >.4>FQ1AE>@GLGAU=!Z;:'"<_/%A7UY,:"^G*>+C
MF(<?YN(]42^T>#TP,_TRX.%IZH_HF/)@8UD0VUA^2<DSP6S34)/WE1AP0=M#
ME/2YIDC6]\Z>6FLL090"90"88=[Y./J!O4'%TO[^PU4F_YRJ,B)Q\U@WF4-K
M^>%5_Q ZN4-=W3>@TR]%'--R'CG!K"+O_[D+F&?*X:L=3$@M]X'Y<)6:*X_J
M7XW%UR?9O5N#E5>W]BCA?FUG3JFMT.WD>_0&.XZ^.[41@#]#^XJ8_8(#@^'<
MMMNK*T?MO=<>RAVT.Q?ZJU-%_IE]/J>*#<H3N!SRX[+C\3[FNL<Y,C6I AJ2
MT.'C+=A6(VB&Q[:A#(*H\K<#Y&#T>K9RL,@9ST-9N>YUY\0?N.T?L_>G,(W'
M\JWJ'#!7'H'GNQY%%Y.5I+UUPJM#5O]5,<2:V_&\74.>N6K/\0"\:)9%K=;_
M_/'(*6.!3@ ;%F,;%[!P6H06/"ZNV+^NC^XQ78"%L-<8=QEX&G1"5>9X"D+[
MM"%#F[9A9I_3_)U.R7J5QOY99"??]#I+AZS8E, ZW$6O[1D):@1XDJ@M[Q_*
MHE'.''UVSQJK*CW&9IPY!PW<Q-1G;4Z[>D-C!/VPC6MU6D_(Y-)D3<==OF_E
M C^/>C3X8R.\N5_$\J,[S/,:$J09]**:>EG+!FYH$EN0=J][Y%Q_29@'W-!X
M]>S\]E+?]IUM8Z+%JMC;BB,/] K$]#B@ZSOUA@9X,%@A[3AP7;:IJ3U?\SKE
M9=B8W",(0!!Z*MG9?-OUPM+-%K:S&N@Z9HDU"C-XG5WV],E4<J=1"9D"GLY"
MZT1I^!I6:H6.11$L/A &LPYZS BP@S+_HJFO35\B>V?/BIT-R6E-QFQ'\0^[
MZF9<8TSD/-_H&N\]7F"#-EVT0I#XG M?(6@,N0/U9%94:MQ?D^6:%\ B^DE1
M8F4$L4:],V\+R5-5=^H9?OA](4$?(VQO@52FKT6+<B(I(6\ILKSMW:D[W^:4
M_FY0/PSM)!(#TZYS9FYH;/YA#U^P4H/;W=>/;><N(L,O.<\^#"#/B0CUB=SX
MH)"#.Y?+RH)3 <]R"]23'^]R:^1X$E=9IBNE\U8#5[@M56*I^"D\[4IM-K<1
MBD_%J:(C8#Z^P_JH3Z'6B[AR0.CAJ)S6%M3NTJ)S=&FR^BBB.7$-&'!^IX7H
M3UG3W"9BE_M<2T9]U9._9295I?19KUO/LM36-C(]#Y,EVJQO$Y/,I;!;@[3,
M]/(F;,ZSS)EWX>9;<&U1[F5MR=!*-C(GZ6&#BG\<=F:5,=O;^$%L/U1P/&&
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MGK3?>_SA;+OJ@)W6A5LJ^,_I )$+<TESO_GS5[!=F0M;%<V3&YK%V<V#J>H
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M,*FV4FP[XAP0!E,O[5Y(#6V$V1G*5ED@!YY'S06@/'.G9/:0=U(XB1@$C!0
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ME19-;':3!Z#K;2KG.AP*%XKZXSO-GN\#I/>]&97\3E'Z^WI_(96!?$<44]P
MV!$5%?6*H#6923ZM)\NYMI&K&#=C\)*G(V0@04NRP,QRRMKI\%Y=19&Z^;V
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M9>7^:0_S]7_;P_PM_%_W,/=3G0:,<3P*2>PX^,D&*#;'0OOZY3$.$*LE6O<
MNY9401LUD;XJ?.;%=A/^4!6+=DLE-P_7I".K$D#\!^"AR?%U1D+0UZ_CN$"
MH27?L$U)AV6.5%D$HAT8 KK:JS(M^3Z)@(ZE^Q[)71 ?2&^_/?63S/"B@XK=
M0N>#U+].3ES]R@@I4;W%;2,7DGY?>$/EFY9X,#8@1$A^<WE^QSS/\++6,CNL
MH^$VUM;0=%<]MW7MRY_IPRF+DI^(UY+SOVZ"PL"R[%UD9OC\-+)'K3X;=XCV
M+U;G\Z/=OGK?($!F8%S"(D%P0%-;HN*M0/@U>ZD@"-^(&6R/F&-*ROK!YI*
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MK]=:"]G85&4\'3]N6*0=QVB%9Y6LS 0+#E2.9!9&RR APC2[\DLT=2),3\\
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MGVC,K@3]_OV+8GW16V>@"^)KU011C;H@J86N/DG\5"5$GC_6-G_CE*Q@A8\
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M_><O'MF(?"]SYEAF68T]CK_C_G>/MSJ&*U[Q>WSPR*331P%+#H02)DQMW7U
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M ;1K"@IJN^3D,_B;$F,]UJ%<79D8"UM^(B"QBLB[Z+(&./7Z [;!"YNRY@L
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M0 &VH:!"<: ?B^)%Q2^%S))O5DH;\'/,Q.X;:_1X()^P>YJU29=IFL3$QNA
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M%MO([F3)JLS$@@B/%R5=?%,MHRM?45HIT2L$>51,DS4J>L"QU!/8TTNI[::
MK1&.),>LD("MN#W[JJMO1HLPQ2)OT4;I:/ -_CX[^0Q2GX!A66 %@JJTY3:^
M(]_Z?"A!Q$RBU"PN6V,UQ'3"MW#(QX1$O.FKS+\[$ATS9ZO0]R2+7NY:!IK*
MSA.+ZFCA,Z2\Z8--+NK'=3_?)^PGJN&MZ4I/&<(*ND+GUQAARQW*;>+8+$=
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M!\0,.ZSWY1R!$]SZ$"_G]>^R; 0@VP;#FQ(H'Q.IJC^8QEY:+!,62FNQ%R6
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MC;OE@/'*5.H[E=D6PGXB.[7E.'UM(@Q1@[TTNZ.JQ!,!M1W93O;WFY2CAVA
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M!^!-5?DX9<V7KT&2)&%T/]K06/G?8TD6S^!=H=2V2?Z\><HM] %/S4%5M /
M*;6DJMR\0#<DZ79D6]M(KXF,?X]I_._I^ &^0RD8;&KBRLZF$K@&J/]L58/
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MK5T:&0JJE@6)(WDKB^W[YI(_F Z2^AW.QZN)@=01<V63%'#TE(E/<H8'E51
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M'<T(@9K+B9E.8."/^8Y!2UK<&=W=-=OFE#,ZD%1;YM9QCL/:X-ZCGLG>X[R
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M$V,--4?9>@4O_V\E9W2C*UF<]1-M65S$LI2NS7U\S#I+H,X5 8'SF;@G*'"
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MLN8G1&KQE>M<F%/ _UP@<(AE6<*KSW#M,GW/=,Y*9<C"8=@<JZ-$QEQ.I?O
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M3G9K=B#H]6W'YR(S/W_L/77A@ J'4=:"99SO48/VBM?<-R2S5(WCHAL=6F-
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M*?".S8*&-/[YOIB;K$R-NAY+A6%PJ%Z)J8EA06X#R@TL1#3X!(\3.#383+^
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M<#;8SKE@C;/V5YG',/H?;_/F4Y<6KS ?X^F,,%FR* [ULGE[YQ\KGRMHZ$M
ME&\53@>!XK =#@@%U9*VSYD<H8YT_792>M 35XEWK^A:"%B>60@O;>VL,5D&
MDC62;Z0:0>[/;!Y6G8A)6(8C,SBNU69I0&'.JCB+_3TXC/1J)5,^EV39TUN
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M>BKW5XZ-2:24$R^*4M&M4U8%^<MNAM&T5_ T=6FP5]8=;9JENXOE3.$]"](
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MX#W@2H%N0P3"T%TX73,I1*(7..F.GY79'\Z*;05OJF#M-@F(3TUYS,/F?K=
M"S[8T'-@B-CB0 @$U?-\T=VU3_A!:(2_=-+NG..&!R;DWKSKC,]K(*>CD>DE
M0&9FCFR2?6%H'O>]MB4Q^TF#@X!!*9=AHHM<Y9D;2(_#,^BS1?;KQ@K773RS
ML:#TH0YS[UBOBT[L5\'J0J6ZQM7C2P!+\%<:;94WX^+CF\H VJ'M*I@P\=BB
M<P>HY##_9*()M]IWBT*]!#B0,8J;B#6(33B"_Z&JM^+1^DR7:O*[DN*.K#LO
M65WRONN&;3:@A]PDJD/&+L(\#QH)/AC?S<CMJXW?\(04!F'<)2 AN&H$VG_L
MN/V!$K:^BPN?)O>S#_J')LQ>W$E ?<=8(>%>L(OMMW27%:U&(*\6,N1>:'S&
MM4WOK5[5"+51,/<4S<LY9-M>Q64C4N$2H%5Z<8\G_J^-A*U>4 1HU "8W:>A
M_[^7'=--59!'$.V1YRQ[!G$UMG,_2MGKY'/T8LE<LPR-1';!.*LJ(KZCVUT;
M<H3GY*:4H*:U-\Y4.;*P0]<TU?P".\K:,B*8UN&",]FYRH3VJP(]S!%%X>8Q
MMSUCQ]9FYC>#B/ZXW)O!!2GVYJE@O9PB.<U]8EG3<"5;YRU7HZ]M'A9&+<7O
MSJ#^$(3C\95UMXA^R$+Z\/8>X=Y,B5*B&@,7^=XB(4VM:#O1-$5B?E+6TW>>
M(D^$1P!Y*JT3OE]@8 1(I1],&*?C&!\LU+X;H %DRC$7CN1.+]5_#^.A/<+.
M5/.ZJ+B('HW4;8!AJ6CHKJ_],_E'62E"G^,X2UU!G>7;,UDZO^8_P;_O4\7E
M;-XH;AU8\!^>;8GB4?V,.@,R9)I^'HA!;7^=L8?.>W\VGZO-;)^%]'UL9TXO
M$7]AC6S/<X'/4U@.S6'*OZUHG"?PZY?#S2-NR'YK*-6^&\_[!6ZM:DNCG*)]
MCKE[6G)EV=V[F[[D;8DIR:'S;QXFXS1:)DH%@,#T)>]V3\2,>()*J*]XUNG1
MRG^$DK(P[)Z+9X3\@I]WM'8F)5_0_TXN+(&.JB8$F8Q &X\=/_LO7@+2RCM8
M-;%\9I28+1KEVVZP9=PD<>0TJNJ"/',6ER'EI)CW!_9"--A*[=JQ\LG[S64O
M\L#;T,Q3-_W'EX SMTM -XC.HIOYDV2[7 (*$7RNFW]W+6A.9U[2# XRL?^.
MH<J! AWZL^>RP7\-SS4NDT[C_Y@_8AOA_,R55C3G4VZ46Z&DM8JH\_)3YF;%
M!U6!-(W"O,/D-1_&VB--?@<5U<EB7S:O:RFFC881"EH#>\UKZ2ZK Z#/NWJ=
MK!V3=\5MC =E9=K69-9@:P%KT;$"^_U;WP6;6V)#1:K$.WP/=@0T[V#E-PA'
MU9:<*BZ_1SP7_0/PCS?B0HCV32^JU)[JGQ=^MDL>'>9%!Z94A^=JR=1Y:T7"
M0__ W5UV#*]=J/HYX]#=5R7K%K /AB?.32/?X$\")SBS[;V&<#'PZ![=!HI3
M=MXD=04-:5..[CWM[%".R^@_$AW:1Y[\K".U\4K\X3DKOHWW_I%'B5**D'!(
M1R*)50%S,EY<,)L<)48LBG/J6?I9>.>27&,U8?\AQ<]E;Q]ED"0X-%GP!^XI
MUN61S$_2X@8PW#[>*17AWH&*"4:N?$%H^2#?G3*!C8[?X[?T/0Z*C,O20.Z5
MX^H\0=B.B3+;P!+@^LKZ TJP1^7($*\/XV3)$DY@HPF[M#]9@IMIA2>4;BMJ
M-K17D+0FVD>(":$J!0M+ZTE=1!AOA7_Y@515\-FWL](,-3$*?XO,ED;QC'!-
MA%2V1T]2WK)]O)*<;0%HJ%.(XLMJD3S7K6M;E_!+""06I[HWCSC<1-3]Y-2:
M!L(DS,\-]?/"_D%_4WG6>@F G_'N,OM+1;&+(DX[$<$CLK2,O\Y_FXD+W42L
MQ]B$J6KR67P*G@YMWN!SEB_9=:K]B0JS-N@"TQV>] AKQ!7"26P5IG'"0GRE
M_4MI_K7R+./_J3K-3W<>G"^X7@)JW"\F6MR=9"\!:GMM6M2W&-W-6]MQE 1&
MUW>CK774>?F>/5A=Z.BG_N#F(T))%;KAF1AMU[#7P3 NC,_APT4V*0@5$)DJ
MJX'F;:UK^VQBDFED#_>:F@+&6IO70_AM./J2H%Y(V2]\0LCSH',)5KFI=9'N
M)>R^K?I@F3R0_E[\[(5!@>!!L^VT3LN+S9!6/4-W8D\6<=U-2_'0HE+-^ NZ
M&9Q2$X34_&>^];501P&:+B/'%[Z PN#L3JYU<!ZQ_:;?V=5REW*F4D&5;.HF
M5M1_W+LE*X3Q3D.8!4FY[,U80\BU=>3;C1ZWE@[K"/^KR>\^Z3SF*I8<\BN=
M);%\R2U*GY/6PD<[KT48^[Z-]>;:J-A8#>=$WF^H8A:2BHE-XX!<+]/>KA#^
M9_&'=3UMCP MY>OPM>&0C="W\:A0T%I.E5>1]EZS4,!0@[9ZST2GE(,]$=QC
MK'V*G.9DVH]+>"MJNAI4D\LB_J&P=J!VH;G17B-''ACFX@*):H=556G-&;>[
M+I4]&?L8\V[\WQ-B^TZ>YV4V_WY"JCQCCE<*>)8H^TVS%"+U\F-LZ$QS [A_
MKIP872;&;UHD(OD%R1\I,!)SQBE!=EZL\H<Q3Q_/)&RX.1_YX&@$GPE(;V%Q
M7N6+L;S&:]0+BQ8SOU7S$=JF9),_<R+M:@/G7?C-E'5V3>M,1A-&#,XI@ 6(
MD!Q6G#^@L+C#&I3B:\JMXZM:.+ 5_<HSS<8L96!'"S]/Q5]GHY1$#X0F]&*#
M?$U.CHN&&73T BOJA,WL71*-BK2^KC;4$RPKE<Q_<M NVP] 8!'Y^.X026EB
M;R1]7;9Z;J@Q-R?HT&MNWX\%$[,Z%[NML2K7AI [Z3V5Y-TX["')!]=_/1,'
MS$J:Z3T8Q#>V09\7T!"MTA7O!3PYI7UPO/&"@H-76^3Y.T_*_8VLH[\V(PC7
M6T\:PSSR\\SV)BO2)N.<^Y7\OH*[F64\1B?Z4C0N ==R!0]WJ^:NAPA#$8HP
M/V\&I'%S+_O\\#U3MX5Q:!'KHY-2?HYZ@PNA66 WTL[9<]=L&,+;9Q5,.;Y/
M#6U>=-^/_M<<O\8-W..%"YZ2OQR(C!8C(YZW0Z&=9R&7@%X$K;@8M(&_!%30
MKY\9#&8CZFB4\T>2['*UJ>%'35,[RXIJDT<'FIQ.BPTY>(<VLD1%2-+X;,7V
M6'F5NLG+C<FIAR_ VV/M]X\4*N_@D$=E;4#!=J/2;N$R9I6%*!DS9LZ7J&[L
MWLH&<^.Z;HE@ZY'U):!Q8T\+(EP+562QVZMMMMRW\!=V?1O5^>D'I*:?RTTO
M[JV[QA<^O@<9>\Z&J-HBF):M'M-JFCZ?HK&>KX-L14-HB&>_Q<A=0KULI<*L
M.X336O)VG*N9:[5!_6G9>@W9TW\5;IEB42\BX^JW%+7+ARA#1&@$O+7GP36F
M&C>'MZ+:WN?<D)X/J- %%DF3*E7"1GL5Z@J46V W>&WXO#;YO19WV'E>+9'A
M2TMB-R!VN!J'BK</^WILQQ0&)4A%0=.%J3E76,!1<6;@.!/208F>3" \U8;U
MEI#1M@:(M38178*.O*80KHUR;7/5ZJ^4^OJF$YT.PUGZ$YKTSI>*Q)G)\4__
MR]X\J&S*G2J3-\2:#!V)OC/I7%DL.=JZ)BX([=J;S9.WRV<B%-1\KW).*" )
M>0(&]>]\)M"JA.3O?/<%5_S6D0976;C95BED8MKQ6^.\M4MF"+XAN_ B[KN"
MP>SGI^D88<%Z-+C2*/I5L;>BTWU@E&G./:T'I542-64MI_<T3X,"<J:Q&,Q-
MUX'53<;A 62\\F^]*@L9BUG]A&XN-GMJRW?I#+:Z#.H;8E83O !4ACZKM%QP
M&M_9#2"HMZSK[/7:N^VF(T7ZIGK75K_WJ,\%Y&E(Q_MCS8H:HLX5"VVT7 L^
M.S")<2\*![FN8T9<RLV3 AIJT P*U5UBMV]&65GJ<647DY_VW(G,?'-OQS#Q
MOYA!_;\<DG.*ZSDMJK\@.M(=S24[O(_49[J0YS?8\AZ>04=6C-IK']]/X&<<
MM?UA5Q-X>\.0\\-WHU2ZB41HKCB[QJ^:(/\'GVJXM<$/U(V_#-H-8>SUP?>1
M.<DN1DUE'$QVZ^9>^M'F6-BO:>KM5Y47I]KC*BRPS4B_9)<![Z0IMF?RVJ"_
M$MU3SS8'FXA]2DV2"L4LD[]OH"K%T9[07X9>DOPT0Q:_D/4@BJ#NS\ &BT\#
M:]Z"^(,:96V29A#;_I^RE3[-51MV9@XWU*TF:N/*.= =59[197([X]D[TZ9;
M^P&^JKR47\)'5#I=A )1>X^%A;/'_:<,>]I0#2%%0@8S2WN&!>X%K#A1X6[S
MW;7/0_WU'JEGW<V<[J&@&)GDD3=E'2:%45_W0[>:3B'=).,6!47PK:.!K9D"
MXPOGC2_-7*=I<WD!M+G6F:PZ<]/IVDKDA.[V6IE]=/1JG.F ;B5'&7>0ES@V
MV&O)I(/,27"_5E%G8:U=IF5+C+'DRX)$^/!K2X#,BT0XM;YV4> 73[*O+H)$
MG9-W'NOZ#7>)X4K4.107#G>R$BS)8BDFRG='(F_N>ME/F2!/=Q215;U6#INR
M?ATN^WVVR8;QF,SR'7T=+F:.SNSWIKNS!FLX#9$E%=M&W,_- #33@)L'!\:Z
M3[7W!"T&(S!&R=63.V[(=J&8YY.N-WZ1^K<Z_L3!:S'1/?9MS4U^&^(_D;!R
MC5>?B3W))HL\I)2'>K-,T2Q":%#:(_(G5D,C5RX!XRW-P^[:23C.CR-='P0%
M3IKE!L?D[\=FB,>4TJECDI^S,SX-K)\]_"39W/\D2S9ID=P686=QDV*:)NRO
M'#K\7&OQ81[?$-5+V;(2;'.O"KSCAHE]H#<0IV!=PO%:I_!+]=[ONQ&+O1HD
MPF##(, #L4JGF369?)0/(]93&DG&JT35M;S@SM<PM^#KN.F2J'GE& *L3$9\
M/G>07/*5 FJ&!%T"3/ D_=.V&U%U>GZAHD.5DOLQ9-J(=9%RI0U#1503/I+O
M 'W;HW>EC,7ZZYH2BLUXW6,^.L!MI]?^5$-L7ZV?EZA&*$D,_D@MIG^U,<0%
MXBZNTS24MZDV.$=:F?-/P,*([!LD,GH$KU-,*+'TQLF@SMC#\[X9*$Z^4\X;
M*:_:U,QC >M<;SB8+1$\54KV1#LQWK"-5_#XMM/6W][O+AQO"'%BX)2#N$#F
M0T)>W,XPJDGK.4)3NZE.9UU)6S%RKM +FF@':?_$#K2GO*XS/>,\&QITCINE
MD?I"2Q^$R4^<"XI_,#Q^58H!C?_X^0*G.V]7/!F^]U]3+69ES3-2IJE47@N:
MH9QCO%.[R=-#9_).NF8NS&"PS96&U&#^N0<KR>O4A\S'5YB>!W:=VP;CU>9+
MDW*A] BS )1R2W[D;R[ ?V-$NYGBC^,/M,\%7@FJ#D)E8E!V9[E]H]07+X(@
MYYNE WNIRT:@^+*4$8N*7Y!51FDL^\]#P NP.AZ"EPPK%6NMFET!=-<ZV%.[
M,047U)VP4G [-B'T=]!W1R0K802G.$X%O:,6FZ**. 4)1-Q-_>PV\UT02]TN
M?$,2(:L8DMALFI101_U :ZOU27064-6RT2^QK;6N(9IH)M2TV.]LK/F4+K_P
M3C&0WMY9)EOB!;VI(I> 9!LFXQ8_N54\*^S+AR>'4SP&3YL"MM#<=Y?[F].D
M[O"^E8../*)[8.?*Y\KO9S9/>!JPB7H;'^?4SDWD/UJG8&4WP[M=TL?D6O,\
M?>]"MYLA2L&H$0YYAR2;.?"9+O0[/=Q>:%6JGO!\2B^ZUD&?M:J@1YZJ!YT1
M39N%.?Q&]_JPB#(I8;V!5] ]$.AV_8*.1YH'2"3,PN T=.Y&UCM?U2%K Q.?
M^Y/(L6[FQ)7Y4NW7:7>B&8VS(98N7=MFM;1,.(G62DNKAV5-]E?)7 )6KVG1
M2MT)HQ(V*JK+Y&.$W2+5*"8W]R\>=@[< N(TS9QVTDC5+^;:C%RCBEOGY6LX
M;L#6.7%FD5\<"]B81M;^9QM"E=&7@  #6I0%B86SS&5?V[J19UPZ>A<'_M=D
MQ3]!F6@<0S$M KA?$/]"RD2VDV_JU*B],H,5TW[,>]=OCOW%'BKU&_ZC_4Q;
M.ZK? T22G"&H8CUTK 8V-=,Z>X\="3]Z(=FE4E[D0O +ZZ_TTC$5OC<Z?;NP
MD"DKT-.YB>_(O<KNQ])4[-6ZJL1+P(O2L]P?U0" T_ 4_4SL-E70!2$KF!KW
M'QZRTGK*E"H[R^-]M7U%8@^-(Q![+C;_2KA554OR$A#YFCQ[3Q@7.$4J#6()
M/.+\8+_Z?WXL_KM^+,38UU0I*7NJ3CF;6X8)NM!-^^T7H3= 8T9/ GG;3&+[
M,WX@ JQH44XDUG3D_E(*'&I5;$. DT S#[$O;#F,H%N 1/HRO?9LA-IX#&-Q
MFY%#/"^[!%PA? )Z9R64L%P">H+!S_\&:(ETG$KMJ2JU_Q@FX#8CF_?\*X*!
MD 3TSD:4L/)^HX(E_UZU(+;0&<..P^W3TB9E;F4R?J[L8+[(U@W8C%D?M'F/
M$)3B"OP WU+ZVX]02!.8%<6<:[E?\*->=6<DM&U.GKPLK\GYV"5#?Y5^+KD1
M'#;0OTQ.$7'BL-\1:E9V:O+RH\3(,UX)>8GLS;MK\;V=]<O)28F-GN0FGY=1
MA6#5/P8*X-)_I;FGE>>(N*KP4#! -<RUJ2SN9>+!R$,<,[?WBS*MRMV5Z#K2
M*_<9-*^-YCNH9<I2@F;4@ V%1\*B5:L"ZLNY34#-ORP:PE(LT%%^'RF/>]L
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MEB+X0NRDUBT/(-8N!Z)<I>9W4O3;4PN2;5E\.M^\_ QXLJH%,#Z!!G+UBB8
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M^WM#0Q(/<FW'>JU',^#W<*#"?F#!D61-ENG;XKAZ,8.O#WVWE.[Y_X9GUC-
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M@H) Y4(F-N,^BOV.-1'\R?7+B5U-,H'3*]@M$Y>@.(HM+.")8#.FA7T@.BC
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M1]WM$GM%D[73=*"^E\>#I&_QY]<0X06';[_>?EWQ']H;Z&?[0W N_W+_T'3
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MV?]S9Q]\([D;Q*/28$F$).)/YYG)9RMQN$]O0/+@XW;H$I(^;BA(/''N4PS
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MI7EZ@^OV,#*"<J%9$A]957RJ\YTJB;#]GN6I]5 K'<&_?3BX=.9O>>)!Y6
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M>P83N3L8DC1"4@C\#=:KB$R9HXK2)#^'CR%ZH*"Y:=+$ C(R.A"E,T7+2F,
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M(B*M=P(JS0#,5Z0=54IH@@:K9W^F+K;Q3HN$V)+!9*[CU3FZW@9(:WD#E,$
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M-QKD6J?//\E.O3B>V^7BJM-[P51[D0'X#1R&80*&49W<&8#.,ZT;PUG#7S/
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M>\/\G:]'Q ,6(OT>UI"V;DLB)M^F:&8GTSB4TYRY;&VH2W"9W ]<6,5:XNB
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MH^E$U;25I+Q@!#3I$#%13)\=2(K1]0IPLHW#"# /8*L&S'#*OY![9V\>!FX
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M9NA"9A(.X7$&J 6-'%AE;188\/B**;<L;,47<!3HWL :['ZMZKXS)W9;VD2
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MYX_TQ_/Q2LS#(J5J!5FE*XU!9[G<2DT\+6A!\LXML8VXK"1#"5^H@__RJX4
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M+\?]OWL_[WOQ7IRS]\59WYMY-Y\QQGQ^OSG&G,^A[:1EZO<.FUN9OJ@)0<^
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M')8<O"/CTT35G8JX'D]T]6RCW24LFM99#S,8 56L[*0NZ#6#ZXZF3?GY#0/
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M1#?9?O,?@*NAN85[GZG0,(&A (3X(N_3@\Z-&:? 2S/3R%02'KL1YSN/+]O
M.![_&N<"2^LPC) [8+X80LH-X\4US:('&UUJ-1U)Y.(>PVQQM_$8LVWK2C%
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M<AX0=#B052G">-X%RQ7;[XL9-=C757X'Z2JNR_.1=:/B;*.L!*.*/ B[NA_
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M(6U0 )8VC%CB%DJN7#-[%EZ_X6=:I"5M1#(W.Z1I79J84U[.'-<,Y-FU</A
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MT$$LQSV[U_NAQ,%$YF@ YI<BLZXSE'25BKC>@%=ZG=Q!#=4^)+#Z",/(%_(
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ME/^SQ\7G]>J.?OX_>UPE(U4EGS]G_QZ5=*&Q^I/I%4.[W+IVPEGXT+%PSK%
MS)&5_GSV#>&DN8MN,WJ(AFS=QHGRC??V<3&6W4'W+=KG*YB]P'[=ZO,>/J[&
MK41J4%(S?'':.Z;$(+D4E!C+C8QILCLR<4(LC8"$FYF6V[H*?*13Q&\4.ED
MJS4:_T+$3?<YARPI_M1I67RD6>C9H;SZOUAY#Z>FM_;MEV<741'9HO2VI4@'
MZ1T?"R @((0:2) ."1U"(*'LK0+2I02D;VH@(<0 (80J4D)'2D+OO87>0<]^
M?N?,><^\\\Z<YU>N/V#-=]9]W9]KW6N^LU2.$N8<)L\X4,<S>M;CQ+,=SXL;
M,[F]*S #Z\U[YBW@V8?5)I(.D9D3_-\_Y#VBKJ;4XGWB11G-9-G>IVL:03>/
M;_.F<*23D$KBYN:NG[TZ]1_5E![!U$MF;TX\9GAP>-AX %J^SD]5GCW0>#&\
MZT,EQ=WWY)UHNVARFYW>\*HB<HAVJ<O\]"!LIK9T1",L',"G7^V\V&UP^;A-
M\WX_7>V&[:>OCRU/6>XHJ6#OBG9$,][@^U3IES:*TH-#:E-'Q'#!^R5M2;?'
M$O/2V$^ZY^PS!3SHV:3OTR$**.(M^O(N(I$[-<DW]$]$HN-1.+5;!?SM]%K6
MFXQWEI%7L<VMNR 6IV)7$1)DNBT*"E7_P9"+XVQ.5 T"Z&3-GCZNO>IH+*XY
M4W6B&6FJ1RWXX].2(BY;O++GD*!6J-U<MQ;E0/D2;48+#HHB$?U-E.U;5T!A
MRGQ;*9^#<[R=5"J6]CFGO8#!TX9.SFE_);.VB<MS2O8.,5U:TRQ'<RP>Y.68
M@40H(Q*;+O 1$FH%IF9G8'AS?KI>NO+NVQU6EK.Z7,*I:.O,X&%I:W]84T 2
MR[S_U>UM;5&5'CNCYOWO0N(9%P4>8V&HQ&ZO3W>,-,@"?M1T']/[,[*8A(&]
M,R F+?-?U._XF_HG?U.?Y4-EES1=;'K HGS@GN]"G)UDPGVUU>.5F(1#CH5&
M(2)ONJ0%G2D&]*EK/Z@C'5K8YOG ?]\R*" IJ &VD$7UU(9XAH5@['1?;</&
MD_L=.[32FV<<$#L26CC%$GQ]7*U'AN2%H=NO8/5\ >Z(!CV[8K \B]R@1*59
M[^JZ8PB:N$.3]5LX.+?9DYO]5MM3F3=ZUC,":M!S6DPT;%.?D62RV DRSNJ_
MT\W3Z)G,^O*:$G:'OV]I @S9_NV8?E5;Y&&<<P$4\):M"K<]%0N).R_>53\,
MR@S)K]=*97'PO3@1-1]:,C*QK YO,B<K<I\*;-5I,9JFKZC+&88?;E%M!"-%
MJB6(L4?/V---D1J/01PEQT<$]8SS-!IM1E_:6IJI+,6PL#<M1.H<,'=P_2TH
M_.6JN)\:_TI( -=SKL\6;1/1(K%+?(*X#P>^ZYS;_3!8Z("M""J6)Z3!5VVT
MF&!6PY;^<@N)&47*-5L!7J.3A/A[E^BL?6BIH,<PB7FZ<,T1!P>\G)K:O*,!
M7@(?J#)^U A= 8YHV,S*Q?#9-3U(FE+/ZW[VH@&W<\8E<LV<Z864?A! 2-IB
MCA*:S\2_M>'<5&=#^UA81+]OT/II >9E3']?9K%G[["G-"S&-YV1<OHI W*Y
MO5'A2[ON5U^5U>P^"@?L;#%ES6S/N=CZV[2Y.E./'RW#=R3E;"3UA,L=BQS+
MW98<B!JFJ=H /;D://^%@2RS!%!#]OE#%2ZCZYK+<0,_D^>)>5^'6X)2G^SY
MH/XFML\G&2IZ_C*O_U2HQ'?UQI&EO 8Z" G_'40J'XJU-:_0*_:#"[M9^75Y
M*D-T'%"L$DIB@FI8Q^E[1O>+-[!(!P_V=3'UI+?B'AO$OW:+,EPSA@T61LTS
M[DP-#1LM)0'NQMRQ.RQ<#&[)(><G/%:6!;;NSTD>R,1%$=-2;E4%^:FGSWWZ
MXE3A[(H#EWCX&)GP4UZM+R8D)EL .]$O#!/$U4;B9TD/+M9KQMZB@8%+\YU&
ML#Q&]!,?JK3-]O/W[C2<8\<67[$?\:5XZYV4R;S11K7(*(EO8PF568:LKY:=
MK$>M)#,*1<VXK'1&\QG%+EV?_Y5=]19X+K)NHN;)F#$7_GG-M]IH0@#NI\-N
MRR-<U3WE)E^ENN3297<NC*RI@7)V%F(P&$%!UC4X-!H#..RM_R<J@2YYJ!2Z
MW!!=_H_;\FJ%VLY-V9:[#37@E_.<_N:?;<-V7;T:H?E=Q7&)[?[LY0X^\QG"
MZP4$1<Z<45E"7(.BGZ'4@]U>8<_0>*@E9F!IFG0/6ZF>K_]]VT#JZ\A,;54!
M!C&RC@,-E*\9D?=]X+/V.=0//5[J)/&3G=ZLNZV:%WFS/60I(9$6H^I1 M)X
M:E/IXOO,VRZS=&N7%%1<FJQY^DOGXV1M7:E:!5(]^KV=FQ%.LK[N)N_&C#7-
MV,!\LV,=43\(V&'U*U@,70[=D%?/Y]]M&!1>K9.<Y+PDT_\Y47,EP.:K_2C!
M8\Y;\_A"7097O'652UBZ=L1Q?WZ:TE6<HMLL<7P%Z- 1S5CI'KCEWZB_)-,;
MS,$I-:4"N9^6R\].ZT,@6(V.)THNY]+G(GB%^J=<6[!!1=/-5P/BR]O-&C;+
MS(:D9NM!C\L<===^36OI%OON15A<C;PJ7Y14J)5DLR2+WG-YT3B\6:%*.E$<
M+?'1UG1TF6"- _;HKYS60%4[4?J>O<]-4TT8"W#<F1M6G9>!4S\8^->G^G/A
M#B,[WNJ)#=63HR?;,@"[25B<39_1*U0NTNG+*N9U[\)AL,=V/1%SXA#K7IK0
M'V **&#)"7JT%!NL*0?,_"C>ZYWC.F)4O(?@IOQ9F-CL/:L?VM)JETT.F(-<
MA60OY\W I2J?NW9M<LO(T^!>"YZE!NVDJKH8HEV@I0*7C$:LC7!6E&X.H)K'
MHO+MP;/Q @+$T"$3@/W5H,&@:BAN]*(QK/DG@2P7-O=1V$[ARM-&7Z =(L?.
MY%UT4:%63<B[D(J-R6-CZJ7;2AZTUQQM%N;#W'%QRN^@)NM/<]=SFF!IW[KO
M>I2 1HQ(..[,>=[32ZHV2A,.]$JBJE5L (##G289.,ZC_5;MO+1,'9^PS*_:
MJZ2T2>I;:^+PM\E-+BQ9X%'XB6KO6]61K).=GS/)+76SOG,GH;67?^UWHNL"
ME".2E*CMYKVMGU9XOU<GC-.GYI1WWHEJ[&B-Z(,%  NV[%+Z"F^VBCY-&5>4
M=W0J.J8SUQ VG+XD;L67'N3>I.6X:<1T+Z;X>P0"*8;.&__-^:S6C<W#(H=/
M35=?M!S=T0Z&AT="'F.PSUY[49B+:>IG7:>'XP?Y:W=4?+-;X%<_4RX%1/?M
M92:C79;M'B5%DS]O3WNUB(A!/6TT+NB/FG*:FIYXI&2M<(@\"- SWCYQ)&X*
MG2J48GMER]4-9K&F.3"G\LI-ZI]/<U90*#CLF8PYNF2A!-U6%+-%02?]X_[?
MAZN=5?W6^IW*::3QBK8Y/J9OMEL=S;8%O,&8>LC9%_7,8[%7P:##4QV\1-BH
ME5Z6U9?:_HIC@YU;PD7K.6ALU!W/S69@HU,23S#LJ )14C5Y^KA((&"RQ_I)
MD[YVK3AQ=$'Y>6YHOB9E9;Z>;_:@.;<G%-]OA^L^WI_BN+?HFPV7#:!JWK#Z
M1V;WTVZ[]Y]NGO <32CU*9K/Z<_6=FJE8Y5[6H5RP?Q9-I'YDG2$MQR:<^M;
MT;".CB?F!T/RJ86%N&5:#>55213W+.?U *MS"_O:<[K>'\K@5=6D7 V?-;IP
MZ^ZG,)Z/,&9TRIE3BJ(1Q+,S'ZJ W[86"-70)L6WM<BE%A%-"98DG.>PCFY;
M5I*N1IO/@(@N)M( \#ZK0S$+<0$2W/GX;/$]Q@QG[!>?XE%74^,.9:^7K'AI
MG\_HRHN:57&MD?0=^&EVHH=7H>O3P*MVCS.:\$1N&\B./P XN<?)/9C%/M%/
ML56X87 30%%*HZ@W2H6.Z%*+>V4>^OB=4]X+?Z;$1<)O;V\.E\R4/DA7>BCE
MNV2M.+QS?%MQ3]07-!WTL(\K%'U[VY;">'CG;#<$R?ZS:.G2C@MNN+<Y\N),
M\P>#@/]=4B;%CJ XNY97Y.64KVD2(/PG<$THW<@2Q80)-C<P/]XZ-+U; -[L
MP0;:1H*,',8]\(\;&3VRT0%A7\\E_*F5P5\/$H>FE0=;9V8AO?:0$?]/.Y>A
MY-2B;KF->P[$X,>?MLAZH (4.IZB9US4]&V=Y\'+-<1-:O!0R2=*BI]YVE]'
M6DR6ZDCAYDDXVT%,?8]QPWL:JF2K[==H4S;^[3F"]BDQ?!=I,1$$[K_$C,'Z
MX61^YH%MGAMP4IY=N\-CZU=ZHI#S.Y5.<J@N"-NZDYQU#]MR7D?,LO/CKQ0M
MNFXAQKY2QJO$QTRN_,:TR&EOS-'+CA+4LG>Y@3FF#)/L5=>KB_JF)5(UG@-&
MLJ6VKNX?59W9T;17165CNRVCZ!JB<5VTE-RKL(L@+F'V#5"YPE*Z*+$O.=$2
M(R&1_,MD,,X]OZ8X!YS6PQ^2<LX(__6+[4!O5UCQ1K: ^LD/AD\-3N+Q5"5K
M*4]-0F<"422.%:I"A/1GJ]7/$[H^]*CQ!@;AZOGCR4S";GC"H^I^<8O8R* B
MJX3-,-[@FV"'%*L"%3.JVK=0IE<9S^^R#8$ >DJ#2A&*X;^,\$P=:R^% (S:
MYL5&V\9H*EK/ =T^6:ORH2Z_M"\2+HTO2Y;/9>V+;CR4O-2^*=O*!Z$[CD$Y
M=XT A"JLC)6C=/.#63[G/;&E3%?SAUT2*?J^B@20)0'$_.CU=D,/8U/E=8B\
M%BD95OET\?OC?D_E@YSDP=#^I#[JP)I(V.D3#65L[)0+ENBO.Y92D\Y%KR6.
MK]/UA+Q!L;H7I+VZ/FF<0_6-$DU%G9 Z=\-3X2"@BU4&41DCKIN-<)$9X-SP
M(70._K.2<9ZNO(/_$*A]=U&326E :ZGB@:IT!-^2/LY@--TVA+?6<NZMBK,"
M>1N729^K6BVJF"8(QWZH7->!4',AB3B]^"G1!^XCI!)NQ?3?8EO#Z2I?S=WV
MXRZ!](#LR\G%'7SD9<!:.)A*N*[P4#^^SH@[B_X(O_J5]]H8N'J%JN#KZRS'
MNQ"HU6R$"4BM<,4YC\+#ZOO4L@E.;'B/Y!#:2VPTQTF:A"OY4M?5'.;E!SR0
M+S(.2'J4+B%=$512]$QX;M^_SOY3W9,:&2<:&1US+OM!61/MK]9'5[%?X;OO
M_DTAA%=XVJGC[*SZ@9^MJ^3]\%D)V[/S>:\/2X$R6;<X$_?ENM)LF@Q@WD(2
M_F:VO,S:'.UV_MQ*[I,#2D5B^J,^-[+FD[@$9]T103-=_/9A8QL(?AR!/I5(
M:9\(]6XJWU1]E===M>8O/_W7^KK#9VL(R3_3L$HI%A=[,^_X!3AF75RJA!,$
M2,LR-:/U7'6RYB98/U51X;OEX5-F=MK34I5W$'S8)TG4&HO8D23C!(S&0M2;
MKM]Y3:ORI!WGNOWZM,ZNW1"ND-</J2%8]\1(X2#=FA5N,5VY" RKY%9VR*3Q
MXW)&43X#_>8)UEXOF8TYLYP-\_@'-23VE,UY!$^R?.#_[*7U/T;4?O9'%VR&
M>*6O_4E'_U05:85!-U0%?(]^5A@<_J1-:C/VV,10$)J[SUV2$1R0I7;#U%8!
M]\XW\;>D!:/U]PB\_0- Z*^[<'^#R[8<TY[UQ;25^)6SQT W&>F_^;,\O"!H
M+Y+<D-$%ZG%V"\.>\P"FR8XZF^<5ULG#O8(_& +:3V4+M&[FO3_B3@H( !XL
MPJWD ^K*5<15<+7[GM.2MA#VH-$=Z<("'^/;<H9F^F\RK+M"#;MJZ^8\<:@M
MJ3IH\VVU"U.\?:#3[)%]H![W%;3R->)BO%D0KZ> 4:(+VQ8UPN!0E839#!?M
MDPJK.SRTC(6GIT.;E ?%7;-G=*KT6O>:1P&XC6LH=3X+F'W%57EB!Q1YY_<"
M/4*V>FB&NP!T0'(G]R;+73F$%@C =J]TKD($@H^7T,0;=RY62C/%&2S&>XOI
M&\<OEG!)BW=4 $ W:K(R@ FVD!$2GN/V7FI\X9&2\)['$>!;F*C#Z'^Q2N)C
M,U&,LV,!FL<?=(N$W"1W.;"ZN>IZAG+Y#9^*6"6,U#$ZQI<\5- B.-<N 8PS
MBNN2.)@0*3$6"&C5SHHUJ?J &@WR=FWA.@$_:LYPS/DLD$%RK;^!ZK2>75%#
ML\6TY/<MEDX=!RL'CV_SQQ0_M[2%!=G"9%4F#ES\Z\[&?N\UJ]4=+5X'L5(D
M>DI%9J^7&LC-Z8;I!@9I+@3I_-L!%,8'M)S[N[[63E* CC?V%5(;7[/J*M)'
MK"M@(I35Q0@D)4>/?Z$6RMG/\>&$><H6Y_+F=#!U$KIQ"$J(I74'\+T%!;S)
M/2ZV9VU/=\-*9BY852E90,.!AS"XV=M<:KNX);3U=4#;7RM$_LI;E9DG(435
MWILZ/9K!"^.MV4K9<PTFNX#:*:3E,6I,Z5I7S]FWRH64'>QYHZV3I\HTJBU;
M3Q(QZFO59Y6P9YT@.7 FSX;"(<$4;>&JX9K!4ZBZN;23VK1[^F_&IM@[OL,I
M5)R'=<?FO(MA+FZE>73R]?JZQZE!@R?GY+CG"?2>H;3>$Q..]*XEC)M?'FEB
M E.#ZP<W ]\:TXS3#AYWIKY(@H+C$4+)'!BNGK05LS2(@0QK&L /,0(%K.->
MQ7>+=7=HFB'.NB$' ?U2O*V]W+L5ZYG&2N59UDU.J9UUS$5<.L+'8 &F:ZMF
M'1-6C&1HV#V.]B:Y'PRJHX1>W%8XLYN %OL/AB&9S.=7VTL4_I'+DLA7S^R_
M_#LV^L7V<+GWB0S=Q)_8,V4]CB"AC5%[P3T[)GK?JVU9_V['X2CLX9\J .2N
M\P^&NTPX Z8^Y;;L+@EDMA/;V?UP1,5<5D0C%_8-G/^?Z/<38D@]#AD-44U4
M&-4_/Q9X?.7;,O::8/DUF&]C/6F])77TO(YL$170J+@=(!%:4E'>7[=CH&YN
M"W1</-*..8VH]FP3F>G).'<Q-J K_9Y6ZR1]UUKKOAG0ZI\[?!WN]94QN6/E
MFW4M+I9-,03(:#B]:_:XNFJI$'H5(IDA[/9R!*V+$;WF,\2K3K!;?%Q5/I+/
MLD.)#_FG3.80D$9.\2N/:OS<I34GU\YK]US&E X1C40@+,WQQ(&7O2?8X6:'
MEB;BE2B6BH]P'7.?2GB$#=#X@'7ED,R:@(YW646Y4_LLFUA?SI93V3A&UA]R
M@21@AY((-DNJ^!B:2T9Q-15D;EP-H4H?-&0=@?O=;4?3[._'\Y@8)S#SA$VS
M<*[7A[_C!P#'))UD6]YTTE)& >"\%S@1SW?Y M>8T1TG 2&>L4)1BQ<*+*JV
M^(_+$S_5]TH7&2Q,/Y/1[V_*X%ILV-"4\^!TR\[='#S$+01EEO1AIK >W3IE
M(C4E=P20;''ZS=W%4;\IE.=?ND56^3?+;6+B[-FR,LMRU=4&BM?5-3"A)G<V
M6RY>=VF.MQHBQ?6O=R22#GP/7\$'TJ;ANA56<Y;%+9("CU-279GM_RT P<Z^
M-#BZ(:=IG^^];$:_G ^39%'4%I7D2>[9OAP8U)SA[2QRSA;(*J.N5QHGDT;&
M,(^Z PQ]NKW[-IM@WJ47L8^3O&4KGQ]N>('+OM_A\&I1?/=<C/W9"Z3M 7'W
M?H.=-%];TI$Z-YYO>3HF8=G;N$>_''+^\MHY67N6_6;92E!"-!_OYZ9$8E+G
M9$6*7-]QGJ+EQZO#<#C\=\P.?;,^(WG,.&4J9=W0(-[^F9G)7W:X*FQOV4ZK
MV @BI\9I^-N<T\^^M;L=Q[NV_TB 72.]YXU6VX22*)%MWAJNHK)2].,X24B+
M^]#C3VJ2G0D0H94FING*JZ^"$LE3X4&GD(H324!#<=WT[V-6KM[61X47+G8'
M3,1Y@^PM_.,88_^=J6P-Z-28[IJ,ZOC9EA-2-"^-"S/TA"\+#6S;-$H>4Q@_
MKWP3],I)BF!#SV+W?+IX%'R1>H57[57 1L!<8 7 I+N](^PT50/96SH+K<*9
M$+P7>-*6;7%QSN8HZUN?C%U/ $2#9S2W\10U22-LTMSE>4\[4IV%H!8#04(<
M=8O^YWDQFZ40"4?W5TUV5,? S=T$'2F-(3\Z:+H97XXUJ N<Y@:EQV+%O&;-
MDJZ7D0@3W7?&?6_=*?  H6IU4'@<3<H5[ )?EC"!9-^[IRUKB8/]8%C^))IW
M"XUT,8DT*[LXB#V\<]XWREW57/YE<P3DWGU>FL_IV_\?SG"C3RSHA]C_C20.
MDX#%0X!@X-:BE6E8Q.V+,/Z8BQ\,._'O^N.52;5I+3=0>N?2(:4::P9(G@++
M)Y' E*OBJZ\&"9^40O^+L?B_]+#-L:O2_LW "FI6J7M5/H0-@2';D;P'74"+
M%A;V'+@MJH610I]WV,0GJP8?#LN:M;7BE=5L?/H4,DF&5&WXJ\'[AVN.1:M<
M3G\HYCPZ;9CH]#37*OJ _J,I.:^EWMM<SZ#77,+J!T.-:593%+G*=E]0:&I1
M%_^OITEL^D_T7/+=4HA]'@?IOJ2T:;\T/XAI[ A['MFIH,)W\=L+M?9!'U+$
MPP2:+2"U,;?]]Y)JKC<Y;J*%!H;FOL-YG/OY^"?N%\WOB(Z?)SN0; 75;^/$
M(1KLJ^2%%.081#>Y&18P.<?,9J'CC[<*?Q;X/%^5B]VJX9PH*54I'R_ZU-C
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MZE+IGUH"?$L^)7:=F=BLZXV)".7=DH+%=>4S6$^^U:N"H4D[.5V6-4#@2<8
M].:&M<2&#+,I=G2(ZTC9_I?,_Y7N_WEA\)FZO_J&+?EG3U+DFX.8%;1L>,=$
M8Z0WK&^?\B>:OT""4M'JQR;/0DUB8]T2>K$]])5?VQA5FXN7QQP*Y3Y17.D@
M7@$'[D<&!JQCH'4+5]SXF)@C$2H+NV/%M\5Y)RQ+UJHV+$Q^<I;;Q?FCUDZ8
MH:I*$W_9FIR#_[&%#^ G^FANV$:!6?WN"M _^#M[7S[(L,K 1V-*K6QSHJV\
MJ$\BUJU0*J)95-(T=F5/R6Z5A#DS'= MRDDX^U"I*VIQE1=S_85E[R>#T+)#
M<"^]F2A@O8I<7FKJ95K0%W8TW.1@(R!(2A]PJ/)M%H[(:^[84?AJ<MGGINN2
M'N>[]G\"67<HUX)+J$:9STMQ]//([%?"_]8+2 R_O#Y\T/U$S$?VA651$-/G
M(WOZ6, ;_XLG#WL%S'\P%!B]FA,OWS4ZRDC3A]6$1,UZF_-IC7Z..W!O;LY7
MI(?5]"0?=(I@8K'*"BKW+9X\! A(S5A]3TR6B-@P.^S/^3R[*9F8:W'.?!Z9
MD7N3[!WF=J;D\:37L%]> &XJIX!PWABCZ<?UM.^:%+4RU^/=7EQ%;FG4I\C
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M[91,!8G' ?%LV<()N*&.-V'I$(&1)(/77?)Y!MZ'M79+)!J4:)IS3TY.3%(
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M\TF=2)E(9C]XW';?8A")XJ858O!/\<]H2AZ(6)F0Z/#'$?Z:J.Y+<.1$\^0
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MK7Z\^%BNPD^NDN!XXPEF@ :'A:BNQP[/L=+W^4BGH]MB_E4C*H62":<<MW3
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MFME^-*?/0^NV3L?1?APS^?5)#_TU;!)^SSVW_X(*663>?%:< WR7%L$NZDL
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M&ZO2_$["R$O:*(.Q;^L=%UHPBA^1M 7H#",BC60SG221UJ8!05]*&C+*"VS
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MG4F ?6J0-K&9.A-V\LPFTP2#&:^[X'HJ#+P\\,5/P$XGKW?PVVSK@N,>%PN
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M^A,F;8%>XV@CP$_*(UW%F!#YHH7.M'=)/MU5RZUM,;-(FP2>(',*83M1H1)
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M_<K=!#E$?#_GV?1Q@N70-/H.06V7+%"8' WTUVG:=0P3Q#6W<WHCC>"]2\I
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MJE9JF7Y-GA21)U<V['L6=ZE.>:@IBY_I@W!E[F5"Q>B[U!XC23WIFT]MGO5
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M'#42_G@MBM9X,-(,AQF'C3&;#M-9VXZV?.P*O[CLJ7TZBQQMDAO _5G73.%
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MD_JK_I*RIEM!PBSDXU3I]AA2UKS'"AM/,H4@..Z?(^U<S8J$,Q-/_.M"7H?
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M$/68=NPO"N[&?I^L!Z*'G.4FF2OS$G)O)G<3F!>OP]?U](PFQ6LCM6F15P.
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M'&3J6L/A&XU2^+"0#NT!V'LS;D.;A++UF0<AO,=E\J*ZRM9V^A[E^4=EUE-
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MPX,#F2ZF K,!)YHF"RH=H6N<CZ-I.'?1XPV4MRR/M4=7=$FW;Z/0#SINK 0
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M?51PT&&)Q[;DD/QK0,;YS?1^%5_]#[9&;IANIOW@27XHUR(D,'-%_4@XS2\
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MSG9XO\H::%+[< :-+IF:2DQRR(@+Q&M3!^0>[=,W;[\)PFTJO '4#_4!^.W
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MR@44W<]0?V(*#_][8>M/=:4Z0Z&G-3Q>S [Y3[5&K?KP[%C&0L6VX)+@-0X
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MJEONF63-&MB:"NA:*/7]LDWX+?!ZI]81CV^AY'B=6I-RK98[3X,Z1WQIM 1
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MK7^_I-+%.QV*[QXGS],?.FMO]"ETN^^F,W--=/CH"GCN&;T\5]7R;L2>U&Z
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MS\IOE0<J?JW<$V;A+K5*\8T;M8;7'=,"2:F9T_3B!9_C4 &^OEL<S%GG!)C
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MZ\7[]18WY1Z[1C(CTE_XB8Z[S)L!;X4F+*&]1VC^XKKWHEP?='Z3_7J@TT1
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M6IE5:&AZJ@QG1S(7W<N.@ALJYE9]_6M^<59Z[/:OS/B3H+=@1:[[#=G@DH-
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MG?>^1?3D!/;;=[4A%.\T*<U[%QIWNI&5[J)PK[]J%O'(=5Z'5?:N&U %E5Y
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M,G9M-R#:(].-U"-75^8KJ3R!LWC>Z2&8$V3;R081L&Y42?]P;FY]R):8,FW
MR.I9YWTI[ZW]6]E D.U!P[!TSYNV79;!J4NNYVXI:-&]TW'J*>-X4?$&?EF/
M8VL3G+I0RSW-/3YAQ\B1J%FQ?"LNEA-DE6/AK4_UPN&[K6'NCI.]ORZ$!#1
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M@6WHS(_-79R;5K_1<V05J[W90_5'=IF3CG3WBEW=WXS(QPBT?5TQFU@VY/D
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M;YCV<HH,XR0I[+0X3M#AL;C1B:?LJX6M=F$+'V;((9; 6NSS_:=IE\8^(HH
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M]T[YYZ J']+^W5YQ NFSPV@ >R@&Q=0A>[/_Z)\ 2?]1:M*4,_&<'E2E_<$
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M<[L^'QU'2O(+-'_T9NJ[[*!]'_>S.4E]Z&E/BI3O>C;<D]6(O&HU8V)HNNR
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M)?(Y] !&#"WJ:8-8;;=KZV\$WW=6&E+I9: [+Z $@H(FBBC-KUT?5UN)XT.
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M=2%!MUO!-U;WP-RV]2 A 9W 5::;XHK@.@J'*THV=\E-+-EW_!HV[OOK@L1
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MUDH630G7V>T1ZO\RT&"_5;%T*7/7CM>SZ+:WYH&=M^WA@K>2TV%K:S/:-MP
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M9U HZ3PT%J4T1,TG-KM^BZ=Q/GI@'>O;^%I*))Z=7JOB43Y6HRH>.A<%,K=
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MQ0A&2:/M#1DHIFC\;Q.S[/E"[@:ZZT3058(ARI!145Q[@F3^] <SFGH:UOH
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MJ3F[F>&0=C:JX7K<;/EH6[/'N&"Z67EIDW_PZ<<I\_HU:GN&VV&_0,-W9.A
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MIH(1H2A(K0=PP?C+U<%@T812WGGOIE/%Y3@4='@F6,(_']G>CJ7+5*WI4D[
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MGDA )RJFI-M7<O&2V]*QN^KW:?&4 Q<\-OO.AH*.]&L#&OH3W4=3 788*#;
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MB8]\3B.*U3S6+7\T^;:6.:TI>.#$M.6WA>.R.,"*B?S'2&9XI/5#:8_@(^3
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M>Z[\ASG&JC.760U#P1?4"T0%#=Y$#ZP;0G2,HI=F6>2%,L/T1VCT"3I&DJ-
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M&-CT4<<!WZC/MOG+5].]$+UV-%?IN@5.3+">L%3W6J[O/JFJ0T;R+:$K^\"
MW?PK*>QQXY#P[Q_3_\=?QO%"@D=\>#X4>7&QA\O:?9@A>GXR[6T9+#\:1R:S
M>C,EQ7[?00:580+6!\,81W:(M:5N?B;T^)AJK)[/>FLQ66Q15>*+__)<I^(Y
M)I?@24Z-'[R86N1-]M7%'SU:-3S5.AD5"-YTV+W@11K!_9F2%VVD0XWHD@^[
M4- 178M+\ZFRC0GOVUM4M"=F1IG\QUH-;VT [>:#H?"EQL^8DZKFXSPKXBP*
MXZ7FM7"A^@F^N.$]H6S[L/]%Y^%?+76RG5D#,@M2CB< 9U)]HP8>A\PMM_O1
MZMM(4EKGC^[7*[^UTJ^&2=YA)38@'GG9=VKAN958VS@7<1QQZKY623D+-$ME
MS^'6/F8WX99O%\Q\^4"3@0O,S(7*RK2*ZIIJ''MS]@][92CK+D2V.BPJN:AB
M?FLQI^>C@]?BCK:Z)3\3B9A4U2H<6( 5.'I]S="@QD;:6T[JHB^K E/0TB7S
MU3FVZG+&;E9XJ!"PBQX(JGLK=*CT:>WG-*-(B'E(;% >+<%/ _G ])N#S&ZN
M1H)?,LV&V0A#6#^_O:IL=PMFE49K3:M(GY!G=9(C5C["+:*2JC1+=>JA[?+5
M20KW=U96Z;3MI>I51S6IWK%X;C]?U"M[82F!KS'-6YW=SM+<FN(LFH2G9 I>
MQD(RT70LC9''@@L2RKFFB-O[LY8DC:AMY%S&IOY%N"/BX[P-$UA+;:Q<>8\D
MW>77NGA]2!$.OQ/0-@9+#96)+Q 0M:BS,.J]=8!/GE[>#ZYG&TE_KB18&G[.
M$@:,#18O J-L'^N65UW\ZU\2_02]\HZZ#PTGD_K>.>47DGY/JGW2R.PMSM $
MZ\"?@?4;4P6G]74@;I*]3$& '<?+PW-X5D##65 KI#GH3=IO$2$>A!_I8<P=
M2?),J5ZV0RA;#K8$X[=A*;W%4KI__+OMP^Y -+E,$FOI@10P:(1H$^5:M0EB
MD37]\ /:U;O)YAS!HF-I"C]"L&*N*D/-&L<^U=5C//GO%;UJ#3\K6LEQE?Y3
MK?'FK-7![U4.B#31&G<W*6NB(DD*()FZWZ^YXU]E+#@S:B>4I ;%-J:"5)R%
M'Z%Y'[YJ.S_,OCLI*K80;%8O\X]ESP\\]<>QW5PF" <_=7A'P/E95US?1#3O
M8'E6N8AUH2/(E.=80*) UKS:FPGYNE^0_+5H8]1SE?-T2M8YP/97; 6VQ&88
M)WO+"&"PYET:[66G:3M+*@_>6H@<;<_ D;5AD35PS60_W@ADS9;MP,HWEZ\7
MNAN@?/W^OTVSD\02WU=<@^+&WTK%F/@00I@>=SF4QR_XRPJ5#M45KF.D.0%N
MJL6G<LWM ,:7.-4:5&O>RK#O9])7J.3M/&^^?'.O;HWZ2;+8BJ6?7C86=A'O
M%L"S4M"CU^LH:,<^.3'%V5D&\:LPLR2MS[]V%^1*T+M\#]H<+EC%+\^<<W>G
M74)\@/[KOHFY<@:-)[Q<_N\2$=SMSM9CII,(:?MXKETZ^^)^^<&CI?)K!M8<
M9]KICO$@S,=PKR>XDZCQ^.)N1E[0R>ZF#QC:FVU*]$G<,,7":P2N&2;-L/[K
M5+N:';^M&L T=HQH6$GH<JPN^#H^WG+_*;5F7#C$RU[R)VF^$AWU0'4QX9E[
M2Z6E9-_BE2"T^Z#IQS7#H%>ABXQ'8Q3D]"BL\N5[S9.+/5,1N]CWI? &NX"I
MZ<&C$YLKX9&*_4N Y=;Y!=U1CK] =P^^XS9H9\3:,G<H<63^RE(SG;/O^^@[
MB:HP6V.9D9B?M,B8JCU+;SI[R--H(4'1VO5L45F/LI?FX*/=IW66&'VU<1Z/
MGY#!<-%(?\!/,=@=-07@+&,&@8(4OC3GS_+447[G,SUEK=.8:GGI0<UPZ+5X
M5%4-"QBEW<S3BHJ 1H^"DY9@5:W#V(#UA<V!Z&7_,V@?+4W5T[*X_N!5VLJH
MFA1V!6NU-342]E;9^\0?J)1CBP^RK?)0_7-B4.<H,5W8MFD:<-/HFJ%&F1%E
M(%R_KLV=!:M06>':Z=6$UA#82B'F81D$Q7A!2&^&T,GM5MS4LC,*PJ42LV7E
ME]HY[Z$ ,[-VG"ZA/-1Z_2?N9\M;#X=UOR ^,_UKAE:#(UX.X7$7[*P!:)4/
MFIMWS9!NA,65-'8)_CJZZ([LW;[-%H Z;X\=?,0UHLV7FVJ]U$?AI1+0+?3W
M/YO,% ^T[KNOL*FB=0-F+%<X]7/=YHUD,.T2.V6ELHHS5:J<0O_9L/??08=1
M"6>#=T!U[4)*O>["P#@7L56\2_5>O?CF^$>+1O&_LD1QMNT"Q%Z0KDG4R&0P
MGHF?R_C-8;&^M^J9WAGLA)5>6J=2E<N1+.Y'U1YK+=@D+-@4C$8WN&\&D4PD
MB,4NE199JT?ZDUG>A@*RYH<<9..E?H]JR QH LJ"@.&U"NLCLG:"?#5FE+9+
M/;4Y\5'4R.XP('=(^Y[QA>+TSU&_CR'4[%H=44>JE+GRJX!&A^$27 /L%]"/
MR5C=*6A'SI*^T-E9SC'Q(5OYQG+RI!\R"]AL:UIDH77?7J8IM$DH;N8 D08:
M=K/ B_N_RX'/;%X6<-5U[X%"OP5?S*37^@7-T>9\3"G;Z/CVK3H^!9IT!86M
M$A!)JS@Z[ JOX!B(KC0L*:&$\;(Y'>?,+XU^M?P#KP?U%-<G\%WLOQJ=53EK
MY;&I7K=(8)>1WS2B7!9PUW5WFS653U$F5!0"$_O :1*?9GDI!8T)R9.'P;9]
M*#!Y):,W]G50M):TQ:PY7  '+Y UT"I&),^^P7N][0)\<A,/F;"7:7Y,[CA
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M:U _E.<SZV,:&KEK&'4Z(2(\O"B&']8D<?R=\.8_'N?^_Q!QC:7YL='F/T^
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M5SS5Q744+K!!?'THA5,=;'I+/F_K=L1L!?[CJ.0&76$#-F#/8^^REH(C=>/
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M#S Z7MJ=\PH+5CHJR0'%<0OR4V977;'V$7_'BS@3R]1QX?3?_7TA:%+&(Z.
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M(S7G;@DM@R;V/2Y*"IP/,I#F=A29TXO1KB9]9J]9;XI#CHS9Z%O7J"L)<>[
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MR](R\]OWC<VM;?#'SM]^[8/L_^^N_P_]$MKSZY<#!_8?X/G;KWV_A/]=0>C
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MW6$Z*6D^X14?2AWN?;^6#0,('#$NI >-$<7VO 5XV.K[ C1Q)"QX#7UAK_N
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MQ+Z]=5Q'>D#]?-=4W4KXL.\S5_]<=&Y*?>7R61?"VNX$N8MQ)4JFTC9_:;Q
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M7/.=G)#*@6JT"K"]&@%4.S '=UKR*D!-6]"?MM<1+MUT0]F^[Y<F8&MS K<
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M=Z9TG"^>6;G79D6R\%BYWC6QB<@S/"<?:$4J$K*7\K\QX''P._\3TT4NQ(3
MGL!VO_(\2+R)@ J@D%N/P"?^C**CG'$/%8#LN1]S *T/M#Z^\7RDPR<<41,@
MU8/*ZG41+4\,IPL83[W2I,^T)^]H-)09$2H#,)) [9?<"RS35?0'70E:Q?4^
M\P3FB^R%8RB7NBM2+P*.K3@67\H\F:)V\(VQO7)?)VJJC%<[?]DXY$Z&KEH
M/A&,Y"--^UB>>'T7-#!2TZ2_",K4UQNT,#MVQK[*2\T'7#Y:*16&MUKYBZQ@
M!37+[RP_66+W=-DNR7-JCF#"%AO>0H!\C$XE&JP'Q@^V;G6!E75^]_078G$
M[UZV9\)C&!8V'^NUA\ZM]$E=66PWG*V/PDN$^30!_7$&U]2;V[,UD&6$5+_
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M/T/0C$;QU5*KC#(3R^"J%>W+V,GE^>ECG%9Q-(Q"F8"H<M55V/XEL(Y5ZL7
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M1%X,QKL7$1 R8;UVE;2+TCD09"[JG<(_@<\03,&]M\@R0I%HCOZ8 @4<)"_
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MWTF_)/CO VI_QCK4W:HV]J/S(RD\]_X**GN<W9)S;KAR*<XCR,M-@O3ICMA
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MBD:PT0YU!/<T4WQR6UN]MN2([3D.R_/^1G.VH]KDR/X36X,L0$'^B*WBM=:
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M:_R 8EW6O%3MK[4D^<^53<J=C\+&#6+Q7?FKTB-E-K/CWM*;(V76@U!UHNE
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MU1$S)-OO%?#ZW.6:6X?-3GLY$[^"DX,4Q:7,A$R4,FN%K?7;]C,_C$?,';.
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M7TJ6, P:Z)%7#@I,=EH:<1H)3';KW_SC)A AC4 ?6C,')"6/:MLOP.L7 #T
MSJF.*)P=T7W4VT6,-C[WEIS&O2:J7'2^]+W/G-A83;N$]X1->%7*>+.U1HM'
ML6NHI^X<^H/=G)V+TXPQ%;;^;]B2U=&;#K>:)'6(*.+RNY,R"4U5U;$QNS!
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M;GMC/TY)"2JZVY!HC<6=5V#[VU0<\$NA$\V#!" ,&L9@3$GX5F<[J'9$3:=
MR*:-ZIFP8\;O  WOSFBPS34M#BR:A]QQ+R/>3Y$8B.GK#CE3(5TK=9IU ;!^
M'T6J 2_4=31V;#A>UTY[ ?8P$00\!W,JU[9\D_ W:*'>;<E^'71UJ\%Q;H7)
M1\^K>* TR ,*@=YL>#@[TPN>HN;+O.CVF!Z &Z'W+IHGUYPSUT0U48J.\G)&
MTI^E9U:XZ38$MWUH; &@ W_8><!!<7$!VS&PW6)P'W5<XII^*4/&/0O5&.1
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M7#.J_\Y0PWCO[W>,=J- \U38),-&4NBDL6L>LYRP2TS%H>T:9*4 .7I44#I
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M<-'S:!RDE$7L2$/HQ%Z.0TH'P43%,_%AO>+#6Y0RU8K'JV?=C-(' GQ_\ V
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M>DRR8Y4_<TX+5*;LJ\IU0VSCZ0%1"Q6B-%""5N7Y&C]W[^DYA+X.X$7?]?'
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M+F85&>L.IH5^@.:F8BMG5W-=/F07"J>/3/LOTH=NT?YKQ*;KR4[D,>Y0_3M
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MF?U$DYCUR[569%/"F#LF_X\GR%V>MRRU:R09K;H<72!/S?T1H1'IT$%48_Q
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MJ:353WI2^ ?9U5 ;^T*W^$&X)V@@@/Y S3N[[W>B_8WN[R?P:I3,=G\[66;
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M>T/]$'W@2TPINALE)TW_&A5CU#5^XF EJ*847 JN;'1I3*$Q$Q;T<+RZ)&F
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M7,:8AJ0G>.4;?@7>UO-CL2(J0=EY)GML).6D;"3%' _(0[9P+YY='4<((2;
M]=KIX$?_ELZK&PC8#%-.[+I &4ED7C5D"Y/WUYQ"DX,XX-!1!<5G [NN,/S=
M1LZZ3W@_^@/*I?0MW:,_Z)<!T9/7281BT(@8I'50XK>4*25N[1U[7CG&DV&Y
M^PQ!PO-A.J6#[R:SO'PM&&Y'2<+GB\WB"3UA,*GQ:L_F_(-Q)L?1D1 \F%&J
M+THY3<KIP<>T-:<Q+P."_<Z+A-00(^#A[$ARAVGXTD["LZ8#+;TBM(=@?.C'
MRY35N/WOW"XWMLR'M?(>N*NW=4S"L;)*N,=X3^8E^"G*- $Y@R(*=H^(P;4
M<S+H-)V7(OCWXPZ4\'<3TB5N17]B6:KG&MG+"TL'XQN:IP(:_3G2>7LJ2SUI
M@U;9YG.^I (VUN[)#ZJPCG&-WJ.(I2>M+M@WWD)S9AH_'8;]B=0LD?84;\MH
M@N>:A?O75)=V)1<FV(!MN#Y-:D3MN6:M\#-!*:R+)O%NF%Q8Q/6'8J:IW2N:
M5XQY@NV(M\M $C%9UTU;%"PF;'ZLT+,8.?BE$[5;MY@*]@SZ6UR"4=(!POFB
MQ *GYDCX='U?(I>'OCHY89ON>7]*E/BP/4(QKMP_G+C%]Z>(<KSF#3:L3->)
MX5X*MZ4TU;]S]=<>GT?>%I?XJ@%E?R0B$=NA7>;\J.L29>I5V4\1[G0/GBB"
MZ6BH__70+>6[=2\1C@$*"@%O&YL286E"KUC_P/-W73BA_'<-I%R 10>J]H R
MYSOZ*> E63'H-A!.ZD%_]WTF?B[')(,M+C^DPE>$NQA)\G\4BC6QR'3Q;3C"
M>M[X*-4Q/AG@T3I6S!!FO&5JKA^S<(-]TA/  AJC1+;- +J$?I'@= -$Q'6]
MQG5]X2KOHRZ!KC%T?._763^K0JA-36M"3Z182&_:QV"1AW:$&)W5O_?$XG6^
MU,F]*C:_W&U;GC_61UPCJAOE+'_S:Z3,I/J)C64]%@>S63IV<&NI92E8Z.ZV
M&G?J-?@B[;T,TN&&Q.P(0H&R?O)IDTM]0](?U3;G%);[/-1=0WU,E",0DA)F
M60:/%Q4&2-=BAVNR2L0L."$:LY5QY7%]=O1?P/01C#G&O)Y#ZL(?Z0#J9J-,
M7CH;5<2W2QF(10:4 4D'4#8<X9U+@\#S_&L-SO;E5_P_8C4"P/<F?S&X_YH,
M"DN]XG2;V497I#(SJ3;$D2B$Y*,4_$R7.F4J$T>XT+3GJ\@H??I];:R)]= X
M/X*6:O #R=7?4#G;!6(D,,\MKBW6IJ*B]W%<C[2?@<4T@GB _+[42)S[MX7O
MOH@;XSEWQQZH*,>&2:4.QBR-5F/%W(:61V1F)7>_M^SAOMF0E%.9'+#Z?E3-
M3I\_UQ4X=*G0QGF**0Y=UQLH0?LRI2C[>UV-2/]BG:_[D,9;.D6K_6V.LOX:
MV0Z'?0Z\1F&E(SR_E3B' 8ST,."B0598E4CIAA5F]#XI2<[269Z_T:]4M2>&
MN=8]BC9+%3NK,"C9/\0A9*G6YQ6B7^<^A37+DK6)WX(C_Z$\1+X*+K+HUCWG
M]/=G^B42^^OUZ>Z!TGIW^:5%#W/9$9UH59QSDR1OKOTG6.9IL<<8-D..G!^_
M.R)316S+[<L=]O/OC6^&^7-LR=LT1AU93%1MAS)N#ZQKYLWN#NP*-K4WML3V
MF-YOB3*]DJ=]UEW;^_ZMJ_A")" 96(P\DF5.0ILA=#[M?L%P-I\ED+@;_"&@
MD/=Z-^(P_>4^9#-2:P76-6%NJE6^-&Q#=$@X6UA55^%J2KJ!6SR_79U>RES
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MXCMN+7T/L9I2D/0/$#Q2<PJ2/I'?\64_\[*SJOHKYFX%$X]9A%SD'QW&+#[
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MXJVP%^GC>W2.KA2]I$X_F]]]J-$6,+Q5UHXD)\"A&N+ZK=2 TJ=&$HGO)M%
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MPW2(JZG,!N;?-$D;D^  R$S0'0!5,0.[/4V2^7L6>8X>.+XR7?U+5F-1Z)&
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MK[2\I/]%?4Q@[]?ILO\FTAN/0@*RTW3^'%+.9O&1)W/X1!F=KH"9_T692J^
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MD%UGWH1WBE1EI"#E9UMIG<6N\[B=]7:6[F2ECL?::,JZI4,!/KA+GJX_9J!
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M>%6QMCV==^G[Y.1G^QPJ1+, _W^Q]]Y13:Y=^V".#:E1Z34JO:M4,9)S0$!
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M)EDP<STVVYYL%4]R_'U9B[YK31$NQ93W/?KM<U.5MOO3K_HP'5,G8\7+?]<
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MDV4@R\)Z8T1J'_:U=,O'P$M>1\YQRM])HZ36&!\*/&GP":_)%>SWL,6II\6
M)SF;V$3X>4>/C'P&57GC^+*#TT?C28;O.71(=[2Y^,K;)FNS6J*=?MY[EM]%
MLG40GJ?A?LV*RI\I.QIEN2ZK3]$9C^@<5>?4K0F'[')3R@-+F14&W221!\7.
M-U+52>*&K%(CG??1FU\MN&'#T+N4 *?+WZ9U;45$2M)=RU8LX<^3@GX^EG83
M[18RLA?[%"R]JGB>K&ZS'&#C]S84'1N+\/-,Z'65H;K?M,@T2Y+"C@WU=/YS
M)QD*X4\-0K #2*HS0OXX$:$#2WP+]%+".M1P-\EM<[A,-\5G_A65\4D%0WJ3
M>],J\, *Q!^5>HOX"Y_>V6J_G;<WVO>]&X"MV%9QE!$<JL8 O]I.%"'@%%@,
M;+'&Z0JP1_P8N:6M?9R!\*6JVSD[3J=2.KS??J<+4A0JWSDL;J7-6DTV*'+!
MHQ\^L<A?3>>1F0)9'UPL68^(;OJUG3,CC)V>B?EBN_YK.V? LP,3?%/:]N#V
MN<L\<:09FY74!'X]\Z<Y5 X)XM\//R#9ELIN-N2Y*U/4,V]*1T)]4^7N+:8;
M3O>N?_FL*'_3<5XI<VX.#UN<5RSK"F_B7VZ8$%> #)4OD@/RA&Y7V978,QL4
M!YCMCQZMG!8>L%)-+3EOJXY9^+5/;VCXO[0WKT:>ID+L-XJ\3S&J>OK6'EYH
M55L_%FIR<7;-ZMH&@RL_^#RI*A"'%6)][V1KJ_31SNZK@_[9CTI\;EJ]MT(L
MC/,UTCA*U(U&"^M+5_D^C;TOEI+YRY^13XR#5E)+^J5U]S-,[EIB]"U2-1JD
M>QI@[K9:P<\P^H/<PC))\C(OYPQ"5C_)]A9<R/Q0S),D];;BL^SA 6,TIN'4
M'A@OU)LJANQ0B^;=."K(((%G,DBJF14TLRB118)*4V>;HHV1S!#55<5URDE8
M(\9)G))Y7),XLD#,TTD/90]4W KLA:0M,/\Z1CP.=QGX0,'TY)@\A3(1F[6=
M?06*__[AZ-A7Y?<S2M"H,2W*T'&J03*5-*9L)#&Y:XY[X6 _J]$K*KG82^,,
MI%^"S$[1652H6K^:Z:DL, &%VH *$<(!CD'6G<%)C^&Z%"KGYVCR4>_7%%M6
MY@V/880L$;$62FA5?E246PD\F12[G\%1 O=SOWB<S4PL>0Z?E^HR/0&Y_<W(
MR"XREJCMZ_QS-CUQ]G'/TQL,ZC%6:3>"GF64L,&@A^:I)R#H4NM#I;-99"O.
MBPA"8M 7'_4C91ED/5$].&5>4KUGXGY8L2Y.$ S%Y94'][3=,T<;?>IQP#=%
MG_NUS=(S$$2# *%DR7N WJ(C(UET_AVRN[@ !O $ 4CRV[&]*,W 1F2GQ1;6
M^P"CF(P-U<VU&T?HBJ+,6R85 A0_]RN_AFB/Z"#R_700=THT]LHG\\HM,-*6
M9=(?+"L5(AH$,\+R;2,GQ%N7*W(]YXCD5PYB5TQ8XXOCT2P67EI<WEIY;GI@
ML*=6^OVDXSF!Z&4IA/+2=K<8 W"YAISE,OW]GR*DU@T^:X<P +PI8.+$"2A+
M#H%<#.0!9,A]K#K[)MQ> G&Q02OOV>Y%&U%W?K/)_!OT$]MM J@A>YHBAC95
M2,[Q=M7IL[: &F6'!'Z^.B9Y><C-'?,%'M@C_>&/!TE'.PE0/?]Z" #4?O"[
M8)E[D([/0P&2JFC)S:@3T%G=XX]X5Z1 5XY'/F6V*QM?#VF?G;HJR*YWUQ!_
M$=X08O];:S*FAZR6Y&DXO92F_N CX$SB<^@B2?ENU%I0\E2Z;1'6M_V@P9]_
MQ,(:/OV)M6=-*^.>,">X31CD6VKX;[XF0W7$LRG9IU?JCN<AW'(;<34JE=N1
M#F/@N![WEQZC3_:;/]>,ED0)VY4%C'ST/ 'QNM$Y;DSP(4L4-P>HTI>_:H96
M:^S$;%Y(24GH5^L],+O!L5'*E'7Y!*1M25O[54E4B5);&F*P9CH+BFH,1*RI
M[)S7JX(CB?$Q4$>?6L-W&RW*+<=[F7DSMZE7N\-]%5+)Z-_QIWC\L]1:+'[(
M=(?YC")U7@8EA01->SB++4&Q\<%0;IOZL5CO!T6I6%Z>C&3+FHQ6NQ9_="6!
MT%/#[Q&:TUUF/@A\3'PLH&2D/DX@7"]PC,M[6/_2":)86BPV\]+,>Z:#@<G_
M+D1PTSXPOJ$%W@/_S+D6M84\ 9W9/"ZAGP7 AH A"<)+'V^11W<=(BX<.$&&
M:;_+(9S))R#+N' HS UJ)Y&M68QV@K?T.FOHI,8X7:T9W[XR2<2?#D6:9M+V
MD1W=Y/ZW],\+=:@N3(A',QFR94_DMQQV)Z7MMN,T)PY0.FI.?'6HV]#>A#!L
M[:+&7E%7LY"<K$4L6[=KM7K.]3*IT2["Q>==H[$:9"/="C<K!C%2$><OD2H1
M>WVXFJ3N=]N8_3-E0LJL+*%/_.GG:GBB6<P&4<;EL1QW1.:U"0>'[X,AWH-Y
MR\:FC]'26D;=]4BM$(M' ]Q=UTU8*_X:$C#B2@JNU;D:GSI^8*W+!GZDH^\L
M$!V/Z_C'JL&_%><X///#N,#9JX0N$8&):+Y^BHG]<1'>GQUB#T2$S"; O"!G
MO"?G>2EYT6"*VA8[Z1AFUM9",6DW3!YB\K+"G24OH^-#A&4)%,0?@$8!+P6=
MBJ\1S]D]D$D"T8*/&3S3X034&4KFI7/K32.)DB>@."6*-4T5O>^TL.4,>#L#
MQKCSC&B%[-R8I3-""BN2?@D&>)LH4@/I$O@O"X%4,,UL@8RRWO3GNL^D>K12
MFK:.8Z>()57TB1EBSY_YZ]3O(9?@Y3=/-0N^U!=0/Q.@X_?GPM:6-3T&RXE<
M='Z./*RLRDD"T4T"D%ZIO/3SC%ER]LHQVJ0K,![/)7&<C?2]?6Z,M/!<&79F
M#<<WWB"OUF.V\=C905ABRIR2]H)H4@U'VD_0+P/(^V,5-'T>M'?1 ESB!VG
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M^VBE:F26:]J%%&ED9,Q<BW%XM_#.W/.'-!F_.%E,]8$+TEF;*#*]G2W81)5
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MO-O]%SWE(&R'R7-MND DG76/LDLR+%\ ]/85 14( <FV<'TWJ[][JB44']O
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MUX8.!&^J*G$FD5JIB8^XUSO*O_@,W>XZ-@XI[^@,R"B.Z1P8?ED2CV%X;-F
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M<P:[*DW-1'-_N4O:\>?+^3L^<^7K7\X>?VG69=[7D.TA:8UVGO_/$WZ@D1C
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MWHQ5$SUKQEBL5QC/S(\>&?%1P 6WB?%BHH2'"4@:V@"P>DD!LSN$I]_740^
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MZ9D+EIBCI0?S3[+'SMWXX]FGJR;;]C^Z7GO51$I5U;"I""9A=BU LU?*7+,
M+UNBM_FP@0]^/)A$C(\+=\\ 1BMSH",'*4:HI2D='&C3-'YVE4*#)0[,G&P[
M">!C#R6^+M18R;\VTI3<S%9(B$19!G:N)76-Y)V/HJ^Z$*5=YALRGCOQ(S;'
MENN"NW MX2LE!7!YL^>.W90]"L[P(KJS;F6KC(--XSVW(W.W 1ZMHPQM%/4
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M0962HSWA%-09'\<0'?D"QQ7]3T69I=[,V[BIG+<R*_I]45'SV9TL[\8D\P=
M"E\ZC',%W/3E]G%!P>+3O-=#1,P3,(1=D2V+2PHBAG,$(K2QH3TW=X^SL:VD
MJ2$OXJV%2+<X:!^,AADSX/;P#X1-9G231S,XG@F<\^X=&Y &\6^E[ U( J)V
M.DXKMMI]$A/'DA8JS+AX4F_&V+0P)I-9FRGGN,R::4)JQ[+&12:];3N0_A27
M;U%(2)^=:9L[-#GJ]5/CLJ?"/G9FKY;3926QFY%N\9U7*%'I;@Y9#^T*'44/
MXN37[,P&\M$G'U.\H&\)%/HE_\H#UKW5CXP-T^74>CSEHL[9YUP5,Y!R5-C[
M/ EM9G[J:6*Z*T8TU/JF4Z*)O%6Y?D@2DLD"E2//\$F")XC)9]#&AD+)#.D-
MB#1)"PEPV<,_BF=QAD<*)SX2:E8MG#U^^Y(L+H;AJ]98%IV663'8O3\QMNI7
M=4T-J6\"+G@L/.J- 1PPHSI?1+=Q8CKC@KRIWN0]F=,QE\"<29D'ED#G[%C:
MPYLG9[=HC3#XI[FB>I=QP>RO=942,X-.V D)W<8-2#"YXU#;#DM 1+A[<?T\
MB+5E%#&(%ERHF"O1B7=9YM8B-EQ X6D*R1(S5:RQ5W':]0O9;(M^,>]&Z:5G
M'R^.>67H'WW^E>I+# -1%+X_>)@7-OFE6%D:(4F2!YGM-KVG5#0P77#%(2UL
MV-0U$5.=O, 0T?F6@12=W?/<+.6CQD<NX_>9[NQ^T>*Z4VXJJ-3H2'E,EOTI
ML"QA]QYGW%7#&?[90I1HS,J PZKO=WLSJ^.]ZFP]3Z6#UT[)%I[S"JYB<"[#
MSXB/7@>N6B:7H,[E)U <.124>&)7V.XZP>R>PMVZ5G[+9*^4)'GQ>1D QM;M
M0>X=LZ!XLZ2(.]G]\B@?79G3$Z[>@7/Z0;KR*3&+FNQD6;_*(-%+$][,C'U=
M!VU=G?J.7BI^D^_(1723HQ&U3!I"BG@=?,UI1FXGZ@#V]6FL.*)EJ,?S66N?
M =_;Y=$Q%&6?,<7HDC)?&9?HZI*9-5Q:<B8%C?Z$1E_8+OW=X"[F+P2 [^_2
M,.I"5 GS@1@Z.KPRGNH%2Q :@L'A!1-5V#E15>?6E!X=97+FFQ[IEQR$Y-?W
MW6\O(S[<O""+(CR1VB2ZG:($QI4Z09)0B:\$".=2#A )@B?$W6PUU].RI9B9
M+,7T>HXJ1--Y!2QB=E3M6CGU*:CF3RWO2IJPO/.J+^AGDV.H]DXE.OCP\?5+
M4V_RR^>?ZI7TY,V*C'4')G)R"E54@@2(Y<XR0]T4V6[)4G='<4;W2>W#*B:A
MS84'#6A#%$M&-D50_$F.03D9&&"U[^%1!D:+W.&"F'R^ :F.F9=;WTVT!Q'K
M!GQ\1 ]:CT>)A<L[N7[% !%$)!#.XA\9<TP.2I&9=6Q8A>L!F&@-378<'X;#
MAHHF#2W%5DH=BWF5V4B^D%<S?=>4)CZ:OW(;]'=;-P#%)U,ZJ;OZI3^5:;:<
MGPP7-V_VN?"Y3Z6OK.;=?$9HSJ?7MZZ3/%]N/B*VO_0?ZOMW$V1HZ!."-+@H
MYA-!U0(0/&$2$>Q+AKO+L&O1,1Y>?FL9<<N(K:_9K49=R))^;[_Z<T2+@.?C
MLS>1_MJ[_!PX :I?"9NA$63+G9V0+>^W?-C3J__VN_/4N8-YRH69#!I[Z2#)
M+2[7RU##/&V3NB:!(=>3CYQL$O/EG7Q>GGA/.1[8?=)>.Y49<P9]E)+G232B
M+W]W>=&"MDV;<M(/U3;$R=N= J^:(.3BDGP)8X_B3&Y6)MQ+H,25RC].?9 $
MNZ7^+%YM2KSYO^4C&"(W)0;!^Z5_T8U1VH!,9?#56:,&)BOKIA\,-0",<&U\
M [)G%?B.&*W\BJ;FIL3G_2<PM-:=7(J,(]=$-R5^DO:L!J@]3R1SHR((8H<D
ME](2W;]<%182\E>^@UO8L'&%=FC52'XQ&,WEAM 1>S&$W(XZ@>8;;L?:@7'O
M)E;LMSJ8Q-Q-W_?HF39EIA9"?%8^/84R[KT*]/JMA8S[??MS^,>+1?AX+$ H
M"V3_9'O;T\_Y.Z 2RK\]F?I6-7J[RZV468*/SCG.;ITQ4"D(\4'T@4;0>[TR
MTK8]UXO9[HC]2XEBBB./KY6ZG_6Y%O#HAK8:WQ[;K[!PP;7Y#?*/L76=^..5
M<8A+_Z&_^&$H:G)6ROP\\*"'! >17/(>D$;/W2LH:8$"7 LFT0S(LP/Q;'(,
M^N &).H648HT-\F*E^^/Q</J<RY.\5$\(]L\XSK>GEY.SLZ."86JD1\IVXJ*
M\ZH>7MG)S?BV9=/7TT*)RCM4X#F\=P.R&\$_G1=/9=<C:E8V(+X;$)KYOPE"
MF:XK"&70K!]YX.;X#MS_M3^4/$[F:0N[U\D?R)STS13_-M7=^]D=O4:FME:(
M/1 2IV+O:7]?L^70@=\+[GP]RK.[^9N_[O%4+?]=$_&C5_X=U:>_4\;Z#^@?
MT#^@?T#_@T'"P'J!U2J;S#]H--EZH>5\F?/K=6-2KXS.M%5HW?:6H6QCH#&.
MZ^C,N(H[D8::3(28PBE2'3JO2G??:C C/Z'^EV>L;*>")RKY*"1XDL4_X,B%
M\L,H"42WYWREEZU3UH>;>.08ON'U7+3TN42$G-_K,U*8$Q6R.7&',5]]VQKC
MJ.%WV>HWAQW9;YQ,UH?>\,!ODAF"9JL<V?'"^\!5.6%_)N\+2D,EFK/V :P8
M"BPK57][?5XP6Z_V3G USV[Q[TPKL@9I/>A=8&A!5R5A ](-EP)T8G0**5_?
MSZ%/\<3NLW..N6(<7D@W.:1)YY>CG9U?E_B&7&X8"X]_ZU?I)VN$DTS=5S_L
M^.;<:Y.S :F1CQ_^R;!^D ([DUCNR>U3^C,;FZ5;/[#JZQ^8IGVNZ2_KAY,%
MC]ER2\?-K9%9)_TDK'$JFLXN_(J/__&$-(:UC?7?4]>0W/)W<?S-1+NC74EE
MA!\"U*Y8"![]F(>B!H(K4UAUTS'S9=S<\*VH)!O6!49>)\NM(<5J9%D%U[1(
M9XFYW@]JX(473;P-[;@<3R;^:'[Y W?6:N ':PLAF6DY> .G]0D^8E"YX^>M
M$0=IWM@8JEL\P>J K'*RU@][*5!Q_=K'GO4_R!T!&Y!KK+MK5\(Q%H(LHBJ9
ME]?=?>AH(]#60K/A+<>VV9A%.V] V&*@X]0KB1WX_3-[%!:UR /:X;>(;:5_
M <E7?Q0#Y_B<,H>L+R]F+D:D+@"/Y \D+4^E8C^E4MN!UNH6VY[1FM42]7XU
M]MJ!VP4UEVMR+MLIKYLJ9EYW5_/IWRFS:#S^=Z3.U#XCVQ!9K ^+71;K<IL^
MN[X!N;$X2NN25ZIEL\1(S$5W7AY;+#,0?A>'*\.NRMQ>3<JO&?1L8CX98$=M
M7H$JF,U>_[-VZ.!'7[18PA_Q<II':J-T$9.%^FF+/0CP9 K_P/3*3;C2\ 1L
M.[8IHZ<\D';3\HE%0*E/ ^EP KTFE,.\^H+1U>2#V*;]]5);6]V?#<UM)[>^
M*]N N&V:XT)VRXN%UNO2J#$8::KGE*7NR@O!8T-7"J&'+5:*>_Y5J# 4W*PR
M] U6#]M;&:M=HOXC&[6N:(%D&-JRPY)"KC0.WEBV/+/6Z5Q^B"?]]";<21!'
M]DP!CSO2-W\$J_.MZT2B/&#:&4I4 XXMM</W- *8!$.%<A]=I4.9974*YX):
M97X',WFZ#HP(D&S/:Z"48WQ="@OS??4?7O%IX*B5'*H5..Y.Z@W8=]55G?:;
MT=E.8,1 @SZIQBFQ[7%XY^U1>J*=>^I#Z+EANDT76\VV5,\V,DU^"&O<^P<7
M]-/5Z ."5=JOO DT=+!,YJI7ZG5XOK@A>ONE)S2F6J]G9<$K@QL0Q#TI:PX>
M)"F5RU\I/=<$$DV4?'5Q%JN,_UB[K/)-RL=_D03Y?UTM[1_0WP6)?[$0[L'Q
M\*:"7.ID&;4J9?X$UQ7J,M"B/5EYCW4 BC8-%W.]N&H"3.3Q;' 71<\YS<DT
M,*Z^QG-W:\S/>[R(#TM(B&7?D_LS2YO\"B^*YN,'27K"URS 80.2$&'=4"]X
M2O83-:O0R"RW>0.#>-]F1?UX-*\55C+=\#*:_O4TT0@P2<Z*JM.Q_MHF-EB1
M_S)+;T&*[(N8;$94>_5 Q\8Y/=_TBHBR@&H<T0Q'+N.;@F0N5=9[36.AY E1
MBT$T>L[7SKO,@R4MS%_LR@=)"I(\^Z4)=#\>'R"X#\^3[+G24MW0](,%:F"^
M,=CD/>2.XUJL'7SX8%1&#,+#-6RRH92-(MB<#L,]^_J]LM-,LR!U%S=T4:6&
M]S:KHO:6I%GPS0R7P@$?:3/3!3GIP/3WO>#9'84F%0@X;9C]L<?)BG"UQ'W)
M7'+&#).56$UH(2D]_])XWE#9Q[EHT\6$_)C:1"L<Y]@U-CK9L1,L0TA/Z229
MV_%>?JYI29%R:%'QV .T>_Q$GXQ\B?\VRRVH?)N%>?DOPFY_>UHJWP;\M7!P
M&N@%(%?"!;D>@&=4,9\H*"7!^7*@%Q>V:].5\:Z^,K=)U5SJ+I^FJ)S59);9
MO47K6K/@A,SKM4#% VP@A[6_5S;Z#=.244%NG"?]M0&Y=YW$<D0T8CJ1,JZ$
MQ<X&C)@003S(^[-M-\@$5JWJAK^I:^&LOH1;K.]T9-S0'L\6H"Y7#S\P&]%Z
M_2,)9=TRK%5.IF4MY[RM0?5X! ;^)*E&+;4<0SGJT*]1++:9[E\.M7N<+]<\
MG/:;JS7.8:VT4LKD7,QOYO9>NTQL\,CQ4T0LC<#G1!M%OBT9>3O'5M*4].F^
M692:O]>"9B$AVX)@ND=GTWMW/=<'GNX>>GQ$LG+-U5C2L3_/[K]GW9;_IQL9
M3@7\X1&<\"/LD&]QO.D.H>(PT:R"+RDH;D$$XWSR1R=</YD$EVOB2#U].CK,
M0!<4"SNQ94"KH-G;!3&O)M ?=K H;7;R^&QH\$M+25 @W(XFD+C"/4?6=_(O
M@+!)\8,3H]0HH2I!QH1W4-XOS:,D.I=YF6F(X.ZN>$IEJJOO:AVY@6MQ+2#D
MCDV,L1GM1:'*]9BO7]J\!-5D+\5M*[6"+#B,N(7958<!\@CF*TS:6,[@3LMM
MW4U8TS*"*EWO>V&:^P#?VJT0_:E@B^?+JN2%5_J%C*SUR[6Q9S(GSY2E&+[V
MY@"$JR;*!]ZFJTF8*D32W*OWE=H0G :FB@HO^@5[R+]IP9;:3A553/U\%]B9
MN:S.,.2@Y3DGP;TTQ<A.NVBDNIA8FVM*M\<+L_>%2$6;IAP?(RESK2I>SL[H
MDBCBL-WL>G4*F\J7G@VW6&D#:1N0[1L0062;))AAN037F5O=@,@L+']\7>*]
M0H*V,:;>&RIR\36C3;W%/DWDZ)BN\]=";?[P*R\G%A]+M%"O%NAMGB!14&L8
M4/Z!_[L@8@/BNY[VGNH+&U6;ARNF+J&'QE"L6+(H\;SRAXY*G4(B=]US ])Y
MJZ^(%EJAGDTT9BM:=$ZH.<.*7C*UM_P2N=I^&C#M2DF@-B)BB5Z\#OST,-4-
M<V?;"GF@//A2;3$!X2C\Q#0485?NN=KP4SFN#K;7B(<PMH\M^3Y_?P=0^UKU
MV_3\YD5LCP MUF\1G0!8MP(UMNT8J,WI@YJ\ &+HX48=\L=RPHJ)5H"%Z5$'
M??N^J4_+C^7AC134)XQ/ 'AO"<E3U\T2';I]+/_9IS&?-?PHG*(GI+^98;^0
MT*9?E%671E=7O0/ T.NE[+.)#D?V)]E+G;2T:I"1RQBFL2EFYJ^;I.R>E#0E
M<,Z%"/Y\]YQKB'Q5E7;24R_91Y#G&,TCO+@&?!!".]Q.A085K]^>&:2Y^\N5
M[_4\DWZXJU$J[AG7QCX\D7J%*,Y38_?3YT0^.;(;4_@2/!$+1N7T8+VH1;OP
MY/L69S>WYZC3J!R=E:4+U"&->?S\!ZG<=Z%'7L3=/6!2( ^>_35A$6NT+DGJ
M55+FZ<;X&;*2H >F,MB-':+*NUP6OB/EL#H5C6A5Z?O2F?.&4@7UW0T5;EEC
MTQ@EQ?<54E8O=U?V]2=C %.H@O"50\,&I"Z/?Z"7@^]"B!!=P1!\D:\+JV,^
MA$Y##Y(TOS;)IH?;6B6*A.MHX.V&KL@M&.[G'%\6%P?OU'?E1BE%E33DX0-H
M0MIF/^O9?/B\!%7?J'[]8Y3VN4EJ!*9VNXMCA' ?43EKW&X#$GEKE2-,.BC3
M)/C4HO_VBBL:!;IW^:C&MUP("-O?I/\!<(ST\QHJ:U$KH4'C[KPZ(Q^X 7%R
MSZ*=9G^LUP??'E-^Z!]:4/W7%,&PHD)\S"&1_<C!QU3"I."K )VNEFLW;8')
M?PM6QJL9"6Q+[@^]!IOU&A0T>]RP%J=>'\X8LG%.#C6%?BO6#WSC?4)OLEJ2
M';<V?$.F-LDW^ <8QNWG2R X4+[$^ I*D+,!F7PFW:8-1I22AB9V@97 -$>U
MQW*GT_"W<1I<'B.%E=&OR/FSQOA9BH1%^2@A?IJFM!.,""PG9* 8+:;%V+'/
MZ2L#3J\5ZWM6,,!X3YL26 HLM>=)M*@$P8@:/(D.H0*/&N,7<21T334^*.P\
M_O+]Q!NOOR@8?"5V.1@<_4CY"_N.ZHNXIX^9/[*NS_<"I4I#3^RD+\;D'@5:
MTX8FM6Y[M@:['6V3'0'>S'WQ1A^-,!]Q^YC\#"O[V@$2P7]%ZB)7(?A2%&XC
M+1S:D7< X<M*050A:.)W;KM.TV#1;0H#SWC1]SEX&2VX\M!RSL6%59K2?C *
M>#6[MB-=VZCP*\E@I+[<1DUPIM]\L$4#%U8P]FDVX >S:X![.8<;V#*]+=W]
M.[%WWW-'.J-4U5;M+5?^T0VXC$A4H>W^V+5<S207?XJYZ!7:\'2VF>MWMRK9
M%+' Y0Q_IMB7T!%'NAS\@!WPP;SN6O&TL]:4J5Q"-S>@WIM]BCHFN]=8?MAW
MI$0FKNN]W4SW]SIR11:-AX@+@OX&8NGPTSRK$I^GH'OG;:5R#F;_G./W73>"
MPG=>K'HQK!UNLV*S*YZ!9,S[:2[\>2@R6N9& .;=0MXOS<T>P5V_"N)YU9@@
M)'A"IL/BXJ /_,2+H4I-DH:SBVJZP\C,EV%W\#Z\Q%_:,U-;T8#35W#TN<O<
M*V>-[*PA^#9RQQ7$9+E+;C9NW0[UB42#5M-OWQ^"P?=[7U_IX5"2YN<'CS74
M,8-P5\E8UL>$* ^+_E@=N (@O(](*_>ABM4W]SJ)@ #[Y*FLKNN$!&7GHSB]
M+TXW;F"9C^6_K$C>;#8]O?;M69;3[1>W Q(LWU#4_831%*7KJI:35405^B#'
M;"+',%\NPX[FYC,$HE7WYTPXF_>ZZ;RL#@JP]]#B/#7-=4AY1NXXP#]?1GJ/
MD=J X&#@"=-DK='RY;P4LD0],H8E>F#9=EX>01,H?>^].EPW'BIR><EGY;TI
ML-1Y:^GHN#1^"YK>9R ZL $Q6OZ<M[5M!_^L()LD23"8K.P4%^MADV,F=C"F
MJM[_J X,"//O#PT+?.Z;E9M/#CG:Z!)=7C;+9(Y5E(099+QH:\D9OA[;(TEJ
M1"/V>SY<2F1))3VULO,G-]&N';=Z_;[=[821:$0!I_!XMWG4<?W[B852-K:^
M-M2S:V('7I_T%UZXVUNM[1;;,]8 TZ)W+IQ[S("BB\Z>*BL\WAD86:W]W.0A
M1?;U0)065^'FL_CCE?O6?O_OU>JKW")X3MI%6S<C]6U %$C;S<C8@GX>DDV-
M-SQ2."=391;L\0R,N,+8Y+5(O$M+0V094Z<)3E7*+OF(:G]M^'ZLQ?_UP;**
M-H$Q-J;2412=?"SRI9K;+*/2Q.<8V^$AU^9QV4*>.B<GRV?<=J^#?/)9T=@.
MSK7G;CP[-;=2!J[0)NGVS4('T:(LF\A"A:*LMN1I;@9?8IMP]XE)_ >4!6(_
M266"$,)IG#__W$@[L@W>T-A,?4]2!,-Q'@.3P#3M1/"XPGF'@<H@AW6E9H[S
M-ZT^!V&G%S!?7A\=I=C51EGK8+,@H$2G/"6^OG\WJ-:)EAGA!S\O:N:&N]/:
M#@[\L+3MUO\<('MDA&A?[--PBTDZ/.Q^-TMR*#BT4G-0V=WYWH'ZD0'7T=R
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MA*A:XDJ=#8=(.O[O2W>(\8X^+WM3H\*,W'I)\B_%[;DGDW^OV#%UP"1YB\(
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M:74^R$,%66#].S2+6B-67^I#E>"?9I^'<?)22"<)%CW0:FHG+&E"=8@8PMV
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MYJI2&)4HJGX+B+DO]/'S6YANK*ZJ:33#:RM>_,)$5C>^:'UY;S=""WZ"CWO
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M OKBW'\?64:(^F8U1M;KD<-*0%TT=6!!NW^G[TVME&*"N_4@7MXY48A=3[N
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MF6BM7;!T2Z0]L $9#X)8&Q,9O&V<GDAB, <63ZYAT183'"9V"@IP<!FHI'=
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M].[ELQIGX,NR2YI3W[K06T+Z1NC3^(E[[/#\2Q;Y&'T.F)V*081)]Z"F@T\
MR=DWR@E]T2$O1L<Z2 IR^L'EDU\6$6L<QZQ=%=C'V)#LT3*?(0QVZLD'$NHF
M]9BBZC'=.4P,7184P H0D#<Z7H6 4WL$6R91ZMJ;'/U$FFO-=.QB862-3R4U
MSA^V@!BU4Z>T0BI ];8_6.ZMS$80L1LQ.F)7\C,<W0[^#*!M,&!58M.GN(O
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MI@8C5TJ^95*ZL8T6W9EP'!0_CE@W]9(H[<I0%1)2!B9784UF,KXB!FB7B*I
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M/3K"^BE+-#;V0=H;%X<*//W5T3G&[]U^T:>ADDV!TK&NK]?/OS,]-XBJT<R
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M\8K[SX+>+-UABF&".:)Q$=]9^8WNH'$;6)AFI'G?85'5D_<T)$6M%18FFV8
MN9#?5YQ8U!.V+2P8V=_4MQ[*^_/]LM?P8<=P[T#NJR'6W.PN+TW^>'ZJ)D0U
MGQ4.;N4:/@#D76JZ.7.\;Y8""*YP]_1X@=BD08*Y9CM4,AX>5#<[0V,HXG\:
MNP)6/JR <L]'QM=!))%L9TI ZR";MB:^3 J[_X%V#-J_[$6E*"3=\M%Y803M
M.%B<H0R/%&JMH6?C*\:R/H*W? OT= &;P332'J)>6KEW=\2>YEUG]%-WM\P
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MJ$\8U=4G(<R+[=Y$=DA"9^>?AJRSBS,QYA)4<LE^5ET#41K=_+Z$IE;[?;W
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MM]9&LPOR5/IA@#92T#VS "H%'7($W?J"9.LQHNP0Q*PD!&F\!\.;NA],V-B
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M,#HIC687[7O%:BZJ\^U8B\ZZM.^*_J9#VIS24(Y>70O*/*?B2\ME0ABJ?*3
M(ZFRD.1054? U4Q)'[>H(]Q-\Z65%='1U6$N]Y*5ZJ6)N+9G^U\7>%E=^'73
M_[)5$E$VX@LX)=_,6Q.ZY,!?=N?E LM=F!T#Z BCA?R'#NBMM9I+8O1N51#C
MZO#L@18.YR60E]7Z#Y0N%DPL$@81UP&6='*PX\6^AK]H_M" @F$!)<^K(Z#
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M]N8#7T8]=TJ?SC_='.FS(;M,X,;E3+1%[D0YI)@-EQ>TKSP)&G/D/^:;:6Z
MXBN M@J9O="7)OY"=QIR8NFKX"G<.]54#/P1W:F?%@+:?=^:'/M@>6L8RM2;
M/45']T?-FX0R3&AP]A<*IZBP5]$6?TQI8&,'VN1$P/0_,8WH2"A7Q#L$].F2
M>2Q1 4_46*CX9E/2Q4SMNJ ^O<KV<<0.XJ*?S:ZF5=@CV]ZA \.'H\B9L@W
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M'?[E!E2^E(WU:,@!RLEE1!0VO97!I$BV I<^&#K+%COIAK7,+M1-,:FPL%M
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M@!$^%*\K2(!ONNCX8/S7/7?DJD[L%JT1-12DP/5WC[= ]MFN2.,(H%(081N
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M/3B+27SSW4F>&_BISQ#.LJIUW*[[^JZ'&]&RMS;89M OG<3;/0X3@N$T4KF
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MAU<+7 ,9RM*_-)0>=>9E71U?OGF^;WUVH,G!!FAU2]K\2WO1?-A5J]GU_[.
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MJP)CQAWO'M;4>ME*^>E%WBV0WZUB^$JYNX"U<;*EI97,N$A9VV053E3,)Y'
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M/66%=5670;ZT5=O+1_*^HWX#SOZ1[]:RC&A4\U=RW2!@K$-\='4SS)+^N 1
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MP$@!;?O C&L?$DX-&'3Q3O0=(IWC#2SD6(4T%0B"!Q8<''Z[,_Y9<+SA:='
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M*,E'TQPOI?.FY6&'[\HF^EX,'8$[@6D& H0 ==$ GLWXA+89Y@AQ-"]QG[0
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M[MR,%M>>+?"C66NG76K:H\PFN/[ ('IIAM$'TLW=U0\=OCSWX&XR/;VXJR?
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MB-3P1&$9B8\*B%3;1#3C@>A(4]+>NAC88LJ#&GR\UQP=U3,DU6YW&E"( #F
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M.)'0L^U)U$X <U>2F_$'H=QUNMEZ@@5BY4W"4->$.;V",4:<-26!70&C.]#
MV&@3UK^I/NQRT=\U,]O=5/R-.@CJ:45<&0 KZY(2E]"EA=UV0^6X&_$QTFA[
MJ-S17II*6C!Q2+0:3&*+Z=E)"V)]#%Y%5Y5RM-PY(NOC L@%9N#\FB!W^=+O
MVDG+;,!@#BTX)?"_)U;90)P/QE(>N%3;+*';J-"[2GCJ&(<]Y21X#+0+*1*C
MA 1FE=16V-%'C?9 ^&W,L8YOL#S).Q"WG?5Y+WXY6?[F;*M>-5/823^?U1_B
MWJ&MVR-[/SNU1">YPQ%=*8!1/0QLRQ+PD0]E5"+&,FYZK.MM'0&M,#8F!A5\
MBF \<.:)2,H0PTO8=A54*3173HW7 ;AA/H)-2KZ-P7H*RI-$F2PVX7'$"*&(
MXDXHI0/G=K1'^&.LBC8&=V"((7&L[>>L ,Q;61#% )>X<*Y2CGHCQ^O4W?@<
M^3$00 3+E0F$53R!P,<.)X9[0KV0+%DFP.X9+0&,+,IJ/5(W4; \A:Y(XM(1
MX51)',!?PJWG90785YKQ!F1LF#9^=UBWFW14FUB(T0M#6!2@D5T)@ERY2)($
M9!U%";P]6O?3YM%&&S<&JB4AG FL(C9(( S%)!;N%:2R9>!*6Q[XZ*SEKQ15
MN*JIW*V46+@;;V2J:  [BQ(3\W&[Y,1(C)/4E?=)<$_=>(]Q[E$3TU4R905
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M*JU(S(VW1V /&5\ UOP4P[LF0\>VZ_?Y+"IK<?6SH^-)<Q+C$BR]GSL:T(7
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M(C:"T D"XTR-TZX*JPDV_1NLSE]Q<?:'M<GM*;\U F+5._VJ65FDPY^3_$'
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M7SK3_M:2.J<[AALVR):1T.=6F-Q;89+-U@F\7"RL]R!,,#@T9/9"FW5ZY:<
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MQC']*#O%F3C)] >W9R+N"0)FVGR=DG"M3^ECX4?$"/9%:#^^;5Y%3.P!!#,
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MI^A_+7-'2Y@W(",^G<N ;DJH2MQU=&\5H"/S00U)4[%/&(A7D,8:?H=NFO
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MJ#W,P#$X>/Q_14SH]Q)F'B,\(^'O;[G!@A&-(J1NU\U+F2<$->1DHJ,4A\=
MRI5UK=F&7CLB+&)\MPC!F\UUT:Z+><C.AS4P0U%-&'0@ "?L7 NV,M"!>;<O
M634%)/CA<L901WB# CJWI!EH\6>VDG8F57#X*II3.6C-U WP4+2;<&;1R#@4
MKD>/15$-I9C?A8T3Y5]Z$YHMUIA ITB>YWTCT_B)7;2#-"WIVFL/HD;'IY%Q
M&8E#O?&^A(_OMDVU7N_J&-2Q[NG>!H%MIHI793#EMS<:W"%D7@OMU9^ %D$O
M*@R!$'OT94"1FOR *H4&5>C<S>:2+- 5,4R$N-PEX2-&0"#J.SZ"UW/EXJZ
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MML\E@N6%Y;HO[W_F(C Y0P>"+Y6+IY.++>Z"-PPMX!*)*HH86/LW#,*IQ31
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MU?:=C/-H!P\_D*9W6T9 O[Y\S?UK-*7_DOF=";2A,5CSZ=MEAAZ:U3YL<Y7
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M$-'&%S^5;ZIY,^4L_E>)Y* (^>?RB&JS0;IY.OD%*7NY\H6\3"'3(<]^T>S
M#K]$CT__ZZ_RC?RA!$'3R=]>M2 DY-'Y>U5NZV(]1N\&T#,F#__UP_'X=WI2
M4[3<.YRH%*1 ZG;-HUJT4GU,IR'N58<I$B/\FJ$EPRV$N[_]-M8G(4 PZ]U\
M58(E85XM<D2%<H-6]2M&1"**<_BG :Y!P]6%AK$2W#(Q1%: LW<PM:K G//[
M]Q^\]45SP$>.$\U@"S0/WSJ[HS X% 8 Q55B"F.)8JP\6\YT1<Z>G(CNFLQ6
M.WF(AJ&LZ)"+GN1/?#7B[L/-D=SN-+2J[64N=E<R*631LMIZ):$>2K;SA1$=
M.SP,#D^&%=^LQ"<7UZ2T]@"IEV6R;VHU>.9"J%>E]].Q3>3]JA4@"ZNRX/@>
M/!X<7QA3<*SZ4*=LL'[.C&E-RR_I(UJ_:O)KE1%7_>+'G]$*&Y?(/\_.'PY@
M;WZS5_QRK/+*#LAWL3;NEX!]T,R$+<*%.><?=]X^L=:7OVC61_O46CI!1#IN
M;LD?"WL,P0A&H7V0?QV 6O1R;:65G2=PX6_+!:!2DV\;Q%2>,@."%;ELNC6+
MQYDS$ZGS[=/+"_T*$93*28H,#1Q!EB^5(H2U%@@2S9RQ:8#?)#:706\ :P6?
M$&"IQ;!1V#:,A*6.=@J8&> FJ\;9+X)7A&]V$?T:H4D& >X\BP=+A5E=M(21
MQ\.Y0D2(*3B"1YU6*U!MH:=-4:WP(RO97>UC37Z2]N)([(%62&YEP;AYD@@]
MAB6=Q@Q;F,S6;*08^4/,RF$T&BW3:("2=X(RI%1<0P]&1%B6>([*&%3/+2K@
M&2K;-0'9U);+78>9:3P@QUBG6GH_@]@&<[!HBQL]P47*1%,%2TMS<"&%!"=U
M2B_5VQ#=%-SH&!Z4T!:6QXID9ZQ@5M&*;/QJE7S0E=4_946PVS5_V:J]@7?;
M=9N8U;4?&.G.@F5+LYW:KE7]CUV8AZ6ZF_;:W,9).33.',CX>$4@D9OBAE=-
M:]1CP#Y4KRN.9MZ2 FF%*5.R_='D'  N^3X/4'U#N4%^&:50D260%2FM]N)A
MU4"LYZCJU\WJ==G]^7B*4'ZX/EG)CC@Q^Y#ONBG;_]7+/$'%^LID6<%D7>#_
M#B8 F:_ZB@MP@B=V?T:L&QFK@Z6*$V4/>^>U^PC\- ].'S[\XLG9D[.'C\[N
M/W[PY(O/OKIIVH4FVOX,7+:,=!7FQY)RG*9;YL5*GAZ'G%*2G=/GGMV__UGO
MKG=E _>(IQ-J)BL?:5@/VI&-K*[6D1:P7Z<0/O?N0XDJ[ OF*U':Z0,VD$L.
M_/SNQ^?35 '&7%V>71V/P7@,?JMCP 2GUE49M G26TV"'WY^ZI"R-7Q[8U")
MT2 3\M<[0+7Z1*DJ\V5SC-MXW,8?>AL'VQM8*E1SQ-[O"6\P'0.ZL+.F:!<4
MNC_\\O44MKZ6/ 4&6!FX;V]MB$G*V5!Q8<U3QZT];NT/GV]L86RXRU4LQ-IF
M^)VYZ=6*E[;-:C74.9:LQ7.9P6B2?'?Y/'=T$4AT6E&KW@!%E8+TC;<JX&/%
ML6>3$IKU2V\7&\$SXXD83\2'S^OMO5O<KD.A8UEV7TW&C3=NO'^CL?SSTXM1
M]HU;\(-O0=&RG5;Z[7O-L[2L""7W:'>\MR8Z*(E2HU>SBR'D_0Z[=<3A?P(X
M_$<C#O]W@\,?-<6H*3Z>IJAJ<N8DA9$Y=8[\R^JL6_\WP]^QET#L+5%U3J"M
MU#E =G6#X7#'W3 4GC\PBX;/O_N)X?#HJ5H5.._.C*[UEDX&%[F%%#1&S]B*
M$]UQUIX(D:T/KFP(T"L=#2A\NFW+(L^I=BYRML@=$-*CI3>>W[MV?F79%1B6
M!3&[Y+ST3^-WE\\CG@-\#U=MPL00NY,4VX*E$..F'S?]!][T"GT**+,B09EA
M3XJ3?7ID%XY(O8PE.LEGO]#T](A@.3Y%,8.O$/8D0U^"Z:[8YHBD"%,&ANE-
M-7?S(($%9.S*/01!M)!B)REKK!FY^7AC_HD>D6S>S![-J*A$.E9K4XTK KPE
M@<RK1M-=SP0HA&';7"D9,R5_;G95-1,,WO"I6.VW0?#K,:SW275FIAB4QWD+
MXE)6P@XUOTAB945'J%=,,%OOGOZ(JUI!0UBNJMZ5L@R@15QZMP],1M7%\MPP
M0W!>\2IS8UM QCKEOGIP7X8-JM"E=N2<E]5FFP"7R(2%A0D]^&!C.L<'Q5-1
M=82)BQYME33G?W88LD(6 TU(2A<;TB8#W43!S3@WD&.OPR4PRCG\3DGAB/HS
M?D:?#=\:KL\Q5&X30"%7Y)#8LRGYME 88'B!V&VP_WQP#C*%+],;Z7&FDR0.
M&A:2RQ4;U_D0@%HOO$M2_^T5DLF6B!\9L/Z)B?-+G[B7G+A1E!^9'MM7AA\T
M!M((I(V.;NP=J[  M!AB2E.VI,)9#*6;(J^[G5BRRG>#^\2&MGDGVG?(N3JL
MQO3-$;%)P1Y^9'S$[&QNW1;#&),>?E5K\KRD_]LI!&)RTVHCW:0_)4M\P!+@
M_)<B(/(3>CKISZS2(=?0@2APX=2 MJZ9P\U>H-GOBO3!QUZHX8A%$@=EQ3M/
MC7VI+=:@A_:&<+M.P:)R,[(RHRHG)J<SUL^:\886JJ@J[.>FNZD>PC!CUKHG
M[5S3)<CV\!L95KW0=+E!H1)JB&']9H*Y5W('8?G+UP%PDH!3T@6)=.6],9I$
M[QG(NM-%CRB7U^%"NHROMD'@=DKC6F0 F<BSAT'R84$#0Z6!@*D<5!4WJ"PV
M8E?M\!:VR4C <)=EY_>#X#U2H 2*X'CBN2O;LK2R.#=<K=T'D8+HH"O[9%5L
MR(;&L,.LJHTUA1=/SJ:QE@*T^\IA3^1WZ&@H_Q197!:K[?6^+Y.5I$3;)X;
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M<#=\[) %(BY":4.JU4K)W!K4%"@ZM=CSOUVS0B-DB^XJ,%P1FNM=;6>3K<F
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MJQ8I[ -SIU?OF$HYJCZ/#HN%Z(F6E_4R9PKS%1KED!Q S'?WJI8D7P8.7Q%
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MV*LFM*_3S4P+BC-Z4W7PW).6-^3#"&E\>65D;:S$&:5GBU1Y'^]")P9G&D<
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MHU[W:\X6 N0LH'K:9^A24@J2_-[H!C(OG@% :VR7%8'UI"$N+5H"O<$-;7Z
MO%]&UI0>F[_AITO:P[O(\Y^. -<+!Q%W+%%6V,?4HL5X4=;+2/E&5X99"%P
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M5F!@Z%M(.!3[[HHX,.9X+(7=FW+VG$[QWYYXS51IU_25C(#PS05"(FZ3RY.
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M/)P1O(N.??_;AX_Q_;Y','*$R:Z<TD41 =_$ZCA&V 7\51N4$.C2@=$-(X@
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M7IO)$Z\JDZ:'C?0"L$NI\6ST%YWR[8AOW8\ !;]'_KT+DW<2/"/5O,\M&=.
MSA-3&SK18LVGBYVS$*/ZB?EQ?U55UL/BW"C'D<3BK^>9UAS5W=M%08C5"F)
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MV^*,9[I=>*:S&<]TRZ$]-X3A^[.;[M&DX=0Q(TG"=*--O0_XQ7S8D-+W5<&
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M3N"VQ0@KR'33R?[ZY_-B$3=Q38S!CTP.!_H[.P4H.%@O(\*0&[<C3E&2IDH
M!Q3U'Y.F6NR*'<JCIXNGHJPB7^V- F<8U3H*@MOLY<P2M#O1TPAA+\7CK?C,
M=!GKNX*B(]_R(TF9A2O.*D]D$MIZ00XR>Z.1&%]<)N^"J2Q,2$VS"R:J0][=
M]O%\O;^XY*BT+">>,@T5= C(J@LGJ]RG[PBJU\:^O;+"]B\88P_(X_AG1?0.
M7=];[[__T<OJ%U@/ET=(@:Y*BB$LW+3*=QPS%3+U^LJV+E<(V<>ZT:JYE4H[
M1?'J?,O)Q6;!R1%640*QD[&%OB !EV-(Z85;L5@O!K^KEZ6H:[4AE4(%/+W
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M@#9I3"B$NB;\UTP^/S+-G!I45!'G$(W'1R\)VR5$#Y.Q-2/O#-8E3@X[-/X
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MXE<<-R-O<O N%".#[<EOPO7!J1<?'H-A"L,GX:05? ?*XTFC!N>H FB1-BG
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M"68[G^W\LVSEMG*:!VQF)!(5'*,4P=EL8_^TT45TR&3DX]J>7%<-&6U3XE&
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MQRUHX/AN;N"8&SANI0?&<EOD(K7$U@-WZ2HG*+4XWK3K4T,@)XP"HCE02A+
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M/BB?\Z#$X>)Q;C93@,GH1TPY%'X*3?4*!;MVUWE1-BG"6:)GB?[H$AT;V46
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M=QO.SQ>'B94&\Z7QS_RBF!ZP_I>40V(5E7T\XED@7%@2^*+K7"2:,KQL)<%
MJOTQQ$QRH%6]#!F%9 8R[X08G<#AEN" *7V;SCS@1:YH#.!H8!LCB75>N=WH
M,"0AW*]O>8=735^$O 2GW.A?<=Y2"T)_4%3Q)OFMYA"0A\94KM11Y'HI$%8,
M^#QX2@OU;=8"VPG\:<F+:[M^O1?V#TB6I+;]*XQ%F8V=*$Z_8 $FVK.2QHR
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MFDRA);>H3)[?>L?&I-KJ'MUC=^9V:L&Z9K: /)^%2?K,>R08">)@8DMO=M2
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M=Y(D..W\R@BBB33#$YG(;#&B?@V;'I(;.)_0)/30%8 ^4G REBY);2OZY_=
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M;^B&Q@#^)/CM+K<"2KEM5>(N:)R35\&?P6P9+5VZBZ(MA9XY*!$3]#8.,.%
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M0Z@]M:Z (, \O""F2FP^^W#1>[?3+74)@Q-MA8H)AU.IMIS&F)84Y2-][R%
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M7RWVXA/FZDT):8#T_[-D\3_X&0.44M"0^KK"X!PNPG%:O.T,GN*:G @9NQ<
M)NF\M 4-5V2>R$('A!0R5AS06#M %9\R%F:JV3CCI**4'OUZY=PH91@M)Y,.
MH"%-F)7T0J9 W$[(E5A56"M3$LHAWQA;Z]5EX:0@WOH7/>(? P(GEN*GP<X[
M_Z<N?\>4:.M>)\/&*K%MM+GLFW7)ZU_1%& .  /PS5*W'3OAHD;D9.=V+J8
M<%M.!-M%(\\N;F7D]N1W;D8? R(WU9D\M>>'B[@93S!9T:CLA!DZ0,+!"MFR
MHS8UD_?8P#^N"P<%S//_]&%N>/=,=2WO?L WMYDX%9L>WHE5CQCU&3P\I/B]
M<Y8WQ6:C3(5^._]"5.=-R@IV\\E0U@&>Z\0SWOUK\Y*UEW,=J/<(TR=W72*[
MW*  T8>92):Q(-/7AL!@)XR3%"P'\=G*7HOH #67;+N4X:2RUVFM*),>O#!A
M:EST4)4N?G%K<N9>AE%50,8ZSNRAI<GV\"CV 4!N^)KS#E,71 W@,)O!8W%U
MP #0YII*YLD;FL]0+I91ZQ@H'<MC>\N8$]@U$;'D%\IM?*0?Q6B0DW\I']KZ
MOP;\\&;/[^SU&9I8(Q,02IYK1RR\X:QFFK08=D  9!G<;B7N2(+.X9B'B,PT
MV91I0GZ3-RNH4(I*EW#S8A"6Z3E)T)^JTZ:&3 P99%$=9(+5*'A_ 9.U?RKV
M:XT0<A2JQ<'8+,#SS*YXRMSY^,YC2B<F3*; .=Z:,7B@Q-67%NIO!>9NB1KV
MQM'[%6RI[!%IF*Z*WX.^U+/%#VR7,E3IANOIJ#.@"O'->RT*!6S1P%I;C-.,
M6$U/70^1C;DB$?3(QR$DF)QZ,O&\*>$F&RG"F9XMGE'KDI?NB!@_HET4,MX*
MOZP0STQ/UR!".3 :CVC'B36M;:=NF3S8H<=8NHF&\D!X,>)'Q024>)"R :,W
M=VHP<-U1TWC\:LL8@)!(2BF3T7!GR7SCJ1S2'PN+\@2O<?J,_-0F_-N LG?)
M,&MQ8Q6N9VKI)H),;RCA[F"A"0UR$G\"BQS6>&5>R'#H.7O9(;!-;ABOSPZ0
MNGS0(U"WE>N2V$$F.)P1UA1QEZC?XY+-ATZ5!=':3?RD8\P$1$R=LT,^=J+E
M$ZA4&$[FW<'\PAV["+B &,:E/G48TA[3K?1KF1PZ.;Z"13+@N@+::[KQ0WHL
M@L8#,3BNF.Q8-O3RDBX.*<>PGCX\6D!5)T4),]/0R3N>S]Z)68!=W)0TDL=P
M+D_F.0Y+["IO+_U%ZNN3G[\R8U=."[ORU8Q=^?*P*Z>BMS_TWKQ)N'\(/^C]
ML#42 =$G@!\K4]>XA:P-'C&<WG5=EGDC-1O3NC]Y"6K-S1&O+MMB75"EL"#:
M(:K FMG6J!FM]J$L+H,5 RS=55=%P[/EZ#<<#2 N]EXSNE8<>_+WJ&Z^Z7GP
M)WDX<N7[/#<11(EV*C)CTU&LHCM5>7C2G[R7VE=KC&1N2F1(%'ALPA#O#=J2
M.>?U_?[XXR9]6%J,;X<;R%!<)_G7?&%*<729D'D-[<;R+&BPB*!FJA@S\E5S
MEEEJ;U$I,M9XF&BS&4 \<GAB33Y0['K)'-;K&/SP8S"*VZ\A?)ESZ,@X'C'U
M]+3NP)"UH<W'JTMFLXUZ#,Z_?QW"..W-)=]]N!,:CJ4[<FP/Y':M'3)GWX0X
M_RR2IMGB\,SKVSPS)SZ9RQFY 69UGMWBTW:+.<JBH>[#B>Y&PU$JXS*V/5.[
M<;>?'B!-5]/V]"'S=!B''D9XQFH/URC,(+J;0TO 23BP&Y5@3MPI/SG)_=!'
M^3>!'43AJ?JM:^J^_7?E<LBC%%$&8ANI:FE)342ID]U@8XOYP:W_7H[>!^J$
M"=DL"GS0_DO,%_G_YLV:EJK"*Y8U;T'0\R(9 *LM[[@9L:\D5T!VI,RW6V1
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MP-H8FQ2Y>UCDX/LKEXGEPJ'#RUA"BHH"OC AE>$,*<= LW]PA_V#X&+")29
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M#J.&8C\OL<]4S.(>2BQ4WD)YF@Q]X3;J+B>H*R5G,GVXD\= :=T/'X<!6/O
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MM">D;"T_*8#+N&S$*:)*//VL<'R4B9)G44MP?\-,;&:.J)LU7B<>@?Y-"$L
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M^T\;&/UM/9:L7%Y+\NO1MQ!X'H/$&=0ZSO$]H [$\C)OK[5@FND-LR5L:_E
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MA89['R*0YK5$S"&7Y=%2K"CRJ$(VA7<#IFP&VP>MBP;K6;D8R;[' Y]W L$
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M+CS S$33]2FEG:KX;?$.[#,PU&;I^M?DHTK7'_+V4^_(KX2Y[[<->-]F<<V
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MJ(R$@V@N0N?HN6A,7^N9L?F^"+/6MQW*U+JMYR;;'7DC*1^.YH)BV$4C!4H
M.:8V-]%'L UOIN,\'+I%.#D3+5CFL:@A#6H&192:JRXC0KI;F^OOW'S4I@PQ
ME"42U4RGR)%B990D1"[ < J#-)7U'(%W>PR6YBB3DL[=T%0<G0=HS^HXR4)W
MZ_N;X /$ENB;:T--)3LO%J)U$9R@5;-SV.V$*;F3J6_H]XT3@8WB/:Q+ ^6V
MYBW /5S515DK8P(VK)V%S+<%=2"V@Y/(N^HT:3#8B2BT]G%29I$E,IPY=UX6
M,FN$X9K!&H8;$K5_B_7A-<.OT Q_B;(RO_ ZX7YS\;=9\'9>Y1C,'TPHF#]H
M)?+?H!<R&80$;2@W6P.@SY(<+GFQA%74E6'C499PQN39!3"HT-4E*52CO0F(
M?^F* RWF4X(F.]?08=<V_=208EN%15-&%(K"[U9XB<@2 <6F.@H'ZU,C?@1#
M%@E8][@PQ&M?L1BA!0;OU#ENV\'/&&R".<BR?\EA ?^=8_#]332/:F):'Z+D
M*LJ>]F573<LF.R/K%]-:DSO'7+0H9WX;$[F.+VN>C&@ !$C^IW7"8.@+:Z4H
MF0+U3#3D+<]EOX),S[CSC.24K36#<"0>QVE(C[K"MN?.I N>]"I'OUU[=K)+
MUN=!*3LW;9C ,]I]TS" NH%D);!["<NSU[^]$*]-\XM;]F2+3*(5M+?'!"*=
M[YN/L)T2/!E,'7_IALY2TRF[Q00#AMQC[PS[ZIARG]CT(,R+(>&_Z?X3FI%)
M-.\^XDC!;4LI-XA4"*/\F>^U-&E7BVMI1B;P^&1L)F8\/"T_(7]JW/Q4TQ?<
M^:76AX8W?<C+AYL*580P-E1$3/:ZA8)H=3$9Z*QYT!^X>[0MN^0SRN@^"\3[
M5ZF #?[?.0<?V]WKV.[4QW8?7FQW)YGMG<.2GNF>%<2PWDE).OSXEG,-0??P
M-NQ-T+>7*JN_JBFDMU._/U<'C3;.2;=@Y.YL;?L\2+@9TP_F<W*)GU.6@Z3P
MXTNV.SN^63!-L YH@-/0"\=YS5?F8S9/78^P.0 %OC%HBZH)_%%/!W0.ZM'
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M#';)VQ9:S+969,+/DM0-_KDK8'6ND:!^+_D<.J;64%%@+9=@E%&I\O;/E]R
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M(6A+S$:?KZ2'5PO-2V5%GJ;$= O2C["_4Y&O>E0;56#+3APVR6K!"N6'%EB
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M^3)LJK:T^3\K[*I)C:A,.G<65=*K$R^;MLTH.YM\98+5JXR@;,'9@756&^:
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MGF[^1^K%\F!RI?L#>0IX?I YD#*01S_C&P8<;J<G@;<'"P;>(@Q#I#!P4CS
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MFX*I"-^T'0"E[8P]?BO#&W 5&X"SC&HZ(+]$"N& "9!(L2CAJD"WSF[JG&C
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M7\9^'8C]:MFU_O'Q*V5# ]J-TC-*[]4I/;M?:_5?*V;?3RXTJFZO:+>?3':
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MY^^-*[@1)34%H_ KO$](8S1A:$=H<B&X!W!OS+DU ;J,A1R@W6MTLA%*">N
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M9)&"\EPV (N)HA23A&?:@>XLB2&(71K\#,([$NXTT$I1:P8<$3P'!Y)&2D&
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M8JI9_PC!?/T+?M3 5#@LI?=<,^\.GDW@'V%@[*HGY$,V"'X6P:M0&SAM=;4
MTN&E("WA7X%1,F7B/;C/][GTFH!IP*=*INAJA0!B$="2]98. ? !HEKT\OZ4
M*, 9\PEXN/$4^,09!S#ET13?4.0Y!9QIA/<4*6, ] 2@%'! 2_BN9GV7O(,+
M_D4Q3X;Y+ FPO])]"LDT:PHG2G?V3H;\BF^_\WR_ %TXC@Y=__"6QS6 +;?<
M#R.Z"^-_/$;H#BNB9HL^*HMX"FZ"R$.>R+DT(@P<L-CUPELFG-1G\$1P<)E?
MPX@>O!#HKP(A(O+@[6&,WBA,7:#+6QSFA+DX=A 50%#P9(>)L16QJ7[-V^.F
M!8SA$Y4R]_UM*_N44%C$/')4OH+7B]3)@ATQGX"D(D)\VWGP%EM&>?0P] C&
M<.6 @RH S10ZM X(#<&I'_#D#K\@PN"_2L+#H!!7H#4?\, 9@QQ1>('?(ZD%
MEY&") Q_(B>&VF.C>RD RWQ@=DMPU(C@Q<7 %13@E>\A6@@/)L1B=,T<[E)
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MA?LOZ?13N\WJ=O>(OZ.;[*ZK_LI; W[4^8%SA[;]XZ;1F)>._^*!C+U2E[V
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M+Y+ORB+Y=P;0/B7<:8)W3PEW$D,:BJUH%!LFEKXR?E!E\H=,,0-H]PO0;ND
M10-H]Q/0=L#=;B&@[;5/^LV>BT>SR6-Z]?CK\,0ZO#MF3G+*)0!\@$M?HL=(
M 7%>HD(0Q68B<I<E$YA?_\0'<<KBJ=4B&-G)6HVP21B,%J%A_,@+@&Y8D&D%
M; +/\B1NON).&GL)(N4?*5"7%;>7&GRZ^@(>U_]UP ;1Q%MW23!S1/ 3F*OU
MOMDU 5>#3RN#3_O;<BX-/-TA/)69=;M_L_-0Z>= >'@0AVY8_ /N=Z;;PVZ&
M[0PU##4,-?82.6W4M/^7@5 O J%:6XO/&PG=KPC?8QMB6K9]T^WM&I%=I0.
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M<CWA^*'@;N/5KN?_LG _"P-8+9PQ=VFO\?Q2%?>;?$[XQ#INVD?LW5'W'3+
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M0B#:'_&ZPN4X''@>#!PO4./^LP[P@-^?UMMG0Y_?UUTOEHKA%&:43H(SL,B
M]::G^.V<3]7H@E>%0].16?A3$4B/D6ZL\\ ] ]7CT9-CCK;IEH/#<(\$P4EF
MOL/]BE[9<];P>8[9II>P7SZY"!9'_<2U'&?!;S4?C^)L=9&P.#EE:1*>E;\
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M]HPPFZ;#Y\ *T]@*97BB1LQ=M/<&0:XZF$7 J RJ!F# +1B$P,S.D'FQ/T6
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ME;WGWK>Q!65 *BOYA'6_97$P%(4JBRH[< BCRJ+*'C:7549X*2,X:FQ13$?
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MQ@#_X9<_W40G=W_BFCGN-L7=D6A/=/11I7AFS!T, \_L/K^+1\BTA-5&:YY
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MBIXZ!+B=MNF^DKJLNX2&>^+60=MO#YNGO$RKJCEVJ\^S@SKJ;N[OELF^V&[
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M2<:'+7%7>]1X3\"H/1F5?#&-<9;V,=UM8>& AOO>:!0MUZ7E/HXY5]\QYGR
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MII,+7V@5E-6,SV0%%[4+^ 6F*K0G:P15U54@I[QM\?"=:^+* ? +X:5 "[S
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M!,LYB&78O3F_=F4!0']8"!AR\"XGM"7FR(C:Q>/X>:.[R!,&U1:8+@0F(:I
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MC43S\-ES'"C7($,:?0D*TEYF(&=WYRMKZV(&VSX1WO4CZ:N;]5=8E )[:BF
M0@%"!,0A+DD)D(G]&C5\#5KW(#HJ;"=^[2I'3#Y)?XE!.J,2CNXA77N!H8RE
MT>?+*<>:[:'MN!LN<U'I<C3I'KNSF!GQ.,O1XIO>A^,*4 P(LL8%_-)EB)BU
MN/?;H8VF& _PT\1D4-ID2'R< F7>5/,NE]+,KT0OG1L/AS#+>H:ZQYDRNHE;
M"@YYOUPATVA:J&$,=UN?_K6Z&IOZ:TH=+=H#9#)3XQGE;O2/@V.N<TVC%TW=
M8O8PX#([>=" O9$#!M^D6SVS0-CDN^ F7V_I/3%X8,:(\W[F8A14IZS \6TB
M*PA3(%=S1@6@M*CD@B=)R,)U4*<2+A)5)B#:.-PH14F*4A:DS)(DBVA&TR);
M!W4O+_CL7+^=C9$=< X.JQQ^==;IV,]S]$6=6BV\,BX#SM%7,'D=TMN'H^RP
MPB&,S+!.AR_;8(TY6&/31=L!<NP$1*FUGS:%\=P \8"+^LHV('F'E28,3@8.
MC#5/7#:V?%<O>#7U-OJ> M_3+3BWPW1BN3#5"]=80KK&ZWM/N7N P/VLQ>T0
M>,!]Q;ZCJ[?6M_^)?\5*,0NL,H; :I_.Z3K(&U8]!G===R,'8-IN2MS*K:.8
MZG8DU07X'/HQ+=DQ3Q44U;0:IO8-S\&[L2/.J$G;.K3#&C;C>3)ST#&GUTQS
M[V&!T,#[9OJP=7_U_!4E=I;GI)]?8(Y?7V2"%;J=],;&=MA48>;<6?8;3"H\
M5ALA+'(3S=$#-ALJ#7OXL1(#VH9%'.PR$]9MFJ+1)6IS#U:&_;J %!#738:'
M&X\X@+=F0[,;!0@C87P@ N2LXQ'#3/3% !!>KD1O[>7NHM=N!!6<87Y^CC/?
M#6>/CG3P]&PI%M;<HR$!P;1/8FG#/#"Q5&P0:;!KW^UA.!^3+MR*];A&'FT[
M9A-C*H$I84;MK'9_%"8\XXI\76;*,#2^[9M"=G:0,6:LM%F/]FRU;NXDI])N
M+OWJB[Y_8S:Q237:6*"]C)MCJM0"(SLC(^@&@6(3<JQT0SF_N(4\\W4&OL[@
ML>H,4E]G\*N94+[.P-<9^#J#&Z9D;+@= 0%&D> 920HM"(MY2@1/,5A"RTSJ
M4%*^X7;\F5CR1RS"7.HW37V)V]( 0/A/P!HO09@ %&UNBB&OS^:XS7+-C(S]
M-F;N_<C$&'<V%#]>"\\1P": PR*F -M=$@L'.V?4O!Y!JYEBC,Y60*D],(ZC
MSO)'3Y*!U? /BA$$9:H%S$!.ZZQH>V=%-_GWQG<.=KG!9L:Z@)L-^/X#]% U
MDW\VM3(-%?[/$MY PZB8!*?8=.>_]$Q+CG_YP[P$UA-:P/\W#D ;;8[@O5S4
MSJZ-CMC$[QC I"YC-GCP+W>,W=SV2VZU/">/WS2NPL'-1V=)ED:A(G$22<(4
M3@$JLI D.:52E:&40F_&@2C+\C0GN8PX81%3A.><$QDS'@J1E 6-?E @O^X:
M3.'(=/C_ZA/_^B18SBK[SL]__WSVZDF 40IX9OK$Q",!0H$51I+5.-%L>4E4
MO2#NBB?_$9Y$G9G7??M^16?@_JES[C7U-9^:PGN;?8UBX/DAL%&91K#OO"12
M1(JPH@Q)H:*,")9SF:>JR-.-SGQ)G.F$B81$O  VR@I&N* %W @:'91[*9)P
MG]@H.P@V>F%4QD$P#:-Y'!9)04H&$H=ISDB1E!DIE8CR+(II%F[(GC LDZ14
M&8E*71#&XI+D'*10DB::17D4%8)[IOE1IGEF-/H!L(SF4G#)$P(ZJR0LY)+P
MJ,A(%D4)BR(9YDF\83^DG(4J34G*8@VRB15$)"PG .$C5JI$"B'VAV58?$#Z
MZN-V['EPZBO3(1>L3 #,B!2D2J&("+.<)%Q38+DP2[*-%.>2,0$Z#HQ1E:#Z
MBA(B(M!A*8\5S7).%97[PU9Q>%(<!%L=D/X*&2U9F"2$9PHX0*B0B)CFI,PS
MS>,H3+-"KG--*EFD="Y)+C0% <9"PD-.02)%@)P4+;3<(]!##X5KGIVL^%RW
M.Y_"..))4D@2EBF 5,5!$5#)2):6991%BH5Z8[]^QOFT&MI\7[K]^X1YB+?U
M/-UFK<;SM ^[L!;+-4/N5IPAEFE;ZW*0CF];UR[5#NEIGW\GDZZ;U_-]47"*
M20_?Z%IR6](^0ECC1_?,?NH=?+;_(S#_[]]<DNQ*  K=RS;"M!KEQ"_!R\F4
M7]=+=TD_L^$D_-?N>H,*YJU^WNHYQZ2:CB*-\4>:^YYT2X U]!&PJZJM;,/%
MY]TS1A?"E:HGF'EMDIVP./K7<83*?;,-4?WE&_<^\&W12932@UBI_\";/I"R
M^_S ?_O+HMEV*%QL-@<1 #;0G^=-O9PIXF1^:?[?=ID_FM9BH\3XBQO.TVJ$
M.,1 \)5NS$@J)[FL--M(5\"(L?N5/=WN[BWAJBUR-=^16+U;]L%&G.3'$XK_
MLE /0]?[I>./119_-ERX3BO8)_SKOS^)PB>>(7^:(?\_E\>_%EIZ%#;=!VK?
M*^/NN;2&O^RQ2/&"^< $,]V)7.ZSQ[I,Q_DB,$F;0<<*WY,EPT&_1UJ;E_\L
MR]ZN9#^D[+Z9]!O$MF(HC/>8W/?/VUX.>#FP!W(@]G+ RP$O!XY>#E O!QY-
M#GA;[@%L.6^Z';*HWE_)L%/^^Q=X1OO8#K-?5,KZ(^R/L#_"_@C[(_P+LIT_
MP@=RA+]CZYA,HTUC1X)Y6,K#,';VHEKYQTL'NQ1/ERW797D^SCEX!,H>ES#>
M&2E_,1#@Z></KC^X!\AXGG[^X/J#>X",=P3T^SF;IPOPW,V\,1^.O;9FB^<4
M7[3U2W=D!(T+.,S+QF\/UPM*#L1&VEIJ2E8[F*SUL/J!PW.;[?"B_+84G-6'
M2;]'(-6.F&T_Q/<#5-VF0K$PR1+"XC BK*"<Y+E@I-"4BS1,8B[5>A5G4<1E
MIDM.BEC&A.4L);SD$3:>B"BE62IU>9]5M_%*U6W\G:K;)&<W%MWZ,WE 9](K
M@(.CW^$RV_$H@##B19DF)-*L &&>"%)(EI-,%32*69F':;JN (!@+,ER0424
M2U :\)^"%A')8AU&)2Q5YOG^*( HGD3LYL8+_E@>T+'T.N#@Z'>XS'8T.J!D
M<4Y97A*N\@+[#68DER(A*HS",J01B_(-(R JXK1,) Z4IV $J*3 @?*2E"J-
MDI!)E2?WVCKN!W4 FS":>!VP^V-YM\P'[P7<2R_@J%GQ_HACK_L/CGY>]^^]
M[F="YF8,*2L+!O9?)HE@G&$CT(+JN*!4T77=3V-9B@+P0LFQ6:/0">$E34F<
MBHB5);8.3?=(]V>3(KFY<ZP_E@=T++T..#CZ'2ZS'8T.4$KK4N'8 I%0T '8
M4#72,=%<9A$M1<:IV/ !AC1F"HQ$':J,L+ 0I"@21A)!6<P+Q7F^1T$@T %A
M2KT.^!6.I=<!!T>_PV6VH]$!(L[SDH(4UYG0A-&($B$S3FBF1:AE4:9QOME^
M.XVQ,3N)60CWB#1!OZ' ]MME(5D9E8G:'QV03FCNS8"]<0'Z1,"]=@':@63[
M(XB]UK_O!D '+('NE1WON9_2P2.'.&%4,TP9B3)&6"HS4H2L('&:@\*E29D6
MV48*(4LS1IDD69CD@#9R1;@J%#&3\-*X*&5!]P<Y4#9)LG@?H,-/MYORA]OK
M&J]K]IX=O:[YWF@Q'BF>IT3'&++B(B5YHAE141SJC):29AO9BC&C!<ZB ;,T
M3-"R%217L28TXGG&65YD\1Y%JS*Z%VY*KVB\HO&*YM=E1Z]HON,.34.=ED*B
MH@&S) ES(F*P;")!&<^HTB'?2(G,=*Y%!%<FJ0:CIDAB(C+0-J!V0AKG.@3[
M:'\4#:6Y5S2'Y##=?<YD]) .T^@7=Y@NZ@6?>FAQ@-!B7^AW$,#A%X %/S?_
MZ :#5)1IGLN"J#@J"5-A1/)8:%+FA6)Y3$NM-J?@/O((]1_#"2R>1)$OH?XE
MSJE7"@='O\-EMN-5"CDFTX01ML5(&6$8&^-)7I*,LC@I1!:*D*\KA9(Q42B\
M1V%.?18E1$0%(RF/%<URCGDV^Z,4XG!2Q'L1$?/G] ")Y97"L3+;\2H%4S$5
MJIQH66:$42%((1*4\E$FL)V2+C:2[%/)(J4Q'5]H2EC(0L)#3C'!4D1*T4++
M<'^4 @6EP$*O%/;%8;C[#$OO,/P)AV%]S:>+2O]LRWFO\7W8\9?!!#[L^&V0
M( 43JBP+4@ILQR@RD-Q"IT1E29JE11PE@JV#!)50DS9)<AF!Y1@Q17C..9$Q
MXZ$025G0:'] 0L3VPI=XC&%'KVB\HCD6=O2*YMN*AH>%U(IC:DLLL.2[( 68
MFB25(DJICD%>ZW5%D\293IA(2,0+=%$6C'!!X48EDC0&12.2/;)&LV@O3%&O
M:+RB\8KFUV5'KVB^K6BTUH700I*4JI*P,(T(5U%,A-)4:A$E41&M*YHP+).D
M5!F)2ET0QN*2Y!QLFR1--(OR*"K$'O66S**]:"QYC(KF,1,I[],->HA^SD^8
M_Q@TX^&;LEX9OBGO.'S3XX;]P0WTA** 4?523+5'#G='#C] T,/"#KN,H49Q
MF95)SD@>%P ,%*=@M>H(T &+>)S$>:'*C6S+(H^XB',29WE(6$Q3PEE!L=<9
MYVE(P7;5^P,F6#RAR1X69JRQYR^+*+P*\BKH>!C2JZ ?5T$I5V52<**%XF#/
MJICPH@B)EH4H0;&46B;K*BB/15$RK4F<9"EAN10D%Z4@<(,L6%F$>;Q'\W+B
M:)*RO<CM]"K(JR"O@GYMAO0JZ,='MB5965 P862J-&&Z 'LHBC(2L3)1<1H)
M(3>:H.1@ZQ1<IB3A2H 5)"CADFJ2ZKP(J4YI6>Y1$Q0**BC90Z_JL:B@L5\5
M_LWA:__#[ 8^H)HMN=L.55W=[T?^ WBM*J]OKSWLZRF\?OS&TZ;BTSNIET?X
MR-N*EF$QWWK_[3_^\PPX/J@6[5J).S]OM+Z$:ZPW]X_1I/!)L+C0P5^;>CD/
M&BUU=:55 %^RG)<-/#>0O+T(YOS:W%V7P;]TI-U@WMM]S$,T .%Q&>41)U0B
M9F>E(CSC@F0B%7%)!2LV>^)'F2ZB@D<@CAG.4BDD*72JB!*Y8D6B:)IM]$/>
M)EE_K[BHIM7B^D9QFJZ(T_2[B?DWBM)]8+@ [I\:RL\"&D8%< YP3Z,##<>C
M0DF[J#NV"MHY?%59 7\I4$_3>HX\-8$_GR^G?%$WUP'?IV^#+Y'U)>RI! F$
M'ZIABV>Z.PSM2;#_1R&*6)ZE*?!^F -;9RDE EB=I*F,5*QIK-(-KVN6)@ K
M<D5B7A:$B; D/$T8$9HG$=C0,4_Z\1#M=/;\CXXR'QQA/CHQLGD$!L9_^^[-
M"N>35DOD?@SDM7KVY#_>U7O/^&O\ %^+TG=Q4;5C@:OA-'!Y46D4K$]I2./G
M6QGGT=B\FKZ LTOI\T.0[51Q@&TA PF9<YQ?7!"1)L#5-)9)*3A+R@T?#@N!
MYQ4-"8WP$!2 HO." 8K.M"XCBG\*?Y*AM\KTY'M>FI/#$.K/ K5LX&J#$*XU
M;P(-'*Z"5T".2P&L'D<3Y!RV71(^UO(_C?%,?3Z#Q[?F$SI(XP[L9,L9G@RG
M&;8PF.NFK6<S/06.:N%WJ-UJ>%0#CW:]A$HX]4BC_K[Z"H4 K'Z"2I%+"1*-
MSZ2VT.OT[&60ANG)/A$L^$&TO('1#Q<POYT!&,9M1+F\"H6Y_.>R:H#=]3[M
M%1KN+8(I4)13!5?HP%BN+0*MQ9<Z@-=+ /=H(0=M]?'=:<#!P.^U$]H&8_B_
M:BA, O@2H 9P]W*Z@&]'#@XN:P6P35I3 DP I%*OX$Z"=W6 -C3^%=X)1\8(
M/^3X6L">F]M:JP<K+ :T$)##:7+OZ9ZY\AYNSBS<8VZ<K;SCO*X5'+0F:'5S
M54EM/E[ *6[JJPHEE+@>;24>VHW'C[\0_SCGS0)@WO0Z:.&"UBSQID]I-,!5
M(Q=K<R^2?<0O"^!^)+@ Z7.)EY7+U>?:3W.K^P(_P==-Z]DY;(][#3ZE[E R
M7MSJ[K$GP=GO[Y(PLLSZ,G:_-R*HJ<\;?HF(^I)7,WA(ATA@_< E%=+N)L-P
M<0'+.;\8C@-(]4&2HAA;SG!=*!:W;595 F_9S4):=GNJOU:M65R74-1]O5TC
M_F5M$Q68#B!"[:LN^X=QX.;9.1@4VW<%GLD7 2"O;1O)%^:5"@B+C^J7,OX&
M^[6Z++7L%[_U0K-CYFWNDA98SI&SHS*\O;>E.X)]\W#B,X&%IM-:=KMOMWF\
M";TZL_Q\F[76EKLO-6^7C?EXPR2Z16I_X8"UT<:93S50QM++H2WW5+N(&V@^
M,4=KM"H0CURAA+<<5?<I96L;\,WU\D N+]$@1"D'OY87!+Y=\+9J;R#& <!6
MK97(8X:3ED1(6%10DHLB(@Q0;**5"LM-.XPF*DSRD!(-1AK<2#4II(Q(GK(B
M5&D>2K'A]]WFDD ?[^)E3].72-+/\]-^HS[5SEO\QV@GWI?=HW8$>J/P0%!O
M=V:V,RBR\$GP=N:4 %Y;.WFVK@ FMSCV*"['!V@1E+QJ@BL^76K+[<//]N34
MH K<W1<<E8R&1<'Q;2Z-Q+<R%&RZD^!S+_S'7S &.4;ZFWL O8*:6J",:)<2
MA'%+X,3!WWJ(;,'OM/[2R6$%HFX1-%V)/))MIA<@1> &U 9&JS;U/S0FD7)U
MA<)C?("_ +F';W=*[HHW%;JLO[$*7 AH[06?60>3(092#B$ZX!>@QP+$\#FJ
MD)/@='8]6B-\IGFZ>;= [337L]:B ',[D-A\@,?G^_'I8WS.)JO(=58[*#DP
MM 4!"[N_\/=@OFQ:3&E>-L9J&_D=US6<Q4X@PT '?^F,7J<;1PKQ QPZ'41!
M?YX7&)^P?'W;JP.0F*@;YVA$&E#EY(W!]O9N;@Z'$RCC9:/DO*H,-W/GH:P6
MJ_XG.$P@#MIN$2M$>SF&?R?!J]L9^&M!@EY<V<ZY!Q(6T+S(.=,Q"76>$*98
M0@I5E(3'(LFH2$.I[^0+O8_8ZX_IV/ D/0P56\UZ:+C5:>K<I ? 5$Q$/"RC
MF$244L)8F(#*2@J2LX*G49&K-(W7F4JGLBBQZT.94NSZ$$5P3Q&3DJ5%*56H
MHBC;'Z:*XI/H(+CJ@+S83(H(F .,@%0I]$B71*B"$R62(I-<%SK;&%'P(U[L
M/> :=G)SLY!]XIIG'NKMQZ??,G?AM 4V_B\]TY+_BJD+L:0J2V+0']@0*,3A
MBCFBE:C4>1S&F4XW!$-1Z(3&<4)PSC/Z"03A$C12&H>\X#G\5FTT$?*I"VNI
M"S2T[,5[6X%?HL?S0/@FS^-(QX4B680MB*,\Q!'@)5%IF851FB6,;\"0/&1Q
M*GE.T@Q;'4NXFQ=4DY##7SC W#B)'X-OOM&'<J_XIA<Y%1JIU\A$*^[:?5HT
MHFLT.F^=EM,;ES>FOZ GYHL&,Q7=X95QV&]W!DW0&\1GUUN]MULCL^;E6]YX
MN]#J=XS:?=J6%77OF/[=$FA>29>B^3^"X-_@?P,YY6V+*;+GFKC$5EP@O %$
M E[@ON2_3<?-K\])_**<ZJ]$54!J/$//X1N7E[,7JFKG4W[]'/^ZD35[DE0S
ML]BN"A]^=#"A6[6YD0!)7\SKU@3DGEM7Z)5^(>JO2"+\[#[Y]NLMDVGO@F2&
M)/)]V-0W9)]8+,I6>,RD_?:<==&W77#4K6;3:@8+6_!F\9PO%_6+U3_ OMM?
M6T8TO1=X"<1_SJ=?^'7[XLE?>I;=FM6-##;BT35>VRU+/596[T;!P*[W].SM
M[Z_?O7P=?/K;ZX^G'UY__O3VY=G-R8C&IPX'MP7M.B62S]M;(Y)[_Y+Y5#Y4
MJO9=NFC<.QW>O?_T^BSX]!ZW-'CY_MW9^]_?OCK]]/I5\.;MN]-W+]^>_AZ<
M?8)?_/'ZW:>SX'_]SYQ&T8O@*>*Q"BQ\]>PQR?APTFQ+[<-82_XX-K> >EP;
MT24:1D!AP3.2%!JK;GA*!$]C$F:TS*0.)>7AWZ/[UVU[9J5OBPCTV:V\ VW[
MI  ' 'D@MER4*2Z*,B5,9S%A15F"/2\+0D.1,PY_3,J-$30939)(84%S&5*<
M><JP? '^DX0IEUD"QA5[R!37PXGV'TZH0>8I=EPK29**G+ 00U=8.QB6)2UH
MS%56;I2U%"K,!' /R7*M@2]H0K@0BH01E:(,$UWP9)=\\3W;_AN-/?>)*[I0
MPJR:/ON!(.D^?<IB+_T0!QL\5BJ7BN<"I#"3A/$R)GG&$Y(*K4L0T2K/-[J[
M_XA0WH.(37XH(OO7B1ZG0J54"4TDE>CDSTJ2AYP3+;,P*1$&Y!NMG']$I.\!
M5V4^>KSS!N ,I =-2Q*RC&$K-4%R2B4185RD<9B*F&XT$>!E7DI&"Y+G(8ZP
MRD.,/6>8CQKK5(2<A1O._L?CFO3DYB8V^\0T0_#X^.*U@S/?>%]-'&11___L
MO6MS&\F1-?Q7.F9MQTP$BJ[[1=IG(SB29JQXQ]3$B'XVGD^.NHI8@P"-!B1Q
M?_U;U0 HDB ED6@ W4!N>#4DB+YE9YZ3=<F39?OVUY9O_V;']>2BK ^\\[-)
M29^(&*PMG7Q9S>U#/):P<T0$Y*6TB)?&H<8KA:REUB2MN(AK S8L*7'82Q1C
MV15.?4[F,2\5C883+HW6ZX+\NUA\(SW90?9C#_R"8T6S2WA$71G(*X:+7T3D
MG,9.12WC^J;_I_A%&;!]U2?.XNQ=.L(]/8-F\;%L?[6?8_W3VO)BAJEY7=+(
MFS%<Q]=N'UJV?51#X9&%VSL+MG=6:I>87&QV-9V$N5\NW#YK>_#-9."=]=LN
MV7.QEMP,/LO#]0!(B%'4Q:11"@+GP6<>(3C!/++"29\BUY2M:^?2F)S/5$0]
MUSE)5!0Y8SV*A%(;<1Z2NIW."-*^C"[[,WI,E#J2M$&!%(9PQB,=61X.6B$X
MQ?G]N[6\(^K L<<2.5;$Q'3F))<(1M$P9H-T- \A=^D6O"=NT:/A(?8Q8J%+
MGF'R\-!RDU.(8)#RJJP:.N:HNN\6S!JKL@\@QLH>0N$),MR5@D,7$@V"!+;;
M]8.3QR7DNN06/_53^F*S#5;'.^9]>S=ES(G/*G?:K!;M2^76\GSWRK3.RP3G
MS@K&'KZ'9^2"70J-WJX\:$MR"A?+[$)1K=9.9I;/_R@EE%;<.,G7MO8^)?G;
M_VP?Y5"WMO,YY!2XL<0A4I:E.%46V3(?'*V542MII%U;3'Y*[KA_K\(GJA=.
MU:/,,A@N-0\1,9G!A*>@D2T5M$(ZI[3GEHDU\;6G9)9=<!K:"Z<YYH6'NTD8
MT;<SCGM+$76<S4;Q)N,=#7V1>U@K*1N-KT?VLE3K9]?P<=[H2]?5V[$_J7XL
M>RTI?KG\4O,;>?G38)'.V<5LXD(UZ\MM+*X;JLE\5L_L2B"NW'^^A]E*LNC.
MQ9L=SPLQCE(#]\?9Z?!F-N[=V>^GY^=_O#NI3NL[ZDI?GN^V$9:/6=^J[%A<
MO)%86EYP(=ZSNGH> =1E3M3>+>6X+A<JN>RD!UJG4>I O33(6)<IC6F.7 88
M)%-R3')I6%A;3/?::QT20R'(F!.EY)$Q(J! 9#2"1!+N2D/^'J>EV,!^B._2
M'PL3O1N?Q=G[,E]Z!X.R>\0;$$+T2=JG^=F[C4)7"S,4[_BB^9)_63GJ2E7M
MS7PZN8KYAO\QOI'8^B)[]M"L]D(&YLOT]$J6[/:PB]T^T7#\<=*HAZU<^=_S
M'"!Q.KINAK#3:1ZKU-5"1B:[RN)6@YW9I3!7'J0MCVCFQ>/59+H,PQP.[GIU
MVI-J^;IO$L!F1'8SIKBY0'GL41E^W6C)+#5I&HV@18PO[>7]?'I<$AR6,9I'
M(!I%7NK>,2OMX'3(XQ+GL,@9P@-;6Z6U%FN-41[%F)RI"I^/(3EB>6+>XQRN
MC'8I@>C'=I=F*+/TZ.'89ZLL^GZNHJ@_(QF3_<F5KO:L\2FB"=*&)D0(Y<YK
M(Q5?\RE+=8@J>,0L4XA;K9##FN8QM=)."".HV&J78AC)[!N("$D9<C!*&83*
MULR$'*<2,>T3YR9(O"[ (96+*H8\4*9E"Q4FV6EB]CO.@U?$\^Q/:W7VX#1/
M&\D\TJAD6=^S>IG+$MG5!!F+ CL6,ZGX,BWA%3+-ZJC"!-/\6HU?R_N>TUGT
M??Q0,NT_FA0A/]_K8>U'DZ*K>9Y/_/-HXO_U0Q7SR[K*!\VF\^5%F_*LT]GW
MWFD/:HJV7@W'3ZJEL9<)63YB_^/=)SSJ#P][*K9:4J$=<DR55$8%Y!RW2!"B
MA.=1J0?$ZUOPU%>3</G[=)*-_-NDKO^^$(/]V^33/S+BO,X>.QU>E6#KR/B^
MY/8;,LB])RD#+#3\C"Z&(<3QBU_^F2S'(O\?<MH6.=8@D?,!(R]\3,E'*S#I
MRG3'JW>O_W[C_'?^TX6[*\.A8?Q45YG>ZLEH&)H!3AD49FBL;\2/FY%-,PZR
M#=.M1CS->*:I9E4OZ]LRPX-J*89<OCF-]60^]<L5K%B7KE;#^J+\*7\Y#\:+
MM]^<I<@PQG&]7+9Z.[Y1#B^#N@=O<ZFEG0V]&H?F(6)&]VF111Z.%SQ;3E >
M9S7^RV/#2_L_^0._)//FYC[$HB-Y=9%C?G'[Y1X>MLVPS+@LAIJ7DTSY^51N
M'C[D/W^,T[I,QOC9W(Z64N6+9V\&G<7@9>CWP0[']>Q!.^83K%;[KN*LG+O9
M_N7BV%]DY/M7-MWM070>I$_SS37?Z7[RY@/7+EJ:1X2L%$BZB)S*A"I)("(/
M")D4I@T8S>"=1^#OT@)'BW#L$ECOSO0L/SRL&9[IS3-7]9**EW,ZRTE%7\VB
MOQCG^_MP7:5A'(4R!U&TC<OJ=LZ!RBSJ%QW=-7&3?;/Y/MEMJ:;?S IG7/##
MQ>Q9F?==1.)"%G]A]M)-J[%[]LV%>'Z1@ X-;;LO#0SN(D ]O\PF::9OZVR$
M1OVYV0NP=N$C7DCX@G\A.V4!_26VUXNYD!6P?YF%O#=CLI"_7S:">:3L(9-+
MM$U+C>7NC6)\>X\Z!C=1M>P=<+,6T,CFWU4M+DL#*UWL&/)+')>MNAF,RGKT
MI#J;9-)B-Q(1RQ%H0UWVUN:3FZQOM98PN[Y:N.%RU6%IA/M+&RM3%6==F>O(
M?>A6=X6;H%THM ]OS2@OYX:='34[JNJ+&!?-,)KY6W\[15@<?<>JCXY^"=8D
M,QM%.AE3.@LX9*,3R!ONI/?>T?55CV>-*?Q%#/-1?)?NCR[>?DF0?KY>_O%[
M1\3?<_<]&!%OPZL6Y.MBD=Q?-K:I;W'QEZ0T@\[\5A;X8L^]3_<J!O.0A!H(
MJX&PVA;NAF@05CNTB4<05@-A-1!6VZZPVG<O@CQ\W6^QV:/7_=Y4,S]R^;__
M7$Y^W$'Q\HX6,'TW52AOLGP=Y00@)V.+KRS,3# ^P7]>?;\9)%[5\44=KVR9
M<EMY1-/$<7'<S2WD>[BAD8_#>K@HZGVQ.L>M+^9OAAN?:2XKU EGY,^W87[Y
MLA<X_]>O'+OCP\@)D;07=PH/^-@#4K[-!_S/O\ZF#P7%,L'1&1*<]?_ZD(<_
MXX"6W).:_WN8>\H\["+)>K%(M<H'C\33W30+EVSJ8YPV6T27R+U \[6<OZ1=
MRX\6T;T\^@',?X!7=$NTLED*O\;/SY"UGH7=V'6[=GP:/3^7<^_;*K^G\M?_
M\P/!/[1AN)M4?S4LO9I5S;Q3M?*%(W79_U<6*-^L;;W<MB-_Y7TL\ NS[KZ1
MK;K_1IB_&;P_^%R ^=O!_"T8^Q")X/L,.)X\S7S/I(/=&W@/MGRZ,VY.KE\"
M=XOV;2[^7'#XKG=0ZA6ZY<U?)U/P9P!7 -=N.R. ZQ=P9=WR9@!7 -<.N2.
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ML5Q-^F4ZN7R53U1NX+^'LXM7\SJ;(4Y7^=>KV^E72UO'*1X8CF'K^"'$)!!
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MP_:#P 7'@\#MH?T@<,'Q('![:#\(7' \"-PN36F *FHWID"@'UJ'L ;$ED$
M_? *><$S>V@L@,%C=;9^P> &.\^IU$P)0I'0GB#NE$"&.(:X3A$GK:(+:X5.
MW HA'66(D101-]8@@VT^QD2F3?32\:[T@>!L0$@GZFHA)GMH+"" 8W6V?A$
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M%LPGCY1,.H,W)AGP641,!II3:NHS?K:QSVV'@(\- /XAQ"  ?N_LUU]G.QK
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MQ@)\/U9G.QI\]]PFJ5U D1E<=$4DTIQ8%$4D5AO"'-FHX<[6\5TS@/=#B#B
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M0#HXKY216HFU^OR6QYJW /+T<I(]YW\;?&PI'R$2].5 7ZX3E@72 ](#TNL
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M[Q?M5N.=.-D^%CMZ ^J-,8L\)Q[QQ!QR(6F4L)0"8QZ\WU*(GJ2@#:8(<V/
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M)B//KK3_^3<:3T/\_!RQ%VD2/Z,PKF,+5KD_R/)L^@)6<CZQY\_SKUL ,Q*
M%7D>FS M?%S3;S.A]D84I^'%?-:TC4V?MQUDQA_CY>80%SCU^8[8\Y"N/ ^K
MC]SU>O]RX9#V8337ZA&N.&W#6:<7<?DU=<?3R7@* UO8>MUVYNH/L.ZKKU>,
MV ;G;0+B/[>33_:\63<"N<R15PV@S&"7>/0:KW7+4EVKC'N',3KO[?WFU]=O
M7[ZN3O[V^O?CWU[_<?+FY?O;F^E]! BP(+@-V+$3!,#:W+DMZ<YG,I_XQ\*!
M3NO/=4V'M^].7K^O3M[E):U>OGO[_MVO;UX=G[Q^5?WRYNWQVY=OCG^MWI_
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MKQ5R) GYX7(NT7K15\E$?_[*O8]\&QTQ3@<QTGO>AD=&'_0$R0C+74[P&R=
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M/6/(Q$B1=\P8YS#F9JN_\GUJ^CZ)8KY%$ ]#$ L0%/Y[:D!@HJ58&H^TH0R
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M28P3.$GF#.[N</(@($NP(ZIH@:P"606R>L:(!;(*9/V#,".CC8 \/(#')'!
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M*_7V9OHJ@I%0QP 7'#=-7#3_9Z/MCC?*KJM-1''$:3$;2@G$XF#VC1$+(!5
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M*>A3T&</Z&.Y5%@ICYB4#G'.(M(I_\.P9$)*P)/M1O(["I@^%OJ0$2_HT[O
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M^MZ?QK"<Q'=IJSC4\31<6N63[(&>P,M^GLS\OYY5L0$C"1ZTJ)=Q"Q3N,GK
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MGRQ##-7X(?'-KD<UK1;K&M"K@]K5N*G^=-, O^/MCW%6E$@7%=4(1\5S%8F
M3(P,B6"UY9P)K=E#'*]F,MV"O6/OEV?+B5VT7ZVJ!/X>5Y]G+V?U?%;#W[#,
ML[,(%WRE7J"\@I'B&U%<->*W0F4?6*B"^R=Y:6:ILE]HU!ZO6#.5;?*/KZ*/
M9R[6%2-'5>XW6_TX %9+@2DPC30R&&PK[ABPF@'%8PG##KQ_S-164:OOL;+Z
MQ&IZ=/NV>*]8[6:&8C]5=5PSW^P.U>P?;^#CQ5VJZS_>>&9@W[1;3J#PI]5?
M(_#$]#SS!C#RFKO@A\Q>68RS!$_#$' A2*^T!'%SF@O$K2'("1>1PY1$38W
M9"LE=J>XD(O(=BJB<B2&(:+7T&"-!)?D,QL>&_8")NS3)/HFKBL!K>##>'$^
M"-2DDH4 )AI@)8N($RZ1E3P@GXCVH*F]M/Q14;-S051#$<1+6-FG\5W![=&%
M<W[)[>O'.+^T:P;/]>)?&&:^9#Q=96YLOK_DW'['8"Z$Z.WR+-9COY8A%RQ6
MWFAD <AR09R$M)(2:4P$U5X:B[<L3VXTL8YIQ%2V5AD%N>.&(N:$M1)3)V2\
M'M][OSP[L_7YN[2=B'("3_YY,O/_>E9%D)(YW+6HE_%NT2]"OS'O[X\9[8L)
M_C[[V,:&6J2Z<H#\XW;>_I5FD_W94-EY5&T34VQ#BIOQK(>?A_K<+A>S3<@U
MCS"_ B:4+T<3>SY;KB^YB N-\ ^;ZV'E)W;>Q.=-G-MLGVX(LPK+MO<]NRG/
MYN.X&;OQ!(#S^>89MR30K%XKY<A(E=_[.9,LCW$]9UB#SR^>_?DK]Y(1D?>\
M\YZWL1$3]QULF>-V0/S[CT'MOIGO=^80W: @=MA[^<N>V^-MAU7WW"G:16Y6
M5W3<<T]0^2@]0;_"CYV!XL,8\DZ$_9]H:W#&<C#_<@AJWQU#]T?='C<,+>KY
ML=>K*.'2F/DQSHGD':1]J]Q#;=+< PTX9,@J8OT@L6;[9LM#%>MR%JD_9Y%N
M*/A1V47U_]KITM;G56EW/L2T\+[0;Q IWSW6PH^Q0TJY#\):1*C)*6S"(X<Y
M1M&PH"577MNM%+9RW+B(X5,2PP(#A?\.' :$Y3$8;)"(6"'N4S[$PR5*7DEM
M-2%$;F6L81T"#4(@'#%!/$J*##P'8:UL2$E)B<->RRLI7'J@EGJ-?5N&;JO4
MO(H>R-C$G_X\GJ[^RKDA-Z2#]$>I%D?N  O6# +C2W6K?5>W4HZQF+1$GA&)
M>* >6<H9HAQ;(U/"EOLND@FWS8KKEL?+4SO]$-],C\\ I;[C('$#"P1_?;/5
M$36],#Z&HT&>2&W'?BB3 H@%$ L@?A.N(J71FI !QP+T8(F1-38@PE3T/H*4
MBZWS(YHYDWB,B D%$*>]R]%1\*>3]88G@S7;BH[N#JZ^@5*8E0K$ W*BRQ[H
M(^Z!7DJJ+,[SX&V%IU%5IQ3'VJN]8 3GQ%+P9V6@B,<D$'BU&-$@<_<"+0W9
M327&)]>EH(CS/DLT]D.@"S 53B[ ="=@<B(E+Z5 $?X"1U8X9".+R"J I.!2
M"GBK36Q)\RGB_%W5&_]\I7S IAA!?]R5U;N_50[@(23:0_W*O=4BL%/[H:U&
M4)W:7%'GXSA^BJ%:%S\9?XQ72J]-0S6O9_^,?E7N:9:JM%PLZ_:B]J#^I0M#
M!$T,[\VU#4[!$1\O<CW Z6Q1G<W@CLGX7W%RGG^:ME^VURQ.XWGU:3R95"["
M8(!D_XYA5!U[#]()DYF<']VT*][ X&&D+L9I'M_'<3Y-.0/1OUI>P;:Z;/20
M3;/=%02Y&]\=4!F,]^,<H8$5K_Y:SY9ST+5QQ1[M6N8*14W62./FM&7/65W-
M)S"JS'1NV0!?-6T!C9>GXZD]NO0<8+)FZ3*/YL)0G\:+T]/9I*U*F7D V.9#
M[CB[J4B6ZME9!1H.6&8:FB/X&K@6WGQ43=HT#'@;<-0<4 18KYZ=V\EB'.&Z
MS.$S>&F]&@!J9LL:!C<''LM"LWKZJ'HSS35IR*7AM09*KMPYA='9JBTCX6;U
MFJ,_U'$EC7G<U=_LM)F=PLLJ-Y[-3RT J8_+%L_@QK-YKK.V(4$[HCKZ"*\/
M<,< ZCHQ$S15WH-5X@3B7 >DI;?(VJ"8!)=;;1=8PY(2A[U$,?*(./4)6<PM
MXL;DPE!&:X&OFS,OX0GYS?\--'T)0@ K4_\ZMJM"'AU5<")RA(=1PFDY!YX'
M#IO;\U[5<()_CRIXG3\%-OZ_RW$6DBWI34/@:R.##3YQ)$64B+.8D,,F(:,9
M]YJDH(2\SM=66,N4C2@JI1 /GB##M4/:NN"C<9@Q=[E>V1^K5?P-%A&& H;Z
M?W\A55<L/9 "GALMRR]IV4N*$*X"?0X/:CF^A9)!<)&(*L3<'%5J0H&+DD4N
MBH@PY^#L1:F2VDZRH3$Y+SFBGFO@(D61,]:C2"BU$=N$';_,17_?T&;-1\WO
M:[IUQ$)T($KQ4!0/YQ'4!4,I]Q'BC A0(OE D E*1D6Y([AKEMF)ZL$C.@B^
MV:@>=EBJAX'EQ9D'[F$*K#/F#3*.4C#,/+,F>2*V\_NB#AQ[+)%CP>7H$D8N
MD?8(&K-!.NH2?DS5PP>K>OHTRD&J028<8*9.")R![%PD,+T,28A23UC*>LVK
MKMEW1VIP&-7Z2TBE'U-_M:Q;204L.H^VOAP5.;6A#:Z<Q\47A,H_U[&!2T$!
MK6)V'^-D-F^A*LN[!X4T7EPIM VWS.OQK&[?,*I.+KTAQP_][,,T!^V&H">2
MHU8)(U"B 4P?1PS*_3X0ED&G0"B306SE!7(?@W<:48P#XHD09.$Y< ^'>ZSR
MDLGK\0?0#2];0KZT=7T.$O_)UN$;*8#?Z:JQ@1A,O:J$/IYF[I_G2"$ 6^9L
MOZSKS/N9M]L.!LMI6K:U^=9A[V85I[8U2$&.;C?-.(>]03#\Q(Y[%4^Y6MCR
MYAK3_T]576Y?-;<?(KI:4_?9E3K4_T9CH,;GYXB]:%LR!;!86F;+Y7"79],7
M5]I;7=]E&XGQM!WN)CT2/M[8Z2E.PXOYK!FW3VZ5#ZBKR\57+S;K/M]Q^^TA
M2OYA12"[7M9?4)^8C,HK7/:EJGGFK-.+?-@U==<MOMI&7JLJRU=_@'5??;UB
MQ#8IUB8@_G,[^63/FW6AW<L<>747.#/8)1Z]QFO=LM2^M@"WRMQVOC'SYM?7
M;U^^KD[^]OKWX]]>_W'RYN7[&_5V^\B/MAY;$-P&@&B"O)TW=X;NG<]D/O'[
M+)_>&SJ\?7?R^GUU\BXO:?7RW=OW[WY]\^KXY/6KZI<W;X_?OGQS_&OU_@2^
M^/OKMR?OJ__\#TT)>5']^'*%&#'\M$\R[K.WXQ64_'XC=F5Y7@;>S9&4)*(V
MFL"-B2!.4T36)XDT]5'P(#Q.\A_TR;5&R+96W2L;,5N%[__^&LSRTW@6JQ]S
ML._Y$)P;%S!/^<22"3X[*KG7APL>898PH]IXNKT)):S+;H]"*0F*N!$8N%(+
M%!Q6)&*I:/"/[]R8T>T)8GU@D8UO\R)'@ND@F -+[Q6V#*6H+>(J6O!\O4)1
M&16<LESJK8V"X**0$C/DA0TY^1 #0RF+DHF>*,IQ2EL[[X_!'&H0S/%3NU60
MC=5%&_0=K[<L/\5UOLNDF0TM?"*%PB2?J-0A(1XT!_@"A@C,@0Y)6'(>KS,1
M\\9Z*P4B6N2CF,0AK81$08""T4000M/C,Q$>W7[*OT],=#T0]_NKUR^'ATQ!
M^^1RE2ICB4?<&8Y,I *Y)*-.2JG(S1;?".R)B 0%(Q3<$PVR,2ID <42I=XH
M3_80=AN10?#-@)#)>9-" HT QC%#G"N,#!4111V,MTK0MBOW->;0T3CI$L*1
M1M!&!/C"24 S3[BTD7,9[#Z88QA*Y5*_O&\&"F_N+6=QL(H(@;RS^5@"X\@*
M,!M3$#01Z9VT6W'T>_666\S\O_(.6ZR;U_]W.5Z<OYTMXJMQXR>S9EG?VF"N
M\AL_]GAQU_'^@_3>^=IYV(#H4?7^U-9Q3?,V+J!>5+&E_9XSYO<9%>BT,R--
M2FA082B*E*$M&:2UCTC;*!C\O_9"=R(]8">$Y22^2ZT<_7S^,@?];VW*>!@-
M^(0:<7;?7G&/>UONA4<',=(RP=LF2/DN)_B-:B.Z]*XJK04/O*M5SE\M#'E?
MAAQ>K\$!MZXKVGI8PE&T=4^;E>VXO&%7M#Z,)H5#)O8@NAC>N^1LT10'S;R#
MZWLX9&(735$TQ6"9MVM-08NFZ%D+U0'YA4^LDFTA5J];4P]7%?2B&W4A7[&G
M"MOUA>T*^8K4%JD=&ML=/OE*TY/^-#TY7BY.9W4^,7#4ED-=+/)?0(M)#-5R
MWA9U2,O)Y+R:6_"WVRJJMCZOFIS6UQS]EZO_O%[MR__.;=V668U5_LQ>/"1M
M]2&)XL RCCF/@F4.<2D)<EX1E+C20G"=B+-=]&%X.3L[FTW;K+C?;/VN?K_(
M2?:YYG7\+=9M!N35G.!_C)L9IT3]]>??_O'9U;E&:2;GY?3@-V]_^49^\,US
MUCI&QH1',=F(. D46><I(EXHQ:U.46\=JKA/B>\^S=D*[X*V GGN8<Z1YUY;
M(B 6K)5,$RG<5EGS^[2MWL^<0=.(&Q+!O_W%O<"K-"MZ*/R7)N'[9+8GT\L!
M&T=%E PEP7.-O9"0%J#%)-7$,A^$"UM*[X'@UFJZCAHW$'Q$M>Y#XX8B<P,D
M5E'P3Y79GHZ"5YYC9P(*@H$M;L&^=<1;9)27#@Q4>/'62<8'6O)=*GA]I/GM
M1^N+R U(Y(I^'QS]ALML3T:_IQ1),B*@Q$&U<^= 5R>1ZQ($18))UONMZ-0#
MHQ;=ZG<B;J]>4$2N)/4\&< HQ.KU1N/AMI\M]"N"6P3WR3%>H5\1W"*X V2\
M)T"_^R7W%$]F1Z&'/AU*+PIV( JB4PY\N\QE0HJZ'2!<%3$>-.,5,2YB7,1X
M\(Q7Q'@P8EQ.-O3'\UEQ>F[,MTJZSAT3QDVSC/W9ZCY(Q5PV>4M>Q5[S*E3T
MG.N D7.:("ZX0M:VB1(Z84N=H2%TG!C='OUHWBT7S<).,^FOY%C<Y] 'X>1(
M*GZ$U>T=G(OX#4C\BJX?'/V&RVQ/1M?C9#0/E*,DDD1<.X9L-!RTO@@N::F=
MV>H<\L <Z1WH>I)SI>61D;+H^D,0OZ+K!T>_X3+;D]'UE'IF7."(Q6RC*V:0
M3<H@IHU4RF@'"KSC?.D=Z'JLCC361US1HNL?+W?Z;MD')0"WFP#<\:OW)?I6
M4+H_:J*@].Y.-?%@< )L%A0<*XZ]0CH0@B1E"N.0'-N.OE%B=7":HV@4^&%4
M)^2XM$@&@HE0#$NYU7^S>VCFZHA2?B1-.=5T$")7]/O@Z#=<9GLR^EUP)\"7
MDLAZ*A WWB&'30"/*G&:&..*T^OZW;G$I4L"6:UR33(=D+8^H1"<42HFF\A6
MT_;N]3LS1Y*((RENJJ951&YP(E?T^^#H-UQF>S+ZG># I!,)D2 =V.),(IT(
M0][I(*ES-!E^7;\;S 0G3B#GG4=<9G2@7J @L4V@Y -\_0CZ71P9)H_ 82CZ
M?;>1-?@[=^G^RX;.ZW[D\#F,/SZY9NY[F.Y=]4#7DS\YC=5?Z]ER7IW:III-
M)^?P3ZQ\;@1_D6DWJHXGD^N5@N&&C[&*_W=I)]7'V0+>5+62T;05AFL[_5<U
MM_48_FF:99;S:@'O"N-F48_=LM5/\'Q@KW&(T]",OG,!"/T&#8:S!N^FU?'R
M XRI(N2HRNV7CEI:K=;%3J>SY=3'4-FJCA^ ?K&&#V%<1[\ $B805*#]C_F.
M__P/32E^\6[]9?N1O/@I$_JF@LW?,9M'P*GHI(@FQYD<;;.\'-+>*Q1C)-@)
M0F-0UW%*$JIMLAQ);G*65_#($.V1CM1BAZFW=FOG_[V=Q'>IW0U:!;3A0\O1
M;W(T.[R9G@#S-JNA/1C" ,$$/@*:W8I@?># S" 7')>YAJ@730[R-T=5M/X4
M& \&T,#%F=7ZSTJ*)86E9RCJ0!%WV>2Q"J-$A#7>!A;]5LCR>UBIF4R?;WCG
MW5HMKGCHEUG]&@AVW,*GG;Z*\UDS7FQ^_DYV0DWTF:7RKA40_]E?%J=UC#WG
MI&OUY"N[ ,4U!VK$S&5_ZC_ST*B4P3JBI#0PCQ86.:L=,C)8;335C/FM;%,;
MHTDX <LHL)>Q$L@HJI U*G+.:#""?D4/_9;)<W/!<?@SAK8L>?,NK=GJU6PR
ML76SOOI[U)$9B9YKHGFLL^(YJCZ-%Z?5%!Z1S8GX&7 OZY[Q%/Z[:,T'L#OR
M3]9[P,-,)?CQ8VP6L[H95=FNL1\^ & "Y:H/]0S,F7D]\S&&9J/M-C!9?0)$
M'0)G*B64#RXB3!APF09W3AM,D1":^A2\2&[+D[L/0OZV)M0O]>PL@Z(%\^-=
M B;]",3\;0)S.H-AWEIU3EZI.B>^A9!R='OXKA<L"?=/\B*X"!,!$S:&I6^9
M<0 L$Y.PDGJ*O* !\62 9;C(&W'9J/("![NES.[%,O8\\T2S5F@;KGDY:Q9-
M1XS"1[=OX_6*3\93F'"(]:=ZW+()^#P>3/@%@*&?G9V-FP:N6KE)H*Y@<EEW
M71CR\?,\3IMXU2&ZT2T'W_V_X+\K9RV'.SY$M&ZLFN>;(S!_:2]8$^;?: S#
M^OP<L1=I$C^CE0L!8WD.)%N>35_ 0.<3>_X\_[H5 1G]_^Q]^W,;1Y+FOX+0
M[5QX(I!P/;)>\NQ$:"QY3A=>VV%I]N)^FLAZ6=BE2 U RM;]]5<%D!*EUIL$
MT0UD["Q-@6@T.ONK_+[,SLPRR]/-M5]5WK1_7@925T;8' @MFOMNHWKZ)Z_*
M"9TO7Y;OXMD?W>+=BJ\W?_WC,],G-XGUWN3VQH"1'V!,B%7N+8QM4CVOD?7L
M=:G5I767IR?+T_;%FIH]OT\7YV??O?V'=M^W+V^!N*FWHMJ,?Y].?J=7Z^_N
M??L:LN_-T'6 7</H.UB[74CM*W_S^_:"XME)WLT]??+XQT<_??]H]O1_/?KU
MP2^/_O'T\?=//ARQO:35DMK"73</>P*)7JP_FY1V?B4O3M)=)>5N4CFW<SO\
M]//31T]F3W_NMW3V_<\_/?GYQ\</'SQ]]'#VP^.?'OST_>,'/\Z>/&TO_,>C
MGYX^V>2 I/QN]LWW9SU<ORCYS_LTXS[SN-=9<J./TM8D='VGJ:: G#0&4J3:
M(C>-0,8;J-FH*FV*ELP_+Z?R;ZSYX/RS#U.[I[?QI3)_3N=GO4I4FDTN4U[/
M96ZX>!.HG9\U_3/[N4F=V7_0ZK_+^:R'P[,'+6+;!!?;?.:]_N+ZS:OW_GP9
M%_[OLI%+[6\__OC][)M[K__=W_'B8M75Y_FLG:1=>GIV[1L\IU=;J;617^MR
M<C*?U1;FS)H.*_V _M_Y;'F^37^U(]MAOUT[X6+VB6NLRY-KN=K5%FOK'L#W
M*YA??J-84M//L_ZIJ9/9[.S-I_;\[_93K[+FRTLYO?W2W5 MA&WG:M]W C&(
M*LZ;D$1_A!@!G=<0347(2B/):HF2?S<&2:KOB"%$D_^QQ2 4)%"P&:KW*MJV
MR$(>M.\^^M?%\OS5KZ4_8=B<_S,CC\^I\1>+D>=-KH*/;7%V@^G#BTTXT>'S
MJM"JK;T6N,X>EA:\=Y#I[:,&?1VZZ\9A$\CNUNQ"<+VU.YG48EH3P M-8&)H
MX/)&DQ\4+%EG:@U2@T&%@%HEH+YQI Z^(2FF1,-V\!L_*/BJ,%<O/MP?/BJD
M;?QC]U"GS7M?SZW1B_:O/S9Q[<FK*3@HZ4T11JCFD8KI?4@$Y'ON-X?D<HA)
MZML&5!-GZV4+63;T\&M;E(T#\L\?1-379TVT6GRX+VE,>)I/,K^F3 ZV^@I"
MB^:+4E$0E+0@O*%D7)$A#[CM:Z!S!_DU.16*6Y[.7EPEH6?T6_]92]DFU,X:
MFZW>Y-!FCT\[R^%UEEO1<MT56L[+R\<(UYW7!##7:(Z\TP:<#:'QGZT06_ !
M633X62>3%(,-@9,P5H;V)HFUXU0@1$P65*"F1"-E@66OCP&46WRXRFM4\)NB
MFR*72&.4X)+M^RE'!^1< 5>];O_SKL'C5B"S>S<E%F$:./E\-W49@JXWP>ZE
M@-\^0MBXK7>"X+<BT,M8$=\7@?:'I^^/0GNT^4,S\NP'T)<!Z:ILOFS>?,Z'
MCEHM?ULVA]E4W?8<9^\+A3\8M+:PNHG#TU?S-]%KNUW7_/ $%I*.+J,*"%7Y
MT(>2-*E8C(&0M*^QAICU8"&58$USV!4*^=QBV4;UH7J$;N[D2K3:#*5B7S[/
M6CQ65NMM7/M+62W/6M"15H76I<5QF_]^YJ*RGPYPI[&H&G)Z;N:R!/%U65+#
M8GSUR77SX/+1_W+=\=M..I]>K&*SC]+F!-)O'L[6 EX)V;%%(@69K(GO E![
MX7(V%5R.+;[)U4&TN3;]&84MT@EAZO72IB'X?BW/:=F_\L?WF_M"P:G#XL/S
M<<8&NPVX5AL[E+P8U;<\ZM+9'TI<7?2",S-DPNNULR^VNO4:)T^B*M:+C-*D
M $9@6^_8-X77UH.JJL6+NO'','F:@]+%Q0I5*PNHL@%"3&"M19^,2IKBGJMB
MG<2Y\B-?_0=6%2MR4_)D,U"@"!BZ!%$]>8I)*:>\*6JP/>F70(FK8@^X*K8(
M4LZA %%;((@A%PA"$<1(K@E<5>UP;]OFLHIO>@2*;W$CFH:@$$4$+8.SRDB/
M2HRA*E;)Q=CU[QV6Q5XF>&:O,SR3J8_5'K.PJE<J]CF01HKFVPHUV9N\*JD(
MZP>S([^&*^\T,2;59)X]3C$SYFRPHD5!8&,# >:DP5.6T )TFU1*493A;.FO
MP<SN,V.3R:!^00+_>FASK7#P"[[?ZQM_63Q[E42O1HNJ,\@6 [=[Z!J?41"@
M=72-GZS09:"KFV22%+4'[;SH#VYLN^]!@8Z&R H5C1UD1)^D9VTYO.:TMZ+J
MI[WG]FG[_+^=M#_=FY5VVU^T8\]7+<8^ME#N83FGY<EK%KK:XF$3?<SRFV*&
M=+%:;7#3P-*^T<OEV<5Z6^'0#IA1?R1]<G+V^_K^GCMZ]UCX=M74O>GI?J>*
MM]?H;<MTWRX5[]?4WPXG].KLXO(MV[-MJE_^=/7^U&76BW6YORXO:-4([\HV
MV[[XS7'WWC>Q\>5RO8S+DX;[^U>?\8%1C-O3>K%0ZD_7JWPO+WE;YOOM1PZ5
M"_1?>>17'F87>H<GY%UHQC@$\YU=:'I,-RBO&L^\$QZN\]GV>]U-<-7Y\N*\
MU\8M\^P*0V.Q\!Z,^>5P_$IS3FM SZ -X 8Q20[622EZ<@41$*N%B#( 9>^L
M[/\CP7L@\)KFR=G3$PW7)V>S8C@4Q3 6^TU"#S#;OUV;IXD0G0&U*2%6C?>)
M@@?C92#G0T <M.CS_-7#7X/[#/HWE]@[L4\O3[1+0K^>F=J<[/K9Q;LYLTGP
M_9,/92][HG(\3I<9?G+V8X8?_<!=DU*HRK2@/?=B^^PJQ!(;0R<4*A8I M[.
MHZ6K!XDE;YL]MR7"6]_3++3YT_K&+*_DO F,N;7,\J-A^=N)TIGE;[;\?WZQ
MZ3*?E3_**FV;RL[?7_-P%]5]Q1LJ28&-.C>O8R105@3%^I!L+$'602%#D<4X
MJ0.H$&*?8M$WUL8"*GM7L1JG9!D4AF^O^M'E-6^*M'99G"46ZG;+7S[+QM_V
M/,W9:F]W,^OD3?M_2"T6;'Q@ @33;H_QY"PFJ<D,>OR$"9%D0,C)$*#-!J(U
M#K(G$X.I3NBX_[LI;K=(Y?/NYMOUE^/11"S )V<_%N"C%^ *K:HB"HC5&$!*
M";Q+KD^=";DZI74>]$@UOVFB#0:<EZG1IXA TO8)OH94M,D[-]SQXF,"_)IW
M75^YUWQS,6[4W."'"9$7).?;6(GO5XF''(SU/D!I'J0/$-?@JU?-E201E2+,
M7K[K?GQ0+H6B(3I1>GM%TWOH1=-[(D:'P1BW=R6N%A]Q/ >KQ&4*+F?95K>P
M356K(MO=;&0B7#4BE"+L<'N\8%0UONEO4453[U+J/CQ9@](RYY!MR5;L^VZ*
MA=_'W60ESDI\9,3/2GQW:8Q08@IDH*B2FR,LMCG"/CBCIA1ZMW9- RI4TF4C
M@X+L-L^VF_.,$@5@$;V]JX^E>?^XC#M6XM;/'>\L/1XESCEQ5N(#]V-J<SH&
M3$AYV[1, A%<"37TW7Q4&FBW*G,I"0/(@M3WCM) +A:HID134$>=]Z[=<-'K
M!(]-B5OTJ@5&$83O=[/XU.X,5J <5/1:H"N#LFBK%>6FT"&'(!OMR @^9P_2
MA&P2>FW)[?MNR@7>[LXFK,19B4^2^%F)[VXV0D[.^2Q!V=JT=$ /0>8(U*>^
MD-1QXPC?4>+:F=I3'\%7#RCZ$/:B!;B@E'%HJLYV!$I<JH]NL,GKD5/B+,3W
M7)SB5<Z*L!FJ;T,77(6 T@$IS*HDKY77@^E![6U2J%[&(GL2M1"$ZB*@1:JD
M@Y44]BW=FA"_W6G]DQ#B2%B:][>@"[HFJDE"=$F!D91]$*7]WZ# D:R,6C7Q
M[D+?T,-7U_@G.4@&46AA2A!VWW>3A?B^B8N%^#B(GX7XSIQG$<ZKSGU1IC[0
M4^DFK\F ["7@TJH<WT.%FKP13H!61C7ZM'V"=(W@A==21:*2OZPZ?#="/,Q#
M^/!P=EZ.G!!G';Y?'8Y)RR*L Z/[L[6@!/A0FE\)HBKC=8YJ,+X^A#[0COKX
M"94 36ZR/2:$$'QVUB@J<N]EQ6;A]Z'<]JS#52D*-^/KK&D_^D/2%DD%$!25
M-#D9-YS)*K371@6"I'6C'Q4LD L2^J#6]D6CRSKO^V[*1=A'5,4ZG'7XR(B?
M=?C.G&=,#J5-"63,C=9L)8@B2XBI"&%E%]F#A'AU!:UKSM,+W1UN4#V-%<"U
M#ZLF)1(YC$"':\>MFJ-1X9P-9Q7^[L27YF"2;-K;N"[>VGF 5 OGDTF&LO"4
M_"!_JKIN\\F#]RWZQU3[HSM=0/C2U)P-B7#OV7"WT+>[U^@D5+CPSD49 \20
M*F ,")%4 5_R9HYT]6$04ZG<[Z<TD&JA%H>U X,@#S*TX[4EH1SM^VZJ!;(*
M9Q7.Q,\J?(<)*>])E+[7MH^E.<],/2_>^1 Q>J_0YSK(AJ<0J5@%4>=VH*X%
M0G$.:C&RN&#21KGO7X4++DL9DQ#G=#@+\7<3J+X4RB@AVTVCN'+02XS!-8'N
MT=NJ_'!'-->4=G<\)I1-W@#!NUX!$0KZJHNL(>U;NKF%/<).3:%B(XQH083:
M>*'%17W^B08JJ% $KUNH-+B;R:'06D)";.)=VUX?;@FDEDVX*Y6"U/N^FVIA
M]E'MST*<A?C(B)^%^,Z<9S(NV$9>D&A3ZRT1FL=T$&J2-HJD2A@TUYBJK-]L
M@>Z=!'2EMTIY#;718 PA.)'5"(2X\3C7<A2[$!S:@N24."OQV^G4+$V Y3[U
M7,:>$+4%O*D!2G(Z"F^2-.%=]^.B-*5OB.URZ:4,KH]8,4V.5S0F51>]Q7UK
M-W^4TPM))^4*(J3:0BJ,IBGQ+ ((':40)$F[P;/5TB1WN^,.'+8?F(R'*'7I
M&PP7B]6;2&K?=U,M'"MQ5N),_*S$=YC&B%GJE*GQ6*^W5'V.H8@:B@U$E")5
M.]@/1& H3NB^8U@QS7EV)5Y3@1 :#Y*QUFH:@1+'7B'N68B/18AS2IR%^+M]
MXE@T186@5;6 I3@(66+S0P:-]C7Z,FA/*=GE5(ML;^JS4ZL+$)16(%UV&KUR
M<?_#"\/B(X[G8(5X"J2R,Q'"IDS<41/52<7VPY0FT 7&/+B;EK*6RI=M0?EF
M9E>TN?1ANLKF%ES9;/9]-_5"LQ!G(<[$ST)\=\Y3)MN<9!/B3O1F*2,JD!&^
M;Z[K1,VA-ZX/]_').FBJ4+7J?)@<>$,.7)840PX>Q2C&B*L/%VKR8N1T.*OP
M/:OP('WRO==;VA;/UR;>HFF>J 814XJ:9!QL_Q)2(4<V])%.ND]8#>!%$J!0
MZ^J*:/=T[^EP*1;V"&5XE@6C;7>RR>=V:U*O,ZI-4B,J)0PBH1KV_)/12=>^
MB47.?>ZX;X&8D:!E";EF*6J4^[Z=>F$^_%B593C+\-';CV7XZ&6X#B9IV?QF
M-3$ 9J_!9],\:$ED4\@BZ\%N/DK:(K3/(*-L@MTHU=QHE)!J5_"INB3T"&2X
M%'/#)>+C4>*<#V<E_FXI@\V],D5!];W<&U,&BE*"4&3[2/!HZJ"HV&I?J6QV
M/<C-^\A4@%S)X'7[@U-*9]R[=)/J*$>FV.)MLD&#\;8I<==$>$@B0!!&QDBN
MRN'(%$R;ROX*)OK8(>#!I]1'X1272K%DPMX?;^!"\;Z:K,29^5F)[\YYNN 3
M:M<?[/;'@Q0UA&(-D!=:Q]C$M1UP89'5-#XD$%BQISX2!$V;?>Z$<B9Y(\8P
M,D6R$!^3$.>4. OQ=^>F:J>-R0*\Z4_6;*(^AM!##3XK#$8YCP/GHZR6M8DV
MD;0#S.WM))MRT[YO=Z!C+G7_*7&UGVEW^RX1-U4[UXB@Q5>-2X3/38CGOF<J
M1D/6HE)FL$>S+$GGHD!+&]HQQH /[>XJXTN(WGLG]MZLB0O-,\19B#/SLQ#?
M(1>:G$3!T(<54N/"TIQG[B.GC-1&BH@D!B7B#HM-A@@<;>:.E\:DWBN(V0@G
ME4ZQC*%$7,W]1S9AX.7(&7$6XOL5XJ9$H4D&4 7[],+4]R$H",)4TII:/!\'
MTPNKB%:CMU"5B8#1:8B]<U-14MH*LB;L?=Z=U/O9$7W?&?&@4A M/")*350G
MWT?9-&I1*E#4P3B1!KV:MMUH[,]3;>AS<[+MPP]+;/<T9.-"K_K?^Q!QW,\,
M'!;B+,1'QOPLQ'?G/*UQ1C=*<Q5EX\+VPR?,4(W"4K/U>9@1;QI=V8T&3S7T
M++IM?M,H*%Y[H[UU)N41"'$]=X);-4<CQ#DCSD+\W10J>E_[X&G<5(H3BMZH
MU_> T<H[H13)02V#1I1:8&GB/53 (BUXGS6H2-)H'50P>Y]>*,U"'V&1>%5(
MS?GW2>#" 89&#E1" EM+<3IKAVX05_5A*IY\ &MD!C2->GRN'ISQP6;GT.+>
MM[<W"\F]FBS$F?E9B._0>>: THO>[=2[90A-?TX<00;I0E9)I"Z)WTE*)5&2
M#M3X,S<2#;(W3%F$_I@Q*U5=J&/855,J.Y<?V8J!%R3GQ%F*[U>*2S31)R<@
M9]''2"N"0#F"53I5(W0N=J#=FD:K,:<$*6V&Y-D^\2EX*)2<IUC)A+WOZ"/M
MPAYA<8I0MHA8*M0:3;N=6H/O PF%B\K$$I33 S8)0:=BD:"*#@'5IX^+O-F:
MPD3=<*'JWHM3S,)\>&<XEN(LQ4=O/Y;BHY?BAE*U(?5M&##V#3(D>*<5)%>U
MJT*;]OJ@LL\&X:4Q[3)M[GI<@;>;M%1VLMJ^4^<HI/A<(>?$1R/$.2?.0OQ=
MYR-<"KD42*1$4VZ4FB.)$;3T1+$I;C+#*G$9O1<A0LT]B>J<A>!*@*IK$W Z
M4$&Q;^4FP\(<87%*C+(%4"Z#1-DW:"JIUQH)J(CD3<"J[4"(6Z>LRZ* )=TK
MRY. X&N!=A>)@G5>T]Z[;^U^[B8+<1;B(V-^%N*[<YX^6E6J:"X3L3_K+4 8
M)&2C4T)OA#?#Y\-.U%@)H<9&B$C-ZY+.":+/5F3$;'HB:^]"W'VD4I,7(^?#
M68;O5X;[X$F8WFZ9@X(FTS*$F#,HY;,L,F,0[]%MP=9J)92^50S*:*&]68$5
M*2HKI*IJ[S)<B<5'NE,.5H:K8"+ZOC>/<8T5?-#08JD 'ATVD1VSZ@-MWKF=
M,C=701Y,S4VZ!R'ZAA8"J*) )1HZR.[[=MK]5/RS#&<9/C+F9QF^,^>)UN<@
M98":>ZV)2K7YP-"?$U;C3"K-2PZ<9TU*!A(5;(BI.=QDP!?O02892]\_+3HS
M AG.\PO'I<0Y(<Y*_!WO$[R4PDB"[%SS)#$[H$ 5HO*B^E!"\S #Z6:#B]6*
M7GJL :DF"%YXL"X6[W(P)/>OQ%7#TO$I\>;Z3<PB 0EL09*3'KRV!*5IZQBU
M%44/"HVL\.WFUQ:,M3\#IBP@]DV>C?3&BT1&R+COV^D6>A]U1JS$68F/C/E9
MB>_,>3;]77IM)9A$S7D:&\#'5, W0K1"HQ%^P(4D^N!"%Z'(GL8@(@BJI\8M
M1HM)>UOJ")2X=G.#'Z[MX_7(.7%6XOM5XC52"-94T$K9YGV" D+2;0T70\9E
MU&DP\4X',E:2[ _NFL\13<<':Q5H'YI7PN2MWWN-N-+[F;2Q9R7NO3"HH@*C
M9'_$01F"C@E,8Y,2DVB\,-BB*2J)4<8,PKL&@:JP*?'86$@G48H+DMS>YU&Z
MA>=)XJS$OX+Y8[N'9?7ZE85Y<3Y;GYTL\^P*)&.Q\"2T^E>:\VC4?$I5)%\E
M"-/K_)1M+)FL!A6TMEE4':H=\"FAI'88*-T'L)1>ZJFP<;!MU&J3C%1P!&K>
MS%%_>&,U7M*CD_NWDWC?I;H?F7S_?6O.>':2O\ 1_'3Q/);5[*QN5<)ZMFS.
MH*_,KNL?EE0V?]9R/E-"(8N(R8L(M5#=Y>2SBWA2#M;GW*&,^ *#3DM(?)U#
M^4#[K\S9UQ+!4.K=:*0@JA:K]2 ]&6V%%H/0+AN*)E<#PE$?[18KA+X%;W7&
M.*F<LL&]JRR^/WO^_.QT(R&V:N+GB_/U.9WV>W'S9_,HY];A7+A1C(XXQG6]
MS]0A:XG/UA+E7Q?+EW327I[UG!)K"M84T_<]K"G&I2ER4@ZM3F V3:9"6 BV
M>/"$,JD@LAIJ"B7)Y^@12G :4/D*$2V!S5)(X[2P=KAEPZT+"73S)G[F-HQB
M6X9C7,O7=43[G=JU_O7J7C0:ZPG_]N^\?+G;2_ROB_7YLK[Z?%9X<_J/G?$F
M5MK#Y7ZN\[CMBW_P'C4RGYT_*ZLR^[W_.'MQOKS)<YK;_L+]P>O9&S_4E=;[
MOMX7G/LNMK@LOI(*'HP*O0E)Y+Y+3@;37'?SQ$:)/&A<^IK0;^.F_T;KDEL0
M^**<KJE_B0>K%9W^5IZW;_BW5V_>\@N]ZB\]^)U6^3+7?,W!;X7LS>-%-T=C
MYCK<[K/<VT;5[)L&?'U_ E#2#JOLXVR2M7W;Z :JH$MOGXJB%EW)Q?<POA,-
M?Q&2$'U[ZMH$0JSM-Z]U1E-"D</VV_%!R<R]T0U.8=10^J[[4#4%**FH21BE
M ','0^W]=V0LI)R-354Y&NY:+GS.*IOFE8J0@,4J"(:PEQY0KM59*X;;#(P/
M2G+>?.@<;[DFX;:A].=^G9M'A+.W"QG6BS%]S=E;"K/9L_]I>7I!EP;M$K+I
MS+^T_\[2":W77;[_5N!2=/>OV".*OV[><'DM_V]3(O;'?=#?U9/R!^3EJFQN
M4/OPDXOGI]_EY?K%";VZW_\Z4/0+TZ1Y_[I7.;'VSTOA=?6]-P=".<W?O3A;
M+S>?O"HG[2N_+"T:^*,;J5_XZ\#@C\^4^E)]PJX?T89O@M<QW-8?8$P@4_XM
ME&W"DM?(>O8Z"7IIW>7IR?*T?;%S6IW?IXOSL^_>_D.[[]N7MT#<9$*I-N/?
MIY/?Z=7ZNWO?OH;L>R/.#K!K&'T':[<+J7W%&H-$Q6W?TR>/?WSTT_>/9D__
MUZ-?'_SRZ!]/'W__Y,.\^9)62VH+=]U<^ DD>K'^;)+<^96\.$EW%4#>:D[[
MMNWPT\]/'SV9/?VYW]+9]S__].3G'Q\_?/#TT</9#X]_>O#3]X\?_#A[\K2]
M\!^/?GKZ9/8__X=74GXW^^;[+6.4_.=]FG&?.8>W6')XV9]BE:W&NTZ\5]NY
MB$RNS\!,D2J@T ADO(&:C:K2IFC)_%.]3;Y?<,FOM>5EQNBJ*KDFF[13$'W?
M228;!R2;OA0UYRJ<PE0&.UBU4$92U!ZT\WW(GK*]/EF!CH;("A7->Z9UIF<E
M7YR4G^OUDJE?STY.?CA;=0GYM*>UGK:3_.VD_?W>K*R;XV@?<+ZZ*+LG])$E
M>QZ6<UJ>K'O.Y/S9-K7S;CJEB<L9K9MZ/CDY^WU]?\]9L3TNR*O$Z"8O^KYF
MAHU\>%O"]FOJ;X<F3)M1MV_9GDT*L1!_NGI_ZG74+];E_KJ\H!6=ERO;;'/+
MF^/NO>\9[\OE>AF7)\OS5_>O/N,##V\O3ZL6 M6?KLN/RVO>ZH]O/W;LG1YF
M%P[O]HQ\?7Q]?'U\?2/[HGQ]1WE];B'4+L_XB:HQ]]&BL??)L!M6DHVE8<5-
MMR3D_Q;:5)IM4L1?631Q&[=ABQ*AOZ1"XK;,OI^"LG9?^U___5X+8AGB.X3X
M_]D<U3NLFS'IMS*[ZH::O>@=J[-O^LW2W_UYC^@?_1W:9WTENQ=V+Q-P+Y?>
MY<JY;'S+-__&7H6]"GN50P3O;KW*@_._Q-6W?_W?='K1*S9NUN-Q%/>#G0D[
MD\F"=[?.Y&K8U&\K:B]E]B+L1=B+'"!X[\:+U+-5+4OV(^Q'V(\<)GCOQH^4
M/UXL5^Q%V(NP%SE(\-Z5%[D<;<=^A/T(^Y$#!.^=)%IO:YS.4=P1=B?L3B8+
MWCLN-GE5:+6>G9]MPYU7LTSG^ZRS&OWMV>E:^*H"QG%.T!W'O*JW0?&!1BX=
M4\8@%31:W31R5?!!&;!.&)U5+4&[P>22X'74L4+JXP$PF (^DP%92W+%"&]%
MN;X?0:]C_+GV6=ATFMYNY=KE_&\EY!NE\.[8HZ]:Y'<VCV_:A/9Y!MSA#D&[
M--\>+'50&W:]?9?N8 I*C%'%JAWH(/M&NM%#C-D#VJ2J#='Z--B^JSI=?<H6
M%-8"*$UH'DXK4"'ZG-'%(G<Y!>5*J#QXNVSM/9NX_'.Y/D,EW=__]LL__XBK
MD^75M)1U@TG[<N+ZW!3UJ=W %GH4P_IXI4_.5DPJ1PJU(R45+0-EYRU((?LL
M@_9;,%:"4S&0T,[(.MA0=S*D\NF=P;Z&77"A-+/+ 2QY9I>)F6^Z4#M2=L%
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MI  [_AS1G>=L:BJA.$/@C!* Y FB- 5"H92-JRFFL973WMINJLH8?JYQ9"Z
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MNH>-,FV8HY=,GTR?3)_'!V6FS\-_BBG(.^<;$RF9!:!2!-$9"SE8HV5QR=*
MO920U9K0V"M1;L=0!(JV0.-!HZ@Z#/V8\9?B>.GG:#73VQ'YA.,C,2XB'X-(
M8)M^IDT/:(/(?0<?.^KV^WG5+I56K_X25]]>WLSK/[<!*;<#LE.?I@-BIWX(
M-N5%SP =-4#9IKSH.0=Y\/D&SD%^.@=IC1$RA@BIN@@8K ,BU."K5P9+K<H.
M<Y#2B4JJ'2.$!G35@X^U_>:USFA**-*//P<IS=P;/4<3. EY1$[A^)*0#-A)
M Y99[-,LEJ)KB[ID<$7T!O60(*A&:EH)'1J=F:+P71;#X"5%[4$[+P"ULD 8
M%.AHB*Q0T=@RA7Y /?="S0TJIK$C\@I,8PS820%V_#3&]93_="KI9(4'%%(!
MDD,@FQ48$8VP41EIRAAX=!?]@%KCO 6VS*)<<,G\>GQ09GYE?MU]/V#0J=1$
MH+)L<6K" B2- "&2EQZC5,--R_?!K[OH!T3CYB%XYE?F5^;7XX,R\ROSZ^[C
M5ZNE\-&!$K%Q95(&8H@50K11BZ!JKO56^/7N^P'E'(6?(W++!!,H$^@10ID)
M]/"?8PI":XNQ(+.4O3==0T2R4&403J'6.0SFL65#T>1J0#CR?>O'1G<U!:C.
M&">54S:X"53CN#D:PP/9CLPI'!^+<2'Y&%0"V_0S;7J]);#]3O&D_'6XS6)>
MOMPM7__7Q?I\65]]_J5O3Z^N@MH/G/$F5MK#Y7ZN)'GS96[GXOL>@[-5:2=9
MMQ=F'X_]/WG>N]A"VY> .;?H7V0$]+5"]"I#*%AC$![-S>;:]NU1M\+GYWK5
MDKD-_G\X6SVB].S!9F70Z</RXFR]/+_Z\Q?*I,T6JDTJ]5;:9OE[?SU_MBKE
M@P)I#%"9G5V:8[:]O%E3B;/S9V56+C,ALQ?-,&7V.[4_G:S/^DWH/KBT=YU=
MPUB[DH:ZRS?3YM_EC_2LZ]/9BL[;Y_WK@D[Z,?W#TTFS\NEOLW2Q6O6C^YZS
ME_](KRY/L>[P.*O-0&5UTM_\HG<QK_M'_./)+)^=G-!J/9\U4Z5GFZ\W?IBG
M%B^T0,&",28 JA# RQ8X!%^C4]6@%O:F,/_^THK?OS;BK\W\OY35PXW%WD+T
MBXL.\76CTW:PN(YL]2GYOU!FW+A^#VQD!\[6#(NW^+-=1S]R>7I!EQ?2";*Q
MZ%\V1/F^#9U]5MD*"N#\)O(S+8H3WH$314A=:FZAW&UD+A\NUWVQM!OU<[T>
M^_U:3MIM;>'@^GP]"/W63]M)_W9REO[[WJRTV_NB?>#YZN*R%*A=9LD/SC_W
M*OXI/R^V_R1Y[XX_WY\AOT4TR;"8/?K7Q?+\57/QY^<GS?MMW"7$;O5FU3<W
MY@LEA]V;T6[;1D^;7__[ZNSBQ>Q9<\;+3;)]:Z79V38+T5Q/BRLW!*"$]+,?
MS]KR?%I6SV>/3[L<7[XLLU].VI5\\S__AU=*?/?CT\>_;'Z5W_UYOCWFI[-3
M>/3\Q<G9JU+>^H"7[_N M]_]UJ=UGEN>MO6]S)V8KG_1S2KI3JW1RUF[L=UW
MT,G)K%Q^TKK3TOG5Y;:/6L]^+^WO[;^/_N/Q%9%^TZW5W[EEJ%5Y3LM&:&\R
M,9TF'Y94NBR9:=DO4.&?%S?EL7L?VH'>&$NV@LS" &:%$)/)X),V-=@LBKD5
MA_75J:K-C_\L#=.GO_W:U_-Z),#^QVO4=@3-9P-0S:\#Z35V-@A;IV>EGY=>
MTO*D!V/SS0==+8CS5R]Z,'OR:O:R7?B,ZOGF3$TT;B11ES?+\V>7>BR5+3J[
M)CI[_N9#?NM-"EL]EIHRZRA[O@'5!J?_75[-VO72UOBS%^WEL]/3<K*8]07[
M<FOO_O+R+'?.[R=;O_GPS6U;S^KJ[/F.@"ECDMDA@HC8@!E2!JK%0%8&E;$8
M&PD-@*F0C'4M2JBI-&!*!)(I04ZY9D2T&6]O@\/KP-P^-Y1#U9\O5L_;5WPV
M$LSJUS3T;N@_(HG6 +L;2%% JTO.4)(-W==)H% *9!&K*#YGLH.R+=T$CZO2
M@0SM0"1K@)QIX&H 5([0D$W'#:E)8&ICL?5B"E_U^I?Y &=7K95#!;7/C<0L
M!'C?2!B%-]&$; D'\>)7<79CJ7QQTD*,]R/Z>H7$@Q;KO6Q"^&EGL\^-,S[G
M0C9QQAANS--K!'VQOMC0\PF]:*2XY><NZS8)B]I"R;/?.WUN"/I*$IP4>GGU
MXD8A?@J-/51H^N&K_=_UV/4+D/.Y@=U=)X%O[TX.DL!7B?%-7OSJ^UQ>07^\
M=)\NSL^NGG_U;]A/T:ZIOQU.Z%53[]NW;,\FA5B(/UV]/_7,0H/)_75Y03WG
M=66;[2.(S7%OYNM=&]?W<KE>QN5)6U3WKS[CN_</XMN>5NF%0]//^T<W6?^.
ME]?<;L,?W]W[]B/'RCL]S"Q0W>T9^?KX^OCZ^/I&]D7Y^H[T^KS?Y1F_:@#P
MMH;G_8+ZAE.!#Z Z8[=EA+.OK(4Y ,/>8:F6%!^KU;K#XMBKDK4=VOK-#;T[
M%/<'%;L&\H2-O\^BN=T7>;(S.38\[]R9:'8F[$S8F1P%GG?N3!0[D_TX$PY&
M.1B=BF''TC<TED;-":-X6]<_.ZN;/98VK0_?R*]M_SZ*^\&2\@!,S/[ECOS+
M_]D<5?+6O32#TF]E\_O5K)#-/S:-+^QTV.D<M(F_RND\7^9\4@XLDMJMSWGP
MVV^K\EMOFWM\>KY:GJZ7:?:?=')Q2Q[F(.\(.YAC=3"'29BWVH_*0=+XL,[N
MA-W)1-T)QT0360#L8\;I8PY2@=^JB^$0B$,@]B?'S8\< ATXUMF=L#N9J#OA
M$&@B"X!]S#A]S$$J< Z!#CD$NJ,*Q_==Y)V4YHV8DZ=4X<@^G@W'*&-C\9(<
M(27\&^./%RLO5EZLHS(C+]91&>M %RNCC(TU56,=Z)*\U80ATR6O35Z;K&W'
M949>K*,RUH$N5D89&VNJQCK0)<G:=IQP8V/QVF1M.W[\?56Y2:I5U'07 [7:
M7T9R:]ZW,_QN 7ZY&<X!POQ]MCP,+WLDQ9ALOE&:CU<MPXY7[=3,QZN68<>K
M=FKFXU7+L.-5.S7S\:IEV/&JG9KY>-4R['C53LU\O&H9=KQJIV8^7K4,.UZU
M4S,?KUJ&':_:L=3'7(UCN5DIS'NOZR#K8SZO'.;B?'U.I_VZ9G0^.W]69K&T
M;]./G)W5S0NO"JV^<B%\CK79*7^F 4_/)FF^/5CJEJ#VN8Y8BEUZXK?OTJVN
M_K\L_^AO^&%%J5?%S9;YW^_]\$\=;)(B)Y ^$6!T!#$% \&0C+[D&+6Y-]M\
MRA_GOY;Z[_>^_V>,%6VL!LB[ BA]!D^I0LXQ.%<J55GOS4[I>;N@BS7\1O3B
M_I-GM"I_HW7)WY\]?U%.U]2_Q(/5BDY_*\_;-_S;JS=O^85>]9<>_$ZK?%G#
M=\UW;4?$WIM=G"ZWW^@?_USW0]?W9KFDY7,Z6?_[O<<__7!O5L]6S^G\W^\M
M_SB_?WKQ'/+9.5R^Y=Y?S5QYG*.W?_GV;<O\E9?O])8O,\7$S#==J!TI4]BJ
ME:K&@LY: PJ+$+-$P!"*M]4%DF5D3'$U_?=R\._5S-]?^KC?M_CC'^W7DI^<
MTWE9_UP?/"_M'?3P[.2$5NO-R5K\W/#2OJ6X3C+J$Q0C<>$%T\L!K'FFEXF9
M;[I0&T5&Z%;Y!!B&TX,A>[R)F6^Z4#M206T*5562!],T,: -"9J$CE"*STD5
M'4F*=P5U$-J@C 9BBOT8:8%4,I"MH-I4=6XOCS_UHN?>N+FTBK7Q 2Q?9HJ)
MF6^Z4#M2IHA!.]L( ;2O$; 6!U0E@??2...J$@)'QA1[3[V8A>34RR&L>::7
MB9EONE#CU O#< 0P9(\W,?--%VI'*JBQ1"UC44!)"4 M"G@;:_MG*B94H:.W
M[PIJHYV3661P*7G :"U$XQ+X*KW#0,;K,/[4BYI;CW.E-6OC UB^S!03,]]T
MH7:D3"%1)PHZ@RBE #JL$+-P@,J7ZH2/(8Z-*?:=>G$+S8G]0UCRS"X3,]]T
MH<:9%X;A[4Y6OEGGV.8*EZ>Y?<W[OIUGEYUDE];MEMR<Z_JY+^_+M/K,_MY$
M2Q,6LWRQ:N_EMC(FMK%XE/$2VZ&%3<EED;(&*DB -4H(Z#P$E415)>CD\[MA
M4R9!V02$1$4#9M4BIE ]D/36IF"H?>1MATT;5[5^?/I+BWW.\M]79^OUC5-L
M<JZLFQN)' 0=P )FKIB8^:8+M2/E"N^R*R$6"*%SA9 5R(0"-LM<I5?)QD$=
M[$ZX8OU%9+'O-)OT"V&88@Y@W3/%3,Q\TX4:Y]D8AB. (7N\B9EONE [4E$M
MM"XV50."! +JXB&ZF"!78[75*2@3!RT#UE5T2@)AE8!&:/ >'<B*(D1+6@0U
MA02,FAOKY@'Y*?0A+&#FBHF9;[I0.U*NR-8Z(PJ!HSZE1^@"(48-,13*(46K
ML-X)5TPL 8,--4PQ![#NF6(F9K[I0HT3, S#$<"0/=[$S#==J!VIJ$Y(B7Q%
MD+$/5J8DP6>3P"4R5F2=JAD\U2QHL_=1@A'.MF-$D]?55Q!.9)3:42V32,#(
M>4 QU\ZQ.CZ !<Q<,3'S31=J1\H5$6M..FF(W@3 [!$H*@])!U4C*1%<N!.N
MF%8"1JF%YAD_A[#NF6(F9K[I0HT3, S#,>U1QIUF-X#^C_2B"979V:H+A5J6
MW'7&)#<^[S)>DMMM'/6Y2_WUC?Q\@W]S9>N]QFW6DS44-&B4IC\$KQ P!;#:
M"5-:V";D8#C(/KK<?M@ZQXM5>1V[W;S(RN)<&-X\[4-P_WQL_7D\?H,I:F+F
M8XJ:6*JO6I0I>0%6U.;^R2$$8RHT(HG:ZX#"T2B:W=[#&?O.]\FP\%S3>PB+
MGWEF8N:;+M0XW\<P' $,V>--S'S3A=HXE/7!)W]R2M8E64%'8[LJ-Q %"B"E
M(NF2O-8#);^/#KM=)'^\D_/V75F+<_*'*8HI:J(4=>>4H6-)M0@!P631W+_&
MQA:V0*S2QZK0>#FH\]I+H]T8DS]^8;C8ZQ 6/_/,Q,PW7:AQ\H=A. (8LL>;
MF/FF"[5Q*.N#3_Z@UD*0,Q"EZCLR5P.^:@7.AQ"L2#7:,H;NOETD?YP(<Z-Y
M\@4G?YBBF**F2E%W3AF-* P&Z2%XVRE#!_ A"? YZD#%%5/NAC(FF/Q18:%X
MUO4A+'[FF8F9;[I0X^0/PY#WE#N03K\KR<']?0= ;;&MF[)Z_<K"O#B?K<].
MEGEVA9:1&'@2Y/>5UAQ'&';PF4*E7 ZVQ6S:QP28@X00A(!J1:A:.1V'<\"^
MJN'C_"S]]^/U^J+DAQL/N8W<-D'7>O/'R_#NM2>]<2(0;9BC'T4B<#(>95JI
MPH^8=3O]0.BQ&):YD+EPXEQXY]Q$5F94I "=%H"E_1:C">"552455ZR^FUU:
M/Y62O.*LT20D[<*,(A_)WH/ICNF. ;L;NN/,*$-Y!%!FW\N G11@QQ]J''S:
MS2H;G'(*K"X$V"(:"*980-M^K4D%TNY66FWN/NW6KFPLS9>3\2B<=F,NG"9R
MF0L/+NT6L]&NU #5%=D9R4%,7D&5NDI!)KB21M$&.KJTFUQXYKUC\AY,=PS8
M20&6TVX,Y0.!,OM>!NRD #O^4./@TV[*)M2J:"@Z&D!I E"O>\O.FJJREXX&
M:;>O:G*Z^[2;<?,@1[&CY60<"F?=F JGB5RFPL/+NDEE,)C8/#H*0$0#D5*
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M]OW;/E+P9IMDW&))QWI*<Q>K?;\A7K0#09=-;JPU[B[ R<NRR(PO9;PG@]O
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MMJ.]/?&)\V^C=A9C'?A,^//6@,P23;N$3F_*%M=PN0RGM>Y79_SG5)I7C^-
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MRZ9+W8854E1VE:&A'XZ6T:'QAR/C-RV%-AY.[8'Q#TM"UY+X$H7;3<PL!N"
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M!MEY(8161-Y<.Z3'?-(?<+0F=TFN#-""$+$[,CD7891=)U7RBZUF&]9G)5I
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MQ(#!5\41- H#\I&=^7$7"VUG,J/ P9./\^@A?,T+<74EIXRP7ALVUKZ^+4@
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MOK3O\(;;366FEU/0'N)H R8#&/?2&[5;74N);:X=GU1>_!J%;C508Z?JTS/
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MCD=YA'#>3HN\(8LF2C-,9H_\4DZ/;5@FJX""&%(GN4&9PV[?W<BH(DF6/%6
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M@;?T%I!/A^&<@N4@]+V%-QQ%2EP@<W*!I.V@M"$D6K*&*V68\8*,(6_06!D
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M.205$ L@./'^^YFN"U+H= ^ZGI?ERT;?N-AN.F\V"Q<KRYK\#E1!WW[@R+*
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M=9E,;&C+=8U%>,G&H94EY=!"YS("RI/Q,*()#6S!C)I]G+[F5V0D!Y@52,0
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M4OS1#SAM'#UC\TX&=W7Y@IEY9YC'GY(OV+67+]@ 6WX)1R69GL<TT#%D&IE
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M9AZJLVWR'$:@NWD,7!PIJB'J\IR)T+\#G=D@GZ8L5@&B!(T[,,D)]LG.X?[
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MCDTV>=S[E)!7-I6!_U\3NE4+6).!*;DJ+.)<2;@&KUZ@"&'8GYTU'*U0060
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MBNX6 ],T-L<$58UYK4"'*'1Q 1U)7S(I^SHV>)4LP"3Y"F0#NWIB0$T7+ #
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M"E"9XOP&_R@R1RHAU>UK!:!*8ZO*M*#5T0H0P2V)\<8@DJTW'(&4BW3MO:P
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M@S]D7P+?O0DB1^+1SC6PCDA!\65]+_9J:WL.6C-K*K$OW:.OY(ND_I5&1RM
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M;EWX;N(_+_&/OMASNJV/%8!QL4RB',G%0P+4)TF(&X-8 ]%Y&"O YQ2'=)O
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M8?=3J_Y#TMJ*7:>Y*8C3['D0$&=3_B>%UE"OIQ5 =LGJ^_R"B:I82]IQ$"M
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M0J-H:AR,.IWG\EC@GX!PH*1(%PP>S<TD/ .&L>*(%W$()7NCS@HA;6X%.,U
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M_'AWZ]5)2.6C<6/E)S]45#;F/UIQE+E4@G+VJ-'(BJ77[$B5*-K.5BA%;RN
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M=87H,I0M-+1@":_AJ.IQCUQ3*W:S65<0O[;JW&72]E8 I*N6'J+2MN4 RK,
MPTN=/$>8!??C0STO0+\1["LDPQ6">?%CFISI.MSBW[R;P*F\*GWZV[++!>T
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M?&O@3DO<CEQ2&!XS-,[4QJ]6,YZC*,;2L(WIM#<.T.<]_COFT'1\455MK;@
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M@R?H:M(Y!L[=0QR]^O@471P^8_:!VX%S+'^]TB('ZEWL,9 QH&D^)H4[$-?
MO(<;1QGT??::76P[8K?A*TK&.&*J@49-J/J(/+0C3])Z\XSBW17:0RKY^B%2
M-C5WG++]/B"'PPGRPW$;;J)X1UF%EI.EV=M\0E.4@ A/RC/*R'&]H1T>4:!
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MCIMISEY%]I4?(Q=+HL1!('4V&V+!Y9[8XK?;D*&KZ/*(=EG(G)./4JU]&>W
M0$:6]X@",,<04%O4VZW=S*G^G,"),6'XU=DBV-'U9N.[^#KS*Y:I_G2ZCEO@
M*G)])WA"F'_%MTSFO2AJ90R_#WAZM-L'$<E/R>RJR0/"E,)3^_;I]#2G6 W(
MN,A[>L'$^,))X$"7VZZ&3+/SJ$?GG 4C(IX$"0Z/N)T=KYHN\:G(+%KW>Q%B
M<Q?T2:G-(@2:/@=-B] M@OGL@SU=>CH%KVF1 -CWJDJH^R19B>WES*D3$G&Q
M0?3 0++A@C$7?CY*+IR#!#]I['*T\> MG4;E-BZ<\/?;$%,FE*0T);G /T31
M<%S6QW5C1+,PL,=,;)D4MS,;YG./#_J>W&<0XF'O5+LK:&T'/=,[L#DUDYV>
M17!IW5 E.=N+X-+T,=5ZI2;AR^Q]*,$!%7.F.:_EN^!=[P<9\%_%<PD\2):R
M]#7XI>0['>6K>>W$(=[S HB6]U+:_+C#V.99ZJ_(W[[@XW2.F6LL>>>I!P@B
MDW66)JD3@F:4G#X)*-W&L W4_#[55]L-6.DHQL"M7PO5#HK;6K-TAES-Q>>M
M[7C\VHA9>^#!J3L]=,%01W*U"/9J!/S):> B%&%=,"@AJXNHXC4$3P4-GZ\"
MU_&P\-R5>X@P]YWZ3A <2#/_%94"([7K(X_8_9W )670@.UG(S:X_S?&?UYK
M(]XY3[UKO+#6 $"5M&.<L8^/D(R$T_ET4E:0G8<8="?IX2%P2*G3ZW]E/HG(
M+XF.M,E1*@VDT+00D?9^YEPR9$O[&,OU"BV=S)%&UZ5E.R&_)CY+KL^<J_8!
MT8M"&H0=.,']07Z7@B&CCF,-;]]NXT>]ZUY#%SLHO?:UK)CH6P[^(NP+O3 W
MWBU;2!*E<<\GN:H+LU'(,7@RV>-/D+?@J8-D]94F1WQ;JZ N3 Z #'E?_2#@
MS(4O4%3D-KQTXOB ):5_.$&&:"H]:'B4%S1?/#X2MWB5X1;RB],HPA(5+9>U
MVQCF\J^R9;9 87Z!-U&,_&UX24(XW0.I8$/551\=/U181CL,8!S(%A!^^V )
MX>QU02K)Z@J IR"@>^)]^Y0Z<6H3<S@:UG3NPB)L5:-A%-^L21AM>A*OPZ:0
M8L5SSERIJI@KW_8&3H_Q,;_Q0S]%=_XK:IR1B\,GYY]1?!DX2:*HP-YE!&-/
MB&*1Y1*A8HHP7UC?42Q(4Z=8LEYVNM8!1O5*OO-=\%>$(-)HDW[%) Y+^=)*
MXZK6-AZUNY:T:5I=;01,I2-O[6:<KUR (*/8!$Z+R6LKN^^F;" ;@9:K^5LZ
MV<'9]7BU>;ZN\VMXJMFD^K^7FNAL[L:IH[(GIY6';B@9@$68HKKP#YJG<$F6
MO,%";Q=:<.J7>3*Z>'?ZF=$FO,]2EFTA=N0)4+I$8W*+?@MB!UV\\S=9FA'7
MON*@L:C"4U-X20&EJF2P@=Z 7V3FN@B!^_ -1J43_!=RXK8P\ZEGM5'&$H!T
MC[?_^2L*7M&G*$Q?>J@,= 8]$F3 #CY_C4;!03[6,8&.9Y:I'_N.=D3@WT19
M7:4Y<+!C AZW'0]X&.Q(@#_?8(%I5 Q41[2>/QOSC=7EEG7>H47(QM;O2_$D
M+L(^?QS;09_I182F'L6&4,9A$2&PQ[$?Y"6?+]#V;3^TV:M1:[K:[WXLU.><
M3F# @LSUM[N]X\?@:]]T,RO2S;>XQ78;PPX",]AXTQ%Q"XM/N'02*!D.?T P
MQZN#!^(UON+O1TDLQ*"T)>17=S)&#MBZKF@-"D@$*=.<BEH:6_;GIX_1*XI#
M$@E?)!,X3RO!,!) ]/J:WI'Z2=$"3:^O'019[QKQ%%AX5A>A7>F.*\T+L@AE
M2.^3UG8'EVC4K9MRN1^/\C7GUJ^3S[O6<E0/]8<8[1U2S2"ATUP*BT@KFQI[
MMLB5P!(AJ5%5)I$6@Z#9R6PJ<-4>*!J:# 6/$C\_$*TUR*7-ISW3TG6UM;;A
M,+0B5=S6CF=00>ER%UDY!5H$F]6"(5U2MPBF2A-7(DHZ']MD/W[D1'L19I@^
M-$F I-.VC72_:@(4C6NI. HAY73L$S2;^!->'X*+< >3P/F3ATZK>IBS/8@7
MI0R,5O<9E5?ECHXH@%G8Q :N=$:Y=?"R\SKCH,=#KRB(2-HG9F,51F-WZ3G5
M<;B31%=+FTTK0^E(3I:\71J4JV)D4U.(4PV*4E$?#?0L(_Q3@U=LXO#4D:+U
MI%8KSFL0X).6]MMHNU3P6!9>&D1(CK=9XBRMD"Z>8\=#I<J'LX/4OAREF,$!
MUL)3BEJ:3$D.M0&2<E'W*%7K[95=[*#LBLVH98I6 +\P+Z3Z]3P=#<"Q7LT@
MB+XZ>#-OHO@JRKZDFRQHGEC9)=7K?%S751,A2[RXF"4E_,6#<Q ]KO7/1WF/
M\\5# G_7C3,G:+O/JA[&GURV.+(_>B^NJ,>HVI*GR/6=@/D\'?)#\^Q\0_G<
M<K<*_;XF,1]G^,+[SA<_H$Y=;)G<3_(]T.AK&K2+*,1DKL7Q0MS6V-+;CY>J
MI2W7.#\-S7/2Z6ZW#V/'DZU!BT6<MI#FG;1FH"/".E+A1;A+=#]K.E1^$:&S
M_5!7?T46X4[1$56JZWC:+A7#2+_&.[DPKPNA@&:-]D4H)PB7++/[*QK;YDTQ
MLU.(/F[O%$;TE@ZF19)3E+9.1!-ACT_1\?G&S&Q<;*>XB_=UT">>_:6%-QDU
M:C^/IWK WORRWKQL+"/X.C1O.1XF=\A)+!*=AJ?60=$6H^#%=S&,:>Q_R5K9
M,V47<R5]A*MB%0&5W)E.3V-@W:$D0?347:'$C7URFU0%O%0]+-L=A2RLZ&#9
M7LCD9MU>HTKV]QD<U_5FO<>$+?7#+9E7(-%+&AK$+:&K:@FWULBRTXPI($KP
M2]*#V-2ZCALG4=GA>_3U&<6["[3UPQ#_^$ *<8KB)G2Z37)VGUZB.(79Z'8K
M#F^]Y23+:5W%P,E'(DO5_0*DK#>74:B^3JT=[>#O=9B42O5:'5[@I-G[#NQ#
M.^).6Z>CSZ*T8VHI K<F)Y2+CS*N9"%74,39\&=)>4E/_2B-0]OKO-<BG%8Z
M$O?62WOJ]=@Z4BT]QGG!)ZV5WC<X^44X1/5$5@U'I^T)U0%'7<2<^9RC+%)&
M/V6[G1,?\'7+]ON 6$"<X,()((SEZ06AE--1/R)2._(YJN+Q*%771Z4RJN+[
MT=^^I.O-YX0F*)>L7=W'$E!R$_:A)1.CNI-MP+1G$FSM9PNA;9,^6D[FFXRF
M=>@7P@;V1),@X=D,/*"-;_2O""X8\IQ7/- 6/2*0<WEVYCST:FU@+'!O?L0O
M]TT45U%\G&&61_QTYYMS+MO ]UHOAL8P=@+,GT8L [NZ3Z3&,,=)Y'0.Q-LC
MVO-@S?>LVOA87$:[?11"AJ/UYAFB2ZH(O(R2](W\STL- >=:](XT-+;HJN9-
ML6A!0[,^((JU*I=X! 2/@O;V%DA/Z)L05;\'"RMAP[]__A\(/WN?G)051ZJ;
MC]\D'T/*,9\$)9/$BU=96]G-3D-8Y4)5*"^XE3:KQTOVK^=PUB.@*-,^".Y\
ME., EY9!'PXP&><H0*:%Q@=#3(8Y#H!)T>CA ,,PU@-<*Y4]".KJ6-:#/A!:
M2P'\''I,=X*\ZV\N;GJ^@W_U@58ZEF5,R*&;7>YH>/]N+-<B9,D^7&B;XX@>
M<_>&WA'16[".BY#R9\4JY5 7X5PW)UXI&[P(?[Q9T4K8SD7D,9L+K366?I+L
M9DO%;8'.GT^[(.:4Z)1+* RWOXR"V[]1W(9H"TZNIX1=J1#$\/?7A1C(<U=O
M#H-E&GK!QZ.T$>1P_.JG+Y=9DD:[,E/4H47?KM?7F#"O7)[:@UBKJ\'D<*\H
MS- -OO6BA;86!='K;>>^M3I+Z_:V$[P^0)T0*+_].&Y>!>5D+$8?\P@O3KA%
MM[M]\]+T'&0^(/+L4**D$9H=YULL(SV?PZ^8(1,E NG2^X1._2^6<(Z=F &>
M9=1[:J=0<;ZB^$MDE[#8\7G6QN/"5/'3'$9!=,BHRF$+S^,TB)S37^SDD(?Y
MG$ETO7N2*. I=>+TJ)'8EW=;A*)W?&QR3.0BU+GC8[#.V8ZJQK57U3@1=?QE
M9%UMA3I>ATT4VJIO/)W<OTO66;'5/R(WVH;^'Z@N^?8<Q X2,)6T(T#:P@KA
MTDSSI#"7-71 J//A%BHKFM1H8JX\)QY[O3F/8^ ;P1RF2 PM;FNRLN@E/M=^
M>NG$\0&?@Z].[-T[.Z1,H=[6:]R*NSLG"-;Q)SQ?MGN":WL=XBN&[VN"$F&R
M8MU>YNH^E=L/E43N\2TL?WG&?TLP"0/F69F+N>LH(RME [R<**;OPC9&9%8@
MNW_'$T<OTHW1[#CJ8CE2<:<H$R9L9NR07&\V"._?:TFT(;0<'J_0Q<\9Q5]Z
M@_ #Y@10/"3#:SA4&DL.SA@C&Z[(A9=1OFHMG)ZJAUV$5_5N2-N/>E,4E67P
MW"!1D$5(;W>W_N9X:ZJO+4X&*YUS@4*T\:5F8'4G8\!<,>:49^Y"KS@PLA/5
MVLTX0'@M[740)8WM%-MFM<4++_CG/9:UPI3Y;6&DP9POT?_?WI<VMZXCA_Z5
MU'R_F269S%(OKTJ6[1/G^5B.[7.G)E]NT20D<0Y%:D#*Q[J__@%<)"Y8*8)H
M4*Q*YAZ+ -G=:#1Z1Q2$\8:QGX7#!P7L*S%J".8QJE+*R'F$R!G%BNGRQQH%
M24HMR01@AXVHR$HTP_[-7SSKL''[--LHFWH_<D6#KO) *QE75Q$;[FF3G5WY
M:O;05=!2Z!!I7"VJ2_2I;E^9E5HGVB"&X57PH8*M6.W?[I$R5593MD ;IZGL
M6)DJM935#3XUIWXOA:;*H>EBF'2YK8[8E_DLKHE0S%M^V80TD5(&8??IL([<
M0S3IXNL^I&K[GB9=1JTEAI0R.*>9+J=")[F3;=+Y<*HD$KC[C-0KNTX?#A,-
MFLSF%)&4?)M75EY<HUF]K+C6A?ND-CJ9\2=6@>G)%,8'LCW*<O,DEG4JO>"%
MMF.7-?\.(LK<(_E6I!G)5'N%]3#@<,M]R1L'C2S5M,P2A!4.-V%<"-<XH)F*
M./4BLF,1V;W8P\?;<$WF4,' 2EVY\(57GLW!SG#*RT#2A_@NS<)=[F$M+Y][
MIF<);5>3EAOI3'56PE.O]YABMS+YE;+%:OTMQJ=<6&KP)"G[JGB]^;8E(XBL
M#MDZW")<I^2+[CHHS+>_J9460(/R-LI1+E8Y&#X\Q;/[*F(T YSRE<UTZ:EZ
M%?16C(D-P?]70<]A!,0%"L>D_?YFI82*,G05Y-44"A>MQE40U(C:( O]3;MM
M@AD1H**'3SHXUE,$ .!%N"[79B[6:GT:5'BJ"^^TDQY8&/Z:@="@^[LJ,FZ+
MCANT3AJK>_=)8";,3<P)?,RC$;3O#PV&)A$!;?- \V81]_(_DU^T;^@W&9XC
M&_H5JPW[#6BDRA$@QFAYMNO1H#T9&G)E1YW&"E0&=Q;28T '6^G;H*%?V',/
M<4W;6!"%(DM_]J)#<;1'4?+#(P>/'B5T7@R-*"=3MB;H]+!GOL%,N7#SPT7>
M]6J]HEXDY*4LV+6GVU^?"3AI>^FNAD[_JW!Z]346AM$3!O4@P.V$-0R1.QK&
M;,TJTTZNP R:%CIU5M12B 9-))TZ9=E:U:")ILZ34%^SNY*.BP-[_DS<A?,V
M10?@<[XR6T2^Y46S-W#NM*3LLH(O),#6*/.:J;LC2PBUXL##P;?O;+J])2?B
M5RKK+%MFV0++':X"O)IOO,^;0*/=TVL^R*M!$^9R?_K07P%-+@U/>^_7#>IV
M5X&"8:DQ//!]WP1L/5F>::T59+Y@UB=G>UZ7M#PG\K23^ P04MFC/(Q[_JJ8
MM(][>7;<:Y-9Z&N>W?4G7W-O=69VVZNS)EM%,NBX=\T3W1&&3CJ#.E@\(;)K
MNG)=L?Y;^376:]]/D-+J%"^BB>E%5OHJ?L,>;07RBOP#5FR0K?XJ^VE);KO]
M.D2G\)6_E7&S9;*C_ZV*$\LP6OJZ)9+SQDM14!^P3+B9Q48^!8=P2V\?4I%+
M6+7>X469V[GSX:#X!1/@5/$I!L,!7MGY!MJAQCH9- X1("I5WV.2TP!/X^29
MLQX5*"E=C:N@HA$F'>1XO0JGEA'R\P_IJ\@V-4+34BLPTG@4:FWOH 2\XJQ2
M(_3,52(CS4M=]ZG,F7P&^["UJ;WP_</N4'1&J6KT3YU2E@FFC7TRQ ]Z#_-.
M>RA2[7L8Q&IO@B&V-+SK W#%56C;IDA:Y\+Q]&:X9\+7Y*.XQJ@1?^R>N//I
M ,C) \)WQ3P16(S3!*&*=I>!,-9AT.,EUM9&'5;AO87:KYDF,_[R;VX=/WUL
MN$'/[3TBKPI>,P]GCI[>?23&53B\-%E07Q!=A8MK^(U,9)01YU:QE>_BKD,&
MA/:8.Z#I-1YDA>_^>2 HGY7(_%FZ.F0IK?$)XXV3VF(-GRSQO]\<EY&7-J_L
M:IUHHAG6#NB\.S-5Z7-@2M#J]R.VD>".M]<0O09)\S*^=A/T[L!!U=G%CFQ*
MWR.FT3Y)0W+*'@M6;]ZE6U-=)1,L,@6A4&/W/B69S!B23 +!'H_M.W8$''(>
M:P_T9+=+XAP:>K+P!$MG& 2 .U)>#GQWBKT=H B]$L@6%!F%TZFNR A.@:E>
M>2L_/2J;0R;6K\+#JG8D-'A*Q(+7Q%6=0Z=YT61;Q(_9#\ ="<4AZ-1OG>[#
M1XRSZRI<(,JTXA-HVMX-J:W'VW#5N5A1Z5_-RFWW/!CNIT9,R^0["T.R,BN<
M,WZ0GZ_/".>K)[=&N#.A;&9=A4R)*N,ILT!W^2((P@+-AWB=X%W^83>W]$0\
ME(?W- Q":G9Y)]!$'DKN>'LHG %Y\G;DGV_8BU.R32EKB3R6"A,']6"^H$V8
MTA[/P6V(\YI=LLW)^<;U8$HF#$OQ%&<U:I._SI0F?Q#Y=J#]J8GH)+*04(O!
M(]QAHP+Z@O8'[&^]%"TV&!4:60LH)E?HS;4?4B@$ZO)T,[=*6($YQU['FB8T
MPKW*'FM5;*)_'BA)/\C_O)%/280F:S0D\,62DCL>@A;*E)_\<>-*(QKG9POX
MUM-1P?KJ?8:[PXX+6/,YB.@2Q.#CXO95-_QXGC(^'W+.[/,S* ))N*/98^=P
M[I6'<^O:_(&R1.5)>DC3 [WRL:;=*Q@$TE<,*E_^&^6J/4H?'Y=<B<(8-"@0
MJSV*OWKX.\HH(4X:,!<>\?A!0:N68U5>GU,LRWV"[SQ_RY&T#(A[O<:^JN]N
M]M S#C\(4,^1Y_-Y23(8@D0AH/DR[R9WN$7J)SY"07Y%%15A-&5RM6Z3F;L:
M2I/M(><=\V*9DN05B+0,G[=!A%,LF\$OB)S]H2]LT-H="&%O+ D@85!V3GM!
M/@H_4+#2.VX5W@%(P7O.TX,?8A\C+T6WJ/BOLJK'F3[H@=G]Z@NB9E$8;UC)
M;DI3[.:+=1IN+#"FA@O=T3?'\Y!RDR]H\XA5'E.IQQ(+#4"4;S;H=P9=T^(*
M=_](-@OM]4AW"A7%"-\F4>2Q-#39#"#!-LUT.G[(8NJ)3^JACBJ]3A9SF'1Z
MG2QND1-)+V0P>0Y3"2\T>JJRG?B3IY,X -"65QQG^]2I)(SP<+(GKD8R,4(#
ME4!JN><G38J+4\5K3OA)$XKIQC\=875FFKI8D88O!>+W*EA%.;NG02@%Y7+R
MG#478IA)"M<*SDQZ;_;*4:J.0%:<:-+4TO01\"V^J=>RZ+L&).&^N:JE(E2_
MX.-5T&_P2MA!:X3<W9^R^.E55%3UT2Y:@=JKH),KE6<.RBFV%]1$RR%(U%+>
M>*H)!B8(YF[5=<N1,V@_<:>Y29C188),[O*0- YAHLFZDUS%2J\QTH$>G%HP
M9 ^(8>Y!=)F/-#.>3- -'(NI$T\YAZJDVY^NFVYJ*5PEK?Y\W;0RF"56$O@O
MUTU@I=RSRMUUE<U+R@X&S:#&W-9@;FMP#6T-2O%Y]XFP'Z94$>(4O K'@BAY
M@UAC.C>XG2LBK[U?K/5"."7!]_8C419\Y['3Z,([(!7)6/4#I#[:KL KE;X#
MS:XOC-N"<$_H1_Z(SZQ*DXW2_#XY8&62UP;#I'C^L UU'^JS7V1V)<(/=>:O
M#38*U&OXJ0S3>:Q9D- 'BM6!JHTV"M9=N-F*"N;YHXV"]11JZ.2UP68%O<8"
MOHVT?)$66S6&&U8M4*0A&!K##9_6(<Z0SDHV)Q@_UK2 :TTP+.G7>K UQIN6
M]UJ@-<>;E_MZP+5FF)?_.M"U)A@_!;2 :TV X:Z>JX5-I@1S77E7D64^7U<R
MEQ69R="<RXJLW<LQ\;TX= ;^7"'#/0YK#MZKJ.X8X,Z7:1-HT!2[N?2%O_'J
M,8&KJ.G0RZQ3B#V8H!K$].FY%L;\=JR'BTR4=DQT-W+B4E=!P0&8KA89,U$+
M,D&2U>)VUU'Q<#G%ZO&?JTCAOYQFC9CG5:3O7TZS>D#V*K+X![ !.AMSVFGY
M VS,B"'-ADW0GR#5FJ'VBFH3]V,,8*$W\P JNDW;2A_&E&+1;;8&9-; FD6V
MV2*06@0LLLUF@8)9P"+<;!LHV 8,NLWV@=P^8-%M!"/!I1++"=P,/]=;SO66
M5U5O.5]@#.$"8RC7YTZH4!?09;!SL>[8Q;K\2[@*$5Q)X+P_)8-!N$/GBE7W
MZH!'KV %6>0YUSO.]8[\T7.]XUSO.-<[#B_AYWK'7O)^KG><ZQWG>L=K3VR]
MMGK'^;9/-3K-]UB:*IR]ELL;Y]+9N71V[(W8\8 V.DLS_9+7L0=-7 8SE\W.
M9;.F2K+GRM"Y,G2N<#2V <5EV9.]Y6NN YVK&%T@V5S%.%<QSE6,$&DV5S'.
M58QS%2-(JLU5C',5XUS%")YN<Q7C7,4X5S%")]Q<Q3A7,0Y3Q7CV3):TJO7,
MG.L7+=^%U;D[MB@U71RR+>'57U'PC9 :UX*GSQ'9$#?'1@SUA=XV*ZI),/ E
M$/4V<TG67)(U[,[J<KNX#M? ETSDIQ:EZP_QWY&'%6IWV<-!;/E'^R5V.576
ME$8>.:/+;Q648Y!4-'JN:I-RJT*Y('LX,.G3ZT[XOZ'<"@@6'T0-W"!10>?8
M7S>^[BH%C;P)4UC[IX.@1'[X[YA>3Y5*4,YX9U?S"QF8I0]QT9#Y"TY2/0W]
MLB\97U&%,EK.>&=7]#[!:Q1F!]H-J"2VH15E?<GTBBK4(+.'.[N>=Y_[$'L%
M9F;7D_4EX^NI4FG+FS#?LVQ@191JUWD3G-UEUK2:7_YD?$55ROXYXTV QE??
MZ<?3MR270\=;8L[QX=5YB7$[0$^"F6UBT-B92GT,N#. Q%LTRP9,N*ROJ3QJ
MKE.<R^X&(Y<Y+W<KN,KQ'E\%4RH5-PH]PE=!)H/!S($.(#[/3UY0S->U@A:I
MUU:KJG?%ZQB1E*L@^WQQ+& 1<'4EQ3:$0.5\,D'@?>%;),9;!HG,<^4VT!U_
M=77,HVUX9M3U*DALB9.OK;Q\-$YF1IL')?%?"A+':$..B0 2D>WP\K75_8_&
MRLQ ^Z DGEE9$/R_BH8,ZLS<(\-@4 K.O"I(B[B*1ACVS-]?_F2&Q(4!?!?/
M[(ROKD>)4I"L3X;*55#/DLOQVKK"V#G9;'62 5&,7&1QI"C+(E2H5^^=DRP(
MP@+OAWB=X%W^HY-ER<7J/Q 8/E'PEN1<4"6RO)'O"LJKE*9:2_^402>LD%2<
M[%YN:^><&RJ9]?'BJD5[1,G_YV>49N1T?Z&'^^#487QA6#*E.*N1B/QU)@_Y
MXY=<_+.S/EM/1P7KJ_<9[@X[+F#-Y^-3C"'\FL_L7:B[VT?)$:':H2^\G98_
MWMYV/4?V9=LJY>TKQ?89%[[?&HG..LEJ70?]!474!;-,TBP]*R@EX*FD_\&%
M+W5;O!<^L]^;E._5)\:5I&$LEJ2-YW;7L*M-=PC\+O<+M<SP%T0U,O+[,HES
M1CUXT1O"NS^(EGID2-S;.DZ7!%],MD64O[<T CM8W7W2?_*.'\7)[O'$O1?B
MG[WH@!;$*MH5R];: C\GY"@)(V(LO71+MBP ,&A5U1V1\CNZL*5.A=^\S]5[
M%&YR^%=Q33*43,THM.KQ$ONZ)L(?H8_8Z_:4Q!_D_$/%49B^)9D7U9]3M>(I
MR?Z.LA?D)YN8NJWJ02N9WFKTV\Z>AS\7:,<!%2=^1GT5]"?]PTFH$<$ T#U)
MV8K'GHZUG$$?"'IAG(9^+LH,':=*GX9+6*Y=QD//1.NA88& $5;0\?K6X[JJ
M3M7)%R<-YG\=)&K.<F!.NH"/X]/,0UI=O^)UD**]9SLTFOJFU(OX-"YKYGM3
M)\T[QERQ#?Z[CH8)P_AJ.7T"+EV5J1,?\'E\\CA/NEQ3=B WW=.3)H51H:JG
MP%]GY?L@VW[L(,55E,\:W1)#,,-UUHE;.R?'KGTDN_ ] ;8EC*R(:N3J*BH?
M@3%]C_C9553U#;M,?2-U5U%S9F9'C!0GO(I**YB:[9#AQBLNDK&M;ZD%)*^X
MOL;X @T<V)PK=#I"[?6PVWGX>+H^T,GBG+G,8TI]W6%<10;Q]L%4]^[!U'HB
M\UR\ /^VMKG^ I+<O=(D\DN1<?/RIJN\3\<ZK]B[LN;?W25:N>[TL#1*M.YW
MG"79M"_[M)_7W#S ;"0U:T#@+ID9!YX-6NN"X2[!IY&O#X384Y#1O_S^=^Y2
MN':@6Z"PZM>=K6VK(=@,39BJ51-\\*J#%;VO*A@T' 'TJH+>]^2E<X7!8)E_
MTKN?)IOX/E<=S/)8(YMRSKB'D%X\Y^./NB%$%U(,D^D-N#/Z?).2):;MWZU_
MF)1WP#P)4DJP8AI&\N,=:CEO>TT8H9DY%1["#E%*1QPTAQZH^0\T?U0G@#3G
MT]M;)^T(U)PU[UI2]IP_#_:DHM$G,[GSLXXW?!2M6JA!O2?7ME"&XG'5VHS0
MOL"Q I13M>^I$B77S1 Y/#!:>I%_R!WUWU(BJVXBS__^ZF_)M]*O28"BN6CE
MZHM66-7BBSCXBK)M$B11LCE*TLW'^/)<V#*=PA8*A31OQ79JR5Q],U??S-4W
MO<6XT?PT^0?=2TECXU3V0##1/EW^P:EP8H%3L^--V2YP',X4 3!I(A=-DBT2
MN01@&D1^"=/O]QA1VYA8=FDV,A^+/C]A H_'PZ+/#VI*M+Q@N;O@ULN\$U ,
M:T(^QST>4 EE58@B'G%L03%Y1Z)I7\959$7/R>-FV5C?>=;A\V;P8>)TGI/T
MYR3]J1'?IO PY*^9D_GG9/YI;QQ#/KKK:+(_I_Q#9NV1/*<FVN?#8_7IKF/E
MV)H[]#NRCD+_[URUX/(JMO;B?#? @*NHZ/$V4:0P:R3C.^?'JU\ D2>Z]/9A
M<<'%+LP*KTX<T+L00D+?.'L,O7=ZY(<H701!6*#_$*\3O,L!<C+_DX.L3Y \
M$T:2I:/WCD'#;]TE8\3;&(-@R)%>Q*_D, OU\1S?,#;L&?=O9!?AUVV"LT=$
MQ-^\0RWLT &BSV3]J/<G7\,ST(M=<HCY*=/"24"0J>($2DB<!CLNIE37]2KB
M=0-3\<Q0XP480 C],@[W[.'L^$:4UI20*]>C)R/Q.1@^2BINI-.LB4(.9,7V
M3U?KVF]ZN#'? *#0@<>C-\?&$Z6B!IUW05OA%I""B@:-%X! 4EB_Q!@XJ-7S
M1"^%13X1FA]HN27V^LZ+N;5+@L$@*-F0X6(U5CH-QDFO*K_KA[N6B+P*?>DB
M::I 6J9LFGI^#5^$56X%D6RY"KY3E4WL#"\M7KTF;E/3"GC[MI7M,%F*F19Z
MCR-G1"E:C %:AW'8LA=;UM@@5F3B'ZC57/V77HY,[/#L6#,9!S'[4N3_ZR;Y
M^&V PD(?(O\XJT'DCU\J$&I?YAEXTN&#Z'&]0&:9,,*A<XGUW#\!3O^$"RCZ
M"Y%9WB$:R,&LOOG>R!L%&RY_;(^>R6Z7Q#F5F+S 'S<R%1=Q?/"B%\*.N&UL
M<H>-O=#TU Z+R@,)F)VA(X-Z'Y*UW&5W&"=XF1!M(=<U[B-O(P!:,&DD\!_\
M-5X<@I"\9Y%E*"WT$P[8@L$C@4N$:!SDE&-#V'P^,@L\5ZW9: J)8-6;XT;G
MT]3WHK\C#]^37T1J5GND%4 +6JF!6A\[$K"%YOR"-B$UC./LR=NQ5IXY;%00
MEX1*F(:% O3Y_]"1"V-[W*A WH><&TV90T8%[<W[? @(;<(UT>&HU)/ R1L_
M*M /L9]@<A@6[?VH,K^DKE1\7"8!GTW%LT9"8'G N"&#^&*5.W146O\-1='_
MBY,?\2ORTB1&07Z5 I]!>.-'!?KG)"(K2YL^DFV%61*6/6Y<T56L;Z'6A?&&
MLB3S-! .'WGC98CZ2<,/1-."2Y $.XXY?%207[>$(6E.K1?S3X?&H-&/!KPD
MNWJ38#Y\S5'CTF_G1='-(0UCE/*9LSEJ5 #O=@AOR'[X@I,?V5:VTNS1HP+\
M?'B/0O\^2CS^SJF/&16X11!@LH3E?Z@;LMU133S6!K!+\L\5?B-GC@S4VD@;
M@.9*QPH_X^0CC#O]_J3#K="V4)&DA"V'V0#Q.2$&>_2_X5ZH_3$'CZ7TT>]C
MY'$ ;#P>":3'A!J66Z*@<17^SI"10'M%_H&&K'[_A_<WFM/' *TS9"30WK!'
MKS)X/>[>DX@!5_/Y2$ ])8W/<CQ(K%$C+^C=I[^EY4P<9P)SV,C.F?1L)**
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M^/\9.OZ-A" 3%/@+/ JPLXR,J#\ E5U. I,1] &J?]W4*".8 ]3]))E71L@
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MTP\6'T2'W"!1S=/87S>^[BHU/[P)4UC[ZK).TZM<?L?T>JH42W'&.[N:7\C
M+'V(BRZ*7W"2ZBG6EWW)^(HJ5)IQQCN[HO<)7J,P.]!V$26Q#:THZTNF5U2A
M3(\]W-GUO/O<A\7MXZ;7D_4EX^NI4HS&FS#?+&=@193*.WD33 .G4N3)&6\"
M-+XF2C^>OB7YECK>$L..#Z_.2XRKM'J;T6S):H/)E*I6N3/FLBZP*>K&$G!-
MN)PA$W*N?U$*Y)ES:;4B?QRGJN/T4RJ6$7IO01/ W7J9D4E@+J WD!#G[U9'
MJ%]ZKR=&_I-7'G2%U$2J@L;,3;5RKE[K-5ECQ&Y<+U.SPY!7>6'7\"$EUZL"
MK3#?5=X'9B( YGH9IAWN,URZ.2(!1^,^9K#.];I7*]QGN%9V1/J-QGS,R*+K
MA<9VF,]TE>&(%'3N)LXQZV*L<->DBKVM4-!T@?B(!%3RO_<)3[M>.&_'W)]0
ML;T=V=:C0!]H35Q1!Y>B+(M0<0J^=W2S( @+?![B=8)W^8^VJ^-ZJY$=\3-4
M/MHCJ+H[&18I#PW%*KT+WV^-1,5N?B [Z1,%;TF^JZMJT#?R74&IB])4L(@)
M"UD4)T\9N8L+;^R)M/Q_?D9I1E2F%ZHQ#2[;&%\8EDPISFHD(G^=R4/^^"4_
MGMEY=*VGHX+UU?L,=X<=%[#F\_$IQA!FS6?V+D+;[:/DB%!-*6-243[>[>U:
M>!]^;W*_5I\8=V<0-5:X,QK/[:YA5^'M$/A=.RS]@NBA0GY?)G&&/3\[>-$;
MPKL_B)9Z9$C<VSI.UW]=3+9%E+^WM-,Z6-U]TG_R='?%R>[QQ+T7XI^]Z( 6
M1+';%<O6V@(_)Q%Y6T3TO9=N48,%  :M.[@C4GY'%[8\(_&;][EZC\)-#O\J
MKDF&DJG;\KC?2^SK#@A_A#YBK]M3$G^0\P\51V'ZEF1>5'^^3-+L*<G^CK(7
MY">;F+J)ZNY_F1YB]-O.GH<_%VC' 14G?D;-+?J3_N$DU(A@ .B>I&Q%MD['
M6LZ@#P2],$Y#/Q=EAHY3I4_#)2S7J<5#ST2?B6&!<+;&;#@',*<@[5(/JB,)
M^X)R"1U?:9V(JMXZ1R@D*FDP2R*S90?6PW07;]8A'::.4ICC'<V#EUT/)6@D
MA3*)Z=.LL&P0 #2.\JVB%^IH7/S']ZE"IDF?JJ5AHIL-]IEP/1,(.7OR=#M*
M8IF@;3J\(2-I=\/I:4Z.%R,9W(]C1RT<+\T!)AFOKH[G4DJKQCX<+Z, QJ8]
M8BN.%Q(,NP!]XS.3K#BXE(M'BOLXGFH/4^48,C TR9Q_VYJ(6E!HFN4"QFD_
M<-QHZ@4'KX?=SL/'TZ4\<ZW!7&O@8JV!@0XC1J+RPS6MG_S=0:GNS4&I]137
MJ5[H,J>+SCWYYS;I0'BE1(&>MT:/JNYWG"79M*\CLI^,UY3%-C+Q-"!PE\P,
MV6V#UKI@N$OP:229 B&V^G%C04:K?MW9<H$:@DU/HZGT?\$'YT3HJTR$!NLS
MAM%]UH5K/E(7LASG.QJ Y)U=6S-[VX)JM!2G::3U#>VOF]/VF#( 1A/0ZTTL
MX[L-Y_PQL]KB^-=G.)]X-JHK<DX_,[$"VE[*.<G,F40G387\ZC5R9:>F$?)/
M0TTWY/2\DLR^4UG!*<4O/R$1$0<8+;W(/T0T8?Y;2O25F\CSO[_Z6_*M]&L2
MH&C.!IRS :\J&Y!5A+.(@Z\HVR9!$B6;X^(]S7/DAV8LC2_/&8/3R1BD4$CC
MFK9#CU><ULC:ED;CT?(/NA>"9N-4%B>9Z$ G_^!4.+' J5D86O9'&(<S10!,
MFLA%MQ^+1"X!F :17\+T^SU&U$PC=DF:C<S'HL]/F,#C\;#H\X.JABTW2V[L
MWGJ9=P**H1W*Y[C' RKN\ I1Q"..+2CF!+$Y0<P%+Z^.N\!QRD\\9<P@Z^G[
ME#J\:3!(,"?=S4EW4T^Z&V '&O(=76MRW@ K8L@1=:U)?*#VB-"K=:T]^^"O
M4.5.N-;\34 K)/2G76O>)_3U,;E_7,@,[;<^BEZ_:TWVM,3T??V/3J=EO: \
MF>K9P]GQC2"7$JKF](9XK3L'V(ZGK.4+EDX#D!C%6X>;8^.)4A*4SKNLH<X!
M<K%+#F3[K=:UW_26E?D&:&BVUD*0FJ+Q A!("K.L& ,'#:4]T5[?R"?R[P,M
MMT1$[SSVS=&2P2Y24G1%O1NA*%7QS@XT:4E0R$Y9!=6J#Z6T!"YD^O1P6O<X
M715(QQ3BD"FGR5GLH)E(QH)&7BG<HW]>\QC%A?B/XCV&0Q-%]^9"H[;3Z9A.
M<5981^0?/R$4['Y[1^>E(9$*=_%A1TRKXNUI-K )1+]\5@[HYT^* ;T]ZBW,
MJ!![B(/P(PP.7O2W,-OF5*6+L WW;\E=G(4<C:'/&X;5?R3H+;<A6I]$RFJ]
M#GV$V5J;9+3]_22^(:SG0E:WB D)!6DG50IO3I-1=Y*&JDVO$5NM%T'2N N1
MJ6PSAUJS$1:^3U6V,-Z\TJI]>I')MWU 1"P9^6^_^Y,0$[6YN@SCET5YQOU6
MYTP!LE^2**20!S=>Y,7TQA>$F.Q4@XXI QA[/*UO<DJ:TPY/:8TB?=5/(8&$
M?5PNTI1"PC@*BR?+ \:YX726/C]R-V-N@DE5A-'QR?,QMDD4G*[@8^:^)+M=
M$N=C2\>H(^@]AMX[C0B&B'J9U9"MS7$13PE*KC%H:ULQ>--+MV1MZ7_HFGYX
M$4U46F1+#^,C$8;.,JP(Y_)J)*IC+ ]IEI!CMYIY='.%66@^XV2/B&7Q3 Z!
MC%XA1=9W3X^()Y35/5N@T>LC@JB\#;,\XXZR=I*?ZN0TK8LDA_#69N&G)/9;
M7 P=7:F<>MTF.*-I70_Y/77YXCJ#G9I8*C70]-D[4G?;BJI^;6D$'5.^-%KM
M<]LFWCPB+T4O%(?5^EN*\AGU?$?0^*D)H!<:#8Y1<.=A>A5?2E;VL"MZ<]P2
M<\$/W4&XC_QEC7(/73D3BP0N=$2Y I<ZLE]0BLC+J&)XBSY0E.1JPPV*"?/2
M^S\1T1.)A&H+)^@XJXEASAJ[ABQ?$G])DN!'2$.-YY1FT*BH29US7LZS%P8/
M\=+;A\4EMI7Q[0S"4FTHUPW8+A,W<.,B]1!G7KRA[M!B8-U6^7?@J"GRZ5D9
M*%2\9+?':$N=P!_H(?:)*O^8I!3QU?K-^W0&>RG35OKM^0 A.+;9UPTL)7N2
MH0_\40^OD?SE#63:#O'BH67@6OS$A+$:8_?J.^;&9UUMUQQHKP%8QRO-!+DS
MS!K JJ9("P'I- @(R6$' :9X-S(&VN-N-;\VF^65YEK<N"KN:\YF5IAJ#3&Q
MPYJ)D'"*5='*=4!SI2QO!DQ&J^LX^KQ6FVVQ'0_+I<P^MUE#;:<YL!W%;#U)
M,,,:&A*/,!,1\1R+R>ERAR\3'X6)0-9'?>/+YPU:V:#KK&S W.,%T-9#O/,E
MDZPA<W9",L$^/;8G9!7<B6Q9*Y]HCX48?D,VVW0'V@6:Z1?D@\X:;O.\UO/X
M\<YPK;=85T_8?CZA?L*< F&WR \]YMANNF@K(=1:ONBYSCD_&-+BAHGP5Y2N
MUE^][(!S,Y[>,U$_/]*RSOD/$)))'Q$A-^(<<&7Y>GI[8-8M">=^BP-"'<J0
M1#'[],G0HA3,F9RP2RC#F=4W V4D%Y4FPFW'E>ITF CR^54?6^Z[H*F]>OJN
M$Y+XM2@;?D'[!.>%",6M/ZMU^:#;;P*$'"9']5G]8*=#?:#X@.[)+)93B+!9
M=*!7+-+CD_Q?4(]Z0A>U4N2724H4,FK/Y.$'A#]"LJM>DRA@B=2?W$3RYI"&
M,5F[FOW,2I1Q##OJ''A&.$WB&$5L+P%=W925>^$8J@TUEHTJ[1,7IX@5J7<4
MV2\H)B(Z(F@N@ET8A[1S$JT?;&/Z1^<Q+9X2N5JB5CJWZ@W?',>P?7867@#R
MOI;J_B=-3,?1<9CHM32;YAB+KNX>ASG']ZW_)HNQ,/XQS@E_<2=80X)Y3#.A
M9XT<U&NO=JYV?/5*T^PZC"2G)]][))YHSU,O.R79#GS)+&OH<(]")AJ\T?:"
MUK)SCAV_ELR":QTSZ]I//Z:T9<3I3 2@IYRAJ8ZU,#Y0@N_+S@[I#2)&/#KQ
M%4KO/LG6(-I)&!-;/^]111W(]$!,(O*%3=555NBLJVL/4[&<C=+2$2(Q%YAA
MR6#RX!DG=9T>.FHC;Y5[\JIP$Q=!);_>K.F+%\84C.)S=><3]&K+B^T^\)ZG
M!F,/ZUF$OKB*6U_-60-^H<<^.*G^088G32([4]TGV1<*3F?P;EG5HT_1B0<>
MWY%V +6BZ8E'/\(QHC$*:F>$9D'AF%:<46(Q+4$S7[0?6Y5Z'UDC9W>I@O>D
M*ZC;GI+:"&M@:FG'3#1TWC [?V;?NQ;:^AY5H,Y4KM[)=PLS1L]1D.DXM)G1
M$34%K1,=49KFL*^7D_(,P?&KD]C=,40Y\_A'*EG8_*\2P^ ?AZ(HK=,T KH3
MD(&YB%HMQ6^:2&IU!0&9CGM!E0/LT@93NU6;%!=\S&95M&P;=*NBN3/<-#Z=
M.W&]='L?)3] G+$4F%93!J+I9#BDU]>631N:/]1&%I<6DE7!-#'\%A7_/1DZ
MY!];>@TBO;OS;KU&[!L4:542>2VQUC]"L@8WQV_$-GJ([\/8BWUJ+I$M^.%6
M[VL=E+H$(=-\A(+<)_:0I@?:;C[7TSH]UQRE0U'PSZ5#43\<H.(N3B*9$-[=
MHGV2AID[+ !V7S&)[TCXCH/2R8\JW5?K,&MHN8XBK+"!G@_$5B5,P]D^X&.7
M8/</D]D<B7!>MG\($V'DA_E'7$=9LH-.(J.L4WQ+%CYA+XRXO9'<B8E>Q@1G
MXX>82XL=37W\M<D1T)NE#LP1[:X(3A4N720-UH@8RH$L'0IZ\]%^5,BOID19
MZ3*H#I2'W=[S:RS@0I'3!2QPOMB>.A7(XC<%P7],<N4;GJ16AM.?I[W>;87J
M(>[V&#EKF+^[-F+4.\"USH+?@]>W^XO!+B$4FW^=J3-QG8G#*N>>-FUNF:CJ
MP.:6-^P%B+!*3I.RF6*-%M/4'_BL(6SQ>2:+9N]SY\DB;:&CJ6V,US%Y?"\&
MH_7RB$#8#")I>MV[$2;5%]CLYRP+#C!QD\^#MFX"@UQMW5@O&+A+*B](T0!3
M.!0:U04"6HWJK!?8W"TGES]O6U0#ABW%Y[C?.XS!&6B-8DTG+Y-FC2'VEE;#
M-<M>>O476&R8R_6V,G'BCX>S3EV'J=KR=.99W",2UR=GVXAG#2I_!+[)C@CB
MC[5XC0#;L\@D+&>P[=[*LAQTVWGG:MX\)OQ*4P$AQO+,*2+&F#KH1KW >];9
MR/W?!6VMNJXQG>7JS#:\8AP/EL+ZL&<"6@V)-TIQ5<1O 82N7E]<]?EPLU45
M.N5^P<EAGQ9;*7<5Y65NZ<WQD:Y*>&J<"R&=]8)JOG/JH? 5E4A=)A%AAP0W
M8Y[0TQ*'I<]+<O2B2S((YQ)/;9=3'^9DN*-ZO,84(C4N$@%Z'N:"-+TE%JM/
M2%'<C^FMUWD;Q5=_BX)#A%;K\V_D%"F8YC3E!>T.<=D! 8!LI>NPV&PPVG@9
MJL/&S GQ(@^31?J;M\GO!EVMUZ&/<,K,$($J+94PIH->$S_THE?DT[L]CLW&
MU5!SB[66\YF@A';[*#G6#(<R*"3H!N,NPHLHEV$H8'L5VCB;:.3"E)="!&H"
MDSW.GB-'21RPW3HJ4P>E,7,W=RC,&F7/NZJR/]G^5869]OS>BKN0[017F^R"
M%E%S%*("[">4G94(YF, &D/#S\GOS%&=HC=>_+WJV\1(#X.J)6ABN?!]C(H(
M<"D\P!M.=CNK,&4TCU<Z8IHS<-A#F;VDW4.9.<X% <2-B9Z%$'<(($&D<@MZ
M0PNL7QE\CG:3?T?Y.M*.-;7HJKPJ"'PRM"Z%N./SUFNPQ9H*KMT\$?X4")>@
M7LBF;$5JJ-?#6^F22_76NICD@MAFWM=[%MGM)X D]7T8DX>/X0=-E.!>3]QH
M0LZ?T91%T/7(05&O[5UFE:9N0<I(+3.52-#NDBF>!!$9D?B13H.($)?==%'D
MO<@%J5OFTK<RZ,]BE_T<D/!E [C(EA[&1V+0_>Q%[ N.RXFW1:2&FE[NB-W>
M2'][_9)\(!SGYM#)K.M,A*P):^'.*"N1S[6-6I,E18@T1EH#6Y&IF(BHS75!
MDN;Z:UMKK?T(2&;6H#KGG;'$197;WQWKB*"L8;KLHID7,V"T+].V6^/<0Y&]
MF$PL&6L)-?BKMI;5J%Q@+((@3V0Y.U';JPKR:!,N)<MSW1EKLP:'(RF8T'.'
M0Z#]4I7PRPN!9I=A<052QT?/'6H6(.[JRD9;6UR94& NM&22"SH),U?[K)TP
M'P/24ZH*C1*T"E(:FCJ@H$I5)OJBX#QHO2-'V;4C_A(Z=-,_JNGYW43E*R\\
M'IVB2.T=K<'5:VH_@<\4,T"1FR0F^'448>A-\H:@@&A/:'9U&2V<U@OI;MA,
M[S50$&[*<Q7<&C,,YN()Q6Q';5*?:Y/R*O*2MP8*<VVCUA9\(E1:8ZV!+F<O
MT4@7E-B\+BT]E7;1O,@D+JXE>$LR+VH6L-'D5D J[ DFUFG3A=P9E52(U^LV
MP1GM#=+%"Z3?I8-,:^><G]N_H5,&*V.@Q98(73Y@ LT8Z)ID"G]%1"!]];(R
MA+%:-U<"DEW]2 O]$*?PMVIB<LN.(*K.?2(T?_N!H@_T-8FSK3NQU3&(\W?D
MX;<?B3/F]F@T(8('?G'6V%2Y3P[8&2M\-**$'ZBO:3Y)HBS6&<(=RFCV7!U+
MW](C1T<=4YP.'L'N(7D1PIW7@2? Z2"\"._J+6Z@6YQQER.<O\<)E(L#[&*,
M\]>X@7 N@B]'F+X&/,*M@^<BK)OO<L$&K'J1U/R8M>S9[D- 9J!2HZQ&RJQH
M@FM!U6&QOSR?:J04TQ[-T8"V0E/C1GV,K+OTE1E-'S=V,@Y8X7KJ.]L4JK4
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MQ+0R!H.[W3Y*COE-M:OW*-P431CBU2&CQFR05V<V#M<^,Z$8VMH1(UZJ!&L
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M(V2AA$Q7L* IORYX\(8^+>O);VY:P4*<ZD$/)C[04YVGM!'LIH0C@9MHQUN
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M3=$ZQ56$/S$J$<Z*+5"<V@1SGUD*K\B''0@3;-9Y*RHPPIC#&K%_-O;0"FG
M8DK!2T$+[GV0UJ_0"Q'A@J$[P?\>B^\9&ECR#3AL;X,>([3O#R-A<O.YD##H
M$BA-UYS))R)(TID&S-B]60/J(QSEW,"J6SCD/F3BL,,K%><?X0:#<F)@7<\F
M3\3))*;$V6DEEW9B'$.%^6)\\=4?1F&&$9ACI945$3N0I;#M1BZ5TA1LX ]8
MKO>4;00/&8E,R<(*77@F#'6J\;7L*BGP1R248?V [%T0]M2H!L..8T^RFNT
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MNJ#SO5R-7+_B3!V*B[$9\T_8;R!1X/C(+'QFIS- ^TXN&>$*9_I)?$VQQ-H
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MG>[&U*RU7*&\S%JE_%BSXP:$N'6FI\&[+3,*]N,J2(N\/XZ\?)NA$(OBB5L
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MLR3ZVD!,:J8;=AL0G[C(J6N&HMR(G:W?+G'7OW=&K^C]XU]*_P)02P,$%
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M>*VC&#LB.^]/ 92@"-\J8;T/EE?X ;L @VKAZ+HH^\?0JU("$/+<[%Z%(O$
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M,_?%;^B='M(_P#O[[O30_>N\_P%02P,$%     @ RX-;6CNV-F/@"   FDX
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MQ<9M!+I)J^>N"GY;3U[1 ZX-AU%;B+.%.-7R4UN(LX4XF_3"K2W$V2S$80*
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M*NL:>G=A%/NEG-$<P/6WKRR^6();)R8.@F9J*U.!@[<=HHZQ#_"LA;N3*T!
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M3(1J1,.Z6A83KQ 61U>]]IU4D<O-GQ"_4?SLC?CY7?..& 2<MTY;>,YD?^V
MQCIB+;:-MOAZ>LTUU.C^LNMMJD"[81PSA!<JZ^"$<H'> D. F8/!T7'6(2%@
MH042:D^=5$-DY@JEAU.I((8J1-N&-&BLQJT.;4<V&/$9:.C)KI<.#8##"M1_
M&0I]EF.O6(X\^*MVXY7N L]+A8(6MA="0;#\1=9H!,RP^N 3ZO-^"LR>D9O7
M],V ]""5J7!Y+9K@"0U57]9O^2\/HTF3L%*(+W,DQ9?Q9W8IR3#P!Z(>KE6!
M%7B$"5IS)I%<>;9?C<6<6J98(EM&T&NISS!*^\&MU(:*^TAR$ISB $SE3.S$
M61L[[IK0VN4W5T&2%9W8[1^F(<@>%;++1L:+1 #O8.HJULEH)F&2@,R_@#[D
M/K(3R<.U3@;L(@.F*^;IV!HH30#Q&,+SE)@=<)Q%A/+A!OXB0OE@%VW_U=4G
MKUSQC;AH,F8Q>N5L3"QB<5\5^WL:/N@($(M38(C.SIPB6!/G%]_<29D$SX(J
M^.WTZC1Q)KW'@[<].[YGK+W2Y*2#.R9<CNLUW2:Q%'VIF&O270;R8"E=^1=)
MVKNQH\-^!=4@_B&&\JN^EU3;1%JA.CSXCV] LJS9;U8HQQH7CL'9_8YCD;A_
M^QN+N#3=D'R^,,Q[SLZ&F<. (_4\L;-UWD,=YDI)^]MX7-]%-[;;@;K[N0G?
MXS+\WC+[G3$%'ULXW0ZRN3.BYOSL[-T@-3.5O<$B<55^(JL_I__;ELOO KXY
M?_I^ )KS]WOL\<4=<3<?[8V/GIV>7WPYI(^8&;=A)9Y.826>;F,E^%1,P26^
MAA][ZTD^??ID!8<$4T02MUFV$15/[PP'>N]SBWX_W=S]V.XOTN>]9_GNN)7[
M,,L?O)W/SV^9:-%\[[2=/^U$O[<%?3<GU]@L^.Q+\DDD3-S[<>_??B446_DF
M:-I'T-H?3TOO4!Y/)Q&-GV;1Z.+[D?!T=UJD'SL"T>#5Q@64#PPP^K&G]TM(
M'Y(=<8N^8U:W3_;<HNC!9&V.?[LDRG9=!Y )=WNO_.X?L6#K9&[>LA._=]-S
MV;L>?T!IR=LAR1U40I]*(1W(EHC':B^/E7=HP7]2VLZ]CV[B&"%YCR]4?],I
M\M2"=SM'A +:H#/M1B1[-!>^\*;Y19?U-2?^17OA &XK#W&/[K07!JA$+M=5
MUM?,CB BS3&?<@$:*3KF$ (!-.F(P4_& Y28OMQ@9&&$$49."2F&-4F=3LC#
M,9CH.#&-<+<B.%.H4X<1&")XDYH>GF8NQ"03OM2#"CTCAI>[%\\2,%140S5#
M?&Q%RG]L\:6-2E".H%M<9]K5-/,QIY^0J3#39M7V94>X[WU<)G@%M+FU)NG@
M-:64:6R7-# L-TU::^41V<.ZTWXN8(8RV#TZ/TU>2:!+X"7(19EW./DAON/&
MLHM<Y0ZU&V%OD; 1B_(@ 4F8$>%?#ITA'@Z//G&AN@7T Y6L(3@(\>*+A!6V
M?0&^!73Z?5&E:%)&R;N'DG=D4A)1M9R#VM7:0T#Z%);=LT&C$)#B6LE8+J<.
M6Q5@OM169H9+,EJ"K-HJ9D%H[T07.G.@SX !&CD10& AS79 11VP21/O016:
MRC[1S=>(3)U9FPD3\="VYMJO$S, DH @6P;IHR=TEO!2D[QQLH*2E"C_AJ='
MF+EO[ #8]2A0A)L+E0PK*:IP->1ZV+U<QA%9^P6K^FOV:#%'NM7X,I$:"210
MINX6A@Q/GPVHNY!."=</?E^ZWW.C53 JF!A\13ZQXC<.#2<Q[9'WE.^%RR(Y
M.OW/IMNEWP[G"O[!1@-3HB(S*B$PL#+8G2\]7^2B4YH\+_27EF8?  /;W\#D
MY[S,[.<$QDT8YS#.X>',873%[8FQ_5\*$^Y-GS7P'\Z(B9ZY Y C#W'+WJD*
M2>OJ@^1(E0HW/;::0\N\S]"9B+^9RK0&B8 #&[TAQ'6-+J<<K6[QMA7H0.-:
M\>\4RQL7&Y%DQW6-AGV)S,'LYK.C-RL[O _L#&!N58CP%UJY"J;!]]:] >]S
M1#O<W\"DT@=?@2@YC'*M.AQ[=!]%\;"'XF'H/KKV6@Y%1*77<&8SL"MP/_NS
MM#2K(&Y/7)3DC]]-UD%> D/LXN@L/M+DT5[6W6(9.#]4\F=7-UUY+/YZA5 N
M<F@HYN?P!TW\1.@R\AZ@K0#GC1XD>L.)DXOL\AY\BQZ=6UOA#GGR^+[J>.^1
ML$2E(X5-"N]+ZMWMGMJ%'$?;L\CBMY]+:H2GG%J2*G48(-XY7SN>(>H$7$'^
ME!=_6E!%.W1/3NTE9\.[))\?.%(13<^H6SX':> G19!AEC6J@6F^!U-]2(K7
M.V=IW;<M$(_181ZCH7U&Y!!\/@(>%+(Q7-3*0\&X+J'8&\0N1#78V/Q <X9N
M@O(]$3$I;];EVL(8E2_AR%2J-?]7PH$4Q?DR9W**:C6R+QQ<(G]D7SC 18O)
MO#&9-R;S'E"J74SFW2<S-B8TQF3>N/?CWH_)O/VB#5;I(]O#GY#69G\\K?=Y
M @_(/_39@P$4?K;F[4D)'RTQ#&[J/& H)T)A=A<AD7;'0>M&"^$8N8'V,RX=
M=_3#W-%###=5JG[WN&[,;SV0U8Y1S(.QW1_B]KPAD+F#C7Z0/W03Y$SB+%+*
M5426EWP#J77HLW@5SHGC]_84!T^^<G.W4B8_Z5:^G.VHPD^FFF:#CTIVKR,E
M;<=K89,C_=:QJ5,>+S2<! US8,PF+<AVVWDN\F.JXBY)J6, 4TU+-;'PJLI=
MXE)8)$89JM21UW"#=278E.=\94,MI5T #Y96%]>:BM-<0_/;;]E/&RU*QD.:
MPT\>F\;T>1,>0R<3P^CTI-R;2'5D.XY#USZ'W\-\?3M2:^Q??5N?QCJ,B8![
M=C@/R/3;SPF,FS#.89S#PYG#Z+/8$]/G1\^J,_)>Q/R_/18?#W&G7O551.^>
M;"?N5KS:SBFG1$J2NBOK#IZFM+_17YS?P'/E4N28U(K>L!/QS<'_S2#WCOE/
MH(]<]6O(UW2:?)(A^Y&=/[YA9,8ZWT$NX]I([L[X,I^\AB'#GN/<1N<3*%7;
M4JJAX[:2PFV. '#H%N_@\9H3$]E?X6Y?W!M7+A(Z=1/M&!>8WG9:A5XJ=%P4
M!64GD8?""AN,@N?J!KKL)L!-EV248HF[[5HO?0]<4W[29AI7X/SL[*N>R2UD
M$L+Y$3@(D0J-^79NVD?;]$"[5B<-4[#@H9YMDS<:_LLZ.A\EM>,F>C?<F:F,
M+FA[O:SAN077B*7<!RR?TV?#/7_R%;V_AN,-W8-=T.F!F]'B(7JG7HP=8]+,
M+G]8]#I%A;97"FW*ZR2IH!^2!LHE/Y'E#]XS8$W<;/GW![ZL@2[#_$X*Q_<_
MF21""\_C\,2?G\$'DM%.'WQ]1D(;WC&OG4M:AA&V@J>=LSY("<S9PR49'_A
M"O*E:U(NX-4UJ#K)G<9_VE%[,62ZSV?@?U.*=+QJ1,F\3[LRL+NW:Q>^"]/'
M-@&LYWJD)'MD_>!FGKW\$XP]D'8H B4RX(U+X7UELE]O_7A"X+2G R9CV@<1
M0L;8:[V3E/9H2$@B0WXKO E_N:E-,ME=]USMQW9@(A\?BSA'$QD42(>*0[@1
MF'?2=X8(.WN%@7SQ04O1@(MB8J_$Q*]WML?HZAF:,_T]S%4.'U'2\H779[^Z
M(U8W_7GC*&%/ Q[8=X:(QS5Q1T\<.Q 8S%I4@95W+0>6\ !R+/$98XEVNS?H
M8"I.VJ7AV&9P;[O%+"0' 67ZSJR6FNWD%.#YP*D+*L_?U;[=2=D[[DWJYVY
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MNV&6<#>!.+BX\/LI< ][%^57HV:_W)P,3P*A=7I=-YG2SCIQGA3U1A4,V9U
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MA^*F^E,5NXHH;M!3,W4-'$X"B'OD(1R;JBMG_*O=QVW@:T+O$CP7%K/V1TK
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MZGSSM__VU[\LV[+XV_\#4$L! A0#%     @ RX-;6CT9RT,_R0$ =[T" !(
M             ( !     &EM9S$W,C8W-#<W-5\P+FIP9U!+ 0(4 Q0    (
M ,N#6UKB<IR?WHH- '(S$0 2              "  6_) 0!I;6<Q-S(V-S0W
M-S5?,2YJ<&=02P$"% ,4    " #+@UM:GQ<QR64; @ 8? ( $@
M    @ %]5 \ :6UG,3<R-C<T-S<U7S(N:G!G4$L! A0#%     @ RX-;6FX<
MDJTW6P0 BS<X !               ( !$G 1 '-L;BTR,#(T,3(S,2YH=&U0
M2P$"% ,4    " #+@UM:GW].)PM' 0#[&!0 $               @ %WRQ4
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M;5!+ 0(4 Q0    ( ,N#6UHA?QTN;%P  "+. P -              "  3B
E%P!S;&XM97@T7S,N:'1M4$L%!@     +  L HP(  ,_<%P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>sln-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sln="http://silence-therapeutics.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sln-20241231.xsd" xlink:type="simple"/>
    <context id="C_803eaafe-148f-4e2c-a1bf-e54187acd2aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_80436ca8-6764-4c9d-a92e-0a804aa65353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="C_8184c077-a478-46ed-ad2a-22ca667a1dda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_82966b62-872d-49bb-aeec-24612fe0285f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_84cedcb8-200d-4f11-afb2-0648fda7c636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_872d05dd-c670-4b96-94c2-e02ca438887f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8927c9e3-b70e-49d9-9480-580bb749557e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8b1b366e-04b7-442e-aae8-9b9874416e85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8cda337c-0dec-4a91-83cb-e2a5eab87ddd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8f5432bd-fe35-4ec3-a327-b8bc31778b49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8fb4cca8-43c3-4e07-8d79-5d79f2a66b76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_92ab0815-ca01-49b9-9495-665a702a4024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9467424c-7058-428d-ad9d-47868639fc92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_952f58d5-0f09-4113-8e23-231dd9d6ed60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_95a23c91-e275-4694-9a2b-078f6e447589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_967f4721-a4f1-4503-8847-1f409b6a3092">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_97969988-6ccc-4333-8d42-d1661f89dba4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_992c3aa9-ad2c-45d7-abc4-998d7652ae1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_993ce64a-f00f-4229-b0de-9e75b3dd02f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_993f7efa-93c3-4846-afa1-f47122276cef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_99e52335-f638-4b2b-ac13-630a9a8f63d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9b38472f-f9ad-4927-aa46-e70d32506104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="C_9cd4f37d-933a-4a85-beca-f7eadbe8fbd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="C_9cea7a69-a5e3-4fc9-80c0-2433f7e0add4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9db27ca0-901f-4c75-883b-ac5848b73bba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicensesAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9f0adb4a-3977-49bd-bd43-31874b535e51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a004f47b-e1d5-4aaa-929b-464b64c386ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0234db5-e0d7-409b-9954-5b243a9daa8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a26298cc-ed94-4046-8318-ff37b7f4550b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a28de7dc-3a37-4a87-b082-7778b559525a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a401c67e-4a4e-4f35-a3e7-52f49f0af333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a5aa37ae-e777-4dc1-948b-8abdce9b033b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a616bd36-1676-406f-a437-69e3e0d34cd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a61b329b-79b8-48f7-91c7-c5440305e906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a74d87d0-a1bb-4a4b-a851-11add28ffc71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a7b20ad2-f774-44ca-92d9-91406a63fde3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ab13cc0c-5775-43dd-a181-db3338b67deb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_add4578b-b18c-498c-9291-73e01f000c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_af8fc429-8807-4280-86d7-4bb3e6b0a403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b214b1bd-0876-4f24-bab9-83c0ee791a74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b68a9405-7a9f-4135-ac8b-98f4d8aa740a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b775d65d-9ac8-4943-bee6-cf41729c880d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b785019b-0762-4563-980b-1d22109b7cc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b8115894-8913-43eb-9042-ef3fc8f7d112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b902af35-3fe5-4f8a-ac84-e8d236da4c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_bf66dbc2-8413-43ec-bd18-e8293742fcfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c0372b91-8945-4668-a516-80774a76ddde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0561958-14fc-4c04-b4c6-29aecabad04e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c0f73974-d468-4883-a299-b1954062293c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1fd8902-0499-4006-8b7a-f16708af1815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c26bf700-deb8-4a91-a96d-f882b6d529d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="C_c2ca9beb-ad6f-462a-9e3e-0385278c2a72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4e5bcd7-a4a8-4fdd-be71-9205e7a10b8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sln:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c5dd0282-7233-442b-9081-aa33c6702629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c74d2467-009d-495a-bebc-222cee797f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c8c88df3-dd6e-4dfc-995d-d16e951e1d00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cae9864b-c68c-4743-b935-6556cbeeae9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cb624ebe-9f9f-415c-9701-66ebfe607196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cc4a6675-6368-4274-a498-7a1407627000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d7a493d2-59ec-46f4-87a1-b9e48f3e1f9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d923e7bf-f326-42d5-a44c-66648c52c3ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="C_d9492943-8f98-4acc-814a-052f211894d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d983b3bf-ce62-495e-8da5-1fec7e50860e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_daee9f0f-917c-4075-9727-a97e4432d952">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="C_dbbea4f8-6415-4dd5-b5eb-4a147b35a1df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_dbe56603-c5ad-4050-8b7a-f9ec17240ff0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dc57ec07-2678-46b9-9794-85b715ab415c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dc582293-5dac-417e-8bcc-6e2300b7b379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_dc740331-c44f-436b-8d6a-1313f822c913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dffb0a10-ead0-498a-9a65-80ec339f4808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1315f97-7497-4c58-b13e-bbae64f85ba2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1b8809b-fd1d-4776-97e9-f3f0de39ae40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1e57139-299b-4037-aa4e-2d87f4f5721e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1f5638a-04f4-4c2c-93a3-b700275c8509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e2631f8b-0c37-4dc8-a1cc-38b6a73bdef4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e46d88b1-5076-4a01-af8f-070d4137afe2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e692684b-2681-444f-8b7c-e8b4ef46529b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e6c9f868-f62a-4111-ba93-f469fcd0d117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e965a87f-ea8d-4a71-9f84-acedc7eb6357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-22</startDate>
            <endDate>2024-10-22</endDate>
        </period>
    </context>
    <context id="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_eb12df02-dc62-4dfe-9745-ea50a6329b7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sln:NonExecutiveChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ed7dcfe1-421c-4f79-9232-17d734827b7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_edac0d25-e5fa-43db-9447-72b4778d22a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionDomesticMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ededf283-aba4-4a6a-b30c-24bb67b0c959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eeb3d142-dc2f-4224-b92c-0c451fa14eb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f0b63486-f25b-4b73-b4df-2ac2360a659a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f1deec49-1e4a-4b33-a7be-f5eb5e43b3d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6142756-44a3-47a1-8793-ebc26a69054b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f7e4679a-8036-4192-9419-7bc7f5cca0d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fa602d40-17ae-4c95-900d-1dd73992f44c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fabcf318-8597-4509-8bb6-bc105007edc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fc0ec39a-48d9-4919-8064-11ecd22f79fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fc219a0f-69bc-48c5-8e88-1c1bea1a3b75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_00a18a89-651d-454d-8df8-75896d774647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_00d2d54e-290c-4d4d-b535-9fdc29adb158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_00f55fd7-1fe9-443f-8a1a-565e418119ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_037e26c3-7b8f-42ed-9595-fc5b17699c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0383529a-c338-4296-a791-e865000b7d3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_049e703a-bbe5-4ce3-afce-99cf7a56663a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_059ba194-dc5a-46d5-b657-d8a5b95f703b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_060925be-2d36-42da-9130-a97cb8b73ba5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0621b0c6-ee4e-42cf-a04a-499414698850">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_08dd2d55-0e01-4e62-95a4-087adff7660d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0bd98068-47df-4b94-a4e2-24b2b7898f0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicensesAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0f952a92-9ec0-42dc-8871-ae65f086585b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11ec3de2-3169-4055-898b-258e9b888703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_16908155-fa6d-48d2-86d3-2bd71f67416e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_16fd02d7-a435-4779-9d74-c3e225640553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sln:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_17e919a1-8144-489c-9e6d-db8d495d267d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1936f5c6-4623-4d59-8f5c-fd61504cd85a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationMallinckrodtPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_193e7dca-2118-430b-a24c-39a8be8f2ec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1945b695-781c-4d0b-a167-a95a2b6c877c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_196e5e80-6700-4ee5-83ef-dbd0df792f21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1aed09de-bc50-4e87-9680-f6533b6e32a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_201f659a-3cad-42ab-ab6e-27152af749a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_216e038d-1b18-4522-bfb1-cfa508cf7c03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_217d5192-d77e-4113-b140-4e04d06c0567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_21a8db84-e973-428f-b46a-6d101573066a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_21f6c7f3-fcd4-4d89-9f96-a6ce7fcf4b29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2375fd1d-98f8-4091-ae30-79225745f3d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_238358c8-8861-4cfb-a53e-08e29a69ca49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_23cfb98f-fa5a-4be5-af26-36b14ff411c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_23dabf2c-86b8-4fd8-9d01-e013311b7293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2477b135-cd13-49b5-a4d8-b62ae8c75cd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_25d05802-ed6f-4b2e-9cc1-86490d680cb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_27344b07-296f-4272-8c49-e68d36c05499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2883aa41-3a94-4d8f-bd1b-0dcd31622bf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2c48633d-504d-4b47-94ba-86f51f5eff2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2c9a8caf-7853-4084-b2c4-9c763a4f1b1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2d238315-cfea-49cf-90a8-194b936a027a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e144a57-0ddb-4baf-a9c3-2a52f32e07bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_30137f17-19dd-4a65-a75e-44bd27a45a6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3429ff17-b505-421b-8d3e-21a87a489736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3441304e-2e9f-4e16-88d3-2ba15339295c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_350c15e1-d957-4be9-aee7-a256f22c97c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_370fbfa4-fb9b-4a15-a3dc-b8d60d44d568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3807dd5f-7db5-4df7-b6df-54b06e17005f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="C_38e9b6bf-0e2e-4817-ab67-ec146ae446da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_39a561a1-a49b-401a-9662-3894f44c8689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3a41af0c-23c8-4e76-9243-d601a6c1bae4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3c9aca65-1850-401b-8756-d571e815112f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:ResearchAndDevelopmentExpenditureCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_40b17d20-2184-49db-8942-a7eef127d200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_424a567f-bfce-4314-a1cc-dcdfd4446d4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_45b856ba-a9f8-4504-b2af-359c27db06df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_46a40d66-643e-4949-b548-2f714fd5cbbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4981ab38-3780-4326-a492-3b5aa602b56e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_49d393af-f321-42c7-85a7-7d1ab9d9840c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4a556b23-31fe-49a9-90a3-49e389ec6b48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4ce48f3f-5b8b-44c8-8ccc-45e7cee6a59e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d5d0d9e-bfe8-4d5b-9352-c404dd2ac67a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_504e865b-e8c6-4526-9b0b-319762518420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="C_50fc6d5c-fae9-4564-892e-b943a5104009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_51326ac8-4cf9-4ab6-b452-e838538675cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_53771d0d-7cc8-4b66-b57c-8f18749a5839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_537e54b5-1a9a-4794-ab29-9db563b5fb50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_53a85070-3252-4961-9ffb-808312baaede">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicenseAndSoftwareNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_54971021-ad19-41ea-9f7b-464afa3961a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_58dfc602-04c5-4cbf-99d1-064ead7260df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5a53c3f0-bfdd-42e8-9d51-31e9dfd10fb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5abd1237-ff52-4950-ac85-db071e0672dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">sln:SmallOrMediumSizedEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5c9bae62-b3d2-43fe-9e77-fe51e795c617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5f26855a-a871-47e3-a783-ff3eb99970d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_608d77f8-a60e-4cd0-baf8-518580ca501b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="C_61dbaca8-5fd5-4900-8f20-af4042005ca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_62b6b471-c432-4ab7-a3bd-bee9095e34fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_632ad642-d991-4f1b-8dd8-159d5c4836a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_638faea5-e2d8-41ce-a7ed-8338f7223d41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_639d80ab-82dd-47c1-b84d-cedb0693edb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_653d019b-7d15-44db-9acd-920ecd68e80d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6697bf60-6fe3-4afc-9808-67be87d95a10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67267d0e-6a3e-40c0-98fe-e40aa96783a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_675ff913-5424-432c-ac71-3989d7bcca97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sln:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6796ff61-ed09-41b6-8d12-60cb26012f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedSeventeenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_67be7eda-a207-4017-be9a-44dc71c47dc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6a334fb1-6955-4d69-b9eb-b49d579d734d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6aaa0880-d729-425c-8313-d4f3cc099532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:RoyaltyIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:SettlementAndLicenseAgreementWithAlnylamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6ad3128e-4140-41e6-b6de-bf526d8f46d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sln:ResearchCollaborationIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6c632d2c-340e-4b65-8cbb-b51f9c4f1f5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d523cee-aad8-4ece-86d0-cf54c441dc67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_72551dd3-af02-4504-9e64-9506ac75dec4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_73d8c6ba-016e-4146-8301-8194bdf092a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sln:LicenseAndSoftwareNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74b750e6-0f2c-44dc-9d32-f425b3eac898">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_74e6c5aa-7ac8-44e0-8882-bd507123cbea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedTwelveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_758fbdcc-cc27-4b6a-8f98-eac78abfa599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:CollaborationAgreementWithMallinckrodtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_79f81678-d929-47d5-a2dd-7b6bfc53386b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sln:OptionsIssuedInYearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7a81abb4-525e-41bc-b9c6-31b36946491e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7b15e4df-7de8-4272-a954-8f455cf7b864">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sln:AmericanDepositaryShareADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sln:OptionsExercisedEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7e8eb108-56e8-4953-b71b-5050238e0174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001479615</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sln:ResearchCollaborationHansohMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_U_iso4217GBP_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>sln:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Lease">
        <measure>sln:Lease</measure>
    </unit>
    <unit id="U_OrdinaryShare">
        <measure>sln:OrdinaryShare</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_93ed6ebd-7729-45b3-b5fe-4244553c6a13">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d476ad6b-0051-439a-9d97-0f0a9375a8f2">FY</dei:DocumentFiscalPeriodFocus>
    <dei:NoTradingSymbolFlag
      contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e"
      id="F_47db74ac-229a-42b9-9b68-46d2c3f239c0">true</dei:NoTradingSymbolFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_0753a7d7-2c2c-46ac-b1c0-45326f17eaa9">0001479615</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_643965fa-a69a-4c0a-b921-781acf881027">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      id="F_d92f026f-ce71-48af-812d-8e0ff8cabed1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      id="F_67dabae8-767d-495f-b035-1a9900d294d1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d068121f-6b77-49ec-9e07-b676d008cab3">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_fa405555-b8a0-41d6-bcd0-c5ceffcea501">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <sln:CapitalCommitments
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      id="F_7e7a64d4-569d-4871-a6b1-2ad84515628e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <sln:CapitalCommitments
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      id="F_40e46a58-04d9-4131-ab73-072c46c316bb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_84b0e8e3-000a-4c2e-81d8-05877a638319">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_e658f97d-0b90-4d94-be1a-97ddce900c11">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8b37d9a2-c539-46fd-94e7-e647fa1a94e9">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6429baa4-677e-4797-a2b1-fb4c58fde5e8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_61bc9c58-c68b-4a0a-b5b1-8c7a9bb2fca8">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_495c1432-3083-4114-9459-e1ef8de59310">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_75d299e7-e762-494e-8d07-19cdc2836027">001-39487</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_0b718fb3-3b57-4f31-bd47-3a3938f4effa">Silence Therapeutics plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3d1ec10e-4150-48bb-b0b6-f1d94995d04b">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_89cbe102-2b94-4e23-9535-f69cdf72cefe">72 Hammersmith Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_a145a88f-2303-4e87-abbf-4b73315d00ee">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_df1d9cd3-5aa8-47f3-8b55-6a50fd1e3065">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d2b5977b-ee1a-43f0-963a-671fee3d8f22">W14 8TH</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_bb16accf-264b-4bd9-8e30-11cb995eda29">+44 20</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8025d2d4-7f99-49a2-a4de-f429ecc97417">3457 6900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      id="F_4b3af8e5-d675-4f8a-9d0f-6bd5cfc50556">American Depositary Shares, each representing three ordinary shares, nominal value &#xa3;0.05 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      id="F_c7d46386-77e3-4360-a960-319ed749bf16">SLN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      id="F_a218c60a-fa6b-4dfb-9b32-d9ecb580f720">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e"
      id="F_d427eb41-32b8-4916-87a5-64bb71997113">Ordinary share, nominal value &#xa3;0.05 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="C_7a81abb4-525e-41bc-b9c6-31b36946491e"
      id="F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_2f5fa6ff-ffd1-4207-aefc-d4d8f29b8b6d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_f6068400-68e0-4970-b021-ec0fb6635755">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_b1bb5dc5-05dd-4a97-8d0e-485258b8f0e8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_04055e4e-6548-48a3-a1bd-18171a8be226">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_128f53b8-896f-4d29-8b45-54a0089912d9">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_f57fecf1-2b4c-45b4-93ee-699195ecec9e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6907d01f-c08f-4d75-b650-f13acd4c1968">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_effefc53-e77b-432c-911e-01d992805120">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_26a8e87e-db93-43cd-bd4f-e57f27023972">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_b4d65b23-f19e-4179-a31a-32e881eae25e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_00d2d54e-290c-4d4d-b535-9fdc29adb158"
      decimals="-5"
      id="F_3f99c1a2-2ff7-42e8-86f7-3ef6f4f32e17"
      unitRef="U_USD">737900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9cd4f37d-933a-4a85-beca-f7eadbe8fbd1"
      decimals="INF"
      id="F_bd2f8962-6eee-4016-9d45-b3cb3236bde5"
      unitRef="U_shares">141674074</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ffeb3b84-2e31-41bd-8d96-9f5e78c24d7d">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with the registrant&#x2019;s 2025 Annual General Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the registrant&#x2019;s fiscal year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6c63665b-d39a-4006-8455-7d718821e821">&lt;p id="cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 1C. Cyber&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;security&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Risk management and strategy&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Information &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Systems and Data.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our information security function, which is led by our Vice President and Head of Information Technology, known as our Head of IT, and supported by our security management, risk management, and legal teams, helps identify, assess, and manage our cybersecurity threats and risks, including through the use of our risk register. The information security function identifies and assesses cybersecurity threats and risks by monitoring and evaluating our threat environment and risk profile using various methods including, for example: automated tools, subscribing to reports and services that identify cybersecurity threats, analyzing reports of threats, evaluating threats reported to us, coordinating with law enforcement concerning threats, internal and external audits, leveraging internal and third party threat assessments, conducting vulnerability identification assessments, and leveraging external threat intelligence.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, vulnerability management, disaster recovery and business continuity plans, risk assessments, achievement of certain security certifications, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, employee training, penetration testing, and asset management and disposal.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain information about our assessment and management of material risks from cybersecurity threats is included in risk management reports as applicable to senior leadership and the audit committee.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers to assist us&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example: threat intelligence providers, cybersecurity consultants and software providers, managed cybersecurity service providers, and penetration testing service providers.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use third-party service providers to perform a variety of functions throughout our business, such as software-as-a-service providers, hosting companies, contract research organizations, and contract manufacturing organizations. Depending on the nature of the services provided, the sensitivity of the critical systems, information and assets at issue, and the identity of the provider, we may conduct a review of security assessments provided by the vendor, review the vendor&#x2019;s written security program and/or requested security assessment and security questionnaire responses, and impose contractual obligations on vendors regarding their cybersecurity practices.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risks from cybersecurity threats that may materially affect us, please&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including &#x201c;Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;related &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#x2019; cybersecurity efforts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Executive Leadership Team, or ELT. The ELT works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit and risk committee of the board of directors, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee receives annual reports from our Head of IT, concerning our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;significant cybersecurity threats and risk and the processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we have implemented to address them.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_aa3fea73-f40d-471a-a47b-6e6accb3525e">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and our clinical trial and related data, or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Information &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Systems and Data.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3812fad3-515f-4099-9efa-b28a2051dbe9">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ea48c297-00d8-4bdc-a951-6b3586834ef4">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depending on the environment or system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident detection and response, vulnerability management, disaster recovery and business continuity plans, risk assessments, achievement of certain security certifications, encryption of certain data, network security controls, data segregation for certain data, access controls, physical controls, systems monitoring, employee training, penetration testing, and asset management and disposal.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_dcdcf659-66f0-4667-9ea3-f98b930b1d1c">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ff6865c3-1924-40a6-b1d6-72554216fdea">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_47bc2d7f-0f8d-4b34-b2a5-05600af51c49">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For a description of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;risks from cybersecurity threats that may materially affect us, please&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including &#x201c;Cybersecurity risks and the failure to maintain the confidentiality, integrity, and availability of our computer hardware, software, data and internet applications and&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;related &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;tools and functions, or those of third parties with whom we work, could result in damage to our reputation and/or subject us to costs, fines or lawsuits.&#x201d;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_fcee8a41-709d-4597-89a0-806b5ca4e650">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_17d1643a-a69e-4bed-a70a-1e07653f2a7d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#x2019; cybersecurity efforts.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity incident processes are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Executive Leadership Team, or ELT. The ELT works with our incident response team to help us mitigate and remediate cybersecurity incidents of which they are notified, in addition to notifying the audit and risk committee of the board of directors, as appropriate.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee receives annual reports from our Head of IT, concerning our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;significant cybersecurity threats and risk and the processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we have implemented to address them.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_93700132-7ea6-41af-bb77-fc9d21d9742b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors addresses the review of our IT and cybersecurity risk management as part of its general oversight function.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_a0e35ebd-d721-4b10-8918-1429c7dd697d">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee is responsible for overseeing our cybersecurity risk management processes.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_31b33efd-b899-4d2a-9986-d4b356d2a696">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by our Head of IT, who has achieved ACC Internetworking Engineer and Global Secure Systems Internetworking Engineer qualifications and has over 25 years of experience leading international IT departments and owning responsibility for organizations&#x2019; cybersecurity efforts.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_7536a90a-08f6-4d29-a8a4-3f5e28a72418">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Head of IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy, and communicating key priorities to relevant personnel. Our Head of IT is also responsible for approving budgets&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_fd96afec-0262-4ab0-9289-e056e8048480">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3566f23e-065a-4814-820e-df51c8dac5a4">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The board of directors&#x2019; audit and risk committee receives annual reports from our Head of IT, concerning our &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;significant cybersecurity threats and risk and the processes &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we have implemented to address them.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The audit and risk committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk, and mitigation.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_38900dd5-6276-4bb1-ba14-d42d7ac1eab8">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_1b4dd69e-68c7-4865-b38f-18b100c18299">&lt;p id="other_information" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Item 9B. Other Info&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;rmation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the three months ended December 31, 2024, no director or officer of the Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;terminated&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a &#x201c;Rule 10b5-1 trading arrangement&#x201d; or &#x201c;non-Rule 10b5-1 trading arrangement,&#x201d; as each term is defined in Item 408(a) of Regulation S-K.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_9daa9c0c-1bc1-40d4-8564-8845c049accc">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_53c8b60f-1c09-47fc-8fd5-2af6f8fdccd6">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_aed62cbf-704a-438f-9f22-479781fde2e7">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_f4ac5f36-a73a-4ee7-833e-2c0406dba51c">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_91d3cee2-ad0b-41a8-9371-2d73a962532b">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_4561052d-b882-44af-afa3-a8928bc66ea4">876</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_a2a6f2da-f4d6-4ae5-b4fe-61bbc853c449">&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinions on the Financial Statements and Internal Control over Financial Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Silence Therapeutics plc&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and its subsidiaries&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the &#x201c;Company&#x201d;) as of December 31, 2024&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and 2023,&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the related consolidated statements of income (loss), of comprehensive income (loss), of changes in shareholders&#x2019; equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have audited the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2013)&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In our opinion, the consolidated&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and the results of its&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operations and its&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;cash flows for each of the three years in the period ended December 31, 2024&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control - Integrated Framework&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(2013)&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;issued by the COSO.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d33137ea-1fc3-4c9a-9359-fe5fa6aa79e1">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_4c44c9ec-1990-4714-bce7-102b8b2c221d">Reading, United Kingdom</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_9cada649-14b9-470f-bc9e-e9e533a46f05"
      unitRef="U_USD">121330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_38441d4e-0779-451c-be87-c9f3cc1b88fa"
      unitRef="U_USD">68789000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_a18e2922-a578-4fb6-b193-53a403da1d92"
      unitRef="U_USD">26004000</us-gaap:ShortTermInvestments>
    <sln:ResearchAndDevelopmentBenefitReceivableCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_0164ad1e-bba8-4a09-85c6-d67b8675b2e8"
      unitRef="U_USD">24396000</sln:ResearchAndDevelopmentBenefitReceivableCurrent>
    <sln:ResearchAndDevelopmentBenefitReceivableCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_33d3c0d4-543d-4553-831b-3ebd980343bc"
      unitRef="U_USD">22442000</sln:ResearchAndDevelopmentBenefitReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_2af90d11-0c18-4372-a1b1-0a44ab917be9"
      unitRef="U_USD">14664000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_ed165592-353d-4cef-a201-7424607e4408"
      unitRef="U_USD">11630000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_4e33dc83-b8d9-44c4-92f6-baf1909c6f44"
      unitRef="U_USD">972000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_d3ad840e-c8a1-480c-b984-19d428ec0c55"
      unitRef="U_USD">290000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_cf6764cc-0479-4fe0-909b-504ee1605a17"
      unitRef="U_USD">187366000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_bedcf160-6870-4d6a-b915-7cd551592f99"
      unitRef="U_USD">103151000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_6bcecd80-205e-4faf-89ed-e666e052dcf8"
      unitRef="U_USD">1818000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_a2f1438a-8c32-4fe0-b90c-df0fccf86748"
      unitRef="U_USD">1938000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_5da30e31-7e59-4d5c-b502-90fc1f3c72ab"
      unitRef="U_USD">157000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_23470c6e-79d3-4793-a3f4-d9137f6d2a4b"
      unitRef="U_USD">370000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_7e8bf80f-13b2-4aa0-939b-d6006fdb6fdf"
      unitRef="U_USD">9392000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_377dfe97-02bd-448a-9916-56f3052ec553"
      unitRef="U_USD">9981000</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_cdce5d68-a546-4c04-bffe-4e0d93eaed42"
      unitRef="U_USD">312000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_f1b0869b-4f34-4802-9791-cb230821c8a9"
      unitRef="U_USD">362000</us-gaap:OtherIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_0da9da5a-d255-4602-8d7c-c7ff5fa74d0c"
      unitRef="U_USD">3590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_ee13e042-58ec-43a9-bea9-b376b7e4b42d"
      unitRef="U_USD">3646000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_1abaa103-f3f7-437f-bf95-202e6285e7f7"
      unitRef="U_USD">202635000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_09f55380-e132-40cd-ad51-60ad8a3231cd"
      unitRef="U_USD">119448000</us-gaap:Assets>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_a3264e12-f8b8-4324-b40b-80b1b41d120b"
      unitRef="U_USD">306000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_8c57939d-7274-4b82-864a-4df59aad5a98"
      unitRef="U_USD">6571000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_29354654-3983-4edf-bbef-439d9546c661"
      unitRef="U_USD">16399000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_3920222f-f24b-482e-9104-34045b28ecb2"
      unitRef="U_USD">15537000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_214e52b5-b083-4f25-ac53-c3dd91450cb3"
      unitRef="U_USD">117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_0a4e3248-734d-4436-8c7f-e4869a5e4e68"
      unitRef="U_USD">228000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_c32e364e-a870-4ae0-a451-5804eef141c3"
      unitRef="U_USD">16822000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_4c39024d-b48c-466c-94aa-7a5ab762dffd"
      unitRef="U_USD">22336000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_bf3a0e44-b4f2-4ba7-a15c-f10b4dbc3616"
      unitRef="U_USD">51790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_1923fefc-e6e1-478c-802d-80e8f01355d3"
      unitRef="U_USD">75001000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_d9bc3265-3fa3-42eb-b8bc-b9574de7e0b2"
      unitRef="U_USD">118000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_f074fa02-49a0-4cc4-9134-49076bb11464"
      unitRef="U_USD">68612000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_e42b2ca3-2b3f-4dd7-a26e-e46008fbc752"
      unitRef="U_USD">97455000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_386de441-e369-44a1-a195-e1f0ff453f06"
      unitRef="U_U_iso4217GBP_xbrlishares">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_6add2350-484d-497a-94c2-08e5b8f9f73a"
      unitRef="U_U_iso4217GBP_xbrlishares">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_d1d0946d-3aa4-44ad-bd76-e826b28a14f2"
      unitRef="U_shares">141674074</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_2534482a-409b-430b-8645-6d49e89692ce"
      unitRef="U_shares">118846966</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_85c1f8be-5b0c-4036-b883-15830f1ea915"
      unitRef="U_USD">10288000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_49267d6a-1d2a-4e10-9e32-e20d717f3b2e"
      unitRef="U_USD">8847000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_0f3aa9d0-f888-4c5c-a4ff-b622bb2c7103"
      unitRef="U_USD">609560000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_87562ef7-0f42-47be-a611-fd1f30c6e5ce"
      unitRef="U_USD">455765000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_85c011a7-af03-4fd3-9006-d8731b803fff"
      unitRef="U_USD">-474044000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_9148e684-f759-4cf3-83bb-36cf5392b1d5"
      unitRef="U_USD">-431894000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_41b06106-2f07-4861-9d70-8b8411af5d47"
      unitRef="U_USD">-11781000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_793475a0-ce94-4837-b04d-f316fdb13e5e"
      unitRef="U_USD">-10725000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_16e0635f-80a3-45f9-a43a-eb4e9a1d2306"
      unitRef="U_USD">134023000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_c3bf9bac-a752-4597-9663-340b46ae0e77"
      unitRef="U_USD">21993000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_3f30ad11-6633-49c0-b422-ea3124ef3138"
      unitRef="U_USD">202635000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_df096ce5-bf51-47a7-96a1-8cf33ab7d2e7"
      unitRef="U_USD">119448000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_ddc15893-7405-4f9a-94f9-f152164800dc"
      unitRef="U_USD">43258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1c1af5f9-8c20-4f7f-8854-265ef0ad46ec"
      unitRef="U_USD">31643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_a24a40cb-53da-4a2f-a60d-f0766b814d8b"
      unitRef="U_USD">21655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_2769a664-1f3b-4af1-a183-da2a340d107f"
      unitRef="U_USD">11810000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_d23168d5-2678-4e24-9c4e-9c7d4b985df7"
      unitRef="U_USD">12867000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_567f9362-4939-4865-afd3-8e9e65a57d6d"
      unitRef="U_USD">13463000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_96142dc6-7dd3-454a-9e74-fa9e40765040"
      unitRef="U_USD">31448000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1870777f-164e-497a-b93f-f4134b1fb6f5"
      unitRef="U_USD">18776000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_432e60cb-538e-4759-9517-0f1fe5f041bd"
      unitRef="U_USD">8192000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_7e1046e6-3e5f-42b2-a6f1-9dadbc1de5ba"
      unitRef="U_USD">67883000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_da930b6d-da16-4c4c-8f57-420c8b219939"
      unitRef="U_USD">56937000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_d5af2133-0569-4663-b55f-b89750e735fb"
      unitRef="U_USD">43550000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d8d694e4-d5fc-427b-ae64-e2c3515bd590"
      unitRef="U_USD">26884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_152787c7-a620-49bb-9d86-381b5c15c878"
      unitRef="U_USD">26222000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_922bb934-b54a-44b0-a252-3dfc96975c68"
      unitRef="U_USD">25682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_958f352c-ba0d-42ee-9a89-5b0749279d66"
      unitRef="U_USD">-63319000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_379f35cf-36c8-4dba-a356-9c6e242ff34d"
      unitRef="U_USD">-64383000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_4584c9e8-9642-49ab-a409-ff6e3221a58f"
      unitRef="U_USD">-61040000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_5c1f4bc3-8d86-4cc9-a079-3ad45b594fd8"
      unitRef="U_USD">646000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_4ee69178-cc84-44ce-ba19-6c420a62be21"
      unitRef="U_USD">-2641000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_818e79e5-3819-4207-8cb2-9c8bd7517378"
      unitRef="U_USD">1294000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_ef386375-b9ce-427b-9310-1121602b18a4"
      unitRef="U_USD">4472000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_997d1aad-ead3-4f69-be80-83fdcd8d0af4"
      unitRef="U_USD">1803000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_89cf974e-fcbe-43d4-a734-371de6f3d463"
      unitRef="U_USD">280000</us-gaap:OtherNonoperatingIncome>
    <sln:GainFromResearchAndDevelopmentCredit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_ce711509-8e06-4dc9-9c89-975bd8866756"
      unitRef="U_USD">13737000</sln:GainFromResearchAndDevelopmentCredit>
    <sln:GainFromResearchAndDevelopmentCredit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_e1458384-e2ef-46c4-8c34-e4bf00ac2fac"
      unitRef="U_USD">11949000</sln:GainFromResearchAndDevelopmentCredit>
    <sln:GainFromResearchAndDevelopmentCredit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_efb603e1-9bee-42bb-b07a-6b52bd5bb205"
      unitRef="U_USD">9820000</sln:GainFromResearchAndDevelopmentCredit>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_7c6531ef-de9a-4b03-9813-6d38a08fd7a4"
      unitRef="U_USD">-44464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1dde919a-cb47-4bf6-b643-f6ced6fbb3bb"
      unitRef="U_USD">-53272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_7684b55d-a189-48a0-910d-bdbb554801d6"
      unitRef="U_USD">-49646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_afbfd5db-fd33-417f-9077-c87afbf6b328"
      unitRef="U_USD">845000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_773b1a02-5418-484a-a988-a06b06a59377"
      unitRef="U_USD">956000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_f8174e9e-ef3b-47b8-b87a-89181ee7b5cb"
      unitRef="U_USD">688000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_6273a348-ef76-4cc6-b2e1-19937d22d33b"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_7deb037e-df9c-426b-9373-c810d5bc846a"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_0f1e549f-7c4c-4397-aa9d-438f865c60be"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="2"
      id="F_ef47ba8a-8663-4f15-b9fd-6955d78b6c70"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="2"
      id="F_a28b619c-6024-4822-8206-da7acffc4e87"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="2"
      id="F_faeb17c5-5c62-4bd3-8548-0b4897180c2b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="2"
      id="F_24b323e6-e8d5-4c63-883e-d7f428aeba2e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="2"
      id="F_e517c3ca-2f0d-4eaa-a723-dcacc3e33abb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="2"
      id="F_715c98f5-f30e-40d5-8a0c-9e305bc1dd20"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_4978773e-7464-462d-996f-ab54d4b5c83a"
      unitRef="U_shares">138752224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_40bfe501-0b8e-445a-94a8-afc1b32e1428"
      unitRef="U_shares">138752224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="0"
      id="F_ba793e5f-a534-4ce2-b919-81f353c75493"
      unitRef="U_shares">111277250</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="0"
      id="F_75521240-ffe0-4767-b3e6-27243db55e18"
      unitRef="U_shares">111277250</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="0"
      id="F_a86fafd8-53e1-40c5-9ef3-d6a984a833ad"
      unitRef="U_shares">96584512</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="0"
      id="F_6177a1f1-687d-4876-acea-1ce70794f5fb"
      unitRef="U_shares">96584512</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_1faa9148-69c8-4da9-b567-f4aec8a497fc"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_71df3dfe-d9b1-4fdb-a944-5433d2f5e0d6"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_0e2017ab-8846-4c8d-b8d8-e6dd61bc4662"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_1112544c-90a7-480c-ab8e-f41339a78717"
      unitRef="U_USD">-1055000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_ae628588-b471-45a0-a20d-d678b7203b8c"
      unitRef="U_USD">789000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_757416dd-afdb-42d4-b72c-e94bb7c4f59d"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_93c0abc0-694c-40a0-83ba-4d445e9236db"
      unitRef="U_USD">-1055000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_45f31816-39fa-4e5d-8e16-b9a9b7e840e9"
      unitRef="U_USD">789000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_dc9521f8-9338-40ed-9fe8-e5ba0d51bab5"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_14431220-ebb7-4ee2-8b5c-4fe674de91d9"
      unitRef="U_USD">-46364000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_a2f2bad0-6c74-4c8f-82f7-f832c39d3066"
      unitRef="U_USD">-53439000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_adcf57bc-1715-478e-be7e-03c6672704e6"
      unitRef="U_USD">-50420000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_8b1b366e-04b7-442e-aae8-9b9874416e85"
      decimals="INF"
      id="F_60bd4205-9b9e-40e8-aa03-7cb1906f7507"
      unitRef="U_shares">89784720</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8b1b366e-04b7-442e-aae8-9b9874416e85"
      decimals="-3"
      id="F_1c4d3ef1-f512-4cb7-b005-e7bf13907c97"
      unitRef="U_USD">7065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8f5432bd-fe35-4ec3-a327-b8bc31778b49"
      decimals="-3"
      id="F_0b7f44a3-7121-4e4f-9f46-e6541d6fc502"
      unitRef="U_USD">346699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d9492943-8f98-4acc-814a-052f211894d1"
      decimals="-3"
      id="F_90d18a7f-370f-4153-a8e2-040b24604a60"
      unitRef="U_USD">-11428000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e692684b-2681-444f-8b7c-e8b4ef46529b"
      decimals="-3"
      id="F_9108ed94-421b-4187-98af-658b78db02a5"
      unitRef="U_USD">-329962000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c0f73974-d468-4883-a299-b1954062293c"
      decimals="-3"
      id="F_e85955f0-1581-4c90-9b3f-a546d623b50d"
      unitRef="U_USD">12374000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0f952a92-9ec0-42dc-8871-ae65f086585b"
      decimals="-3"
      id="F_f3085b7d-1db6-4b02-81a4-89d707a6e033"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_4efabbb7-5bec-46d7-b65f-b3737da4b5e2"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_bf66dbc2-8413-43ec-bd18-e8293742fcfe"
      decimals="-3"
      id="F_367ecff9-be99-4daf-b60d-42d326e8b89d"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_9a1e615b-3bf5-4921-90f0-921c699f0f20"
      unitRef="U_USD">-86000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_27344b07-296f-4272-8c49-e68d36c05499"
      decimals="-3"
      id="F_413f3e0d-f79a-4a95-80f1-8e571d91035b"
      unitRef="U_USD">12686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_76e15a61-e876-48a0-bad1-fe66fd1ae4c4"
      unitRef="U_USD">12686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf"
      decimals="INF"
      id="F_b9b30149-48ff-409c-8bc5-d03b6d5580b4"
      unitRef="U_shares">173752</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_27344b07-296f-4272-8c49-e68d36c05499"
      decimals="-3"
      id="F_fec954ee-1503-48bd-87ca-4adb7af98659"
      unitRef="U_USD">-238000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0f952a92-9ec0-42dc-8871-ae65f086585b"
      decimals="-3"
      id="F_52446e0d-5d93-4f97-a8e2-f74e20b8c12a"
      unitRef="U_USD">238000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf"
      decimals="INF"
      id="F_c03c1fad-f9c3-4d99-8354-488faac0dc04"
      unitRef="U_shares">17850000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2d46438f-772a-4fe1-8f30-924c1f08f6cf"
      decimals="-3"
      id="F_9fb4ef26-7e74-4f81-a8d8-05e0c14da614"
      unitRef="U_USD">1086000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_27344b07-296f-4272-8c49-e68d36c05499"
      decimals="-3"
      id="F_4a951004-4ff1-47d9-a979-31a217a6dda3"
      unitRef="U_USD">51495000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_07b78d2d-51bb-4988-ace3-3a096de86491"
      unitRef="U_USD">52581000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_c0372b91-8945-4668-a516-80774a76ddde"
      decimals="INF"
      id="F_01829c9e-8603-480a-9b11-e7aaee35d4f2"
      unitRef="U_shares">107808472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c0372b91-8945-4668-a516-80774a76ddde"
      decimals="-3"
      id="F_1facde38-5642-47d0-bba9-cef289c5550b"
      unitRef="U_USD">8151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50fc6d5c-fae9-4564-892e-b943a5104009"
      decimals="-3"
      id="F_7cec66dd-0920-4ede-9207-d3cf1b16ab92"
      unitRef="U_USD">410642000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_58dfc602-04c5-4cbf-99d1-064ead7260df"
      decimals="-3"
      id="F_cd890d6c-8d73-48c7-9ec7-8a109be9e913"
      unitRef="U_USD">-11514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62b6b471-c432-4ab7-a3bd-bee9095e34fb"
      decimals="-3"
      id="F_e2c457ee-eee9-442d-ac44-3826e40c6203"
      unitRef="U_USD">-380058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_2c45c876-3ba5-4bd3-87a1-c47b08e3513f"
      unitRef="U_USD">27221000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_97969988-6ccc-4333-8d42-d1661f89dba4"
      decimals="-3"
      id="F_c6268581-7d16-4bc8-9541-77ab749b1984"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_cdd92954-8b7f-4349-b0d7-27d6a2dff8d0"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_45b856ba-a9f8-4504-b2af-359c27db06df"
      decimals="-3"
      id="F_e66cc954-603a-4ac5-ad44-3c4db3e9923e"
      unitRef="U_USD">789000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_871a7793-2061-48dd-a911-a0bd4ea382b4"
      unitRef="U_USD">789000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f"
      decimals="-3"
      id="F_df441d9b-7d90-465c-91db-b81373f28942"
      unitRef="U_USD">16274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_68c84470-c79f-479e-a7d6-7cfbfbc05767"
      unitRef="U_USD">16274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c"
      decimals="INF"
      id="F_260dbc9b-8a94-4f7d-b297-acfe6fbefad5"
      unitRef="U_shares">807927</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f"
      decimals="-3"
      id="F_271eb552-ccfa-45d0-be24-8abcecf37c3b"
      unitRef="U_USD">-2392000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_97969988-6ccc-4333-8d42-d1661f89dba4"
      decimals="-3"
      id="F_34b95401-d722-42e0-bd7d-1e68cbc1597a"
      unitRef="U_USD">2392000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c"
      decimals="INF"
      id="F_3b336f7c-0784-4d57-9d0f-a2b4839c77a0"
      unitRef="U_shares">10230567</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_fa602d40-17ae-4c95-900d-1dd73992f44c"
      decimals="-3"
      id="F_e955e3a4-ae31-4ed6-850c-1361af786808"
      unitRef="U_USD">696000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_872d05dd-c670-4b96-94c2-e02ca438887f"
      decimals="-3"
      id="F_1190195c-311f-440b-9b49-750c70ed358b"
      unitRef="U_USD">31241000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_c757988f-1db2-4480-851a-ae9977cce85b"
      unitRef="U_USD">31937000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1"
      decimals="INF"
      id="F_72f18367-5eae-46d0-8884-929446bd6c7b"
      unitRef="U_shares">118846966</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_eb52b022-b340-4c12-a338-fcd3e74ee3e1"
      decimals="-3"
      id="F_7310112f-ffd6-45a8-9c6e-fe676496936e"
      unitRef="U_USD">8847000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2477b135-cd13-49b5-a4d8-b62ae8c75cd6"
      decimals="-3"
      id="F_74ee280a-8579-4602-b637-3f338f493b5b"
      unitRef="U_USD">455765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4d5d0d9e-bfe8-4d5b-9352-c404dd2ac67a"
      decimals="-3"
      id="F_4b02c5ac-54bd-4cd6-8662-5baf16e1b30d"
      unitRef="U_USD">-10725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8184c077-a478-46ed-ad2a-22ca667a1dda"
      decimals="-3"
      id="F_c43a5b4f-9c71-42ea-9213-e752044b7895"
      unitRef="U_USD">-431894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_e1a99459-4e41-47e7-a9c6-c938321f6897"
      unitRef="U_USD">21993000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_c5dd0282-7233-442b-9081-aa33c6702629"
      decimals="-3"
      id="F_10d6382a-5f68-48ca-b19f-43cfa781542e"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_eca50113-b32a-4c30-86a6-4e4eaf578908"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_2c48633d-504d-4b47-94ba-86f51f5eff2e"
      decimals="-3"
      id="F_b9d2fa20-44b6-4630-85b2-28da7bf8013c"
      unitRef="U_USD">-1055000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_64ae4663-c1cb-41d9-85a4-a2775853b659"
      unitRef="U_USD">-1055000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379"
      decimals="-3"
      id="F_c6ab8aa1-1713-4a2d-b25d-583570625225"
      unitRef="U_USD">16307000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_9dda6d0d-d316-40d5-8e04-8886d68e29aa"
      unitRef="U_USD">16307000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b"
      decimals="INF"
      id="F_8ba99959-96dd-4325-ba79-c312b7a7dcb9"
      unitRef="U_shares">1408443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379"
      decimals="-3"
      id="F_d3015d3a-660e-4df1-b2f4-f0f8124e2e25"
      unitRef="U_USD">-3158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c5dd0282-7233-442b-9081-aa33c6702629"
      decimals="-3"
      id="F_aefc55ba-ac83-4ad5-82af-6a6ab0453fcf"
      unitRef="U_USD">3158000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b"
      decimals="INF"
      id="F_b1a39d7f-1edd-4faf-b448-343438c7d98d"
      unitRef="U_shares">21418665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_a26298cc-ed94-4046-8318-ff37b7f4550b"
      decimals="-3"
      id="F_e86aaabb-a878-4a8f-8fb9-bbc06c1b900c"
      unitRef="U_USD">1441000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_dc582293-5dac-417e-8bcc-6e2300b7b379"
      decimals="-3"
      id="F_5b2a4426-4e3d-42a1-b808-6560b6b72774"
      unitRef="U_USD">140646000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_ee37ba0c-e202-440d-9c03-e6c578796a7f"
      unitRef="U_USD">142087000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="C_dffb0a10-ead0-498a-9a65-80ec339f4808"
      decimals="INF"
      id="F_6bbf9481-7d17-46a9-b9dc-6560131f035f"
      unitRef="U_shares">141674074</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dffb0a10-ead0-498a-9a65-80ec339f4808"
      decimals="-3"
      id="F_0900b4ce-014e-4be4-81b5-997290707f4a"
      unitRef="U_USD">10288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eeb3d142-dc2f-4224-b92c-0c451fa14eb6"
      decimals="-3"
      id="F_d5171efe-d075-4a55-895d-10a56384b874"
      unitRef="U_USD">609560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_037e26c3-7b8f-42ed-9595-fc5b17699c67"
      decimals="-3"
      id="F_d2ca34ee-e0c6-4a04-8db1-9dde63875b40"
      unitRef="U_USD">-11780000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2883aa41-3a94-4d8f-bd1b-0dcd31622bf3"
      decimals="-3"
      id="F_f6d49beb-4bd0-4484-887d-f7c279656a3e"
      unitRef="U_USD">-474045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_580b777c-56b8-4d06-82ff-30c5af96e60d"
      unitRef="U_USD">134023000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_7a181edc-cb84-4c77-90e5-a9b2f25e96de"
      unitRef="U_USD">-45309000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_552e5ce8-e951-4e5c-878a-9ac942c6d663"
      unitRef="U_USD">-54228000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_b0db2712-cc01-4514-8716-e19eff8c9794"
      unitRef="U_USD">-50334000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_1f149c84-b09b-493e-8e1b-7e49e1af96e6"
      unitRef="U_USD">336000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_10cb4804-62b8-4583-9e54-51d8b3eeeb7d"
      unitRef="U_USD">369000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_41f10c52-c286-4153-b622-a1e2bbf106ca"
      unitRef="U_USD">379000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_fbb59535-0cc0-444b-8873-77476875ce87"
      unitRef="U_USD">257000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_81326a0d-0d97-4ad6-bdcb-45c5e7c029d5"
      unitRef="U_USD">252000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_ba6f85cc-41e9-4655-be7b-cf7b31584ca3"
      unitRef="U_USD">217000</us-gaap:AdjustmentForAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d730f7e5-9256-4027-bae0-e13ce88e4cfa"
      unitRef="U_USD">16307000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_a8600c19-e865-40d1-bef4-9e34c8d81e03"
      unitRef="U_USD">16274000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_3e71aad2-4f57-4f20-9b9c-08aceaa5b6a8"
      unitRef="U_USD">12686000</us-gaap:ShareBasedCompensation>
    <sln:NetForeignExchangeImpacts
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_c94727a8-9d5e-4552-a189-45d6b0d779a9"
      unitRef="U_USD">2581000</sln:NetForeignExchangeImpacts>
    <sln:NetForeignExchangeImpacts
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_d07885af-1632-4662-9b72-5b4a6189435f"
      unitRef="U_USD">-3962000</sln:NetForeignExchangeImpacts>
    <sln:NetForeignExchangeImpacts
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_20552555-0e8e-454a-9bbe-3fb7d306f2ee"
      unitRef="U_USD">1003000</sln:NetForeignExchangeImpacts>
    <us-gaap:OtherIncome
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_f33fae15-4f60-4afd-b659-4ab1afa4e38c"
      unitRef="U_USD">4472000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_14e73c61-c3d2-4c8a-b955-d3e44dae7625"
      unitRef="U_USD">1803000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_84fab173-45bd-4c9d-8edc-03565d326149"
      unitRef="U_USD">280000</us-gaap:OtherIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_c25e0d30-b722-4bc7-b9bc-3cdbc32bb1ef"
      unitRef="U_USD">845000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_c6302002-9611-4261-baca-1757b6d342df"
      unitRef="U_USD">956000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_75b853b8-8d2d-445b-939d-9b028b095a85"
      unitRef="U_USD">688000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_0e104cdc-d5a0-412f-8136-c5befcf89cde"
      unitRef="U_USD">904000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_bf462d0c-5a70-407d-92b5-fb7ab714d729"
      unitRef="U_USD">-392000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_fbd25819-e037-4002-9273-5472a3eed5e9"
      unitRef="U_USD">723000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_bbfd5bca-3ab3-4ef8-a330-05d6423f114b"
      unitRef="U_USD">1330000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_3a1baa57-5432-45fb-94b2-d3e49da843c3"
      unitRef="U_USD">-1955000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_b766a8d1-5533-411c-8f90-0b7b118ae086"
      unitRef="U_USD">5199000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_17daf8f3-46d6-4254-aa47-5bc55240d830"
      unitRef="U_USD">2337000</sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable>
    <sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_5aef5a8b-e282-4910-a3a8-075a9c29efd3"
      unitRef="U_USD">3403000</sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable>
    <sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_c0f6d90c-ddc1-4a0e-beee-af7e5470f910"
      unitRef="U_USD">9821000</sln:IncreaseDecreaseInResearchAndDevelopmentBenefitReceivable>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_b9d60d4e-65ff-4057-8d65-5d2c00a6cb0a"
      unitRef="U_USD">-0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_475af9c9-8902-410e-b0c6-1416121d5a99"
      unitRef="U_USD">3217000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <sln:IncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_e657ca07-f6fa-4b48-b1ea-d645d338b12f"
      unitRef="U_USD">499000</sln:IncreaseDecreaseInTradeAndOtherPayables>
    <sln:IncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_39ccbc03-d044-46e8-bff5-16ca422f2db7"
      unitRef="U_USD">-473000</sln:IncreaseDecreaseInTradeAndOtherPayables>
    <sln:IncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_ecbe8867-0315-44e2-a1b0-0ded61a73c44"
      unitRef="U_USD">2024000</sln:IncreaseDecreaseInTradeAndOtherPayables>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_c505319d-b88f-49cd-8586-05631a0f7e14"
      unitRef="U_USD">-28786000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_b2a93e3b-348d-49e8-890a-74a02f1a35b8"
      unitRef="U_USD">-10323000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_95b5ff4f-743e-4c25-bee8-6bf2a0db33ca"
      unitRef="U_USD">-5443000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_69fab691-7d46-4bad-bd59-bca278e87b83"
      unitRef="U_USD">-165000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_612cdabe-044b-4127-a747-412626a757a7"
      unitRef="U_USD">-175000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_f3b53d9f-83fc-40db-8461-5a4aaebc1cca"
      unitRef="U_USD">-235000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_561e3266-84ef-459f-bc6c-c85d78113ac9"
      unitRef="U_USD">-67640000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_3bf8670e-bc60-4298-9e1e-0a3efbe1c005"
      unitRef="U_USD">-49462000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_a905074c-feae-4eb9-b9e1-1c2e81ee3b3b"
      unitRef="U_USD">-57044000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sln:RedemptionOfTermDeposits
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_2d4e31eb-d20f-4b91-8b2d-df8215637be5"
      unitRef="U_USD">117412000</sln:RedemptionOfTermDeposits>
    <sln:RedemptionOfTermDeposits
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_f0331494-c2b4-4f19-9da7-9c32f59f8c8d"
      unitRef="U_USD">45121000</sln:RedemptionOfTermDeposits>
    <sln:PurchaseOfTermDeposits
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_bec21ca6-a245-4544-bd42-ebf4e977fc08"
      unitRef="U_USD">139167000</sln:PurchaseOfTermDeposits>
    <sln:PurchaseOfTermDeposits
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_dfff9cce-9442-4b75-b374-4791da4ccdea"
      unitRef="U_USD">25771000</sln:PurchaseOfTermDeposits>
    <sln:PurchaseOfTermDeposits
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_2c6ad5b9-57a9-4154-8fc3-a34aba997f79"
      unitRef="U_USD">19953000</sln:PurchaseOfTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_2a5efa09-02d3-4db5-878f-a0b8f3bbe2d2"
      unitRef="U_USD">211000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_c1729cb7-cc9e-44b9-a434-7a5df7fda03e"
      unitRef="U_USD">56000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_f61b7cb1-e22e-487c-a593-fa812b553749"
      unitRef="U_USD">173000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_baeffc46-ea17-4e56-a18c-d2c020c31681"
      unitRef="U_USD">372000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_c19c3615-7ab3-4fc6-b215-720271e07c1a"
      unitRef="U_USD">-21966000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_91338688-931b-4a7a-abc6-699c4eb97ae8"
      unitRef="U_USD">19294000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_dfb937ea-43cd-484f-9f69-7380711692b2"
      unitRef="U_USD">-20498000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_3351b119-1e65-4fab-98d9-a974960cd298"
      unitRef="U_USD">142087000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_71863ef6-8053-480b-822b-766ff302d695"
      unitRef="U_USD">31937000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_44fbcf45-30ad-48f8-a3fb-d0ea3fa53d09"
      unitRef="U_USD">52581000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_560ddec1-2666-4580-b359-ece13b5ca9e9"
      unitRef="U_USD">142087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_20db223f-f9c4-4af5-942c-052889405840"
      unitRef="U_USD">31937000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_7f807eaa-710c-47c0-ab5f-f907536a02cf"
      unitRef="U_USD">52581000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_677f3a26-d9d9-49f7-ae42-76f655ec18f6"
      unitRef="U_USD">52481000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_8c53be3a-2bb1-4713-82a0-bae1b4d5db6d"
      unitRef="U_USD">1769000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_cb0895e2-e962-4765-8cae-203f987a0472"
      unitRef="U_USD">-24961000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_ea937718-a278-4d0b-8203-402ccdbc446b"
      unitRef="U_USD">68789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_e7244ca3-7263-4a75-979a-b2d315910c13"
      unitRef="U_USD">66271000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_c0f73974-d468-4883-a299-b1954062293c"
      decimals="-3"
      id="F_6a7239a7-b03f-4ddc-b0b4-9e70482037a4"
      unitRef="U_USD">99351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_ccd37273-b83b-408f-9a60-242abad74b0a"
      unitRef="U_USD">60000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_acdda2cd-b77c-47cc-b85a-ce1939462a6a"
      unitRef="U_USD">749000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_03772c50-6bc0-43bd-98ed-554dd8ee382a"
      unitRef="U_USD">-8119000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_49d79adb-c8be-4d63-b381-a251c8088558"
      unitRef="U_USD">121330000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_81293dc2-d1cb-4cfe-88ef-c7e53ea7d512"
      unitRef="U_USD">68789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_1f133222-9d8b-45d7-9348-bb174896e4c4"
      unitRef="U_USD">66271000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_63a4a303-448d-4b48-a66d-7a2d6069d751"
      unitRef="U_USD">-433000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_371c86e2-e30d-429b-9cdd-3593009c67b9"
      unitRef="U_USD">-801000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_e356bab4-54c3-43bd-bc0a-fd3a31c8e927">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1. General information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.1. Nature of the business&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Silence Therapeutics plc and its subsidiaries (together the "Group") are primarily involved in the discovery, delivery and development of RNA therapeutics. Silence Therapeutics plc, a public Company limited by shares registered in England and Wales, with company number 02992058, is the Group&#x2019;s ultimate parent Company. The Company&#x2019;s registered office is 27 Eastcastle Street, London, W1W 8DH and the principal place of business is 72 Hammersmith Road, London, W14 8TH.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_0433767f-4829-4fc0-af1a-928b452bfc5f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2. Summary of significant accounting policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.1. Basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC"). Any reference in these notes to the applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of the Group and its wholly owned subsidiaries, after elimination of intercompany accounts and transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group previously prepared its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;)  when the Group qualified as a foreign private issuer under the rules and regulations of the SEC. In connection with the loss of the Group&#x2019;s status as a foreign private issuer, the Group is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Group&#x2019;s inception.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.2. Functional and reporting currency&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reporting currency of the consolidated financial statements is the U.S. Dollars (&#x201c;USD&#x201d; or &#x201c;$&#x201d;). The functional currency of the Group&#x2019;s subsidiaries reflects the economic environment of their respective operations. All amounts disclosed have been rounded to the nearest thousand, unless otherwise stated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the loss of the Group&#x2019;s status as a foreign private issuer, the Group as a domestic filer, changed its reporting currency of the consolidated financial statements from GBP to USD. The change in reporting currency was applied retrospectively. Consolidated financial statements for all periods have been recast into USD and presented to the nearest thousand dollars.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.3. Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial information comprises the financial statements of Silence Therapeutics plc and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4. Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, the recognition of revenue and research and development expenses. The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.5. Going concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has incurred recurring losses since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024. As of December 31, 2024, the Group had accumulated losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash outflows from operating activities for the year ended 31, December 2024 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group expects to incur operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Group may develop.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Group has funded its operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options to support its continued operations. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, the Group raised additional proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses, from sales of ADSs under its Sales Agreement. On February 5, 2024, the Group announced a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,714,286&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Group&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;), each representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS, with new and existing institutional and accredited investors (the &#x201c;Private Placement&#x201d;). The aggregate gross proceeds of the Private Placement were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses. In 2024, the Group received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment from the AstraZeneca Collaboration and achieved another $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments from the Hansoh collaboration. As of December 31, 2024, the Group had cash and cash equivalents and short-term investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group believes that its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months from the issuance date of these consolidated financial statements. For this reason, the Group continues to adopt the going concern basis in preparing the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group will need to raise additional funding to fund its operation expenses and capital expenditure requirements in relation to its clinical development activities. The Group may seek additional funding through public or private financings, debt financing or collaboration agreements. Specifically, the Group may receive future milestone payments from existing collaboration agreements which will extend the ability to fund operations. However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur. The inability to obtain future funding could impact; the Group&#x2019;s financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6. Segment reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has determined that its chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Group has concluded that it operates as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment (see Note 4).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.7. Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s revenue for the year ended December 31, 2024, consists of royalty income and revenue from collaboration agreements. To determine revenue recognition for arrangements that the Group determines are within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ASC 606: Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;revenue when, or as, the Group satisfies the performance obligations. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s royalty income is generated by a settlement and license agreement with Alnylam. Under this contract, Alnylam is obliged to pay royalties to the Group on the net sales of ONPATTRO&#x99; in the EU in a manner commensurate with the contractual terms. Invoices are raised in arrears on a quarterly basis based on sales information provided by Alnylam no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days after the quarter end.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC 606, royalty income is recognized at the later date of (i) when the subsequent sale of the commercial partner&#x2019;s product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has considered the Mallinckrodt, AstraZeneca, and Hansoh contracts and assessed whether the research and development services and license of the IP in respect of each target are distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For all contracts the Group has concluded the license of the intellectual property and the R&amp;amp;D services are not distinct, as Mallinckrodt, AstraZeneca, and Hansoh cannot benefit from the intellectual property absent the R&amp;amp;D services, as those R&amp;amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, and these services could not be performed by another party, indicating that the two are highly interrelated. On this basis, the Group has concluded that there is a single performance obligation covering both the R&amp;amp;D services and the license of the intellectual property in respect of each target. The Group recognizes revenue over the duration of the contract based on an input method based on cost to cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contracts have multiple elements of consideration (some or all of the following), namely:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments (fixed);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent milestone payments (variable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FTE costs rechargeable (variable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recharges of direct costs for certain research activities (variable).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s effort under the contracts continues throughout their entire duration. On this basis revenue is recognized over the contract period based on costs to completion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been calculated on the following ongoing basis for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total contract costs which includes actual FTE and direct costs incurred up to December 31, 2024 and forecast FTE and direct costs for the remainder of the contract&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Actual costs incurred up until December 31, 2024 are calculated as a percentage of total contract costs (actual and forecast)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This percentage is then multiplied by the transaction price allocated to the performance obligation in question, thus calculating the cumulative revenue which is then used to calculate the revenue to be recognized in that period. In the case of the upfront and milestones, the consideration that is multiplied is in relation to the upfront and completed milestones only. Consideration in relation to milestones not yet been achieved is excluded from the calculation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Forecast costs are monitored each period, with revenue recognized reflecting any changes in forecast or over/under spend in actuals.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further details of the revenue amounts recognized in the year ended December 31, 2024 can be found in note 3.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.8. Research and development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs consist of salary and personnel related costs and third party costs for the Group's research and development activities. Personnel related costs include a share based compensation charge relating to its stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group recognizes expenditure incurred in carrying out its research and development activities in line with management&#x2019;s best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion. In all cases, the full cost of each study or activity is expensed by the time the final report or, where applicable, product, has been received. Further details on research and development can be found in note 2.15.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.9. Taxation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current tax liabilities are calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a company that carries out extensive research and development activities, the Group currently benefits from the U.K. research and development tax credit regime for small or medium-sized enterprises (&#x201c;SMEs&#x201d;). A benefit receivable arises from the U.K. legislation regarding the treatment of certain qualifying research and development costs, allowing for the surrender of tax losses attributable to such costs in return for a tax rebate. Research and development tax credits are recognized when the receipt is probable. Research and development costs which are not eligible for reimbursement under the U.K. Research and Development Tax Credit scheme, such as expenditure incurred on research projects for which the group receives income, may be reimbursed under the U.K. Research and Development Expenditure Credit (&#x201c;RDEC&#x201d;) scheme. Amounts receivable under either scheme are presented within the consolidated statements of income (loss) within Benefit from R&amp;amp;D credit. The U.K. R&amp;amp;D tax credit is fully refundable to the Group and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the U.K. R&amp;amp;D tax credit as a benefit which is included in net loss before income tax and, accordingly, not reflected it as part of the income tax provision.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Group&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Group assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in consolidated statements of income (loss) in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.10. Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies area remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of income (loss) and comprehensive income (loss) for each respective period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For financial reporting purposes, the consolidated financial statements of the Group have been presented in USD, the reporting currency. The financial statements of the Group&#x2019;s entities are translated from their functional currency into USD as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, revenues and expenses are translated at the average exchange rates for the periods presented, and shareholders&#x2019; equity is translated at the prevailing historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.11. Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group considers cash and cash equivalents to comprise of cash on hand and demand deposits with original maturities of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.12. Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group only holds equipment and furniture. These are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life of furniture and equipment is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Estimated useful life and residual values are reviewed each year and amended if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is assessed for impairment upon triggering events that indicate the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group&#x2019;s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.13. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group determines if an arrangement contains a lease at inception. The Group currently only has operating leases. The Group recognizes a right-of-use ("ROU") operating lease asset and associated short- and long-term operating lease liability in its consolidated balance sheets for operating leases greater than one year. Its right-of-use assets represent its right to use an underlying asset for the lease term and its lease liabilities represent its obligation to make lease payments arising from the lease arrangement. The Group recognizes its right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments it will pay over the lease term. The Group determines the lease term at the inception of each lease, and in certain cases its lease term could include renewal options if the Group concludes it is reasonably certain to exercise the renewal option. When the Group exercises a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lease option that was not previously included in the initial lease term, it reassesses its right-of-use asset and lease liabilities for the new lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As its operating lease do not provide an interest rate implicit in the lease, the Group uses its incremental borrowing rate, based on the information available as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Group recognizes lease expense for its minimum lease payments on a straight-line basis over the expected term of its lease. Its leases do not include material variable or contingent lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. Instead, these lease payments are recognized on the consolidated statements of income (loss) on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Similar to property, plant and equipment, ROU lease asset impairment is assessed upon triggering events that indicate the carrying amount may not be recovered by comparison to the future net undiscounted cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.14. Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill is the excess of the purchase price over the estimated fair values of the underlying net assets of an acquired business. The Group assesses goodwill for impairment annually, or immediately if conditions indicate that such impairment could exist. Impairment testing for goodwill is performed at the reporting unit level. The Group first evaluates qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates potential impairment, or if the Group elects to bypass the qualitative assessment, a quantitative test is performed. The quantitative test calculates the excess of the reporting unit&#x2019;s fair value over its carrying amount, including goodwill, utilizing a discounted cash flow method. The test for impairment of goodwill requires the Group to make several assumptions and estimates regarding market conditions and its future profitability to determine the fair value of the goodwill at the reporting unit. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit net assets exceeds the estimated fair value of the reporting unit. Impairment losses recognized for the reporting unit to which goodwill has been allocated are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All goodwill for the Group is attributed to an acquisition that occurred in 2005 and the Group has determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment was recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.15. Other intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other intangible assets that are acquired by the Group are stated at cost less accumulated amortization and less accumulated impairment losses. Amortization is charged to the consolidated statements of income (loss) on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. Other intangible assets are amortized from the date they are available for use. The estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Licenses and software: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs associated with research activities are treated as an expense in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs that are directly attributable to the development phase of software will only be recognized as intangible assets provided they meet the following requirements:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;an asset is created that can be separately identified;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the technical feasibility exists to complete the intangible asset so that it will be available for sale or use and the Group has the intention and ability to do so;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;it is probable that the asset created will generate future economic benefits either through internal use or sale; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sufficient technical, financial and other resources are available for completion of the asset; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the expenditure attributable to the intangible asset during its development can be reliably measured.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Careful judgment by management is applied when deciding whether recognition requirements for software development costs have been met. This is necessary as the economic success of any product development is uncertain and may be subject to future technical problems at the time of recognition. Judgments are based on the information available at each balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.16. Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s financial instruments include cash and cash equivalents, trade receivables, U.S. treasury bills, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.17. Share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Historically the Group has issued equity settled share-based compensation to certain employees (see note 19). Equity settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value so determined is expensed on a straight-line basis over the vesting period, based on the number of stock that will eventually vest and adjusted for the effect of non-market-based vesting conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The value of the charge is adjusted to reflect expected and actual levels of award vesting, except where failure to vest is as a result of not meeting a market condition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cancellations of equity instruments are treated as an acceleration of the vesting period and therefore any amount unrecognized that would otherwise have been recorded in future accounting periods is recognized immediately. The Group has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period in which the forfeiture occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is measured using a Black Scholes model. The key assumptions used in the model have been adjusted, based on management&#x2019;s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any payment made to a counterparty on the cancellation or settlement of a grant of equity instruments (even if this occurs after the vesting date) should be accounted for as a repurchase of an equity interest (that is, as a deduction from equity). But, if the payment exceeds the fair value of the equity instruments repurchased (measured at the repurchase date), any such excess should be recognized as an expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.18. Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ordinary shares is determined using the nominal value of shares issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The additional paid-in capital account includes any premiums received on the initial issuing of the ordinary shares. Any transaction costs associated with the issuing of shares are deducted from the additional paid-in capital account, net of any related income tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity settled share-based payments are credited to a share-based payment reserve as a component of additional paid-in capital, until related options or warrants are exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation differences are included in the accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated deficit includes all current and prior period results as disclosed in the consolidated statements of income (loss).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.19. Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic income/(loss) per share is computed by dividing the net income/(loss) attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net income/(loss) attributable to ordinary shareholders is computed as if all net income/(loss) for the period had been distributed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group computes diluted income/(loss) per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, except where the effect of such non-participating securities would be antidilutive. The Group been loss making for each fiscal year and therefore all potentially dilutive ordinary equivalents are considered to be antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.20. Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d068121f-6b77-49ec-9e07-b676d008cab3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Group &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the new accounting standard for fiscal year end 2024. See the Segment Reporting policy above and Note 4 below for further detail.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting standards issued but not yet adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures, which provides for improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance is effective for annual periods beginning after December 15, 2024, and the adoption of this standard is not anticipated to have a material impact on the Group&#x2019;s consolidated financial statements other than adding new disclosures, which the Group is currently evaluating.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The amendments in this update require disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The amendments are effective for annual periods beginning after December 15, 2026, and reporting periods beginning after December 15, 2027, with early adoption permitted. The Group is currently evaluating the impact to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_12044e2d-e616-4cab-976a-df1c6b650793">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.1. Basis of preparation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC"). Any reference in these notes to the applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of the Group and its wholly owned subsidiaries, after elimination of intercompany accounts and transactions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group previously prepared its consolidated financial statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;)  when the Group qualified as a foreign private issuer under the rules and regulations of the SEC. In connection with the loss of the Group&#x2019;s status as a foreign private issuer, the Group is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. The transition to U.S. GAAP was made retrospectively for all periods from the Group&#x2019;s inception.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <sln:FunctionalAndReportingCurrencyPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_89a48719-df7e-4741-a494-87ddeb2a4bec">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.2. Functional and reporting currency&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The reporting currency of the consolidated financial statements is the U.S. Dollars (&#x201c;USD&#x201d; or &#x201c;$&#x201d;). The functional currency of the Group&#x2019;s subsidiaries reflects the economic environment of their respective operations. All amounts disclosed have been rounded to the nearest thousand, unless otherwise stated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to the loss of the Group&#x2019;s status as a foreign private issuer, the Group as a domestic filer, changed its reporting currency of the consolidated financial statements from GBP to USD. The change in reporting currency was applied retrospectively. Consolidated financial statements for all periods have been recast into USD and presented to the nearest thousand dollars.&lt;/span&gt;&lt;/p&gt;</sln:FunctionalAndReportingCurrencyPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_9df30208-8049-4b01-8c37-d0377ba9ff24">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.3. Principles of consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial information comprises the financial statements of Silence Therapeutics plc and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d326b1a8-da71-435d-a3ac-00ae53d0faaf">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4. Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, the recognition of revenue and research and development expenses. The&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <sln:GoingConcernPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_e13acd15-1e6a-4247-bb28-bc016b7185dd">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.5. Going concern&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has incurred recurring losses since inception, including net losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2024. As of December 31, 2024, the Group had accumulated losses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and cash outflows from operating activities for the year ended 31, December 2024 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group expects to incur operating losses for the foreseeable future as it continues its research and development efforts, seeks to obtain regulatory approval of its product candidates and pursues any future product candidates the Group may develop.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Group has funded its operations through upfront payments and milestones from collaboration agreements, equity offerings and proceeds from private placements, as well as management of expenses and other financing options to support its continued operations. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2024, the Group raised additional proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses, from sales of ADSs under its Sales Agreement. On February 5, 2024, the Group announced a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,714,286&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Group&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;), each representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS, with new and existing institutional and accredited investors (the &#x201c;Private Placement&#x201d;). The aggregate gross proceeds of the Private Placement were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses. In 2024, the Group received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million milestone payment from the AstraZeneca Collaboration and achieved another $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in milestone payments from the Hansoh collaboration. As of December 31, 2024, the Group had cash and cash equivalents and short-term investments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group believes that its current cash and cash equivalents are sufficient to fund its operating expenses for at least the next twelve months from the issuance date of these consolidated financial statements. For this reason, the Group continues to adopt the going concern basis in preparing the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group will need to raise additional funding to fund its operation expenses and capital expenditure requirements in relation to its clinical development activities. The Group may seek additional funding through public or private financings, debt financing or collaboration agreements. Specifically, the Group may receive future milestone payments from existing collaboration agreements which will extend the ability to fund operations. However, these future milestone payments are dependent on achievement of certain development or regulatory objectives that may not occur. The inability to obtain future funding could impact; the Group&#x2019;s financial condition and ability to pursue its business strategies, including being required to delay, reduce or eliminate some of its research and development programs, or being unable to continue operations or unable to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</sln:GoingConcernPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_05b87a8c-58e2-42b9-b003-ddc9769d5b49"
      unitRef="U_USD">-45300000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_712ffbfa-a980-4b0c-b285-5541f1cc0b53"
      unitRef="U_USD">-474000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_44226c9c-6505-42e8-a444-e29b2183dbea"
      unitRef="U_USD">-67600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e"
      decimals="-5"
      id="F_583036d2-7163-4480-a712-7e15d1e6bc8c"
      unitRef="U_USD">27700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e"
      decimals="-5"
      id="F_7fdcc719-1fc6-4541-8270-7fcdcea0785c"
      unitRef="U_USD">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="INF"
      id="F_20fc6b4b-f3bd-4638-8e59-c0fe4c5bcaca"
      unitRef="U_shares">5714286</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sln:NumberOfOrdinarySharesDenominatedInTemporaryEquity
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="INF"
      id="F_7a2543e2-e460-4ad3-82dd-54db06baf60e"
      unitRef="U_OrdinaryShare">3</sln:NumberOfOrdinarySharesDenominatedInTemporaryEquity>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_504e865b-e8c6-4526-9b0b-319762518420"
      decimals="INF"
      id="F_5a4982d9-c079-41b8-a032-7967896d8554"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_9b38472f-f9ad-4927-aa46-e70d32506104"
      decimals="-5"
      id="F_dcb176de-7912-4ac6-ba16-2c40fe84adb8"
      unitRef="U_USD">120000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="-5"
      id="F_49678b9b-8e97-44f9-b1ee-ca368d8671ad"
      unitRef="U_USD">7700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <sln:MilestonePaymentsReceived
      contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4"
      decimals="-5"
      id="F_882e8dac-5760-452f-bcd1-6e210c801574"
      unitRef="U_USD">10000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentsReceived
      contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"
      decimals="-5"
      id="F_63fb85ad-cbac-4f89-92ab-ea29eb96f6ee"
      unitRef="U_USD">2000000</sln:MilestonePaymentsReceived>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_be682d3b-be44-44b6-9c28-1af77cf08612"
      unitRef="U_USD">147300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_75b2bfdb-21b8-4e3a-8545-592f8686964d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.6. Segment reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has determined that its chief executive officer is the chief operating decision maker (&#x201c;CODM&#x201d;). The CODM reviews financial information presented on a consolidated basis. Resource allocation decisions are made by the CODM based on consolidated results. There are no segment managers who are held accountable by the CODM for operations, operating results, and planning for levels or components below the consolidated unit level. As such, the Group has concluded that it operates as a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_79e5b7cd-3fee-4eb3-bedc-4309e0e173b5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment (see Note 4).&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_690210e3-461c-4bc7-bada-f104a6746e2a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.7. Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s revenue for the year ended December 31, 2024, consists of royalty income and revenue from collaboration agreements. To determine revenue recognition for arrangements that the Group determines are within the scope of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ASC 606: Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, (&#x201c;ASC 606&#x201d;), it performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;revenue when, or as, the Group satisfies the performance obligations. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Royalty income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s royalty income is generated by a settlement and license agreement with Alnylam. Under this contract, Alnylam is obliged to pay royalties to the Group on the net sales of ONPATTRO&#x99; in the EU in a manner commensurate with the contractual terms. Invoices are raised in arrears on a quarterly basis based on sales information provided by Alnylam no later than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; days after the quarter end.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under ASC 606, royalty income is recognized at the later date of (i) when the subsequent sale of the commercial partner&#x2019;s product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from collaboration agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has considered the Mallinckrodt, AstraZeneca, and Hansoh contracts and assessed whether the research and development services and license of the IP in respect of each target are distinct.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For all contracts the Group has concluded the license of the intellectual property and the R&amp;amp;D services are not distinct, as Mallinckrodt, AstraZeneca, and Hansoh cannot benefit from the intellectual property absent the R&amp;amp;D services, as those R&amp;amp;D services are used to discover and develop a drug candidate and to enhance the value in the underlying intellectual property, and these services could not be performed by another party, indicating that the two are highly interrelated. On this basis, the Group has concluded that there is a single performance obligation covering both the R&amp;amp;D services and the license of the intellectual property in respect of each target. The Group recognizes revenue over the duration of the contract based on an input method based on cost to cost.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The contracts have multiple elements of consideration (some or all of the following), namely:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments (fixed);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Subsequent milestone payments (variable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;FTE costs rechargeable (variable);&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recharges of direct costs for certain research activities (variable).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s effort under the contracts continues throughout their entire duration. On this basis revenue is recognized over the contract period based on costs to completion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been calculated on the following ongoing basis for the year ended December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total contract costs which includes actual FTE and direct costs incurred up to December 31, 2024 and forecast FTE and direct costs for the remainder of the contract&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Actual costs incurred up until December 31, 2024 are calculated as a percentage of total contract costs (actual and forecast)&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;This percentage is then multiplied by the transaction price allocated to the performance obligation in question, thus calculating the cumulative revenue which is then used to calculate the revenue to be recognized in that period. In the case of the upfront and milestones, the consideration that is multiplied is in relation to the upfront and completed milestones only. Consideration in relation to milestones not yet been achieved is excluded from the calculation. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Forecast costs are monitored each period, with revenue recognized reflecting any changes in forecast or over/under spend in actuals.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Further details of the revenue amounts recognized in the year ended December 31, 2024 can be found in note 3.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <sln:InvoiceRaiseDurationAfterQuarterEnd
      contextRef="C_30137f17-19dd-4a65-a75e-44bd27a45a6c"
      id="F_4ec00f81-c075-43c5-9aac-2e3ecd5c0206">P75D</sln:InvoiceRaiseDurationAfterQuarterEnd>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_7b4266c3-7b37-4261-a531-bd41232c5929">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.8. Research and development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development costs consist of salary and personnel related costs and third party costs for the Group's research and development activities. Personnel related costs include a share based compensation charge relating to its stock option plan. The largest component of third party costs is for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group recognizes expenditure incurred in carrying out its research and development activities in line with management&#x2019;s best estimation of the costs incurred to date for each separately contracted study or activity. This includes the calculation of research and development accruals and prepayments at each period to account for expenditure that has been incurred. This requires estimations of the full costs to complete each study or activity and also estimation of the current stage of completion. In all cases, the full cost of each study or activity is expensed by the time the final report or, where applicable, product, has been received. Further details on research and development can be found in note 2.15.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_cc18885c-1042-47ad-9b26-051cd669ab4e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.9. Taxation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current tax liabilities are calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a company that carries out extensive research and development activities, the Group currently benefits from the U.K. research and development tax credit regime for small or medium-sized enterprises (&#x201c;SMEs&#x201d;). A benefit receivable arises from the U.K. legislation regarding the treatment of certain qualifying research and development costs, allowing for the surrender of tax losses attributable to such costs in return for a tax rebate. Research and development tax credits are recognized when the receipt is probable. Research and development costs which are not eligible for reimbursement under the U.K. Research and Development Tax Credit scheme, such as expenditure incurred on research projects for which the group receives income, may be reimbursed under the U.K. Research and Development Expenditure Credit (&#x201c;RDEC&#x201d;) scheme. Amounts receivable under either scheme are presented within the consolidated statements of income (loss) within Benefit from R&amp;amp;D credit. The U.K. R&amp;amp;D tax credit is fully refundable to the Group and is not dependent on current or future taxable income. As a result, the Company has recorded the entire benefit from the U.K. R&amp;amp;D tax credit as a benefit which is included in net loss before income tax and, accordingly, not reflected it as part of the income tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Group&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Group assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in consolidated statements of income (loss) in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_77862921-7478-4a57-98fa-cb407ca41f11">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.10. Foreign currency translation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at exchange rates prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies area remeasured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the consolidated statements of income (loss) and comprehensive income (loss) for each respective period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For financial reporting purposes, the consolidated financial statements of the Group have been presented in USD, the reporting currency. The financial statements of the Group&#x2019;s entities are translated from their functional currency into USD as follows: assets and liabilities are translated at the exchange rates at the balance sheet dates, revenues and expenses are translated at the average exchange rates for the periods presented, and shareholders&#x2019; equity is translated at the prevailing historical exchange rates. Translation adjustments are not included in determining net loss but are included as a foreign exchange adjustment to other comprehensive income, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_26f82fa5-0fae-460e-8e46-1f9d9c65c691">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.11. Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group considers cash and cash equivalents to comprise of cash on hand and demand deposits with original maturities of three months or less that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_eef2ae45-2bf7-45e5-9c08-e03d5f4ed1a5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.12. Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group only holds equipment and furniture. These are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful life of the asset. The estimated useful life of furniture and equipment is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years. Estimated useful life and residual values are reviewed each year and amended if necessary.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant and equipment is assessed for impairment upon triggering events that indicate the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group&#x2019;s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_16fd02d7-a435-4779-9d74-c3e225640553"
      id="F_ac2e9195-6dd6-4c77-b0ca-6992cf439655">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c4e5bcd7-a4a8-4fdd-be71-9205e7a10b8e"
      id="F_48fa7100-39cb-4fdc-aa88-a275aa4a1832">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_223db406-b6d1-4f49-a9dc-7b4308de83ee">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.13. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group determines if an arrangement contains a lease at inception. The Group currently only has operating leases. The Group recognizes a right-of-use ("ROU") operating lease asset and associated short- and long-term operating lease liability in its consolidated balance sheets for operating leases greater than one year. Its right-of-use assets represent its right to use an underlying asset for the lease term and its lease liabilities represent its obligation to make lease payments arising from the lease arrangement. The Group recognizes its right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments it will pay over the lease term. The Group determines the lease term at the inception of each lease, and in certain cases its lease term could include renewal options if the Group concludes it is reasonably certain to exercise the renewal option. When the Group exercises a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lease option that was not previously included in the initial lease term, it reassesses its right-of-use asset and lease liabilities for the new lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As its operating lease do not provide an interest rate implicit in the lease, the Group uses its incremental borrowing rate, based on the information available as of the lease inception date or at the lease option extension date in determining the present value of future payments. The Group recognizes lease expense for its minimum lease payments on a straight-line basis over the expected term of its lease. Its leases do not include material variable or contingent lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. Instead, these lease payments are recognized on the consolidated statements of income (loss) on a straight-line basis over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Similar to property, plant and equipment, ROU lease asset impairment is assessed upon triggering events that indicate the carrying amount may not be recovered by comparison to the future net undiscounted cash flows.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3da53614-4cd7-4f96-a8de-a9e612175142">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.14. Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill is the excess of the purchase price over the estimated fair values of the underlying net assets of an acquired business. The Group assesses goodwill for impairment annually, or immediately if conditions indicate that such impairment could exist. Impairment testing for goodwill is performed at the reporting unit level. The Group first evaluates qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates potential impairment, or if the Group elects to bypass the qualitative assessment, a quantitative test is performed. The quantitative test calculates the excess of the reporting unit&#x2019;s fair value over its carrying amount, including goodwill, utilizing a discounted cash flow method. The test for impairment of goodwill requires the Group to make several assumptions and estimates regarding market conditions and its future profitability to determine the fair value of the goodwill at the reporting unit. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unit net assets exceeds the estimated fair value of the reporting unit. Impairment losses recognized for the reporting unit to which goodwill has been allocated are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All goodwill for the Group is attributed to an acquisition that occurred in 2005 and the Group has determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment was recorded as of December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_67fc6ac1-fa02-4586-bdda-4690af7da5b4"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_962e7236-c178-4aa6-88e1-6d65cf87b92c"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ddd93d49-45e4-4e34-bc33-3a6a61ce80e3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.15. Other intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other intangible assets that are acquired by the Group are stated at cost less accumulated amortization and less accumulated impairment losses. Amortization is charged to the consolidated statements of income (loss) on a straight-line basis over the estimated useful lives of intangible assets unless such lives are indefinite. Intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. Other intangible assets are amortized from the date they are available for use. The estimated useful lives are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Licenses and software: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs associated with research activities are treated as an expense in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs that are directly attributable to the development phase of software will only be recognized as intangible assets provided they meet the following requirements:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;an asset is created that can be separately identified;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the technical feasibility exists to complete the intangible asset so that it will be available for sale or use and the Group has the intention and ability to do so;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;it is probable that the asset created will generate future economic benefits either through internal use or sale; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;sufficient technical, financial and other resources are available for completion of the asset; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the expenditure attributable to the intangible asset during its development can be reliably measured.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Careful judgment by management is applied when deciding whether recognition requirements for software development costs have been met. This is necessary as the economic success of any product development is uncertain and may be subject to future technical problems at the time of recognition. Judgments are based on the information available at each balance sheet date.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0bd98068-47df-4b94-a4e2-24b2b7898f0c"
      id="F_5017aa2f-48d8-4edb-b20f-63b1ad0320f4">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_9db27ca0-901f-4c75-883b-ac5848b73bba"
      id="F_5216c8d2-963f-4736-a808-f41a38554272">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_cf5503d1-812e-4556-8d59-68adcf3ac71b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.16. Fair value measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s financial instruments include cash and cash equivalents, trade receivables, U.S. treasury bills, trade and other payables and accrued expenses. These are initially recorded at fair value and subsequently measured at cost, which is considered to approximate their fair value due to the short-term nature of such financial instruments.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; or&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_a752ec57-7de7-4c26-8ba2-6d9485e8e5d5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.17. Share-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Historically the Group has issued equity settled share-based compensation to certain employees (see note 19). Equity settled share-based payments are measured at fair value (excluding the effect of non-market-based vesting conditions) at the date of grant. The fair value so determined is expensed on a straight-line basis over the vesting period, based on the number of stock that will eventually vest and adjusted for the effect of non-market-based vesting conditions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The value of the charge is adjusted to reflect expected and actual levels of award vesting, except where failure to vest is as a result of not meeting a market condition.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cancellations of equity instruments are treated as an acceleration of the vesting period and therefore any amount unrecognized that would otherwise have been recorded in future accounting periods is recognized immediately. The Group has elected to recognize the effect of forfeitures on share-based compensation when they occur. Any differences in compensation recognized at the time of forfeiture are recorded as a cumulative adjustment in the period in which the forfeiture occurs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value is measured using a Black Scholes model. The key assumptions used in the model have been adjusted, based on management&#x2019;s best estimate, for the effects of non-transferability, exercise restrictions and behavioral considerations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Any payment made to a counterparty on the cancellation or settlement of a grant of equity instruments (even if this occurs after the vesting date) should be accounted for as a repurchase of an equity interest (that is, as a deduction from equity). But, if the payment exceeds the fair value of the equity instruments repurchased (measured at the repurchase date), any such excess should be recognized as an expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8ae650d9-58c7-4c37-994c-049625d3c83f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.18. Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ordinary shares is determined using the nominal value of shares issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The additional paid-in capital account includes any premiums received on the initial issuing of the ordinary shares. Any transaction costs associated with the issuing of shares are deducted from the additional paid-in capital account, net of any related income tax benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Equity settled share-based payments are credited to a share-based payment reserve as a component of additional paid-in capital, until related options or warrants are exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Foreign currency translation differences are included in the accumulated other comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accumulated deficit includes all current and prior period results as disclosed in the consolidated statements of income (loss).&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8661e360-7c36-460b-af15-8f5da7b7cfeb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.19. Loss per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic income/(loss) per share is computed by dividing the net income/(loss) attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding for the reporting period without consideration for potentially dilutive securities. Net income/(loss) attributable to ordinary shareholders is computed as if all net income/(loss) for the period had been distributed.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group computes diluted income/(loss) per ordinary share after giving consideration to all potentially dilutive ordinary equivalents, except where the effect of such non-participating securities would be antidilutive. The Group been loss making for each fiscal year and therefore all potentially dilutive ordinary equivalents are considered to be antidilutive.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6694d1d7-e24a-42c1-a517-42410b10ed1f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.20. Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Recently adopted accounting standards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the FASB issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d068121f-6b77-49ec-9e07-b676d008cab3;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This guidance expands public entities&#x2019; segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The amendments are required to be applied retrospectively to all prior periods presented in an entity&#x2019;s financial statements. The Group &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; the new accounting standard for fiscal year end 2024. See the Segment Reporting policy above and Note 4 below for further detail.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounting standards issued but not yet adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes (Topic 740): &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures, which provides for improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This guidance is effective for annual periods beginning after December 15, 2024, and the adoption of this standard is not anticipated to have a material impact on the Group&#x2019;s consolidated financial statements other than adding new disclosures, which the Group is currently evaluating.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The amendments in this update require disclosure, in the notes to financial statements, of specified information about certain costs and expenses at each interim and annual reporting period. The amendments are effective for annual periods beginning after December 15, 2026, and reporting periods beginning after December 15, 2027, with early adoption permitted. The Group is currently evaluating the impact to its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      id="F_92e64978-4b79-4d77-842b-a41faba55040">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_21211ba7-59eb-43a6-ba63-072f7ce0c2a0">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3. Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from collaboration agreements for the years ended December 31, 2024, 2023 and 2022 predominately relates to the research collaboration agreements the Group entered into with Mallinckrodt in July 2019, AstraZeneca in March 2020, and Hansoh in October 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue comprised $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of royalty income (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of Research collaboration income (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of revenue from contracts with customers is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Arial;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - Mallinckrodt plc&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - AstraZeneca&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - Hansoh&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;30,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue from contracts with customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under its collaboration agreement with Mallinckrodt, the Group received an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2019 and are eligible to receive specified development, regulatory a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd commercial milestone payments. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; milestone payments under this agreement were achieved (2023: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nil; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) during the year ended December 31, 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group recognizes the upfront payment, milestone payments, payments for personnel costs and other research funding payments over time, in accordance with ASC 606.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2023, the Group reacquired e&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;xclusive worldwide rights to two preclinical siRNA assets under its Mallinckrodt collaboration, which resulted in a modification of the agreement. No additional performance obligations were identified as a result of the modification as there were no additional goods or services to be provided by the Group and the modification resulted in the partially satisfied performance obligations relating to the two reacquired targets becoming fully satisfied as the Group was no longer obligated to develop these targets. SLN501, the C3 targeting program, remained under the original collaboration agreement through March 2024. The Group accounted for the modification as if it were part of the existing contract as the remaining services to be delivered form part of a single performance obligation that is partially satisfied at the date of contract modification. The effect of the contract modification was that the consideration originally received for the two preclinical siRNA assets was reallocated to SLN501. The Group recognized the effect of the contract modification on the measure of progress towards complete satisfaction of the SLN501 performance obligation, and recognized an adjustment to revenue at the date of the contract modification on a cumulative catch-up basis. The Group recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on the contract modification date. In relation to the reacquired targets, the two preclinical siRNA assets were recognized at fair value. The fair value of those assets has been determined to be nil. Under the modification, the Group agreed to pay future success-based milestones and low single digit royalties on net sales if the projects advance. The Group will recognize these variable success-based milestones as an intangible asset at cost when triggered. Any royalties payable will be expensed in cost of sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2024, Mallinckrodt notified the Group that it will not pursue further development of the SLN501 program following the completion of the Phase 1 clinical trial. The completion of the Phase 1 clinical trial also represented the conclusion of all required development activities and commitments under the terms of the Mallinckrodt Collaboration. During the year ended December 31, 2024, the Group recognized a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue under this agreement (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under its collaboration agreement with AstraZeneca, the Group received an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2020 with a further amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million received in May 2021. The Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is also eligible to receive specified development and commercial milestone payments as well as tiered royalties on net sales, if any. The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606. During the year ended December&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;31, 2024, the Group achieved a milesto&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ne payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: nil). During the year ended December 31, 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recognized a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue under this agreement (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group entered into a collaboration agreement with Hansoh on October 15, 2021. The Group received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, net of taxes) upfront payment to us in December 2021. The Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is eligible to receive development, regulatory and commercial milestones as well as royalties on Hansoh net product sales. During the year ended December 31, 2024, the Group achieved milestone pay&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ments totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group recognizes the upfront payment and milestone payments over time, in accordance with ASC 606.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, Hansoh notified the Group that it will not pursue further development under the Hansoh Collaboration. This represented the conclusion of all required development activities and commitments under the terms of the Hansoh Collaboration. During the year ended December 31, 2024, the Group &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;recognized a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue under this agreement (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2018, the Group entered into a settlement and license agreement with Alnylam Pharmaceuticals Inc. (&#x201c;Alnylam&#x201d;), pursuant to which the Group settled outstanding patent litigation with Alnylam related to its RNAi product ONPATTRO. As part of the settlement, the Group licenses specified patents to Alnylam, and Alnylam pays us a tiered royalty of up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; percent of net sales of ONPATTRO in the European Union. The Group was eligible to receive these royalties through December 2023. The Group invoices Alnylam quarterly in arrears based on sales data for that quarter as reported to us by Alnylam. Royalty revenue is recognized based on the level of sales when the related sales occur. During the year ended December 31, 2024, the Group recognized a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in royalty income from Alnylam (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921"
      decimals="-5"
      id="F_5457610d-351c-4d34-b970-5822cdf0ccbe"
      unitRef="U_USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_537e54b5-1a9a-4794-ab29-9db563b5fb50"
      decimals="-5"
      id="F_f61b5faf-cb1d-49f0-9d17-b48ac86d9865"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_00f55fd7-1fe9-443f-8a1a-565e418119ba"
      decimals="-5"
      id="F_42830959-f470-4ea4-95f7-fdb18713270e"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_46a40d66-643e-4949-b548-2f714fd5cbbb"
      decimals="-5"
      id="F_eacbaca5-610f-40ac-a197-7115411c0853"
      unitRef="U_USD">43100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c"
      decimals="-5"
      id="F_7e0ab4f5-41b6-449d-b078-5ae2eac0757f"
      unitRef="U_USD">30900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0"
      decimals="-5"
      id="F_042f4055-a7da-4bd0-b328-f87ea310679c"
      unitRef="U_USD">20900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_031a559c-0f6d-4da9-b2c4-76ff171d40ec">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Disaggregation of revenue from contracts with customers is as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - Mallinckrodt plc&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,425&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - AstraZeneca&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,957&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - Hansoh&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration - total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;30,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue from contracts with customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_993f7efa-93c3-4846-afa1-f47122276cef"
      decimals="-3"
      id="F_6bd40575-4301-492a-88b4-9e2ab6053acd"
      unitRef="U_USD">584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_add4578b-b18c-498c-9291-73e01f000c88"
      decimals="-3"
      id="F_601a9f65-1e49-485b-9c48-7d92134f8066"
      unitRef="U_USD">13149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1936f5c6-4623-4d59-8f5c-fd61504cd85a"
      decimals="-3"
      id="F_f438248f-ad89-49f7-8cb5-d010f021418d"
      unitRef="U_USD">14425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_23cfb98f-fa5a-4be5-af26-36b14ff411c6"
      decimals="-3"
      id="F_4bc85df5-4f94-487c-b4a4-a1992e3922d2"
      unitRef="U_USD">17957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a0234db5-e0d7-409b-9954-5b243a9daa8f"
      decimals="-3"
      id="F_ddeefd0d-3b52-488c-81e3-eac712fb7a2b"
      unitRef="U_USD">17062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6c632d2c-340e-4b65-8cbb-b51f9c4f1f5d"
      decimals="-3"
      id="F_b388f29b-e7be-4212-bc7a-27eb0ec9f638"
      unitRef="U_USD">6287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9467424c-7058-428d-ad9d-47868639fc92"
      decimals="-3"
      id="F_3542e448-7174-46c7-9049-36828725f697"
      unitRef="U_USD">24573000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3429ff17-b505-421b-8d3e-21a87a489736"
      decimals="-3"
      id="F_7ea1da86-e3f5-4ab6-85e4-d130e72fc276"
      unitRef="U_USD">722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7e8eb108-56e8-4953-b71b-5050238e0174"
      decimals="-3"
      id="F_b60e6fbc-e3fd-4508-b3c7-1b24a72de0ad"
      unitRef="U_USD">228000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_46a40d66-643e-4949-b548-2f714fd5cbbb"
      decimals="-3"
      id="F_7bf688c9-d31f-4d01-83be-f89d4832fedc"
      unitRef="U_USD">43114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f44b9d16-ad5a-4715-b194-6a3d278a2d2c"
      decimals="-3"
      id="F_8b388016-af64-4448-a58f-724359b70b0a"
      unitRef="U_USD">30933000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6c41de8c-8be2-4040-a0a2-b51b1dd29ec0"
      decimals="-3"
      id="F_fb98f0d8-ecf7-42bb-9b55-b117b7efae9b"
      unitRef="U_USD">20940000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d5247868-8c1a-414d-a8aa-c34a0bb5f921"
      decimals="-3"
      id="F_cb4bdff9-fb01-4b7d-bbe6-d756769315b4"
      unitRef="U_USD">144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_537e54b5-1a9a-4794-ab29-9db563b5fb50"
      decimals="-3"
      id="F_a09cedad-453b-4889-91de-6cb162e3dece"
      unitRef="U_USD">710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_00f55fd7-1fe9-443f-8a1a-565e418119ba"
      decimals="-3"
      id="F_eee9bebc-62df-4061-ad13-bde2ceb15191"
      unitRef="U_USD">715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_13f7f584-8399-4da2-91e1-8a41a35389df"
      unitRef="U_USD">43258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_16adf59a-ebda-40d3-a990-ec9bfa49fec5"
      unitRef="U_USD">31643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_657f9292-c6de-4e94-8117-14f5d361bbc6"
      unitRef="U_USD">21655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_17e919a1-8144-489c-9e6d-db8d495d267d"
      decimals="-6"
      id="F_ba3f181a-2c76-44fd-a7ab-7b6b3f2b492b"
      unitRef="U_USD">20000000</us-gaap:ContractWithCustomerLiability>
    <sln:MilestonePaymentsReceived
      contextRef="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f"
      decimals="INF"
      id="F_1148766b-7084-4762-b17e-66c1d3e23d6f"
      unitRef="U_USD">0</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentsReceived
      contextRef="C_40b17d20-2184-49db-8942-a7eef127d200"
      decimals="-5"
      id="F_2daff004-de8a-4989-b652-b23c5fba45f5"
      unitRef="U_USD">3000000</sln:MilestonePaymentsReceived>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="C_25d05802-ed6f-4b2e-9cc1-86490d680cb6"
      decimals="-5"
      id="F_eedb834e-4bb0-4192-8b91-4e8a5edd0f6f"
      unitRef="U_USD">10000000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_76502e8d-3af9-4b0f-a654-bea5116a3a5f"
      decimals="-5"
      id="F_ea98a4e3-0e85-4d45-9d9f-a3b572b60cef"
      unitRef="U_USD">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e6c9f868-f62a-4111-ba93-f469fcd0d117"
      decimals="-5"
      id="F_4b1a0f13-1222-4405-ba59-849a6198d663"
      unitRef="U_USD">13100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_40b17d20-2184-49db-8942-a7eef127d200"
      decimals="-5"
      id="F_4cb11982-86dd-49df-bd9a-db597cae9e7d"
      unitRef="U_USD">14400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_99e52335-f638-4b2b-ac13-630a9a8f63d1"
      decimals="-6"
      id="F_b3c2d753-841a-408d-a885-41fe83037e6d"
      unitRef="U_USD">20000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_80436ca8-6764-4c9d-a92e-0a804aa65353"
      decimals="-6"
      id="F_8831e39d-715a-4180-bc7f-d6f7016754a3"
      unitRef="U_USD">40000000</us-gaap:ContractWithCustomerLiability>
    <sln:MilestonePaymentsReceived
      contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4"
      decimals="-5"
      id="F_17dab9f6-4e73-49ff-acc9-20b84a7da5fa"
      unitRef="U_USD">10000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentsReceived
      contextRef="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5"
      decimals="-6"
      id="F_c865191f-56b8-409f-a117-0ff2923ad7fb"
      unitRef="U_USD">10000000</sln:MilestonePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_72551dd3-af02-4504-9e64-9506ac75dec4"
      decimals="-5"
      id="F_dd8cda8b-204c-4af3-87a5-6beef9ffd884"
      unitRef="U_USD">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9d07bacc-78ee-4525-abbd-012cbf05e9a5"
      decimals="-5"
      id="F_6bd62dbe-c2c5-417f-80aa-ec705fdab98e"
      unitRef="U_USD">17100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_af8fc429-8807-4280-86d7-4bb3e6b0a403"
      decimals="-5"
      id="F_a4ac726f-0474-4dab-822c-b0396306b326"
      unitRef="U_USD">6300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850"
      decimals="-6"
      id="F_0396b15d-c66a-4f64-9c77-aa2a9f8745ea"
      unitRef="U_USD">16000000</us-gaap:ContractWithCustomerLiability>
    <sln:ContractWithCustomerLiabilityNetOfTax
      contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850"
      decimals="-5"
      id="F_4072c66c-2b73-4730-9c7e-bb80b7e86e6f"
      unitRef="U_USD">14400000</sln:ContractWithCustomerLiabilityNetOfTax>
    <sln:MilestonePaymentsReceived
      contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"
      decimals="-5"
      id="F_1972bef8-fd50-4aaa-b53c-a5b6cfe4823f"
      unitRef="U_USD">2000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentsReceived
      contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0"
      decimals="-5"
      id="F_f22b1f89-d14a-4b9c-8e35-aa55420efbba"
      unitRef="U_USD">4000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentsReceived
      contextRef="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34"
      decimals="-5"
      id="F_0cee058e-bb94-4a49-a0d9-7c78211b3b27"
      unitRef="U_USD">1500000</sln:MilestonePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"
      decimals="-5"
      id="F_8a12c4ed-c6da-48b6-8eb6-77578749b643"
      unitRef="U_USD">24600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0"
      decimals="-5"
      id="F_afd49a1b-1504-427a-a6d7-eaa6e87696ab"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3a9a7e93-3338-45c1-94be-9cbdf2d51d34"
      decimals="-5"
      id="F_d94684de-36ac-4fd8-ad9f-56bb78c4a355"
      unitRef="U_USD">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sln:PercentageOfRoyaltyOnNetSales
      contextRef="C_c8c88df3-dd6e-4dfc-995d-d16e951e1d00"
      decimals="INF"
      id="F_e68d2c69-9ab4-4384-b2d5-6ffb364693de"
      unitRef="U_pure">0.01</sln:PercentageOfRoyaltyOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6aaa0880-d729-425c-8313-d4f3cc099532"
      decimals="-5"
      id="F_a33222a8-e4dd-4034-838d-e1bb053335fa"
      unitRef="U_USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a28de7dc-3a37-4a87-b082-7778b559525a"
      decimals="-5"
      id="F_92a8ba9a-34dd-4181-892f-1124bc89674a"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_67be7eda-a207-4017-be9a-44dc71c47dc1"
      decimals="-5"
      id="F_a11fbb00-f403-450f-b426-38cf449d607d"
      unitRef="U_USD">700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_83e50b3e-e4cb-48c7-953c-a70102b429ce">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. Segment reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_fa405555-b8a0-41d6-bcd0-c5ceffcea501;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;CODM&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reviews Consolidated net loss for the year when assessing the Group&#x2019;s performance, allocating resources and establishing management&#x2019;s compensation. In addition to Consolidated net loss, the CODM receives discrete information for revenue by major customer and geographic location. Consolidated net loss is used to monitor budget versus actual results and is reviewed against the Group&#x2019;s peers and competitors as benchmarking. The Group operates as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reportable segment in the specific technology field of RNA therapeutics.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of its operating segment are the same as those described in the Group&#x2019;s summary of significant accounting policies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group derives revenues from customers through royalty income and research collaboration agreements, each representing a major customer, specifically related to the development of RNAi-based medicines. Refer to Note 3 &#x2013; Revenue for a further description of the types of products from which the Group derives its revenues.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The measure of segment assets is reported on the balance sheet as total consolidated assets.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below provides segment information about the Group:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contracted development costs (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel research and development costs (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other R&amp;amp;D costs (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General &amp;amp; administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items (d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;45,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;54,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;50,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Personnel R&amp;amp;D costs primarily consist of salaries and personnel-related costs for personnel performing R&amp;amp;D activities or managing those activities that have been out-sourced; and consultants&#x2019; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other R&amp;amp;D costs include associated facility costs, equipment and other overheads that are directly attributable to R&amp;amp;D and depreciation of capital assets used for research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(d)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The other segment items include foreign currency gain (loss), net, benefit from R&amp;amp;D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An analysis of the group&#x2019;s assets and revenues by location is shown below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S.A.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.K.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;As at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31,&lt;br/&gt;&#160;&#160;&#160;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_0a86258b-b379-427d-bb4a-51175c4e77f5">The CODM reviews Consolidated net loss for the year when assessing the Group&#x2019;s performance, allocating resources and establishing management&#x2019;s compensation. In addition to Consolidated net loss, the CODM receives discrete information for revenue by major customer and geographic location. Consolidated net loss is used to monitor budget versus actual results and is reviewed against the Group&#x2019;s peers and competitors as benchmarking. The Group operates as one reportable segment in the specific technology field of RNA therapeutics.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_cd48bea2-d733-49be-b7cb-61d150993659"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_10811ab2-8f99-419b-aeb5-c94b6cccb2de">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below provides segment information about the Group:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contracted development costs (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,322&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Personnel research and development costs (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other R&amp;amp;D costs (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,421&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General &amp;amp; administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other segment items (d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;45,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;54,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;50,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contracted development costs primarily consist of costs incurred under agreements with CROs and investigative sites that conduct its preclinical studies and clinical trials; costs related to manufacturing active pharmaceutical ingredients and drug products for its preclinical studies and clinical trials; and costs for materials used for in-house research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(b)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Personnel R&amp;amp;D costs primarily consist of salaries and personnel-related costs for personnel performing R&amp;amp;D activities or managing those activities that have been out-sourced; and consultants&#x2019; costs associated with target selection, preclinical and clinical research activities, and the progression of programs towards clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(c)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other R&amp;amp;D costs include associated facility costs, equipment and other overheads that are directly attributable to R&amp;amp;D and depreciation of capital assets used for research and development activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(d)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The other segment items include foreign currency gain (loss), net, benefit from R&amp;amp;D credit, and other income/ (expense), net inclusive of bank interest receivable and accretion on U.S. Treasury Bills.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d0c1822c-7758-40b0-a9f6-ab703a988bad"
      unitRef="U_USD">43258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_cd36498b-f66e-41e4-a543-b15e4d6b0771"
      unitRef="U_USD">31643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_1f759411-2ffd-4af7-83b8-2aa7a0941df0"
      unitRef="U_USD">21655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_40be5b6d-ca66-4a01-a01c-a70cb0ceaf35"
      unitRef="U_USD">11810000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_17aab1ea-a86f-46e8-a510-75a5b0c76453"
      unitRef="U_USD">12867000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_997091e2-66ee-491f-a63f-d7b14a830b2e"
      unitRef="U_USD">13463000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:BusinessDevelopment
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_2ed5d897-f1d3-4cce-8ce6-be1e14f87908"
      unitRef="U_USD">42902000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_151a73a5-9833-48eb-96b0-8b925ac3cad7"
      unitRef="U_USD">35048000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_950df6ba-4447-4362-bef2-900a8a155706"
      unitRef="U_USD">24322000</us-gaap:BusinessDevelopment>
    <sln:PersonnelResearchAndDevelopmentCosts
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_a6c376b2-cbc0-4aac-9073-00f9be17b3cf"
      unitRef="U_USD">20503000</sln:PersonnelResearchAndDevelopmentCosts>
    <sln:PersonnelResearchAndDevelopmentCosts
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_029f4cbb-757d-4e88-84c2-1e721a8f5166"
      unitRef="U_USD">19468000</sln:PersonnelResearchAndDevelopmentCosts>
    <sln:PersonnelResearchAndDevelopmentCosts
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_dbdf465b-4e61-4a98-9d41-02453b50c480"
      unitRef="U_USD">17187000</sln:PersonnelResearchAndDevelopmentCosts>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_4b3ad048-6347-4722-9c12-2627bf88c679"
      unitRef="U_USD">4478000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_801f3eaa-fbf2-4025-be22-02ee158bd261"
      unitRef="U_USD">2421000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_992f1a7e-0c14-4484-b66f-e9a54bc619d4"
      unitRef="U_USD">2041000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_85dfbdd0-2a7c-46d7-ad4d-c4775fcd3b25"
      unitRef="U_USD">26884000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_a19aae6a-819d-4ae8-a39e-c4c243a2ec29"
      unitRef="U_USD">26222000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_438141c2-6a35-466a-a2cd-733b4fa8d059"
      unitRef="U_USD">25682000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_a018856f-39ec-4936-a7d7-5253eb987d35"
      unitRef="U_USD">845000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_2d348d52-f1c6-48fe-8adb-8aad2f7d5fd2"
      unitRef="U_USD">956000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_472df5b6-918a-46d2-950f-d2ba7bf45f83"
      unitRef="U_USD">688000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_63a4bbb1-7faa-4594-aabd-a0117abf4f29"
      unitRef="U_USD">-18855000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_da33f6f7-e3d1-4630-aaab-3605b2e166ef"
      unitRef="U_USD">-11111000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_f53758e8-e8ee-4192-bb15-59749d5cc4c8"
      unitRef="U_USD">-11394000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_fdd7ecaf-0861-471b-8443-f7c827992629"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_dcfed922-0896-45f5-aa7e-641347067582"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_6b1ae6cd-d4aa-41e5-9bff-b87c1233e536"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_b9f47298-b3d1-4f9a-a46f-68ebd16f95a8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;An analysis of the group&#x2019;s assets and revenues by location is shown below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S.A.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.K.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Germany&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;As at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;As at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue analysis for the year ended December 31,&lt;br/&gt;&#160;&#160;&#160;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research collaboration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;43,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:AssetsNoncurrent
      contextRef="C_2e144a57-0ddb-4baf-a9c3-2a52f32e07bc"
      decimals="-3"
      id="F_21f39027-f4ae-4c62-9f2c-e5877baa02c5"
      unitRef="U_USD">4467000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_b8115894-8913-43eb-9042-ef3fc8f7d112"
      decimals="-3"
      id="F_2c1a40b9-c543-46c9-88bf-3488af2c3f36"
      unitRef="U_USD">11831000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_c5cabd21-99c5-46c9-ae03-5a81751b5305"
      unitRef="U_USD">16298000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_6d523cee-aad8-4ece-86d0-cf54c441dc67"
      decimals="-3"
      id="F_1f0c31db-fdbd-48f2-839c-2e701166742a"
      unitRef="U_USD">4103000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_8cda337c-0dec-4a91-83cb-e2a5eab87ddd"
      decimals="-3"
      id="F_8ff557a2-1573-4a46-9e4c-8ecaeb828cb6"
      unitRef="U_USD">11166000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_9c5ca09b-bd04-44a8-8e8e-a4567a875b5c"
      unitRef="U_USD">15269000</us-gaap:AssetsNoncurrent>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7"
      decimals="-3"
      id="F_4c632918-4242-4371-affb-91ff05055dfb"
      unitRef="U_USD">20940000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_bd679cde-bf3b-4750-b8e1-9767feffc534"
      unitRef="U_USD">20940000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromRoyalties
      contextRef="C_c74d2467-009d-495a-bebc-222cee797f05"
      decimals="-3"
      id="F_0d3a9a68-1a90-4dd4-9aa7-ed2287a76337"
      unitRef="U_USD">715000</sln:RevenueFromRoyalties>
    <sln:RevenueFromRoyalties
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_c8d08ea7-913c-4fa5-b76c-bd27fdd423fd"
      unitRef="U_USD">715000</sln:RevenueFromRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ac1267fa-62cd-4592-bcfa-229b63cffbe7"
      decimals="-3"
      id="F_af51d196-bb5c-4253-a7f4-6448957ff9a2"
      unitRef="U_USD">20940000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c74d2467-009d-495a-bebc-222cee797f05"
      decimals="-3"
      id="F_24b7fa77-c439-47e5-8b4d-d5955628cf54"
      unitRef="U_USD">715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_c18e337e-3079-439d-a93c-3d607d84fd24"
      unitRef="U_USD">21655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_95a23c91-e275-4694-9a2b-078f6e447589"
      decimals="-3"
      id="F_8fd18fd3-ea87-458a-8509-14dec665dc18"
      unitRef="U_USD">30934000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_30c6fc0b-e894-474f-8a03-cd92306933ca"
      unitRef="U_USD">30934000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromRoyalties
      contextRef="C_193e7dca-2118-430b-a24c-39a8be8f2ec5"
      decimals="-3"
      id="F_dd6d5e57-3d44-471d-ac2a-92cf3af9040c"
      unitRef="U_USD">709000</sln:RevenueFromRoyalties>
    <sln:RevenueFromRoyalties
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_357d358d-f98e-4e28-9579-3db9199c9fe7"
      unitRef="U_USD">709000</sln:RevenueFromRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_95a23c91-e275-4694-9a2b-078f6e447589"
      decimals="-3"
      id="F_86345829-4c8f-462a-92a5-4897aead0c3b"
      unitRef="U_USD">30934000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_193e7dca-2118-430b-a24c-39a8be8f2ec5"
      decimals="-3"
      id="F_9ced3a16-57dd-4c33-be18-53d8476a1a9b"
      unitRef="U_USD">709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1a097bf4-826b-429d-a439-b816aee4b267"
      unitRef="U_USD">31643000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_4a556b23-31fe-49a9-90a3-49e389ec6b48"
      decimals="-3"
      id="F_26837512-58c1-4b75-91b3-48fe0f87ebdb"
      unitRef="U_USD">43114000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromContractWithCustomerResearchCollaboration
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d80a3404-094e-402c-a80d-b28b14c28d73"
      unitRef="U_USD">43114000</sln:RevenueFromContractWithCustomerResearchCollaboration>
    <sln:RevenueFromRoyalties
      contextRef="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8"
      decimals="-3"
      id="F_523c4f06-634a-4764-98fa-08818088e11c"
      unitRef="U_USD">144000</sln:RevenueFromRoyalties>
    <sln:RevenueFromRoyalties
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_41ec6126-fe50-4cc9-9dc7-8050adc6a28c"
      unitRef="U_USD">144000</sln:RevenueFromRoyalties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4a556b23-31fe-49a9-90a3-49e389ec6b48"
      decimals="-3"
      id="F_c566bb76-2ade-471f-a230-9de4e896a4c2"
      unitRef="U_USD">43114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0cae454a-bf7d-4c1e-a3ae-45a10ab091a8"
      decimals="-3"
      id="F_7250f64d-854d-49fd-a7a3-25e76b6e81a7"
      unitRef="U_USD">144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_e8c92648-0469-486e-b1dc-6699b99f7e44"
      unitRef="U_USD">43258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sln:DirectorsAndEmployeeRemunerationTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_df35884c-e688-4b62-9d8c-fc8404ac71e9">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. Directors and staff costs&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Staff costs, including Directors&#x2019; remuneration, during the year for the Group were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other pension costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payments charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total aggregate remuneration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;38,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;37,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;33,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</sln:DirectorsAndEmployeeRemunerationTextBlock>
    <sln:DirectorsAndEmployeeRemunerationTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3d52df96-08c5-4c74-b9a0-11f226c56fb7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Staff costs, including Directors&#x2019; remuneration, during the year for the Group were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Wages and salaries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,774&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other pension costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payments charge&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total aggregate remuneration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;38,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;37,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;33,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sln:DirectorsAndEmployeeRemunerationTableTextBlock>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_0db961ee-71a7-45f4-9a2d-a9972c068363"
      unitRef="U_USD">19434000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_6354bc47-fb22-47c1-9429-cfe49364b27f"
      unitRef="U_USD">19158000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_0dcf95ad-6d95-4232-9688-ff3cee7a61ef"
      unitRef="U_USD">18264000</us-gaap:SalariesWagesAndOfficersCompensation>
    <sln:SocialSecurityCosts
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_4893a2ca-1f06-4e47-81f8-8681fbcde302"
      unitRef="U_USD">1744000</sln:SocialSecurityCosts>
    <sln:SocialSecurityCosts
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_bb365f8f-9086-4fb7-94a0-d1b19eb76061"
      unitRef="U_USD">1901000</sln:SocialSecurityCosts>
    <sln:SocialSecurityCosts
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_46328cd7-a58e-46f4-8f3b-519d738c28b0"
      unitRef="U_USD">1774000</sln:SocialSecurityCosts>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d1c4ba11-db57-4130-ade4-e4fc9fb96821"
      unitRef="U_USD">666000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1c853cfc-76f8-4301-ad3e-36d20fc2c666"
      unitRef="U_USD">609000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:PostemploymentBenefitsPeriodExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_cead5b5c-fce5-4560-bced-e5f4f1966812"
      unitRef="U_USD">531000</us-gaap:PostemploymentBenefitsPeriodExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d6e56222-3159-4c67-aeb2-e280ff465def"
      unitRef="U_USD">16307000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_fa6da419-9d6d-42e9-9c27-bd441119450c"
      unitRef="U_USD">16274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_453baa39-58f7-430c-aafd-b64b3bc9a0c0"
      unitRef="U_USD">12686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sln:AggregateRemuneration
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_098e5947-f5b2-4a5b-a6ff-4c9da2096ef0"
      unitRef="U_USD">38151000</sln:AggregateRemuneration>
    <sln:AggregateRemuneration
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_a9e074eb-47ae-4187-b084-6bea59512937"
      unitRef="U_USD">37942000</sln:AggregateRemuneration>
    <sln:AggregateRemuneration
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_85b3a556-c7a1-4036-b366-4f8ac0ee8892"
      unitRef="U_USD">33255000</sln:AggregateRemuneration>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_1fc23923-f680-42eb-8a55-1c44a4ef45a0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. Other income/(expense), net&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bank interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion on U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_53092b32-42d7-4e9c-b174-245750c9f156">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bank interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accretion on U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,720&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;4,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <sln:BankInterestReceivable
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_34192e61-ebe2-479d-aeda-30909f9079d6"
      unitRef="U_USD">704000</sln:BankInterestReceivable>
    <sln:BankInterestReceivable
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_c4af68bd-e390-4a56-841a-e5e1a8913b16"
      unitRef="U_USD">83000</sln:BankInterestReceivable>
    <sln:BankInterestReceivable
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_a56fcff1-c096-4cc8-b8c5-f9afa2efb194"
      unitRef="U_USD">29000</sln:BankInterestReceivable>
    <sln:AccretionOfSecurities
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_9cca0c38-93b1-4eb9-b198-b2881a5e43b7"
      unitRef="U_USD">3768000</sln:AccretionOfSecurities>
    <sln:AccretionOfSecurities
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_f9891e85-54d6-481a-9f93-8103e631886d"
      unitRef="U_USD">1720000</sln:AccretionOfSecurities>
    <sln:AccretionOfSecurities
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_e448d44d-f8a3-438c-b7f4-9d4295919b6c"
      unitRef="U_USD">251000</sln:AccretionOfSecurities>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_60f1856a-bd7a-462c-87a8-4abfef7cda71"
      unitRef="U_USD">4472000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_7e892f9e-714b-442d-9411-49cac942d2ce"
      unitRef="U_USD">1803000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_0aaa8701-3edb-4649-a998-ada7158f5309"
      unitRef="U_USD">280000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_178d3eaf-8caa-40c6-8d11-6888575590ac">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. Loss per share (basic and diluted)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing net loss (the numerator) by the weighted average shares outstanding for the period (the denominator). Diluted net loss per share is computed by dividing net income by the weighted average shares outstanding during the period adjusted for the dilutive effects of the exercise of the stock options. In periods when losses from continuing operations are reported, the weighted-average shares outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The computation of net loss per share for the years ended December 31, 2024, 2023 and 2022, respectively was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares outstanding (basic and diluted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,752,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,277,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,584,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share (basic and diluted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Potentially Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,455,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,853,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,571,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_319362a9-55c9-4f0b-a13b-0a560be6c0cf">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The computation of net loss per share for the years ended December 31, 2024, 2023 and 2022, respectively was as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.040000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares outstanding (basic and diluted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;138,752,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;111,277,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,584,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss per share (basic and diluted)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_cd126128-3052-4f5a-a037-418a3fc49433"
      unitRef="U_USD">-45309000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_e0ddf6c2-82f2-4db2-b098-ec6d20bbc10d"
      unitRef="U_USD">-54228000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_b8ea20c7-469b-4b35-aebb-c72f1a4ca019"
      unitRef="U_USD">-50334000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_23af2cea-c57f-43a5-a659-c16b265a1de9"
      unitRef="U_shares">138752224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_6cf70a9c-19ae-4304-9224-9d76265f99bd"
      unitRef="U_shares">138752224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="0"
      id="F_3ba623df-da37-4197-98a1-e7df2cb4a078"
      unitRef="U_shares">111277250</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="0"
      id="F_f4855dc1-323d-413d-a691-3c0dd0eef10d"
      unitRef="U_shares">111277250</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="0"
      id="F_64556d71-97ab-44bc-848c-145e53519387"
      unitRef="U_shares">96584512</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="0"
      id="F_7ad5728e-9918-48d8-9ca6-f4586ecd1344"
      unitRef="U_shares">96584512</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="2"
      id="F_bda6a63d-67ae-4c98-a008-938e08e71917"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="2"
      id="F_b23bcbfc-c5d3-4d37-9735-a1ea1a57a492"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="2"
      id="F_81d2de6c-126d-4fdf-bdd3-1d071bf5f58e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="2"
      id="F_c9f76d3a-7b81-41d0-90c8-cadcf05e708d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="2"
      id="F_92b525da-a40d-4b1e-9cff-6faa1903d4a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.52</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="2"
      id="F_75537514-8605-4eeb-9bcf-85a90738698d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_286cf21f-2c95-4a24-8b36-82f023c04e1b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share because their impact would have been anti-dilutive for the period presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.52%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Potentially Dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,455,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,853,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,571,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_dd7a71f6-d4fb-4855-84db-1eba17d52e0b"
      unitRef="U_shares">17455390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="0"
      id="F_cabdcdd3-bcf4-49dd-a17e-049ec9037eeb"
      unitRef="U_shares">15853459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="0"
      id="F_39f8a5b7-e322-499d-9948-fbafeeffbe6a"
      unitRef="U_shares">11571487</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_48883b26-b200-4530-b957-a9dd25a806ae">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant, and equipment balances were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equipment &amp;amp; Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized in fiscal years 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_094bb875-0f0e-44e2-a315-3551c01d6ffa">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property, plant, and equipment balances were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equipment &amp;amp; Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Property, plant, and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_8f793ddc-c01f-47e9-95b1-cdd564af0f71"
      unitRef="U_USD">6343000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_1e596af4-689f-48c8-bcc0-6ea978f623f5"
      unitRef="U_USD">6436000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_1617ada5-b858-4b66-b21e-8bbda63e9599"
      unitRef="U_USD">4525000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_0174e389-7b0b-4017-9387-2ac69ace4662"
      unitRef="U_USD">4498000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_1d922455-dce7-46ed-a9b3-1821cb0ac518"
      unitRef="U_USD">1818000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_cf92625a-50dd-4db2-b188-1761df0f22c1"
      unitRef="U_USD">1938000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_ad8833bc-8b86-4673-b77d-4db0a93fe7c1"
      unitRef="U_USD">300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-5"
      id="F_4dd47f6a-9d99-41ec-98ea-fd9c9e2d2b02"
      unitRef="U_USD">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-5"
      id="F_16354d26-7e48-401c-816d-2022d53b95c5"
      unitRef="U_USD">400000</us-gaap:Depreciation>
    <us-gaap:GoodwillDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_d56e1c4f-f5dd-4abe-8bd3-4614ffa04ba4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill is assessed annually at a reporting unit level, or whenever events and circumstances indicate impairment may have occurred. The Group has one reporting unit and performs a qualitative impairment test (also known as &#x201c;Step 0"), and when necessary, a quantitative test. After assessing the totality of events and circumstances as part of the Step 0 test, it was determined that it is not more likely than not (a likelihood that is more than 50%) that the fair value of the reporting unit is less than its carrying amount and therefore a quantitative test is unnecessary. No triggering events were identified during the year.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at start of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Translation adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_e6c43e52-b94f-4e21-98fb-6716ab5e2e2a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the changes in the carrying amount of goodwill:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at start of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Translation adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;9,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_46503387-8164-43dd-a2bd-eac4118be16a"
      unitRef="U_USD">9981000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_e9f3f78d-c453-4ac0-9f6c-9a3c08471138"
      unitRef="U_USD">9683000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_b44ba554-8433-4507-b95d-89593d90972a"
      unitRef="U_USD">-589000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_3935dbf7-3d68-4a78-9d00-168f966dd37e"
      unitRef="U_USD">298000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_4dab10bb-07f8-48ff-8aa9-98f1f9b4f5f3"
      unitRef="U_USD">9392000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_9261b033-066d-48a3-80b2-d7a471471c9b"
      unitRef="U_USD">9981000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_83a3f959-2ae6-40ea-a977-ef5296fbce74">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. Other intangible assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.451%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and software, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The intangible assets are amortized beginning from the date of acquisition, over their useful life or written down if they are considered to be impaired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amortization expense is included in General and administrative expenses, which included on the consolidated statements of income (loss), and was nominal for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected future amortization expense is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:48.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expected Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; impairment charges related to intangible assets were recorded for the years ended December 31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_4b1b713b-0549-4a1c-808e-706b6eca3645">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets as of December 31, 2024 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.451%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:17.077%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.017%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;169&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;License and software, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143"
      decimals="-3"
      id="F_36285826-5b3a-4bdc-9047-c895ad3acc6a"
      unitRef="U_USD">481000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6"
      decimals="-3"
      id="F_f315bde4-447a-4e9e-badd-0c63c2034189"
      unitRef="U_USD">547000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143"
      decimals="-3"
      id="F_e9e7c87a-4c2e-408b-ab8d-8dbc77968753"
      unitRef="U_USD">169000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6"
      decimals="-3"
      id="F_3c6dde8f-f969-48d0-b82a-23a3379a7192"
      unitRef="U_USD">185000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_54139503-e7ec-49a7-a8d0-b3b2dfcc5143"
      decimals="-3"
      id="F_490f3c38-3c45-447e-8b98-d8ea80f5fcb0"
      unitRef="U_USD">312000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_73d8c6ba-016e-4146-8301-8194bdf092a6"
      decimals="-3"
      id="F_6d8d56b8-5ad6-45f4-b562-bdc74be40085"
      unitRef="U_USD">362000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_747eb9d1-fa25-4079-a7cd-3b95ad2a36f6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected future amortization expense is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:48.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Expected Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_78214a1b-5028-4ded-ad97-6b29934ada06"
      unitRef="U_USD">45000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_05943c7f-0b45-4c33-ab45-60089c2415d8"
      unitRef="U_USD">45000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_3a47b450-40c0-4bff-9d04-38ba9b07dd81"
      unitRef="U_USD">40000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_6422589d-68a5-4471-a88f-940226df93f1"
      unitRef="U_USD">40000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_85435901-f8ef-46e3-96c6-29dd29446355"
      unitRef="U_USD">40000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_5f19bb86-3e3f-4e64-8e0a-fe70ce8c3dd1"
      unitRef="U_USD">102000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_af4a5032-0a81-4131-9d11-4a83097f13af"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_bfddf3eb-7194-4044-aba2-3e25007538b7"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_887b0d58-a902-496a-9812-fcb9ea225558"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_2d979015-a314-4a9b-8c04-44b7a3e85af3">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash at bank and in hand&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;121,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;68,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cash at bank comprises balances held by the Group in current, short-term bank deposits, and U.S. Treasury Bills with an original maturity of three months or less. The carrying amount of these assets approximates to their fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_1e7030e8-8f89-4217-ac28-9c50b13877d4">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash at bank and in hand&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,819&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;US Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;121,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;68,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndDueFromBanks
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_49b1c797-68bb-49d7-9535-0c4e8b34c33f"
      unitRef="U_USD">56590000</us-gaap:CashAndDueFromBanks>
    <us-gaap:CashAndDueFromBanks
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_117052b5-148c-4417-89d9-43c0676e78ca"
      unitRef="U_USD">31819000</us-gaap:CashAndDueFromBanks>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_51e57a05-248a-461c-830c-4c9dd7f5667e"
      unitRef="U_USD">64740000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_015a3425-3b7c-48be-873e-db1ddb94a211"
      unitRef="U_USD">36970000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_3948324c-9f11-47e4-b0e8-b408b4f588bc"
      unitRef="U_USD">121330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_1e7dfbec-db89-4eb3-8d15-14622ac89059"
      unitRef="U_USD">68789000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6dd7ed1a-3008-41b9-ace9-0560f33c94ed">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. Other assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;VAT receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deposits for properties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024 and 2023, the largest component of prepayments are prepaid third party costs for clinical trials, as well as manufacturing for clinical supplies and associated development, and pre-clinical studies which fluctuate based on timing of payments and related expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included within prepayments at December 31, 2024 and 2023 is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million respectively, are expenditures relating to research and development.&lt;/span&gt;&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_78d6535f-5887-4d03-bd73-afb4ee02b1d2">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.76%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;VAT receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;14,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;11,630&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deposits for properties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepayments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,234&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other long-term assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,590&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <sln:PrepaymentsAssetsCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_d909e679-427b-400a-a305-e90f42969fa9"
      unitRef="U_USD">13124000</sln:PrepaymentsAssetsCurrent>
    <sln:PrepaymentsAssetsCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_c8850a48-c635-445a-a891-1f9c06613fde"
      unitRef="U_USD">10385000</sln:PrepaymentsAssetsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_45897bf8-4d6d-431e-9979-6b362fbbb7e6"
      unitRef="U_USD">1540000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_c6397b8b-b947-4b44-a028-a74c5c896b5d"
      unitRef="U_USD">1245000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_dfd3b2db-f281-49de-8183-1fc7fcd21b52"
      unitRef="U_USD">14664000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_b3c36774-1f8c-4935-84d2-32dc98f7afc8"
      unitRef="U_USD">11630000</us-gaap:OtherAssetsCurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_3ed92d00-15e5-4aa8-af39-1c30115b52e1"
      unitRef="U_USD">356000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_fa952ac1-26a9-4c60-93de-87b48682d4bb"
      unitRef="U_USD">362000</us-gaap:DepositsAssetsNoncurrent>
    <sln:PrepaymentsAssetsNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_d532dbbd-8abd-4c87-a4df-b608fbff2c9c"
      unitRef="U_USD">3234000</sln:PrepaymentsAssetsNoncurrent>
    <sln:PrepaymentsAssetsNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_e5904c15-269f-4f2b-ab61-8f1ee1881ff5"
      unitRef="U_USD">3284000</sln:PrepaymentsAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_2f149ff3-acfa-49f5-a5f9-a6fb64bd2700"
      unitRef="U_USD">3590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_d70ae540-829d-4535-a6cd-ce3885f9478f"
      unitRef="U_USD">3646000</us-gaap:OtherAssetsNoncurrent>
    <sln:PrepaymentsAssets
      contextRef="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19"
      decimals="-5"
      id="F_569ebf76-2e64-41f4-9908-295a70d7de33"
      unitRef="U_USD">11000000</sln:PrepaymentsAssets>
    <sln:PrepaymentsAssets
      contextRef="C_1aed09de-bc50-4e87-9680-f6533b6e32a6"
      decimals="-5"
      id="F_bf96ed83-5844-4804-abbc-2dd97617e52d"
      unitRef="U_USD">8700000</sln:PrepaymentsAssets>
    <sln:AccountsReceivableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_aac79947-5e58-4662-9946-4c01b619485a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Directors consider that the carrying amount of trade receivables approximates to their fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No interest is charged on outstanding receivables. There were no overdue trade receivables balances.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has applied an expected credit loss model to the balance and determined that &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowance is required for the periods ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;</sln:AccountsReceivableTextBlock>
    <sln:ScheduleOfAccountsReceivableTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_068b9ed5-0d51-4df8-91af-50df5fd623b5">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sln:ScheduleOfAccountsReceivableTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_978c1b5a-f08e-44df-af22-013653a97e48"
      unitRef="U_USD">972000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_e80ef37e-bbce-44ff-9526-0528d43c7776"
      unitRef="U_USD">290000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_9db6a867-df2f-4023-960a-69a8f1e62f04"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_b8f1c3e2-60f3-443f-9a2e-b9e941cd00cf"
      unitRef="U_USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_33d7da59-d1d0-431b-8918-aadfb4e3c710">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security and other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bonus accrual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate income tax payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;16,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Directors consider that the carrying amount of trade and other payables approximates to their fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included within accruals and other payables at December 31, 2024 a&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nd 2023 is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; respectively, are expenditures relating to research and development&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_de00a1a8-55db-4d3e-b62c-6273fd506314">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Social security and other taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Bonus accrual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,134&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate income tax payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;16,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,537&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_faea8a00-f855-4269-9de7-109f1fd14c64"
      unitRef="U_USD">3697000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_c0ec4651-3fe2-47b1-8359-61670ef395ca"
      unitRef="U_USD">3348000</us-gaap:AccountsPayableTradeCurrent>
    <sln:SocialSecurityAndOtherTaxesPayableCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_a5e94b60-2e8a-4aa9-8e2f-15e166d690d7"
      unitRef="U_USD">244000</sln:SocialSecurityAndOtherTaxesPayableCurrent>
    <sln:SocialSecurityAndOtherTaxesPayableCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_84d47691-52f7-4905-93bd-f274e87aaeeb"
      unitRef="U_USD">734000</sln:SocialSecurityAndOtherTaxesPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_4e59034a-dd69-4dde-b097-5f14c8cd1b6a"
      unitRef="U_USD">8361000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_d15b6407-bc08-40c6-a48f-cf725e6ad8f6"
      unitRef="U_USD">7847000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_22521970-f790-4a5a-b0a1-50370ddae33c"
      unitRef="U_USD">3445000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_5384962c-8148-4e13-99e6-bf428d2c9535"
      unitRef="U_USD">3134000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_b15a0b56-0f52-4e5d-b8db-0131d1e2e189"
      unitRef="U_USD">652000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_3fcb7413-254f-4bed-be16-d16fd06160bb"
      unitRef="U_USD">474000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_89e46409-23bc-4024-ab47-e253f064184f"
      unitRef="U_USD">16399000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_7a562dd1-80b7-4734-adc7-a9e8f2b0a1d9"
      unitRef="U_USD">15537000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_81c24346-1f04-45a3-900d-ddb8e8aa6c19"
      decimals="-5"
      id="F_6cfdb3b3-e635-454d-98c2-214190aac987"
      unitRef="U_USD">5900000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_1aed09de-bc50-4e87-9680-f6533b6e32a6"
      decimals="-5"
      id="F_3b9b3b99-24c6-4c26-9945-6cc80826e827"
      unitRef="U_USD">5600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_5acb5ab9-39cd-4b49-9fb5-b5de7ecc4708">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating lease for office space in London, which was renegotiated upon completion of the original term, with the new term beginning in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Group determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Group recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Group&#x2019;s right to use the underlying asset for the lease term. Lease liabilities are the Group&#x2019;s obligation to make the lease payments arising from a lease. As the Group&#x2019;s lease does not provide an implicit rate, the Group&#x2019;s lease liabilities are measured on a discounted basis using the Group&#x2019;s incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There are &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; short-term leases in Berlin, Germany and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;eight&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; leases in Hoboken, U.S., that have not been recognized as right-of-use assets. Both leases in Berlin are on a rolling contract basis with either party being able to end the lease with a cancellation notice period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months, while the leases in the United States are on a rolling contract basis with a notice period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Expense related to these short-term leases are recorded to the consolidated statements of income (loss) over the lease term.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents supplemental balance sheet information related to the Group&#x2019;s operating lease:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:28.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability - current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability - non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Group&#x2019;s operating leases at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturities of the Group&#x2019;s operating leases at December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:31.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total expected lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sln:NumberOfOperatingLease
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_34591838-a703-41b9-8821-8eb160cdaaeb"
      unitRef="U_Lease">1</sln:NumberOfOperatingLease>
    <sln:OperatingLeaseNewTermBeginningPeriod
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_bb29405c-0b00-4088-b4f0-69bc041f4ab0">2022-09</sln:OperatingLeaseNewTermBeginningPeriod>
    <sln:NumberOfShortTermLeases
      contextRef="C_cc4a6675-6368-4274-a498-7a1407627000"
      decimals="INF"
      id="F_0619db50-b86b-47c5-904a-72cf1034956c"
      unitRef="U_Lease">2</sln:NumberOfShortTermLeases>
    <sln:NumberOfLeases
      contextRef="C_edac0d25-e5fa-43db-9447-72b4778d22a3"
      decimals="INF"
      id="F_047abed3-a636-49e9-b085-37b1e7326606"
      unitRef="U_Lease">8</sln:NumberOfLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_196e5e80-6700-4ee5-83ef-dbd0df792f21"
      id="F_f12b097c-c546-4dbb-9333-bcaa4571ebca">P11M15D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_c1fd8902-0499-4006-8b7a-f16708af1815"
      id="F_c9eda33a-c41c-4f3b-bdf8-f0665004dcc6">P3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sln:SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_adea3861-a285-4c8f-983f-969af54d7740">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents supplemental balance sheet information related to the Group&#x2019;s operating lease:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.7%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:28.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability - current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liability - non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sln:SupplementalBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_bf1c7359-bb32-4a8d-badb-2cb431cb5055"
      unitRef="U_USD">157000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_50b64087-5132-4f4a-85cf-4069847c2768"
      unitRef="U_USD">370000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_dcb3af80-f943-4f97-8841-f97516789490"
      unitRef="U_USD">117000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_932e8406-69e8-4cba-87ea-559ad17187fe"
      unitRef="U_USD">228000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_ae33b6df-8fd8-4f4c-a7c7-2117067703a0"
      unitRef="U_USD">118000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <sln:OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8fe48b28-2976-4613-bf4e-d5f81e6b0c51">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Group&#x2019;s operating leases at December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.883%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</sln:OperatingLeaseWeightedAverageRemainingLeaseTermAndWeightedAverageDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      id="F_4c848435-53a1-4b6b-b0e1-0b7c0f250acd">P0Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      id="F_41d5ee42-643c-45df-be1a-07db63b1a462">P1Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="3"
      id="F_5512b6c6-d2e9-4d9e-8034-8fda007eb2d0"
      unitRef="U_pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="3"
      id="F_78845f92-b070-43bb-a8a4-f5240988c948"
      unitRef="U_pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_856d7e64-c47b-44fa-b68d-e89877ff1e5c">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the components of total operating lease cost for fiscal year 2024, 2023, and 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;842&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_061ef0aa-a677-41b5-8446-f35854526647"
      unitRef="U_USD">248000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_432f0dcd-0339-4aed-bb18-b4f6a29a43de"
      unitRef="U_USD">242000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_059597a7-911a-462f-b156-b47e85fb50e0"
      unitRef="U_USD">80000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_9744cda3-b763-43be-b6ef-bb9c46d80676"
      unitRef="U_USD">736000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_a83f8322-df82-443c-896f-70625a8ab346"
      unitRef="U_USD">600000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_17c83cdf-7963-4a8e-bdb8-6459517012af"
      unitRef="U_USD">507000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_36c60df7-e241-4d5a-afe0-b1cac9a7208c"
      unitRef="U_USD">984000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1579900a-f119-4771-953d-9b08165d5f98"
      unitRef="U_USD">842000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_372e8425-8127-4bae-a22f-444d5e22de4c"
      unitRef="U_USD">587000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_c3dba137-f0ec-466a-8aa4-7e6ecf203c97">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the maturities of the Group&#x2019;s operating leases at December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.18%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:31.44%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fiscal year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total expected lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_bd58e4ec-0445-4894-873e-54c4d317099f"
      unitRef="U_USD">117000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_62e2f3cc-28cf-4af3-95dc-e8b22045d00d"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_8979070a-c701-40ca-90fb-057d3768f253"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_86ab66bd-da9c-45d5-aad7-0b188d270b08"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_0fe7e48f-27f1-4dcd-83a6-7cffe44d2796"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_1a6d82ad-9619-4828-b903-40d726638505"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_2cb485a7-2d40-45ba-9c5a-82b17f52ee7c"
      unitRef="U_USD">117000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_996a5b03-dd91-4bc8-92e9-1494cb11ce7e"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_8af69c6d-de14-4159-a786-f28a1bc40f15"
      unitRef="U_USD">117000</us-gaap:OperatingLeaseLiability>
    <sln:ContractWithCustomerLiabilityTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8c96db42-f01d-466f-9b64-138086d46d49">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. Contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities represent the Group&#x2019;s obligation to transfer services to a customer for which the Group has received advanced consideration, before the performance obligation has been satisfied. These liabilities are recognized when a customer prepays for services or when the Group has an unconditional right to consideration before the performance obligation is fulfilled.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities comprise entirely of advance consideration received from customers (deferred revenue) in respect of the Mallinckrodt, AstraZeneca plc, and Hansoh research collaborations. The current contract liabilities represent the amount of estimated revenue to be reported in the next 12 months related to amounts invoiced to its partners, while the non-current portion represents everything beyond 12 months. Current and non-current contract liabilities include future revenue from collaboration recharged expenses, upfront payments, and milestones achieved to December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;At January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions during period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue unwound during period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024 and 2023 contract liabilities decreased primarily due to the recognition of revenue in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, that was included in the contract liabilities balance at the beginning of the year.&lt;/span&gt;&lt;/p&gt;</sln:ContractWithCustomerLiabilityTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_c0d86e13-4ab4-4587-8f2a-54d04f91b403">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,571&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total contract liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contract liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;At January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;87,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Additions during period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue unwound during period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;52,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;81,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_faaebc17-0046-42cd-9480-0d57e4b1a7bf"
      unitRef="U_USD">306000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_03948d5c-5474-4e8b-a63b-9d17d5be0af2"
      unitRef="U_USD">6571000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_5a379158-57f0-4e3f-9a3d-97d01e8f2b06"
      unitRef="U_USD">51790000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_2459ed9c-623e-4ad1-9c2f-ca60dafb5f41"
      unitRef="U_USD">75001000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_142e57bb-8c72-4e6e-b111-f63abd303638"
      unitRef="U_USD">52096000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_ce86ed23-b2c7-4a2d-8859-ca49bb99c7de"
      unitRef="U_USD">81572000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_53733a8b-f92f-4e74-a224-5eef8d79bcba"
      unitRef="U_USD">81572000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_07b37100-835b-4333-89ce-d62d12148224"
      unitRef="U_USD">87467000</us-gaap:ContractWithCustomerLiability>
    <sln:ContractWithCustomerLiabilityForeignExchangeImpact
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_b97ef2f8-39fe-4926-8a68-2eb91efe520c"
      unitRef="U_USD">-691000</sln:ContractWithCustomerLiabilityForeignExchangeImpact>
    <sln:ContractWithCustomerLiabilityForeignExchangeImpact
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_93042e9d-9e69-44e7-903c-0bf3a7dc4f7e"
      unitRef="U_USD">4428000</sln:ContractWithCustomerLiabilityForeignExchangeImpact>
    <sln:ContractWithCustomerLiabilityAdditions
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_51065678-1108-4aa2-b0df-b3371317fb84"
      unitRef="U_USD">14328000</sln:ContractWithCustomerLiabilityAdditions>
    <sln:ContractWithCustomerLiabilityAdditions
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_80e52d6e-6d4b-4e97-afdf-89156379b3d3"
      unitRef="U_USD">20611000</sln:ContractWithCustomerLiabilityAdditions>
    <sln:ContractWithCustomerLiabilityRevenueUnwound
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_83636b50-f315-4057-a281-c387bfce9dbe"
      unitRef="U_USD">43113000</sln:ContractWithCustomerLiabilityRevenueUnwound>
    <sln:ContractWithCustomerLiabilityRevenueUnwound
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_4fb6ddd0-9c6d-431b-a972-f67ec3347ede"
      unitRef="U_USD">30934000</sln:ContractWithCustomerLiabilityRevenueUnwound>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_bea01076-0255-4ae4-8dae-512062b9023c"
      unitRef="U_USD">52096000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_d3d0aeaf-7532-44da-8c5f-fc19db33357e"
      unitRef="U_USD">81572000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_c72b6cf7-2dcf-48e9-9974-04a39ead2d7c"
      unitRef="U_USD">43100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-5"
      id="F_8752c915-1454-4912-a3f4-f7b33e59c1a9"
      unitRef="U_USD">30900000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ef5e8981-faf1-42fe-acf6-82ce54d5c0f6">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;17. Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;he Group operates in the U.K. and is subject to income taxes in that jurisdiction. The U.K. tax rate applied for 2024 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for 2023), which results from applying the enacted statutory rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from January 1, 2023 through April 1, 2023, and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for the remainder of 2023 and 2024. U.K. deferred tax assets and liabilities have been measured at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The entire tax expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million relates to current tax as shown below. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; deferred tax was recognized in the year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.611%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.062%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Current Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in estimate related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Origination and reversal of temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of previously unrecognized tax losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of previously unrecognized tax losses (derecognition of&lt;br/&gt;&#160;&#160;&#160;previously recognized) deductible temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Taxation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of the income tax credit at standard rate of U.K. corporation tax to the current tax credit are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit at the standard rate of U.K. corporation tax of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;br/&gt;&#160;&#160;&#160;(2023: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%; 2022: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income not taxable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment in respect of prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the standard U.K. statutory income tax rate to the effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax using U.K. statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income not taxable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment in respect of prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate for loss from continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t have any deferred tax liabilities as at December 31, 2024 and 2023. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Components of the Group&#x2019;s deferred tax assets as at December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trading Losses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capital losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included i&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n trading losses is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of accumulated tax losses as of December 31, 2024 ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2023) related to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;its &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operations in Germany for corporate income taxes and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of accumulated losses related to trade taxes in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;its &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;German entity ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of Decem&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ber 31, 2023).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Movements in deferred tax valuation allowance:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(Decrease)/increase in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Management has reviewed cumulative tax losses and projections of future taxable losses and determined that it is not more likely than not that they will be realized. Accordingly, valuation allowances have been provided over deferred tax assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the Group does not have an establishment or place of business in China, the Group is subject to withholding tax on gross income from dividends, interest, lease of property, royalties, and other China-source passive income. In 2021 the Group entered into a collaboration agreement with Hansoh, a biopharmaceutical company in China and received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upfront paym&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ent, which required withholding tax of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In 2024 the Group received a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which required withholding tax of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In 2023 the Group received a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which required w&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ithholding tax of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year, the Group had not yet received the research and development tax credit related to the prior year. The Group has recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;in respect of the current year for unfunded projects that are permissible to claim&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;under &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the SME scheme (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million). In addition, in 2024 we have also recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million related to the RDEC scheme (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_419c51b2-00d9-444c-ab52-2d38509b8d09"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_0907f9cc-4a64-4578-9f26-d51f98788abe"
      unitRef="U_pure">0.235</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_ab13cc0c-5775-43dd-a181-db3338b67deb"
      decimals="INF"
      id="F_ad8afcd4-fcfe-4e9e-89be-0c5cd82d2b5e"
      unitRef="U_pure">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a616bd36-1676-406f-a437-69e3e0d34cd4"
      decimals="INF"
      id="F_b7e61535-ce13-4c47-88de-805924556a07"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_682eded1-5f78-4afe-acd7-7d24cdc6a58c"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_67678a47-3f01-4f0e-9e92-7d97b228d95a"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_76171aa8-01c8-48f9-810a-27e42c345914"
      unitRef="U_USD">800000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_71683d20-9411-4109-83d0-78659d9ec890"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_c116dbd4-c27f-4d53-a552-5035d8c85c13">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.611%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.342%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.982%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.062%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Current Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current Year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in estimate related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred Tax Expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Origination and reversal of temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of previously unrecognized tax losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Recognition of previously unrecognized tax losses (derecognition of&lt;br/&gt;&#160;&#160;&#160;previously recognized) deductible temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Taxation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_df4c913a-d053-4cdc-90d7-8e23e5f250a6"
      unitRef="U_USD">845000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_9e722f6e-ac45-4d38-b9ee-7001343c0775"
      unitRef="U_USD">956000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_d0c66fa0-9df1-4730-8dcc-31012ac37e3e"
      unitRef="U_USD">192000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <sln:ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_d72f301d-76b1-43e2-8546-d3aba3906b2f"
      unitRef="U_USD">496000</sln:ChangesInEstimateRelatedToPriorYearsCurrentTaxExpense>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_db5cd6e2-5e32-4b2c-a01d-a3bc011539cf"
      unitRef="U_USD">845000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_9f58d19f-596c-4460-9573-189db530294c"
      unitRef="U_USD">956000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_7f7d90c8-0150-4238-8996-d5f0fb4d5907"
      unitRef="U_USD">688000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_261f0435-0ae7-4c33-9ee2-cb399bb00495"
      unitRef="U_USD">845000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_9ea2069c-8923-4c5c-91c3-501ea893c46c"
      unitRef="U_USD">956000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_7f79fcfa-f380-418b-99bb-a21342c41444"
      unitRef="U_USD">688000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_da80fd34-9d8a-43c3-a400-e619ad916d83">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of the income tax credit at standard rate of U.K. corporation tax to the current tax credit are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss before tax&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit at the standard rate of U.K. corporation tax of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;br/&gt;&#160;&#160;&#160;(2023: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%; 2022: &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,530&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income not taxable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,346&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,423&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,456&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment in respect of prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;202&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the standard U.K. statutory income tax rate to the effective tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax using U.K. statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income not taxable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowances&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Adjustment in respect of prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effect of overseas taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate for loss from continuing operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_23069a25-f7ac-43ff-952d-542d12e9c31b"
      unitRef="U_USD">-44464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_2e88f1ab-43ae-4707-be5e-619b50f63b90"
      unitRef="U_USD">-53272000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_1396eae6-44d0-450d-a611-200099353293"
      unitRef="U_USD">-49646000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_22119616-e1b3-4cd7-9090-7e96267e9b35"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_a616bd36-1676-406f-a437-69e3e0d34cd4"
      decimals="INF"
      id="F_f842c1f3-ab92-4623-8a35-32b5e91f3419"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_28515016-3de8-402f-9141-24d3ecf88e11"
      unitRef="U_pure">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_5718b0fe-c8a2-4799-8159-0bfede0f8acf"
      unitRef="U_USD">-11116000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_8378b258-9bc0-4b93-a1c9-031974628840"
      unitRef="U_USD">-12530000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_7e6ed798-4a93-4826-8946-186c0633c221"
      unitRef="U_USD">-9432000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_dcfd932f-adda-4373-bd8e-6e7ab2999ea4"
      unitRef="U_USD">3356000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_daa1186c-7976-4485-a3fa-c265c4a34df2"
      unitRef="U_USD">2286000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_1e0a48e8-627e-4c6a-a8a8-a12540ddfef2"
      unitRef="U_USD">1346000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_d4cb2efd-e950-49c8-b25b-15243f2628da"
      unitRef="U_USD">-308000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_4a337ac6-dbde-4d16-9c43-32049f528729"
      unitRef="U_USD">-334000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_2bbf868e-d3bb-4858-aba7-ef76116edf1e"
      unitRef="U_USD">-673000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_35c53771-6f07-4b42-b80d-e40176d2d211"
      unitRef="U_USD">15423000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_2f6c6282-ab99-4978-84c6-4d4068f09844"
      unitRef="U_USD">15641000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_57a3b885-263b-49c9-a967-f64605ee6548"
      unitRef="U_USD">11456000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_5d1c3c15-75e8-4364-a06c-847dcdbb0d50"
      unitRef="U_USD">495000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <sln:IncomeTaxReconciliationEffectOfOverseasTaxes
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_12a5fa5a-02ba-4d50-aec2-7151ebceb194"
      unitRef="U_USD">202000</sln:IncomeTaxReconciliationEffectOfOverseasTaxes>
    <sln:IncomeTaxReconciliationEffectOfOverseasTaxes
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_21c7bfe9-c756-4369-ae2b-abcb2a1d75ad"
      unitRef="U_USD">465000</sln:IncomeTaxReconciliationEffectOfOverseasTaxes>
    <sln:IncomeTaxReconciliationEffectOfOverseasTaxes
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_6d87def8-1a39-4e30-8840-70ace771d03c"
      unitRef="U_USD">188000</sln:IncomeTaxReconciliationEffectOfOverseasTaxes>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_c65a6ac0-5e41-429e-ad07-d40f22ddc2cf"
      unitRef="U_USD">845000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_1a13aef4-5eba-43bc-adc5-45951a4b8c98"
      unitRef="U_USD">956000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-3"
      id="F_3be669ad-7f7a-4aca-b150-307c20402b4f"
      unitRef="U_USD">688000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_de1bfaf8-e22d-4a56-9beb-536d46c2a250"
      unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_7b53b193-bd1e-486b-9a79-085a5cc051f3"
      unitRef="U_pure">0.235</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_5f3fccce-3250-4083-b64d-23e6729e6518"
      unitRef="U_pure">0.19</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="3"
      id="F_d2055922-f6ba-4c09-be3e-47a9418c256f"
      unitRef="U_pure">-0.075</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="3"
      id="F_64ad15f9-e5e6-4d0d-a524-ce2c7d1100a3"
      unitRef="U_pure">-0.043</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="3"
      id="F_21bda1a6-3e68-4b5e-b39b-be623b55b901"
      unitRef="U_pure">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="3"
      id="F_4f3b851b-b205-4040-9790-d402fa086d09"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="3"
      id="F_2c886dec-c174-49c5-af92-262d44b331b4"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="3"
      id="F_a467077c-366b-443e-8f3e-83063566ac9d"
      unitRef="U_pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="3"
      id="F_0acdf5e2-e949-46e8-a97e-afa5f5d1c7f8"
      unitRef="U_pure">-0.347</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="3"
      id="F_dbbb7f64-7d1c-42f5-b394-061273b7d1e9"
      unitRef="U_pure">-0.294</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="3"
      id="F_9d5f9600-7750-4137-9244-8a1fa10fd828"
      unitRef="U_pure">-0.231</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="3"
      id="F_2d748b6b-8016-429c-94e1-702a451376e6"
      unitRef="U_pure">-0.005</sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax>
    <sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="3"
      id="F_daa63b8a-9cbd-478c-9482-95c286c2b663"
      unitRef="U_pure">-0.009</sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax>
    <sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="3"
      id="F_960a9638-2649-44b1-802b-e49a710918ae"
      unitRef="U_pure">-0.004</sln:EffectiveIncomeTaxRateReconciliationEffectOfOverseasTax>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="3"
      id="F_332d5259-9ded-404e-bbc8-468a6bd8744f"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="3"
      id="F_9654c233-9941-4470-acb3-5ac20d1e6f2c"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="3"
      id="F_ec57e86b-a1cf-416c-a7cc-e49823849c99"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_61cc3f90-b36a-43b9-b5b3-3b4b05503d20"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_7550b65f-42c2-4162-91c6-3aa95444bd42"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_46c2fe0d-90d0-4aa8-b08c-1f6c3f2a7976">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Components of the Group&#x2019;s deferred tax assets as at December 31, 2024 and 2023 are as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$000s&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trading Losses &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capital losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Included i&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n trading losses is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of accumulated tax losses as of December 31, 2024 ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2023) related to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;its &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;operations in Germany for corporate income taxes and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of accumulated losses related to trade taxes in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;its &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;German entity ($&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of Decem&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ber 31, 2023).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_9c3b9baf-8b05-468b-9c79-830cf81ddc15"
      unitRef="U_USD">55316000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_f045ca95-9039-40d5-91da-1e05384a3b3e"
      unitRef="U_USD">57563000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_9fe116b0-83f7-424a-9875-5d04dc2e26fa"
      unitRef="U_USD">3663000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_f91a4b01-0de2-468e-b128-f27b8be39038"
      unitRef="U_USD">3670000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_936dd851-2df9-4506-b868-477a040d0228"
      unitRef="U_USD">2467000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_333825b7-8657-47fe-9e19-dce74644af19"
      unitRef="U_USD">2506000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_17492ded-6d49-4083-932d-f04d5fd87daf"
      unitRef="U_USD">61446000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_f1988aab-cb96-45c4-b5d8-08c8a4189e51"
      unitRef="U_USD">63739000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_fe875719-e82e-484f-bbb7-eb4f98863f4d"
      unitRef="U_USD">61446000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_8963d9c6-13d1-4f89-838f-a2a3da314c48"
      unitRef="U_USD">63739000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_756ab1fa-dab8-400e-ba4e-37bfdf5de1cb"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_a0c40743-c463-4c1b-b880-8ee5e88597a2"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_916be728-0e74-468d-9ee3-5da8a4435883"
      unitRef="U_USD">7400000</sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes>
    <sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-5"
      id="F_fd373d48-9080-4b3d-9920-a130bab1037a"
      unitRef="U_USD">8600000</sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToCorporateIncomeTaxes>
    <sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_d6c786f8-b845-4a91-b5be-b021e8295011"
      unitRef="U_USD">6500000</sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes>
    <sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-5"
      id="F_263ddbe7-993e-4146-a64d-cf18c023c6a4"
      unitRef="U_USD">7500000</sln:DeferredTaxAssetAccumulatedTaxLossesRelatedToTradeTaxes>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_bda07c98-a4a9-450f-8766-801528c69a0a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Movements in deferred tax valuation allowance:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(Decrease)/increase in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,293&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_224cd5aa-1294-465c-b040-e93d8647c8a3"
      unitRef="U_USD">63739000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_5a4ed909-5e07-4cfb-b846-fc768a811161"
      unitRef="U_USD">61703000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-3"
      id="F_7b33ef86-c316-4d2c-a243-240a96ff0a4c"
      unitRef="U_USD">-2293000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-3"
      id="F_e22ea9d6-a4a0-4060-a9ad-137ecceff054"
      unitRef="U_USD">2036000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_95441a23-26d2-4ef5-96f0-2d675718691b"
      unitRef="U_USD">61446000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_b5ffc665-eb5f-405b-ae3e-a7691dbffd0f"
      unitRef="U_USD">63739000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0621b0c6-ee4e-42cf-a04a-499414698850"
      decimals="-5"
      id="F_39d827cc-47b5-448d-86ca-aad73696f711"
      unitRef="U_USD">16000000</us-gaap:ContractWithCustomerLiability>
    <sln:UpfrontPaymentTaxWithholding
      contextRef="C_a5aa37ae-e777-4dc1-948b-8abdce9b033b"
      decimals="-5"
      id="F_96dadcf4-65e6-43ef-b09f-9834c81fd756"
      unitRef="U_USD">1600000</sln:UpfrontPaymentTaxWithholding>
    <sln:MilestonePaymentsReceived
      contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"
      decimals="-5"
      id="F_5e7debb7-6812-43fa-be5e-04491de67f7c"
      unitRef="U_USD">2000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentTaxWithholding
      contextRef="C_42efbc64-2c48-4d72-b9ac-e122ae0af0b4"
      decimals="-5"
      id="F_944ebdc3-f1fa-4315-9494-49d76e724b10"
      unitRef="U_USD">200000</sln:MilestonePaymentTaxWithholding>
    <sln:MilestonePaymentsReceived
      contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0"
      decimals="-5"
      id="F_3f7143c5-937c-43c9-9b22-aac3a9fc154c"
      unitRef="U_USD">4000000</sln:MilestonePaymentsReceived>
    <sln:MilestonePaymentTaxWithholding
      contextRef="C_e8d40c06-b3db-4830-bf10-e933ad6b2bf0"
      decimals="-5"
      id="F_35b6818f-885c-47ff-991f-22c13f122ac7"
      unitRef="U_USD">400000</sln:MilestonePaymentTaxWithholding>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_84cedcb8-200d-4f11-afb2-0648fda7c636"
      decimals="-5"
      id="F_fb2a7595-f2d8-4b19-a443-06d8fd1236d5"
      unitRef="U_USD">13200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_5abd1237-ff52-4950-ac85-db071e0672dc"
      decimals="-5"
      id="F_bd04fbfb-9dcd-4f66-8bdc-03f03289c256"
      unitRef="U_USD">9900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_dbe56603-c5ad-4050-8b7a-f9ec17240ff0"
      decimals="-5"
      id="F_06cc70a3-fe8a-47ea-a4c7-e797db7a4680"
      unitRef="U_USD">9700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_3c9aca65-1850-401b-8756-d571e815112f"
      decimals="-5"
      id="F_f65701a0-48df-4d84-827a-d3b237f0644e"
      unitRef="U_USD">300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_350c15e1-d957-4be9-aee7-a256f22c97c1"
      decimals="-5"
      id="F_d8cfb909-9a1c-4b94-9e25-bf6e8f777e49"
      unitRef="U_USD">1100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_38e9b6bf-0e2e-4817-ab67-ec146ae446da"
      decimals="-5"
      id="F_bc9fdf56-9813-4470-925e-e8d9ca7521b1"
      unitRef="U_USD">1300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_a0da7155-cbaf-4034-a585-fd52f16cb6a5">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;18. Shareholders&#x2019; equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Authorized, allotted, called up and fully paid ordinary shares,&lt;br/&gt;&#160;&#160;&#160;par value &#xa3;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,674,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,846,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,808,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of ADS in issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,224,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,615,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,936,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has only one class of share. All ordinary shares have equal voting rights and rank pari passu for the distribution of dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 11, 2022, the Group announced a registered direct offering (the &#x201c;Offering&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,950,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Group&#x2019;s ADSs, each representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in underwriting discounts, commissions and estimated offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 15, 2021, the Group entered into an Open Market Sale Agreement (the "Sales Agreement"), with Jefferies LLC ("Jefferies"), pursuant to which the Group may offer and sell, from time to time, its ADSs through Jefferies. On October 15, 2021, the Group filed a registration statement, which became effective on October 22, 2021, for the issuance and sale of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of ADSs. During the year ended December 31, 2023, the Group sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million ADSs for net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses. In 2024, the Group raised additional proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses, from sales of ADSs under the Sales Agreement. On October 22, 2024, the Group filed a new registration statement on Form F-3 which replaced the registration statement originally filed on October 15, 2021, for the issuance and sale, if any, of up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of its shares represented by ADSs under the Sales Agreement. As of this filing, approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of ADSs remained.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 5, 2024, the Group announced a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,714,286&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Group&#x2019;s ADSs, each representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares, at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS, with new and existing institutional and accredited investors. The aggregate gross proceeds of the Private Placement were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million before deducting $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in placement agent fees and other expenses.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the shares issued during the current and previous year are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;118,846,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of ADS in issue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;39,615,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issued during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,418,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;268,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;141,674,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of equivalent ADS in issue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;47,224,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, there were opti&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ons outstanding of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,455,390&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2023: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,853,459&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;; 2022: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,571,487&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) unissued ordinary shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the options outstanding are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:12.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year of issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted average Exercise price (&#xa3;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;WeightedaverageExerciseprice($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At&lt;br/&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At&lt;br/&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted average years to expiry date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2014&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2015&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2016&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2017&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;347,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.42&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,419,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,310,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.33&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,269,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,148,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,255,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total (ADSs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;111,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;152,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;469,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,818,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total (Ordinary&lt;br/&gt;&#160;&#160;&#160;Shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,853,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,802,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;334,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;457,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,408,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,455,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ADSs represent &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares and the exercise price was also converted to represent an ADS price at an exchange rate equal to the closing current year currency conversion of sterling pounds to US dollars, which was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sterling pounds to 1 US Dollar.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_2f75838e-e5f7-4bf9-88ce-8ae535358c58">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Authorized, allotted, called up and fully paid ordinary shares,&lt;br/&gt;&#160;&#160;&#160;par value &#xa3;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,674,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,846,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,808,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of ADS in issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,224,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,615,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,936,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_dff0b3bc-da3b-4661-bc71-f4785548f1ba"
      unitRef="U_U_iso4217GBP_xbrlishares">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_88ee335c-efae-41d2-abc2-1c5774a8fe8e"
      unitRef="U_U_iso4217GBP_xbrlishares">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="INF"
      id="F_a5cbd8a5-c4ce-4e4b-8b5d-3daa638165bf"
      unitRef="U_U_iso4217GBP_xbrlishares">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-3"
      id="F_09b25e63-f54c-43df-8562-6281a3cd5bdf"
      unitRef="U_USD">10288000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-3"
      id="F_07c40b9d-d533-4aa5-b1ca-97c6bf760001"
      unitRef="U_USD">8847000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-3"
      id="F_ffe1f95d-f4a5-4bb8-8f59-aed71d9facca"
      unitRef="U_USD">8151000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_7ec448d0-bb81-4547-aa62-958f0a2b92dd"
      unitRef="U_shares">141674074</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_0f984d24-f5f6-48b3-ae94-455dbf868b95"
      unitRef="U_shares">118846966</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="INF"
      id="F_22c39bd4-3ea8-4739-af79-38967798b483"
      unitRef="U_shares">107808472</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="INF"
      id="F_f4d90f39-52f8-40c7-8d11-623700dfb3dd"
      unitRef="U_shares">47224691</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_54b5e016-ac25-49cb-b09d-08f42f334742"
      unitRef="U_shares">39615655</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="INF"
      id="F_10d36b5f-1d6b-4236-8f13-cb8d62bb2f94"
      unitRef="U_shares">35936157</us-gaap:SharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8"
      decimals="INF"
      id="F_eb65e939-5b21-454b-8cc7-eee10b512ed7"
      unitRef="U_shares">5950000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare
      contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8"
      decimals="INF"
      id="F_73f706c3-e8d2-4b36-8a70-f15a9cad3ecd"
      unitRef="U_shares">3</sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_daee9f0f-917c-4075-9727-a97e4432d952"
      decimals="INF"
      id="F_2e77908e-f782-485a-ba8b-96da8982833c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.5</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8"
      decimals="-5"
      id="F_7757cdbe-013c-486b-8902-5582cfdc5fb4"
      unitRef="U_USD">56500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_6128afa4-6498-4cdc-918c-8e2a0b02caa8"
      decimals="-5"
      id="F_ef5a62c2-c52d-4f9b-845a-6de10bc50dac"
      unitRef="U_USD">4100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityRestrictions
      contextRef="C_c26bf700-deb8-4a91-a96d-f882b6d529d7"
      decimals="INF"
      id="F_2e7859c0-a2cb-4783-b5f4-d234a1f6aac8"
      unitRef="U_USD">100000000</us-gaap:EquityRestrictions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97"
      decimals="-5"
      id="F_fd7997f5-0c5c-4f59-803a-5b9478853a82"
      unitRef="U_shares">3400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97"
      decimals="-5"
      id="F_185e0502-d2e5-473a-a882-4d9c7d9bc132"
      unitRef="U_USD">32200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_675ff913-5424-432c-ac71-3989d7bcca97"
      decimals="-5"
      id="F_25d96f8f-030c-4ce2-9216-085ac57e19d8"
      unitRef="U_USD">1000000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e"
      decimals="-5"
      id="F_b94a8735-7699-4f6f-ba58-d0ce2671c10e"
      unitRef="U_USD">27700000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_c0561958-14fc-4c04-b4c6-29aecabad04e"
      decimals="-5"
      id="F_a7ca34b1-7c6e-4eb7-a77e-7f83f8387056"
      unitRef="U_USD">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockholdersEquityPeriodIncreaseDecrease
      contextRef="C_e965a87f-ea8d-4a71-9f84-acedc7eb6357"
      decimals="-6"
      id="F_3b7d4294-f289-455a-ae55-9c38fbf9bd36"
      unitRef="U_USD">100000000</us-gaap:StockholdersEquityPeriodIncreaseDecrease>
    <sln:StockholdersEquityRemainingValue
      contextRef="C_3807dd5f-7db5-4df7-b6df-54b06e17005f"
      decimals="-5"
      id="F_6d8b16dc-1898-4cfe-8201-ea8a0c91c65b"
      unitRef="U_USD">139600000</sln:StockholdersEquityRemainingValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="INF"
      id="F_80d415c9-5048-44df-8368-2f23983c7ec8"
      unitRef="U_shares">5714286</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="INF"
      id="F_0d14fa6d-a9ab-4984-a259-84c227285e2a"
      unitRef="U_shares">3</sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_504e865b-e8c6-4526-9b0b-319762518420"
      decimals="INF"
      id="F_e0a27740-0f04-49de-902a-bba7e962f6ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="-5"
      id="F_384d062c-8e03-4510-84ea-7dc82ece0685"
      unitRef="U_USD">120000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_d923e7bf-f326-42d5-a44c-66648c52c3ab"
      decimals="-5"
      id="F_7696006e-6bbf-4dc3-8ad1-f846c2ccb0ed"
      unitRef="U_USD">7700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_bf530f3d-1b06-427e-9a90-33b7319603e8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the shares issued during the current and previous year are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:16.3%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;118,846,966&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of ADS in issue at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;39,615,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shares issued during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,418,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.07&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;268,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.44&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;584,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.33&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.81&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.38&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.13&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.64&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.55&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,248&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.41&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Options exercised at $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23.60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ADS or $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;/ordinary share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of shares in issue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;141,674,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of equivalent ADS in issue at December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;47,224,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_d967110a-bb44-44f6-b419-ad87617617a0"
      unitRef="U_shares">118846966</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_a3aa4475-230c-420a-aa98-5819a789944c"
      unitRef="U_shares">39615655</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_5cc9f256-bd6e-4d7f-bebd-8c402be10948"
      unitRef="U_shares">21418665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sln:StockOptionExercisePrice
      contextRef="C_e1e57139-299b-4037-aa4e-2d87f4f5721e"
      decimals="INF"
      id="F_0e85aec2-6b3d-4d51-ad2a-e689c6be91fd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.2</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_059ba194-dc5a-46d5-b657-d8a5b95f703b"
      decimals="INF"
      id="F_d3c853c8-caa9-4359-9537-58a764c13a5e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.07</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1945b695-781c-4d0b-a167-a95a2b6c877c"
      decimals="INF"
      id="F_2462f0b0-bf55-4acc-87c7-b5f9df7233db"
      unitRef="U_shares">252540</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_8927c9e3-b70e-49d9-9480-580bb749557e"
      decimals="INF"
      id="F_9d956889-ea16-4853-8f82-a9c0b22a4d81"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.4</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_952f58d5-0f09-4113-8e23-231dd9d6ed60"
      decimals="INF"
      id="F_1c97dd1d-b06a-42e1-8fc7-07f509ee0642"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.8</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_217d5192-d77e-4113-b140-4e04d06c0567"
      decimals="INF"
      id="F_d9ebc9a5-e2ed-41e6-8e89-4fcc92024fc1"
      unitRef="U_shares">268791</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_f1deec49-1e4a-4b33-a7be-f5eb5e43b3d0"
      decimals="INF"
      id="F_d95f41e5-59cd-49de-a044-7e9f9da892c2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.23</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_632ad642-d991-4f1b-8dd8-159d5c4836a7"
      decimals="INF"
      id="F_64829d9b-08cd-4e8c-a74f-ad92b83047e0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.41</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2375fd1d-98f8-4091-ae30-79225745f3d6"
      decimals="INF"
      id="F_3dc778d1-26f0-4948-91db-a5e2aa13b6a7"
      unitRef="U_shares">12000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_54971021-ad19-41ea-9f7b-464afa3961a9"
      decimals="INF"
      id="F_082dd2a4-fa2d-497f-9417-a24d2ec83283"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.24</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_a61b329b-79b8-48f7-91c7-c5440305e906"
      decimals="INF"
      id="F_4a4e45f6-3e47-4fa1-b7c2-51ad890e0e08"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.41</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_53a85070-3252-4961-9ffb-808312baaede"
      decimals="INF"
      id="F_e0782417-b1c8-4423-98a5-14981162db83"
      unitRef="U_shares">9999</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_992c3aa9-ad2c-45d7-abc4-998d7652ae1b"
      decimals="INF"
      id="F_4c31e067-537e-4920-89e0-390f2583db26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.81</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_0383529a-c338-4296-a791-e865000b7d3d"
      decimals="INF"
      id="F_2ee24b06-4656-4140-8329-0ab215dc57ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.94</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f7e4679a-8036-4192-9419-7bc7f5cca0d9"
      decimals="INF"
      id="F_bc7416cc-1bdc-46fa-b0d1-bce006149617"
      unitRef="U_shares">375</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_238358c8-8861-4cfb-a53e-08e29a69ca49"
      decimals="INF"
      id="F_a006c120-5706-4000-a2fb-c5c5ad08ac88"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.32</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_2d238315-cfea-49cf-90a8-194b936a027a"
      decimals="INF"
      id="F_0877b1b9-b9cf-4b94-ba2e-8ed19603f896"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.44</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5c9bae62-b3d2-43fe-9e77-fe51e795c617"
      decimals="INF"
      id="F_488a0e82-48be-4bda-b1c0-a244b88248df"
      unitRef="U_shares">30000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_d7a493d2-59ec-46f4-87a1-b9e48f3e1f9c"
      decimals="INF"
      id="F_28eead41-d655-4a27-829d-70068486f28a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.6</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_dc740331-c44f-436b-8d6a-1313f822c913"
      decimals="INF"
      id="F_02b824b6-09f2-4e29-b653-ae42409838e2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.53</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5f26855a-a871-47e3-a783-ff3eb99970d2"
      decimals="INF"
      id="F_c5796e1f-caf8-4014-9837-9fc16b0c2e90"
      unitRef="U_shares">584316</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_7b15e4df-7de8-4272-a954-8f455cf7b864"
      decimals="INF"
      id="F_dec44d98-51ba-496e-85f9-ec73b085c159"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.2</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_e1315f97-7497-4c58-b13e-bbae64f85ba2"
      decimals="INF"
      id="F_a3c27e44-cf27-4b59-bd09-03b100a1a377"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.73</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_049e703a-bbe5-4ce3-afce-99cf7a56663a"
      decimals="INF"
      id="F_0bd13cda-8f2c-42b0-b0b3-e69aaacbaf6c"
      unitRef="U_shares">49998</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_ed7dcfe1-421c-4f79-9232-17d734827b7e"
      decimals="INF"
      id="F_34e3ab24-32f6-4ee7-9d14-4254538fb8e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.98</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_6ad3128e-4140-41e6-b6de-bf526d8f46d5"
      decimals="INF"
      id="F_c9a2d75b-9b06-47a8-bc2b-bc5e7e404bd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.33</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_49d393af-f321-42c7-85a7-7d1ab9d9840c"
      decimals="INF"
      id="F_1c6e7eda-707e-450f-a508-47f70fd94403"
      unitRef="U_shares">222</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_9cea7a69-a5e3-4fc9-80c0-2433f7e0add4"
      decimals="INF"
      id="F_3918c852-4165-4f06-b5da-f90bccb3a1be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.68</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_5a53c3f0-bfdd-42e8-9d51-31e9dfd10fb1"
      decimals="INF"
      id="F_d1e4b665-d8f3-4c27-8fde-44220544a423"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.56</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_216e038d-1b18-4522-bfb1-cfa508cf7c03"
      decimals="INF"
      id="F_395c31f3-f5b9-4d83-8d57-8eca6c9d0d3b"
      unitRef="U_shares">10500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_638faea5-e2d8-41ce-a7ed-8338f7223d41"
      decimals="INF"
      id="F_a6dc44d2-f8ec-44cd-ab11-02a6f5ebb5f2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.81</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_4ce48f3f-5b8b-44c8-8ccc-45e7cee6a59e"
      decimals="INF"
      id="F_6e86c693-5863-47de-9c09-9051bba7f1ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.27</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e1f5638a-04f4-4c2c-93a3-b700275c8509"
      decimals="INF"
      id="F_798c4372-178e-4ab3-9e65-a8033bbcfa62"
      unitRef="U_shares">1500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_e2631f8b-0c37-4dc8-a1cc-38b6a73bdef4"
      decimals="INF"
      id="F_e37355d0-8521-46ca-abc8-f98d24952784"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.94</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_11ec3de2-3169-4055-898b-258e9b888703"
      decimals="INF"
      id="F_a5f377a3-6dce-408d-9cd9-ea4b5a664225"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.31</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_74e6c5aa-7ac8-44e0-8882-bd507123cbea"
      decimals="INF"
      id="F_e5dc0e49-bcea-46ed-9d2e-8513510b4a0c"
      unitRef="U_shares">2841</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_f0b63486-f25b-4b73-b4df-2ac2360a659a"
      decimals="INF"
      id="F_5eb03a19-2e46-40cb-80e4-05fa33a509b8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.8</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_6a334fb1-6955-4d69-b9eb-b49d579d734d"
      decimals="INF"
      id="F_692c9037-aac9-4c81-b949-229ab39570c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.6</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_51326ac8-4cf9-4ab6-b452-e838538675cd"
      decimals="INF"
      id="F_6657535b-7f41-4041-8c4d-f524efd68d62"
      unitRef="U_shares">3708</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_3441304e-2e9f-4e16-88d3-2ba15339295c"
      decimals="INF"
      id="F_a488f1b9-4852-4a40-b6d0-833287022a1a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.38</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_00a18a89-651d-454d-8df8-75896d774647"
      decimals="INF"
      id="F_f24a675f-9007-49f9-ae9c-6fee73d37478"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.13</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fc0ec39a-48d9-4919-8064-11ecd22f79fe"
      decimals="INF"
      id="F_fd941800-24dd-4a45-852b-19179d2c0ced"
      unitRef="U_shares">126144</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_758fbdcc-cc27-4b6a-8f98-eac78abfa599"
      decimals="INF"
      id="F_145b8c70-dd0f-432a-9adb-623cf503de68"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.64</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_993ce64a-f00f-4229-b0de-9e75b3dd02f3"
      decimals="INF"
      id="F_026e0bef-ffb5-4333-8c58-07b25be9273d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.55</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_16908155-fa6d-48d2-86d3-2bd71f67416e"
      decimals="INF"
      id="F_5acf69c6-094b-46f1-8732-c7f37f035094"
      unitRef="U_shares">1248</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_e1b8809b-fd1d-4776-97e9-f3f0de39ae40"
      decimals="INF"
      id="F_507c9dee-ca20-43ac-86bb-318aab58fa54"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.5</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_67267d0e-6a3e-40c0-98fe-e40aa96783a1"
      decimals="INF"
      id="F_bb13cf7d-1415-4aec-80e0-f44a8594f36d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.5</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_370fbfa4-fb9b-4a15-a3dc-b8d60d44d568"
      decimals="INF"
      id="F_b8b62ef0-8044-4e1e-a491-d53cc485085a"
      unitRef="U_shares">780</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_6796ff61-ed09-41b6-8d12-60cb26012f20"
      decimals="INF"
      id="F_898a05c8-ad92-4f3d-9bdd-228d1e1d490d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.41</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_61dbaca8-5fd5-4900-8f20-af4042005ca6"
      decimals="INF"
      id="F_295b4897-757b-4893-b589-8474a3ebd241"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.8</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fc219a0f-69bc-48c5-8e88-1c1bea1a3b75"
      decimals="INF"
      id="F_468d9119-fd9a-42cf-af9a-f0f575cebac1"
      unitRef="U_shares">10500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_6697bf60-6fe3-4afc-9808-67be87d95a10"
      decimals="INF"
      id="F_9811051a-d77c-4bd7-a9af-b280f89e969b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.01</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_608d77f8-a60e-4cd0-baf8-518580ca501b"
      decimals="INF"
      id="F_1a35bd0c-a049-4718-836a-e8f2bb360e38"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.34</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a004f47b-e1d5-4aaa-929b-464b64c386ef"
      decimals="INF"
      id="F_d9aec78a-5ca9-4569-8bce-89af6034508b"
      unitRef="U_shares">37545</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:StockOptionExercisePrice
      contextRef="C_39a561a1-a49b-401a-9662-3894f44c8689"
      decimals="INF"
      id="F_fba9965f-3226-4592-a4a3-dee5a57d43c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.6</sln:StockOptionExercisePrice>
    <sln:StockOptionExercisePrice
      contextRef="C_b214b1bd-0876-4f24-bab9-83c0ee791a74"
      decimals="INF"
      id="F_880542b2-5212-4fad-93bc-589aebc06efe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.87</sln:StockOptionExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3a41af0c-23c8-4e76-9243-d601a6c1bae4"
      decimals="INF"
      id="F_ccf0c8f1-053e-4261-ac63-29336d0f39f6"
      unitRef="U_shares">5436</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_01dd8feb-5acd-48a2-b224-57d4c536030e"
      unitRef="U_shares">141674074</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="INF"
      id="F_dc27463c-5d1d-4006-96e8-8a41c290d20e"
      unitRef="U_shares">47224691</us-gaap:SharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_7e8fa298-5299-410d-888d-563cb84520dd"
      unitRef="U_shares">17455390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_374f1a6d-c66b-4498-93eb-48b0fe3fa7be"
      unitRef="U_shares">15853459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="INF"
      id="F_2b3a0522-4df3-4f93-ba56-cdd56cf27aca"
      unitRef="U_shares">11571487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ffc6c372-b8b9-4d57-a193-0fddf0724ce2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Details of the options outstanding are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:12.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:6.741%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:7.021%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year of issue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted average Exercise price (&#xa3;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;WeightedaverageExerciseprice($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At&lt;br/&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;At&lt;br/&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted average years to expiry date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2014&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2015&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2016&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.19&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2017&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.26&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;577,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;347,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.77&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.42&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,015&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;576,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,419,863&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,310,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.33&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,269,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,148,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,255,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total (ADSs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;111,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;152,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;469,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,818,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total (Ordinary&lt;br/&gt;&#160;&#160;&#160;Shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;15,853,459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;3,802,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;334,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;457,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,408,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;17,455,390&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_d983b3bf-ce62-495e-8da5-1fec7e50860e"
      id="F_3bcd4912-0249-4d5f-8925-67053d2fe937">2014</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d"
      decimals="2"
      id="F_bbb2bf37-391a-42b8-bbd8-46c2f69b68cb"
      unitRef="U_U_iso4217GBP_xbrlishares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f73f8cd6-24fe-4159-8d32-29b8dd47be1d"
      decimals="2"
      id="F_319ad786-1010-4386-9561-72b9a03751f8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a401c67e-4a4e-4f35-a3e7-52f49f0af333"
      decimals="INF"
      id="F_49a6b996-7364-4020-8961-6327f496b75e"
      unitRef="U_shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d983b3bf-ce62-495e-8da5-1fec7e50860e"
      decimals="INF"
      id="F_b88efba3-b7e9-4a2f-968c-8a4a97127130"
      unitRef="U_shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_b785019b-0762-4563-980b-1d22109b7cc9"
      id="F_9e14dbc1-5b73-4a52-92d8-25c270736d4a">2015</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b"
      decimals="2"
      id="F_59b4860f-ff93-4467-86dc-6152eca49df6"
      unitRef="U_U_iso4217GBP_xbrlishares">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b"
      decimals="2"
      id="F_6e021709-fee6-441d-bb0d-b78e379648da"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_23dabf2c-86b8-4fd8-9d01-e013311b7293"
      decimals="INF"
      id="F_a78d216c-4c02-4e38-b2a1-d964519d3f50"
      unitRef="U_shares">3333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_79f81678-d929-47d5-a2dd-7b6bfc53386b"
      decimals="INF"
      id="F_d0e1c204-a71f-4a38-b988-0918ba29f31c"
      unitRef="U_shares">3333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_b785019b-0762-4563-980b-1d22109b7cc9"
      id="F_be29c85e-65cf-4cb8-84e5-782902707133">P0Y6M3D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d"
      id="F_0b5ef63f-9851-4879-bf47-345198506368">2016</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b"
      decimals="2"
      id="F_ceea0f8c-b164-4b4c-b883-b888125aa338"
      unitRef="U_U_iso4217GBP_xbrlishares">4.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b"
      decimals="2"
      id="F_2defc8b5-4753-4833-971e-cd2ebc67b224"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_74b750e6-0f2c-44dc-9d32-f425b3eac898"
      decimals="INF"
      id="F_5ee5315d-7097-42c3-bb0f-3e236a60b281"
      unitRef="U_shares">9857</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d"
      decimals="INF"
      id="F_747da366-04de-4f65-883e-8fbbc3c4c75b"
      unitRef="U_shares">3333</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f6142756-44a3-47a1-8793-ebc26a69054b"
      decimals="INF"
      id="F_962d6085-a00d-4537-80a6-d9506d3aeaac"
      unitRef="U_shares">6524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_653d019b-7d15-44db-9acd-920ecd68e80d"
      id="F_725785b1-8e68-4fde-b7ba-7ab51403915a">P1Y2M8D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4"
      id="F_dc380b0f-45d5-4c2a-ac5f-45ca869f2104">2017</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576"
      decimals="2"
      id="F_8562f03f-b00d-42a3-825a-59fbd76aae17"
      unitRef="U_U_iso4217GBP_xbrlishares">6.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576"
      decimals="2"
      id="F_43393e2e-044b-44de-a74d-fe642957e702"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b68a9405-7a9f-4135-ac8b-98f4d8aa740a"
      decimals="INF"
      id="F_a574c74b-7433-4ed2-bcb1-51aaa87c206b"
      unitRef="U_shares">39999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4"
      decimals="INF"
      id="F_b1f8ae2f-20c6-4bff-bdce-e1ea2d391ec5"
      unitRef="U_shares">16666</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ea1adf0f-8420-420c-a7ad-bcd9a02d2576"
      decimals="INF"
      id="F_d11d0f86-8bdb-4623-9b5a-d099403f6744"
      unitRef="U_shares">23333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_d8ea71a2-0b5d-4090-933f-f6d7821b4db4"
      id="F_5ccda493-c3d5-48a7-8863-79aca02457bf">P2Y11M1D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196"
      id="F_59e819a2-0ca5-4fc9-b05d-08768dd4a010">2018</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0"
      decimals="2"
      id="F_5cf5fe0e-619f-427b-87c6-b5e65fd791ce"
      unitRef="U_U_iso4217GBP_xbrlishares">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0"
      decimals="2"
      id="F_21500a79-a1fd-4546-9098-66a33e76842c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_dbbea4f8-6415-4dd5-b5eb-4a147b35a1df"
      decimals="INF"
      id="F_89730130-786c-4ace-8ae5-36750a35499c"
      unitRef="U_shares">36596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196"
      decimals="INF"
      id="F_b56834a0-aa77-435f-a791-7b95278cb5fb"
      unitRef="U_shares">6003</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fabcf318-8597-4509-8bb6-bc105007edc0"
      decimals="INF"
      id="F_af46d2d0-a159-46ac-98ab-a3b18b2e02dc"
      unitRef="U_shares">30593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_cb624ebe-9f9f-415c-9701-66ebfe607196"
      id="F_cf4b7efa-7ae8-438c-83eb-11b2690aa56d">P3Y3M3D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4"
      id="F_a0b8a464-fd98-43cc-897c-f6b9cf63b429">2019</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb"
      decimals="2"
      id="F_3624f262-9d97-4d7c-b3ea-1a1ff64244cb"
      unitRef="U_U_iso4217GBP_xbrlishares">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb"
      decimals="2"
      id="F_e53a6677-671e-4770-8ac3-df397a74030d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a7b20ad2-f774-44ca-92d9-91406a63fde3"
      decimals="INF"
      id="F_4717a6a5-25f1-43f9-8696-a68856254e0e"
      unitRef="U_shares">577698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4"
      decimals="INF"
      id="F_a54f28dd-eddf-4e48-bc4e-1d40e2bee210"
      unitRef="U_shares">347701</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_f60db7e0-9ef4-4c52-95d0-486ccf42c0bb"
      decimals="INF"
      id="F_15aaea55-a913-4225-b5f0-5481eab859e0"
      unitRef="U_shares">229997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_639d80ab-82dd-47c1-b84d-cedb0693edb4"
      id="F_aa0bbdf6-c8c6-4ad5-8fad-e189533ee6af">P4Y9M7D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c"
      id="F_0d4071e6-462e-4899-9d2b-1494fb53e3d0">2020</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99"
      decimals="2"
      id="F_dc4ea2a8-af69-4250-914b-119d11e3b113"
      unitRef="U_U_iso4217GBP_xbrlishares">6.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99"
      decimals="2"
      id="F_9d46415e-0876-453a-92ab-bd8ed1acfeb3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_b902af35-3fe5-4f8a-ac84-e8d236da4c41"
      decimals="INF"
      id="F_4ee8b4b9-77be-4a64-9ae1-b114df01b47b"
      unitRef="U_shares">261207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c"
      decimals="INF"
      id="F_4d5af7d0-a140-425e-a4b4-fbf3f518caf8"
      unitRef="U_shares">532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c"
      decimals="INF"
      id="F_2827161f-1ea9-4c7d-bcdd-dcb551df56cf"
      unitRef="U_shares">26497</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_5e045a6a-1c4d-4d4b-aa4d-bbb546d17a99"
      decimals="INF"
      id="F_047adb86-1350-43f2-a4d9-8e6198d0405e"
      unitRef="U_shares">234178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_dc57ec07-2678-46b9-9794-85b715ab415c"
      id="F_27a54c9d-c614-43b2-b148-5cefda5291c0">P5Y5M1D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5"
      id="F_b13e3ee1-027f-4a4a-b189-e5950d70989d">2021</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a"
      decimals="2"
      id="F_e8801919-34be-4048-b0a4-5257bedc6480"
      unitRef="U_U_iso4217GBP_xbrlishares">17.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a"
      decimals="2"
      id="F_dd53c3fa-f50d-41b5-a70e-9a664e996856"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_21f6c7f3-fcd4-4d89-9f96-a6ce7fcf4b29"
      decimals="INF"
      id="F_3d4b9f7f-8eec-4659-89fc-6f09bc683293"
      unitRef="U_shares">662344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5"
      decimals="INF"
      id="F_88962d52-60fa-435d-9658-974fc4ff9488"
      unitRef="U_shares">7691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5"
      decimals="INF"
      id="F_e87ce54c-7cb5-483d-be91-83cd7394b270"
      unitRef="U_shares">62502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5"
      decimals="INF"
      id="F_b61a7f8b-f977-42e9-b02a-731c3622a339"
      unitRef="U_shares">16015</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e09fc92a-7db4-44e2-8a46-98027d2bcc6a"
      decimals="INF"
      id="F_569341cc-e2e0-4ecd-a31b-b1a0b3b8c7cd"
      unitRef="U_shares">576136</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_060925be-2d36-42da-9130-a97cb8b73ba5"
      id="F_f599f708-0261-465c-acf6-8443dffa44ef">P6Y3M</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"
      id="F_27374314-fd67-44d9-b29d-c911cc79ac07">2022</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e"
      decimals="2"
      id="F_86afa2bc-51e9-4621-b7db-bdc3cefff345"
      unitRef="U_U_iso4217GBP_xbrlishares">14.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e"
      decimals="2"
      id="F_88fa6e53-c3b4-4d51-af65-a42da48014f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_92ab0815-ca01-49b9-9495-665a702a4024"
      decimals="INF"
      id="F_95a61320-4282-4a0e-8989-1a32fdbcf2c6"
      unitRef="U_shares">1419863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"
      decimals="INF"
      id="F_11fcfbfd-9aff-4375-9ca3-a863aea8e911"
      unitRef="U_shares">27309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"
      decimals="INF"
      id="F_a77193a0-8ab2-4f7b-9031-ccc881f76f4b"
      unitRef="U_shares">75037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"
      decimals="INF"
      id="F_ac2df501-49ec-40d8-81ee-f1e832dd515b"
      unitRef="U_shares">7019</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_cae9864b-c68c-4743-b935-6556cbeeae9e"
      decimals="INF"
      id="F_c3b20866-a262-4a0c-9dcb-5aa18ee27fe5"
      unitRef="U_shares">1310498</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_ededf283-aba4-4a6a-b30c-24bb67b0c959"
      id="F_14de4bfe-e0ef-40d1-a37c-f842e1c2de2d">P7Y3M29D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      id="F_b6d2d2dd-d7d2-4095-92f5-19ff38b8d2e9">2023</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f"
      decimals="2"
      id="F_f337d1cf-3693-4b3f-9454-750b889d5ccd"
      unitRef="U_U_iso4217GBP_xbrlishares">10.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f"
      decimals="2"
      id="F_ed1b5060-6f13-465a-9506-0c54f1b2e291"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c2ca9beb-ad6f-462a-9e3e-0385278c2a72"
      decimals="INF"
      id="F_9fb1cf01-89cb-46a5-98a7-bef0590c5346"
      unitRef="U_shares">2269589</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      decimals="INF"
      id="F_ef707f66-ab11-44ef-a4db-b1d60f1c2506"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      decimals="INF"
      id="F_64029db5-fd8f-48ad-b40b-bf4d3f7f47d3"
      unitRef="U_shares">63858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      decimals="INF"
      id="F_76dc5b76-ea79-476b-b4fb-766be7e242f0"
      unitRef="U_shares">15127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      decimals="INF"
      id="F_0c4e36d4-cb89-4d24-8250-a92eaf4bf0d8"
      unitRef="U_shares">42247</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_82966b62-872d-49bb-aeec-24612fe0285f"
      decimals="INF"
      id="F_32372a3c-8e0e-4f92-80b2-29bc98b73633"
      unitRef="U_shares">2148357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_b775d65d-9ac8-4943-bee6-cf41729c880d"
      id="F_7c367416-7ae6-4618-9417-ed349c331ab5">P8Y2M12D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <sln:YearOfIssuanceOfStockOption
      contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1"
      id="F_36630d4e-67e4-4f57-b7a5-4e73dcb264a0">2024</sln:YearOfIssuanceOfStockOption>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3"
      decimals="2"
      id="F_a2db0602-cc96-417d-99e0-705fe405a27b"
      unitRef="U_U_iso4217GBP_xbrlishares">14.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3"
      decimals="2"
      id="F_bef2ec95-2cb8-4f18-b6c1-77e7c15d7507"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1"
      decimals="INF"
      id="F_e7b2afaf-527a-498d-a023-2d3db6d4edc3"
      unitRef="U_shares">1267514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1"
      decimals="INF"
      id="F_8fa402a4-35d9-4510-a460-fdc796a451cd"
      unitRef="U_shares">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ca483b90-7ea2-4cb8-84a3-17a86c1ee6b3"
      decimals="INF"
      id="F_fce9e75a-7520-4a8a-b15e-9eacd57fcbcb"
      unitRef="U_shares">1255514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:OptionsOutstandingWeightedAverageYearsToExpiryDate
      contextRef="C_393b6538-cdc2-426e-83b5-6ffeb73ae1c1"
      id="F_654dc77b-3522-4cd5-ae2c-43c47b80488a">P9Y21D</sln:OptionsOutstandingWeightedAverageYearsToExpiryDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_803eaafe-148f-4e2c-a1bf-e54187acd2aa"
      decimals="INF"
      id="F_911fd7a0-1913-40eb-870d-d402abf63168"
      unitRef="U_shares">5284486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="INF"
      id="F_49055aa5-ea52-4566-8384-ce03fd7c7c89"
      unitRef="U_shares">1267514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="INF"
      id="F_8e28ca48-e265-48ac-be30-0d597fef61f2"
      unitRef="U_shares">111390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="INF"
      id="F_a7678e3a-62f1-4d7e-bdd7-f95ebabff037"
      unitRef="U_shares">152666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="INF"
      id="F_70271439-b1cb-41a3-88dd-80e53dfa8ef5"
      unitRef="U_shares">469481</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_201f659a-3cad-42ab-ab6e-27152af749a5"
      decimals="INF"
      id="F_0a87784a-21d0-422a-b756-d96531e7c6a5"
      unitRef="U_shares">5818463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_65501b9b-cf7b-4967-aa43-8f8254eff265"
      unitRef="U_shares">15853459</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_cb7fffed-7e0f-4e9c-929b-32039a435e24"
      unitRef="U_shares">3802542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_72c3c608-4012-4a74-a6d2-50b506b2515e"
      unitRef="U_shares">334170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_a93cefca-2d1f-4c4e-a150-00c8184b12c3"
      unitRef="U_shares">457998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_763108b7-20b0-4c25-b9bf-9b6b3092fdff"
      unitRef="U_shares">1408443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_0a466e56-1d11-49b3-b4a6-f19072433d92"
      unitRef="U_shares">17455390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="INF"
      id="F_f8e94dd5-b0d4-48ff-b82d-9e4fb90845f2"
      unitRef="U_shares">3</sln:NumberOfOrdinarySharesForEachAmericanDepositaryShare>
    <sln:CurrencyConversionRatePerDollar
      contextRef="C_9f0adb4a-3977-49bd-bd43-31874b535e51"
      decimals="2"
      id="F_c0a4d116-5559-4299-8111-98fb72f54306"
      unitRef="U_pure">1.25</sln:CurrencyConversionRatePerDollar>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_8d2d60a9-7811-495f-9087-70e013efd712">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;19. Equity-settled share-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group has issued share options under the 2018 Long Term Incentive Plan (&#x201c;LTIP&#x201d;), 2018 Non-Employee Long Term Inventive Plan (&#x201c;Non-Employee LTIP&#x201d;), and individual share option contracts, open to all employees of the Group, as well as EMI shares (none of which remain outstanding at December 31, 2024). &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the LTIP, Non-Employee LTIP, individual contracts and schemes available, the options typically vest after three years, with the exception of some options granted to certain members of key management personnel. The vesting period for these options ranges from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; months.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The options usually lapse after one year following the employee leaving the Group.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.881%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,857,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,684,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,567,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,940,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lapsed or forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;871,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;469,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at the year-end (ADS/$)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,818,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,264,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,857,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;578,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at the year-end&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,870,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,420,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,889,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table above shows the number of options in relation to ordinary shares and equivalent ADSs outstanding and exercisable at year end, on the conversion ratio of three ordinary share options to one ADS.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The options outstanding at the year-end have a weighted average remaining contractual life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years (2023: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years; 2022: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of total unrecognized compensation cost related to stock options granted but not vested under the Company&#x2019;s plans. That cost will be recognized over an expected remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In the years ended December 31, 2024, 2023 and 2022 the total intrinsic value of stock options exercised was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The weighted average share price at the date of exercise of the options during the year was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.26&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x37e; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.06&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,802,542&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; share options during the year (2023: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,703,826&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;; 2022: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,821,131&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options granted were calculated using Black Scholes model. Inputs into the model were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs and assumptions for options granted in the year:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average ADS price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average ADS price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Option life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.39&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average grant data fair value ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group recognized total charges of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) related to equity settled &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;share-based payment transactions during the year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group does not bear any responsibility to settle any employee tax obligations that arise on the exercise of share options. The estimated employer tax obligation on outstanding options at the year-end was nominal (2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million).&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_65556a6f-1d05-4d24-bc5d-8c35f96d0e52">Under the LTIP, Non-Employee LTIP, individual contracts and schemes available, the options typically vest after three years, with the exception of some options granted to certain members of key management personnel. The vesting period for these options ranges from 3 to 33 months.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_424a567f-bfce-4314-a1cc-dcdfd4446d4a"
      id="F_1bc1d744-0b45-49cd-afe5-d2542564bd71">P3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_30137f17-19dd-4a65-a75e-44bd27a45a6c"
      id="F_a9463edd-ec69-4d21-a9ee-d0bf0e8dda63">P33M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_6f332742-f2ab-4d00-8826-4085b59d6a46">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The options usually lapse after one year following the employee leaving the Group.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:23.745%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.421%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:5.881%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;br/&gt;ADSs (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:center;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,857,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,684,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,567,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,940,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lapsed or forfeited during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;264,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;871,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;709,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:8pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:8pt;text-indent:0;font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;469,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.55&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding at the year-end (ADS/$)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,818,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,284,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,264,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,857,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;578,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercisable at the year-end&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,870,106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,420,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,889,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_396c10dc-18ca-4b7a-bc95-95a1b8edbb35"
      unitRef="U_shares">5284486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="2"
      id="F_6f322f56-3d33-4064-bd14-499e86f79a1e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="INF"
      id="F_5eaf2ec8-58ac-469c-a1eb-ee8dc2e3ba10"
      unitRef="U_shares">3857162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="2"
      id="F_b9376e3b-38fb-4fe7-af1a-8815757f2004"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_53771d0d-7cc8-4b66-b57c-8f18749a5839"
      decimals="INF"
      id="F_4eb31be2-ac20-430e-86bf-acce59f03b86"
      unitRef="U_shares">2684233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_53771d0d-7cc8-4b66-b57c-8f18749a5839"
      decimals="2"
      id="F_143ca93d-0eee-474f-bd07-428ef708b9b6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="INF"
      id="F_1c7d0cd3-ae4a-4fb1-9478-92c0f2e93c8d"
      unitRef="U_shares">1267514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="2"
      id="F_87d7e9be-994a-401f-a59e-6d1df182c6b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="INF"
      id="F_033e6cf5-0a04-43e8-b7bc-df56363c925b"
      unitRef="U_shares">2567942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="2"
      id="F_d66750ea-7a7e-403e-9bb3-b9ead9cb624f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="INF"
      id="F_c4aca8f4-1bca-4ac1-8d5c-7ca560d3cf50"
      unitRef="U_shares">1940377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="2"
      id="F_b4fdc3c3-b859-4d84-ab28-c392fba20979"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="INF"
      id="F_68a65a93-3415-450f-94c9-63705e209016"
      unitRef="U_shares">264056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="2"
      id="F_f641cc80-60f3-4a74-955f-a65b3839407a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="INF"
      id="F_dcc67c1f-3b56-4d25-b040-a22ba3ec833a"
      unitRef="U_shares">871309</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="2"
      id="F_3becfe00-95d0-4534-a26e-bf18bf245819"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="INF"
      id="F_43300a75-b12b-4ff5-8f32-7899960cfb6e"
      unitRef="U_shares">709531</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="2"
      id="F_12b54918-986b-4f39-89c0-8db39ae7e5ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">29.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="INF"
      id="F_227d968f-38bc-4d91-9900-f609f3273b50"
      unitRef="U_shares">469481</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_da0ad594-cae3-4d2c-89f8-a1866c95a7d0"
      decimals="2"
      id="F_a61d42a2-4730-4ea2-bb59-8262ece7e63d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="INF"
      id="F_62697272-63ea-4826-95e6-46826fc29a37"
      unitRef="U_shares">269309</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_967f4721-a4f1-4503-8847-1f409b6a3092"
      decimals="2"
      id="F_bd537ef9-f7e1-4687-bc82-f13f10a597ec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="INF"
      id="F_26c432e3-e3b5-4159-a8bc-d765f2d817a7"
      unitRef="U_shares">57917</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e46d88b1-5076-4a01-af8f-070d4137afe2"
      decimals="2"
      id="F_b125495b-de40-4445-bac9-b282e771eb3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="INF"
      id="F_ffeb1e13-630a-491f-8cc4-27ca4043d6bc"
      unitRef="U_shares">5818463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="2"
      id="F_33f0c167-252f-48d1-8ece-291002123dcf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_b51c59c7-58cc-401e-870a-5a0bc1b8395d"
      unitRef="U_shares">5284486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="2"
      id="F_c6ab5f30-aefb-4044-83e7-3c00831ae3ba"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="-3"
      id="F_d3763114-a02f-4b04-923d-097396ca0da6"
      unitRef="U_USD">13264060000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="INF"
      id="F_978ed2f1-53d3-4b19-b965-67bf362120c5"
      unitRef="U_shares">3857162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="2"
      id="F_fa3ed41c-217e-44ec-a538-59fed76d49c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="-3"
      id="F_f271f5d6-e78b-41ac-8aea-fdc85feb1471"
      unitRef="U_USD">578574000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="INF"
      id="F_ca9e6883-34c1-4b17-be4a-caed54686cb9"
      unitRef="U_shares">2870106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="2"
      id="F_0fd0c13b-3e55-44c4-aa5d-403f02e4c26c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_c6e51f57-b986-4fe8-bb80-480d15c88561"
      unitRef="U_shares">2420614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="2"
      id="F_df1eebb9-0e12-4221-89df-871a960a68bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="INF"
      id="F_52e53983-3f1d-43b0-bc3d-3dc06475dfa2"
      unitRef="U_shares">1889460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="2"
      id="F_44526125-e85d-470a-a823-129992518097"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_29091bec-ead3-4646-a3a7-be9d68e65cb5">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      id="F_4a680e1f-353e-441f-afa5-0cb39031dc2f">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      id="F_9450ee87-b530-45f8-bdc9-433c9bcbb591">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_79b1325b-5e60-4c50-bf85-e33a477b6820"
      unitRef="U_USD">29100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      id="F_4e501264-0cee-4a37-b8a7-1ba9bf2fd088">P1Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_ab224e0d-2585-4bab-b1db-bfdb4e72659e"
      unitRef="U_USD">6800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-5"
      id="F_a82f8422-853a-4313-99ed-4ac463b8c607"
      unitRef="U_USD">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-5"
      id="F_8526a0d1-ca26-460b-aa6e-4c4ad354e8c1"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="2"
      id="F_44dca2d1-2815-48d8-bb8c-74148580f869"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="2"
      id="F_40043ca6-2a44-430e-8408-ea9dd4ba727f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="2"
      id="F_f3ac726b-e460-4179-944d-e2000d289948"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2c9a8caf-7853-4084-b2c4-9c763a4f1b1e"
      decimals="INF"
      id="F_ae9f4296-a516-4d77-b73c-8f0f8ba730bb"
      unitRef="U_shares">3802542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8fb4cca8-43c3-4e07-8d79-5d79f2a66b76"
      decimals="INF"
      id="F_8d723a4b-8259-4a0e-868d-cee21f8f56e7"
      unitRef="U_shares">7703826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a74d87d0-a1bb-4a4b-a851-11add28ffc71"
      decimals="INF"
      id="F_68c1c85b-6fae-4277-92d7-791c55e5a2f8"
      unitRef="U_shares">5821131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_9a28e27d-2488-4ddc-8f55-b695f48d0cb3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of options granted were calculated using Black Scholes model. Inputs into the model were as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs and assumptions for options granted in the year:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average ADS price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average ADS price ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Option life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;78.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.39&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.97&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.43&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted average grant data fair value ($)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_21a8db84-e973-428f-b46a-6d101573066a"
      decimals="INF"
      id="F_4d9b89cc-ac90-469f-bf50-af29f68b42b2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.1</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_bbf46bf5-a87e-418d-8acf-ddb977efaf1f"
      decimals="INF"
      id="F_da7afbad-d0e1-4dc9-a59c-1fb46ae98642"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_903541b5-bcbc-4616-a2c5-d60afddbdcbc"
      decimals="INF"
      id="F_333914c5-e848-4c2e-a2d1-21c6fdcdcf19"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.5</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_fe304509-1160-4215-9c02-9ce905f39827"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.1</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="INF"
      id="F_791a8a4f-214b-4a24-8775-1923d914e2dd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="INF"
      id="F_78706f1c-c26e-4391-82ce-3fb97655f0a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.4</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_ddda9de0-4e6a-406a-b6ff-5ae31d3a6db5">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      id="F_e3704e78-1f08-427f-bc5e-0f2cd20f3e0b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      id="F_31ea69d0-9e35-437e-a6f2-d6c9f3322c66">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_01f36c72-8bd1-468f-8d67-ff20bd4abc08"
      unitRef="U_pure">0.744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_e30a640b-68d9-4ac5-9041-e300d4eaf91b"
      unitRef="U_pure">0.786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_900a5e03-0da3-49c9-a752-0e26f7e21680"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_83e2b013-0e03-45a1-a60b-de5271dfd867"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_8feec9a3-38f0-4930-b65e-3be348a7d8ee"
      unitRef="U_pure">0.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_a338ae17-e903-4904-aebc-f82b18a6c753"
      unitRef="U_pure">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_2dc56286-f48f-4ef9-9527-90e5131d67b7"
      unitRef="U_pure">0.0339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="INF"
      id="F_c2149665-a833-45ab-8e78-c827c7f8386c"
      unitRef="U_pure">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_60d33dfb-b336-4ed6-a40e-d5ba8784a592"
      unitRef="U_pure">0.0316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="INF"
      id="F_402559fc-ee69-4944-b202-12fc260436bc"
      unitRef="U_pure">0.0443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_138208f3-5574-4a62-89b3-7e14f26c6230"
      unitRef="U_pure">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="INF"
      id="F_40e11127-898c-472e-8a62-80676b8ba9c8"
      unitRef="U_pure">0.0357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="1"
      id="F_c898583e-09fe-407d-8134-eec9c456fe3f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="1"
      id="F_c99be7f6-3181-48c7-8e3c-8548283ce9df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="1"
      id="F_3a4c008d-266a-4759-be1e-d0735ccdb565"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="-5"
      id="F_d38a4fdf-da67-48a2-adc7-f92d39b78700"
      unitRef="U_USD">16300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83b9f4ee-3576-48cb-8bfb-bfac94f90838"
      decimals="-5"
      id="F_7ca29d16-2299-4756-b237-035cb9c22e7e"
      unitRef="U_USD">16300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8aa69ac6-5adb-43b2-ac2e-6e8902e62ff6"
      decimals="-5"
      id="F_32243d79-3908-46fa-a28a-f8c35ffb49ac"
      unitRef="U_USD">12700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sln:EstimatedEmployerTaxObligationOnOutstandingOptions
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-5"
      id="F_732ba615-bab1-43d6-b5a7-79bb8a6fffc4"
      unitRef="U_USD">300000</sln:EstimatedEmployerTaxObligationOnOutstandingOptions>
    <sln:EstimatedEmployerTaxObligationOnOutstandingOptions
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-5"
      id="F_0517a443-72ce-4e0b-8e62-82cb5e334eae"
      unitRef="U_USD">500000</sln:EstimatedEmployerTaxObligationOnOutstandingOptions>
    <us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_3741a0cd-8fd5-47f9-a7b3-976a294f4903">&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;20. Capital commitments and contingent liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; capital commitments at December 31, 2024 (2023: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7e7a64d4-569d-4871-a6b1-2ad84515628e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;; 2022: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_40e46a58-04d9-4131-ab73-072c46c316bb;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;nil&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;).&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock>
    <sln:CapitalCommitments
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="INF"
      id="F_f2325ba1-305d-45c8-a9da-f9f36f8d1c32"
      unitRef="U_USD">0</sln:CapitalCommitments>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_65016b21-ed7e-4deb-b5d9-b9074c857792">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;21. Commitments under short leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At December 31, 2024, the Group had&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; a gross commitment on its office rental and service charge in Berlin, Germany and the Hoboken, U.S. lease equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (2023: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million; 2022: $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) in the next year. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; amounts are payable after more than one year.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, the Group enters into contracts in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;normal course of business with contract research organizations to assist in the performance of research and development activities and other services and products for operating purposes. These contracts generally provide for termination on notice, and therefore are cancellable contracts and not reflected in the disclosure above.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="C_d5ab5df5-07a8-4cbf-9fc9-f75571272697"
      decimals="-5"
      id="F_72a1564e-1dbe-453a-b802-e3ffda17d1a2"
      unitRef="U_USD">500000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="C_2170fa2b-c003-47f8-8bf3-4833d45e9e18"
      decimals="-5"
      id="F_c852cdb3-a948-4c87-b280-3c4bf6610373"
      unitRef="U_USD">500000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="C_08dd2d55-0e01-4e62-95a4-087adff7660d"
      decimals="-5"
      id="F_cfe21161-410f-4a09-86c2-70218c282e96"
      unitRef="U_USD">400000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:ShortTermLeasePayments
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      decimals="0"
      id="F_9705cc1f-1748-4fdf-b2d9-44a091c53480"
      unitRef="U_USD">0</us-gaap:ShortTermLeasePayments>
    <sln:FinancialInstrumentsAndRiskManagementDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_cf97fa44-3599-4996-a04e-a5a79ee67bfb">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;22. Financial instruments and risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s financial instruments comprise primarily cash and other financial assets and various items such as receivables and trade payables which arise directly from its operations. The main purpose of these financial instruments is to provide working capital for the Group&#x2019;s operations. The Group assesses counterparty risk on a regular basis. Board approval is required for adoption of any new financial instrument or counterparty. The primary focus of the treasury function is preservation of capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Directors consider that the carrying amount of these financial instruments approximates to their fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Concentration of credit risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents and U.S. Treasury Bills. Cash and cash equivalents, term deposits and U.S. Treasury Bills are not considered to be exposed to significant credit risk due to the fact they are held in a financial institution with an &#x201c;A&#x201d; rating. The Group considers the possibility of significant loss in the event of non-performance by a financial counterparty to be remote.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group regularly monitors the creditworthiness of its collaborators and at the reporting date, no financial assets are credit impaired.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capital management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group considers its capital to be equal to the sum of its total equity. The Group monitors its capital using a number of measures including cash flow projections, working capital ratios, the cost to achieve preclinical and clinical milestones and potential revenue from existing partnerships and ongoing licensing activities. The Group&#x2019;s objective when managing its capital is to ensure it obtains sufficient funding for continuing as a going concern. The Group funds its capital requirements through the issue of new shares to investors, milestone and research support payments received from existing licensing partners and potential new licensees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest rate risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The nature of the Group&#x2019;s activities and the basis of funding are such that the Group has significant liquid resources. The Group uses these resources to meet the cost of future research and development activities. Consequently, it seeks to minimize risk in the holding of its bank deposits while maintaining a reasonable rate of interest. The Group is not financially dependent on the income earned on these resources and therefore the risk of interest rate fluctuations is not significant to the business. Nonetheless, the Directors take steps to secure rates of interest which generate a return for the Group.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Credit and liquidity risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Credit risk is managed on a Group basis. Funds are deposited with financial institutions with a credit rating equivalent to, or above, the main U.K. clearing banks. The Group&#x2019;s liquid resources are invested having regard to the timing of payments to be made in the ordinary course of the Group&#x2019;s activities. All financial liabilities are payable in the short term (between zero and three months) and the Group maintains adequate bank balances in either instant access or short-term deposits to meet those liabilities as they fall due.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group only enters into collaboration agreements with large, reputable companies and the creditworthiness of collaborators is monitored on an ongoing basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expected loss rates are based on payment profiles of past receivables and the aging profiles of outstanding balances at the reporting period end date. The historical loss rates are adjusted to reflect current and forward-looking information on macroeconomic factors affecting the ability of the customer to settle the receivables. At the year-end there were no debts that were past due or are expected to be past due. It was therefore concluded on this basis that there were no expected credit losses for the trade receivable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Trade receivables are written off where there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery includes, but is not limited to, a failure to engage in a repayment plan with the Group.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Currency risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Group&#x2019;s transactions are commonly denominated in U.K pounds sterling; however, the Group receives payments under its collaboration agreements in U.S. dollars and it incurs a portion of its expenses in other currencies, primarily Euros, and are exposed to the effects of these exchange rates. The Group seeks to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in these other currencies. Where significant foreign currency cash receipts are expected, the Group considers the use of forward exchange contracts to manage its exchange rate exposure.&lt;/span&gt;&lt;/p&gt;</sln:FinancialInstrumentsAndRiskManagementDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_c3b28bc4-2607-45a9-a510-d0b6ccc07dd4">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;23. Related party transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2022, the Group agreed to pay Gladstone Consultancy Partnership, a company controlled by the Group&#x2019;s Non-Executive Chairman, Iain Ross, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand (plus any applicable value added tax) for consulting and advisory services provided by Mr. Ross. Gladstone Consulting Partnership is no longer being engaged by the Group in 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_eb12df02-dc62-4dfe-9745-ea50a6329b7c"
      decimals="-3"
      id="F_ae3a3997-8b87-4601-a4df-c4e965e5360c"
      unitRef="U_USD">60000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_4981ab38-3780-4326-a492-3b5aa602b56e"
      id="F_0f5223e2-80ba-4cea-831a-bec8a74e270a">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24. Subsequent events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;None.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a"
          xlink:label="F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a"
          xlink:type="locator"/>
        <link:footnote id="FNT_d8df02ac-0265-43fc-a0ef-821a94501a40" xlink:label="FNT_d8df02ac-0265-43fc-a0ef-821a94501a40" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a6f9b1b0-87db-4e2c-b41b-ecfb70ab693a"
          xlink:to="FNT_d8df02ac-0265-43fc-a0ef-821a94501a40"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_f045ca95-9039-40d5-91da-1e05384a3b3e"
          xlink:label="F_f045ca95-9039-40d5-91da-1e05384a3b3e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9c3b9baf-8b05-468b-9c79-830cf81ddc15"
          xlink:label="F_9c3b9baf-8b05-468b-9c79-830cf81ddc15"
          xlink:type="locator"/>
        <link:footnote id="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1" xlink:label="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Included i</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n trading losses is $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated tax losses as of December 31, 2024 ($</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.6</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2023) related to </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">operations in Germany for corporate income taxes and $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of accumulated losses related to trade taxes in </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">its </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">German entity ($</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of Decem</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ber 31, 2023).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f045ca95-9039-40d5-91da-1e05384a3b3e"
          xlink:to="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9c3b9baf-8b05-468b-9c79-830cf81ddc15"
          xlink:to="FNT_b9ae580a-632a-4c20-b27f-3f5ff89b81b1"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
